PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Harris, MJ; Kuwano, M; Webb, M; Board, PG				Harris, MJ; Kuwano, M; Webb, M; Board, PG			Identification of the apical membrane-targeting signal of the multidrug resistance-associated protein 2 (MRP2/cMOAT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; CHRONIC CONJUGATED HYPERBILIRUBINEMIA; CANCER CELL-LINES; MUTANT RATS; CMOAT MRP2; DRUG-RESISTANCE; EXPORT ACTIVITY; HUMAN LUNG; GENE; LOCALIZATION	The human canalicular multispecific organic anion transporter (cMOAT), known as the multidrug resistance-associated protein 2 (MRP2), is normally expressed in the liver and to a lesser extent in the kidney proximal tubules. In these tissues MRP2 specifically localizes to the apical membrane. The construction of MRP2 fused to the green fluorescent protein, and subsequent site-directed mutagenesis enabled the identification of a targeting signal in MRP2 that is responsible for its apical localization in polarized cells. The specific apical localization of MRP2 is due to a C-terminal tail that is not present in the basolaterally targeted MRP1. Deletion of three amino acids from the C-terminal of MRP2 (Delta MRP2) causes the protein to be localized predominantly in the basolateral membrane in polarized Madin-Darby canine kidney cells. Interestingly, MRP2 expressed in a mouse leukemia cell line (L1210 cells) predominantly accumulates intracellularly with minimal cell membrane localization. In contrast, Delta MRP2 was shown to predominantly localize in the cell membrane in L1210 cells. Increased transport of 2,4-dinitrophenyl glutathione from L1210 cells expressing Delta MRP2 showed that the re-targeted protein retains its normal function.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Med, Mol Genet Grp, Canberra, ACT 0200, Australia; Kyushu Univ, Grad Sch Med Sci, Dept Biochem Med, Fukuoka 8128582, Japan; Australian Natl Univ, Biotron Ltd, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Kyushu University; Australian National University	Board, PG (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Med, Mol Genet Grp, Canberra, ACT 0200, Australia.							ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chen ZS, 1999, MOL PHARMACOL, V56, P1219, DOI 10.1124/mol.56.6.1219; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; Keller P, 1997, J CELL SCI, V110, P3001; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; Kocher O, 1999, LAB INVEST, V79, P1161; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1997, CANCER RES, V57, P3537; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Narasaki F, 1997, BIOCHEM BIOPH RES CO, V240, P606, DOI 10.1006/bbrc.1997.7703; OLIVE C, 1994, BBA-MOL CELL RES, V1224, P264, DOI 10.1016/0167-4889(94)90199-6; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Sai Y, 1999, J CELL SCI, V112, P4535; Schaub TP, 1999, J AM SOC NEPHROL, V10, P1159; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Taniguchi K, 1996, CANCER RES, V56, P4124	29	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20876	20881		10.1074/jbc.M010566200	http://dx.doi.org/10.1074/jbc.M010566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274200	hybrid			2022-12-27	WOS:000169297900013
J	He, CH; Gong, PF; Hu, B; Stewart, D; Choi, ME; Choi, AMK; Alam, J				He, CH; Gong, PF; Hu, B; Stewart, D; Choi, ME; Choi, AMK; Alam, J			Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein - Implication for heme oxygenase-1 gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; VASCULAR ENDOTHELIAL-CELLS; LEUCINE ZIPPER PROTEIN; DNA-BINDING PROTEINS; OXIDATIVE STRESS; MEDIATED EXPRESSION; FACTOR NF-E2; FACTOR NRF2; INDUCTION; FAMILY	Nrf2 regulates expression of genes encoding enzymes with antioxidant (e.g. heme oxygenase-l (HO-1)) or xenobiotic detoxification (e.g, NAD(P)H:quinone oxidoreductase, glutathione S-transferase) functions via the stress- or antioxidant-response elements (StRE/ARF), Nrf2 heterodimerizes with small Maf proteins, but the role of such dimers in gene induction is controversial, and other partners may exist. By using the yeast two-hybrid assay, we identified activating transcription factor (ATF) 4 as a potential Nrf2-interacting protein. Association between Nrf2 and ATF4 in mammalian cells was confirmed by co-immunoprecipitation and mammalian two-hybrid assays. Furthermore, Nrf2.ATF4 dimers bound to an StRE sequence from the ho-1 gene. CdCl2, a potent inducer of HO-1, increased expression of ATF4 in mouse hepatoma cells, and detectable induction of ATF4 protein preceded that of HO-1 (30 min versus 2 h). A dominant-negative mutant of ATF4 inhibited basal and CdCl2-stimulated expression of a StRE-dependent/luciferase fusion construct (pE1-luc) in hepatoma cells but only basal expression in mammary epithelial MCF-7 cells. A dominant mutant of Nrf2 was equally inhibitory in both cell types in the presence or absence of CdCl2. These results indicate that ATF4 regulates basal and CdCl2-induced expression of the ho-1 gene in a cell-specific manner and possibly in a complex with Nrf2.	Alton Ochsner Med Fdn, Dept Mol Genet, New Orleans, LA 70121 USA; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15231 USA; Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15231 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Ochsner Health System; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Alam, J (corresponding author), Alton Ochsner Med Fdn, Dept Mol Genet, 1516 Jefferson Hwy, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R29HL055330, R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60234, HL-55330] Funding Source: Medline; NIAID NIH HHS [AI-42365] Funding Source: Medline; NIDDK NIH HHS [DK-43135] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ITOH K, 1998, GENE DEV, V13, P67; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Levenson VV, 2000, CANCER RES, V60, P5027; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513	44	365	379	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20858	20865		10.1074/jbc.M101198200	http://dx.doi.org/10.1074/jbc.M101198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274184	hybrid			2022-12-27	WOS:000169297900011
J	Lim, CP; Cao, XM				Lim, CP; Cao, XM			Regulation of Stat3 activation by MEK kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; SERINE PHOSPHORYLATION; PROTEIN-KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SRC ONCOPROTEIN; TRANSCRIPTION; JNK; REQUIRES	Stat3 is a latent transcription factor activated by various cytokines and growth factors. Phosphorylation on Tyr-705 is a prerequisite for dimer formation, nuclear translocation, binding to its cognate DNA sequences, and regulation of the target gene transcription. Ser-727 phosphorylation of Stat3 plays an additional role in the regulation of transcription. MEK kinase 1 (MEKK1) is a mitogen-activated protein kinase (MAPK) kinase kinase (MAPKKK) that activates the c-Jun NH2-terminal kinase signaling pathway. Here we report that MEKK1 is involved in the regulation of Stat3 activation by growth factors. Kinase-inactive MEKK1 inhibits Stat3 phosphorylation on tyrosine and serine, and its transcriptional activity stimulated by epidermal growth factor and platelet-derived growth factor in different cell types. In contrast, active MEKK1 induces Stat3 tyrosine and serine phosphorylation leading to a functionally active Stat3 capable of binding DNA and enhancing transcription. Ser-727 is phosphorylated by MEKK1 in vitro, whereas Tyr-705 phosphorylation induced by MEKK1 involves Src and Janus kinases in vivo. These data demonstrate for the first time a novel role of MEKK1 to modulate tyrosine kinases that results in the activation of specific members of STAT family.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Cao, XM (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAMELL JE, 1994, SCIENCE, V264, P1415; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gollob JA, 1999, J IMMUNOL, V162, P4472; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turkson J, 1999, MOL CELL BIOL, V19, P7519; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	44	78	80	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21004	21011		10.1074/jbc.M007592200	http://dx.doi.org/10.1074/jbc.M007592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278353	hybrid			2022-12-27	WOS:000169297900029
J	Polevoda, B; Sherman, F				Polevoda, B; Sherman, F			NatC N-alpha-terminal acetyltransferase of yeast contains three subunits, Mak3p, Mak10p, and Mak31p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-RNA VIRUS; SACCHAROMYCES-CEREVISIAE; METHIONINE AMINOPEPTIDASE; MESSENGER-RNA; PROTEINS; IDENTIFICATION; SPECIFICITIES; REPLICATION; ACETYLATION; GENE	The yeast Saccharomyces cerevisiae contains three types of N-alpha-terminal acetyltransferases, NatA, NatB, and NatC, with each having a different catalytic subunit, Ard1p, Nat3p, and Mak3p, respectively, and each acetylating different sets of proteins with different N-alpha-terminal regions. We show that the NatC N-alpha-terminal acetyltransferases contains Mak10p and Mak31p subunits, in addition to Mak3p, and that all three subunits are associated with each other to form the active complex. Genetic deletion of any one of the three subunits results in identical abnormal phenotypes, including the lack of acetylation of a NatC substrate in vivo, diminished growth at 37 degreesC on media containing nonfermentable carbon sources, and the lack of maintenance or assembly of the L-A dsRNA viral particle.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, POB 712, Rochester, NY 14642 USA.	FredSherman@urmc.rochester.edu	Polevoda, Bogdan/A-4880-2008		NCRR NIH HHS [RR14682] Funding Source: Medline; NIGMS NIH HHS [GM12702] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014682] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; FUJIMURA T, 1987, MOL CELL BIOL, V7, P420, DOI 10.1128/MCB.7.1.420; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; ISONO K, 1980, MOL GEN GENET, V177, P645; Kimura Y, 2000, J BIOL CHEM, V275, P4635, DOI 10.1074/jbc.275.7.4635; LEE YJ, 1992, GENETICS, V132, P87; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SHERMAN F, 1968, J BIOL CHEM, V243, P5446; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang XY, 1996, J BIOL CHEM, V271, P6594, DOI 10.1074/jbc.271.12.6594; WICKNER RB, 1982, GENETICS, V100, P159; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104	34	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20154	20159		10.1074/jbc.M011440200	http://dx.doi.org/10.1074/jbc.M011440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274203	hybrid			2022-12-27	WOS:000169135100065
J	Tamura, N; Konishi, S; Iwaki, S; Kimura-Someya, T; Nada, S; Yamaguchi, A				Tamura, N; Konishi, S; Iwaki, S; Kimura-Someya, T; Nada, S; Yamaguchi, A			Complete cysteine-scanning mutagenesis and site-directed chemical modification of the Tn10-encoded metal-tetracycline/H+ antiporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-FILLED CHANNEL; ESCHERICHIA-COLI; LACTOSE PERMEASE; TRANSPOSON TN10; RESISTANCE PROTEIN; H+ ANTIPORTER; MEMBRANE; TOPOLOGY; RESIDUES; REVEALS	Bacterial Tn10-encoded metal-tetracycline/H+ antiporter was the first found drug exporter and has been studied as a paradigm of antiporter-type major facilitator superfamily transporters. Here the 400 amino acid residues of this protein were individually replaced by cysteine except for the initial methionine. As a result, we could obtain a complete map of the functionally or structurally important residues. In addition, we could determine the precise boundaries of all the transmembrane segments on the basis of the reactivity with N-ethylmaleimide (NEM). The NEM binding results indicated the presence of a transmembrane water-filled channel in the transporter. The twelve transmembrane segments can be divided into three groups; four are totally embedded in the hydrophobic interior, four face a putative water-filled channel along their full length, and the remaining four face the channel for half their length, the other halves being embedded in the hydrophobic interior. These three types of transmembrane segments are mutually arranged with a 4-fold symmetry. The competitive binding of membrane-permeable and -impermeable SH reagents in intact cells indicates that the transmembrane water-filled channel has a thin barrier against hydrophilic molecules in the middle of the transmembrane region. Inhibition and stimulation of NEM binding in the presence of tetracycline reflects the substrate-induced protection or conformational change of the Tn10-encoded metal-tetracycline/H+ antiporter, The mutations protected from NEM binding by tetracycline were mainly located around the permeability barrier in the N-terminal half, suggesting the location of the substrate binding site.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; ECKERT B, 1989, J BIOL CHEM, V264, P11663; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; Iwaki S, 2000, J BIOL CHEM, V275, P22704, DOI 10.1074/jbc.M910354199; Kawabe T, 1999, FEBS LETT, V457, P169, DOI 10.1016/S0014-5793(99)01032-7; Kimura T, 1997, J BIOL CHEM, V272, P580; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Konishi S, 1999, FEBS LETT, V461, P315, DOI 10.1016/S0014-5793(99)01490-8; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1993, BIOCHEMISTRY-US, V32, P5698, DOI 10.1021/bi00072a027; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Yin CC, 2000, MOL MICROBIOL, V38, P482, DOI 10.1046/j.1365-2958.2000.02149.x	37	77	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20330	20339		10.1074/jbc.M007993200	http://dx.doi.org/10.1074/jbc.M007993200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278375	hybrid			2022-12-27	WOS:000169135100090
J	Yoon, SO; Kim, MM; Chung, AS				Yoon, SO; Kim, MM; Chung, AS			Inhibitory effect of selenite on invasion of HT1080 tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; MATRIX METALLOPROTEINASE-2 ACTIVATION; BREAST-CARCINOMA CELLS; HUMAN TISSUE INHIBITOR; IV COLLAGENASE; DNA-BINDING; MATRIX-METALLOPROTEINASE-9 EXPRESSION; EXPERIMENTAL METASTASIS; MONOCLONAL-ANTIBODIES	Selenium, an essential biological trace element, has been shown to reduce and prevent the incidence of cancer. Our previous studies have shown that selenite is involved in the chemoprevention of cancer and induction of apoptosis of cancer cells. In this study, we demonstrate that selenite also inhibits the invasion of tumor cells. Cancer cell invasion requires coordinated processes, such as changes in cell-cell and cell-matrix adhesion, degradation of the extracellular matrix, and cell migration. We found that selenite inhibited invasion of HT1080 human fibrosarcoma cells. Adhesion of HT1080 cells to the collagen matrix was also inhibited by treatment with selenite, but cell-cell interaction and cell motility were not affected by selenite. Moreover, selenite reduced expression of matrix metalloproteinase-2 and -9 and urokinase-type plasminogen activator, which are involved in matrix degradation, but increased a tissue inhibitor of metalloproteinase-1. This inhibitory effect of selenite on the protease expressions was mediated by the suppression of transcription factors, NF-kappaB and AP-1. However, selenate showed no remarkable effect on all the steps of cancer cell invasion.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, AS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	aschung@mail.kaist.ackr						ABDULLAEV FI, 1992, CANCER LETT, V65, P43, DOI 10.1016/0304-3835(92)90211-D; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; AZZAM HS, 1992, CANCER RES, V52, P4540; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cha HJ, 1996, CANCER RES, V56, P2281; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; de Veas RG, 1998, EUR J CANCER, V34, P1736, DOI 10.1016/S0959-8049(98)00285-8; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DENA G, 2000, J BIOL CHEM, V275, P32664; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; George SJ, 1998, HUM GENE THER, V9, P867, DOI 10.1089/hum.1998.9.6-867; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilles C, 1997, LAB INVEST, V76, P651; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P25, DOI 10.1006/abbi.1997.0334; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; HEARING VJ, 1988, CANCER RES, V48, P1270; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hua J, 1996, CANCER RES, V56, P5279; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Kaczarek E, 1999, INT J DEV NEUROSCI, V17, P625, DOI 10.1016/S0736-5748(99)00047-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; Koli K, 2000, CELL GROWTH DIFFER, V11, P221; Li JJ, 1997, CANCER RES, V57, P3569; Liabakk NB, 1996, CANCER RES, V56, P190; LIN Y, 1992, CANCER RES, V52, P5803; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIU W, 1995, MOL CELL BIOL, V15, P1005; MACKAY AR, 1990, CANCER RES, V50, P5997; Manna SK, 2000, CANCER RES, V60, P3838; MEDINA D, 1981, CANCER LETT, V13, P333, DOI 10.1016/0304-3835(81)90062-8; Migita K, 1996, IMMUNOLOGY, V89, P553, DOI 10.1046/j.1365-2567.1996.d01-789.x; Montero L, 1999, CANCER RES, V59, P5286; Murono S, 2000, CANCER RES, V60, P2555; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; NERLOV C, 1991, ONCOGENE, V6, P1583; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Shao ZM, 1998, CANCER RES, V58, P4851; Simon C, 1998, CANCER RES, V58, P1135; SPYROU G, 1995, FEBS LETT, V368, P59, DOI 10.1016/0014-5793(95)00599-5; Spyrou G, 1996, CANCER RES, V56, P4407; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P3729, DOI 10.1073/pnas.80.12.3729; VOLLMERS HP, 1984, FEBS LETT, V172, P17, DOI 10.1016/0014-5793(84)80863-7; WATANABE H, 1993, J CELL SCI, V104, P991; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yan Chunhong, 1997, Invasion and Metastasis, V17, P189; Yu M, 1997, CANCER RES, V57, P5028	69	151	160	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20085	20092		10.1074/jbc.M101143200	http://dx.doi.org/10.1074/jbc.M101143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274215	hybrid			2022-12-27	WOS:000169135100056
J	Chung, HK; Derse, D				Chung, HK; Derse, D			Binding sites for Rev and ASF/SF2 map to a 55-nucleotide purine-rich exonic element in equine infectious anemia virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; RESPONSE ELEMENT; SR PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT; SPLICING FACTORS; TYPE-1; HIV-1; IDENTIFICATION; ENHANCER; ACTIVATION	The equine infectious anemia virus (EIAV) Rev protein (ERev) negatively regulates its own synthesis by inducing alternative splicing of its mRNA. This bicistronic mRNA contains four exons; exons 1 and 2 encode Tat, and exons 3 and 4 encode Rev. When Rev is expressed, exon 3 is skipped to produce an mRNA that contains only exons 1, 2, and 4, The interaction of ERev with its cis-acting RNA response element, the RRE, is also essential for nuclear export of intron-containing viral mRNAs that encode structural and enzymatic gene products. The primary ERev binding site and the manner in which ERev interacts with RNA or cellular proteins to exert its regulatory function have not been defined. We have performed in vitro RNA binding experiments to show that recombinant ERev binds to a 55-nucleotide, purine-rich tract proximal to the 5 ' splice site of exon 3, Because of its proximity to the 5 ' splice site and since it contains elements related to consensus exonic splicing enhancer sequences, we asked whether cellular proteins recognize the EIAV RRE, The cellular protein, ASF/SF2, a member of the serine- and arginine-rich family of splicing factors (SR proteins) bound to repeated sequences within the 55-nucleotide RRE region, Electrophoretic mobility shift and UV cross-linking experiments indicated that ERev and SR proteins bind simultaneously to the RRE, Furthermore, in vitro protein-protein interaction studies revealed an association between ERev and SR proteins. These data suggest that EIAV Rev-induced exon skipping observed in vivo may be initiated by simultaneous binding of Rev and SR proteins to the RRE that alter the subsequent assembly or catalytic activity of the spliceosomal complex.	NCI, Basic Res Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Derse, D (corresponding author), NCI, Basic Res Lab, NIH, Frederick, MD 21702 USA.	derse@ncifcrf.gov						Askjaer P, 1998, J BIOL CHEM, V273, P11463, DOI 10.1074/jbc.273.19.11463; Bakker A, 1996, J VIROL, V70, P5511, DOI 10.1128/JVI.70.8.5511-5518.1996; Belshan M, 2000, MOL CELL BIOL, V20, P3550, DOI 10.1128/MCB.20.10.3550-3557.2000; BLACK AC, 1994, VIROLOGY, V200, P29, DOI 10.1006/viro.1994.1159; BLACK AC, 1995, J VIROL, V69, P6852, DOI 10.1128/JVI.69.11.6852-6858.1995; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukumori T, 1999, INT J MOL MED, V3, P297; Gontarek RR, 1996, MOL CELL BIOL, V16, P2325; Grate D, 1997, STRUCTURE, V5, P7, DOI 10.1016/S0969-2126(97)00161-5; Harris ME, 1998, MOL CELL BIOL, V18, P3889, DOI 10.1128/MCB.18.7.3889; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MARTARANO L, 1994, J VIROL, V68, P3102, DOI 10.1128/JVI.68.5.3102-3111.1994; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Powell DM, 1997, P NATL ACAD SCI USA, V94, P973, DOI 10.1073/pnas.94.3.973; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; Van Ryk DI, 1999, J BIOL CHEM, V274, P17452, DOI 10.1074/jbc.274.25.17452; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zemmel RW, 1996, J MOL BIOL, V258, P763, DOI 10.1006/jmbi.1996.0285; Zheng ZM, 1999, J VIROL, V73, P29, DOI 10.1128/JVI.73.1.29-36.1999; Zheng ZM, 1998, P NATL ACAD SCI USA, V95, P14088, DOI 10.1073/pnas.95.24.14088	49	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18960	18967		10.1074/jbc.M008996200	http://dx.doi.org/10.1074/jbc.M008996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278454	hybrid			2022-12-27	WOS:000169091000043
J	Imamura, T; Banbula, A; Pereira, PJB; Travis, J; Potempa, J				Imamura, T; Banbula, A; Pereira, PJB; Travis, J; Potempa, J			Activation of human prothrombin by arginine-specific cysteine proteinases (gingipains R) from Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; CREVICULAR FLUID; ARG-GINGIPAIN; TISSUE FACTOR; ACTIVE-SITE; THROMBIN; GENES; PERIODONTITIS; PERMEABILITY; PURIFICATION	The effect of 95- (HRgpA) and 50-kDa gingipain R (RgpB), arginine-specific cysteine proteinases from periodontopathogenic bacterium Porphyromonas gingivalis on human prothrombin activation was investigated. Each enzyme released thrombin from prothrombin in a dose- and time-dependent manner with the former enzyme, containing adhesion domains, being 17-fold more efficient than the single chain RgpB. A close correlation between the generation of fibrinogen clotting activity and amidolytic activity indicated that alpha -thrombin was produced by gingipains R, and this was confirmed by SDS-polyacrylamide gel electrophoresis, thrombin active site labeling, and amino-terminal sequence analysis of prothrombin digestion fragments. Significantly, the catalytic efficiency of HRgpA to generate thrombin (k(cat)/K-m = 1.2 x 10(6) M-1 s(-1)) was 100-fold higher than that of RgpB (k(cat)/K-m = 1.2 x 10(4) M-1 s(-1)). The superior prothrombinase activity of HRgpA over RgpB correlates with the fact that only the former enzyme was able to clot plasma, and kinetic data indicate that prothrombin activation can occur in vivo. At P. gingivalis-infected periodontitis sites HRgpA may be involved in the direct production of thrombin and, therefore, in the generation of prostaglandins and interleukin-1, both have been found to be associated with the development and progression of the disease. Furthermore, by taking into account that the P. gingivalis bacterium has been immunolocalized in carotid atherosclerotic plaques at thrombus formation sites (Chiu, B. (1999) Am. Heart J. 138, S534-S536), our results indicate that bacterial proteinases may potentially participate in the pathogenesis of cardiovascular disease associated with periodontitis.	Jagiellonian Univ, Inst Mol Biol, Dept Microbiol, PL-31120 Krakow, Poland; Kumamoto Univ, Grad Sch Med Sci, Dept Neurosci & Immunol, Div Mol Pathol, Ikeda, Kumamoto 860, Japan; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Jagiellonian University; Kumamoto University; Max Planck Society; University System of Georgia; University of Georgia	Potempa, J (corresponding author), Jagiellonian Univ, Inst Mol Biol, Dept Microbiol, Al Mickiewicza 3, PL-31120 Krakow, Poland.	potempa@mol.uj.edu.pl	Pereira, Pedro/F-8972-2011	Pereira, Pedro/0000-0003-0969-5438	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], HOST PARASITE INTERA; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Chiu B, 1999, AM HEART J, V138, pS534, DOI 10.1016/S0002-8703(99)70294-2; COLMAN RW, 1987, HEMOSTASIS THROMBOSI, P3; Coughlin SR, 1999, THROMB HAEMOSTASIS, V82, P353; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DEMICHELE MAA, 1990, J APPL PHYSIOL, V69, P1599, DOI 10.1152/jappl.1990.69.5.1599; DRAKE TA, 1989, AM J PATHOL, V134, P1087; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; Halkier T., 1991, MECH BLOOD COAGULATI; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HOFFMANN O, 1986, PROSTAGLANDINS, V31, P601, DOI 10.1016/0090-6980(86)90168-1; HOLT SC, 1988, SCIENCE, V239, P55, DOI 10.1126/science.3336774; Hosotaki K, 1999, BIOL CHEM, V380, P75, DOI 10.1515/BC.1999.009; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; Imamura T, 1997, J BIOL CHEM, V272, P16062, DOI 10.1074/jbc.272.25.16062; Imamura T, 2001, BIOCHEM J, V353, P325, DOI 10.1042/0264-6021:3530325; JONES A, 1990, IMMUNOLOGY, V71, P236; KISIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103, DOI 10.1016/0304-4165(73)90119-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER UH, 1988, BIOCHIM BIOPHYS ACTA, V964, P309, DOI 10.1016/0304-4165(88)90031-1; LIPINSKI B, 1974, BRIT J HAEMATOL, V28, P221, DOI 10.1111/j.1365-2141.1974.tb06657.x; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MASADA MP, 1990, J PERIODONTAL RES, V25, P156, DOI 10.1111/j.1600-0765.1990.tb01038.x; Menkin V, 1938, PHYSIOL REV, V18, P366, DOI 10.1152/physrev.1938.18.3.366; Mikolajczyk-Pawlinska J, 1998, BIOL CHEM, V379, P205, DOI 10.1515/bchm.1998.379.2.205; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; NEMERSON Y, 1988, BLOOD, V71, P1; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; Page R C, 1998, Ann Periodontol, V3, P108, DOI 10.1902/annals.1998.3.1.108; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; PIKE R, 1994, J BIOL CHEM, V269, P406; Pike RN, 1996, J BACTERIOL, V178, P2876, DOI 10.1128/jb.178.10.2876-2882.1996; Potempa J, 1997, BIOL CHEM, V378, P223, DOI 10.1515/bchm.1997.378.3-4.223; Potempa J, 1998, J BIOL CHEM, V273, P21648, DOI 10.1074/jbc.273.34.21648; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; Rangarajan M, 1997, MOL MICROBIOL, V23, P955, DOI 10.1046/j.1365-2958.1997.2831647.x; RIVERS RPA, 1975, BRIT J HAEMATOL, V30, P311, DOI 10.1111/j.1365-2141.1975.tb00547.x; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547, DOI 10.1093/oxfordjournals.jbchem.a131310; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; SPEIJER H, 1986, J BIOL CHEM, V261, P3258; TANS G, 1985, J BIOL CHEM, V260, P9366; TUBB M, 1990, ARCH ORAL BIOL, V35, P529, DOI 10.1016/0003-9969(90)90083-M; WEGRZYNOWICZ Z, 1980, J CLIN MICROBIOL, V12, P138, DOI 10.1128/JCM.12.2.138-139.1980; WIKSTROM M, 1994, J PERIODONTOL, V65, P47, DOI 10.1902/jop.1994.65.1.47; ZAMBON JJ, 1990, CONT PERIODONTICS, P147	53	50	56	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18984	18991		10.1074/jbc.M006760200	http://dx.doi.org/10.1074/jbc.M006760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278315	hybrid			2022-12-27	WOS:000169091000046
J	Mitchell, CJ; Kelly, MM; Blewitt, M; Wilson, JR; Biden, TJ				Mitchell, CJ; Kelly, MM; Blewitt, M; Wilson, JR; Biden, TJ			Phospholipase C-gamma mediates the hydrolysis of phosphatidylinositol, but not of phosphatidylinositol 4,5-bisphoshate, in carbamylcholine-stimulated islets of langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INSULIN-SECRETION; TYROSINE PHOSPHORYLATION; PANCREATIC-ISLETS; INOSITOL 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE HYDROLYSIS; RAT ISLETS; BETA-CELLS; ACTIVATION; RELEASE	In pancreatic islets the activation of phospholipase C (PLC) by the muscarinic receptor agonist carbamyol-choline (carbachol) results in the hydrolysis of both phosphatidylinositol 4,5-bisphosphate (PtdInsP(2)) and phosphatidylinositol (PtdIns). Here we tested the hypothesis that PtdIns hydrolysis is mediated by PLC gamma1, which is known to be regulated by activation of tyrosine kinases and PtdIns 3-kinase, PtdIns breakdown was more sensitive than that of PtdInsP(2) to the tyrosine kinase inhibitor, genistein. Conversely, the tyrosine phosphatase inhibitor, vanadate, alone promoted PtdIns hydrolysis and acted non-additively with carbachol, Vanadate did not stimulate PtdInsP(2) breakdown. Carbachol also stimulated a rapid (maximal at 1-2 min) tyrosine phosphorylation of several islet proteins, although not of PLC gamma1 itself. Two structurally unrelated inhibitors of PtdIns 3-kinase, wortmannin and LY294002, more effectively attenuated the hydrolysis of PtdIns compared with PtdInsP(2). Adenovirally mediated overexpression of PLC gamma1 significantly increased carbachol-stimulated PtdIns hydrolysis without affecting that of PtdInsP(2). Conversely overexpression of PLC beta1 up-regulated the PtdInsP(2), but not PtdIns, response. These results indicate that the hydrolysis of PtdIns and PtdInsP(2) are independently regulated in pancreatic islets and that PLC gamma1 selectively mediates the breakdown of PtdIns. The activation mechanism of PLC gamma involves tyrosine phosphorylation (but not of PLC gamma directly) and PtdIns 3-kinase. Our findings point to a novel bifurcation of signaling pathways downstream of muscarinic receptors and suggest that hydrolysis of PtdIns and PtdInsP(2) might serve different physiological ends.	St Vincents Hosp, Garvan Inst Med Res, Cell Signaling Grp, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Biden, TJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Cell Signaling Grp, 384 Victoria St, Sydney, NSW 2010, Australia.	t.biden@garvan.unsw.edu.au	Stehn, Justine/G-5115-2013; Blewitt, Marnie/B-1796-2012; Biden, Trevor/AAW-2829-2021	Stehn, Justine/0000-0002-2136-5450; Biden, Trevor/0000-0001-5211-0234; Blewitt, Marnie/0000-0002-2984-1474				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Baldassare JJ, 1997, BIOCHEM J, V324, P283, DOI 10.1042/bj3240283; BANNO Y, 1994, J BIOL CHEM, V269, P15846; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1992, BIOCHEM J, V285, P541, DOI 10.1042/bj2850541; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BIDEN TJ, 1993, J BIOL CHEM, V268, P11065; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; EASOM RA, 1990, J BIOL CHEM, V265, P14938; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gasa R, 1999, DIABETES, V48, P1035, DOI 10.2337/diabetes.48.5.1035; GILON P, 1995, BIOCHEM J, V311, P259, DOI 10.1042/bj3110259; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HERNANDEZSOTOMAYOR SMT, 1993, BIOCHEM J, V293, P507, DOI 10.1042/bj2930507; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Iismaa TP, 2000, DIABETES, V49, P392, DOI 10.2337/diabetes.49.3.392; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V254, P77, DOI 10.1006/bbrc.1998.9468; Jonas JC, 1996, BIOCHEM J, V315, P49, DOI 10.1042/bj3150049; JONAS JC, 1995, BRIT J PHARMACOL, V114, P872, DOI 10.1111/j.1476-5381.1995.tb13285.x; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MORGAN NG, 1985, BIOCHEM J, V228, P713, DOI 10.1042/bj2280713; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKUWA Y, 1986, J BIOL CHEM, V261, P4670; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; ZHANG A, 1991, J BIOL CHEM, V266, P21649	47	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19072	19077		10.1074/jbc.M101406200	http://dx.doi.org/10.1074/jbc.M101406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11274217	hybrid			2022-12-27	WOS:000169091000059
J	Kuhelj, R; Rizzo, CJ; Chang, CH; Jadhav, PK; Towler, EM; Korant, BD				Kuhelj, R; Rizzo, CJ; Chang, CH; Jadhav, PK; Towler, EM; Korant, BD			Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; CYCLIC UREA AMIDES; HIV PROTEASE; HERV-K; MOLECULAR RECOGNITION; STRUCTURAL-ANALYSIS; DRUG-RESISTANCE; GERM-CELL; WILD-TYPE; EXPRESSION	A full-length and C-terminally truncated version of human endogenous retrovirus (HERV)-K10 protease were expressed in Escherichia coli and purified to homogeneity. Both versions of the protease efficiently processed HERV-K10 Gag polyprotein substrate. HERV-K10 Gag was also cleaved by human immunodeficiency virus, type 1 (HIV-1) protease, although at different sites. To identify compounds that could inhibit protein processing dependent on the HERV-K10 protease, a series of cyclic ureas that had previously been shown to inhibit HIV-1 protease was tested. Several symmetric bisamides acted as very potent inhibitors of both the truncated and full-length form of HERV-K10 protease, in subnanomolar or nanomolar range, respectively. One. of the cyclic ureas, SD146, can inhibit the processing of in vitro translated HERV-K10 Gag polyprotein substrate by HERV-K10 protease. In addition, in virus-like particles isolated from the teratocarcinoma cell line NCCIT, there is significant accumulation of Gag and Gag-Pol precursors upon treatment with SD146, suggesting the compound efficiently blocks HERV-K Gag processing in cells. This is the first report of an inhibitor able to block cell-associated processing of Gag polypeptides of an endogenous retrovirus.	Dupont Merck Pharmaceut Co, Dept Virol, Expt Stn E336 22, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Chem & Phys Sci, Expt Stn E336 22, Wilmington, DE 19880 USA; NCI, SAIC Frederick, Frederick Canc Res & Dev Ctr, Prot Chem Lab,NIH, Frederick, MD USA	DuPont; DuPont; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Korant, BD (corresponding author), Dupont Merck Pharmaceut Co, Dept Virol, Expt Stn E336 22, POB 80336, Wilmington, DE 19880 USA.	bruce.d.korant@dupontpharma.com						Ala PJ, 1998, J BIOL CHEM, V273, P12325, DOI 10.1074/jbc.273.20.12325; Ala PJ, 1998, BIOCHEMISTRY-US, V37, P15042, DOI 10.1021/bi980386e; Ala PJ, 1997, BIOCHEMISTRY-US, V36, P1573, DOI 10.1021/bi962234u; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bing OHL, 1998, J MOL CELL CARDIOL, V30, P1257, DOI 10.1006/jmcc.1998.0723; Boeke J. D., 1997, P343; BOLLER K, 1993, VIROLOGY, V196, P349, DOI 10.1006/viro.1993.1487; BRONSON DL, 1979, JNCI-J NATL CANCER I, V63, P337; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; De Lucca G V, 1998, Pharm Biotechnol, V11, P257; ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628; Herbst H, 1998, APMIS, V106, P216, DOI 10.1111/j.1699-0463.1998.tb01338.x; Herbst H, 1996, AM J PATHOL, V149, P1727; Jadhav PK, 1997, J MED CHEM, V40, P181, DOI 10.1021/jm960586t; KAGEYAMA S, 1994, AIDS RES HUM RETROV, V10, P735, DOI 10.1089/aid.1994.10.735; KING RW, 1995, ANTIVIR RES, V28, P13, DOI 10.1016/0166-3542(95)00033-I; Klabe RM, 1998, BIOCHEMISTRY-US, V37, P8735, DOI 10.1021/bi972555l; Knerr I, 1999, PEDIATR RES, V46, P57, DOI 10.1203/00006450-199907000-00010; KURTH R, 1980, ONCONAVIRUS SYTHETIS, P835; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LAMBERT DM, 1992, ANTIMICROB AGENTS CH, V36, P982, DOI 10.1128/AAC.36.5.982; Larsson E, 1998, SCAND J IMMUNOL, V48, P329; LEIBMOSCH C, 1993, GENOMICS, V18, P261, DOI 10.1006/geno.1993.1464; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; LOWER R, 1993, VIROLOGY, V192, P501, DOI 10.1006/viro.1993.1066; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUELLERLANTZSCH N, 1993, AIDS RES HUM RETROV, V9, P343, DOI 10.1089/aid.1993.9.343; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Padow M, 2000, AIDS RES HUM RETROV, V16, P1973, DOI 10.1089/088922200750054701; Patience C, 1996, J VIROL, V70, P2654, DOI 10.1128/JVI.70.4.2654-2657.1996; RAYNER MM, 1994, ANTIMICROB AGENTS CH, V38, P1635, DOI 10.1128/AAC.38.7.1635; Rodgers JD, 1998, BIOORG MED CHEM LETT, V8, P715, DOI 10.1016/S0960-894X(98)00118-8; SAUTER M, 1995, J VIROL, V69, P414, DOI 10.1128/JVI.69.1.414-421.1995; Schommer S, 1996, J GEN VIROL, V77, P375, DOI 10.1099/0022-1317-77-2-375; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; Taruscio D, 1996, TERATOLOGY, V54, P108; Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V13, pS261; Tonjes RR, 1997, VIROLOGY, V233, P280, DOI 10.1006/viro.1997.8614; Tonjes RR, 1999, J VIROL, V73, P9187; Towler EM, 1998, BIOCHEMISTRY-US, V37, P17137, DOI 10.1021/bi9818927; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; WONDRAK EM, 1991, FEBS LETT, V280, P347, DOI 10.1016/0014-5793(91)80328-Z	48	11	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16674	16682		10.1074/jbc.M008763200	http://dx.doi.org/10.1074/jbc.M008763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278433	hybrid			2022-12-27	WOS:000168730400013
J	Manji, GA; Friesen, PD				Manji, GA; Friesen, PD			Apoptosis in motion - An apical, P35-insensitive caspase mediates programmed cell death in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT INTERFERENCE; BACULOVIRUS P35; SUPPRESSOR P35; INHIBITOR; PROTEASE; DRONC; REPLICATION; PROTEINS; CLEAVES; REAPER	Activation of caspases by proteolytic processing is a critical step during apoptosis in metazoans. Here we use high resolution time lapse microscopy to show a tight link between caspase activation and the morphological events delineating apoptosis in cultured SF21 cells from the moth Spodoptera frugiperda, a model insect system. The principal effector caspase, Sf-caspase-1, is proteolytically activated during SF21 apoptosis. To define the potential role of initiator caspases in vivo, we tested the effect of cell-permeable peptide inhibitors on pro-Sf-caspase-1 processing. Anti-caspase peptide analogues prevented apoptosis induced by diverse signals, including W radiation and baculovirus infection. IETD-fmk potently inhibited the initial processing of pro-Sf-caspase-1 at the junction (TETD-G) of the large and small subunit, a cleavage that is blocked by inhibitor of apoptosis Op-IAP but not pancaspase inhibitor P35, Because Sf-caspase-1 was inhibited poorly by IETD-CHO, our data indicated that the protease responsible for the first step in pro-Sf-caspase-1 activation is a distinct apical caspase, Thus, Sf-caspase-1 activation is mediated by a novel, P35-resistant caspase, These findings support the hypothesis that apoptosis in insects, like that in mammals, involves a cascade of caspase activations.	Univ Wisconsin, Inst Mol Virol, RM Bock Labs, Madison, WI 53706 USA; Univ Wisconsin, Grad Sch, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Friesen, PD (corresponding author), Univ Wisconsin, Inst Mol Virol, RM Bock Labs, 1525 Linden Dr, Madison, WI 53706 USA.	pfriesen@facstaff.wisc.edu			NIAID NIH HHS [AI25557, AI40482] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025557, R01AI040482, R56AI040482, R29AI025557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; FRIESEN PD, 2001, IN PRESS FIELDS VIRO; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; HERSHBERGER PA, 1992, J VIROL, V66, P5525, DOI 10.1128/JVI.66.9.5525-5533.1992; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Huang QH, 2000, P NATL ACAD SCI USA, V97, P1427, DOI 10.1073/pnas.97.4.1427; Jones G, 2000, J BIOL CHEM, V275, P22157, DOI 10.1074/jbc.M000369200; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; LaCount DJ, 1997, J VIROL, V71, P1530, DOI 10.1128/JVI.71.2.1530-1537.1997; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEE HH, 1978, J VIROL, V27, P754, DOI 10.1128/JVI.27.3.754-767.1978; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; MONSMA SA, 1995, J VIROL, V69, P2583, DOI 10.1128/JVI.69.4.2583-2595.1995; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nordstrom W, 2000, CELL DEATH DIFFER, V7, P1035, DOI 10.1038/sj.cdd.4400766; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049	53	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16704	16710		10.1074/jbc.M010179200	http://dx.doi.org/10.1074/jbc.M010179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278634	hybrid			2022-12-27	WOS:000168730400017
J	Skovronsky, DM; Lee, VMY; Pratico, D				Skovronsky, DM; Lee, VMY; Pratico, D			Amyloid precursor protein and amyloid beta peptide in human platelets - Role of cyclooxygenase and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; ARACHIDONIC-ACID; INHIBITION; ACTIVATION; ANGIOPATHY; EXPRESSION; INCREASES; MEMBRANE; PATHWAY	The main component of Alzheimer's disease (AD) senile plaques is amyloid-beta peptide (A beta), a proteolytic fragment of the amyloid precursor protein (APP), Platelets contain both APP and A beta and may contribute to the perivascular amyloid deposition seen in AD. However, no data are available concerning the biochemical mechanism(s) involved in their formation and release by these cells. We found that human platelets released APP and A beta following activation with collagen or arachidonic acid. Inhibition of platelet cyclooxygenase (COX) reduced APP but not A beta release following those stimuli. In contrast, activation of platelets by thrombin and calcium ionophore caused release of both APP and A beta in a COX-independent fashion. Ex vivo studies showed that, despite suppression of COX activity, administration of aspirin did not modify A beta or APP levels in serum or plasma, suggesting that this enzyme plays only a minor role in vivo, We examined the regulation of APP cleavage and release from activated platelets and found that cleavage requires protein kinase C (PKC) activity and is regulated by the intracellular second messengers phosphatidylinositol S-phosphate and Ca2+. Our data provide the first evidence that in human platelets COX is a minor component of APP secretion whereas PKC plays a major role in the secretory cleavage of APP. By contrast, A beta release may represent secretion of preformed peptide and is totally independent of both COX and PKC activity.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Pratico, D (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 812 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Pratico, Domenico/ABA-9590-2020		NIA NIH HHS [AG11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHEN M, 1995, BIOCHEM BIOPH RES CO, V213, P96, DOI 10.1006/bbrc.1995.2103; Chen M, 2000, BIOCHEM BIOPH RES CO, V273, P170, DOI 10.1006/bbrc.2000.2919; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; Emmerling MR, 1996, ANN NY ACAD SCI, V777, P310, DOI 10.1111/j.1749-6632.1996.tb34438.x; Henry A, 1998, BRIT J HAEMATOL, V103, P402, DOI 10.1046/j.1365-2141.1998.01005.x; KINOUCHI T, 1995, BIOCHEM BIOPH RES CO, V209, P841, DOI 10.1006/bbrc.1995.1576; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Lee RKK, 1999, J NEUROSCI, V19, P940; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; Li QX, 1998, LAB INVEST, V78, P461; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; Pasinetti GM, 1998, J NEUROSCI RES, V54, P1; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PRATICO D, 1992, J LAB CLIN MED, V119, P364; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1999, CIRCULATION, V99, P3118, DOI 10.1161/01.CIR.99.24.3118; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Smith CCT, 1997, NEUROSCI LETT, V235, P157, DOI 10.1016/S0304-3940(97)00738-6; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI N, 1994, AM J PATHOL, V145, P452; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Urmoneit B, 1997, LAB INVEST, V77, P157; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VIOLI F, 1990, ATHEROSCLEROSIS, V82, P247, DOI 10.1016/0021-9150(90)90046-L; Wagner SL, 1999, J CLIN INVEST, V104, P1329, DOI 10.1172/JCI8729; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966	34	89	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17036	17043		10.1074/jbc.M006285200	http://dx.doi.org/10.1074/jbc.M006285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278299	hybrid			2022-12-27	WOS:000168730400058
J	Xu, AM; Wang, Y; Xu, LY; Gilmour, RS				Xu, AM; Wang, Y; Xu, LY; Gilmour, RS			Protein kinase C alpha-mediated negative feedback regulation is responsible for the termination of insulin-like growth factor I-induced activation of nuclear phospholipase C beta 1 in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G(2)/M PHASE-TRANSITION; PHORBOL ESTER; PHOSPHOINOSITIDE HYDROLYSIS; C-BETA-3 PHOSPHORYLATION; EPITHELIAL-CELLS; SAOS-2 CELLS; 2 FORMS; IGF-I; TRANSLOCATION; CYCLE	Previous studies from several independent laboratories have demonstrated the existence of an autonomous phosphoinositide (PI) cycle within the nucleus, where it is involved in both cell proliferation and differentiation. Stimulation of Swiss 3T3 cells with insulin-like growth factor-I (IGF-I) has been shown to induce a transient and rapid increase in the activity of nuclear-localized phospholipase C (PLC) beta1, which in turn leads to the production of inositol trisphosphate and diacylglycerol in the nucleus. Nuclear diacylglycerol provides the driving force for the nuclear translocation of protein kinase C (PKC) alpha. Here, we report that treatment of Swiss 3T3 cells with Go6976, a selective inhibitor of PKC alpha, caused a sustained elevation of IGF-I-stimulated nuclear PLC activity. A time course study revealed an inverse relationship between nuclear PKC activity and the activity of nuclear PLC in IGF-I-treated cells. A time-dependent association between PKC alpha and PLC beta1 in the nucleus was also observed following IGF-I treatment. Two-dimensional phosphopeptide mapping and site-directed mutagenesis demonstrated that PKC promoted phosphorylation of PLC beta1 at serine 887 in the nucleus of IGF-I-treated cells. Overexpression of either a PLC beta1 mutant in which the PKC phosphorylation site Ser(887) was replaced by alanine, or a dominant-negative PKC alpha, resulted in a sustained activation of nuclear PLC following IGF-I stimulation. These results indicate that a negative feedback regulation of PLC beta1 by PKC a plays a critical role in the termination of the IGF-I-dependent signal that activates the nuclear PI cycle.	Univ Auckland, Sch Med, Liggins Inst, Auckland, New Zealand; Univ Auckland, Sch Biol Sci, Auckland, New Zealand	University of Auckland; University of Auckland	Gilmour, RS (corresponding author), Univ Auckland, Sch Med, Liggins Inst, Private Bag 92019, Auckland, New Zealand.		Xu, Aimin/D-3291-2013	Xu, Aimin/0000-0002-0668-033X; wang, yu/0000-0001-8697-2940				Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Cocco L, 1999, BBA-MOL CELL BIOL L, V1438, P295, DOI 10.1016/S1388-1981(99)00061-X; Cocco L, 1998, ADV ENZYME REGUL, V38, P351, DOI 10.1016/S0065-2571(97)00014-9; Cocco L, 1996, ADV ENZYME REGUL, V36, P101, DOI 10.1016/0065-2571(95)00007-0; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; Crouch MF, 1997, FASEB J, V11, P189, DOI 10.1096/fasebj.11.2.9039962; Divecha N, 2000, CELL MOL LIFE SCI, V57, P379, DOI 10.1007/PL00000700; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Exton JH, 1997, ADV EXP MED BIOL, V400, P3; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; Frey MR, 1997, J BIOL CHEM, V272, P9424; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; Hornia A, 1999, MOL CELL BIOL, V19, P7672; IIDA T, 1989, J ANTIBIOT, V42, P1475, DOI 10.7164/antibiotics.42.1475; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Litosch I, 1996, RECEPT SIGNAL TRANS, V6, P87; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; Manzoli L, 1997, CANCER RES, V57, P2137; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; Martelli AM, 1999, J CELL BIOCHEM, V72, P339, DOI 10.1002/(SICI)1097-4644(19990301)72:3<339::AID-JCB3>3.0.CO;2-L; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matteucci A, 1998, CANCER RES, V58, P5057; Neri LM, 1997, CELL SIGNAL, V9, P353, DOI 10.1016/S0898-6568(96)00178-7; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RYU SH, 1990, J BIOL CHEM, V265, P17941; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Woodruff ML, 1999, AM J PHYSIOL-LUNG C, V276, pL669, DOI 10.1152/ajplung.1999.276.4.L669; Xu AM, 1998, J VIROL, V72, P9865, DOI 10.1128/JVI.72.12.9865-9872.1998; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zini N, 1997, MICROSC RES TECHNIQ, V36, P172, DOI 10.1002/(SICI)1097-0029(19970201)36:3<172::AID-JEMT5>3.0.CO;2-R; ZINI N, 1994, EUR J CELL BIOL, V65, P206; ZINI N, 1995, EUR J CELL BIOL, V68, P25	58	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14980	14986		10.1074/jbc.M009144200	http://dx.doi.org/10.1074/jbc.M009144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278470	hybrid			2022-12-27	WOS:000168528800062
J	Kitaura, Y; Matsumoto, S; Satoh, H; Hitomi, K; Maki, M				Kitaura, Y; Matsumoto, S; Satoh, H; Hitomi, K; Maki, M			Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT INTERACTION; CRYSTAL-STRUCTURE; BINDING PROTEIN; GENE ALG-3; DOMAIN-VI; CALPAIN; APOPTOSIS; GRANCALCIN; ACTIVATION; NEUTROPHILS	Peflin, a newly identified 30-kDa Ca2+-binding protein, belongs to the penta-EF-hand (PEF) protein family, which includes the calpain small subunit, sorcin, grancalcin, and ALG-2 (apoptosis-linked gene 2). We prepared a monoclonal antibody against human peflin, The antibody immunoprecipitated a 22-kDa protein as well as the 30-kDa protein from the lysate of Jurkat cells. Western blotting of the immunoprecipitates revealed that the 22-kDa protein corresponds to ALG-2, This was confirmed by Western blotting of the immunoprecipitates of epitope-tagged peflin or ALG-2 whose cDNA expression constructs were transfected to human embryonic kidney (HEK) 293 cells. Gel filtration of the cytosolic fraction of Jurkat cells revealed co-elution of peflin and ALG-S in fractions eluting earlier than recombinant ALG-S, further supporting the notion of heterodimerization of the two PEF proteins. Surprisingly, peflin dissociated from ALG-S in the presence of Ca2+ Peflin and ALG-S co-localized in the cytoplasm, but ALG-2 was also detected in the nuclei as revealed by immunofluorescent staining and subcellular fractionation, Peflin was recovered in the cytosolic fraction in the absence of Ca2+ but in the membrane/cytoskeletal fraction in the presence of Ca2+. These results suggest that peflin has features common to those of other PEF proteins (dimerization and translocation to membranes) and may modulate the function of ALG-2 in Ca2+ signaling.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Lab Mol & Cellular Regulat,Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Maki, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Lab Mol & Cellular Regulat,Chikusa Ku, Nagoya, Aichi 4648601, Japan.		Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				Blanchard H, 1996, PROTEIN SCI, V5, P535; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BOYHAN A, 1992, J BIOL CHEM, V267, P2928; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Goll DE, 1990, INTRACELLULAR CALCIU, P3; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Krebs J, 2000, BBA-MOL CELL RES, V1498, P153, DOI 10.1016/S0167-4889(00)00091-4; Lacana E, 1997, J IMMUNOL, V158, P5129; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Maki M, 1997, BIOCHEM J, V328, P718; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Verzili D, 2000, FEBS LETT, V471, P197, DOI 10.1016/S0014-5793(00)01396-X; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348	26	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14053	14058		10.1074/jbc.M008649200	http://dx.doi.org/10.1074/jbc.M008649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278427	hybrid			2022-12-27	WOS:000168356600075
J	Montesano-Roditis, L; Glitz, DG; Traut, RR; Stewart, PL				Montesano-Roditis, L; Glitz, DG; Traut, RR; Stewart, PL			Cryo-electron microscopic localization of protein L7/L12 within the Escherichia coli 70 S ribosome by difference mapping and Nanogold labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; ELONGATION-FACTOR TU; TRANSFER-RNA BINDING; C-TERMINAL DOMAIN; ANGSTROM-RESOLUTION; CRYOELECTRON MICROSCOPY; CROSS-LINKING; 3-DIMENSIONAL RECONSTRUCTION; MONOCLONAL-ANTIBODIES; GTP HYDROLYSIS	The Escherichia coli ribosomal protein L7/L12 is central to the translocation step of translation, and it is known to be flexible under some conditions. The assignment of electron density to L7/L12 was not possible in the recent 2.4 Angstrom resolution x-ray crystallographic structure (Ban, N,, Nissen, P,, Hansen, J,, Moore, P, B,, and Steitz, T, A. (2000) Science 289, 905-920), We have localized the two dimers of L7/L12 within the structure of the 70 S ribosome using two reconstitution approaches together with cryo-electron microscopy and single particle reconstruction. First, the structures were determined for ribosomal cores from which protein L7/L12 had been removed by treatment with NH4Cl and ethanol and for reconstituted ribosomes in which purified L7/L12 had been restored to core particles. Difference mapping revealed that the reconstituted ribosomes had additional density within the L7/L12 shoulder next to protein L11. Second, ribosomes were reconstituted using an L7/L12 variant in which a single cysteine at position 89 in the C-terminal domain was modified with Nanogold (Nanoprobes, Inc.), a 14 Angstrom gold derivative. The reconstruction from cryo-electron microscopy images and difference mapping placed the gold at four interfacial positions. The finding of multiple sites for the C-terminal domain of L7/L12 suggests that the conformation of this protein may change during the steps of elongation and translocation.	Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 96517 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Davis	Stewart, PL (corresponding author), Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, A-324 CIMI,Box 951770, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017924, R55GM051195, R01GM051195, R37GM017924] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 17924, GM51195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1999, INT J BIOCHEM CELL B, V31, P243, DOI 10.1016/S1357-2725(98)00149-6; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Cundliffe E., 1981, MOL BASIS ANTIBIOTIC, V2nd, P402; CYRKLAFF M, 1990, J ELECTRON MICR TECH, V16, P351, DOI 10.1002/jemt.1060160407; Dey D, 1995, BIOCHIMIE, V77, P925, DOI 10.1016/0300-9084(95)80003-4; Dey D, 1998, J BIOL CHEM, V273, P1670, DOI 10.1074/jbc.273.3.1670; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAINFELD JF, 1992, J HISTOCHEM CYTOCHEM, V40, P177, DOI 10.1177/40.2.1552162; HAMEL E, 1972, J BIOL CHEM, V247, P805; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16672, DOI 10.1021/bi9615001; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16680, DOI 10.1021/bi9624189; Harms J, 1999, STRUCTURE, V7, P931, DOI 10.1016/S0969-2126(99)80120-8; Hoffman DW, 1996, J MOL BIOL, V264, P1058, DOI 10.1006/jmbi.1996.0696; KERLAVAGE AR, 1983, J BIOL CHEM, V258, P6313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; Louie DF, 1996, J BIOL CHEM, V271, P28189, DOI 10.1074/jbc.271.45.28189; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Matadeen R, 1999, STRUCTURE, V7, P1575, DOI 10.1016/S0969-2126(00)88348-3; Moore PB, 1998, ANNU REV BIOPH BIOM, V27, P35, DOI 10.1146/annurev.biophys.27.1.35; NAG B, 1991, J BIOL CHEM, V266, P22129; NOMURA M, 1990, RIBOSOME, P3; OLSON HM, 1986, J BIOL CHEM, V261, P6924; OLSON HM, 1988, J BIOL CHEM, V263, P15196; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Shah AK, 1998, J STRUCT BIOL, V123, P17, DOI 10.1006/jsbi.1998.4011; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; STOFFLERMEILICKE M, 1983, P NATL ACAD SCI-BIOL, V80, P6780, DOI 10.1073/pnas.80.22.6780; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; TRAUT RR, 1993, TRANSLATIONAL APPARATUS, P521; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3; ZANTEMA A, 1982, BIOCHEMISTRY-US, V21, P3077, DOI 10.1021/bi00256a007; ZECHERLE GN, 1992, J BIOL CHEM, V267, P5889	60	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14117	14123		10.1074/jbc.M008430200	http://dx.doi.org/10.1074/jbc.M008430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278411	hybrid			2022-12-27	WOS:000168356600083
J	Planz, O; Dumrese, T; Hulpusch, S; Schirle, M; Stevanovic, S; Stitz, L				Planz, O; Dumrese, T; Hulpusch, S; Schirle, M; Stevanovic, S; Stitz, L			A naturally processed rat major histocompatibility complex class I-associated viral peptide as target structure of Borna disease virus-specific CD8(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; NEWLY SYNTHESIZED PROTEINS; PSYCHIATRIC-DISORDERS; REACTIVE ANTIBODIES; ANTIGEN; MOLECULES; ENCEPHALITIS; TRANSPORTER; MOTIFS; IDENTIFICATION	The first naturally processed peptide synthesized by a virus and recognized by classical CD8(+) T cells in association with the RT1.A(1) major histocompatibility complex class I molecule of the Lewis rat is reported. Borna disease virus-specific CD8(+) T cells recognize syngeneic target cells pulsed with peptides extracted from Borna disease virus-infected cells. The predicted peptide sequence ASYAQMTTY from the viral p40 protein coeluted with the cytotoxic T-lymphocyte-reactive fraction was identified among natural ligands by tandem mass spectrometry. Numerous naturally processed peptides derived from intracellular bacteria, viruses, or tumors and recognized by CD8(+) T cells of man and mice are known, leading to a better understanding of cellular immune mechanisms against pathogens in these two species. In contrast, for the rat little information exists with regard to the function and role of CD8(+) T cells as part of their cellular immune defense system. This first naturally processed viral epitope in the rat contributes to the understanding of the rat cellular immune response and might trigger the identification of more cytotoxic T-lymphocyte epitopes in this animal.	Bundesforschungsanstalt Viruskrankheiten Tiere, Inst Immunol, D-72076 Tubingen, Germany; Interfak Inst Zellbiol, Immunol Abt, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Planz, O (corresponding author), Bundesforschungsanstalt Viruskrankheiten Tiere, Inst Immunol, Paul Ehrlich Str 28, D-72076 Tubingen, Germany.							AMSTERDAM JD, 1985, ARCH GEN PSYCHIAT, V42, P1093; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; BRIESE T, 1992, P NATL ACAD SCI USA, V89, P11486, DOI 10.1073/pnas.89.23.11486; DESCHL U, 1990, ACTA NEUROPATHOL, V81, P41, DOI 10.1007/BF00662636; DUCHALA CS, 1989, J GEN VIROL, V70, P3507, DOI 10.1099/0022-1317-70-12-3507; FU ZF, 1993, J AFFECT DISORDERS, V27, P61, DOI 10.1016/0165-0327(93)90098-5; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HAAS B, 1986, J GEN VIROL, V67, P235, DOI 10.1099/0022-1317-67-2-235; HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; IRANI DN, 1991, J IMMUNOL METHODS, V139, P223, DOI 10.1016/0022-1759(91)90192-I; JAMESON SC, 1992, J EXP MED, V175, P1749, DOI 10.1084/jem.175.6.1749; Joly E, 1996, J IMMUNOL, V157, P1551; Joly E, 1998, IMMUNOL TODAY, V19, P580, DOI 10.1016/S0167-5699(98)01348-6; Kishi M, 1996, J VIROL, V70, P635, DOI 10.1128/JVI.70.1.635-640.1996; Leong LYW, 1999, J IMMUNOL, V162, P743; LUDWIG H, 1977, MED MICROBIOL IMMUN, V163, P215, DOI 10.1007/BF02125505; NARAYAN O, 1983, J INFECT DIS, V148, P305, DOI 10.1093/infdis/148.2.305; Noske K, 1998, J VIROL, V72, P4387; Planz O, 1998, LANCET, V352, P623, DOI 10.1016/S0140-6736(05)79577-5; Planz O, 1999, J VIROL, V73, P1715, DOI 10.1128/JVI.73.2.1715-1718.1999; PLANZ O, 1993, J EXP MED, V178, P163, DOI 10.1084/jem.178.1.163; PLANZ O, 1995, J VIROL, V69, P896, DOI 10.1128/JVI.69.2.896-903.1995; POWIS SJ, 1993, TRANSPLANT P, V25, P2752; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; RADA C, 1990, P NATL ACAD SCI USA, V87, P2167, DOI 10.1073/pnas.87.6.2167; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Reizis B, 1997, IMMUNOGENETICS, V45, P278, DOI 10.1007/s002510050204; ROTT R, 1985, SCIENCE, V228, P755, DOI 10.1126/science.3922055; ROTT R, 1995, CURR TOP MICROBIOL, V190, P17; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Schirle M, 2000, EUR J IMMUNOL, V30, P2216, DOI 10.1002/1521-4141(2000)30:18<2216::AID-IMMU2216>3.3.CO;2-F; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; Stevanovic S, 1999, SEMIN IMMUNOL, V11, P375, DOI 10.1006/smim.1999.0195; Stevens J, 1998, EUR J IMMUNOL, V28, P1272, DOI 10.1002/(SICI)1521-4141(199804)28:04<1272::AID-IMMU1272>3.0.CO;2-E; Stevens J, 2000, J BIOL CHEM, V275, P29217, DOI 10.1074/jbc.M002565200; Stitz L, 1993, Arch Virol Suppl, V7, P135; STITZ L, 1991, J IMMUNOL, V147, P3581; STITZ L, 1999, ENCY VIROLOGY, P167; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; Waltrip RW, 1997, SCHIZOPHR RES, V23, P253, DOI 10.1016/S0920-9964(96)00114-4; Yamaguchi K, 1999, CLIN DIAGN LAB IMMUN, V6, P696, DOI 10.1128/CDLI.6.5.696-700.1999; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	49	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13689	13694		10.1074/jbc.M009889200	http://dx.doi.org/10.1074/jbc.M009889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278578	hybrid			2022-12-27	WOS:000168356600027
J	Kulms, D; Schwarz, T				Kulms, D; Schwarz, T			Ultraviolet radiation inhibits interleukin-2-induced tyrosine phosphorylation and the activation of STAT5 in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR BETA-CHAIN; MICE LACKING JAK3; IFN-GAMMA; CYTOPLASMIC DOMAINS; SEVERE PSORIASIS; GENE-EXPRESSION; SKIN-CANCER; DNA-DAMAGE; CELL-CYCLE; LIGHT	UV radiation was recently found to hinder interferon-gamma from exerting its biological effects by inhibiting the phosphorylation of signal transducer and activator of transcription (STAT)-1, a crucial signal transducing protein in the interferon-gamma pathway. Because this activity by UV may contribute to its immunosuppressive properties we studied whether this is specific for STAT1 or whether UV also affects other members of the STAT family. STATE is crucially involved in signaling of interleukin (IL)-2, enabling up-regulation of the IL-2 receptor cu chain, an essential component of the high affinity IL-2 receptor. Exposure of the murine T cell line CTLL to IL-2 caused tyrosine phosphorylation of STATE that was remarkably reduced when cells were exposed to W. Accordingly, STATE binding activity was significantly impaired in UV-exposed cells. m contrast, IL-2-induced tyrosine phosphorylation of the kinases Jak1 and Jak3 located upstream of STATE was not affected by UV. The effect of W on STATE phosphorylation was antagonized by orthovanadate, implying involvement of a phosphatase in this process. Accordingly, up-regulation of the IL-2 receptor alpha chain was reduced in cells that were treated with IL-2 plus W, Because STATE-mediated IL-2 effects are vital for normal immune functions, inhibition of STATE signaling by W may contribute to its well known immunosuppressive properties.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany	University of Munster	Schwarz, T (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Von Esmarchstr 58, D-48149 Munster, Germany.		Kulms, Dagmar/H-1653-2014					Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; Aragane Y, 1997, J IMMUNOL, V158, P5393; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Bianchi M, 2000, P NATL ACAD SCI USA, V97, P9573, DOI 10.1073/pnas.160099797; Bright JJ, 1997, J IMMUNOL, V159, P175; Butt A, 1997, LANCET, V349, P179, DOI 10.1016/S0140-6736(05)60981-6; CHAPMAN RS, 1995, PHOTOCHEM PHOTOBIOL, V61, P223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGRUIJL FR, 1993, CANCER RES, V53, P53; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fujihara M, 1996, BLOOD, V87, P2386, DOI 10.1182/blood.V87.6.2386.bloodjournal8762386; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; LEONARD WJ, 1999, FUNDAMENTAL IMMUNOLO, P293; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Luger TA, 1995, PHOTOIMMUNOLOGY, P55; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Mrowietz U, 2000, ARCH DERMATOL, V136, P675, DOI 10.1001/archderm.136.5.675; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Owen CM, 2000, CLIN EXP DERMATOL, V25, P195, DOI 10.1046/j.1365-2230.2000.00612.x; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; RUSCETTI FW, 1990, IMMUNOPHYSIOLOGY, P46; Scholzen T, 1998, J INVEST DERMATOL, V111, P50, DOI 10.1046/j.1523-1747.1998.00229.x; Schwarz T, 1999, ALLERGY, V54, P1252, DOI 10.1034/j.1398-9995.1999.00105.x; SCHWARZ T, 1996, FUNDAMENTALS BASES P, P99; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; STADLER BM, 1981, J IMMUNOL, V127, P1936; STREILEIN JW, 1994, IMMUNOL TODAY, V15, P174, DOI 10.1016/0167-5699(94)90315-8; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; ULLRICH SE, 2000, J DERMATOL SCI S, V3, P10; URBANSKI A, 1990, J INVEST DERMATOL, V94, P808, DOI 10.1111/1523-1747.ep12874666; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Young AR, 1998, J INVEST DERMATOL, V111, P982, DOI 10.1046/j.1523-1747.1998.00436.x; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599	54	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12849	12855		10.1074/jbc.M006372200	http://dx.doi.org/10.1074/jbc.M006372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278301	hybrid			2022-12-27	WOS:000168198600055
J	Lu, ML; Schneider, MC; Zheng, YX; Zhang, XB; Richie, JP				Lu, ML; Schneider, MC; Zheng, YX; Zhang, XB; Richie, JP			Caveolin-1 interacts with androgen receptor - A positive modulator of androgen receptor mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MOUSE PROSTATE-CANCER; HUMAN BREAST-CANCER; MAP KINASE CASCADE; HEAT-SHOCK-PROTEIN; TYROSINE KINASE; PLASMA-MEMBRANE; IN-VIVO; NUCLEAR TRANSLOCATION; BINDING PROTEIN	Androgen receptor (AR) belongs to the steroid hormone nuclear receptor superfamily. It functions as an androgen dependent transcriptional factor that regulates genes for cell proliferation and differentiation. Caveolin is a principal component of caveolae membranes serving as a scaffold protein of many signal transduction pathways. Recent results correlate caveolin-1 expression with androgen sensitivity in murine prostate cancer. Furthermore, immunohistochemical staining of patient specimens suggests that caveolin expression may be an independent predictor of progression of prostate cancer. In this study, we investigate the potential interactions between AR signaling and caveolin-1 and demonstrate that overexpression of caveolin-1 potentiates ligand-dependent AR activation. Conversely, down-regulation of caveolin-1 expression by a caveolin-1 antisense expression construct can downregulate ligand-dependent AR activation. Association between these two molecules is also demonstrated by co-localization of AR with caveolin-rich, low-density membrane fractions isolated by an equilibrium sucrose gradient centrifugation method. Co-immunoprecipitation and glutathione S-transferase fusion protein pull-down experiments demonstrate that interaction be tween AR and caveolin-1 is an androgen-dependent process, offering further evidence for a physiological role of this interaction. Using a mammalian two-hybrid assay system, we determine that the NH2 terminus region of caveolin-1 is responsible for the interaction with both the NH2-terminal domain and the ligand-binding domain of AR.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Div Urol Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lu, ML (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Div Urol Surg, LMRC-BLI143,221 Longwood Ave, Boston, MA 02115 USA.	mlu@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054713] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM54713] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LU M, UNPUB; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; Michel JB, 1997, FEBS LETT, V405, P356, DOI 10.1016/S0014-5793(97)00222-6; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; THOMPSON TC, 1995, ONCOGENE, V10, P869; THOMPSON TC, 1991, CANCER SURV, V11, P55; Thompson TC, 1998, CANCER METAST REV, V17, P439, DOI 10.1023/A:1006110326366; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	56	206	213	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13442	13451		10.1074/jbc.M006598200	http://dx.doi.org/10.1074/jbc.M006598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278309	hybrid			2022-12-27	WOS:000168198600133
J	Garcia, F; Kierbel, A; Larocca, MC; Gradilone, SA; Splinter, P; LaRusso, NF; Marinelli, RA				Garcia, F; Kierbel, A; Larocca, MC; Gradilone, SA; Splinter, P; LaRusso, NF; Marinelli, RA			The water channel aquaporin-8 is mainly intracellular in rat hepatocytes, and its plasma membrane insertion is stimulated by cyclic AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT WATER; APICAL DOMAIN; VESICLE; CLONING; LIVER; CHOLANGIOCYTES; TRANSLOCATION; MECHANISMS; EXPRESSION; GLUCAGON	We previously found that water transport across hepatocyte plasma membranes occurs mainly via a nonchannel mediated pathway. Recently, it has been reported that mRNA for the water channel, aquaporin-8 (AQP8), is present in hepatocytes. To further explore this issue, we studied protein expression, subcellular localization, and regulation of AQP8 in rat hepatocytes. By subcellular fractionation and immunoblot analysis, we detected an N-glycosylated band of similar to 34 kDa corresponding to AQP8 in hepatocyte plasma and intracellular microsomal membranes. Confocal immunofluorescence microscopy for AQP8 in cultured hepatocytes showed a predominant intracellular vesicular localization. Dibutyryl cAMP (Bt(2)cAMP) stimulated the redistribution of AQP8 to plasma membranes. Bt,cAMP also significantly increased hepatocyte membrane water permeability, an effect that was prevented by the water channel blocker dimethyl sulfoxide. The microtubule blocker colchicine but not its inactive analog lumicolchicine inhibited the Bt(2)cAMP effect on both AQP8 redistribution to cell surface and hepatocyte membrane water permeability. Our data suggest that in rat hepatocytes AQP8 is localized largely in intracellular vesicles and can be redistributed to plasma membranes via a microtubule-depending, cAMP-stimulated mechanism. These studies also suggest that aquaporins contribute to water transport in cAMP-stimulated hepatocytes, a process that could be relevant to regulated hepatocyte bile secretion.	Univ Nacl Rosario, CONICET, Fac Ciencias Bioquim & Farmaceut, Inst Fisiol Expt, RA-2000 Rosario, Santa Fe, Argentina; Mayo Clin & Mayo Fdn, Mayo Med Sch, Ctr Basic Res Digest Dis, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Ctr Basic Res Digest Dis, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Mayo Clinic; Mayo Clinic	Marinelli, RA (corresponding author), Univ Nacl Rosario, CONICET, Fac Ciencias Bioquim & Farmaceut, Inst Fisiol Expt, Suipacha 570, RA-2000 Rosario, Santa Fe, Argentina.	rmarinel@fbioyf.unr.edu.ar	Gradilone, Sergio/AAJ-7214-2020	Gradilone, Sergio/0000-0002-1753-3634				BENEDETTI A, 1994, P NATL ACAD SCI USA, V91, P792, DOI 10.1073/pnas.91.2.792; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; EDMONDSON JW, 1980, BIOCHEM BIOPH RES CO, V96, P61, DOI 10.1016/0006-291X(80)91181-X; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; Koyama Y, 1997, J BIOL CHEM, V272, P30329, DOI 10.1074/jbc.272.48.30329; LENZEN R, 1990, AM J PHYSIOL, V259, pG736, DOI 10.1152/ajpgi.1990.259.5.G736; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA TH, 1993, J BIOL CHEM, V268, P22756; Ma TH, 1997, BIOCHEM BIOPH RES CO, V240, P324, DOI 10.1006/bbrc.1997.7664; Marinelli RA, 2000, HEPATOLOGY, V31, P1313, DOI 10.1053/jhep.2000.7986; Marinelli RA, 1997, J BIOL CHEM, V272, P12984, DOI 10.1074/jbc.272.20.12984; Marinelli RA, 1999, AM J PHYSIOL-GASTR L, V276, pG280, DOI 10.1152/ajpgi.1999.276.1.G280; Meier PJ, 2000, NEWS PHYSIOL SCI, V15, P89; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; RICHTERLANDSBERG C, 1985, J NEUROCHEM, V45, P1218, DOI 10.1111/j.1471-4159.1985.tb05545.x; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; Roelofsen H, 1998, J CELL SCI, V111, P1137; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Soroka CJ, 1999, J BIOL CHEM, V274, P26416, DOI 10.1074/jbc.274.37.26416; Tietz PS, 1999, HEPATOLOGY, V30, p424A; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; VANHOEK AN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P203, DOI 10.1016/0005-2736(90)90296-Z; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	29	161	166	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12147	12152		10.1074/jbc.M009403200	http://dx.doi.org/10.1074/jbc.M009403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278499	hybrid			2022-12-27	WOS:000168081800096
J	Stoletov, KV; Ratcliffe, KE; Spring, SC; Terman, BI				Stoletov, KV; Ratcliffe, KE; Spring, SC; Terman, BI			NCK and PAK participate in the signaling pathway by which vascular endothelial growth factor stimulates the assembly of focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN NCK; TYROSINE PHOSPHORYLATION; P21-ACTIVATED KINASE; PERMEABILITY FACTOR; ACTIN ORGANIZATION; ACTIVATING PROTEIN; IN-VIVO; RECEPTOR; EXPRESSION; KDR	Vascular endothelial growth factor (VEGF)-induced endothelial cell migration is a key step in the angiogenic response and is mediated, in part, by an accelerated rate of focal adhesion complex assembly and disassembly, We investigated the signaling pathway by which VEGF regulates focal adhesion complex assembly by examining the signaling proteins involved. VEGF stimulated the tyrosine phosphorylation of the SH2 domain containing signaling proteins NCK and CRK in human umbilical vein endothelial cells. The signaling pathways that couple the kinase insert domain-containing receptor to NCK and CRK is most likely mediated by another cellular protein, as NCK and CRK were tyrosine phosphorylated in response to VECF in cells expressing receptors mutated at each of several candidate SH2 domain-interacting cytosolic tyrosines, In the absence of VEGF treatment, NCK (but not CRK) associated with the p21 GTPase-activated kinase PAK. PAK catalytic activity was augmented after VEGF treatment; an association of PAK with 60- and 90-kDa tyrosine-phosphorylated proteins accompanied this. VEGF stimulated the recruitment of PAK to focal adhesions, and FAK immunoprecipitated with both NCK and PAK in VEGF-treated (but not untreated) human umbilical vein endo thelial cells. Inhibition of NCK protein expression using antisense oligonucleotides led to the inhibition of both VEGF-induced focal adhesion assembly and VEGF-induced cell migration, demonstrating a necessary role of NCK in these cellular responses.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Cardiol, 1300 Morris Pk Ave,Forchheimer 715, Bronx, NY 10461 USA.	terman@aecom.yu.edu		Stoletov, Konstantin/0000-0002-7384-2917	NCI NIH HHS [R01 CA86289-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Esser S, 1998, J CELL SCI, V111, P1853; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203; ILLE D, 1995, NATURE, V377, P539; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Majesky MW, 1996, CIRCULATION, V94, P3062, DOI 10.1161/01.CIR.94.12.3062; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEER J, 1995, LAB INVEST, V72, P638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SONYANG Z, 1993, CELL, V72, P767; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; TAO Q, 2001, J BIOL CHEM; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Yoshiji H, 1996, CANCER RES, V56, P2013; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; ZVELEBIL MJJM, 1995, PROTEIN ENG, V8, P527, DOI 10.1093/protein/8.6.527	69	46	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22748	22755		10.1074/jbc.M009720200	http://dx.doi.org/10.1074/jbc.M009720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11278553	hybrid			2022-12-27	WOS:000169412700103
J	Ulloa, L; Creemers, JWM; Roy, S; Liu, SH; Mason, J; Tabibzadeh, S				Ulloa, L; Creemers, JWM; Roy, S; Liu, SH; Mason, J; Tabibzadeh, S			Lefty proteins exhibit unique processing and activate the MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; BONE MORPHOGENETIC PROTEINS; PROPROTEIN CONVERTASE; MESODERM INDUCTION; KEX2-LIKE ENDOPROTEASE; NODAL EXPRESSION; EPITHELIAL-CELLS; BETA SUPERFAMILY; AXIS DEVELOPMENT; SITUS-INVERSUS	Lefty polypeptides, novel members of the transforming growth factor-beta (TGF-beta) superfamily, are involved in the formation of embryonic lateral patterning. Members of the TGF-beta superfamily require processing fear their activation, suggesting cleavage to be an essential step for lefty activation. Transfection of different cell lines with lefty resulted in expression of a 42-kDa protein, which was proteolytically processed to release two polypeptides of 34 and 28 kDa, Since members of the proprotein convertase (PC) family cleave different TGF-beta factors and are involved in the establishment of embryonic laterality, we studied their role in lefty processing. Cotransfection analysis showed that PC5A processed the lefty precursor to the 34-kDa form in vivo, whereas furin, PACE4, PC5B, and PC7 had a limited activity. None of these PCs showed activity in the processing of the lefty polypeptide to the 28-kDa lefty form. The mutation of the consensus sequences for PC cleavage in the lefty protein allowed the lefty cleavage sites to be identified. Mutations of the sequence RGKR to (G) under bar GK (G) under bar (amino acids 74-77) and of RHGR to GHGR (amino acids 132-135) prevented the proteolytic processing of the lefty precursor to the 34- and 28-kDa forms, respectively. To identify the biologically active form of lefty, we studied the effect of lefty treatment on pluripotent P19 cells. Lefty did not induce Smad2 or Smad5 phosphorylation, Smad2/Smad4 heterodimerization, or nuclear translocation of Smad2 or Smad4, but activated the MAPK pathway in a time- and dose-dependent fashion, Further analysis showed the 28-kDa (but not the 34-kDa) polypeptide to induce MAPK activity, Surprisingly, the 42-kDa lefty protein was also capable of inducing MAPK activity, indicating that the lefty precursor is biologically active. The data support a molecular model of processing as a mechanism for regulation of lefty signaling.	Biomed Res Ctr, Dept Pathol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Hlth Syst, Dept Pathol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Hlth Syst, Gene Therapy & Viral Vector Lab, Manhasset, NY 11030 USA; Univ Louvain, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Northwell Health; Northwell Health	Tabibzadeh, S (corresponding author), Biomed Res Ctr, Dept Pathol, 350 Community Dr, Manhasset, NY 11030 USA.		Ulloa, Luis/AAE-8751-2019	Ulloa, Luis/0000-0002-7702-7549	NCI NIH HHS [CA46866] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046866, R01CA046866] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu T, 1999, DEV DYNAM, V216, P481, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<481::AID-DVDY16>3.0.CO;2-M; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASSING CH, 1994, J BIOL CHEM, V269, P14861; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; Cheng AMS, 2000, DEVELOPMENT, V127, P1049; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Constam DB, 2000, DEVELOPMENT, V127, P245; Constam DB, 2000, GENE DEV, V14, P1146; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HOSAKA M, 1991, J BIOL CHEM, V266, P12120; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Johansson N, 2000, J CELL SCI, V113, P227; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kosaki K, 1999, AM J HUM GENET, V64, P712, DOI 10.1086/302289; Kothapalli R, 1997, J CLIN INVEST, V99, P2342, DOI 10.1172/JCI119415; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Rancourt SL, 1997, DEV GENET, V21, P75, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;75::AID-DVG9&gt;3.0.CO;2-5; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Supp DM, 2000, TRENDS CELL BIOL, V10, P41, DOI 10.1016/S0962-8924(99)01701-8; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Tabibzadeh S, 2000, J CLIN ENDOCR METAB, V85, P2526, DOI 10.1210/jc.85.7.2526; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Tanegashima K, 2000, MECH DEVELOP, V99, P3, DOI 10.1016/S0925-4773(00)00465-2; Thisse B, 2000, NATURE, V403, P425, DOI 10.1038/35000200; Thisse C, 1999, DEVELOPMENT, V126, P229; Tsuji A, 1999, J BIOCHEM, V126, P591, DOI 10.1093/oxfordjournals.jbchem.a022491; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; ULMER JB, 1987, J BIOL CHEM, V262, P1748; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Varlet I, 1997, COLD SPRING HARB SYM, V62, P105; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; Visser JA, 1998, MOL CELL ENDOCRINOL, V146, P7, DOI 10.1016/S0303-7207(98)00198-1; Vogan KJ, 1999, NATURE, V397, P295, DOI 10.1038/16796; Wakefield L M, 1991, Growth Factors, V5, P243, DOI 10.3109/08977199109000288; Yonekura A, 1999, ENDOCR J, V46, P545, DOI 10.1507/endocrj.46.545; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zheng M, 1997, ANN NY ACAD SCI, V814, P108, DOI 10.1111/j.1749-6632.1997.tb46150.x; Zheng M, 1997, DEV BIOL, V181, P268, DOI 10.1006/dbio.1996.8402	72	57	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21387	21396		10.1074/jbc.M006933200	http://dx.doi.org/10.1074/jbc.M006933200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278322	hybrid			2022-12-27	WOS:000169297900080
J	Gonzalo, P; Lavergne, JP; Reboud, JP				Gonzalo, P; Lavergne, JP; Reboud, JP			Pivotal role of the P1N-terminal domain in the assembly of the mammalian ribosomal stalk and in the proteosynthetic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; PROTEIN-SEQUENCE ANALYSIS; ELONGATION-FACTOR TU; SACCHAROMYCES-CEREVISIAE; P-PROTEINS; ANGSTROM-RESOLUTION; RAT-LIVER; ACIDIC PHOSPHOPROTEINS; 70S RIBOSOME; L7/L12	In the 60 S ribosomal subunit, the lateral stalk made of the P-proteins plays a major role in translation, It contains PO, an insoluble protein anchoring P1 and P2 to the ribosome, Here, rat recombinant PO was overproduced in inclusion bodies and solubilized in complex with the other P-proteins. This method of solubilization appeared suitable to show protein complexes and revealed that P1, but not P2, interacted with PO. Furthermore, the use of truncated mutants of PI and P2 indicated that residues 1-68 in P1 connected PO to residues 1-65 in P2. Additional experiments resulted in the conclusion that P1 and P2 bound one another, either connected with PO or free, as found in the cytoplasm. Accordingly, a model of association for the P-proteins in the stalk is proposed. Recombinant PO in complex with phosphorylated P2 and either PI or its (1-63) domain efficiently restored the proteosynthetic activity of 60 S subunits deprived of native P-proteins. Therefore, refolded PO was functional and residues 1-63 only in P1 were essential, Furthermore, our results emphasize that the refolding principle used here is worth considering for solubilizing other insoluble proteins.	Inst Biol & Chim Prot, Lab Biochim Med, CNRS, UMR 5086, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Gonzalo, P (corresponding author), Inst Biol & Chim Prot, Lab Biochim Med, CNRS, UMR 5086, 7 Passage Vercors, F-69367 Lyon 07, France.							Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Ballesta JPG, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P115; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Bargis-Surgey P, 1999, EUR J BIOCHEM, V262, P606, DOI 10.1046/j.1432-1327.1999.00434.x; BERMEJO B, 1995, BBA-GENE STRUCT EXPR, V1263, P45, DOI 10.1016/0167-4781(95)00081-Q; Blanchet C, 2000, BIOINFORMATICS, V16, P286, DOI 10.1093/bioinformatics/16.3.286; BUSHUEV VN, 1989, J BIOL CHEM, V264, P4498; Chaffotte AF, 1997, BIOCHEMISTRY-US, V36, P16040, DOI 10.1021/bi9708500; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CONQUET F, 1987, EUR J BIOCHEM, V163, P15, DOI 10.1111/j.1432-1033.1987.tb10730.x; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; Dey D, 1998, J BIOL CHEM, V273, P1670, DOI 10.1074/jbc.273.3.1670; Fabien N, 1999, J AUTOIMMUN, V13, P103, DOI 10.1006/jaut.1999.0291; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Griaznova O, 2000, BIOCHEMISTRY-US, V39, P4075, DOI 10.1021/bi992621e; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16680, DOI 10.1021/bi9624189; Hamman BD, 1996, J BIOL CHEM, V271, P7568, DOI 10.1074/jbc.271.13.7568; HIGLAND JH, 1975, J BIOL CHEM, V250, P813; Ibba M, 1999, SCIENCE, V286, P1893, DOI 10.1126/science.286.5446.1893; JOSE MP, 1995, BIOCHEMISTRY-US, V34, P7941, DOI 10.1021/bi00024a019; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACCONNELL WP, 1980, BIOCHEM BIOPH RES CO, V92, P46, DOI 10.1016/0006-291X(80)91517-X; MADJAR JJ, 1977, ANAL BIOCHEM, V83, P304, DOI 10.1016/0003-2697(77)90539-5; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; NIETO MA, 1989, MOL CELL BIOCHEM, V86, P55; PESTKA S, 1968, J BIOL CHEM, V243, P2810; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; SCHOP EN, 1982, EUR J BIOCHEM, V128, P371; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Szick K, 1998, P NATL ACAD SCI USA, V95, P2378, DOI 10.1073/pnas.95.5.2378; TASAYCO ML, 1995, PROTEINS, V22, P41, DOI 10.1002/prot.340220106; Tchorzewski M, 2000, INT J BIOCHEM CELL B, V32, P737, DOI 10.1016/S1357-2725(00)00017-0; TSURUGI K, 1985, J BIOCHEM-TOKYO, V98, P1427, DOI 10.1093/oxfordjournals.jbchem.a135410; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1991, J BIOL CHEM, V266, P2054; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Vard C, 1997, J BIOL CHEM, V272, P20259, DOI 10.1074/jbc.272.32.20259; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; Yang X M, 1999, Pac Symp Biocomput, P590; ZINKER S, 1976, J BIOL CHEM, V251, P1799; Zurdo J, 2000, BIOCHEMISTRY-US, V39, P8929, DOI 10.1021/bi000362j	50	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19762	19769		10.1074/jbc.M101398200	http://dx.doi.org/10.1074/jbc.M101398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274186	hybrid			2022-12-27	WOS:000169135100013
J	Wu, JW; Fairman, R; Penry, J; Shi, YG				Wu, JW; Fairman, R; Penry, J; Shi, YG			Formation of a stable heterodimer between Smad2 and Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; CRYSTAL-STRUCTURE; IN-VIVO; ACTIVATION; PROTEINS; PATHWAY; GENE; SARA	Smad proteins mediate transforming growth factor beta signaling from the cell membrane to the nucleus. Upon phosphorylation by the activated receptor kinases, the receptor-regulated Smad, such as Smad2, forms a heterocomplex with the co-mediator Smad, Smad4. This heterocomplex is then translocated into the nucleus, where it associates with other transcription factors and regulates expression of ligand-responsive genes. The stoichiometry between receptor-regulated Smad and co-mediator Smad is important for understanding the molecular mechanisms of the signaling process. Using purified recombinant proteins, we demonstrate that Smad2 and Smad4 form a stable heterodimer and that the Smad4 activation domain is important for the formation of this complex. Many tumor-derived missense mutations disrupt the formation of this heterocomplex in in vitro interaction assays. Mapping these mutations onto the structures of Smad4 and Smad2 identifies a symmetric interface between these two Smad proteins. importantly, two previous models on the formation of a heterocomplex are incompatible with our observations and other reported evidence.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Haverford Coll, Dept Mol Cell & Dev Biol, Haverford, PA 19041 USA	Princeton University; Haverford College	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.			Shi, Yigong/0000-0003-2030-168X	NCI NIH HHS [R01-CA82171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Funaba M, 2000, MOL ENDOCRINOL, V14, P1583, DOI 10.1210/me.14.10.1583; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uchida K, 1996, CANCER RES, V56, P5583; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649	26	65	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20688	20694		10.1074/jbc.M100174200	http://dx.doi.org/10.1074/jbc.M100174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274206	hybrid			2022-12-27	WOS:000169135100135
J	Wang, QMJ; Fang, TW; Nacro, K; Marquez, VE; Wang, SM; Blumberg, PM				Wang, QMJ; Fang, TW; Nacro, K; Marquez, VE; Wang, SM; Blumberg, PM			Role of hydrophobic residues in the C1b domain of protein kinase C delta on ligand and phospholipid interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHORBOL ESTER-BINDING; CYSTEINE-RICH REGION; INDUCED TRANSLOCATION; MEMBRANE-BINDING; TUMOR PROMOTERS; DIACYLGLYCEROL; AFFINITY; ALPHA; LOCALIZATION	The C1 domains of conventional and novel protein kinase C (PKC) isoforms bind diacylglycerol and phorbol esters with high affinity. Highly conserved hydrophobic residues at or near the rim of the binding cleft in the second cysteine-rich domain of PKC-delta (PKC-delta C1b) were mutated to probe their roles in ligand recognition and lipid interaction. [H-3]Phorbol 12,13-dibutyrate (PDBu) binding was carried out both in the presence and absence of phospholipids to determine the contribution of lipid association to the ligand affinity. Lipid dependence was determined as a function of lipid concentration and composition. The binding properties of a high affinity branched diacylglycerol with lipophilicity similar to PDBu were compared with those of PDBu to identify residues important for ligand selectivity. As expected, Leu-20 and Leu-24 strongly influenced binding. Substitution of either by aspartic acid abolished binding in either the presence or absence of phosphatidylserine, Mutation of Leu-20 to Arg or of Leu-24 to Lys caused a dramatic (340- and 250-fold, respectively) reduction in PDBu binding in the presence of lipid but only a modest reduction in the weaker binding of PDBu observed in the absence of lipid, suggesting that the main effect was on C1 domain -phospholipid interactions. Mutation of Leu-20 to Lys or of Trp-22 to Lys had modest (S-fold) effects and mutation of Phe-13 to Tyr or Lys was without effect. Binding of the branched diacylglycerol was less dependent on phospholipid and was more sensitive to mutation of Trp-22 to Tyr or Lys, especially in the presence of phospholipid, than was PDBu, In terms of specific PKC isoforms, our results suggest that the presence of Arg-20 in PKC-zeta may contribute to its lack of phorbol ester binding activity. More generally, the results emphasize the interplay between the C1 domain, ligand, and phospholipid in the ternary binding complex.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Mol Mechanisms Tumor Promot Sect, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; Georgetown University; Georgetown University	Blumberg, PM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Mol Mechanisms Tumor Promot Sect, NIH, Bldg 37,Rm 3A01,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Wang, Qiming Jane/B-6064-2012; Marquez, Victor/AAP-3549-2021	Wang, Qiming Jane/0000-0002-9502-4851; Wang, Shaomeng/0000-0002-8782-6950				BLUMBERG PM, 1988, CANCER RES, V48, P1; Bogi K, 1999, FEBS LETT, V456, P27, DOI 10.1016/S0014-5793(99)00927-8; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Marquez VE, 1999, PHARMACOL THERAPEUT, V82, P251, DOI 10.1016/S0163-7258(98)00048-5; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; Nacro K, 2000, J MED CHEM, V43, P921, DOI 10.1021/jm9904607; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SHARKEY NA, 1985, CANCER RES, V45, P19; Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160; Slater SJ, 2000, BIOCHEMISTRY-US, V39, P271, DOI 10.1021/bi9916527; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang SM, 1999, J MED CHEM, V42, P3436, DOI 10.1021/jm990129n; Wang SM, 1996, J MED CHEM, V39, P2541, DOI 10.1021/jm950403n; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	37	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19580	19587		10.1074/jbc.M010089200	http://dx.doi.org/10.1074/jbc.M010089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278612	hybrid			2022-12-27	WOS:000169091000122
J	Avila, G; O'Connell, KMS; Groom, LA; Dirksen, RT				Avila, G; O'Connell, KMS; Groom, LA; Dirksen, RT			Ca2+ release through ryanodine receptors regulates skeletal muscle L-type Ca2+ channel expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; EXCITATION-CONTRACTION; CALCIUM CURRENTS; CHARGE MOVEMENT; DIHYDROPYRIDINE; PROTEIN; CELLS; HYPERTROPHY; CALCINEURIN; MYOTUBES	Skeletal muscle obtained from mice that lack the type 1 ryanodine receptor (RyR-1), termed dyspedic mice, exhibit a 2-fold reduction in the number of dihydropyridine binding sites (DHPRs) compared with skeletal muscle obtained from wild-type mice (Buck, E. D., Nguyen, H. T., Pessah, I. N., and Allen, P. D. (1997) J. Biol. Chem. 272, 7360-7367 and Fleig, A., Takeshima, H., and Penner, R. (1996) J. Physiol (Lond) 496, 339-345). To probe the role of RyR-1 in influencing L-type Ca2+ channel (L-channel) expression, we have monitored functional L-channel expression in the sarcolemma using the whole-cell patch clamp technique in normal, dyspedic, and RyR-1-expressing dyspedic myotubes. Our results indicate that dyspedic myotubes exhibit a 45% reduction in maximum immobilization-resistant charge movement (Q(max)) and a 90% reduction in peak Ca2+ current density. Calcium current density was significantly increased in dyspedic myotubes 3 days after injection of cDNA encoding either wild-type RyR-1 or E4032A, a mutant RyR-1 that is unable to restore robust voltage-activated release of Ca2+ from the sarcoplasmic reticulum (SR) following expression in dyspedic myotubes (O'Brien, J. J., Alien, P. D., Beam, K., and Chen, S. R. W. (1999) Biophys. J. 76, A302 (abstr.)). The increase in L-current density 3 days after expression of either RyR-1 or E4032A occurred in the absence of a change in Q(max). However, Q(max) was increased 85% 6 days after injection of dyspedic myotubes with cDNA encoding the wild-type RyR-1 but not E4032A Because normal and dyspedic myotubes exhibited a similar density of T-type Ca2+ current (T-current), the presence of RyR-1 does not appear to cause a general overall increase in protein synthesis. Thus, long-term expression of L-channels in skeletal myotubes is promoted by Ca2+ released through RyRs occurring either spontaneously or during excitation-contraction coupling.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Dirksen, RT (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.	Robert_Dirksen@URMC.rochester.edu	Avila, Guillermo/B-5782-2013; Tuluc, Petronel/C-2527-2011	Avila, Guillermo/0000-0001-7615-8945; O'Connell, Kristen/0000-0002-4187-747X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044657, R29AR044657] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44657] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; Anderson ME, 2000, CIRC RES, V86, P717, DOI 10.1161/01.RES.86.7.717; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; Buck ED, 1997, J BIOL CHEM, V272, P7360, DOI 10.1074/jbc.272.11.7360; Cartin L, 2000, CIRC RES, V86, P760, DOI 10.1161/01.RES.86.7.760; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Davidoff AJ, 1997, J MOL CELL CARDIOL, V29, P1791, DOI 10.1006/jmcc.1997.0406; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; DIRKSEN RT, 1995, J GEN PHYSIOL, V105, P227, DOI 10.1085/jgp.105.2.227; Du GG, 1998, J BIOL CHEM, V273, P31867, DOI 10.1074/jbc.273.48.31867; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; Garcia MC, 1999, J MEMBRANE BIOL, V168, P141, DOI 10.1007/s002329900504; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; O'Brien JJ, 1999, BIOPHYS J, V76, pA302; O'Connell KMS, 2000, J PHYSIOL-LONDON, V529, P647, DOI 10.1111/j.1469-7793.2000.00647.x; RAY A, 1995, J BIOL CHEM, V270, P25837, DOI 10.1074/jbc.270.43.25837; Renganathan M, 1999, PFLUG ARCH EUR J PHY, V438, P649, DOI 10.1007/s004240051089; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x	30	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17732	17738		10.1074/jbc.M009685200	http://dx.doi.org/10.1074/jbc.M009685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278546	hybrid			2022-12-27	WOS:000168866500017
J	Goodson, ML; Hong, Y; Rogers, R; Matunis, MJ; Park-Sarge, OK; Sarge, KD				Goodson, ML; Hong, Y; Rogers, R; Matunis, MJ; Park-Sarge, OK; Sarge, KD			SUMO-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED MODIFIER; GTPASE-ACTIVATING PROTEIN; COVALENT MODIFICATION; PORE COMPLEX; PML; RANGAP1; P53; LOCALIZATION; HSF2; CONJUGATION	Heat shock transcription factor 2 (HSF2) is a transcription factor that regulates heat shock protein gene expression, but the mechanisms regulating the function of this factor are unclear, Here we report that HSF2 is a substrate for modification by the ubiquitin-related protein SUMO-1 and that HSF2 colocalizes in cells with SUMO-1 in nuclear granules. Staining with anti-promyelocytic leukemia antibodies indicates that these HSF2-containing nuclear granules are PML bodies. Our results identify lysine 82 as the major site of SUMO-1 modification in HSF2, which is located in a "wing" within the DNA-binding domain of this protein. Interestingly, SUMO-1 modification of HSF2 results in conversion of this factor to the active DNA binding form. This is the first demonstration that SUMO-1 modification can directly alter the DNA binding ability of a transcription factor and reveals a new mechanism by which SUMO-1 modification can regulate protein function.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	University of Kentucky; University of Kentucky; Johns Hopkins University	Sarge, KD (corresponding author), Univ Kentucky, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.	kdsarge@pop.uky.edu	Goodson, Michael L/G-4175-2010	Goodson, Michael/0000-0002-3464-490X; Matunis, Michael/0000-0002-9350-6611	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD032008] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32008] Funding Source: Medline; NIEHS NIH HHS [ES 07266] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Cotto JJ, 1999, BIOCHEM SOC SYMP, P105; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; James P, 1996, GENETICS, V144, P1425; Jolly C, 1997, J CELL SCI, V110, P2935; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; Lee S, 1998, APPL COMPOS MATER, V5, P273, DOI 10.1023/A:1008802903351; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Morano KA, 1999, GENE EXPRESSION, V7, P271; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Stein GS, 2000, J CELL SCI, V113, P2527; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	41	146	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18513	18518		10.1074/jbc.M008066200	http://dx.doi.org/10.1074/jbc.M008066200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278381	hybrid			2022-12-27	WOS:000168866500120
J	Hanyaloglu, AC; Vrecl, M; Kroeger, KM; Miles, LEC; Qian, HW; Thomas, WG; Eidne, KA				Hanyaloglu, AC; Vrecl, M; Kroeger, KM; Miles, LEC; Qian, HW; Thomas, WG; Eidne, KA			Casein kinase II sites in the intracellular C-terminal domain of the thyrotropin-releasing hormone receptor and chimeric gonadotropin-releasing hormone receptors contribute to beta-arrestin-dependent internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LINKED MUSCARINIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; PARATHYROID-HORMONE; CARBOXYL-TERMINUS; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; AP-2 ADAPTER; ENDOCYTOSIS	We have previously shown that the mammalian gonadotropin-releasing hormone receptor (GnRHR), a unique G-protein-coupled receptor (GPCR) lacking an intracellular carboxyl tail (C-tail), does not follow a beta -arrestin-dependent internalization pathway. However, internalization of a chimeric GnRHR with the thyrotropin-releasing hormone receptor (TRHR) C-tail does utilize beta -arrestin, Here, we have investigated the sites within the intracellular C-tail domain that are important for conferring beta -arrestin-dependent internalization. In contrast to the chimeric GnRHR with a TRHR C-tail, a chimeric GnRHR with the catfish GnRHR C-tail is not beta -arrestin-dependent. Sequence comparisons between these chimeric receptors show three consensus phosphorylation sites for casein kinase II (CKII) in the TRHR C-tail but none in the catfish GnRHR C-tail, We thus investigated a role for CKII sites in determining GPCR internalization via beta -arrestin. Sequential introduction of three CKII sites into the chimera with the catfish C-tail (H354D,A366E,G371D) resulted in a change in the pattern of receptor phosphorylation and beta -arrestin-dependence, which only occurred when all three sites were introduced. Conversely, mutation of the putative CKII sites (T365A/T371A,S383A) in the C-tail of a p-arrestin-sensitive GPCR, the TRHR, resulted in decreased receptor phosphorylation and a loss of beta -arrestin-dependence. Mutation of all three CKII sites was necessary before a loss of beta -arrestin-dependence was observed. Visualization of beta -arrestin/GFP redistribution confirmed a loss or gain of beta -arrestin sensitivity for receptor mutants. Internalization of receptors without C-tail CKII sites was promoted by a phosphorylation-independent beta -arrestin mutant (R169E), suggesting that these receptors do not contain the necessary phosphorylation sites required for beta -arrestin-dependent internalization. Apigenin, a specific CKII inhibitor, blocked the increase in receptor internalization by beta -arrestin, thus providing further support for the involvement of CKII, This study presents evidence of a novel role for C-tail CKII consensus sites in targeting these GPCRs to the beta -arrestin-dependent pathway.	Sir Charles Gairdner Hosp, Western Australian Inst Med Res, 7TM Receptor Lab, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Keogh Inst Med Res, Perth, WA 6009, Australia; Univ Western Australia, Perth, WA 6009, Australia; Univ Ljubljana, Fac Vet, Ljubljana 1000, Slovenia; Baker Med Res Inst, Melbourne, Vic 8008, Australia	University of Western Australia; University of Western Australia; University of Western Australia; University of Ljubljana; Baker Heart and Diabetes Institute	Eidne, KA (corresponding author), Sir Charles Gairdner Hosp, Western Australian Inst Med Res, 7TM Receptor Lab, B Block,Hosp Ave, Perth, WA 6009, Australia.	keidne@waimr.uwa.edu.au	Vrecl, Milka/A-6127-2008; Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952; /0000-0003-4206-737X				ANDERSON L, 1993, J ENDOCRINOL, V136, P51, DOI 10.1677/joe.0.1360051; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; BRAMLEY TA, 1992, PLACENTA, V13, P555, DOI 10.1016/0143-4004(92)90020-T; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Cotlin LF, 1999, J BIOL CHEM, V274, P30550, DOI 10.1074/jbc.274.43.30550; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; KORNER C, 1994, J BIOL CHEM, V269, P16529; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PAULOIN A, 1984, NATURE, V311, P265, DOI 10.1038/311265a0; PAULOIN A, 1993, BIOCHEM J, V296, P409, DOI 10.1042/bj2960409; Pinna LA, 1997, INT J BIOCHEM CELL B, V29, P551, DOI 10.1016/S1357-2725(96)00142-2; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Thomas WG, 1998, MOL ENDOCRINOL, V12, P1513, DOI 10.1210/me.12.10.1513; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; Tobin AB, 1996, J BIOL CHEM, V271, P3907; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Waugh MG, 1999, BIOCHEM J, V338, P175, DOI 10.1042/0264-6021:3380175; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Williams BY, 1998, MOL PHARMACOL, V54, P889, DOI 10.1124/mol.54.5.889; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745	51	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18066	18074		10.1074/jbc.M009275200	http://dx.doi.org/10.1074/jbc.M009275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278484	hybrid			2022-12-27	WOS:000168866500061
J	Tuo, WB; Zhuang, DY; Knowles, DP; Cheevers, WP; Sy, MS; O'Rourke, KI				Tuo, WB; Zhuang, DY; Knowles, DP; Cheevers, WP; Sy, MS; O'Rourke, KI			PrP-C and PrP-Sc at the fetal-maternal interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CELLULAR PRION PROTEINS; SCRAPIE-ASSOCIATED FORM; EMBRYO-TRANSFER; SHEEP PLACENTA; TRANSMISSION; RESISTANT; DIAGNOSIS; CELLS; BRAIN	Scrapie is a naturally occurring prion (PrP) disease causing a fatal neurodegenerative disorder in sheep and goats. Previous studies suggest that scrapie is transmitted naturally through exposure to the scrapie agent in wasted placentas of infected ewes, This study determined the distribution and biochemical properties of PrP cellular (PrP-C) and the distribution of PrP scrapie (PrP-Sc) in reproductive, placental, and selected fetal tissues and fetal fluids in sheep. Glycosylated, N-terminally truncated, proteinase K-sensitive PrP-C with apparent molecular masses of 23-37 kDa was present in reproductive, placental, and fetal tissues and fetal fluids. PrP-C was low or undetectable in intercotyledonary chorioallantois, amnion, urachus, amniotic fluid, and fetal urine. In pregnant ewes, cotyledonary chorioallantois, allantoic fluid, and caruncular endometrium contained higher levels of PrP-C than did intercaruncular endometrium, myometrium, oviduct, ovary, fetal bladder, or fetal kidney, Caruncular endometrial PrP-C was up-regulated during pregnancy, Despite the wide distribution of PrP-C in reproductive, placental, and selected fetal tissues and fetal fluid, PrP-Sc was detected only in caruncular endometrium and cotyledonary chorioallantois of pregnant scrapie-infected ewes, The embryo/fetus may not be exposed to scrapie in utero because it is separated physically from PrP-positive allantois and chorioallantois by PrP-negative amnion.	ARS, Anim Dis Res Unit, USDA, Pullman, WA 99164 USA; Washington State Univ, Coll Vet Med, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	United States Department of Agriculture (USDA); Washington State University; Case Western Reserve University	Tuo, WB (corresponding author), ARS, Anim Dis Res Unit, USDA, Pullman, WA 99164 USA.	wtuo@vetmed.wsu.edu						BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BURTON GJ, 1976, Q J EXP PHYSIOL CMS, V61, P275, DOI 10.1113/expphysiol.1976.sp002359; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; FOOTE WC, 1993, AM J VET RES, V54, P1863; Foster J, 1999, J GEN VIROL, V80, P517, DOI 10.1099/0022-1317-80-2-517; FOSTER JD, 1992, VET REC, V130, P341, DOI 10.1136/vr.130.16.341; Foster JD, 1996, VET REC, V138, P559, DOI 10.1136/vr.138.23.559; Green JA, 1998, REV REPROD, V3, P62; Hadlow W. J., 1979, Slow transmissible diseases of the nervous system. Volume 2., P3; Hansen PJ, 1997, ADV EXP MED BIOL, V425, P143; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; HORIUCHI M, 1995, J GEN VIROL, V76, P2583, DOI 10.1099/0022-1317-76-10-2583; HOURRIGAN JL, 1990, J AM VET MED ASSOC, V196, P1678; IKEGAMI Y, 1991, VET REC, V128, P271, DOI 10.1136/vr.128.12.271; Kubosaki A, 2000, BIOCHEM BIOPH RES CO, V273, P890, DOI 10.1006/bbrc.2000.3035; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; McFarlane JR, 1999, ENDOCRINOLOGY, V140, P4745, DOI 10.1210/en.140.10.4745; MYAGKAYA G, 1976, ACTA ANAT, V95, P234, DOI 10.1159/000144616; O'Rourke KI, 1998, J CLIN MICROBIOL, V36, P1750; O'Rourke KI, 2000, J CLIN MICROBIOL, V38, P3254, DOI 10.1128/JCM.38.9.3254-3259.2000; ONODERA T, 1993, MICROBIOL IMMUNOL, V37, P311, DOI 10.1111/j.1348-0421.1993.tb03215.x; ORourke KI, 1997, J GEN VIROL, V78, P975, DOI 10.1099/0022-1317-78-4-975; PATTISON IH, 1974, BRIT VET J, V130, pR65, DOI 10.1016/S0007-1935(17)35851-7; PATTISON IH, 1972, VET REC, V90, P465, DOI 10.1136/vr.90.17.465; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Race R, 1998, J INFECT DIS, V178, P949, DOI 10.1086/515669; RACE R, 1992, AM J VET RES, V53, P883; Ridley RM, 1996, NATURE, V384, P17, DOI 10.1038/384017a0; RIDLEY RM, 1995, BRIT MED J, V311, P1071, DOI 10.1136/bmj.311.7012.1071; SHISONG C, 1989, BRIT VET J, V145, P129, DOI 10.1016/0007-1935(89)90095-X; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Sigurdson CJ, 1999, J GEN VIROL, V80, P2757, DOI 10.1099/0022-1317-80-10-2757; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; WIMSATT WA, 1950, AM J ANAT, V87, P391, DOI 10.1002/aja.1000870304; WINTOUR EM, 1986, AUST VET J, V63, P216, DOI 10.1111/j.1751-0813.1986.tb02999.x; Wrathall AE, 1997, REV SCI TECH OIE, V16, P240, DOI 10.20506/rst.16.1.1016; XIE SC, 1991, P NATL ACAD SCI USA, V88, P10247, DOI 10.1073/pnas.88.22.10247; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	48	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18229	18234		10.1074/jbc.M008887200	http://dx.doi.org/10.1074/jbc.M008887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11274195	hybrid, Green Submitted			2022-12-27	WOS:000168866500083
J	Kramer, ML; Kratzin, HD; Schmidt, B; Romer, A; Windl, O; Liemann, S; Hornemann, S; Kretzschmar, H				Kramer, ML; Kratzin, HD; Schmidt, B; Romer, A; Windl, O; Liemann, S; Hornemann, S; Kretzschmar, H			Prion protein binds copper within the physiological concentration range	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; SCRAPIE PRION; RESISTANT; SITES; PRP; FLUORESCENCE; CONVERSION; DISEASES; PEPTIDES; DESIGN	The prion protein is known to be a copper-binding protein, but affinity and stoichiometry data for the full-length protein at a physiological pH of 7 were lacking. Furthermore, it was unknown whether only the highly flexible N-terminal segment with its octarepeat region is involved in copper binding or whether the structured C-terminal domain is also involved, Therefore we systematically investigated the stoichiometry and affinity of copper binding to full-length prion protein PrP23-231 and to different N- and C-terminal fragments using electrospray ionization mass spectrometry and fluorescence spectroscopy. Our data indicate that the unstructured N-terminal segment is the cooperative copper-binding domain of the prion protein. The prion protein binds up to five copper(II) ions with half-maximal binding at similar to2 muM. This argues strongly for a direct role of the prion protein in copper metabolism, since it is almost saturated at about 5 muM, and the exchangeable copper Fool concentration in blood is about 8 muM.	Univ Gottingen, Dept Neuropathol, D-37075 Gottingen, Germany; Max Planck Inst Expt Med, Dept Immunochem, D-37075 Gottingen, Germany; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Tech Univ Munich, GSF, Ctr Environm & Hlth Res, Inst Mol Virol, D-81675 Munich, Germany	University of Gottingen; Max Planck Society; University of Gottingen; Harvard University; Boston Children's Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Kramer, ML (corresponding author), Univ Gottingen, Dept Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany.		Windl, Otto/C-6760-2011					ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CHEN RF, 1976, BIOCH FLUORESCENCE C, P573; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARTTER DE, 1988, J BIOL CHEM, V263, P799; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Hjelmeland L M, 1986, Methods Enzymol, V124, P135; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Linder Maria C., 1996, American Journal of Clinical Nutrition, V63, p797S; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Post K, 1998, BIOL CHEM, V379, P1307, DOI 10.1515/bchm.1998.379.11.1307; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; RICK R, 1997, FEBS LETT, V413, P282; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Sandmeier E, 1999, BIOCHEM BIOPH RES CO, V261, P578, DOI 10.1006/bbrc.1999.1056; SOVAGO I, 1990, P135; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SYVERTSEN C, 1987, BIOCHIM BIOPHYS ACTA, V914, P6, DOI 10.1016/0167-4838(87)90155-5; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Whittal RM, 2000, PROTEIN SCI, V9, P332; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204	43	234	236	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16711	16719		10.1074/jbc.M006554200	http://dx.doi.org/10.1074/jbc.M006554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278306	Green Published, hybrid			2022-12-27	WOS:000168730400018
J	Satoh, K; Ichihara, K; Landon, EJ; Inagami, T; Tang, H				Satoh, K; Ichihara, K; Landon, EJ; Inagami, T; Tang, H			3-hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells - Involvement of geranylgeranylation of small G protein Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; MAP KINASE; RAS; RECEPTOR; ADHESION; STATINS; PHOSPHORYLATION; LOVASTATIN; BENEFITS	We recently reported the calcium-dependent activation of tyrosine kinase Pyk2 by angiotensin II (Ang II) in pulmonary vein endothelial cells (PVEC). Since Pyk2 has no calcium binding domain, and neither Ca2+ nor Ca2+/calmodulin directly activates Pyk2, it is not clear how Ca2+ transduces the signal to activate Pyk2, a key tyrosine kinase, in the early events of Ang II signaling. In the present study, we investigated the mechanism of the calcium-dependent activation of Pyk2 in response to Ang II by using 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors and isoprenoid intermediates in PVEC, We have obtained substantial evidence indicating that Ang II activates Pyk2 through calcium-mediated activation of the geranylgeranylated small G protein Rap1 and the Rap1 association with Pyk2. Thus, the small G protein Rap1 is an intermediary signaling molecule linking Ang II-induced calcium signal to Pyk2 activation in PVEC. In addition, our results indicate that 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, a class of cholesterol-lowering drugs, could interrupt Ang II signaling independent of cholesterol lowering in endothelial cells.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Hokkaido Coll Pharm, Dept Pharmacol, Otaru, Hokkaido 0470264, Japan	Vanderbilt University; Vanderbilt University	Tang, H (corresponding author), Univ Texas Hlth Ctr, Dept Biochem, Tyler, TX 75708 USA.	Tang37232@yahoo.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058205, R01HL058205] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58205] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Anderson TJ, 1999, J AM COLL CARDIOL, V34, P631, DOI 10.1016/S0735-1097(99)00259-4; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Bassa BV, 1999, BBA-MOL CELL RES, V1449, P137, DOI 10.1016/S0167-4889(99)00007-5; Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021-9150(97)00319-5; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Delanty N, 1997, STROKE, V28, P2315, DOI 10.1161/01.STR.28.11.2315; EARP HS, 1995, J BIOL CHEM, V270, P28440; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HORI Y, 1991, ONCOGENE, V6, P515; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; Hughes AD, 1996, J HUM HYPERTENS, V10, P387; ILLINGWORTH DR, 1994, CLIN THER, V16, P366; KOGA T, 1992, EUR J BIOCHEM, V209, P315, DOI 10.1111/j.1432-1033.1992.tb17291.x; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; Luscinskas FW, 1996, ANNU REV MED, V47, P413, DOI 10.1146/annurev.med.47.1.413; MIZUNO M, 1995, EUR J PHARMACOL, V285, P181, DOI 10.1016/0014-2999(95)00401-6; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Oi S, 1999, EUR J PHARMACOL, V376, P139, DOI 10.1016/S0014-2999(99)00282-4; Packard CJ, 1998, CIRCULATION, V97, P1440; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; THEKKUMKARA TJ, 1993, FASEB J, V7, pA491; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; Vaughan DE, 1997, AM J CARDIOL, V79, P12, DOI 10.1016/S0002-9149(97)00124-0; Wang DM, 2000, J BIOL CHEM, V275, P12223, DOI 10.1074/jbc.275.16.12223; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	51	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15761	15767		10.1074/jbc.M009165200	http://dx.doi.org/10.1074/jbc.M009165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278472	hybrid			2022-12-27	WOS:000168623100027
J	Spurway, TD; Dalley, JA; High, S; Bulleid, NJ				Spurway, TD; Dalley, JA; High, S; Bulleid, NJ			Early events in glycosylphosphatidylinositol anchor addition - Substrate proteins associate with the transamidase subunit Gpi8p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; CARBOXYL-TERMINAL SIGNAL; MEMBRANE-PROTEINS; ATTACHMENT; CLEAVAGE; PEPTIDE; SITE; BIOSYNTHESIS; CELLS; TRANSLOCATION	The addition of glycosylphosphatidylinositol (GPI) anchors to proteins occurs by a transamidase-catalyzed reaction mechanism soon after completion of polypeptide synthesis and translocation. We show that placental alkaline phosphatase becomes efficiently GPI-anchored when translated in the presence of semipermeabilized K562 cells but is not GPI-anchored in cell lines defective in the transamidase subunit hGpi8p. By studying the synthesis of placental alkaline phosphatase, we demonstrate that folding of the protein is not influenced by the addition of a GPI anchor and conversely that GPI anchor addition does not require protein folding. These results demonstrate that folding of the ectodomain and GPI addition are two distinct processes and can be mutually exclusive. When GPI addition is prevented, either by synthesis of the protein in the presence of cell lines defective in GPI addition or by mutation of the GPI carboxyl-terminal signal sequence cleavage site, the substrate forms a prolonged association with the transamidase subunit hGpi8p. The ability of the transamidase to recognize and associate with GPI anchor signal sequences provides an explanation for the retention of GPI-anchored protein within the ER in the absence of GPI anchor addition.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Bulleid, Neil/0000-0002-9839-5279; High, Stephen/0000-0002-4532-8152	Biotechnology and Biological Sciences Research Council [SF16973] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		AMTHAUER R, 1993, P NATL ACAD SCI USA, V90, P3973, DOI 10.1073/pnas.90.9.3973; AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BENGHEZAL M, 1996, EMBO J, V15, P6675; BERGER J, 1987, P NATL ACAD SCI USA, V84, P4885, DOI 10.1073/pnas.84.14.4885; Chen R, 1996, P NATL ACAD SCI USA, V93, P2280, DOI 10.1073/pnas.93.6.2280; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hiroi Y, 1998, FEBS LETT, V421, P252, DOI 10.1016/S0014-5793(97)01576-7; HIROSE S, 1992, J BIOL CHEM, V267, P5272; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P7939, DOI 10.1073/pnas.87.20.7939; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; Nozaki M, 1999, LAB INVEST, V79, P293; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ramalingam S, 1996, P NATL ACAD SCI USA, V93, P7528, DOI 10.1073/pnas.93.15.7528; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Tomita M, 1999, BBA-MOL BASIS DIS, V1455, P269, DOI 10.1016/S0925-4439(99)00068-X; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; Wang JY, 1999, J MOL BIOL, V286, P1303, DOI 10.1006/jmbi.1999.2584; Wilbourn B, 1998, BIOCHEM J, V332, P111, DOI 10.1042/bj3320111; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Yan W, 1998, J MOL BIOL, V275, P25, DOI 10.1006/jmbi.1997.1447; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	35	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15975	15982		10.1074/jbc.M010128200	http://dx.doi.org/10.1074/jbc.M010128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278620	hybrid			2022-12-27	WOS:000168623100056
J	Poteser, M; Romanin, C; Schreibmayer, W; Mayer, B; Groschner, K				Poteser, M; Romanin, C; Schreibmayer, W; Mayer, B; Groschner, K			S-nitrosation controls gating and conductance of the alpha 1 subunit of class C L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DONORS; ENDOTHELIAL-CELLS; CALCIUM-CHANNEL; VENTRICULAR MYOCYTES; GUANYLYL CYCLASE; PROTEIN-KINASE; SMOOTH-MUSCLE; CYCLIC-GMP; CGMP; NITROSOGLUTATHIONE	Modulation of smooth muscle, L-type Ca2+ channels (class C, Ca(V)1.2b) by thionitrite S-nitrosoglutathione (GSNO) was investigated in the human embryonic kidney 293 expression system at the level of whole-cell and single-channel currents. Extracellular administration of GSNO (2 mM) rapidly reduced whole-cell Ba2+ currents through channels derived either by expression of alpha 1C-b or by coexpression of alpha 1C-b plus beta 2a and alpha2-delta, The non-thiol nitric oxide (NO) donors 2,2-diethyl-1-nitroso-oxhydrazin (2 mM) and 3-morpholinosydnonimine-hydrochloride (2 mM), which elevated cellular cGMP levels to a similar extent as GSNO, failed to affect Ba2+ currents significantly. Intracellular administration of copper ions, which promote decomposition of the thionitrite, antagonized its inhibitory effect, and loading of cells with high concentrations of dithiothreitol (2 mM) prevented the effect of GSNO on alpha 1C-b channels. Intracellular loading of cells with oxidized glutathione (2 mM) affected neither alpha 1C-b channel function nor their modulation by GSNO, Analysis of single-channel behavior revealed that GSNO inhibited Ca2+ channels mainly by reducing open probability, The development of GSNO-induced inhibition was associated with the transient occurrence of a reduced conductance state of the channel. Our results demonstrate that GSNO modulates the alpha1 subunit of smooth muscle L-type Ca2+ channels by an intracellular mechanism that is independent of NO release and stimulation of guanylyl cyclase. We suggest S-nitrosation of intracellularly located sulfhydryl groups as an important determinant of Ca2+ channel gating and conductance.	Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria; Karl Franzens Univ Graz, Dept Med Phys & Biophys, A-8010 Graz, Austria; Johannes Kepler Univ Linz, Dept Biophys, A-4040 Linz, Austria	University of Graz; University of Graz; Johannes Kepler University Linz	Groschner, K (corresponding author), Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria.		Mayer, Bernd/B-9391-2008; Groschner, Klaus/A-2550-2010; Romanin, Christoph/D-5399-2009	Groschner, Klaus/0000-0002-8659-377X; Romanin, Christoph/0000-0003-3756-4136; Mayer, Bernd/0000-0002-2921-3494; Schreibmayer, Wolfgang/0000-0002-4631-7922; Poteser, Michael/0000-0002-9962-1098				Angelotti T, 1996, FEBS LETT, V397, P331, DOI 10.1016/S0014-5793(96)01205-7; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P979, DOI 10.1006/jmcc.1998.0662; Baumgartner W, 1998, J NEUROSCI METH, V82, P175, DOI 10.1016/S0165-0270(98)00057-0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Butler AR, 1997, ANAL BIOCHEM, V249, P1; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; DeMan JG, 1996, BRIT J PHARMACOL, V119, P990; DeMaster EG, 1997, ALCOHOL, V14, P181, DOI 10.1016/S0741-8329(96)00142-5; Dicks AP, 1996, J CHEM SOC PERK T 2, P481, DOI 10.1039/p29960000481; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GORDGE MP, 1995, BRIT J PHARMACOL, V114, P1083, DOI 10.1111/j.1476-5381.1995.tb13317.x; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Ho YS, 1999, MOL CARCINOGEN, V26, P201, DOI 10.1002/(SICI)1098-2744(199911)26:3<201::AID-MC9>3.0.CO;2-K; Hu H, 1997, CIRC RES, V81, P742; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Kumar R, 1997, CARDIOVASC RES, V33, P573, DOI 10.1016/S0008-6363(96)00258-1; Loweth AC, 1997, FEBS LETT, V400, P285, DOI 10.1016/S0014-5793(96)01392-0; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MERY PF, 1993, J BIOL CHEM, V268, P26286; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Quignard JF, 1997, J CLIN INVEST, V99, P185, DOI 10.1172/JCI119146; Reimer D, 2000, FEBS LETT, V467, P65, DOI 10.1016/S0014-5793(00)01124-8; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; Schmidt K, 1998, FREE RADICAL BIO MED, V24, P859, DOI 10.1016/S0891-5849(97)00366-3; Schrammel A, 1998, MOL PHARMACOL, V54, P207, DOI 10.1124/mol.54.1.207; SUMMERS BA, 1999, AM J PHYSIOL, V93, P1449; Vandecasteele G, 1998, J PHYSIOL-LONDON, V506, P653, DOI 10.1111/j.1469-7793.1998.653bv.x; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003	34	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14797	14803		10.1074/jbc.M008244200	http://dx.doi.org/10.1074/jbc.M008244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278396	hybrid			2022-12-27	WOS:000168528800037
J	Vaden, DL; Ding, D; Peterson, B; Greenberg, ML				Vaden, DL; Ding, D; Peterson, B; Greenberg, ML			Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; AFFECTIVE-DISORDERS; RAT-BRAIN; MONOPHOSPHATASE; SODIUM; MYOINOSITOL; CORTEX; ACCUMULATION; HYDROLYSIS	Bipolar affective disorder (manic-depressive illness) is a chronic, severe, debilitating illness affecting 1-2% of the population. The Food and Drug Administration-approved drugs lithium and valproate are not completely effective in the treatment of this disorder, and the mechanisms underlying their therapeutic effects have not been established, We are employing genetic and molecular approaches to identify common targets of lithium and valproate in the yeast Saccharomyces cerevisiae, We show that both drugs affect molecular targets in the inositol metabolic pathway. Lithium and valproate cause a decrease in intracellular myo-inositol mass and an increase in expression of both a structural (INO1) and a regulatory ((INO2) gene required for inositol biosynthesis. The opi1 mutant, which exhibits constitutive expression of INO1, is more resistant to inhibition of growth by lithium but not by valproate, suggesting that valproate may inhibit the Ino1p-catalyzed synthesis of inositol 1-phosphate. Consistent with this possibility, growth in valproate leads to decreased synthesis of inositol monophosphate, Thus, both lithium and valproate perturb regulation of the inositol biosynthetic pathway, albeit via different mechanisms. This is the first demonstration of increased expression of genes in the inositol biosynthetic pathway by both lithium and valproate, Because inositol is a key regulator of many cellular processes, the effects of lithium and valproate on inositol synthesis have far-reaching implications for predicting genetic determinants of responsiveness and resistance to these agents.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.				NIMH NIH HHS [MH56220] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056220] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGST J, 1986, PSYCHOPATHOLOGY, V19, P47, DOI 10.1159/000285131; ASENSIO J, 1976, A VAN LEEUW J MICROB, V42, P1, DOI 10.1007/BF00399443; ASHBURNER BP, 1995, P NATL ACAD SCI USA, V92, P9722, DOI 10.1073/pnas.92.21.9722; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CASEBOLT TL, 1989, BIOL PSYCHIAT, V25, P329, DOI 10.1016/0006-3223(89)90180-7; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; CHEN G, 1994, J NEUROCHEM, V63, P2361; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; CHOU JCY, 1991, J CLIN PSYCHOPHARM, V11, P3; Dixon JF, 1997, P NATL ACAD SCI USA, V94, P4757, DOI 10.1073/pnas.94.9.4757; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; GODFREY PP, 1989, J NEUROCHEM, V52, P498, DOI 10.1111/j.1471-4159.1989.tb09148.x; GOODWIN FK, 1990, MANIC DEPRESSIVE ILL, P665; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; HUBERWALCHLI V, 1979, ARCH MICROBIOL, V120, P141, DOI 10.1007/BF00409100; KENDALL DA, 1987, J PHARMACOL EXP THER, V241, P1023; LI R, 1993, PHARMACOL BIOCHEM BE, V46, P323, DOI 10.1016/0091-3057(93)90360-6; Lopez F, 1999, MOL MICROBIOL, V31, P1255, DOI 10.1046/j.1365-2958.1999.01267.x; Lubrich B, 1999, NEUROPSYCHOPHARMACOL, V21, P519, DOI 10.1016/S0893-133X(99)00037-8; Manji HK, 1996, NEUROPSYCHOPHARMACOL, V15, P370, DOI 10.1016/0893-133X(95)00243-7; Manji HK, 1996, J CLIN PSYCHIAT, V57, P34; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; Murray M, 1997, MOL MICROBIOL, V25, P541, DOI 10.1046/j.1365-2958.1997.4881840.x; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; PERKINS J, 1993, FEMS MICROBIOL LETT, V107, P255; RODRIGUEZNAVARRO A, 1977, FEBS LETT, V75, P169, DOI 10.1016/0014-5793(77)80078-1; VADNAL R, 1995, NEUROPSYCHOPHARMACOL, V12, P277, DOI 10.1016/0893-133X(94)00088-H; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WELIHINDA AA, 1994, BBA-BIOMEMBRANES, V1193, P107, DOI 10.1016/0005-2736(94)90339-5; Williamson JR, 1987, DIABETIC COMPLICATIO, P213	34	98	104	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15466	15471		10.1074/jbc.M004179200	http://dx.doi.org/10.1074/jbc.M004179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278273	hybrid			2022-12-27	WOS:000168528800124
J	Cheng, N; Chen, J				Cheng, N; Chen, J			Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASES; VASCULAR DEVELOPMENT; GROWTH-FACTOR; CARDIOVASCULAR DEVELOPMENT; TRANSMEMBRANE LIGANDS; ADHESION MOLECULE-1; IN-VITRO; ANGIOGENESIS; TRAF2	Tumor necrosis factor-alpha (TNF-alpha) is a multifunctional cytokine that induces a broad spectrum of responses including angiogenesis. Angiogenesis promoted by TNF-alpha is mediated, at least in part, by ephrin A1, a member of the ligand family for Eph receptor tyrosine kinases. Although TNF-alpha induces ephrin A1 expression in endothelial cells, the signaling pathways mediating ephrin A1 induction remain unknown. In this study, we investigated the signaling mechanisms of TNF-alpha -dependent induction of ephrin A1 in endothelial cells. Both TNFR1 and TNFR2 appear to be involved in regulating ephrin A1 expression in endothelial cells, because neutralizing antibodies to either TNFR1 or TNFR2 inhibited TNF-alpha induced ephrin A1 expression. Inhibition of nuclear factor-kappaB (NF-kappaB) activation by a trans-dominant inhibitory isoform of mutant I kappaB alpha did not affect ephrin A1 induction, suggesting that NF-kappaB proteins are not major regulators of ephrin A1 expression. In contrast, ephrin A1 induction was blocked by inhibition of p38 mitogen-activated protein kinase (MAPK) or SAPK/ JNK, but not p42/44 MAPK, using either selective chemical inhibitors or dominant-negative forms of p88 MAPK or TNF receptor-associated factor 2, These findings indicate that TNF-alpha -induced ephrin A1 expression is mediated through JNK and p38 MAPK signaling pathways. Taken together, the results of our study demonstrated that induction of ephrin A1 in endothelial cells by TNF-alpha is mediated through both p38 MAPK and SAPK/JNK, but not p42/44 MAPK or NF-kappaB, pathways.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Rheumatol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, A-4323,Med Ctr N, Nashville, TN 37232 USA.	jin.chen@mcmail.vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036400] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009592] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA09592] Funding Source: Medline; NICHD NIH HHS [R01 HD36400] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BECKER TC, 1994, METHOD CELL BIOL, V4, P161; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Boyle EM, 1998, CIRCULATION, V98, pII282; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11586; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Chen CL, 1999, BIOCHEM BIOPH RES CO, V257, P798, DOI 10.1006/bbrc.1999.0548; Daniel TO, 1996, KIDNEY INT, V50, pS73; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; De Cesaris P, 1999, J BIOL CHEM, V274, P28978, DOI 10.1074/jbc.274.41.28978; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Illi B, 2000, CIRC RES, V86, pE110; KERR LD, 1995, METHOD ENZYMOL, V254, P619; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lee SY, 1998, J EXP MED, V188, P1381, DOI 10.1084/jem.188.7.1381; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Marino MW, 1996, J BIOL CHEM, V271, P28624, DOI 10.1074/jbc.271.45.28624; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Peschon JJ, 1998, J IMMUNOL, V160, P943; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	44	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13771	13777		10.1074/jbc.M009147200	http://dx.doi.org/10.1074/jbc.M009147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278471	hybrid			2022-12-27	WOS:000168356600038
J	Seger, R; Hanoch, T; Rosenberg, R; Dantes, A; Merz, WE; Strauss, JF; Amsterdam, A				Seger, R; Hanoch, T; Rosenberg, R; Dantes, A; Merz, WE; Strauss, JF; Amsterdam, A			RETRACTED: The ERK signaling cascade inhibits gonadotropin-stimulated steroidogenesis (Retracted article. See vol. 292, pg. 8847, 2017)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							ACUTE REGULATORY PROTEIN; OVARIAN GRANULOSA-CELLS; ARTERIAL SMOOTH-MUSCLE; LEYDIG TUMOR-CELLS; GROWTH-FACTOR; COUPLED RECEPTORS; STAR GENE; KINASE-A; ACTIVATION; HORMONE	The response of granulosa cells to luteinizing hormone (LH) and follicle-stimulating hormone (FSH) is mediated mainly by cAMP/protein kinase A (PKA) signaling. Notably, the activity of the extracellular signal-regulated kinase (ERK) signaling cascade is elevated in response to these stimuli as well. We studied the involvement of the ERK cascade in LH- and FSH-induced steroidogenesis in two granulosa derived cell lines, rLHR-4 and rFSHR-17, respectively. We found that stimulation of these cells with the appropriate gonadotropin induced ERK activation as well as progesterone production downstream of PKA. Inhibition of ERR activity enhanced gonadotropin-stimulated progesterone production, which was correlated with increased expression of the steroidogenic acute regulatory protein (StAR), a key regulator of progesterone synthesis. Therefore, it is likely that gonadotropin-stimulated progesterone formation is regulated by a pathway that includes PKA and StAR, and this process is down-regulated by ERK, due to attenuation of StAR expression. Our results suggest that activation of PKA signaling by gonadotropins not only induces steroidogenesis but also activates down-regulation machinery involving the ERR cascade. The activation of ERK by gonadotropins as well as by other agents may be a key mechanism for the modulation of gonadotropin-induced steroidogenesis.	Weizmann Inst Sci, Dept Regulat Biol, IL-71600 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-71600 Rehovot, Israel; Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Univ Penn, Ctr Res Reprod Womens Hlth, Philadelphia, PA 19104 USA	Weizmann Institute of Science; Weizmann Institute of Science; Ruprecht Karls University Heidelberg; University of Pennsylvania; Pennsylvania Medicine	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-71600 Rehovot, Israel.	rony.seger@weizmann.ac.il; abraham.amsterdam@weizmann.ac.il			NICHD NIH HHS [HD-06224] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aharoni D, 1997, CURR BIOL, V7, P43, DOI 10.1016/S0960-9822(06)00026-1; Amsterdam A, 1999, TRENDS ENDOCRIN MET, V10, P255, DOI 10.1016/S1043-2760(99)00164-2; AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440; Amsterdam A, 1997, ENDOCR REV, V18, P435, DOI 10.1210/er.18.4.435; AMSTERDAM A, 1992, BIOL REPROD, V46, P513, DOI 10.1095/biolreprod46.4.513; AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; Clark BJ, 1997, ENDOCRINOLOGY, V138, P4893, DOI 10.1210/en.138.11.4893; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DAY RN, 1989, J BIOL CHEM, V264, P431; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; HANUKOGLU I, 1990, J CELL BIOL, V111, P1373, DOI 10.1083/jcb.111.4.1373; KARENTAL I, 1993, MOL CELL ENDOCRINOL, V95, pR1; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; Lalli E, 1998, ENDOCRINOLOGY, V139, P4237, DOI 10.1210/en.139.10.4237; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MERZ WE, 1988, BIOCHEM BIOPH RES CO, V156, P1271, DOI 10.1016/S0006-291X(88)80770-8; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pollack SE, 1997, J CLIN ENDOCR METAB, V82, P4243, DOI 10.1210/jc.82.12.4243; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1995, J BIOL CHEM, V270, P28325; Selvaraj N, 1996, MOL CELL ENDOCRINOL, V123, P171, DOI 10.1016/S0303-7207(96)03916-0; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Stocco DM, 2000, J ENDOCRINOL, V164, P247, DOI 10.1677/joe.0.1640247; Stocco DM, 1998, REV REPROD, V3, P82, DOI 10.1530/ror.0.0030082; Strauss JF, 1999, RECENT PROG HORM RES, V54, P369; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; SUH BS, 1992, J CELL BIOL, V119, P439, DOI 10.1083/jcb.119.2.439; VANLOENEN HJ, 1995, J ENDOCRINOL, V147, P367, DOI 10.1677/joe.0.1470367; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; Yamamoto N, 1999, J NEUROCHEM, V73, P2415, DOI 10.1046/j.1471-4159.1999.0732415.x; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zeleznik AJ, 1999, TRENDS ENDOCRIN MET, V10, P189, DOI 10.1016/S1043-2760(98)00145-3; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	51	203	206	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13957	13964		10.1074/jbc.M006852200	http://dx.doi.org/10.1074/jbc.M006852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278318	hybrid, Green Published			2022-12-27	WOS:000168356600063
J	Goalstone, ML; Leitner, JW; Berhanu, P; Sharma, PM; Olefsky, JM; Draznin, B				Goalstone, ML; Leitner, JW; Berhanu, P; Sharma, PM; Olefsky, JM; Draznin, B			Insulin signals to prenyltransferases via the Shc branch of intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; RECEPTOR SUBSTRATE-1; MOLECULAR MECHANISMS; 3T3-L1 ADIPOCYTES; DNA-SYNTHESIS; FACTOR-I; FARNESYLTRANSFERASE; PHOSPHORYLATION; DOMAIN	We assessed the roles of insulin receptor substrate-1 (IRS-I) and She in insulin action on farnesyltransferase (FTase) and geranylgeranyltransferase I(GGTase I) using Chinese hamster ovary (CHO) cells that overexpress wild-type human insulin receptors (CHO-hIR-WT) or mutant insulin receptors lacking the NPEY domain (CHO-Delta NPEY) or 3T3-L1 fibroblasts transfected with adenoviruses that express the PTB or SAIN domain of IRS-1 and She, the pleckstrin homology (PH) domain of IRS-1, or the Src homology 2 (SH2) domain of She. Insulin promoted phosphorylation of the alpha -subunit of FTase and GGTase I in CHO-hIR-WT cells, but was without effect in CHO-Delta NPEY cells. Insulin increased FTase and GGTase I activities and the amounts of prenylated Pas and RhoA proteins in CHO-hIR-WT (but not CHO-Delta NPEY) cells. Overexpression of the PTB or SAIN domain of IRS-l (which blocked both IRS-1 and She signaling) prevented insulin-stimulated phosphorylation of the FTase and GGTase I alpha -subunit activation of FTase and GGTase I and subsequent increases in prenylated Res and RhoA proteins. In contrast, overexpression of the IRS-1 PH domain, which impairs IRS-1 (but not She) signaling, did not alter insulin action on the prenyltransferases, but completely inhibited the insulin effect on the phosphorylation of IRS-1 and on the activation of phosphatidylinositol 3-kinase and Akt. Finally, overexpression of the Shc SH2 domain completely blocked the insulin effect on FTase and GGTase I activities without interfering with insulin signaling to MAPK. These data suggest that insulin signaling from its receptor to the prenyltransferases FTase and GGTase I is mediated by the She pathway, but not the IRS-1/phosphatidylinositol 3-kinase pathway. She-mediated insulin signaling to MAPK may be necessary (but not sufficient) for activation of prenyltransferase activity, An additional pathway involving the She SH2 domain may be necessary to mediate the insulin effect on FTase and GGTase I.	VA Med Ctr 151, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA; Vet Affairs Med Ctr, Res Serv, La Jolla, CA 92161 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Whittier Diabet Inst, La Jolla, CA 92093 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego	Draznin, B (corresponding author), VA Med Ctr 151, Res Serv, 1055 Clermont St, Denver, CO 80220 USA.				NIDDK NIH HHS [DK 54475] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054475] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; Berhanu P, 1997, J BIOL CHEM, V272, P22884, DOI 10.1074/jbc.272.36.22884; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Draznin B, 2000, ENDOCRINOLOGY, V141, P1310, DOI 10.1210/en.141.4.1310; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; Goalstone ML, 1998, ENDOCRINOLOGY, V139, P4067, DOI 10.1210/en.139.10.4067; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1999, J BIOL CHEM, V274, P2880, DOI 10.1074/jbc.274.5.2880; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kim SJ, 1997, BIOCHEM J, V323, P621, DOI 10.1042/bj3230621; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WHITE MF, 1997, DIABETOLOGIA, V40, P2; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12805	12812		10.1074/jbc.M009443200	http://dx.doi.org/10.1074/jbc.M009443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278505	hybrid			2022-12-27	WOS:000168198600049
J	Ke, N; Godzik, A; Reed, JC				Ke, N; Godzik, A; Reed, JC			Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CYTOCHROME-C; PROTEINS; EXPRESSION; MECHANISMS; APOPTOSIS; HOMOLOG; APAF-1	A novel human member of the Bcl-2 family was identified, Bcl-B, which is closest in amino acid sequence homology to the Boo (Diva) protein. The Bcl-B protein contains four Bcl-2 homology (BH) domains (BH1, BH2, BH3, BH4) and a predicted carboxyl-terminal transmembrane (TM) domain. The BCL-B mRNA is widely expressed in adult human tissues. The Bcl-B protein binds Bcl-2, Bcl-X-L, and Bax but not Bah. In transient transfection assays, Bcl-B suppresses apoptosis induced by Bax but not Bah. Deletion of the TM domain of Bcl-B impairs its association with intracellular organelles and diminishes its anti-apoptotic function. Bcl-B thus displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Godzik, Adam/AAW-1467-2020; Godzik, Adam/A-7279-2009	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-60554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Krajewska M, 1996, AM J PATHOL, V148, P1567; Middleton G, 1996, DEVELOPMENT, V122, P695; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	17	94	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12481	12484		10.1074/jbc.C000871200	http://dx.doi.org/10.1074/jbc.C000871200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278245	hybrid			2022-12-27	WOS:000168198600002
J	Yamamoto, K; Ishikawa, H; Takahashi, S; Ishimori, K; Morishima, I; Nakajima, H; Aono, S				Yamamoto, K; Ishikawa, H; Takahashi, S; Ishimori, K; Morishima, I; Nakajima, H; Aono, S			Binding of CO at the Pro(2) side is crucial for the activation of CO-sensing transcriptional activator CooA - H-1 NMR spectroscopic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; RHODOSPIRILLUM-RUBRUM; HEME PROTEIN; CYTOCHROME-F; AQUEOUS-SOLUTIONS; LIGAND; LIGATION; IDENTIFICATION; HISTIDINE-77; SPECTRA	CooA is a heme-containing transcriptional activator that anaerobically binds to DNA at CO atmosphere. To obtain information on the conformational transition of CooA induced by CO binding to the heme, we assigned ring current-shifted H-1 NMR signals of CooA using two mutants whose axial Ligands of the heme were replaced. In the absence of CO, the NMR spectral pattern of H77T CooA in which the axial histidine (His(77)) was replaced with tyrosine, was similar to that of wild-type CooA. In contrast, the spectra of CooA Delta N5, in which the NH2 termini including the other axial ligand (Pro(2)) were deleted, were drastically modulated. We assigned three signals of wild-type CooA at -4.5, -3.6, and -2.8 ppm to delta (1)-, alpha-, and delta (2)-protons of Pro(2), respectively. The Pro(2) signals were undetectable in the upfield region of the spectrum of the CO-bound state, which confirms that CO displaces Pro(2), Interestingly, the Pro(2) signals were observed for CO-bound H77Y CooA implying that CO binds to the trans position of Pro(2) in H77Y CooA. The abolished CO-dependent transcriptional activity of H77Y CooA is therefore the consequence of Pro(2) ligation. These observations are consistent with the view that the movement of the NH2 terminus triggers the conformational transition to the DNA binding form.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Kyoto University; Japan Advanced Institute of Science & Technology (JAIST)	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Aono, Shigetoshi/ABD-7618-2020; Ishimori, Koichiro/AAQ-4434-2021; Ishimori, Koichiro/S-1247-2016; Ishikawa, Haruto/B-1562-2012	Aono, Shigetoshi/0000-0002-2870-3694; Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Ishikawa, Haruto/0000-0001-6362-5719				Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; DAVIS DJ, 1988, BIOCHIM BIOPHYS ACTA, V936, P61, DOI 10.1016/0005-2728(88)90251-4; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; GAO F, 1999, BIOCHIM BIOPHYS ACTA, V1430, P3; GUILES RD, 1992, BIOCHEMISTRY-US, V31, P11365, DOI 10.1021/bi00161a014; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HORE PJ, 1983, J MAGN RESON, V54, P539, DOI 10.1016/0022-2364(83)90335-9; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KITAGAWA T, 1975, J BIOCHEM-TOKYO, V78, P719, DOI 10.1093/oxfordjournals.jbchem.a130960; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; RIGBY SEJ, 1988, BIOCHEM J, V256, P571, DOI 10.1042/bj2560571; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; UBBINK M, 1994, BIOCHEMISTRY-US, V33, P10051, DOI 10.1021/bi00199a032; Uchida T, 1997, BIOCHEMISTRY-US, V36, P324, DOI 10.1021/bi960591z; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r	27	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11473	11476		10.1074/jbc.C100047200	http://dx.doi.org/10.1074/jbc.C100047200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278259	hybrid			2022-12-27	WOS:000168081800008
J	Bandeira-Melo, C; Phoofolo, M; Weller, PF				Bandeira-Melo, C; Phoofolo, M; Weller, PF			Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C-4 production in eosinophils and basophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PLATELET-ACTIVATING-FACTOR; HUMAN BLOOD EOSINOPHILS; 5-LIPOXYGENASE PATHWAY; EICOSANOID GENERATION; ARACHIDONIC-ACID; BODY FORMATION; CELLS; COMPARTMENTALIZATION	Eosinophils and basophils, when activated, become major sources of cysteinyl leukotrienes, eicosanoid mediators pertinent to allergic inflammation. We show that the C-C chemokines, eotaxin and RANTES (regulated upon activation normal T cell expressed and secreted), activate eosinophils and basophils for enhanced leukotriene C-4 (LTC4) generation by distinct signaling and compartmentalization mechanisms involving the induced formation of new cytoplasmic lipid body organelles, Chemokine-induced lipid body formation and enhanced LTC4 release were both mediated by CCR3 receptor G protein-linked downstream signaling involving activation of phosphoinositide 3-kinase, extracellular signal-regulated kinases 1 and 2, and p38 mitogen-activated protein kinases. Chemokine-elicited lipid body numbers correlated with increased calcium ionophore-stimulated LTC4 production and as demonstrated by intracellular immunofluorescent localization of newly formed eicosanoid, lipid bodies were the predominant sites of LTC4 synthesis in both chemokine-stimulated eosinophils and chemokine-primed and ionophore-activated eosinophils. Eotaxin and RANTES initiated signaling via phosphoinositide S-kinase and mitogen-activated protein kinases both elicits the formation of lipid body domains and promotes LTC4 formation at these specific extranuclear sites.	Harvard Univ, Beth Israel Deaconess Med Ctr, Charles A Dana Res Inst, Harvard Thorndike Labs,Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Weller, PF (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Charles A Dana Res Inst, Harvard Thorndike Labs,Dept Med, DA-617,330 Brookline Ave, Boston, MA 02215 USA.		Bandeira-Melo, Christianne/X-5619-2019; de Melo, Christianne Bandeira/B-7724-2009	Bandeira-Melo, Christianne/0000-0003-3305-3865; de Melo, Christianne Bandeira/0000-0003-3305-3865	NHLBI NIH HHS [HL56386] Funding Source: Medline; NIAID NIH HHS [AI41995, AI22571, AI20241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241, U19AI041995, R37AI020241, R01AI022571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bandeira-Melo C, 2000, J IMMUNOL METHODS, V244, P105, DOI 10.1016/S0022-1759(00)00264-7; Bartemes KR, 1999, J IMMUNOL, V162, P2982; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091; Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515; Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563, DOI 10.1002/jlb.64.4.563; Brock TG, 1999, J IMMUNOL, V162, P1669; COIMBRA A, 1971, J HISTOCHEM CYTOCHEM, V19, P551, DOI 10.1177/19.9.551; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Cowburn AS, 1999, J IMMUNOL, V163, P456; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245; DVORAK AM, 1992, INT ARCH ALLERGY IMM, V99, P208, DOI 10.1159/000236250; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; HAINES KA, 1986, BIOCHEM J, V233, P583, DOI 10.1042/bj2330583; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIU LX, 1992, AM J TROP MED HYG, V46, P520, DOI 10.4269/ajtmh.1992.46.520; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; OGAWA H, 1998, PROSTAGLANDINS, V36, P891; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; ROBINSON JM, 1982, J CELL BIOL, V95, P933, DOI 10.1083/jcb.95.3.933; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; Sabroe I, 1999, J IMMUNOL, V162, P2946; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; Scarfo LM, 2001, AM J PHYSIOL-HEART C, V280, pH294, DOI 10.1152/ajpheart.2001.280.1.H294; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELLER PF, 1991, J CELL BIOL, V113, P137, DOI 10.1083/jcb.113.1.137; WELLER PF, 1991, AM J PATHOL, V138, P141; WELLER PF, 1993, IMMUNOPHARMACOLOGY E, P25; WELLER PF, 2000, ASTHMA RHINITIS, P351; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; [No title captured]	43	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22779	22787		10.1074/jbc.M101436200	http://dx.doi.org/10.1074/jbc.M101436200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11274187	hybrid			2022-12-27	WOS:000169412700107
J	Campanacci, V; Krieger, J; Bette, S; Sturgis, JN; Lartigue, A; Cambillau, C; Breer, H; Tegoni, M				Campanacci, V; Krieger, J; Bette, S; Sturgis, JN; Lartigue, A; Cambillau, C; Breer, H; Tegoni, M			Revisiting the specificity of Mamestra brassicae and Antheraea polyphemus pheromone-binding proteins with a fluorescence binding assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ODORANT-BINDING; MOLECULAR-CLONING; MANDUCA-SEXTA; SILKWORM MOTH; EXPRESSION; SITE; DNA	Pheromone-binding proteins (PBPs), located in the sensillum lymph of pheromone-responsive antennal hairs, are thought to transport the hydrophobic pheromones to the chemosensory membranes of olfactory neurons. It is currently unclear what role PBPs may play in the recognition and discrimination of species-specific pheromones, We have investigated the binding properties and specificity of PBPs from Mamestra brassicae (MbraPBP1), Antheraea polyphemus (ApolPBP1), Bombyx mori (BmorPBP), and a hexa-mutant of MbraPBP1 (Mbra1-M6), mutated at residues of the internal cavity to mimic that of BmorPBP, using the fluorescence probe 1-aminoanthracene (AMA), AMA binds to MbraPBP1 and ApolPBP1, however, no binding was observed with either BmorPBP or Mbra1-M6. The latter result indicates that relatively limited modifications to the PBP cavity actually interfere with AMA binding, suggesting that ARIA binds in the internal cavity. Several pheromones are able to displace AMA from the MbraPBP1- and ApolPBP1-binding sites, without, however, any evidence of specificity for their physiologically relevant pheromones. Moreover, some fatty acids are also able to compete with AMA binding. These findings bring into doubt the currently held belief that all PBPs are specifically tuned to distinct pheromonal compounds.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Univ Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany; CNRS, Lab Ingn Syst Macromol, UPR 9027, IFR1, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University Hohenheim; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Tegoni, M (corresponding author), CNRS, UMR 6098, 31 Ch Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs.mrs.fr; tegoni@afmb.cnrs-mrs.fr	Sturgis, James/F-6051-2011; Sturgis, James/AAU-8103-2020	Sturgis, James/0000-0001-5125-7699; Campanacci, Valerie/0000-0001-6407-6395				Briand L, 2000, EUR J BIOCHEM, V267, P3079, DOI 10.1046/j.1432-1033.2000.01340.x; Briand L, 2000, FEBS LETT, V476, P179, DOI 10.1016/S0014-5793(00)01719-1; Campanacci V, 1999, EUR J BIOCHEM, V264, P707, DOI 10.1046/j.1432-1327.1999.00666.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DU GH, 1994, BIOCHEMISTRY-US, V33, P4812, DOI 10.1021/bi00182a009; DU GH, 1995, BIOCHEMISTRY-US, V34, P8726, DOI 10.1021/bi00027a023; FEIXAS J, 1995, EUR J BIOCHEM, V234, P521, DOI 10.1111/j.1432-1033.1995.521_b.x; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kaissling KE, 1996, CHEM SENSES, V21, P257, DOI 10.1093/chemse/21.2.257; KRIEGER J, 1991, BIOCHIM BIOPHYS ACTA, V1088, P277, DOI 10.1016/0167-4781(91)90064-S; KRIEGER J, 1993, INSECT BIOCHEM MOLEC, V23, P449, DOI 10.1016/0965-1748(93)90052-T; Krieger J, 1996, INSECT BIOCHEM MOLEC, V26, P297, DOI 10.1016/0965-1748(95)00096-8; KRIEGER J, 1992, EUR J BIOCHEM, V203, P161, DOI 10.1111/j.1432-1033.1992.tb19841.x; Krieger Juergen, 1997, Invertebrate Neuroscience, V3, P137, DOI 10.1007/BF02480368; Leal WS, 2000, BIOCHEM BIOPH RES CO, V268, P521, DOI 10.1006/bbrc.2000.2158; Leal WS, 1999, FEBS LETT, V464, P85, DOI 10.1016/S0014-5793(99)01683-X; Lobel D, 1998, EUR J BIOCHEM, V254, P318, DOI 10.1046/j.1432-1327.1998.2540318.x; Maibeche-Coisne M, 1998, INSECT BIOCHEM MOLEC, V28, P815, DOI 10.1016/S0965-1748(98)00080-0; MaibecheCoisne M, 1997, INSECT BIOCHEM MOLEC, V27, P213, DOI 10.1016/S0965-1748(96)00088-4; Maida R, 2000, EUR J BIOCHEM, V267, P2899, DOI 10.1046/j.1432-1327.2000.01303.x; Merritt TJS, 1998, J MOL EVOL, V46, P272, DOI 10.1007/PL00006303; Patel RC, 1997, PROTEIN ENG, V10, P621, DOI 10.1093/protein/10.6.621; Pelosi P, 1996, J NEUROBIOL, V30, P3; Plettner E, 2000, BIOCHEMISTRY-US, V39, P8953, DOI 10.1021/bi000461x; Pophof B, 2000, J COMP PHYSIOL A, V186, P315, DOI 10.1007/s003590050432; PRESTWICH GD, 1995, CHEM SENSES, V20, P461, DOI 10.1093/chemse/20.4.461; PRESTWICH GD, 1993, PROTEIN SCI, V2, P420; RAMING K, 1989, FEBS LETT, V256, P215, DOI 10.1016/0014-5793(89)81751-X; Robertson HM, 1999, INSECT MOL BIOL, V8, P501, DOI 10.1046/j.1365-2583.1999.00146.x; ROUSSEL A, 1991, TURBO FRODO GRAPHICS, V81; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; Spinelli S, 1998, BIOCHEMISTRY-US, V37, P7913, DOI 10.1021/bi980179e; Tegoni M, 2000, BBA-PROTEIN STRUCT M, V1482, P229, DOI 10.1016/S0167-4838(00)00167-9; Tegoni M, 1996, NAT STRUCT BIOL, V3, P863, DOI 10.1038/nsb1096-863; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1985, P NATL ACAD SCI USA, V82, P8827, DOI 10.1073/pnas.82.24.8827; VOGT RG, 1991, J NEUROSCI, V11, P2972; Wojtasek H, 1999, J BIOL CHEM, V274, P30950, DOI 10.1074/jbc.274.43.30950; ZIEGELBERGER G, 1995, EUR J BIOCHEM, V232, P706, DOI 10.1111/j.1432-1033.1995.tb20864.x	42	169	184	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20078	20084		10.1074/jbc.M100713200	http://dx.doi.org/10.1074/jbc.M100713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274212	hybrid			2022-12-27	WOS:000169135100055
J	Dayanir, V; Meyer, RD; Lashkari, K; Rahimi, N				Dayanir, V; Meyer, RD; Lashkari, K; Rahimi, N			Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PHOSPHOLIPASE-C; IN-VIVO; FLT-1; ANGIOGENESIS; BINDING; SITE; MICE; KDR; PI-3-KINASE	Activation of vascular endothelial growth factor receptor-2 (VEGFR-8) plays a critical role in vasculogenesis and angiogenesis, However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular domain of human CSF-1R/c-fms, fused with the entire transmembrane and cytoplasmic domains of murine VEGFR-2 (Rahimi, N., Dayanir, V., and Lashkari, K, (2000) J. Biol, Chem, 275, 16986-16992), In this study we used VEGFR-2 chimera (herein named CKR) to elucidate the signal transduction relay of VEGFR-2 in porcine aortic endothelial (PAE) cells. Mutation of tyrosines 799 and 1173 individually on CKR resulted in partial loss of CKR's ability to stimulate cell growth. Double mutation of these sites caused total loss of CKR's ability to stimulate cell growth. Interestingly, mutation of these sites had no effect on the ability of CKR to stimulate cell migration. Further analysis revealed that tyrosines 799 and 1173 are docking sites for p85 of phosphatidylinositol 3-kinase (PI3K), Pretreatment of cells with wortmannin, an inhibitor of PI3K, and rapamycin, a potent inhibitor of S6 kinase, abrogated CKR-mediated cell growth. However, expression of a dominant negative form of res (N(17)ras) and inhibition of the mitogen-activated protein kinase (MAPK) pathway by PD98059 did not attenuate CKR-stimulated cell growth. Altogether, these results demonstrate that activation of VEGFR-2 results in activation of PI3K and that activation of PI3K/S6kinase pathway, but not Ras/MAPK, is responsible for VEGFR-2-mediated cell growth.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Rm L921, Boston, MA 02118 USA.			Lashkari, Kameran/0000-0003-3855-0246; Rahimi, Nader/0000-0002-6745-1725				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Derman MP, 1996, J BIOL CHEM, V271, P4251; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SONYANG Z, 1993, CELL, V72, P767; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; YANO H, 1993, J BIOL CHEM, V268, P25846	39	135	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17686	17692		10.1074/jbc.M009128200	http://dx.doi.org/10.1074/jbc.M009128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278468	hybrid			2022-12-27	WOS:000168866500010
J	Hu, BC; Zhou, XY; Wang, X; Zeng, ZC; Iliakis, G; Wang, Y				Hu, BC; Zhou, XY; Wang, X; Zeng, ZC; Iliakis, G; Wang, Y			The radioresistance to killing of A1-5 cells derives from activation of the Chk1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND BREAKS; INDUCED G2 DELAY; ONCOGENES H-RAS; 7-HYDROXYSTAUROSPORINE UCN-01; PROTEIN-KINASE; RADIOSENSITIZING AGENT; EUKARYOTIC CELLS; CYCLE REGULATION; MAMMALIAN-CELLS	Checkpoints respond to DNA damage by arresting the cell cycle to provide time for facilitating repair. In mammalian cells, the G(2) checkpoint prevents the Cdc25C phosphatase from removing inhibitory phosphate groups from the mitosis-promoting kinase Cdc2. Both Chk1 and Chk2, the checkpoint kinases, can phosphorylate Cdc25C and inactivate its in vitro phosphatase activity. Therefore, both Chk1 and Chk2 are thought to regulate the activation of the G(2) checkpoint. Here we report that A1-5, a transformed rat embryo fibroblast cell line, shows much more radioresistance associated with a much stronger G(2) arrest response when compared with its counterpart, B4, although A1-5 and B4 cells have a similar capacity for nonhomologous end-joining DNA repair. These phenotypes of A1-5 cells are accompanied by a higher Chk1 expression and a higher phosphorylation of Cdc2, On the other hand, Chk2 expression increases slightly following radiation; however, it has no difference between A1-5 and B4 cells. Caffeine or UCN-01 abolishes the extreme radioresistance with the strong G(2) arrest and at the same time reduces the phosphorylation of Cdc2 in A1-5 cells. In addition, Chk1 but not Chk2 antisense oligonucleotide sensitizes A1-5 cells to radiation-induced killing and reduces the G(2) arrest of the cells. Taken together these results suggest that the Chk1/Cdc25C/Cdc2 pathway is the major player for the radioresistance with G(2) arrest in A1-5 cells.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University	Wang, Y (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Thompson Bldg,B13,11th & Walnut St, Philadelphia, PA 19107 USA.				NCI NIH HHS [T32-CA09137, P30-CA56036, CA76203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, R29CA076203, T32CA009137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; Busby EC, 2000, CANCER RES, V60, P2108; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Dibiase SJ, 2000, CANCER RES, V60, P1245; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; ILIAKIS G, 1991, BIOESSAYS, V13, P641; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; Kanaar Roland, 1997, Genes and Function, V1, P165; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; KIMLER BF, 1982, INT J RADIAT BIOL, V41, P47, DOI 10.1080/09553008214550041; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; Liu QH, 2000, GENE DEV, V14, P1448; LUCKEHUHLE C, 1982, RADIAT RES, V89, P298, DOI 10.2307/3575776; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWERS SK, 1995, INT J SPORTS MED, V16, P13, DOI 10.1055/s-2007-972956; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROWLEY R, 1992, RADIAT RES, V132, P144, DOI 10.2307/3578519; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shao RG, 1997, CANCER RES, V57, P4029; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG Y, 1992, CANCER RES, V52, P508; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	45	57	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17693	17698		10.1074/jbc.M009340200	http://dx.doi.org/10.1074/jbc.M009340200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278490	hybrid			2022-12-27	WOS:000168866500011
J	Yoshimura, K; Takeuchi, H; Sato, O; Hidaka, K; Doira, N; Terunuma, M; Harada, K; Ogawa, Y; Ito, Y; Kanematsu, T; Hirata, M				Yoshimura, K; Takeuchi, H; Sato, O; Hidaka, K; Doira, N; Terunuma, M; Harada, K; Ogawa, Y; Ito, Y; Kanematsu, T; Hirata, M			Interaction of p130 with, and consequent inhibition of, the catalytic subunit of protein phosphatase 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE BINDING DOMAIN; INACTIVE PROTEIN; STRUCTURAL BASIS; INOSITOL; PLECKSTRIN; IDENTIFICATION	The protein p130 was originally isolated from rat brain as an inositol 1,4,5-trisphosphate-binding protein with a domain organization similar to that of phospholipase C-delta1 but which lacks phospholipase C activity. Yeast two-hybrid screening of a human brain cDNA library for clones that encode proteins that interact with p130 has now led to the identification of the catalytic subunit of protein phosphatase 1 alpha (PP1c alpha) as a p130-binding protein. The association between p130 and PP1c alpha was also confirmed in vitro by an overlay assay, a "pull-down" assay, and surface plasmon resonance analysis. The interaction of p130 with PP1c alpha resulted in inhibition of the catalytic activity of the latter in a p130 concentration-dependent manner. Immunoprecipitation and immunoblot analysis of COS-1 cells that stably express p130 and of mouse brain extract with antibodies to p130 and to PP1c alpha also detected the presence of a complex of p130 and PP1c alpha, The activity of glycogen phosphorylase, which is negatively regulated by dephosphorylation by PP1c alpha, was higher in COS-1 cells that stably express p130 than in control COS-1 cells. These results suggest that, in addition to its role in inositol 1,4,5-trisphosphate and Ca2+ signaling, p130 might also contribute to regulation of protein dephosphorylation through its interaction with PP1c alpha.	Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med Sci, Stn Collaborat Res, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med Sci, Pharmacol Lab, Fukuoka 8128582, Japan; Juntendo Univ, Sch Med, Dept Pharmacol, Tokyo 1138421, Japan	Kyushu University; Kyushu University; Kyushu University; Juntendo University	Hirata, M (corresponding author), Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.	hirata1@dent.kyushu-u.ac.jp	Harada, Kae/AAT-1162-2020	Harada, Kae/0000-0001-7620-9212; Terunuma, Miho/0000-0003-1876-9726				Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CORI GT, 1955, METHOD ENZYMOL, V1, P200, DOI 10.1016/0076-6879(55)01027-6; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; HIRATA M, 1985, NATURE, V317, P723, DOI 10.1038/317723a0; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; Hirata M, 1998, JPN J PHARMACOL, V76, P255, DOI 10.1254/jjp.76.255; HIRATA M, 1994, BIOCHEM BIOPH RES CO, V205, P1563, DOI 10.1006/bbrc.1994.2845; Kanematsu T, 1996, BIOCHEM J, V313, P319, DOI 10.1042/bj3130319; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kanematsu T, 2000, EUR J BIOCHEM, V267, P2731, DOI 10.1046/j.1432-1327.2000.01291.x; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; KOHNO T, 1995, HUM MOL GENET, V4, P667, DOI 10.1093/hmg/4.4.667; Koyanagi M, 1998, FEBS LETT, V439, P66, DOI 10.1016/S0014-5793(98)01339-8; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Otsuki M, 1999, BIOCHEM BIOPH RES CO, V266, P97, DOI 10.1006/bbrc.1999.1784; OZAKI S, 1986, TETRAHEDRON LETT, V27, P3157, DOI 10.1016/S0040-4039(00)84742-5; Sato O, 1999, J BIOCHEM-TOKYO, V126, P787, DOI 10.1093/oxfordjournals.jbchem.a022518; STRYER L, 1995, BIOCHEMISTRY-US, P581; Takeuchi H, 2000, BIOCHEM J, V349, P357, DOI 10.1042/0264-6021:3490357; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Takeuchi H, 1996, BIOCHEM J, V318, P561, DOI 10.1042/bj3180561; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOSHIDA M, 1994, J BIOCHEM, V115, P973, DOI 10.1093/oxfordjournals.jbchem.a124447	26	57	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17908	17913		10.1074/jbc.M009677200	http://dx.doi.org/10.1074/jbc.M009677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278544	hybrid			2022-12-27	WOS:000168866500041
J	Fiedler, E; Golbik, R; Schneider, G; Tittmann, K; Neef, H; Konig, S; Hubner, G				Fiedler, E; Golbik, R; Schneider, G; Tittmann, K; Neef, H; Konig, S; Hubner, G			Examination of donor substrate conversion in yeast transketolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE-DEPENDENT ENZYME; SITE-DIRECTED MUTAGENESIS; THIAMIN DIPHOSPHATE; PYRUVATE DECARBOXYLASE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; CATALYSIS; COMPLEX; CRYSTALLOGRAPHY	The cleavage of the donor substrate D-xylulose 5-phosphate by wild-type and H263A mutant yeast transketolase was studied using enzyme kinetics and circular dichroism spectroscopy. The enzymes are able to catalyze the cleavage of donor substrates, the first half-reaction, even in the absence of any acceptor substrate yielding D-glyceraldehyde 3-phosphate as measured in the coupled optical test according to Kochetov (Kochetov, G. A. (1982) Methods Enzymol. 90, 209-223) and compared with the H263A variant. Overall, the H263A mutant enzyme is less active than the wild-type. However, an increase in the rate constant of the release of the enzyme-bound glycolyl moiety was observed and related to a stabilization of the "active glycolaldehyde" (alpha -carbanion) by histidine 263. Chemically synthesized DL-(alpha,beta -dihydroxyethyl)thiamin diphosphate is bound to wild-type transketolase with an apparent K-D of 4.3 +/- 0.8 muM (racemate) calculated from titration experiments using circular dichroism spectroscopy. Both enantiomers are cleaved by the enzyme at different rates. In contrast to the enzyme-generated alpha -carbanion of (alpha,beta -dihydroxyethyl)thiamin diphosphate formed by decarboxylation of hydroxylactylthiamin diphosphate after incubation of transketolase with beta -hydroxypyruvate, the synthesized DL-(alpha,beta -dihydroxyethyl)thiamin diphosphate did not work as donor substrate when erythrose 4-phosphate is used as acceptor substrate in the coupled enzymatic test according to Sprenger.	Univ Halle Wittenberg, Inst Biochem, Dept Biochem & Biotechnol, D-06120 Halle, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden	Martin Luther University Halle Wittenberg; Karolinska Institutet	Hubner, G (corresponding author), Univ Halle Wittenberg, Inst Biochem, Dept Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.		Koenig, Stephan/GRX-2480-2022	Schneider, Gunter/0000-0003-0622-5713; Fiedler, Erik/0000-0001-7345-5266				Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HASSON MS, 1995, PROTEIN SCI, V4, P955; HEINRICH PC, 1971, BIOCHEM BIOPH RES CO, V44, P275; HOLZER H, 1962, BIOCHEM BIOPH RES CO, V7, P167, DOI 10.1016/0006-291X(62)90168-7; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; KOCHETOV GA, 1970, FEBS LETT, V9, P265, DOI 10.1016/0014-5793(70)80372-6; KOCHETOV GA, 1973, BIOCHEM BIOPH RES CO, V54, P1619, DOI 10.1016/0006-291X(73)91172-8; KOHORI Y, 1992, J ORG CHEM, V57, P5899; KONIG S, 1994, J BIOL CHEM, V269, P10879; Krampitz L.O., 1966, METHOD ENZYMOL, V9, P65; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; Nilsson U, 1997, J BIOL CHEM, V272, P1864, DOI 10.1074/jbc.272.3.1864; Nilsson U, 1998, FEBS LETT, V424, P49, DOI 10.1016/S0014-5793(98)00136-7; Schenk G, 1998, INT J BIOCHEM CELL B, V30, P1297, DOI 10.1016/S1357-2725(98)00095-8; Schneider G, 1998, BBA-PROTEIN STRUCT M, V1385, P387, DOI 10.1016/S0167-4838(98)00082-X; Sprenger GA, 1999, J MOL CATAL B-ENZYM, V6, P145, DOI 10.1016/S1381-1177(98)00107-6; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; SPRENGER GA, 1995, EUR J BIOCHEM, V230, P525; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; WIKNER C, 1995, EUR J BIOCHEM, V233, P750, DOI 10.1111/j.1432-1033.1995.750_3.x; WIKNER C, 1994, J BIOL CHEM, V269, P32144; Wikner C, 1997, BIOCHEMISTRY-US, V36, P15643, DOI 10.1021/bi971606b	33	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16051	16058		10.1074/jbc.M007936200	http://dx.doi.org/10.1074/jbc.M007936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278369	hybrid			2022-12-27	WOS:000168623100066
J	Rosado, JA; Porras, T; Conde, M; Sage, SO				Rosado, JA; Porras, T; Conde, M; Sage, SO			Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein-tyrosine phosphatases and altered actin polymerization in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FURA-2-LOADED HUMAN-PLATELETS; STIMULATED PHOSPHOPROTEIN VASP; PLASMA-MEMBRANE CA2+-ATPASE; VASCULAR ENDOTHELIAL-CELLS; INTRACELLULAR CA2+ STORES; INTACT HUMAN PLATELETS; IN-VITRO; KINASE-B; PHOSPHORYLATION; CYTOSKELETON	Agonists elevate the cytosolic calcium concentration in human platelets via a receptor-operated mechanism, involving both Ca2+ release from intracellular stores and subsequent Ca2+ entry, which can be inhibited by platelet inhibitors, such as prostaglandin E-1 and nitroprusside which elevate cAMP and cGMP, respectively. In the present study we investigated the mechanisms by which cAMP and cGMP modulate store-mediated Ca2+ entry. Both prostaglandin E-1 and sodium nitroprusside inhibited thapsigargin-evoked store-mediated Ca2+ entry and actin polymerization. However, addition of these agents after induction of store-mediated Ca2+ entry did not affect either Ca2+ entry or actin polymerization. Furthermore, prostaglandin E-1 and sodium nitroprusside dramatically inhibited the tyrosine phosphorylation induced by depletion of the internal Ca2+ stores or agonist stimulation without affecting the activation of Ras or the Ras-activated phosphatidylinositol 3-kinase or extracellular signal-related kinase (ERK) pathways. Inhibition of cyclic nucleotide-dependent protein kinases prevented inhibition of agonist-evoked Ca2+ release but it did not have any effect on the inhibition of Ca2+ entry or actin polymerization. Phenylarsine oxide and vanadate, inhibitors of protein-tyrosine phosphatases prevented the inhibitory effects of the cGMP and cAMP elevating agents on Ca2+ entry and actin polymerization. These results suggest that Ca2+ entry in human platelets is directly down-regulated by cGMP and cAMP by a mechanism involving the inhibition of cytoskeletal reorganization via the activation of protein tyrosine phosphatases.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Cambridge	Sage, SO (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.		Rosado, Juan A/H-3488-2015	Rosado, Juan A/0000-0002-9749-2325; Sage, Stewart/0000-0001-8578-3558				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUTT E, 1994, J BIOL CHEM, V269, P14509; Catalan RE, 1997, FEBS LETT, V400, P280, DOI 10.1016/S0014-5793(96)01405-6; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Kwan HY, 2000, J BIOL CHEM, V275, P6758, DOI 10.1074/jbc.275.10.6758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMOR G, 1997, SCIENCE, V277, P1103; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; NAKAMURA K, 1995, BIOCHEM J, V310, P263, DOI 10.1042/bj3100263; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; RINK TJ, 1987, J PHYSIOL-LONDON, V393, P513, DOI 10.1113/jphysiol.1987.sp016837; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; Rosado JA, 2000, J BIOL CHEM, V275, P19529, DOI 10.1074/jbc.M001319200; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SARGEANT P, 1994, CELL CALCIUM, V16, P413, DOI 10.1016/0143-4160(94)90034-5; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130	41	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15666	15675		10.1074/jbc.M009217200	http://dx.doi.org/10.1074/jbc.M009217200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278478	hybrid			2022-12-27	WOS:000168623100015
J	Sahlgren, CM; Mikhailov, A; Hellman, J; Chou, YH; Lendahl, U; Goldman, RD; Eriksson, JE				Sahlgren, CM; Mikhailov, A; Hellman, J; Chou, YH; Lendahl, U; Goldman, RD; Eriksson, JE			Mitotic reorganization of the intermediate filament protein nestin involves phosphorylation by cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; MONOCLONAL-ANTIBODIES DISTINGUISH; RHO-ASSOCIATED KINASE; HUMAN KERATIN-18; STEM-CELLS; IN-VITRO; VIMENTIN; IDENTIFICATION; EXPRESSION; SITES	The intermediate filament protein nestin is expressed during early stages of development in the central nervous system and in muscle tissues. Nestin expression is associated with morphologically dynamic cells, such as dividing and migrating cells. However, little is known about regulation of nestin during these cellular processes. We have characterized the phosphorylation-based regulation of nestin during different stages of the cell cycle in a neuronal progenitor cell line, ST15A. Confocal microscopy of nestin organization and P-32 in vivo labeling studies show that the mitotic reorganization of nestin is accompanied by elevated phosphorylation of nestin. The phosphorylation-induced alterations in nestin organization during mitosis in ST15A cells are associated with partial disassembly of nestin filaments. Comparative in vitro and in vivo phosphorylation studies identified cdc2 as the primary mitotic kinase and Thr(316) as a cdc2-specific phosphorylation site on nestin. We generated a phosphospecific nestin antibody recognizing the phosphorylated form of this site. By using this antibody we observed that nestin shows constitutive phosphorylation at Thr316, which is increased during mitosis. This study shows that nestin is reorganized during mitosis and that cdc2-mediated phosphorylation is an important regulator of nestin organization and dynamics during mitosis.	Univ Turku, Dept Biol, Physiol Anim Lab, FIN-20014 Turku, Finland; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Northwestern Univ, Sch Med, Dept Cell Mol & Struct Biol, Chicago, IL 60611 USA; Russian Acad Med Sci, Canc Res Ctr, Moscow 115478, Russia; Abo Akad Univ, BioCity, Dept Biol, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20521 Turku, Finland	University of Turku; Karolinska Institutet; Northwestern University; Russian Academy of Medical Sciences; Abo Akademi University; University of Turku	Eriksson, JE (corresponding author), Univ Turku, Dept Biol, Physiol Anim Lab, Sci Bldg 1, FIN-20014 Turku, Finland.	john.eriksson@utu.fi		Sahlgren, Cecilia/0000-0003-3350-4937; , cecilia/0000-0001-6365-6275; Lendahl, Urban/0000-0001-9543-8141				Ando S, 1996, BIOCHEM BIOPH RES CO, V221, P67, DOI 10.1006/bbrc.1996.0546; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chou YH, 1996, J CELL SCI, V109, P817; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Eriksson JE, 1998, METHOD ENZYMOL, V298, P542, DOI 10.1016/S0076-6879(98)98044-2; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Frojdman K, 1997, DIFFERENTIATION, V61, P243, DOI 10.1046/j.1432-0436.1997.6140243.x; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; Goldman RD, 1999, FASEB J, V13, pS261, DOI 10.1096/fasebj.13.9002.S261; GOSS VL, 1994, J BIOL CHEM, V269, P19074; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; Klymkowsky MW, 1996, CANCER METAST REV, V15, P417, DOI 10.1007/BF00054010; Kosako H, 1997, J BIOL CHEM, V272, P10333; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LEE VMY, 1987, J NEUROSCI, V7, P3474; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; SEJERSEN T, 1993, J CELL SCI, V106, P1291; SJOBERG G, 1994, EXP CELL RES, V214, P447, DOI 10.1006/excr.1994.1281; SKALLI O, 1992, Trends in Cell Biology, V2, P308, DOI 10.1016/0962-8924(92)90121-3; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TOHYAMA T, 1992, LAB INVEST, V66, P303; Toivola DM, 1997, J CELL SCI, V110, P23; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Vaittinen S, 1999, AM J PATHOL, V154, P591, DOI 10.1016/S0002-9440(10)65304-7; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1; [No title captured]	60	100	102	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16456	16463		10.1074/jbc.M009669200	http://dx.doi.org/10.1074/jbc.M009669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278541	hybrid			2022-12-27	WOS:000168623100118
J	Su, B; Cheng, JK; Yang, JH; Guo, ZJ				Su, B; Cheng, JK; Yang, JH; Guo, ZJ			MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PROTEIN-KINASE; C-JUN; MOLECULAR-CLONING; PATHWAYS; TRANSDUCTION; MKK7; P38; IDENTIFICATION; SAPK/JNK	The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) gene family and are essential for cell proliferation, differentiation, and apoptosis. Previously we found that activation of JNK in T-cells required costimulation of both T-cell receptor and auxiliary receptors such as CD28, In this study, we cloned a full-length human MEK kinase (MEKK) 2 cDNA from Jurkat T-cells and demonstrated that it was a major upstream MAPK kinase kinase for the JNK cascade in T-cells. The human MEKK2 cDNA encoded a polypeptide of 619 amino acids and was the human counterpart of the reported murine MEKK2, It was 94% homologous with human and murine MEKK3 at the catalytic domains and 60% homologous at the N-terminal noncatalytic region. Northern blot analysis showed that MEKK2 was ubiquitously expressed, with the highest level in peripheral blood leukocytes, In T cells, MEKK2 was found to be a strong activator of JNK but not of extracellular signal-regulated kinase MAPKs and to activate JNK-dependent AP-1 reporter gene expression. MEKK2 also synergized with anti-CD3 antibody to activate JNK in T cells, and stimulation of T cells led to induction of MEKK2 tyrosine phosphorylation, Significantly, the JNK activation induced by anti-CDS and anti-CD28 antibodies, but not by 12-O-tetradecanoylphorbol-13-acetate and Ca2+ ionophore A23187, was inhibited by dominant negative MEKK2 mutants. AP-1 and interleukin-2 reporter gene induction in T-cells was also inhibited by dominant negative MEKK2 mutants. Taken together, our results showed that human MEKK2 is a key signaling molecule for T-cell receptor/CD3-mediated JNK MAPK activation and interleukin-2 gene expression.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Su, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 178,1515 Holcombe Blvd, Houston, TX 77030 USA.							Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; CHOI KY, 1994, CELL, V78, P499; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaga S, 1998, J IMMUNOL, V160, P4182; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaefer BC, 1999, IMMUNITY, V11, P411, DOI 10.1016/S1074-7613(00)80116-8; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9	41	54	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14784	14790		10.1074/jbc.M010134200	http://dx.doi.org/10.1074/jbc.M010134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278622	hybrid			2022-12-27	WOS:000168528800035
J	Boehning, D; Mak, DOD; Foskett, JK; Joseph, SK				Boehning, D; Mak, DOD; Foskett, JK; Joseph, SK			Molecular determinants of ion permeation and selectivity in inositol 1,4,5-trisphosphate receptor Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE; AFFINITY; OLIGOMERIZATION; IDENTIFICATION; GLYCOSYLATION; ASSOCIATION; CONDUCTION; TOPOLOGY; BINDING; LOCUS	We tested the hypothesis that key residues in a putative intraluminal loop contribute to determination of ion permeation through the intracellular Ca2+ release channel (inositol 1,4,5-trisphosphate receptors (IP(3)Rs)) that is gated by the second messenger inositol 1,4,5-trisphophate (IP3), To accomplish this, we mutated residues within the putative pore forming region of the channel and analyzed the functional properties of mutant channels using a Ca-45(2+) flux assay and single channel electrophysiological analyses. Two IP3R mutations, V2548I and D2550E, retained the ability to release Ca-45(2+) in response to IP3. When analyzed at the single channel level; both recombinant channels had IP3-dependent open probabilities similar to those observed in wild-type channels. The mutation V2548I resulted in channels that exhibited a larger K+ conductance (489 +/- 13 picosiemens (pS) for V2548I versus 364 +/- 5 pS for wildtype), but retained a Ca2+ selectivity similar to wild-type channels (PCa2+:PK+ similar to 4:1). Conversely, D2550E channels were nonselective for Ca2+ over K+ (PCa2+:PK+ similar to 0.6:1), while the Kf conductance was effectively unchanged (391 +/- 4 pS), These results suggest that amino acid residues Val(2548) and Asp(2550) contribute to the ion conduction pathway. We propose that the pore of IP3R channels has two distinct sites that control monovalent cation permeation (Val(2548)) and Ca2+ selectivity (Asp(2550)).	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Philadelphia, PA 19103 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Jefferson University; University of Pennsylvania	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, 1020 Locust St,Room 230A,JAH, Philadelphia, PA 19107 USA.		Foskett, Kevin/R-2549-2019; Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922; Foskett, J. Kevin/0000-0002-8854-0268	NIAAA NIH HHS [T32 AA007463, T32-AA07463] Funding Source: Medline; NIDDK NIH HHS [R01 DK034804, R01-DK34804] Funding Source: Medline; NIMH NIH HHS [R01-MH59937, R01 MH059937] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Cibulsky SM, 2000, J GEN PHYSIOL, V116, P349, DOI 10.1085/jgp.116.3.349; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Hille B., 1992, IONIC CHANNELS EXCIT; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1999, METHODS CALCIUM SIGN; Mak DOD, 1998, AM J PHYSIOL-CELL PH, V275, pC179, DOI 10.1152/ajpcell.1998.275.1.C179; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; Neher Erwin, 1995, P147; PARK CS, 1995, BIOCHEMISTRY-US, V34, P13328, DOI 10.1021/bi00041a008; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Seifert R, 1999, EMBO J, V18, P119, DOI 10.1093/emboj/18.1.119; SIGEL E, 1987, METHOD ENZYMOL, V141, P25; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; Wu XS, 2000, J BIOL CHEM, V275, P31778, DOI 10.1074/jbc.M004829200; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	28	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13509	13512		10.1074/jbc.C100094200	http://dx.doi.org/10.1074/jbc.C100094200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278266	hybrid			2022-12-27	WOS:000168356600002
J	Nuszkowski, A; Grabner, R; Marsche, G; Unbehaun, A; Malle, E; Heller, R				Nuszkowski, A; Grabner, R; Marsche, G; Unbehaun, A; Malle, E; Heller, R			Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; PLASMALEMMAL CAVEOLAE; ARTERIAL RELAXATION; PROTEIN OXIDATION; RELAXING FACTOR; DUAL ACYLATION; MODIFIED LDL; MEMBRANE; CHOLESTEROL; EXPRESSION	Hypochlorous acid/hypochlorite, generated by the myeloperoxidase/H2O2/halide system of activated phagocytes, has been shown to oxidize/modify low density lipoprotein (L-DL) in vitro and may be involved in the formation of atherogenic lipoproteins in vivo. Accordingly, hypochlorite-modified (lipo)proteins have been detected in human atherosclerotic lesions where they colocalize with macrophages and endothelial cells. The present study investigates the influence of hypochlorite-modified LDL on endothelial synthesis of nitric oxide (NO) measured as formation of citrulline (coproduct of NO) and cGMP (product of the NO-activated soluble guanylate cyclase) upon cell stimulation with thrombin or ionomycin. Pretreatment of human umbilical vein endothelial cells with hypochlorite-modified LDL led to a time- and concentration-dependent inhibition of agonist-induced citrulline and cGMP synthesis compared with preincubation of cells with native LDL. This inhibition was neither due to a decreased expression of endothelial NO synthase (eNOS) nor to a deficiency of its cofactor tetrahydrobiopterin. Likewise the uptake of L-arginine, the substrate of eNOS, into the cells was not affected. Hypochlorite-modified LDL caused remarkable changes of intracellular eNOS distribution including translocation from the plasma membrane and disintegration of the Golgi location without altering myristoylation or palmitoylation of the enzyme. In contrast, cyclodextrin known to deplete plasma membrane of cholesterol and to disrupt caveolae induced only a disappearance of eNOS from the plasma membrane that was not associated with decreased agonist-induced citrulline and cGMP formation, The present findings suggest that mislocalization of NOS accounts for the reduced NO formation in human umbilical vein endothelial cells treated with hypochlorite-modified LDL and point to an important role of Golgi-located NOS in these processes. We conclude that inhibition of NO synthesis by hypochlorite-modified LDL may be an important mechanism in the development of endothelial dysfunction and early pathogenesis of atherosclerosis.	Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany; Karl Franzens Univ Graz, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria	Friedrich Schiller University of Jena; University of Graz	Heller, R (corresponding author), Univ Jena, Ctr Vasc Biol & Med, Nordhauser Str 78, D-99089 Erfurt, Germany.		Heller, Regine/AAC-9353-2019; Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381				Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Bult H, 1999, EUR J PHARMACOL, V375, P157, DOI 10.1016/S0014-2999(99)00328-3; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Deckert V, 1998, ARTERIOSCL THROM VAS, V18, P1054, DOI 10.1161/01.ATV.18.7.1054; Deckert V, 1997, CIRCULATION, V95, P723, DOI 10.1161/01.CIR.95.3.723; ENOUF J, 1984, BIOCHEM BIOPH RES CO, V123, P50, DOI 10.1016/0006-291X(84)90378-4; ERBER WN, 1986, LANCET, V1, P761; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1999, CURR OPIN NEPHROL HY, V8, P55, DOI 10.1097/00041552-199901000-00010; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Fu S, 1998, BIOCHEM J, V333, P519, DOI 10.1042/bj3330519; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GALLE J, 1991, ARTERIOSCLER THROMB, V11, P198, DOI 10.1161/01.ATV.11.1.198; GALLE J, 1992, ARTERIOSCLER THROMB, V12, P180, DOI 10.1161/01.ATV.12.2.180; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1999, BIOCHEM J, V339, P489, DOI 10.1042/0264-6021:3390489; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hein TW, 1998, CIRC RES, V83, P404, DOI 10.1161/01.RES.83.4.404; Hein TW, 2000, AM J PHYSIOL-HEART C, V278, pH175, DOI 10.1152/ajpheart.2000.278.1.H175; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Kopprasch S, 1998, ATHEROSCLEROSIS, V136, P315, DOI 10.1016/S0021-9150(97)00233-5; Kritharides L, 1998, J LIPID RES, V39, P2394; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LIAO JK, 1995, J CLIN INVEST, V95, P1457, DOI 10.1172/JCI117816; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIU J, 1996, BIOCHEMISTRY-US, V35, P13227; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; Malle E, 1997, AM J PATHOL, V150, P603; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; MARSCHE G, 2001, FASEB J; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Opper C, 1998, PLATELETS, V9, P339, DOI 10.1080/09537109876582; Peterson TE, 1999, CIRC RES, V85, P29; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; THORIN E, 1995, ATHEROSCLEROSIS, V114, P185, DOI 10.1016/0021-9150(94)05482-X; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Vergnani L, 2000, CIRCULATION, V101, P1261, DOI 10.1161/01.CIR.101.11.1261; Woenckhaus C, 1998, CLIN IMMUNOL IMMUNOP, V86, P27, DOI 10.1006/clin.1997.4453	69	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14212	14221		10.1074/jbc.M007659200	http://dx.doi.org/10.1074/jbc.M007659200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278358	hybrid			2022-12-27	WOS:000168356600094
J	Ou, XM; Storring, JM; Kushwaha, N; Albert, PR				Ou, XM; Storring, JM; Kushwaha, N; Albert, PR			Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PROLACTIN GENE; MESSENGER-RNA; MEDIATED REPRESSION; DENTATE GYRUS; TRANSCRIPTIONAL ENHANCEMENT; SEROTONIN(1A) RECEPTOR; REDUCED ANXIETY; NERVOUS-SYSTEM; MICE LACKING; DNA ELEMENT	Negative regulation of neuronal serotonin (5-HT1A) receptor levels by glucocorticoids in vivo may contribute to depression. Both types I (mineralocorticoid) and II (glucocorticoid) receptors (MR and GR, respectively) participate in corticosteroid-induced transcriptional repression of the 5-HT1A gene; however, the precise mechanism is unclear. A direct repeat 6-base pair glucocorticoid response element (GRE) half site 5'-TGTCCT separated by 6 nucleotides was conserved in human, mouse, and rat 5-HT1A receptor promoters. In SN-48 neuronal cells that express MR, GR, and 5-HT1A receptors, deletion or inactivation of the nGRE (negative GRE) eliminated negative regulation of the rat 5-HT1A or heterologous promoters by corticosteroids, whereas its inclusion conferred corticosteroid-induced inhibition to a heterologous promoter. Bacterially expressed recombinant MR and GR preferentially bound to the nGRE as a heterodimer, as identified in nuclear extracts of MR/GR-transfected COS-7 cells, and with higher affinity than MR or GR homodimers. In SN48 and COS-7 cells, concentration-dependent coactivation of MR and GR was required for maximal inhibitory action by corticosteroids and was abrogated in the L501P-GR mutant lacking DNA binding activity. Corticosteroid-mediated transcriptional inhibition was greater for MR/GR in combination than for MR or GR alone. These data represent the first identification of an nMRE/GRE and indicate that heterodimerization of MR and GR mediates direct corticosteroid-induced transrepression of the 5-HT1A receptor promoter.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; McGill University	Albert, PR (corresponding author), Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada.	palbert@uottawa.ca	Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554				Abdouh M, 2001, J BIOL CHEM, V276, P4382, DOI 10.1074/jbc.M004559200; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; AUNE TM, 1994, J IMMUNOL, V153, P489; AZMITIA EC, 1969, SCIENCE, V166, P1274, DOI 10.1126/science.166.3910.1274; Bahouth SW, 1996, RECEPT SIGNAL TRANS, V6, P141; Beato M, 1996, ANN NY ACAD SCI, V784, P93, DOI 10.1111/j.1749-6632.1996.tb16231.x; CHALMERS DT, 1993, J NEUROSCI, V13, P914; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; CHAREST A, 1993, J NEUROSCI, V13, P5164, DOI 10.1523/JNEUROSCI.13-12-05164.1993; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diaz R, 1998, J NEUROSCI, V18, P2570; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Funder JW, 1996, J STEROID BIOCHEM, V56, P179, DOI 10.1016/0960-0760(95)00235-9; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; HOYER D, 1994, PHARMACOL REV, V46, P157; Huang J, 1999, NEUROSCI LETT, V270, P5, DOI 10.1016/S0304-3940(99)00439-5; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; Joels M, 1998, MOL NEUROBIOL, V17, P87, DOI 10.1007/BF02802026; LAARIS N, 1995, NEUROPHARMACOLOGY, V34, P1201, DOI 10.1016/0028-3908(95)00095-N; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; LIAO BL, 1993, MOL BRAIN RES, V19, P328, DOI 10.1016/0169-328X(93)90134-B; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Lopez JF, 1998, BIOL PSYCHIAT, V43, P547, DOI 10.1016/S0006-3223(97)00484-8; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Malkoski SP, 1999, MOL ENDOCRINOL, V13, P1629, DOI 10.1210/me.13.10.1629; McAllister-Williams RH, 1998, PSYCHOL MED, V28, P573, DOI 10.1017/S0033291798006680; MEIJER OC, 1995, J NEUROENDOCRINOL, V7, P653, DOI 10.1111/j.1365-2826.1995.tb00804.x; MEIJER OC, 1994, EUR J PHARM-MOLEC PH, V266, P255, DOI 10.1016/0922-4106(94)90134-1; Meijer OC, 1997, MOL BRAIN RES, V46, P290, DOI 10.1016/S0169-328X(97)00002-8; Meijer OC, 1998, CRIT REV NEUROBIOL, V12, P1; MENDELSON SD, 1992, NEUROENDOCRINOLOGY, V55, P444, DOI 10.1159/000126160; NAKAI Y, 1991, J STEROID BIOCHEM, V40, P301, DOI 10.1016/0960-0760(91)90195-B; Neumaier JF, 2000, MOL BRAIN RES, V82, P65, DOI 10.1016/S0169-328X(00)00181-9; Nishi M, 1996, BRAIN RES, V722, P190, DOI 10.1016/0006-8993(96)00193-X; Ou XM, 2000, J BIOL CHEM, V275, P8161, DOI 10.1074/jbc.275.11.8161; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pineyro G, 1999, PHARMACOL REV, V51, P533; POMPEIANO M, 1992, J NEUROSCI, V12, P440; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; Stockmeier CA, 1998, J NEUROSCI, V18, P7394; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Trapp T, 1996, TRENDS PHARMACOL SCI, V17, P145, DOI 10.1016/0165-6147(96)81590-2; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; VERGE D, 1985, EUR J PHARMACOL, V113, P463, DOI 10.1016/0014-2999(85)90099-8; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Wissink S, 2000, J BIOL CHEM, V275, P1321, DOI 10.1074/jbc.275.2.1321; Zhang GR, 1997, DNA CELL BIOL, V16, P145, DOI 10.1089/dna.1997.16.145; ZHONG PY, 1995, MOL BRAIN RES, V29, P23, DOI 10.1016/0169-328X(94)00225-4	63	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14299	14307		10.1074/jbc.M005363200	http://dx.doi.org/10.1074/jbc.M005363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278286	hybrid			2022-12-27	WOS:000168356600104
J	Browning, DD; McShane, M; Marty, C; Ye, RD				Browning, DD; McShane, M; Marty, C; Ye, RD			Functional analysis of type 1 alpha cGMP-dependent protein kinase using green fluorescent fusion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APPARENT CONFORMATIONAL CHANGE; INTACT HUMAN PLATELETS; VASP IN-VITRO; ANCHORING PROTEINS; ENA/VASP PROTEINS; CYCLIC-AMP; BINDING; LOCALIZATION; ALPHA; PHOSPHORYLATION	The cGMP-dependent protein kinases (PKGs) are ubiquitous effector enzymes that regulate a variety of physiological processes in response to nitric oxide and natriuretic agonists, We have constructed green fluorescent fusion proteins (GFP) using full-length (PKG-GFP) and truncations encoding either the regulatory domain of PKG1 alpha (G1 alphaR-GFP) or the catalytic domains of PKG1 alpha: (GFP-G1C) to examine the enzymatic properties and intracellular location. When transiently transfected into mammalian cells, these constructs were detected on Western blots at the expected sizes using anti-GFP antibodies. The GFP-G1C and the full-length PKG1 alpha -GFP fusion proteins were found to have constitutive activity both in vivo and in vitro. The G1 alphaR-GFP protein was found to dimerize with endogenous type I PKG and behaved in a dominant negative manner both in vivo and in vitro, When expressed transiently in either HEK-293 or A549 epithelial cells, the fusion proteins encoding the amino-terminal regulatory domains (PKG-GFP, G1 alphaR-GFP) were present in the cytosol and were rarely observed in the nucleus. In contrast, the GFP-G1C (lacking regulatory domains) concentrated in the nucleus. Of the fusion proteins containing the regulatory region, the constitutive PKC-GFP protein was present in a more centralized location, whereas the G1LYR-GFP protein colocalized with F-actin on stress fibers and in dynamic regions of the plasma membrane. Microscopic and immunoprecipitation studies indicated that both the G1 alphaR-GFP and the PKG1 alpha -GFP fusion proteins colocalized with vasodilator-stimulated phosphoprotein (VASP), These constructs thus represent novel tools with which to visualize inactive, and activated, PKG1 alpha in vivo, and we have used them to demonstrate two functionally independent domains. In addition, we show for the first time in living cells that PKC is found in dynamic membrane regions in association with VASP.	Univ Illinois, Dept Pharmacol MC 868, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Browning, DD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol CB2062A, Augusta, GA 30912 USA.		MARTY, Caroline/I-1721-2017; Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	MARTY, Caroline/0000-0003-4350-2302; Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033503, R01AI040176, R56AI040176, R56AI033503] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33503, AI40176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; BUTT E, 1994, J BIOL CHEM, V269, P14509; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hofmann F, 2000, J CELL SCI, V113, P1671; HUGGINS JP, 1994, EUR J BIOCHEM, V221, P581, DOI 10.1111/j.1432-1033.1994.tb18770.x; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Machesky LM, 2000, CELL, V101, P685, DOI 10.1016/S0092-8674(00)80879-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; Orstavik S, 1996, BIOCHEM BIOPH RES CO, V220, P759, DOI 10.1006/bbrc.1996.0477; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Witczak O, 1998, BIOCHEM BIOPH RES CO, V245, P113, DOI 10.1006/bbrc.1998.8399; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	43	46	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13039	13048		10.1074/jbc.M009187200	http://dx.doi.org/10.1074/jbc.M009187200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278473	hybrid			2022-12-27	WOS:000168198600082
J	Rivoal, J; Trzos, S; Gage, DA; Plaxton, WC; Turpin, DH				Rivoal, J; Trzos, S; Gage, DA; Plaxton, WC; Turpin, DH			Two unrelated phosphoenolpyruvate carboxylase polypeptides physically interact in the high molecular mass isoforms of this enzyme in the unicellular green alga Selenastrum minutum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; REGULATORY PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE; AMMONIUM ASSIMILATION; BANANA FRUIT; GENE; PURIFICATION; SORGHUM; CLONING; CARBON	In the chlorophyte Selenastrum minutum, phosphoenolpyruvate carboxylase (PEPC) exists as two kinetically distinct classes of isoforms sharing the same 102-kDa catalytic subunit (p102), Class 1 PEPC is homotetrameric, whereas Class 2 PEPCs consist of three large protein complexes. The different Class 2 PEPCs contain p102 and 130-, 73-, and 65-kDa polypeptides in different stoichiometric combinations. Immunoblot, immunoprecipitation, and chemical cross-linking studies indicated that p102 physically interacts with the 130-kDa polypeptide (p130) in Class 2 PEPCs, Immunological data and mass spectrometric and sequence analyses revealed that p102 and p130 are not closely related even if a p130 tryptic peptide had significant similarity to a conserved PEPC C-terminal domain from several sources. Evidence supporting the hypothesis that p130 has PEPC activity includes the following. (i) Specific activity expressed relative to the amount of p102 was lower in Class 1 than in Class 2 PEPCs; (ii) reductive pyridoxylation of both p102 and p130 was inhibited by magnesium-phosphoenolpyruvate; and (iii) biphasic phosphoenolpyruvate binding kinetics were observed with Class 2 PEPCs, These data support the view that unicellular green algae uniquely express, regulate, and assemble divergent PEPC polypeptides, This probably serves an adaptive purpose by poising these organisms for survival in different environments varying in nutrient content.	Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Victoria, Dept Biol, Victoria, BC V8W 3N5, Canada	University of Manitoba; Michigan State University; Queens University - Canada; Queens University - Canada; University of Victoria	Rivoal, J (corresponding author), Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.	rivoalj@ms.umanitoba.ca	Rivoal, Jean/J-6544-2014; Plaxton, William C/O-3353-2013; Turpin, David/E-1850-2012	Rivoal, Jean/0000-0002-8991-0566; Plaxton, William C/0000-0002-8447-7249; 				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; BARBER RT, 1992, ENVIR SCI R, V43, P89; Baret P, 1999, CR ACAD SCI III-VIE, V322, P29, DOI 10.1016/S0764-4469(99)80014-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; BROOKS SPJ, 1994, BIOTECHNIQUES, V17, P1154; Chollet R, 1996, ANNU REV PLANT PHYS, V47, P273, DOI 10.1146/annurev.arplant.47.1.273; CRETIN C, 1991, GENE, V99, P87, DOI 10.1016/0378-1119(91)90037-C; CUSHMAN JC, 1989, NUCLEIC ACIDS RES, V17, P6743, DOI 10.1093/nar/17.16.6743; Dong LY, 1999, ARCH BIOCHEM BIOPHYS, V371, P124, DOI 10.1006/abbi.1999.1433; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; FALKOWSKI PG, 1997, AQUATIC PHOTOSYNTHES, P300; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUJITA N, 1984, J BIOCHEM-TOKYO, V95, P909, DOI 10.1093/oxfordjournals.jbchem.a134718; HUPPE HC, 1994, ANNU REV PLANT PHYS, V45, P577, DOI 10.1146/annurev.pp.45.060194.003045; IZUI K, 1986, NUCLEIC ACIDS RES, V14, P1615, DOI 10.1093/nar/14.4.1615; JIAO JA, 1990, BIOCHIM BIOPHYS ACTA, V1041, P291, DOI 10.1016/0167-4838(90)90287-P; Kai Y, 1999, P NATL ACAD SCI USA, V96, P823, DOI 10.1073/pnas.96.3.823; KOIZUMI N, 1991, PLANT MOL BIOL, V17, P535, DOI 10.1007/BF00040652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law RD, 1997, EUR J BIOCHEM, V247, P642, DOI 10.1111/j.1432-1033.1997.00642.x; LAW RD, 1995, BIOCHEM J, V307, P807, DOI 10.1042/bj3070807; LUINENBURG I, 1992, J GEN MICROBIOL, V138, P685, DOI 10.1099/00221287-138-4-685; NAKAMURA T, 1995, J BIOCHEM-TOKYO, V118, P319, DOI 10.1093/oxfordjournals.jbchem.a124909; Nhiri M, 1998, PLANT CELL PHYSIOL, V39, P241, DOI 10.1093/oxfordjournals.pcp.a029363; OREGAN M, 1989, GENE, V77, P237, DOI 10.1016/0378-1119(89)90072-3; PLAXTON WC, 1989, ANAL BIOCHEM, V178, P391, DOI 10.1016/0003-2697(89)90658-1; PODESTA FE, 1986, ARCH BIOCHEM BIOPHYS, V246, P546, DOI 10.1016/0003-9861(86)90309-7; RAJAGOPALAN AV, 1994, PHOTOSYNTH RES, V39, P115, DOI 10.1007/BF00029380; RAVEN JA, 1992, NEW PHYTOL, V121, P5, DOI 10.1111/j.1469-8137.1992.tb01087.x; Rivoal J, 1996, ARCH BIOCHEM BIOPHYS, V332, P47, DOI 10.1006/abbi.1996.0315; Rivoal J, 1998, BIOCHEM J, V331, P201, DOI 10.1042/bj3310201; SCHULLER KA, 1990, PLANT PHYSIOL, V93, P1303, DOI 10.1104/pp.93.4.1303; SMITH RG, 1989, PLANT PHYSIOL, V91, P749, DOI 10.1104/pp.91.2.749; SRERE PA, 1990, METHOD ENZYMOL, V182, P539; Tipton Keith F., 1993, P1; TOH H, 1994, PLANT CELL ENVIRON, V17, P31, DOI 10.1111/j.1365-3040.1994.tb00263.x; Turpin D.H., 1988, P316; TURPIN DH, 1991, J PHYCOL, V27, P14, DOI 10.1111/j.0022-3646.1991.00014.x; VANLERBERGHE GC, 1990, PLANT PHYSIOL, V94, P284, DOI 10.1104/pp.94.1.284; Vidal J, 1997, TRENDS PLANT SCI, V2, P230, DOI 10.1016/S1360-1385(97)01046-7; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	44	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12588	12597		10.1074/jbc.M010150200	http://dx.doi.org/10.1074/jbc.M010150200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278626	hybrid			2022-12-27	WOS:000168198600018
J	Zhang, L; Saffen, D				Zhang, L; Saffen, D			Muscarinic acetylcholine receptor regulation of TRP6 Ca2+ channel isoforms - Molecular structures and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CA2+-PERMEABLE CATION CHANNEL; PROTEIN-KINASE-C; DROSOPHILA TRP; STORE DEPLETION; HUMAN HOMOLOG; EXPRESSION; CLONING; CELLS; DIACYLGLYCEROL	In this study, we report the molecular cloning of cDNAs encoding three distinct isoforms of rat (r) TRPG Ca2+ channels. The longest isoform, rTRP6A, contains 930 amino acid residues; rTRP6B lacks 54 amino acids (3-56) at the N terminus, and rTRP6C is missing an additional 68 amino acids near the C terminus. Transient transfection of CGS cells with expression vectors encoding rTRP6A or rTRP6B increased Ca2+ influx and gave rise to a novel Ba2+ influx after activation of M-5 muscarinic acetylcholine receptors, By contrast, passive depletion of intracellular Ca2+ stores with thapsigargin did not induce Ba2+ influx in cells expressing rTRP6 isoforms, Ba2+ influx was also stimulated in rTRP6A-expressing cells after exposure to the diacylglycerol analog, l-oleoyl-2-acetyl-sn-glycerol (OAG), but rTRP6B-expressing cells failed to show GAG-induced Ba2+ influx. Expression of a rTRP6 N-terminal fragment of rTRP6B or rTRP6A antisense RNA blocked M-5 muscarinic acetylcholine receptor-dependent Ba2+ influx in COS cells that were transfected with rTRP6 cDNAs, Together these results suggest that rTRP6 participates in the formation of Ca2+ channels that are regulated by a G-protein-coupled receptor, but not by intracellular Ca2+ stores. In contrast to the results we obtained with rTRP6A and rTRP6B, cells expressing rTRP6C showed no increased Ca2+ or Ba2+ influxes after stimulation with carbachol and also did not show GAG-induced Ba2+ influx, Glycosylation analysis indicated that rTRP6A and rTRP6B are glycosylated in CGS cells, but that rTRP6C is mostly not glycosylated. Together these results suggest that the N terminus (3-56 amino acids) is crucial for the activation of rTRP6A by diacylglycerol and that the 735-802 amino acid segment located just downstream from the 6th transmembrane segment may be required for processing of the rTRP6 protein.	Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Zhang, L (corresponding author), Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.							Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; Freichel M, 1998, FEBS LETT, V422, P354, DOI 10.1016/S0014-5793(98)00041-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MORI T, 1982, J BIOCHEM, V91, P427, DOI 10.1093/oxfordjournals.jbchem.a133714; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Usachev YM, 1999, BIOESSAYS, V21, P743, DOI 10.1002/(SICI)1521-1878(199909)21:9<743::AID-BIES5>3.0.CO;2-M; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	46	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13331	13339		10.1074/jbc.M008914200	http://dx.doi.org/10.1074/jbc.M008914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278449	hybrid			2022-12-27	WOS:000168198600119
J	Kim, S; Lee, SH; Park, D				Kim, S; Lee, SH; Park, D			Leucine zipper-mediated homodimerization of the p21-activated kinase-interacting factor, beta Pix - Implication for a role in cytoskeletal reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ACTIN STRESS FIBERS; RHO GTPASES; PROTEIN; DOMAIN; PAK; RAC; CLONING; PHOSPHORYLATION; TRANSFORMATION	Pix, a p21-activated kinase-interacting exchange factor, is known to be involved in the regulation of Cdc42/ Pac GTPases, The 85-kDa beta Pix-a protein contains an Src homology 3 domain, the tandem Dbl homology and Pleckstrin homology domains, a proline-rich region, and a GIT1-binding domain. In addition to those domains, beta Pix-a also contains a putative leucine zipper domain at the C-terminal end. In this study, we demonstrate that the previously identified putative leucine zipper domain mediates the formation of beta Pix-a homodimers. Using in vittro and in vivo methodologies, we show that deletion of the leucine zipper domain is sufficient to abolish beta Pix-a homodimerization. In NIH3T3 fibroblast cells, expression of wild type beta Pix-a induces the formation of membrane ruffles. However, cells expressing the leucine zipper domain deletion mutant could not form membrane ruffle structures. Moreover, platelet derived growth factor-mediated cytoskeletal changes were completely blocked by the leucine zipper domain deletion mutant. The results suggest that the leucine zipper domain enables beta Pix-a to homodimerize, and homodimerization is essential for beta Pix-a signaling functions leading to the cytoskeletal reorganization.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Park, D (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.		Kim, Seyun/B-3387-2012					Aelst L, 1997, GENE DEV, V11, P2295; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang H, 1999, CURR BIOL, V9, P1271, DOI 10.1016/S0960-9822(99)80511-9; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	27	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10581	10584		10.1074/jbc.C000806200	http://dx.doi.org/10.1074/jbc.C000806200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278242	hybrid			2022-12-27	WOS:000167980900002
J	Goodwin, DJ; Whitehouse, A				Goodwin, DJ; Whitehouse, A			A gamma-2 herpesvirus nucleocytoplasmic shuttle protein interacts with importin alpha 1 and alpha 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNAL; READING FRAME 57; GENE-PRODUCT; KARYOPHERIN ALPHA; TRANSPORT FACTORS; BINDING-PROTEIN; EXPORT; REV; RNA; IDENTIFICATION	Herpesvirus saimiri (HVS) is the prototype gamma -2 herpesvirus. This is an increasing important subfamily of herpesviruses due to the identification of the first human gamma -2 herpesvirus, Kaposi's sarcoma-associated herpesvirus. The HVS open reading frame (ORF) 57 protein is a multifunctional trans-regulatory protein homologous to genes identified in all classes of herpesviruses. Recent analysis has demonstrated that ORF 57 has the ability to bind viral RNA and to shuttle between the nucleus and cytoplasm, and is required for efficient nuclear export of viral transcripts. Here we have investigated the nucleocytoplasmic shuttling mechanism utilized by the ORF 57 protein. The yeast two hybrid system was employed 60 identify interacting cellular proteins using ORF 57 as bait. We demonstrate that ORF 57 interacts with importin alpha isoforms 1 and 5. In addition, the binding of ORF 57 to importin alpha was mediated by the importin a hydrophobic internal armadillo repeats. An ORF 57 amino-terminal arginine rich sequence, which functions as a nuclear localization sequence, was also required for this interaction. Furthermore, the ORF 57 protein is responsible for the redistribution of importin a into the nucleoli. These results identify novel cellular interactions essential for the functioning of this important herpesvirus regulatory protein.	Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Whitehouse, A (corresponding author), Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England.	a.whitehouse@leeds.ac.uk		Whitehouse, Adrian/0000-0003-3866-7110				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Cooper M, 1999, J GEN VIROL, V80, P1311, DOI 10.1099/0022-1317-80-5-1311; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; Fischer N, 1997, J BIOL CHEM, V272, P3999, DOI 10.1074/jbc.272.7.3999; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Goodwin DJ, 2000, J GEN VIROL, V81, P2253, DOI 10.1099/0022-1317-81-9-2253; Goodwin DJ, 1999, J VIROL, V73, P10519, DOI 10.1128/JVI.73.12.10519-10524.1999; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Ito S, 2000, VIROLOGY, V266, P110, DOI 10.1006/viro.1999.0054; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kim AL, 1997, VIROLOGY, V239, P340, DOI 10.1006/viro.1997.8874; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Michienzi A, 2000, P NATL ACAD SCI USA, V97, P8955, DOI 10.1073/pnas.97.16.8955; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; NICHOLAS J, 1991, J VIROL, V65, P2457, DOI 10.1128/JVI.65.5.2457-2466.1991; O'Neill RE, 1998, EMBO J, V17, P288, DOI 10.1093/emboj/17.1.288; ONEILL RE, 1995, J BIOL CHEM, V270, P22701, DOI 10.1074/jbc.270.39.22701; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Truant R, 1999, MOL CELL BIOL, V19, P1210; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; Wang P, 1997, J VIROL, V71, P1850, DOI 10.1128/JVI.71.3.1850-1856.1997; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Whitehouse A, 1997, J VIROL, V71, P2550, DOI 10.1128/JVI.71.3.2550-2554.1997; Whitehouse A, 1998, J VIROL, V72, P1967, DOI 10.1128/JVI.72.3.1967-1973.1998; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	54	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19905	19912		10.1074/jbc.M009513200	http://dx.doi.org/10.1074/jbc.M009513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278515	hybrid			2022-12-27	WOS:000169135100031
J	Choi, EK; Zaidi, NF; Miller, JS; Crowley, AC; Merriam, DE; Lilliehook, C; Buxbaum, JD; Wasco, W				Choi, EK; Zaidi, NF; Miller, JS; Crowley, AC; Merriam, DE; Lilliehook, C; Buxbaum, JD; Wasco, W			Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial Alzheimer's disease-associated C-terminal fragment of presenilin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; NEURONAL CA2+ SENSOR-1; IN-VIVO; BETA-CATENIN; GUANYLATE-CYCLASE; NERVOUS-SYSTEM; CELLS; APOPTOSIS; ENDOPROTEOLYSIS; STAUROSPORINE	Calsenilin is a member of the recoverin family of neuronal calcium-binding proteins that we have previously shown to interact with presenilin 1 (PS1) and presenilin 2 (PS2) holoproteins. The expression of calsenilin can regulate the levels of a proteolytic product of PS2 (Buxbaum, J. D., Choi, E, K., Luo, Y., Lilliehook, C., Crowley, A. C., Merriam, D. E., and Wasco, W. (1998) Not. Med. 4, 1177-1181) and reverse the presenilin-mediated enhancement of calcium signaling (Leissring, M. A., Yamasaki, T. R., Wasco, W., Buxbaum, J. I)., Parker, I., and LaFerla, F. M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8590-8593). Here, we have used cultured mammalian cells that transiently or stably express calsenilin to extend the characterization of calsenilin and of the calsenilin-PS2 interaction. We have found that calsenilin has the ability to interact with endogenous 25-kDa C-terminal fragment (CTF) that is a product of regulated endoproteolytic cleavage of PS2 and that the presence of the N141I PS2 mutation does not significantly alter the interaction of calsenilin with PS2. Interestingly, when the 25-kDa PS2 CTF and the 20-kDa PS2 CTF are both present, calsenilin preferentially interacts with the 20-kDa CTF. Increases in the 20-kDa fragment are associated with the presence of familial Alzheimer's disease-associated mutations (Kim, T., Pettingell, W, H., Jung, Y., Kovacs, D. M., and Tanzi, R. E. (1997) Science 277, 373-376). However, the finding that the production of the 20-kDa fragment is regulated by the phosphorylation of PS2 (Walter, J., Schindzielorz, A., Grunberg, J., and Haass, C, (1999) Proc. Natl. Acad Sci. U.S.A. 96, 1391-1396) suggests that it is a regulated physiological event that also occurs in the absence of the familial Alzheimer's disease-associated mutations in PS2. Finally, we have demonstrated that calsenilin is a substrate for caspase-3, and we have used site-directed mutagenesis to map the caspase-3 cleavage site to a region that is proximal to the calcium binding domain of calsenilin.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Genet & Aging Unit, Charlestown, MA 02129 USA; Mt Sinai Sch Med, Dept Psychiat & Neurobiol, New York, NY 10029 USA	Harvard University; Massachusetts General Hospital; Icahn School of Medicine at Mount Sinai	Wasco, W (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Genet & Aging Unit, 114 16th St, Charlestown, MA 02129 USA.	wasco@helix.mgh.harvard.edu	Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313	NIA NIH HHS [AG05138, AG16361, AG15801] Funding Source: Medline; NINDS NIH HHS [NS35975] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015801, R01AG016361] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alberici A, 1999, J BIOL CHEM, V274, P30764, DOI 10.1074/jbc.274.43.30764; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cruts M, 1998, ANN MED, V30, P560, DOI 10.3109/07853899809002605; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Dumanchin C, 1999, HUM MOL GENET, V8, P1263, DOI 10.1093/hmg/8.7.1263; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hendriks L, 1997, NEUROREPORT, V8, P1717, DOI 10.1097/00001756-199705060-00030; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; Kovacs DM, 1999, J NEUROCHEM, V73, P2278, DOI 10.1046/j.1471-4159.1999.0732278.x; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Mattson MP, 1998, J NEUROCHEM, V70, P1; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shinozaki K, 1998, INT J MOL MED, V1, P797; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Smine A, 1998, J BIOL CHEM, V273, P16281, DOI 10.1074/jbc.273.26.16281; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Van Gassen G, 2000, NEUROBIOL DIS, V7, P135, DOI 10.1006/nbdi.2000.0306; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; YE Y, 1909, NATURE, V398, P525; Zhang WJ, 1998, J NEUROSCI, V18, P914	64	61	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19197	19204		10.1074/jbc.M008597200	http://dx.doi.org/10.1074/jbc.M008597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278424	hybrid			2022-12-27	WOS:000169091000076
J	Herrera, C; Morimoto, C; Blanco, J; Mallol, J; Arenzana, F; Lluis, C; Franco, R				Herrera, C; Morimoto, C; Blanco, J; Mallol, J; Arenzana, F; Lluis, C; Franco, R			Comodulation of CXCR4 and CD26 in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD26/DIPEPTIDYL PEPTIDASE-IV; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL ACTIVATION; ADENOSINE-DEAMINASE; HIV-1 ENTRY; FACTOR 1-ALPHA; SURFACE; RECEPTOR; EXPRESSION; BINDING	We provide convergent and multiple evidence for a CD26/CXCR4 interaction. Thus, CD26 codistributes with CXCR4, and both coimmunoprecipitate from membranes of T (CD4(+)) and B (CD4(-)) cell lines. Upon induction with stromal cell-derived factor 1 alpha (SDF-1 alpha), CD26 is cointernalized with CXCR4. CXCR4-mediated downregulation of CD26 is not induced by antagonists or human immunodeficiency virus (HIV)-1 gp120. SDF-1 alpha -mediated down-regulation of CD26 is not blocked by pertussis toxin but does not occur in cells expressing mutant CXCR4 receptors unable to internalize. Codistribution and cointernalization also occurs in peripheral blood lymphocytes. Since CD26 is a cell surface endopeptidase that has the capacity to cleave SDF-1 alpha, the CXCR4CD26 complex is likely a functional unit in which CD26 may directly modulate SDF-1 alpha -induced chemotaxis and antiviral capacity. CD26 anchors adenosine deaminase (ADA) to the lymphocyte cell surface, and this interaction is blocked by HIV-1 gp120. Here we demonstrate that gp120 interacts with CD26 and that gp120-mediated disruption of ADA/CD26 interaction is a consequence of a first interaction of gp120 with a domain different from the ADA binding site. SDF-1 alpha and gp120 induce the appearance of pseudopodia in which CD26 and CXCR4 colocalize and in which ADA is not present. The physical association of CXCR4 and CD26, direct or part of a supramolecular structure, suggests a role on the function of the immune system and the pathophysiology of HIV infection.	Univ Barcelona, Dept Bioquim & Biol Mol, Fac Chem, E-08028 Barcelona, Spain; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Biol, Boston, MA 02115 USA; Natl Inst Infect Dis, Ctr AIDS Res, Tokyo 1620052, Japan; Inst Pasteur, Dept SIDA Retrovirus, F-75724 Paris, France; Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Recerca SIDA IRSI Caixa Fdn, Badalona 08916, Spain	University of Barcelona; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institute of Infectious Diseases (NIID); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa	Franco, R (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Fac Chem, Marti Franques 1, E-08028 Barcelona, Spain.		Mallol, Josefa/I-4194-2015; Franco, Rafael/C-3694-2015; Blanco, Julià/A-5347-2008	Mallol, Josefa/0000-0002-2479-4162; Franco, Rafael/0000-0003-2549-4919; Blanco, Julià/0000-0002-2225-0217				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ARAN JM, 1991, J HISTOCHEM CYTOCHEM, V39, P1001, DOI 10.1177/39.8.1856451; Blanco J, 2000, FEBS LETT, V477, P123, DOI 10.1016/S0014-5793(00)01751-8; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; BRODER CC, 1994, SCIENCE, V264, P1156, DOI 10.1126/science.7909959; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; Callebaut C, 1998, EXP CELL RES, V241, P352, DOI 10.1006/excr.1998.4063; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; DEMEESTER I, 1994, EUR J IMMUNOL, V24, P566, DOI 10.1002/eji.1830240311; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Iwata S, 1999, INT IMMUNOL, V11, P417, DOI 10.1093/intimm/11.3.417; Iyengar S, 1998, J VIROL, V72, P5251, DOI 10.1128/JVI.72.6.5251-5255.1998; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Mirabet M, 1999, J CELL SCI, V112, P491; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ohtsuki T, 1998, FEBS LETT, V431, P236, DOI 10.1016/S0014-5793(98)00763-7; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Saura CK, 1998, J BIOL CHEM, V273, P17610, DOI 10.1074/jbc.273.28.17610; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SORENSEN K, 1986, EXPERIENTIA, V42, P161, DOI 10.1007/BF01952446; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; Valenzuela A, 1997, J IMMUNOL, V158, P3721	38	86	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19532	19539		10.1074/jbc.M004586200	http://dx.doi.org/10.1074/jbc.M004586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278278	hybrid			2022-12-27	WOS:000169091000116
J	Hietaranta, AJ; Singh, VP; Bhagat, L; van Acker, GJD; Song, AM; Mykoniatis, A; Steer, ML; Saluja, AK				Hietaranta, AJ; Singh, VP; Bhagat, L; van Acker, GJD; Song, AM; Mykoniatis, A; Steer, ML; Saluja, AK			Water immersion stress prevents caerulein-induced pancreatic acinar cell NF-kappa B activation by attenuating caerulein-induced intracellular Ca2+ changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; B/REL ACTIVATION; EXPRESSION; CHOLECYSTOKININ; TRYPSINOGEN; INDUCTION; REQUIRES; CALCIUM	Prior stress ameliorates caerulein-induced pancreatitis in rats. NF-kappaB is a proinflammatory transcription factor activated during caerulein pancreatitis. However, the effects of prior stress on pancreatic NF-kappaB activation are unknown. In the current study, the effect of prior water immersion stress on caerulein and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation in the pancreas was evaluated. Water immersion of rats for up to 6 h prevents supramaximal caerulein-induced pancreatic I kappaB-alpha degradation and NF-kappaB activation in vivo, NF-kappaB activity is also inhibited in vitro in pancreatic acini prepared from water-immersed animals. TNF alpha -induced NF-kappaB activation in pancreas or in pancreatic acini is unaffected by prior water immersion. Chelation of intracellular Ca2+ by 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate/acetoxymethyl ester has similar effects to water immersion in preventing caerulein but not TNF-alpha -induced NF-kappaB activation in pancreas. Both the spike response and the sustained rise in [Ca2+], in response to supramaximal caerulein stimulation are reduced markedly in acini prepared from water-immersed animals as compared with normal animals. Our findings indicate that, in addition to Ca2+-dependent mechanisms, Ca2+-independent signaling events also may lead to NF-kappaB activation in pancreatic acinar cells. Water immersion stress prevents supramaximal caerulein-induced NF-kappaB activation in pancreas in vivo and in vitro by affecting intracellular Ca2+ homeostasis.	Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Saluja, AK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA.	asaluja@bidmc.harvard.edu		Singh, Vijay/0000-0001-6611-1908	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031396, R01DK031396, R01DK058694] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-58694, DK-31396] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAWRA RK, 1993, J BIOL CHEM, V268, P20237; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Grady T, 1997, GASTROENTEROLOGY, V113, P1966, DOI 10.1016/S0016-5085(97)70017-9; Grisham MB, 1999, GASTROENTEROLOGY, V116, P489, DOI 10.1016/S0016-5085(99)70148-4; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; Han B, 1999, AM J PHYSIOL-CELL PH, V277, pC74, DOI 10.1152/ajpcell.1999.277.1.C74; Hietaranta AJ, 2001, BIOCHEM BIOPH RES CO, V280, P388, DOI 10.1006/bbrc.2000.4120; HOLBAUSER B, 1998, AM J PHYSIOL, V275, pG352; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Lee HS, 2000, GASTROENTEROLOGY, V119, P220, DOI 10.1053/gast.2000.8551; OTAKA M, 1994, INT J BIOCHEM, V26, P805; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; POWERS RE, 1986, J CLIN INVEST, V77, P1668, DOI 10.1172/JCI112484; Saluja AK, 1999, AM J PHYSIOL-GASTR L, V276, pG835, DOI 10.1152/ajpgi.1999.276.4.G835; Saluja AK, 1997, GASTROENTEROLOGY, V113, P304, DOI 10.1016/S0016-5085(97)70108-2; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; Steinle AU, 1999, GASTROENTEROLOGY, V116, P420, DOI 10.1016/S0016-5085(99)70140-X; Tando Y, 1999, AM J PHYSIOL-GASTR L, V277, pG678, DOI 10.1152/ajpgi.1999.277.3.G678	21	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18742	18747		10.1074/jbc.M009721200	http://dx.doi.org/10.1074/jbc.M009721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278554	hybrid			2022-12-27	WOS:000169091000015
J	Lee, KK; Ohyama, T; Yajima, N; Tsubuki, S; Yonehara, S				Lee, KK; Ohyama, T; Yajima, N; Tsubuki, S; Yonehara, S			MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STE20-LIKE KINASE; SIGNALING COMPLEX DISC; GERMINAL CENTER KINASE; NUCLEAR EXPORT; PROTEIN-KINASE; MEDIATED ACTIVATION; CELL-DEATH; STE20-RELATED KINASE; MOLECULAR-CLONING; OXIDANT STRESS	The human serine/threonine kinase, mammalian STE20-like kinase (MST), is considerably homologous to the budding yeast kinases, SPS1 and STE20, throughout their kinase domains. The cellular function and physiological activation mechanism of MST is unknown except for the proteolytic cleavage-induced activation in apoptosis, In this study, we show that MST1 and MST2 are direct substrates of caspase-3 both in vivo and in vitro. cDNA cloning of MST homologues in mouse and nematode shows that caspase-cleaved sequences are evolutionarily conserved. Human MST1 has two caspase-cleavable sites, which generate biochemically distinct catalytic fragments, Staurosporine activates MST either caspase-dependently or independently, whereas Fas ligation activates it only caspase-dependently. Immunohistochemical analysis reveals that MST is localized in the cytoplasm, During Fas-mediated apoptosis, cleaved MST translocates into the nucleus before nuclear fragmentation is initiated, suggesting it functions in the nucleus. Transiently expressed MST1 induces striking morphological changes characteristic of apoptosis in both nucleus and cytoplasm, which is independent of caspase activation. Furthermore, when stably expressed in HeLa cells, MST highly sensitizes the cells to death receptor-mediated apoptosis by accelerating caspase-3 activation. These findings suggest that MST1 and MST2 play a role in apoptosis both upstream and downstream of caspase activation.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Kyoto University; RIKEN	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kawahara Cho, Kyoto 6068507, Japan.			Yajima, Nobuyuki/0000-0002-8292-3962				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fornerod M, 1997, CELL, V90, P1051; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Watabe M, 2000, J BIOL CHEM, V275, P8766, DOI 10.1074/jbc.275.12.8766; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	46	156	168	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19276	19285		10.1074/jbc.M005109200	http://dx.doi.org/10.1074/jbc.M005109200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278283	hybrid			2022-12-27	WOS:000169091000086
J	Schenk, G; Boutchard, CL; Carrington, LE; Noble, CJ; Moubaraki, B; Murray, KS; de Jersey, J; Hanson, GR; Hamilton, S				Schenk, G; Boutchard, CL; Carrington, LE; Noble, CJ; Moubaraki, B; Murray, KS; de Jersey, J; Hanson, GR; Hamilton, S			A purple acid phosphatase from sweet potato contains an antiferromagnetically coupled binuclear Fe-Mn center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; PIG ALLANTOIC FLUID; BOVINE SPLEEN; SPECTROSCOPIC CHARACTERIZATION; FLUORIDE COMPLEX; ACTIVE-SITE; ENZYME; UTEROFERRIN; METAL; MAGNETIZATION	A purple acid phosphatase from sweet potato is the first reported example of a protein containing an enzymatically active binuclear Fe-Mn center. Multifield saturation magnetization data over a temperature range of 2 to 200 K indicates that this center is strongly antiferromagnetically coupled. Metal ion analysis shows an excess of iron over manganese. Low temperature EPR spectra reveal only resonances characteristic of high spin Fe(III) centers (Fe(III)-apo and Fe(III)-Zn(II)) and adventitious Cu(II) centers. There were no resonances from either Mn(II) or binuclear Fe-Mn centers. Together with a comparison of spectral properties and sequence homologies between known purple acid phosphatases, the enzymatic and spectroscopic data strongly indicate the presence of catalytic Fe(III)-Mn(II) centers in the active site of the sweet potato enzyme. Because of the strong antiferromagnetism it is likely that the metal ions in the sweet potato enzyme are linked via a mu -oxo bridge, in contrast to other known purple acid phosphatases in which a mu -hydroxo bridge is present. Differences in metal ion composition and bridging may affect substrate specificities leading to the biological function of different purple acid phosphatases.	Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Magnet Resonance, St Lucia, Qld 4072, Australia; Monash Univ, Dept Chem, Clayton, Vic 3168, Australia	University of Queensland; University of Queensland; Monash University	Hamilton, S (corresponding author), Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia.		Schenk, Gerhard/AAG-5101-2022; /C-3940-2008; Schenk, Gerhard/AFJ-8595-2022	Schenk, Gerhard/0000-0001-8619-0631; /0000-0003-0306-4360; Schenk, Gerhard/0000-0001-8619-0631				ANTANAITIS BC, 1983, J BIOL CHEM, V258, P3166; AVERILL BA, 1987, J AM CHEM SOC, V109, P3760, DOI 10.1021/ja00246a039; BECK JL, 1988, INORG CHIM A-BIOINOR, V153, P39, DOI 10.1016/S0020-1693(00)83354-X; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BECK JL, 1984, BIOCHIM BIOPHYS ACTA, V791, P357, DOI 10.1016/0167-4838(84)90347-9; BECK JL, 1988, J AM CHEM SOC, V110, P3317, DOI 10.1021/ja00218a061; CAMPBELL HD, 1978, BIOCHEM BIOPH RES CO, V82, P615, DOI 10.1016/0006-291X(78)90919-1; DAY EP, 1988, J BIOL CHEM, V263, P15561; DAY EP, 1993, METHOD ENZYMOL, V227, P437, DOI 10.1016/0076-6879(93)27018-C; DOI K, 1988, J BIOL CHEM, V263, P5757; Durmus A, 1999, EUR J BIOCHEM, V260, P709, DOI 10.1046/j.1432-1327.1999.00230.x; Dutta SK, 1996, INORG CHEM, V35, P2292, DOI 10.1021/ic9508334; Gehring S, 1996, INORG CHIM ACTA, V252, P13, DOI 10.1016/S0020-1693(96)05292-9; Ghiladi M, 1997, J CHEM SOC DALTON, P4011, DOI 10.1039/a704388k; Griffin M., 1999, Molecular Physics Reports, V26, P60; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; HEFLER SK, 1987, BIOCHEM BIOPH RES CO, V146, P1173, DOI 10.1016/0006-291X(87)90771-6; HOLMAN TR, 1990, J AM CHEM SOC, V112, P7611, DOI 10.1021/ja00177a024; KAWABE H, 1984, BIOCHIM BIOPHYS ACTA, V784, P81, DOI 10.1016/0167-4838(84)90176-6; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Merkx M, 1999, J AM CHEM SOC, V121, P6683, DOI 10.1021/ja9837147; MOUBARAKI B, 1997, J INORG BIOCHEM, V67, P261; PILBROW JR, 1993, METHOD ENZYMOL, V227, P330, DOI 10.1016/0076-6879(93)27013-7; Pinkse MWH, 1999, BIOCHEMISTRY-US, V38, P9926, DOI 10.1021/bi990446w; Schenk G, 1999, ARCH BIOCHEM BIOPHYS, V370, P183, DOI 10.1006/abbi.1999.1407; Schenk G, 1999, ACTA CRYSTALLOGR D, V55, P2051, DOI 10.1107/S0907444999012597; SUGIURA Y, 1981, J BIOL CHEM, V256, P664; Wang D, 1996, APPL MAGN RESON, V11, P401, DOI 10.1007/BF03162236; WANG DM, 1995, J MAGN RESON SER A, V117, P1, DOI 10.1006/jmra.1995.9978; Wang XD, 1999, J AM CHEM SOC, V121, P9235, DOI 10.1021/ja990732v; Wilcox DE, 1996, CHEM REV, V96, P2435, DOI 10.1021/cr950043b	31	83	83	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19084	19088		10.1074/jbc.M009778200	http://dx.doi.org/10.1074/jbc.M009778200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278566	Green Accepted, hybrid			2022-12-27	WOS:000169091000061
J	Ward, G; Hadar, Y; Bilkis, I; Konstantinovsky, L; Dosoretz, CG				Ward, G; Hadar, Y; Bilkis, I; Konstantinovsky, L; Dosoretz, CG			Initial steps of ferulic acid polymerization by lignin peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHANEROCHAETE-CHRYSOSPORIUM; ANTIOXIDANT PROPERTIES; CELL-WALLS; OXIDATION; IDENTIFICATION; ENZYMES; DIMERS	The major products of the initial steps of ferulic acid polymerization by lignin peroxidase included three dehydrodimers resulting from beta -5' and beta-beta 'coupling and two trimers resulting from the addition of ferulic acid moieties to decarboxylated derivatives of beta -O-4'- and beta -5'-coupled dehydrodimers. This is the first time that trimers have been identified from peroxidase-catalyzed oxidation of ferulic acid, and their formation appears to be favored by decarboxylation of dehydrodimer intermediates. After initial oxidation, the coupling reactions appear to be determined by the chemistry of ferulic acid phenoxy radicals, regardless of the enzyme and of whether the reaction is performed in vitro or in vivo. This claim is supported by our finding that horseradish peroxidase provides a similar product profile. Furthermore, two of the dehydrodimers were the two products obtained from laccase-catalyzed oxidation (Tatsumi, K. S., Freyer, A., Minard, R. D., and Bollag, J.-M.. (1994) Environ. Sci. Technol. 28, 210-215), and the most abundant dehydrodimer is the most prominent in grass cell walls (Ralph, J,, Quideau, S,, Grabber, J. H., and Hatfield, R. D. (1994) J. Chem. Sec. Perkin Trans. 1, 3485-3498). Our results also indicate that the dehydrodimers and trimers are further oxidized by lignin peroxidase, suggesting that they are only intermediates in the polymerization of ferulic acid. The extent of polymerization appears to be dependent on the ionization potential of formed intermediates, H2O2 concentration, and, probably, enzyme stability.	Technion Israel Inst Technol, Fac Civil Engn, Div Environm & Water Resources Engn, IL-32000 Haifa, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Dept Plant Pathol & Microbiol, IL-76100 Rehovot, Israel; MIGAL Galilee Technol Ctr, Dept Environn Biotechnol, IL-10200 Kiryat Shmona, Israel	Technion Israel Institute of Technology; Weizmann Institute of Science; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Dosoretz, CG (corresponding author), Technion Israel Inst Technol, Fac Civil Engn, Div Environm & Water Resources Engn, IL-32000 Haifa, Israel.	carlosd@techunix.technion.ac.il	Bilkis, Itzhak/Q-9675-2017	Dosoretz, Carlos G./0000-0002-1759-9203				ADAM W, 1999, ADV BIOCHEM ENG BIOT, V63, P74; AITKEN MD, 1993, CHEM ENG J BIOCH ENG, V52, pB49, DOI 10.1016/0300-9467(93)80057-U; Bartolome B, 1997, APPL ENVIRON MICROB, V63, P208; BUMPUS JA, 1985, SCIENCE, V228, P1434, DOI 10.1126/science.3925550; Colonna S, 1999, TRENDS BIOTECHNOL, V17, P163, DOI 10.1016/S0167-7799(98)01288-8; Frisch M. J., 1995, GAUSSIAN, V94; Fry SC, 2000, PLANTA, V211, P679, DOI 10.1007/s004250000330; Garcia-Conesa MT, 1999, J SCI FOOD AGR, V79, P379, DOI 10.1002/(SICI)1097-0010(19990301)79:3<379::AID-JSFA259>3.0.CO;2-V; GarciaConesa MT, 1997, REDOX REP, V3, P239, DOI 10.1080/13510002.1997.11747116; HAMMEL KE, 1986, J BIOL CHEM, V261, P6948; HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0; Kalinowski H.O., 1988, CARBON 13 NMR SPECTR; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KIRK TK, 1986, ENZYME MICROB TECH, V8, P27, DOI 10.1016/0141-0229(86)90006-2; KLIBANOV AM, 1983, SCIENCE, V221, P259, DOI 10.1126/science.221.4607.259-a; Kroon PA, 1999, J SCI FOOD AGR, V79, P355, DOI [10.1002/(SICI)1097-0010(19990301)79:3<355::AID-JSFA255>3.0.CO;2-G, 10.1002/(SICI)1097-0010(19990301)79:3&lt;355::AID-JSFA255&gt;3.0.CO;2-G]; May SW, 1999, CURR OPIN BIOTECH, V10, P370, DOI 10.1016/S0958-1669(99)80067-6; Micard V, 1997, PHYTOCHEMISTRY, V44, P1365, DOI 10.1016/S0031-9422(96)00699-1; RALPH J, 1994, J CHEM SOC PERK T 1, P3485, DOI 10.1039/p19940003485; Ralph J., 1997, POLYPHENOLS ACTUALIT, V17, P4; Rosazza JPN, 1995, J IND MICROBIOL, V15, P457, DOI 10.1007/BF01570016; Rothschild N, 1997, APPL ENVIRON MICROB, V63, P857, DOI 10.1128/AEM.63.3.857-861.1997; TATSUMI K, 1994, ENVIRON SCI TECHNOL, V28, P210, DOI 10.1021/es00051a005; ten Have R, 1998, FEBS LETT, V430, P390, DOI 10.1016/S0014-5793(98)00682-6; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TIEN M, 1986, J BIOL CHEM, V261, P1687; Waldron KW, 1996, PHYTOCHEM ANALYSIS, V7, P305, DOI 10.1002/(SICI)1099-1565(199611)7:6&lt;305::AID-PCA320&gt;3.0.CO;2-A	27	81	84	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18734	18741		10.1074/jbc.M009785200	http://dx.doi.org/10.1074/jbc.M009785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278569	hybrid			2022-12-27	WOS:000169091000014
J	Murata, Y; Okado, H; Kubo, Y				Murata, Y; Okado, H; Kubo, Y			Characterization of heteromultimeric G protein-coupled inwardly rectifying potassium channels of the tunicate tadpole with a unique pore property	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; ARRESTED ASCIDIAN BLASTOMERES; FUNCTIONAL EXPRESSION; NEURAL DIFFERENTIATION; PERMEATION PROPERTIES; MOLECULAR-PROPERTIES; I-KACH; RESIDUE; CLONING; SUBUNIT	Two cDNAs that encode the G protein-coupled inwardly rectifying K+ channel (GIRK, Kir3) of tunicate tadpoles (tunicate G protein-coupled inwardly rectifying K+ channel-A and -B; TuGIRK-A and -B) have been isolated, The deduced amino acid sequences showed similar to 60% identity with the mammalian Kir3 family, Detected by whole mount in situ hybridization, both TuGIRK-A and -B were expressed similarly in the neural cells of the head and neck region from the tail bud stage to the young tadpole stage. By co-injecting cRNAs of TuGIRK-A and G protein beta (1)/gamma (2) subunits (G beta gamma) in Xenopus oocytes, an inwardly rectifying K+ current was expressed. In contrast, coinjection of TuGIRK-B with G beta gamma did not express any current. When both TuGIRK-A and -B were coexpressed together with G beta gamma, an inwardly rectifying K+ current was also detected. The properties of this current clearly differed from those of TuGIRK-A current, since it displayed a characteristic decline of the macroscopic conductance at strongly hyperpolarized potentials. TuGIRK-A/B current also differed from TuGIRK-A current in terms of the lower sensitivity to the Ba2+ block, the higher sensitivity to the Cs+ block, and the smaller single channel conductance, Taken together, we concluded that TuGIRK-A and -B form functional heteromultimeric G protein-coupled inwardly rectifying K+ channels in the neural cells of the tunicate tadpole. By introducing a mutation of Lys(161) to Thr in TuGIRK-B, TuGIRK-A/B channels acquired a higher sensitivity to the Ba2+ block and a slightly lower sensitivity to the Cs+ block, and the decrease in the macroscopic conductance at hyperpolarized potentials was no longer observed. Thus, the differences in the electrophysiological properties between TuGIRK-A and TuGIRK-A/B channels were shown to be, at least partly, due to the presence of Lys(161) at the external mouth of the pore of the TuGIRK-B subunit.	Tokyo Med & Dent Univ, Grad Sch, Dept Physiol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Tokyo 1838526, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Kubo, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Physiol, Bunkyo Ku, D566,Yushima 1-5-45, Tokyo 1138519, Japan.			Murata, Yoshimichi/0000-0002-2070-7949; Kubo, Yoshihiro/0000-0001-6707-0837				Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Doring F, 1998, J NEUROSCI, V18, P8625; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HIRANO T, 1984, J PHYSIOL-LONDON, V347, P327, DOI 10.1113/jphysiol.1984.sp015068; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Inanobe A, 2000, HANDB EXP PHARM, V147, P297; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kubo Y, 1996, RECEPTOR CHANNEL, V4, P73; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; OKADO H, 1988, P NATL ACAD SCI USA, V85, P6197, DOI 10.1073/pnas.85.16.6197; OKADO H, 1993, J PHYSIOL-LONDON, V463, P269, DOI 10.1113/jphysiol.1993.sp019594; OKADO H, 1990, J PHYSIOL-LONDON, V427, P603, DOI 10.1113/jphysiol.1990.sp018190; OKAMURA Y, 1993, J PHYSIOL-LONDON, V463, P245, DOI 10.1113/jphysiol.1993.sp019593; OKAMURA Y, 1990, J PHYSIOL-LONDON, V431, P39, DOI 10.1113/jphysiol.1990.sp018320; OKAMURA Y, 1994, NEURON, V13, P937, DOI 10.1016/0896-6273(94)90259-3; OKAMURA Y, 1993, BIOESSAYS, V15, P723, DOI 10.1002/bies.950151105; Ono F, 1999, J NEUROSCI, V19, P6874, DOI 10.1523/JNEUROSCI.19-16-06874.1999; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sabirov RZ, 1997, J GEN PHYSIOL, V110, P665, DOI 10.1085/jgp.110.6.665; SHIDARA M, 1991, J PHYSIOL-LONDON, V443, P277, DOI 10.1113/jphysiol.1991.sp018834; Takahashi K, 1998, PHYSIOL REV, V78, P307, DOI 10.1152/physrev.1998.78.2.307; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; WADA S, 1995, MECH DEVELOP, V51, P115, DOI 10.1016/0925-4773(95)00359-9; Wischmeyer E, 2000, FEBS LETT, V466, P115, DOI 10.1016/S0014-5793(99)01769-X	35	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18529	18539		10.1074/jbc.M009644200	http://dx.doi.org/10.1074/jbc.M009644200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278535	hybrid			2022-12-27	WOS:000168866500122
J	Roux, MJ; Martinez-Maza, R; Le Goff, A; Lopez-Corcuera, B; Aragon, C; Supplisson, S				Roux, MJ; Martinez-Maza, R; Le Goff, A; Lopez-Corcuera, B; Aragon, C; Supplisson, S			The glial and the neuronal glycine transporters differ in their reactivity to sulfhydryl reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; CYSTEINE ACCESSIBILITY METHOD; CFTR CHLORIDE CHANNEL; SEROTONIN TRANSPORTER; GABA TRANSPORTER; RAT-BRAIN; ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE TOPOLOGY; SUBSTITUTED CYSTEINES; RECOMBINANT GLYT1	The neuronal (GlyT2) and glial (GlyT1) glycine transporters, two members of the Na+/Cl--dependent neurotransmitter transporter superfamily, differ by many aspects, such as substrate specificity and Na+ coupling. We have characterized under voltage clamp their reactivity toward the membrane impermeant sulfhydryl reagent [2-(trimethylammonium) -ethyl] -methanethiosulfonate (MTSET). In Xenopus oocytes expressing GlyT1b, application of MTSET reduced to the same extent the Na+-dependent charge movement, the glycine-evoked current, and the glycine uptake, indicating a complete inactivation of the transporters following cysteine modification. In contrast, this compound had no detectable effect on the glycine uptake and the glycine-evoked current of GlyT2a, The sensitivities to MTSET of the two transporters can be permutated by suppressing a cysteine (C62A) in the first extracellular loop (EL1) of GlyT1b and introducing one at the equivalent position in GlyT2a, either by point mutation (A223C) or by swapping the EL1 sequence (GlyT1b-EL1 and GlyT2a-EL1) resulting in AFQ <----> CYR modification. Inactivation by MTSET was five times faster in GlyT2a-A223C than in GlyT2a-EL1 or GlyT1b, suggesting that the arginine in position +2 reduced the cysteine reactivity, Protection assays indicate that EL1 cysteines are less accessible in the presence of all co-transported substrates: Na+, Cl-, and glycine, Application of dithioerythritol reverses the inactivation by MTSET of the sensitive transporters. Together, these results indicate that EL1 conformation differs between GlyT1b and GlyT2a and is modified by substrate binding and translocation.	Ecole Normale Super, Neurobiol Lab, CNRS, Unite Mixte Rech 8544, F-75230 Paris 05, France; Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Supplisson, S (corresponding author), Ecole Normale Super, Neurobiol Lab, CNRS, Unite Mixte Rech 8544, 46 Rue Ulm, F-75230 Paris 05, France.		SUPPLISSON, Stéphane/AAD-7482-2019; SUPPLISSON, Stéphane/L-6658-2017; Corcuera, Beatriz López/D-5188-2009; Roux, Michel J/A-3213-2009; Aragon, Carmen/K-9783-2014; Maza, Rodrigo Martínez/ABH-3989-2020	SUPPLISSON, Stéphane/0000-0002-0062-9752; SUPPLISSON, Stéphane/0000-0002-0062-9752; Corcuera, Beatriz López/0000-0002-0383-4241; Roux, Michel J/0000-0002-5812-5215; Aragon, Carmen/0000-0001-8287-9386; Maza, Rodrigo Martínez/0000-0002-7249-9205				Akabas MH, 1997, J BIOENERG BIOMEMBR, V29, P453, DOI 10.1023/A:1022482923122; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Barker EL, 1999, J NEUROSCI, V19, P4705; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU QR, 1993, J BIOL CHEM, V268, P22802; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Lopez-Corcuera B, 1998, J NEUROCHEM, V71, P2211; Mager S, 1996, J NEUROSCI, V16, P5405; Nunez E, 2000, BRIT J PHARMACOL, V129, P200, DOI 10.1038/sj.bjp.0703049; Nunez E, 2000, BRIT J PHARMACOL, V129, P802, DOI 10.1038/sj.bjp.0703100; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; Supplisson S, 1997, J NEUROSCI, V17, P4580; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0	32	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17699	17705		10.1074/jbc.M009196200	http://dx.doi.org/10.1074/jbc.M009196200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278474	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000168866500012
J	Ben-Shushan, E; Marshak, S; Shoshkes, M; Cerasi, E; Melloul, D				Ben-Shushan, E; Marshak, S; Shoshkes, M; Cerasi, E; Melloul, D			A pancreatic beta-cell-specific enhancer in the human PIX-1 gene is regulated by hepatocyte nuclear factor 3 beta (HNF-3 beta), HNF-1 alpha, and SPs transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE; PDX-1 GENE; DNA METHYLATION; FACTORS 1-ALPHA; CPG ISLAND; BINDING; EXPRESSION; ACTIVATION; PROMOTER; MOUSE	The PDX-1 transcription factor plays a key role in pancreas development. Although expressed in all cells at the early stages, in the adult it is mainly restricted to the beta -cell, To characterize the regulatory elements and potential transcription factors necessary for human PDX-1 gene expression in beta -cells, we constructed a series of 5' and 3' deletion fragments of the 5'-flanking region of the gene, fused to the luciferase reporter gene, In this report, we identify by transient transfections in beta- and non-beta -cells a novel beta -cell-specific distal enhancer element located between -3.7 and -3.45 kilobases, DNase I footprinting analysis revealed two protected regions, one binding the transcription factors SP1 and SP3 and the other hepatocyte nuclear factor 3 beta (HNF-3 beta) and HNF-1 alpha, Cotransfection experiments suggest that HNF-3 beta, HNF-1 alpha, and SP1 are positive regulators of the herein-described human PDX-I enhancer element. Furthermore, mutations within each motif abolished the binding of the corresponding factor(s) and dramatically impaired the enhancer activity, therefore suggesting cooperativity between these factors.	Hebrew Univ Jerusalem, Med Ctr, Dept Endocrinol & Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Melloul, D (corresponding author), Hadassah Univ Hosp, Dept Endocrinol & Metab, POB 12000, IL-91120 Jerusalem, Israel.		Shoshkes Carmel, Michal/AAY-5113-2021	Shoshkes Carmel, Michal/0000-0002-8406-2158				Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUZ Y, 1995, DEVELOPMENT, V121, P11; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; LevinsonDushnik M, 1997, MOL CELL BIOL, V17, P3817, DOI 10.1128/MCB.17.7.3817; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Song YH, 1998, J BIOL CHEM, V273, P28408, DOI 10.1074/jbc.273.43.28408; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231	43	87	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17533	17540		10.1074/jbc.M009088200	http://dx.doi.org/10.1074/jbc.M009088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278466	hybrid			2022-12-27	WOS:000168730400125
J	Fairlie, WD; Zhang, HP; Wu, WM; Pankhurst, SL; Bauskin, AR; Russell, PK; Brown, PK; Breit, SN				Fairlie, WD; Zhang, HP; Wu, WM; Pankhurst, SL; Bauskin, AR; Russell, PK; Brown, PK; Breit, SN			The propeptide of the transforming growth factor-beta superfamily member, macrophage inhibitory cytokine-1 (MIC-1), is a multifunctional domain that can facilitate protein folding and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; X-RAY STRUCTURE; RECEPTOR-BINDING; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; MORPHOGENETIC PROTEIN; OSTEOGENIC PROTEIN-1; ANGSTROM RESOLUTION; BIOLOGICAL-ACTIVITY	Macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor-beta (TGF-beta) superfamily, While it is synthesized in a pre-pro form, it is unique among superfamily members because it does not require its propeptide for correct folding or secretion of the mature peptide. To investigate! factors that enable these propeptide independent events to occur, we constructed MIC-1/TGF-beta1 chimeras, both with and without a propeptide, All chimeras without a propeptide secreted less efficiently compared with the corresponding constructs with propeptide. Folding and secretion were most affected after replacement of the predicted major alpha -helix in the mature protein, residues 56-68, Exchanging the human propeptide in this chimera with either the murine MIC-1 or TGF-beta1 propeptide resulted in secretion of the unprocessed, monomeric chimera, suggesting a specific interaction between the human MIC-1 propeptide and Mature peptide. Propeptide deletion mutants enabled identification of a region between residues 56 and 78, which is important for the interaction between the propeptide and the mature peptide. Cotransfection experiments demonstrated that the propeptide must be in cia with the mature peptide for this phenomenon to occur. These results suggest a model for TGF-beta superfamily protein folding.	St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; St Vincents Hosp, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney	Breit, SN (corresponding author), St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia.		Fairlie, Walter/M-8401-2015	Fairlie, Walter/0000-0002-2498-1160; Russell, Patricia/0000-0003-4351-3271				AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fairlie WD, 2001, BIOCHEMISTRY-US, V40, P65, DOI 10.1021/bi001064p; Fairlie WD, 2000, GENE, V254, P67, DOI 10.1016/S0378-1119(00)00295-X; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Israel DI, 1992, GROWTH FACTORS, V7, P139, DOI 10.3109/08977199209046403; JONES WK, 1994, GROWTH FACTORS, V11, P215, DOI 10.3109/08977199409046919; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; LOPEZ AR, 1992, MOL CELL BIOL, V12, P1674, DOI 10.1128/MCB.12.4.1674; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Moore AG, 2000, J CLIN ENDOCR METAB, V85, P4781, DOI 10.1210/jc.85.12.4781; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; Strelau J, 2000, J NEUROSCI, V20, P8597; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; WILSON CA, 1993, MOL ENDOCRINOL, V7, P247, DOI 10.1210/me.7.2.247; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622	33	35	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16911	16918		10.1074/jbc.M010000200	http://dx.doi.org/10.1074/jbc.M010000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278594	hybrid			2022-12-27	WOS:000168730400042
J	Yoh, SM; Privalsky, ML				Yoh, SM; Privalsky, ML			Transcriptional repression by thyroid hormone receptors - A role for receptor homodimers in the recruitment of SMRT corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; DNA-BINDING DOMAIN; V-ERBA; RESPONSE ELEMENTS; N-COR; HISTONE DEACETYLASES; NUCLEAR RECEPTORS; GENE-EXPRESSION; ACID RECEPTORS; PROTEIN	Nuclear hormone receptors, such as the thyroid hormone receptors (T3Rs) and retinoid X receptors (RXRs), are ligand-regulated transcription factors that control key aspects of metazoan gene expression. T3Rs can bind to DNA either as receptor homodimers or as heterodimers with RXRs, Once bound to DNA, nuclear hormone receptors regulate target gene expression by recruiting auxiliary proteins, denoted corepressors and coactivators, We report here that T3R homodimers assembled on DNA exhibit particularly strong interactions with the SMRT corepressor, whereas T3R.RXR heterodimers are inefficient at binding to SMRT, Mutants of T3R that exhibit enhanced repression properties, such as the v-Erb A oncoprotein or the T3R beta-Delta 432 mutant found in human resistance to thyroid hormone syndrome, display enhanced homodimerization properties and exhibit unusually strong interactions with the SMRT corepressor. Significantly, the topology of a DNA binding site can determine whether that site recruits primarily homodimers or heterodimers and therefore whether corepressor is efficiently or inefficiently recruited to the resulting receptor-DNA complex. We suggest that T3R homodimers, and not heterodimers, may be important mediators of transcriptional repression and that the nature of the DNA binding site, by selecting for receptor homodimers or heterodimers, can influence the ability of the receptor to recruit corepressor.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu			NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528, R01DK054064] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA-53394] Funding Source: Medline; NIDDK NIH HHS [R01 DK-53528, R01 DK-54064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Clifton-Bligh RJ, 1998, MOL ENDOCRINOL, V12, P609, DOI 10.1210/me.12.5.609; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kao HY, 2000, GENE DEV, V14, P55; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAUDET V, 1992, Current Biology, V2, P293; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, COLD SPRING HARB SYM, V63, P577, DOI 10.1101/sqb.1998.63.577; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Nagaya T, 1998, BIOCHEM BIOPH RES CO, V247, P620, DOI 10.1006/bbrc.1998.8854; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	84	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16857	16867		10.1074/jbc.M010022200	http://dx.doi.org/10.1074/jbc.M010022200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278601	hybrid			2022-12-27	WOS:000168730400036
J	Peneff, C; Mengin-Lecreulx, D; Bourne, Y				Peneff, C; Mengin-Lecreulx, D; Bourne, Y			The crystal structures of apo and complexed Saccharomyces cerevisiae GNA1 shed light on the catalytic mechanism of an amino-sugar N-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5; DOMAIN; SUPERFAMILY; EXPRESSION; FORMS; MODEL	The yeast enzymes involved in UDP-GlcNAc biosynthesis are potential targets for antifungal agents, GNA1, a novel member of the Gcn5-related N-acetyltransferase (GNAT) superfamily, participates in UDP-GlcNAc biosynthesis by catalyzing the formation of GlcNAc6P from AcCoA and GlcN6P. We have solved three crystal structures corresponding to the apo Saccharomyces cerevisiae GNA1, the GNA1-AcCoA, and the GNA1-CoA-GlcNAc6P complexes and have refined them to 2.4, 1.3, and 1.8 Angstrom resolution, respectively. These structures not only reveal a stable, beta -intertwined, dimeric assembly with the GlcNAc6P binding site located at the dimer interface but also shed light on the catalytic machinery of GNA1 at an atomic level. Hence, they broaden our understanding of structural features required for GNAT activity, provide structural details for related aminoglycoside N-acetyltransferases, and highlight the adaptability of the GNAT superfamily members to acquire various specificities.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Paris 11, CNRS, UMR 8619, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bourne, Y (corresponding author), CNRS, UMR 6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	yves@afmb.cnrs-mrs.fr	Bourne, Yves/AAC-4635-2022	Bourne, Yves/0000-0003-3850-0548; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Boehmelt G, 2000, J BIOL CHEM, V275, P12821, DOI 10.1074/jbc.275.17.12821; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1998, SPOCK; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Kukuruzinska MA, 1999, BBA-GEN SUBJECTS, V1426, P359, DOI 10.1016/S0304-4165(98)00136-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lin RY, 1996, GENES CELLS, V1, P923, DOI 10.1046/j.1365-2443.1996.d01-215.x; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Mio T, 2000, MICROBIOL-SGM, V146, P1753, DOI 10.1099/00221287-146-7-1753; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; OIKAWA S, 1985, INT J BIOCHEM, V17, P73, DOI 10.1016/0020-711X(85)90088-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sternglanz R, 1999, P NATL ACAD SCI USA, V96, P8807, DOI 10.1073/pnas.96.16.8807; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vessal M, 1998, COMP BIOCHEM PHYS B, V121, P379, DOI 10.1016/S0305-0491(98)10119-0; Vitagliano L, 1999, J MOL BIOL, V293, P569, DOI 10.1006/jmbi.1999.3158; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5	39	67	71	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16328	16334		10.1074/jbc.M009988200	http://dx.doi.org/10.1074/jbc.M009988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278591	hybrid			2022-12-27	WOS:000168623100101
J	Solow, S; Salunek, M; Ryan, R; Lieberman, PM				Solow, S; Salunek, M; Ryan, R; Lieberman, PM			TAF(II) 250 phosphorylates human transcription factor IIA on serine residues important for TBP binding and transcription activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; GENERAL INITIATION-FACTORS; CELL-CYCLE PROGRESSION; TATA-BOX-BINDING; ACTIVATED TRANSCRIPTION; FACTOR TFIIA; DNA-BINDING; ACETYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE	Transcription factor IIA (TFIIA) is a positive acting general factor that contacts the TATA-binding protein (TBP) and mediates an activator-induced conformational change in the transcription factor IID (TFIID) complex. Previously, we have found that phosphorylation of yeast TFIIA stimulates TFIIA.TBP.TATA complex formation and transcription activation in vivo. We now show that human TFIIA is phosphorylated in vivo on serine residues that are partially conserved between yeast and human TFIIA large subunits. Alanine substitution mutation of serine residues 316 and 321 in TFIIA alpha beta reduced TFIIA phosphorylation significantly in vivo. Additional alanine substitutions at serines 280 and 281 reduced phosphorylation to undetectable levels. Mutation of all four serine residues reduced the ability of TFIIA to stimulate transcription in transient transfection assays with various activators and promoters, indicating that TFIIA phosphorylation is required globally for optimal function. In vitro, holo-TFIID and TBP-associated factor 250 (TAF(II)250) phosphorylated TFIIA on the beta subunit. Mutation of the four serines required for in vivo phosphorylation eliminated TFIID and TAF(II)250 phosphorylation in vitro. The NH2-terminal kinase domain of TAF(II)250 was sufficient for TFIIA phosphorylation, and this activity was inhibited by full-length retinoblastoma protein but not by a retinoblastoma protein mutant defective for TAF(II)250 interaction or tumor suppressor activity. TFIIA phosphorylation had little effect on the TFIIA.TBP.TATA complex in electrophoretic mobility shift assay. However, phosphorylation of TFIIA containing a gamma subunit Y65A mutation strongly stimulated TFIIA.TBP.TATA complex formation. TFIIA-gamma Y65A is defective for binding to the beta -sheet domain of TBP identified in the crystal structure. These results suggest that TFIIA phosphorylation is important for strengthening the TFIIA.TBP contact or creating a second contact between TFIIA and TBP that was not visible in the crystal structure.	Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Lieberman, PM (corresponding author), Wistar Inst, Philadelphia, PA 19104 USA.				NIGMS NIH HHS [GM 54687-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054687] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bagby S, 2000, FEBS LETT, V468, P149, DOI 10.1016/S0014-5793(00)01213-8; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chou S, 1999, GENETICS, V153, P1573; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HAYASHIDA T, 1994, GENE, V141, P267; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Ozer J, 1998, MOL CELL BIOL, V18, P2559, DOI 10.1128/MCB.18.5.2559; Ramboarina S, 1998, PROTEIN ENG, V11, P729, DOI 10.1093/protein/11.9.729; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Solow SP, 1999, MOL CELL BIOL, V19, P2846; Spector D. L., 1998, CELLS LAB MANUAL; Stargell LA, 2000, J BIOL CHEM, V275, P12374, DOI 10.1074/jbc.275.17.12374; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	56	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15886	15892		10.1074/jbc.M009385200	http://dx.doi.org/10.1074/jbc.M009385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278496	hybrid			2022-12-27	WOS:000168623100044
J	Dusing, MR; Florence, EA; Wiginton, DA				Dusing, MR; Florence, EA; Wiginton, DA			PDX-1 is required for activation in vivo from a duodenum-specific enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADENOSINE-DEAMINASE; PANCREATIC-ISLET CELLS; ELASTASE-I ENHANCER; TRANSCRIPTION FACTOR; INSULIN-GENE; COOPERATIVE INTERACTIONS; SOMATOSTATIN GENE; TRANSGENIC MICE; BINDING-PROTEIN; HOMEOBOX FACTOR	The purine metabolic gene adenosine deaminase (ADA) is expressed along a defined spatiotemporal pattern in the developing mammalian small intestine, where high-level expression is limited to the villous epithelium of the duodenum. This activation is observed in rodents as the intestine completes the final maturation resulting in adult crypt-villus structures at 2-3 weeks postpartum, A regulatory module responsible for this pattern of expression has been identified in the second intron of the human ADA gene. Of the multiple duodenal proteins that can interact with this small duodenal enhancer region, the studies contained in this work describe the identification of five of these proteins as the dispersed homeobox protein PDX-1, This transcription factor exhibits a profile of expression in the small intestine similar to that observed for ADA, making it an ideal candidate factor for the duodenum-specific ADA enhancer. Loss of PDX-1 binding, via a PDX-1 mutated enhancer transgenic construction, resulted in complete loss of high-level activation in the duodenum, demonstrating the absolute requirement for this factor in vivo, However, co-transfection experiments suggest that other proteins that bind the enhancer are also required for enhancer function because PDX-1 alone was incapable of significant transactivation.	Univ Cincinnati, Coll Med, Dept Pediat, Div Dev Biol, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA	University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Wiginton, DA (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Div Dev Biol, Cincinnati, OH 45229 USA.	dan.wiginton@chmcc.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052343] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52343] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS A, 1976, CLIN EXP IMMUNOL, V26, P647; Andersen FG, 1999, FEBS LETT, V445, P315, DOI 10.1016/S0014-5793(99)00144-1; ARONOW B, GENES DEV, V3, P1384; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Barley NF, 1999, BIOCHEM J, V341, P491, DOI 10.1042/0264-6021:3410491; Ben Shushan E, 1999, DNA CELL BIOL, V18, P471, DOI 10.1089/104454999315196; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; Dusing MR, 2000, AM J PHYSIOL-GASTR L, V279, pG1080, DOI 10.1152/ajpgi.2000.279.5.G1080; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GUTIERREZ ED, 1995, AM J PHYSIOL-GASTR L, V269, pG500, DOI 10.1152/ajpgi.1995.269.4.G500; GUZ Y, 1995, DEVELOPMENT, V121, P11; Heimberg H, 2000, DIABETES, V49, P571, DOI 10.2337/diabetes.49.4.571; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEV R, 1981, TXB GASTROENTEROLOGY, P57; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MOOG F, 1981, TXB GASTROENTEROLOGY, P139; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; ORKIN SH, 1992, BLOOD, V80, P575; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; SEIDMAN EG, 1987, PAEDIAT GASTROENTERO; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWIFT GH, 1994, J BIOL CHEM, V269, P12809; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; THOMASSET M, 1982, AM J PHYSIOL, V243, pE483, DOI 10.1152/ajpendo.1982.243.6.E483; VANDERWEYDEN MB, 1976, J BIOL CHEM, V251, P5448; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P176, DOI 10.1210/endo-119-1-176; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179	49	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14434	14442		10.1074/jbc.M009249200	http://dx.doi.org/10.1074/jbc.M009249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278481	hybrid			2022-12-27	WOS:000168356600122
J	Kihara, T; Shimohama, S; Sawada, H; Honda, K; Nakamizo, T; Shibasaki, H; Kume, T; Akaike, A				Kihara, T; Shimohama, S; Sawada, H; Honda, K; Nakamizo, T; Shibasaki, H; Kume, T; Akaike, A			alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a beta-amyloid-induced neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CORTICAL-NEURONS; MEDIATED GLUTAMATE CYTOTOXICITY; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; INDUCED PROTECTION; NITRIC-OXIDE; INHIBITS APOPTOSIS; TYROSINE KINASE; HIGH-AFFINITY; RAT	Multiple lines of evidence, from molecular and cellular to epidemiological, have implicated nicotinic transmission in the pathogenesis of Alzheimer's disease (AD). Here we show the signal transduction mechanism involved in nicotinic receptor-mediated protection against beta -amyloid-enhanced glutamate neurotoxicity. Nicotine-induced protection was suppressed by an alpha7 nicotinic receptor antagonist (alpha -bungarotoxin), a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002 and wortmannin), and a Src inhibitor (PP2). Levels of phosphorylated Akt, an effector of PI3K, and Bcl-2 were increased by nicotine. The alpha7 nicotinic receptor was physically associated with the PI3K p85 subunit and Fyn. These findings indicate that the alpha7 nicotinic receptor trans duces signals to PI3K in a cascade, which ultimately contributes to a neuroprotective effect. This might form the basis of a new treatment for AD.	Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan.		Nakamizo, Tomoki/AAM-8615-2021	Nakamizo, Tomoki/0000-0002-8377-1235; Sawada, Hideyuki/0000-0002-5909-3366				AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Allen CM, 1996, J NEUROSCI RES, V44, P421, DOI 10.1002/(SICI)1097-4547(19960601)44:5<421::AID-JNR2>3.0.CO;2-H; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; DEL PL, 1997, SCIENCE, V278, P687; DORNAN WA, 1993, NEUROREPORT, V5, P165, DOI 10.1097/00001756-199311180-00018; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Giannakopoulos P, 1996, J NEUROPATH EXP NEUR, V55, P1210, DOI 10.1097/00005072-199612000-00004; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Harris ME, 1996, J NEUROCHEM, V67, P277; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; HUNTER BE, 1994, NEUROSCI LETT, V168, P130, DOI 10.1016/0304-3940(94)90433-2; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kihara T, 1999, JPN J PHARMACOL, V79, P393, DOI 10.1254/jjp.79.393; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kihara T, 1998, BRAIN RES, V792, P331, DOI 10.1016/S0006-8993(98)00138-3; Kume T, 1997, BRAIN RES, V756, P200, DOI 10.1016/S0006-8993(97)00195-9; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Meyer EM, 1997, BRAIN RES, V768, P49, DOI 10.1016/S0006-8993(97)00536-2; Morimoto K, 1998, NEUROSCIENCE, V84, P479, DOI 10.1016/S0306-4522(97)00507-1; O'Mahony S, 1998, BRAIN RES BULL, V45, P405, DOI 10.1016/S0361-9230(97)00405-X; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; Sawada H, 1998, ANN NEUROL, V44, P110, DOI 10.1002/ana.410440117; SHIMOHAMA S, 1993, BRAIN RES, V632, P296, DOI 10.1016/0006-8993(93)91164-N; SHIMOHAMA S, 1986, J NEUROCHEM, V46, P288, DOI 10.1111/j.1471-4159.1986.tb12960.x; Shimohama S, 1996, ANN NY ACAD SCI, V777, P356, DOI 10.1111/j.1749-6632.1996.tb34445.x; TAMURA Y, 1992, BRAIN RES, V592, P317, DOI 10.1016/0006-8993(92)91691-7; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; WHITEHOUSE PJ, 1995, ALZ DIS ASSOC DIS, V9, P3, DOI 10.1097/00002093-199501002-00002; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G; Zoli M, 1999, EMBO J, V18, P1235, DOI 10.1093/emboj/18.5.1235	34	362	388	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13541	13546		10.1074/jbc.M008035200	http://dx.doi.org/10.1074/jbc.M008035200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278378	hybrid			2022-12-27	WOS:000168356600007
J	Merithew, E; Hatherly, S; Dumas, JJ; Lawe, DC; Heller-Harrison, R; Lambright, DG				Merithew, E; Hatherly, S; Dumas, JJ; Lawe, DC; Heller-Harrison, R; Lambright, DG			Structural plasticity of an invariant hydrophobic triad in the switch regions of Rab GTPases is a determinant of effector recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; ACTIVATING PROTEIN; CRYSTAL-STRUCTURE; NUCLEOTIDE EXCHANGE; AUTOANTIGEN EEA1; FYVE DOMAIN; IDENTIFICATION; SUBFAMILY; FUSION	Rab GTPases function as regulatory components of an evolutionarily conserved machinery that mediates docking, priming, and fusion of vesicles with intracellular membranes. We have previously shown that the active conformation of Rab3A is stabilized by a substantial hydrophobic interface between the putative conformational switch regions (Dumas, J, J,, Zhu, Z., Connolly, J. L,, and Lambright, D.G. (1999) Structure 7, 413-423), A triad of invariant hydrophobic residues at this switch interface (Phe-59, Trp-76, and Tyr-91) represents a major interaction determinant between the switch regions of Rab3A and the Rab3A-specific effector Rabphilin3A (Ostermeier, C., and Brunger, A. T, (1999) Cell 96, 363-374), Here, we report the crystal structure of the active form of Rab5C, a prototypical endocytic Rab GTPase, As is true for Rab3A, the active conformation of Rab5C is stabilized by a hydrophobic interface between the switch regions. However, the conformation of the invariant hydrophobic triad (residues Phe-58, Trp-75, and Tyr-90 in Rab5C) is dramatically altered such that the resulting surface is noncomplementary to the switch interaction epitope of Rabphilin3A This structural rearrangement reflects a set of nonconservative substitutions in the hydrophobic core between the central beta sheet and the alpha2 helix. These observations demonstrate that structural plasticity involving an invariant hydrophobic triad at the switch interface contributes to the mechanism by which effecters recognize distinct Rab subfamilies. Thus, the active conformation of the switch regions conveys information about the identity of a particular Rab GTPase as well as the state of the bound nucleotide.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lambright, DG (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 2 Biotech,373 Plantat St, Worcester, MA 01605 USA.	David.Lambright@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Chattopadhyay D, 2000, ACTA CRYSTALLOGR D, V56, P937, DOI 10.1107/S0907444900007575; Chou JH, 2000, J BIOL CHEM, V275, P9433, DOI 10.1074/jbc.275.13.9433; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; Esters H, 2000, J MOL BIOL, V298, P111, DOI 10.1006/jmbi.2000.3645; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jones S, 1998, MOL BIOL CELL, V9, P2819, DOI 10.1091/mbc.9.10.2819; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	58	84	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13982	13988		10.1074/jbc.M009771200	http://dx.doi.org/10.1074/jbc.M009771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278565	hybrid			2022-12-27	WOS:000168356600066
J	El Kouhen, R; Burd, AL; Erickson-Herbrandson, LJ; Chang, CY; Law, PY; Loh, HH				El Kouhen, R; Burd, AL; Erickson-Herbrandson, LJ; Chang, CY; Law, PY; Loh, HH			Phosphorylation of Ser(363), Thr(370), and Ser(375) residues within the carboxyl tail differentially regulates mu-opioid receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; PROTEIN-KINASE PHOSPHORYLATION; DYNAMIN-DEPENDENT ENDOCYTOSIS; INDUCED DOWN-REGULATION; COOH-TERMINAL TAIL; OPIATE RECEPTOR; HEK-293 CELLS; AMINO-ACIDS; C-TERMINUS; INVOLVEMENT	Prolonged activation of opioid receptors leads to their phosphorylation, desensitization, internalization, and down-regulation. To elucidate the relationship between mu -opioid receptor (MOR) phosphorylation and the regulation of receptor activity, a series of receptor mutants was constructed in which the 12 Ser/Thr residues of the COOH-terminal portion of the receptor were substituted to Ale, either individually or in combination, All these mutant constructs were stably expressed in human embryonic kidney 293 cells and exhibited similar expression levels and ligand binding properties, Among those 12 Ser/Thr residues, Ser(363), Thr(370), and Ser(375) have been identified as phosphorylation sites, In the absence of the agonist, a basal phosphorylation of Ser(363) and Thr(370) was observed, whereas [D-Ala(2), Me-Phe(4), Gly(5)-ol] enkephalin (DAMGO)-induced receptor phosphorylation occurs at Thr(370) and Ser(375) residues, Furthermore, the role of these phosphorylation sites in regulating the internalization of MOR was investigated, The mutation of Ser(375) to Ala reduced the rate and extent of receptor internalization, whereas mutation of Ser(363) and Thr(370) to Ala accelerated MOR internalization kinetics, The present data show that the basal phosphorylation of MOR could play a role in modulating agonist-induced receptor internalization kinetics, Furthermore, even though mu -receptors and delta -opioid receptors have the same motif encompassing agonist-induced phosphorylation sites, the different agonist-induced internalization properties controlled by these sites suggest differential cellular regulation of these two receptor subtypes,	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	El Kouhen, R (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	elkou001@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA000564, R37DA001583, R01DA007339, P50DA011806, R01DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00564, DA01583, DA11806, DA07339] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Bernstein MA, 1998, MOL BRAIN RES, V55, P237, DOI 10.1016/S0169-328X(98)00005-9; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; Chakrabarti S, 1998, J NEUROCHEM, V71, P231; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105, DOI 10.1124/mol.52.1.105; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 1997, J NEUROCHEM, V69, P1767; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LAW PY, 1983, MOL PHARMACOL, V24, P413; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mestek A, 1996, NIDA Res Monogr, V161, P104; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; OZCELEBI F, 1995, J BIOL CHEM, V270, P3435, DOI 10.1074/jbc.270.7.3435; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Raynor K, 1996, NIDA Res Monogr, V161, P83; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Segredo V, 1997, J NEUROCHEM, V68, P2395; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Trapaidze N, 2000, MOL BRAIN RES, V76, P220, DOI 10.1016/S0169-328X(00)00002-4; Wang CH, 1998, BIOCHEM BIOPH RES CO, V249, P321, DOI 10.1006/bbrc.1998.9080; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; Wang ZJ, 1996, FEBS LETT, V387, P53, DOI 10.1016/0014-5793(96)00467-X; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	52	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12774	12780		10.1074/jbc.M009571200	http://dx.doi.org/10.1074/jbc.M009571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278523	hybrid			2022-12-27	WOS:000168198600044
J	Wappl, E; Mitterdorfer, J; Glossmann, H; Striessnig, J				Wappl, E; Mitterdorfer, J; Glossmann, H; Striessnig, J			Mechanism of dihydropyridine interaction with critical binding residues of L-type Ca2+ channel alpha 1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; AMINO-ACID-RESIDUES; 1,4-DIHYDROPYRIDINE SENSITIVITY; MOLECULAR DETERMINANTS; MESSENGER-RNAS; RECEPTOR-SITE; SEGMENT; EXPRESSION; MUSCLE; BLOCK	We investigated the mechanism of interaction of individual L-type channel amino acid residues with dihydropyridines within a dihydropyridine-sensitive alpha 1A subunit (alpha 1A(DHP)). Mutation of individual residues in repeat III and expression in Xenopus oocytes revealed that Thr(1393) is not required for dihydropyridine interaction but that bulky side chains (tyrosine, phenylalanine) in this position sterically inhibit dihydropyridine coordination. In position 1397 a side chain carbonyl group was required for high antagonist sensitivity. Agonist function required the complete amide group of a glutamine residue. Val(1516) and Met(1512) side chains were required for agonist (Val(1516)) and antagonist (Val(1516) Met(1512)) sensitivity, Replacement of Ile(1504) and Ile(1507) by alpha 1A phenylalanines was tolerated. Substitution of Thr(1393) by phenylalanine or Val(1516) by alanine introduced voltage dependence of antagonist action into alpha 1A(DHP), suggesting that these residues form part of a mechanism mediating voltage dependence of dihydropyridine sensitivity. Our data provide important insight into dihydropyridine binding to alpha 1A(DHP) which could facilitate the development of alpha 1A-selective modulators. By modulating P/Q-type Ca2+ channels such drugs could serve as new anti-migraine therapeutics.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria		Striessnig, J (corresponding author), Inst Biochem Pharmakol, Peter Maystr 1, A-6020 Innsbruck, Austria.		Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266				Berjukow S, 2000, J BIOL CHEM, V275, P22114, DOI 10.1074/jbc.M908836199; Bodi I, 1997, J BIOL CHEM, V272, P24952, DOI 10.1074/jbc.272.40.24952; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huber I, 2000, BIOCHEM J, V347, P829, DOI 10.1042/0264-6021:3470829; Ito H, 1997, MOL PHARMACOL, V52, P735, DOI 10.1124/mol.52.4.735; Kraus RL, 1998, J BIOL CHEM, V273, P27205, DOI 10.1074/jbc.273.42.27205; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lacinova L, 1999, FEBS LETT, V451, P152, DOI 10.1016/S0014-5793(99)00573-6; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; Yamaguchi S, 2000, J BIOL CHEM, V275, P41504, DOI 10.1074/jbc.M007165200	29	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12730	12735		10.1074/jbc.M010164200	http://dx.doi.org/10.1074/jbc.M010164200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278630	hybrid			2022-12-27	WOS:000168198600037
J	Xu, HX; Cui, NR; Yang, ZJ; Wu, JP; Giwa, LR; Abdulkadir, L; Sharma, P; Jiang, C				Xu, HX; Cui, NR; Yang, ZJ; Wu, JP; Giwa, LR; Abdulkadir, L; Sharma, P; Jiang, C			Direct activation of cloned K-ATP channels by intracellular acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; PANCREATIC BETA-CELLS; FROG SKELETAL-MUSCLE; EXTRACELLULAR PH; INHIBITION; IDENTIFICATION; MODULATION; PROTONS; CO2; H+	ATP-sensitive K+ (K-ATP) channels may be regulated by protons in addition to ATP, phospholipids, and other nucleotides, Such regulation allows a control of cellular excitability in conditions when pH is low but ATP concentration is normal. However, whether the K-ATP changes its activity with pH alterations remains uncertain, In this study we showed that the reconstituted K-ATP was strongly activated during hypercapnia and intracellular acidosis using whole-cell recordings. Further characterizations in excised patches indicated that channel activity increased with a moderate drop in intracellular pH and decreased with strong acidification. The channel activation was produced by a direct action of protons on the Kir6 subunit and relied on a histidine residue that is conserved in all K-ATP. The inhibition appeared to be a result of channel rundown and was not seen in whole-cell recordings. The biphasic response may explain the contradictory pH sensitivity observed in cell-endogenous K-ATP in excised patches. Site-specific mutations of two residues showed that pH and ATP sensitivities were independent of each other. Thus, these results demonstrate that the proton is a potent activator of the K-ATP. The pH-dependent activation may enable the K-ATP to control vascular tones, insulin secretion, and neuronal excitability in several pathophysiologic conditions.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Cent Ave, Atlanta, GA 30303 USA.			Yang, Zhenjiang/0000-0002-9315-154X; Wu, Jianping/0000-0002-2684-6122	NHLBI NIH HHS [R01 HL058410, HL58410] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLARD B, 1995, J PHYSIOL-LONDON, V485, P283, DOI 10.1113/jphysiol.1995.sp020730; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DAVIES NW, 1992, J PHYSIOL-LONDON, V445, P549, DOI 10.1113/jphysiol.1992.sp018939; Dost R, 2000, EPILEPSY RES, V38, P53; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FAN Z, 1994, AM J PHYSIOL-CELL PH, V267, pC1036; Gramolini A, 1997, AM J PHYSIOL-CELL PH, V272, pC1936, DOI 10.1152/ajpcell.1997.272.6.C1936; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; Ishizaka H, 1999, CIRCULATION, V99, P558, DOI 10.1161/01.CIR.99.4.558; KOYANO T, 1993, J PHYSIOL-LONDON, V463, P747, DOI 10.1113/jphysiol.1993.sp019620; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LIGHT PE, 1994, J PHYSIOL-LONDON, V475, P495, DOI 10.1113/jphysiol.1994.sp020088; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PROKS P, 1994, J PHYSIOL-LONDON, V475, P33, DOI 10.1113/jphysiol.1994.sp020047; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; Reimann F, 1999, J PHYSIOL-LONDON, V520, P661, DOI 10.1111/j.1469-7793.1999.00661.x; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Trapp S, 1996, J PHYSIOL-LONDON, V496, P695, DOI 10.1113/jphysiol.1996.sp021720; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VIVAUDOU M, 1995, J PHYSIOL-LONDON, V486, P629, DOI 10.1113/jphysiol.1995.sp020840; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wei EP, 1999, STROKE, V30, P851, DOI 10.1161/01.STR.30.4.851; WILDING TJ, 1992, J GEN PHYSIOL, V100, P593, DOI 10.1085/jgp.100.4.593; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I	32	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12898	12902		10.1074/jbc.M009631200	http://dx.doi.org/10.1074/jbc.M009631200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278532	hybrid			2022-12-27	WOS:000168198600062
J	Dupuy, AJ; Morgan, K; von Lintig, FC; Shen, HF; Acar, H; Hasz, DE; Jenkins, NA; Copeland, NG; Boss, GR; Largaespada, DA				Dupuy, AJ; Morgan, K; von Lintig, FC; Shen, HF; Acar, H; Hasz, DE; Jenkins, NA; Copeland, NG; Boss, GR; Largaespada, DA			Activation of the Rap1 guanine nucleotide exchange gene, CalDAG-GEF I, in BXH-2 murine myeloid leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; R-RAS; SIGNALING PATHWAY; MEMBRANE-PROTEIN; INTEGRATION SITE; MAP KINASE; TRANSFORMATION; PRODUCT; TC21; RHO	Here we report the recurrent proviral activation of the Rap1-specific guanine nucleotide exchange factor CalDAG-GEF I (Kawasaki, H., Springett, G. M., Toki, S., Canales, J. J., Harlan, P., Blumenstiel, J. P., Chen, E. J., Bany, I. A., Mochizuki, N., Ashbacher, A., Matsuda, M., Housman, D. E., and Graybiel, A. M. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 13288-13283; Correction (1999) Proc. Natl. Acad Sci. U.S.A. 96, 318) gene in BXH-2 acute myeloid leukemia. We also show that CalDAG-GEF I encodes two protein isoforms, a full-length isoform (CalDAG-GEF Ia) and a C-terminally truncated isoform (CalDAG-GEF Ib). Expression of the full-length CalDAG-GEF la isoform in Rat2 fibroblasts enhances growth in low serum, whereas expression in Swiss 3T3 cells causes morphological transformation and increased saturation density. In FDCP1 myeloid cells, CalDAG-GEF Pa expression increases growth and saturation density in the presence of the diacylglycerol analogs phorbol 12-myristate 13-acetate (PMA), which activates CalDAG-GEF Pa exchange activity. Likewise, in 32DcI3 myeloblast cells, CalDAG-GEF Ia expression increases cell adherence to fibronectin in response to PMA and calcium ionophore and allows higher saturation densities and prolonged growth on fibronectin-coated plates. These effects were correlated with increased Rap1, but not Ras, protein activation following PMA. and calcium ionophore treatment. Our results suggest that Rap1-GTP delivers signals that favor progression through the cell cycle and morphological transformation, The identification of CalDAG-GEF I as a proto-oncogene in BXH-2 acute myeloid leukemia is the first evidence implicating Rap1 signaling in myeloid leukemia.	Univ Minnesota, Ctr Canc, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Largaespada, DA (corresponding author), Univ Minnesota, Ctr Canc, Inst Human Genet, Minneapolis, MN 55455 USA.	larga002@tc.umn.edu	Largaespada, David/C-9832-2014	Boss, Gerry/0000-0002-9758-8714; Dupuy, Adam/0000-0002-8561-4911				Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Barker KT, 1998, BRIT J CANCER, V78, P296, DOI 10.1038/bjc.1998.490; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; Clark GJ, 1996, ONCOGENE, V12, P169; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; COX AD, 1994, ONCOGENE, V9, P3281; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; Gutmann DH, 1997, ONCOGENE, V15, P1611, DOI 10.1038/sj.onc.1201314; HUANG Y, 1995, ONCOGENE, V11, P1255; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hussey DJ, 1999, BLOOD, V94, P2072; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1999, P NATL ACAD SCI USA, V96, P318; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Osada M, 1999, MOL CELL BIOL, V19, P6333; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tian EM, 2000, ONCOGENE, V19, P2098, DOI 10.1038/sj.onc.1203577; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	65	58	61	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11804	11811		10.1074/jbc.M008970200	http://dx.doi.org/10.1074/jbc.M008970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278453	hybrid			2022-12-27	WOS:000168081800052
J	Igarashi, J; Bernier, SG; Michel, T				Igarashi, J; Bernier, SG; Michel, T			Sphingosine 1-phospbate and activation of endothelial nitric-oxide synthase - Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; LYSOPHOSPHATIDIC ACID; 1-PHOSPHATE RECEPTOR; GROWTH-FACTOR; PHOSPHORYLATION SITES; PLASMALEMMAL CAVEOLAE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	Sphingosine 1-phosphate (S1P) is a platelet-derived sphingolipid that elicits numerous biological responses in endothelial cells mediated by a family of G protein-coupled EDG receptors, Stimulation of EDG receptors by S1P has been shown to activate the endothelial isoform of nitric-oxide synthase (eNOS) in heterologous expression systems (Igarashi, J,, and Michel, T. (2000) J. Biol Chem. 275, 32363-32370), However, the signaling pathways that modulate eNOS regulation by S1P/EDG in vascular endothelial cells remain less well understood. We now report that SIP treatment of bovine aortic endothelial cells (BAEC) acutely increases eNOS enzyme activity; the EC50 for S1P activation of eNOS is similar to 10 nar. The magnitude of eNOS activation by S1P in BAEC is equivalent to that elicited by the agonist bradykinin. S1P treatment activates Akt, a protein kinase implicated in phosphorylation of eNOS. S1P treatment of BAEC leads to eNOS phosphorylation at Ser(1179), a residue phosphorylated by Akt; an eNOS mutant in which this Akt phosphorylation site is inactivated shows attenuated S1P-induced eNOS activation. S1P-induced activation both of Akt and of eNOS is inhibited by pertussis toxin, by the phosphoinositide 3-kinase inhibitor wortmannin, and by the intracellular calcium chelator BAPTA (1,2-bis(aminophenoxy)ethane-N,N,N',N'-tetraacetic acid). By contrast to S1P, activation of G protein-coupled bradykinin B2 receptors neither activates kinase Akt nor promotes Ser1179 eNOS phosphorylation despite robustly activating eNOS enzyme activity. Understanding the differential regulation of protein kinase pathways by S1P and bradykinin may lead to the identification of new points for eNOS regulation in vascular endothelial cells.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.							Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; HLA T, 1990, J BIOL CHEM, V265, P9308; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KU DD, 1993, AM J PHYSIOL, V265, P586; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Sekiguchi K, 1999, CIRC RES, V85, P1000; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Spiegel S, 2000, ANN NY ACAD SCI, V905, P54; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yatomi Y, 1997, J BIOCHEM, V121, P969; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	50	214	218	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12420	12426		10.1074/jbc.M008375200	http://dx.doi.org/10.1074/jbc.M008375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278407	hybrid			2022-12-27	WOS:000168081800130
J	Jiang, YP; Ballou, LM; Lin, RZ				Jiang, YP; Ballou, LM; Lin, RZ			Rapamycin-insensitive regulation of 4E-BP1 in regenerating rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PROTEIN PHOSPHATASE 2A; MESSENGER-RNA TRANSLATION; MAMMALIAN TARGET; PHAS-I; PHOSPHORYLATION SITES; 3-KINASE INHIBITORS; INITIATION-FACTORS; SIGNALING PATHWAY; TOR PROTEINS	In cultured cells, growth factor-induced phosphorylation of two translation modulators, p70 S6 kinase and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), is blocked by nanomolar concentrations of the immunosuppressant rapamycin. Rapamycin also attenuates liver regeneration after partial hepatectomy, but it is not known if this growth-suppressive effect is due to dephosphorylation of p70 S6 kinase and/or 4E-BP1. We found that partial hepatectomy induced a transient increase in liver p70 S6 kinase activity and 4E-8P1 phosphorylation as compared with sham-operated rats. The amount of p70 S6 kinase protein in regenerating liver did not increase, but active kinase from partially hepatectomized animals was highly phosphorylated. Phosphorylated 4E-BP1 from regenerating liver was unable to form an inhibitory complex with initiation factor 4E. Rapamycin blocked the activation of p70 S6 kinase in response to partial hepatectomy in a dose-dependent manner, but 4E-BP1 phosphorylation was not inhibited. By contrast, functional phosphorylation of 4E-BP1 induced by injection of cycloheximide or growth factors was partially reversed by the drug. The mammalian target of rapamycin (mTOR) has been proposed to directly phosphorylate 4E-BP1. Western blot analysis using phospho-specific antibodies showed that phosphorylation of Thr-36/45 and Ser-64 increased in response to partial hepatectomy in a rapamycin-resistant manner. Thus, rapamycin inhibits p70 S6 kinase activation and liver regeneration, but not functional phosphorylation of 4E-BP1, in response to partial hepatectomy. These results indicate that the effect of rapamycin on 4E-BP1 function in vivo can be significantly different from its effect in cultured cells.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Hosp, Res Serv, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Lin, RZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Mail Code 7764,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Alexandre J, 1999, B CANCER, V86, P808; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fadden P, 1997, J BIOL CHEM, V272, P10240; FRANCAVILLA A, 1989, LANCET, V2, P1248; FRANCAVILLA A, 1992, TRANSPLANTATION, V53, P496; Gallant-Haidner HL, 2000, THER DRUG MONIT, V22, P31, DOI 10.1097/00007691-200002000-00006; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GOTTLIEB LI, 1964, J BIOL CHEM, V239, P555; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Higgins GM, 1931, ARCH PATHOL, V12, P186; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MIZUTA K, 1987, BIOCHEM BIOPH RES CO, V146, P239, DOI 10.1016/0006-291X(87)90716-9; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1997, BIOCHEM J, V328, P329; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rybkin II, 2000, J BIOL CHEM, V275, P5460, DOI 10.1074/jbc.275.8.5460; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 1999, J BIOL CHEM, V274, P36168, DOI 10.1074/jbc.274.51.36168; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; STRAIN A, 1998, LIVER GROWTH REGENER; TSUKADA K, 1968, J BIOL CHEM, V243, P1160; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Watson CJE, 1999, TRANSPLANTATION, V67, P505, DOI 10.1097/00007890-199902270-00002; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	63	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10943	10951		10.1074/jbc.M007758200	http://dx.doi.org/10.1074/jbc.M007758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278364	hybrid			2022-12-27	WOS:000167980900052
J	DeMarco, SJ; Strehler, EE				DeMarco, SJ; Strehler, EE			Plasma membrane Ca2+-ATPase isoforms 2b and 4b interact promiscuously and selectively with members of the membrane-associated guanylate kinase family of PDZ (PSD95/Dlg/ZO-1) domain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP ISOFORMS; CALCIUM-PUMP; EPITHELIAL-CELLS; RAT-BRAIN; BASOLATERAL MEMBRANE; MESSENGER-RNAS; ATPASE; SAP97; LOCALIZATION; EXPRESSION	Spatial and temporal regulation of intracellular Ca2+ signaling depends on localized Ca2+ microdomains containing the requisite molecular components for Ca2+ influx, efflux, and signal transmission. Plasma membrane Ca2+-ATPase (PMCA) isoforms of the "b" splice type contain predicted PDZ (PSD95/Dlg/ZO-1) interaction domains. The COOH-terminal tail of PMCA2b isolated the membrane-associated guanylate kinase (MAGUK) protein SAP97/hDlg as a binding partner in a yeast two-hybrid screen, The related MAGUKs SAP90/PSD95, PSD93/chapsyn-110, SAP97, and SAP102 all bound to the COOH-terminal tail of PMCA4b, whereas only the first three bound to the tail of PMCA2b, Coimmunoprecipitations confirmed the interaction selectivity between PMCA4b and SAP102 as opposed to the promiscuity of PMCA2b and 4b in interacting with other SAPs. Confocal immunofluorescence microscopy revealed the exclusive presence and colocalization of PMCA4b and SAP97 in the basolateral membrane of polarized Madin-Darby canine kidney epithelial cells. In hippocampal neurons, PMCA2b was abundant throughout the somatodendritic compartment and often extended into the neck and head of individual spines where it colocalized with SAP90/PSD95. These data show that PMCA "b" splice forms interact promiscuously but also with specificity with different members of the PSD95 family of SAPs, PMCA-SAP interactions may play a role in the recruitment and maintenance of the PMCA at specific membrane domains involved in local Ca2+ regulation.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Biochem & Mol Biol, Program Mol Neurosci, Rochester, MN 55905 USA	Mayo Clinic	Strehler, EE (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Biochem & Mol Biol, Program Mol Neurosci, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058710] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-58710] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Blackstone C, 1999, CELL CALCIUM, V26, P181, DOI 10.1054/ceca.1999.0071; BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; BORKE JL, 1990, PFLUG ARCH EUR J PHY, V417, P120, DOI 10.1007/BF00370781; BRANDT P, 1992, J NEUROCHEM, V59, P1566, DOI 10.1111/j.1471-4159.1992.tb08476.x; Brenman JE, 1996, J NEUROSCI, V16, P7407; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1998, J LAB CLIN MED, V132, P149, DOI 10.1016/S0022-2143(98)90010-5; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; GARCIA ML, 1999, FRONT BIOSCI, V4, P869; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; Hillman DE, 1996, NEUROSCIENCE, V72, P315, DOI 10.1016/0306-4522(95)00518-8; HOWARD A, 1993, AM J PHYSIOL, V265, pG917, DOI 10.1152/ajpgi.1993.265.5.G917; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nagano T, 1998, J BIOCHEM-TOKYO, V124, P869, DOI 10.1093/oxfordjournals.jbchem.a022200; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ponting CP, 1997, PROTEIN SCI, V6, P464; Reuver SM, 1998, J CELL SCI, V111, P1071; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; Stauffer TP, 1997, BRAIN RES, V748, P21, DOI 10.1016/S0006-8993(96)01282-6; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; WACH A, 1994, MOL GENETICS YEAST P, P1; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu HJ, 1998, J CELL SCI, V111, P2365; Zabe M, 2001, J BIOL CHEM, V276, P14704, DOI 10.1074/jbc.M009850200; Zacharias DA, 1999, BBA-GEN SUBJECTS, V1428, P397, DOI 10.1016/S0304-4165(99)00058-6; ZACHARIAS DA, 1995, MOL BRAIN RES, V28, P263, DOI 10.1016/0169-328X(94)00215-Z	59	140	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21594	21600		10.1074/jbc.M101448200	http://dx.doi.org/10.1074/jbc.M101448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274188	hybrid			2022-12-27	WOS:000169297900106
J	Banecki, B; Wawrzynow, A; Puzewicz, J; Georgopoulos, C; Zylicz, M				Banecki, B; Wawrzynow, A; Puzewicz, J; Georgopoulos, C; Zylicz, M			Structure-function analysis of the zinc-binding region of the ClpX molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; SPECIFICITY COMPONENT; MU-TRANSPOSASE; PROTEASES; DOMAINS; HSP104; DNAJ; REPLICATION; REQUIREMENT	The ClpX heat shock protein of Escherichia coli is a member of the universally conserved Hsp100 family of proteins, and possesses a putative zinc finger motif of the C-4 type, The ClpX is an ATPase which functions both as a substrate specificity component of the ClpXP protease and as a molecular chaperone. Using an improved purification procedure we show that the ClpX protein is a metalloprotein complexed with Zn(II) cations. Contrary to other Hsp100 family members, ClpXZn(II) exists in an oligomeric form even in the absence of ATP. We show that the single ATP-binding site of ClpX is required for a variety of tasks, namely, the stabilization of the ClpXZn(II) oligomeric structure, binding to ClpP, and the ClpXP dependent proteolysis of the AO replication protein. Release of Zn(II) from ClpX protein affects the ability of ClpX to bind ATP. ClpX, free of Zn(II), cannot oligomerize, bind to ClpP, or participate in ClpXP-dependent proteolysis. We also show that ClpX Delta Cys, a mutant protein whose four cysteine residues at the putative zinc finger motif have been replaced by serine, behaves in similar fashion as wild type ClpX protein whose Zn(II) has been released either by denaturation and renaturation, or chemically by p-hydroxymercuriphenylsulfonic acid.	UNESCO, Int Inst Mol & Cell Biol, Dept Mol Biol, PL-02109 Warsaw, Poland; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Fahrenheit Universities; University of Gdansk; University of Geneva	Zylicz, M (corresponding author), UNESCO, Int Inst Mol & Cell Biol, Dept Mol Biol, 4 Ks Trojdena St, PL-02109 Warsaw, Poland.	zylicz@iimcb.gov.pl		Zylicz, Alicja/0000-0003-4174-3073				Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BERG JM, 1990, J BIOL CHEM, V265, P6513; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Brazil BT, 1998, J BIOL CHEM, V273, P3257, DOI 10.1074/jbc.273.6.3257; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUPP TR, 1993, J BIOL CHEM, V268, P13128; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Mitterauer T, 1999, BIOCHEM J, V342, P33, DOI 10.1042/0264-6021:3420033; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; SEOL JH, 1995, BIOCHEM BIOPH RES CO, V217, P41, DOI 10.1006/bbrc.1995.2743; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	39	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18843	18848		10.1074/jbc.M007507200	http://dx.doi.org/10.1074/jbc.M007507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278349	hybrid			2022-12-27	WOS:000169091000027
J	Madamanchi, NR; Li, SZ; Patterson, C; Runge, MS				Madamanchi, NR; Li, SZ; Patterson, C; Runge, MS			Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; TYROSINE PHOSPHORYLATION; JANUS KINASE; SIGNAL TRANSDUCER; C-SRC; PHOSPHOLIPASE C-GAMMA-1; COUPLED RECEPTOR; NEURONAL CELLS; CYCLE CONTROL; ACTIVATION	The growth-stimulating effects of thrombin are mediated primarily via activation of a G protein-coupled receptor, PAR-1. Because PAR-1 has no intrinsic tyrosine kinase activity, yet requires tyrosine phosphorylation events to induce mitogenesis, we investigated the role of the Janus tyrosine kinases (JAKs) in thrombin-mediated signaling. JAK2 was activated rapidly in rat vascular smooth muscle cells (VSMC) treated with thrombin, and signal transducers and activators of transcription (STAT1 and STAT3) were phosphorylated and translocated to the nucleus in a JAK2-dependent manner. AG-490, a JAK2-specific inhibitor, and a dominant negative JAK2 mutant inhibited thrombin-induced ERK2 activity and VSMC proliferation suggesting that JAK2 is upstream of the Ras/Raf/MEK/ERK pathway. To elucidate the functional significance of JAR-STAT activation, we studied the effect of thrombin on heat shock protein (Hsp) expression, based upon the following: 1) reports that thrombin stimulates reactive oxygen species production in VSMC; 2) the putative role of Hsps in modulating cellular responses to reactive oxygen species; and 3) the presence of functional STAT1/3-binding sites in Hsp70 and Hsp90 beta promoters. Indeed, thrombin up-regulated Hsp70 and Hsp90 protein expression via enhanced binding of STATs to cognate binding sites in the Hsp70 and Hsp90 promoters. Together, these results suggest that JAK-STAT pathway activation is necessary for thrombin-induced VSMC growth and Hsp gene expression.	Univ N Carolina, Dept Med, Program Mol Cardiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Runge, MS (corresponding author), Univ N Carolina, Dept Med, Program Mol Cardiol, 3033 Old Clin Bldg,CB 7005, Chapel Hill, NC 27599 USA.	mrunge@med.unc.edu		Madamanchi, Nageswara/0000-0003-0590-0908	NHLBI NIH HHS [HL57352] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057352] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; AMIN V, 1995, NEUROSCI LETT, V200, P85, DOI 10.1016/0304-3940(95)12074-E; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GaleaLauri J, 1996, EXP CELL RES, V226, P243, DOI 10.1006/excr.1996.0225; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM DJ, 1990, J VASC SURG, V11, P307, DOI 10.1067/mva.1990.17098; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; Ishida M, 1998, CIRC RES, V82, P7; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kirken RA, 1999, J LEUKOCYTE BIOL, V65, P891, DOI 10.1002/jlb.65.6.891; Lange BMH, 2000, EMBO J, V19, P1252, DOI 10.1093/emboj/19.6.1252; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; Morano KA, 1999, GENE EXPRESSION, V7, P271; Nishizawa J, 1999, CIRCULATION, V99, P934, DOI 10.1161/01.CIR.99.7.934; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Plumier JCL, 1996, J MOL CELL CARDIOL, V28, P1251, DOI 10.1006/jmcc.1996.0115; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schieffer B, 2000, CIRC RES, V87, P1195, DOI 10.1161/01.RES.87.12.1195; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; VANDONGEN G, 1988, RADIAT RES, V113, P252, DOI 10.2307/3577201; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	67	100	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18915	18924		10.1074/jbc.M008802200	http://dx.doi.org/10.1074/jbc.M008802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278437	Green Published, hybrid			2022-12-27	WOS:000169091000037
J	Maga, G; Frouin, I; Spadari, S; Hubscher, U				Maga, G; Frouin, I; Spadari, S; Hubscher, U			Replication protein a as a "fidelity clamp" for DNA polymerase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; COMPLEX-FORMATION; PRIMER SYNTHESIS; T-ANTIGEN; RPA; SUBUNIT; DELTA; INITIATION; TEMPLATE	The current view of DNA replication in eukaryotes predicts that DNA polymerase alpha (pol alpha)-primase synthesizes the first 10-ribonucleotide-long RNA primer on the leading strand and at the beginning of each Okazaki fragment on the lagging strand. Subsequently, pol alpha elongates such an RNA primer by incorporating about 20 deoxynucleotides. pol alpha displays a low processivity and, because of the lack of an intrinsic or associated 3'--> 5' exonuclease activity, it is more error-prone than other replicative pols. Synthesis of the RNA/DNA primer catalyzed by pol alpha -primase is a critical step in the initiation of DNA synthesis, but little is known about the role of the DNA replication accessory proteins in its regulation. In this paper we provide evidences that the single-stranded DNA-binding protein, replication protein A (RP-A), acts as an auxiliary factor for pol alpha playing a dual role: (i) it stabilizes the pol alpha /primer complex, thus acting as a pol clamp; and (ii) it significantly reduces the misincorporation efficiency by pol alpha. Based on these results, we propose a hypothetical model in which RP-A is involved in the regulation of the early events of DNA synthesis by acting as a "fidelity clamp" for pol alpha.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland	Consiglio Nazionale delle Ricerche (CNR); University of Zurich	Maga, G (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.	maga@igbe.pv.cnr.it	Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; CARTY MP, 1992, MUTAT RES, V274, P29, DOI 10.1016/0921-8777(92)90041-Z; CARTY MP, 1990, MUTAT RES, V232, P141, DOI 10.1016/0027-5107(90)90119-O; Cho JM, 2000, NUCLEIC ACIDS RES, V28, P3478, DOI 10.1093/nar/28.18.3478; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Fletcher R, 1980, PRACTICAL METHODS OP, V1; FOCHER F, 1990, FEBS LETT, V259, P349, DOI 10.1016/0014-5793(90)80045-K; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Henricksen LA, 1998, LEUKEMIA RES, V22, P1, DOI 10.1016/S0145-2126(97)00113-6; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1991, MUTAT RES, V250, P175, DOI 10.1016/0027-5107(91)90174-M; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; Lavrik OI, 1998, FEBS LETT, V441, P186, DOI 10.1016/S0014-5793(98)01544-0; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Lavrik OI, 1998, NUCLEIC ACIDS RES, V26, P602, DOI 10.1093/nar/26.2.602; Lee BE, 1999, MOL CELLS, V9, P185; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Maga G, 2000, J MOL BIOL, V295, P791, DOI 10.1006/jmbi.1999.3394; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; Mossi R, 2000, J MOL BIOL, V295, P803, DOI 10.1006/jmbi.1999.3395; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; THOMAS DC, 1990, BASIC LIFE SCI, V52, P289; Treuner K, 1999, J BIOL CHEM, V274, P15556, DOI 10.1074/jbc.274.22.15556; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; Walther AP, 1999, NUCLEIC ACIDS RES, V27, P656, DOI 10.1093/nar/27.2.656; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; WEISER T, 1991, J BIOL CHEM, V266, P10420; WEISS SJ, 1992, J BIOL CHEM, V267, P18520; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	59	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18235	18242		10.1074/jbc.M009599200	http://dx.doi.org/10.1074/jbc.M009599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278525	hybrid, Green Accepted			2022-12-27	WOS:000168866500084
J	Arnold, R; Liou, J; Drexler, HCA; Weiss, A; Kiefer, F				Arnold, R; Liou, J; Drexler, HCA; Weiss, A; Kiefer, F			Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NF kappa B into an inhibitor of NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; STE20-RELATED PROTEIN-KINASE; TERMINAL KINASE; ADAPTER PROTEINS; CELL-LINE; APOPTOSIS; PATHWAY; COMPLEX; FAMILY; BETA	Hematopoietic progenitor kinase 1 (HPK1), a mammalian Ste20-related protein kinase, is a potent stimulator of the stress-activated protein kinases (SAPKs/JNKs). Here we report activation of NF kappaB transcription factors by HPK1 that was independent of SAPK/JNK activation. Overexpression of a dominant-negative SEK1 significantly inhibited SAPK/JNK activation, whereas NF kappaB stimulation by HPK1 remained unaffected. Furthermore, activation of NF kappaB required the presence of full-length, kinase-active HPK1, whereas the isolated kinase domain of HPK1 was sufficient for activation of SAPK/JNK. We also demonstrate that overexpression of a dominant-negative IKK beta blocks HPK1-mediated NF kappaB activation suggesting that HPK1 acts upstream of the I kappaB kinase complex. In apoptotic myeloid progenitor cells HPK1 was cleaved at a DDVD motif resulting in the release of the kinase domain and a C-terminal part. Although expression of the isolated HPK1 kinase domain led to SAPK/JNK activation, the C-terminal part inhibited NF kappaB activation. This dominant-negative effect was not only restricted to HPK1-mediated but also to NIK- and tumor necrosis factor alpha -mediated NF kappaB activation, suggesting an impairment of the I kappaB kinase complex. Thus HPK1 activates both the SAPK/JNK and NF kappaB pathway in hematopoietic cells but is converted into an inhibitor of NF kappaB activation in apoptotic cells.	Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, D-61231 Bad Nauheim, Germany; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Kiefer, F (corresponding author), Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Pk Str 1, D-61231 Bad Nauheim, Germany.	F.Kiefer@kerckhoff.mpg.de	Drexler, Hannes/AAI-3449-2020	Kiefer, Friedemann/0000-0002-3002-8237				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Arnold R, 1996, NUCLEIC ACIDS RES, V24, P2640, DOI 10.1093/nar/24.14.2640; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; KARASUYAMA H, 1988, J EXP MED, V167, P1377, DOI 10.1084/jem.167.4.1377; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kyriakis JM, 1999, GENE EXPRESSION, V7, P217; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; SAKAKEENY MA, 1982, J NATL CANCER I, V68, P305; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAN MH, 1994, NATURE, V372, P798; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	54	58	63	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14675	14684		10.1074/jbc.M008343200	http://dx.doi.org/10.1074/jbc.M008343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278403	hybrid			2022-12-27	WOS:000168528800022
J	Chen, CR; Tanaka, K; Chazenbalk, GD; McLachlan, SM; Rapoport, B				Chen, CR; Tanaka, K; Chazenbalk, GD; McLachlan, SM; Rapoport, B			A full biological response to autoantibodies in Graves' disease requires a disulfide-bonded loop in the thyrotropin receptor N terminus homologous to a laminin epidermal growth factor-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; TSH RECEPTOR; CRYSTAL-STRUCTURE; GONADOTROPIN RECEPTORS; EXTRACELLULAR DOMAIN; IDIOPATHIC MYXEDEMA; THYROID-DISEASE; GAMMA-1 CHAIN; BINDING; PROTEIN	We observed amino acid homology between the cysteine-rich N terminus of the thyrotropin receptor (TSHR) ectodomain and epidermal growth factor-like repeats in the laminin yl chain, Thyroid-stimulating autoantibodies (TSAb), the cause of Graves' disease, interact with this region of the TSHR in a manner critically dependent on antigen conformation. We studied the role of the cluster of four cysteine (Cys) residues in this region of the TSHR on the functional response to TSAb in Graves' patients' sera. As a benchmark we also studied TSH binding and action. Removal in various permutations of the four cysteines at TSHR positions 24, 29, 31, and 41 (signal peptide residues are 1-21) revealed Cys(41) to be the key residue for receptor expression Forced pairing of Cys(41) with any one of the three upstream Cys residues was necessary for trafficking to the cell surface of a TSHR with high affinity TSH binding similar to the wild-type receptor. However, for a full biological response to TSAb, forced pairing of Cys(41) with Cys(29) or with Cys(31), but not with Cys(24), retained functional activity comparable with the wild-type TSHR, These data suggest that an N-terminal disulfide-bonded loop between Cys(41) and Cys(29) or its close neighbor Cys(31) comprises, in part, the highly conformational epitope for TSAb at the critical N terminus of the TSHR, Amino acid homology, as well as cysteine pairing similar to the laminin gamma1 chain epidermal growth factor-like repeat 11, suggests conformational similarity between the two molecules and raises the possibility of molecular mimicry in the pathogenesis of Graves' disease.	Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Res Inst, Autoimmune Dis Unit, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Rapoport, B (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Suite B-131, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK19289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baumgartner R, 1996, J MOL BIOL, V257, P658, DOI 10.1006/jmbi.1996.0192; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Chazenbalk GD, 1997, J BIOL CHEM, V272, P18959, DOI 10.1074/jbc.272.30.18959; Chazenbalk GD, 1999, J CLIN ENDOCR METAB, V84, P702, DOI 10.1210/jc.84.2.702; DEFORTEZA R, 1994, J CLIN ENDOCR METAB, V78, P1271, DOI 10.1210/jc.78.5.1271; FUKUSHIMA Y, 1988, CYTOGENET CELL GENET, V48, P137, DOI 10.1159/000132610; Jaume JC, 1997, J CLIN ENDOCR METAB, V82, P500, DOI 10.1210/jc.82.2.500; JOHNSTONE AP, 1994, MOL CELL ENDOCRINOL, V105, P1; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Kakinuma A, 1996, ENDOCRINOLOGY, V137, P2664, DOI 10.1210/en.137.7.2664; KASAGI K, 1982, J CLIN ENDOCR METAB, V54, P108, DOI 10.1210/jcem-54-1-108; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSUGI S, 1992, MOL ENDOCRINOL, V6, P168, DOI 10.1210/me.6.2.168; KOSUGI S, 1992, BIOCHEM BIOPH RES CO, V189, P1754, DOI 10.1016/0006-291X(92)90281-O; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P114, DOI 10.1210/me.7.1.114; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1992, J CLIN ENDOCR METAB, V75, P1425, DOI 10.1210/jc.75.6.1425; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SETO P, 1993, MOL CELL ENDOCRINOL, V94, P5; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; TAHARA K, 1991, BIOCHEM BIOPH RES CO, V179, P70, DOI 10.1016/0006-291X(91)91335-A; TOMER Y, 1993, ENDOCR REV, V14, P107, DOI 10.1210/er.14.1.107; VanSande J, 1996, MOL CELL ENDOCRINOL, V119, P161, DOI 10.1016/0303-7207(96)03804-X; WADSWORTH HL, 1992, MOL ENDOCRINOL, V6, P394, DOI 10.1210/me.6.3.394; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649	29	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14767	14772		10.1074/jbc.M008001200	http://dx.doi.org/10.1074/jbc.M008001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278376	hybrid			2022-12-27	WOS:000168528800033
J	Sagi, SA; Seasholtz, TM; Kobiashvili, M; Wilson, BA; Toksoz, D; Brown, JH				Sagi, SA; Seasholtz, TM; Kobiashvili, M; Wilson, BA; Toksoz, D; Brown, JH			Physical and functional interactions of G alpha(q) with Rho and its exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASTEURELLA-MULTOCIDA TOXIN; PROTEIN-COUPLED RECEPTORS; STRESS FIBER FORMATION; GROWTH-FACTOR RECEPTOR; SERUM RESPONSE FACTOR; LYSOPHOSPHATIDIC ACID; NEURITE RETRACTION; THROMBIN-RECEPTOR; FAMILY GTPASES; GENE-TRANSCRIPTION	Recent reports have shown that several heterotrimeric protein-coupled receptors that signal through G alpha (q) can induce Rho dependent responses, but the pathways that mediate the interaction between G alpha (q) and Rho have not yet been identified. In this report we present evidence that G alpha (q) expressed in COS-7 cells coprecipitates with the Rho guanine nucleotide exchange factor (GEF) Lbc, Furthermore, G alpha (q) expression enhances Rho-dependent responses. Coexpressed G alpha (q) and Lbc have a synergistic effect on the Rho-dependent rounding of 1321N1 astrocytoma cells. In addition, serum response factor-dependent gene expression, as assessed by the SRE.L reporter gene, is synergistically activated by G alpha (q) and Rho GEFs. The synergistic effect of G alpha (q) on this response is inhibited by C3 exoenzyme and requires phiospholipase C activation. Surprisingly, expression of G alpha (q), in contrast to that of G alpha (12) and G alpha (13), does not increase the amount of activated Rho. We also observe that G alpha (q) enhances SRE.L stimulation by activated Rho, indicating that the effect of G alpha (q) occurs downstream of Rho activation. Thus, G alpha (q) interacts physically and/or functionally with Rho GEFs; however this does not appear to lead to or result from increased activation of Rho. We suggest that G alpha (q)-generated signals enhance responses downstream of Rho activation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University of California System; University of California San Diego; University of Illinois System; University of Illinois Urbana-Champaign; Tufts University	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R29CA062029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038396, R01AI038396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM036927, R01GM036927] Funding Source: NIH RePORTER; NCI NIH HHS [CA62029] Funding Source: Medline; NIAID NIH HHS [AI38396, R29 AI038396, R01 AI038396] Funding Source: Medline; NIGMS NIH HHS [GM36927, R56 GM036927, R01 GM036927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Beekman A, 1998, CANCER RES, V58, P910; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATSUI T, 1996, EMBO J, V15, P2203; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Tigyi G, 1996, J NEUROCHEM, V66, P537; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wilson BA, 1999, INFECT IMMUN, V67, P80, DOI 10.1128/IAI.67.1.80-87.1999; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961	49	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15445	15452		10.1074/jbc.M008961200	http://dx.doi.org/10.1074/jbc.M008961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278452	hybrid, Green Accepted			2022-12-27	WOS:000168528800121
J	Wang, T; Piefer, AJ; Jonsson, CB				Wang, T; Piefer, AJ; Jonsson, CB			Interactions of the human T-cell leukemia virus type-II integrase with the conserved CA in the retroviral long terminal repeat end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA; PROTEIN; SUBSTRATE; BINDING; RECOGNITION; O-6-METHYLGUANINE; SEQUENCES; CLEAVAGE; CRYSTAL; FINGER	Retroviral integrases (INs) interact with termini of retroviral DNA in the conserved 5'-C(A/G)T. For most integrases, modifications of critical moieties in the major and minor grooves of these sequences decrease 3'-processing. However, for human immunodeficiency virus type-2 (HTLV-2) IN, the replacement of the guanine with B-methylguanine or hypoxanthine not only reduced 3'-processing, but also promoted cleavage at a second site. This novel cleavage activity required an upstream ACA, unique to the HTLV-2 U5 end. 3'-Processing assays with additional isosteric modifications at Gua and filter binding experiments revealed that the mechanism of the second site cleavage differed among the major groove, minor groove, and mismatch modifications. Importantly, the decrease in 3'-processing activity noted with the minor groove and mismatch modifications were attributed to a decrease in binding. Major groove modifications, however, decreased the level of 3'-processing, but did not affect binding. This suggests that integrase binds the viral end through the minor groove, but relies on major groove contacts for 3'-processing. Several modifications were also examined in strand transfer and disintegration substrates, HTLV-2 IN showed reduced activity with strand transfer and disintegration substrates containing major groove, but not minor groove modifications. This suggests major groove interactions at guanine also provide an important role in these reactions.	New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA	New Mexico State University	Jonsson, CB (corresponding author), New Mexico State Univ, Dept Chem & Biochem, Box 30001,MSC 3C, Las Cruces, NM 88003 USA.	cjonsson@nmsu.edu	Jonsson, Colleen/X-2360-2019; Jonsson, Colleen/GPC-4424-2022	Jonsson, Colleen/0000-0002-2640-7672	NATIONAL CANCER INSTITUTE [R15CA074398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008136] Funding Source: NIH RePORTER; NCI NIH HHS [R15CA74398-01] Funding Source: Medline; NIGMS NIH HHS [S06 GM008136-260035, S06 GM008136-270035, S06 GM008136-280035, S06 GM008136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; Balakrishnan M, 1996, VIROLOGY, V219, P77, DOI 10.1006/viro.1996.0224; Balakrishnan M, 1997, J VIROL, V71, P1025, DOI 10.1128/JVI.71.2.1025-1035.1997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG CE, 1970, J AM CHEM SOC, V92, P7441, DOI 10.1021/ja00728a031; BUSHMAN FD, 1990, J VIROL, V64, P5645, DOI 10.1128/JVI.64.11.5645-5648.1990; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; CHOW SA, 1994, J VIROL, V68, P3896, DOI 10.1128/JVI.68.6.3896-3907.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DONZELLA GA, 1993, J VIROL, V67, P7077, DOI 10.1128/JVI.67.12.7077-7087.1993; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; JONSSON CB, 1993, J VIROL, V67, P5562, DOI 10.1128/JVI.67.9.5562-5571.1993; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; MASUDA T, 1995, J VIROL, V69, P6687, DOI 10.1128/JVI.69.11.6687-6696.1995; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; Spratt TE, 1997, NUCLEIC ACIDS RES, V25, P3354, DOI 10.1093/nar/25.16.3354; THEWALT U, 1972, J AM CHEM SOC, V94, P8892, DOI 10.1021/ja00780a041; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VOIGT JM, 1990, BIOCHEMISTRY-US, V29, P1632, DOI 10.1021/bi00458a039; Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n	34	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14710	14717		10.1074/jbc.M007754200	http://dx.doi.org/10.1074/jbc.M007754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278363	hybrid			2022-12-27	WOS:000168528800026
J	Chu, D; Kakazu, N; Gorrin-Rivas, MJ; Lu, HP; Kawata, M; Abe, T; Ueda, K; Adachi, Y				Chu, D; Kakazu, N; Gorrin-Rivas, MJ; Lu, HP; Kawata, M; Abe, T; Ueda, K; Adachi, Y			Cloning and characterization of LUN, a novel RING finger protein that is highly expressed in lung and specifically binds to a palindromic sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; DNA-BINDING; E-CADHERIN; TRANSCRIPTION FACTOR; SUMO-1 MODIFICATION; NEGATIVE REGULATOR; CRYSTAL-STRUCTURE; TOPOISOMERASE-I; GENE-EXPRESSION; ALPHA	We isolated cDNAs encoding a novel RING finger protein (LUN), the mRNAs of which were expressed at high levels in the lung. In, situ hybridization revealed that LUN mRNAs were expressed in the alveolar epithelium of the lung. The LUN gene locus was assigned to chromosome 9p21, which contains candidate tumor suppressor genes associated with loss of heterozygosity in more than 86% of small cell lung cancers. We clarified that LUN is localized to the nucleus and reveals Zn2+-dependent DNA binding activity. The region from amino acids 51 to 374 of LUN is responsible for DNA binding. Furthermore, we identified a novel palindromic binding consensus (5'-TCCCAGCACTTTGGGA-3') for the LUN binding. Interestingly, this LUN binding palindromic sequence is found in the upstream transcriptional regulatory region of the E-cadherin gene and two intervening regions of the talin gene. Our results suggested that LUN might be an important trans-acting transcriptional regulator for lung cancer-associated genes including E-cadherin and talin genes.	Kyoto Univ, Inst Chem Res, Lab Mol Clin Chem, Kyoto 6110011, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Univ, Grad Sch Med, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Prefectural Univ Med, Dept Anat, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto University; Kyoto Prefectural University of Medicine; Kyoto University; Kyoto Prefectural University of Medicine	Adachi, Y (corresponding author), Kyoto Univ, Inst Chem Res, Lab Mol Clin Chem, Kyoto 6110011, Japan.	adachi@scl.kyoto-u.ac.jp						ADACHI Y, 1992, J BIOL CHEM, V267, P19373; ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BOHM M, 1994, CLIN EXP METASTAS, V12, P55, DOI 10.1007/BF01784334; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Chen YY, 1996, J BIOL CHEM, V271, P5183; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DRIEVEN W, 1999, NATURE, V337, P138; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GOEBL MG, 1991, CELL, V66, P623, DOI 10.1016/0092-8674(91)90106-9; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Inazawa J, 1996, HUM GENET, V98, P508, DOI 10.1007/s004390050249; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kim SK, 1997, CANCER RES, V57, P400; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Morimoto M, 1996, NEUROSCI RES, V26, P235, DOI 10.1016/S0168-0102(96)01105-4; OKA H, 1993, CANCER RES, V53, P1696; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI H, 1995, CANCER RES, V55, P2998; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	53	23	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14004	14013		10.1074/jbc.M010262200	http://dx.doi.org/10.1074/jbc.M010262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278651	hybrid, Green Submitted			2022-12-27	WOS:000168356600069
J	Kamizono, S; Hanada, T; Yasukawa, H; Minoguchi, S; Kato, R; Minoguchi, M; Hattori, K; Hatakeyama, S; Yada, M; Morita, S; Kitamura, T; Kato, H; Nakayama, K; Yoshimura, A				Kamizono, S; Hanada, T; Yasukawa, H; Minoguchi, S; Kato, R; Minoguchi, M; Hattori, K; Hatakeyama, S; Yada, M; Morita, S; Kitamura, T; Kato, H; Nakayama, K; Yoshimura, A			The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JANUS TYROSINE KINASE; JAK-STAT PATHWAY; CONSTITUTIVE ACTIVATION; FUNCTIONAL-ANALYSIS; T-CELLS; C-CBL; PROTEIN; SUPPRESSION; RECEPTOR; FAMILY	Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia. TEL-mediated oligomerization of JAK2 results in constitutive activation of the tyrosine kinase (JH1) domain and confers cytokine-independent proliferation on interleukin-3-dependent Ba/F3 cells. Forced expression of the JAK inhibitor gene SOCS1/JAB/SSI-1 induced apoptosis of TEL-JAK2-transformed Ba/F3 cells, This suppression of TEL-JAK2 activity was dependent on SOCS box-mediated proteasomal degradation of TEL-JAK2 rather than on kinase inhibition. Degradation of JAK2 depended on its phosphorylation and its high affinity binding with SOCS1 through the kinase inhibitory region and the SH2 domain. It has been demonstrated that von Hippel-Lindau disease (VHL) tumor-suppressor gene product possesses the SOCS box that forms a complex with Elongin B and C and Cullin-2, and it functions as a ubiquitin ligase. The SOCS box of SOCS1/JAB has also been shown to interact with Elongins; however, ubiquitin ligase activity has not been demonstrated. We found that the SOCS box interacted with Cullin-8 and promoted ubiquitination of TEL-JAK2. Furthermore, overexpression of dominant negative Cullin-2 suppressed SOCS1-dependent TEL-JAK2 degradation. Our study demonstrates the substrate-specific E3 ubiquitinligase-like activity of SOCS1 for activated JAK2 and may provide a novel strategy for the suppression of oncogenic tyrosine kinases.	Kyushu Univ, Med Inst Bioregulat, Dept Immunol, Fukuoka 8128582, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Pediat, Kurume, Fukuoka 830, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1088639, Japan	Kyushu University; Kurume University; Kurume University; Kyushu University; University of Tokyo	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Immunol, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.acjp	Yoshimura, Akihiko/K-5515-2013; Kitamura, Toshio/AAA-2071-2021; Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Chai SK, 1997, J IMMUNOL, V159, P4720; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shuai K, 1996, ONCOGENE, V13, P247; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	38	261	273	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12530	12538		10.1074/jbc.M010074200	http://dx.doi.org/10.1074/jbc.M010074200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278610	hybrid			2022-12-27	WOS:000168198600011
J	Angelastro, JM; Moon, NY; Liu, DX; Yang, AS; Greene, LA; Franke, TF				Angelastro, JM; Moon, NY; Liu, DX; Yang, AS; Greene, LA; Franke, TF			Characterization of a novel isoform of capase-9 that inhibits apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-9; DEATH; IDENTIFICATION; PROCASPASE-9; ACTIVATION	We have identified a novel isoform of rat caspase-9 in which the C terminus of full-length caspase-9 is replaced with an alternative peptide sequence. Casp-9-CTD (where CTD is carboxyl-terminal divergent) is expressed in multiple tissues, with the relative highest expression observed in ovary and heart. Casp-9-CTD was found primarily in the cytoplasm and was not detected in the nucleus. Structural predictions suggest that in contrast to full-length caspase-9, casp-9-CTD will not be processed. Our model is supported by reduced protease activity of casp-9-CTD preparations in vitro and by the lack of detectable processing of casp-9-CTD proenzyme or the induction of cell death following transfection into cells. Both neuronal and non-neuronal cell types transfected with casp-9-CTD were resistant to death evoked by trophic factor deprivation or DNA damage. In addition, cytosolic lysates prepared from cells permanently expressing exogenous casp-9-CTD were resistant to caspase induction by cytochrome c in reconstitution assays. Taken together, our observations indicate that casp-9-CTD acts as a dominant-negative variant. Its expression in various tissues indicates a physiological role in regulating cell death.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Angelastro, JM (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St,P&S15-401, New York, NY 10032 USA.	jma14@columbia.edu; TFF5@columbia.edu		Yang, An-Suei/0000-0002-4699-873X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016036, R01NS033689] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33689, NS16036] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Angelastro JM, 1998, J NEUROCHEM, V70, P540; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1998, CULTURING NERVE CELL, P161; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; Ritter PM, 2000, EUR J CELL BIOL, V79, P358, DOI 10.1078/S0171-9335(04)70040-0; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; Stefanis L, 1999, J NEUROSCI, V19, P6235; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 1997, J NEUROSCI, V17, P1911; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Yang AS, 1999, PROTEINS, P66; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	34	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12190	12200		10.1074/jbc.M009523200	http://dx.doi.org/10.1074/jbc.M009523200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278518	hybrid			2022-12-27	WOS:000168081800102
J	Brandt, J; Andersen, AS; Kristensen, C				Brandt, J; Andersen, AS; Kristensen, C			Dimeric fragment of the insulin receptor alpha-subunit finds insulin with full holoreceptor affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-BINDING DOMAIN; STRUCTURAL BASIS; MONOCLONAL-ANTIBODIES; NEGATIVE COOPERATIVITY; EXTRACELLULAR DOMAIN; QUATERNARY STRUCTURE; HUMAN-PLACENTA; III DOMAIN; ECTODOMAIN	The insulin receptor (IR) is a dimeric receptor, and its activation is thought to involve cross-linking between monomers initiated by binding of a single insulin molecule to separate epitopes on each monomer, We have previously shown that a minimized insulin receptor consisting of the first three domains of the human IR fused to 16 amino acids from the C-terminal of the alpha -subunit was monomeric and bound insulin with nanomolar affinity (Kristensen, C,, Wiberg, F, C,, Schaffer, L,, and Andersen, A. S, (1998) J, Biol, Chem, 273, 17780-17786). To investigate the insulin binding properties of dimerized alpha -subunits, we have reintroduced the domains containing alpha-alpha disulfide bonds into this minireceptor, When inserting either the first fibronectin type III domain or the full-length sequence of exon 10, the receptor fragments were predominantly secreted as disulfide-linked dimers that both had nanomolar affinity for insulin, similar to the affinity found for the minireceptor, However, when both these domains were included we obtained a soluble dimeric receptor that bound insulin with 1000-fold higher affinity (4-8 pM) similar to what was obtained for the solubilized holoreceptor (14-24 PM). Moreover, dissociation of labeled insulin from this receptor was accelerated in the presence of unlabeled insulin, demonstrating another characteristic feature of the holoreceptor, This is the first direct demonstration showing that the alpha -subunit of LR contains all the epitopes required for binding insulin with full holoreceptor affinity.	Novo Nordisk AS, Insulin Res, DK-2880 Bagsvaerd, Denmark	Novo Nordisk	Brandt, J (corresponding author), Novo Nordisk AS, Insulin Res, Novo Alle 6B1-74, DK-2880 Bagsvaerd, Denmark.		Kristensen, Claus/O-8047-2015	Kristensen, Claus/0000-0002-2594-7722				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Elleman TC, 2000, BIOCHEM J, V347, P771, DOI 10.1042/0264-6021:3470771; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; FABRY M, 1992, BIOL CHEM H-S, V373, P915, DOI 10.1515/bchm3.1992.373.2.915; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Hoyne PA, 2000, FEBS LETT, V479, P15, DOI 10.1016/S0014-5793(00)01872-X; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KRISTENSEN C, 1995, BIOCHEM J, V305, P981, DOI 10.1042/bj3050981; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; Marino-Buslje C, 1999, BIOCHEM SOC T, V27, P715, DOI 10.1042/bst0270715; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; Molina L, 2000, FEBS LETT, V467, P226, DOI 10.1016/S0014-5793(00)01161-3; Mulhern TD, 1998, TRENDS BIOCHEM SCI, V23, P465, DOI 10.1016/S0968-0004(98)01288-2; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; OBRIEN RM, 1987, EMBO J, V6, P4003, DOI 10.1002/j.1460-2075.1987.tb02743.x; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; PANG DT, 1984, J BIOL CHEM, V259, P8589; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SWANSON ML, 1989, J MEMBRANE BIOL, V108, P217, DOI 10.1007/BF01871736; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; Tulloch PA, 1999, J STRUCT BIOL, V125, P11, DOI 10.1006/jsbi.1998.4066; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063; Woldin CN, 1999, J BIOL CHEM, V274, P34981, DOI 10.1074/jbc.274.49.34981; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	47	34	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12378	12384		10.1074/jbc.M009402200	http://dx.doi.org/10.1074/jbc.M009402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278498	hybrid			2022-12-27	WOS:000168081800125
J	Calero, M; Whittaker, GR; Collins, RN				Calero, M; Whittaker, GR; Collins, RN			Yop1p, the yeast homolog of the polyposis locus protein 1, interacts with Yip1p and negatively regulates cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GOLGI MEMBRANE-PROTEIN; BINDING PROTEIN; RAB-GTPASES; 2-HYBRID; COMPLEX; CANCER; IDENTIFICATION; SYSTEM; YPT51P	Rab proteins are small GTPases that are essential elements of the protein transport machinery of eukaryotic cells. Each round of membrane transport requires a cycle of Rab protein nucleotide binding and hydrolysis. We have recently characterized a protein, Yip1p, which appears to play a role in Rab-mediated membrane transport in Saccharomyces cerevisiae. In this study, we report the identification of a Yip1p-associated protein, Yop1p. Yop1p is a membrane protein with a hydrophilic region at its N terminus through which it interacts specifically with the cytosolic domain of Yip1p. Yop1p could also be coprecipitated with Rab proteins from total cellular lysates. The TB2 gene is the human homolog of Yop1p (Rinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levey, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., Finniear, R., Markham, A., Groffen, J., Boguski, M. S., Altschul, S. F., Horii, A., Ando, H. M., Y., Miki, Y., Nishisho, I., and Nakamura, Y. (1991) Science 258, 661-665). Our data demonstrate that Yop1p negatively regulates cell growth. Disruption of YOP1 has no apparent effect on cell viability, while overexpression results in cell death, accumulation of internal cell membranes, and a block in membrane traffic. These results suggest that Yop1p acts in conjunction with Yip1p to mediate a common step in membrane traffic.	Cornell Univ, Dept Mol Med, Ithaca, NY 14850 USA; Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY 14850 USA	Cornell University; Cornell University	Collins, RN (corresponding author), Cornell Univ, Dept Mol Med, C4-109 VMC, Ithaca, NY 14850 USA.	rnc8@cornell.edu						ARAKI S, 1990, J BIOL CHEM, V265, P13007; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Collins RN, 2000, FR MOLEC B, V24, P137; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Drees BL, 1999, CURR OPIN CHEM BIOL, V3, P64, DOI 10.1016/S1367-5931(99)80012-X; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P77; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; James P, 1996, GENETICS, V144, P1425; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Whittaker GR, 1998, VIROLOGY, V246, P1, DOI 10.1006/viro.1998.9165; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954; Young KH, 1998, BIOL REPROD, V58, P302, DOI 10.1095/biolreprod58.2.302	44	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12100	12112		10.1074/jbc.M008439200	http://dx.doi.org/10.1074/jbc.M008439200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278413	hybrid			2022-12-27	WOS:000168081800090
J	Stutz, AM; Hoeck, J; Natt, F; Cuenoud, B; Woisetschlager, M				Stutz, AM; Hoeck, J; Natt, F; Cuenoud, B; Woisetschlager, M			Inhibition of interleukin-4-and CD40-induced IgE germline gene promoter activity by 2 '-aminoethoxy-modified tripler-forming oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOUBLE-STRANDED DNA; TRANSCRIPTION FACTOR; T-CELLS; IL-4-INDUCED ACTIVATION; EPSILON-TRANSCRIPTS; RESPONSIVE ELEMENT; DUAL RECOGNITION; GROWTH-FACTOR; I-EPSILON	Elevated levels of IgE are intimately associated with a number of allergic diseases, such as allergic rhinitis or asthma, Therefore, prevention of IgE production in human B-cells represents an attractive therapeutic target. IL-8-induced IgE germline gene transcription represents a crucial early step during IgE isotype switch differentiation. Gene induction is orchestrated by the coordinated action of the transcription factors STAT6 (signal transducer and activator of transcription), NF-kappaB, PU.1, and C/EBP, This study shows that 2'-aminoethoxy-modified oligonucleotides, which partially overlap with the STAT6 and the adjacent PU.1/NF-kappaB binding site, inhibit DNA binding of all three proteins with high affinity in a dose- and time-dependent fashion in vitro. Loss of protein binding correlated strongly with increasing DNA tripler formation. Importantly, the oligomers also effectively displaced pre-bound recombinant NF-KB p50 from double-stranded DNA in vitro, Functionally, the oligonucleotides led to a selective inhibition of IL-4-induced reporter gene activity from a construct driven by the IgE germline gene promoter in human B-cells. These data confirm the critical role of this cytokine-responsive regulatory region in IgE germline gene induction and further support the concept of specific modulation of gene expression by DNA tripler formation induced with chemically modified oligonucleotides.	Novartis Res Inst, Dept Allerg Dis, A-1230 Vienna, Austria; Novartis Pharma Res, CH-4002 Basel, Switzerland; Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England	Novartis; Novartis; Novartis	Woisetschlager, M (corresponding author), Novartis Res Inst, Dept Allerg Dis, Brunnerstr 59, A-1230 Vienna, Austria.		Horejs-Hoeck, Jutta/E-5010-2011; Horejs-Hoeck, Jutta/AAF-1735-2019	Horejs-Hoeck, Jutta/0000-0002-0984-204X; Horejs-Hoeck, Jutta/0000-0002-0984-204X; Stuetz, Adrian/0000-0001-7650-3470				ALBRECHT B, 1994, INT IMMUNOL, V6, P1143, DOI 10.1093/intimm/6.8.1143; Albrecht B, 1996, J IMMUNOL, V157, P1538; BEST GC, 1995, J AM CHEM SOC, V117, P1187, DOI 10.1021/ja00109a001; Blommers MJJ, 1998, BIOCHEMISTRY-US, V37, P17714, DOI 10.1021/bi9816352; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Cuenoud B, 1998, ANGEW CHEM INT EDIT, V37, P1288, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1288::AID-ANIE1288>3.0.CO;2-U; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FENGHAO X, 1995, J CLIN INVEST, V96, P907, DOI 10.1172/JCI118138; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; Giovannangeli C, 1997, ANTISENSE NUCLEIC A, V7, P413, DOI 10.1089/oli.1.1997.7.413; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Hoey T, 1999, Adv Immunol, V71, P145; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; ICHIKI T, 1993, J IMMUNOL, V150, P5408; Iciek LA, 1997, J IMMUNOL, V158, P4769; Kochetkova M, 1996, J BIOL CHEM, V271, P14438, DOI 10.1074/jbc.271.24.14438; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; Kovacs A, 1996, J BIOL CHEM, V271, P1805, DOI 10.1074/jbc.271.3.1805; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LI SC, 1991, ADV EXP MED BIOL, V292, P245; Lu BF, 1997, J IMMUNOL, V159, P1255; Matsukura S, 1999, J IMMUNOL, V163, P6876; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; Messner B, 1997, J IMMUNOL, V159, P3330; Mikita T, 1998, J IMMUNOL, V161, P1822; Mochizuki M, 1998, J IMMUNOL, V160, P60; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; Neidle S, 1997, ANTI-CANCER DRUG DES, V12, P433; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; Porumb H, 1996, CANCER RES, V56, P515; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; Stutz AM, 1999, J IMMUNOL, V163, P4383; THORNHILL MH, 1991, J IMMUNOL, V146, P592; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	47	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11759	11765		10.1074/jbc.M010260200	http://dx.doi.org/10.1074/jbc.M010260200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278649	hybrid			2022-12-27	WOS:000168081800046
J	Caprini, M; Ferroni, S; Planells-Cases, R; Rueda, J; Rapisarda, C; Ferrer-Montiel, A; Montal, M				Caprini, M; Ferroni, S; Planells-Cases, R; Rueda, J; Rapisarda, C; Ferrer-Montiel, A; Montal, M			Structural compatibility between the putative voltage sensor of voltage-gated K+ channels and the prokaryotic KcsA channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNEL; 2 PORE DOMAINS; SODIUM-CHANNEL; TRANSMEMBRANE SEGMENTS; GATING CURRENTS; EXPRESSION; MUTATIONS; RESIDUES; STOICHIOMETRY; ACTIVATION	Sequence similarity among and electrophysiological studies of known potassium channels, along with the three-dimensional structure of the Streptomyces lividans K+ channel (KcsA), support the tenet that voltage-gated K+ channels (Kv channels) consist of two distinct modules: the "voltage sensor" module comprising the N-terminal portion of the channel up to and including the S4 transmembrane segment and the "pore" module encompassing the C-terminal portion from the S5 transmembrane segment onward. To substantiate this modular design, we investigated whether the pore module of Ky channels may be replaced with the pore module of the prokaryotic KcsA channel. Biochemical and immunocytochemical studies showed that chimeric channels were expressed on the cell surface of Xenopus oocytes, demonstrating that they were properly synthesized, glycosylated, folded, assembled, and delivered to the plasma membrane. Unexpectedly, surface-expressed homomeric chimeras did not exhibit detectable voltage-dependent channel activity upon both hyperpolarization and depolarization regardless of the expression system used. Chimeras were, however, strongly dominant-negative when coexpressed with wild-type Kv channels, as evidenced by the complete suppression of wild-type channel activity. Notably, the dominant-negative phenotype correlated well with the formation of stable, glycosylated, nonfunctional, heteromeric channels. Collectively, these findings imply a structural compatibility between the prokaryotic pore module and the eukaryotic voltage sensor domain that leads to the biogenesis of non-responsive channels. Our results lend support to the notion that voltage-dependent channel gating depends on the precise coupling between both protein domains, probably through a localized interaction surface.	Univ Miguel Hernandez, Ctr Biol Mol & Celular, Elche Alicante 03202, Spain; Univ Bologna, Dept Human & Gen Physiol, I-40127 Bologna, Italy; Univ Miguel Hernandez, Dept Histol, Elche Alicante 03202, Spain; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Universidad Miguel Hernandez de Elche; University of Bologna; Universidad Miguel Hernandez de Elche; University of California System; University of California San Diego	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Ctr Biol Mol & Celular, Avda Ferrocarril S-N, Elche Alicante 03202, Spain.	aferrer@umh.es	Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Rueda, Joaquin/0000-0002-3774-8763				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Ferrer-Montiel Antonio V., 1994, Methods (Orlando), V6, P60, DOI 10.1006/meth.1994.1008; FerrerMontiel AV, 1996, J BIOL CHEM, V271, P18322, DOI 10.1074/jbc.271.31.18322; FERRONI S, 1992, EUR BIOPHYS J BIOPHY, V21, P185; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lesage F, 1996, J BIOL CHEM, V271, P4183; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; Montal M, 1996, CURR OPIN STRUC BIOL, V6, P499, DOI 10.1016/S0959-440X(96)80115-1; MONTAL M, 1995, ANNU REV BIOPH BIOM, V24, P31, DOI 10.1146/annurev.bb.24.060195.000335; NELSON R, 2000, J MOL MICROB BIOTECH, V1, P281; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Patten CD, 1999, FEBS LETT, V463, P375, DOI 10.1016/S0014-5793(99)01659-2; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; SUN W, 1992, P NATL ACAD SCI USA, V89, P1443, DOI 10.1073/pnas.89.4.1443; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	50	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21070	21076		10.1074/jbc.M100487200	http://dx.doi.org/10.1074/jbc.M100487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274182	hybrid			2022-12-27	WOS:000169297900038
J	Czuwara-Ladykowska, J; Shirasaki, F; Jackers, P; Watson, DK; Trojanowska, M				Czuwara-Ladykowska, J; Shirasaki, F; Jackers, P; Watson, DK; Trojanowska, M			Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ETS TRANSCRIPTION FACTORS; HUMAN SKIN FIBROBLASTS; DNA-BINDING; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; TGF-BETA; PROMOTER; SP1; ACTIVATION	Fibrosis is characterized by the excessive deposition of extracellular matrix (ECM), especially collagen. Because Ets factors are implicated in physiological and pathological ECM remodeling, the aim of this study was to investigate the role of Ets factors in collagen production. We demonstrate that the expression of collagenous proteins and collagen alpha2(I) (COL1A2) mRNA was inhibited following stable transfection of Fli-1 in dermal fibroblasts, Subsequent analysis of the COL1A2 promoter identified a critical Ets binding site that mediates Fli-1 inhibition. In contrast, Ets-1 stimulates COL1A2 promoter activity. In vitro binding assays demonstrate that both Fli-1 and Ets-1 form DNA-protein complexes with sequences present in COL1A2 promoter. Furthermore, Fli-1 binding to the COL1A2 is enhanced via Sp1-dependent interaction. Studies using Fli-1 dominant interference and DNA binding mutants indicate that Fli-1 inhibition is mediated by both direct (DNA binding) and indirect (via protein-protein interaction) mechanisms and that Spl is an important mediator of the Fli-1 function. Furthermore, experiments using the Gal4 system in the context of different cell types as well as experiments with the COL1A2 promoter in different cell lines demonstrate that the direction and magnitude of the effect of Fli-1 is promoter- and cell context-specific. We propose that Fli-1 inhibits COL1A2 promoter activity by competition with Ets-1, In addition, we postulate that another factor (co-repressor) may be required for maximal inhibition after recruitment to the Fli-1-Sp1 complex. We conclude that the ratio of Fli-1 to Ets-1 and the presence of co-regulatory proteins ultimately control ECM production in fibroblasts.	Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29401 USA; Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29401 USA; Kanazawa Univ, Dept Dermatol, Kanazawa, Ishikawa 9200947, Japan	Medical University of South Carolina; Medical University of South Carolina; Kanazawa University	Czuwara-Ladykowska, J (corresponding author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Ste 912, Charleston, SC 29401 USA.		Czuwara, Joanna/AAK-4504-2020	Trojanowska, Maria/0000-0001-9550-7178	NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA78582] Funding Source: Medline; NIAMS NIH HHS [AR 42334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BOLON I, 1995, AM J PATHOL, V147, P1298; Border WA, 1996, DIABETES METAB REV, V12, P309; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Mager AM, 1998, INT J DEV BIOL, V42, P561; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Teitell MA, 1999, LAB INVEST, V79, P1535; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	43	143	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20839	20848		10.1074/jbc.M010133200	http://dx.doi.org/10.1074/jbc.M010133200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278621	hybrid			2022-12-27	WOS:000169297900009
J	Ratner, AJ; Bryan, R; Weber, A; Nguyen, S; Barnes, D; Pitt, A; Gelber, S; Cheung, A; Prince, A				Ratner, AJ; Bryan, R; Weber, A; Nguyen, S; Barnes, D; Pitt, A; Gelber, S; Cheung, A; Prince, A			Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA; CALCIUM INFLUX; INFECTION; RECEPTOR; BACTERIA; SURFACE; PILI; BIND; OVERPRODUCTION	Much of the pulmonary disease in cystic fibrosis is associated with polymorphonuclear leukocyte-dominated airway inflammation caused by bacterial infection. Respiratory epithelial cells express the polymorphonuclear chemokine interleukin-8 (IL-8) in response to ligation of asialylated glycolipid receptors, which are increased on damaged or regenerating cells and those with cystic fibrosis transmembrane conductance regulator mutations. Because both Pseudomonas aeruginosa and Staphylococcus aureus, the most common pathogens in cystic fibrosis, bind asialylated glycolipid receptors such as asialoGM1, we postulated that diverse bacteria can activate a common epithelial signaling pathway to elicit IL-8 expression. P, aeruginosa PAO1 but not pil mutants and S. aureus RN6390 but not the agr mutant RN6911 stimulated increases in [Ca2+](i) in 1HAEo- airway epithelial cells. This response stimulated p38 and ERK1/2 mitogen-activated protein kinase (MAPK) signaling cascades resulting in NF-KB activation and IL-8 expression. Ligation of the asialoGM1 receptor or thapsigargin-elicited Ca2+ release activated this pathway, whereas P. aeruginosa lipopolysaccharide did not. The rapid kinetics of epithelial activation precluded bacterial invasion of the epithelium, Recognition of asialylated glycolipid receptors on airway epithelial cells provides a common pathway for Gram-positive and Gram-negative organisms to initiate an epithelial inflammatory response.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Dartmouth Coll, Sch Med, Dept Microbiol, Hanover, NH 03755 USA	Columbia University; Dartmouth College	Prince, A (corresponding author), Columbia Univ, Dept Pediat, 650 W 168th St, New York, NY 10032 USA.	asp7@columbia.edu		Ratner, Adam/0000-0003-1761-794X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056194, P50HL060293] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60293, HL56194] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; Booth MC, 1997, INFECT IMMUN, V65, P1550, DOI 10.1128/IAI.65.4.1550-1556.1997; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Bryan R, 1998, AM J RESP CELL MOL, V19, P269, DOI 10.1165/ajrcmb.19.2.2889; COYNE MJ, 1994, J BACTERIOL, V176, P3500, DOI 10.1128/JB.176.12.3500-3507.1994; DeBentzmann S, 1996, INFECT IMMUN, V64, P1582, DOI 10.1128/IAI.64.5.1582-1588.1996; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Evans JH, 1999, AM J PHYSIOL-LUNG C, V277, pL30, DOI 10.1152/ajplung.1999.277.1.L30; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kallstrom H, 1998, J BIOL CHEM, V273, P21777, DOI 10.1074/jbc.273.34.21777; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUNZELMANN K, 1994, J CELL PHYSIOL, V161, P393, DOI 10.1002/jcp.1041610302; Lagaud GJL, 1999, AM J PHYSIOL-HEART C, V276, pH300, DOI 10.1152/ajpheart.1999.276.1.H300; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee A, 1999, AM J PHYSIOL-LUNG C, V277, pL204, DOI 10.1152/ajplung.1999.277.1.L204; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Muller A, 1999, EMBO J, V18, P339, DOI 10.1093/emboj/18.2.339; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Rajan S, 2000, AM J RESP CELL MOL, V23, P304, DOI 10.1165/ajrcmb.23.3.4098; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SHETH HB, 1994, MOL MICROBIOL, V11, P715, DOI 10.1111/j.1365-2958.1994.tb00349.x; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tomono M, 1998, ARCH BIOCHEM BIOPHYS, V353, P374, DOI 10.1006/abbi.1998.0667; Unno N, 1998, AM J PHYSIOL-GASTR L, V274, pG700, DOI 10.1152/ajpgi.1998.274.4.G700; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	38	137	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19267	19275		10.1074/jbc.M007703200	http://dx.doi.org/10.1074/jbc.M007703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278360	hybrid			2022-12-27	WOS:000169091000085
J	Depienne, C; Mousnier, A; Leh, H; Le Rouzic, E; Dormont, D; Benichou, S; Dargemont, C				Depienne, C; Mousnier, A; Leh, H; Le Rouzic, E; Dormont, D; Benichou, S; Dargemont, C			Characterization of the nuclear import pathway for HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN IMPORT; NONDIVIDING CELLS; PREINTEGRATION COMPLEXES; KARYOPHILIC PROPERTIES; RETROVIRAL INTEGRASE; RIBOSOMAL-PROTEINS; TRANSPORT FACTOR; MAMMALIAN-CELLS; MATRIX PROTEIN	The karyophilic properties of the human immunodeficiency virus, type I (HIV-1) pre-integration complex (PIC) allow the virus to infect non-dividing cells. To better understand the mechanisms responsible for nuclear translocation of the PIG, we investigated nuclear import of HIV-1 integrase (IN), a PIG-associated viral enzyme involved in the integration of the viral genome in the host cell DNA. Accumulation of HIV-1 IN into nuclei of digitonin-permeabilized cells does not result from passive diffusion but rather from an active transport that occurs through the nuclear pore complexes. HIV-1 IN is imported by a saturable mechanism, implying that a limiting cellular factor is responsible for this process. Although IN has been previously proposed to contain classical basic nuclear localization signals, we found that nuclear accumulation of IN does not involve karyopherins alpha, beta1, and beta2-mediated pathways. Neither the non-hydrolyzable GTP analog, guanosine 5'-O-(thiotriphosphate), nor the GTP hydrolysis-deficient Ran mutant, RanQ69L, significantly affects nuclear import of IN, which depends instead on ATP hydrolysis, Therefore these results support the idea that IN import is not mediated by members of the karyopherin beta family. More generally, in vitro nuclear import of IN does not require addition of cytosolic factors, suggesting that cellular factor(s) involved in this active but atypical pathway process probably remain associated with the nuclear compartment or the nuclear pore complexes from permeabilized cells.	Univ Paris 07, Univ Paris 06, Inst Jacques Monod, CNRS,UMR 7592,Equipe Transport Nucleocytoplasm, F-75251 Paris 05, France; CEA Saclay, Serv Neurovirol, F-92265 Fontenay Aux Roses, France; Inst Gustave Roussy, UMR 8532, F-94805 Villejuif, France; Inst Cochin Genet Mol, INSERM, U529, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CEA; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dargemont, C (corresponding author), Univ Paris 07, Univ Paris 06, Inst Jacques Monod, CNRS,UMR 7592,Equipe Transport Nucleocytoplasm, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.	dargemont@ijm.jussieu.fr	Depienne, Christel/AAL-3835-2021	Depienne, Christel/0000-0002-7212-9554; Mousnier, Aurelie/0000-0002-7317-1009; Benichou, Serge/0000-0003-3602-3530				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Cannon PM, 1996, J VIROL, V70, P651, DOI 10.1128/JVI.70.1.651-657.1996; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hetzer M, 2000, J CELL BIOL, V148, P293, DOI 10.1083/jcb.148.2.293; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LI GR, 1993, J VIROL, V67, P3969, DOI 10.1128/JVI.67.7.3969-3977.1993; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Petit C, 2000, J VIROL, V74, P7119, DOI 10.1128/JVI.74.15.7119-7126.2000; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	52	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18102	18107		10.1074/jbc.M009029200	http://dx.doi.org/10.1074/jbc.M009029200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278458	hybrid			2022-12-27	WOS:000168866500066
J	Strachan, L; Murison, JG; Prestidge, RL; Sleeman, MA; Watson, JD; Kumble, KD				Strachan, L; Murison, JG; Prestidge, RL; Sleeman, MA; Watson, JD; Kumble, KD			Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RELATED PROTEIN; FACTOR-ALPHA; FACTOR RECEPTOR; EGF RECEPTOR; ANGIOGENIC ACTIVITY; HUMAN BETACELLULIN; MESSENGER-RNA; AMPHIREGULIN; EPIREGULIN; EXPRESSION	High throughput sequencing of a mouse keratinocyte library was used to identify an expressed sequence tag with homology to the epidermal growth factor (EGF) family of growth factors. We have named the protein encoded by this expressed sequence tag Epigen, for epithelial mitogen, Epigen encodes a protein of 152 amino acids that contains features characteristic of the EGF superfamily, Two hydrophobic regions, corresponding to a putative signal sequence and transmembrane domain, flank a core of amino acids encompassing six cysteine residues and two putative N-linked glycosylation sites. Epigen shows 24-37% identity to members of the EGF superfamily including EGF, transforming growth factor a, and Epiregulin, Northern blotting of several adult mouse tissues indicated that Epigen was present in testis, heart, and liver. Recombinant Epigen was synthesized in Escherichia coli and refolded, and its biological activity was compared with that of EGF and transforming growth factor alpha in several assays. In epithelial cells, Epigen stimulated the phosphorylation of c-erbB-l and mitogen-activated protein kinases and also activated a reporter gene containing enhancer sequences present in the c-fos promoter. Epigen also stimulated the proliferation of HaCaT cells, and this proliferation was blocked by an antibody to the extracellular domain of the receptor tyrosine kinase c-erbB-1. Thus, Epigen is the newest member of the EGF superfamily and, with its ability to promote the growth of epithelial cells, may constitute a novel molecular target for wound-healing therapy.	Genesis Res & Dev Corp Ltd, Auckland 1015, New Zealand; Genometrix Inc, The Woodlands, TX 77381 USA		Strachan, L (corresponding author), Genesis Res & Dev Corp Ltd, POB 50, Auckland 1015, New Zealand.	l.strachan@genesis.co.nz	Sleeman, Matthew A/E-6675-2016					ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COHEN S, 1963, J INVEST DERMATOL, V40, P1; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Davis-Fleischer Karen M., 1998, Frontiers in Bioscience, V3, pD288; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; Downing MT, 1997, HISTOCHEM J, V29, P735, DOI 10.1023/A:1026417202351; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GOSPODAROWICZ D, 1979, EXP EYE RES, V28, P501, DOI 10.1016/0014-4835(79)90038-1; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; IMANISHI K, 1989, BRIT J CANCER, V59, P761, DOI 10.1038/bjc.1989.159; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Nakamura M, 1999, CORNEA, V18, P452, DOI 10.1097/00003226-199907000-00011; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Piepkorn M, 1996, AM J DERMATOPATH, V18, P165, DOI 10.1097/00000372-199604000-00010; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SAKAI Y, 1994, CELL GROWTH DIFFER, V5, P527; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SATO E, 1991, ENDOCRINOLOGY, V128, P2402, DOI 10.1210/endo-128-5-2402; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Taylor DS, 1999, P NATL ACAD SCI USA, V96, P1633, DOI 10.1073/pnas.96.4.1633; TOU JS, 1990, BIOCHEM BIOPH RES CO, V167, P484, DOI 10.1016/0006-291X(90)92049-6; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TURBITT ML, 1990, J INVEST DERMATOL, V95, P229, DOI 10.1111/1523-1747.ep12478077; VIOLAND BN, 1991, INT J PEPT PROT RES, V37, P463; WATANABE T, 1994, J BIOL CHEM, V269, P9966; WINKLER ME, 1986, J BIOL CHEM, V261, P3838; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	62	114	122	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18265	18271		10.1074/jbc.M006935200	http://dx.doi.org/10.1074/jbc.M006935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278323	hybrid			2022-12-27	WOS:000168866500088
J	Yamada, A; Takaki, S; Hayashi, F; Georgopoulos, K; Perlmutter, RM; Takatsu, K				Yamada, A; Takaki, S; Hayashi, F; Georgopoulos, K; Perlmutter, RM; Takatsu, K			Identification and characterization of a transcriptional regulator for the lck proximal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DISSECTION; THYMOCYTE DEVELOPMENT; BINDING PROTEIN; GENE-EXPRESSION; FACTOR ZBP-89; IKAROS GENE; T-CELLS; FINGER; ENHANCER; RECEPTOR	The lck gene encodes a protein-tyrosine kinase that plays a key role in signaling mediated through T cell receptor (TCR) and pre-TCR complexes. Transcription of the lck gene is regulated by two independent promoter elements: the proximal and distal promoters. Previous studies employing transgenic mice demonstrated that the sequence between -584 and -240 from the transcription start site in the mouse lck proximal promoter is required for its tissue-specific expression in the thymus, In this study, we demonstrate that a Kruppel-like zinc finger protein, mt beta (BFCOL1, BERF-1, ZBP-89, ZNF148), previously cloned as a protein that binds to the CD3 delta gene enhancer, binds to the -365 to -328 region of the lck proximal promoter. mt beta is ubiquitously expressed in various cell lines and mouse tissues. Overexpressed mt beta is more active in T-lineage cells than B-lineage cells for transactivating an artificial promoter consisting of the mt beta binding site and a TATA box. Activity of the lck proximal promoter was significantly impaired by mutating the mt beta binding site or by reducing mt beta protein expression level by using antisense mRNA. Our results indicate that mt beta activity is regulated in a tissue-specific manner and that mt beta is a critical transactivator for the lck proximal promoter.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Immunol,Minato Ku, Tokyo 1088639, Japan; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; AMGEN, Thousand Oaks, CA 91320 USA	University of Tokyo; University of Washington; University of Washington Seattle; Harvard University; Massachusetts General Hospital; Amgen	Takaki, S (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Immunol,Minato Ku, Tokyo 1088639, Japan.							ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BRAY P, 1991, P NATL ACAD SCI USA, V88, P9563, DOI 10.1073/pnas.88.21.9563; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Crossley M, 1996, MOL CELL BIOL, V16, P1695; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KARASUYAMA H, 1988, J EXP MED, V167, P1377, DOI 10.1084/jem.167.4.1377; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MUISEHELMERICKS RC, 1995, J BIOL CHEM, V270, P27538, DOI 10.1074/jbc.270.46.27538; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; WILDIN RS, 1995, J IMMUNOL, V155, P1286; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18082	18089		10.1074/jbc.M008387200	http://dx.doi.org/10.1074/jbc.M008387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278409	hybrid			2022-12-27	WOS:000168866500063
J	Fan, GH; Yang, W; Sai, JQ; Richmond, A				Fan, GH; Yang, W; Sai, JQ; Richmond, A			Phosphorylation-independent association of CXCR2 with the protein phosphatase 2A core enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; RECEPTOR INTERNALIZATION; CHEMOKINE RECEPTORS; SIGNAL-TRANSDUCTION; CALYCULIN-A; SUBCELLULAR-DISTRIBUTION; CROSS-REGULATION; IL-8 RECEPTOR; DESENSITIZATION; DEPHOSPHORYLATION	Protein phosphatase 2A (PP2A) is postulated to be involved in the dephosphorylation of G protein-coupled receptors, In the present study, we demonstrate that the carboxyl terminus of CXCR2, physically interacts with the PP2A core enzyme, a dimer formed by PP2Ac and PR65, but not with the PP2Ac monomer, suggesting direct interaction of the receptor with PR65, The integrity of a sequence motif in the C terminus of CXCR2, KFRHGL, which is conserved in all CC and CXC chemokine receptors, is required for the receptor binding to the PP2A core enzyme. CXCR2 co-immunoprecipitates with the PP2A core enzyme in HEK293 cells and in human neutrophils, Overexpression of dominant negative dynamin 1 (dynamin 1 K44A) in CXCR2-expressing cells blocks the receptor association with the PP2A core enzyme, and an internalization-deficient mutant form of CXCR2 (I323A,L324A) also exhibits impaired association with the PP2A core enzyme, suggesting that the receptor internalization is required for the receptor binding to PP2A. A phosphorylation-deficient mutant of CXCR2 (331T), which has previously been shown to undergo internalization in HEK293 cells, binds to an almost equal amount of the PP2A core enzyme in comparison with the wild-type CXCR2, suggesting that the interaction of the receptor with PP2A is phosphorylation-independent. The dephosphorylation of CXCR2 is reversed by treatment of the cells with okadaic acid. Moreover, pretreatment of the cells with okadaic acid increases basal phosphorylation of CXCR2 and attenuates CXCR2-mediated calcium mobilization and chemotaxis, Taken together, these data indicate that PP2A is involved in the dephosphorylation of CXCR2, We postulate that this interaction results from direct binding of the regulatory subunit A (PR65) of PP2A to the carboxyl terminus of CXCR2 after receptor sequestration and internalization.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Dept Vet Affairs, Nashville, TN 37212 USA	Vanderbilt University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [R01 CA034590-18, P30 CA068485, CA 34590, R01 CA034590, R01 CA034590-17, CA68485] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA034590, R23CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Feniger-Barish R, 2000, BLOOD, V95, P1551, DOI 10.1182/blood.V95.5.1551.005a36_1551_1559; GIANNINI E, 1995, J IMMUNOL, V154, P4055; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; Guinamard R, 1999, J EXP MED, V189, P1461, DOI 10.1084/jem.189.9.1461; GUY GR, 1992, J BIOL CHEM, V267, P1846; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HARPER JW, 1993, CELL, V75, P805; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KING AJ, 1989, J BIOL CHEM, V264, P15770; Krueger KM, 1997, J BIOL CHEM, V272, P5; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NAMBOODIRIPAD AN, 1996, AM J PHYSIOL, V39, pC449; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; Sabroe I, 1997, J IMMUNOL, V158, P1361; Schraufstatter IU, 1998, BIOCHEM BIOPH RES CO, V244, P243, DOI 10.1006/bbrc.1998.8246; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; Summers RJ, 1997, J AUTON PHARMACOL, V17, P331, DOI 10.1046/j.1365-2680.1997.00055.x; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; Wuyts A, 2000, BIOCHEMISTRY-US, V39, P14549, DOI 10.1021/bi0011227; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; YU SS, 1993, J BIOL CHEM, V268, P337; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	43	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16960	16968		10.1074/jbc.M009292200	http://dx.doi.org/10.1074/jbc.M009292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278485	hybrid, Green Accepted			2022-12-27	WOS:000168730400048
J	Hieda, M; Tachibana, T; Fukumoto, M; Yoneda, Y				Hieda, M; Tachibana, T; Fukumoto, M; Yoneda, Y			Nuclear import of the U1A splicesome protein is mediated by importin alpha/beta and ran in living mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; PREMATURE CHROMOSOME CONDENSATION; GTP-BOUND RAN; KARYOPHERIN-ALPHA; LOCALIZATION SIGNAL; CRYSTALLOGRAPHIC ANALYSIS; TRANSCRIPTION FACTOR; BINDING; RCC1; IDENTIFICATION	U1A is a component of the uracil-rich small nuclear ribonucleoprotein, The molecular mechanism of nuclear import of U1A was investigated in vivo and in vitro, When recombinant deletion mutants of U1A are injected into the BHK21 cell cytoplasm, the nuclear localization signal (NLS) of U1A is found in the N-terminal half of the central domain (residues 100-144 in mouse U1A), In an in vitro assay, it was found that the U1A-NLS accumulated in only a portion of the nuclei in the absence of cytosolic extract. In contrast, the addition of importin alpha/beta and Ran induced the uniform nuclear accumulation of U1A-NLS in all cells. Furthermore, U1A was found to bind the C-terminal portion of importin alpha. In addition, the in vitro nuclear migration of full-length U1A was found to be exclusively dependent on importin alpha/beta and Ran. Moreover, in living cells, the full-length U1A accumulated in the nucleus in a Ran-dependent manner, and nuclear accumulation was inhibited by the importin alpha binding domain of importin cu, These results suggest that the nuclear import of U1A is mediated by at least two distinct pathways, an importin alpha/beta and Ran-dependent and an -independent pathway in permeabilized cells, and that the latter pathway may be suppressed in intact cells.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Matsumura, Miki/AAD-1823-2021	Hieda, Miki/0000-0002-9492-7506				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEENEY RJ, 1990, J CELL BIOL, V110, P871, DOI 10.1083/jcb.110.4.871; GOLDFARB DS, 1997, CURR BIOL, V7, P13; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hetzer M, 2000, J CELL BIOL, V148, P293, DOI 10.1083/jcb.148.2.293; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; Kohler M, 1999, MOL CELL BIOL, V19, P7782; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Lutz CS, 1998, RNA, V4, P1493, DOI 10.1017/S1355838298981183; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; O'Connor JP, 1997, RNA, V3, P1444; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Tachibana T, 2000, CELL STRUCT FUNCT, V25, P115, DOI 10.1247/csf.25.115; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Yoneda Y, 1999, CELL STRUCT FUNCT, V24, P425, DOI 10.1247/csf.24.425; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	46	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16824	16832		10.1074/jbc.M008299200	http://dx.doi.org/10.1074/jbc.M008299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278401	hybrid			2022-12-27	WOS:000168730400032
J	Wang, TW; Lu, L; Wang, D; Thompson, JE				Wang, TW; Lu, L; Wang, D; Thompson, JE			Isolation and characterization of senescence-induced cDNAs encoding deoxyhypusine synthase and eucaryotic translation initiation factor 5A from tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HOMOSPERMIDINE SYNTHASE; PROTEIN-SYNTHESIS; LEAF SENESCENCE; CHILLING INJURY; EIF-5A; EXPRESSION; HYPUSINE; IDENTIFICATION; SPERMIDINE	Full-length cDNA clones encoding deoxyhypusine synthase (DHS) and eucaryotic initiation factor 5A (eIF-5A) have been isolated from a cDNA expression library prepared from tomato leaves (Lycopersicon esculentum, cv. Match) exposed to environmental stress. DHS mediates the first of two enzymatic reactions that activate eIF-5A by converting a conserved lysine to the unusual amino acid, deoxyhypusine, Recombinant protein obtained by expressing tomato DHS cDNA in Escherichia coli proved capable of carrying out the deoxyhypusine synthase reaction in vitro in the presence of eIF-5A Of particular interest is the finding that DHS mRNA and eIF-5A mRNA show a parallel increase in abundance in senescing tomato flowers, senescing tomato fruit, and environmentally stressed tomato leaves exhibiting programmed cell death. Western blot analyses indicated that DHS protein also increases at the onset of senescence. It is apparent from previous studies with yeast and mammalian cells that hypusine-modified eIF-5A facilitates the translation of a subset of mRNAs mediating cell division. The present study provides evidence for senescence-induced DHS and eIF-5A in tomato tissues that may facilitate the translation of mRNA species required for programmed cell death.	Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada	University of Waterloo	Thompson, JE (corresponding author), Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada.	jet@sciborg.uwaterloo.ca						Bevec D, 1997, BIOL SIGNAL, V6, P124; Bevec D, 1996, FEBS LETT, V378, P195, DOI 10.1016/0014-5793(95)01456-X; BLANK A, 1991, PLANT PHYSIOL, V97, P1402, DOI 10.1104/pp.97.4.1402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BuchananWollaston V, 1997, J EXP BOT, V48, P181, DOI 10.1093/jxb/48.2.181; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHAMOT D, 1992, NUCLEIC ACIDS RES, V20, P665, DOI 10.1093/nar/20.4.665; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; HANAUSKEABEL HM, 1995, FEBS LETT, V366, P92, DOI 10.1016/0014-5793(95)00493-S; Hong YW, 2000, P NATL ACAD SCI USA, V97, P8717, DOI 10.1073/pnas.140213697; JAKUS J, 1993, J BIOL CHEM, V268, P13151; Junker U, 1996, HUM GENE THER, V7, P1861, DOI 10.1089/hum.1996.7.15-1861; Kaiser A, 1999, PLANT J, V19, P195, DOI 10.1046/j.1365-313X.1999.00509.x; KANG HA, 1994, J BIOL CHEM, V269, P3934; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; Liu Y, 1997, MOL BIOL CELL, V8, P2476; NOODEN LD, 1988, SENESCENCE AGING PLA, P57; Ober D, 1999, J BIOL CHEM, V274, P32040, DOI 10.1074/jbc.274.45.32040; Ober D, 1999, P NATL ACAD SCI USA, V96, P14777, DOI 10.1073/pnas.96.26.14777; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1988, J BIOL CHEM, V263, P15264; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rosorius O, 1999, J CELL SCI, V112, P2369; Sambrook J., 2002, MOL CLONING LAB MANU; SHAROM M, 1994, PLANT PHYSIOL, V105, P305, DOI 10.1104/pp.105.1.305; SMART CM, 1994, NEW PHYTOL, V126, P419, DOI 10.1111/j.1469-8137.1994.tb04243.x; Tome ME, 1997, BIOL SIGNAL, V6, P150; WANG TW, 1995, PLANT PHYSIOL, V109, P627, DOI 10.1104/pp.109.2.627; Wang TW, 1997, PLANT J, V11, P475, DOI 10.1046/j.1365-313X.1997.11030475.x; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WRIGHT M, 1973, J EXP BOT, V24, P400, DOI 10.1093/jxb/24.2.400; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914	34	73	109	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17541	17549		10.1074/jbc.M008544200	http://dx.doi.org/10.1074/jbc.M008544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278418	hybrid			2022-12-27	WOS:000168730400126
J	Liu, XR; Green, CB				Liu, XR; Green, CB			A novel promoter element, photoreceptor conserved element II, directs photoreceptor-specific expression of nocturnin in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRL; MAF NUCLEAR ONCOPROTEIN; CIS-ACTING ELEMENT; RAT OPSIN PROMOTER; GENE-EXPRESSION; PROTEIN-BINDING; HOMEOBOX GENE; UPSTREAM REGION; DIFFERENTIAL DISPLAY; RETINAL DEVELOPMENT	Nocturnin is a vertebrate circadian clock-regulated gene, and in Xenopus laevis its mRNA is specifically expressed in retinal photoreceptor cells. We have investigated the transcriptional regulatory mechanism that drives this precise spatial expression pattern of the nocturnin gene. A deletion series of the nocturnin 5'-flanking sequence driving the green fluorescence protein (GFP) reporter was used to generate transgenic Xenopus tadpoles. We found that a construct containing 2.6 kilobase pairs of 5'-flanking sequence targeted high level GFP reporter expression specifically to photoreceptor cells, in a pattern identical to endogenous nocturnin. This photoreceptor-specific expression pattern was maintained with several further deletions of 5'-upstream sequence, including a short 59-base pair fragment. Within this region of 59 base pairs, three perfect repeats of a novel protein binding site were identified by electrophoretic mobility shift assay. Competitions using varying oligonucleotide sequences demonstrated that the sequence required for protein binding is CAGA-CAGGCTATA, designated photoreceptor-conserved element II (PCE II). The protein complex that binds to this element is enriched in retinal extracts, and mutations of PCE II which fail to bind the protein complex also fail to direct GFP reporter expression to photoreceptors, These results indicate that the PCE II in the proximal promoter of the nocturnin gene is sufficient for driving the photoreceptor-specific expression of nocturnin.	Univ Virginia, Dept Biol, Natl Sci Fdn, Ctr Biol Timing, Charlottesville, VA 22904 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia	Green, CB (corresponding author), Univ Virginia, Dept Biol, Natl Sci Fdn, Ctr Biol Timing, 264 Gilmer Hall, Charlottesville, VA 22904 USA.	cbg8b@virginia.edu			NATIONAL EYE INSTITUTE [R01EY011489] Funding Source: NIH RePORTER; NEI NIH HHS [EY11489] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1995, BRAIN RES DEV BRAIN, V90, P134; Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Amaya E, 1999, METH MOL B, V97, P393, DOI 10.1385/1-59259-270-8:393; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Boatright J H, 1997, Mol Vis, V3, P15; Casarosa S, 1997, MECH DEVELOP, V61, P187, DOI 10.1016/S0925-4773(96)00640-5; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DiPolo A, 1997, NUCLEIC ACIDS RES, V25, P3863, DOI 10.1093/nar/25.19.3863; FREDERICK M, 1993, CURRENT PROTOCOLS MO; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Green C B, 1997, Methods Mol Biol, V85, P219; Green CB, 1996, MOL BRAIN RES, V37, P157, DOI 10.1016/0169-328X(95)00307-E; Harris WA, 1997, CURR OPIN GENET DEV, V7, P651, DOI 10.1016/S0959-437X(97)80013-5; He L, 1998, Mol Vis, V4, P32; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.3.CO;2-V; Hitchcock PF, 1996, J NEUROBIOL, V29, P399; JAMRICH M, 1989, DEVELOPMENT, V105, P779; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Mani SS, 1999, J BIOL CHEM, V274, P15590, DOI 10.1074/jbc.274.22.15590; Mao CA, 1996, DEVELOPMENT, V122, P1489; Marsh-Armstrong N, 1999, P NATL ACAD SCI USA, V96, P14389, DOI 10.1073/pnas.96.25.14389; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Moritz OL, 1999, INVEST OPHTH VIS SCI, V40, P3276; Morrow EM, 1999, DEVELOPMENT, V126, P23; Morrow EM, 1998, TRENDS CELL BIOL, V8, P353, DOI 10.1016/S0962-8924(98)01341-5; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Quiambao AB, 1997, VISUAL NEUROSCI, V14, P617, DOI 10.1017/S095252380001258X; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; Yu X, 1996, J NEUROCHEM, V67, P2494; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186	49	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15146	15154		10.1074/jbc.M009970200	http://dx.doi.org/10.1074/jbc.M009970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278588	hybrid			2022-12-27	WOS:000168528800083
J	Handlogten, ME; Huang, CF; Shiraishi, N; Awata, H; Miller, RT				Handlogten, ME; Huang, CF; Shiraishi, N; Awata, H; Miller, RT			The Ca2+-sensing receptor activates cytosolic phospholipase A(2) via a G(q)alpha-dependent ERK-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; CALCIUM-SENSING RECEPTOR; PARATHYROID-HORMONE SECRETION; CANINE KIDNEY-CELLS; PROTEIN-KINASE; SMOOTH-MUSCLE; ALPHA(1)-ADRENERGIC RECEPTORS; PANCREATIC-ISLETS; MAP KINASE; INHIBITION	The Ca2+-sensing receptor (CaR) stimulates a number of phospholipase activities, but the specific phospholipases and the mechanisms by which the CaR activates them are not defined. We investigated regulation of phospholipase A(2) (PLA(2)) by the Ca2+-sensing receptor (CaR) in human embryonic kidney 293 cells that express either the wild-type receptor or a nonfunctional mutant (R796W) CaR. The PLA(2) activity was attributable to cytosolic PLA(2) (cPLA(2)) based on its inhibition by arachidonyl trifluoromethyl ketone, lack of inhibition by bromoenol lactone, and enhancement of the CaR-stimulated phospholipase activity by coexpression of a cDNA encoding the 85-kDa human cPLA(2). No CaR-stimulated cPLA(2) activity was found in the cells that expressed the mutant CaR. Pertussis toxin treatment had a minimal effect on CaR-stimulated arachidonic acid release and the CaR-stimulated rise in intracellular Ca2+ (Ca-i(2+)), whereas inhibition of phospholipase C (PLC) with U73122 completely inhibited CaR-stimulated PLC and cPLA(2) activities. CaR-stimulated PLC activity was inhibited by expression of RGS4, an RGS (Regulator of G protein Signaling) protein that inhibits G alpha (q) activity. CaR-stimulated cPLA(2) activity was inhibited 80% by chelation of extracellular Ca2+ and depletion of intracellular Ca2+ with EGTA and inhibited 90% by treatment with W7, a calmodulin inhibitor, or with KN-93, an inhibitor of Ca2+, calmodulin-dependent protein kinases. Chemical inhibitors of the ERK activator, MEK, and a dominant negative MEK, MEKK97R, had no effect on CaR-stimulated cPLA(2) activity but inhibited CaR-stimulated ERK activity. These results demonstrate that the CaR activates cPLA(2), via a G alpha (q), PLC, Ca2+-CaM, and calmodulin-dependent protein kinase-dependent pathway that is independent the ERK pathway.	Univ Florida, Dept Med, Div Nephrol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Miller, RT (corresponding author), Case Western Reserve Univ, Dept Med, Louis Stokes VAMC, 10701 East Blvd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041726, R29DK041726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41726] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balboa MA, 1998, MOL PHARMACOL, V53, P221, DOI 10.1124/mol.53.2.221; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bonventre JV, 1999, J AM SOC NEPHROL, V10, P404; BOURDEAU A, 1992, ENDOCRINOLOGY, V130, P1339, DOI 10.1210/en.130.3.1339; BOURDEAU A, 1994, ENDOCRINOLOGY, V135, P1109, DOI 10.1210/en.135.3.1109; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cui XL, 2000, AM J PHYSIOL-CELL PH, V279, pC403, DOI 10.1152/ajpcell.2000.279.2.C403; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Handlogten ME, 2000, AM J PHYSIOL-RENAL, V279, pF1083, DOI 10.1152/ajprenal.2000.279.6.F1083; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; HOPE WC, 1993, AGENTS ACTIONS, V39, pC39, DOI 10.1007/BF01972714; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; Pages C, 1999, BIOCHEM BIOPH RES CO, V265, P572, DOI 10.1006/bbrc.1999.1726; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Rokolya A, 2000, AM J PHYSIOL-CELL PH, V278, pC537, DOI 10.1152/ajpcell.2000.278.3.C537; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Thomas AP, 2000, NAT CELL BIOL, V2, pE126, DOI 10.1038/35017143; VANDERZEE J, 1989, ARCH BIOCHEM BIOPHYS, V271, P64, DOI 10.1016/0003-9861(89)90256-7; Wang WH, 1996, AM J PHYSIOL-CELL PH, V271, pC103, DOI 10.1152/ajpcell.1996.271.1.C103; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, AM J PHYSIOL-CELL PH, V272, pC1380, DOI 10.1152/ajpcell.1997.272.4.C1380; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227	42	77	78	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13941	13948		10.1074/jbc.M007306200	http://dx.doi.org/10.1074/jbc.M007306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278341	hybrid			2022-12-27	WOS:000168356600061
J	Kayyali, US; Donaldson, C; Huang, HL; Abdelnour, R; Hassoun, PM				Kayyali, US; Donaldson, C; Huang, HL; Abdelnour, R; Hassoun, PM			Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; NITRATE REDUCTASE; OXIDASE; BINDING; STRESS; MECHANISM; 14-3-3-PROTEINS; GENERATION; CONVERSION; PHOSPHORUS	The enzyme xanthine oxidase (XO) has been implicated in the pathogenesis of several disease processes, such as ischemia-reperfusion injury, because of its ability to generate reactive oxygen species. The expression of XO and its precursor xanthine dehydrogenase (XDH) is regulated at pre- and posttranslational levels by agents such as lipopolysaccharide and hypoxia. Post-translational modification of the protein, for example through thiol oxidation or proteolysis, has been shown to be important in converting XDH to XO. The possibility of posttranslational modification of XDH/XO through phosphorylation has not been adequately investigated in mammalian cells, and studies have reported conflicting results. The present report demonstrates that XDH/XO is phosphorylated in rat pulmonary microvascular endothelial cells (RPMEC) and that phosphorylation is greatly increased (similar to 50-fold) in response to acute hypoxia (4 h). XDH/XO phosphorylation appears to be mediated, at least in part, by casein kinase II and p38 kinase as inhibitors of these kinases partially prevent XDH/XO phosphorylation. In addition, the results indicate that p38 kinase, a stress activated kinase, becomes activated in response to hypoxia (an similar to4-fold increase after 1 h of exposure of RPMEC to hypoxia) further supporting a role for this kinase in hypoxia-stimulated XDH/XO phosphorylation. Finally, hypoxia-induced XDH/XO phosphorylation is accompanied by a 2-fold increase in XDH/XO activity, which is prevented by inhibitors of phosphorylation. In summary, this study shows that XDH/XO is phosphorylated in hypoxic RPMEC through a mechanism involving p38 kinase and casein kinase II and that phosphorylation is necessary for hypoxia-induced enzymatic activation.	New England Med Ctr, Tupper Res Inst, Div Pulm & Crit Care, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Hassoun, PM (corresponding author), New England Med Ctr, Tupper Res Inst, Div Pulm & Crit Care, Dept Med, 750 Washington St,POB 257, Boston, MA 02111 USA.				NHLBI NIH HHS [HL48441] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BECKMAN JS, 1989, FREE RADICAL BIO MED, V6, P607, DOI 10.1016/0891-5849(89)90068-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; DAVIS MD, 1984, EUR J BIOCHEM, V145, P237, DOI 10.1111/j.1432-1033.1984.tb08544.x; EDMONDSON DE, 1984, FLAVINS FLAVOPROTEIN, P309; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Galley HF, 1996, CRIT CARE MED, V24, P1649, DOI 10.1097/00003246-199610000-00008; Grum C.M., 1987, J CRIT CARE, V2, P22; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Harris CM, 1999, J BIOL CHEM, V274, P4561, DOI 10.1074/jbc.274.8.4561; HASSOUN PM, 1994, AM J PHYSIOL, V266, pL163, DOI 10.1152/ajplung.1994.266.2.L163; Hassoun PM, 1998, AM J RESP CRIT CARE, V158, P299, DOI 10.1164/ajrccm.158.1.9709116; HOWES BD, 1991, BIOCHEMISTRY-US, V30, P3969, DOI 10.1021/bi00230a024; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; JACKSON RM, 1989, AM J MED SCI, V298, P44, DOI 10.1097/00000441-198907000-00009; JOHNSON JL, 1989, P NATL ACAD SCI USA, V86, P6493, DOI 10.1073/pnas.86.17.6493; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; LONGO LD, 1993, P NATL ACAD SCI USA, V90, P692, DOI 10.1073/pnas.90.2.692; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Nakai T, 1998, PLANT CELL PHYSIOL, V39, P1337, DOI 10.1093/oxfordjournals.pcp.a029339; O'Rourke JF, 1997, ONCOL RES, V9, P327; Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440; Poss WB, 1996, AM J PHYSIOL-LUNG C, V270, pL941, DOI 10.1152/ajplung.1996.270.6.L941; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; SCHIEBER A, 1993, EUR J BIOCHEM, V215, P307, DOI 10.1111/j.1432-1033.1993.tb18036.x; Seko Y, 1997, BIOCHEM BIOPH RES CO, V239, P840, DOI 10.1006/bbrc.1997.7570; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Terada LS, 1997, ARCH BIOCHEM BIOPHYS, V348, P163, DOI 10.1006/abbi.1997.0367; WANG GL, 1993, J BIOL CHEM, V268, P21513; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	44	96	102	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14359	14365		10.1074/jbc.M010100200	http://dx.doi.org/10.1074/jbc.M010100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278616	hybrid			2022-12-27	WOS:000168356600112
J	Li, FQ; Horwitz, M				Li, FQ; Horwitz, M			Characterization of mutant neutrophil elastase in severe congenital neutropenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING-FACTOR-RECEPTOR; HUMAN-LEUKOCYTE ELASTASE; ACUTE MYELOID-LEUKEMIA; SPLEEN FIBRINOLYTIC PROTEINASE; G-CSF THERAPY; CATHEPSIN-G; POINT MUTATIONS; CELL LINES; VAL-PNA; GENE	Severe congenital neutropenia is a heritable human disorder characterized by neutropenia and acute myelogenous leukemia. me recently determined that the majority of cases result from de novo or autosomal dominantly inherited heterozygous mutations in ELA2, encoding neutrophil elastase. Neutrophil elastase is a chymotryptic serine protease localized in granules of neutrophils and monocytes and is the major target of inhibition of the serpin alpha (1)-antitrypsin. The mutations causing severe congenital neutropenia consist of amino acid missense substitutions, in-frame deletion, splice donor mutation producing a deletion, splice acceptor mutation causing insertion of novel residues, and protein truncating mutations of the carboxyl terminus resulting from nonsense substitutions and deletions leading to frameshifts. We have expressed 14 mutant forms of neutrophil elastase in vitro and have characterized their biochemical properties. The mutations have variable effects on proteolytic activity, eliminating the possibility that the disease results from haploinsufficiency. There is no evidence that the mutant enzymes are cytotoxic. The mutant enzymes retain vulnerability to inhibition by ai-antitrypsin, but demonstrate variable avidity for interaction with this serpin. Somewhat surprisingly, the mutant enzymes inhibit the wild type enzyme when both are coexpressed within the same cell, suggesting the potential to interfere with normal subcellular trafficking or post-translational processing.	Univ Washington, Sch Med, Dept Med, Div Med Genet,Markey Mol Med Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Horwitz, M (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet,Markey Mol Med Ctr, 1705 NE Pacific St,HSB-K236B, Seattle, WA 98195 USA.			Horwitz, Marshall/0000-0002-1683-1680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055820, R01DK058161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55820, DK58161] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikyan AAG, 1999, BLOOD, V94, p482A; Avalos BR, 1998, LEUKEMIA LYMPHOMA, V28, P265, DOI 10.3109/10428199809092682; BARR D, 1995, GENE THER, V2, P151; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P581; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Bernard T, 1998, BRIT J HAEMATOL, V101, P141, DOI 10.1046/j.1365-2141.1998.00652.x; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; BIETH JG, 1998, HDB PROTEOLYTIC ENZY, P54; Champagne B, 1998, J IMMUNOL, V161, P6398; Cregge RJ, 1998, J MED CHEM, V41, P2461, DOI 10.1021/jm970812e; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; DALE DC, 1979, MEDICINE, V58, P128, DOI 10.1097/00005792-197903000-00002; Dall'Acqua W, 1999, PROTEIN ENG, V12, P981, DOI 10.1093/protein/12.11.981; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; EVANS E, 1995, GENOMICS, V28, P235, DOI 10.1006/geno.1995.1136; FACCHINETTI A, 1991, J IMMUNOL METHODS, V136, P125, DOI 10.1016/0022-1759(91)90258-H; Freedman MH, 2000, BLOOD, V96, P429; Garwicz D, 1997, J LEUKOCYTE BIOL, V61, P113, DOI 10.1002/jlb.61.1.113; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; KAGAN HM, 1972, BIOCHEMISTRY-US, V11, P3412, DOI 10.1021/bi00768a014; KOSTMANN R, 1975, ACTA PAEDIATR SCAND, V64, P362, DOI 10.1111/j.1651-2227.1975.tb03847.x; Li FQ, 1996, J CELL BIOL, V135, P1043, DOI 10.1083/jcb.135.4.1043; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; LINDEMANN RA, 1994, ORAL MICROBIOL IMMUN, V9, P186, DOI 10.1111/j.1399-302X.1994.tb00057.x; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NAGAMATSU Y, 1984, THROMB HAEMOSTASIS, V51, P243; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; OKAMOTO U, 1980, BIOCHEM BIOPH RES CO, V97, P28, DOI 10.1016/S0006-291X(80)80129-X; Perlmutter DH, 1999, LAB INVEST, V79, P623; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; Tidow N, 1997, BLOOD, V89, P2369, DOI 10.1182/blood.V89.7.2369; Tidow N, 1997, STEM CELLS, V15, P113, DOI 10.1002/stem.5530150815; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Trevani AS, 1996, LAB INVEST, V74, P711; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147	47	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14230	14241		10.1074/jbc.M010279200	http://dx.doi.org/10.1074/jbc.M010279200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278653	hybrid			2022-12-27	WOS:000168356600096
J	Xu, H; Goldfarb, M				Xu, H; Goldfarb, M			Multiple effector domains within SNT1 coordinate ERK activation and neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TYROSINE-PHOSPHATASE; SIGNAL TRANSDUCTION; NEURITE OUTGROWTH; KINASE ACTIVATION; SH3 DOMAIN; MAP KINASE; RAS; FGF; PROTEIN	Differentiation of neuronal precursor cells in response to neurotrophic differentiation factors is accompanied by the activation of membrane-anchored SNT signaling adaptor proteins. Two classes of differentiation factors, the neurotrophins and fibroblast growth factors, induce rapid tyrosine phosphorylation of SNT1(FRS2 alpha), which in turn enables SNT1 to recruit Shp2 tyrosine phosphatase and GrbB adaptor protein in complex with the Res GDP/GTP exchange factor Sos. To determine effector functions of SNT that promote neuronal differentiation of PC12 pheochromocytoma cells, we engineered a chimeric protein, SNT1(IRS)CX, bearing the effector region of SNT1 and the insulin receptor recognition domains of IRS2. Insulin promoted tyrosine phosphorylation of SNT1(IRS)CX in transfected PC12 cells accompanied by sustained activation of ERK1/2 mitogen-activated protein kinases and neuronal differentiation. The SNT1 (IRS)CX-mediated response was dependent on endogenous Res, MEK, and Shp2 activities. Mutagenesis of SNT1(IRS)CX identified three classes of effector motifs within SNT critical for both sustained ERK activation and neuronal differentiation: 1) four phosphotyrosine motifs that mediate recruitment of Grb2, 2) two phosphotyrosine motifs that mediate recruitment of Shp2, and 3) a C-terminal motif that functions by helping to recruit Sos. We discuss possible mechanisms by which three functionally distinct SNT effector motifs collaborate to promote a downstream biochemical and biological response.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Mt Sinai Sch Med, Grad Training Program Mol Cellular Biochem & Dev, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Goldfarb, M (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, Box 1020, New York, NY 10029 USA.				NIGMS NIH HHS [R01 GM059432-01, R21-GM55666, R01-GM39906] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059432, R21GM055666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; Keegan K, 1993, Curr Opin Neurobiol, V3, P14, DOI 10.1016/0959-4388(93)90029-X; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lin HY, 1996, J NEUROSCI, V16, P4579; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Wang JK, 1996, ONCOGENE, V13, P721; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	37	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13049	13056		10.1074/jbc.M009925200	http://dx.doi.org/10.1074/jbc.M009925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278583	hybrid			2022-12-27	WOS:000168198600083
J	Casalini, P; Botta, L; Menard, S				Casalini, P; Botta, L; Menard, S			Role of p53 in HER2-induced proliferation or apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-TUMOR CELLS; CANCER-CELLS; GROWTH; DIFFERENTIATION; C-ERBB-2; EXPRESSION; TRANSFORMATION; SUPPRESSION; STABILITY; ONCOGENE	HER2 oncogene overexpression has been associated either with proliferation or differentiation and apoptosis. The role of p53 on these different chances was investigated. Wild type (wt) p53-IGROV1 cells showed growth inhibition and apoptosis after HER2 transfection, whereas no anti-proliferative effect was observed in its mutated p53 sub-line unless wt p53 was cotransfected with HER2. Stable HER2 transfectants derived from wt p53 line treated with heregulin-beta1 or epidermal growth factor showed a decrease in proliferation due to a G(2)/M cell cycle block. despite normal mitogen activated protein kinase activation. In these HER2 transfectants, c-Myc and p53 expression were increased, whereas MDM2 was dramatically down-modulated. Ey contrast, growth factors stimulation of HER2 transfectants with mutated-p53 induced progression through the cell cycle. Together, our data point to a regulatory role for p53 in HERS signaling.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	menard@istitutotumori.mi.it	menard, sylvie mm/C-7940-2011					Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bacus SS, 1996, ONCOGENE, V12, P2535; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CASCINELLI N, 1991, CANCER-AM CANCER SOC, V68, P427, DOI 10.1002/1097-0142(19910715)68:2<427::AID-CNCR2820680236>3.0.CO;2-Y; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; Daly JM, 1997, CANCER RES, V57, P3804; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Menard S, 1999, BREAST CANCER RES TR, V55, P169; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Park M, 2000, CANCER RES, V60, P542; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Perego P, 1996, CANCER RES, V56, P556; SLAMON DJ, 1989, CANCER CEL, V7, P371; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	32	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12449	12453		10.1074/jbc.M009732200	http://dx.doi.org/10.1074/jbc.M009732200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278558	hybrid			2022-12-27	WOS:000168081800134
J	Sun, H; Nathans, J				Sun, H; Nathans, J			ABCR, the ATP-binding cassette transporter responsible for Stargardt macular dystrophy, is an efficient target of all-trans-retinal-mediated photooxidative damage in vitro - Implications for retinal disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR OUTER SEGMENTS; RECESSIVE RETINITIS-PIGMENTOSA; LIGHT-DAMAGE; RAT RETINA; GENE ABCR; VITAMIN-A; FUNDUS FLAVIMACULATUS; VISIBLE-LIGHT; LIPOFUSCIN FLUOROPHORE; OXYGEN DISTRIBUTION	A large body of experimental and clinical data have documented the damaging effects of light exposure on photoreceptor cells although the identities of the biologically relevant molecular targets of photodamage are still uncertain. Several lines of evidence point to retinoids or retinoid derivatives as chromophores that can mediate light damage. We report here that ABCR, a photoreceptor-specific transporter involved in the recycling of all-trans-retinal, is unusually sensitive to photooxidation damage mediated by all-trans-retinal in vitro, Partial loss of ABCR function is responsible for Stargardt macular dystrophy, which is associated with accumulation of A2E, a diretinoid adduct within the retinal pigment epithelium, Photodamage to ABCR causes it to aggregate in SDS gels and results in the loss of retinal-stimulated ATPase activity. Peripherin/RDS and ROM-1, two structural proteins that colocalize with ABCR at the outer segment disc rim, are also significantly more susceptible to all-trans-retinal-mediated photodamage than are the major proteins from the rod outer segment. These observations imply that there may be specific protein targets of photodamage within the outer segment, and they may be especially relevant to assessing the risk of light exposure in those individuals who already have diminished ABCR activity due to mutation in one or both copies of the ABCR gene.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 Preclin Teaching Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018; ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; ALPERN M, 1970, J PHYSIOL-LONDON, V207, P449, DOI 10.1113/jphysiol.1970.sp009072; BAYLOR DA, 1982, J PHYSIOL-LONDON, V328, P49, DOI 10.1113/jphysiol.1982.sp014252; BESHARSE JC, 1998, RETINAL PIGMENT EPIT, P152; Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135; BORLEY WE, 1945, US NAVAL MED B, V45, P511; BURKE JM, 1998, RETINAL PIGMENT EPIT, P86; CLARK B, 1946, AM J OPHTHALMOL, V29, P828, DOI 10.1016/0002-9394(46)92161-7; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COOPER A, 1987, J AM CHEM SOC, V109, P7254, DOI 10.1021/ja00258a002; Cordes F. C., 1944, AM J OPHTHALMOL, V27, P803; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; Darrow RA, 1997, CURR EYE RES, V16, P144, DOI 10.1076/ceyr.16.2.144.5092; DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V27, P731, DOI 10.1111/j.1751-1097.1978.tb07671.x; DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V28, P357, DOI 10.1111/j.1751-1097.1978.tb07718.x; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718; DUKEELDER S, 1954, TXB OPHTHALMOLOGY, V6, P6494; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; FARNSWORTH CC, 1976, BIOCHIM BIOPHYS ACTA, V443, P556, DOI 10.1016/0005-2787(76)90517-7; FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0; HSU SC, 1994, J BIOL CHEM, V269, P17954; HSU SC, 1990, J BIOL CHEM, V265, P13308; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; KAGAN VE, 1973, BIOCHIM BIOPHYS ACTA, V330, P76, DOI 10.1016/0005-2736(73)90285-X; KAPLAN MW, 1985, EXP EYE RES, V40, P721, DOI 10.1016/0014-4835(85)90141-1; Keys SA, 1999, EXP EYE RES, V68, P693, DOI 10.1006/exer.1999.0657; KLIEN BA, 1967, AM J OPHTHALMOL, V64, P3, DOI 10.1016/0002-9394(67)93339-9; KUWABARA T, 1968, ARCH OPHTHALMOL-CHIC, V79, P69, DOI 10.1001/archopht.1968.03850040071019; LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0; LANUM J, 1978, SURV OPHTHALMOL, V22, P221, DOI 10.1016/0039-6257(78)90070-X; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521; LION Y, 1976, NATURE, V263, P442, DOI 10.1038/263442a0; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; MARLOR RL, 1973, INVEST OPHTH VISUAL, V12, P5; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; Noell W K, 1966, Invest Ophthalmol, V5, P450; NOELL WK, 1971, SCIENCE, V172, P76, DOI 10.1126/science.172.3978.76; NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3; NOELL WK, 1971, SCIENCE, V172, P72, DOI 10.1126/science.172.3978.72; ORANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1; ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599; OSTROVSKY MA, 1994, BIOFIZIKA+, V39, P13; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; POGOZHEVA ID, 1981, BIOFIZIKA+, V26, P398; RAPP LM, 1992, INVEST OPHTH VIS SCI, V33, P3367; RAPP LM, 1990, INVEST OPHTH VIS SCI, V31, P1186; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; REME CE, 1991, PHOTOCHEM PHOTOBIOL, V54, P137, DOI 10.1111/j.1751-1097.1991.tb01997.x; Reme CE, 1998, RETINAL PIGMENT EPIT, P563; ROSEN E, 1948, BRIT J OPHTHALMOL, V32, P23, DOI 10.1136/bjo.32.1.23; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; Rozet JM, 1999, J MED GENET, V36, P447; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SMITH HE, 1944, US NAVAL MED B, V42, P675; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; STAROSTIN AV, 1985, BIOFIZIKA+, V30, P995; STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; SYKES SM, 1981, INVEST OPHTH VIS SCI, V20, P425; Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163; TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035; Verhoeff FH, 1916, P AM ACAD ARTS SCI, V51, P627, DOI 10.2307/20025610; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433; WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285; WILLIAMS TP, 1985, J GEN PHYSIOL, V86, P413, DOI 10.1085/jgp.86.3.413; WYSZECKI G, 1982, COLOR SCI CONCEPTS M, P108; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9; ZIMMERMAN WF, 1974, NATURE, V250, P66, DOI 10.1038/250066a0	96	70	74	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11766	11774		10.1074/jbc.M010152200	http://dx.doi.org/10.1074/jbc.M010152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278627	Green Submitted, hybrid			2022-12-27	WOS:000168081800047
J	Fraser, F; Padovese, R; Zammit, VA				Fraser, F; Padovese, R; Zammit, VA			Distinct kinetics of carnitine palmitoyltransferase I in contact sites and outer membranes of rat liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA SENSITIVITY; CHIMERIC PROTEINS; CPT-I; TOPOLOGY; CYTOSKELETON; ENVIRONMENT; INHIBITION; ENRICHMENT; ISOFORMS; TISSUES	Carnitine palmitoyltransferase I (CPT I) of rat liver mitochondria is an integral, polytopic protein of the outer membrane that is enriched at contact sites. As CPT I kinetics are highly dependent on its membrane environment, we have measured the kinetic parameters of CPT I present in rat liver submitochondrial membrane fractions enriched in either outer membrane or contact sites. The K-m for palmitoyl-CoA was 2.4-fold higher for GPT I in outer membranes than that for the enzyme in contact sites. In addition, whereas in contact sites malonyl-CoA behaved as a competitive inhibitor of CPT I with respect to palmitoyl-CoA, in outer membranes malonyl-CoA inhibition was non-competitive. As a result of the combination of these changes, the IC50 for malonyl-CoA was severalfold higher for CPT I in contact sites than for the enzyme in bulk outer membrane, The K-i for malonyl-CoA, the K-m for carnitine, and the catalytic constant of the enzyme were all unaffected. It is concluded that the different membrane environments in outer membranes and contact sites result in an altered conformation of L-CPT I that specifically affects the long-chain acyl-CoA binding site. The accompanying changes in the kinetics of the enzyme provide an additional potent mechanism for the regulation of L-CPT I activity.	Hannah Res Inst, Ayr KA6 5HL, Scotland		Zammit, VA (corresponding author), Hannah Res Inst, Ayr KA6 5HL, Scotland.	zammitv@hri.sari.ac.uk						ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; BERNERT JT, 1979, BIOCHIM BIOPHYS ACTA, V573, P436, DOI 10.1016/0005-2760(79)90218-2; BRDICZKA D, 1990, BIOCHIM BIOPHYS ACTA, V1018, P234, DOI 10.1016/0005-2728(90)90256-4; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; Broadway NM, 1997, BIOCHEM J, V322, P435, DOI 10.1042/bj3220435; COOK GA, 1984, J BIOL CHEM, V259, P2030; Daum G, 1997, PROG LIPID RES, V36, P103, DOI 10.1016/S0163-7827(97)00006-4; Fraser F, 1999, FEBS LETT, V446, P69, DOI 10.1016/S0014-5793(99)00179-9; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fraser F, 1998, BIOCHEM J, V329, P225, DOI 10.1042/bj3290225; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; JACKSON VN, 2000, J BIOL CHEM; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; LINDEN M, 1989, J BIOENERG BIOMEMBR, V21, P507, DOI 10.1007/BF00762522; McGarry JD, 2000, BIOCHEM J, V349, P179, DOI 10.1042/0264-6021:3490179; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MYNASTT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P1055; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; MYNATT RL, 1994, BIOCHEM J, V248, P727; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1990, BIOCHIM BIOPHYS ACTA, V1018, P239, DOI 10.1016/0005-2728(90)90257-5; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1997, ADV ENZYME REGUL, V37, P295, DOI 10.1016/S0065-2571(96)00015-5	31	26	27	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20182	20185		10.1074/jbc.M101078200	http://dx.doi.org/10.1074/jbc.M101078200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274214	hybrid			2022-12-27	WOS:000169135100069
J	Orsini, G; Kolb, A; Buc, H				Orsini, G; Kolb, A; Buc, H			The Escherichia coli RNA polymerase center dot anti-sigma(70) AsiA complex utilizes alpha-carboxyl-terminal domain upstream promoter contacts to transcribe from a-10/-35 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 TRANSCRIPTIONAL ACTIVATOR; PROTEIN-DNA INTERACTIONS; MIDDLE PROMOTER; CAMP-CRP; SIGMA-SUBUNIT; LAC PROMOTER; MOTA PROTEIN; POLYMERASE; BINDING; MECHANISM	During infection of Escherichia coli, the phage T4 early protein AsiA inhibits open complex formation by the RNA polymerase holoenzyme E sigma (70) at -10/-35 bacterial promoters through binding to region 4.2 of the sigma (70) subunit. We used the -10/-35 lacUV5 promoter to study the properties of the E sigma (70).AsiA complex in the presence of the glutamate anion. Under these experimental conditions, inhibition by AsiA was significantly decreased. KMnO4 probing showed that the observed residual transcriptional activity was due to the slow transformation of the ternary complex E sigma (70).AsiA.lacUV5 into an open complex. In agreement with this observation, affinity of the enzyme for the promoter was 10-fold lower in the ternary complex than in the binary complex E sigma 70.lacUV5. A tau plot analysis of abortive transcription reactions showed that AsiA binding to E sigma 70 resulted in a 120-fold decrease in the second-order on-rate constant of the reaction of E sigma (70) with lacUV5 and a 55-fold decrease in the rate constant of the isomerization step leading to the open complex. This ternary complex still responded to activation by the cAMP catabolite activator protein complex. We show that compensatory E sigma 70/promoter upstream contacts involving the C-terminal domains of alpha subunits in E sigma (70) become essential for the binding of E sigma (70).AsiA to the lacUV5 promoter.	Inst Pasteur, Dept Biol Mol, Unite Physicochim Macromol Biol, CNRS,URA 1773, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kolb, A (corresponding author), Inst Pasteur, Dept Biol Mol, Unite Physicochim Macromol Biol, CNRS,URA 1773, 25 Rue Dr Roux, F-75724 Paris 15, France.							Adelman K, 1997, J BIOL CHEM, V272, P27435, DOI 10.1074/jbc.272.43.27435; ALBERTS BM, 1994, MOL BIOL BACTERIOP T, V4, P487; ARAKAWA T, 1984, J BIOL CHEM, V259, P4979; BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Busby S, 1994, Methods Mol Biol, V30, P397; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; Gerber JS, 1996, J BACTERIOL, V178, P6133, DOI 10.1128/jb.178.21.6133-6139.1996; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GOFF CG, 1984, METHOD ENZYMOL, V106, P418; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HINTON DM, 1991, J BIOL CHEM, V266, P18034; Hinton DM, 1996, J MOL BIOL, V256, P235, DOI 10.1006/jmbi.1996.0082; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; Kolesky S, 1999, J MOL BIOL, V291, P267, DOI 10.1006/jmbi.1999.2953; LEDERER H, 1991, J MOL BIOL, V219, P747, DOI 10.1016/0022-2836(91)90669-W; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Marshall P, 1999, J MOL BIOL, V285, P931, DOI 10.1006/jmbi.1998.2373; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Noel RJ, 1998, J MOL BIOL, V282, P495, DOI 10.1006/jmbi.1998.2040; OUHAMMOUCH M, 1994, J BACTERIOL, V176, P3956, DOI 10.1128/JB.176.13.3956-3965.1994; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; Pahari S, 1997, FEBS LETT, V411, P60, DOI 10.1016/S0014-5793(97)00668-6; Pene C, 2000, MOL MICROBIOL, V35, P1180, DOI 10.1046/j.1365-2958.2000.01787.x; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Ross W, 1998, J BACTERIOL, V180, P5375, DOI 10.1128/JB.180.20.5375-5383.1998; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHAEFFER F, 1982, EMBO J, V1, P99, DOI 10.1002/j.1460-2075.1982.tb01131.x; SCHMIDT RP, 1992, J BIOL CHEM, V267, P11399; Severinova E, 1998, J MOL BIOL, V279, P9, DOI 10.1006/jmbi.1998.1742; Sharma M, 1999, J MOL BIOL, V290, P905, DOI 10.1006/jmbi.1999.2928; Sharma UK, 1999, J BACTERIOL, V181, P5855, DOI 10.1128/JB.181.18.5855-5859.1999; STITT B, 1994, MOL BIOL BACTERIOP T, V4, P142	49	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19812	19819		10.1074/jbc.M010105200	http://dx.doi.org/10.1074/jbc.M010105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278617	hybrid			2022-12-27	WOS:000169135100020
J	Foster, KA; Mackey, AT; Gilbert, SP				Foster, KA; Mackey, AT; Gilbert, SP			A mechanistic model for Ncd directionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; MOTOR DOMAIN; MICROTUBULE-MOTOR; CRYSTAL-STRUCTURE; DIMERIC KINESIN; ATP HYDROLYSIS; PROTEIN; DROSOPHILA; MOTILITY; BINDING	Ncd is a kinesin-related protein that drives movement to the minus-end of microtubules. Pre-steady-state kinetic experiments have been employed to investigate the cooperative interactions between the motor domains of the MC1 dimer and to establish the ATPase mechanism. Our results indicate that the active sites of dimeric Ncd free in solution are not equivalent; ADP is held more tightly at one site than at the other. Upon microtubule binding, fast release of ADP from the first motor domain is stimulated at 18 s(-1), yet rate-limiting ADP release from the second motor domain occurs at 1.4 s(-1). We propose that the head with the low affinity for ADP binds the microtubule first to establish the directional bias of the microtubule Ncd intermediate where one motor domain is bound to the microtubule with the second head detached and directed toward the minus-end of the microtubule. The force generating cycle is initiated as ATP binds to the empty site of the microtubule-bound head. ATP hydrolysis at head 1 is required for head 2 to bind to the microtubule. The kinetics indicate that two ATP molecules are required for a single step and force generation for minus-end directed movement generated by this non-processive dimeric motor.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Harvard Univ, Sch Med, Dept Neurosci, 220 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054141, R37GM054141] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54141, R01 GM054141] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; deCastro MJ, 1999, BIOCHEMISTRY-US, V38, P5076, DOI 10.1021/bi9829175; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; Hoenger A, 1998, J CELL BIOL, V141, P419, DOI 10.1083/jcb.141.2.419; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mackey AT, 2000, BIOCHEMISTRY-US, V39, P1346, DOI 10.1021/bi991918+; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Naber N, 1997, BIOCHEMISTRY-US, V36, P9681, DOI 10.1021/bi9706881; Pechatnikova E, 1999, BIOPHYS J, V77, P1003, DOI 10.1016/S0006-3495(99)76951-1; Pechatnikova E, 1997, J BIOL CHEM, V272, P30735, DOI 10.1074/jbc.272.49.30735; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	39	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19259	19266		10.1074/jbc.M008347200	http://dx.doi.org/10.1074/jbc.M008347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278404	hybrid			2022-12-27	WOS:000169091000084
J	Ottolia, M; John, S; Qiu, ZY; Philipson, KD				Ottolia, M; John, S; Qiu, ZY; Philipson, KD			Split Na+-Ca2+ exchangers - Implications for function and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; DYNAMIC PROPERTIES; STEADY-STATE; MUTATIONAL ANALYSIS; IDENTIFICATION; LOCALIZATION; RESIDUES; SEGMENTS; DOMAIN; GENE	The Na+-Ca2+ exchanger has nine transmembrane segments, with a large cytoplasmic loop between the fifth and sixth transmembrane segments. The protein was split within the cytoplasmic loop into two domains consisting of the first five transmembrane segments and the last four transmembrane segments, respectively. The two domains were either expressed individually or coexpressed. Each of the two domains with different lengths of the cytoplasmic loop was fused to green fluorescent protein. We show that coexpression of both domains is required for proper membrane targeting and for expression of functional exchange activity. Fusion to green fluorescent protein does not alter biophysical properties of the exchange process. In addition, truncation of a large portion of the cytoplasmic loop does not alter important properties of the exchanger such as Na+ dependent inactivation, activation by chymotrypsin, or exchanger Inhibitory peptide (XIP) sensitivity.	Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, MRL 3-645, Los Angeles, CA 90095 USA.	kphilipson@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101, R01HL048509, R37HL048509] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48509, HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Chan KM, 2000, J GEN PHYSIOL, V116, P163, DOI 10.1085/jgp.116.2.163; Gabellini N, 1996, EUR J BIOCHEM, V239, P897, DOI 10.1111/j.1432-1033.1996.0897u.x; Groves JD, 1998, FEBS LETT, V433, P223, DOI 10.1016/S0014-5793(98)00909-0; Hale CC, 1997, BIOCHEM BIOPH RES CO, V236, P113, DOI 10.1006/bbrc.1997.6912; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; IWAMOTO I, 2000, J BIOL CHEM, V275, P38751; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Li XF, 1999, J BIOL CHEM, V274, P8153, DOI 10.1074/jbc.274.12.8153; LI ZP, 1991, J BIOL CHEM, V266, P1014; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; QUI Z, 2001, J BIOL CHEM, V276, P194; Saba RI, 1999, BIOCHEM J, V338, P139, DOI 10.1042/0264-6021:3380139; Saba RI, 2000, BIOPHYS J, V78, p388A; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Terada T, 1996, FEBS LETT, V394, P196, DOI 10.1016/0014-5793(96)00952-0; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5	30	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19603	19609		10.1074/jbc.M101489200	http://dx.doi.org/10.1074/jbc.M101489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11274218	hybrid			2022-12-27	WOS:000169091000125
J	Teo, M; Tan, L; Lim, L; Manser, E				Teo, M; Tan, L; Lim, L; Manser, E			The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							56-KDA SELENIUM-BINDING; ACTIN STRESS FIBERS; PROTEIN; CDC42; GTPASES; DOMAIN; RHO; ENDOCYTOSIS; FILOPODIA; RECEPTOR	One target for the small GTPase Cdc42 is the nonreceptor tyrosine kinase activated Cdc42-associated kinase (ACK), which binds selectively to Cdc42.GTP. We report that ACK1 can associate directly with the heavy chain of clathrin. A central region in ACK1 containing a conserved motif behaves as a clathrin adaptor and competes with beta -arrestin for a common binding site on the clathrin N-terminal head domain. Overexpressed ACK1 perturbs clathrin distribution, an activity dependent on the presence of C-terminal "adaptor" sequences that are also present in the related nonkinase gene 33, ACK1 interacts with the adaptor Nck via SH3 interactions but does not form a trimeric complex with p21-activated serine/threonine kinase, which also binds Nck, Stable low level expression of green fluorescent protein-ACK1 in NIH 3T3 cells has been used to localize ACK1 to clathrin-containing vesicles. The cc-localization of ACK1 in vivo with clathrin and AP-2 indicates that it participates in trafficking, underlying an ability to increase receptor-mediated transferrin uptake.	Inst Mol & Cell Biol, Glaxo IMCB Grp, Singapore 117609, Singapore; Inst Neurol, Miriam Marks Dept Neurochem, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Manser, E (corresponding author), Inst Mol & Cell Biol, Glaxo IMCB Grp, 30 Med Dr, Singapore 117609, Singapore.		Manser, Edward/ABD-2301-2020					Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hoehn GT, 1996, ONCOGENE, V12, P903; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; LANFEAR J, 1993, CARCINOGENESIS, V14, P335, DOI 10.1093/carcin/14.3.335; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Porat A, 2000, J BIOL CHEM, V275, P14457, DOI 10.1074/jbc.275.19.14457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCLAEPFER DD, 1997, MOL CELL BIOL, V17, P1702; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; VAN AL, 1997, GENE DEV, V11, P2295; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	42	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18392	18398		10.1074/jbc.M008795200	http://dx.doi.org/10.1074/jbc.M008795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278436	hybrid			2022-12-27	WOS:000168866500103
J	Tye, AJ; Ghebrehiwet, B; Guo, N; Sastry, KN; Chow, BKC; Peerschke, EIB; Lim, BL				Tye, AJ; Ghebrehiwet, B; Guo, N; Sastry, KN; Chow, BKC; Peerschke, EIB; Lim, BL			The human gC1qR/p32 gene, C1qBP - Genomic organization and promoter analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; GLOBULAR HEADS; BINDING-PROTEIN; CELLULAR-PROTEIN; RECEPTOR; TRANSCRIPTION; GC1Q-R; GLYCOPROTEIN; VITRONECTIN; EXPRESSION	gC1qR is an ubiquitously expressed cell protein that interacts with the globular heads of Clq (gC1q) and many other ligands. In this study, the 7.8-kilobase pair (kb) human gC1qR/p32 (C1qBP) gene was cloned and found to consist of 6 exons and 5 introns. Analysis of a 1.3-kb DNA fragment at the 5'-flanking region of this gene revealed the presence of multiple TATA, CCAAT, and Sp1 binding sites. Luciferase reporter assays performed in different human cell lines demonstrated that the reporter gene was ubiquitously driven by this 1.3-kb fragment. Subsequent 5' and 3' deletion of this fragment confined promoter elements to within 400 base pairs (bp) upstream of the translational start site. Because the removal of the 8-bp consensus TATATATA at -399 to -406 and CCAAT at -410 to -414 did not significantly affect the transcription efficiency of the promoter; GC-rich sequences between this TATA box and the translation start site may be very important for the promoter activity of the C1qBP gene. One of seven GC-rich sequences in this region binds specifically to PANC-1 nuclear extracts, and the transcription factor Sp1 was shown to bind to this GC-rich sequence by the supershift assay. Primer extension analysis mapped three major transcription start regions. The farthest transcription start site is 49 bp upstream of the ATG translation initiation codon and is in close proximity of the specific SP1 binding site.	Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; Cornell Univ, Weill Coll Med, Dept Pathol, New York, NY 10021 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	University of Hong Kong; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Boston University	Lim, BL (corresponding author), Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China.	bllim@hkucc.hku.hk	Chow, Billy/D-3064-2009; Lim, Boon Leong/D-3104-2009	Chow, Billy/0000-0003-3390-0307; Lim, Boon Leong/0000-0002-2720-2353				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423; Dedio J, 1998, J IMMUNOL, V160, P3534; Ghebrehiwet B, 1998, IMMUNOBIOLOGY, V199, P225, DOI 10.1016/S0171-2985(98)80029-6; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Guo N, 1997, CYTOGENET CELL GENET, V77, P283, DOI 10.1159/000134598; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huggon IC, 1997, BBA-GENE STRUCT EXPR, V1353, P98, DOI 10.1016/S0167-4781(97)00049-3; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 1999, CLIN IMMUNOL, V92, P246, DOI 10.1006/clim.1999.4753; Kiang JG, 2000, MOL CELL BIOCHEM, V204, P169, DOI 10.1023/A:1007016822939; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; Lim BL, 1998, GENE, V209, P229, DOI 10.1016/S0378-1119(98)00055-9; Lu PD, 1999, CLIN IMMUNOL, V90, P360, DOI 10.1006/clim.1998.4660; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lynch NJ, 1997, FEBS LETT, V418, P111, DOI 10.1016/S0014-5793(97)01348-3; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	31	11	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17069	17075		10.1074/jbc.M009064200	http://dx.doi.org/10.1074/jbc.M009064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278463	hybrid			2022-12-27	WOS:000168730400063
J	Lafont, V; Liautard, J; Sable-Teychene, M; Sainte-Marie, Y; Favero, J				Lafont, V; Liautard, J; Sable-Teychene, M; Sainte-Marie, Y; Favero, J			Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing down-modulation of T cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE P56LCK; FACTOR-ALPHA PRODUCTION; N-TERMINAL REGION; IMMUNOLOGICAL SYNAPSE; PLASMODIUM-FALCIPARUM; NONPEPTIDE ANTIGENS; ACTIN CYTOSKELETON; CYTOKINE ANALYSIS; PROTEIN-KINASE; ACTIVATION	The V gamma 9V delta2 T cell subset, which represents up to 90% of the circulating gamma delta T cells in humans, was shown to be activated, via the T cell receptor (TcR), by non-peptidic phosphorylated small organic molecules. These phosphoantigens, which are not presented by professional antigen-presenting cells, induce production of high amounts of interferon-gamma and tumor necrosis factor (TNF-alpha). To date, the specific signals triggered by these antigens have not been characterized. Here we analyze proximal and later intracellular signals triggered by isopentenyl pyrophosphate (IPP), a mycobacterial antigen that specifically stimulates V gamma 9V delta2 T cells, and compare these to signals induced by the non-physiological model using an anti-CD3 antibody. During antigenic stimulation we noticed that, except for the proximal p56(lck) signal, which is triggered early, the signals appear to be delayed and highly sustained. This delay, which likely accounts for the delay observed in TNF-alpha production, is discussed in terms of the ability of the antigen to cross-link and recruit transducing molecules mostly anchored to lipid rafts. Moreover, we demonstrate that, in contrast to anti-CD3 antibody, IPP does not induce down-modulation of the TcR-CD3 complex, which likely results in the highly sustained signaling and release of high levels of TNF-alpha.	Univ Montpellier 2, INSERM, U431, F-34095 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Favero, J (corresponding author), Univ Montpellier 2, INSERM, U431, 2 Pl Eugene Bataillon,CC 100, F-34095 Montpellier 5, France.		Lafont, Virginie/R-9356-2017	Lafont, Virginie/0000-0001-9612-3934; Sainte-Marie, Yannis/0000-0002-0646-1591				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506; Battistini L, 1997, J IMMUNOL, V159, P3723; BERTOTTO A, 1993, EUR J IMMUNOL, V23, P1177, DOI 10.1002/eji.1830230531; BIGBY M, 1993, J IMMUNOL, V151, P4465; Boudewijn MT, 1995, NATURE, V376, P599; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Bukowski JF, 1999, IMMUNITY, V11, P57, DOI 10.1016/S1074-7613(00)80081-3; Burk MR, 1997, J EXP MED, V185, P91, DOI 10.1084/jem.185.1.91; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; Cantrell D, 1998, TRENDS CELL BIOL, V8, P180, DOI 10.1016/S0962-8924(98)01264-1; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DEPAOLI P, 1991, CLIN EXP IMMUNOL, V83, P187, DOI 10.1111/j.1365-2249.1991.tb05612.x; DEPAOLI P, 1990, J INFECT DIS, V161, P1013, DOI 10.1093/infdis/161.5.1013; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; FOLLOWS GA, 1992, INFECT IMMUN, V60, P1229, DOI 10.1128/IAI.60.3.1229-1231.1992; Garcia VE, 1997, J IMMUNOL, V159, P1328; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOODIER MR, 1995, PARASITE IMMUNOL, V17, P413, DOI 10.1111/j.1365-3024.1995.tb00909.x; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HARA T, 1992, J CLIN INVEST, V90, P204, DOI 10.1172/JCI115837; Hayes AL, 1999, J BIOL CHEM, V274, P33455, DOI 10.1074/jbc.274.47.33455; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; HO M, 1990, IMMUNOL LETT, V25, P139, DOI 10.1016/0165-2478(90)90105-Y; Itoh Y, 1999, J IMMUNOL, V162, P2073; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JouenBeades F, 1997, INFECT IMMUN, V65, P4267, DOI 10.1128/IAI.65.10.4267-4272.1997; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kabelitz D, 1999, SPRINGER SEMIN IMMUN, V21, P55, DOI 10.1007/BF00815178; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Lafont V, 2000, J BIOL CHEM, V275, P19282, DOI 10.1074/jbc.M910487199; LANG F, 1995, J IMMUNOL, V154, P5986; Lanzavecchia A, 2000, CURR OPIN IMMUNOL, V12, P92, DOI 10.1016/S0952-7915(99)00056-4; Lanzavecchia A, 1997, J EXP MED, V185, P1717, DOI 10.1084/jem.185.10.1717; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; MARTH JD, 1989, J IMMUNOL, V142, P2430; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; Ottones F, 2000, IMMUNOLOGY, V100, P252, DOI 10.1046/j.1365-2567.2000.00024.x; PARKER CM, 1990, J EXP MED, V171, P1597, DOI 10.1084/jem.171.5.1597; PERRERA MK, 1994, J EXP MED, V179, P311; Poquet Y, 1998, INFECT IMMUN, V66, P2107, DOI 10.1128/IAI.66.5.2107-2114.1998; Ramirez M, 1999, INT IMMUNOL, V11, P1479, DOI 10.1093/intimm/11.9.1479; RAZIUDDIN S, 1992, EUR J IMMUNOL, V22, P1143, DOI 10.1002/eji.1830220506; SCALISE F, 1992, IMMUNOLOGY, V76, P668; SOULA M, 1993, J BIOL CHEM, V268, P27420; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; Wadsworth SA, 1999, J PHARMACOL EXP THER, V291, P680; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176	62	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15961	15967		10.1074/jbc.M008684200	http://dx.doi.org/10.1074/jbc.M008684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278429	hybrid			2022-12-27	WOS:000168623100054
J	Hashizume, R; Fukuda, M; Maeda, I; Nishikawa, H; Oyake, D; Yabuki, Y; Ogata, F; Ohta, T				Hashizume, R; Fukuda, M; Maeda, I; Nishikawa, H; Oyake, D; Yabuki, Y; Ogata, F; Ohta, T			The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULLIN PARTNERS; BRCA1 PROTEINS; FINGER DOMAIN; BARD1; SCF; DEGRADATION; COMPLEX; GENE	BRCA1-BARD1 constitutes a heterodimeric RING finger complex associated through its N-terminal regions. Here we demonstrate that the BRCA1-BARD1 heterodimeric RING finger complex contains significant ubiquitin ligase activity that can be disrupted by a breast cancer-derived RING finger mutation in BRCA1, Whereas individually BRCA1 and BARD1 have very low ubiquitin ligase activities in vitro, BRCA1 combined with BARD1 exhibits dramatically higher activity. Bacterially purified RING finger domains comprising residues 1-304 of BRCA1 and residues 25-189 of BARD1 are capable of polymerizing ubiquitin, The steady-state level of transfected BRCA1 in vivo was increased by co-transfection of BARD1, and reciprocally that of transfected BARD1 was increased by BRCA1 in a dose-dependent manner. The breast cancer-derived BARD1 interaction-deficient mutant, BRCA1(C61G), does not exhibit ubiquitin ligase activity in vitro. These results suggest that the BRCA1-BARD1 complex contains a ubiquitin ligase activity that is important in prevention of breast and ovarian cancer development.	St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan	Saint Marianna University	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.			Ohta, Tomohiko/0000-0002-9700-7342				Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Ohta T, 2001, CANCER RES, V61, P1347; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Venkitaraman AR, 1999, SCIENCE, V286, P1100, DOI 10.1126/science.286.5442.1100; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	24	512	538	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14537	14540		10.1074/jbc.C000881200	http://dx.doi.org/10.1074/jbc.C000881200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278247	hybrid			2022-12-27	WOS:000168528800002
J	Lambert, G; Sakai, N; Vaisman, BL; Neufeld, EB; Marteyn, B; Chan, CC; Paigen, B; Lupia, E; Thomas, A; Striker, LJ; Blanchette-Mackie, J; Csako, G; Brady, JN; Costello, R; Striker, GE; Remaley, AT; Brewer, HB; Santamarina-Fojo, S				Lambert, G; Sakai, N; Vaisman, BL; Neufeld, EB; Marteyn, B; Chan, CC; Paigen, B; Lupia, E; Thomas, A; Striker, LJ; Blanchette-Mackie, J; Csako, G; Brady, JN; Costello, R; Striker, GE; Remaley, AT; Brewer, HB; Santamarina-Fojo, S			Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; FAMILIAL PLASMA LECITHIN; CELL MEMBRANE-LIPIDS; FISH-EYE DISEASE; LCAT GENE; TRANSGENIC MICE; MOLECULAR DEFECT; ESTER DEFICIENCY; RENAL-FAILURE	To evaluate the biochemical and molecular mechanisms leading to glomerulosclerosis and the variable development of atherosclerosis in patients with familial lecithin cholesterol acyl transferase (LCAT) deficiency, we generated LCAT knockout (KO) mice and cross-bred them with apolipoprotein (apo) E KO, low density lipoprotein receptor (LDLr) KO, and cholesteryl ester transfer protein transgenic mice, LCAT-KO mice had normochromic normocytic anemia with increased reticulocyte and target cell counts as well as decreased red blood cell osmotic fragility. A subset of LCAT-KO mice accumulated lipoprotein X and developed proteinuria and glomerulosclerosis characterized by mesangial cell proliferation, sclerosis, lipid accumulation, and deposition of electron dense material throughout the glomeruli. LCAT deficiency reduced the plasma high density lipoprotein (HDL) cholesterol (-70 to -94%) and non-HDL cholesterol (-48 to -85%) levels in control, apoE-KO, LDLr-KO, and cholesteryl ester transfer protein-Tg mice. Transcriptome and Western blot analysis demonstrated up-regulation of hepatic LDLr and apoE expression in LCAT-KO mice. Despite decreased HDL, aortic atherosclerosis was significantly reduced (-35% to -99%) in all mouse models with LCAT deficiency. Our studies indicate (i) that the plasma levels of apoB containing lipoproteins rather than HDL may determine the atherogenic risk of patients with hypoalphalipoproteinemia due to LCAT deficiency and (ii) a potential. etiological role for lipoproteins X in the development of glomerulosclerosis in LCAT deficiency. The availability of LCAT-KO mice characterized by lipid, hematologic, and renal abnormalities similar to familial LCAT deficiency patients will permit future evaluation of LCAT gene transfer as a possible treatment for glomerulosclerosis in LCAT-deficient states.	NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Miami, Sch Med, Renal Cell Biol Lab, Miami, FL 33101 USA; Jackson Lab, Bar Harbor, ME 04609 USA; NIDDK, Lipid Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIH, Dept Clin Pathol, Ctr Clin, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Miami; Jackson Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lambert, G (corresponding author), NHLBI, Mol Dis Branch, NIH, Bldg 10,Rm 7N115,10 Ctr Dr, Bethesda, MD 20892 USA.	gl68i@nih.gov	Vaisman, Boris L/B-3453-2008; Neufeld, Edward/R-3819-2019; Lupia, Enrico/AAB-7505-2019	Lambert, Gilles/0000-0001-5632-0685; Marteyn, Benoit/0000-0001-5638-702X	NATIONAL EYE INSTITUTE [Z01EY000222, ZIAEY000222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL010306] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); CLINICAL CENTER		ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Berard AM, 1997, NAT MED, V3, P744, DOI 10.1038/nm0797-744; BLANCHETTEMACKIE EJ, 1976, ANAT REC, V184, P599, DOI 10.1002/ar.1091840402; Boisfer E, 1999, J BIOL CHEM, V274, P11564, DOI 10.1074/jbc.274.17.11564; BORYSIEWICZ LK, 1982, Q J MED, V51, P411; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; Burstein M, 1973, Adv Lipid Res, V11, P67; BURSTEIN M, 1970, J LIPID RES, V11, P583; CARLSON LA, 1979, LANCET, V2, P921; CHEN CH, 1982, J LIPID RES, V23, P680; CHU FC, 1979, ARCH OPHTHALMOL-CHIC, V97, P1926; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; EISENBERG S, 1984, J LIPID RES, V25, P121; FIELDING CJ, 1995, J LIPID RES, V36, P211; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; FUNKE H, 1991, P NATL ACAD SCI USA, V88, P4855, DOI 10.1073/pnas.88.11.4855; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GJONE E, 1974, CLIN CHIM ACTA, V54, P11, DOI 10.1016/0009-8981(74)90037-0; GJONE E, 1974, SCAND J CLIN LAB INV, V33, P73, DOI 10.3109/00365517409100633; GJONE E, 1968, ACTA MED SCAND, V183, P107; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GODIN DV, 1978, SCAND J CLIN LAB INV, V38, P162, DOI 10.3109/00365517809104920; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; He CJ, 1996, J CLIN INVEST, V97, P1242, DOI 10.1172/JCI118539; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; IMBASCIATI E, 1986, AM J NEPHROL, V6, P66, DOI 10.1159/000167056; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jimi S, 1999, ARTERIOSCL THROM VAS, V19, P794, DOI 10.1161/01.ATV.19.3.794; KLEIN HG, 1993, J LIPID RES, V34, P49; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; Kuivenhoven JA, 1996, ARTERIOSCL THROM VAS, V16, P294, DOI 10.1161/01.ATV.16.2.294; Kuivenhoven JA, 1995, J CLIN INVEST, V96, P2783, DOI 10.1172/JCI118348; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; LAGER DJ, 1991, MODERN PATHOL, V4, P331; Lynn EG, 1997, MOL CELL BIOCHEM, V175, P187, DOI 10.1023/A:1006865420286; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MCINTYRE N, 1988, J INHERIT METAB DIS, V11, P45, DOI 10.1007/BF01800570; MURAYAMA N, 1984, AM J HEMATOL, V16, P129, DOI 10.1002/ajh.2830160205; MYHRE E, 1977, NEPHRON, V18, P239, DOI 10.1159/000180835; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; NISHINA PM, 1990, J LIPID RES, V31, P859; NORUM KR, 1971, J CLIN INVEST, V50, P1131, DOI 10.1172/JCI106585; NORUM KR, 1967, SCAND J CLIN LAB INV, V20, P231, DOI 10.3109/00365516709076948; NORUM RA, 1982, NEW ENGL J MED, V306, P1513, DOI 10.1056/NEJM198206243062503; O K, 1997, MOL CELL BIOCHEM, V173, P17, DOI 10.1023/A:1006836704042; OHTA Y, 1986, AM J KIDNEY DIS, V7, P41, DOI 10.1016/S0272-6386(86)80055-5; Owen JS, 1996, HUM MUTAT, V8, P79, DOI 10.1002/(SICI)1098-1004(1996)8:1<79::AID-HUMU13>3.3.CO;2-M; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PATSCH JR, 1977, J BIOL CHEM, V252, P2113; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sakai N, 1997, J BIOL CHEM, V272, P7506, DOI 10.1074/jbc.272.11.7506; SANTAMARINAFOJO S, 1999, METABOLIC MOL BASIS; Seidel D, 1974, Horm Metab Res, VSuppl 4, P6; SEIDEL D, 1973, CLIN CHEM, V19, P737; Shamburek RD, 1997, CIRCULATION, V96, P4055; SKRETTING G, 1992, FEBS LETT, V309, P307, DOI 10.1016/0014-5793(92)80795-I; SOLAJICBOZICEVIC N, 1994, CLIN INVESTIGATOR, V72, P951, DOI 10.1007/BF00577734; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Tall AR, 1998, EUR HEART J, V19, pA31; TORSVIK H, 1972, FEBS LETT, V24, P165, DOI 10.1016/0014-5793(72)80758-0; TORSVIK H, 1968, ACTA MED SCAND, V183, P387; UTERMANN G, 1972, HUMANGENETIK, V16, P295; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; WIEBUSCH H, 1995, HUM MOL GENET, V4, P143; Yang XP, 1997, J LIPID RES, V38, P585; YAWATA Y, 1984, BIOCHIM BIOPHYS ACTA, V769, P440, DOI 10.1016/0005-2736(84)90328-6; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zheng F, 1998, KIDNEY INT, V54, P1999, DOI 10.1046/j.1523-1755.1998.00219.x	71	97	100	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15090	15098		10.1074/jbc.M008466200	http://dx.doi.org/10.1074/jbc.M008466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278414	hybrid			2022-12-27	WOS:000168528800076
J	Roy, J; Audette, M; Tremblay, MJ				Roy, J; Audette, M; Tremblay, MJ			Intercellular adhesion molecule-1 (ICAM-1) gene expression in human T cells is regulated by phosphotyrosyl phosphatase activity - Involvement of NF-kappa B, Ets, and palindromic interferon-gamma-responsive element-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-TYROSINE PHOSPHATASES; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; PEROXOVANADIUM COMPOUNDS; MEDIATED INDUCTION; ENDOTHELIAL-CELLS; FAMILY MEMBERS; TNF-ALPHA	Intercellular adhesion molecule-1 (ICAM-1) plays an important role in adhesion phenomena involved in the immune response. The strength of adhesion has been shown to be modulated by changes in ICAM-1 gene expression. in T cells, signaling pathways are intimately regulated by an equilibrium between protein-tyrosine kinases and protein tyrosine phosphatases (PTP). The use of bis-peroxovanadium (bpV) compounds, a class of potent PTP inhibitors, enabled us to investigate the involvement of phosphotyrosyl phosphatases In the regulation of ICAM-1 gene expression in human T cells. Here, we demonstrate for the first time that inhibition of PTP results in an increase of ICAM-1 surface expression on both human T lymphoid and primary mononuclear cells. The crucial role played by the NF-kappaB-, Ets-, and pI gamma RE-binding sites in bpV[pic]-mediated activation of ICAM-1 was demonstrated using various 5' deletion and site-specific mutants of the ICAM-1 gene promoter driving the luciferase reporter gene. Co-transfection experiments with trans-dominant mutants and electrophoretic mobility shift assays confirmed the importance of constitutive and inducible transcription factors that bind to specific responsive elements in bpV-dependent up-regulation of ICAM-1 surface expression, Altogether, these observations suggest that expression of ICAM-1 in human T cells is regulated by phosphotyrosyl phosphatase activity through NF-kappaB-, Ets-, and STAT-1-dependent signaling pathways.	Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Lab Immunoretrovirol Humaine, Quebec City, PQ G1V 4G2, Canada; Ctr Hosp Univ Quebec, Ctr Rech Oncol & Endocrinol Mol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Tremblay, MJ (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Lab Immunoretrovirol Humaine, RC709,Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chadwick CC, 1998, EXP CELL RES, V239, P423, DOI 10.1006/excr.1997.3913; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Coccia EM, 1999, INT IMMUNOL, V11, P1075, DOI 10.1093/intimm/11.7.1075; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Dhawan S, 1997, EUR J IMMUNOL, V27, P2172, DOI 10.1002/eji.1830270909; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Duff JL, 1997, J INVEST DERMATOL, V108, P295, DOI 10.1111/1523-1747.ep12286465; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; GAZDAR AF, 1980, BLOOD, V55, P409; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; LAHM HW, 1985, J CHROMATOGR, V326, P357, DOI 10.1016/S0021-9673(01)87461-6; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee SJ, 1999, GLIA, V25, P21, DOI 10.1002/(SICI)1098-1136(19990101)25:1<21::AID-GLIA3>3.0.CO;2-R; Li WM, 1999, INVEST OPHTH VIS SCI, V40, P976; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; Naik SM, 1997, J BIOL CHEM, V272, P1283, DOI 10.1074/jbc.272.2.1283; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; NORAZ N, 1995, AIDS RES HUM RETROV, V11, P145, DOI 10.1089/aid.1995.11.145; Olivero S, 1998, M S-MED SCI, V14, P262, DOI 10.4267/10608/1028; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song S, 1997, BLOOD, V89, P4461, DOI 10.1182/blood.V89.12.4461; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Sun SC, 1996, MOL CELL BIOL, V16, P1058; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Weeks BS, 1996, BIOCHEM BIOPH RES CO, V226, P82, DOI 10.1006/bbrc.1996.1314; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLARDGALLO KE, 1990, P NATL ACAD SCI USA, V87, P6713, DOI 10.1073/pnas.87.17.6713; Wissink S, 1997, IMMUNOBIOLOGY, V198, P50, DOI 10.1016/S0171-2985(97)80026-5; Wu AJ, 1997, J CELL PHYSIOL, V173, P110, DOI 10.1002/(SICI)1097-4652(199710)173:1<110::AID-JCP13>3.0.CO;2-M	58	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14553	14561		10.1074/jbc.M005067200	http://dx.doi.org/10.1074/jbc.M005067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278281	hybrid			2022-12-27	WOS:000168528800006
J	Schuur, ER; McPherson, LA; Yang, GP; Weigel, RJ				Schuur, ER; McPherson, LA; Yang, GP; Weigel, RJ			Genomic structure of the promoters of the human estrogen receptor-alpha gene demonstrate changes in chromatin structure induced by AP2 gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; MESSENGER-RNA; START SITES; DNASE-I; IDENTIFICATION; EXPRESSION; CARCINOMA; CELLS; TRANSCRIPTS; SEQUENCE	Expression of human estrogen receptor-alpha (ER alpha) involves the activity from several promoters that give rise to alternate untranslated 5' exons, However, the genomic locations of the alternate 5' exons have not been reported previously, We have developed a contig map of the human ER alpha gene that includes all of the known alternate 5' exons, By using S1 nuclease and 5'-rapid amplification of cDNA ends, the cap sites for the alternate ER alpha transcripts E and H were identified. DNase I-hypersensitive sites specific to ER alpha -positive cells were associated with each of the cap sites. A DNase I-hypersensitive site, HS1, was localized to binding sites for AP2 in the untranslated region of exon 1 and was invariably present in the chromatin structure of ER alpha -positive cells, Overexpression of AP2 gamma in human mammary epithelial cells generated the HS1-hypersensitive site. The ER alpha promoter was induced by AP2 gamma in mammary epithelial cells, and trans-activation was dependent upon the region of the promoter containing the HS1 site. These results demonstrate that AP2 gamma trans-activates the ER alpha gene in hormone-responsive tumors by Inducing changes in the chromatin structure of the ER alpha promoter. These data are further evidence for a critical role for AP2 in the oncogenesis of hormone-responsive breast cancers.	Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA	Stanford University	Weigel, RJ (corresponding author), Stanford Univ, Sch Med, Dept Surg, MSLS,Rm P214,1201 Welch Rd, Stanford, CA 94305 USA.			Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA77350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; BRADBEER JW, 1983, CLIN ONCOL, V9, P31; Carmeci C, 1997, AM J PATHOL, V150, P1563; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Grandien K, 1996, MOL CELL ENDOCRINOL, V116, P207, DOI 10.1016/0303-7207(95)03716-0; GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223; GRANDIEN KFH, 1993, J MOL ENDOCRINOL, V10, P269, DOI 10.1677/jme.0.0100269; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JORDAN VC, 1988, CRC CR REV CL LAB SC, V26, P97, DOI 10.3109/10408368809106860; KEAVENEY M, 1991, J MOL ENDOCRINOL, V6, P111, DOI 10.1677/jme.0.0060111; KNIGHT WA, 1977, CANCER RES, V37, P4669; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; LAPDIUS RG, 1996, CLIN CANCER RES, V2, P805; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Penolazzi L, 2000, BBA-GENE STRUCT EXPR, V1492, P560, DOI 10.1016/S0167-4781(00)00145-7; PIVA R, 1993, J STEROID BIOCHEM, V46, P531, DOI 10.1016/0960-0760(93)90179-Z; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; RICKETTS D, 1991, CANCER RES, V51, P1817; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P903, DOI 10.1093/nar/27.3.903; Thompson DA, 1997, J STEROID BIOCHEM, V62, P143, DOI 10.1016/S0960-0760(97)00029-0; Treilleux I, 1997, MOL ENDOCRINOL, V11, P1319, DOI 10.1210/me.11.9.1319; Turner BC, 1998, CANCER RES, V58, P5466; WEIGEL RJ, 1995, CELL GROWTH DIFFER, V6, P707; WEIGEL RJ, 1993, CANCER RES, V53, P3472; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	36	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15519	15526		10.1074/jbc.M009001200	http://dx.doi.org/10.1074/jbc.M009001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278455	Green Published, hybrid			2022-12-27	WOS:000168528800131
J	Wu, DH; Shi, GY; Chuang, WJ; Hsu, JM; Young, KC; Chang, CW; Wu, HL				Wu, DH; Shi, GY; Chuang, WJ; Hsu, JM; Young, KC; Chang, CW; Wu, HL			Coiled coil region of streptokinase gamma-domain is essential for plasminogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUSTERED CHARGE; BINDING REGION; ACTIVE-SITE; COMPLEX; MECHANISM; FRAGMENTS; MUTAGENESIS; PROTEINS; CLEAVAGE; ILE1	The specific functions of the amino acid residues in the streptokinase (SK) gamma -domain were analyzed by studying the interactions of human plasminogen (HPlg) and SK mutants prepared by charge-to-alanine mutagenesis. SK with mutations of groups of amino acids outside the coiled coil region of SK gamma -domain, SKK278A,K279A,E281A,K282A, and SKD360A,R363A had similar HPlg activator activities as wild-type SK. However, significant changes of the functions of SK with mutations within the coiled coil region were observed. Both SKD322A,R324A,D325A and SKR330A,D331A,K332A,K334A had decreased amounts of complex formation with microplasminogen and failed to activate HPlg. SKD328A,R330A had a 21-fold reduced catalytic efficiency for HPlg activation. The studies of SK with single amino acid mutation to Ala demonstrate that Arg(324), Asp(325), Lys(332), and Lys(334) play important roles in the formation of a HPlg SK complex. On the other hand, amino acid residues Asp(322), Asp(328), and Arg(330) of SK are involved in the virgin enzyme induction. Potential contact between Lys(332) of SK and Glu(623) of human microplasmin and strong interactions between Asp(328) and Lys(330), Asp(331) and Lys(334), and Asp(322) and Lys(334) of SK are noticed. These interactions are important in maintaining a coiled coil conformation, Therefore, we conclude that the coiled coil region of SK gamma -domain, SK(Leu(314)-Ala(342)), plays very important roles in HPlg activation by participating in virgin enzyme induction and stabilizing the activator complex.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 701, Taiwan; Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan 710, Taiwan	National Cheng Kung University; National Cheng Kung University; Chia Nan University of Pharmacy & Science	Wu, HL (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan.		Hsu, Jung-Mao/AAP-8045-2020; Hsu, Jung-Mao/AAC-9527-2019; Young, Kung-Chia/G-1529-2011					BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BROCKWAY WJ, 1972, ARCH BIOCHEM BIOPHYS, V151, P194, DOI 10.1016/0003-9861(72)90488-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; CHIBBER BAK, 1986, P NATL ACAD SCI USA, V83, P1237, DOI 10.1073/pnas.83.5.1237; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Esmon CT, 1998, NAT STRUCT BIOL, V5, P933, DOI 10.1038/2906; GONZALEZGRONOW M, 1977, J BIOL CHEM, V252, P1090; Grella DK, 1997, BLOOD, V89, P1585, DOI 10.1182/blood.V89.5.1585.1585_1585_1589; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NAGENDRA K, 1974, J BIOL CHEM, V249, P4851; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI GY, 1994, BIOCHEM J, V304, P235, DOI 10.1042/bj3040235; SHI GY, 1988, J BIOL CHEM, V263, P17071; Shi GY, 1998, THROMB HAEMOSTASIS, V79, P992; SHI GY, 1993, BIOCHEM BIOPH RES CO, V195, P192, DOI 10.1006/bbrc.1993.2029; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SIEFRING GE, 1976, J BIOL CHEM, V251, P3913; SILENCE K, 1995, J BIOL CHEM, V270, P27192, DOI 10.1074/jbc.270.45.27192; SUMMARIA L, 1982, BIOCHEMISTRY-US, V21, P2056, DOI 10.1021/bi00538a012; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; UESHIMA S, 1994, THROMB HAEMOSTASIS, V71, P134; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1990, J BIOL CHEM, V265, P19658; WULF RJ, 1969, CAN J BIOCHEM CELL B, V47, P927, DOI 10.1139/o69-145; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	41	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15025	15033		10.1074/jbc.M005935200	http://dx.doi.org/10.1074/jbc.M005935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278293	hybrid			2022-12-27	WOS:000168528800068
J	Jakacka, M; Ito, M; Weiss, J; Chien, PY; Gehm, BD; Jameson, JL				Jakacka, M; Ito, M; Weiss, J; Chien, PY; Gehm, BD; Jameson, JL			Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; GENE-EXPRESSION; ER-ALPHA; C-JUN; BETA; ACTIVATION; TRANSCRIPTION; ANTIESTROGENS	In the classical signaling pathway, the estrogen receptor (ER) binds directly to estrogen response elements (EREs) to regulate gene transcription. To test the hypothesis that the nonclassical pathway involves ER interactions with other proteins rather than direct binding to DNA, mutations were introduced into the DNA binding domain (DBD) of the mouse ER alpha. The effects of these DBD mutations were examined in DNA binding assays using reporter constructs containing either EREs (classical) or AP1 (nonclassical) response elements. Using the AP1 reporter, there was a reversal of ER action relative to that seen with the ERE reporter. Estradiol induced suppression, and the antiestrogen ICI 182,780 stimulated transcription of the AP1 reporter. DBD mutations in the proximal (P-box) of the first zinc finger of the ER (E207A/G208A and E207G/G208S) eliminated ERE binding. These mutants were inactive using the ERE reporter but retained partial or full activity with the AP1 reporter. The DBD mutant ERs interacted with Jun when tested in mammalian cell two-hybrid assays. Two mutations (K366D and I362R) in the ER ligand binding domain known to alter coactivator interactions impaired transcriptional responses using either the ERE or AP1 reporters. We concluded that ER action through the AP1 response element involves interactions with other promoter-bound proteins instead of, or in addition to, direct binding to DNA, Interactions with coactivators were required for both pathways. These data supported a model in which ER-mediated transcriptional activation or repression is dependent on the ligand and the nature of the response element in the target gene.	Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University	Jameson, JL (corresponding author), Northwestern Univ, Sch Med, Dept Med, 250 E Super St,Weasley 296, Chicago, IL 60611 USA.			Jameson, James/0000-0001-9538-4059	NCI NIH HHS [IP50 CA89018-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chien PY, 1999, MOL ENDOCRINOL, V13, P2122, DOI 10.1210/me.13.12.2122; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miller CD, 1996, ENDOCRINOLOGY, V137, P3437, DOI 10.1210/en.137.8.3437; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHMITT M, 1995, J NEUROSCI RES, V40, P152, DOI 10.1002/jnr.490400203; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	43	228	235	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13615	13621		10.1074/jbc.M008384200	http://dx.doi.org/10.1074/jbc.M008384200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278408	hybrid			2022-12-27	WOS:000168356600017
J	Kroesen, BJ; Pettus, B; Luberto, C; Busman, M; Sietsma, H; de Leij, L; Hannun, YA				Kroesen, BJ; Pettus, B; Luberto, C; Busman, M; Sietsma, H; de Leij, L; Hannun, YA			Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated C16-ceramide and involves mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CERAMIDE GENERATION; ANTIGEN RECEPTOR; WEHI-231 CELLS; CYTOCHROME-C; T-CELLS; ACTIVATION; INVOLVEMENT; SPHINGOMYELIN; CASPASES	B-cells, triggered via their surface E-cell receptor (BcR), start an apoptotic program known as activation-induced cell death (AICD), and it is widely believed that this phenomenon plays a role in the restriction and focusing of the immune response. Although both ceramide and caspases have been proposed to be involved in AICD, the contribution of either and the exact molecular events through which AICD commences are still unknown. Here we show that in Ramos B-cells, BcR-triggered cell death is associated with an early rise of C16 ceramide that derives from activation of the de novo pathway, as demonstrated using a specific inhibitor of ceramide synthase, fumonisin B1 (FB1), and using pulse labeling with the metabolic sphingolipid precursor, palmitate, There was no evidence for activation of sphingomyelinases or hydrolysis of sphingomyelin. Importantly, FB1 inhibited several specific apoptotic hallmarks such as poly(A)DP-ribose polymerase cleavage and DNA fragmentation. Electron microscopy revealed morphological evidence of mitochondrial damage, suggesting the involvement of mitochondria in BcR-triggered apoptosis, and this was inhibited by FB1, Moreover; a loss of mitochondrial membrane potential was observed in Ramos cells after BcR cross-linking, which was inhibited by the addition of FB1. Interestingly, benzyloxycarbonyl-Val-Ala-DL-Asp, a broad spectrum caspase inhibitor did not inhibit BcR-induced mitochondrial membrane permeability transition but did block DNA fragmentation, These results suggest a crucial role for de novo generated C16 ceramide in the execution of AICD, and, they further suggest an ordered and more specific sequence of biochemical events in which de novo generated C16 ceramide is involved in mitochondrial damage resulting in a downstream activation of caspases and apoptosis.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Groningen Hosp, Dept Pathol & Lab Med, NL-9713 G2 Groningen, Netherlands; Univ Groningen Hosp, Dept Pediat Oncol & Hematol, NL-9713 G2 Groningen, Netherlands; US Dept Commerce, Natl Ocean Serv, Charleston, SC 29412 USA	Medical University of South Carolina; University of Groningen; University of Groningen; National Oceanic Atmospheric Admin (NOAA) - USA; National Ocean Service, NOAA	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		Busman, Mark/AAH-3042-2022; Busman, Mark/AFM-0629-2022	Busman, Mark/0000-0001-9750-064X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825, GM08716] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; An S, 1997, CELL IMMUNOL, V181, P139, DOI 10.1006/cimm.1997.1211; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Anjum R, 1998, FEBS LETT, V439, P81, DOI 10.1016/S0014-5793(98)01343-X; Berard R, 1999, J IMMUNOL, V163, P4655; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Borst J, 1999, IMMUNOL TODAY, V20, P156, DOI 10.1016/S0167-5699(98)01433-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Darzynkiewicz Z, 1998, Adv Biochem Eng Biotechnol, V62, P33, DOI 10.1007/BFb0102305; Dawson G, 1998, ACTA BIOCHIM POL, V45, P287, DOI 10.18388/abp.1998_4225; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Fang W, 1997, AM J PHYSIOL-CELL PH, V272, pC950, DOI 10.1152/ajpcell.1997.272.3.C950; Frasca L, 1998, CRIT REV IMMUNOL, V18, P569, DOI 10.1615/CritRevImmunol.v18.i6.50; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garzotto M, 1998, CANCER RES, V58, P2260; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; HAIMOVITZ FA, 1997, BR MED B, V53, P539; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Hollowood K, 1998, J PATHOL, V185, P229, DOI 10.1002/(SICI)1096-9896(199807)185:3<229::AID-PATH86>3.0.CO;2-L; Kawatani M, 2000, EXP CELL RES, V259, P389, DOI 10.1006/excr.2000.4986; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Luberto C, 1999, LIPIDS, V34, pS5, DOI 10.1007/BF02562221; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; PREISS J, 1986, J BIOL CHEM, V261, P8597; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Scott DW, 1996, J IMMUNOL, V156, P2352; Scurlock B, 1999, J NEUROSCI RES, V55, P514, DOI 10.1002/(SICI)1097-4547(19990215)55:4<514::AID-JNR11>3.0.CO;2-V; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; ULLMAN MD, 1972, ARCH BIOCHEM BIOPHYS, V152, P767, DOI 10.1016/0003-9861(72)90272-X; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189	50	137	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13606	13614		10.1074/jbc.M009517200	http://dx.doi.org/10.1074/jbc.M009517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278517	hybrid			2022-12-27	WOS:000168356600016
J	Vasconcelles, MJ; Jiang, YD; McDaid, K; Gilooly, L; Wretzel, S; Porter, DL; Martin, CE; Goldberg, MA				Vasconcelles, MJ; Jiang, YD; McDaid, K; Gilooly, L; Wretzel, S; Porter, DL; Martin, CE; Goldberg, MA			Identification and characterization of a low oxygen response element involved in the hypoxic induction of a family of Saccharomyces cerevisiae genes - Implications for the conservation of oxygen sensing in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; INDUCIBLE FACTOR 1-ALPHA; DNA-BINDING PROTEIN; BHLH-PAS PROTEIN; TRANSCRIPTIONAL REGULATION; ENHANCER ELEMENT; DESATURASE GENE; OLE1 GENE; YEAST; EXPRESSION	An organism's ability to respond to changes in oxygen tension depends in large part on alterations in gene expression. The oxygen sensing and signaling mechanisms in eukaryotic cells are not fully understood. To further define these processes, we have studied the Delta9 fatty acid desaturase gene OLE1 in Saccharomyces cerevisiae, We have confirmed previous data showing that the expression of OLE1 mRNA is increased in hypoxia and in the presence of certain transition metals. OLE1 expression was also increased in the presence of the iron chelator 1,10-phenanthroline. A 142-base pair (bp) region 3' to the previously identified fatty acid response element was identified as critical for the induction of OLE1 in response to these stimuli using OLE1 promoter-lacZ reporter constructs. Electromobility shift assays confirmed the presence of an inducible band shift in response to hypoxia:a and cobalt. Mutational analysis defined the nonameric sequence ACTCAACAA as necessary for transactivation. A 20-base pair oligonucleotide containing this nonamer confers up regulation by hypoxia and inhibition by unsaturated fatty acids when placed upstream of a heterologous promoter in a lacZ reporter construct. Additional yeast genes were identified which respond to hypoxia and cobalt in a manner similar to OLE1. A number of mammalian genes are also up-regulated by hypoxia, cobalt, nickel, and iron chelators. Hence, the identification of a family of yeast genes regulated in a similar manner has implications for understanding oxygen sensing and signaling in eukaryotes.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Bur Biol Res, Nelson Biol Lab, Piscataway, NJ 08854 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Rutgers State University New Brunswick	Goldberg, MA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, 221 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [K08 HL03599] Funding Source: Medline; NIDDK NIH HHS [DK45098] Funding Source: Medline; NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bacon NCM, 1998, BIOCHEM BIOPH RES CO, V249, P811, DOI 10.1006/bbrc.1998.9234; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; Bourdineaud JP, 2000, RES MICROBIOL, V151, P43, DOI 10.1016/S0923-2508(00)00128-5; BOUROT S, 1995, GENE, V165, P97, DOI 10.1016/0378-1119(95)00478-O; Brown T., 1997, CURRENT PROTOCOLS MO; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Choi JY, 1996, J BIOL CHEM, V271, P3581; COLLART MA, 1997, CURRENT PROTOCOLS MO; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Deckert J, 1998, GENETICS, V150, P1429; DECKERT J, 1995, GENETICS, V139, P1149; Donzeau M, 1996, MOL MICROBIOL, V20, P449, DOI 10.1111/j.1365-2958.1996.tb02631.x; Ebert BL, 1999, BLOOD, V94, P1864; ELBIE R, 1992, BIOTECHNIQUES, V13, P18; Fujimori K, 1997, FEBS LETT, V413, P226, DOI 10.1016/S0014-5793(97)00846-6; Fujiwara D, 1999, YEAST, V15, P1183, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1183::AID-YEA444>3.0.CO;2-J; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Horiguchi H, 2000, BBA-MOL CELL RES, V1495, P231, DOI 10.1016/S0167-4889(99)00169-X; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Kingston R., 1997, CURRENT PROTOCOLS MO; Kitagaki H, 1997, EUR J BIOCHEM, V249, P343, DOI 10.1111/j.1432-1033.1997.t01-1-00343.x; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Kwast KE, 1998, J EXP BIOL, V201, P1177; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LOWRY CV, 1986, MOL CELL BIOL, V6, P4145, DOI 10.1128/MCB.6.12.4145; Luo G, 1997, GENE EXPRESSION, V6, P287; Maniatis T., 1982, MOL CLONING LAB MANU; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Rachidi N, 2000, MOL MICROBIOL, V35, P1421, DOI 10.1046/j.1365-2958.2000.01807.x; Reynolds A., 1997, CURRENT PROTOCOLS MO; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Sertil O, 1997, GENE, V192, P199, DOI 10.1016/S0378-1119(97)00028-0; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; TRECO DA, 1997, CURRENT PROTOCOLS MO; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F; Zhu H, 1999, P NATL ACAD SCI USA, V96, P14742, DOI 10.1073/pnas.96.26.14742; Zitomer RS, 1997, METHODS, V11, P279, DOI 10.1006/meth.1996.0422; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71; ZITOMER RS, 1992, MICROBIOL REV, V5, P1	69	85	89	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14374	14384		10.1074/jbc.M009546200	http://dx.doi.org/10.1074/jbc.M009546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278521	hybrid			2022-12-27	WOS:000168356600114
J	Sandy, JD; Westling, J; Kenagy, RD; Iruela-Arispe, ML; Verscharen, C; Rodriguez-Mazaneque, JC; Zimmermann, DR; Lemire, JM; Fischer, JW; Wight, TN; Clowes, AW				Sandy, JD; Westling, J; Kenagy, RD; Iruela-Arispe, ML; Verscharen, C; Rodriguez-Mazaneque, JC; Zimmermann, DR; Lemire, JM; Fischer, JW; Wight, TN; Clowes, AW			Versican V1 proteolysis in human aorta in vivo occurs at the Glu(441)-Ala(442) bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; AGGRECANASE-DEPENDENT CLEAVAGE; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; MATRIX-METALLOPROTEINASE; PROTEOGLYCAN VERSICAN; THROMBOSPONDIN MOTIFS; EXTRACELLULAR-MATRIX; MEDIATED CATABOLISM; MOLECULAR-CLONING	Mature human aorta contains a 70-kDa versican fragment, which reacts with a neoepitope antiserum to the C-terminal peptide sequence DPEAAE. This protein therefore appears to represent the G1 domain of versican V1 (G1-DPEAAE(441)), which has been generated in vivo by proteolytic cleavage at the Glu(441)-Ala(442) bond, within the sequence DPEAAE(441)-A(442)RRGQ. Because the equivalent aggrecan product (G1-NITEGE(341)) and brevican product (GI-EAVESE(395)) are generated by ADAMTS-mediated cleavage of the respective proteoglycans, we tested the capacity of recombinant ADAMTS-1 and ADAMTS-4 to cleave versican at Glu(441)-Ala(442). Both enzymes cleaved a recombinant versican substrate and native human versican at the Glu(441)-Ala(442) bond and the mature form of ADAMTS-4 was detected by Western analysis of extracts of aortic intima. We conclude that versican V1 proteolysis in vivo can be catalyzed by one or more members of the ADAMTS family of metalloproteinases.	Shriners Hosp Children, Tampa, FL 33612 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Zurich, Dept Pathol, Mol Biol Lab, CH-8091 Zurich, Switzerland	University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of Zurich	Sandy, JD (corresponding author), Shriners Hosp Children, 12502 N Pine Dr, Tampa, FL 33612 USA.	jsandy@shctampa.usf.edu	Rodriguez-Manzaneque, Juan Carlos/F-3899-2012; Iruela-Arispe, M. Luisa/AAJ-1297-2020	Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029; Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Kenagy, Richard/0000-0002-2021-5565	NCI NIH HHS [R01CA 77420] Funding Source: Medline; NCRR NIH HHS [RR00166] Funding Source: Medline; NHLBI NIH HHS [HL30946, HL07828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077420] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; BAYKAL D, 1995, AM J CARDIOL, V75, pB82, DOI 10.1016/0002-9149(95)80019-O; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HASCALL VC, 1994, METHOD ENZYMOL, V230, P390; Hering TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P259, DOI 10.1006/abbi.1997.0261; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Lemire JM, 1999, ARTERIOSCL THROM VAS, V19, P1630, DOI 10.1161/01.ATV.19.7.1630; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; MAJACK RA, 1984, J CELL PHYSIOL, V118, P253, DOI 10.1002/jcp.1041180306; Matsui F, 1998, BRAIN RES, V790, P45, DOI 10.1016/S0006-8993(98)00009-2; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; Olin KL, 1999, J BIOL CHEM, V274, P34629, DOI 10.1074/jbc.274.49.34629; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Sandy JD, 2000, BIOCHEM J, V351, P161, DOI 10.1042/0264-6021:3510161; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; Sandy JD, 1998, BIOCHEM J, V335, P59, DOI 10.1042/bj3350059; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8198; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Sorrell JM, 1999, ANAT EMBRYOL, V199, P45, DOI 10.1007/s004290050208; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; WAHLBERG JA, 1986, CRYOBIOLOGY, V23, P477, DOI 10.1016/0011-2240(86)90056-8; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	45	364	375	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13372	13378		10.1074/jbc.M009737200	http://dx.doi.org/10.1074/jbc.M009737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278559	hybrid			2022-12-27	WOS:000168198600124
J	Smirlis, D; Muangmoonchai, R; Edwards, M; Phillips, IR; Shephard, EA				Smirlis, D; Muangmoonchai, R; Edwards, M; Phillips, IR; Shephard, EA			Orphan receptor promiscuity in the induction of cytochromes P450 by xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-RESPONSIVE ENHANCER; NUCLEAR; CAR; GENES; IDENTIFICATION; DEFINES; ELEMENT; TARGET	The mechanisms by which different classes of chemicals induce the same cytochrome P450 (CYP) or the same chemical differentially induces more than one CYP are not well understood. We show that in primary hepatocytes and in vivo in liver (transfected by particle-mediated delivery) two orphan nuclear receptors, constitutive androstane receptor and pregnane X receptor (PXR1), transactivate a CYP gene via the same response element in a xenobiotic-specific manner. The constitutive androstane receptor mediates the barbiturate activation of expression of CYP2B1 and CYP3A1. PXR1 activates both genes in response to synthetic steroids. To exert their effect the receptors bind to the same direct repeat site (DR4) within the phenobarbital response element of the CYP2B1 promoter and to the same DR3 site in the pregnane X response element of CYP3A1. The receptors are therefore promiscuous with respect to DNA binding but not ligand binding. Differences in enhancer half-site spacing may influence the efficiency of interactions between the receptor and the transcription machinery and hence form the basis for the differential induction of CYP2B1 and CYP3A1 in response to barbiturates and synthetic steroids.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; Queen Mary University London; University of London; University College London	Phillips, IR (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	I.R.Phillips@qmw.ac.uk; e.shephard@ucl.ac.uk	Phillips, Ian R/A-7337-2008	Smirlis, Despina/0000-0003-4996-2879				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Dell H, 1998, Methods Mol Biol, V107, P381; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Frueh FW, 1997, MOL PHARMACOL, V51, P363; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V2; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Kassam A, 2000, J BIOL CHEM, V275, P4345, DOI 10.1074/jbc.275.6.4345; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; ONATE SA, 1995, SCIENCE, V270, P1354; PHILLIPS IR, 1985, DRUG METABOLISM MOL, P93; Quattrochi LC, 1998, ARCH BIOCHEM BIOPHYS, V349, P251, DOI 10.1006/abbi.1997.0467; Rastinejad Fraydoon, 1998, P105; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112	30	85	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12822	12826		10.1074/jbc.M005930200	http://dx.doi.org/10.1074/jbc.M005930200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278292	hybrid			2022-12-27	WOS:000168198600051
J	Shirotani, K; Tsubuki, S; Iwata, N; Takaki, Y; Harigaya, W; Maruyama, K; Kiryu-Seo, S; Kiyama, H; Iwata, H; Tomita, T; Iwatsubo, T; Saido, TC				Shirotani, K; Tsubuki, S; Iwata, N; Takaki, Y; Harigaya, W; Maruyama, K; Kiryu-Seo, S; Kiyama, H; Iwata, H; Tomita, T; Iwatsubo, T; Saido, TC			Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-CONVERTING ENZYME; PROTEIN FIBRILLOGENESIS; NEUTRAL ENDOPEPTIDASE; EXTRACELLULAR LEVELS; MOLECULAR-CLONING; ALZHEIMER-DISEASE; EC 3.4.24.11; RAT-BRAIN; DEGRADATION; METALLOPROTEASE	To identify the amyloid beta peptide (A beta) 1-42-degrading enzyme whose activity is inhibited by thiorphan and phosphoramidon in vivo, we searched for neprilysin (NEP) homologues and cloned neprilysin-like peptidase (NEPLP) alpha, NEPLP beta, and NEPLP gamma cDNAs. We expressed NEP, phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PEX), NEPLPs, and damage-induced neuronal endopeptidase (DINE) in 293 cells as 95- to 125-kDa proteins and found that the enzymatic activities of PEX, NEPLP alpha, and NEPLP beta, as well as those of NEP and DINE, were sensitive to thiorphan and phosphoramidon. Among the peptidases tested, NEP degraded both synthetic and cell-secreted A beta1-40 and A beta1-42 most rapidly and efficiently. PEX degraded cold A beta1-40 and NEPLP alpha degraded both cold A beta1-40 and A beta1-42, although the rates and the extents of the digestion were slower and less efficient than those exhibited by NEP, These data suggest that, among the endopeptidases whose activities are sensitive to thiorphan and phosphoramidon, NEP is the most potent A beta -degrading enzyme in vivo. Therefore, manipulating the activity of NEP would be a useful approach in regulating A beta levels in the brain.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Tokyo 1130033, Japan; Saitama Med Sch, Dept Pharmacol, Moroyama, Saitama 3500495, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan	RIKEN; University of Tokyo; Saitama Medical University; Asahikawa Medical College	Shirotani, K (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kshiro@brain.riken.go.jp	Kiryu-Seo, Sumiko/M-8865-2014; Saido, Takaomi C/N-5472-2015; Kiyama, Hiroshi/M-8867-2014; Tomita, Taisuke/L-5427-2015; Sado, Takaomi/AAN-2759-2021	Kiryu-Seo, Sumiko/0000-0001-6213-1258; Saido, Takaomi C/0000-0003-1970-6903; Kiyama, Hiroshi/0000-0001-5963-046X; Tomita, Taisuke/0000-0002-0075-5943; Sado, Takaomi/0000-0003-1970-6903				Backstrom JR, 1996, J NEUROSCI, V16, P7910; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1080; DIXON M, 1958, ENZYMES, P118; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; Hamazaki H, 1996, FEBS LETT, V396, P139, DOI 10.1016/0014-5793(96)01087-3; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LADROR US, 1994, J BIOL CHEM, V269, P18422; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872; RONCO P, 1988, LAB INVEST, V58, P210; Saido T. C., 2000, NEUROSCI NEWS, V3, P52; Saido TC, 2001, NEUROSCIENTIFIC BASIS OF DEMENTIA, P249; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Soleilhac JM, 1996, EUR J CLIN INVEST, V26, P1011, DOI 10.1046/j.1365-2362.1996.2420580.x; SPILLANTINI MG, 1990, BIOCHEM PHARMACOL, V39, P1353, DOI 10.1016/0006-2952(90)90012-A; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Tucker HM, 2000, J NEUROSCI, V20, P3937; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; Van Nostrand WE, 1999, BIOCHEMISTRY-US, V38, P11570, DOI 10.1021/bi990610f; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WILCOX JN, 1989, NEUROPEPTIDES, V14, P77, DOI 10.1016/0143-4179(89)90062-0; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X	40	249	261	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21895	21901		10.1074/jbc.M008511200	http://dx.doi.org/10.1074/jbc.M008511200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278416	hybrid			2022-12-27	WOS:000169297900142
J	Pierrugues, O; Brutesco, C; Oshiro, J; Gouy, M; Deveaux, Y; Carman, GM; Thuriaux, P; Kazmaier, M				Pierrugues, O; Brutesco, C; Oshiro, J; Gouy, M; Deveaux, Y; Carman, GM; Thuriaux, P; Kazmaier, M			Lipid phosphate phosphatases in Arabidopsis - Regulation of the AtLPP1 gene in response to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; PHOSPHOLIPASE-D ACTIVITY; ACID SIGNAL-TRANSDUCTION; G-PROTEIN ACTIVATION; SACCHAROMYCES-CEREVISIAE; SUSPENSION-CULTURES; SEQUENCE MOTIF; IDENTIFICATION; EXPRESSION; PLANTS	An Arabidopsis thaliana gene (AtLPP1) was isolated on the basis that it was transiently induced by ionizing radiation. The putative AtLPP1 gene product showed homology to the yeast and mammalian lipid phosphate phosphatase enzymes and possessed a phosphatase sig nature sequence motif. Heterologous expression and biochemical characterization of the AtLPP1 gene in yeast showed that it encoded an enzyme (AtLpp1p) that exhibited both diacylglycerol pyrophosphate phosphatase and phosphatidate phosphatase activities. Kinetic analysis indicated that diacylglycerol pyrophosphate was the preferred substrate for AtLpp1p in vitro. A second Arabidopsis gene (AtLPP2) was identified based on sequence homology to AtLPP1 that was also heterologously expressed in yeast. The AtLpp2p enzyme also utilized diacylglycerol pyrophosphate and phosphatidate but with no preference for either substrate. The AtLpp1p and AtLpp2p enzymes showed differences in their apparent affinities for diacylglycerol pyrophosphate and phosphatidate as well as other enzymological properties. Northern blot analyses showed that the AtLPP1 gene was preferentially expressed in leaves and roots, whereas the AtLPP2 gene was expressed in all tissues examined. AtLPP2, but not AtLPP2, was regulated in response to various stress conditions. The AtLPP1 gene was transiently induced by genotoxic stress (gamma ray or UV-B) and elicitor treatments with mastoparan and harpin. The regulation of the AtLPP1 gene in response to stress was consistent with the hypothesis that its encoded lipid phosphate phosphatase enzyme may attenuate the signaling functions of phosphatidate and/or diacylglycerol pyrophosphate that form in response to stress in plants.	CEA Cadarache, DSV, DEVM, Lab Radiobiol Vegetale, F-13108 St Paul Les Durance, France; Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France; CEA Saclay, DSV, Serv Genet & Biol Mol, F-91108 Gif Sur Yvette, France	CEA; Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; CEA; UDICE-French Research Universities; Universite Paris Saclay	Kazmaier, M (corresponding author), CEA Cadarache, DSV, DEVM, Lab Radiobiol Vegetale, F-13108 St Paul Les Durance, France.	mkazmaier@cea.fr	Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023; DEVEAUX, YVES/0000-0002-3297-1317	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An YQ, 1996, PLANT J, V10, P107, DOI 10.1046/j.1365-313X.1996.10010107.x; AUSUEBEL FM, 1994, CURRENT PROTOCOLS MO; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; Balboa MA, 1999, J BIOL CHEM, V274, P522, DOI 10.1074/jbc.274.1.522; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chapman KD, 1998, TRENDS PLANT SCI, V3, P419, DOI 10.1016/S1360-1385(98)01326-0; Desikan R, 1998, BIOCHEM J, V330, P115, DOI 10.1042/bj3300115; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Frank W, 2000, PLANT CELL, V12, P111, DOI 10.1105/tpc.12.1.111; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; Furneisen JM, 2000, BBA-MOL CELL BIOL L, V1484, P71, DOI 10.1016/S1388-1981(99)00202-4; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Jacob T, 1999, P NATL ACAD SCI USA, V96, P12192, DOI 10.1073/pnas.96.21.12192; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KLOPPSTECH K, 1991, MOL GEN GENET, V225, P468, DOI 10.1007/BF00261689; Lee SM, 1997, PLANT J, V12, P547, DOI 10.1046/j.1365-313X.1997.00547.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MINET M, 1992, PLANT J, V2, P417; Montane MH, 1997, PLANTA, V202, P293, DOI 10.1007/s004250050131; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Munnik T, 1998, PLANTA, V207, P133, DOI 10.1007/s004250050465; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; Ritchie S, 1998, P NATL ACAD SCI USA, V95, P2697, DOI 10.1073/pnas.95.5.2697; Ryu SB, 1998, BBA-LIPID LIPID MET, V1393, P193, DOI 10.1016/S0005-2760(98)00048-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SIKORSKI RS, 1989, GENETICS, V122, P19; Stukey J, 1997, PROTEIN SCI, V6, P469; Taylor ATS, 1997, BIOCHEM BIOPH RES CO, V237, P10, DOI 10.1006/bbrc.1997.6965; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Toke DA, 1999, BIOCHEMISTRY-US, V38, P14606, DOI 10.1021/bi991472x; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181	48	72	80	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20300	20308		10.1074/jbc.M009726200	http://dx.doi.org/10.1074/jbc.M009726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278556	hybrid			2022-12-27	WOS:000169135100086
J	Zieseniss, S; Zahler, S; Muller, I; Hermetter, A; Engelmann, B				Zieseniss, S; Zahler, S; Muller, I; Hermetter, A; Engelmann, B			Modified phosphatidylethanolamine as the active component of oxidized low density lipoprotein promoting platelet prothrombinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR EXPRESSION; HUMAN ENDOTHELIAL-CELLS; PLASMALOGEN PHOSPHOLIPIDS; APOLIPOPROTEIN-B; LYSINE RESIDUES; OXIDATION; RECEPTORS; LDL; AMINOPHOSPHOLIPIDS; DEGRADATION	We analyzed the influence of the atherogenic oxidized low density lipoproteins (LDL) on the activity of the platelet prothrombinase complex, a major contributor to overall thrombin formation in vivo, Platelet dependent thrombin generation was found to be strongly stimulated by in vitro oxidized LDL. The enhancement was additive to that observed with the platelet agonist thrombin. Oxidized LDL increased the platelet binding of annexin-V, suggesting that the augmented surface exposure of aminophospholipids promoted the prothrombinase activity, All of the stimulatory activity of the oxidized LDL could be recovered in the microemulsions prepared hom the Lipid portion of the modified particles. Phospholipid vesicles were prepared containing the total lipids of the oxidized LDL but lacking specifically in one lipid component. Following the selective removal of the ethanolamine phospholipids (PE) from the LDL lipids, the platelet-dependent thrombin formation was markedly reduced. Vesicles enriched with the isolated PE fraction alone enhanced the thrombin generation. Analyses with autoxidized phospholipids indicated that oxidation products of unsaturated diacyl-PE Fc-ere mainly responsible for the increased prothrombinase activity. Oxidized LDL and its PE fraction lost their stimulatory activity after treatment with NaCNBH3, a chemical reductant of Schiff base adducts. Phospholipid vesicles supplemented with synthetic aldehyde-PE adducts largely reproduced the stimulation of the thrombin generation. Ne conclude that the oxidized LDL particles elicit a pronounced prothrombotic response by increasing the activity of the platelet prothrombinase complex, Specific oxidative modifications of the EDL associated ethanolamine phospholipids are mainly responsible for this stimulation.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Graz Tech Univ, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria	University of Munich; Graz University of Technology	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.			Zahler, Stefan/0000-0002-5140-7287				BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; Bligh E.G., 1959, CAN J BIOCHEM PHYSIO, V37, P912; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND K, 1994, ARTERIOSCLER THROMB, V14, P790, DOI 10.1161/01.ATV.14.5.790; Brautigam C, 1996, ATHEROSCLEROSIS, V119, P77, DOI 10.1016/0021-9150(95)05632-7; Coughlin SR, 1999, THROMB HAEMOSTASIS, V82, P353; DRAKE TA, 1991, AM J PATHOL, V138, P601; Engelmann B, 1998, J BIOL CHEM, V273, P27800, DOI 10.1074/jbc.273.43.27800; ENGELMANN B, 1992, BIOCHIM BIOPHYS ACTA, V1165, P32, DOI 10.1016/0005-2760(92)90072-4; Esterbauer H, 1996, REV PHYSIOL BIOCH P, V127, P31, DOI 10.1007/BFb0048264; Ettelaie C, 1999, ARTERIOSCL THROM VAS, V19, P1784, DOI 10.1161/01.ATV.19.7.1784; Fuster V, 1997, ANN NY ACAD SCI, V811, P207, DOI 10.1111/j.1749-6632.1997.tb52003.x; Guichardant M, 1998, FREE RADICAL BIO MED, V25, P1049, DOI 10.1016/S0891-5849(98)00149-X; Hahnel D, 1999, BIOCHEM J, V340, P377, DOI 10.1042/0264-6021:3400377; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Ishii H, 1996, J BIOL CHEM, V271, P8458, DOI 10.1074/jbc.271.14.8458; James PF, 1997, J BIOL CHEM, V272, P23532, DOI 10.1074/jbc.272.38.23532; Khaselev N, 2000, J LIPID RES, V41, P564; Martens JS, 1999, J BIOL CHEM, V274, P10903, DOI 10.1074/jbc.274.16.10903; MARTIN TW, 1985, J BIOL CHEM, V260, P2852; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; Preissner KT, 2000, J PATHOL, V190, P360; Reiss D, 1997, BIOCHEM J, V323, P807, DOI 10.1042/bj3230807; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Volf I, 1999, FEBS LETT, V449, P141, DOI 10.1016/S0014-5793(99)00437-8; Zaman AG, 2000, ATHEROSCLEROSIS, V149, P251, DOI 10.1016/S0021-9150(99)00479-7; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	31	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19828	19835		10.1074/jbc.M007506200	http://dx.doi.org/10.1074/jbc.M007506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278348	hybrid			2022-12-27	WOS:000169135100022
J	Ciruela, F; Escriche, M; Burgueno, J; Angulo, E; Casado, V; Soloviev, MM; Canela, EI; Mallol, J; Chan, WY; Lluis, C; McIlhinney, RAJ; Franco, R				Ciruela, F; Escriche, M; Burgueno, J; Angulo, E; Casado, V; Soloviev, MM; Canela, EI; Mallol, J; Chan, WY; Lluis, C; McIlhinney, RAJ; Franco, R			Metabotropic glutamate 1 alpha and adenosine A1 receptors assemble into functionally interacting complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; G-PROTEIN; SYNAPTIC TRANSMISSION; HETEROMERIC COMPLEXES; GABA(B) RECEPTOR; SPLICE VARIANTS; A(1) RECEPTORS; PSD-95 FAMILY; C-TERMINUS; MEMBRANE	Recently, evidence has emerged that seven transmembrane G protein-coupled receptors may be present as homo- and heteromers in the plasma membrane. Here we describe a new molecular and functional interaction between two functionally unrelated types of G protein-coupled receptors, namely the metabotropic glutamate type 1 alpha (mGlu(1 alpha) receptor) and the adenosine Al receptors in cerebellum, primary cortical neurons, and heterologous transfected cells. Co-immunoprecipitation experiments showed a close and subtype-specific interaction between mGlu(1 alpha) and Al receptors in both rat cerebellar synaptosomes and co-transfected HEK-293 cells. By using transiently transfected HEK-293 cells a synergy between mGlu(1 alpha) and Al receptors in receptor-evoked [Ca2+](i) signaling has been shown. In primary cultures of cortical neurons we observed a high degree of co-localization of the two receptors, and excitotoxicity experiments in these cultures also indicate that mGlu(1 alpha) and Al receptors are functionally related. Our results provide a molecular basis for adenosine/glutamate receptors cross-talk and open new perspectives for the development of novel agents to treat neuropsychiatric disorders in which abnormal glutamatergic neurotransmission is involved.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England	University of Barcelona	Ciruela, F (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, C Marti & Franques 1, E-08028 Barcelona, Spain.		Canela, Enric I./M-8726-2013; Ciruela, F./A-5096-2013; Pueyo, Ester Angulo/D-2436-2019; Mallol, Josefa/I-4194-2015; Franco, Rafael/C-3694-2015; Casadó, Vicent/K-1660-2014	Canela, Enric I./0000-0003-4992-7440; Ciruela, F./0000-0003-0832-3739; Pueyo, Ester Angulo/0000-0001-7442-3450; Mallol, Josefa/0000-0002-2479-4162; Franco, Rafael/0000-0003-2549-4919; Casadó, Vicent/0000-0002-1764-3825; Soloviev, Mikhail/0000-0002-3235-1134				BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CASADO V, 1990, J NEUROSCI RES, V26, P461, DOI 10.1002/jnr.490260409; CASADO V, 1992, BIOCHEM J, V281, P477, DOI 10.1042/bj2810477; Ciruela F, 1999, FEBS LETT, V448, P91, DOI 10.1016/S0014-5793(99)00341-5; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Ciruela F, 1999, J NEUROCHEM, V72, P346, DOI 10.1046/j.1471-4159.1999.0720346.x; Ciruela F, 2000, MOL CELL NEUROSCI, V15, P36, DOI 10.1006/mcne.1999.0808; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; Gao ZH, 1999, BIOCHEM J, V338, P729, DOI 10.1042/0264-6021:3380729; GENAZZANI AA, 1994, BRAIN RES, V659, P10, DOI 10.1016/0006-8993(94)90857-5; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; GRANDES P, 1994, NEUROREPORT, V5, P2249, DOI 10.1097/00001756-199411000-00011; Herrero I, 1998, J BIOL CHEM, V273, P1951, DOI 10.1074/jbc.273.4.1951; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hunt CA, 1996, J NEUROSCI, V16, P1380; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382; Mirabet M, 1997, BRIT J PHARMACOL, V122, P1075, DOI 10.1038/sj.bjp.0701495; Mistry R, 1998, BRIT J PHARMACOL, V123, P581, DOI 10.1038/sj.bjp.0701626; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ochiishi T, 1999, J COMP NEUROL, V411, P301; OGATA T, 1994, NEUROSCI LETT, V170, P5, DOI 10.1016/0304-3940(94)90225-9; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; PHILLIS JW, 1981, PROG NEUROBIOL, V16, P187, DOI 10.1016/0301-0082(81)90014-9; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Rodriguez-Moreno A, 1998, NEURON, V21, P1477, DOI 10.1016/S0896-6273(00)80665-0; Schoepp DD, 1996, NEUROPHARMACOLOGY, V35, P1661, DOI 10.1016/S0028-3908(96)00121-9; Schubert P, 1997, ANN NY ACAD SCI, V825, P1, DOI 10.1111/j.1749-6632.1997.tb48409.x; Soloviev MM, 2000, J MOL BIOL, V295, P1185; Toms NJ, 1999, NEUROPHARMACOLOGY, V38, P1511, DOI 10.1016/S0028-3908(99)00090-8; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7	56	148	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18345	18351		10.1074/jbc.M006960200	http://dx.doi.org/10.1074/jbc.M006960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278325	hybrid, Green Published			2022-12-27	WOS:000168866500098
J	Liendo, A; Stedman, TT; Ngo, HM; Chaturvedi, S; Hoppe, HC; Joiner, KA				Liendo, A; Stedman, TT; Ngo, HM; Chaturvedi, S; Hoppe, HC; Joiner, KA			Toxoplasma gondii ADP-ribosylation factor 1 mediates enhanced release of constitutively secreted dense granule proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EXOCYTOSIS; MICRONEME DISCHARGE; ADAPTER COMPLEX; PLASMA-MEMBRANE; GTP; BINDING; AP-1; ARF1; ORGANELLES; COATOMER	Toxoplasma gondii dense granules are morphologically similar to dense matrix granules in specialized secretory cells, yet are secreted in a constitutive, calcium-independent fashion. We previously demonstrated that secretion of dense granule proteins in permeabilized parasites was augmented by the non-hydrolyzable GTP analogue guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) (Chaturvedi, S., Qi, H., Coleman, D. L., Hanson, P., Rodriguez, A., and Joiner, K. A (1998) J. Biol. Chem. 274, 2424-2431). As now demonstrated by pharmacological and electron microscopic approaches, GTP gammaS enhanced release of dense granule proteins in the permeabilized cell system. To investigate the role of ADP-ribosylation factor 1 (ARF1) in this process, a cDNA encoding T. gondii ARF1 (TgARF1) was isolated. Endogenous and transgenic TgARF1 localized to the Golgi of T. gondii, but not to dense granules. An epitope-tagged mutant of TgARF1 predicted to be impaired in GTP hydrolysis (Q71L) partially dispersed the Golgi signal, with localization to scattered vesicles, whereas a mutant impaired in nucleotide binding (T31N) was cytosolic in location. Both mutants caused partial dispersion of a Golgi/trans-Golgi network marker. TgARF1 mutants inhibited delivery of the secretory reporter, Escherichia coli alkaline phosphatase, to dense granules, precluding an in vivo assessment of the role of TgARF1 in release of intact dense granules. To circumvent this limitation, recombinant TgARF1 was purified using two separate approaches, and used in the permeabilized cell assay. TgARF1 protein purified on a Cibacron G3 column and able to bind GTP stimulated dense granule secretion in the permeabilized cell secretion assay. These results are the first to show that ARF1 can augment release of constitutively secreted vesicles at the target membrane.	Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis,LCI 808, New Haven, CT 06520 USA	Yale University	Joiner, KA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis,LCI 808, 333 Cedar St, New Haven, CT 06520 USA.	keith.joiner@yale.edu	Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X; Hoppe, Heinrich/0000-0003-4409-1955; Stedman, Timothy/0000-0002-5847-7931	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010044, R01AI030060, F32AI009938, T32AI007404] Funding Source: NIH RePORTER; NIAID NIH HHS [1F32-AI09938, 1F32-AI10044-01A1, R01-AI30060, T32-AI 07404-09, T32-AI07404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Austin C, 2000, J BIOL CHEM, V275, P21862, DOI 10.1074/jbc.M908875199; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chaturvedi S, 1999, J BIOL CHEM, V274, P2424, DOI 10.1074/jbc.274.4.2424; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; COPPENS I, 2001, EXPERT REV MOL MED; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; Dohke Y, 1998, ARCH BIOCHEM BIOPHYS, V357, P147, DOI 10.1006/abbi.1998.0793; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fucini RV, 2000, J BIOL CHEM, V275, P18824, DOI 10.1074/jbc.M000024200; Glenn DE, 1998, J NEUROCHEM, V71, P2023; Hager KM, 1999, J CELL SCI, V112, P2631; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Hoppe HC, 2000, CELL MICROBIOL, V2, P569, DOI 10.1046/j.1462-5822.2000.00081.x; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Newman TM, 1996, EUR J CELL BIOL, V70, P209; Ngo HM, 2000, TRENDS CELL BIOL, V10, P67, DOI 10.1016/S0962-8924(99)01698-0; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stedman TT, 1999, ADV CELL MOL BIOL ME, V6, P233, DOI 10.1016/S1874-5172(99)80014-5; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; Turner MD, 2000, J BIOL CHEM, V275, P14025, DOI 10.1074/jbc.275.19.14025; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	44	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18272	18281		10.1074/jbc.M008352200	http://dx.doi.org/10.1074/jbc.M008352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278405	hybrid			2022-12-27	WOS:000168866500089
J	Fukumoto, S; Hsieh, CM; Maemura, K; Layne, RD; Yet, SF; Lee, KH; Matsui, T; Rosenzweig, A; Taylor, WG; Rubin, JS; Perrella, MA; Lee, ME				Fukumoto, S; Hsieh, CM; Maemura, K; Layne, RD; Yet, SF; Lee, KH; Matsui, T; Rosenzweig, A; Taylor, WG; Rubin, JS; Perrella, MA; Lee, ME			Akt participation in the Wnt signaling pathway through dishevelled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN STABILITY; PROTEIN-KINASE-B; PC12 CELLS; CYCLIN D1; GENE; ACTIVATION; EXPRESSION; WINGLESS; AXIN	Inactivation of glycogen synthase kinase 3 beta (GSKS beta) and the resulting stabilization of free beta -catenin are critical steps in the activation of Wnt target genes. While Akt regulates GSK3 alpha/beta in the phosphatidylinositide 3-OH kinase signaling pathway, its role in Wnt signaling is unknown. Here we report that expression of Wnt or Dishevelled (Dvl) increased Akt activity. Activated Akt bound to the Axrin-GSK3 beta complex in the presence of Dvl, phosphorylated GSK3 beta and increased free beta -catenin levels. Furthermore, in Wnt-overexpressing PC12 cells, dominant-negative Akt decreased free beta -catenin and derepressed nerve growth factor-induced differentiation. Therefore, Akt acts in association with Dvl as an important regulator of the Wnt signaling pathway.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA; NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Perrella, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pulm, 75 Francis St,Thorn Bldg,Rm TH1133, Boston, MA 02115 USA.		Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL57977, HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057977, R01HL060788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Issack PS, 1998, CELL GROWTH DIFFER, V9, P837; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mao C, 2000, ARTERIOSCL THROM VAS, V20, P43, DOI 10.1161/01.ATV.20.1.43; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Rezvani M, 2000, J BIOL CHEM, V275, P18470, DOI 10.1074/jbc.M000870200; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	35	294	306	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17479	17483		10.1074/jbc.C000880200	http://dx.doi.org/10.1074/jbc.C000880200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278246	hybrid			2022-12-27	WOS:000168730400119
J	Cafferata, EGA; Guerrico, AMG; Pivetta, OH; Santa-Coloma, TA				Cafferata, EGA; Guerrico, AMG; Pivetta, OH; Santa-Coloma, TA			NF-kappa B activation is involved in regulation of cystic fibrosis transmembrane conductance regulator (CFTR) by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GENE-EXPRESSION; EPITHELIAL-CELLS; DITHIOCARBAMATE; IDENTIFICATION; INHIBITION; DISEASE; DNA	Interleukin-1 beta (IL-1 beta) regulates the levels of cystic fibrosis transmembrane conductance regulator (CFTR) mRNA and protein in the T84 human carcinoma cell line. Here, we studied the role of the transcription factor NF-kappaB in this regulation. Initially, T84 cells were pretreated with the NF-kappaB inhibitor pyrrolidine dithiocarbamate, Cells were then stimulated with IL-1 beta, and CFTR mRNA levels were determined after 4 h by Northern blot analysis. As a result of PDTC treatment, IL-1 beta stimulation of CFTR mRNA was blocked, On the other hand, daunorubicin, an NF-kappaB activator, increased the steady-state levels of CFTR mRNA, Furthermore, after treatment with IL-1 beta for 1 h, cytoplasmic I kappaB alpha degradation occurred simultaneously with translocation of p65 into the nucleus, The T84 cells were also transduced with an adenoviral vector expressing a dominant negative form of I kappaB alpha, which prevents I kappaB alpha phosphorylation and the subsequent nuclear translocation of NF-kappaB, After viral transduction, the cells were stimulated with IL-1 beta for 4 h, and CFTR mRNA levels were measured by Northern blot analysis. The stimulation of CFTR, induced by IL-1 beta, was also blocked in the presence of the dominant negative mutant. These results indicate that NF-kappaB is involved in the pathway by which IL-1 beta regulates CFTR.	UBA, IIB, Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; CONICET, IIBBA, Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; ANLIS, Ctr Nacl Genet Med, RA-1405 Buenos Aires, DF, Argentina	Leloir Institute; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute	Santa-Coloma, TA (corresponding author), UBA, IIB, Fdn Campomar, Inst Invest Bioquim, 435 Patricias Argentinas, RA-1405 Buenos Aires, DF, Argentina.		Santa-Coloma, Tomas/I-1254-2019	Santa-Coloma, Tomas/0000-0002-3266-1095; Cafferata, Eduardo G/0000-0001-5089-3757				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; Cafferata EG, 1996, CELL MOL BIOL, V42, P797; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; Jobin C, 1998, J IMMUNOL, V160, P410; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; RIORDAN JR, 1989, SCIENCE, V245, P1066; Watanabe K, 1999, CELL SIGNAL, V11, P371, DOI 10.1016/S0898-6568(99)00022-4	14	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15441	15444		10.1074/jbc.M010061200	http://dx.doi.org/10.1074/jbc.M010061200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278608	hybrid, Green Published			2022-12-27	WOS:000168528800120
J	Huang, NK; Lin, YW; Huang, CL; Messing, RO; Chern, YJ				Huang, NK; Lin, YW; Huang, CL; Messing, RO; Chern, YJ			Activation of protein kinase A and atypical protein kinase C by A(2A) adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CYCLIC-AMP; PHOSPHATIDYLINOSITOL 3-KINASE; SYMPATHETIC NEURONS; GENE-EXPRESSION; PHOSPHATASE 2A; VI ACTIVITY; PKC-ZETA; SURVIVAL; RAT	We found in the present study that stimulation of A(2A) adenosine receptors (A(2A)-R) prevents apoptosis in PC12 cells. This A(2A)-protective effect was blocked by protein kinase A (PKA) inhibitors and was not observed in a PKA deficient PC12 variant. Stimulation of PKA also prevented apoptosis, suggesting that PKA is required for the protective effect of A(2A)-R. A general PKC inhibitor, but not down-regulation of conventional and novel PKCs, readily blocked the protective effect of A(2A)-R stimulation and PKA activation, suggesting that atypical PKCs (aPKCs) serve a critical role downstream of PKA Consistent with this hypothesis, stimulation of A(2A)-R or PRA enhanced nuclear aPKC activity. In addition, the A(2A)-protective effect was blocked by a specific inhibitor of one aPKC, PKC zeta, whereas overexpression of a dominant-positive PKC zeta enhanced survival. In contrast, inhibitors of MAP kinase and phosphatidylinositol 3-kinase did not modulate the A(2A)-protective effect. Dominant-negative Akt also did not alter the A(2A)-protective effect, whereas it significantly reduced the protective action of nerve growth factor. Collectively, these data suggest that aPKCs can function downstream of PKA to mediate the A(2A)-R-promoted survival of PC12 cells. Furthermore, the results indicate that different extracellular stimuli can employ distinct signaling pathways to protect against apoptosis induced by the same insult.	Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 11529, Taiwan; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94608 USA; Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA	Academia Sinica - Taiwan; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 11529, Taiwan.		chern, yijuang/S-7013-2018; Messing, Robert/D-3642-2015	chern, yijuang/0000-0002-5842-5429; Messing, Robert/0000-0002-5345-4431				Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; CHERN YJ, 1995, MOL PHARMACOL, V48, P1; CHERN YJ, 1992, BIOCHEM BIOPH RES CO, V185, P304, DOI 10.1016/S0006-291X(05)90000-4; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chu YY, 1996, DNA CELL BIOL, V15, P329, DOI 10.1089/dna.1996.15.329; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Crowder RJ, 1999, J NEUROCHEM, V73, P466, DOI 10.1046/j.1471-4159.1999.0730466.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; Dixon AK, 1996, BRIT J PHARMACOL, V118, P1461, DOI 10.1111/j.1476-5381.1996.tb15561.x; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; Francois F, 1999, J NEUROCHEM, V73, P1773, DOI 10.1046/j.1471-4159.1999.731773.x; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kobayashi S, 1999, J BIOL CHEM, V274, P20358, DOI 10.1074/jbc.274.29.20358; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lambeng N, 1999, BRAIN RES, V821, P60, DOI 10.1016/S0006-8993(99)01061-6; Li YS, 1996, MOL CELL BIOL, V16, P5947; Liu HL, 1997, J BIOL CHEM, V272, P6038, DOI 10.1074/jbc.272.9.6038; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; Richardson PJ, 1997, TRENDS PHARMACOL SCI, V18, P338, DOI 10.1016/S0165-6147(97)01096-1; Rosin DL, 1998, J COMP NEUROL, V401, P163; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Taylor SC, 2000, J BIOL CHEM, V275, P26786; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Walker BAM, 1997, J IMMUNOL, V158, P2926; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Wooten MW, 1996, J NEUROCHEM, V67, P1023; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU G, 1997, J BIOL CHEM, V272, P3110	48	83	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13838	13846		10.1074/jbc.M008589200	http://dx.doi.org/10.1074/jbc.M008589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278423	hybrid			2022-12-27	WOS:000168356600048
J	Matveeva, EA; Whiteheart, SW; Vanaman, TC; Slevin, JT				Matveeva, EA; Whiteheart, SW; Vanaman, TC; Slevin, JT			Phosphorylation of the N-ethylmaleimide-sensitive factor is associated with depolarization-dependent neurotransmitter release from synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; RAT HIPPOCAMPAL SLICES; SYNAPTIC VESICLE DOCKING; FUSION PROTEIN; GLUTAMATE RELEASE; SNARE COMPLEX; ALPHA-SNAP; MEMBRANE-FUSION; IN-VITRO	Critical to SNARE protein function in neurotransmission are the accessory proteins, soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein (SNAP), and NSF, that play a role in activation of the SNAREs for membrane fusion. In this report, we demonstrate the depolarization-induced, calcium-dependent phosphorylation of NSF in rat synaptosomes, Phosphorylation of NSF is coincident with neurotransmitter release and requires an influx of external calcium. Phosphoamino acid analysis of the radiolabeled NSF indicates a role for a serine/threonine-specific kinase. Synaptosomal phosphorylation of NSF is stimulated by phorbol esters and is inhibited by staurosporine, chelerythrine, bisindolylmaleimide I, calphostin C, and Ro31-8220 but not the calmodulin kinase II inhibitor, Kn-93, suggesting a role for protein kinase C (PKC). Indeed, NSF is phosphorylated by PKC in vitro at Ser-237 of the catalytic D1 domain. Mutation of this residue to glutamic acid or to alanine eliminates in vitro phosphorylation. Molecular modeling studies suggest that Ser-237 is adjacent to an inter-subunit interface at a position where its phosphorylation could affect NSF activity. Consistently, mutation of Ser-237 to Glu, to mimic phosphorylation, results in a hexameric form of NSF that does not bind to SNAP-SNARE complexes, whereas the S237A mutant does form complex. These data suggest a negative regulatory role for PKC phosphorylation of NSF.	Dept Vet Affairs Med Ctr, Neurol Serv, Lexington, KY 40511 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Neurol & Pharmacol, Lexington, KY 40536 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky; University of Kentucky	Slevin, JT (corresponding author), Dept Vet Affairs Med Ctr, Neurol Serv, Lexington, KY 40511 USA.	jslevin@pop.uky.edu		Whiteheart, Sidney/0000-0001-5577-0473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021868] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56652] Funding Source: Medline; NINDS NIH HHS [NS21868] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA K, 1995, BRAIN RES, V679, P212, DOI 10.1016/0006-8993(95)00221-B; ANGENSTEIN F, 1994, NEUROREPORT, V5, P381; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHEN SJ, 1992, J NEUROCHEM, V59, P1761, DOI 10.1111/j.1471-4159.1992.tb11008.x; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DiLuca M, 1997, EUR J NEUROSCI, V9, P472, DOI 10.1111/j.1460-9568.1997.tb01624.x; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; DWYER LD, 1992, J BIOL CHEM, V267, P22606; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488; He P, 1999, J NEUROPHYSIOL, V82, P3406, DOI 10.1152/jn.1999.82.6.3406; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Hilfiker S, 1999, J NEUROCHEM, V73, P921, DOI 10.1046/j.1471-4159.1999.0730921.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; JARVIE PA, 1990, BRAIN RES, V508, P188, DOI 10.1016/0006-8993(90)90395-R; KOHIRA I, 1992, BRAIN RES, V593, P82, DOI 10.1016/0006-8993(92)91267-I; LEAHY JC, 1993, NEUROSCIENCE, V52, P563, DOI 10.1016/0306-4522(93)90406-6; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Lonart G, 2000, J BIOL CHEM, V275, P27703; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; MALENKA RC, 1987, BRAIN RES, V403, P198, DOI 10.1016/0006-8993(87)90145-4; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; OSONOE K, 1994, EPILEPSIA, V35, P850, DOI 10.1111/j.1528-1157.1994.tb02522.x; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sanyal S, 1999, J NEUROSCI, V19, part. no., DOI 10.1523/JNEUROSCI.19-24-j0005.1999; Schweizer FE, 1998, SCIENCE, V279, P1203, DOI 10.1126/science.279.5354.1203; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Son H, 1996, BRAIN RES, V739, P282, DOI 10.1016/S0006-8993(96)00836-0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swanton E, 1998, MOL BIOL CELL, V9, P1633, DOI 10.1091/mbc.9.7.1633; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Tagaya M, 1996, FEBS LETT, V394, P83, DOI 10.1016/0014-5793(96)00932-5; Terrian D M, 1991, Hippocampus, V1, P303, DOI 10.1002/hipo.450010321; TERRIAN DM, 1995, J NEUROCHEM, V64, P181; Tolar LA, 1998, J NEUROSCI, V18, P10250; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Verona M, 2000, J NEUROCHEM, V74, P209, DOI 10.1046/j.1471-4159.2000.0740209.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; YAMAGATA Y, 1995, NEUROSCIENCE, V64, P1, DOI 10.1016/0306-4522(94)00492-N	69	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12174	12181		10.1074/jbc.M007394200	http://dx.doi.org/10.1074/jbc.M007394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278345	hybrid			2022-12-27	WOS:000168081800100
J	Wei, WX; Dorjsuren, D; Lin, Y; Qin, WP; Nomura, T; Hayashi, N; Murakami, S				Wei, WX; Dorjsuren, D; Lin, Y; Qin, WP; Nomura, T; Hayashi, N; Murakami, S			Direct interaction between the subunit RAP30 of transcription factor IIF (TFIIF) and RNA polymerase subunit 5, which contributes to the association between TFIIF and RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X-PROTEIN; ACTIVATED TRANSCRIPTION; PREINITIATION COMPLEX; INITIATION-FACTOR; BINDING; DNA; TRANSACTIVATION; DOMAIN; PURIFICATION; RPB5	The general transcription factor IIF (TFIIF) assembled in the initiation complex, and RAP30 of TFIIF, have been shown to associate with RNA polymerase II (pol II), although it remains unclear which pol II subunit is responsible for the interaction. We examined whether TFIIF interacts with RNA polymerase II subunit 5 (RPB5), the exposed domain of which binds transcriptional regulatory factors such as hepatitis B virus X protein and a novel regulatory protein, RPB5-mediating protein. The results demonstrated that RPB5 directly binds RAP30 in vitro using purified recombinant proteins and in vivo in COS1 cells transiently expressing recombinant RAP30 and RPB5. The RAP30-binding region was mapped to the central region (amino acids (aa) 47-120) of RPB5, which partly overlaps the hepatitis B virus X protein-binding region. Although the middle part (aa 101-170) and the N-terninus (aa 1-100) of RAP30 independently bound RPB5, the latter was not involved in the RPB5 binding when RAP30 was present in TFIIF complex. Scanning of the middle part of RAP30 by clustered alanine substitutions and then point alanine substitutions pinpointed two residues critical for the RPB5 binding in in vitro and in vivo assays. Wild type hut not mutants Y124A and Q131A of RAP30 coexpressed with FLAG-RAP74 efficiently recovered endogenous RPB5 to the FLAG-RAP74-bound anti-FLAG M2 resin. The recovered endogenous RPB5 is assembled in pol II as demonstrated immunologically. Interestingly, coexpression of the central region of RPB5 and wild type RAP30 inhibited recovery of endogenous pol II to the FLAG-RAP74-bound M2 resin, strongly suggesting that the RAP30-binding region of RPB5 inhibited the association of TFIIF and pol II. The exposed domain of RPB5 interacts with RAP30 of TFIIF and is important for the association between pol II and TFIIF.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, Takaramachi 13-1, Kanazawa, Ishikawa 9200934, Japan.			Hayashi, Naoyuki/0000-0001-9626-3689				CHANG CH, 1993, J BIOL CHEM, V268, P20482; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; INOSTROZA JA, 1992, CELL, V70, P477; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1997, CANCER RES, V57, P5137; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Ren DL, 1999, MOL CELL BIOL, V19, P7377; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; Tan Q, 2000, GENE DEV, V14, P339; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; Todone F, 2000, P NATL ACAD SCI USA, V97, P6306, DOI 10.1073/pnas.97.12.6306; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273	48	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12266	12273		10.1074/jbc.M009634200	http://dx.doi.org/10.1074/jbc.M009634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278533	hybrid			2022-12-27	WOS:000168081800111
J	Lee, A; Morrow, JS; Fowler, VM				Lee, A; Morrow, JS; Fowler, VM			Caspase remodeling of the spectrin membrane skeleton during lens development and aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; BETA-II-SPECTRIN; CHICK LENS; SURFACE-MORPHOLOGY; LIGHT-SCATTERING; PLASMA-MEMBRANE; APOPTOTIC CELLS; BRAIN SPECTRIN; ALPHA-SPECTRIN; CALPAIN	Terminal differentiation of lens fiber cells resembles the apoptotic process in that organelles are lost, DNA is fragmented, and changes in membrane morphology occur. However, unlike classically apoptotic cells, which are disintegrated by membrane blebbing and vesiculation, aging lens fiber cells are compressed into the center of the lens, where they undergo cell-cell fusion and the formation of specialized membrane interdigitations. In classically apoptotic cells, caspase cleavage of the cytoskeletal protein alpha -spectrin to similar to 150-kDa fragments is believed to be important for membrane blebbing, We report that caspase(s) cleave alpha -spectrin to similar to 150-kDa fragments and beta -spectrin to similar to 120- and similar to 80-kDa fragments during late embryonic chick lens development. These fragments continue to accumulate with age so that in the oldest fiber cells of the adult lens, most, if not all, of the spectrin is cleaved to discrete fragments. Thus, unlike classical apoptosis, where caspase-cleaved spectrin is short lived, lens fiber cells contain spectrin fragments that appear to be stable for the lifetime of the organism. Moreover, fragmentation of spectrin results in reduced membrane association and thus may lead to permanent remodeling of the membrane skeleton. Partial and specific proteolysis of membrane skeleton components by caspases may be important for age-related membrane changes in the lens.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Scripps Research Institute; Yale University	Fowler, VM (corresponding author), Scripps Res Inst, Dept Cell Biol, MB24,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL EYE INSTITUTE [R01EY010814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS032578] Funding Source: NIH RePORTER; NEI NIH HHS [EY10814] Funding Source: Medline; NIDDK NIH HHS [DK43812] Funding Source: Medline; NINDS NIH HHS [NS32578] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		al-Ghoul K J, 1997, Mol Vis, V3, P2; Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERTHOUD VM, 1994, INVEST OPHTH VIS SCI, V35, P4109; Boyle DL, 1998, CURR EYE RES, V17, P1118, DOI 10.1076/ceyr.17.12.1118.5130; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; DISTASI AMM, 1991, NEURON, V6, P445, DOI 10.1016/0896-6273(91)90252-U; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1992, J CELL BIOL, V119, P1559, DOI 10.1083/jcb.119.6.1559; FOX JEB, 1987, BLOOD, V69, P537; Fukiage C, 1998, CURR EYE RES, V17, P623, DOI 10.1080/02713689808951235; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; GLANTZ S, 1995, TISSUE OXYGEN DEPRIV, P153; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JAFFE N, 1992, LENS CATARACT TXB OP, V3; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kilic F, 1998, BIOCHEM MOL BIOL INT, V45, P963; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUSZAK J, 1980, AM J ANAT, V159, P395, DOI 10.1002/aja.1001590406; Kuszak JR, 1996, MICROSC RES TECHNIQ, V33, P441, DOI 10.1002/(SICI)1097-0029(19960415)33:6<441::AID-JEMT1>3.0.CO;2-O; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; Lee A, 2000, DEV DYNAM, V217, P257, DOI 10.1002/(SICI)1097-0177(200003)217:3<257::AID-DVDY4>3.0.CO;2-5; Lin JS, 1997, EUR J CELL BIOL, V73, P141; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; MORROW JS, 1997, HDB PHYSIOL 14, P485; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NELSON WJ, 1983, J CELL BIOL, V97, P1271, DOI 10.1083/jcb.97.4.1271; PATEK C, 1994, INT J DEV BIOL, V38, P717; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G; Rafferty N. S., 1985, OCULAR LENS STRUCTUR, P1; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; SANDILANDS A, 1995, EUR J CELL BIOL, V67, P238; Shestopalov VI, 2000, J CELL SCI, V113, P1913; Shestopalov VI, 2000, INVEST OPHTH VIS SCI, V41, P859; SPEICHER DW, 1982, J CELL BIOCHEM, V18, P479, DOI 10.1002/jcb.1982.240180409; STIRLING RJ, 1987, J ANAT, V155, P11; SUN ST, 1984, P NATL ACAD SCI-BIOL, V81, P785, DOI 10.1073/pnas.81.3.785; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375	59	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20735	20742		10.1074/jbc.M009723200	http://dx.doi.org/10.1074/jbc.M009723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278555	hybrid			2022-12-27	WOS:000169135100141
J	Piwien-Pilipuk, G; Van Mater, D; Ross, SE; MacDougald, OA; Schwartz, J				Piwien-Pilipuk, G; Van Mater, D; Ross, SE; MacDougald, OA; Schwartz, J			Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein beta by modulating Akt and glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; SERUM RESPONSE ELEMENT; C-FOS; TYROSINE PHOSPHORYLATION; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; ADIPOCYTE DIFFERENTIATION; SIGNAL-TRANSDUCTION; MOLECULAR MECHANISM	Growth hormone (GH) regulates transcription factors associated with c-fos, including C/EBP beta, Two forms of C/EBP beta, liver-activating protein (LAP) and liver inhibitory protein (LIP), are dephosphorylated in GH-treated 3T3-F442A fibroblasts. GH-induced dephosphorylation of LAP and LIP is reduced when cells are preincubated with phosphatidylinositol 3 ' -kinase (PI3K) inhibitors. GH activates Akt and inhibits glycogen synthase kinase-3 (GSK-3). Lithium, a GSK-3 inhibitor, increases GH-dependent dephosphorylation of LAP and LIP. Both are in vitro substrates of GSK-3, suggesting that GSK-3 inactivation contributes to GH-promoted dephosphorylation of C/EBP beta. Alkaline phosphatase increases binding of LAP homodimers and decreases binding of LIP homodimers to c-fos, suggesting that dephosphorylation of C/EBP beta modifies their ability to bind DNA. Both alkaline phosphatase- and GH-mediated dephosphorylation comparably increase binding of endogenous LAP in 3T3-F442A cells. In cells overexpressing LAP and GSK-3, LAP binding decreases, suggesting that GSK-3-mediated phosphorylation interferes with LAP binding. Expression of constitutively active GSK-3 reduced GH-stimulated c-fos promoter activity. These studies indicate that PI3K/Akt/GSK-3 mediates signaling between GH receptor and the nucleus, promoting dephosphorylation of C/EBP beta. Dephosphorylation increases binding of LAP complexes to the c-fos promoter and may contribute to the participation of C/EBP beta in GH-stimulated c-fos expression.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schwartz, J (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.			MacDougald, Ormond/0000-0001-6907-7960	NIDDK NIH HHS [DK51563, DK46072] Funding Source: Medline; NIGMS NIH HHS [GM07863] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563, R01DK046072] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BILLESTRUP N, 1994, P SOC EXP BIOL MED, V206, P205; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DEGROOT RP, 1993, ONCOGENE, V8, P841; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DOGLIO A, 1987, EMBO J, V6, P4011, DOI 10.1002/j.1460-2075.1987.tb02744.x; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; Ross SE, 1999, MOL CELL BIOL, V19, P8433; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; SMIT LS, 1999, HDB PHYSL, V5, P445; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	61	92	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19664	19671		10.1074/jbc.M010193200	http://dx.doi.org/10.1074/jbc.M010193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278638	hybrid			2022-12-27	WOS:000169091000133
J	Ten Hagen, KG; Bedi, GS; Tetaert, D; Kingsley, PD; Hagen, FK; Balys, MM; Beres, TM; Degand, P; Tabak, LA				Ten Hagen, KG; Bedi, GS; Tetaert, D; Kingsley, PD; Hagen, FK; Balys, MM; Beres, TM; Degand, P; Tabak, LA			Cloning and characterization of a ninth member of the UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase family, ppGaNTase-T9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; ALPHA-D-GALACTOSAMINE; O-LINKED GLYCOSYLATION; CDNA CLONING; TANDEM REPEAT; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; EXPRESSION; MUCIN; SITE	We have cloned, expressed and characterized the gene encoding a ninth member of the mammalian UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (ppGaNTase) family, termed ppGaNTase-T9. This type II membrane protein consists of a 9-amino acid N-terminal cytoplasmic region, a 20-amino acid hydrophobic/transmembrane region, a 94-amino acid stem region, and a 480-amino acid conserved region. Northern blot analysis revealed that the gene encoding this enzyme is expressed in a broadly distributed manner across many adult tissues. Significant levels of 5- and 4.2-kilobase transcripts were found in rat sublingual gland, testis, small intestine, colon, and ovary, with lesser amounts in heart, brain, spleen, lung, stomach, cervix, and uterus. In situ hybridization to mouse embryos (embryonic day 14.5) revealed significant hybridization in the developing mandible, maxilla, intestine, and mesencephalic ventricle. Constructs expressing this gene transiently in COS7 cells resulted in no detectable transferase activity in vitro against a panel of unmodified peptides, including MUC5AC (GTTPSPVPTTSTTSAP) and E6A2 (PTTDSTTPAPTTK). However, when incubated with MUC5AC and EA2 glycopeptides (obtained by the prior action of ppGaNTase-T1), additional incorporation of GalNAc was achieved, resulting in new hydroxyamino acid modification. The activity of this glycopeptide transferase is distinguished from that of ppGaNTase-T7 in that it forms a tetra-glycopeptide species from the MUC5AC tri-glycopeptide substrate, whereas ppGaNTase-T7 forms a hexa-glycopeptide species. This isoform thus represents the second example of a glycopeptide transferase and is distinct from the previously identified form in enzymatic activity as well as expression in embryonic and adult tissues. These findings lend further support to the existence of a hierarchical network of differential enzymatic activity within the diversely regulated ppGaNTase family, which may play a role in the various processes governing development.	Univ Rochester, Aab Inst Biomed Sci, Ctr Oral Biol, Rochester, NY 14627 USA; INSERM, Unite 377, F-59045 Lille, France	University of Rochester; Institut National de la Sante et de la Recherche Medicale (Inserm)	Tabak, LA (corresponding author), NIDCR, NIH, 31 Ctr Dr,MSC 2290,Bldg 31,Rm 2C39, Bethesda, MD 20892 USA.	lawrence.tabak@nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008108, R37DE008108] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08108] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; Allen A, 1998, INT J BIOCHEM CELL B, V30, P797, DOI 10.1016/S1357-2725(98)00028-4; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GERKEN TA, 1997, TECHNIQUES GLYCOBIOL, P247; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hennet T, 1999, BBA-GEN SUBJECTS, V1473, P123, DOI 10.1016/S0304-4165(99)00173-7; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Kingsley PD, 2000, GLYCOBIOLOGY, V10, P1317, DOI 10.1093/glycob/10.12.1317; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; Marinaro JA, 2000, EUR J BIOCHEM, V267, P5378, DOI 10.1046/j.1432-1327.2000.01575.x; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; Moore DD, 1995, GLOB MOB SURV; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Rottger S, 1998, J CELL SCI, V111, P45; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WOODWARD HD, 1987, BIOCHEMISTRY-US, V26, P5315, DOI 10.1021/bi00391a015; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	39	83	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17395	17404		10.1074/jbc.M009638200	http://dx.doi.org/10.1074/jbc.M009638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278534	hybrid			2022-12-27	WOS:000168730400107
J	Cong, M; Perry, SJ; Lin, FT; Fraser, ID; Hu, LYA; Chen, W; Pitcher, JA; Scott, JD; Lefkowitz, RJ				Cong, M; Perry, SJ; Lin, FT; Fraser, ID; Hu, LYA; Chen, W; Pitcher, JA; Scott, JD; Lefkowitz, RJ			Regulation of membrane targeting of the G protein-coupled receptor kinase 2 by protein kinase A and its anchoring protein AKAP79	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; GAMMA-SUBUNITS; AGONIST OCCUPANCY; SIGNALING ENZYMES; CALCIUM CHANNELS; BINDING-SITE; PHOSPHORYLATION; DESENSITIZATION; SPECIFICITY; SCAFFOLD	The beta2 adrenergic receptor (beta 2AR) undergoes desensitization by a process involving its phosphorylation by both protein kinase A (PKA) and G protein-coupled receptor kinases (GRKs). The protein kinase A-anchoring protein AKAP79 influences beta 2AR phosphorylation by complexing PKA with the receptor at the membrane. Here we show that AMAP79 also regulates the ability of GRK2 to phosphorylate agonist-occupied receptors. In human embryonic kidney 293 cells, overexpression of AKAP79 enhances agonist-induced phosphorylation of both the beta 2AR and a mutant of the receptor that cannot be phosphorylated by PKA (beta 2AR/PKA-). Mutants of AKAP79 that do not bind PKA or target to the beta 2AR markedly inhibit phosphorylation of beta 2AR/PKA-. We show that PKA directly phosphorylates GRK2 on serine 685. This modification increases G beta gamma subunit binding to GRK2 and thus enhances the ability of the kinase to translocate to the membrane and phosphorylate the receptor. Abrogation of the phosphorylation of serine 685 on GRK2 by mutagenesis (S685A) or by expression of a dominant negative AKAP79 mutant reduces GRK2-mediated translocation to beta 2AR and phosphorylation of agonist-occupied beta 2AR, thus reducing subsequent receptor internalization. Agonist-stimulated PKA-mediated phosphorylation of GRK2 may represent a mechanism for enhancing receptor phosphorylation and desensitization.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Oregon Health & Science University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Fraser, Iain DC/L-4735-2017; Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Fraser, Iain DC/0000-0003-2272-3907; Chen, Wei/0000-0002-9934-4000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [GM48231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; CARR DW, 1992, J BIOL CHEM, V267, P16816; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Haske TN, 1996, J BIOL CHEM, V271, P2941, DOI 10.1074/jbc.271.6.2941; Hisatomi O, 1998, FEBS LETT, V424, P159, DOI 10.1016/S0014-5793(98)00162-8; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KIM CM, 1993, RECEPTOR, V3, P39; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SIMON JR, 1991, MICRON MICROSC ACTA, V22, P405, DOI 10.1016/0739-6260(91)90058-8; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Weiss E R, 1998, Mol Vis, V4, P27; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	54	129	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15192	15199		10.1074/jbc.M009130200	http://dx.doi.org/10.1074/jbc.M009130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278469	hybrid, Green Accepted			2022-12-27	WOS:000168528800089
J	Jin, TR; Li, HQ				Jin, TR; Li, HQ			POU homeodomain protein OCT1 is implicated in the expression of the caudal-related homeobox gene Cdx-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTAMER TRANSCRIPTION FACTORS; GLUCOCORTICOID RECEPTOR; INTESTINAL EPITHELIUM; COLORECTAL-CANCER; B-CELL; BINDING; DNA; ACTIVATION; PROMOTER; DOMAIN	The caudal homeobox gene Cdx-2 is a transcriptional activator for approximately a dozen genes specifically expressed in pancreatic islets and intestinal cells. It is also involved in preventing the development of colorectal tumors. Studies using "knockout" approaches demonstrated that Cdx-2 is haplo-insufficient in certain tissues including the intestines but not the pancreatic islets, The mechanisms, especially transcription factors, which regulate Cdx-2 expression, are virtually unknown. We found previously that Cdx-2 expression could be autoregulated in a cell type-specific manner. In this study, we located an octamer (OCT) binding site within the mouse Cdx-2 gene promoter, This site, designated as Cdx-2(P)OCT, is involved in the expression of the Cdx-2 promoter. Both pancreatic and intestinal cell lines were found to express a number of POU (OCT binding) homeodomain proteins examined by electrophoretic mobility shift assay. However, it appears that Cdx-2(P)OCT interacts only with OCT1 in the nuclear extracts of the intestinal cell lines examined, although it interacts with OCT1 and at least two other POU proteins that are to be identified in the pancreatic InR1-G9 cell nuclear extract. Co-transfecting OCT1 cDNA but not five other POU gene cDNAs activates the Cdx-2 promoter in the pancreatic InR1-G9 and the intestinal Caco-2 cell lines. In contrast, Cdx-2(P)OCT cannot act as an enhancer element if it is fused to a thymidine kinase promoter. Furthermore, Cdx-2(P)OCT-thymidine kinase fusion promoters cannot be activated by OCT1 co-transfection, Cell type-specific expression, cell type-specific binding affinity of POU proteins to the cis-element Cdx-2(P)OCT, and the DNA content-dependent activation of Cdx-2 promoter via Cdx-2POCT by OCT1 suggest that POU proteins play important and complicated roles in modulating Cdx-2 expression in cell type-specific manners.	Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto	Jin, TR (corresponding author), Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Rm 421,67 Coll St, Toronto, ON M5G 2M1, Canada.							ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; Colnot S, 1998, J BIOL CHEM, V273, P31939, DOI 10.1074/jbc.273.48.31939; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HE, 1995, AM J PHYSIOL, V273, pG3; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Graef IA, 1997, SCIENCE, V277, P193, DOI 10.1126/science.277.5323.193; Grenfell SJ, 1996, BIOCHEM J, V315, P889, DOI 10.1042/bj3150889; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; JIN T, 1995, MOL ENDOCRINOL, V9, P1306, DOI 10.1210/me.9.10.1306; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Jin TR, 1996, MOL CELL BIOL, V16, P19; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Song CS, 1998, J BIOL CHEM, V273, P21856, DOI 10.1074/jbc.273.34.21856; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TAKEDA J, 1992, NUCLEIC ACIDS RES, V20, P4613, DOI 10.1093/nar/20.17.4613; Tamai Y, 1999, CANCER RES, V59, P2965; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Xu FH, 1999, J BIOL CHEM, V274, P34310, DOI 10.1074/jbc.274.48.34310; Yamamoto H, 1999, J BONE MINER RES, V14, P240, DOI 10.1359/jbmr.1999.14.2.240; Zhang HQ, 1999, CELL GROWTH DIFFER, V10, P457	46	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14752	14758		10.1074/jbc.M008277200	http://dx.doi.org/10.1074/jbc.M008277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278400	hybrid			2022-12-27	WOS:000168528800031
J	Wu, J; Parkhurst, KM; Powell, RM; Brenowitz, M; Parkhurst, LJ				Wu, J; Parkhurst, KM; Powell, RM; Brenowitz, M; Parkhurst, LJ			DNA bends in TATA-binding protein center dot TATA complexes in solution are DNA sequence-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; DISTANCE DISTRIBUTION; ENERGY-TRANSFER; FACTOR-IIB; BOX; TRANSCRIPTION; PROMOTER; ELEMENT	The TATA-binding protein (TBP) initiates assembly of transcription preinitiation complexes on eukaryotic class II promoters, binding to and restructuring consensus and variant "TATA box" sequences. The sequence dependence of the DNA structure in TBP TATA complexes has been investigated in solution using fluorescence resonance energy transfer. The mean 5'dye-3'dye distance varies significantly among oligomers bearing the adenovirus major late promoter sequence (AdMLP) and five single-site variants bound to Saccharomyces cerevisiae TBP, consistent with solution bend angles for AdMLP of 76 degrees and for the variants ranging from 30 degrees to 62 degrees, These solution bends contrast sharply with the corresponding co-crystal structures, which show similar to 80 degrees bends for all sequences. Transcription activities for these TATA sequences are strongly correlated with the solution bend angles but not with TBP.DNA binding affinities, Our results support a model in which transcription efficiency derives primarily from the sequence-dependent structure of the TBP.TATA binary complex, Specifically, the distance distribution for the average solution structure of the TBP.TATA complex may reflect the sequence-dependent probability for the complex to assume a conformation in which the TATA box DNA is severely bent. Upon assumption of this geometry, the binary complex becomes a target for binding and correctly orienting the other components of the preinitiation complex.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	University of Nebraska System; University of Nebraska Lincoln; Yeshiva University; Albert Einstein College of Medicine	Parkhurst, LJ (corresponding author), Univ Nebraska, Dept Chem, 525 Hamilton Hall, Lincoln, NE 68588 USA.				NCI NIH HHS [CA76049] Funding Source: Medline; NIGMS NIH HHS [GM59346, GM39929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039929, R01GM059346, R29GM039929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; BUCCI E, 1988, BIOPHYS CHEM, V30, P199, DOI 10.1016/0301-4622(88)85017-8; CANTOR CR, 1971, P NATL ACAD SCI USA, V68, P2099, DOI 10.1073/pnas.68.9.2099; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; DURBIN J, 1951, BIOMETRIKA, V38, P159, DOI 10.1093/biomet/38.1-2.159; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.1093/biomet/37.3-4.409; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAMBURG M, 1974, BASIC STAT MODERN AP, P285; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Naimushin AN, 2000, BIOPHYS J, V78, P1498, DOI 10.1016/S0006-3495(00)76703-8; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Okonogi T, 1999, BIOPHYS J, V77, P3256, DOI 10.1016/S0006-3495(99)77157-2; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P293, DOI 10.1021/bi00001a036; PARKHURST LJ, 1994, P SOC PHOTO-OPT INS, V2137, P475, DOI 10.1117/12.182758; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STARR DB, 1995, J MOL BIOL, V250, P434; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200; Yang MS, 1996, BIOCHEMISTRY-US, V35, P7959, DOI 10.1021/bi952892z	35	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14614	14622		10.1074/jbc.M004402200	http://dx.doi.org/10.1074/jbc.M004402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278276	hybrid			2022-12-27	WOS:000168528800014
J	Watanabe, H; de Caestecker, MP; Yamada, Y				Watanabe, H; de Caestecker, MP; Yamada, Y			Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecangene expression in chondrogenic ATDC5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CHONDROCYTE DIFFERENTIATION; MICROMASS CULTURES; MESENCHYMAL CELLS; TUMOR-SUPPRESSOR; LINE ATDC5; IN-VITRO; RECEPTORS	In chondrogenesis, members of the transforming growth factor-beta (TGF-beta) superfamily play critical roles by inducing gene expression of cartilage-specific molecules. By using a chondrogenic cell line, ATDC5, we investigated the TGF-beta -mediated signaling pathways involved in expression of the aggrecan gene (Agc). At confluency, TGF-beta induced Age expression within 3 h, and cycloheximide blocked this induction, indicating that de novo protein synthesis is essential for this response. At this stage, TGF-beta induced rapid, transient phosphorylation of Smad2, extracellular signal-activated kinase 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (MAPK). Inhibition of the Smad pathways by transfection with a dominant negative Smad4 construct significantly reduced TGF-beta -induced Age expression, indicating that Smad signaling is essential for this response. Furthermore, an inhibitor of the ERK1/2 pathway, U0126, or inhibitors of the p38 MAPK pathway, SB203580 and SKF86002, repressed TGF-beta -induced Age expression in a dose-dependent manner, indicating that ERK1/2 or p38 MAPK activation is also required for TGF-beta -induced Agc expression in confluent ATDC5 cells. In differentiated ATDC5 cells, persistently high basal levels of ERK1/2 and p38 MAPK phosphorylation correlated with elevated basal Age expression, which was inhibited by incubation with inhibitors of these pathways. Whereas Smad2 was rapidly phosphorylated by TGF-beta and involved in the initial activation of Agc expression in confluent cells, Smad2 activation was not required for maintaining the high level of Age expression. Taken together, these results suggest an important role for transcriptional cross-talk between Smad and MAPK pathways in expression of early chondrocytic phenotypes and identify important changes in the regulation of Age expression following chondrocyte differentiation.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yamada, Y (corresponding author), NICDR, NIH, Bldg 30,Rm 405,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.							ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BERNIER SM, 1993, J BONE MINER RES, V8, P475; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; ChimalMonroy J, 1997, INT J DEV BIOL, V41, P91; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frey RS, 1997, CANCER RES, V57, P628; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; Grigoriadis AE, 1996, DIFFERENTIATION, V60, P299, DOI 10.1046/j.1432-0436.1996.6050299.x; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520-6408(1998)22:4&lt;301::AID-DVG1&gt;3.0.CO;2-A; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu Y, 1997, J BIOL CHEM, V272, P29880, DOI 10.1074/jbc.272.47.29880; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; POLIARD A, 1995, J CELL BIOL, V130, P1461, DOI 10.1083/jcb.130.6.1461; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schwartz NB, 1996, PERSPECT DEV NEUROBI, V3, P291; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takigawa M, 1997, ENDOCRINOLOGY, V138, P4390, DOI 10.1210/en.138.10.4390; Wallis GA, 1996, CURR BIOL, V6, P1577, DOI 10.1016/S0960-9822(02)70776-8; Wang LW, 1998, J BIOL CHEM, V273, P8522, DOI 10.1074/jbc.273.14.8522; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zanin MKB, 1999, ANAT RECORD, V256, P366; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	62	250	261	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14466	14473		10.1074/jbc.M005724200	http://dx.doi.org/10.1074/jbc.M005724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278290	hybrid			2022-12-27	WOS:000168356600126
J	Russell, RL; Cao, DL; Zhang, DK; Handschumacher, RE; Pizzorno, G				Russell, RL; Cao, DL; Zhang, DK; Handschumacher, RE; Pizzorno, G			Uridine phosphorylase association with vimentin - Intracellular distribution and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; MICE LACKING VIMENTIN; PYRIMIDINE NUCLEOSIDES; 5-FLUOROURACIL THERAPY; MOLECULAR-PROPERTIES; CIRCULATING URIDINE; URACIL NUCLEOTIDES; HUMAN NEUTROPHILS; LIVING CELLS; RAT-LIVER	Uridine phosphorylase (UPase), a key enzyme in the pyrimidine salvage pathway, is associated with the intermediate filament protein vimentin, in NIH 3T3 fibroblasts and colon 26 cells. Affinity chromatography was utilized to purify UPase from colon 26 and NIH 3T3 cells using the uridine phosphorylase inhibitor 5'-amino benzylacyclouridine linked to an agarose matrix. Vimentin copurification with UPase was confirmed using both Western blot analysis and MALDI-MS methods. Separation of cytosolic proteins using gel filtration chromatography yields a high molecular weight complex containing UPase and vimentin, Purified recombinant UPase and recombinant vimentin were shown to bind in vitro with an affinity of 120 pM and a stoichiometry of 1:2. Immunofluorescence techniques confirm that UPase is associated with vimentin in both NIH 3T3 and colon 26 cells and that depolymerization of the microtubule system using nocodazole results in UPase remaining associated with the collapsed intermediate filament, vimentin, Our data demonstrate that UPase is associated with both the soluble and insoluble pools of vimentin, Approximately 60-70% of the total UPase exists in the cytosol as a soluble protein. Sequential extraction of MH 3T3 or colon 26 cells liberates an additional 30-40% UPase activity associated with a detergent extractable fraction. All pools of UPase have been shown to possess enzymatic activity. We demonstrate for the first time that UPase is associated with vimentin and the existence of an enzymatically active cytoskeleton-associated UPase.	Yale Univ, Sch Med, Sect Med Oncol, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Pizzorno, G (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Oncol, 333 Cedar,SHM I 220, New Haven, CT 06520 USA.							Anderson CM, 1997, TRENDS PHARMACOL SCI, V18, P387, DOI 10.1016/S0165-6147(97)01106-1; AUSSEDAT J, 1983, CARDIOVASC RES, V17, P145, DOI 10.1093/cvr/17.3.145; BENZI G, 1984, J NEUROSCI RES, V11, P437, DOI 10.1002/jnr.490110410; BIRNIE GD, 1963, BIOCHEMISTRY-US, V2, P566, DOI 10.1021/bi00903a031; BOSE R, 1974, BIOCHEMISTRY-US, V13, P2051, DOI 10.1021/bi00707a008; BROWN KD, 1992, J CELL SCI, V102, P19; CASS CE, 1972, J BIOL CHEM, V247, P3314; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; CHU SH, 1988, NUCLEOS NUCLEOT, V7, P91, DOI 10.1080/07328318808068705; CIESIELSKITRESK.J, 1996, EUR J CELL BIOL, V68, P369; Colucci-Guyon E, 1999, GLIA, V25, P33, DOI 10.1002/(SICI)1098-1136(19990101)25:1<33::AID-GLIA4>3.0.CO;2-J; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; CONNOLLY GP, 1993, BRIT J PHARMACOL, V110, P1297, DOI 10.1111/j.1476-5381.1993.tb13959.x; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; DAGNINO L, 1991, J BIOL CHEM, V266, P6308; DARNOWSKI JW, 1985, CANCER RES, V45, P5364; DARNOWSKI JW, 1986, CANCER RES, V46, P3490; DOHERTY FJ, 1987, BIOCHEM J, V241, P793, DOI 10.1042/bj2410793; Eckes B, 1998, J CELL SCI, V111, P1897; EDA H, 1993, JPN J CANCER RES, V84, P341, DOI 10.1111/j.1349-7006.1993.tb02876.x; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; Evans RM, 1998, BIOESSAYS, V20, P79, DOI 10.1002/(SICI)1521-1878(199801)20:1<79::AID-BIES11>3.3.CO;2-I; Fenyo D, 1999, BIOINFORMATICS, V15, P339, DOI 10.1093/bioinformatics/15.4.339; Fenyo D, 1996, ANAL CHEM, V68, pA721, DOI 10.1021/ac9621579; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; GASSER T, 1981, SCIENCE, V213, P777, DOI 10.1126/science.7256279; GEIGER A, 1956, J NEUROCHEM, V1, P93, DOI 10.1111/j.1471-4159.1956.tb12059.x; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Iyer SS, 1999, J BIOL CHEM, V274, P2350, DOI 10.1074/jbc.274.4.2350; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P47, DOI 10.1113/jphysiol.1982.sp014100; JARVIS SM, 1989, BIOCHEM SOC T, V17, P4448; KARKISHCHENKO NN, 1990, FARMAKOL TOKSIKOL, V53, P67; KIMURA N, 1993, HDB EXPT PHARM; Kimura T, 1996, EUR J PHARMACOL, V311, P265, DOI 10.1016/0014-2999(96)00434-7; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; KRENITSKY TA, 1964, J BIOL CHEM, V239, P805; KRENITSKY TA, 1965, J BIOL CHEM, V240, P1281; LEE CW, 1988, BIOCHIM BIOPHYS ACTA, V942, P139, DOI 10.1016/0005-2736(88)90283-0; LEHIR M, 1985, PFLUG ARCH EUR J PHY, V404, P238, DOI 10.1007/BF00581245; LEYVA A, 1984, CANCER RES, V44, P5928; LIAO GJ, 1995, J CELL SCI, V108, P3473; Liu MP, 1998, CANCER RES, V58, P5418; MARTIN DS, 1989, CANCER CHEMOTH PHARM, V24, P9; MONKS A, 1983, BIOCHEM PHARMACOL, V32, P2003, DOI 10.1016/0006-2952(83)90419-7; MUKHERJEE KL, 1963, CANCER RES, V23, P49; Otero AD, 1997, J BIOL CHEM, V272, P14690, DOI 10.1074/jbc.272.23.14690; PARENTI F, 1992, CLIN NEUROPHARMACOL, V15, P369; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; PONTIS H, 1961, BIOCHIM BIOPHYS ACTA, V51, P138, DOI 10.1016/0006-3002(61)91024-1; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; Stone KL, 1998, ELECTROPHORESIS, V19, P1046, DOI 10.1002/elps.1150190620; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VANGROENINGEN CJ, 1991, J NATL CANCER I, V83, P437; VITA A, 1986, INT J BIOCHEM, V18, P431, DOI 10.1016/0020-711X(86)90185-0; WATANABE SI, 1995, J BIOL CHEM, V270, P12191, DOI 10.1074/jbc.270.20.12191; WATANABE SI, 1995, BIOCHEM BIOPH RES CO, V216, P265, DOI 10.1006/bbrc.1995.2619; WOHLHUETER RM, 1979, BIOCHIM BIOPHYS ACTA, V553, P262, DOI 10.1016/0005-2736(79)90231-1; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; YANG HY, 1985, J CELL BIOL, V100, P620, DOI 10.1083/jcb.100.2.620; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	69	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13302	13307		10.1074/jbc.M008512200	http://dx.doi.org/10.1074/jbc.M008512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278417	hybrid			2022-12-27	WOS:000168198600115
J	Yu, TW; Muller, R; Muller, M; Zhang, XH; Draeger, G; Kim, CG; Leistner, E; Floss, HG				Yu, TW; Muller, R; Muller, M; Zhang, XH; Draeger, G; Kim, CG; Leistner, E; Floss, HG			Mutational analysis and reconstituted expression of the biosynthetic genes involved in the formation of 3-amino-5-hydroxybenzoic acid, the starter unit of rifamycin biosynthesis in Amycolatopsis mediterranei S699	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-COELICOLOR A3(2); ANSAMYCIN ANTIBIOTICS; NOCARDIA-MEDITERRANEI; ACTINORHODIN BIOSYNTHESIS; ENGINEERED BIOSYNTHESIS; GLUCOSE REPRESSION; MC(7)N UNITS; ANSA CHAIN; CHROMOPHORE; PRECURSOR	To investigate a novel branch of the shikimate biosynthesis pathway operating in the formation of 3-amino-5-hydroxybenzoic acid (AHBA), the unique biosynthetic precursor of rifamycin and related ansamycins, a series of target-directed mutations and heterologous gene expressions were investigated in Amycolatopsis mediterranei and Streptomyces coelicolor. The genes involved in AHBA formation were inactivated individually, and the resulting mutants were further examined by incubating the cell-free extracts with known intermediates of the pathway and analyzing for AHBA formation. The rifL, -M, and -N genes were shown to be involved in the step(s) from either phosphoenolpyruvate/D-erythrose 4-phosphate or other precursors to 3,4-dideoxy-4-amino-D-arabino-heptulosonate 7-phosphate. The gene products of the rifH, -G, and -J genes resemble enzymes involved in the shikimate biosynthesis pathway (August, P. R., Tang, L., Yoon, Y. J,, Ning, S., Muller, it,, Yu, T.-W., Taylor, M., Hoffmann, D., Kim, C.-G., Zhang, X., Hutchinson, C. it., and Floss, H. G, (1998) Chem. Biol. 5, 89-79). Mutants of the rifH and -J genes produced rifamycin B at 1% and 10%, respectively, of the yields of the wild type; inactivation of the rifG gene did not affect rifamycin production significantly. Finally, coexpressing the rifG-N and -J genes in S. coelicolor YU105 under the control of the act promoter led to significant production of AHBA in the fermented cultures, confirming that seven of these genes are indeed necessary and sufficient for AHBA formation. The effects of deletion of individual genes from the heterologous expression cassette on AHBA formation duplicated the effects of the genomic rifG-N and -J mutations on rifamycin production, indicating that all these genes encode proteins with catalytic rather than regulatory functions in AHBA formation for rifamycin biosynthesis by A. mediterranei.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Bonn, Lehrstuhl Pharmazeut Biol, D-53115 Bonn, Germany; Inje Univ, Dept Chem Engn, Kimhae 621749, Kyongnam, South Korea	University of Washington; University of Washington Seattle; University of Bonn; Inje University	Leistner, E (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	yu@u.washington.edu	Müller, Rolf/B-1559-2008	Müller, Rolf/0000-0002-1042-5665	NIAID NIH HHS [AI 20264] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020264] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MG, 1980, J CHEM SOC CHEM COMM, P1277, DOI 10.1039/c39800001277; ANGELL S, 1992, MOL MICROBIOL, V6, P2833, DOI 10.1111/j.1365-2958.1992.tb01463.x; Arias P, 1999, J BACTERIOL, V181, P6958, DOI 10.1128/JB.181.22.6958-6968.1999; August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; BECKER AM, 1983, J ANTIBIOT, V36, P1323, DOI 10.7164/antibiotics.36.1323; BESANZON GS, 1971, CAN J BIOCHEM, V49, P911; Chen S, 1999, EUR J BIOCHEM, V261, P98, DOI 10.1046/j.1432-1327.1999.00244.x; DAMBERG M, 1982, TETRAHEDRON LETT, V23, P59, DOI 10.1016/S0040-4039(00)97531-2; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; GHISALBA O, 1978, J ANTIBIOT, V31, P202, DOI 10.7164/antibiotics.31.202; GHISALBA O, 1978, J ANTIBIOT, V31, P215, DOI 10.7164/antibiotics.31.215; GHISALBA O, 1981, J ANTIBIOT, V34, P58, DOI 10.7164/antibiotics.34.58; GHISALBA O, 1981, J ANTIBIOT, V34, P64, DOI 10.7164/antibiotics.34.64; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; GYGAX D, 1990, J ANTIBIOT, V43, P324, DOI 10.7164/antibiotics.43.324; HARBER A, 1977, J AM CHEM SOC, V99, P3541; HIGASHIDE E, 1977, NATURE, V270, P721, DOI 10.1038/270721a0; Hopwood D.A., 1985, GENETIC MANIPULATION; HORNEMANN U, 1974, J CHEM SOC CHEM COMM, P1045, DOI 10.1039/c39740001045; HORNEMANN U, 1980, J CHEM SOC CHEM COMM, P11, DOI 10.1039/c39800000011; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KARLSSON A, 1974, EUR J BIOCHEM, V47, P251, DOI 10.1111/j.1432-1033.1974.tb03688.x; KIBBY JJ, 1980, J CHEM SOC CHEM COMM, P768, DOI 10.1039/c39800000768; Kim CG, 1998, J BIOL CHEM, V273, P6030, DOI 10.1074/jbc.273.11.6030; KIM CG, 1992, J AM CHEM SOC, V114, P4941, DOI 10.1021/ja00038a090; Kim CG, 1996, J AM CHEM SOC, V118, P7486, DOI 10.1021/ja9601292; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P1354, DOI 10.1021/ja00759a054; KUPCHAN SM, 1975, J AM CHEM SOC, V97, P5294, DOI 10.1021/ja00851a054; LOOS H, 1993, FEMS MICROBIOL LETT, V107, P293, DOI 10.1016/0378-1097(93)90325-V; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; Mao YQ, 1999, CHEM BIOL, V6, P251, DOI 10.1016/S1074-5521(99)80040-4; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; MEIER RM, 1992, J ANTIBIOT, V45, P400, DOI 10.7164/antibiotics.45.400; Muller M, 1998, J ORG CHEM, V63, P9753, DOI 10.1021/jo981291l; NING S, 1996, THESIS U WASHINGTON; OPPOLZER W, 1973, HELV CHIM ACTA, V56, P2287, DOI 10.1002/hlca.19730560717; Rinehart K L Jr, 1976, Fortschr Chem Org Naturst, V33, P231; RINEHART KL, 1972, J ANTIBIOT, V25, P71, DOI 10.7164/antibiotics.25.71; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasaki K, 1970, J Am Chem Soc, V92, P7591, DOI 10.1021/ja00729a018; SCHAFERJOHANN J, 1993, J BACTERIOL, V175, P7329; SENSI P, 1959, Farmaco Sci, V14, P146; SEPKOWITZ KA, 1995, CLIN MICROBIOL REV, V8, P180, DOI 10.1128/CMR.8.2.180; SHIBATA M, 1971, J ANTIBIOT, V24, P810, DOI 10.7164/antibiotics.24.810; Spath C, 1997, J BACTERIOL, V179, P7603; SUGITA M, 1982, J ANTIBIOT, V35, P1460, DOI 10.7164/antibiotics.35.1460; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANI MC, 1973, J CHEM SOC CHEM COMM, P390, DOI 10.1039/c39730000390; WHITE RJ, 1974, FEBS LETT, V49, P233, DOI 10.1016/0014-5793(74)80519-3; WILLIAMS TH, 1975, J ANTIBIOT, V28, P85, DOI 10.7164/antibiotics.28.85; YU TW, 1995, MICROBIOL-UK, V141, P2779, DOI 10.1099/13500872-141-11-2779	54	84	91	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12546	12555		10.1074/jbc.M009667200	http://dx.doi.org/10.1074/jbc.M009667200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278540	Green Published, hybrid			2022-12-27	WOS:000168198600013
J	Zhang, DW; Cole, SPC; Deeley, RG				Zhang, DW; Cole, SPC; Deeley, RG			Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; SUBSTRATE-SPECIFICITY; PHARMACOLOGICAL CHARACTERIZATION; TRANSMEMBRANE SEGMENT-6; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; DEPENDENT TRANSPORT; MEMBRANE-VESICLES; MRP; GLUTATHIONE	Murine multidrug resistance protein 1 (mrp1), unlike human MRP1, does not confer resistance to anthracyclines, Previously, we have shown that a human/murine hybrid protein containing amino acids 959-1187 of MRP1 can confer resistance to these drugs. We have now examined the functional characteristics of mutant proteins in which we have converted individual amino acids in the comparable region of mrp1 to those present at the respective locations in MRP1. These mutations had no effect on the drug resistance profile conferred by mrp1 with the exception of converting glutamine 1086 to glutamate, as it is in the corresponding position (1089) in MRP1. This mutation created a protein that conferred resistance to doxorubicin without affecting vincristine resistance, or the ability of mrp1 to transport leukotriene C, (LTC4) and 17 beta -estradiol 17-(beta -D-glucuronide) (E(2)17 betaG). Furthermore, mutation Q1086D conferred the same phenotype as mutation Q1086E while the mutation Q1086N did not detectably alter the drug resistance profile of mrp1, suggesting that an anionic side chain was required for anthracycline resistance. To confirm the importance of MRP1 E10S9 for conferring resistance to anthracyclines, we mutated this residue to Gin, Asp, Ala, Leu, and Lys in the human protein. The mutation E1089D showed the same phenotype as MRP1, while the E1089Q substitution markedly decreased resistance to anthracyclines without affecting LTC4 and E(2)17 betaG transport. Conversion of Glu-1089 to Asn, Ala, or Leu had a similar effect on resistance to anthracyclines, while conversion to a positive amino acid, Lys, completely eliminated resistance to anthracyclines and vincristine without affecting transport of LTC4, E(2)17 betaG, and the GSH-dependent substrate, estrone-3-sulfate. These results demonstrate that an acidic amino acid residue at position 1089 in predicted TM14 of MRP1 is critical for the ability of the protein to confer drug resistance particularly to the anthracyclines, but is not essential for its ability to transport conjugated organic anions such as LTC4 and E(2)17 betaG.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Zhang, Dawei/0000-0001-8279-8041				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Ding GY, 1999, ANTICANCER RES, V19, P3243; Grant CE, 1998, METHOD ENZYMOL, V292, P594; GRANT CE, 1994, CANCER RES, V54, P357; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Higgins CF, 1997, SEMIN CANCER BIOL, V8, P135, DOI 10.1006/scbi.1997.0067; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Keppler D, 1999, ADV ENZYME REGUL, V39, P237, DOI 10.1016/S0065-2571(98)00015-6; Kool M, 1999, CANCER RES, V59, P175; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Stride BD, 1996, MOL PHARMACOL, V49, P962; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1997, SEMIN CANCER BIOL, V8, P151, DOI 10.1006/scbi.1997.0066	37	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13231	13239		10.1074/jbc.M010008200	http://dx.doi.org/10.1074/jbc.M010008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278596	hybrid			2022-12-27	WOS:000168198600106
J	Kawanaka, K; Han, DH; Gao, JP; Nolte, LA; Holloszy, JO				Kawanaka, K; Han, DH; Gao, JP; Nolte, LA; Holloszy, JO			Development of glucose-induced insulin resistance in muscle requires protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; TYROSINE KINASE-ACTIVITY; TRANSPORT SYSTEM; TRANSGENIC MICE; HEXOSAMINE BIOSYNTHESIS; INDUCED DESENSITIZATION; IN-VIVO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT-4 TRANSLOCATION	Muscles and fat cells develop insulin resistance when exposed to high concentrations of glucose and insulin. We used an isolated muscle preparation incubated with high levels of glucose and insulin to further evaluate how glucose-induced insulin resistance (GIIR) is mediated. Incubation with 2 milliunits/ml insulin and 36 mM glucose for 5 h resulted in an similar to 50% decrease in insulin-stimulated muscle glucose transport. The decrease in insulin responsiveness of glucose transport induced by glucose was not due to impaired insulin signaling, as insulin-stimulated phosphatidylinositol 3-kinase activity and protein kinase B phosphorylation were not reduced, It has been hypothesized that entry of glucose into the hexosamine biosynthetic pathway with accumulation of UDP-N-acetylhexosamines (UDP-HexNAcs) mediates GIIR. However, inhibition of the rate-limiting enzyme GFAT (glutamine:fructose-g-phosphate amido-transferase) did not protect against GIIR despite a marked reduction of UDP-HexNAcs, The mRNA synthesis inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide both completely protected against GIIR despite the massive increases in UDP-HexNAcs and glycogen that resulted from increased glucose entry. Activation of AMP-activated protein kinase also protected against GIIR, These results provide evidence that GIIR can occur in muscle without increased accumulation of hexosamine pathway end products, that neither high glycogen concentration nor impaired insulin signaling is responsible for GIIR, and that synthesis of a protein with a short half-life mediates GIIR, They also suggest that dephosphorylation of a transcription factor may be involved in the induction of GIIR.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Div Geriatr & Gerontol, 4566 Scott Ave,Campus Box 8113, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu			NIDDK NIH HHS [DK18986, DK20579] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P60DK020579, R01DK018986] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CODERRE L, 1994, DIABETES, V43, pA159; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; DAVIDSON MB, 1994, AM J PHYSIOL-ENDOC M, V267, pE808, DOI 10.1152/ajpendo.1994.267.6.E808; FELL RD, 1982, J APPL PHYSIOL, V52, P434, DOI 10.1152/jappl.1982.52.2.434; Filippis A, 1997, BIOCHEM J, V324, P981, DOI 10.1042/bj3240981; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; GARVEY WT, 1987, J BIOL CHEM, V262, P189; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GOHEER MA, 1987, MOL CELL BIOCHEM, V75, P137; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HAGER SR, 1991, AM J PHYSIOL, V260, pE353, DOI 10.1152/ajpendo.1991.260.3.E353; HANSEN BF, 1992, AM J PHYSIOL, V262, pE440, DOI 10.1152/ajpendo.1992.262.4.E440; Hansen PA, 1997, AM J PHYSIOL-REG I, V273, pR1704, DOI 10.1152/ajpregu.1997.273.5.R1704; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Hawkins M, 1999, J BIOL CHEM, V274, P31312, DOI 10.1074/jbc.274.44.31312; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLSTEGE A, 1982, EUR J BIOCHEM, V121, P469, DOI 10.1111/j.1432-1033.1982.tb05811.x; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Jensen J, 1997, AM J PHYSIOL-ENDOC M, V272, pE649, DOI 10.1152/ajpendo.1997.272.4.E649; KARASIK A, 1990, J BIOL CHEM, V265, P10226; Kawanaka K, 1999, AM J PHYSIOL-ENDOC M, V276, pE907, DOI 10.1152/ajpendo.1999.276.5.E907; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; Laybutt DR, 1999, AM J PHYSIOL-ENDOC M, V277, pE1070, DOI 10.1152/ajpendo.1999.277.6.E1070; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; NOLTE LA, 1994, J APPL PHYSIOL, V76, P2054, DOI 10.1152/jappl.1994.76.5.2054; Pillay TS, 1996, J CLIN INVEST, V97, P613, DOI 10.1172/JCI118457; REN JM, 1993, J BIOL CHEM, V268, P16113; REN JM, 1994, J BIOL CHEM, V269, P14396; RICHTER EA, 1988, BIOCHEM J, V252, P733, DOI 10.1042/bj2520733; RICHTER EA, 1988, AM J PHYSIOL, V255, pE261; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	53	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20101	20107		10.1074/jbc.M010599200	http://dx.doi.org/10.1074/jbc.M010599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274201	hybrid			2022-12-27	WOS:000169135100058
J	Pritchard, KA; Ackerman, AW; Gross, ER; Stepp, DW; Shi, YH; Fontana, JT; Baker, JE; Sessa, WC				Pritchard, KA; Ackerman, AW; Gross, ER; Stepp, DW; Shi, YH; Fontana, JT; Baker, JE; Sessa, WC			Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; GENERATION; CELLS; TETRAHYDROBIOPTERIN; HSP90; ACTIVATION; MECHANISM; RELEASE	The balance of nitric oxide ( NO) and superoxide anion (O-2(radical anion)) plays an important role in vascular biology. The association of heat shock protein 90 (Hsp90) with endothelial nitric-oxide synthase (eNOS) is a critical step in the mechanisms by which eNOS generates . NO. As eNOS is capable of generating both . NO and O-2(radical anion) we hypothesized that Hsp90 might also mediate eNOS-dependent O-2(.--) production. To test this hypothesis, bovine coronary endothelial cells (BCEC) were pretreated with geldanamycin (GA, 10 mug/ml; 17.8 muM) and then stimulated with the calcium ionophore, A23187 (5 muM). GA significantly decreased A23187-stimulated eNOS-dependent nitrite production (p < 0.001, n = 4) and significantly increased A23187-stimulated eNOS-dependent O-2(radical anion) production (p < 0.001, n = 8). A23187 increased phospho-eNOS(Ser-1179) levels by >1.6-fold over vehicle (V)-treated levels. Pretreatment with GA by itself or with A23187 increased phospho-eNOS levels. In unstimulated V-treated BCEC cultures low amounts of Hsp90 were found to associate with eNOS. Pretreatment with GA and/or A23187 increased the association of Hsp90 with eNOS. These data show that Hsp90 is essential for eNOS-dependent . NO production and that inhibition of ATP-dependent conformational changes in Hsp90 uncouples eNOS activity and increases eNOS-dependent O-2(radical anion) production.	Med Coll Wisconsin, Div Pediat Surg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Med Sci Training Program, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Pediat Surg Pharmacol & Toxicol, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Yale University	Pritchard, KA (corresponding author), Med Coll Wisconsin, Div Pediat Surg Pharmacol & Toxicol, Cardiovasc Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Stepp, David W/F-4250-2011; Zhu, Longjun/C-2938-2012; Sessa, William C/B-6844-2011; Baker, John/V-8897-2019	Sessa, William C/0000-0001-5759-1938; Baker, John/0000-0001-7899-3266; Gross, Eric/0000-0002-0589-6446	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R37HL061371, R01HL061371, R01HL054075] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57665, HL 61371, HL61414, HL54075] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chataigneau T, 1999, BRIT J PHARMACOL, V126, P219, DOI 10.1038/sj.bjp.0702300; Chen PF, 1998, J BIOL CHEM, V273, P34164, DOI 10.1074/jbc.273.51.34164; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; FUKUTO JM, 1996, METHODS NITRIC OXIDE, P145; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; Kinoshita H, 1997, AM J PHYSIOL-HEART C, V273, pH718, DOI 10.1152/ajpheart.1997.273.2.H718; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Milstien S, 1999, BIOCHEM BIOPH RES CO, V263, P681, DOI 10.1006/bbrc.1999.1422; Munzel T, 2000, CIRC RES, V86, pE7, DOI 10.1161/01.RES.86.1.e7; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Su YC, 2000, AM J PHYSIOL-LUNG C, V278, pL1204, DOI 10.1152/ajplung.2000.278.6.L1204; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, FREE RADICAL RES, V31, P607, DOI 10.1080/10715769900301181; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; VasquezVivar J, 1997, FEBS LETT, V403, P127, DOI 10.1016/S0014-5793(97)00036-7; Vergnani L, 2000, CIRCULATION, V101, P1261, DOI 10.1161/01.CIR.101.11.1261; Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	27	270	286	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17621	17624		10.1074/jbc.C100084200	http://dx.doi.org/10.1074/jbc.C100084200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278264	hybrid			2022-12-27	WOS:000168866500001
J	Suarez, E; Bach, D; Cadefau, J; Palacin, M; Zorzano, A; Guma, A				Suarez, E; Bach, D; Cadefau, J; Palacin, M; Zorzano, A; Guma, A			A novel role of neuregulin in skeletal muscle - Neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; RECEPTOR GENE-EXPRESSION; BREAST-CANCER CELLS; GLIAL GROWTH-FACTOR; GA-BINDING-PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; MYOGENIC DIFFERENTIATION; DEVELOPMENTAL REGULATION; TRANSCRIPTION FACTOR; CARDIAC DEVELOPMENT	Neuregulins regulate the expression of acetylcholine receptor genes and induce development of the neuromuscular junction in muscle. In studying whether neuregulins regulate glucose uptake in muscle, we analyzed the effect of a recombinant neuregulin, (r)heregulin-beta1-(177-244) (HRG), on L6E9 muscle cells, which express the neuregulin receptors ErbB2 and ErbB3. L6E9 responded acutely to HRG by a time- and concentration-dependent stimulation of 8-deoxyglucose uptake. HRG-induced stimulation of glucose transport was additive to the effect of insulin. The acute stimulation of the glucose transport induced by HRG was a consequence of the translocation of GLUT4, GLUT1, and GLUT3 glucose carriers to the cell surface. The effect of HRG on glucose transport was dependent on phosphatidylinositol 3-kinase activity. HRG also stimulated glucose transport in the incubated soleus muscle and was additive to the effect of insulin. Chronic exposure of L6E9 cells to HRG: potentiated myogenic differentiation, and under these conditions, glucose transport was also stimulated. The activation of glucose transport after chronic HRG exposure was due to enhanced cell content of GLUT1 and GLUT3 and to increased abundance of these carriers at the plasma membrane. However, under these conditions, GLUT4 expression was markedly down-regulated. Muscle denervation is associated with GLUT1 induction and GLUT4 repression. In this connection, muscle denervation caused a marked increase in the content of ErbB2 and ErbB3 receptors, which occurred in the absence of alterations in neuregulin mRNA levels. This fact suggests that neuregulins regulate glucose transporter expression in denervated muscle. We conclude that neuregulins regulate glucose uptake in L6E9 muscle cells by mechanisms involving the recruitment of glucose transporters to the cell surface and modulation of their expression. Neuregulins may also participate in the adaptations in glucose transport that take place in the muscle fiber after denervation.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Fac Med, Dept Ciencies Fisiol 1, Unitat Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona	Zorzano, A (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Palacín, Manuel/G-9786-2015; Cadefau, Joan AurelI/M-7934-2018; Cadefau, Joan Aureli/G-2906-2016; Gumà, Anna/C-5165-2017; Zorzano, Antonio/R-5479-2018	Cadefau, Joan AurelI/0000-0001-6020-189X; Cadefau, Joan Aureli/0000-0001-6020-189X; Gumà, Anna/0000-0001-9390-5252; Palacin, Manuel/0000-0002-8670-293X				Alroy I, 1999, MOL CELL BIOL, V19, P1961; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; CARLSEN RC, 1975, J PHYSIOL-LONDON, V247, P343, DOI 10.1113/jphysiol.1975.sp010935; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHU GC, 1995, NEURON, V329, P95; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; CRETTAZ M, 1980, BIOCHEM J, V186, P525, DOI 10.1042/bj1860525; DIDYK RB, 1994, METABOLISM, V43, P1389, DOI 10.1016/0026-0495(94)90033-7; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; Elmendorf JS, 1997, AM J PHYSIOL-ENDOC M, V272, pE661, DOI 10.1152/ajpendo.1997.272.4.E661; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fandos C, 1999, J MOL BIOL, V294, P103, DOI 10.1006/jmbi.1999.3216; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Florini JR, 1996, J BIOL CHEM, V271, P12699, DOI 10.1074/jbc.271.22.12699; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; GUMA A, 1988, BIOCHEM J, V253, P625, DOI 10.1042/bj2530625; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Jones JP, 1998, J APPL PHYSIOL, V84, P1661, DOI 10.1152/jappl.1998.84.5.1661; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Kim DG, 1999, J BIOL CHEM, V274, P15395, DOI 10.1074/jbc.274.22.15395; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEGENEY LA, 1993, AM J PHYSIOL, V264, pE583, DOI 10.1152/ajpendo.1993.264.4.E583; Meyer D, 1997, DEVELOPMENT, V124, P3575; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; Sevilla L, 1997, ENDOCRINOLOGY, V138, P3006, DOI 10.1210/en.138.7.3006; Si JT, 1997, J BIOL CHEM, V272, P10367; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; Vinals F, 1997, ENDOCRINOLOGY, V138, P2521, DOI 10.1210/en.138.6.2521; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	56	89	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18257	18264		10.1074/jbc.M008100200	http://dx.doi.org/10.1074/jbc.M008100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278386	hybrid			2022-12-27	WOS:000168866500087
J	Hassaine, G; Courcoul, M; Bessou, G; Barthalay, Y; Picard, C; Olive, D; Collette, Y; Vigne, R; Decroly, E				Hassaine, G; Courcoul, M; Bessou, G; Barthalay, Y; Picard, C; Olive, D; Collette, Y; Vigne, R; Decroly, E			The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral Vif protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SRC-FAMILY KINASES; CRYSTAL-STRUCTURE; SOR GENE; TYPE-1; MUTANTS; CELLS; CORE; NEF; GAG	The virus infectivity factor (Vif) protein facilitates the replication of human immunodeficiency virus type 1 (HIV-1) in primary lymphocytes and macrophages, Its action is strongly dependent on the cellular environment, and it has been proposed that the Vif protein counteracts cellular activities that would otherwise limit HIV-1 replication. Using a glutathione S-transferase pull-down assay, we identified that Vif binds specifically to the Src homology 3 domain of Hck, a tyrosine kinase from the Src family. The interaction between Vif and the full-length Hck was further assessed by co-precipitation assays in vitro and in human cells, The Vif protein repressed the kinase activity of Hck and was not itself a substrate for Hck phosphorylation, Within one single replication cycle of HIV-1, lick was able to inhibit the production and the infectivity of vif-deleted virus but not that of wild-type virus. Accordingly, HIV-1 vif(-) replication was delayed in Jurkat T cell clones stably expressing Hck. Our data demonstrate that Hck controls negatively HIV-1 replication and that this inhibition is suppressed by the expression of Vif. lick, which is present in monocyte-macrophage cells, represents the first identified cellular inhibitor of HIV-1 replication overcome by Vif.	Univ Mediterranee, INSERM, U372, F-13276 Marseille 09, France; Univ Mediterranee, INSERM, U119, Inst Paoli Calmettes, F-13009 Marseille, France; Free Univ Brussels, LCPMI, B-1050 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vigne, R (corresponding author), Univ Mediterranee, INSERM, U372, 163 Ave Luminy, F-13276 Marseille 09, France.	rvigne@inserm-u372.univ-mrs.fr; edecroly@ulb.ac.be	COLLETTE, Yves/F-2270-2013	COLLETTE, Yves/0000-0001-5359-7099; DECROLY, Etienne/0000-0002-6046-024X				Arni S, 1996, BIOCHEM BIOPH RES CO, V225, P801, DOI 10.1006/bbrc.1996.1254; Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; Bouyac M, 1997, J VIROL, V71, P2473, DOI 10.1128/JVI.71.3.2473-2477.1997; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; DURDEN DL, 1995, J IMMUNOL, V154, P4039; FAN LJ, 1992, VIROLOGY, V190, P19, DOI 10.1016/0042-6822(92)91188-Z; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P333, DOI 10.1089/aid.1994.10.333; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Hatakeyama S, 1996, MICROBIOL IMMUNOL, V40, P223, DOI 10.1111/j.1348-0421.1996.tb03338.x; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SIMM M, 1995, J VIROL, V69, P4582, DOI 10.1128/JVI.69.7.4582-4586.1995; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Tokunaga K, 1998, J VIROL, V72, P6257, DOI 10.1128/JVI.72.7.6257-6259.1998; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200; Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000	40	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16885	16893		10.1074/jbc.M009076200	http://dx.doi.org/10.1074/jbc.M009076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278465	hybrid			2022-12-27	WOS:000168730400039
J	Chapeaurouge, A; Johansson, JS; Ferreira, ST				Chapeaurouge, A; Johansson, JS; Ferreira, ST			Folding intermediates of a model three-helix bundle protein - Pressure and cold denaturation studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HELIX BUNDLE; CHYMOTRYPSIN INHIBITOR-2; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; ENERGY SURFACE; BINDING DOMAIN; STABILITY; STATE; THERMODYNAMICS; DISSOCIATION	The stability and equilibrium unfolding of a model three-helix bundle protein, alpha (3)-1, by guanidine hydrochloride (GdnHCl), hydrostatic pressure, and temperature have been investigated. The combined use of these denaturing agents allowed detection of two partially folded states of alpha (3)-1, as monitored by circular dichroism, intrinsic fluorescence emission, and fluorescence of the hydrophobic probe bis-ANS (4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid). The overall free-energy change for complete unfolding of (alpha (3)-1, determined from GdnHCl unfolding data, is +4.6 kcal/mol, The native state is stabilized by -1.4 kcal/mol relative to a partially folded pressure-denatured intermediate (I-1). Cold denaturation at high pressure gives rise to a second partially (un)folded conformation (I-2), suggesting a significant contribution of hydrophobic interactions to the stability of alpha (3)-1. The free energy of stabilization of the native-like state relative to I-2 is evaluated to be -2.5 kcal/mol, Bis-ANS binding to the pressure- and cold denatured states indicates the existence of significant residual hydrophobic structure in the partially (un)folded states of alpha (3)-1, The demonstration of folding intermediates of alpha (3)-1 lends experimental support to a number of recent protein folding simulation studies of other three-helix bundle proteins that predicted the existence of such intermediates. The results are discussed in terms of the significance of de novo designed proteins for protein folding studies.	Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Penn, Johnson Res Fdn, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA	Universidade Federal do Rio de Janeiro; University of Pennsylvania; University of Pennsylvania	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Ferreira, Sergio/AAZ-1576-2020	Ferreira, Sergio/0000-0001-7160-9866	NIGMS NIH HHS [GM55876] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCUS VL, 1994, P NATL ACAD SCI USA, V91, P9412, DOI 10.1073/pnas.91.20.9412; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; BRANDTS JF, 1970, BIOCHEMISTRY-US, V9, P1038, DOI 10.1021/bi00806a045; BRIDGMAN PW, 1931, PHYSICS HIGH PRESSUR; Clarke J, 1996, FOLD DES, V1, P243, DOI 10.1016/S1359-0278(96)00038-7; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P1193, DOI 10.1021/bi00219a005; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; GOROVITS BM, 1995, BIOCHEMISTRY-US, V34, P13928, DOI 10.1021/bi00042a026; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Johansson JS, 1998, J AM CHEM SOC, V120, P3881, DOI 10.1021/ja973538m; KHORASANIZADEH S, 1993, BIOCHEMISTRY-US, V32, P7054, DOI 10.1021/bi00078a034; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; KIPPEN AD, 1994, BIOCHEMISTRY-US, V33, P3778, DOI 10.1021/bi00178a039; KRAGELUND BB, 1995, BIOCHEMISTRY-US, V34, P7217, DOI 10.1021/bi00021a037; LIEBERMAN M, 1994, J AM CHEM SOC, V116, P5035, DOI 10.1021/ja00091a002; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; PREVELIGE PE, 1994, BIOPHYS J, V66, P1631, DOI 10.1016/S0006-3495(94)80955-5; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; ROYER CA, 1993, BIOCHEMISTRY-US, V32, P5222, DOI 10.1021/bi00070a034; RUAN KC, 1988, BIOCHEMISTRY-US, V27, P3295, DOI 10.1021/bi00409a026; Scalley ML, 1997, BIOCHEMISTRY-US, V36, P3373, DOI 10.1021/bi9625758; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sosnick TR, 1996, PROTEINS, V24, P413; Spector S, 1998, J MOL BIOL, V276, P479, DOI 10.1006/jmbi.1997.1522; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WEBER G, 1987, NATO ASI SER C, V197, P401; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YORK SS, 1978, BIOCHEMISTRY-US, V17, P4480, DOI 10.1021/bi00614a019; Zhou YQ, 1999, NATURE, V401, P400, DOI 10.1038/43940; Zhou YQ, 1997, P NATL ACAD SCI USA, V94, P14429, DOI 10.1073/pnas.94.26.14429; ZIPP A, 1973, BIOCHEMISTRY-US, V12, P4217, DOI 10.1021/bi00745a028	49	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14861	14866		10.1074/jbc.M009622200	http://dx.doi.org/10.1074/jbc.M009622200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278529	hybrid			2022-12-27	WOS:000168528800046
J	Hirashima, Y; Kobayashi, H; Suzuki, M; Tanaka, Y; Kanayama, N; Fujie, M; Nishida, T; Takigawa, M; Terao, T				Hirashima, Y; Kobayashi, H; Suzuki, M; Tanaka, Y; Kanayama, N; Fujie, M; Nishida, T; Takigawa, M; Terao, T			Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL FRAGMENT; DOMAIN-II; INVASION; UROKINASE; PROTEIN; IDENTIFICATION; METASTASIS	Urinary trypsin inhibitor (UTI) forms membrane complexes with UTI-binding proteins (UTI-BPs) and initiates modulation of urokinase-type plasminogen activator (uPA) expression, which results in UTI-mediated suppression of cell invasiveness, It has been established that suppression of uPA expression and invasiveness by UTI is mediated through inhibition of protein kinase C-dependent signaling pathways and that human chondrosarcoma cell line HCS-2/8 expresses two types of UTI-BPs; a 40-kDa UTI-BP (UTI-BP40), which:is identical to link protein (LP), and a 45-kDa UTI-BP (UTI-BP40). Here we characterize binding properties of UTI-BPs UTI complexes in the cells, In vitro ligand blot, cell binding and competition assays, and Scatchard analyses demonstrate that both UTI-BP40 and UTP-BP45 bind I-125-UTL A deglycosylated form of UTI (NG-UTI), from which the chondroitin-sulfate side chain has been removed, binds only to UTI-BP40 Additional experiments, using various reagents to block binding of I-125-UTI and NG-UTI to the UTI-BP40 and UTI-BP45 confirm that the chondroitin sulfate Side chain of UTI is required for its binding to UTI-BP45 analysis of binding of I-125-UTI and NG-UTI to the cells suggests that low affinity binding sites are the UTI-BP40 (which can bind NG-UTI), and the high affinity sites are the UTI-BP45, In addition, UTI-induced suppression of phorbol ester stimulated up-regulation of uPA is inhibited by reagents that were shown to prevent binding of UTI to the 40- and 45-kDa proteins. We conclude that UTI must bind to both of the UTI-BPs to suppress uPA up-regulation.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Equipment Ctr, Hamamatsu, Shizuoka 4313192, Japan; Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Okayama University	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handacho 3600, Hamamatsu, Shizuoka 4313192, Japan.	hirame@hama-med.ac.jp						DAVEAU M, 1993, BIOCHEM J, V292, P485, DOI 10.1042/bj2920485; Kobayashi H, 1999, ENDOCRINOLOGY, V140, P3835, DOI 10.1210/en.140.8.3835; Kobayashi H, 1996, EUR J CELL BIOL, V71, P380; KOBAYASHI H, 1995, CANCER RES, V55, P1847; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; Kobayashi H, 1996, J BIOL CHEM, V271, P11362, DOI 10.1074/jbc.271.19.11362; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; Kobayashi H, 2000, J BIOL CHEM, V275, P21185, DOI 10.1074/jbc.M907862199; Kobayashi H, 1998, KIDNEY INT, V53, P1727, DOI 10.1046/j.1523-1755.1998.00940.x; Kobayashi H, 1998, PFLUG ARCH EUR J PHY, V436, P16, DOI 10.1007/s004240050599; Kobayashi H, 2000, MOL HUM REPROD, V6, P735, DOI 10.1093/molehr/6.8.735; KOBAYASHI H, 2001, IN PRESS J BIOL CHEM; Sugino D, 1998, BIOTECHNOL APPL BIOC, V27, P145; Takigawa M, 1997, ENDOCRINOLOGY, V138, P4390, DOI 10.1210/en.138.10.4390	21	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13650	13656		10.1074/jbc.M009906200	http://dx.doi.org/10.1074/jbc.M009906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278581	hybrid			2022-12-27	WOS:000168356600022
J	Crandall, WV; Lowe, ME				Crandall, WV; Lowe, ME			Colipase residues Glu(64) and Arg(65) are essential for normal lipase-mediated fat digestion in the presence of bile salt micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC LIPASE; BINDING; TAURODEOXYCHOLATE; PURIFICATION; INHIBITION; SUBSTRATE; ABSENCE; DOMAIN	Pancreatic triglyceride lipase (PTL) requires colipase for activity. Various constituents in meals and in bile, particularly bile acids, inhibit PTL, Colipase restores activity to lipase in the presence of inhibitory substances like bile acids. Presumably, colipase functions by anchoring and orienting PTL at the oil-water interface. The x-ray structure of the colipase PTL complex supports this model. In the x-ray structure, colipase has a hydrophobic surface positioned to bind substrate and a hydrophilic surface, lying opposite the hydrophobic surface, with two putative lipase-binding domains, Glu(45)/Asp(89) and Glu(64)/Arg(65). To determine whether the hydrophilic surface interacts with PTL in solution, we introduced mutations into the putative PTL binding domains of human colipase, Each mutant was expressed, purified, and assessed for activity against various substrates, Most of the mutants showed impaired ability to reactivate PTL, with mutations in the Glu(64)/Arg(65) binding site causing the greatest effect. Analysis indicated that the mutations decreased the affinity of the colipase mutants for PTL and prevented the formation of PTL colipase complexes. The impaired function of the mutants was most apparent when assayed in micellar bile salt solutions. Most mutants stimulated PTL activity normally in monomeric bile salt solutions. We also tested the mutants for their ability to bind substrate and anchor lipase to tributyrin, Even though the ability of the mutants to anchor PTL to an interface decreased in proportion to their activity, each mutant colipase bound to tributyrin to the same extent as wild type colipase, These results demonstrate that the hydrophilic surface of colipase interacts with PTL in solution to form active colipase PTL complexes, that bile salt micelles influence that binding, and that the proper interaction of colipase with PTL requires the Glu(64)/Arg(65) binding site.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Lowe, ME (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	Lowe@kids.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33060] Funding Source: Medline; NIDDK NIH HHS [DK52574] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayvazian L, 1998, J BIOL CHEM, V273, P33604, DOI 10.1074/jbc.273.50.33604; BORGSTROM B, 1975, J LIPID RES, V16, P287; BORGSTROM B, 1975, J LIPID RES, V16, P411; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; Cordle RA, 1998, PROTEIN EXPRES PURIF, V13, P30, DOI 10.1006/prep.1998.0873; Cordle RA, 1998, J LIPID RES, V39, P1759; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; EGLOFF MP, 1995, PROTEIN SCI, V4, P44; Hernell O., 1992, SEMINARS GASTROINTES, V3, P189; JENNENS ML, 1995, J LIPID RES, V36, P1029; LAIRON D, 1978, BIOCHEMISTRY-US, V17, P205, DOI 10.1021/bi00595a001; Lowe ME, 1999, METH MOL B, V109, P59; Lowe ME, 1997, J BIOL CHEM, V272, P9; MOMSEN WE, 1976, J BIOL CHEM, V251, P384; PATTON JS, 1978, J BIOL CHEM, V253, P4195; PATTON JS, 1978, BIOCHIM BIOPHYS ACTA, V529, P67, DOI 10.1016/0005-2760(78)90104-2; PATTON JS, 1978, FEBS LETT, V86, P179, DOI 10.1016/0014-5793(78)80558-4; Pignol D, 2000, J BIOL CHEM, V275, P4220, DOI 10.1074/jbc.275.6.4220; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARI H, 1975, EUR J BIOCHEM, V58, P561, DOI 10.1111/j.1432-1033.1975.tb02406.x; VANDERMEERS A, 1976, BIOCHEM BIOPH RES CO, V69, P790, DOI 10.1016/0006-291X(76)90944-X; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R., 1984, LIPASES, P84; VERGER R, 1980, METHOD ENZYMOL, V64, P341	25	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12505	12512		10.1074/jbc.M009986200	http://dx.doi.org/10.1074/jbc.M009986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278590	hybrid			2022-12-27	WOS:000168198600008
J	Gluzman-Poltorak, Z; Cohen, T; Shibuya, M; Neufeld, G				Gluzman-Poltorak, Z; Cohen, T; Shibuya, M; Neufeld, G			Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLT TYROSINE KINASE; FACTOR VEGF; SIGNAL-TRANSDUCTION; SEMAPHORIN-III; TUMOR-CELLS; IN-VIVO; BINDING; FAMILY; GENE; IDENTIFICATION	The products of the neuropilin-1 (Np-1) and neuropilin-2 (Np-2) genes are receptors for factors belonging to the class 3 semaphorin family and participate in the guidance of growing axons to their targets. In the presence of heparin-like molecules, both receptors also function as receptors for the heparin-binding 165-amino acid isoform of vascular endothelial growth factor (VEGF(165)). Both receptors are unable to bind to the 121-amino acid isoform of vascular endothelial growth factor (VEGF(121)), which lacks a heparin-binding domain. Interestingly, complexes corresponding in size to I-125-VEGF(121) neuropilin complexes are formed when I-125-VEGF(121) is bound and cross-linked to porcine aortic endothelial cells co-expressing VEGFR-1 and either Np-1 or Np-2. These complexes do not seem to represent complexes of I-125-VEGF With a truncated form of VEGFR-1, presumably formed as a result of the presence of Np-1 or Np-2 in the cells, because such truncated forms could not be detected with anti-VEGFR-1 antibodies. Antibodies directed against VEGFR-1 co-immunoprecipitated the I-125-VEGF(121) Np-2 sized cross-linked complex along with I-125-VEGF(121). VEGFR-1 complexes from cells expressing both VEGFR-1 and Np-2 but not from control cells, indicating that VEGFR-1 and Np-2 associate with each other. To perform the reciprocal experiment we have expressed in porcine aortic endothelial cells a Np-2 receptor containing an in-frame myc epitope at the C terminus. Surprisingly, the myc-tagged Np-2 receptor lost most of its VEGF(165) binding capacity but not its semaphorin-3F binding ability. Nevertheless, when Np-2myc was co-expressed in cells with VEGFR-1, it partially regained its VEGF(165) binding ability. Antibodies directed against the myc epitope co-immunoprecipitated I-125-VEGF(165). Np-2myc and I-125-VEGF(165) VEGFR-1 complexes from cells co-expressing VEGFR-1 and Np-2myc, indicating again that VEGFR-1 associates with Np-2, Our experiments therefore indicate that Np-2, and possibly also Np-1, associate with VEGFR-1 and that such complexes may be part of a cell membrane-associated signaling complex.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 108, Japan	Technion Israel Institute of Technology; University of Tokyo	Neufeld, G (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Neufeld, Gera/F-1524-2019					Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 2000, J BIOL CHEM, V275, P26690; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1993, ONCOGENE, V8, P925; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Omura T, 1997, J BIOL CHEM, V272, P23317, DOI 10.1074/jbc.272.37.23317; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILCHEK M, 1982, BIOCHEM INT, V4, P629; YAMANE A, 1994, ONCOGENE, V9, P2683; Ziche M, 1997, LAB INVEST, V76, P517	55	105	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18688	18694		10.1074/jbc.M006909200	http://dx.doi.org/10.1074/jbc.M006909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278319	hybrid			2022-12-27	WOS:000169091000007
J	Rutthard, H; Banerjee, A; Makinen, MW				Rutthard, H; Banerjee, A; Makinen, MW			Mg2+ is not catalytically required in the intrinsic and kirromycin-stimulated GTPase action of Thermus thermophilus EF-Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; ELECTRON-PARAMAGNETIC-RESONANCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; BACILLUS-STEAROTHERMOPHILUS; ANGSTROM RESOLUTION; NUCLEOTIDE BINDING; EFFECTOR REGION; TS COMPLEX; P21 RAS	The influence of divalent metal ions on the intrinsic and kirromycin-stimulated GTPase activity in the absence of programmed ribosomes and on nucleotide binding affinity of elongation factor Tu (EF-Tu) from Thermus thermophilus prepared as the nucleotide- and Mg2+-free protein has been investigated. The intrinsic GTPase activity under single turnover conditions varied according to the series: Mn2+ (0.069 min(-1)) > Mg2+ (0.037 min(-1)) similar to no Me2+ (0.034 min(-1)) > VO2+ (0.014 min(-1)). The kirromycin-stimulated activity showed a parallel variation. Under multiple turnover conditions (GTP/EF-Tu ratio of 10:1), Mg2+ retarded the rate of hydrolysis in comparison to that in the absence of divalent metal ions, an effect ascribed to kinetics of nucleotide exchange, In the absence of added divalent metal ions, GDP and GTP were bound with equal affinity (R, similar to 10(-7) hr). In the presence of added divalent metal ions, GDP affinity increased by up to two orders of magnitude according to the series: no Me2+ < VO2+ < Mn2+ similar to Mg2+ whereas the binding affinity of G;TP increased by one order of magnitude: no Me2+ < Mg2+ < VO2+ < Mn2+ Estimates of equilibrium (dissociation) binding constants for GDP and GTP by EF-Tu on the basis of Scatchard plot analysis, together with thermodynamic data for hydrolysis of triphosphate nucleotides (Phillips, R, C,, George, P., and Rutman, R, J; (1969) J, Biol, Chem, 244, 3330-3342), showed that divalent metal ions stabilize the EF-Tu . Me2+ GDP complex over the protein-free Me2+ GDP complex in solution, with the effect greatest in the presence of Mg2+ by similar to 10 kJ/mol. These combined results show that Mg2+ is not a catalytically obligatory cofactor in intrinsic and kirromycin-stimulated GTPase action of EF-Tu in the absence of programmed ribosomes, which highlights the differential role of Mg2+ in EF-Tu function.	Univ Chicago, Dept Biochem & Mol Biol, Cummings Life Sci Ctr, Chicago, IL 60637 USA; Univ Bayreuth, Biochem Lab, D-95440 Bayreuth, Germany	University of Chicago; University of Bayreuth	Makinen, MW (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, Cummings Life Sci Ctr, 920 E 58Th St, Chicago, IL 60637 USA.	makinen@uchicago.edu						AHMADIAN MR, 1991, BIOCHIMIE, V73, P1037, DOI 10.1016/0300-9084(91)90145-Q; ALBANESE NF, 1978, J PHYS CHEM-US, V82, P910, DOI 10.1021/j100497a014; ANTONSSON B, 1981, H-S Z PHYSIOL CHEM, V362, P735, DOI 10.1515/bchm2.1981.362.1.735; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P293, DOI 10.1093/oxfordjournals.jbchem.a130571; BANERJEE A, 1998, ACS SYM SER, V711, P104; Bellew BF, 1996, BIOCHEMISTRY-US, V35, P12186, DOI 10.1021/bi960594b; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUTLER A, 1991, COORDIN CHEM REV, V109, P61, DOI 10.1016/0010-8545(91)80002-U; CHASTEEN ND, 1983, STRUCT BOND, V53, P105; GEORGE P, 1963, BIOCHEMISTRY-US, V2, P508, DOI 10.1021/bi00903a020; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P12194, DOI 10.1021/bi9605954; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; IVELL R, 1981, BIOCHEMISTRY-US, V20, P6852, DOI 10.1021/bi00527a017; JIANG FS, 1995, INORG CHEM, V34, P1736, DOI 10.1021/ic00111a021; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KALBITZER HR, 1984, EUR J BIOCHEM, V141, P591, DOI 10.1111/j.1432-1033.1984.tb08234.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kennedy RS, 1997, AUK, V114, P1; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; LACAL JC, 1993, RAS SUPERFAMILY GTPA, P526; LEE E, 1992, J BIOL CHEM, V267, P1212; LEUPOLD CM, 1983, EUR J BIOCHEM, V135, P237, DOI 10.1111/j.1432-1033.1983.tb07643.x; LIMMER S, 1992, BIOCHEMISTRY-US, V31, P2970, DOI 10.1021/bi00126a018; LoBrutto R, 1998, J AM CHEM SOC, V120, P4410, DOI 10.1021/ja973517s; LOWRY DF, 1992, BIOCHEMISTRY-US, V31, P2977, DOI 10.1021/bi00126a019; MARTELL AE, 1988, CRITICAL STABILITY C, V6, P447; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; MULKS CF, 1982, J AM CHEM SOC, V104, P5906, DOI 10.1021/ja00386a011; MUSTAFI D, 1992, J AM CHEM SOC, V114, P6219, DOI 10.1021/ja00041a046; Neuhard, 1987, ESCHERICHIA COLI SAL, V1, P445; PETER ME, 1990, BIOCHEMISTRY-US, V29, P2876, DOI 10.1021/bi00463a033; PHILLIPS RC, 1969, J BIOL CHEM, V244, P3330; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCATCHARD G, 1950, J AM CHEM SOC, V72, P535, DOI 10.1021/ja01157a138; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; SEIDLER L, 1987, NUCLEIC ACIDS RES, V15, P9263, DOI 10.1093/nar/15.22.9263; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; WAGNER A, 1995, BIOCHEMISTRY-US, V34, P12535, DOI 10.1021/bi00039a007; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WILSON GE, 1977, J BIOL CHEM, V252, P2004; WITTINGHOFER A, 1976, EUR J BIOCHEM, V62, P373, DOI 10.1111/j.1432-1033.1976.tb10169.x; WITTINGHOFER A, 1979, EUR J BIOCHEM, V93, P95, DOI 10.1111/j.1432-1033.1979.tb12798.x; WITTINGHOFER A, 1982, EUR J BIOCHEM, V124, P109, DOI 10.1111/j.1432-1033.1982.tb05912.x; ZEIDLER W, 1995, EUR J BIOCHEM, V229, P596, DOI 10.1111/j.1432-1033.1995.tb20503.x	51	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18728	18733		10.1074/jbc.M102122200	http://dx.doi.org/10.1074/jbc.M102122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11274193	hybrid			2022-12-27	WOS:000169091000013
J	Kondo, T; Higashi, H; Nishizawa, H; Ishikawa, S; Ashizawa, S; Yamada, M; Makita, Z; Koike, T; Hatakeyama, M				Kondo, T; Higashi, H; Nishizawa, H; Ishikawa, S; Ashizawa, S; Yamada, M; Makita, Z; Koike, T; Hatakeyama, M			Involvement of pRB-related p107 protein in the inhibition of S phase progression in response to genotoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; ACTIVE TRANSCRIPTIONAL REPRESSION; DEPENDENT KINASE-ACTIVITY; CYCLIN-CDK COMPLEXES; CELL-CYCLE; DNA-REPLICATION; FUNCTIONAL INACTIVATION; REGULATED EXPRESSION; MAMMALIAN-CELLS; E1A PROTEINS	PRE family pocket proteins consisting of pRB, p107, and p130 are thought to act as a set of growth regulators that inhibit the cell cycle transition from G(1) to S phases by virtue of their interaction with E2F transcription factors. When cells are committed to progressing through the cell cycle at the late G(1) restriction point, they are hyperphosphorylated by G(1) cyclin-cyclin-dependent kinase and are functionally inactivated. Consistent with such a G(1) regulatory role, pRB and p130 are abundantly expressed in quiescent cells. In contrast, p107 is present at low levels in the hypophosphorylated form in quiescent cells. As cells progress toward late G(1) to S phases, the levels of p107 increase, and the majority become hyperphosphorylated, suggesting a possible role of p107 in post-G(1) cell cycle regulation. In this study, we have demonstrated that a nonphosphorylatable and thus constitutively active p107 has the potential to inhibit S phase progression. The levels of the phosphorylation-resistant p107 required for the S phase inhibition are significantly less than those of endogenous p107. We further show herein that the exposure of cells to the DNA-damaging agent, cisplatin, provokes S phase arrest, which is concomitantly associated with the accumulation of hypophosphorylated p107. Furthermore, the S phase inhibitory response to cisplatin is augmented by the ectopic expression of wild type p107, although it is diminished by the adenovirus E1A oncoprotein, which counteracts the pocket protein functions. Because p107 is a major pRB family protein expressed in S phase cells, our results indicate that p107 participates in an inhibition of cell cycle progression in response to DNA damage in S phase cells.	Hokkaido Univ, Sch Med, Dept Med 2, Kita Ku, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 060, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 170, Japan	Hokkaido University; Hokkaido University; Japanese Foundation for Cancer Research	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Higashi, Hideaki/F-6872-2012					ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; HOSHIKAWA Y, 1998, ANAL BIOCHEM, V272, P22355; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Johnson DG, 1998, FRONT BIOSCI, V3, pd447; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Mori A, 1999, ONCOGENE, V18, P6209, DOI 10.1038/sj.onc.1203044; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	68	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17559	17567		10.1074/jbc.M009911200	http://dx.doi.org/10.1074/jbc.M009911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278582	hybrid, Green Published			2022-12-27	WOS:000168730400128
J	Parat, MO; Fox, PL				Parat, MO; Fox, PL			Palmitoylation of caveolin-1 in endothelial cells is post-translational but irreversible	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN ALPHA-SUBUNITS; PLASMA-MEMBRANE; SUBCELLULAR-DISTRIBUTION; ENDOPLASMIC-RETICULUM; LIPID MODIFICATIONS; CHAPERONE COMPLEX; FATTY ACYLATION; HEAT-SHOCK; IN-VITRO	Caveolin-1 is a palmitoylated protein involved in assembly of signaling molecules in plasma membrane subdomains termed caveolae and in intracellular cholesterol transport. Three cysteine residues in the C terminus of caveolin-1 are subject to palmitoylation, which is not necessary for caveolar targeting of caveolin-1. Protein palmitoylation is a post-translational and reversible modification that may be regulated and that in turn may regulate conformation, membrane association, protein-protein interactions, and intracellular localization of the target protein. We have undertaken a detailed analysis of [H-3]palmitate incorporation into caveolin-1 in aortic endothelial cells. The linkage of palmitate to caveolin-1 was hydroxylamine-sensitive and thus presumably a thioester bond. However, contrary to expectations, palmitate incorporation was blocked completely by the protein synthesis inhibitors cycloheximide and puromycin. In parallel experiments to show specificity, palmitoylation of aortic endothelial cell-specific nitric-oxide synthase was unaffected by these reagents. Inhibitors of protein trafficking, brefeldin A and monensin, blocked caveolin-1 palmitoylation, indicating that the modification was not cotranslational but rather required caveolin-1 transport from the endoplasmic reticulum and Golgi to the plasma membrane. In addition, immunophilin chaperones that form complexes with caveolin-1, i.e. FK506-binding protein 52, cyclophilin A, and cyclophilin 40, were not necessary for caveolin-1 palmitoylation because agents that bind immunophilins did not inhibit palmitoylation. Pulse-chase experiments showed that caveolin-1 palmitoylation is essentially irreversible because the release of [SH]palmitate was not significant even after 24 h. These results show that [H-3]palmitate incorporation is limited to newly synthesized caveolin-1, not because incorporation only occurs during synthesis but because the continuous presence of palmitate on caveolin-1 prevents subsequent repalmitoylation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, PL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Parat, Marie-Odile/G-4410-2010	Parat, Marie-Odile/0000-0003-4895-7381	NHLBI NIH HHS [HL/CA54519] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054519] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker TL, 2000, J BIOL CHEM, V275, P22037, DOI 10.1074/jbc.M001813200; CAMP LA, 1993, J BIOL CHEM, V268, P22566; Christner C, 1999, J MED CHEM, V42, P3615, DOI 10.1021/jm991038t; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Das AK, 1997, J BIOL CHEM, V272, P11021; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Field FJ, 1998, J LIPID RES, V39, P333; Fielding CJ, 1997, J LIPID RES, V38, P1503; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Kang YS, 2000, EXP CELL RES, V255, P221, DOI 10.1006/excr.1999.4792; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kurzchalia TV, 1996, FEBS LETT, V389, P52, DOI 10.1016/0014-5793(96)00585-6; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; Yeh DC, 1999, J BIOL CHEM, V274, P33148, DOI 10.1074/jbc.274.46.33148	51	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15776	15782		10.1074/jbc.M006722200	http://dx.doi.org/10.1074/jbc.M006722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278313	hybrid			2022-12-27	WOS:000168623100029
J	Soh, JW; Mao, YH; Liu, L; Thompson, WJ; Pamukcu, R; Weinstein, IB				Soh, JW; Mao, YH; Liu, L; Thompson, WJ; Pamukcu, R; Weinstein, IB			Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; EXPRESSION; APOPTOSIS; SIGNAL; IDENTIFICATION; NUCLEUS; DOMAIN	We recently obtained evidence that treatment of human colon cancer cells with exisulind (sulindac sulfone) and related compounds induces apoptosis by activation of protein kinase G (PKG) and c-Jun kinase (JNK1), The present study further explores this mechanism, We demonstrate that in NIH3T3 cells a constitutively active mutant of PKG causes a dose-dependent activation of JNK1 and thereby transactivates c-Jun and stimulates transcription from the AP-I enhancer element. The activation of JNK1 and the transactivation of c-Jun by this mutant of PKG were inhibited by a dominant negative MEKK1. In vitro assays showed that a purified PKG directly phosphorylated the N-terminal domain of MEKK1. PKG also directly phosphorylated a full-length MEKK1, and this was associated with enhanced MEKK1 phosphorylation. Thus, it appears that PKG activates JNK1 through a novel PKG-MEKK1-SEK1-JNK1 pathway, by directly phosphorylating and activating MEKK1.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Cell Pathways Inc, Horsham, PA 19044 USA	Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, HHSC-1509,701 W 168th St, New York, NY 10032 USA.							Barancik M, 1999, J CARDIOVASC PHARM, V34, P182, DOI 10.1097/00005344-199908000-00002; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Li WQ, 1996, ONCOGENE, V13, P731; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Soh JW, 2000, CLIN CANCER RES, V6, P4136; Stacey P, 1998, BIOCHEM BIOPH RES CO, V247, P249, DOI 10.1006/bbrc.1998.8769; Thompson WJ, 2000, CANCER RES, V60, P3338; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291	21	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16406	16410		10.1074/jbc.C100079200	http://dx.doi.org/10.1074/jbc.C100079200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278263	hybrid			2022-12-27	WOS:000168623100111
J	Lagrue-Lak-Hal, AH; Debili, N; Kingbury, G; Lecut, C; Le Couedic, JP; Villeval, JL; Jandrot-Perrus, M; Vainchenker, W				Lagrue-Lak-Hal, AH; Debili, N; Kingbury, G; Lecut, C; Le Couedic, JP; Villeval, JL; Jandrot-Perrus, M; Vainchenker, W			Expression and function of the collagen receptor GPVI during megakaryocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; GLYCOPROTEIN-VI; HUMAN PLATELETS; GAMMA-CHAIN; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); IMMUNOGLOBULIN SUPERFAMILY; INTRACELLULAR CALCIUM; MOUSE MEGAKARYOCYTES; THROMBOXANE SYNTHASE	In this report, the expression and function of the platelet collagen receptor glycoprotein VI (GPVI) were studied in human megakaryocytes during differentiation and maturation of mobilized blood and cord blood derived CD34(+) cells. By flow cytometry, using an anti-GPVI monoclonal antibody or convulxin, a GPVI-specific ligand, GPVI was detected only on CD41(+) cells including some CD41(+)/CD34(+) cells, suggesting expression at a stage of differentiation similar to CD41, These results were confirmed at the mRNA level using reverse transcription-polymerase chain reaction. GPVI expression was low during megakaryocytic differentiation but increased in the more mature megakaryocytes (CD41(high)). As in platelets, megakaryocyte GPVI associates with the Fc receptor gamma chain (FcR gamma). The FcR gamma chain was detected at the RNA and protein level at all stages of megakaryocyte maturation preceding the expression of GPVI. The other collagen receptor, alpha (2)beta (1) integrin (CD49b/CD29), had a pattern of expression similar to GPVI, Megakaryocytic GPVI was recognized as a 55-kDa protein by immunoblotting and ligand blotting, and thus it presented a slightly lower apparent molecular mass than platelet GPVI (58 kDa), Megakaryocytes began to adhere to immobilized convulxin via GPVI after only 8-10 days of culture, at a time when megakaryocytes were maturing. At this stage of maturation, they also adhered to immobilized collagen by alpha (2)beta (1) integrin-dependent and -independent mechanisms. Convulxin induced a very similar pattern of protein tyrosine phosphorylation in megakaryocytes and platelets including Syk, FcR gamma, and PLCgamma2. Our results showed that GPVI is expressed early during megakaryocytic differentiation but functionally allows megakaryocyte adherence to collagen only at late stages of differentiation when its expression increases.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Millenium Pharmaceut Inc, Cambridge, MA 02139 USA; Fac Xavier Bichat, INSERM, E9907, F-75870 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Vainchenker, W (corresponding author), Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France.		Jandrot-Perrus, Martine/GZM-1526-2022	Villeval, Jean-Luc/0000-0002-0562-925X; JANDROT-PERRUS, Martine/0000-0002-8450-9247; Vainchenker, William/0000-0003-4705-202X				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Barnes M J, 1998, Curr Opin Hematol, V5, P314, DOI 10.1097/00062752-199809000-00002; Briddon SJ, 1999, BLOOD, V93, P3847, DOI 10.1182/blood.V93.11.3847.411k17_3847_3855; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; DEBILI N, 1992, BLOOD, V80, P3022; DEBILI N, 1995, BLOOD, V86, P2516; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; FALLI A, 1994, BIOCHEM J, V298, P87; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Kilpatrick KE, 1998, HYBRIDOMA, V17, P569, DOI 10.1089/hyb.1998.17.569; Kunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; Lagrue AH, 1999, FEBS LETT, V448, P95, DOI 10.1016/S0014-5793(99)00340-3; Lecine P, 2000, BLOOD, V96, P1366, DOI 10.1182/blood.V96.4.1366.h8001366_1366_1373; Lecine P, 1998, BLOOD, V92, P1608, DOI 10.1182/blood.V92.5.1608.417k27_1608_1616; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; Miura Y, 2000, THROMB RES, V98, P301, DOI 10.1016/S0049-3848(00)00182-1; Monnet E, 2000, J BIOL CHEM, V275, P10912, DOI 10.1074/jbc.275.15.10912; Mossuz P, 1997, BRIT J HAEMATOL, V98, P819, DOI 10.1046/j.1365-2141.1997.3013118.x; Mountford JC, 1999, THROMB HAEMOSTASIS, V82, P1153; Murray LJ, 1996, EXP HEMATOL, V24, P236; Nakamura T, 1999, J BIOL CHEM, V274, P11897, DOI 10.1074/jbc.274.17.11897; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RABELLINO EM, 1979, J EXP MED, V149, P1273, DOI 10.1084/jem.149.6.1273; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAVASSOLI M, 1981, BRIT J HAEMATOL, V48, P25; TRONIKLEROUX D, 1995, J EXP MED, V181, P2141, DOI 10.1084/jem.181.6.2141; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; VINCI G, 1984, BRIT J HAEMATOL, V56, P589, DOI 10.1111/j.1365-2141.1984.tb02184.x; Vitrat N, 2000, THROMB HAEMOSTASIS, V83, P759, DOI 10.1055/s-0037-1613905; Vyas P, 1999, BLOOD, V93, P2867; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; ZUTTER MM, 1995, BLOOD, V86, P3006; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	48	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15316	15325		10.1074/jbc.M009117200	http://dx.doi.org/10.1074/jbc.M009117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278467	Green Published, hybrid			2022-12-27	WOS:000168528800105
J	Shigematsu, S; Miller, SL; Pessin, JE				Shigematsu, S; Miller, SL; Pessin, JE			Differentiated 3T3L1 adipocytes are composed of heterogenous cell populations with distinct receptor tyrosine kinase signaling properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; INDUCED GLUCOSE-TRANSPORT; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; INSULIN-RECEPTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE	Various studies have demonstrated that the platelet-derived growth factor (PDGF) receptor in adipocytes can activate PI 3-kinase activity without affecting insulin-responsive glucose transporter (GLUT4) translocation, To investigate this phenomenon of receptor signaling specificity, we utilized single cell analysis to determine the cellular distribution and signaling properties of PDGF and insulin in differentiated 3T3L1 adipocytes, The insulin receptor was highly expressed in a large percentage of the cell population (>95%) that also expressed caveolin 2 and GLUT4 with very low levels of the PDGF receptor. In contrast, the PDGF receptor was only expressed in similar to 10% of the differentiated 3T3L1 cell population with relatively low levels of the insulin receptor, caveolin 2, and GLUT4, Consistent with this observation, insulin stimulated the phosphorylation of Akt in the caveolin 2- and GLUT4-positive cells, whereas PDGF primarily stimulated Akt phosphorylation in the caveolin 2- and GLUT4-negative cell population. Furthermore, transfection of the PDGF receptor in the insulin receptor-, GLUT4-, and caveolin 2-positive cells resulted in the ability of PDGF to stimulate GLUT4 translocation, These data demonstrate that differentiated 3T3L1 adipocytes are not a homogeneous population of cells, and the lack of PDGF receptor expression in the GLUT4-positive cell population accounts for the inability of the endogenous PDGF receptor to activate GLUT4 translocation.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	Jeffrey-Pessin@uiowa.edu		Miller, Sarah/0000-0002-2726-962X	NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823, P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Elmendorf JS, 1999, J BIOL CHEM, V274, P37357, DOI 10.1074/jbc.274.52.37357; FAN JY, 1983, J CELL SCI, V61, P219; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; HARDY RW, 1995, ENDOCRINOLOGY, V136, P431, DOI 10.1210/en.136.2.431; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kazlauskas A, 2000, NAT CELL BIOL, V2, pE78, DOI 10.1038/35010508; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang LH, 1999, J BIOL CHEM, V274, P19246, DOI 10.1074/jbc.274.27.19246; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317	50	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15292	15297		10.1074/jbc.M009684200	http://dx.doi.org/10.1074/jbc.M009684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278545	hybrid			2022-12-27	WOS:000168528800102
J	Seth, KA; Majzoub, JA				Seth, KA; Majzoub, JA			Repressor element silencing transcription factor/neuronrestrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; CELL-ADHESION MOLECULE; SODIUM-CHANNEL GENE; MONOPHOSPHATE-RESPONSIVE ELEMENT; ACETYLCHOLINE-RECEPTOR GENE; HISTONE DEACETYLASE; TARGET GENES; PHEOCHROMOCYTOMA CELLS; REGULATORY ELEMENTS; NG108-15 CELLS	The repressor element-1/neuron-restrictive silencing element (RE-1/NRSE) mediates transcriptional repression by the repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) in many neuron-specific genes. REST/NRSF is expressed most highly in non-neural tissues, where it is thought to repress gene transcription, but is also found in developing neurons and at low levels in the brain. Its null mutation in vivo results in embryonic lethality in mice. While the RE-1/NRSE-mediated repressive influence of REST/NRSF is well established, results in transgenic studies have suggested that the action of the system is more complex. Here, we report that transcription of the corticotropin releasing hormone (CRH) gene is regulated by REST/NRSF, in part through the RE-1/NRSE. Expression of transfected Crh-luciferase constructs was down-regulated by REST/NRSF in a RE-1/NRSE-dependent fashion in both muscle-derived L6 and REST/NRSF co-transfected neuronal PC12 cells. Treatment of L6 cells with trichostatin A revealed that REST/NRSF repression depends, in part, on histone deacetylase activity in these cells. In another neuronal cell line, NG108, REST/NRSF also repressed expression from constructs containing an intact RE-1/NRSE. However, unexpectedly, REST/NRSF up-regulated expression levels of constructs lacking an intact RE-1/NRSE. These results suggest that REST/NRSF can act as both a repressor of Crh transcription, via the Crh RE-1/NRSE, and an enhancer of Crh transcription, via a mechanism independent of the Crh RE-1/NRSE.	Harvard Univ, Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Majzoub, JA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA.							Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; BERGSBAKEN CL, 1993, J PHARMACOL EXP THER, V264, P1474; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; GRUNSTEIN M, 1997, NATURE, V398, P349; GUARDIOLADIAZ HM, 1994, J BIOL CHEM, V269, P14784; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kallunki P, 1998, P NATL ACAD SCI USA, V95, P3233, DOI 10.1073/pnas.95.6.3233; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; Karalis KP, 1999, P NATL ACAD SCI USA, V96, P7093, DOI 10.1073/pnas.96.12.7093; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; MAKINO S, 1994, BRAIN RES, V640, P105, DOI 10.1016/0006-8993(94)91862-7; Malkoski SP, 1999, MOL ENDOCRINOL, V13, P1629, DOI 10.1210/me.13.10.1629; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Mu WT, 1999, MOL BRAIN RES, V67, P137, DOI 10.1016/S0169-328X(99)00049-2; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; MUGLIA LJ, 1994, J CLIN INVEST, V93, P2066, DOI 10.1172/JCI117201; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Myers SJ, 1998, J NEUROSCI, V18, P6723; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Palm K, 1998, J NEUROSCI, V18, P1280; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Sambrook J., 2002, MOL CLONING LAB MANU; Scatena CD, 1998, MOL ENDOCRINOL, V12, P1228, DOI 10.1210/me.12.8.1228; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Tojima T, 2000, NEUROSCI RES, V37, P153, DOI 10.1016/S0168-0102(00)00110-3; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAN LP, 1990, ENDOCRINOLOGY, V127, P1412, DOI 10.1210/endo-127-3-1412; Venihaki M, 1997, ENDOCRINOLOGY, V138, P698, DOI 10.1210/en.138.2.698; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	57	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13917	13923		10.1074/jbc.M007745200	http://dx.doi.org/10.1074/jbc.M007745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278361	hybrid			2022-12-27	WOS:000168356600058
J	You, J; Reilly, GC; Zhen, XC; Yellowley, CE; Chen, Q; Donahue, HJ; Jacobs, CR				You, J; Reilly, GC; Zhen, XC; Yellowley, CE; Chen, Q; Donahue, HJ; Jacobs, CR			Osteopontin gene regulation by oscillatory fluid flow via intracellular calcium mobilization and activation of mitogen-activated protein kinase in MC3T3-E1 osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CA2+ RELEASE; SMOOTH-MUSCLE-CELLS; BONE-CELLS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; SHEAR-STRESS; INOSITOL TRISPHOSPHATE; MECHANICAL STRAIN; CYCLIC-AMP; INHIBITION	Recently fluid flow has been shown to be a potent physical stimulus in the regulation of bone cell metabolism. However, most investigators have applied steady or pulsing flow profiles rather than oscillatory fluid flow, which occurs in vivo because of mechanical loading. Here oscillatory fluid flow was demonstrated to be a potentially important physical signal for loading-induced changes in bone cell metabolism. We selected three well known biological response variables including intracellular calcium (Ca-i(2+)), mitogen-activated protein kinase (MAPK) activity, and osteopontin (OPN) mRNA levels to examine the response of MC3T3-E1 osteoblastic cells to oscillatory fluid flow with shear stresses ranging from 2 to -2 Newtons/m(2) at 1 Hz, which is in the range expected to occur during routine physical activities. Our results showed that within 1 min, oscillatory flow induced cell Ca-i(2+) mobilization, whereas two MAPKs (ERK and p38) were activated over a 2-h time frame. However, there was no activation of JNK. Furthermore 2 h of oscillatory fluid flow increased steady-state OPN mRNA expression levels by approximately 4-fold, 24 h after exposure to fluid flow. The presence of both ERK and p38 inhibitors and thapsigargin completely abolished the effect of oscillatory flow on steady-state OPN mRNA levels. In addition, experiments using a variety of pharmacological agents suggest that oscillatory flow induces Ca-i(2+) mobilization via the L-type voltage-operated calcium channel and the inositol 1,4,5-trisphosphate pathway.	Stanford Univ, Biomech Engn Div, Dept Mech Engn, Stanford, CA 94305 USA; Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA; Drexel Univ, MCP Hahneman Sch Med, Dept Physiol & Pharmacol, Philadelphia, PA 19129 USA; Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, Dept Vet Affairs, Palo Alto, CA 94304 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Drexel University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Jacobs, CR (corresponding author), Stanford Univ, Biomech Engn Div, Dept Mech Engn, Durand 211, Stanford, CA 94305 USA.	christopher.jacobs@stanford.edu	Chen, Qian/C-4354-2011; Reilly, Gwendolen C./C-3456-2009	Chen, Qian/0000-0003-4406-5618; Reilly, Gwendolen C./0000-0003-1456-1071; zhen, xuechu/0000-0001-7458-2566	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013087, R01AG017021] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45989] Funding Source: Medline; NIA NIH HHS [AG13087, AG00811, AG17021] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Ajubi NE, 1999, AM J PHYSIOL-ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P320, DOI 10.2106/00004623-199173030-00002; Brown TD, 2000, J BIOMECH, V33, P3, DOI 10.1016/S0021-9290(99)00177-3; BUCKLEY MJ, 1988, BONE MINER, V4, P225; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; Chin TY, 1998, AM J PHYSIOL-CELL PH, V275, pC1255, DOI 10.1152/ajpcell.1998.275.5.C1255; COWIN SC, 1995, J BIOMECH, V28, P1281, DOI 10.1016/0021-9290(95)00058-P; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FERRANTE J, 1990, BIOCHEM PHARMACOL, V39, P1267, DOI 10.1016/0006-2952(90)90001-2; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; GERSTENFELD LC, 1995, ANN NY ACAD SCI, V760, P67, DOI 10.1111/j.1749-6632.1995.tb44621.x; Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945-053X(00)00108-6; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hamada T, 1999, NEUROSCI LETT, V263, P125, DOI 10.1016/S0304-3940(99)00111-1; Hamill OP, 1996, PHARMACOL REV, V48, P231; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; HASSELBACH W, 1987, FEBS LETT, V221, P119, DOI 10.1016/0014-5793(87)80364-2; HUNG CT, 1995, CLIN ORTHOP RELAT R, P256; Hung CT, 2000, J BIOMECH, V33, P73, DOI 10.1016/S0021-9290(99)00176-1; Hung CT, 1996, J BIOMECH, V29, P1403, DOI 10.1016/0021-9290(96)84535-0; Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021-9290(96)84536-2; Jacobs CHRISTOPHER R., 2000, Comput Methods Biomech Biomed Engin, V3, P31, DOI 10.1080/10255840008915252; Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Khodakhah K, 1997, BIOPHYS J, V73, P3349, DOI 10.1016/S0006-3495(97)78359-0; KUBOTA T, 1993, ARCH ORAL BIOL, V38, P23, DOI 10.1016/0003-9969(93)90150-K; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; McDonald F, 1996, ARCH BIOCHEM BIOPHYS, V326, P31, DOI 10.1006/abbi.1996.0043; MCLEOD KJ, 1991, ELECTROMAGNETICS IN MEDICINE AND BIOLOGY, P111; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; PAVALKO FM, 1998, AM J PHYSIOL, V275, pR1591; PIEKARSKI K, 1977, NATURE, V269, P80, DOI 10.1038/269080a0; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756-3282(96)00260-8; Reilly GC, 2000, J BONE MINER RES, V15, pS508; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RODAN GA, 1975, SCIENCE, V189, P467, DOI 10.1126/science.168639; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Tate MLK, 1998, BONE, V22, P107; Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; Walker LM, 2000, J CELL BIOCHEM, V79, P648, DOI 10.1002/1097-4644(20001215)79:4<648::AID-JCB130>3.0.CO;2-Q; Weigl LG, 2000, J PHYSIOL-LONDON, V525, P461, DOI 10.1111/j.1469-7793.2000.t01-1-00461.x; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yellowley CE, 1997, AM J PHYSIOL-CELL PH, V273, pC30, DOI 10.1152/ajpcell.1997.273.1.C30; Yellowley CE, 1999, J CELL PHYSIOL, V180, P402, DOI 10.1002/(SICI)1097-4652(199909)180:3<402::AID-JCP11>3.0.CO;2-4; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453	63	295	315	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13365	13371		10.1074/jbc.M009846200	http://dx.doi.org/10.1074/jbc.M009846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278573	hybrid			2022-12-27	WOS:000168198600123
J	Machida, K; Tsukiyama-Kohara, K; Seike, E; Tone, S; Shibasaki, F; Shimizu, M; Takahashi, H; Hayashi, Y; Funata, N; Taya, C; Yonekawa, H; Kohara, M				Machida, K; Tsukiyama-Kohara, K; Seike, E; Tone, S; Shibasaki, F; Shimizu, M; Takahashi, H; Hayashi, Y; Funata, N; Taya, C; Yonekawa, H; Kohara, M			Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; KAPPA-B; APOPTOSIS; MITOCHONDRIA; ACTIVATION; DEATH; ANTIBODY; LIGAND; CELLS; BCL-2	Persistent hepatitis C virus (HCV) infection often progresses to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Numerous viruses have been reported to escape from apoptotic mechanism to maintain persistent infection. In the present study, we characterized the effect of HCV proteins on the Fas signal using HCV transgenic mice, which expressed core, E1, E2, and NS2 proteins, regulated by the Cre/loxP switching system. The transgene expression of HCV transgenic mice caused resistance to Fas antibody stimulated lethality. Apoptotic cell death in the liver of HCV protein expressing mice was significantly reduced compared with nonexpressing mice. Histopathological analysis and DNA fragmentation analysis revealed that the HCV proteins suppressed Fas-mediated apoptotic cell death. To identify the target pathway of HCV proteins, we characterized caspase activity. The activation of caspase-9 and -3/7 but not caspase-8 was inhibited by HCV proteins. Cytochrome c release from mitochondria was inhibited in HCV protein expressing mice. These results indicated that the expression of HCV proteins may directly or indirectly inhibit Fas-mediated apoptosis and death in mice by repressing the release of cytochrome c from mitochondria, thereby suppressing caspase-9 and -3/7 activation. These results suggest that HCV may cause persistent infection, as a result of suppression of Fas-mediated cell death.	Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Self Def Forces Cent Hosp, Dept Internal Med, Setagaya Ku, Tokyo 1540001, Japan; Kawasaki Med Sch, Dept Biochem, Okayama 710192, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Bunkyo Ku, Tokyo 1138613, Japan; Nippon Med Sch, Dept Microbiol & Immunol, Bunkyo Ku, Tokyo 1138602, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Inst Med Sci, Lab Anim Sci, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; University of Tokyo; Kawasaki Medical School; Tokyo Metropolitan Institute of Medical Science; Nippon Medical School; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Institute of Medical Science	Kohara, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	mkohara@rinshoken.or.jp	Tone, Shigenobu/L-2694-2019					ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chen P, 1998, J BIOL CHEM, V273, P5815, DOI 10.1074/jbc.273.10.5815; Derfuss T, 1998, J VIROL, V72, P5897, DOI 10.1128/JVI.72.7.5897-5904.1998; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Honda A, 2000, J HEPATOL, V33, P440, DOI 10.1016/S0168-8278(00)80280-9; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kashiwakuma T, 1996, J IMMUNOL METHODS, V190, P79, DOI 10.1016/0022-1759(95)00261-8; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kishi S, 1997, J EXP MED, V186, P57, DOI 10.1084/jem.186.1.57; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; ROUQUET N, 1995, ONCOGENE, V11, P1061; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1999, J IMMUNOL, V163, P4909; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	35	89	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12140	12146		10.1074/jbc.M010137200	http://dx.doi.org/10.1074/jbc.M010137200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278624	hybrid			2022-12-27	WOS:000168081800095
J	Tarabykina, S; Scott, DJ; Herzyk, P; Hill, TJ; Tame, JRH; Kriajevska, M; Lafitte, D; Derrick, PJ; Dodson, GG; Maitland, NJ; Lukanidin, EM; Bronstein, IB				Tarabykina, S; Scott, DJ; Herzyk, P; Hill, TJ; Tame, JRH; Kriajevska, M; Lafitte, D; Derrick, PJ; Dodson, GG; Maitland, NJ; Lukanidin, EM; Bronstein, IB			The dimerization interface of the metastasis-associated protein S100A4 (Mts1) - In vivo and in vitro studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; HYDROPHOBIC CORE SUBSTITUTIONS; RESONANCE MASS-SPECTROMETRY; NONMUSCLE MYOSIN; CALBINDIN D-9K; 2-HYBRID SYSTEM; APO CALCYCLIN; LAMM EQUATION; ION-BINDING; HEAVY-CHAIN	The S100 calcium-binding proteins are implicated in signal transduction, motility, and cytoskeletal dynamics. The three-dimensional structure of several 5100 proteins revealed that the proteins form non-covalent dimers. However, the mechanism of the S100 dimerization is still obscure. In this study we characterized the dimerization of S100A4 (also named Mts1) in vitro and in vivo. Analytical ultracentrifugation revealed that apoS100A4 was present in solution as a mixture of monomers and dimers in a rapidly reversible equilibrium (K-d = 4 +/- 2 muM) The binding of calcium promoted dimerization. Replacement of Tyr-75 by Phe resulted in the stabilization of the dimer. Helix IV is known to form the major part of the dimerization interface in homologous S100 proteins. By using the yeast two-hybrid system we showed that only a few residues of helix TV, namely Phe-72, Tyr-75, Phe-78, and Leu-79, are essential for dimerization in vivo. A homology model demonstrated that these residues form a hydrophobic cluster on helix TV. Their role is to stabilize the structure of individual subunits rather than provide specific interactions across the dimerization surface. Our mutation data showed that the specificity at the dimerization surface is not particularly stringent, which is consistent with recent: data indicating that S100 proteins can form heterodimers.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen, Denmark; Univ York, Dept Biol, Heslington, England; Univ York, Dept Chem, York Struct Biol Ctr, York YO1 5DD, N Yorkshire, England; Univ York, Dept Biol, YCR Canc Res Unit, York YO10 5DD, N Yorkshire, England; Univ Warwick, Dept Chem, Inst Mass Spectrometry, Coventry CV4 7AL, W Midlands, England; Natl Inst Med Res, London NW7 1AA, England	Danish Cancer Society; University of York - UK; University of York - UK; University of York - UK; University of Warwick; MRC National Institute for Medical Research	Tarabykina, S (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, Inst Mol Biol, DK-1353 Copenhagen, Denmark.	panina@hotmail.com		Maitland, Norman/0000-0003-1607-9035; Scott, David/0000-0002-6726-2078; lafitte, daniel/0000-0001-9921-7522				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Brodersen DE, 1998, STRUCTURE, V6, P477, DOI 10.1016/S0969-2126(98)00049-5; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Davies MPA, 1996, ONCOGENE, V13, P1631; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V10, P1597; Gribenko AV, 1998, J MOL BIOL, V283, P679, DOI 10.1006/jmbi.1998.2116; Heck AJR, 1997, ANAL CHEM, V69, P3603, DOI 10.1021/ac970254b; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Ishikawa K, 2000, ACTA CRYSTALLOGR D, V56, P559, DOI 10.1107/S0907444900002833; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Julenius K, 1998, BIOCHEMISTRY-US, V37, P8915, DOI 10.1021/bi972642d; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; Kragelund BB, 1998, BIOCHEMISTRY-US, V37, P8926, DOI 10.1021/bi9726436; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lafitte D, 1999, EUR J BIOCHEM, V261, P337, DOI 10.1046/j.1432-1327.1999.00284.x; Landar A, 1998, BIOCHEMISTRY-US, V37, P17429, DOI 10.1021/bi9817921; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Lavanant H, 1998, ANAL BIOCHEM, V255, P74, DOI 10.1006/abio.1997.2441; LOO JA, 1995, J MASS SPECTROM, V30, P180, DOI 10.1002/jms.1190300127; Maler L, 1999, J BIOMOL NMR, V13, P233, DOI 10.1023/A:1008315517955; Mandinova A, 1998, J CELL SCI, V111, P2043; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Moroz OV, 2001, ACTA CRYSTALLOGR D, V57, P20, DOI 10.1107/S090744490001458X; Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Osterloh D, 1998, CELL CALCIUM, V24, P137, DOI 10.1016/S0143-4160(98)90081-1; Potts BCM, 1996, PROTEIN SCI, V5, P2162, DOI 10.1002/pro.5560051103; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	53	46	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24212	24222		10.1074/jbc.M009477200	http://dx.doi.org/10.1074/jbc.M009477200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11278510	hybrid			2022-12-27	WOS:000169531100130
J	Zhang, LQ; Ikegami, M; Crouch, EC; Korfhagen, TR; Whitsett, JA				Zhang, LQ; Ikegami, M; Crouch, EC; Korfhagen, TR; Whitsett, JA			Activity of pulmonary surfactant protein-D (SP-D) in vivo is dependent on oligomeric structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TARGETED MICE; CARBOHYDRATE-RECOGNITION DOMAIN; MANNOSE-BINDING PROTEIN; ALVEOLAR MACROPHAGES; TRANSGENIC MICE; IN-VIVO; EXPRESSION; LOCALIZATION; PHAGOCYTOSIS; ACCUMULATION	Pulmonary surfactant protein-D (SP-D) is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung. SP-D is assembled predominantly as dodecamers consisting of four homotrimeric subunits each. Association of these subunits is stabilized by interchain disulfide bonds involving two conserved amino-terminal cysteine residues (Cys-IB and Cys-20), Mutant recombinant rat SP-D lacking these residues (RrSP-Dser15/20) is secreted in cell culture as trimeric subunits rather than as dodecamers. In this study, transgenic mice that express this mutant were generated to elucidate the functional importance of SP-D oligomerization in vivo. Expression of RrSP-Dser15/20 failed to correct the pulmonary phospholipid accumulation and emphysema characteristic of SP-D null (mSP-D-/-) mice. Expression of high concentrations of the mutant protein in wild-type mice reduced the abundance of disulfide cross-linked oligomers of endogenous SP-D in the bronchoalveolar lavage fluid and demonstrated a phenotype that partially overlapped with that of the SP-D-/- mice; the animals developed emphysema and foamy macrophages without the associated abnormalities in alveolar phospholipids typical of SP-D-/- mice. Development of foamy macrophages in SP-D-deficient mice is not secondary to the increased abundance of surfactant phospholipids. Disulfide cross-linked SP-D oligomers are required for the regulation of surfactant phospholipid homeostasis and the prevention of emphysema and foamy macrophages in vivo.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Cincinnati Children's Hospital Medical Center; Washington University (WUSTL)	Whitsett, JA (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329, P01HL061646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63329, HL61646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beck DC, 2000, J BIOL CHEM, V275, P3371, DOI 10.1074/jbc.275.5.3371; Borron PJ, 1998, J IMMUNOL, V161, P4599; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Cai GZ, 1999, AM J PHYSIOL-LUNG C, V276, pL131, DOI 10.1152/ajplung.1999.276.1.L131; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1993, AM J PATHOL, V142, P241; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; Ferguson JS, 1999, J IMMUNOL, V163, P312; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156, DOI 10.1152/ajplung.1997.273.6.L1156; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; HULL WM, 2000, AM J RESP CRIT CARE, V161, P42; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; MATSUSHITA M, 1995, BIOCHEM J, V311, P1021, DOI 10.1042/bj3111021; MOTWANI M, 1995, J IMMUNOL, V155, P5671; Poulain FR, 1999, AM J RESP CELL MOL, V20, P1049, DOI 10.1165/ajrcmb.20.5.3497; Reid KBM, 1998, BBA-MOL BASIS DIS, V1408, P290, DOI 10.1016/S0925-4439(98)00074-X; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; Wang JY, 1996, CLIN EXP IMMUNOL, V106, P367, DOI 10.1046/j.1365-2249.1996.d01-838.x; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997	37	56	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19214	19219		10.1074/jbc.M010191200	http://dx.doi.org/10.1074/jbc.M010191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278637	hybrid			2022-12-27	WOS:000169091000078
J	Sellers, LK; Simon, J; Lundahl, TS; Cousens, DJ; Humphrey, PPA; Barnard, EA				Sellers, LK; Simon, J; Lundahl, TS; Cousens, DJ; Humphrey, PPA; Barnard, EA			Adenosine nucleotides acting at the human P2Y(1) receptor stimulate mitogen-activated protein kinases and induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; GLOMERULAR MESANGIAL CELLS; HETEROTRIMERIC G-PROTEINS; SIGNAL-REGULATED KINASE; COUPLED RECEPTORS; PHOSPHOLIPASE-C; PHOSPHOINOSITIDE 3-KINASE; NEURONAL DIFFERENTIATION; MEDIATED PROLIFERATION; PURINERGIC RECEPTOR	For the widely distributed P2Y receptors for nucleotides, the transductional and functional responses downstream of their coupling to G proteins are poorly characterized. Here we describe apoptotic induction and the associated differential stimulation of mitogen-activated protein (MAP) kinase family members by the human P2Y(1) receptor. The potent P2Y(1) receptor agonist, 2-methylthio-ADP (2-MeSADP), stimulated the extracellular-signal regulated kinases (ERK1/2) (EC50 similar to5 nM) as well as several, but not all isoforms detected, of the stress-activated protein kinase (SAPK) family. Phospho-isoforms of p38 were unaffected. The induced kinase activity was blocked by the P2Y(1) receptor-selective antagonist, adenosine-2'-phosphate-5'-phosphate, but unaffected by pertussis toxin, In addition, the endogenous ligand ADP, and significantly also 2-MeSATP, induced concentration-dependent phosphorylation changes in the same MAP kinase family members. The sustained activation of ERK1/2 was associated with Elk-1 phosphorylation that was abolished by the MEK1 inhibitor, PD 98059, However, the concomitant transient activation of the SAPKs was not sufficient to induce c-Jun or ATF-2 phosphorylation, The transient phase of the ERK activity was partially inhibited either by the phosphatidylinositol 3-kinase inhibitor, LY 294002, or the PKC inhibitor, Go 6976, In addition, the Src inhibitor, PP1, or expression of dominant negative Has also attenuated the transient phase of ERK phosphorylation. In contrast, inhibition of Ras or Src had no effect on the sustained ERK activity, which was critically dependent on phosphatidylinositol 3-kinase, The transient SAPK activity was suppressed by expression of a dominant negative form of MKK4. Furthermore, this kinase-deficient mutant inhibited 2-MeSADP-induced caspase-3 stimulation and the associated decrease in cell number. In conclusion, adenosine di- and triphosphate stimulation of the human P2Y(1) receptor can transiently activate the Ras-ERK cascade via the cooperative effects of phosphatidylinositol 3-kinase, Src and PKC, The sustained ERK stimulation, via a Ras-insensitive pathway, culminates in Elk-1 activation without inducing a proliferation effect. The transient SAPK activity did not evoke transcription factor phosphorylation but was required for the P2Y(1) receptor-mediated apoptotic function.	Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Cambridge CB2 1QJ, England; Glaxo Wellcome Med Res Ctr, Dept Mol Pharmacol, Receptor Syst Unit 7TM, Stevenage 2G1 2NY, Herts, England	University of Cambridge; GlaxoSmithKline	Sellers, LK (corresponding author), Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.							Albert JL, 1997, BRIT J PHARMACOL, V122, P935, DOI 10.1038/sj.bjp.0701453; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Barnard EA, 1997, MOL NEUROBIOL, V15, P103, DOI 10.1007/BF02740631; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; Charlesworth A, 1997, ONCOGENE, V14, P2323, DOI 10.1038/sj.onc.1201075; Coso OA, 1996, J BIOL CHEM, V271, P3963; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FADOK VA, 1992, J IMMUNOL, V148, P2207; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Filippov AK, 2000, BRIT J PHARMACOL, V129, P1063, DOI 10.1038/sj.bjp.0703185; Guizzetti M, 1996, EUR J PHARMACOL, V297, P265, DOI 10.1016/0014-2999(95)00746-6; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Harada H, 2000, KIDNEY INT, V57, P949, DOI 10.1046/j.1523-1755.2000.00911.x; Harper S, 1998, BRIT J PHARMACOL, V124, P703, DOI 10.1038/sj.bjp.0701895; Hechler B, 1998, MOL PHARMACOL, V53, P727, DOI 10.1124/mol.53.4.727; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Huwiler A, 2000, BRIT J PHARMACOL, V129, P612, DOI 10.1038/sj.bjp.0703077; HUWILER A, 1994, BRIT J PHARMACOL, V113, P1455, DOI 10.1111/j.1476-5381.1994.tb17160.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lenz G, 2000, BRIT J PHARMACOL, V129, P927, DOI 10.1038/sj.bjp.0703138; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; Moore D, 2000, J COMP NEUROL, V421, P374, DOI 10.1002/(SICI)1096-9861(20000605)421:3<374::AID-CNE6>3.0.CO;2-Z; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; Patel V, 1996, BIOCHEM J, V320, P221, DOI 10.1042/bj3200221; Paul A, 2000, J BIOL CHEM, V275, P13243, DOI 10.1074/jbc.275.18.13243; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Ralevic V, 1998, PHARMACOL REV, V50, P413; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Sellers LA, 1999, J BIOL CHEM, V274, P16423, DOI 10.1074/jbc.274.23.16423; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Sellers LA, 1999, J BIOL CHEM, V274, P24280, DOI 10.1074/jbc.274.34.24280; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Simon J, 1995, EUR J PHARM-MOLEC PH, V291, P281, DOI 10.1016/0922-4106(95)90068-3; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tu MT, 2000, BRIT J PHARMACOL, V129, P1481, DOI 10.1038/sj.bjp.0703182; VALEINS H, 1992, MOL PHARMACOL, V42, P1033; Webb TE, 1998, NEUROSCIENCE, V84, P825, DOI 10.1016/S0306-4522(97)00478-8; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	62	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16379	16390		10.1074/jbc.M006617200	http://dx.doi.org/10.1074/jbc.M006617200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278310	hybrid			2022-12-27	WOS:000168623100108
J	Howe, AK				Howe, AK			Cell adhesion regulates the interaction between Nck and p21-activated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN NCK; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MEMBRANE LOCALIZATION; ACTIVATION; PAK; ACTIN; RECEPTOR; RAC; PHOSPHORYLATION	The p21-activated kinases (PAKs) are important mediators of cytoskeletal reorganization, cell motility and transcriptional events regulated by the Rho family GTPases Pac and Cdc42. PAK activation by serum components is strongly dependent on cell adhesion to the extracellular matrix (ECM). PAK binds directly to the Nck adapter protein, an interaction thought to play an important role in regulation and localization of PAK activity. This report demonstrates that the interaction of PAK with Nck is regulated dynamically by cell adhesion. PAK-Nck binding is rapidly lost after cell detachment and rapidly restored after re-adhesion to the ECM protein fibronectin, suggesting a rapidly reversible mode of regulation. Furthermore, the loss of Nck binding correlates with changes in the phosphorylation state of PAK in nonadherent cells, as evidenced by electrophoretic mobility shift and phosphorylation within a sequence known to mediate interaction with Nck. The ability of cell adhesion to regulate PAK phosphorylation and interaction with Nck may contribute to the anchorage-dependence of PAK activation as well as to the localization of activated PAK within a cell.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Howe, AK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM26165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KING CC, 2000, J BIOL CHEM; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Symons M, 2000, CURR BIOL, V10, pR535, DOI 10.1016/S0960-9822(00)00588-1; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; Voisin L, 1999, BIOCHEM J, V341, P217, DOI 10.1042/0264-6021:3410217; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	34	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14541	14544		10.1074/jbc.C000797200	http://dx.doi.org/10.1074/jbc.C000797200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278241	Green Submitted, hybrid			2022-12-27	WOS:000168528800003
J	Narita, M; Mizoguchi, H; Suzuki, T; Narita, M; Dun, NJ; Imai, S; Yajima, Y; Nagase, H; Suzuki, T; Tseng, LF				Narita, M; Mizoguchi, H; Suzuki, T; Narita, M; Dun, NJ; Imai, S; Yajima, Y; Nagase, H; Suzuki, T; Tseng, LF			Enhanced mu-opioid responses in the spinal cord of mice lacking protein kinase C gamma isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR AGONIST; FUNCTIONAL EXPRESSION; CELLULAR-RESPONSES; MOLECULAR-CLONING; MUTANT MICE; PKC-GAMMA; MOUSE; RAT; LOCALIZATION; IMMUNOREACTIVITY	The protein kinase C (PKC)gamma isoform is a major pool of the PKC family in the mammalian spinal cord. PKC gamma is distributed strategically in the superficial layers of the dorsal horn and, thus, may serve as an important biochemical substrate in sensory signal processing including pain. Here we report that mu -opioid receptor-mediated analgesia/antinociception and activation of G-proteins in the spinal cord are enhanced in PKC gamma knockout mice. In contrast, delta- and kappa -opioidergic and ORL-1 receptor-mediated activation of G-proteins in PKC gamma knockout mice was not altered significantly relative to the wildtype mice. Deletion of PKC gamma had no significant effect on the mRNA product of spinal mu -opioid receptors but caused an increase of maximal binding of the mu -opioid receptor agonist [H-3][D-Ala(2),N-Me-Phe(4),Gly(5)-ol] enkephalin in spinal cord membranes obtained from PKC gamma knockout mice. These findings suggest that deletion of PKC gamma genes protects the functional mu -opioid receptors from degradation by phosphorylation. More importantly the present data provide direct evidence that PKC gamma constitutes an essential pathway through which phosphorylation of mu -opioid receptors occurs.	Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA; Hoshi Univ, Sch Pharm, Dept Toxicol, Tokyo 1428501, Japan; Toray Ind Inc, Pharmaceut Res Labs, Kamakura, Kanagawa 2488555, Japan; E Tennessee State Univ, James H Quillen Coll Med, Dept Pharmacol, Johnson City, TN 37614 USA	Medical College of Wisconsin; Hoshi University; Toray Industries, Inc.; East Tennessee State University	Tseng, LF (corresponding author), Med Coll Wisconsin, Dept Anesthesiol, Med Educ Bldg,Rm M4308,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			Imai, Satoshi/0000-0003-4737-8695	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039646, R01NS018710, R37NS018710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003811] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 03811] Funding Source: Medline; NINDS NIH HHS [NS39646, NS18710] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; Aicher SA, 2000, SYNAPSE, V36, P12, DOI 10.1002/(SICI)1098-2396(200004)36:1<12::AID-SYN2>3.0.CO;2-E; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DUN NJ, 1993, NEUROSCIENCE, V54, P845, DOI 10.1016/0306-4522(93)90579-5; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MAO JR, 1992, BRAIN RES, V588, P144, DOI 10.1016/0006-8993(92)91354-H; MAO JR, 1995, BRAIN RES, V677, P257, DOI 10.1016/0006-8993(95)00161-I; Martin WJ, 1999, NEUROSCIENCE, V88, P1267, DOI 10.1016/S0306-4522(98)00314-5; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; Narita M, 1996, EUR J PHARMACOL, V311, P121, DOI 10.1016/0014-2999(96)00359-7; Narita M, 1997, NEUROSCIENCE, V76, P291; NARITA M, 1995, EUR J PHARMACOL, V280, pR1, DOI 10.1016/0014-2999(95)00322-C; Narita M, 1996, EUR J PHARMACOL, V310, pR1, DOI 10.1016/0014-2999(96)00493-1; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PEI G, 1995, MOL PHARMACOL, V48, P173; Polgar E, 1999, BRAIN RES, V833, P71, DOI 10.1016/S0006-8993(99)01500-0; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958	30	54	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15409	15414		10.1074/jbc.M009716200	http://dx.doi.org/10.1074/jbc.M009716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278552	hybrid			2022-12-27	WOS:000168528800116
J	Vincent, T; Jourdan, M; Sy, MS; Klein, B; Mechti, N				Vincent, T; Jourdan, M; Sy, MS; Klein, B; Mechti, N			Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-I; MULTIPLE-MYELOMA; ADHESION MOLECULES; INTERFERON-ALPHA; IFN-ALPHA; CD44; APOPTOSIS; BINDING; EXPRESSION	Originating from a post switch memory B cell or plasma cell compartment in peripheral lymphoid tissues, malignant myeloma cells accumulate in the bone marrow of patients with multiple myeloma, In this favorable microenvironment their growth and survival are dependent upon both soluble factors and physical cell-to cell and cell-to-extracellular matrix contacts. In this report we show that hyaluronan (HA), a major nonprotein glycosaminoglycan component of the extracellular matrix in mammalian bone marrow, is a survival and proliferation factor for human myeloma cells. The effect of HA is mainly mediated through a gp 80-interleukin 6 (IL-6) receptor pathway by a CD44-independent mechanism, suggesting that HA retains and concentrates IL-6 close to its site of secretion, thus favoring its autocrine activity. In addition, we show that HA-mediated survival and proliferation of myeloma cells is associated with a down-regulation in the expression of p27(kip1) cyclin-dependent kinase inhibitor and a hyperphosphorylation of the retinoblastoma protein (pRb), These data suggest that HA could be an important component in the myeloma cell physiopathology in vivo by potentiating autocrine and/or paracrine IL-6 activities.	INSERM, U475, F-34197 Montpellier 5, France; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc Res, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Case Western Reserve University; Case Western Reserve University	Mechti, N (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier 5, France.	mechti@u475.montp.inserm.fr						Arora T, 1998, J BIOL CHEM, V273, P11799, DOI 10.1074/jbc.273.19.11799; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Assoian Richard K., 1997, Cytokine and Growth Factor Reviews, V8, P165, DOI 10.1016/S1359-6101(97)00011-7; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BARILLE S, 1995, BLOOD, V86, P3151; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Dahl IMS, 1999, BLOOD, V93, P4144, DOI 10.1182/blood.V93.12.4144.412a36_4144_4148; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; Ferlin-Bezombes M, 1998, J IMMUNOL, V161, P2692; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GALANDRINI R, 1994, J IMMUNOL, V153, P21; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; Gunthert U, 1998, ADV EXP MED BIOL, V451, P43; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; HAMANN KJ, 1993, AM J PHYSIOL, V265, pL301, DOI 10.1152/ajplung.1993.265.3.L301; Han ZC, 1996, J CELL PHYSIOL, V168, P97; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Khaldoyanidi S, 1999, BLOOD, V94, P940, DOI 10.1182/blood.V94.3.940.415k27_940_949; Klein B, 1999, LEUKEMIA LYMPHOMA, V34, P63, DOI 10.3109/10428199909083381; Klein B, 1990, Eur Cytokine Netw, V1, P193; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KNUDSON W, 1989, CIBA F SYMP, V143, P150; Kogerman P, 1997, P NATL ACAD SCI USA, V94, P13233, DOI 10.1073/pnas.94.24.13233; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; LESLEY J, 1992, EUR J IMMUNOL, V22, P2719, DOI 10.1002/eji.1830221036; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; LIU D, 1998, FRONT BIOSCI, V3, P631; Liu DC, 1998, CELL IMMUNOL, V190, P132, DOI 10.1006/cimm.1998.1397; LOKHORST HM, 1994, BLOOD, V84, P2269; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; MAZARS GR, 1992, ONCOGENE, V7, P1015; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; Rafi A, 1997, BLOOD, V89, P2901, DOI 10.1182/blood.V89.8.2901; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICZKOWSKI M, 1993, EXP HEMATOL, V21, P126; Stauder R, 1996, BLOOD, V88, P3101, DOI 10.1182/blood.V88.8.3101.bloodjournal8883101; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi K, 1995, ONCOGENE, V11, P2223; Teoh G, 1997, BLOOD, V90, P1982, DOI 10.1182/blood.V90.5.1982; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Urashima M, 1996, BLOOD, V88, P2219, DOI 10.1182/blood.V88.6.2219.bloodjournal8862219; van Driel M, 1998, LEUKEMIA, V12, P1821, DOI 10.1038/sj.leu.2401179; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; ZHANG XG, 1994, BLOOD, V83, P3654	73	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14728	14736		10.1074/jbc.M003965200	http://dx.doi.org/10.1074/jbc.M003965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278272	hybrid, Green Published			2022-12-27	WOS:000168528800028
J	Bellovino, D; Morimoto, T; Mengheri, E; Perozzi, G; Garaguso, I; Nobili, F; Gaetani, S				Bellovino, D; Morimoto, T; Mengheri, E; Perozzi, G; Garaguso, I; Nobili, F; Gaetani, S			Unique biochemical nature of carp retinol-binding protein - N-linked glycosylation and uncleavable NH2-terminal signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; CARRIER PROTEIN; VITAMIN-A; TRANSTHYRETIN; SECRETION; PLASMA; ACID; SEQUENCE; COMPLEX	Retinol transport and metabolism have been well characterized in mammals; however, very little is known in fish. To study the mechanism by which fish retinol-binding protein (RBP) is able to remain in plasma besides its small molecular size, we isolated REP cDNA from a carp liver cDNA library. Comparison of the deduced amino acid sequence with that of known vertebrate RBPs showed that carp REP has high homology to the other cloned vertebrate RBPs, but it lacks the COOH-terminal tetrapeptide, RNL(S)L, which is most likely involved in the interaction with transthyretin in mammalian RBPs, In addition, the primary structure of carp REP contains two consensus N-linked glycosylation sites that represent a unique feature. We have obtained experimental evidence, by in vitro and in vivo expression experiments, that both sites are indeed glycosylated, We have also characterized the protein as a complex type N-linked glycoprotein by lectin binding assay, neuraminidase and endoglycosidase H and F digestion. Inhibition of glycosylation by tunicamycin treatment of transfected cells caused a great reduction of REP secretion. Since kidney filtration of anionic proteins is less than half that of neutral protein of the same size, this finding strongly suggests that the amount of carp REP filtration through kidney glomeruli may be reduced by a glycosylation-dependent increase in the molecular size and negative charge of the protein. A second unique feature of carp REP as secretory protein is the presence of a nonconserved NH2-terminal hydrophobic domain, which functions as an insertion signal but is not cleaved cotranslationally and remains in the secreted RBP.	Ist Nazl Ric Alimenti & Nutr, I-00178 Rome, Italy; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); New York University	Gaetani, S (corresponding author), Ist Nazl Ric Alimenti & Nutr, Via Ardeatina 546, I-00178 Rome, Italy.		Perozzi, Giuditta/AFV-2497-2022; Perozzi, Giuditta/A-7460-2016	Perozzi, Giuditta/0000-0003-1755-6104				Bellovino D, 1999, J CELL PHYSIOL, V181, P24, DOI 10.1002/(SICI)1097-4652(199910)181:1<24::AID-JCP3>3.3.CO;2-S; Bellovino D, 1996, EXP CELL RES, V222, P77, DOI 10.1006/excr.1996.0010; BERNI R, 1992, EUR J BIOCHEM, V204, P99, DOI 10.1111/j.1432-1033.1992.tb16610.x; Blomhoff R., 1994, Vitamin A in health and disease., P1; BREBBIRM BM, 1978, HOSP PRACT, V13, P35; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V268, P5182; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLANTUONI V, 1983, NUCLEIC ACIDS RES, V11, P7769, DOI 10.1093/nar/11.22.7769; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GANONG WF, 1999, REV MED PHYSL, P673; Hauri HP, 2000, J CELL SCI, V113, P587; HEVERT DN, 1995, CELL, V81, P425; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; Hofmann Clementine, 1994, P387; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURENT BC, 1985, J BIOL CHEM, V260, P1476; LEE SY, 1992, EXP EYE RES, V55, P163, DOI 10.1016/0014-4835(92)90104-Z; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; MCKEARIN DM, 1987, J BIOL CHEM, V262, P4939; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i; ONG DE, 1994, BIOCHEMISTRY-US, V33, P1835, DOI 10.1021/bi00173a029; RASK L, 1983, EXP CELL RES, V143, P91, DOI 10.1016/0014-4827(83)90112-X; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5469; Santos CRA, 1999, ENDOCRINOLOGY, V140, P2430, DOI 10.1210/en.140.5.2430; SHIDOJI Y, 1977, J LIPID RES, V18, P679; Soprano Dianne Robert, 1994, P257; SOPRANO DR, 1986, J LIPID RES, V27, P166; STAINIER DYR, 1992, DEV BIOL, V153, P91, DOI 10.1016/0012-1606(92)90094-W; STALLINGSMANN ML, 1993, BIOL REPROD, V48, P998, DOI 10.1095/biolreprod48.5.998; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; VIEIRA AV, 1995, DNA CELL BIOL, V14, P403, DOI 10.1089/dna.1995.14.403; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; Yamauchi K, 1999, EUR J BIOCHEM, V265, P944, DOI 10.1046/j.1432-1327.1999.00825.x; YE RD, 1988, J BIOL CHEM, V263, P4869; ZANOTTI G, 1994, J BIOL CHEM, V269, P29613; ZAPPONI MC, 1992, EUR J BIOCHEM, V210, P937, DOI 10.1111/j.1432-1033.1992.tb17498.x	42	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13949	13956		10.1074/jbc.M006779200	http://dx.doi.org/10.1074/jbc.M006779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278316	hybrid			2022-12-27	WOS:000168356600062
J	Kourmouli, N; Dialynas, G; Petraki, C; Pyrpasopoulou, A; Singh, PB; Georgatos, SD; Theodoropoulos, PA				Kourmouli, N; Dialynas, G; Petraki, C; Pyrpasopoulou, A; Singh, PB; Georgatos, SD; Theodoropoulos, PA			Binding of heterochromatin protein 1 to the nuclear envelope is regulated by a soluble form of tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN B-RECEPTOR; DROSOPHILA HETEROCHROMATIN; CHROMODOMAIN PROTEINS; CHROME DOMAIN; HP1; MEMBRANE; VIMENTIN; HOMOLOG; COMPLEX; IDENTIFICATION	We have previously shown that the mouse heterochromatin protein 1 homologue M31 interacts dynamically with the nuclear envelope. Using quantitative in vitro assays, we now demonstrate that this interaction is potently inhibited by soluble factors present in mitotic and interphase cytosol, As indicated by depletion and order-of-addition experiments, the inhibitory activity co-isolates with a 56 kDa protein, which binds avidly to the nuclear envelope and presumably blocks M31-binding sites. Purification of this protein and microsequencing of tryptic peptides identify it as alpha2/6:beta2-tubulin. Consistent with this observation, bona fide tubulin, isolated from rat brain and maintained in a nonpolymerized state, abolishes binding of M31 to the nuclear envelope and aborts M31-mediated nuclear envelope reassembly in an in vitro system. These observations provide a new example of "moonlighting," a process whereby multimeric proteins switch function when their aggregation state or localization is altered.	Univ Crete, Sch Med, Dept Basic Sci, Iraklion 71110, Crete, Greece; Univ Thessaloniki, Sch Med, Pathol Lab, GR-54006 Thessaloniki, Greece; Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland	University of Crete; Aristotle University of Thessaloniki; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Theodoropoulos, PA (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, Iraklion 71110, Crete, Greece.	takis@med.uoc.gr	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Georgatos, Spyros/0000-0002-2078-7467; Pyrpasopoulou, Athina/0000-0002-6906-2504				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Cleard F, 1997, EMBO J, V16, P5280, DOI 10.1093/emboj/16.17.5280; Frankel S, 1997, J CELL SCI, V110, P1999; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Georgatos SD, 1999, CRIT REV EUKAR GENE, V9, P373, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.220; Horsley D, 1996, CYTOGENET CELL GENET, V73, P308, DOI 10.1159/000134363; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Kourmouli N, 2000, EMBO J, V19, P6558, DOI 10.1093/emboj/19.23.6558; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Maison C, 1997, EMBO J, V16, P4839, DOI 10.1093/emboj/16.16.4839; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; MAISON C, 1995, EMBO J, V14, P3311, DOI 10.1002/j.1460-2075.1995.tb07338.x; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; OLMSTED JB, 1981, J CELL BIOL, V89, P418, DOI 10.1083/jcb.89.3.418; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; REAVEN EP, 1977, J CELL BIOL, V75, P731, DOI 10.1083/jcb.75.3.731; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; WATERMANSTORER CM, 1998, CURRENT PROTOCOLS CE, V1; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; ZHAI Y, 1994, J CELL SCI, V107, P881; Zhao T, 2000, J BIOL CHEM, V275, P28332	39	22	23	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13007	13014		10.1074/jbc.M007135200	http://dx.doi.org/10.1074/jbc.M007135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278332	hybrid			2022-12-27	WOS:000168198600078
J	Krieger, CJ; Roseboom, W; Albracht, SPJ; Spormann, AM				Krieger, CJ; Roseboom, W; Albracht, SPJ; Spormann, AM			A stable organic free radical in anaerobic benzylsuccinate synthase of Azoarcus sp strain T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CLUSTERS; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; TOLUENE METABOLISM; ACTIVATING ENZYME; INITIAL REACTIONS; PROTEIN; HYPOPHOSPHITE; BACTERIUM	The novel enzyme benzylsuccinate synthase initiates anaerobic toluene metabolism by catalyzing the addition of toluene to fumarate, forming benzylsuccinate. Based primarily on its sequence similarity to the glycyl radical enzymes, pyruvate formate-lyase and anaerobic ribonucleotide reductase, benzylsuccinate synthase was speculated to be a glycyl radical enzyme. In this report we use EPR spectroscopy to demonstrate for the first time that active benzylsuccinate synthase from the denitrifying bacterium Azoarcus sp. strain T harbors an oxygen-sensitive stable organic free radical. The EPR signal of the radical was centered at g = 2.0021 and was characterized by a major S-fold splitting of about 1.5 millitesla. The strong similarities between the EPR signal of the benzylsuccinate synthase radical and that of the glycyl radicals of pyruvate formate-lyase and anaerobic ribonucleotide reductase provide evidence that the benzylsuccinate synthase radical is located on a glycine residue, presumably glycine 828 in Azoarcus sp. strain T benzylsuccinate synthase.	Stanford Univ, Dept Civil & Environm Engn Environm Engn & Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Amsterdam, Swammerdam Inst Life Sci, Dept Biochem, NL-1018 TV Amsterdam, Netherlands	Stanford University; Stanford University; University of Amsterdam	Spormann, AM (corresponding author), Stanford Univ, Dept Civil & Environm Engn Environm Engn & Sci, Stanford, CA 94305 USA.			Spormann, Alfred/0000-0001-5103-9704; Roseboom, Winfried/0000-0002-4034-8330				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALBRACHT SPJ, 1984, CURR TOP BIOENERG, V13, P79; ALBRACHT SPJ, 1979, FEBS LETT, V104, P197, DOI 10.1016/0014-5793(79)81114-X; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; Beller HR, 1999, FEMS MICROBIOL LETT, V178, P147, DOI 10.1111/j.1574-6968.1999.tb13771.x; Beller HR, 1997, J BACTERIOL, V179, P670, DOI 10.1128/jb.179.3.670-676.1997; Beller HR, 1998, J BACTERIOL, V180, P5454, DOI 10.1128/JB.180.20.5454-5457.1998; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coschigano PW, 1998, APPL ENVIRON MICROB, V64, P1650; DOLFING J, 1990, ARCH MICROBIOL, V154, P336, DOI 10.1007/BF00276528; Gibson D. T., 1984, MICROBIAL DEGRADATIO, P181; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; Krieger CJ, 1999, J BACTERIOL, V181, P6403, DOI 10.1128/JB.181.20.6403-6410.1999; Leuthner B, 1998, MOL MICROBIOL, V28, P615, DOI 10.1046/j.1365-2958.1998.00826.x; Muller JA, 1999, ARCH MICROBIOL, V172, P287, DOI 10.1007/s002030050782; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; Plaga W, 2000, FEBS LETT, V466, P45, DOI 10.1016/S0014-5793(99)01752-4; Rabus R, 1998, ARCH MICROBIOL, V170, P377, DOI 10.1007/s002030050656; Smith MR, 1990, BIODEGRADATION, V1, P191, DOI 10.1007/BF00058836; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Zengler K, 1999, ARCH MICROBIOL, V172, P204, DOI 10.1007/s002030050761	29	82	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12924	12927		10.1074/jbc.M009453200	http://dx.doi.org/10.1074/jbc.M009453200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278506	hybrid			2022-12-27	WOS:000168198600066
J	Nesterov, A; Lu, XJ; Johnson, M; Miller, GJ; Ivashchenko, Y; Kraft, AS				Nesterov, A; Lu, XJ; Johnson, M; Miller, GJ; Ivashchenko, Y; Kraft, AS			Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; NF-KAPPA-B; FADD-DEPENDENT APOPTOSIS; PHOSPHOINOSITIDE 3-KINASE; DEATH RECEPTORS; CD95 APO-1/FAS; APO-2 LIGAND; FAS; KINASE; ACTIVATION	We find that the prostate cancer cell lines ALVA-31, PC-3, and DU 145 are highly sensitive to apoptosis induced by TRAIL ((t) under bar umor-necrosis factor-(r) under bar elated (a) under bar poptosis-(i) under bar nducing (l) under bar igand), while the cell lines TSU-Prl and JCA-1 are moderately sensitive, and the LNCaP cell line is resistant. LNCaP cells lack active lipid phosphatase PTEN, a negative regulator of the phosphatidylinositol (PI) 3-kinase/Akt pathway, and demonstrate a high constitutive Akt activity. Inhibition of PI 3-kinase using wortmannin and LY-294002 suppressed constitutive Akt activity and sensitized LNCaP cells to TRAIL, Treatment of LNCaP cells with TRAIL alone induced cleavage of the caspase 8 and XIAP proteins. However, processing of BID, mitochondrial release of cytochrome c, activation of caspases 7 and 9, and apoptosis did not occur unless TRAIL was combined with either wortmannin, LY-294002, or cycloheximide, Blocking cytochrome c release by Bcl-2 overexpression rendered LNCaP cells resistant to TRAIL plus wortmannin treatment but did not affect caspase 8 or BID processing. This indicates that in these cells mitochondria are required for the propagation rather than the initiation of the apoptotic cascade, Infection of LNCaP cells with an adenovirus expressing a constitutively active Akt reversed the ability of wortmannin to potentiate TRAIL-induced BID cleavage. Thus, the PI 5-kinase-dependent blockage of TRAIL-induced apoptosis in LNCaP cells appears to be mediated by Akt through the inhibition of BID cleavage.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Pulm Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Aventis Pharmaceut, D-65926 Frankfurt, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Sanofi-Aventis	Nesterov, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.	Alexander.Nesterov@UCHSC.edu			NCI NIH HHS [CA 78631, CA 53520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078631, R01CA053520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BUDAVARI S, 1989, MERCK INDEX, P1585; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carson JP, 1999, CANCER RES, V59, P1449; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; Gleeson MAG, 1998, METH MOL B, V103, P81; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hedlund TE, 1998, PROSTATE, V36, P92, DOI 10.1002/(SICI)1097-0045(19980701)36:2<92::AID-PROS4>3.0.CO;2-G; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kataoka T, 1998, J IMMUNOL, V161, P3936; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mori S, 1999, J IMMUNOL, V162, P5616; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ozes ON, 1999, NATURE, V401, P82; Pawlowski JE, 2000, ANTICANCER RES, V20, P4243; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Uslu R, 1997, CLIN CANCER RES, V3, P963; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Webber MM, 1997, PROSTATE, V30, P58; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	65	252	257	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10767	10774		10.1074/jbc.M005196200	http://dx.doi.org/10.1074/jbc.M005196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278284	hybrid			2022-12-27	WOS:000167980900029
J	Armstrong, D; Strange, PG				Armstrong, D; Strange, PG			Dopamine D-2 receptor dimer formation - Evidence from ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; H-3 SPIPERONE; SULPIRIDE BINDING; RAT; D-2; BRAIN; DIMERIZATION; SODIUM; D-2(SHORT); RACLOPRIDE	We have examined the binding of two radioligands ([H-3]spiperone and [SH]raclopride) to D-2 dopamine receptors expressed in Chinese hamster ovary cells. In saturation binding experiments in the presence of sodium ions, both radioligands labeled a similar number of sites, whereas in the absence of sodium ions [H-3]raclopride labeled about half the number of sites labeled by [H-3]spiperone. In competition experiments in the absence of sodium ions, however, raclopride was able to inhibit [H-3]spiperone binding fully. In saturation analyses with [H-3]spiperone in the absence of sodium ions raclopride exerted noncompetitive effects, decreasing the number of sites labeled by the radioligand. These data are interpreted in terms of a model where the receptor exists as a dimer, and in the absence of sodium ions, raclopride exerts negative cooperativity across the dimer both for its own binding and the binding of spiperone. A model of the receptor has been produced that provides a good description of the experimental phenomena described here.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Strange, PG (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.		soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DSOUZA UM, 1995, BIOCHEMISTRY-US, V34, P13635, DOI 10.1021/bi00041a044; Gardner BR, 1997, J NEUROCHEM, V69, P2589; GOLDS PR, 1980, BRIT J PHARMACOL, V68, P541, DOI 10.1111/j.1476-5381.1980.tb14570.x; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; HALL H, 1990, J NEUROCHEM, V55, P2048, DOI 10.1111/j.1471-4159.1990.tb05794.x; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hoare SRJ, 2000, BRIT J PHARMACOL, V130, P1045, DOI 10.1038/sj.bjp.0703370; Hoare SRJ, 1996, MOL PHARMACOL, V50, P1295; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; IMAFUKU J, 1987, BRAIN RES, V402, P331, DOI 10.1016/0006-8993(87)90040-0; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KLOTZ IM, 1974, ACCOUNTS CHEM RES, V7, P162, DOI 10.1021/ar50077a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Malmberg A, 1996, EUR J PHARMACOL, V303, P123, DOI 10.1016/0014-2999(96)00080-5; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NEVE KA, 1990, J PHARMACOL EXP THER, V252, P1108; NEVE KA, 1991, MOL PHARMACOL, V39, P570; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; NIZNIK HB, 1985, N-S ARCH PHARMACOL, V329, P333, DOI 10.1007/BF00496365; PARKER EM, 1991, J BIOL CHEM, V266, P519; READER TA, 1990, BIOCHEM PHARMACOL, V40, P1739, DOI 10.1016/0006-2952(90)90350-T; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Schetz JA, 1997, J NEUROCHEM, V68, P1990; SCHREURS J, 1995, J NEUROCHEM, V64, P1622; SEEMAN P, 1984, J NEUROCHEM, V43, P221, DOI 10.1111/j.1471-4159.1984.tb06700.x; SEEMAN P, 1992, EUR J PHARM-MOLEC PH, V227, P139, DOI 10.1016/0922-4106(92)90121-B; STEFANINI E, 1980, BRAIN RES, V198, P229, DOI 10.1016/0006-8993(80)90360-1; Strange PG, 1997, NEUROPSYCHOPHARMACOL, V16, P116; STRANGE PG, 1994, TRENDS PHARMACOL SCI, V15, P317, DOI 10.1016/0165-6147(94)90020-5; TERAI M, 1989, EUR J PHARMACOL, V173, P177, DOI 10.1016/0014-2999(89)90516-5; THEODOROU AE, 1983, LIFE SCI, V32, P1243, DOI 10.1016/0024-3205(83)90194-7; VILE JM, 1995, J NEUROCHEM, V64, P940; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; ZAHNISER NR, 1983, J PHARMACOL EXP THER, V227, P592; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9	49	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22621	22629		10.1074/jbc.M006936200	http://dx.doi.org/10.1074/jbc.M006936200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11278324	hybrid			2022-12-27	WOS:000169412700088
J	Leo, C; Yang, XF; Liu, JL; Li, H; Chen, JD				Leo, C; Yang, XF; Liu, JL; Li, H; Chen, JD			Role of retinoid receptor coactivator pockets in cofactor recruitment and transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; LIGAND-BINDING; STRUCTURAL BASIS; CO-REPRESSOR; X-RECEPTOR; TIF2; TRANSACTIVATION; HETERODIMERS; DETERMINANTS; SPECIFICITY	The nuclear receptor for retinoic acid (RAR) forms a heterodimeric complex with the retinoid X receptor (RXR). This RXR/RAR heterodimer binds to the promoter of retinoic acid target genes and recruits coactivators and corepressors to regulate gene expression. Currently, the relative role of each receptor monomer in regulating coactivator and corepressor recruitment re mains unclear. Here we show that the receptor-associated coactivator 3 (RAC3) uses two separate LXXLL motifs to bind RAR and RXR. The mutation of the coactivator-binding pockets of RAR and RXR abolishes RAC3 binding. Although the coactivator pocket of RXR is essential for the function of the RXR homodimer, it has a minor role for the recruitment of RAGS and transactivation by the RXR/RAR heterodimer. Consistently, deletion of the activation helix of RXR enhances binding of RAC3 to the heterodimer, and mutation of the coactivator pocket of RXR had little effect on RXR/RAR activity. In contrast, the coactivator pocket and the activation helix of RAR are absolutely required. We also show that different residues of the RAR coactivator pocket are used differently for interactions with the corepressor silencing mediator for retinoid and thyroid hormone receptor (SMRT) and coactivator. These results indicate a differential role for each retinoid receptor to the overall binding of cofactors and regulation of transcription by the retinoid receptor heterodimer.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, JD (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, 55 Lake Ave N, Worcester, MA 01655 USA.				NIDDK NIH HHS [DK52542, DK52888] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052542, R01DK052888] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Leo C, 2000, J BIOL CHEM, V275, P5976, DOI 10.1074/jbc.275.8.5976; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040	28	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23127	23134		10.1074/jbc.M100462200	http://dx.doi.org/10.1074/jbc.M100462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11274211	hybrid			2022-12-27	WOS:000169412700153
J	Espinosa, A; Yan, L; Zhang, Z; Foster, L; Clark, D; Li, E; Stanley, SL				Espinosa, A; Yan, L; Zhang, Z; Foster, L; Clark, D; Li, E; Stanley, SL			The bifunctional Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) protein is necessary for amebic growth and survival and requires an intact C-terminal domain for both alcohol dehydrogenase and acetaldehyde dehydrogenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; ANTISENSE INHIBITION; CLOSTRIDIUM-ACETOBUTYLICUM; ZYMOMONAS-MOBILIS; GENE; EXPRESSION; CLONING; ADHE; COMPLEMENTATION	The intestinal protozoan pathogen Entamoeba histolytica lacks mitochondria and derives energy from the fermentation of glucose to ethanol with pyruvate, acetyl enzyme Go-A, and acetaldehyde as intermediates. A key enzyme in this pathway may be the 97-kDa bifunctional E. histolytica alcohol dehydrogenase 2 (EhADH2), which possesses both alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase activity (ALDH). EhADH2 appears to be a fusion protein, with separate N-terminal ALDH and C-terminal ADH domains. Here, we demonstrate that EhADH2 expression is required for E. histolytica growth and survival. We find that a mutant EhADH2 enzyme containing the C-terminal 453 amino acids of EhADH2 has ADH activity but lacks ALDH activity. However, a mutant consisting of the N-terminal half of EhADH2 possessed no ADH or ALDH activity. Alteration of a single histidine to arginine in the putative active site of the ADH domain eliminates both ADH and ALDH activity, and this mutant EhADH2 can serve as a dominant negative, eliminating both ADH and ALDH activity when co-expressed with wild-type EhADH2 in Escherichia coli, These data indicate that EhADH2 enzyme is required for E, histolytica growth and survival and that the C-terminal ADH domain of the enzyme functions as a separate entity. However, ALDH activity requires residues in both the N- and C-termimal halves of the molecule.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; So Illinois Univ, Dept Microbiol, Carbondale, IL 62901 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Southern Illinois University System; Southern Illinois University	Stanley, SL (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037977, R01AI030084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37977, R01 AI030084, AI30084] Funding Source: Medline; NIDDK NIH HHS [DK52574, P30 DK052574] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ankri S, 1999, MOL MICROBIOL, V33, P327, DOI 10.1046/j.1365-2958.1999.01476.x; Ankri S, 1998, MOL MICROBIOL, V28, P777, DOI 10.1046/j.1365-2958.1998.00837.x; Arnau J, 1998, J BACTERIOL, V180, P3049, DOI 10.1128/JB.180.12.3049-3055.1998; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; Bracha R, 1999, MOL MICROBIOL, V34, P463, DOI 10.1046/j.1365-2958.1999.01607.x; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUCHHAUS I, 1994, BIOCHEM J, V303, P743, DOI 10.1042/bj3030743; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CONWAY T, 1987, J BACTERIOL, V169, P2591, DOI 10.1128/jb.169.6.2591-2597.1987; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; FISCHER RJ, 1993, J BACTERIOL, V175, P6959, DOI 10.1128/jb.175.21.6959-6969.1993; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; Guagliardi A, 1996, INT J BIOCHEM CELL B, V28, P239, DOI 10.1016/1357-2725(95)00138-7; Hamann L, 1997, MOL BIOCHEM PARASIT, V84, P83, DOI 10.1016/S0166-6851(96)02771-5; KESSLER D, 1991, FEBS LETT, V281, P59, DOI 10.1016/0014-5793(91)80358-A; KUMAR A, 1992, P NATL ACAD SCI USA, V89, P10188, DOI 10.1073/pnas.89.21.10188; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LO HS, 1978, BIOCHEM J, V171, P225, DOI 10.1042/bj1710225; MATAYOSHI S, 1989, J GEN MICROBIOL, V135, P525; NAIR RV, 1994, J BACTERIOL, V176, P871, DOI 10.1128/jb.176.3.871-885.1994; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; Rodriguez MA, 1996, BBA-GENE STRUCT EXPR, V1306, P23, DOI 10.1016/0167-4781(96)00014-0; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; Samuelson J, 1999, ANTIMICROB AGENTS CH, V43, P1533, DOI 10.1128/AAC.43.7.1533; Sanchez LB, 1998, ARCH BIOCHEM BIOPHYS, V354, P57, DOI 10.1006/abbi.1998.0664; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; YANG WG, 1994, MOL BIOCHEM PARASIT, V64, P253, DOI 10.1016/0166-6851(93)00020-A; Yong TS, 1996, P NATL ACAD SCI USA, V93, P6464, DOI 10.1073/pnas.93.13.6464; ZHANG MQ, 1994, CHINESE J CHEM ENG, V2, P63	31	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20136	20143		10.1074/jbc.M101349200	http://dx.doi.org/10.1074/jbc.M101349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274185	Green Accepted, hybrid			2022-12-27	WOS:000169135100063
J	Hill, J; Duckworth, M; Murdock, P; Rennie, G; Sabido-David, C; Ames, RS; Szekeres, P; Wilson, S; Bergsma, DJ; Gloger, IS; Levy, DS; Chambers, JK; Muir, AI				Hill, J; Duckworth, M; Murdock, P; Rennie, G; Sabido-David, C; Ames, RS; Szekeres, P; Wilson, S; Bergsma, DJ; Gloger, IS; Levy, DS; Chambers, JK; Muir, AI			Molecular cloning and functional characterization of MCH2, a novel human MCH receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING-HORMONE; PROTEIN-COUPLED RECEPTOR; BINDING-SITES; ALPHA-MSH; IDENTIFICATION; SLC-1; LIGAND; GENE; RAT; SOMATOSTATIN	Melanin-concentrating hormone (MCH) is involved in the regulation of feeding and energy homeostasis. Recently, a 353-amino acid splice variant form of the human orphan receptor SLC-1 (1) (hereafter referred to as MCH1) was identified as an MCH receptor. This report describes the cloning and functional characterization of a novel second human MCH receptor, which we designate MCH2, initially identified in a genomic survey sequence as being homologous to MCH1 receptors, Using this sequence, a full-length cDNA was generated with an open reading frame of 1023 base pairs, encoding a polypeptide of 340 amino acids, with 38% identity to MCH1 and with many of the structural features conserved in G protein-coupled receptors, This newly discovered receptor belongs to class 1 (rhodopsin-like) of the G protein-coupled receptor superfamily, HEK293 cells transfected with MCH2 receptors responded to nanomolar concentrations of MCH with an increase in intracellular Ca2+ levels and increased cellular extrusion of protons. In addition, fluorescently labeled MCH bound with nanomolar affinity to these cells. The tissue localization of MCH2 receptor mRNA, as determined by quantitative reverse transcription-polymerase chain reaction, was similar to that of MCH1 in that both receptors are expressed predominantly in the brain. The discovery of a novel MCH receptor represents a new potential drug target and will allow the further elucidation of MCH-mediated responses.	GlaxoSmithKline, Dept Mol Biol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Bioinformat, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Gene Express Sci, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Computat & Struct Sci, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Vasc Biol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Mol Biol, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hill, J (corresponding author), GlaxoSmithKline, Dept Mol Biol, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Jeffrey_2_Hill@gsk.com						Bachner D, 1999, FEBS LETT, V457, P522, DOI 10.1016/S0014-5793(99)01092-3; Befort K, 1999, J BIOL CHEM, V274, P18574, DOI 10.1074/jbc.274.26.18574; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bittencourt JC, 1998, BRAIN RES, V804, P140, DOI 10.1016/S0006-8993(98)00662-3; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; Burgaud JL, 1997, BIOCHEM BIOPH RES CO, V241, P622, DOI 10.1006/bbrc.1997.7849; Cardot J, 1999, J COMP NEUROL, V411, P239, DOI 10.1002/(SICI)1096-9861(19990823)411:2<239::AID-CNE5>3.0.CO;2-7; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chapman CG, 2000, MOL BRAIN RES, V82, P74; DROZDZ R, 1995, FEBS LETT, V359, P199, DOI 10.1016/0014-5793(95)00043-9; Gonzalez MI, 1997, PEPTIDES, V18, P387, DOI 10.1016/S0196-9781(96)00337-3; Hervieu GJ, 2000, EUR J NEUROSCI, V12, P1194, DOI 10.1046/j.1460-9568.2000.00008.x; JEZOVA D, 1992, ENDOCRINOLOGY, V130, P1024, DOI 10.1210/en.130.2.1024; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; Kokkotou E, 2000, NEUROPEPTIDES, V34, P240, DOI 10.1054/npep.2000.0821; Kolakowski LF, 1996, FEBS LETT, V398, P253, DOI 10.1016/S0014-5793(96)01160-X; Lakaye B, 1998, BBA-MOL CELL RES, V1401, P216, DOI 10.1016/S0167-4889(97)00135-3; Lembo PMC, 1999, NAT CELL BIOL, V1, P267, DOI 10.1038/12978; Macdonald D, 2000, MOL PHARMACOL, V58, P217, DOI 10.1124/mol.58.1.217; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MILLER CL, 1993, PEPTIDES, V14, P431, DOI 10.1016/0196-9781(93)90128-4; Monzon ME, 1999, PHYSIOL BEHAV, V67, P813, DOI 10.1016/S0031-9384(99)00117-1; Murray JF, 2000, J NEUROENDOCRINOL, V12, P217; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Saito Y, 2000, TRENDS ENDOCRIN MET, V11, P299, DOI 10.1016/S1043-2760(00)00290-3; Sanchez M, 1997, PEPTIDES, V18, P393, DOI 10.1016/S0196-9781(96)00327-0; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimomura Y, 1999, BIOCHEM BIOPH RES CO, V261, P622, DOI 10.1006/bbrc.1999.1104; Sone M, 2000, PEPTIDES, V21, P245, DOI 10.1016/S0196-9781(99)00206-5; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRNAD J, 1995, BIOCHEM BIOPH RES CO, V216, P913, DOI 10.1006/bbrc.1995.2708; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; [No title captured]	37	186	203	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20125	20129		10.1074/jbc.M102068200	http://dx.doi.org/10.1074/jbc.M102068200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274220	hybrid			2022-12-27	WOS:000169135100061
J	Li, PF; Nicosia, SV; Bai, WL				Li, PF; Nicosia, SV; Bai, WL			Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTEN TUMOR-SUPPRESSOR; HUMAN ESTROGEN-RECEPTOR; PROTEIN-KINASE-B; SIGNALING PATHWAY; PHOSPHATASE-ACTIVITY; CELLULAR GROWTH; SURVIVAL; CLONING; GENE; PHOSPHORYLATION	PTEN/MMAC1/TEP-1 (PTEN) tumor suppressor and androgen receptor play important roles in prostatic tumorigenesis by exerting opposite effects on homeostasis of prostatic epithelium. Here, we describe a mutual repression and selective dominance between PTEN and the androgen receptor (AR) in the growth and the apoptosis of prostatic cancer cells. On the one hand, PTEN and an inhibitor of phosphoinositide 3-kinase repressed the transcriptional activity of the AR as well as androgen-induced cell proliferation and production of prostate-specific antigen. On the other hand, androgens protected prostate cancer cells from PTEN-induced apoptosis in an AR-dependent manner. Whereas the repression of the transcriptional activity of the AR by PTEN is likely to involve the down-regulation of AKT, androgens protected prostate cancer cells from PTEN-induced apoptosis without an effect on AKT activity, demonstrating a differential involvement of AKT in the interaction between PTEN and the AR. Our data suggest that the loss of PTEN function may induce tumorigenesis through unopposed activity of the AR as well as contribute to the resistance of prostate cancers to androgen ablation therapy.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Program Mol Oncol & Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.		Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [R29 CA 79530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA079530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bai WL, 1995, VITAM HORM, V51, P289, DOI 10.1016/S0083-6729(08)61042-0; Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; BERCHEM GJ, 1995, CANCER RES, V55, P735; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; Carson JP, 1999, CANCER RES, V59, P1449; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Kuratsukuri K, 1999, PROSTATE, V41, P121; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; ONATE SA, 1995, SCIENCE, V270, P1354; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Snoek R, 1998, PROSTATE, V36, P256; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	37	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20444	20450		10.1074/jbc.M010226200	http://dx.doi.org/10.1074/jbc.M010226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278645	hybrid			2022-12-27	WOS:000169135100104
J	Di Pierro, M; Lu, RL; Uzzau, S; Wang, WL; Margaretten, K; Pazzani, C; Maimone, F; Fasano, A				Di Pierro, M; Lu, RL; Uzzau, S; Wang, WL; Margaretten, K; Pazzani, C; Maimone, F; Fasano, A			Zonula occludens toxin structure-function analysis - Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING CHOLERA-TOXIN; VIBRIO-CHOLERAE; GENE; ZOT; BACTERIOPHAGE; ENTEROTOXIN; EXPRESSION; PILUS; ACE	Zonula occludens toxin (Zot) is an enterotoxin elaborated by Vibrio cholerae that increases intestinal permeability by interacting with a mammalian cell receptor with subsequent activation of intracellular signaling leading to the disassembly of the intercellular tight junctions. Zot localizes in the bacterial outer membrane of V. cholerae with subsequent cleavage and secretion of a carboxyl-terminal fragment in the host intestinal milieu. To identify the Zot domain(s) directly involved in the protein permeating effect, several tot gene deletion mutants were constructed and tested for their biological activity in the Ussing chamber assay and their ability to bind to the target receptor on intestinal epithelial cell cultures. The Zot biologically active domain was localized toward the carboxyl terminus of the protein and coincided with the predicted cleavage product generated by V. cholerae. This domain shared a putative receptor-binding motif with zonulin, the Zot mammalian analogue involved in tight junction modulation. Amino acid comparison between the Zot active fragment and zonulin, combined with site-directed mutagenesis experiments, confirmed the presence of an octapeptide receptor-binding domain toward the amino terminus of the processed Zot.	Univ Maryland, Sch Med, Div Pediat Gastroenterol & Nutr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Gastrointestinal Pathophysiol Sect, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Sassari, Dipartimento Sci Biomed, Sez Microbiol Sperimentale & Clin, I-07100 Sassari, Italy; Univ La Sapienza, Cent Interuniv Ricera Paesi, I-07100 Sassari, Italy; Univ Bari, Dipartimento Anat Patol & Genet, I-70126 Bari, Italy	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Sassari; Sapienza University Rome; Universita degli Studi di Bari Aldo Moro	Fasano, A (corresponding author), Univ Maryland, Sch Med, Div Pediat Gastroenterol & Nutr, 685 W Baltimore St,HSF Bldg,Rm 465, Baltimore, MD 21201 USA.		Pazzani, Carlo/AAX-9028-2021; Uzzau, Sergio/F-3233-2015; Fasano, Alessio/K-5486-2016	Pazzani, Carlo/0000-0003-0414-2965; Uzzau, Sergio/0000-0001-6246-2794; Fasano, Alessio/0000-0002-2134-0261	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048373] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48373] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; BAUDRY B, 1992, INFECT IMMUN, V60, P428, DOI 10.1128/IAI.60.2.428-434.1992; COLOMBO MM, 1994, J INFECT DIS, V170, P750, DOI 10.1093/infdis/170.3.750; COREIJIDO M, 1992, TIGHT JUNCTIONS, P1; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fasano A, 1997, GASTROENTEROLOGY, V112, P839, DOI 10.1053/gast.1997.v112.pm9041245; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HORABIN JI, 1986, J MOL BIOL, V188, P403, DOI 10.1016/0022-2836(86)90164-6; JOHNSON JA, 1993, J CLIN MICROBIOL, V31, P143; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; KARASAWA T, 1993, FEMS MICROBIOL LETT, V106, P143, DOI 10.1016/0378-1097(93)90072-A; KOONIN EV, 1992, FEBS LETT, V321, P3; KURAZONO H, 1995, MICROB PATHOGENESIS, V18, P231, DOI 10.1016/S0882-4010(95)90076-4; Lu R, 2000, J NEUROCHEM, V74, P320, DOI 10.1046/j.1471-4159.2000.0740320.x; MILKS LC, 1986, J CELL BIOL, V103, P2729, DOI 10.1083/jcb.103.6.2729; PAPPO J, 1996, CLIN EXP IMMUNOL, V189, P487; PEARSON GD, 1993, GENE, V67, P31; Quaroni A, 1980, Methods Cell Biol, V21B, P403; Sears Cynthia L., 1995, P617; SHASBY DM, 1988, AM J PHYSIOL, V255, pC781, DOI 10.1152/ajpcell.1988.255.6.C781; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; TRUCKSIS M, 1993, P NATL ACAD SCI USA, V90, P5267, DOI 10.1073/pnas.90.11.5267; Uzzau S, 1999, MICROB PATHOGENESIS, V27, P377, DOI 10.1006/mpat.1999.0312; Uzzau S, 2001, FEMS MICROBIOL LETT, V194, P1, DOI 10.1016/S0378-1097(00)00478-X; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Wang WL, 2000, J CELL SCI, V113, P4435; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179	32	144	153	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19160	19165		10.1074/jbc.M009674200	http://dx.doi.org/10.1074/jbc.M009674200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278543	hybrid			2022-12-27	WOS:000169091000071
J	Gabus, C; Derrington, E; Leblanc, P; Chnaiderman, J; Dormont, D; Swietnicki, W; Morillas, M; Surewicz, WK; Marc, D; Nandi, P; Darlix, JL				Gabus, C; Derrington, E; Leblanc, P; Chnaiderman, J; Dormont, D; Swietnicki, W; Morillas, M; Surewicz, WK; Marc, D; Nandi, P; Darlix, JL			The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCp7 of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROVIRAL DNA-SYNTHESIS; RETROTRANSPOSON CONTAINS; REVERSE TRANSCRIPTION; ANNEALING ACTIVITIES; SIGNAL-TRANSDUCTION; RECEPTOR PRECURSOR; STRAND TRANSFER; POSSIBLE ROLES; INTERACTS; PRP	Transmissible spongiform encephalopathies are fatal neurodegenerative diseases associated with the accumulation of a protease-resistant form of the prion protein (PrP). Although PrP is conserved in vertebrates, its function remains to be identified. In vitro PrP binds large nucleic acids causing the formation of nucleoprotein complexes resembling human immunodeficiency virus type 1 (HIV-1) nucleocapsid-RNA complexes and in vivo MuLV replication accelerates the scrapie infectious process, suggesting possible interactions between retroviruses and PrP. Retroviruses, including HIV-1 encode a major nucleic acid binding protein (NC protein) found within the virus where 2000 NC protein molecules coat the dimeric genome. NC is required in virus assembly and infection to chaperone RNA dimerization and packaging and in proviral DNA synthesis by reverse transcriptase (RT). In HIV-1, 5'-leader RNA/NC interactions appear to control these viral processes. This prompted us to compare and contrast the interactions of human and ovine PrP and HIV-1 NCp7 with HIV-1 5'-leader RNA. Results show that PrP has properties characteristic of NCp7 with respect to viral RNA dimerization and proviral DNA synthesis by RT. The NC-like properties of huPrP map to the N-terminal region of huPrP. Interestingly, PrP localizes in the membrane and cytoplasm of PrP-expressing cells. These findings suggest that PrP is a multifunctional protein possibly participating in nucleic acid metabolism.	Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, LaboRetro, F-69364 Lyon, France; CEA, Dept Rech Med, F-92265 Fontenay Aux Roses, France; INRA, Ctr Rech Tours, F-37380 Nouzilly, France; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; INRAE; Case Western Reserve University	Darlix, JL (corresponding author), Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, LaboRetro, ENS 412,46 Allee Italie, F-69364 Lyon, France.	Jean-Luc.Darlix@ens-lyon.fr	Swietnicki, Wieslaw/GOP-2576-2022; Marc, Daniel/M-4296-2015; Swietnicki, Wieslaw/AAU-1536-2020; LUC, DARLIX JEAN/AAE-9268-2020; Derrington, Ed/G-9478-2017; Swietnicki, Wieslaw/AAL-2452-2021; Leblanc, Pascal/D-4027-2019	Marc, Daniel/0000-0003-3604-1958; Swietnicki, Wieslaw/0000-0002-9354-8184; Leblanc, Pascal/0000-0003-3214-5880; Morillas, Manuel/0000-0002-6489-6737	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKOWITZ A, 1994, NUCLEIC ACIDS RES, V22, P1101, DOI 10.1093/nar/22.6.1101; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Ardini E, 1998, MOL BIOL EVOL, V15, P1017, DOI 10.1093/oxfordjournals.molbev.a026000; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Berthoux L, 1997, J VIROL, V71, P6973, DOI 10.1128/JVI.71.9.6973-6981.1997; Brockes JP, 1999, CURR OPIN NEUROBIOL, V9, P571, DOI 10.1016/S0959-4388(99)00016-1; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Carp RI, 1999, J GEN VIROL, V80, P5, DOI 10.1099/0022-1317-80-1-5; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHEN MJ, 1980, P NATL ACAD SCI-BIOL, V77, P1296, DOI 10.1073/pnas.77.3.1296; Cimarelli A, 2000, J VIROL, V74, P3046, DOI 10.1128/JVI.74.7.3046-3057.2000; Cristofari G, 2000, J BIOL CHEM, V275, P19210, DOI 10.1074/jbc.M001371200; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Demianova M, 1996, J BIOL CHEM, V271, P11383, DOI 10.1074/jbc.271.19.11383; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Evans BN, 2000, J BIOL CHEM, V275, P31438, DOI 10.1074/jbc.M005604200; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Jaegly A, 1998, MOL CELL NEUROSCI, V11, P127, DOI 10.1006/mcne.1998.0675; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Nandi PK, 1999, ARCH VIROL, V144, P1751, DOI 10.1007/s007050050702; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rascle JB, 1998, J MOL BIOL, V280, P215, DOI 10.1006/jmbi.1998.1873; Rezaei H, 2000, EUR J BIOCHEM, V267, P2833, DOI 10.1046/j.1432-1033.2000.01347.x; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	50	158	168	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19301	19309		10.1074/jbc.M009754200	http://dx.doi.org/10.1074/jbc.M009754200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278562	Green Published, hybrid			2022-12-27	WOS:000169091000089
J	Hudrisier, D; Riond, J; Burlet-Schiltz, O; von Herrath, MG; Lewicki, H; Monsarrat, B; Oldstone, MBA; Gairin, JE				Hudrisier, D; Riond, J; Burlet-Schiltz, O; von Herrath, MG; Lewicki, H; Monsarrat, B; Oldstone, MBA; Gairin, JE			Structural and functional identification of major histocompatibility complex class I-restricted self-peptides as naturally occurring molecular mimics of viral antigens - Possible role in CD8(+) T cell-mediated, virus-induced autoimmune disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; DEPENDENT DIABETES-MELLITUS; NON-ANCHOR RESIDUES; RECEPTOR ANTAGONISTS; RECOGNITION; EPITOPES; ACTIVATION; INDUCTION; H-2D(B); LIGANDS	Structural similarity (molecular mimicry) between viral epitopes and self-peptides can lead to the induction of autoaggressive CD4(+) as well as CD8(+) T cell responses. Based on the flexibility of T cell receptor/antigen/major histocompatibility complex recognition, it has been proposed that a self-peptide could replace a viral epitope for T cell recognition and therefore participate in pathophysiological processes in which T cells are involved. To address this issue, we used, as a molecular model of viral antigen, the H-2D(b)-restricted immunodominant epitope nucleoprotein (NP)-(396-404) (FQPQNGQFI) of lymphocytic choriomeningitis virus (LCMV). We identified peptide sequences from murine self-proteins that share structural and functional homology with LCMV NP(396-404) and that bound to H-2D(b) with high affinity. One of these self-peptides, derived from tumor necrosis factor receptor I (FGPSNWHFM, amino acids 302-310), maintained LCMV-specific CD8+ T cells in an active state as observed both in vitro in cytotoxic assays and in vivo in a model of virus-induced autoimmune diabetes, the rat insulin promoter-LCMV NP transgenic mouse. The natural occurrence and molecular concentration at the surface of H-2(b) spleen cells of tumor necrosis factor receptor I-(302-310) were determined by on-line p-high pressure liquid chromatography/mass spectrometry and supported its biological relevance.	Inst Pharmacol & Biol Struct, CNRS, F-31400 Toulouse, France; Scripps Res Inst, Div Virol, Dept Neuropharmacol, La Jolla, CA 92037 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Scripps Research Institute	Gairin, JE (corresponding author), Inst Pharmacol & Biol Struct, CNRS, 205 Route Narbonne, F-31400 Toulouse, France.	gairin@ipbs.fr	Riond, Joelle/R-6414-2016	Riond, Joelle/0000-0002-6281-2376; Schiltz, Odile/0000-0002-3606-2356; Hudrisier, Denis/0000-0002-3631-9561	NIAID NIH HHS [AI44451, AI41439, AI09484] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI044451, R01AI009484, R01AI041439] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; Bachmaier K, 1997, CIRCULATION, V95, P655, DOI 10.1161/01.CIR.95.3.655; Bachmann MF, 1999, IMMUNOL TODAY, V20, P568, DOI 10.1016/S0167-5699(99)01543-1; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CAO WX, 1995, NATURE, V378, P295, DOI 10.1038/378295a0; CHEN WS, 1994, MOL IMMUNOL, V31, P1069; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; GAIRIN JE, 1993, J VIROL, V67, P2903, DOI 10.1128/JVI.67.5.2903-2907.1993; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Green EA, 1999, CURR OPIN IMMUNOL, V11, P663, DOI 10.1016/S0952-7915(99)00034-5; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Hemmer B, 1998, J IMMUNOL, V160, P3631; Hogquist KA, 1997, IMMUNITY, V6, P389, DOI 10.1016/S1074-7613(00)80282-4; Hu QH, 1997, IMMUNITY, V7, P221, DOI 10.1016/S1074-7613(00)80525-7; HUDRISIER D, 1995, MOL IMMUNOL, V32, P895, DOI 10.1016/0161-5890(95)00043-E; Hudrisier D, 1996, J BIOL CHEM, V271, P17829, DOI 10.1074/jbc.271.30.17829; Hudrisier D, 1998, J IMMUNOL, V161, P553; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; Kagi D, 1996, J EXP MED, V183, P2143, DOI 10.1084/jem.183.5.2143; Kammer AR, 1999, J EXP MED, V190, P169, DOI 10.1084/jem.190.2.169; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Manning TC, 1999, IMMUNOL TODAY, V20, P417, DOI 10.1016/S0167-5699(99)01508-X; Martin S, 1996, J IMMUNOL, V157, P2358; Misko IS, 1999, P NATL ACAD SCI USA, V96, P2279, DOI 10.1073/pnas.96.5.2279; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Murali-Krishna K, 1998, ADV EXP MED BIOL, V452, P123; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ohteki T, 1999, EUR J IMMUNOL, V29, P2886, DOI 10.1002/(SICI)1521-4141(199909)29:09<2886::AID-IMMU2886>3.0.CO;2-A; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; Ono T, 1998, J IMMUNOL, V161, P5454; Ruiz PJ, 1999, J EXP MED, V189, P1275, DOI 10.1084/jem.189.8.1275; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SIGAL LJ, 1995, MOL IMMUNOL, V32, P623, DOI 10.1016/0161-5890(95)00031-9; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; Sourdive DJD, 1998, J EXP MED, V188, P71, DOI 10.1084/jem.188.1.71; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; STORKUS WJ, 1993, J IMMUNOTHER, V14, P94, DOI 10.1097/00002371-199308000-00003; Veronese FD, 1996, J EXP MED, V183, P2509, DOI 10.1084/jem.183.6.2509; Vizler C, 1999, IMMUNOL REV, V169, P81; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6	57	25	28	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19396	19403		10.1074/jbc.M008864200	http://dx.doi.org/10.1074/jbc.M008864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278441	Green Published, hybrid			2022-12-27	WOS:000169091000101
J	Belkin, AM; Akimov, SS; Zaritskaya, LS; Ratnikov, BI; Deryugina, EI; Strongin, AY				Belkin, AM; Akimov, SS; Zaritskaya, LS; Ratnikov, BI; Deryugina, EI; Strongin, AY			Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A; TISSUE TRANSGLUTAMINASE; INTEGRIN ALPHA-V-BETA-3; EXTRACELLULAR-MATRIX; COLLAGEN MATRIX; MT1-MMP MMP-14; ACTIVATION; MIGRATION; EXPRESSION; BINDING	Cell invasion requires cooperation between adhesion receptors and matrix metalloproteinases (MMPs). Membrane type (MT)-MMPs have been thought to be primarily involved in the breakdown of the extracellular matrix. Our report presents evidence that MT-MMPs in addition to the breakdown of the extracellular matrix may be engaged in proteolysis of adhesion receptors on tumor cell surfaces. Overexpression of MT1-MMP by glioma and fibrosarcoma cells led to proteolytic degradation of cell surface tissue transglutaminase (tTG) at the leading edge of motile cancer cells. In agreement, structurally related MT1-MMP, MT2-MMP, and MT3-MMP but not evolutionary distant MT4-MMP efficiently degraded purified tTG in vitro, Because cell surface tTG; represents a ubiquitously expressed, potent integrin-binding adhesion coreceptor involved in the binding of cells to fibronectin (Fn), the proteolytic degradation of tTG by MT1-MMP specifically suppressed cell adhesion and migration on Fn, Reciprocally, Fn in vitro and in cultured cells protected its surface receptor, tTG, from proteolysis by MT1-MMP, thereby supporting cell adhesion and locomotion. In contrast, the proteolytic degradation of tTG stimulated migration of cells on collagen matrices. Together, our observations suggest both an important coreceptor role for cell surface tTG and a novel regulatory function of membrane-anchored MMPs in cancer cell adhesion and locomotion. Proteolysis of adhesion proteins colocalized with MT-MMPs at discrete regions on the surface of migrating tumor cells might be controlled by composition of the surrounding ECM.	Amer Red Cross, Holland Lab, Dept Biochem, Rockville, MD 20855 USA; Amer Red Cross, Holland Lab, Dept Immunol, Rockville, MD 20855 USA; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA; Burnham Inst, La Jolla, CA 92037 USA	American Red Cross; American Red Cross; George Washington University; Sanford Burnham Prebys Medical Discovery Institute	Belkin, AM (corresponding author), Amer Red Cross, Holland Lab, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	belkina@usa.redcross.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470, R29CA077697] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77697, CA77470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cockett MI, 1998, BIOCHEM SOC SYMP, P295; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1997, J CELL SCI, V110, P2473; Deryugina EI, 1998, CANCER RES, V58, P3743; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Haroon ZA, 1999, LAB INVEST, V79, P1679; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hettasch JM, 1996, LAB INVEST, V75, P637; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Maidment JM, 1999, J BIOL CHEM, V274, P34706, DOI 10.1074/jbc.274.49.34706; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Monsonego A, 1998, J MOL BIOL, V282, P713, DOI 10.1006/jmbi.1998.2052; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohkubo S, 1999, BIOCHEM BIOPH RES CO, V266, P308, DOI 10.1006/bbrc.1999.1816; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; RADEK JT, 1993, P NATL ACAD SCI USA, V90, P3152, DOI 10.1073/pnas.90.8.3152; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TURNER PM, 1989, BIOCHEMISTRY-US, V28, P628, DOI 10.1021/bi00428a032; Velasco G, 2000, CANCER RES, V60, P877; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	49	210	225	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18415	18422		10.1074/jbc.M010135200	http://dx.doi.org/10.1074/jbc.M010135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278623	hybrid			2022-12-27	WOS:000168866500106
J	Brandstetter, H; Grams, F; Glitz, D; Lang, A; Huber, R; Bode, W; Krell, HW; Engh, RA				Brandstetter, H; Grams, F; Glitz, D; Lang, A; Huber, R; Bode, W; Krell, HW; Engh, RA			The 1.8-angstrom crystal structure of a matrix metallaproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; C-TERMINAL DOMAIN; ACID-BASED INHIBITORS; CATALYTIC DOMAIN; CONVERTING ENZYME; TISSUE INHIBITOR; METALLOPROTEINASES; STROMELYSIN; HYDROXAMATE; SPECIFICITY	The individual zinc endoproteinases of the tissue degrading matrix metalloproteinase (MMP) family share a common catalytic architecture but are differentiated with respect to substrate specificity, localization, and activation. Variation in domain structure and more subtle structural differences control their characteristic specificity profiles for substrates from among four distinct classes (Nagase, H., and Woessner, J. F. J. (1999) J. Biol. Chem. 274, 21491-21494). Exploitation of these differences may be decisive for the design of anticancer or other drugs, which should be highly selective for their particular MMP targets. Based on the 1.8-Angstrom crystal structure of human neutrophil collagenase (MMP-8) in complex with an active site-directed inhibitor (RO200-1770), we identify and describe new structural determinants for substrate and inhibitor recognition in addition to the primary substrate recognition sites. RO200-1770 induces a major rearrangement at a position relevant to substrate recognition near the MMP-8 active site (Ala(206)-Asn(218)). In stromelysin (MMP-3), competing stabilizing interactions at the analogous segment hinder a similar rearrangement, consistent with kinetic profiling of several MMPs. Despite the apparent dissimilarity of the inhibitors, the central 2-hydroxypyrimidine-4,6-dione (barbiturate) ring of the inhibitor RO200-1770 mimics the interactions of the hydroxamate-derived inhibitor batimastat (Grams, F., Reinemer, P., Powers, J. C., Kleine, T., Pieper, RI., Tschesche, H., Huber, R., and Bode, W. (1995) fur. J. Biochem. 228, 830-841) for binding to MMP-8. The two additional phenyl and piperidyl ring substituents of the inhibitor bind into the S1 ' and S2 ' pockets of MMP-8, respectively. The crystal lattice contains a hydrogen bond between the O-gamma group of Ser(209) and N-delta1 of His(207) of a symmetry related molecule; this interaction suggests a model for recognition of hydroxyprolines present in physiological substrates. We also identify a collagenase-characteristic cis-peptide bond, Asn(188)-Tyr(189), on a loop essential for collagenolytic activity. The sequence conservation pattern at this position marks this cis-peptide bond as a determinant for triple-helical collagen recognition and processing.	Max Planck Inst Biochem, Dept Struct Res, D-82152 Martinsried, Germany; Roche Diagnost GmbH, Pharmaceut Res, D-82372 Penzberg, Germany; F Hoffmann La Roche & Co Ltd, Div Pharmaceut, Mol Design, CH-4070 Basel, Switzerland	Max Planck Society; Roche Holding; Roche Holding	Brandstetter, H (corresponding author), Max Planck Inst Biochem, Dept Struct Res, D-82152 Martinsried, Germany.		Brandstetter, Hans/E-6754-2011	Brandstetter, Hans/0000-0002-6089-3045; Engh, Richard/0000-0002-6207-0560				ALLAN JA, 1991, J CELL SCI, V99, P789; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BOSIES E, 1996, NEW BARBITURIC ACID; Botos I, 1999, J MOL BIOL, V292, P837, DOI 10.1006/jmbi.1999.3068; Brandstetter H, 1998, PROTEIN SCI, V7, P1303, DOI 10.1002/pro.5560070605; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Budavari S., 1989, MERCK INDEX; Chen LY, 1999, J MOL BIOL, V293, P545, DOI 10.1006/jmbi.1999.3147; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Dhanaraj V, 1999, CROAT CHEM ACTA, V72, P575; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; Ghose AK, 1998, J PHYS CHEM A, V102, P3762, DOI 10.1021/jp980230o; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GRAMS F, 2001, IN PRESS MATRIX META; HOPPE W, 1957, ACTA CRYSTALLOGR, V10, P750; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Ottl J, 1996, FEBS LETT, V398, P31, DOI 10.1016/S0014-5793(96)01212-4; Ottl J, 1999, J AM CHEM SOC, V121, P653, DOI 10.1021/ja983456d; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STOCKER W, 1995, PROTEIN SCI, V4, P823; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TURK D, 1992, CHEMISTRY; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; von Roedern EG, 1998, J MED CHEM, V41, P3041, DOI 10.1021/jm980112p; von Roedern EG, 1998, J MED CHEM, V41, P339, DOI 10.1021/jm9706426; Wahl MC, 1997, TRENDS BIOCHEM SCI, V22, P97, DOI 10.1016/S0968-0004(97)01004-9; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768	57	112	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17405	17412		10.1074/jbc.M007475200	http://dx.doi.org/10.1074/jbc.M007475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278347	hybrid			2022-12-27	WOS:000168730400108
J	Chong, C; Tan, L; Lim, L; Manser, E				Chong, C; Tan, L; Lim, L; Manser, E			The mechanism of PAK activation - Autophosphorylation events in both regulatory and kinase domains control activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; P21-ACTIVATED KINASE; GAMMA-PAK; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION PATHWAYS; MORPHOLOGICAL-CHANGES; MOLECULAR-CLONING; EXCHANGE FACTOR; LIGHT-CHAIN; MYOSIN-II	The p21-activated kinases (PAKs), in common with many kinases, undergo multiple autophosphorylation events upon interaction with appropriate activators. The Cdc48-induced phosphorylation of PAK serves in part to dissociate the kinase from its partners PM and Nck, Here we investigate in detail how autophosphorylation events affect the catalytic activity of PAK by altering the autophosphorylation sites in both alpha- and beta PAK, Both in vivo and in vitro analyses demonstrate that, although most phosphorylation events in the PAH N-terminal regulatory domain play no direct role in activation, a phosphorylation of alpha PAK serine 144 or beta PAK serine 139, which lie in the kinase inhibitory domain, significantly contribute to activation. By contrast, sphingosine-mediated activation is independent of this residue, indicating a different mode of activation. Thus two autophosphorylation sites direct activation while three others control association with focal complexes via PM and Nck.	Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; Inst Neurol, Dept Neurochem, Miriam Marks Dept Neurochem, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Manser, E (corresponding author), Glaxo IMCB Grp, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Manser, Edward/ABD-2301-2020					Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Harden N, 1996, MOL CELL BIOL, V16, P1896; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Ohtakara K, 2000, BIOCHEM BIOPH RES CO, V272, P712, DOI 10.1006/bbrc.2000.2854; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tu H, 1999, MOL CELL BIOL, V19, P602; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zeng Q, 2000, J CELL SCI, V113, P471; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	41	190	198	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17347	17353		10.1074/jbc.M009316200	http://dx.doi.org/10.1074/jbc.M009316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278486	hybrid			2022-12-27	WOS:000168730400100
J	Hossain, A; Saunders, GF				Hossain, A; Saunders, GF			The human sex-determining gene SRY is a direct target of WT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLERIAN-INHIBITING SUBSTANCE; TESTIS-DETERMINING REGION; TUMOR SUPPRESSOR GENE; DENYS-DRASH-SYNDROME; WILMS-TUMOR; STEROIDOGENIC FACTOR-1; GONADAL DEVELOPMENT; EXPRESSION; DELETION; MUTATIONS	The product of the Wilms' tumor gene, WT1, is essential for male sex determination and differentiation in mammals. In addition to causing Wilms' tumor, mutations in WT1 often cause two distinct but overlapping urogenital defects in men, Denys-Drash syndrome and Frasier syndrome. In this study we investigated the regulation of the sex determination gene SRY by WT1, Our results showed that WT1 up-regulates the SRY;gene through the proximal early growth response gene-1-like DNA-binding sequences in the core promoter. Mutant WT1 proteins in Denys-Drash syndrome patients were unable to activate this promoter. These mutants did not act in a dominant negative manner, as expected over the wild-type WT1 in this promoter. We also found that WT1 could transactivate the endogenous SRY plene, These observations, together with the overlapping expression patterns of WT1 and SRY in human gonads, led us to propose that WT1 regulates SRY in the initial sex determination process in humans and activates a cascade of genes ultimately leading to the complete organogenesis of the testis.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsaunders@odin.mdacc.tmc.edu			NCI NIH HHS [CA 16672, CA 34936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HACKER A, 1995, DEVELOPMENT, V121, P1603; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Hanley NA, 1999, MECH DEVELOP, V87, P175, DOI 10.1016/S0925-4773(99)00123-9; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Hu SX, 1997, CANCER RES, V57, P3339; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy PR, 1996, INDIAN J ENG MATER S, V3, P1; Shimamura R, 1997, CLIN CANCER RES, V3, P2571; SU H, 1993, AM J HUM GENET, V52, P24; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Tajinda K, 1999, ENDOCRINOLOGY, V140, P4713, DOI 10.1210/en.140.10.4713; WANG ZY, 1993, J BIOL CHEM, V268, P9172	37	146	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16817	16823		10.1074/jbc.M009056200	http://dx.doi.org/10.1074/jbc.M009056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278460	hybrid			2022-12-27	WOS:000168730400031
J	Kimura, MT; Irie, S; Shoji-Hoshino, S; Mukai, J; Nadano, D; Oshimura, M; Sato, TA				Kimura, MT; Irie, S; Shoji-Hoshino, S; Mukai, J; Nadano, D; Oshimura, M; Sato, TA			14-3-3 is involved in p75 neurotrophin receptor-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ZINC-FINGER PROTEIN; HUMAN NGF RECEPTOR; NF-KAPPA-B; CELL-DEATH; NUCLEAR EXPORT; PHOSPHORYLATION; 14-3-3-PROTEINS; EXPRESSION; INDUCTION	The low affinity neurotrophin receptor (p75NTR) has been shown to mediate the apoptosis signaling to neural cells. However, the specific mechanisms of intracellular signal transduction of this process are largely unknown, To understand p75NTR-mediated signal transduction, we previously identified a protein that interacts with the intracellular domain of p75NTR, and we named it p75NTR-associated cell death executor (NADE), To elucidate further the signaling mechanisms utilized by p75NTR and NADE, we screened for NADE-binding protein(s) with the yeast two-hybrid method, and we identified 14-3-3 is an element of as a NADE-binding protein in vivo. To examine whether 14-3-3 is an element of affects the induction of p75NTR-mediated apoptosis, wild type or various deletion mutant forms of 14-3-3 were co-expressed in HEK293, PC12nnr5, and oligodendrocytes. Interestingly, transient expression of the mutant form of 14-3-3 is an element of lacking the 208-255 amino acid region blocked nerve growth factor-dependent p75NTR/NADE-mediated apoptosis, although this mutant form of 14-3-3 is an element of continued to associate with NADE, These results suggest that 14-3-3 is an element of plays an important role in the modulation of nerve growth factor-dependent p75NTR/NADE-mediated apoptosis.	Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, Div Mol Oncol, New York, NY 10032 USA; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Yonago, Tottori 6838503, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Inst, Mol Oncol Lab, Tsukuba, Ibaraki 3050074, Japan	Columbia University; Tottori University; RIKEN	Sato, TA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, Div Mol Oncol, 30 W 168th St,P&S 11-451, New York, NY 10032 USA.		Shoji, Shisako/AAJ-2654-2020; Shoji, Shisako/C-3690-2017	Shoji, Shisako/0000-0001-8787-2159; Shoji, Shisako/0000-0001-8787-2159; Mukai, Jun/0000-0003-2065-4784	NIGMS NIH HHS [R01 GM55147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; BARBACID M, 1993, ONCOGENE, V8, P2033; Brown AL, 1999, HUM MOL GENET, V8, P611, DOI 10.1093/hmg/8.4.611; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; Lachyankar MB, 1997, EXP NEUROL, V144, P350, DOI 10.1006/exnr.1997.6434; Ladiwala U, 1998, J NEUROSCI, V18, P1297; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	44	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17291	17300		10.1074/jbc.M005453200	http://dx.doi.org/10.1074/jbc.M005453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278287	hybrid			2022-12-27	WOS:000168730400093
J	Zolotarjova, NI; Hollis, GF; Wynn, R				Zolotarjova, NI; Hollis, GF; Wynn, R			Unusually stable and long-lived ligand-induced conformations of integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN COMPLEXES; CELL-ADHESION; GPIIB-IIIA; SDS; ALPHA(IIB)BETA(3); FIBRINOGEN; RECEPTOR; CONFORMERS; MODULATION	Integrins are a large family of cell surface receptors that are involved in a wide range of biological processes. The integrin alpha (IIb)beta (3) (glycoprotein IIb-IIIa) is a major platelet glycoprotein heterodimeric receptor that mediates platelet aggregation and is currently a target for pharmaceutical intervention. Ligand binding to the receptor has been shown to induce conformational changes by physical methods and the exposure of neoepitopes (the ligand-induced binding sites). Here we show that the antagonist XP280 induces a conformation that is stable to treatment with SDS and that the protein retains this conformation for several days even after dissociation of the inhibitor. These ligand-induced conformational changes take place with purified protein and on intact platelets. They are competable with an RGDS peptide and are stable to reduction but not boiling or treatment with EDTA. The retention of an altered conformation in the absence of the ligand implies the possibility of ligand-induced alteration of biological function even in the absence of ligand, Finally, similar behavior is observed with the integrin alpha (v)beta (3), suggesting that access to SDS stable conformations may be conserved throughout the integrin superfamily. The unusual stability, long-lived nature, and potential generality of these conformations could have profound implications for integrin biology.	DuPont Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, Wilmington, DE 19880 USA	DuPont	Wynn, R (corresponding author), DuPont Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, E336-241B,POB 80336, Wilmington, DE 19880 USA.							Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; CALVETE JJ, 1995, P SOC EXP BIOL MED, V208, P346; CALVETE JJ, 1994, BIOCHEM J, V298, P1; Chang TE, 1996, ANN NY ACAD SCI, V777, P183, DOI 10.1111/j.1749-6632.1996.tb34417.x; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749-6632.1996.tb52952.x; Glaser T, 1997, FEBS LETT, V413, P50, DOI 10.1016/S0014-5793(97)00876-4; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HORTON MA, 1996, ADHESION RECEPTORS T, P1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOOSTERMAN DA, 1993, PEPTIDE RES, V6, P211; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1992, BLOOD, V80, P2539; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; Mondoro TH, 1996, BLOOD, V88, P3824, DOI 10.1182/blood.V88.10.3824.bloodjournal88103824; MOUSA SA, 1994, LIFE SCI, V54, P1155, DOI 10.1016/0024-3205(94)00837-X; Najbar LV, 1997, BIOCHEMISTRY-US, V36, P11525, DOI 10.1021/bi970730s; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PARKER W, 1992, BIOPHYS J, V61, P1435, DOI 10.1016/S0006-3495(92)81949-5; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; PERVUSHIN K V, 1991, Journal of Biomolecular NMR, V1, P313, DOI 10.1007/BF02192857; ROCCO M, 1993, PROTEIN SCI, V2, P2154, DOI 10.1002/pro.5560021215; Thibault G, 2001, J PHARMACOL EXP THER, V296, P690; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; TSAO PW, 1995, THROMB RES, V77, P543, DOI 10.1016/0049-3848(95)00029-1; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; ZHANG SG, 1994, BIOPOLYMERS, V34, P663, DOI 10.1002/bip.360340508	35	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17063	17068		10.1074/jbc.M009627200	http://dx.doi.org/10.1074/jbc.M009627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278530	hybrid			2022-12-27	WOS:000168730400062
J	Mukhopadhyay, B; Concar, EM; Wolfe, RS				Mukhopadhyay, B; Concar, EM; Wolfe, RS			A GTP-dependent vertebrate-type phosphoenolpyruvate carboxykinase from Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; TRYPANOSOMA-CRUZI; RELAXATION RATE; LIVER; GENE; PURIFICATION; CHICKEN; CDNA; PROTEINS	This is the first report on a bacterial verterbrate-type GTP-dependent phosphoenolpyruvate carboxykinase (PCK). The pck gene of Mycobacterium smegmatis was cloned. The recombinant PCK was overexpressed in Escherichia coli in a soluble form and with high activity. The purified enzyme was found to be monomeric (72 kDa), thermophilic (optimum temperature, 70 degreesC), very stable upon storage at 4 degreesC, stimulated by thiol-containing reducing agents, and inhibited by oxalate and by cu-ketoglutarate. The requirement for a divalent cation for activity was fulfilled best by Mn2+ and Co2+ and poorly by Mg2+. At 37 degreesC, the highest V-m value (32.5 units/mg) was recorded with Mn2+ and in the presence of 37 mM dithiothreitol (DTT), The presence of Mg2+ (2 mM) greatly lowered the apparent K-m, values for Mn2+ (by 144-fold in the presence of DTT and by 9.4-fold in the absence of DTT) and Co2+ (by 230-fold). In the absence of DTT but in the presence of Mg2+ (2 mM) as the co-divalent cation, Co2+ was 21-fold more efficient than Mn2+. For producing oxaloacetate, the enzyme utilized both GDP and IDP; ADP served very poorly. The apparent K-m values for phosphoenolpyruvate, GDP, and bicarbonate were >100, 66, and 8300 muM, respectively, whereas those for GTP and oxaloacetate (for the phosphoenolpyruvate formation activity) were 13 and 12 muM, respectively. Thus, this enzyme preferred the gluconeogenesis/glycerogenesis direction, This property fits the suggestion that in M. smegmatis, pyruvate carboxylase is not anaplerotic but rather gluconeogenic (Mukhopadhyay, B., and Purwantini, E. (2000) Biochim. Biophys. Acta. 1475, 191-206). Both in primary structure and kinetic properties, the mycobacterial PCR was very similar to its vertebrate-liver counterparts and thus could serve as a model for these enzymes; examples for several immediate targets are presented.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Mukhopadhyay, B (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	biswarup@life.uiuc.edu		Mukhopadhyay, Biswarup/0000-0003-0736-0298	NIGMS NIH HHS [GM 51334] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASH DE, 1990, J BIOL CHEM, V265, P7377; BARBIERI JT, 1981, INFECT IMMUN, V31, P1071, DOI 10.1128/IAI.31.3.1071-1077.1981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGELAND ES, 1967, BIOCHEM J, V104, pP9; CANTOR CR, 1980, TECHNIQUES STUDY BIO, V2, P674; CERNIGLIA CE, 1976, APPL ENVIRON MICROB, V32, P764, DOI 10.1128/AEM.32.6.764-768.1976; CHANG HC, 1966, J BIOL CHEM, V241, P2413; CHEN CY, 1991, J BIOL CHEM, V266, P16645; Cleland W. W, 1970, ENZYMES, V2, P1; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; CYMERYNG C, 1995, MOL BIOCHEM PARASIT, V73, P91, DOI 10.1016/0166-6851(95)00099-M; DUFFY TH, 1985, BIOCHEMISTRY-US, V24, P1152, DOI 10.1021/bi00326a014; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Good R. C., 1992, The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. Volume II.., P1238; GUIDINGER PF, 1990, ARCH BIOCHEM BIOPHYS, V278, P131, DOI 10.1016/0003-9861(90)90241-P; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; HARTMANS S, 1992, PROKARYOTES, P1214; HEBDA CA, 1982, J BIOL CHEM, V257, P5503; HEBDA CA, 1982, J BIOL CHEM, V257, P5515; Hlavaty JJ, 1997, BIOCHEMISTRY-US, V36, P3389, DOI 10.1021/bi962255o; Hlavaty JJ, 1997, BIOCHEMISTRY-US, V36, P15514, DOI 10.1021/bi970574p; Hlavaty JJ, 2000, BIOCHEMISTRY-US, V39, P1373, DOI 10.1021/bi991692a; HUSSON RN, 1990, J BACTERIOL, V172, P519, DOI 10.1128/jb.172.2.519-524.1990; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JOMAINBAUM M, 1978, J BIOL CHEM, V253, P3648; KLEIN RD, 1992, MOL BIOCHEM PARASIT, V50, P285, DOI 10.1016/0166-6851(92)90226-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lardy H, 1972, ENZYMES, P117; LEE MH, 1984, BIOCHEMISTRY-US, V23, P6506, DOI 10.1021/bi00321a036; LEE MH, 1981, J BIOL CHEM, V256, P2793; LEWIS CT, 1989, J BIOL CHEM, V264, P27; LEWIS CT, 1993, J BIOL CHEM, V268, P1628; LINSS J, 1993, GENE, V136, P69, DOI 10.1016/0378-1119(93)90449-D; Matte A, 1996, J MOL BIOL, V256, P126, DOI 10.1006/jmbi.1996.0072; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; MEDINA V, 1990, J BACTERIOL, V172, P7151, DOI 10.1128/jb.172.12.7151-7156.1990; MEYUHAS O, 1971, BIOCHIM BIOPHYS ACTA, V250, P224, DOI 10.1016/0005-2744(71)90138-0; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Modaressi S, 1998, BIOCHEM J, V333, P359, DOI 10.1042/bj3330359; Mukhopadhyay B, 2000, BBA-GEN SUBJECTS, V1475, P191, DOI 10.1016/S0304-4165(00)00064-7; NOCE PS, 1975, J BIOL CHEM, V250, P9099; Ratledge C, 1982, BIOL MYCOBACTERIA, P186; REYMOND P, 1992, GENE, V110, P57, DOI 10.1016/0378-1119(92)90444-T; ROHRER SP, 1986, J BIOL CHEM, V261, P3049; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schocke L, 1997, ARCH MICROBIOL, V167, P289, DOI 10.1007/s002030050446; Shirai M, 2000, NUCLEIC ACIDS RES, V28, P2311, DOI 10.1093/nar/28.12.2311; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOFFEL M, 1993, HUM MOL GENET, V2, P1, DOI 10.1093/hmg/2.1.1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITHERADGE MA, 1992, BIOCHEM J, V285, P767, DOI 10.1042/bj2850767; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; WEAST RC, 1985, CRC HDB CHEM PHYSICS; WELDON SL, 1990, J BIOL CHEM, V265, P7308; Wong DK, 1999, INFECT IMMUN, V67, P327, DOI 10.1128/IAI.67.1.327-336.1999; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1172, P267, DOI 10.1016/0167-4781(93)90213-W	59	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16137	16145		10.1074/jbc.M008960200	http://dx.doi.org/10.1074/jbc.M008960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278451	hybrid			2022-12-27	WOS:000168623100077
J	Wijffels, G; Eisemann, C; Riding, G; Pearson, R; Jones, A; Willadsen, P; Tellam, R				Wijffels, G; Eisemann, C; Riding, G; Pearson, R; Jones, A; Willadsen, P; Tellam, R			A novel family of chitin-binding proteins from insect type 2 peritrophic matrix - cDNA sequences, chitin binding activity, and cellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; LUCILIA-CUPRINA; MEMBRANE; CLONING; LECTIN; LARVAE; IDENTIFICATION; RECOGNITION; EXPRESSION; ARTHROPOD	The peritrophic matrix is a prominent feature of the digestive tract of most insects, but its function, formation, and even its composition remain contentious. This matrix is a molecular sieve whose toughness and elasticity are generated by glycoproteins, proteoglycans, and chitin fibrils. We now describe a small, highly conserved protein, peritrophin-15, which is an abundant component of the larval peritrophic matrices of the Old World screwworm fly, Chrysomya bezziana, and sheep blowfly, Lucilia cuprina. Their deduced amino acid sequences code for a 8-kDa secreted protein characterized by a highly conserved and novel register of six cysteines. Two Drosophila homologues have also been identified from unannotated genomic sequences. Recombinant peritrophin-15 binds strongly and specifically to chitin; however, the stoichiometry of binding is low (1:10,000 N-acetyl glucosamine), We propose that peritrophin-15 caps the ends of the chitin polymer. Immunogold studies localized peritrophin-15 to the peritrophic matrix and specific vesicles in cells of the cardia, the small organ of the foregut responsible for peritrophic matrix synthesis. The vesicular contents are disgorged at the base of microvilli underlying the newly formed peritrophic matrix. This is the first time that the process of synthesis and integration of a peritrophic matrix protein into the nascent peritrophic matrix has been observed.	CSIRO, Mol Anim Genet Ctr, St Lucia, Qld 4072, Australia; Univ Queensland, Gehrmann Labs, Inst Mol Biosci, St Lucia, Qld 4072, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Queensland	Wijffels, G (corresponding author), CSIRO, Mol Anim Genet Ctr, St Lucia, Qld 4072, Australia.		Wijffels, Gene/H-7938-2013; Tellam, Ross/T-2423-2019; Tellam, Ross/H-2798-2013	Wijffels, Gene/0000-0001-5552-4416; Tellam, Ross/0000-0003-2353-1640				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER B, 1977, ZOOMORPHOLOGIE, V87, P247, DOI 10.1007/BF00995823; BINNINGTON KC, 1988, TISSUE CELL, V20, P269, DOI 10.1016/0040-8166(88)90048-1; CASU RE, 1994, INSECT MOL BIOL, V3, P202; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; EAST IJ, 1993, INT J PARASITOL, V23, P221, DOI 10.1016/0020-7519(93)90144-N; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; GARDNER KH, 1975, BIOPOLYMERS, V14, P1581, DOI 10.1002/bip.1975.360140804; HIRANO S, 1976, CARBOHYD RES, V47, P315, DOI 10.1016/S0008-6215(00)84198-1; Jacobs-Lorena Marcelo, 1996, P318; KING DG, 1988, J MORPHOL, V196, P253, DOI 10.1002/jmor.1051960302; Lehane MJ, 1997, ANNU REV ENTOMOL, V42, P525, DOI 10.1146/annurev.ento.42.1.525; LOTAN R, 1973, BIOCHEM BIOPH RES CO, V55, P1340, DOI 10.1016/S0006-291X(73)80041-5; MALTASHEWSKI G, 1987, MOL CELL BIOL, V7, P961; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Muharsini S, 2000, INT J PARASITOL, V30, P705, DOI 10.1016/S0020-7519(00)00055-2; Okuyama K, 1997, MACROMOLECULES, V30, P5849, DOI 10.1021/ma970509n; PETERS W, 1979, ENTOMOL GEN, V5, P241; PETERS W, 1992, PERITROPHIC MEMBRANE, V30; PRIVAT JP, 1974, EUR J BIOCHEM, V47, P5, DOI 10.1111/j.1432-1033.1974.tb03661.x; Proft T, 1996, GENE, V171, P79, DOI 10.1016/0378-1119(96)00014-5; QUICHO FA, 1993, BIOCHEM SOC T, V21, P442; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; Schorderet S, 1998, INSECT BIOCHEM MOLEC, V28, P99, DOI 10.1016/S0965-1748(97)00103-3; Shen ZC, 1998, J BIOL CHEM, V273, P17665, DOI 10.1074/jbc.273.28.17665; Tellam R. L., 1996, P86; Tellam RL, 1999, INSECT BIOCHEM MOLEC, V29, P87, DOI 10.1016/S0965-1748(98)00123-4; TIMONEY JF, 1995, INFECT IMMUN, V63, P1440, DOI 10.1128/IAI.63.4.1440-1445.1995; UNDENFRIEND S, 1969, FLUORESCENCE ASSAY B, V2, P229; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUOCOLO T, 2001, IN PRESS INSECT BIOC; Wang P, 1997, P NATL ACAD SCI USA, V94, P6977, DOI 10.1073/pnas.94.13.6977; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Wijffels G, 1996, EUR J BIOCHEM, V237, P414, DOI 10.1111/j.1432-1033.1996.0414k.x; WILLADSEN P, 1989, J IMMUNOL, V143, P1346	39	39	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15527	15536		10.1074/jbc.M009393200	http://dx.doi.org/10.1074/jbc.M009393200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278497	hybrid			2022-12-27	WOS:000168528800132
J	Pike, BL; Hammet, A; Heierhorst, J				Pike, BL; Hammet, A; Heierhorst, J			Role of the N-terminal forkhead-associated domain in the cell cycle checkpoint function of the Rad53 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; FHA DOMAIN; PROTEIN-KINASE; PHOSPHATASE PTC2P; BUDDING YEAST; PATHWAYS; REPLICATION; ATM	Forkhead-associated (FHA) domains are multifunctional phosphopeptide-binding modules and are the hallmark of the conserved family of Rad53-like checkpoint protein kinases, Rad53-like kinases, including the human tumor suppressor protein Chk2, play crucial roles in cell cycle arrest and activation of repair processes following DNA damage and replication blocks. Here we show that ectopic expression of the N-terminal FHA domain (FHA1) of the yeast Rad53 kinase causes a growth defect by arresting the cell cycle in G(1). This phenotype was highly specific for the Rad53-FHA1 domain and not observed with the similar Rad53-FHA2, Dun1-FHA, and Chk2-FHA domains, and it was abrogated by mutations that abolished binding to a phosphothreonine-containing peptide in vitro. Furthermore, replacement of the RAD53 gene with alleles containing amino acid substitutions in the FHA1 domain resulted in an increased DNA damage sensitivity in vivo, Taken together, these data demonstrate that the FHA1 domain contributes to the checkpoint function of Rad53, possibly by associating with a phosphorylated target protein in response to DNA damage in G(1).	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Heierhorst, J (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Pike, Brietta L./H-5317-2019	Pike, Brietta L./0000-0002-4763-1729				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; de los Santos T, 1999, J BIOL CHEM, V274, P1783, DOI 10.1074/jbc.274.3.1783; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dohrmann PR, 1999, GENETICS, V151, P965; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; Fay DS, 1997, CURR GENET, V31, P97, DOI 10.1007/s002940050181; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Hammet A, 2000, FEBS LETT, V471, P141, DOI 10.1016/S0014-5793(00)01392-2; HIAO A, 2000, SCIENCE, V287, P1824; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Marsolier MC, 2000, GENETICS, V154, P1523; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shieh SY, 2000, GENE DEV, V14, P289; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14019	14026		10.1074/jbc.M009558200	http://dx.doi.org/10.1074/jbc.M009558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278522	hybrid			2022-12-27	WOS:000168356600071
J	Seebohm, G; Scherer, CR; Busch, AE; Lerche, C				Seebohm, G; Scherer, CR; Busch, AE; Lerche, C			Identification of specific pore residues mediating KCNQ1 inactivation - A novel mechanism for long QT syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL GENE; INHERITED CARDIAC-ARRHYTHMIAS; K+ CHANNEL; MOLECULAR MECHANISM; SODIUM-CHANNEL; MINK SUBUNITS; MUTATIONS; KVLQT1; EPILEPSY; DOMINANT	KCNQ1 inactivation bears electrophysiological characteristics different from classical N- and C-type inactivation in Shaker-like potassium channels, However, the molecular site of KCNQ1 inactivation has not yet been determined. KCNQ2 channels do not exert a fast inactivation in contrast to KCNQ1 channels, By expressing functional chimeras between KCNQ1 and KCNQ2 in Xenopus oocytes, we mapped the region of this inactivation to transmembrane domain S5 and the pore loop H5 and finally narrowed down the site to positions Gly(272) and Val(307) in KCNQ1. Exchanging these two amino acids individually with the analogous KCNQ2 residue abolished inactivation. Furthermore, a KCNQ1-like inactivation was introduced into KCNQ2 by mutagenesis in the corresponding region, confirming its relevance for the inactivation process. As KCNQ1 inactivation involves the regions S5 and H5, it exhibits a geography distinct from N- or C-type inactivation Native cardiac I-Ks channels comprising KCNQ1 and accessory MinK subunits do not inactivate because of the functional interaction of KCNQ1 with MinK, Mutations in KCNQ1 can lead to long QT1 syndrome, an inherited form of arrhythmia. The long QT1 mutant KCNQ1(L273F) displays a pronounced KCNQ1 inactivation. Here we show that when expressing mutant I-Ks channels formed from KCNQ1(L273F) and MinK, MinK association no longer eliminates KCNQ1 inactivation. This results in smaller repolarizing currents in the heart and therefore represents a novel mechanism leading to long QT syndrome.	Aventis Pharma Deutschland GmbH, DG Cardiovasc Dis, D-65926 Frankfurt, Germany	Sanofi-Aventis	Lerche, C (corresponding author), Aventis Pharma Deutschland GmbH, DG Cardiovasc Dis, Bldg H821, D-65926 Frankfurt, Germany.							ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Hadley JK, 2000, BRIT J PHARMACOL, V129, P413, DOI 10.1038/sj.bjp.0703086; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lerche C, 2000, J BIOL CHEM, V275, P22395, DOI 10.1074/jbc.M002378200; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; Pusch M, 2000, BIOPHYS J, V78, P211, DOI 10.1016/S0006-3495(00)76586-6; Pusch M, 1998, BIOPHYS J, V75, P785, DOI 10.1016/S0006-3495(98)77568-X; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Shalaby FY, 1997, CIRCULATION, V96, P1733, DOI 10.1161/01.CIR.96.6.1733; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943	35	54	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13600	13605		10.1074/jbc.M008373200	http://dx.doi.org/10.1074/jbc.M008373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278406	hybrid			2022-12-27	WOS:000168356600015
J	Ebisawa, T; Fukuchi, M; Murakami, G; Chiba, T; Tanaka, K; Imamura, T; Miyazono, K				Ebisawa, T; Fukuchi, M; Murakami, G; Chiba, T; Tanaka, K; Imamura, T; Miyazono, K			Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; DEPENDENT DEGRADATION; NUCLEAR EXPORT; ANTAGONIST; P53	Smad7 is an inhibitory Smad that acts as a negative regulator of signaling by the transforming growth factor-beta (TGF-beta) superfamily proteins. Smad7 is induced by TGF-beta, stably interacts with activated TGF-beta type I receptor (T betaR-I), and interferes with the phosphorylation of receptor-regulated Smads. Here we show that Smurf1, an E3 ubiquitin ligase for bone morphogenetic protein-specific Smads, also interacts with Smad7 and induces Smad7 ubiquitination and translocation into the cytoplasm. In addition, Smurf1 associates with T betaR-I via Smad7, with subsequent enhancement of turnover of T betaR-I and Smad7. These results thus reveal a novel function of Smad7, i.e. induction of degradation of T betaR-I through recruitment of an E3 ligase to the receptor.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Res Future Program, Toshima Ku, Tokyo 1708455, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 1999, J CELL SCI, V112, P3519; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	20	661	708	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12477	12480		10.1074/jbc.C100008200	http://dx.doi.org/10.1074/jbc.C100008200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278251	hybrid			2022-12-27	WOS:000168198600001
J	Egelund, R; Einholm, AP; Pedersen, KE; Nielsen, RW; Christensen, A; Deinum, J; Andreasen, PA				Egelund, R; Einholm, AP; Pedersen, KE; Nielsen, RW; Christensen, A; Deinum, J; Andreasen, PA			A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands - Ligand-induced serpin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; MOLECULAR-WEIGHT INHIBITOR; UROKINASE-TYPE; PROTEINASE COMPLEX; STRUCTURAL BASIS; BINDING-SITE; PROTEASE COMPLEXES; CELL-MIGRATION; VITRONECTIN; RECEPTOR	We have characterized the neutralization of the inhibitory activity of the serpin plasminogen activator inhibitor-1 (PAI-1) by a number of structurally distinct organo-chemicals, including compounds with environment-sensitive spectroscopic properties. In contrast to latent and reactive center-cleaved PAI-1 and PAI-1 in complex with urokinase-type plasminogen activator (uPA), active PAI-1 strongly increased the fluorescence of the PAI-1-neutralizing compounds 1-anilinonaphthalene-8-sulfonic acid and 4,4'-dianilino-1,1'-bisnaphthyl-5,5'-dis acid, The fluorescence increase could be competed by all tested nonfluorescent neutralizers, indicating that all neutralizers bind to a common hydrophobic area preferentially accessible in active PAI-1, Activity neutralization proceeded through two consecutive steps as follows: first step is conversion to forms displaying substrate behavior toward uPA, and second step is to forms inert to uPA With some neutralizers, the second step was associated with PAI-1 polymerization, Vitronectin reduced the susceptibility to the neutralizers. Changes in sensitivity to activity neutralization by point mutations were compatible with the various neutralizers having overlapping but not identical, binding sites in the region around alpha -helices D and E and beta -strand 1A, known to act as a flexible joint when beta -sheet A opens and the reactive center loop inserts as beta -strand 4A during reaction with target proteinases. The defined binding area may be a target for development of compounds for neutralizing PAI-1 in cancer and cardiovascular diseases.	Aarhus Univ, Dept Mol & Struct Biol, Lab Cellular Prot Sci, DK-8000 Aarhus C, Denmark; Astra Zeneca, R&D Molndal, S-43183 Molndal, Sweden	Aarhus University; AstraZeneca	Andreasen, PA (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Lab Cellular Prot Sci, 10C Gustav Wieds Vej, DK-8000 Aarhus C, Denmark.	pa@mbio.aau.dk						AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; Andreasen PA, 1999, THROMB HAEMOSTASIS, V81, P407; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DEVENDITTIS E, 1981, ANAL BIOCHEM, V115, P278, DOI 10.1016/0003-2697(81)90006-3; Egelund R, 1997, EUR J BIOCHEM, V248, P775, DOI 10.1111/j.1432-1033.1997.t01-1-00775.x; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Ehnebom J, 1997, FIBRINOLYSIS PROTEOL, V11, P165, DOI 10.1016/S0268-9499(97)80061-6; EITZMAN DT, 1995, J CLIN INVEST, V95, P2416, DOI 10.1172/JCI117937; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Friederich PW, 1997, CIRCULATION, V96, P916; Gardsvoll H, 1998, FEBS LETT, V431, P170, DOI 10.1016/S0014-5793(98)00742-X; Gils A, 1998, THROMB HAEMOSTASIS, V80, P286, DOI 10.1055/s-0037-1615189; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Helenius A, 1979, Methods Enzymol, V56, P734; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KEIJER J, 1991, BLOOD, V78, P401; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Rodenburg KW, 1998, BIOCHEM J, V329, P55; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; Vaughan DE, 1998, J INVEST MED, V46, P370; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Wohn KD, 1999, BRIT J HAEMATOL, V104, P901, DOI 10.1046/j.1365-2141.1999.01242.x; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200	70	62	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13077	13086		10.1074/jbc.M009024200	http://dx.doi.org/10.1074/jbc.M009024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278457	hybrid			2022-12-27	WOS:000168198600087
J	Kim, S; Jee, K; Kim, D; Koh, H; Chung, J				Kim, S; Jee, K; Kim, D; Koh, H; Chung, J			Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; CELL-SURVIVAL; DNA-SYNTHESIS; S6 KINASE; ACTIVATION	Akt is a protein serine/threonine kinase that plays an important role in the mitogenic responses of cells to variable stimuli. Akt contains a pleckstrin homology (PH) domain and is activated by phosphorylation at threonine 308 and serine 473, Binding of 3 ' -OH phosphorylated phosphoinositides to the PH domain results in the translocation of Akt to the plasma membrane where it is activated by upstream kinases such as (phosphoinositide-dependent kinase-l (PDK1), Over-expression of constitutively active forms of Akt promotes cell proliferation and survival, and also stimulates p70 S6 kinase (p70S6K), In many cells, an increase in levels of intracellular cyclic AMP (cAMP) diminishes cell growth and promotes differentiation, and in certain conditions cAMP is even antagonistic to the effect of growth factors. Here, we show that cAMP has inhibitory effects on the phosphatidylinositol 3-kinase/PDK/Akt signaling pathway. cAMP potently inhibits phosphorylation at threonine 308 and serine 473 of Akt, which is required for the protein kinase activities of Akt, cAMP also negatively regulates PDK1 by inhibiting its translocation to the plasma membrane, despite not affecting its protein kinase activities. Furthermore, when we co-expressed myristoylated Akt and PDK1 mutants which constitutively co-localize in the plasma membrane, Akt activity was no longer sensitive to raised intracellular cAMP concentrations. Finally, cAMP was also found to inhibit the lipid kinase activity of PI3K and to decrease the levels of phosphatidylinositol 3,4,5-triphosphate in vivo, which are required for the membrane localization of PDK1, Collectively, these data strongly support the theory that the cAMP-dependent signaling pathway inhibits Akt activity by blocking the coupling between Akt and its upstream regulators, PDK, in the plasma membrane.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong, Taejon 305701, South Korea.		Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; David M, 1996, J BIOL CHEM, V271, P4585; DeBernardi MA, 1996, P NATL ACAD SCI USA, V93, P4577, DOI 10.1073/pnas.93.10.4577; DEL PL, 1997, SCIENCE, V278, P687; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rogue PJ, 1998, P NATL ACAD SCI USA, V95, P9178, DOI 10.1073/pnas.95.16.9178; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang B, 1997, SCIENCE, V277, P251, DOI 10.1126/science.277.5323.251; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	50	163	167	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12864	12870		10.1074/jbc.M001492200	http://dx.doi.org/10.1074/jbc.M001492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278269	hybrid			2022-12-27	WOS:000168198600057
J	Miura, K; Inouye, S; Sakai, K; Takaoka, H; Kishi, F; Tabuchi, M; Tanaka, T; Matsumoto, H; Shirai, M; Nakazawa, T; Nakazawa, A				Miura, K; Inouye, S; Sakai, K; Takaoka, H; Kishi, F; Tabuchi, M; Tanaka, T; Matsumoto, H; Shirai, M; Nakazawa, T; Nakazawa, A			Cloning and characterization of adenylate kinase from Chlamydia pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEATION-CONDENSATION MECHANISM; ESCHERICHIA-COLI; THERMAL-STABILITY; TRANSITION-STATE; PROTEIN; ZINC; TRACHOMATIS; SEQUENCE; PURIFICATION; NUCLEOTIDE	Chlamydiae proliferate only within the infected host cells and are thought to be "energy parasites," because they take up ATP from the host cell as an energy source. In the present study, we isolated from Chlamydia pneumoniae the gene encoding adenylate kinase (AK), Using the enzyme produced in Escherichia coli, its properties were characterized. K-m values for AMP and for ADP of the purified C, pneumoniae AK (AKcpn) were each 330 muM, which is significantly higher than the reported values of other AKs, whereas K-m for ATP was 24 muM, which was rather lower than others. AKcpn contains 1 g atom of zinc/mol of 24,000-dalton protein. Mass spectrometric analysis of AKcpn and analysis of properties of mutated AKcpn strongly suggested that zinc is associated with four cysteine residues in the LID domain of the enzyme. The apo-AKcpn that lost zinc retained AK activity, although K-m for AMP of apo-AKcpn increased about 2-fold and V-max decreased about one-half from that of holo-AKcpn. The apo-AKcpn was more thermolabile and sensitive to trypsin digestion than the holo-AKcpn. Moreover, the recovery in vitro of the AK activity during the renaturation process of the denatured apo-AKcpn was dependent on zinc. A mutated protein in which cysteine residues in the LID domain were substituted by other amino acids lost both zinc and enzyme activity. The mutated protein was more sensitive to protease than the apo AKcpn. These results indicate that zinc in AKcpn, although not essential for the catalysis, stabilizes the enzyme and probably plays a crucial role in proper folding of the protein. Furthermore, the catalytic properties of AKcpn suggest a distinctive regulatory mechanism in the metabolism compared with AKs in other organisms.	Yamaguchi Univ, Sch Med, Dept Microbiol, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Biochem, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Cent Lab Biomed Res, Yamaguchi 7558505, Japan; Yamaguchi Univ, Ctr Gene Res, Yamaguchi 7558505, Japan; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Natl Sci Fdn, EPSCoR Oklahoma Laser Mass Spectrometry Facil, Oklahoma City, OK 73190 USA	Yamaguchi University; Yamaguchi University; Yamaguchi University; Yamaguchi University; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Science Foundation (NSF); University of Oklahoma System; University of Oklahoma Health Sciences Center	Miura, K (corresponding author), Yamaguchi Univ, Sch Med, Dept Microbiol, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	koshirom@po.cc.yamaguchi-u.ac.jp	Inouye, Sharon/R-7216-2019	Tabuchi, Mitsuaki/0000-0002-2042-691X				ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burlacu-Miron S, 1998, J BIOL CHEM, V273, P19102, DOI 10.1074/jbc.273.30.19102; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; CRONAN JE, 1972, MOL GEN GENET, V116, P199, DOI 10.1007/BF00269765; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FukamiKobayashi K, 1996, FEBS LETT, V385, P214, DOI 10.1016/0014-5793(96)00367-5; GILLES AM, 1994, J BACTERIOL, V176, P520, DOI 10.1128/JB.176.2.520-523.1994; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; GRAYSTON JT, 1989, INT J SYST BACTERIOL, V39, P88, DOI 10.1099/00207713-39-1-88; HATCH TP, 1982, J BACTERIOL, V150, P662, DOI 10.1128/JB.150.2.662-670.1982; HOLMES RK, 1973, J BIOL CHEM, V248, P2014; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Iliffe-Lee ER, 1999, MOL MICROBIOL, V33, P177, DOI 10.1046/j.1365-2958.1999.01464.x; Inouye S, 1999, BIOCHEM BIOPH RES CO, V254, P618, DOI 10.1006/bbrc.1998.0116; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kimura M, 2000, J BIOCHEM, V127, P955, DOI 10.1093/oxfordjournals.jbchem.a022711; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsushima H, 1999, INFECT IMMUN, V67, P3175, DOI 10.1128/IAI.67.6.3175-3179.1999; McClarty G, 1999, CHLAMYDIA, P69; Miura T, 1998, BBA-PROTEIN STRUCT M, V1384, P171, DOI 10.1016/S0167-4838(98)00015-6; MOLDER JW, 1991, MICROBIOL REV, V55, P143; MULLER CW, 1995, STRUCTURE, V44, P147; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; NOHUMOTO M, 1998, J BIOCH MOL BIOL BIO, V2, P13; Perrier V, 1998, J BIOL CHEM, V273, P19097, DOI 10.1074/jbc.273.30.19097; Perrier V, 1998, PROTEIN ENG, V11, P917, DOI 10.1093/protein/11.10.917; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; Shirai M, 2000, NUCLEIC ACIDS RES, V28, P2311, DOI 10.1093/nar/28.12.2311; Song S, 1996, GENE, V175, P65, DOI 10.1016/0378-1119(96)00121-7; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; TANIZAWA Y, 1987, J BIOCHEM-TOKYO, V101, P1289, DOI 10.1093/oxfordjournals.jbchem.a121993; TAO S, 1991, J BACTERIOL, V173, P2818, DOI 10.1128/JB.173.9.2818-2822.1991; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; Tjaden J, 1999, J BACTERIOL, V181, P1196, DOI 10.1128/JB.181.4.1196-1202.1999	48	19	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13490	13498		10.1074/jbc.M009461200	http://dx.doi.org/10.1074/jbc.M009461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278507	hybrid			2022-12-27	WOS:000168198600139
J	Kondo, M; Oya-Ito, T; Kumagai, T; Osawa, T; Uchida, K				Kondo, M; Oya-Ito, T; Kumagai, T; Osawa, T; Uchida, K			Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENIUM-GLUTATHIONE-PEROXIDASE; AMYLOID BETA-PEPTIDE; LIPID-PEROXIDATION; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; ALDEHYDIC PRODUCT; IN-VIVO; PROTEIN; MECHANISMS; CELLS	In the present study, we find that cyclopentenone prostaglandins (PGs) of the J(2) series, naturally occurring derivatives of PGD(2), are potential inducers of intracellular oxidative stress that mediates cell degeneration. Based on an extensive screening of diverse chemical agents on induction of intracellular production of reactive oxygen species (ROS), we found that the cyclopentenone PGs, such as PGA(2), PGJ(2), Delta (12)-PGJ(2), and 15-deoxy-Delta (12,14)-PGJ(2), showed the most potent pro-oxidant effect on SH-SY5Y human neuroblastoma cells. As the intracellular events that mediate the PG cytotoxicity, we observed (i) the cellular redox alteration represented by depletion of antioxidant defenses, such as glutathione and glutathione peroxidase; (ii) a transient decrease in the mitochondrial membrane potential (Delta psi); (iii) the production of protein-bound lipid peroxidation products, such as acrolein and 4-hydroxy-2-nonenal; and (iv) the accumulation of ubiquitinated proteins. These events correlated well with the reduction in cell viability. In addition, the thiol compound, N-acetylcysteine, could significantly inhibit the PG-induced ROS production, thereby preventing cytotoxicity, suggesting that the redox alteration is closely related to the pro-oxidant effect of cyclopentenone PGs. More strikingly, the lipid peroxidation end products, acrolein and 4-hydroxy-2-nonenal, detected in the PG-treated cells potently induced the ROS production, which was accompanied by the accumulation of ubiquitinated proteins and cell death, suggesting that the membrane Lipid peroxidation products may represent one of the causative factors that; potentiate the cytotoxic effect of cyclopentenone PGs by accelerating intracellular oxidative stress. These data suggest that the intracellular oxidative stress, represented by ROS production/lipid peroxidation and redox alteration, may underlie the well documented biological effects, such as antiproliferative and antitumor activities, of cyclopentenone PGs.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan	Nagoya University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.		OYA-ITO, Tomoko/M-8906-2014	Uchida, Koji/0000-0003-3894-5299				ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; Blanc EM, 1997, J NEUROCHEM, V69, P570; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chen Y, 1999, BBA-MOL CELL BIOL L, V1436, P550, DOI 10.1016/S0005-2760(98)00168-4; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FIZPATRICK FA, 1983, J BIOL CHEM, V258, P11713; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HUBER RE, 1967, ARCH BIOCHEM BIOPHYS, V122, P164, DOI 10.1016/0003-9861(67)90136-1; Keller JN, 1997, J NEUROCHEM, V69, P273; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Mark RJ, 1997, J NEUROCHEM, V68, P255; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Narayanan PK, 1997, CANCER RES, V57, P3963; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; Prasad KN, 1998, P SOC EXP BIOL MED, V219, P120; Prasad KN, 1998, IN VITRO CELL DEV-AN, V34, P265, DOI 10.1007/s11626-998-0133-7; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1992, AM J PHYSIOL, V263, P181; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN TC, 1980, ANNU REV BIOCHEM, V49, P93, DOI 10.1146/annurev.bi.49.070180.000521; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; TOYOKUNI S, 1995, FEBS LETT, V359, P189, DOI 10.1016/0014-5793(95)00033-6; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572	49	184	192	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12076	12083		10.1074/jbc.M009630200	http://dx.doi.org/10.1074/jbc.M009630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278531	hybrid			2022-12-27	WOS:000168081800087
J	Lacasa, D; Le Liepvre, X; Ferre, P; Dugail, I				Lacasa, D; Le Liepvre, X; Ferre, P; Dugail, I			Progesterone stimulates adipocyte determination and differentiation 1/sterol regulatory element-binding protein 1c gene expression - Potential mechanism for the lipogenic effect of progesterone in adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; TRANSCRIPTIONAL ACTIVITY; BREAST-CARCINOMA; ENZYME GENE; RAT; METABOLISM; GLUCOSE; IDENTIFICATION; CHOLESTEROL; ADD1/SREBP1	Fatty acid synthase (FAS), a nutritionally regulated lipogenic enzyme, is transcriptionally controlled by ADD1/SREBP1c (adipocyte determination and differentiation 1/sterol regulatory element-binding protein 1c), through insulin-mediated stimulation of ADD1/SREBP1c expression. Progesterone exerts lipogenic effects on adipocytes, and FAS is highly induced in breast tumor cell lines upon progesterone treatment. We show here that progesterone up-regulates ADD1/SREBP1c expression in the MCF7 breast cancer cell line and the primary cultured preadipocyte from rat parametrial adipose tissue. In MCF7, progesterone induced ADD1/SREBP1c and Meta-Ilothionein II (a well known progesterone-regulated gene) mRNAs, with comparable potency, In preadipocytes, progesterone increased ADD1/SREBP1c mRNA dose-dependently, but not SREBP1a or SREBP2, Run-on experiments demonstrated that progesterone action on ADD1/SREBP1c was primarily at the transcriptional level. The membrane-bound and mature nuclear forms of ADD1/SREBP1 protein accumulated in preadipocytes cultured with progesterone, and FAS induction could be abolished by adenovirus-mediated overexpression of a dominant negative form of ADD1/SREBP1 in these cells, Finally, in the presence of insulin, progesterone was unable to up-regulate ADD1/SREBP1c mRNA in preadipocytes, whereas its effect was restored after 24 h of insulin deprivation, Together these results demonstrate that ADD1/SREBP1c is controlled by progesterone, which, like insulin, acts by increasing ADD1/SREBP1c gene transcription, This provides a potential mechanism for the lipogenic actions of progesterone on adipose tissue.	INSERM, U465, F-75006 Paris, France; Univ Paris 05, Fac Med Paris Ouest, Lab Biochim & Biol Mol, F-75270 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dugail, I (corresponding author), INSERM, U465, 15 Rue Ecole Med, F-75006 Paris, France.		Dugail, Isabelle/L-1567-2017; Ferré, Pascal/K-1250-2013	Dugail, Isabelle/0000-0003-3631-2252; Ferré, Pascal/0000-0003-0115-7045				Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHALBOS D, 1990, REV ESP FISIOL, V46, P43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; DUGAIL I, 1992, BIOCHEM J, V281, P607, DOI 10.1042/bj2810607; Ekhterae D, 1996, BIOCHEM BIOPH RES CO, V227, P547, DOI 10.1006/bbrc.1996.1543; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; GRAY JM, 1979, ENDOCRINOLOGY, V104, P1377, DOI 10.1210/endo-104-5-1377; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; Homko CJ, 1999, SEMIN REPROD ENDOCR, V17, P119, DOI 10.1055/s-2007-1016219; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 2000, J LIPID RES, V41, P99; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LORENZO M, 1981, BIOCHEM J, V198, P425, DOI 10.1042/bj1980425; MENDES AM, 1985, J ENDOCRINOL, V106, P225, DOI 10.1677/joe.0.1060225; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Nakamura I, 1999, INT J MOL MED, V4, P381; RYAN EA, 1988, J CLIN ENDOCR METAB, V67, P341, DOI 10.1210/jcem-67-2-341; SLATER EP, 1988, MOL ENDOCRINOL, V2, P485, DOI 10.1210/mend-2-6-485; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	37	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11512	11516		10.1074/jbc.M008556200	http://dx.doi.org/10.1074/jbc.M008556200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278421	hybrid			2022-12-27	WOS:000168081800014
J	Subbaramaiah, K; Lin, DT; Hart, JC; Dannenberg, AJ				Subbaramaiah, K; Lin, DT; Hart, JC; Dannenberg, AJ			RETRACTED: Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2 - Evidence for involvement of activator protein-1 and CREB-binding protein/p300 (Retracted article. See vol. 295, pg. 291, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							N-TERMINAL KINASE; CANCER CELL-GROWTH; PPAR-GAMMA; PHORBOL ESTER; SELECTIVE-INHIBITION; EPITHELIAL-CELLS; GENE-EXPRESSION; BREAST-CANCER; IN-VITRO; CHEMOPREVENTIVE ACTIVITY	We investigated whether peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands (ciglitazone, troglitazone, and 15-deoxy-Delta (12,14) prostaglandin J(2)) inhibited cyclooxygenase-2 (COX-2) induction in human epithelial cells. Ligands of PPAR gamma inhibited phorbol ester (phorbol 12-myristate 13-acetate, PMA)-mediated induction of COX-2 and prostaglandin E-2 synthesis. Nuclear run-offs revealed increased rates of COX-2 transcription after treatment with PMA, an effect that was inhibited by PPAR gamma ligands, PMA-mediated induction of COX-2 promoter activity was inhibited by PPAR gamma ligands; this suppressive effect was prevented by overexpressing a dominant negative form of PPAR gamma or a PPAR response element decoy oligonucleotide, The stimulatory effects of PMA were mediated by a cyclic AMP response element in the COX-2 promoter. Treatment with PMA increased activator protein-1 (AP-1) activity and the binding of c-Jun, c-Fos, and ATF-2 to the cyclic AMP response element, effects that were blocked by PPAR gamma ligands. These findings raised questions about the mechanism underlying the anti-AP-1 effect of PPAR gamma ligands. The induction of c-Jun by PMA was blocked by PPAR gamma ligands. Overexpression of either c-Jun or CREB-binding protein/p300 partially relieved the suppressive effect of PPAR gamma ligands. When CREB-binding protein and c-Jun were overexpressed together, the ability of PPAR gamma ligands to suppress PMA-mediated induction of COX-2 promoter activity was essentially abrogated. Bisphenol A diglycidyl ether, a compound that binds to PPAR gamma but lacks the ability to activate transcription, also inhibited PMA-mediated induction of AP-1 activity and COX-2. Taken together, these findings are likely to be important for understanding the anti-inflammatory and anti-cancer properties of PPAR gamma ligands.	New York Presbyterian Hosp, Dept Med, Div Gastroenterol & Hepatol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA	NewYork-Presbyterian Hospital; Cornell University; Memorial Sloan Kettering Cancer Center	Subbaramaiah, K (corresponding author), New York Presbyterian Hosp, Dept Med, Div Gastroenterol & Hepatol, Cornell Campus,1300 York Ave,Rm F-203A, New York, NY 10021 USA.	ksubba@med.cornell.edu			NCI NIH HHS [1 RO1 CA89578, P01 CA29502, T32 CA09685] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009685, R01CA089578, P01CA029502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chan G, 1999, CANCER RES, V59, P991; Chang TH, 2000, CANCER RES, V60, P1129; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Harris RE, 2000, CANCER RES, V60, P2101; Inoue H, 2000, J BIOL CHEM, V275, P28028; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kawamori T, 1998, CANCER RES, V58, P409; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kubota T, 1998, CANCER RES, V58, P3344; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HY, 1998, J BIOL CHEM, V273, P7066, DOI 10.1074/jbc.273.12.7066; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Lipsky PE, 1997, J RHEUMATOL, V24, P9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Parrett ML, 1997, INT J ONCOL, V10, P503; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ristimaki A, 1997, CANCER RES, V57, P1276; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; Rubin GL, 2000, CANCER RES, V60, P1604; Sacks PG, 1996, CANCER METAST REV, V15, P27, DOI 10.1007/BF00049486; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Subbaramaiah K, 2000, CANCER RES, V60, P2399; Suh N, 1999, CANCER RES, V59, P5671; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tucker ON, 1999, CANCER RES, V59, P987; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; ZHAI YF, 1993, CANCER RES, V53, P2272; Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	76	274	280	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12440	12448		10.1074/jbc.M007237200	http://dx.doi.org/10.1074/jbc.M007237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278336	hybrid			2022-12-27	WOS:000168081800133
J	Zhou, H; Thiele, DJ				Zhou, H; Thiele, DJ			Identification of a novel high affinity copper transport complex in the fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTOR; FET3 GENE; EXPRESSION; OXIDASE; PROTEIN; REDUCTASE; MEMBRANE	Copper is an essential nutrient that serves as a cofactor for enzymes involved in critical cellular processes including energy generation, peptide hormone maturation, oxidative stress protection, and iron homeostasis. Although genes have been identified from yeast and mammals encoding a homologous subunit of a plasma membrane high affinity copper transporter, the presence of additional subunits that function as part of a copper transport complex has not been reported. We observed that ctr4(+), a previously identified copper transport protein from the fission yeast Schizosaccharomyces pombe, fails to complement bakers' yeast cells defective in high affinity copper transport and fails to be targeted to the plasma membrane. However, selection for S. pombe genes, which, when co-expressed with Ctr4, confer high affinity copper transport to S. cerevisiae cells resulted in the identification of ctr5(+). Both Ctr4 and Ctr5 are integral membrane proteins, are coregulated by copper levels and the copper-sensing transcription factor Cuf1, physically associate in vivo, are interdependent for secretion to the plasma membrane, and are each essential for high affinity copper transport, These studies in S. pombe identify Ctr4 and Ctr5 as components of a novel eukaryotic heteromeric plasma membrane complex that is essential for high affinity copper transport.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dthiele@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41840] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Forsburg SL, 1999, TRENDS GENET, V15, P340, DOI 10.1016/S0168-9525(99)01798-9; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaiser C., 1994, METHODS YEAST GENETI; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; McNabb DS, 1997, BIOTECHNIQUES, V22, P1134, DOI 10.2144/97226rr01; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moynihan EB, 1999, MOL BIOL CELL, V10, P245, DOI 10.1091/mbc.10.2.245; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	37	87	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20529	20535		10.1074/jbc.M102004200	http://dx.doi.org/10.1074/jbc.M102004200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274192	hybrid			2022-12-27	WOS:000169135100115
J	Brady, JD; Robins, SP				Brady, JD; Robins, SP			Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; ARTICULAR-CARTILAGE; BIOCHEMICAL-CHANGES; BONE-COLLAGEN; I COLLAGEN; CHROMOGEN; PYRIDINOLINE; LOCATION; ELASTIN	The structures of pyrrolic forms of cross-links in collagen have been confirmed by reacting collagen peptides with a biotinylated Ehrlich's reagent. This reagent was synthesized by converting the cyano group of N-methyl-N-cyanoethyl-4-aminobenzaldehyde to a carboxylic acid, followed by conjugation with biotin pentylamine. Derivatization of peptides from bone collagen both stabilized the pyrroles and facilitated selective isolation of the pyrrole-containing peptides using a monomeric avidin column. Reactivity of the biotinylated reagent with collagen peptides was similar to that of the standard Ehrlich reagent, but heat denaturation of the tissue before enzyme digestion resulted in the loss of about 50% of the pyrrole cross-links. Identification of a series of peptides by mass spectrometry confirmed the presence of derivatized pyrrole structures combined with between 1 and 16 amino acid residues. Almost all of the pyrrole-containing peptides appeared to be derived from N-terminal telopeptide sequences, and the nonhydroxylated (lysine-derived) form predominated over pyrrole cross-links derived from helical hydroxylysine.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland	University of Aberdeen	Robins, SP (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.							Adamczyk M, 1999, ANGEW CHEM INT EDIT, V38, P3537, DOI 10.1002/(SICI)1521-3773(19991203)38:23<3537::AID-ANIE3537>3.3.CO;2-I; Bailey AJ, 1999, CALCIFIED TISSUE INT, V65, P203, DOI 10.1007/s002239900683; Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1980, BIOCHEM BIOPH RES CO, V92, P403, DOI 10.1016/0006-291X(80)90347-2; Hanson DA, 1996, J BIOL CHEM, V271, P26508, DOI 10.1074/jbc.271.43.26508; HORGAN DJ, 1991, MEAT SCI, V29, P251, DOI 10.1016/0309-1740(91)90054-T; HORGAN DJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P21, DOI 10.1016/0003-9861(90)90407-P; KEMP PD, 1988, BIOCHEM J, V252, P387, DOI 10.1042/bj2520387; Knott L, 1997, BIOCHEM J, V322, P535, DOI 10.1042/bj3220535; KNOTT L, 1995, BIOCHEM J, V310, P1045, DOI 10.1042/bj3101045; KUYPERS R, 1992, BIOCHEM J, V283, P129, DOI 10.1042/bj2830129; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; ROBINS SP, 1983, BIOCHEM J, V215, P175, DOI 10.1042/bj2150175; ROBINS SP, 1987, BIOCHIM BIOPHYS ACTA, V914, P233, DOI 10.1016/0167-4838(87)90282-2; SCOTT JE, 1981, BIOSCIENCE REP, V1, P611, DOI 10.1007/BF01116276; SCOTT JE, 1983, J BIOCHEM-TOKYO, V93, P921, DOI 10.1093/jb/93.3.921	17	22	24	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18812	18818		10.1074/jbc.M009506200	http://dx.doi.org/10.1074/jbc.M009506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278513	hybrid			2022-12-27	WOS:000169091000023
J	Xie, B; Zhao, JH; Kitagawa, M; Durbin, J; Madri, JA; Guan, JL; Fu, XY				Xie, B; Zhao, JH; Kitagawa, M; Durbin, J; Madri, JA; Guan, JL; Fu, XY			Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; DNA-BINDING PROTEINS; FOS GENE-EXPRESSION; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; INTERFERON-ALPHA	Recent studies suggest that focal adhesion kinase (FAK) is important for cell migration. We now suggest a mechanism by which FAK activates the signal transducer and activator of transcription (STAT) pathway, regulating cell adhesion and migration. In particular, we observe that FAK is capable of activating Stat1, but not Stat3, Co-immunoprecipitation and in vitro binding assays demonstrate that Stat1 is transiently and directly associated with FAK during cell adhesion, and Stat1 is activated in this process. FAK with a C-terminal deletion (FAK Delta IC14) completely abolishes this interaction, indicating this association is dependent on the C-terminal domain of FAK, which is required for FAK localization at focal contacts. Moreover, Stat1 activation during cell adhesion is diminished in FAK-deficient cells, correlating with decreased migration in these cells. Finally, we show that depletion of Stat1 results in an enhancement of cell adhesion and a decrease in cell migration. Thus, our results have demonstrated, for the first time, a critical signaling pathway from integrin/FAK to Stat1 that reduces cell adhesion and promotes cell migration,	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA; Ohio State Univ, Sch Med, Dept Pediat, Columbus, OH 43205 USA	Yale University; Cornell University; University System of Ohio; Ohio State University	Fu, XY (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.		Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X	NIAID NIH HHS [AI34522] Funding Source: Medline; NIGMS NIH HHS [GM52890, GM48050] Funding Source: Medline; PHS HHS [R01 44906] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050, R01GM052890] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brizzi MF, 1999, MOL BIOL CELL, V10, P3463, DOI 10.1091/mbc.10.10.3463; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DARNELL JE, 1994, SCIENCE, V264, P1416; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FORM DM, 1986, LAB INVEST, V55, P521; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FURUTA Y, 1995, ONCOGENE, V11, P1989; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu X., 1999, SCIENCE, V285, P167; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; MADRI JA, 1988, AM J PATHOL, V132, P18; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	58	69	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19512	19523		10.1074/jbc.M009063200	http://dx.doi.org/10.1074/jbc.M009063200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278462	hybrid			2022-12-27	WOS:000169091000114
J	Fujiwara, H; Kikkawa, Y; Sanzen, N; Sekiguchi, K				Fujiwara, H; Kikkawa, Y; Sanzen, N; Sekiguchi, K			Purification and characterization of human laminin-8 - Laminin-8 stimulates cell adhesion and migration through alpha(3)beta(1) and alpha(6)beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANES; ALPHA-3-BETA-1 INTEGRIN; CHROMOSOMAL ASSIGNMENT; MUSCULAR-DYSTROPHIES; MUSCLE DEVELOPMENT; ALPHA-4 CHAIN; FETAL TISSUES; A-CHAIN; EXPRESSION; ISOFORMS	Recently identified laminin isoforms containing the alpha4 chain have been shown to be expressed in the basement membrane of restricted organs such as heart, skeletal muscle, and blood vessels, especially those in embryos. We screened 38 human cell lines for the expression of the laminin alpha4 chain by reverse transcriptase-polymerase chain reaction and found that T98G glioblastoma cells express only alpha4, but not other alpha chains. Laminin-8, an isoform containing the alpha4 and beta1 chains, was purified from conditioned medium of T98G cells by gel filtration and immunoaffinity chromatography using a monoclonal antibody against laminin beta1 chain. The purified laminin isoform was composed of disulfide-linked 230-, 220-, and 200-kDa subunits, which immunoblot analysis identified as the beta1, gamma1, and alpha4 chains. Purified laminin-8 had cell adhesive activity comparable to laminin-1 but significantly weaker than laminin-5 and laminin-10/11. T98G cells adhering to laminin-8 became more elongated than those adhering to other laminin isoforms and extended multiple pseudopods. Cell adhesion to laminin-8 was abolished by an antibody against the integrin beta (1) subunit or a combination of antibodies against the integrin alpha (3) and alpha (6) subunits, but not by either anti-alpha (3) or anti-alpha (6) antibody alone, suggesting that both alpha (3)beta (1) and alpha (6)beta (1) integrins serve as adhesion receptors for laminin-8. Consistent with these observations, K562 erythroleukemic cells transfected with either integrin alpha (3) or alpha (6) cDNA were capable of adhering to laminin-8 when beta (1) integrins were stimulated by the beta (1)-activating antibody 8A2. Despite its moderate cell adhesive activity, laminin-8 was significantly potent in promoting cell migration when compared with other laminin isoforms and fibronectin. Cell migration on laminin-8 was completely inhibited by a combination of antibodies against alpha (3) and alpha (6) integrins, and substantially inhibited by anti-alpha (3) antibody alone, suggesting that laminin-8-mediated cell migration is predominantly mediated by alpha (3)beta (1) integrin. Given its potency to stimulate cell migration and preferential localization to the basement membrane of capillaries and embryonic tissues, laminin-8 may play a role in processes requiring enhanced cell migration during development, wound healing, and angiogenesis.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Osaka 5941101, Japan	Osaka University	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fujiwara, Hironobu/A-5971-2016; Kikkawa, Yamato/D-1503-2010	Fujiwara, Hironobu/0000-0003-0883-3384; Sanzen, Noriko/0000-0001-6518-403X				Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; Baker SE, 1996, J CELL SCI, V109, P2509; Bendel-Stenzel M, 1998, SEMIN CELL DEV BIOL, V9, P393, DOI 10.1006/scdb.1998.0204; BRONNERFRASER M, 1988, J CELL BIOL, V106, P1321, DOI 10.1083/jcb.106.4.1321; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Dogic D, 1998, J CELL SCI, V111, P793; Ekblom M, 1998, ANN NY ACAD SCI, V857, P194, DOI 10.1111/j.1749-6632.1998.tb10117.x; Engvall E, 1996, J CELL BIOCHEM, V61, P493; Ferletta M, 1999, J CELL SCI, V112, P1; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Geberhiwot T, 1999, EXP CELL RES, V253, P723, DOI 10.1006/excr.1999.4653; Gu YC, 1999, BLOOD, V93, P2533, DOI 10.1182/blood.V93.8.2533.408k22_2533_2542; Gullberg G, 1999, CELL MOL LIFE SCI, V56, P442, DOI 10.1007/PL00000616; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Perris R, 2000, MECH DEVELOP, V95, P3, DOI 10.1016/S0925-4773(00)00365-8; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; Richards A, 1996, EUR J BIOCHEM, V238, P813, DOI 10.1111/j.1432-1033.1996.0813w.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; Sorokin LM, 2000, EXP CELL RES, V256, P500, DOI 10.1006/excr.2000.4842; TANZER ML, 1993, KIDNEY INT, V43, P66, DOI 10.1038/ki.1993.12; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Wang ZM, 1999, J CELL SCI, V112, P2925; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598	64	140	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17550	17558		10.1074/jbc.M010155200	http://dx.doi.org/10.1074/jbc.M010155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278628	Green Published, hybrid			2022-12-27	WOS:000168730400127
J	Klein, U; Muller, C; Chu, P; Birnbaumer, M; von Zastrow, M				Klein, U; Muller, C; Chu, P; Birnbaumer, M; von Zastrow, M			Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of beta-arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V2 VASOPRESSIN RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; OPIOID RECEPTOR; KINASE-2 GRK2; SUBSTANCE-P; INTERNALIZATION; DESENSITIZATION; RESENSITIZATION; MECHANISMS; CELLS	We have observed an unexpected type of nonreciprocal "cross-regulation" of the agonist-induced endocytosis of G protein-coupled receptors by clathrin-coated pits, Isoproterenol-dependent internalization of beta (2)-adrenergic receptors in stably transfected HEK293 cells was specifically blocked (> 65% inhibition) by vasopressin-induced activation of V2 vasopressin receptors co-expressed at similar levels. In contrast, activation of beta (2) receptors caused no detectable effect on V2 receptor internalization in the same cells. Several pieces of evidence suggest that this nonreciprocal inhibition of endocytosis is mediated by receptor-specific intracellular trafficking of beta -arrestins. First, previous studies showed that the activation of V2 but not beta (2) receptors caused pronounced recruitment of beta -arrestins to endocytic membranes (Oakley, R. H,, Laporte, S, A., Holt, J, A., Barak, L, S,, and Caron, M, G, (1999) J, Biol. Chem. 274, 32248-32257), Second, overexpression of arrestin 2 or 3 (beta -arrestin 1 or 2) abolished the V2 receptor-mediated inhibition of beta (2) receptor internalization. Third, mutations of the V2 receptor that block endomembrane recruitment of beta -arrestins eliminated the V2 receptor-dependent blockade of beta (2) receptor internalization. These results identify a novel type of heterologous regulation of G protein-coupled receptors, define a new functional role of receptor-specific intracellular trafficking of beta -arrestins, and suggest an experimental method to rapidly modulate the functional activity of beta -arrestins in intact cells.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles	Klein, U (corresponding author), Adv Med Inc, Dept Biochem, 901 Gateway Blvd, San Francisco, CA 94080 USA.	uklein@advmedicine.com						Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Blanchard EM, 1997, CIRC RES, V81, P1005; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; BOUVIER M, 1990, ANN NY ACAD SCI, V594, P120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GOODMAN OB, 1996, ADV PHARMACOL, V383, P447; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laugwitz KL, 1999, CIRCULATION, V99, P925, DOI 10.1161/01.CIR.99.7.925; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Pfeiffer R, 1998, EXP CELL RES, V244, P327, DOI 10.1006/excr.1998.4159; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VON ZM, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang X, 1998, NEUROSCIENCE, V82, P1225	43	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17442	17447		10.1074/jbc.M009214200	http://dx.doi.org/10.1074/jbc.M009214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278476	hybrid			2022-12-27	WOS:000168730400113
J	Zhang, H; Wada, J; Hida, K; Tsuchiyama, Y; Hiragushi, K; Shikata, K; Wang, HY; Lin, S; Kanwar, YS; Makino, H				Zhang, H; Wada, J; Hida, K; Tsuchiyama, Y; Hiragushi, K; Shikata, K; Wang, HY; Lin, S; Kanwar, YS; Makino, H			Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; BLOOD-PRESSURE; DEFICIENT MICE; RECEPTOR GENE; MOUSE KIDNEY; EXPRESSION; CLONING; RENIN; CARBOXYPEPTIDASE; IDENTIFICATION	Collectrin, a novel homolog of angiotensin-converting enzyme-related carboxypeptidase (ACE2), was identified during polymerase chain reaction-based cDNA subtraction and up-regulated in 5/6 ablated kidneys at hypertrophic phase. Collectrin, with 222 amino acids, has an apparent signal peptide and a transmembrane domain; the sequence is conserved in mouse, rat, and human and shares 81.9% identity. Human collectrin has 47.8% identity with non-catalytic extracellular, transmembrane, and cytosolic domains of AGES; however, unlike ACE and AGES, collectrin lacks active dipeptidyl carboxypeptidase catalytic domains. The collectrin mRNA transcripts are expressed exclusively in the kidney. In situ hybridization reveals its mRNA expression in renal collecting ducts, and immunohistochemistry shows that it is localized to the luminal surface and cytoplasm of collecting ducts. Immunoprecipitation studies, using [S-35]methionine-labeled renal cortical and inner medullar collecting duct cells, i.e. M-1 and mIMCD-3, indicate that the protein size is similar to 32 kDa. During the development of mouse kidney, mRNA signal is detectable at day 13 of gestation, and the protein product is observed in the ureteric bud branches. Its expression is progressively increased during later stages of the gestation extending into the neonatal periods and then is decreased in adult life. Up-regulated expression of collectrin in the hypertrophic kidneys after renal ablation and restricted spatio-temporal expression during development indicates a possible role(s) in the process of progressive renal failure and renal organogenesis.	Okayama Univ, Sch Med, Dept Med 3, Okayama 7008558, Japan; Beijing Med Univ, Teaching Hosp 1, Dept Nephrol, Beijing 100034, Peoples R China; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Okayama University; Peking University; Northwestern University	Wada, J (corresponding author), Okayama Univ, Sch Med, Dept Med 3, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		WADA, Jun/B-2023-2011	WADA, Jun/0000-0003-1468-5170				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; Esther CR, 1996, LAB INVEST, V74, P953; FRIBERG P, 1994, KIDNEY INT, V45, P485, DOI 10.1038/ki.1994.63; Gilbert RE, 1999, AM J PATHOL, V155, P429, DOI 10.1016/S0002-9440(10)65139-5; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOSTETTER T, 1981, AM J PHYSIOL, V241, P85; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Largo R, 1999, HYPERTENSION, V33, P732, DOI 10.1161/01.HYP.33.2.732; Matsusaka T, 1996, J CLIN INVEST, V98, P1867, DOI 10.1172/JCI118988; Miyazaki Y, 1998, J CLIN INVEST, V102, P1489, DOI 10.1172/JCI4401; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Niimura F, 1995, J CLIN INVEST, V96, P2947, DOI 10.1172/JCI118366; Oliverio MI, 1998, AM J PHYSIOL-RENAL, V274, pF43, DOI 10.1152/ajprenal.1998.274.1.F43; STRIKER GE, 1995, LAB INVEST, V73, P596; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; TUFROMCREDDIE A, 1995, AM J PHYSIOL-RENAL, V269, pF110, DOI 10.1152/ajprenal.1995.269.1.F110; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1996, J CELL BIOL, V132, P1161, DOI 10.1083/jcb.132.6.1161; Wada J, 1997, KIDNEY INT, V51, P1629, DOI 10.1038/ki.1997.225; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Waldherr R, 1988, Contrib Nephrol, V60, P64; Wolf G, 1997, SEMIN NEPHROL, V17, P448; Yang QW, 2000, P NATL ACAD SCI USA, V97, P9896, DOI 10.1073/pnas.160266197; Zhang H, 1999, KIDNEY INT, V56, P549, DOI 10.1046/j.1523-1755.1999.00561.x; Zhang SL, 1999, KIDNEY INT, V55, P454, DOI 10.1046/j.1523-1755.1999.00271.x	33	172	194	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17132	17139		10.1074/jbc.M006723200	http://dx.doi.org/10.1074/jbc.M006723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278314	hybrid			2022-12-27	WOS:000168730400072
J	Alam, K; Meidell, RS; Spady, DK				Alam, K; Meidell, RS; Spady, DK			Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ADENOVIRUS-MEDIATED TRANSFER; APOLIPOPROTEIN-A-I; PERFUSED RAT-LIVER; TRANSGENIC MICE; CELLULAR CHOLESTEROL; RECEPTOR GENE; APOA-I; PLASMA; EFFLUX	Cholesterol acquired by extrahepatic tissues (from de novo synthesis or lipoproteins) is returned to the liver for excretion in a process called reverse cholesterol transport (RCT). We undertook studies to determine if RCT could be enhanced by up-regulating individual steps in the RCT pathway. Overexpression 7 alpha -hydroxylase, Scavenger receptor B1, lecithin:cholesterol acyltransferase (LCAT), or apoA-I in the liver did not stimulate cholesterol efflux from any extrahepatic tissue, In contrast, infusion of apoA-I phospholipid complexes (rHDL) that resemble nascent HDL markedly stimulated cholesterol efflux from tissues into plasma. Cholesterol effluxed to rHDL was initially unesterified but by 24 h this cholesterol was largely esterified and had shifted to normal HDL (in mice lacking cholesteryl ester transfer protein) or to apoB containing lipoproteins (in cholesteryl ester transfer protein transgenic mice). Most of the cholesterol effluxed into plasma in response to rHDL came from the liver. However, an even greater proportion of effluxed cholesterol was cleared by the liver resulting in a transient increase in liver cholesterol concentrations. Fecal sterol excretion was not increased by rHDL. Thus, although rHDL stimulated cholesterol efflux from most tissues and increased net cholesterol movement from extrahepatic tissues to the liver, cholesterol flux through the entire RCT pathway was not increased.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Spady, DK (corresponding author), Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047551, R01HL038049] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47551, HL-38049] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Berard AM, 1997, NAT MED, V3, P744, DOI 10.1038/nm0797-744; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; CASTLE CK, 1991, J LIPID RES, V32, P439; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Eriksson M, 1999, CIRCULATION, V100, P594, DOI 10.1161/01.CIR.100.6.594; FIELDING CJ, 1995, J LIPID RES, V36, P211; Foger B, 1999, J BIOL CHEM, V274, P36912, DOI 10.1074/jbc.274.52.36912; Francone OL, 1997, J LIPID RES, V38, P813; FRIEDMAN M, 1957, P SOC EXP BIOL MED, V95, P586; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Halperin G, 1986, Methods Enzymol, V129, P816; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HORTON JD, 1995, J BIOL CHEM, V270, P5381, DOI 10.1074/jbc.270.10.5381; HOUGH JL, 1984, BIOCHIM BIOPHYS ACTA, V792, P338, DOI 10.1016/0005-2760(84)90202-9; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nanjee MN, 1999, ARTERIOSCL THROM VAS, V19, P979, DOI 10.1161/01.ATV.19.4.979; Nordskog BK, 1999, J LIPID RES, V40, P1806; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PASTZY C, 1994, J CLIN INVEST, V94, P899; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Rodrigueza WV, 1998, BBA-BIOMEMBRANES, V1368, P306, DOI 10.1016/S0005-2736(97)00198-3; Rothblat GH, 1999, J LIPID RES, V40, P781; Schwarz M, 1998, J LIPID RES, V39, P1833; SPADY DK, 1986, J CLIN INVEST, V77, P1474, DOI 10.1172/JCI112460; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J LIPID RES, V39, P1483; Spady DK, 1999, J LIPID RES, V40, P1384; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P247, DOI 10.1016/0005-2760(80)90206-4; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; WILLIAMS KJ, 1984, PERSPECT BIOL MED, V27, P417; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; WINDMUELLER HG, 1973, J LIPID RES, V14, P215; Woollett LA, 1997, J LIPID RES, V38, P2289; WOOLLETT LA, 1997, J CLIN INVEST, V99, P1703; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0; Young SG, 1999, NAT GENET, V22, P316, DOI 10.1038/11878	51	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15641	15649		10.1074/jbc.M010230200	http://dx.doi.org/10.1074/jbc.M010230200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278646	hybrid			2022-12-27	WOS:000168623100012
J	Bernhard, M; Buhrke, T; Bleijlevens, B; De Lacey, AL; Fernandez, VM; Albracht, SPJ; Friedrich, B				Bernhard, M; Buhrke, T; Bleijlevens, B; De Lacey, AL; Fernandez, VM; Albracht, SPJ; Friedrich, B			The H-2 sensor of Ralstonia eutropha - Biochemical characteristics, spectroscopic properties, and its interaction with a histidine protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND HYDROGENASE; ALCALIGENES-EUTROPHUS; CHROMATIUM-VINOSUM; ACTIVE-SITE; TRANSCRIPTIONAL REGULATION; DESULFOVIBRIO-GIGAS; SOLUBLE HYDROGENASE; OXYGEN SENSOR; NICKEL; REDOX	Previous genetic studies have revealed a multicomponent signal transduction chain, consisting of an H-2 sensor, a histidine protein kinase, and a response regulator, which controls hydrogenase gene transcription in the proteobacterium Ralstonia eutropha. In this study, we isolated the H-2 sensor and demonstrated that the purified protein forms a complex with the histidine protein kinase, Biochemical and spectroscopic analysis revealed that the H-2 sensor is a cytoplasmic [NiFe]-hydrogenase with unique features. The H-2-oxidizing activity was 2 orders of magnitude lower than that of standard hydrogenases and insensitive to oxygen, carbon monoxide, and acetylene, Interestingly, only H-2 production but no HD formation was detected in the D-2/H+ exchange assay. Fourier transform infrared data showed an active site similar to that of standard [NiFe]-hydrogenases. It is suggested that the protein environment accounts for a restricted gas diffusion and for the typical kinetic parameters of the H-2 sensor. EPR analysis demonstrated that the [4Fe-4S] clusters within the small subunit were not reduced under hydrogen even in the presence of dithionite. Optical spectra revealed the presence of a novel, redox-active, n = 2 chromophore that is reduced by H-2. The possible involvement of this chromophore in signal transduction is discussed.	Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; Univ Amsterdam, Dept Biochem, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands; CSIC, Inst Catalysis, E-28049 Madrid, Spain	Humboldt University of Berlin; University of Amsterdam; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP)	Friedrich, B (corresponding author), Humboldt Univ, Inst Biol, Chausseestr 117, D-10115 Berlin, Germany.		De Lacey, Antonio L/H-3311-2015	De Lacey, Antonio L/0000-0002-9347-0452				BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAGLEY KA, 1994, BIOCHEMISTRY-US, V33, P9229, DOI 10.1021/bi00197a026; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; Bernhard M, 1996, J BACTERIOL, V178, P4522, DOI 10.1128/jb.178.15.4522-4529.1996; Bibikov SI, 2000, P NATL ACAD SCI USA, V97, P5830, DOI 10.1073/pnas.100118697; BLACK LK, 1994, J BACTERIOL, V176, P7102, DOI 10.1128/JB.176.22.7102-7106.1994; COREMANS JMCC, 1989, BIOCHIM BIOPHYS ACTA, V997, P256, DOI 10.1016/0167-4838(89)90196-9; CORNISHBOWDEN A, 1995, ANAL ENZYME KINETIC, P133; COVINGTON AK, 1968, ANAL CHEM, V40, P700, DOI 10.1021/ac60260a013; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; EBERZ G, 1991, J BACTERIOL, V173, P1845, DOI 10.1128/jb.173.6.1845-1854.1991; Elsen S, 1996, J BACTERIOL, V178, P5174, DOI 10.1128/jb.178.17.5174-5181.1996; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Happe RP, 2000, FEBS LETT, V466, P259, DOI 10.1016/S0014-5793(99)01799-8; Happe RP, 1999, EUR J BIOCHEM, V259, P602, DOI 10.1046/j.1432-1327.1999.00057.x; HYMAN MR, 1987, BIOCHEMISTRY-US, V26, P6447, DOI 10.1021/bi00394a023; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; Kleihues L, 2000, J BACTERIOL, V182, P2716, DOI 10.1128/JB.182.10.2716-2724.2000; KRASNA AI, 1979, ENZYME MICROB TECH, V1, P165, DOI 10.1016/0141-0229(79)90023-1; Lenz O, 1998, P NATL ACAD SCI USA, V95, P12474, DOI 10.1073/pnas.95.21.12474; Lenz O, 1997, J BACTERIOL, V179, P1655, DOI 10.1128/jb.179.5.1655-1663.1997; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Pierik AJ, 1998, FEBS LETT, V438, P231, DOI 10.1016/S0014-5793(98)01306-4; PONTING CP, 1997, CURR BIOL, V7, P674; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; SCHINK B, 1979, BIOCHIM BIOPHYS ACTA, V567, P315, DOI 10.1016/0005-2744(79)90117-7; SCHNEIDER K, 1979, BIOCHIM BIOPHYS ACTA, V578, P445, DOI 10.1016/0005-2795(79)90175-2; SCHNEIDER K, 1976, BIOCHIM BIOPHYS ACTA, V452, P66, DOI 10.1016/0005-2744(76)90058-9; Schwartz E, 1998, J BACTERIOL, V180, P3197, DOI 10.1128/JB.180.12.3197-3204.1998; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; TEIXEIRA M, 1987, EUR J BIOCHEM, V167, P47, DOI 10.1111/j.1432-1033.1987.tb13302.x; VANDERZWAAN JW, 1987, EUR J BIOCHEM, V169, P377; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9; ZIMMER D, 1995, J BACTERIOL, V177, P2373, DOI 10.1128/jb.177.9.2373-2380.1995; Zorin NA, 1996, EUR J BIOCHEM, V241, P675, DOI 10.1111/j.1432-1033.1996.00675.x	41	97	99	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15592	15597		10.1074/jbc.M009802200	http://dx.doi.org/10.1074/jbc.M009802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278570	hybrid			2022-12-27	WOS:000168623100006
J	Chen, MJ; Lin, YT; Lieberman, HB; Chen, G; Lee, EYHP				Chen, MJ; Lin, YT; Lieberman, HB; Chen, G; Lee, EYHP			ATM-dependent phosphorylation of human Rad9 is required for ionizing radiation-induced checkpoint activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE CHECKPOINTS; SCHIZOSACCHAROMYCES-POMBE RAD1(+); PROTEIN-KINASE; FISSION YEAST; HUMAN HOMOLOG; ATAXIA-TELANGIECTASIA; CONTROL GENE; S-PHASE; STRUCTURAL HOMOLOG	ATM (ataxia-telangiectasia-mutated) is a Ser/Thr kinase involved in cell cycle checkpoints and DNA repair. Human Rad9 (hRad9) is the homologue of Schizosaccharomyces pombe Rad9 protein that plays a critical role in cell cycle checkpoint control. To examine the potential signaling pathway linking ATM and hRad9, we investigated the modification of hRad9 in response to DNA damage, Here we show that hRad9 protein is constitutively phosphorylated in undamaged cells and undergoes hyperphosphorylation upon treatment with ionizing radiation (IR), ultraviolet light (UV), and hydroxyurea (HU). Interestingly, hyperphosphorylation of hRad9 induced by IR is dependent on ATM. Ser(272) Of hRad9 is phosphorylated directly by ATM in vitro. Furthermore, hRad9 is phosphorylated on Ser(272) in response to IR in vivo, and this modification is delayed in ATM-deficient cells. Expression of hRad9 S272A mutant protein in human lung fibroblast VA13 cells disturbs IR-induced G(1)/S checkpoint activation and increased cellular sensitivity to IR. Together, our results suggest that the ATM-mediated phosphorylation of hRad9 is required for IR-induced checkpoint activation.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	University of Texas System; University of Texas Health San Antonio; Columbia University	Lee, EYHP (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.				NCI NIH HHS [CA81020] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline; NINDS NIH HHS [NS37381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carr AM, 1998, MICROBIOL-UK, V144, P5, DOI 10.1099/00221287-144-1-5; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DENHAESE GJ, 1995, MOL BIOL CELL, V6, P371, DOI 10.1091/mbc.6.4.371; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Harlow E., 1999, USING ANTIBODIES LAB; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu QH, 2000, GENE DEV, V14, P1448; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shieh SY, 2000, GENE DEV, V14, P289; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stewart E, 1996, CURR OPIN CELL BIOL, V8, P781, DOI 10.1016/S0955-0674(96)80078-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Weiss RS, 2000, GENE DEV, V14, P1886; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Ziv Y, 2000, METH MOL B, V99, P99	75	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16580	16586		10.1074/jbc.M008871200	http://dx.doi.org/10.1074/jbc.M008871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278446	hybrid			2022-12-27	WOS:000168623100135
J	Masaoka, A; Terato, H; Kobayashi, M; Ohyama, Y; Ide, H				Masaoka, A; Terato, H; Kobayashi, M; Ohyama, Y; Ide, H			Oxidation of thymine to 5-formyluracil in DNA promotes misincorporation of dGMP and subsequent elongation of a mismatched primer terminus by DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FRAGMENTATION PRODUCTS; REPLICATION FIDELITY; SEQUENCE CONTEXT; ENZYMATIC REPAIR; KLENOW FRAGMENT; BASE EXCISION; LESION BYPASS; STEADY-STATE; IN-VITRO	5-Formyluracil (fU) is a major oxidative thymine lesion generated by ionizing radiation and reactive oxygen species. In the present study, we have assessed the influence of fU on DNA replication to elucidate its genotoxic potential. Oligonucleotide templates containing fU at defined sites were replicated in vitro by Escherichia coli DNA polymerase I Klenow fragment deficient in 3'-5'-exonuclease, Gel electrophoretic analysis of the reaction products showed that fU constituted very weak replication blocks to DNA synthesis, suggesting a weak to negligible cytotoxic effect of this lesion. However, primer extension assays with a single dNTP revealed that fU directed incorporation of not only correct dAMP but also incorrect dGMP, although much less efficiently. No incorporation of dCMP and dTMP was observed. When fU was substituted for T in templates, the incorporation efficiency of dAMP (f(A) = V-max/K-m) decreased to 1/4 to 1/2, depending on the nearest neighbor base pair, and that of dGMP (f(G)) increased 1.1-5.6-fold. Thus, the increase in the replication error frequency (f(G)/f(A) for fU versus T) was 3.1-14.3-fold. The misincorporation rate of dGMP opposite fU (pK(a) = 8.6) but not T (pK(a) = 10.0) increased with pH (7.2-8.6) of the reaction mixture, indicating the participation of the ionized (or enolate) form of fU in the mispairing with G, The resulting mismatched fU:G primer terminus was more efficiently extended than the T:G terminus (8.2-11.3-fold). These results show that when T is oxidized to fU in DNA, fU promotes both misincorporation of dGMP at this site and subsequent elongation of the mismatched primer, hence potentially mutagenic.	Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan	Hiroshima University	Ide, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan.	ideh@hiroshima-u.ac.jp		Terato, Hiroaki/0000-0002-7070-5263				Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; ARMSTRONG VW, 1976, NUCLEIC ACIDS RES, V3, P1791, DOI 10.1093/nar/3.7.1791; Asagoshi K, 2000, J BIOL CHEM, V275, P24781, DOI 10.1074/jbc.M000576200; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; BJELLAND S, 1995, BIOCHEMISTRY-US, V34, P14758, DOI 10.1021/bi00045a017; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CLINE RE, 1959, J AM CHEM SOC, V81, P2521, DOI 10.1021/ja01519a056; Creighton S, 1995, METHOD ENZYMOL, V262, P232; DECARROZ C, 1986, INT J RADIAT BIOL, V50, P491, DOI 10.1080/09553008614550901; Douki T, 1996, CHEM RES TOXICOL, V9, P1145, DOI 10.1021/tx960095b; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fujikawa K, 1998, NUCLEIC ACIDS RES, V26, P4582, DOI 10.1093/nar/26.20.4582; Gasparutto D, 2000, BIOCHIMIE, V82, P19, DOI 10.1016/S0300-9084(00)00347-3; Gasparutto D, 2000, CHEM RES TOXICOL, V13, P575, DOI 10.1021/tx000005+; Hatahet Z, 1998, CONT CANC RES, P229; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; IDE H, 1987, BIOCHEMISTRY-US, V26, P964, DOI 10.1021/bi00377a042; IDE H, 1995, NUCLEIC ACIDS RES, V23, P123, DOI 10.1093/nar/23.1.123; IDE H, 1988, NUCLEIC ACIDS RES, V16, P11339, DOI 10.1093/nar/16.23.11339; IDE H, 1991, J BIOL CHEM, V266, P1469; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; IDE H, 1994, BIOCHEMISTRY-US, V33, P7127, DOI 10.1021/bi00189a016; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; La Francois CJ, 2000, CHEM RES TOXICOL, V13, P462, DOI 10.1021/tx990209u; LaFrancois CJ, 1998, CHEM RES TOXICOL, V11, P75, DOI 10.1021/tx970186o; LAWLEY P. D., 1962, JOUR MOLECULAR BIOL, V4, P216, DOI 10.1016/S0022-2836(62)80053-9; LEVY DD, 1991, NUCLEIC ACIDS RES, V19, P3337, DOI 10.1093/nar/19.12.3337; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Martini M, 1997, CHEM RES TOXICOL, V10, P234, DOI 10.1021/tx960154l; Masaoka A, 1999, J BIOL CHEM, V274, P25136, DOI 10.1074/jbc.274.35.25136; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Mi LJ, 1997, MUTAT RES-FUND MOL M, V374, P287, DOI 10.1016/S0027-5107(96)00247-3; Miyabe I, 2001, INT J RADIAT BIOL, V77, P53, DOI 10.1080/095530001453113; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Murata-Kamiya N, 1999, NUCLEIC ACIDS RES, V27, P4385, DOI 10.1093/nar/27.22.4385; MurataKamiya N, 1997, J RADIAT RES, V38, P121, DOI 10.1269/jrr.38.121; Privat EJ, 1996, MUTAT RES-FUND MOL M, V354, P151, DOI 10.1016/0027-5107(96)00005-X; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P3930, DOI 10.1093/nar/22.19.3930; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; Saenger N., 1984, PRINCIPLES NUCL ACID; SAITO I, 1995, J AM CHEM SOC, V117, P5590, DOI 10.1021/ja00125a023; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shimizu H, 1997, NUCLEIC ACIDS RES, V25, P597, DOI 10.1093/nar/25.3.597; SOWERS LC, 1989, J MOL BIOL, V205, P437, DOI 10.1016/0022-2836(89)90353-7; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Sugiyama H, 1996, TETRAHEDRON LETT, V37, P9067, DOI 10.1016/S0040-4039(96)02130-2; Suzuki T, 1998, BIOCHEMISTRY-US, V37, P11592, DOI 10.1021/bi980971f; Terato H, 1999, J BIOL CHEM, V274, P25144, DOI 10.1074/jbc.274.35.25144; Terato H, 1998, NUCLEOS NUCLEOT, V17, P131, DOI 10.1080/07328319808005164; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Yoshida M, 1997, NUCLEIC ACIDS RES, V25, P1570, DOI 10.1093/nar/25.8.1570; YU H, 1993, J BIOL CHEM, V268, P15935; Zhang QM, 1995, INT J RADIAT BIOL, V68, P603, DOI 10.1080/09553009514551601; Zhang QM, 2000, J BIOL CHEM, V275, P35471, DOI 10.1074/jbc.M006125200; Zhang QM, 1997, NUCLEIC ACIDS RES, V25, P3969, DOI 10.1093/nar/25.20.3969; Zhang QM, 1999, INT J RADIAT BIOL, V75, P59, DOI 10.1080/095530099140816	69	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16501	16510		10.1074/jbc.M008598200	http://dx.doi.org/10.1074/jbc.M008598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278425	hybrid			2022-12-27	WOS:000168623100124
J	Wei, LN; Farooqui, M; Hu, XL				Wei, LN; Farooqui, M; Hu, XL			Ligand-dependent formation of retinoid receptors, receptor-interacting protein 140 (RIP140), and histone deacetylase complex is mediated by a novel receptor-interacting motif of RIP140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; 9-CIS-RETINOIC ACID; ESTROGEN-RECEPTOR; BINDING-SITES; COREPRESSOR; ACTIVATION; REPRESSION; SRC-1; ACETYLTRANSFERASE	Receptor-interacting protein 140 (RIP140) interacts with retinoic acid receptor and retinoid X receptor in a ligand-dependent manner and suppresses retinoic acid (RA) induction of its target genes. The receptor-interacting motif is mapped to a C-terminal peptide sequence (LTKTNPILYYMLQK) of RIP140. The functional role of this motif in mediating the suppressive effects of RIP140 on RA induction is demonstrated in mutation studies. RA induces coimmunoprecipitation of histone deacetylase 3 with retinoic acid receptor/retinoid X receptor in the presence of wild type RIP140, but not in the presence of the C-terminal motif-deleted RIP140. A decrease in histone acetylation on the promoter region that carries a RA response element is associated with the expression of wild type RIP140, but not with expression of the mutant RIP140, in a dose-dependent manner. These data provide a molecular explanation for RIP140 acting as a novel ligand-dependent, negative modulator of RA-regulated gene expression.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Farooqui, Mariya/0000-0002-2136-8694	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe M, 1998, J ENDOCRINOL, V156, P349, DOI 10.1677/joe.0.1560349; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Haugen BR, 1997, MOL ENDOCRINOL, V11, P481, DOI 10.1210/me.11.4.481; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400	35	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16107	16112		10.1074/jbc.M010185200	http://dx.doi.org/10.1074/jbc.M010185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278635	hybrid			2022-12-27	WOS:000168623100074
J	Nelson, JM; Fry, DW				Nelson, JM; Fry, DW			Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; IRREVERSIBLE INHIBITORS; TYROSINE KINASES; PATHWAY; CHEMOTHERAPY; EXPRESSION; INDUCTION; CLEAVAGE	The ErbB receptor family is implicated in the malignant transformation of several tumor types and is overexpressed frequently in breast, ovarian, and other tumors. The mechanism by which CI-1033 and gemcitabine, either singly or in combination, kill tumor cells was examined in two breast lines, MDA-MB-453 and BT474; both overexpress the ErbB-2 receptor. CI-1033, a potent inhibitor of the ErbB family of receptor tyrosine kinases, reduced levels of activated Akt in MDA-MB-453 cells. This effect alone, however, did not induce apoptosis in these cells. Gemcitabine treatment resulted in a moderate increase in the percentage of apoptotic cells that was accompanied by activation of p38 and MAPK (ERK1/2), CI-1033 given 24 h after gemcitabine produced a significant increase in the apoptotic fraction over treatment with either drug alone. During the combined treatment p38 remained activated, whereas Akt and activated MAPK were suppressed. Substitution of CI-1033 with the phosphatidylinositol 3-kinase inhibitor LY294002 and the MAPK/ERK kinase inhibitor PD 098059 in combination with gemcitabine produced the same results as the combination of CI-1033 and gemcitabine, p38 suppression by SB203580 prevented the enhanced cell kill by CI-1033, In contrast to MDA-MB-453, BT474 cells exhibited activated p38 under unstressed conditions as well as activated Akt and MAPK, Treatment of BT474 cells with CI-1033 inhibited both the phosphorylation of Akt and MAPK and resulted in a 47% apoptotic fraction. Gemcitabine did not cause apoptosis in the BT474 cells. These data indicate that suppression of Akt and MAPK in the presence of activated p38 results in cell death and a possible mechanism for the enhanced apoptosis produced by the combination of CI-1033 and gemcitabine in MDA-MB-453 cells. Furthermore, tumors that depend on ErbB receptor signaling for survival and exhibit activated p38 in the basal state may be susceptible to apoptosis by CI-1033 as a single agent.	Pfizer Inc, Global Res & Dev, Ann Arbor, MI 48105 USA	Pfizer	Nelson, JM (corresponding author), Pfizer Inc, Global Res & Dev, Ann Arbor, MI 48105 USA.							BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; Barton-Burke M, 1999, CANCER NURS, V22, P176, DOI 10.1097/00002820-199904000-00011; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Du W, 1999, CANCER RES, V59, P4208; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Marushige K, 1999, ANTICANCER RES, V19, P3865; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherwood V., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P723; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Vincent PW, 2000, CANCER CHEMOTH PHARM, V45, P231, DOI 10.1007/s002800050034; Waksal HW, 1999, CANCER METAST REV, V18, P427, DOI 10.1023/A:1006302101468; Weiner LM, 1999, SEMIN ONCOL, V26, P43; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang LS, 1999, CLIN CANCER RES, V5, P343; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	31	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14842	14847		10.1074/jbc.M008786200	http://dx.doi.org/10.1074/jbc.M008786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278435	hybrid			2022-12-27	WOS:000168528800043
J	Mato, IP; del Pino, MMS; Chamberlin, ME; Mudd, SH; Mato, JM; Corrales, FJ				Mato, IP; del Pino, MMS; Chamberlin, ME; Mudd, SH; Mato, JM; Corrales, FJ			Biochemical basis for the dominant inheritance of hypermethioninemia associated with the R264H mutation of the MAT1A gene - A monomeric methionine adenosyltransferase with tripolyphosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; ISOLATED PERSISTENT HYPERMETHIONINEMIA; RAT-LIVER; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; I/III DEFICIENCY; MESSENGER-RNA; PURIFICATION; SITE	Methionine adenosyltransferase (MAT) catalyzes the synthesis of S-adenosylmethionine (AdoMet), the main alkylating agent in living cells. Additionally, in the liver, MAT is also responsible for up to 50% of methionine catabolism. Humans with mutations in the gene MAT1A, the gene that encodes the catalytic subunit of MAT I and III, have decreased MAT activity in liver, which results in a persistent hypermethioninemia without homocystinuria. The hypermethioninemic phenotype associated with these mutations is inherited as an autosomal recessive trait. The only exception is the dominant mild hypermethioninemia associated with a G-A transition at nucleotide 791 of exon VII, This change yields a MAT1A-encoded subunit in which arginine 264 is replaced by histidine, Our results indicate that in the homologous rat enzyme, replacement of the equivalent arginine 265 by histidine (R265H) results in a monomeric MAT with only 0.37% of the AdoMet synthetic activity. However the tripolyphosphatase activity is similar to that found in the wild type (WT) MAT and is inhibited by PP,, Our in vivo studies demonstrate that the R265H MAT I/III mutant associates with the WT subunit resulting in a dimeric R265H-WT MAT unable to synthesize AdoMet. Tripolyphosphatase activity is maintained in the hybrid MAT, but is not stimulated by methionine and ATP, indicating a deficient binding of the substrates. Our data indicate that the active site for tripolyphosphatase activity is functionally active in the monomeric R265H MAT I/III mutant. Moreover, our results provide a molecular mechanism that might explain the dominant inheritance of the hypermethioninemia associated with the R264H mutation of human MAT I/III.	Univ Navarra, Div Hepatol & Gene Therapy, Pamplona 31008, Spain; Univ Tennessee, Sch Med, Vet Affairs Med Ctr, Memphis, TN 38104 USA; NIMH, Mol Biol Lab, Bethesda, MD 20892 USA	University of Navarra; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Corrales, FJ (corresponding author), Univ Navarra, Div Hepatol & Gene Therapy, Irunlarrea 1, Pamplona 31008, Spain.		del Pino, Manuel M. Sánchez/I-3977-2015; MATO, JOSE/A-5187-2011	del Pino, Manuel M. Sánchez/0000-0001-9696-7600; MATO, JOSE/0000-0003-1264-3153; Corrales, Fernando/0000-0002-0231-5159	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012677] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-12677] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Avila MA, 1997, HEPATOLOGY, V25, P391; BLOM HJ, 1992, J INHERIT METAB DIS, V15, P188, DOI 10.1007/BF01799629; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1953, J BIOL CHEM, V204, P403; Chamberlin ME, 2000, AM J HUM GENET, V66, P347, DOI 10.1086/302752; Chamberlin ME, 1997, AM J HUM GENET, V60, P540; Chamberlin ME, 1996, J CLIN INVEST, V98, P1021, DOI 10.1172/JCI118862; Chamberlin ME, 2000, ARCH BIOCHEM BIOPHYS, V373, P56, DOI 10.1006/abbi.1999.1542; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P261; del Pino MMS, 2000, J BIOL CHEM, V275, P23476, DOI 10.1074/jbc.M002730200; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P1491, DOI 10.1016/0006-291X(75)90527-6; GAHL WA, 1987, AM J HUM GENET, V40, P39; GAULL GE, 1981, J PEDIATR-US, V98, P734, DOI 10.1016/S0022-3476(81)80833-5; GAULL GE, 1974, SCIENCE, V186, P59, DOI 10.1126/science.186.4158.59; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; GOUT JP, 1977, ARCH FR PEDIATR, V34, P416; Hazelwood S, 1998, AM J MED GENET, V75, P395, DOI 10.1002/(SICI)1096-8628(19980203)75:4<395::AID-AJMG9>3.0.CO;2-P; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; KOTB M, 1985, J BIOL CHEM, V260, P3923; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; McQueney MS, 2000, BIOCHEMISTRY-US, V39, P4443, DOI 10.1021/bi992876s; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; MUDD SH, 1963, J BIOL CHEM, V238, P2156; MUDD SH, 1962, J BIOL CHEM, V237, P1372; MUDD SH, 1995, AM J HUM GENET, V57, P882; MUDD SH, 2001, IN PRESS METABOLIC M; Nagao M, 1997, ACTA PAEDIATR JAPON, V39, P601; NAGAO M, 1996, 39 M JAP SOC INH MET; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Reczkowski RS, 1998, BIOCHEMISTRY-US, V37, P13499, DOI 10.1021/bi9811011; Reczkowski RS, 1999, BIOCHEMISTRY-US, V38, P9063, DOI 10.1021/bi990528k; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; TSUKADA K, 1980, BIOCHEM BIOPH RES CO, V94, P1078, DOI 10.1016/0006-291X(80)90529-X; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240	44	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13803	13809		10.1074/jbc.M009017200	http://dx.doi.org/10.1074/jbc.M009017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278456	hybrid			2022-12-27	WOS:000168356600043
J	Sampath, V; Zhao, XJ; Caughey, WS				Sampath, V; Zhao, XJ; Caughey, WS			Anesthetic-like interactions of nitric oxide with albumin and hemeproteins - A mechanism for control of protein function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; HUMAN SERUM-ALBUMIN; SOLUBLE GUANYLATE-CYCLASE; INFRARED-SPECTROSCOPY; NITROUS-OXIDE; TRYPTOPHAN FLUORESCENCE; MOLECULE ENVIRONMENTS; HALOTHANE BINDING; CARBON-MONOXIDE; HEMOGLOBIN	Noncovalent bonding interactions of nitric oxide (NO) with human serum albumin (HSA), human hemoglobin A,bovine myoglobin, and bovine cytochrome c oxidase (CcO) have been explored. The anesthetic nitrous oxide (NNO) occupies multiple sites within each protein, but does not bind to heme iron. Infrared (IR) spectra of NNO molecules sequestered within albumin, with NO present, support the binding of NO and NNO to the same sites with comparable affinities. Perturbations of IR spectra of the Cys(34) thiol of HSA indicate NO, NNO, halothane, and chloroform can induce similar changes in protein structure. Experiments evaluating the relative affinities of binding of NO and carbon monoxide (CO) to iron(II) sites of the hemeproteins led to evidence of NO binding to noniron, nonsulfur sites as well. With HbA, IR spectra of cysteine thiols and/or the iron(II) N-O stretching region denote changes in protein structure due to NO, NNO, or CO occupying noniron sites with an order of decreasing affinities of NO > NNO > CO. Loss of NO from some, not all, noniron sites in hemeproteins is very slow (t(1/2) similar to hours). These findings provide examples in which NO and anesthetics alter the structure and properties of protein similarly, and support the hypothesis that some physiological effects of NO land possibly CO) result from anesthetic-like noncovalent bonding to sites within protein or other tissue components. Such bonding may be involved in mechanisms for control of oxygen transport, mitochondrial respiration, and activation of soluble guanylate cyclase by NO.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University	Caughey, WS (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, 903 4th St, Hamilton, MT 59840 USA.				NHLBI NIH HHS [HL-15890] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7982, DOI 10.1021/ja00312a031; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CAUGHEY JM, 1977, BIOCHEM BIOPH RES CO, V78, P897, DOI 10.1016/0006-291X(77)90507-1; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DONG AC, 1994, J BIOL CHEM, V269, P23911; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Eckenhoff RG, 1998, BIOPHYS J, V75, P477, DOI 10.1016/S0006-3495(98)77536-8; Eckenhoff RG, 1998, MOL PHARMACOL, V54, P610; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P9199; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gallivan JP, 1999, ORG LETT, V1, P103, DOI 10.1021/ol990577p; GORGA JC, 1985, ARCH BIOCHEM BIOPHYS, V240, P734, DOI 10.1016/0003-9861(85)90082-7; Guarrera L, 1999, BIOCHEMISTRY-US, V38, P10079, DOI 10.1021/bi990942k; HAZZARD JH, 1985, ARCH BIOCHEM BIOPHYS, V240, P747, DOI 10.1016/0003-9861(85)90083-9; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Henry Y, 1999, CELL MOL LIFE SCI, V55, P1003, DOI 10.1007/s000180050351; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; Johansson JS, 1997, J BIOL CHEM, V272, P17961, DOI 10.1074/jbc.272.29.17961; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; Kosaka H, 1999, BBA-BIOENERGETICS, V1411, P370, DOI 10.1016/S0005-2728(99)00026-2; Liu DH, 1999, J AM CHEM SOC, V121, P11798, DOI 10.1021/ja990606r; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; MOH PP, 1987, BIOCHEMISTRY-US, V26, P6243, DOI 10.1021/bi00393a044; Narazaki R, 1997, BBA-PROTEIN STRUCT M, V1338, P275, DOI 10.1016/S0167-4838(96)00221-X; Narazaki R, 1996, PHARMACEUT RES, V13, P1317, DOI 10.1023/A:1016057513490; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Rathore R, 2000, ANGEW CHEM INT EDIT, V39, P2123, DOI 10.1002/1521-3773(20000616)39:12<2123::AID-ANIE2123>3.0.CO;2-4; Rathore R, 1998, ANGEW CHEM INT EDIT, V37, P1585, DOI 10.1002/(SICI)1521-3773(19980619)37:11<1585::AID-ANIE1585>3.0.CO;2-W; SAMPATH V, 1994, BIOCHEM BIOPH RES CO, V198, P281, DOI 10.1006/bbrc.1994.1039; SAMPATH V, 1996, METHODS NITRIC OXIDE, P413; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Tanner JW, 1999, BBA-PROTEIN STRUCT M, V1430, P46, DOI 10.1016/S0167-4838(98)00258-1; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Xue L, 2000, P NATL ACAD SCI USA, V97, P1851, DOI 10.1073/pnas.97.4.1851; YOSHIKAWA S, 1991, J CRYST GROWTH, V110, P247, DOI 10.1016/0022-0248(91)90892-9; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271; ZHAO XJ, 1994, BIOCHEM BIOPH RES CO, V204, P537, DOI 10.1006/bbrc.1994.2492; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	51	23	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13635	13643		10.1074/jbc.M006588200	http://dx.doi.org/10.1074/jbc.M006588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278308	hybrid			2022-12-27	WOS:000168356600020
J	Daniel, PB; Kieffer, TJ; Leech, CA; Habener, JF				Daniel, PB; Kieffer, TJ; Leech, CA; Habener, JF			Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PHOSPHOLIPASE-C ACTIVATION; MOLECULAR CHARACTERIZATION; FUNCTIONAL EXPRESSION; TISSUE DISTRIBUTION; CELL-MEMBRANES; MESSENGER-RNA; I RECEPTOR; G-PROTEINS; CLONING	The expression of the paracrine signaling hormone pituitary adenylate cyclase-activating polypeptide (PACAP) is regulated in a cyclical fashion during the Ig-day spermatogenic cycle of the adult rat testis. The precise functions of PACAP in the development of germ cells are uncertain, but cycle- and stage-specific expression may augment cAMP-regulated gene expression in germ cells and associated Sertoli cells. Here we report the existence of a heretofore unrecognized exon in the extracellular domain of the PACAP type 1 receptor (PAC1R) that is alternatively spliced during the spermatogenic cycle in the rat testis, This splice variant encodes a full-length receptor with the insertion of an additional 72 base pairs encoding 24 amino acids (exon 3a) between coding exons 3 and 4. The PAC1R(3a) mRNA is preferentially detected in seminiferous tubules and is expressed at the highest levels in round spermatids and Sertoli cells. Analyses of ligand binding and signaling functions in stably transfected HEK293 cells expressing the two receptor isoforms reveals a 6-fold increase in the affinity of the PAC1R(3a) to bind PACAP-38, and alterations in its coupling to both cAMP and inositol phosphate signaling pathways relative to the wild type PAC1R. These findings suggest that the extracellular region between coding exons 3 and g of PAC1R may play an important role in the regulation of the relative ligand affinities and the relative coupling to G, (cAMP) and G, (inositol phosphates) signal transduction pathways during spermatogenesis.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Lab Mol Endocrinol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Habener, JF (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Lab Mol Endocrinol, 55 Fruit St, Boston, MA 02114 USA.	tim.kieffer@ualberta.ca; jhabener@partners.org						ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BUCHER P, 1994, ISMB, V2, P53; Cao YJ, 1997, EUR J BIOCHEM, V244, P400, DOI 10.1111/j.1432-1033.1997.00400.x; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Cao YJ, 1998, ANN NY ACAD SCI, V865, P82, DOI 10.1111/j.1749-6632.1998.tb11166.x; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; Chatterjee TK, 1997, J BIOL CHEM, V272, P12122, DOI 10.1074/jbc.272.18.12122; Daniel PB, 2000, ENDOCRINOLOGY, V141, P1218, DOI 10.1210/en.141.3.1218; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; GHATEI MA, 1993, J ENDOCRINOL, V136, P159, DOI 10.1677/joe.0.1360159; HANNIBAL J, 1995, REGUL PEPTIDES, V55, P111, DOI 10.1016/0167-0115(94)00110-J; HEINDEL JJ, 1992, BIOL REPROD, V47, P800, DOI 10.1095/biolreprod47.5.800; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; HURLEY JD, 1995, ENDOCRINOLOGY, V136, P550, DOI 10.1210/en.136.2.550; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; INOOKA H, 1992, INT J PEPT PROT RES, V40, P456; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JOURNOT L, 1995, BIOCHEM SOC T, V23, P133, DOI 10.1042/bst0230133; Kieffer TJ, 1996, ENDOCRINOLOGY, V137, P5119, DOI 10.1210/en.137.11.5119; KONONEN J, 1994, ENDOCRINOLOGY, V135, P2291, DOI 10.1210/en.135.5.2291; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MacKenzie CJ, 1996, ANN NY ACAD SCI, V805, P579; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; ROBBERECHT P, 1992, MOL PHARMACOL, V42, P347; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; Rossato M, 1997, ENDOCRINOLOGY, V138, P3228, DOI 10.1210/en.138.8.3228; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SREEDHARAN SP, 1993, BIOCHEM BIOPH RES CO, V193, P546, DOI 10.1006/bbrc.1993.1658; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V195, P881, DOI 10.1006/bbrc.1993.2127; VanRampelbergh J, 1997, BBA-MOL CELL RES, V1357, P249, DOI 10.1016/S0167-4889(97)00028-1; Vaudry D, 2000, PHARMACOL REV, V52, P269; WEST AP, 1995, J ENDOCRINOL, V144, P215, DOI 10.1677/joe.0.1440215; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016	39	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12938	12944		10.1074/jbc.M009941200	http://dx.doi.org/10.1074/jbc.M009941200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278585	hybrid			2022-12-27	WOS:000168198600069
J	Suk, K; Chang, I; Kim, YH; Kim, S; Kim, JY; Kim, H; Lee, MS				Suk, K; Chang, I; Kim, YH; Kim, S; Kim, JY; Kim, H; Lee, MS			Interferon gamma (IFN gamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis IFN gamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; GENE-EXPRESSION; TNF-ALPHA; DEATH; INDUCTION; RECEPTORS; BINDING; BCL-2; PROMOTER; IRF-1	We investigated the molecular mechanism of the synergism between interferon gamma (IFN gamma) and tumor necrosis factor alpha (TNF alpha) documented in a variety of biological occasions such as tumor cell death and inflammatory responses. IFN gamma /TNF alpha synergistically induced apoptosis of ME-180 cervical cancer cells. IFN gamma induced STAT1 phosphorylation and interferon regulatory factor 1 (IRF-1) expression. Transfection of phosphorylation-defective STAT1 inhibited IFN gamma /TNF alpha -induced apoptosis, whereas IRF-1 transfection induced susceptibility to TNF alpha. Dominant-negative I kappaB alpha transfection sensitized ME-180 cells to TNF alpha. IFN gamma pretreatment attenuated TNF alpha- or p65-induced NF-KB reporter activity, whereas it did not inhibit p65 translocation or DNA binding of NF-KB, IRF-1 transfection alone inhibited TNF alpha -induced NF-KB activity, which was reversed by coactivator p300 overexpression. Caspases were activated by IFN gamma /TNF alpha combination; however, caspase inhibition did not abrogate IFN gamma /TNF alpha -induced cell death. Instead, caspase inhibitors directed IFN gamma TNF alpha -treated ME-180 cells to undergo necrosis, as demonstrated by Hoechst 33258/propidium iodide staining and electron microscopy. Taken together, our results indicate that IFN gamma and TNFa synergistically act to destroy ME-180 tumor cells by either apoptosis or necrosis, depending on caspase activation, and STAT1/IRF-1 pathways initiated by IFN gamma play a critical role in IFN gamma /TNF alpha synergism by inhibiting cytoprotective NF-KB, IFN gamma /TNF alpha synergism appears to activate cell death machinery independently of caspase activation, and caspase activation seems to merely determine the mode of cell death.	Sungkyunkwan Univ, Samsung Biomed Res Inst, Clin Res Ctr, Seoul 135710, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea; Kyung Hee Univ, Grad Sch EW Med Sci, Seoul 130701, South Korea	Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Kyung Hee University	Lee, MS (corresponding author), Sungkyunkwan Univ, Samsung Biomed Res Inst, Clin Res Ctr, Seoul 135710, South Korea.	mslee@smc.samsung.co.kr	Lee, Myung Shik/C-9606-2011					AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Dong YS, 1999, J IMMUNOL, V162, P4731; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; Eguchi Y, 1997, CANCER RES, V57, P1835; EKNER R, 1994, GENE DEV, V8, P869; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KIRSTEIN M, 1986, J IMMUNOL, V137, P2277; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; OHMORI Y, 1995, J IMMUNOL, V154, P5235; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Shimizu S, 1996, CANCER RES, V56, P2161; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TSUJIMOTO M, 1986, J IMMUNOL, V137, P2272; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680	38	128	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13153	13159		10.1074/jbc.M007646200	http://dx.doi.org/10.1074/jbc.M007646200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278357	hybrid			2022-12-27	WOS:000168198600096
J	Umeda, H; Takeuchi, M; Suyama, K				Umeda, H; Takeuchi, M; Suyama, K			Two new elastin cross-links having pyridine skeleton - Implication of ammonia in elastin cross-linking in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; AMINO-ACIDS; AGE; AORTA; COLLAGEN; RAT; MATURATION; CIRRHOSIS; ALKANALS; TISSUE	Isolation and structure analysis of two amino acids from bovine ligamentum nuchae elastin hydrolysates revealed the presence of pyridine cross-links in elastin. The structures of these amino acids were determined to have 3,4,5- and 2,3,5-trisubstituted pyridine skeletons both with three carboxylic acids and a mass of 396 (C18H28N4O6) identified as 4-(4-amino-4-carboxybutyl)3,5-di-(3-amino-3-carboxypropyl)-pyridine and 2-(4-amino-4-carboxybutyl)-3,5-di-(3-amino-3-carboxypropyl)-pyridine, We have named these pyridine cross-links desmopyridine (DESP) and isodesmopyridine (IDP), respectively. Structure analysis of these pyridine crosslinks implied that the formation of these cross-links involved the condensation reaction between ammonia and allysine. The elastin incubated with ammonium chloride showed that DESP and IDP levels increased as the allysine content decreased. DESP and IDP were measured by high pressure liquid chromatography (HPLC) with W detection and were found in a variety of bovine tissues. The DESP/desmosine (DES) and IDP/isodesmosine (IDE) ratios in aorta elastin were higher than in other tissues. DESP and IDP contents in human aorta elastin were found to be gradually increased with age. The concentration of IDP was significantly elevated in aorta elastin of rat with chronic liver cirrhosis induced by carbon tetrachloride (mean +/- S.D.; 11.1 +/- 0.9 nmol/mg elastin) when compared with normal rats (5.9 +/- 1.5 nmol/mg elastin), Although DESP and IDP are present at only trace concentrations in the tissue elastin, these pyridine cross-links may be useful biomarkers for the aortic elastin damaged by ammonia.	Tohoku Univ, Dept Appl Bioorgan Chem, Div Life Sci, Grad Sch Agr Sci,Aoba Ku, Sendai, Miyagi 9818555, Japan	Tohoku University	Suyama, K (corresponding author), Tohoku Univ, Dept Appl Bioorgan Chem, Div Life Sci, Grad Sch Agr Sci,Aoba Ku, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.							Akagawa M, 1999, ARCH BIOCHEM BIOPHYS, V372, P112, DOI 10.1006/abbi.1999.1462; Akagawa M, 2000, CONNECT TISSUE RES, V41, P131, DOI 10.3109/03008200009067665; ANWAR RA, 1966, J BIOL CHEM, V241, P4638; BERRY CL, 1976, CARDIOVASC RES, V10, P437, DOI 10.1093/cvr/10.4.437; BERRY JN, 1959, CLIN RES, V7, P154; CARO CG, 1978, MECH CIRCULATION, P254; Cope A. C., 1960, ORG REACTIONS, V11, P317; COX RH, 1983, MECH AGEING DEV, V23, P21, DOI 10.1016/0047-6374(83)90096-9; DAVIS EC, 1993, HISTOCHEMISTRY, V100, P17, DOI 10.1007/BF00268874; DAVIS NR, 1970, J AM CHEM SOC, V92, P3778, DOI 10.1021/ja00715a040; DAVIS NR, 1978, BIOCHIM BIOPHYS ACTA, V358, P258; FARLEY CP, 1956, J AM CHEM SOC, V78, P3477, DOI 10.1021/ja01595a057; FRANK RL, 1949, J AM CHEM SOC, V71, P2629, DOI 10.1021/ja01176a008; FRANZBLAU C, 1965, BIOCHEM BIOPH RES CO, V21, P575, DOI 10.1016/0006-291X(65)90524-3; GEBHARDT R, 1994, HEPATOLOGY, V20, P684, DOI 10.1016/0270-9139(94)90105-8; HORNEBECK W, 1978, EXP GERONTOL, V13, P293, DOI 10.1016/0531-5565(78)90037-2; LEBELLA FS, 1964, J GERONTOL, V20, P54; LENT R, 1967, BIOCHEM BIOPH RES CO, V26, P43, DOI 10.1016/0006-291X(67)90250-1; LENT RW, 1969, BIOCHEMISTRY-US, V8, P2837, DOI 10.1021/bi00835a022; LOOKER T, 1972, J ANAT, V113, P17; MECHAM RP, 1979, BIOCHIM BIOPHYS ACTA, V577, P145; MICHEL JB, 1994, AM J PHYSIOL, V267, pR124, DOI 10.1152/ajpregu.1994.267.1.R124; NAKAMURA F, 1994, ANAL BIOCHEM, V223, P21, DOI 10.1006/abio.1994.1540; NAKAMURA F, 1991, J CHROMATOGR SCI, V29, P217, DOI 10.1093/chromsci/29.5.217; NEUMAN RE, 1950, J BIOL CHEM, V186, P549; OWEN EE, 1961, J CLIN INVEST, V42, P215; PARTRIDGE SM, 1963, NATURE, V197, P1297, DOI 10.1038/1971297a0; PAZ MA, 1971, BIOCHEM BIOPH RES CO, V44, P289; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1989, J BIOL CHEM, V264, P21597; Slatter DA, 1999, J BIOL CHEM, V274, P19661, DOI 10.1074/jbc.274.28.19661; SNODGRASS PJ, 1989, HEPATOLOGY, V9, P373, DOI 10.1002/hep.1840090306; SNOWDEN JM, 1982, BIOCHIM BIOPHYS ACTA, V706, P153, DOI 10.1016/0167-4838(82)90481-2; STARCHER BC, 1967, BIOCHEMISTRY-US, V6, P2425, DOI 10.1021/bi00860a019; SUYAMA K, 1992, BIOORG MED CHEM LETT, V2, P1767, DOI 10.1016/S0960-894X(00)80472-2; SUYAMA K, 1980, J AGR FOOD CHEM, V28, P546, DOI 10.1021/jf60229a048; SUYAMA K, 1979, J ORG CHEM, V44, P1417, DOI 10.1021/jo01323a012; TAKEUCHI T, 1969, GASTROENTEROLOGY, V56, P744; THOMAS J, 1963, NATURE, V200, P651, DOI 10.1038/200651a0; TYOR MP, 1960, GASTROENTEROLOGY, V39, P420; Umeda H, 2001, ARCH BIOCHEM BIOPHYS, V385, P209, DOI 10.1006/abbi.2000.2145; Umeda H, 2001, AMINO ACIDS, V20, P187, DOI 10.1007/s007260170059; VOGEL HG, 1978, CONNECT TISSUE RES, V6, P161, DOI 10.3109/03008207809152626; VOGEL HG, 1991, MECH AGEING DEV, V57, P15, DOI 10.1016/0047-6374(91)90021-Q; Watanabe M, 1996, TOHOKU J EXP MED, V180, P115, DOI 10.1620/tjem.180.115	47	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12579	12587		10.1074/jbc.M009744200	http://dx.doi.org/10.1074/jbc.M009744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278561	hybrid			2022-12-27	WOS:000168198600017
J	Kumar, P; Hosaka, S; Koch, AE				Kumar, P; Hosaka, S; Koch, AE			Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-ADHESION; CHEMOATTRACTANT PROTEIN-1; DIFFERENTIAL REGULATION; RAS; PATHWAYS; INTERLEUKIN-1; INVOLVEMENT; EXPRESSION; PRODUCT	Cellular adhesion molecules such as E-selectin function to recruit leukocytes into the inflammatory lesions of diseases such as rheumatoid arthritis (ELA) and atherosclerosis. Monocytes are the key components of the cellular infiltrates present in these disorders. We hypothesized that soluble E-selectin (sE-selectin) might mediate the chemotaxis of monocytes, in this report, we show that sE-selectin induced normal human peripheral blood monocyte migration in the nanomolar range in a concentration-dependent manner. Neutralization studies using RA human joint synovial fluids and anti-E-selectin antibody showed a mean 31% reduction in RA synovial fluid-mediated monocyte chemotaxis (p < 0.05), indicating that sE-selectin is a major monocyte recruiter in RA. Next, we investigated the role of tyrosine phosphorylation pathways in sE-selectin-induced monocyte chemotaxis, Human peripheral blood monocytes stimulated with sE-selectin showed a time-dependent increase in the tyrosine phosphorylation of a broad range of cellular proteins, predominantly in the molecular size range of Src family kinases (50-60 kDa) and mitogen-activated protein kinases (MAPKs), Western blot analysis of Src family kinases showed a time-dependent increase in Src, Hck, and Lyn phosphorylation. The pretreatment of monocytes with the Src inhibitor AG1879: 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol- [3,4-d]pyrimidine (PP2) prior to stimulation with sE-selectin markedly inhibited Hck and Lyn phosphorylation, whereas the phosphorylation of Src was partially inhibited. In addition, the sE-selectin stimulation of monocytes resulted in the increased phosphorylation of extracellular signal-related kinase (ERK1/2) and p38 MAPK. The pretreatment of monocytes with PP2 showed 89 and 83% inhibition of ERK1/2 and p38 MAPK phosphorylation, respectively. sE-selectin also showed a time-dependent activation of has kinase, Furthermore, the pretreatment of monocytes with PP2 completely inhibited sE-selectin-mediated monocyte chemotaxis, Taken together, our data demonstrate a novel function for sE-selectin as a monocyte chemotactic agent and suggest that sE-selectin might be mediating its biological functions through the Src-MAPK pathway.	Northwestern Univ, Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA; Chicago Hlth Care Syst, Vet Affairs, Lakeside Div, Chicago, IL 60611 USA	Northwestern University	Koch, AE (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Rheumatol, 303 E Chicago Ave,Ward 3-315, Chicago, IL 60611 USA.	ae-koch@northwestern.edu	Kumar, Pawan/H-7777-2013; Koch, Alisa E/B-6894-2011		NIAMS NIH HHS [AR-30692, AR-41492] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692, R29AR041492] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CARLOS TM, 1994, BLOOD, V84, P2068; CHAPMAN PT, 1995, BRIT MED BULL, V51, P296, DOI 10.1093/oxfordjournals.bmb.a072962; Chisholm LJ, 1996, J VASC SURG, V23, P288, DOI 10.1016/S0741-5214(96)70273-2; DENHOLM EM, 1991, J IMMUNOL METHODS, V144, P247, DOI 10.1016/0022-1759(91)90092-T; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Haas M, 2000, J BIOL CHEM, V275, P27832; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huttunen P, 1998, VIROLOGY, V250, P85, DOI 10.1006/viro.1998.9343; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KOCH AE, 1993, CLIN IMMUNOL IMMUNOP, V69, P29, DOI 10.1006/clin.1993.1146; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Tokuhira M, 2000, ARTHRITIS RHEUM, V43, P1122, DOI 10.1002/1529-0131(200005)43:5<1122::AID-ANR23>3.0.CO;2-7; VILLIGER PM, 1992, J IMMUNOL, V149, P722; Volin MV, 1998, CLIN IMMUNOL IMMUNOP, V89, P44, DOI 10.1006/clin.1998.4590; Yoshida M, 1998, SEIKAGAKU, V70, P1270; YU SF, 1990, J LEUKOCYTE BIOL, V48, P412, DOI 10.1002/jlb.48.5.412	38	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21039	21045		10.1074/jbc.M009099200	http://dx.doi.org/10.1074/jbc.M009099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274196	hybrid			2022-12-27	WOS:000169297900034
J	Curtain, CC; Ali, F; Volitakis, I; Cherny, RA; Norton, RS; Beyreuther, K; Barrow, CJ; Masters, CL; Bush, AI; Barnham, KJ				Curtain, CC; Ali, F; Volitakis, I; Cherny, RA; Norton, RS; Beyreuther, K; Barrow, CJ; Masters, CL; Bush, AI; Barnham, KJ			Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; A-BETA; OXIDATIVE STRESS; IN-VITRO; HYDROGEN-PEROXIDE; RESONANCE-SPECTRA; SENILE PLAQUES; PRION PROTEIN; FREE-RADICALS; HUMAN BRAIN	Amyloid beta peptide (A beta) is the major constituent of extracellular plaques and perivascular amyloid deposits, the pathognomonic neuropathological lesions of Alzheimer's disease. Gu(2+) and Zn2+ bind A beta, inducing aggregation and giving rise to reactive oxygen species. These reactions may play a deleterious role in the disease state, because high concentrations of iron, copper, and zinc have been located in amyloid in diseased brains. Here we show that coordination of metal ions to A beta is the same in both aqueous solution and lipid environments, with His(6), His(13), and His(14) all involved. At Cu2+/peptide molar ratios >0.3, A beta coordinated a second Cu2+ atom in a highly cooperative manner. This effect was abolished if the histidine residues were methylated at. N-epsilon2, indicating the presence of bridging histidine residues, as found in the active site of superoxide dismutase, Addition of Cu2+ Or Zn2+ to A beta in a negatively charged lipid environment caused a conformational change from beta -sheet to alpha -helix, accompanied by peptide oligomerization and membrane penetration, These results suggest that metal binding to A beta generated an allosterically ordered membrane-penetrating oligomer linked by superoxide dismutase-like bridging histidine residues.	Biomol Res Inst, Parkville, Vic 3052, Australia; Monash Univ, Dept Phys, Melbourne, Vic 3168, Australia; Univ Melbourne, Sch Chem, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Harvard Univ, Massachusetts Gen Hosp E, Sch Med, Genet & Aging Unit,Lab Oxidat Biol, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp E, Sch Med, Dept Psychiat, Charlestown, MA 02129 USA	Monash University; University of Melbourne; University of Melbourne; Ruprecht Karls University Heidelberg; Harvard University; Harvard University	Barnham, KJ (corresponding author), Biomol Res Inst, 343 Royal Parade, Parkville, Vic 3052, Australia.	kevin.barnham@bioresi.com.au	Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Curtain, Cyril/0000-0001-6955-320X; Norton, Raymond/0000-0001-8893-0584				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 1999, BBA-PROTEIN STRUCT M, V1435, P127, DOI 10.1016/S0167-4838(99)00214-9; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BLACKBURN WD, 1991, J LIPID RES, V32, P1911; Bush A. I., 1999, Society for Neuroscience Abstracts, V25, P14; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; CHERNY RC, 2001, IN PRESS NEURON; Cole GM, 2000, MICROSC RES TECHNIQ, V50, P316, DOI 10.1002/1097-0029(20000815)50:4<316::AID-JEMT11>3.0.CO;2-E; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; DAVOUST J, 1982, J MAGN RESON, V48, P475, DOI 10.1016/0022-2364(82)90079-8; Farhangrazi ZS, 1997, NEUROREPORT, V8, P1127, DOI 10.1097/00001756-199703240-00013; Furlaneto C, 1997, CELL BIOCHEM FUNCT, V15, P39, DOI 10.1002/(SICI)1099-0844(199703)15:1<39::AID-CBF718>3.0.CO;2-D; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Gordon L.M., 1988, METHODS STUDYING MEM, V1, P25; GORDON LM, 1992, BIOCHIM BIOPHYS ACTA, V1139, P257, DOI 10.1016/0925-4439(92)90099-9; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harkany T, 1999, PROG NEURO-PSYCHOPH, V23, P963, DOI 10.1016/S0278-5846(99)00058-5; He WL, 1999, BIOCHEMISTRY-US, V38, P10871, DOI 10.1021/bi990563r; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Jost P C, 1978, Methods Enzymol, V49, P369; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; Kremer JJ, 2000, BIOCHEMISTRY-US, V39, P10309, DOI 10.1021/bi0001980; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Marcinowski KJ, 1998, J AM CHEM SOC, V120, P11082, DOI 10.1021/ja9738687; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Marsh D., 1993, PROTEIN LIPID INTERA, P41; Marsh D., 1989, SPIN LABELING THEORY, V8, P255; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCINTYRE JO, 1982, BIOPHYS J, V37, P53, DOI 10.1016/S0006-3495(82)84595-5; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Muller WE, 1998, AMYLOID, V5, P10, DOI 10.3109/13506129809007284; Multhaup G, 1998, ALZHEIMERS REP, V1, P147; Navab M, 2000, J LIPID RES, V41, P1495; Ohtsu H, 2000, J AM CHEM SOC, V122, P5733, DOI 10.1021/ja994050j; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SALIKHOV KM, 1971, J MAGN RESON, V5, P189, DOI 10.1016/0022-2364(71)90005-9; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; SUNDBERG RJ, 1974, CHEM REV, V74, P471, DOI 10.1021/cr60290a003; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1992, NEUROBIOL AGING, V13, P615, DOI 10.1016/0197-4580(92)90067-8; Yatin SM, 1999, NEUROBIOL AGING, V20, P325	69	550	565	0	88	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20466	20473		10.1074/jbc.M100175200	http://dx.doi.org/10.1074/jbc.M100175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274207	hybrid			2022-12-27	WOS:000169135100107
J	Amblar, M; de Lacoba, MG; Corrales, MA; Lopez, P				Amblar, M; de Lacoba, MG; Corrales, MA; Lopez, P			Biochemical analysis of point mutations in the 5 '-3 ' exonuclease of DNA polymerase I of Streptococcus pneumoniae - Functional and structural implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; POLA GENE; FLAP ENDONUCLEASE-1; 5'-NUCLEASE DOMAIN; CRYSTAL-STRUCTURE; RNA-POLYMERASE; CLONED GENES; 5'-3'-EXONUCLEASE; PURIFICATION	To define the active site of the 5 ' -3 ' exonucleolytic domain of the Streptococcus pneumoniae DNA polymerase I (Spn pol I), we have constructed His-tagged Spn pol I fusion protein and introduced mutations at residues Asp(10), Glu(88), and Glu(114), which are conserved among all prokaryotic and eukaryotic 5 ' nucleases, The mutations, but not the fusion to the C-terminal end of the wild-type, reduced the exonuclease activity. The residual exonuclease activity of the mutant proteins has been kinetically studied, together with potential alterations in metal binding at the active site. Comparison of the catalytic rate and dissociation constant of the D10G, E114G, and E88K mutants and the control fusion protein support: (i) a critical function of Asp(10) in the catalytic event, (ii) a role of Glu(114) in the exonucleolytic reaction, being secondarily involved in both catalysis and DNA binding, and (iii) a nonessential function of Glu(88) for the exonuclease activity of Spn pol I. Moreover, the pattern of metal activation of the mutant proteins indicates that none of the three residues is a metal-ligand at the active site. These findings and those previously obtained with D190A mutant of Spn pol I are discussed in relation to structural and mutational data for related 5 ' nucleases.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Amblar, M (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apt 127, P-2781901 Deiras, Portugal.		Amblar, Monica/E-2366-2016; López, Paloma/L-1583-2014; Amblar, 2405/C-3941-2011; lópez, paloma/W-7556-2019	Amblar, Monica/0000-0003-3530-615X; López, Paloma/0000-0001-8755-8952; lópez, paloma/0000-0001-8755-8952				Amblar M, 1998, J BIOTECHNOL, V63, P17, DOI 10.1016/S0168-1656(98)00071-6; Amblar M, 1998, EUR J BIOCHEM, V252, P124, DOI 10.1046/j.1432-1327.1998.2520124.x; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Ceska TA, 1998, TRENDS BIOCHEM SCI, V23, P331, DOI 10.1016/S0968-0004(98)01259-6; Cornish-Bowden A, 1995, FUNDAMENTALS ENZYME, p[30, 30, 56]; DIAZ A, 1992, J BACTERIOL, V174, P2014, DOI 10.1128/jb.174.6.2014-2024.1992; DIAZ A, 1992, MOL MICROBIOL, V6, P3009, DOI 10.1111/j.1365-2958.1992.tb01759.x; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JOYCE CM, 1985, J MOL BIOL, V186, P283, DOI 10.1016/0022-2836(85)90105-6; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LOPEZ P, 1989, J BIOL CHEM, V264, P4255; LOPEZ P, 1987, J BACTERIOL, V169, P4869, DOI 10.1128/jb.169.10.4869-4871.1987; MARTINEZ S, 1986, GENE, V44, P79, DOI 10.1016/0378-1119(86)90045-4; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Pickering TJ, 1999, NUCLEIC ACIDS RES, V27, P730, DOI 10.1093/nar/27.3.730; PONS ME, 1991, EUR J BIOCHEM, V201, P147, DOI 10.1111/j.1432-1033.1991.tb16267.x; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; STEINBERG RA, 1994, ANAL BIOCHEM, V219, P155, DOI 10.1006/abio.1994.1246; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19172	19181		10.1074/jbc.M008678200	http://dx.doi.org/10.1074/jbc.M008678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278428	hybrid			2022-12-27	WOS:000169091000073
J	Kalafatis, M; Mann, KG				Kalafatis, M; Mann, KG			The role of the membrane in the inactivation of factor Va by plasmin - Amino acid region 307-348 of factor V plays a critical role in factor Va cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; BOVINE FACTOR-V; FACTOR-XA; COMPLETE CDNA; BINDING-SITE; THROMBIN; FIBRINOLYSIS; SEQUENCE; PURIFICATION	The mechanism of inactivation of bovine factor Va by plasmin was studied in the presence and absence of phospholipid vesicles (PCPS vesicles). Following 60-min incubation with plasmin (4 nM) membrane-bound factor Va (400 nM) is completely inactive, whereas in the absence of phospholipid vesicles following a 1-h incubation period, the cofactor retains 90% of its initial cofactor activity. Amino acid sequencing of the fragments deriving from cleavage of factor Va by plasmin demonstrated that while both chains of factor Va are cleaved by plasmin, only cleavage of the heavy chain correlates with inactivation of the cofactor. In the presence of a membrane surface the heavy chain of the bovine cofactor is first cleaved at Arg(348) to generate a fragment of M-r 47,000 containing the NH2-terminal part of the cofactor (amino acid residues 1-348) and a M-r 42,000 fragment (amino acid residues 349-713), This cleavage is associated with minimal loss in cofactor activity. Complete loss of activity of the membrane-bound cofactor coincides with three cleavages at the COOH-terminal portion of the M-r 47,000 fragment: Lys(309), Lys(310), and Arg(313). These cleavages result in the release of the COOH terminus of the molecule and the production of a M-r 40,000 fragment containing the NH2-terminal portion of the factor Va molecule. Factor Va was treated with plasmin in the absence of phospholipid vesicles followed by the addition of PCPS vesicles and activated protein C (APC), A rapid inactivation of the cofactor was observed as a result of cleavage of the M-r 47,000 fragment at Arg(306) by APC and appearance of a M-r 39,000 fragment. These data suggest a critical role of the amino acid sequence 307-348 of factor Va. A 42-amino acid peptide encompassing the region 307-348 of human factor Va (N42R) was found to be a good inhibitor of factor Va clotting activity with an IC50 of similar to1.3 muM These data suggest that plasmin is a potent inactivator of factor Va and that region 307-348 of the cofactor plays a critical role in cofactor function and may be responsible for the interaction of the cofactor with factor Xa and/or prothrombin.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; University of Vermont	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, Sci Bldg,2351 Euclid Ave, Cleveland, OH 44115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL34575] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bick RL, 1999, HAEMOSTASIS, V29, P111; CONLON SJ, 1997, THROMB HAEMOSTASIS, V77, P2505; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; Hockin MF, 1997, ARTERIOSCL THROM VAS, V17, P2765, DOI 10.1161/01.ATV.17.11.2765; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; Kalafatis M, 1999, ARTERIOSCL THROM VAS, V19, P336, DOI 10.1161/01.ATV.19.2.336; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; OMAR MN, 1987, J BIOL CHEM, V262, P9750; Pryzdial ELG, 1999, J BIOL CHEM, V274, P8500, DOI 10.1074/jbc.274.13.8500; Samis JA, 2000, BLOOD, V95, P943, DOI 10.1182/blood.V95.3.943.003k34_943_951; Tracy RP, 1997, J AM COLL CARDIOL, V30, P716, DOI 10.1016/S0735-1097(97)00230-1; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607; WYSHOCK EG, 1995, THROMB RES, V80, P377, DOI 10.1016/0049-3848(95)00190-3; Yang TL, 1998, BLOOD, V91, P4593, DOI 10.1182/blood.V91.12.4593.412a02_4593_4599	38	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18614	18623		10.1074/jbc.M007134200	http://dx.doi.org/10.1074/jbc.M007134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278331	hybrid			2022-12-27	WOS:000168866500132
J	Luo, X; Crawley, SW; Steimle, PA; Egelhoff, TT; Cote, GP				Luo, X; Crawley, SW; Steimle, PA; Egelhoff, TT; Cote, GP			Specific phosphorylation of threonine by the Dictyostelium myosin II heavy chain kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE MYOSIN; MYELIN BASIC-PROTEIN; ELONGATION FACTOR-II; SITE SUBSTRATE-SPECIFICITY; 20,000-DALTON LIGHT CHAIN; CATALYTIC DOMAIN; RABBIT RETICULOCYTES; SECONDARY STRUCTURE; COILED-COIL	Dictyostelium myosin II heavy chain kinase A (MHCK A), MHCK B, and MHCK C contain a novel type of protein kinase catalytic domain that displays no sequence identity to the catalytic domain present in conventional serine, threonine, and/or tyrosine protein kinases. Several proteins, including myelin basic protein, myosin regulatory light chain, caldesmon, and casein were phosphorylated by the bacterially expressed MHCK A, MHCK B, and MHCK C catalytic domains. Phosphoamino acid analyses of the proteins showed that 91 to 99% of the phosphate was incorporated into threonine with the remainder into serine, Acceptor amino acid specificity was further examined using a synthetic peptide library (MAXXXX(S/T)XXXXAKKK; where X is any amino acid except cysteine, tryptophan, serine, and threonine and position 7 contains serine and threonine in a 1.7:1 ratio). Phosphorylation of the peptide library with the three MHCK catalytic domains resulted in 97 to 99% of the phosphate being incorporated into threonine, while phosphorylation with a conventional serine/threonine protein kinase, the p21-activated kinase, resulted in 80% of the phosphate being incorporated into serine, The acceptor amino acid specificity of MHCK A was tested directly by substituting serine for threonine in a synthetic peptide and a glutathione S-transferase fusion peptide substrate, The serine-containing substrates were phosphorylated at a 25-fold lower rate than the threonine-containing substrates. The results indicate that the MHCKs are specific for the phosphorylation of threonine.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Queens University - Canada; Case Western Reserve University	Cote, GP (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	coteg@post.queensu.ca			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050009, R01GM050009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARANY G, 1979, PEPTIDES ANAL SYNTHE, P1; Bitte L, 1974, Methods Enzymol, V30, P563; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; COTE GP, 1987, J BIOL CHEM, V262, P1065; COTE GP, 1987, J BIOL CHEM, V262, P13033; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERSKOVITS TT, 1966, BIOCHEMISTRY-US, V5, P1018, DOI 10.1021/bi00867a030; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1986, J BIOL CHEM, V261, P36; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kolman MF, 1996, J CELL BIOL, V132, P101, DOI 10.1083/jcb.132.1.101; Komatsu S, 1996, BIOCHEM BIOPH RES CO, V223, P741, DOI 10.1006/bbrc.1996.0966; KWON YG, 1993, J BIOL CHEM, V268, P10713; KWON YG, 1994, J BIOL CHEM, V269, P4839; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; MITSUI K, 1993, J BIOL CHEM, V268, P13422; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRICE NT, 1991, FEBS LETT, V282, P253, DOI 10.1016/0014-5793(91)80489-P; PROROK M, 1989, BIOCHEM BIOPH RES CO, V158, P136, DOI 10.1016/S0006-291X(89)80188-3; RAMWANI JJ, 1989, BIOCHEMISTRY-US, V28, P6538, DOI 10.1021/bi00442a002; REDPATH NT, 1993, EUR J BIOCHEM, V212, P511, DOI 10.1111/j.1432-1033.1993.tb17688.x; Ridsdale RA, 1997, J BIOL CHEM, V272, P4269, DOI 10.1074/jbc.272.7.4269; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; SINGH TJ, 1983, FEBS LETT, V159, P217, DOI 10.1016/0014-5793(83)80449-9; Steimle PA, 2001, J BIOL CHEM, V276, P6853, DOI 10.1074/jbc.M008992200; STONE AL, 1985, BIOCHEMISTRY-US, V24, P6666, DOI 10.1021/bi00344a055; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; WAWRZYNOW A, 1991, FEBS LETT, V289, P213, DOI 10.1016/0014-5793(91)81072-G; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	54	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17836	17843		10.1074/jbc.M009366200	http://dx.doi.org/10.1074/jbc.M009366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278493	hybrid			2022-12-27	WOS:000168866500031
J	Campbell, WA; Thompson, NL				Campbell, WA; Thompson, NL			Overexpression of LAT1/CD98 light chain is sufficient to increase system L-amino acid transport activity in mouse hepatocytes but not fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINURIC PROTEIN INTOLERANCE; 4F2 HEAVY-CHAIN; CELL-LINES; SUBSTRATE SELECTIVITY; MEMBRANE-PROTEIN; SURFACE-ANTIGEN; MOLECULAR-CLONING; RAT HEPATOCYTES; CANDIDATE GENE; LIVER-INJURY	L-amino acid transporter-1 (LAT1) is a highly conserved gene identified as a light chain of the CD98 amino acid transporter and cellular activation marker. In our previous studies we found increased expression of LAT1 in primary human cancers. We have demonstrated also that LAT1 response to arginine availability is lost in transformed and tumorigenic cells such that expression is constitutively high. System L-amino acid transport activity correlates with changes in LAT1. To assess the functional relevance of increased LAT1 expression and the requirement for 4F2 heavy chain, we overexpressed these CD98 subunits together and separately in nontransformed hepatocytes and fibroblasts. Antigen tags in the expression constructs confirmed that expressed proteins were localized to both cytoplasmic and plasma membrane locations within the cells. Overexpression of LAT1 alone in mouse hepatocytes, but not fibroblasts, was sufficient to increase system L transport, and these cells displayed a growth advantage in conditions of limited arginine, Our results suggest that loss of regulation leading to constitutive expression of LAT1 can contribute to oncogenesis. We hypothesize that the altered LAT1 expression observed in hepatocarcinogenesis gives cells a growth or survival advantage through increased transport activity in a tumor microenvironment of limited amino acid availability.	Rhode Isl Hosp, Grad Program Pathobiol, Providence, RI 02903 USA; Brown Univ, Sch Med, Div Med Oncol, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Thompson, NL (corresponding author), Rhode Isl Hosp, Grad Program Pathobiol, 593 Eddy St, Providence, RI 02903 USA.	Nancy_Thompson@brown.edu			NCI NIH HHS [CA73611] Funding Source: Medline; NIEHS NIH HHS [T32ESO7272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BODE BP, 1994, ANN SURG, V220, P411, DOI 10.1097/00000658-199410000-00001; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; Campbell WA, 2000, J BIOL CHEM, V275, P5347, DOI 10.1074/jbc.275.8.5347; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DUMENCO L, 1995, HEPATOLOGY, V22, P1279, DOI 10.1016/0270-9139(95)90640-1; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HANDLOGTEN ME, 1981, J BIOL CHEM, V256, P7905; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; HEMLER ME, 1982, J IMMUNOL, V129, P623; INOUE Y, 1995, CANCER RES, V55, P3525; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NOVAK DA, 1994, BIOCHEM J, V301, P671, DOI 10.1042/bj3010671; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; SANG JS, 1995, CANCER RES, V55, P1152; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; Shultz VD, 1999, TOXICOL APPL PHARM, V154, P84, DOI 10.1006/taap.1998.8555; Shultz VD, 1997, PATHOBIOLOGY, V65, P14, DOI 10.1159/000164099; Singh RK, 1996, CANCER INVEST, V14, P6, DOI 10.3109/07357909609018433; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Tsurudome M, 1999, J IMMUNOL, V162, P2462; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WARREN RS, 1985, SURGERY, V98, P275; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WHITE MF, 1982, J BIOL CHEM, V257, P4450; Wolf DA, 1996, CANCER RES, V56, P5012; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674	46	45	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16877	16884		10.1074/jbc.M008248200	http://dx.doi.org/10.1074/jbc.M008248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278397	hybrid			2022-12-27	WOS:000168730400038
J	Mercatante, DR; Bortner, CD; Cidlowski, JA; Kole, R				Mercatante, DR; Bortner, CD; Cidlowski, JA; Kole, R			Modification of alternative splicing of Bcl-x Pre-mRNA in prostate and breast cancer cells - Analysis of apoptosis and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; IMMUNOHISTOCHEMICAL ANALYSIS; BCL-X(S) ADENOVIRUS; REGULATORY GENES; DRUG-RESISTANCE; PROTEIN FAMILY; MAMMARY-TUMORS; IN-VIVO; EXPRESSION	There is ample evidence that deregulation of apoptosis results in the development, progression, and/or maintenance of cancer. Since many apoptotic regulatory genes (e.g. bcl-x) code for alternatively spliced protein variants with opposing functions, the manipulation of alternative splicing presents a unique way of regulating the apoptotic response. Here we have targeted oligonucleotides antisense to the 5'-splice site of bcl-x(L), an anti-apoptotic gene that is overexpressed in various cancers, and shifted the splicing pattern of Bcl-x pre-mRNA from Bcl-x(L) to Bcl-x(S), a pro-apoptotic splice variant. This approach induced significant apoptosis in PC-3 prostate cancer cells. In contrast, the same olgonucleotide treatment elicited a much weaker apoptotic response in MCF-7 breast cancer cells. Moreover, although the shift in Bcl-x pre-mRNA splicing inhibited colony formation in both cell lines, this effect was much less pronounced in MCF-7 cells. These differences in responses to oligonucleotide treatment were analyzed in the context of expression of Bcl-x(L), Bcl-x(S), and Bcl-2 proteins. The results indicate that despite the presence of Bcl-x pre-mRNA in a number of cell types, the effects of modification of its splicing by antisense oligonucleotides vary depending on the expression profile of the treated cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kole, R (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NHLBI NIH HHS [HL-51940-05] Funding Source: Medline; PHS HHS [P01-59299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051940] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brown JM, 1999, CANCER RES, V59, P1391; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Ealovega MW, 1996, CANCER RES, V56, P1965; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; Han JS, 1998, SPRINGER SEMIN IMMUN, V19, P279, DOI 10.1007/BF00787225; ISAACS WB, 1991, CANCER RES, V51, P4716; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kawakami K, 1999, ANTICANCER RES, V19, P3927; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mercatante D, 2000, PHARMACOL THERAPEUT, V85, P237, DOI 10.1016/S0163-7258(99)00067-4; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; Olopade OI, 1997, CANCER J SCI AM, V3, P230; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Sergeev IN, 1998, ENDOCRINE, V9, P321, DOI 10.1385/ENDO:9:3:321; Shinoura N, 1999, ONCOGENE, V18, P5703, DOI 10.1038/sj.onc.1202966; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Sproat BS, 1993, ANTISENSE RES APPLIC, P351; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stein D, 1997, ANTISENSE NUCLEIC A, V7, P151, DOI 10.1089/oli.1.1997.7.151; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Tu YP, 1998, CANCER RES, V58, P256; Wang DG, 1999, CLIN ENDOCRINOL, V51, P1, DOI 10.1046/j.1365-2265.1999.00756.x; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195	47	124	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16411	16417		10.1074/jbc.M009256200	http://dx.doi.org/10.1074/jbc.M009256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278482	hybrid			2022-12-27	WOS:000168623100112
J	Parker, BS; Cutts, SM; Phillips, DR				Parker, BS; Cutts, SM; Phillips, DR			Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOMYCIN-C; FORMALDEHYDE; CELLS; GENE	Recently, we have shown that mitoxantrone can be activated by formaldehyde in vitro to form DNA adducts that are specific for CpG and CpA sites in DNA. The CpG specificity of adduct formation prompted investigations into the effect of cytosine methylation (CpG) on adduct formation, since the majority of CpG dinucleotides in the mammalian genome are methylated and hypermethylation in subsets of genes is associated with various neoplasms. Upon methylation of a 512-base pair DNA fragment (containing the lac UV5 promoter) using HpaII methylase, three CCGG sites downstream of the promoter were methylated at C5 of the internal cytosine residue. In vitro transcription studies of mitoxantrone-reacted DNA revealed a 3-fold enhancement in transcriptional blockage (and hence adduct formation) exclusively at these methylated sites. lit vitro cross-linking assays also revealed that methylation enhanced mitoxantrone adduct formation by 2-3-fold, and methylation of cytosine at a single potential drug binding site on a duplex oligonucleotide also enhanced adduct levels by 3-fold. Collectively, these results indicate preferential adduct formation at methylated CpG sites. However, adducts at these methylated sites exhibited the same stability as nonmethylated sites, suggesting that cytosine methylation increases drug accessibility to DNA rather than being involved in kinetic stabilization of the adduct.	La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia	La Trobe University	Phillips, DR (corresponding author), La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia.	d.phillips@latrobe.edu.au	Cutts, Suzanne/B-2467-2012	Cutts, Suzanne/0000-0002-6055-0405; Parker, Belinda/0000-0002-8333-1926				BAYLIN SB, 1986, CANCER RES, V46, P2917; CLARK S, 1999, P AUST SOC BIOCH MOL, V30, P9; CORNBLEET MA, 1984, EUR J CANCER CLIN ON, V20, P1141, DOI 10.1016/0277-5379(84)90122-6; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CULLINANE C, 1993, NUCLEIC ACIDS RES, V21, P1857, DOI 10.1093/nar/21.8.1857; De Vita Jr VT, 1993, CANC PRINCIPLES PRAC; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Feofanov A, 1997, BIOPHYS J, V73, P3328, DOI 10.1016/S0006-3495(97)78357-7; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H; JOHNSON WS, 1995, BIOORGAN MED CHEM, V3, P851, DOI 10.1016/0968-0896(95)00067-Q; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; Melki JR, 1999, CANCER RES, V59, P3730; MILLARD JT, 1993, BIOCHEMISTRY-US, V32, P12850, DOI 10.1021/bi00210a038; Myers CE, 1988, ANTHRACYCLINE ANTHRA, P527; Parker BS, 1999, NUCLEIC ACIDS RES, V27, P2918, DOI 10.1093/nar/27.14.2918; Parker BS, 2000, NUCLEIC ACIDS RES, V28, P982, DOI 10.1093/nar/28.4.982; PHILLIPS DR, 1997, DRUG DNA INTERACTION, P127; PRATT WB, 1994, ANTICANCER DRUGS; Szyf M, 2000, ANN NY ACAD SCI, V910, P156; THORNDIKE J, 1977, CANCER RES, V37, P1125; Vargason JM, 2000, NAT STRUCT BIOL, V7, P758; Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7	24	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15953	15960		10.1074/jbc.M009216200	http://dx.doi.org/10.1074/jbc.M009216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278477	hybrid			2022-12-27	WOS:000168623100053
J	Tiwari, S; Weissman, AM				Tiwari, S; Weissman, AM			Endoplasmic reticulum (ER)-associated degradation of T cell receptor subunits - Involvement of ER-associated ubiquitin-conjugating enzymes (E2s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; PROTEASOME; PROTEIN; MEMBRANE; IDENTIFICATION; PATHWAY; CHAINS; RETROTRANSLOCATION; LOCALIZATION; ANTIBODY	Degradation of proteins from the endoplasmic reticulum is fundamental to quality control within the secretory pathway, serves as a way of regulating levels of crucial proteins, and is utilized by viruses to enhance pathogenesis. In yeast two ubiquitin-conjugating enzymes (E2s), UBC6p and UBC7p are implicated in this process. We now report the characterization of murine homologs of these E2s. MmUBC6 is an integral membrane protein that is anchored via its hydrophobic C-terminal tail to the endoplasmic reticulum. MmUBC7, which is not an integral membrane protein, shows significant endoplasmic reticulum colocalization with MmUBC6. Overexpression of catalytically inactive MmUBC7 significantly delayed degradation from the endoplasmic reticulum of two T cell antigen receptor subunits, alpha and CD3-delta, and suggests a role for the ubiquitin conjugating system at the initiation of retrograde movement from the endoplasmic reticulum. These findings also implicate, for the first time, a specific E2 in degradation from the endoplasmic reticulum in mammalian cells.	NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weissman, AM (corresponding author), NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	amw@nih.gov						Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haas AL, 1997, FASEB J, V11, P1257; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Katsanis N, 1998, GENOMICS, V51, P128, DOI 10.1006/geno.1998.5263; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBO RT, 1989, J IMMUNOL, V142, P2736; Lin HJ, 1999, J BIOL CHEM, V274, P14685, DOI 10.1074/jbc.274.21.14685; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Pari G S, 1997, Methods Mol Biol, V62, P301; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	36	108	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16193	16200		10.1074/jbc.M007640200	http://dx.doi.org/10.1074/jbc.M007640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278356	hybrid			2022-12-27	WOS:000168623100084
J	Lee, J; Gravel, M; Gao, E; O'Neill, RC; Braun, PE				Lee, J; Gravel, M; Gao, E; O'Neill, RC; Braun, PE			Identification of essential residues in 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase - Chemical modification and site-directed mutagenesis to investigate the role of cysteine and histidine residues in enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPTIC-NERVE REGENERATION; RIBOSE 1'',2''-CYCLIC PHOSPHATE; MYELIN-ASSOCIATED ENZYME; AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; CDNA CLONING; CYCLIC PHOSPHODIESTERASE; MOLECULAR-CLONING; MESSENGER-RNAS; WHEAT-GERM	2',3'-Cyclic nucleotide 3'-phosphodiesterase (CNP; EC 3.1.4.37) catalyzes in vitro hydrolysis of 3'-phosphodiester bonds in 2',3'-cyclic nucleotides to produce 2'-nucleotides exclusively. N-terminal deletion mapping of the C-terminal two-thirds of recombinant rat CNP1 identified a region that possesses the catalytic domain, with further truncations abolishing activity. Proteolysis and kinetic analysis indicated that this domain forms a compact globular structure and contains all of the catalytically essential features. Subsequently, this catalytic fragment of CNP1 (CNP-CF) was used for chemical modification studies to identify amino acid residues essential for activity. 5,5'-Dithiobis-(2-nitrobenzoic acid) modification studies and kinetic analysis of cysteine CNP-CF mutants revealed the nonessential role of cysteines for enzymatic activity. On the other hand, modification studies with diethyl pyrocarbonate indicated that two histidines are essential for CNPase activity. Consequently, the only two conserved histidines, His-230 and His-309, were mutated to phenylalanine and leucine. All four histidine mutants had k(cat) values 1000-fold lower than wild-type CNP-CF, but K-m values were similar. Circular dichroism studies demonstrated that the low catalytic activities of the histidine mutants were not due to gross changes in secondary structure. Taken together, these results demonstrate that both histidines assume critical roles for catalysis.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Braun, PE (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.							Ballestero RP, 1997, J BIOL CHEM, V272, P11479; BALLESTERO RP, 1995, P NATL ACAD SCI USA, V92, P8621, DOI 10.1073/pnas.92.19.8621; Ballestero RP, 1999, J NEUROCHEM, V72, P1362, DOI 10.1046/j.1471-4159.1999.721362.x; BERNIER L, 1987, J NEUROSCI, V7, P2703; BIRCHMEIER W, 1973, J BIOL CHEM, V248, P1751; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN PE, 1990, ANN NY ACAD SCI, V605, P55, DOI 10.1111/j.1749-6632.1990.tb42380.x; BRAUN PE, 1988, J NEUROSCI, V8, P3057; BRAUN PE, 1991, J NEUROSCI RES, V30, P540, DOI 10.1002/jnr.490300311; Christendat D, 1996, BIOCHEMISTRY-US, V35, P4468, DOI 10.1021/bi9525637; CHURCH FC, 1985, J BIOL CHEM, V260, P4936; CULVER GM, 1994, J BIOL CHEM, V269, P24928; DEAKYNE CA, 1979, J AM CHEM SOC, V101, P3951, DOI 10.1021/ja00508a039; DEANGELIS DA, 1994, J NEUROSCI RES, V39, P386, DOI 10.1002/jnr.490390405; DeAngelis DA, 1996, J NEUROCHEM, V67, P943; DeAngelis DA, 1996, J NEUROCHEM, V66, P2523; DEGANI Y, 1974, J BIOL CHEM, V249, P7929; DOMANSKAJANIK K, 1987, NEUROTOXICOLOGY, V8, P23; DOUGLAS AJ, 1993, BIOCHEM SOC T, V21, P295, DOI 10.1042/bst0210295; DOUGLAS AJ, 1992, ANN HUM GENET, V56, P243, DOI 10.1111/j.1469-1809.1992.tb01149.x; DRUMMOND GI, 1962, J BIOL CHEM, V237, P3535; DYER CA, 1989, J NEUROSCI RES, V24, P201, DOI 10.1002/jnr.490240211; FUJIOKA M, 1987, BIOCHEMISTRY-US, V26, P5696, DOI 10.1021/bi00392a018; Genschik P, 1997, J BIOL CHEM, V272, P13211, DOI 10.1074/jbc.272.20.13211; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; GRAVEL M, 1994, J NEUROSCI RES, V38, P243, DOI 10.1002/jnr.490380302; Gravel M, 1996, MOL CELL NEUROSCI, V7, P453, DOI 10.1006/mcne.1996.0033; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; HUGLI TE, 1973, BRAIN RES, V58, P191, DOI 10.1016/0006-8993(73)90832-9; KasamaYoshida H, 1997, J NEUROCHEM, V69, P1335; KITZ R, 1962, J BIOL CHEM, V237, P3245; KURIHARA T, 1988, BIOCHEM BIOPH RES CO, V152, P837, DOI 10.1016/S0006-291X(88)80114-1; KURIHARA T, 1981, BIOCHEM J, V195, P153, DOI 10.1042/bj1950153; KURIHARA T, 1987, J BIOL CHEM, V262, P3256; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; LUNDBLAD RL, 1995, TECHNIQUES PROTEIN M, P110; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MONOH K, 1989, BIOCHEM BIOPH RES CO, V165, P1213, DOI 10.1016/0006-291X(89)92731-9; MULLER HW, 1981, J NEUROCHEM, V36, P2004, DOI 10.1111/j.1471-4159.1981.tb10826.x; NISHIZAWA Y, 1980, BIOCHEM J, V191, P71, DOI 10.1042/bj1910071; OLAFSON RW, 1969, CAN J BIOCHEM CELL B, V47, P961, DOI 10.1139/o69-151; PADGETTE SR, 1988, J BIOL CHEM, V263, P1798; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; Salleh HM, 1996, BIOCHEMISTRY-US, V35, P8942, DOI 10.1021/bi952373w; Scopes R. K., 1987, PROTEIN PURIFICATION, P280; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; SPRINKLE TJ, 1981, BRAIN RES, V214, P455, DOI 10.1016/0006-8993(81)91212-9; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; STARICH GH, 1980, LIFE SCI, V27, P567, DOI 10.1016/0024-3205(80)90305-7; STAUGAITIS SM, 1990, J NEUROSCI RES, V25, P556, DOI 10.1002/jnr.490250413; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; TSOU C, 1962, SCI SINICA, V11, P1535; Tsukada Yasuzo, 1992, P449; TYE K, 1987, J BIOL CHEM, V262, P12994; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; WEISSBARTH S, 1981, J NEUROCHEM, V37, P677; WILMOT GR, 1993, J NEUROSCI, V13, P387; WILSON R, 1989, J NEUROSCI RES, V22, P439, DOI 10.1002/jnr.490220409; Yin X, 1997, J NEUROSCI RES, V50, P238, DOI 10.1002/(SICI)1097-4547(19971015)50:2<238::AID-JNR12>3.0.CO;2-4	66	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14804	14813		10.1074/jbc.M009434200	http://dx.doi.org/10.1074/jbc.M009434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278504	hybrid			2022-12-27	WOS:000168528800038
J	Rigamonti, D; Sipione, S; Goffredo, D; Zuccato, C; Fossale, E; Cattaneo, E				Rigamonti, D; Sipione, S; Goffredo, D; Zuccato, C; Fossale, E; Cattaneo, E			Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE HOMOLOG; INCREASED APOPTOSIS; BRAIN; MICE; INACTIVATION; HDH	Huntington's Disease is an inherited neurodegenerative disease that affects the medium spiny neurons in the striatum. The disease is caused by the expansion of a polyglutamine sequence in the N terminus of Hunting-tin (Htt), a widely expressed protein. Recently, we have found that Htt is an antiapoptotic protein in striatal cells and acts by preventing caspase-3 activity. Here we report that Htt overexpression in other CNS-derived cells can protect them from more than 20 days exposure to fatal stimuli. In particular, we found that cytochrome c continues to be released from mitochondria into the cytosol of cells that overexpress normal Htt. However, procaspase-9 is not processed, indicating that wild-type Htt (wtHtt) acts downstream of cytochrome c release. These data show that Htt inhibits neuronal cell death by interfering with the activity of the apoptosome complex.	Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy	University of Milan	Cattaneo, E (corresponding author), Univ Milan, Inst Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.			CATTANEO, ELENA/0000-0002-0755-4917; ZUCCATO, CHIARA/0000-0003-1771-3392	Telethon [E.0840] Funding Source: Medline	Telethon(Fondazione Telethon)		Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Ehrlich ME, 2001, EXP NEUROL, V167, P215, DOI 10.1006/exnr.2000.7551; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; O'Kusky JR, 1999, BRAIN RES, V818, P468, DOI 10.1016/S0006-8993(98)01312-2; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	19	121	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14545	14548		10.1074/jbc.C100044200	http://dx.doi.org/10.1074/jbc.C100044200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278258	hybrid, Green Published			2022-12-27	WOS:000168528800004
J	Bostrom, K; Tsao, D; Shen, S; Wang, Y; Demer, LL				Bostrom, K; Tsao, D; Shen, S; Wang, Y; Demer, LL			Matrix GLA protein modulates differentiation induced by done morphogenetic protein-2 in C3H10T1/2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL PROGENITORS C3H10T1/2; ALPHA-1(IX) COLLAGEN CHAIN; TGF-BETA; OSTEOBLASTIC DIFFERENTIATION; EXPRESSION; MOUSE; CDNA; CARTILAGE; RECEPTOR; GENE	Matrix GLA protein (MGP) is ubiquitously expressed with high accumulation in bone and cartilage, where it was found to associate with bone morphogenetic proteins (BMP) during protein purification. To test whether MGP affects BMP-induced differentiation, three sets of experiments were performed. First, pluripotent C3H10T1/2 cells transfected with human MPG (hMGP) or antisense to hMGP (AS-hMGP) were treated with BMP-2. In cells overexpressing hMGP, osteogenic and chondrogenic differentiation was inhibited indicating decreased BMP-2 activity. Conversely, in cells overexpressing AS-hMGP, BMP-2 activity was enhanced. Second, cells were prepared from homozygous and heterozygous MPG-deficient mice aortas. When treated with BMP-2, these cells underwent chondrogenic and osteogenic differentiation, respectively, whereas controls did not. Third, FLAG-tagged hMGP with the same biological effect as native hMGP inhibited BMP-induced differentiation, when exogenously added to culture media. Together, these results suggest that MGP modulates BMP activity. To test whether hMGP fragments would retain the effect of full-length hMGP, three subdomains were overexpressed in C3H10T1/2 cells, In cells expressing the mid-region, alone (amino acids (aa) 35-54) or in combination with the N terminus (aa 1-54) but not the C terminus (aa 35-84), osteogenic differentiation was enhanced and occurred even without added BMP-2. Thus, two subdomains had the opposite effect of full-length hMGP, possibly due to different expression levels or domain characteristics.	Univ Calif Los Angeles, Sch Med, Div Cardiol, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bostrom, K (corresponding author), Univ Calif Los Angeles, Sch Med, Div Cardiol, Dept Med, Box 951679,Rm 47-123 CHS, Los Angeles, CA 90095 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	PHS HHS [04270, 30568] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABE N, 1994, BBA-PROTEIN STRUCT M, V1204, P61, DOI 10.1016/0167-4838(94)90033-7; ASAHINA I, 1993, J CELL BIOL, V123, P921, DOI 10.1083/jcb.123.4.921; Bachner D, 1998, DEV DYNAM, V213, P398; Balica M, 1997, CIRCULATION, V95, P1954; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Butterwith S. C., 1996, BIOCHEM SOC T, V24, p163S; Cancela ML, 1997, J CELL PHYSIOL, V171, P125, DOI 10.1002/(SICI)1097-4652(199705)171:2<125::AID-JCP2>3.0.CO;2-Q; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHEN L, 1990, ONCOGENE, V5, P1391; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P115; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; HALE JE, 1988, J BIOL CHEM, V263, P5820; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; IKEDA T, 1991, J BONE MINER RES, V6, P1013; Kaps C, 1998, BIOCHEM SOC T, V26, P27, DOI 10.1042/bst0260027; KIEFER MC, 1988, NUCLEIC ACIDS RES, V16, P5213, DOI 10.1093/nar/16.11.5213; KOLETTAS E, 1995, J CELL SCI, V108, P1991; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUO GB, 1995, J BONE MINER RES, V10, P325; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PRICE PA, 1985, J BIOL CHEM, V260, P4971; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WARMAN M, 1993, MATRIX, V13, P149, DOI 10.1016/S0934-8832(11)80073-9; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097	35	186	187	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14044	14052		10.1074/jbc.M008103200	http://dx.doi.org/10.1074/jbc.M008103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278388	hybrid			2022-12-27	WOS:000168356600074
J	Furukawa, Y; Morishima, I				Furukawa, Y; Morishima, I			The role of water molecules in the association of cytochrome P450cam with putidaredoxin - An osmotic pressure study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN RECOGNITION; ELECTRON-TRANSFER COMPLEX; C-TERMINAL REGION; REDUCED PUTIDAREDOXIN; BOUND WATER; SURFACE RESIDUES; REDOX PARTNERS; BINDING; REDUCTASE; DNA	We have investigated the osmotic pressure dependence of the association between ferric cytochrome P450cam and putidaredoxin (Pdx) to gain an insight into the role of water molecules in the P450cam-reduced Pdx complexation amenable to physiological electron transfer. The association constant was evaluated from the electron transfer rates from reduced Pdx to P450cam. The natural logarithm of the association constant K, was linearly reduced by the osmotic pressure, and osmotic stress yields uptake of 25 waters upon association. In contrast, uptake of only 13 waters is observed from the osmotic pressure dependence of the association in the nonphysiological redox partners P450cam and oxidized Pdx, Although general protein-protein associations proceed through dehydration around the complex interface, the interfacial waters could mediate hydrogen-bonding interactions. Therefore, about 10 more interfacial waters imply an additional water-mediated hydrogen-bonding network in the P450cam.reduced Pdx complex, which does not exist in the complex with oxidized Pdx, It is also possible that the water-mediated hydrogen-bonding interactions support a high P450cam affinity for reduced (K-alpha = 0.83 muM(-1)) relative to oxidized (K-a = 0.058 muM(-1)) Pdx. This study points to a novel role of solvents in assisting redox state-dependent interaction between P450cam and Pdx.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan	Kyoto University	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.	morisima@mds.moleng.kyoto-u.ac.jp	Furukawa, Yoshiaki/F-2871-2014	Furukawa, Yoshiaki/0000-0002-1918-372X				Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P157, DOI 10.1016/S0167-4838(98)00094-6; Aoki M, 1998, BBA-PROTEIN STRUCT M, V1384, P180, DOI 10.1016/S0167-4838(98)00017-X; Aoki M, 1998, INORG CHIM ACTA, V272, P80, DOI 10.1016/S0020-1693(97)05946-X; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; DIPRIMO C, 1995, BIOPHYS J, V68, P2056, DOI 10.1016/S0006-3495(95)80384-X; DIPRIMO C, 1992, FEBS LETT, V312, P252, DOI 10.1016/0014-5793(92)80946-E; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; Furukawa Y, 2000, BIOCHEMISTRY-US, V39, P10996, DOI 10.1021/bi000874y; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HARRIS D, 1993, J AM CHEM SOC, V115, P8775, DOI 10.1021/ja00072a034; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; JELESAROV I, 1994, BIOCHEMISTRY-US, V33, P13321, DOI 10.1021/bi00249a019; KIDO T, 1979, J BIOL CHEM, V254, P1806; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; KORNBLATT JA, 1993, BIOPHYS J, V65, P1059, DOI 10.1016/S0006-3495(93)81168-8; KORNBLATT MJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P495, DOI 10.1006/abbi.1993.1542; KRESHECK GC, 1995, BIOCHEMISTRY-US, V34, P8398, DOI 10.1021/bi00026a022; Langhorst U, 2000, BIOCHEMISTRY-US, V39, P6586, DOI 10.1021/bi992131m; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MAUK MR, 1982, BIOCHEMISTRY-US, V21, P1843, DOI 10.1021/bi00537a021; Mueller Ernest J., 1995, P83; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6433, DOI 10.1021/bi00187a007; Pochapsky TC, 1999, BIOCHEMISTRY-US, V38, P4681, DOI 10.1021/bi983030b; RAND RP, 1993, BIOCHEMISTRY-US, V32, P5925, DOI 10.1021/bi00074a001; Robinson CR, 1996, PROTEIN SCI, V5, P2119, DOI 10.1002/pro.5560051019; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P2186, DOI 10.1073/pnas.95.5.2186; Roitberg AE, 1998, J AM CHEM SOC, V120, P8927, DOI 10.1021/ja9739906; Roitberg AE, 1997, BIOPHYS J, V73, P2138, DOI 10.1016/S0006-3495(97)78244-4; Sari N, 1999, BIOCHEMISTRY-US, V38, P9862, DOI 10.1021/bi9906423; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; WEAST RC, 1997, CRC HDB CHEM PHYSICS, pD228; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; Xavier KA, 1997, BIOPHYS J, V73, P2116, DOI 10.1016/S0006-3495(97)78242-0	53	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12983	12990		10.1074/jbc.M010217200	http://dx.doi.org/10.1074/jbc.M010217200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278642	hybrid			2022-12-27	WOS:000168198600075
J	Rogers, GW; Lima, WF; Merrick, WC				Rogers, GW; Lima, WF; Merrick, WC			Further characterization of the helicase activity of eIF4A - Substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX RNA HELICASE; INITIATION-FACTOR 4A; NUCLEOSIDE TRIPHOSPHATE PHOSPHOHYDROLASE; VIRUS NONSTRUCTURAL PROTEIN-3; TRANSLATION INITIATION; MESSENGER-RNA; MUTATIONAL ANALYSIS; ANTISENSE OLIGONUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; KINETIC CHARACTERIZATION	Eukaryotic initiation factor (eIF) 4A is the archetypal member of the DEAD box family of RNA helicases and is proposed to unwind structures in the 5 ' -untranslated region of mRNA to facilitate binding of the 40 S ribosomal subunit. The helicase activity of eIF4A has been further characterized with respect to substrate specificity and directionality. Results confirm that the initial rate and amplitude of duplex unwinding by eIF4A is dependent on the overall stability, rather than the length or sequence, of the duplex substrate. eIF4A helicase activity is minimally dependent on the length of the single-stranded region adjacent to the double-stranded region of the substrate. Interestingly, eIF4A is able to unwind blunt-ended duplexes. eIF4A helicase activity is also affected by substitution of 2 ' -OH (RNA) groups with 2 ' -H (DNA) or 2 ' -methoxyethyl groups. These observations, taken together with results from competitive inhibition experiments, suggest that eIF4A may interact directly with double-stranded RNA, and recognition of helicase substrates occurs via chemical and/or structural features of the duplex. These results allow for refinement of a previously proposed model for the mechanism of action of eIF4A helicase activity.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Case Western Reserve University; Isis Pharmaceuticals Inc	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wcma@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07319] Funding Source: Medline; NIGMS NIH HHS [GM26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Altmann KH, 1996, BIOCHEM SOC T, V24, P630, DOI 10.1042/bst0240630; Altmann KH, 1996, CHIMIA, V50, P168; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; CROOKE ST, 1995, THERAPEUTIC APPL OLI, P53; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; GOSS DJ, 1987, BIOCHEMISTRY-US, V26, P1551, DOI 10.1021/bi00380a009; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; Gross CH, 1996, J VIROL, V70, P2615, DOI 10.1128/JVI.70.4.2615-2619.1996; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Gwack Y, 1999, J VIROL, V73, P2909, DOI 10.1128/JVI.73.4.2909-2915.1999; Hesson T, 2000, BIOCHEMISTRY-US, V39, P2619, DOI 10.1021/bi992127a; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Johnson ER, 1999, RNA, V5, P1526, DOI 10.1017/S1355838299991410; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick WC., 1996, TRANSLATION CONTROL, P31; Okanami M, 1998, NUCLEIC ACIDS RES, V26, P2638, DOI 10.1093/nar/26.11.2638; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Peck ML, 1999, RNA, V5, P1210, DOI 10.1017/S1355838299990817; Richter NJ, 1999, J BIOL CHEM, V274, P35415, DOI 10.1074/jbc.274.50.35415; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stauber N, 1997, J VIROL, V71, P7220; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Teplova M, 1999, NAT STRUCT BIOL, V6, P535; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; Valdez BC, 1997, EUR J BIOCHEM, V250, P800, DOI 10.1111/j.1432-1033.1997.00800.x; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; Zhong WD, 1999, VIROLOGY, V261, P216, DOI 10.1006/viro.1999.9871	58	109	112	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12598	12608		10.1074/jbc.M007560200	http://dx.doi.org/10.1074/jbc.M007560200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278350	hybrid			2022-12-27	WOS:000168198600019
J	Sazonova, IY; Houng, AK; Chowdhry, SA; Robinson, BR; Hedstrom, L; Reed, GL				Sazonova, IY; Houng, AK; Chowdhry, SA; Robinson, BR; Hedstrom, L; Reed, GL			The mechanism of a bacterial plasminogen activator intermediate between streptokinase and staphylokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING REGION; DOMAIN; KINETICS; SITE; PURIFICATION; COMPLEXES; TRYPSIN; PLASMA; STATE	The therapeutic properties of plasminogen activators are dictated by their mechanism of action. Unlike staphylokinase, a single domain protein, streptokinase, a 3-domain (alpha, beta, and gamma) molecule, nonproteolytically activates human (h)-plasminogen and protects plasmin from inactivation by alpha (2)-antiplasmin. Because a streptokinase-like mechanism was hypothesized to require the streptokinase gamma -domain, we examined the mechanism of action of a novel two-domain (alpha,beta) Streptococcus uberis plasminogen activator (SUPA), Under conditions that quench trace plasmin, SUPA nonproteolytically generated an active site in bovine (b)-plasminogen, SUPA also competitively inhibited the inactivation of plasmin by alpha (2)-antiplasmin, Still, the lag phase in active site generation and plasminogen activation by SUPA was at least 8-fold longer than that of streptokinase. Recombinant streptokinase gamma -domain bound to the b-plasminogen SUPA complex and significantly reduced these lag phases. The SUPA-b.plasmin complex activated b-plasminogen with kinetic parameters comparable to those of streptokinase for h-plasminogen. The SUPA-b.plasmin complex also activated h-plasminogen but with a lower k(cat) (25-fold) and k(cat)/K-m (7.9-fold) than SK. We conclude that a gamma -domain is not required for a streptokinase-like activation of b-plasminogen, However, the streptokinase gamma -domain enhances the rates of active site formation in b-plasminogen and this enhancing effect may be required for efficient activation of plasminogen from other species.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Brandeis Univ, Grad Dept Biochem, Waltham, MA 02453 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Brandeis University	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, HSPH 2-127,677 Huntington Ave, Boston, MA 02115 USA.	reed@cvlab.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057314] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57314] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BUCK FF, 1968, J BIOL CHEM, V243, P3648; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; CHIBBER BAK, 1986, P NATL ACAD SCI USA, V83, P1237, DOI 10.1073/pnas.83.5.1237; COLLEN D, 1993, EUR J BIOCHEM, V216, P307, DOI 10.1111/j.1432-1033.1993.tb18147.x; COLLEN D, 1993, J BIOL CHEM, V268, P8284; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Johnsen LB, 1999, INFECT IMMUN, V67, P1072, DOI 10.1128/IAI.67.3.1072-1078.1999; Johnsen LB, 2000, BIOCHEMISTRY-US, V39, P6440, DOI 10.1021/bi9922502; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LEIGH JA, 1993, FEMS MICROBIOL LETT, V114, P67, DOI 10.1111/j.1574-6968.1993.tb06552.x; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; Peisach E, 1999, BIOCHEMISTRY-US, V38, P11180, DOI 10.1021/bi991130r; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; REED GL, 1993, J IMMUNOL, V150, P4407; Rosey EL, 1999, FEMS MICROBIOL LETT, V178, P27, DOI 10.1111/j.1574-6968.1999.tb13755.x; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; SAZONOVA I, UNPUB; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Wang XQ, 1999, FEBS LETT, V459, P85, DOI 10.1016/S0014-5793(99)01214-4; Wang XQ, 2000, J MOL BIOL, V295, P903, DOI 10.1006/jmbi.1999.3397; WOHL RC, 1983, BIOCHIM BIOPHYS ACTA, V745, P20, DOI 10.1016/0167-4838(83)90165-6; WOHL RC, 1978, J BIOL CHEM, V253, P1402; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110	34	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12609	12613		10.1074/jbc.M009265200	http://dx.doi.org/10.1074/jbc.M009265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278483	hybrid			2022-12-27	WOS:000168198600020
J	Klussmann, E; Tamma, G; Lorenz, D; Wiesner, B; Maric, K; Hofmann, F; Aktories, K; Valenti, G; Rosenthal, W				Klussmann, E; Tamma, G; Lorenz, D; Wiesner, B; Maric, K; Hofmann, F; Aktories, K; Valenti, G; Rosenthal, W			An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; WATER PERMEABILITY RESPONSE; RABBIT COLLECTING TUBULES; GTP-BINDING PROTEINS; MAST-CELLS; ACTIN CYTOSKELETON; CHROMAFFIN CELLS; F-ACTIN; ANCHORING PROTEINS; SECRETORY GRANULES	Vasopressin regulates water reabsorption in renal collecting duct principal cells by a cAMP-dependent translocation of the water channel aquaporin-2 (AQP2) from intracellular vesicles into the cell membrane. In the present work primary cultured inner medullary collecting duct cells were used to study the role of the proteins of the Rho family in the translocation of AQP2. Clostridium difficile toxin B, which inhibits all members of the Rho family, Clostridium limosum C3 toxin, which inactivates only Rho, and the Rho kinase inhibitor, Y-27632, induced both depolymerization of actin stress fibers and AQP2 translocation in the absence of vasopressin. The data suggest an inhibitory role of Rho in this process, whereby constitutive membrane localization is prevented in resting cells. Expression of constitutively active RhoA induced formation of actin stress fibers and abolished AQP2 translocation in response to elevation of intracellular cAMP, confirming the inhibitory role of Rho, Cytochalasin D induced both depolymerization of the F-actin cytoskeleton and AQP2 translocation, indicating that depolymerization of F-actin is sufficient to induce AQP2 translocation. Thus Rho is likely to control the intracellular localization of AQP2 via regulation of the F-actin cytoskeleton.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Freiburg, Inst Pharmakol & Toxicol, D-79104 Freiburg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Universita degli Studi di Bari Aldo Moro; University of Freiburg; Free University of Berlin	Klussmann, E (corresponding author), Forschungsinst Mol Pharmakol, Campus Berlin Buch,Robert Rossle Str 10, D-13125 Berlin, Germany.		Aktories, Klaus/CAJ-5682-2022; Tamma, Grazia/F-8823-2016	Aktories, Klaus/0000-0002-5397-0436; Tamma, Grazia/0000-0002-8890-0278; VALENTI, GIOVANNA/0000-0003-0233-0778				Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; Djouder N, 2000, J BIOL CHEM, V275, P18732, DOI 10.1074/jbc.M001425200; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lerm M, 2000, FEMS MICROBIOL LETT, V188, P1; LIEBENHOFF U, 1995, FEBS LETT, V365, P209, DOI 10.1016/0014-5793(95)00476-P; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; Maric K, 2001, BIOPHYS J, V80, P1783, DOI 10.1016/S0006-3495(01)76148-6; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEARL M, 1983, AM J PHYSIOL, V245, pC28, DOI 10.1152/ajpcell.1983.245.1.C28; PHILLIPS ME, 1989, J PHYSIOL-LONDON, V411, P529, DOI 10.1113/jphysiol.1989.sp017588; PHILLIPS ME, 1992, J PHYSIOL-LONDON, V456, P591, DOI 10.1113/jphysiol.1992.sp019355; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Rose F, 1999, AM J RESP CRIT CARE, V159, P206, DOI 10.1164/ajrccm.159.1.9801106; Schulein R, 1998, FEBS LETT, V441, P170, DOI 10.1016/S0014-5793(98)01519-1; SIMON H, 1993, AM J PHYSIOL, V265, pC757, DOI 10.1152/ajpcell.1993.265.3.C757; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; TAYLOR A, 1973, SCIENCE, V181, P347, DOI 10.1126/science.181.4097.347; UEDA T, 1990, J BIOL CHEM, V265, P9373; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Valenti G, 2000, J CELL SCI, V113, P1985; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; Valenti G, 1998, J BIOL CHEM, V273, P22627, DOI 10.1074/jbc.273.35.22627; Valenti G, 1997, J BIOL CHEM, V272, P26794; VALENTI G, 1988, AM J PHYSIOL, V255, pF1098, DOI 10.1152/ajprenal.1988.255.6.F1098; VAN AL, 1997, GENE DEV, V11, P2295; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vitale N, 2000, BIOCHIMIE, V82, P365, DOI 10.1016/S0300-9084(00)00198-X; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x	51	135	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20451	20457		10.1074/jbc.M010270200	http://dx.doi.org/10.1074/jbc.M010270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278652	Green Published, hybrid			2022-12-27	WOS:000169135100105
J	Ito, Y; Pandey, P; Sathyanarayana, P; Ling, P; Rana, A; Weichselbaum, R; Tan, TH; Kufe, D; Kharbanda, S				Ito, Y; Pandey, P; Sathyanarayana, P; Ling, P; Rana, A; Weichselbaum, R; Tan, TH; Kufe, D; Kharbanda, S			Interaction of hematopoietic progenitor kinase 1 and c-abl tyrosine kinase in response to genotoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; GERMINAL CENTER KINASE; TUMOR-NECROSIS-FACTOR; BETA SIGNAL-TRANSDUCTION; DAMAGE-INDUCED APOPTOSIS; DNA-DAMAGE; IONIZING-RADIATION; 1-BETA-D-ARABINOFURANOSYLCYTOSINE INCORPORATION; CELLULAR-RESPONSE	The c-Abl protein tyrosine kinase is activated by certain DNA-damaging agents and regulates induction of the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK). The hematopoietic progenitor kinase 1 (HPK1) has also been shown to act upstream to the SAPK/JNK signaling pathway. We report here that exposure of hematopoietic Jurkat T cells to genotoxic agents is associated with activation of HPK1. The results demonstrate that exposure of Jurkat cells to DNA-damaging agents is associated with translocation of active c-Abl from nuclei to cytoplasm and binding of c-Abl to HPK1. Our findings also demonstrate that c-Abl phosphorylates HPK1 in cytoplasm and stimulates HPK1 activity. The functional significance of the c-Abl-HPK1 interaction is supported by the demonstration that this complex regulates SAPK/JNK activation. Overexpression of c-Abl(K-R) inhibits HPK1-induced activation of SAPK/JNK. Conversely, the dominant negative mutant of HPK1 blocks c-Abl-mediated induction of SAPK/JNK. These findings indicate that activation of HPK1 and formation of HPK1/c-Abl complexes are functionally important in the stress response of hematopoietic cells to genotoxic agents.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Mol Biol,Diabet Res Lab, Boston, MA 02114 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Chicago; Baylor College of Medicine	Kharbanda, S (corresponding author), ILEX Oncol Inc, 20 Overland St, Boston, MA 02215 USA.	skharbanda@ilexonc.com	Tan, Tse-Hua/E-3983-2010; Rana, Ajay/ABE-3739-2020; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Rana, Ajay/0000-0003-0951-2566; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL CANCER INSTITUTE [R01CA075216, R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29431, CA75216, CA 55241] Funding Source: Medline; NIAID NIH HHS [AI8738649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hirai S, 1996, ONCOGENE, V12, P641; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OHNO Y, 1988, CANCER RES, V48, P1494; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	60	13	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18130	18138		10.1074/jbc.M007294200	http://dx.doi.org/10.1074/jbc.M007294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278340	hybrid			2022-12-27	WOS:000168866500070
J	Tuganova, A; Yoder, MD; Popov, KM				Tuganova, A; Yoder, MD; Popov, KM			An essential role of Glu-243 and His-239 in the phosphotransfer reaction catalyzed by pyruvate dehydrogenase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90 MOLECULAR CHAPERONE; HISTIDINE KINASE; PROTEIN-KINASE; BINDING PROTEIN; ATP BINDING; IN-VIVO; EXPRESSION; PHOSPHORYLATION; INHIBITION; COMPLEX	This study was undertaken to examine the mechanistic significance of two highly conserved residues positioned in the active site of pyruvate dehydrogenase kinase, Glu-243 and His-239. We used site-directed mutagenesis to convert Glu-243 to Ale, Asp, or Gin and His-239 to Ala. The resulting mutant kinases demonstrated a greatly reduced capacity for phosphorylation of pyruvate dehydrogenase, The Glu-243 to Asp mutant had similar to2% residual activity, whereas the Glu-243 to Ala or Gin mutants exhibited less than 0.5 and 0.1% residual activity, respectively. Activity of the His-239 to Ala mutant was decreased by similar to 90%. Active-site titration with [alpha-P-32]ATP revealed that neither Glu-243 nor His-239 mutations affected nucleotide binding. All mutant kinases showed similar or even somewhat greater affinity than the wild-type kinase toward the protein substrate, pyruvate dehydrogenase complex. Furthermore, neither of the mutations affected the inter-subunit interactions. Finally, pyruvate dehydrogenase kinase was found to possess a weak ATP hydrolytic activity, which required Glu-243 and His-239 similar to the kinase activity. Based on these observations, we propose a mechanism according to which the invariant glutamate residue (Glu-243) acts as a general base catalyst, which activates the hydroxyl group on a serine residue of the protein substrate for direct attack on the gamma phosphate. The glutamate residue in turn might be further polarized through interaction with the neighboring histidine residue (His-239).	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City	Popov, KM (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5110 Rockhill Rd, Kansas City, MO 64110 USA.				NIDDK NIH HHS [R01 DK056898, DK 56898] Funding Source: Medline; NIGMS NIH HHS [R29 GM051262, GM 51262, R01 GM051262-09, R01 GM051262] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Jeng JJ, 1998, COMP BIOCHEM PHYS B, V120, P205, DOI 10.1016/S0305-0491(98)10010-X; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLL GW, 1976, J BIOL CHEM, V251, P3993; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PAUDEL HK, 1991, J BIOL CHEM, V266, P16524; Popov KM, 1997, FEBS LETT, V419, P197, DOI 10.1016/S0014-5793(97)01453-1; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; PRATT ML, 1979, J BIOL CHEM, V254, P7191; RANDLE PJ, 1995, P NUTR SOC, V54, P317, DOI 10.1079/PNS19950057; Robinson VL, 2000, NAT STRUCT BIOL, V7, P626, DOI 10.1038/77915; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; SALE GJ, 1982, BIOCHEM J, V203, P99, DOI 10.1042/bj2030099; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; STEPP LR, 1983, J BIOL CHEM, V258, P9454; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; Thelen JJ, 2000, BIOCHEM J, V349, P195, DOI 10.1042/0264-6021:3490195; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197	35	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17994	17999		10.1074/jbc.M009327200	http://dx.doi.org/10.1074/jbc.M009327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278487	hybrid, Green Accepted			2022-12-27	WOS:000168866500051
J	Cutrone, EC; Langer, JA				Cutrone, EC; Langer, JA			Identification of critical residues in bovine IFNAR-1 responsible for interferon binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-INTERFERON; HUMAN GROWTH-HORMONE; HUMAN TISSUE FACTOR; HUMAN IFN-ALPHA; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; HIGH-AFFINITY; BETA RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-BASIS	Interferons have antiviral, antigrowth and immunomodulatory effects. The human type I interferons, IFN-alpha, IFN-beta, and IFN-omega, induce somewhat different cellular effects but act through a common receptor complex, IFNAR, composed of subunits IFNAR-1 and IFNAR-2. Human IFNAR-2 binds all type I IFNs but with lower affinity and different specificity than the IFNAR complex, Human IFNAR-1 has low intrinsic binding of human IFNs but strongly affects the affinity and differential ligand specificity of the IFNAR complex. Understanding IFNAR-1 interactions with the interferons is critical to elucidating the differential ligand specificity and activation by type I IFNs. However, studies of ligand interactions with human IFNAR-1 are compromised by its low affinity. The homologous bovine IFNAR-1 serendipitously binds human IFN-alphas with nanomolar affinity. Exploiting its strong binding of human IFN-alpha2, we have identified residues important for ligand binding. Mutagenesis of any of five aromatic residues of bovine IFNAR-1 caused strong decreases in ligand binding, whereas mutagenesis of proximal neutral or charged residues had smaller effects. These residues were mapped onto a homology model of IFNAR-1 to identify the ligand-binding face of IFNAR-1, which is consistent with previous structure/function studies of human IFNAR-1. The topology of IFNAR-1/IFN interactions appears novel when compared with previously studied cytokine receptors.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Langer, JA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes LN, Piscataway, NJ 08854 USA.	langer@umdnj.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007403] Funding Source: NIH RePORTER; NIAID NIH HHS [IH AI07403-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen G, 1996, J INTERF CYTOK RES, V16, P181, DOI 10.1089/jir.1996.16.181; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1995, NATURE, V376, P217; BENOIT P, 1993, J IMMUNOL, V150, P707; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; Eid P, 2000, EUR CYTOKINE NETW, V11, P560; EID P, 1995, J INTERF CYTOK RES, V15, P205, DOI 10.1089/jir.1995.15.205; FLORES I, 1991, J BIOL CHEM, V266, P19875; GABORIAUD C, 1990, FEBS LETT, V269, P1, DOI 10.1016/0014-5793(90)81103-U; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Goldman LA, 1998, BIOCHEMISTRY-US, V37, P13003, DOI 10.1021/bi980073j; Hayes M P, 1994, Prog Drug Res, V43, P239; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hwang SY, 1996, INT J BIOCHEM CELL B, V28, P911, DOI 10.1016/1357-2725(96)00023-4; Karpusas M, 1998, CELL MOL LIFE SCI, V54, P1203, DOI 10.1007/s000180050248; Kossiakoff AA, 1999, ADV PROTEIN CHEM, V52, P67; Kumaran J, 2000, J INTERF CYTOK RES, V20, P479, DOI 10.1089/10799900050023898; Langer J, 1996, BIOTHERAPY, V8, P163, DOI 10.1007/BF01877201; Langer JA, 1998, FEBS LETT, V421, P131, DOI 10.1016/S0014-5793(97)01550-0; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIM JK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P314, DOI 10.1016/0167-4781(93)90129-2; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lu J, 1998, J IMMUNOL, V160, P1782; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; MOUCHELVIELH E, 1992, FEBS LETT, V313, P255, DOI 10.1016/0014-5793(92)81204-Y; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; Nguyen NY, 1996, J INTERF CYTOK RES, V16, P835, DOI 10.1089/jir.1996.16.835; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; NOVICK D, 1992, FEBS LETT, V314, P445, DOI 10.1016/0014-5793(92)81523-O; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Prejean C, 2000, SEMIN CANCER BIOL, V10, P83, DOI 10.1006/scbi.2000.0311; REHBERG E, 1982, J BIOL CHEM, V257, P1497; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SETO MH, 1995, PROTEIN SCI, V4, P655; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; Thiel DJ, 2000, STRUCTURE, V8, P927, DOI 10.1016/S0969-2126(00)00184-2; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; ZOON K, 1982, J BIOL CHEM, V257, P4695; ZOON KC, 1984, PHARMACOL THERAPEUT, V24, P259, DOI 10.1016/0163-7258(84)90037-8; ZOON KC, 1992, J BIOL CHEM, V267, P15210	70	38	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17140	17148		10.1074/jbc.M009663200	http://dx.doi.org/10.1074/jbc.M009663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278538	hybrid			2022-12-27	WOS:000168730400073
J	Hill, KM; Huang, YH; Yip, SC; Yu, JH; Segall, JE; Backer, JM				Hill, KM; Huang, YH; Yip, SC; Yu, JH; Segall, JE; Backer, JM			N-terminal domains of the class IA phosphoinositide 3-kinase regulatory subunit play a role in cytoskeletal but not mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ADP-RIBOSYLATION FACTOR-6; PHOSPHATIDYLINOSITOL 3-KINASE; ARP2/3 COMPLEX; ACTIN REORGANIZATION; P85-ALPHA SUBUNIT; CELL-MIGRATION; RHO-GTPASE; ACTIVATION; KINASE	Phosphoinositide (PI) 3-kinases are required for the acute regulation of the cytoskeleton by growth factors. We have shown previously that in the MTLn3 rat adenocarcinoma cells line, the p85/p110 alpha PI 3-kinase is required for epidermal growth factor (EGF)-stimulated lamellipod extension and formation of new actin barbed ends at the leading edge of the cell. We have now examined the role of the p85 alpha regulatory subunit in greater detail. Microinjection of recombinant p85 alpha into MTLn3 cells blocked both EGF-stimulated mitogenic signaling and lamellipod extension. In contrast, a truncated p85(1-333), which lacks the SH2 and iSH2 domains and does not bind p110, had no effect on EGF-stimulated mitogenesis but still blocked EGF-stimulated lamellipod extension. Additional deletional analysis showed that the SH3 domain was not required for inhibition of lamellipod extension, as a construct containing only the proline-rich and breakpoint cluster region (BCR) homology domains was sufficient for inhibition. Although the BCR domain of p85 binds Rac, the effects of the p85 constructs were not because of a general inhibition of Rac signaling, because sorbitol-induced JNK activation in MTLn3 cells was not inhibited. These data show that the proline-rich and BCR homology domains of p85 are involved in the coupling of p85/p110 PI 5-kinases to regulation of the actin cytoskeleton. These data provide evidence of a distinct cellular function for the N-terminal domains of p85.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Backer, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM556982, 5T32 GM07260] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Bhargavi V, 1998, BIOCHEM MOL BIOL INT, V46, P241; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee KH, 2000, EUR J IMMUNOL, V30, P892, DOI 10.1002/1521-4141(200003)30:3<892::AID-IMMU892>3.0.CO;2-U; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Pasteris NG, 1999, GENOMICS, V60, P57, DOI 10.1006/geno.1999.5903; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Shin BC, 1998, BIOCHEM BIOPH RES CO, V246, P313, DOI 10.1006/bbrc.1998.8606; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang Q, 1999, MOL CELL BIOL, V19, P8158; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	44	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16374	16378		10.1074/jbc.M006985200	http://dx.doi.org/10.1074/jbc.M006985200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278326	hybrid			2022-12-27	WOS:000168623100107
J	Klausberger, T; Ehya, N; Fuchs, K; Fuchs, T; Ebert, V; Sarto, I; Sieghart, W				Klausberger, T; Ehya, N; Fuchs, K; Fuchs, T; Ebert, V; Sarto, I; Sieghart, W			Detection and binding properties of GABA(A) receptor assembly intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTORS; ALLOSTERIC LIGANDS; GAMMA-SUBUNIT; CHANNEL; EXPRESSION; STOICHIOMETRY; PROTEIN; SITE; OLIGOMERIZATION; IDENTIFICATION	Density gradient centrifugation of native and recombinant gamma -aminobutyric acid, type A (GABA(A)) receptors was used to detect assembly intermediates. No such intermediates could be identified in extracts from adult rat brain or from human embryonic kidney (HEK) 293 cells transfected with alpha (1), beta (3), and gamma (2) subunits and cultured at 37 degreesC. However, subunit dimers, trimers, tetramers, and pentamers were found in extracts from the brain of 8-10-day-old rats and from alpha (1)beta (3)gamma (2) transfected HEK cells cultured at 25 degreesC. In both systems, alpha (1), beta (3), and gamma (2) , subunits could be identified in subunit dimers, indicating that different subunit dimers are formed during GABA(A) receptor assembly. Co-transfection of HEK cells with various combinations of full-length and C-terminally truncated alpha (1) and beta (3) or alpha (1) and gamma (2) subunits and coimmunoprecipitation with subunit-specific antibodies indicated that even subunits containing no transmembrane domain can assemble with each other. Whereas alpha (1)gamma (2), alpha N-1 gamma (2), alpha (1)gamma N-2, and alpha N-1 gamma N-2, combinations exhibited specific [H-3]Ro 15-1788 binding, specific [H-3]muscimol binding could only be found in alpha (1)beta (3) and alpha (1)beta N-3, but not in alpha N-1 beta (3) or alpha N-1 beta N-3 combinations. This seems to indicate that a full-length alpha (1) subunit is necessary for the formation of the muscimol-binding site and for the transduction of agonist binding into channel gating.	Univ Vienna, Brain Res Inst, Div Biochem & Mol Biol, A-1090 Vienna, Austria; Univ Clin Psychiat, Sect Biochem Psychiat, A-1090 Vienna, Austria	University of Vienna	Sieghart, W (corresponding author), Univ Vienna, Brain Res Inst, Div Biochem & Mol Biol, Spitalgasse 4, A-1090 Vienna, Austria.		Ebert, Volker/I-6604-2019; Sieghart, Werner/A-4877-2013	Ebert, Volker/0000-0002-1394-3097; Sieghart, Werner/0000-0002-0443-0302				Barnard EA, 1998, PHARMACOL REV, V50, P291; BERTRAND D, 1995, SEMIN NEUROSCI, V7, P75, DOI 10.1006/smns.1995.0010; Birnir B, 1997, SYNAPSE, V26, P324, DOI 10.1002/(SICI)1098-2396(199707)26:3<324::AID-SYN13>3.0.CO;2-V; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Ebert V, 1999, NEUROCHEM INT, V34, P453, DOI 10.1016/S0197-0186(99)00039-X; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Gorrie GH, 1997, J NEUROSCI, V17, P6587; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jursky F, 2000, J NEUROCHEM, V74, P1310; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; Nusser Z, 1999, EUR J NEUROSCI, V11, P1685, DOI 10.1046/j.1460-9568.1999.00581.x; O'Shea SM, 2000, J BIOL CHEM, V275, P22764, DOI 10.1074/jbc.M001299200; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SERFOZO P, 1992, FEBS LETT, V310, P55, DOI 10.1016/0014-5793(92)81145-C; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SLANY A, 1995, EUR J PHARM-MOLEC PH, V291, P99, DOI 10.1016/0014-2999(95)90084-5; SLANY A, 1995, MOL PHARMACOL, V48, P385; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Tretter V, 1997, J NEUROSCI, V17, P2728; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZEZULA J, 1991, BRAIN RES, V563, P325, DOI 10.1016/0006-8993(91)91556-G; Zezula J, 1996, EUR J PHARMACOL, V301, P207, DOI 10.1016/0014-2999(96)00066-0	37	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16024	16032		10.1074/jbc.M009508200	http://dx.doi.org/10.1074/jbc.M009508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278514	hybrid			2022-12-27	WOS:000168623100062
J	Yoshida, H; Kato, N; Shiratori, Y; Otsuka, M; Maeda, S; Kato, J; Omata, M				Yoshida, H; Kato, N; Shiratori, Y; Otsuka, M; Maeda, S; Kato, J; Omata, M			Hepatitis C virus core protein activates nuclear factor kappa B-dependent signaling through tumor necrosis factor receptor-associated factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA RECEPTOR; FACTOR TNF RECEPTOR-1; FACTOR-ALPHA; KINASE-BETA; SUBCELLULAR-LOCALIZATION; MOLECULAR-CLONING; GENE-EXPRESSION; TAX PROTEIN; CELL-DEATH; IKK-ALPHA	Hepatitis C virus (HCV) core protein, a viral nucleocapsid, has been shown to affect various intracellular events including the nuclear factor kappaB (NF-kappaB) signaling supposedly associated with inflammatory response, cell proliferation, and apoptosis. In order to elucidate the effect of HCV core protein on the NF-kappaB signaling in HeLa and HepG2 cells, a reporter assay was utilized. HCV core protein significantly activated NF-kappaB signaling in a dose-dependent manner not only in HeLa and HepG2 cells transiently transfected with core protein expression plasmid, but also in HeLa cells induced to express core protein under the control of doxycycline. HCV core protein increased the DNA binding affinity of NF-kappaB in the electrophoretic mobility shift assay. Acetyl salicylic acid, an IKK beta -specific inhibitor, and dominant negative form of IKK beta significantly blocked NF-kappaB activation by HCV core protein, suggesting HCV core protein activates the NF-kappaB pathway mainly through IKK beta. Moreover, the dominant negative forms of TRAF2/6 significantly blocked activation of the pathway by HCV core protein, suggesting HCV core protein mimics proinflammatory cytokine activation of the NF-kappaB pathway through TRAF2/6. In fact, HCV core protein activated interleukin-lp promoter mainly through NF-kappaB pathway. Therefore, this function of HCV core protein may play an important role in the inflammatory reaction induced by this hepatotropic virus.	Univ Tokyo, Fac Med, Dept Gastroenterol, Tokyo 1138655, Japan	University of Tokyo	Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Tokyo 1138655, Japan.		Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239; Cacciarelli TV, 1996, HEPATOLOGY, V24, P6, DOI 10.1053/jhep.1996.v24.pm0008707283; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cerny A, 1999, HEPATOLOGY, V30, P595, DOI 10.1002/hep.510300312; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Fukuda R, 1996, LIVER, V16, P390; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Larrea E, 1996, HEPATOLOGY, V23, P210, DOI 10.1002/hep.510230203; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OMATA M, 1991, LANCET, V338, P914, DOI 10.1016/0140-6736(91)91774-O; QUIROGA JA, 1994, DIGEST DIS SCI, V39, P2485, DOI 10.1007/BF02087671; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shimoda K, 1998, HEPATOLOGY, V28, P108, DOI 10.1002/hep.510280116; Shiratori Y, 2000, ANN INTERN MED, V132, P517, DOI 10.7326/0003-4819-132-7-200004040-00002; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Togo G, 1996, CANCER RES, V56, P5620; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; Weil R, 1999, MOL CELL BIOL, V19, P6345; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	58	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16399	16405		10.1074/jbc.M006671200	http://dx.doi.org/10.1074/jbc.M006671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278312	hybrid			2022-12-27	WOS:000168623100110
J	Rogalski, SL; Chavkin, C				Rogalski, SL; Chavkin, C			Eicosanoids inhibit the G-protein-gated inwardly rectifying potassium channel (Kir3) at the Na+/PIP2 gating site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-DEPENDENT ACTIVATION; RAT-BRAIN NEURONS; K-ACH CHANNEL; ARACHIDONIC-ACID; MOLECULAR MECHANISM; KINASE CASCADES; GAMMA-SUBUNITS; BETA-GAMMA; RECEPTORS; HEART	We previously showed that activation of the human endothelin A receptor (HETAR) by endothelin-1 (Et-1) selectively inhibits the response to mu opioid receptor (MOR) activation of the G-protein-gated inwardly rectifying potassium channel (Kir3). The Et-1 effect resulted from PLA2 production of an eicosanoid that inhibited Kir3, In this study, we show that Kir3 inhibition by eicosanoids is channel subunit-specific, and we identify the site within the channel required for arachidonic acid sensitivity. Activation of the G-protein-coupled MOR by the selective opioid agonist D-Ala(2)Glyol, enkephalin, released G beta gamma that activated Kir3, The response to MOR activation was significantly inhibited by Et-1 activation of HETAR in homomeric channels composed of either Kir3.2 or Kir3.4. In contrast, homomeric channels of Kir3.1 were substantially less sensitive. Domain deletion and channel chimera studies suggested that the sites within the channel required for Et-1-induced inhibition were within the region responsible for channel gating. Mutation of a single amino acid in the homomeric Kir3.1 to produce Kir3.1(F137S) (N217D) dramatically increased the channel sensitivity to arachidonic acid and Et-1 treatment. Complementary mutation of the equivalent amino acid in Kir3.4 to produce Kir3.4(S143T)(D223N) significantly reduced the sensitivity of the channel to arachidonic acid- and Et-1-induced inhibition. The critical aspartate residue required for eicosanoid sensitivity is the same residue required for Na+ regulation of PIP2 gating. The results suggest a model of Kir3 gating that incorporates a series of regulatory steps, including G beta gamma, PIP2, Na+, and arachidonic acid binding to the channel gating domain.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010		NIDA NIH HHS [R37 DA011672, R01 DA004123, DA 04123] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA011672, R01DA004123] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Jan LY, 1997, CURR OPIN CELL BIOL, V9, P155, DOI 10.1016/S0955-0674(97)80057-9; Kim D, 2000, J GEN PHYSIOL, V115, P287, DOI 10.1085/jgp.115.3.287; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KOYANO K, 1994, NEUROSCI RES, V20, P345, DOI 10.1016/0168-0102(94)90057-4; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LEONARD JP, 1991, MOL NEUROBIOLOGY PRA, P161; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; Macica CM, 1996, AM J PHYSIOL-RENAL, V271, pF588, DOI 10.1152/ajprenal.1996.271.3.F588; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sugden PH, 1998, ADV ENZYME REGUL, V38, P87, DOI 10.1016/S0065-2571(97)00010-1; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; VanderVusse GJ, 1997, PROSTAG LEUKOTR ESS, V57, P85, DOI 10.1016/S0952-3278(97)90497-X; VELIMIROVIC BM, 1995, P NATL ACAD SCI USA, V92, P1590, DOI 10.1073/pnas.92.5.1590; VICKERS JD, 1993, J PHARMACOL EXP THER, V266, P1156; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Yamazaki T, 1999, ANN NY ACAD SCI, V874, P38, DOI 10.1111/j.1749-6632.1999.tb09223.x; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	33	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14855	14860		10.1074/jbc.M010097200	http://dx.doi.org/10.1074/jbc.M010097200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278615	hybrid, Green Accepted			2022-12-27	WOS:000168528800045
J	Lai, CF; Chaudhary, L; Fausto, A; Halstead, LR; Ory, DS; Avioli, LV; Cheng, SL				Lai, CF; Chaudhary, L; Fausto, A; Halstead, LR; Ory, DS; Avioli, LV; Cheng, SL			Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; COFFIN-LOWRY SYNDROME; MARROW STROMAL CELLS; BONE SIALOPROTEIN; GENE-EXPRESSION; FACTOR-BETA; MAP KINASE; EXTRACELLULAR-MATRIX; TRANSCRIPTIONAL ACTIVITY; ALKALINE-PHOSPHATASE	Extracellular signal-regulated kinases (Erks), members of the mitogen-activated protein kinase superfamily, play an important role in cell proliferation and differentiation. In this study we employed a dominant negative approach to determine the role of Erks in the regulation of human osteoblastic cell function. Human osteoblastic cells were transduced with a pseudotyped retrovirus encoding either a mutated Erk1 protein with a dominant negative action against both Erk1 and Erk2 (Erk1DN cells) or the LacZ protein (LacZ cells) as a control. Both basal and growth factor-stimulated MAPK activity and cell proliferation were inhibited in Erk1DN cells. Expression of Erk1DN protein suppressed both osteoblast differentiation and matrix mineralization by decreasing alkaline phosphatase activity and the deposition of bone matrix proteins. Cell adhesion to collagen, osteopontin, and vitronectin was decreased in Erk1DN cells as compared with LacZ cells. Cell spreading and migration on these matrices were also inhibited. In Erk1DN cells, expression of alpha beta (1), alpha (v)beta (3) and alpha (v)beta (5) integrins on the surface was decreased. Metabolic labeling indicated that the synthesis of these integrins was inhibited in Erk1DN cells. These data suggest that Erks are not only essential for the growth and differentiation of osteoblasts but also are important for osteoblast adhesion, spreading, migration, and integrin expression.	Washington Univ, Sch Med, Dept Internal Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Cardiovasc, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Cheng, SL (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp St Louis, Div Bone & Mineral Dis, 216 S Kingshighway Blvd, St Louis, MO 63110 USA.	scheng@im.wustl.edu			NIAMS NIH HHS [AR07033, AR32087] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007033, P01AR032087] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Carter KB, 2000, J BIOL CHEM, V275, P27858; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cheng SL, 2000, J CELL BIOCHEM, V77, P265, DOI 10.1002/(SICI)1097-4644(20000501)77:2<265::AID-JCB9>3.0.CO;2-6; CLOVER J, 1992, J CELL SCI, V103, P267; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COFFIN GS, 1966, AM J DIS CHILD, V112, P205, DOI 10.1001/archpedi.1966.02090120073006; Danen EHJ, 1998, CELL ADHES COMMUN, V6, P217, DOI 10.3109/15419069809004477; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fryns JP, 1996, CLIN GENET, V50, P112; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRONOWICZ GA, 1994, J BONE MINER RES, V9, P193, DOI 10.1002/jbmr.5650090208; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HEINEGARD D, 1995, ANN NY ACAD SCI, V760, P213, DOI 10.1111/j.1749-6632.1995.tb44632.x; Hoshi K, 1999, BONE, V25, P639, DOI 10.1016/S8756-3282(99)00223-9; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; ICHIMURA S, 1993, J JPN ORTHOP ASSOC, V67, P963; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Jiang HP, 1999, MECH DEVELOP, V81, P169, DOI 10.1016/S0925-4773(98)00232-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; Kim LT, 1997, P SOC EXP BIOL MED, V214, P123; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Li YQ, 1999, IMMUNOLOGY, V96, P524; Lian J.B., 1999, PRIMER METABOLIC BON, P14; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Liu YK, 1997, FEBS LETT, V420, P112, DOI 10.1016/S0014-5793(97)01498-1; Liu ZJ, 1999, J IMMUNOL, V163, P4901; LOMRI A, 1990, J BONE MINER RES, V5, P1149; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; LOWRY B, 1971, AM J DIS CHILD, V121, P496, DOI 10.1001/archpedi.1971.02100170078009; LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Moursi AM, 1996, J CELL SCI, V109, P1369; Mundy GR, 1996, CLIN ORTHOP RELAT R, P24, DOI 10.1097/00003086-199603000-00004; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PALEY S, 1999, BIOCHEM J, V343, P21; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; Schneider GB, 1999, BONE, V24, P321, DOI 10.1016/S8756-3282(99)00007-1; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shibayama H, 1999, BLOOD, V93, P1540, DOI 10.1182/blood.V93.5.1540.405k10_1540_1548; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; Takeshita A, 1998, J BIOL CHEM, V273, P14738, DOI 10.1074/jbc.273.24.14738; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Temtamy S A, 1975, Birth Defects Orig Artic Ser, V11, P133; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Wang JS, 1996, ACTA ORTHOP SCAND, V67, P1; Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; ZHOU HY, 1995, CALCIFIED TISSUE INT, V56, P403, DOI 10.1007/BF00301610; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	70	325	352	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14443	14450		10.1074/jbc.M010021200	http://dx.doi.org/10.1074/jbc.M010021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278600	hybrid			2022-12-27	WOS:000168356600123
J	Liu, YF; Paz, K; Herschkovitz, A; Alt, A; Tennenbaum, T; Sampson, SR; Ohba, M; Kuroki, T; LeRoith, D; Zick, Y				Liu, YF; Paz, K; Herschkovitz, A; Alt, A; Tennenbaum, T; Sampson, SR; Ohba, M; Kuroki, T; LeRoith, D; Zick, Y			RETRACTED: Insulin stimulates PKC zeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1) - A self-attenuated mechanism to negatively regulate the function of IRS proteins (Retracted article. See vol. 293, pg. 7264, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							KINASE-C-ZETA; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORT; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHOTYROSINE PROTEIN; JUXTAMEMBRANE REGION; S6 KINASE; ACTIVATION; DOMAIN	Incubation of rat hepatoma Fao cells with insulin leads to a transient rise in Tyr phosphorylation of insulin receptor substrate (IRS) proteins. This is followed by elevation in their P-Ser/Thr content, and their dissociation from the insulin receptor (IR), Wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, abolished the increase in the P-Ser/Thr content of IRS-1, its dissociation from the IR, and the decrease in its P-Tyr content following 60 min of insulin treatment, indicating that the Ser kinases that negatively regulate IRS-l function are downstream effectors of PI3K. PKC zeta fulfills this criterion, being an insulin-activated downstream effector of PI3K, Overexpression of PKC zeta in Fao cells, by infection of the cells with adenovirus-based PKC zeta construct, had no effect on its own, but it accelerated the rate of insulin-stimulated dissociation of IR IRS-1 complexes and the rate of Tyr dephosphorylation of IRS-1, The insulin-stimulated negative regulatory role of PKC zeta was specific and could not be mimic by infecting Fao cells with adenoviral constructs encoding for PKC alpha, delta, or eta. Because the reduction in P-Tyr content of IRS-1 was accompanied by a reduced association of IRS-1 with p85, the regulatory subunit of PI3K, it suggests that this negative regulatory process induced by PKC zeta has a built-in attenuation signal. Hence, insulin triggers a sequential cascade in which PI3K-mediated activation of PKC zeta inhibits IRS-1 functions, reduces complex formation between IRS-1 and PI3K, and inhibits further activation of PKC zeta itself. These findings implicate PKC zeta as a key element in a multistep negative feedback control mechanism of IRS-1 functions.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Bar Ilan Univ, Gonda Goldschmied Ctr, Fac Life Sci, IL-52900 Ramat Gan, Israel; Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan; NIDDK, Mol & Cellular Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Weizmann Institute of Science; Bar Ilan University; Showa University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	yehiel.zick@weizmann.ac.il	Kuroki, Toshio/A-9500-2011; Zick, Yehiel/K-1479-2012	Kuroki, Toshio/0000-0001-6369-4351; 				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Etgen GJ, 1999, J BIOL CHEM, V274, P22139, DOI 10.1074/jbc.274.32.22139; Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZICK Y, 1983, J BIOL CHEM, V258, P75	46	157	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14459	14465		10.1074/jbc.M007281200	http://dx.doi.org/10.1074/jbc.M007281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278339	hybrid			2022-12-27	WOS:000168356600125
J	McVey, M; Ramsay, D; Kellett, E; Rees, S; Wilson, S; Pope, AJ; Milligan, G				McVey, M; Ramsay, D; Kellett, E; Rees, S; Wilson, S; Pope, AJ; Milligan, G			Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer - The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(B) RECEPTORS; LIGAND REGULATION; INVERSE AGONISM; DIMERIZATION; DOPAMINE; HETERODIMERIZATION; SOMATOSTATIN; ASSEMBLE; SUBTYPES	Oligomerization of the human delta -opioid receptor and its regulation by ligand occupancy were explored following expression in HEK293 cells using each of co-immunoprecipitation of differentially epitope-tagged forms of the receptor, bioluminescence resonance energy transfer and time-resolved fluorescence resonance energy transfer. All of the approaches identified constitutively formed receptor oligomers, and the time-resolved fluorescence studies confirmed the presence of such homo-oligomers at the cell surface. Neither the agonist Ligand [D-Ala(2),D-Leu(5)]enkephalin nor the inverse agonist ligand ICI174864 were able to modulate the oligomerization status of this receptor. Interactions between co-expressed delta -opioid receptors and beta (2)-adrenoreceptors mere observed in co-immunoprecipitation studies. Such hetero-oligomers could also be detected using bioluminescence resonance energy transfer although the signal obtained was substantially smaller than for homo-oligomers of either receptor type. Signal corresponding; to the delta -opioid receptor-beta (2)-adrenoreceptor hetero-oligomer was increased in the presence of agonist for either receptor. However, substantial levels of this hetero-oligomer were not detected at the cell surface using time-resolved fluorescence resonance energy transfer. These studies demonstrate that, following transient transfection of HEK293 cells, constitutively formed oligomers of the human delta -opioid receptor can be detected by a variety of approaches. However, these are not regulated by ligand occupancy. They also indicate that time-resolved fluorescence resonance energy transfer represents a means to detect such oligomers at the cell surface in populations of intact cells.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; Glaxo Wellcome Res & Dev Ltd, Biol Chem Unit, Stevenage SG1 2NY, Herts, England	University of Glasgow; GlaxoSmithKline; GlaxoSmithKline	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg,Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Fukushima Y, 1997, FEBS LETT, V409, P283, DOI 10.1016/S0014-5793(97)00531-0; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; McLean AJ, 1999, MOL PHARMACOL, V56, P1182, DOI 10.1124/mol.56.6.1182; Merkouris M, 1997, J NEUROCHEM, V69, P2115; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Milligan G, 2000, SCIENCE, V288, P65, DOI 10.1126/science.288.5463.65; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MILLIGAN G, 2001, IN PRESS J CELL SCI; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	35	212	226	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14092	14099		10.1074/jbc.M008902200	http://dx.doi.org/10.1074/jbc.M008902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278447	hybrid			2022-12-27	WOS:000168356600080
J	Ortega, A; Lambotte, S; Bechinger, B				Ortega, A; Lambotte, S; Bechinger, B			Calorimetric investigations of the structural stability and interactions of colicin B domains in aqueous solution and in the presence of phospholipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING DOMAIN; PLANAR LIPID BILAYERS; E1 CHANNEL DOMAIN; MEMBRANE-INSERTION; CRYSTAL-STRUCTURE; FUNCTIONAL-PROPERTIES; TERMINAL FRAGMENT; DIPHTHERIA-TOXIN; MOLECULAR-BASIS; ION CHANNELS	The effects of pH and temperature on the stability of interdomain interactions of colicin B have been studied by differential-scanning calorimetry, circular dichroism, and fluorescence spectroscopy. The calorimetric properties were compared with those of the isolated pore-forming fragment. The unfolding profile of the full-length toxin is consistent with two endothermic transitions. Whereas peak A (T-m = 55 degreesC) most likely corresponds to the receptor/translocation domain, peak B (T-m = 59 degreesC) is associated with the pore-forming domain. By lowering the pH from 7 to 3.5, the transition temperature of peaks A and B are reduced by 25 and 18 degreesC, respectively, due to proton exchange upon denaturation, The isolated pore-forming fragment unfolds at much higher temperatures (T-m = 65 degreesC) and is stable throughout a wide pH range, indicating that intramolecular interactions between the different colicin B domains result in a less stable protein conformation. In aqueous solution circular dichroism spectra have been used to estimate the content of helical secondary structure of colicin B (approximate to 40%) or its pore-forming fragment (approximate to 80%). Upon heating, the ellipticities at 222 nm strongly decrease at the transition temperature. In the presence of lipid vesicles the differential-scanning calorimetry profiles of the pore forming fragment exhibit a low heat of transition multicomponent structure. The heat of transition of membrane-associated colicin B (T-m = 54 degreesC at pH 3.5) is reduced and its secondary structure is conserved even at intermediate temperatures indicating incomplete unfolding due to strong protein-lipid interactions.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Natl Autonomous Univ Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico	Max Planck Society; Universidad Nacional Autonoma de Mexico	Bechinger, B (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.							BATY D, 1987, P NATL ACAD SCI USA, V84, P1152, DOI 10.1073/pnas.84.5.1152; BULLOCK JO, 1990, J MEMBRANE BIOL, V114, P79, DOI 10.1007/BF01869387; BULLOCK JO, 1992, J MEMBRANE BIOL, V125, P255; Butko P, 1997, BIOCHEMISTRY-US, V36, P12862, DOI 10.1021/bi9702389; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P13180, DOI 10.1021/bi960990u; FRENETTE M, 1989, BIOCHEMISTRY-US, V28, P2509, DOI 10.1021/bi00432a024; GHOSH P, 1993, J MEMBRANE BIOL, V134, P85; Gouaux E, 1997, STRUCTURE, V5, P313, DOI 10.1016/S0969-2126(97)00188-3; Haltia Tuomas, 1995, Biochimica et Biophysica Acta, V1241, P295, DOI 10.1016/0304-4157(94)00161-6; JEANTEUR D, 1994, J MOL BIOL, V235, P898, DOI 10.1006/jmbi.1994.1047; Kienker PK, 1997, J MEMBRANE BIOL, V157, P27, DOI 10.1007/s002329900213; LAKEY JH, 1994, TOXICOLOGY, V87, P85, DOI 10.1016/0300-483X(94)90156-2; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAKEY JH, 1994, EUR J BIOCHEM, V220, P155, DOI 10.1111/j.1432-1033.1994.tb18610.x; Lambotte S, 1998, BIOCHEMISTRY-US, V37, P16, DOI 10.1021/bi9724671; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; LIU Q R, 1986, Proteins Structure Function and Genetics, V1, P218, DOI 10.1002/prot.340010304; MARTINEZ MC, 1983, EMBO J, V2, P1501, DOI 10.1002/j.1460-2075.1983.tb01614.x; MEL SF, 1993, BIOCHEMISTRY-US, V32, P2082, DOI 10.1021/bi00059a028; Merrill AR, 1997, BIOCHEMISTRY-US, V36, P6874, DOI 10.1021/bi970222i; MUGA A, 1993, J BIOL CHEM, V268, P1553; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PATTUS F, 1983, BIOCHEMISTRY-US, V22, P5698, DOI 10.1021/bi00294a003; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; PRESSLER U, 1986, J BIOL CHEM, V261, P2654; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PRIVALOV PL, 1969, BIOPOLYMERS, V8, P559, DOI 10.1002/bip.1969.360080502; Privalov PL, 1980, BIOL MICROCALORIM, P413; RAMSAY G, 1989, BIOCHEMISTRY-US, V28, P529, DOI 10.1021/bi00428a018; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; VANDERGOOT FG, 1993, EUR J BIOCHEM, V213, P217; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Vecsey-Semjen B, 1999, BIOCHEMISTRY-US, V38, P4296, DOI 10.1021/bi982472k; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; WALLACE BA, 1984, ANAL BIOCHEM, V142, P317, DOI 10.1016/0003-2697(84)90471-8; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; YU YH, 1994, BIOCHEMISTRY-US, V33, P3312, DOI 10.1021/bi00177a023; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282	48	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13563	13572		10.1074/jbc.M007675200	http://dx.doi.org/10.1074/jbc.M007675200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278359	hybrid			2022-12-27	WOS:000168356600010
J	Zuscik, MJ; Chalothorn, D; Hellard, D; Deighan, C; McGee, A; Daly, CJ; Waugh, DJJ; Ross, SK; Gaivin, RJ; Morehead, AJ; Thomas, JD; Plow, EF; McGrath, JC; Piascik, MT; Perez, DM				Zuscik, MJ; Chalothorn, D; Hellard, D; Deighan, C; McGee, A; Daly, CJ; Waugh, DJJ; Ross, SK; Gaivin, RJ; Morehead, AJ; Thomas, JD; Plow, EF; McGrath, JC; Piascik, MT; Perez, DM			Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha(1B)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ALPHA-1-ADRENERGIC STIMULATION; ALPHA-1A-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; PRESSOR-RESPONSE; EXPRESSION; SUBTYPE; CELLS; GENE	alpha (1)-Adrenergic receptors (alpha (1A), alpha (1B), and alpha (1D)) are regulators of systemic arterial blood pressure and blood flow. Whereas vasoconstrictory action of the alpha (1A) and alpha (1D) subtypes is thought to be mainly responsible for this activity, the role of the alpha (1B)-adrenergic receptor (alpha (1B)AR) in this process is controversial, We have generated transgenic mice that overexpress either wild type or constitutively active alpha (1B)ARs. Transgenic expression was under the control of the isogenic promoter, thus assuring appropriate developmental and tissue-specific expression. Cardiovascular phenotypes displayed by transgenic mice included myocardial hypertrophy and hypotension. Indicative of cardiac hypertrophy, transgenic mice displayed an increased heart to body weight ratio, which was confirmed by the echocardiographic finding of an increased thickness of the interventricular septum and posterior wall. Functional deficits included an increased isovolumetric relaxation time, a decreased heart rate, and cardiac output. Transgenic mice were hypotensive and exhibited a decreased presser response. Vasoconstrictory regulation by alpha (1B)AR was absent as shown by the lack of phenylephrine-induced contractile differences between ex vivo mesenteric artery preparations. Plasma epinephrine, norepinephrine, and cortisol levels were also reduced in transgenic mice, suggesting a loss of sympathetic nerve activity, Reduced catecholamine levels together with basal hypotension, bradycardia, reproductive problems, and weight loss suggest autonomic failure, a phenotype that is consistent with the multiple system atrophy-like neurodegeneration that has been reported previously in these mice. These results also suggest that this receptor subtype is not involved in the classic vasoconstrictory action of alpha (1)ARs that is important in systemic regulation of blood pressure.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci & Biomed Syst, Autonom Physiol Unit, Glasgow G12 8QQ, Lanark, Scotland; Univ Kentucky, Coll Med, Vasc Biol Res Grp, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Pharmacol, Lexington, KY 40536 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Glasgow; University of Kentucky; University of Kentucky	Perez, DM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, 9500 Euclid Ave, Cleveland, OH 44195 USA.	perezd@ccf.org	McGrath, John C/G-6485-2012	McGrath, John C/0000-0002-5276-0381; WAUGH, DAVID/0000-0002-4022-3765; Zuscik, Michael/0000-0003-0461-8708	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061438, F32HL010004] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL61438, R01HL31820, F32HL10004] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; ANYUKHOVSKY EP, 1992, CIRC RES, V71, P526, DOI 10.1161/01.RES.71.3.526; Autelitano DJ, 1998, J MOL CELL CARDIOL, V30, P1515, DOI 10.1006/jmcc.1998.0717; BALZO UD, 1990, CIRC RES, V67, P1535; BURT AM, 1993, TXB NEUROANATOMY, P367; BYLUND DB, 1995, CAN J PHYSIOL PHARM, V73, P533, DOI 10.1139/y95-068; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chen LQ, 1995, J BIOL CHEM, V270, P30980, DOI 10.1074/jbc.270.52.30980; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; ELHAWARY AM, 1992, J PHARMACOL EXP THER, V260, P709; Guarino RD, 1996, CELL SIGNAL, V8, P323, DOI 10.1016/0898-6568(96)00066-6; Hrometz SL, 1999, J PHARMACOL EXP THER, V290, P452; Hwa J, 1997, BIOCHEMISTRY-US, V36, P633, DOI 10.1021/bi962141c; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOPP UC, 1996, KIDNEY, P789; KUNOS G, 1987, BIOCHEM PHARMACOL, V36, P1185, DOI 10.1016/0006-2952(87)90068-2; Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710, DOI 10.1152/ajpheart.1996.270.2.H710; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Makaritsis KP, 1999, HYPERTENSION, V34, P403, DOI 10.1161/01.HYP.34.3.403; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Montastruc JL, 1996, ADV NEUROL, V69, P377; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Piascik MT, 1997, J PHARMACOL EXP THER, V283, P854; Piascik MT, 1995, J PHARMACOL EXP THER, V275, P1583; ROBERTSON D, 1994, ARCH INTERN MED, V154, P1620, DOI 10.1001/archinte.154.14.1620; Sasaguri T, 2000, BIOCHEM BIOPH RES CO, V268, P25, DOI 10.1006/bbrc.1999.2066; Shannon JR, 2000, CIRCULATION, V101, P2710, DOI 10.1161/01.CIR.101.23.2710; Siwik DA, 1996, J CARDIOVASC PHARM, V27, P508, DOI 10.1097/00005344-199604000-00009; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Vikstrom KL, 1996, MOL MED, V2, P556, DOI 10.1007/BF03401640; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; Zhou L, 1996, EUR J PHARMACOL, V305, P173, DOI 10.1016/0014-2999(96)00229-4; Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288; Zuscik MJ, 2000, NAT MED, V6, P1388, DOI 10.1038/82207	44	81	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13738	13743		10.1074/jbc.M008693200	http://dx.doi.org/10.1074/jbc.M008693200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278430	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000168356600033
J	Fagioli, C; Sitia, R				Fagioli, C; Sitia, R			Glycoprotein quality control in the endoplasmic reticulum - Mannose trimming by endoplasmic reticulum mannosidase I times the proteasomal degradation of unassembled immunoglobulin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; RESISTANT ALPHA-MANNOSIDASE; CHAIN BINDING-PROTEIN; CELL ANTIGEN RECEPTOR; HEAVY-CHAINS; LIGHT-CHAINS; SECRETORY PATHWAY; CULTURED-CELLS; RAT-LIVER; MEMBRANE	Quality control in the endoplasmic reticulum must discriminate nascent proteins in their folding process from terminally unfolded molecules, selectively degrading the latter. Unassembled Ig-mu and J chains, two glycoproteins with five N-linked glycans and one N-linked glycan, respectively, are degraded by cytosolic proteasomes after a lag from synthesis, during which glycan trimming occurs. Inhibitors of mannosidase I (kifunensine), but not of mannosidase II (swainsonine), prevent the degradation of mu chains, Kifunensine also inhibits J chain dislocation and degradation, without inhibiting secretion of IgM polymers. In contrast, glucosidase inhibitors do not significantly affect the kinetics of mu and J degradation. These results suggest that removal of the terminal mannose from the central branch acts as a timer in dictating the degradation of transport-incompetent, glycosylated Ig subunits in a calnexin-independent way. Kifunensine does not inhibit the degradation of an unglycosylated substrate (lambda Ig light chains) or of chimeric mu chains extended with the transmembrane region of the alpha T cell receptor chain, implying the existence of additional pathways for extracting proteins from the endoplasmic reticulum lumen for proteasomal degradation.	San Raffaele Sci Inst, DIBIT, Dept Mol Pathol & Med, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Sitia, R (corresponding author), Via Olgettina 58, I-20132 Milan, Italy.		Fagioli, Claudio/AAN-4147-2020; Sitia, Roberto/AAB-5005-2019	Fagioli, Claudio/0000-0001-9889-4695; Sitia, Roberto/0000-0001-7086-4152				Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Cals MM, 1996, MOL IMMUNOL, V33, P15, DOI 10.1016/0161-5890(95)00132-8; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Ho SC, 2000, J IMMUNOL, V164, P4713, DOI 10.4049/jimmunol.164.9.4713; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAJI H, 1974, NATURE, V249, P45, DOI 10.1038/249045a0; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; O'Hare T, 1999, J IMMUNOL, V163, P11; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SU K, 1993, J BIOL CHEM, V268, P14301; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Urano F, 2000, J CELL SCI, V113, P3697; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	59	91	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12885	12892		10.1074/jbc.M009603200	http://dx.doi.org/10.1074/jbc.M009603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278527	hybrid			2022-12-27	WOS:000168198600060
J	Fujino, H; Regan, JW				Fujino, H; Regan, JW			FP prostanoid receptor activation of a T-cell factor/beta-catenin signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PROSTAGLANDIN-E; EARLY-PREGNANCY; CORPUS-LUTEUM; COMPLEX; TRANSCRIPTION; CANCER; PRODUCT; TAIL; APC	FP prostanoid receptors are G-protein-coupled receptors (GPCR) that consist of two known isoforns, FPA and FPB. These isoforms, which are generated by alternative mRNA splicing, are identical except for their carboxyl-terminal domains. Previously we have shown that stimulation of both isoforms with prostaglandin F-2 alpha (PGF(2 alpha)) activates the small G-protein Rho, leading to morphological changes consisting of cell rounding and the formation of cell aggregates. Following the removal of PGF(2 alpha), however, FPA-expressing cells show rapid reversal of cell rounding, whereas FPB-expressing cells do not. We now show that acute treatment of FPB-expressing cells with PGF(2 alpha) leads to a subcellular reorganization of beta -catenin, a decrease in the phosphorylation of cytoplasmic beta -catenin, and persistent stimulation of Tcf/Lef-mediated transcriptional activation. This does not occur in FPA-expressing cells and may underlie the differences between these isoforms with respect to the reversal of cell rounding. The Tcf/beta -catenin signaling pathway is known to mediate the actions of Wnt acting through the heptahelical receptor, Frizzled, and has not been associated previously with GPCR activation. Our findings expand the signaling possibilities for GPCRs and suggest novel roles for FP receptors in normal tissue development and malignant transformation.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER; NEI NIH HHS [EY11291] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dale TC, 1998, BIOCHEM J, V329, P209; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Pierce KL, 1998, LIFE SCI, V62, P1479, DOI 10.1016/S0024-3205(98)00093-9; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rezvani M, 2000, J BIOL CHEM, V275, P18470, DOI 10.1074/jbc.M000870200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUEDA BR, 1995, ENDOCRINE, V3, P781, DOI 10.1007/BF02935681; SILVIA WJ, 1986, J ANIM SCI, V63, P1201, DOI 10.2527/jas1986.6341201x; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787	26	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12489	12492		10.1074/jbc.C100039200	http://dx.doi.org/10.1074/jbc.C100039200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278257	hybrid			2022-12-27	WOS:000168198600004
J	Xia, ZQ; Costa, MA; Pelissier, HC; Davin, LB; Lewis, NG				Xia, ZQ; Costa, MA; Pelissier, HC; Davin, LB; Lewis, NG			Secoisolariciresinol dehydrogenase purification, cloning, and functional expression - Implications for human health protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PINORESINOL-LARICIRESINOL; FORSYTHIA-INTERMEDIA; LIGNAN BIOSYNTHESIS; CDNA CLONING; PROTEINS; GENES; REDUCTASES; PRECURSOR	Matairesinol is a central precursor in planta in the biosynthesis of numerous lignans, including that of the important antiviral and anticancer agent, podophyllotoxin, In this study, the similar to 32-kDa NAD-dependent secoisolariciresinol dehydrogenase, which catalyzes the enantiospecific conversion of (-)-secoisolariciresinol into (-)-matairesinol in Forsythia intermedia, was purified >6,000-fold to apparent homogeneity, The 831-base pair cDNA clone encoding this 277-amino acid protein was next obtained from a library constructed from F intermedia stem tissue, whose fully functional recombinant protein, produced by expression of this cDNA in Escherichia coli, catalyzed the same enantiospecific conversion via the corresponding lactol intermediate. A homologous secoisolariciresinol dehydrogenase gene was also isolated from a Podophyllum peltatum rhizome cDNA library, whose 834-base pair cDNA clone encoded a 278-amino acid protein with a calculated molecular mass of similar to 32 kDa, Expression of this protein in E, coli produced a fully functional recombinant protein that also catalyzed the enantiospecific conversion of (-)-secoisolariciresinol into (-)-matairesinol via the intermediary lactol, Various kinetic parameters were defined and established conversion of the intermediary lactol as being rate-limiting. With this overall enzymatic conversion now unambiguously defined, the entire biochemical pathway to the lignans, secoisolariciresinol and matairesinol, has been elucidated. Last, both secoisolariciresinol and matairesinol are metabolized in the gut of mammals, following digestion of high fiber dietary grains, seeds, and berries, into the so-called "mammalian" lignans, enterodiol and enterolactone, respectively; these in turn confer significant protection against the onset of breast and prostate cancers.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Lewis, NG (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	lewisn@wsu.edu		Lewis, Norman/0000-0001-5742-032X; Davin, Laurence/0000-0002-3248-6485				Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ayres D.C, 1990, LIGANES CHEM BIOL CL; BORRIELLO SP, 1985, J APPL BACTERIOL, V58, P37, DOI 10.1111/j.1365-2672.1985.tb01427.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; BROOMHEAD AJ, 1991, PHYTOCHEMISTRY, V30, P1489, DOI 10.1016/0031-9422(91)84194-W; Davin LB, 2000, PLANT PHYSIOL, V123, P453, DOI 10.1104/pp.123.2.453; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; FAURE M, 1990, PHYTOCHEMISTRY, V29, P3773, DOI 10.1016/0031-9422(90)85329-E; Fujita M, 1999, J BIOL CHEM, V274, P618, DOI 10.1074/jbc.274.2.618; Gang DR, 1999, CHEM BIOL, V6, P143, DOI 10.1016/S1074-5521(99)89006-1; Gang DR, 1999, J BIOL CHEM, V274, P7516, DOI 10.1074/jbc.274.11.7516; Gang DR, 1998, ACS SYM SER, V697, P389, DOI DOI 10.1021/BK-1998-0697.CH025; GARDNER JAF, 1959, CAN J CHEM, V37, P1703, DOI 10.1139/v59-246; *GEN COMP GROUP, 1997, GCG SEQ AN SOFTW PAC; HARMATHA J, 1984, BIOCHEM SYST ECOL, V12, P95, DOI 10.1016/0305-1978(84)90015-2; Herbers K, 1995, PLANT MOL BIOL, V29, P1027, DOI 10.1007/BF00014975; Iuchi S, 1996, J PLANT RES, V109, P415, DOI 10.1007/BF02344557; Jenab M, 1996, CARCINOGENESIS, V17, P1343, DOI 10.1093/carcin/17.6.1343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis N. G., 1999, COMPREHENSIVE NATURA, V1, P639, DOI DOI 10.1016/B978-0-08-091283-7.00027-8; MACLEAN H., 1956, Forest Products Journal, V6, P510; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NISHIBE S, 1988, Shoyakugaku Zasshi, V42, P324; Sambrook J, 1994, MOL CLONING LAB MANU; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SCHRODER HC, 1990, Z NATURFORSCH C, V45, P1215; UMEZAWA T, 1991, J BIOL CHEM, V266, P10210; UMEZAWA T, 1990, J CHEM SOC CHEM COMM, P1405, DOI 10.1039/c39900001405; Xia ZQ, 2000, PHYTOCHEMISTRY, V55, P537, DOI 10.1016/S0031-9422(00)00242-9	32	118	126	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12614	12623		10.1074/jbc.M008622200	http://dx.doi.org/10.1074/jbc.M008622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278426	hybrid			2022-12-27	WOS:000168198600021
J	Birchwood, CJ; Saba, JD; Dickson, RC; Cunningham, KW				Birchwood, CJ; Saba, JD; Dickson, RC; Cunningham, KW			Calcium influx and signaling in yeast stimulated by intracellular sphingosine 1-phosphate accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; SECRETORY PATHWAY; GROWTH-CONTROL; CA2+ ATPASES; HEAT-STRESS; CALCINEURIN; PMR1; GENE	In mammalian cells, intracellular sphingosine 1-phosphate (SIP) can stimulate calcium release from intracellular organelles, resulting in the activation of downstream signaling pathways. The budding yeast Saccharomyces cerevisiae expresses enzymes that can synthesize and degrade S1P and related molecules, but their possible role in calcium signaling has not yet been tested. Here we examine the effects of S1P accumulation on calcium signaling using a variety of yeast mutants. Treatment of yeast cells with exogenous sphingosine stimulated Ca2+ accumulation through two distinct pathways. The first pathway required the Cch1p and Mid1p subunits of a Ca2+ influx channel, depended upon the function of sphingosine kinases (Lcb4p and Lcb5p), and was inhibited by the functions of S1P lyase (DpI1p) and the S1P phosphatase (Lcb3p). The biologically inactive stereoisomer of sphingosine did not activate this Ca2+ influx pathway, suggesting that the active S1P isomer specifically stimulates a calcium-signaling mechanism in yeast. The second Ca2+ influx pathway stimulated by the addition of sphingosine was not stereospecific, was not dependent on the sphingosine kinases, occurred only at higher doses of added sphingosine, and therefore was likely to be nonspecific, Mutants lacking both S1P lyase and phosphatase (dpl1 lcb3 double mutants) exhibited constitutively high Ca2+ accumulation and signaling in the absence of added sphingosine, and these effects were dependent on the sphingosine kinases. These results show that endogenous S1P-related molecules can also trigger Ca2+ accumulation and signaling, Several stimuli previously shown to evoke calcium signaling in wild-type cells were examined in lcb4 lcb5 double mutants. All of the stimuli produced calcium signals independent of sphingosine kinase activity, suggesting that phosphorylated sphingoid bases might serve as messengers of calcium signaling in yeast during an unknown cellular response.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA	Johns Hopkins University; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Kentucky	Cunningham, KW (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.				NCI NIH HHS [CA77528] Funding Source: Medline; NIGMS NIH HHS [GM53082, GM41302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BEELER T, 1994, J BIOL CHEM, V269, P7279; Choi OH, 1996, NATURE, V380, P634; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; EILAM Y, 1983, BIOCHIM BIOPHYS ACTA, V733, P242, DOI 10.1016/0005-2736(83)90528-X; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Fu LW, 2000, J BIOL CHEM, V275, P5431, DOI 10.1074/jbc.275.8.5431; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; Kim S, 2000, GENETICS, V156, P1519; KOCKE EG, 2000, MOL CELL BIOL, V20, P6686; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OHSUMI Y, 1985, J BIOL CHEM, V260, P482; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Sorin A, 1997, J BIOL CHEM, V272, P9895; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0	40	80	85	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11712	11718		10.1074/jbc.M010221200	http://dx.doi.org/10.1074/jbc.M010221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278643	hybrid			2022-12-27	WOS:000168081800040
J	Grigorian, M; Andresen, S; Tulchinsky, E; Kriajevska, M; Carlberg, C; Kruse, C; Cohn, M; Ambartsumian, N; Christensen, A; Selivanova, G; Lukanidin, E				Grigorian, M; Andresen, S; Tulchinsky, E; Kriajevska, M; Carlberg, C; Kruse, C; Cohn, M; Ambartsumian, N; Christensen, A; Selivanova, G; Lukanidin, E			Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein - Functional consequences of their interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; CARCINOMA CELL-LINES; DNA-BINDING FUNCTION; C-TERMINAL DOMAIN; GENE-EXPRESSION; MUTANT P53; KINASE-C; IN-VITRO; GROWTH SUPPRESSION; NONMUSCLE MYOSIN	A physical and functional interaction between the Ca2+-binding protein Mts1 (S100A4) and the tumor suppressor p53 protein is shown here for the first time. We demonstrate that Mts1 binds to the extreme end of the C-terminal regulatory domain of p53 by several in vitro and in vivo approaches: co-immunoprecipitation, affinity chromatography, and far Western blot analysis. The Mts1 protein in vitro inhibits phosphorylation of the full-length p53 and its C-terminal peptide by protein kinase C but not by casein kinase II. The Mts1 binding to p53 interferes with the DNA binding activity of p53 in vitro and reporter gene transactivation in, vivo, and this has a regulatory function. A differential modulation of the p53 target gene (p21/WAF: box, thrombospondin-l, and mdm-2) transcription was observed upon Mts1 induction in tet-inducible cell lines expressing wild type p53. Mts1 cooperates with wild type p53 in apoptosis induction. Our data imply that the ability of Mts1 to enhance p53 dependent apoptosis might accelerate the loss of wild type p53 function in tumors, In this way, Mts1 can contribute to the development of a more aggressive phenotype during tumor progression.	Danish Canc Soc, Inst Canc Biol, Dept Mol Canc Biol, DK-2100 Copenhagen 0, Denmark; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden	Danish Cancer Society; Karolinska Institutet	Grigorian, M (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Mol Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen 0, Denmark.		Tulchinsky, Eugene/ABD-7070-2021	Cohn, Martin/0000-0002-2988-3009; Selivanova, Galina/0000-0002-8698-4332				CASEY G, 1991, ONCOGENE, V6, P1791; CHENG YT, 1995, MOL CARCINOGEN, V13, P173, DOI 10.1002/mc.2940130307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EBRALIDZE A, 1989, GENE DEV, V3, P10886; ELSTNER E, 1995, CANCER RES, V55, P2822; FELIX CA, 1992, CANCER RES, V52, P2243; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Hayashi S, 1999, J EXP CLIN CANC RES, V18, P181; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISAACS WB, 1991, CANCER RES, V51, P4716; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Katayose D, 1995, CLIN CANCER RES, V1, P889; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kimura M, 1997, ANTICANCER RES, V17, P879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCONNELL KA, 1990, J IMMUNOL, V144, P521; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Oren M., 1996, BIOCHIM BIOPHYS ACTA, V1288, P13, DOI DOI 10.1016/S0304-419X(96)00030-3; PARKER C, 1994, DNA CELL BIOL, V13, P1021, DOI 10.1089/dna.1994.13.1021; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; ROBERTS DD, 1996, FASEB J, V10, P183; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; Rudland PS, 2000, CANCER RES, V60, P1595; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wang H, 1998, INT J MOL MED, V1, P915; WANG NP, 1993, ONCOGENE, V8, P279; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; YAGINUMA Y, 1991, CANCER RES, V51, P6506; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	52	252	266	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22699	22708		10.1074/jbc.M010231200	http://dx.doi.org/10.1074/jbc.M010231200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11278647	hybrid			2022-12-27	WOS:000169412700097
J	Cao, ZY; Zhao, Z; Mohan, R; Alroy, J; Stanley, P; Panjwani, N				Cao, ZY; Zhao, Z; Mohan, R; Alroy, J; Stanley, P; Panjwani, N			Role of the Lewis(x) glycan determinant in corneal epithelial cell adhesion and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LE(X) CARBOHYDRATE; STEM-CELLS; EXPRESSION; ANTIBODY; EPITOPE; LIMBAL; GLYCOSPHINGOLIPIDS; GLYCOLIPIDS; MOLECULES; EMBRYOS	In this study we demonstrate that in corneal epithelium there is cell-cell contact-regulated expression of a 145-kDa glycoprotein (GP) bearing the glycan determinant Lewis(x) (Le(x)) (Gal beta (1,4)[Fuc alpha (1,3)]GlcNAc), This glycoprotein (Le(x)-GP) was expressed in confluent/contact-inhibited cultures but not in sparse cultures of corneal epithelium. In contrast, a 135-kDa glycoprotein bearing precursor, unfucosylated, lactosamine-containing glycans (Gal beta1-4GlcNAc beta1-R) was expressed in sparse cultures. Immunofluorescence staining and confocal microscopy of confluent cultures revealed that in corneal epithelium, Le(x) antigen is located in high density at sites of cell-cell adhesion. In in vitro cell-cell adhesion assays, anti-Le(x), but not anti-sialyl-Le(x) monoclonal antibodies, inhibited the formation of corneal epithelial cell-cell adhesion. Also, when added to confluent cultures, antibodies to Le(x) disrupted the monolayer and caused tightly packed polygonal cells to round up, Analysis of the expression of Fut genes that encode alpha -1,3-fucosyltransferases, the enzymes that generate the Le(x) determinant, revealed that confluent/contact-inhibited cultures of rabbit corneal epithelium contain markedly elevated levels of Fut4 and Fut3/5/6 gene transcripts compared with sparse cultures. These data suggest that the Fut4 and Fut3/5/6 genes are targets of cell-cell contact-regulated signals and that Fut gene products direct cell-cell contact-associated expression of Le(x) on the Le(x)-GP in corneal epithelium. Immunohistochemical analysis revealed that the expression of Le(x) antigen in the epithelium of adult and developing corneas is related to the stage of differentiation of the cells. Although early differentiated cells robustly expressed Le(x), relatively undifferentiated cells did not, and the expression level was relatively low in terminally differentiated cells. Overall, these data provide evidence that a Le(x)-bearing glycoprotein plays a role through the Le(x) determinant in corneal epithelial cell-cell adhesion, and these data suggest that Le(x)-mediated cell-cell interactions contribute to mechanisms that mediate corneal epithelial cell differentiation.	Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Tufts University; Tufts University; Tufts University; Tufts University; Yeshiva University; Albert Einstein College of Medicine	Panjwani, N (corresponding author), Tufts Univ, Sch Med, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.	Noorjahan.Panjwani@tufts.edu		Stanley, Pamela/0000-0001-5704-3747	NATIONAL EYE INSTITUTE [R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EY07088, EY09349] Funding Source: Medline; PHS HHS [R01 36434] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLENDOERFER KL, 1995, MOL CELL NEUROSCI, V6, P381, DOI 10.1006/mcne.1995.1029; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; Boubelik M, 1998, GLYCOBIOLOGY, V8, P139, DOI 10.1093/glycob/8.2.139; CAMPBELL RJ, 1981, OPHTHALMOLOGY, V88, P1231; CHALOINDUFAU C, 1990, CELL DIFFER DEV, V32, P97, DOI 10.1016/0922-3371(90)90103-4; CHUNG EH, 1992, INVEST OPHTH VIS SCI, V33, P2199; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; FUKUSHIMA K, 1984, J BIOL CHEM, V11, P5279; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; IWAMOTO T, 1977, ANN OPHTHALMOL, V9, P1095; JENSEN P, 1977, ARCH OPHTHALMOL-CHIC, V95, P837; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KRICKA LJ, 1991, CLIN CHEM, V37, P1472; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; LAVKER RM, 1991, INVEST OPHTH VIS SCI, V32, P1864; LEVINE JF, 1985, J CELL BIOL, V100, P1415, DOI 10.1083/jcb.100.5.1415; LIU CY, 1993, CURR EYE RES, V12, P963, DOI 10.3109/02713689309029222; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MARSH JM, 1995, CIBA F SYMP, P189; Matic M, 1997, DIFFERENTIATION, V61, P251, DOI 10.1046/j.1432-0436.1997.6140251.x; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PANJWANI N, 1995, J BIOL CHEM, V270, P14015, DOI 10.1074/jbc.270.23.14015; PANJWANI N, 1990, INVEST OPHTH VIS SCI, V31, P689; Patnaik SK, 2000, ARCH BIOCHEM BIOPHYS, V375, P322, DOI 10.1006/abbi.1999.1693; ROBERTS C, 1991, DEVELOPMENT, V112, P959; RODRIGUES M, 1987, DIFFERENTIATION, V34, P60, DOI 10.1111/j.1432-0436.1987.tb00051.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SIUZDAK G, 1993, J AM CHEM SOC, V115, P2877, DOI 10.1021/ja00060a040; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STANLEY JR, 1995, CIBA F SYMP, V189, P107; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Streit A, 1996, J NEUROCHEM, V66, P834; WARING GO, 1984, AM J OPHTHALMOL, V97, P547, DOI 10.1016/0002-9394(84)90371-4; WITKOP CJ, 1982, BIRTH DEFECTS-ORIG, V18, P493; Wolosin JM, 2000, PROG RETIN EYE RES, V19, P223, DOI 10.1016/S1350-9462(99)00005-1; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; YOUNG WW, 1981, J BIOL CHEM, V256, P967; ZAVALA EY, 1980, ARCH OPHTHALMOL-CHIC, V98, P2007; Zhang AM, 1999, J BIOL CHEM, V274, P10439, DOI 10.1074/jbc.274.15.10439; ZIESKE JD, 1993, J CELL SCI, V106, P145	47	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21714	21723		10.1074/jbc.M009672200	http://dx.doi.org/10.1074/jbc.M009672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278542	hybrid			2022-12-27	WOS:000169297900122
J	Chen, M; Keene, DR; Costa, FK; Tahk, SH; Woodley, DT				Chen, M; Keene, DR; Costa, FK; Tahk, SH; Woodley, DT			The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis bullosa acquisita autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOLLAGENOUS NC1 DOMAIN; ANCHORING FIBRILS; EXTRACELLULAR-MATRIX; NC-2 DOMAIN; GENE; PROCOLLAGEN; CDNA; IDENTIFICATION; CLONING; SKIN	Type VII collagen, the major component of anchoring fibrils, consists of a central collagenous triple-helical domain flanked by two noncollagenous domains, NC1 and NC2, The NC2 domain has been implicated in catalyzing the antiparallel dimer formation of type VII procollagen, In this study, we produced the entire 161 amino acids of the NC2 domain plus 186 amino acids of adjacent collagenous domain (NC2/COL) and purified large quantities of the recombinant NC2/COL protein. Recombinant NC2/COL readily formed disulfide-bonded hexamers, each representing one antiparallel dimer of collagen VII, Removal of the collagenous helical domain from NC2/COL by collagenase digestion abolished the antiparallel dimer formation. Using site-directed mutagenesis, we found that mutation of either cysteine 2802 or cysteine 2804 alone within the NC2 domain blocked antiparallel dimer formation. In contrast, a single cysteine mutation, 2634, within the collagenous helical domain had no effect. A generated methionine to lysine substitution, M2798K, that is associated with recessive dystrophic epidermolysis bullosa, was unable to form antiparallel dimers, Furthermore, autoantibodies from epidermolysis bullosa acquisita patients also reacted with NC2/COL. We conclude that NC2 and its adjacent collagenous segment mediate antiparallel dimer formation of collagen VII, Epidermolysis bullosa acquisita autoantibodies bound to this domain may destabilize anchoring fibrils by interfering with antiparallel dimer assembly leading to epidermal-dermal disadherence.	Univ So Calif, Dept Med, Div Dermatol, CRL 108, Los Angeles, CA 90033 USA; Shriners Hosp Children, Portland, OR 97201 USA	University of Southern California	Woodley, DT (corresponding author), Univ So Calif, Dept Med, Div Dermatol, CRL 108, 1303 Mission Rd, Los Angeles, CA 90033 USA.				NIAMS NIH HHS [R01 AR33625] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen M, 1997, J INVEST DERMATOL, V108, P68, DOI 10.1111/1523-1747.ep12285634; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Chen M, 1999, J INVEST DERMATOL, V112, P177, DOI 10.1046/j.1523-1747.1999.00491.x; Chen M, 2000, J BIOL CHEM, V275, P24429, DOI 10.1074/jbc.M003440200; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; CHRISTIANO AM, 1993, NAT GENET, V4, P62, DOI 10.1038/ng0593-62; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; DUFTON MJ, 1985, EUR J BIOCHEM, V153, P647, DOI 10.1111/j.1432-1033.1985.tb09349.x; GAMMON WR, 1990, J AM ACAD DERMATOL, V22, P664, DOI 10.1016/0190-9622(90)70094-X; GAMMON WR, 1992, J INVEST DERMATOL, V99, P691, DOI 10.1111/1523-1747.ep12614080; GREENSPAN DS, 1993, HUM MOL GENET, V2, P273, DOI 10.1093/hmg/2.3.273; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LAPIERE JC, 1994, J INVEST DERMATOL, V103, P637, DOI 10.1111/1523-1747.ep12398270; LAPIERE JC, 1993, J CLIN INVEST, V92, P1831, DOI 10.1172/JCI116774; Lin AN, 1992, EPIDERMOLYSIS BULLOS; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NIEBOER C, 1980, BRIT J DERMATOL, V102, P383, DOI 10.1111/j.1365-2133.1980.tb06550.x; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; Tanaka H, 1997, LAB INVEST, V77, P623; TANAKA T, 1994, J INVEST DERMATOL, V102, P706, DOI 10.1111/1523-1747.ep12374333; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P373; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; UITTO J, 1993, SEMIN DERMATOL, V12, P191; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1995, P ASSOC AM PHYSICIAN, V107, P245; UITTO J, 1992, J INVEST DERMATOL, V38, P391; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WOODLEY D, 1983, J INVEST DERMATOL, V81, P149, DOI 10.1111/1523-1747.ep12543517; WOODLEY DT, 1984, NEW ENGL J MED, V310, P1007, DOI 10.1056/NEJM198404193101602; WOODLEY DT, 1988, J CLIN INVEST, V81, P683, DOI 10.1172/JCI113373; WUN TC, 1988, J BIOL CHEM, V263, P6001	37	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21649	21655		10.1074/jbc.M100180200	http://dx.doi.org/10.1074/jbc.M100180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274208	hybrid			2022-12-27	WOS:000169297900113
J	Maltese, WA; Wilson, S; Tan, YZ; Suomensaari, S; Sinha, S; Barbour, R; McConlogue, L				Maltese, WA; Wilson, S; Tan, YZ; Suomensaari, S; Sinha, S; Barbour, R; McConlogue, L			Retention of the Alzheimer's amyloid precursor fragment C99 in the endoplasmic reticulum prevents formation of amyloid beta-peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GTP-BINDING PROTEIN; GAMMA-SECRETASE CLEAVAGE; TRANS-GOLGI NETWORK; TRANSMEMBRANE DOMAIN; BAFILOMYCIN A1; WILD-TYPE; DISEASE; PRESENILIN-1; MEMBRANE; MUTANT	gamma-Secretase is a membrane-associated endoprotease that catalyzes the final step in the processing of Alzheimer's beta-amyloid precursor protein (APP), resulting in the release of amyloid beta-peptide (A beta). The molecular identity of gamma-secretase remains in question, although recent studies have implicated the presenilins, which are membrane-spanning proteins localized predominantly in the endoplasmic reticulum (ER). Based on these observations, we have tested the hypothesis that gamma-secretase cleavage of the membrane-anchored C-terminal stump of APP (i.e. C99) occurs in the ER compartment. When recombinant C99 was expressed in 293 cells, it was localized mainly in the Golgi apparatus and gave rise to abundant amounts of A beta. Co-expression of C99 with mutant forms of presenilin-1 (PS1) found in familial Alzheimer's disease resulted in a characteristic elevation of the A beta (42)/A beta (40) ratio, indicating that the N-terminal exodomain of APP is not required for mutant PS1 to influence the site of gamma-secretase cleavage. Biogenesis of both A beta (40) and A beta (42) was almost completely eliminated when C99 was prevented from leaving the ER by addition of a di-lysine retention motif (KKQN) or by co-expression with a dominant-negative mutant of the Rab1B GTPase. These findings indicate that the ER is not a major intracellular site for gamma-secretase cleavage of C99. Thus, by inference, PS1 localized in this compartment does not appear to be active as gamma-secretase. The results suggest that presenilins may acquire the characteristics of gamma-secretase after leaving the ER, possibly by assembling with other proteins in peripheral membranes.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Penn State Coll Med, Weis Ctr Res, Danville, PA 17822 USA; Elan Pharmaceut, San Francisco, CA 94080 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Maltese, WA (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.	wmaltese@mco.edu			NIA NIH HHS [R01-AG16166] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016166] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHIMA A, 1997, BIOCHEM BIOPH RES CO, V227, P423; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ANTONY C, 1992, J CELL SCI, V103, P785; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Castellano F, 1995, J RECEPT SIGNAL TR R, V15, P847, DOI 10.3109/10799899509049861; CHA Y, 1990, J BIOL CHEM, V265, P5008; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449; DESILVA HAR, 1997, NEUROREPORT, V8, P1; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Durkin JT, 1999, J BIOL CHEM, V274, P20499, DOI 10.1074/jbc.274.29.20499; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GANDY S, 1994, INT REV NEUROBIOL, V36, P29, DOI 10.1016/S0074-7742(08)60302-5; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOO EH, 1994, J BIOL CHEM, V269, P17386; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Lah JJ, 1997, J NEUROSCI, V17, P1971; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Lotti LV, 1999, J BIOL CHEM, V274, P10413, DOI 10.1074/jbc.274.15.10413; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mattson MP, 1997, J NEUROSCI RES, V50, P505; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; Octave JN, 2000, J BIOL CHEM, V275, P1525, DOI 10.1074/jbc.275.3.1525; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PIPER RC, 1994, METHOD CELL BIOL, V43, P55; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Sheridan KM, 1998, J MOL NEUROSCI, V10, P121, DOI 10.1007/BF02737123; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1993, J BIOL CHEM, V268, P16602; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Tan YZ, 1998, BBA-MOL BASIS DIS, V1407, P69, DOI 10.1016/S0925-4439(98)00031-3; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	114	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20267	20279		10.1074/jbc.M007238200	http://dx.doi.org/10.1074/jbc.M007238200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278337	hybrid			2022-12-27	WOS:000169135100082
J	Soitamo, AJ; Rabergh, CMI; Gassmann, M; Sistonen, L; Nikinmaa, M				Soitamo, AJ; Rabergh, CMI; Gassmann, M; Sistonen, L; Nikinmaa, M			Characterization of a hypoxia-inducible factor (HIF-1 alpha) from rainbow trout - Accumulation of protein occurs at normal venous oxygen tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; ARYL-HYDROCARBON RECEPTOR; ARNT TRANSCRIPTION FACTOR; FACTOR 1-ALPHA; ONCORHYNCHUS-MYKISS; SIGNAL-TRANSDUCTION; DEGRADATION DOMAIN; ALPHA-SUBUNIT; HEAT-SHOCK	The mammalian hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription factor that controls the induction of several genes involved in glycolysis, erythropoiesis, and angiogenesis when cells are exposed to hypoxic conditions. Until now, the expression and function of HIF-1 alpha have not been studied in fish, which experience wide fluctuations of oxygen tensions in their natural environment. Using electrophoretic mobility shift assay, we have ascertained that a hypoxia-inducible factor is present in rainbow trout cells. We have also cloned the full-length cDNA (3605 base pairs) of the HIF-1 alpha from rainbow trout with a predicted protein sequence of 766 amino acids that showed a 61% similarity to human and mouse HIF-1 alpha. Polyclonal antibodies against the N-terminal part (amino acids 12-363) and the C-terminal part (amino acids 330-730) of rainbow trout HIF-1 alpha protein recognized rainbow trout and chinook salmon HIF-1 alpha protein in Western blot analysis. Also, the human and mouse HIF-1 alpha proteins were recognized by the N-terminal rainbow trout anti-HIF-1 alpha antibody but not by the C-terminal HIF-1 alpha antibody. The accumulation of HIF-1 alpha was studied by incubating rainbow trout and chinook salmon cells at different oxygen concentrations from 20 to 0.2% O-2 for 1 h. The greatest accumulation of HIF-1 alpha protein occurred at 5% O-2 (38 torr), a typical oxygen tension of venous blood in normoxic animals. The protein stability experiments in the absence or presence of a proteasome inhibitor, MG-132, demonstrated that the inhibitor is able to stabilize the protein, which normally is degraded via the proteasome pathway both in normoxia and hypoxia. Notably, the hypoxia response element of oxygen dependent degradation domain is identical in mammalian, Xenopus, and rainbow trout HIF-1 alpha proteins, suggesting a high degree of evolutionary conservation in degradation of HIF-1 alpha protein.	Univ Turku, Dept Biol, Physiol Anim Lab, FIN-20014 Turku, Finland; Abo Akad Univ, Univ Turku, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biol, FIN-20521 Turku, Finland; Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland	University of Turku; Abo Akademi University; University of Turku; Abo Akademi University; University of Zurich	Soitamo, AJ (corresponding author), Univ Turku, Dept Biol, Physiol Anim Lab, FIN-20014 Turku, Finland.		Nikinmaa, Mikko/AAZ-2803-2021; Soitamo, Arto J/C-4435-2015	Nikinmaa, Mikko/0000-0003-0593-1018; Sistonen, Lea/0000-0003-1341-2867				Airaksinen S, 1998, J EXP BIOL, V201, P2543; BOYLE JS, 1995, BIOTECOLOGY THEORY T, V2, P35; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graham JB, 1997, AIR BREATHING FISHES, DOI DOI 10.1016/B978-012294860-2/50006-4; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hahn ME, 1998, COMP BIOCHEM PHYS C, V121, P23, DOI 10.1016/S0742-8413(98)10028-2; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNAN CN, 1984, IN VITRO CELL DEV B, V20, P671, DOI 10.1007/BF02618871; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; NIKINMAA M, 1982, J EXP ZOOL, V219, P173, DOI 10.1002/jez.1402190206; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rabergh Christina M., 1995, Methods in Cell Science, V17, P207, DOI 10.1007/BF00996128; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sambrook J., 2002, MOL CLONING LAB MANU; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHOUBRIDGE EA, 1981, MOL PHYSIOL, V1, P315; Soncin F, 1997, PROTEIN EXPRES PURIF, V9, P27, DOI 10.1006/prep.1996.0672; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Weber R.E., 1982, P87; Wenger RH, 1998, INT J MOL MED, V2, P317; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; WOLF K, 1962, SCIENCE, V135, P1065, DOI 10.1126/science.135.3508.1065	48	141	150	5	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19699	19705		10.1074/jbc.M009057200	http://dx.doi.org/10.1074/jbc.M009057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278461	hybrid			2022-12-27	WOS:000169135100005
J	Vancurova, I; Miskolci, V; Davidson, D				Vancurova, I; Miskolci, V; Davidson, D			NF-kappa B activation in tumor necrosis factor alpha-stimulated neutrophils is mediated by protein kinase C delta - Correlation to nuclear I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; TRANSCRIPTIONAL ACTIVATION; SELECTIVE ACTIVATION; SIGNAL-TRANSDUCTION; T-LYMPHOCYTES; PKC-DELTA; APOPTOSIS; INHIBITOR; INTERLEUKIN-8; EXPRESSION	The transcription factor NF-kappaB is critical for the expression of multiple genes involved in inflammatory responses and apoptosis. However, the signal transduction pathways regulating NF-kappaB activation in human neutrophils in response to stimulation with tumor necrosis factor-alpha (TNF alpha) are undefined. Since recent studies implicated activation of NP-kappaB as well as protein kinase C-delta (PKC delta) in neutrophil apoptosis, we investigated involvement of PKC delta in the activation of NF-kappaB in TNF alpha -stimulated neutrophils. Specific inhibition of PKC delta by rottlerin prevented I kappaB alpha degradation and NF-kappaB activation in TNF alpha -stimulated neutrophils. This regulation of NF-kappaB activation by PKC delta was specific only for TNF alpha signaling, since lipopolysaccharide- or interleukin-1 beta -induced NF-kappaB activation and I kappaB alpha degradation were not inhibited by rottlerin. In addition, we show that in human neutrophils, but not monocytes, I kappaB alpha localizes in significant amounts in the nucleus of unstimulated cells, and the amount of I kappaB alpha in the nucleus, as well as in the cytoplasm, correlates with the NF-kappaB DNA binding. These results suggest that in human neutrophils, the presence of I kappaB alpha in the nucleus may function as a safeguard against initiation of NF-kappaB dependent transcription of pro-inflammatory and anti-apoptotic genes, and represents a distinct and novel mechanism of NF-kappaB regulation.	Schneider Childrens Hosp, Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Div Neonatal Perinatal Med, New Hyde Pk, NY 11040 USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Yeshiva University	Vancurova, I (corresponding author), Schneider Childrens Hosp, Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Div Neonatal Perinatal Med, Long Isl Campus,Res Bldg,B-49,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	vancurov@lij.edu						ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Cassatella MA, 1997, ANN NY ACAD SCI, V832, P233, DOI 10.1111/j.1749-6632.1997.tb46251.x; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; de Lera TL, 1999, ONCOGENE, V18, P1581, DOI 10.1038/sj.onc.1202455; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hay RT, 1999, PHILOS T R SOC B, V354, P1601, DOI 10.1098/rstb.1999.0504; HENSON PM, 1988, HUMAN INFLAMMATORY D, V1, P69; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kent JD, 1996, J IMMUNOL, V157, P4641; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kilpatrick LE, 2000, AM J PHYSIOL-CELL PH, V279, pC2011, DOI 10.1152/ajpcell.2000.279.6.C2011; Kozawa O, 1997, J BIOL CHEM, V272, P25099, DOI 10.1074/jbc.272.40.25099; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Nixon JB, 1999, J IMMUNOL, V163, P4574; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; POWIS G, 1992, CANCER RES, V52, P2853; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith RJ, 1996, J PHARMACOL EXP THER, V278, P320; STRIETER RM, 1992, AM J PATHOL, V141, P397; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; TAN ND, 1995, PEDIATR RES, V38, P11, DOI 10.1203/00006450-199507000-00003; TIKU K, 1986, J IMMUNOL, V136, P3677; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Vancurova I, 2001, PEDIATR RES, V49, P257, DOI 10.1203/00006450-200102000-00021; Wang JP, 1997, EUR J PHARMACOL, V319, P131, DOI 10.1016/S0014-2999(96)00836-9; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Zentay Z, 1999, PEDIATR RES, V46, P406, DOI 10.1203/00006450-199910000-00008	53	112	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19746	19752		10.1074/jbc.M100234200	http://dx.doi.org/10.1074/jbc.M100234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274209	hybrid			2022-12-27	WOS:000169135100011
J	Dembowski, M; Kunkele, KP; Nargang, FE; Neupert, W; Rapaport, D				Dembowski, M; Kunkele, KP; Nargang, FE; Neupert, W; Rapaport, D			Assembly of Tom6 and Tom7 into the TOM core complex of Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; GENERAL IMPORT PORE; PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; INTERMEMBRANE-SPACE; YEAST MITOCHONDRIA; RECEPTOR COMPLEX; CYTOSOLIC DOMAIN; BIOGENESIS; ISP6	Translocation of preproteins across the mitochondrial outer membrane is mediated by the translocase of the outer mitochondrial membrane (TOM) complex. We report the molecular identification of Tom6 and Tom7, two small subunits of the TOM core complex in the fungus Neurospora crassa, Cross-linking experiments showed that both proteins were found to be in direct contact with the major component of the pore, Tom40, In addition, Tom6 was observed to interact with Tom22 in a manner that depends on the presence of preproteins in transit, Precursors of both proteins are able to insert into the outer membrane in vitro and are assembled into authentic TOM complexes. The insertion pathway of these proteins shares a common binding site with the general import pathway as the assembly of both Tom6 and Tom7 was competed by a matrix-destined precursor protein. This assembly was dependent on the integrity of receptor components of the TOM machinery and is highly specific as in vitro-synthesized yeast Tom6 was not assembled into N. crassa TOM complex. The targeting and assembly information within the Tome sequence was found to be located in the transmembrane segment and a flanking segment toward the N-terminal, cytosolic side. A hybrid protein composed of the C-terminal domain of yeast Tome and the cytosolic domain of N. crassa Tome was targeted to the mitochondria but was not taken up into TOM complexes. Thus, both segments are required for assembly into the TOM complex. A model for the topogenesis of the small Tom subunits is discussed.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	Hebrew University of Jerusalem; University of Alberta; University of Munich	Rapaport, D (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.		Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; Cao W, 1996, BIOCHEM BIOPH RES CO, V224, P457, DOI 10.1006/bbrc.1996.1048; Court DA, 1996, MOL CELL BIOL, V16, P4035; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kunkele KP, 1998, J BIOL CHEM, V273, P31032, DOI 10.1074/jbc.273.47.31032; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLOSSMANN J, 1995, J BIOL CHEM, V270, P27116, DOI 10.1074/jbc.270.45.27116; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; Stan T, 2000, EMBO J, V19, P4895, DOI 10.1093/emboj/19.18.4895; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	33	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17679	17685		10.1074/jbc.M009653200	http://dx.doi.org/10.1074/jbc.M009653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278536	hybrid			2022-12-27	WOS:000168866500009
J	Harris, TJC; Awrey, DE; Cox, BJ; Ravandi, A; Tsang, A; Siu, CH				Harris, TJC; Awrey, DE; Cox, BJ; Ravandi, A; Tsang, A; Siu, CH			Involvement of a Triton-insoluble floating fraction in Dictyostelium cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; ENRICHED MEMBRANE SUBDOMAINS; SIGNAL-TRANSDUCING MOLECULES; POLYUNSATURATED FATTY-ACIDS; GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE; LIPID RAFTS; T-CADHERIN; BIOLOGICAL-MEMBRANES; SURFACE GLYCOPROTEIN	We have isolated and characterized a Triton-insoluble floating fraction (TIFF) from Dictyostelium, Ten major proteins were consistently detected in TIFF, and six species were identified by mass spectrometry as actin, porin, comitin, regulatory myosin light chain, a novel member of the CD36 family, and the phospholipid-anchored cell adhesion molecule gp80, TIFF was enriched with many acylated proteins. Also, the sterol phospholipid ratio of TIFF was 10-fold higher than that of the bulk plasma membrane. Immunoelectron microscopy showed that TIFF has vesicular morphology and confirmed the association of gp80 and comitin with TIFF membranes. Several TIFF properties were similar to those of Dictyostelium contact regions, which were isolated as a cytoskeleton-associated membrane fraction. Mass spectrometry demonstrated that TIFF and contact regions shared the same major proteins. During development, gp80 colocalized with F-actin, porin, and comitin at cell-cell contacts. These proteins were also recruited to gp80 caps induced by antibody crosslinking. Filipin staining revealed high sterol levels in both gp80-enriched cell-cell contacts and gp80 caps. Moreover, sterol sequestration by filipin and digitonin inhibited gp80-mediated cell-cell adhesion. This study reveals that Dictyostelium TIFF has structural properties previously attributed to vertebrate TIFF and establishes a role for Dictyostelium TIFF in cell-cell adhesion during development.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada; Integrat Proteom Inc, Toronto, ON M5G 1L5, Canada; Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada	University of Toronto; University of Toronto; Concordia University - Canada	Siu, CH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Ravandi, Amir/O-7552-2019					Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Asou H, 1996, J NEUROSCI RES, V45, P571, DOI 10.1002/(SICI)1097-4547(19960901)45:5<571::AID-JNR7>3.0.CO;2-9; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BRAR SK, 1993, J BIOL CHEM, V268, P24902; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; DESBARATS L, 1994, J CELL SCI, V107, P1705; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; FAIX J, 1990, EMBO J, V9, P2709, DOI 10.1002/j.1460-2075.1990.tb07457.x; FAVARDSERENO C, 1981, J CELL SCI, V51, P63; Funatsu N, 1999, J BIOL CHEM, V274, P8224, DOI 10.1074/jbc.274.12.8224; GAO EN, 1992, J BIOL CHEM, V267, P9409; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; GELTOSKY JE, 1979, CELL, V18, P391, DOI 10.1016/0092-8674(79)90058-8; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; GREENWOOD MT, 1992, BIOCHEM CELL BIOL, V70, P1047, DOI 10.1139/o92-149; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HARLOFF C, 1989, GENE DEV, V3, P2011, DOI 10.1101/gad.3.12a.2011; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1990, CELL REGUL, V1, P715, DOI 10.1091/mbc.1.10.715; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM TY, 1981, DIFFERENTIATION, V20, P22, DOI 10.1111/j.1432-0436.1981.tb01151.x; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; MURRAY BA, 1982, DEV DICTYOSTELIUM DI, P71; MYNES RO, 1999, TRENDS CELL BIOL, V9, pM33; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; OCHIAI H, 1982, CELL DIFFER DEV, V11, P1, DOI 10.1016/0045-6039(82)90011-2; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Ponte E, 1998, P NATL ACAD SCI USA, V95, P9360, DOI 10.1073/pnas.95.16.9360; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; Ravandi A, 1999, J BIOL CHEM, V274, P16494, DOI 10.1074/jbc.274.23.16494; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SADEGHI H, 1988, P NATL ACAD SCI USA, V85, P5512, DOI 10.1073/pnas.85.15.5512; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sesaki H, 1997, J CELL BIOL, V138, P939, DOI 10.1083/jcb.138.4.939; Sesaki H, 1996, DEV BIOL, V177, P504, DOI 10.1006/dbio.1996.0181; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SIU CH, 1977, J MOL BIOL, V116, P469, DOI 10.1016/0022-2836(77)90080-8; Spaltmann F, 1996, J NEUROSCI, V16, P1770; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TROLL H, 1992, J BIOL CHEM, V267, P21072; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WALSH FS, 1991, CELL BIOL INT REP, V15, P1151, DOI 10.1016/0309-1651(91)90061-M; Wang J, 2000, DEV BIOL, V227, P734, DOI 10.1006/dbio.2000.9881; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wong EFS, 1996, J BIOL CHEM, V271, P16399, DOI 10.1074/jbc.271.27.16399; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Xiao Z, 1997, MOL BIOL CELL, V8, P855, DOI 10.1091/mbc.8.5.855; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	79	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18640	18648		10.1074/jbc.M010016200	http://dx.doi.org/10.1074/jbc.M010016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278598	hybrid			2022-12-27	WOS:000168866500135
J	Sheng, HM; Shao, JY; Washington, MK; DuBois, RN				Sheng, HM; Shao, JY; Washington, MK; DuBois, RN			Prostaglandin E-2 increases growth and motility of colorectal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; PROTEIN-COUPLED RECEPTORS; CYCLOOXYGENASE-2 INHIBITOR; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; EXPRESSION; RAS; APOPTOSIS; AKT	Chronic use of nonsteroidal anti-inflammatory drugs results in a significant reduction of risk and mortality from colorectal cancer in humans. All of the mechanism(s) by which nonsteroidal anti-inflammatory drugs exert their protective effects are not completely understood, but they are known to inhibit cyclooxygenase activity. The cyclooxygenase enzymes catalyze a key reaction in the conversion of arachidonic acid to prostaglandins, such as prostaglandin E-2 (PGE(2)). Here we demonstrate that PGE(2) treatment of LS-174 human colorectal carcinoma cells leads to increased motility and changes in cell shape. The prostaglandin EP4 receptor signaling pathway appears to play a role in transducing signals which regulate these effects. PGE(2) treatment results in an activation of phosphatidylinositol 3-kinase/ protein kinase B pathway that is required for the PGE(2)-induced changes in carcinoma cell motility and colony morphology. Our results suggest that PGE(2) might enhance the invasive potential of colorectal carcinoma cells via activation of major intracellular signal transduction pathways not previously reported to be regulated by prostaglandins.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [P01CA77839, P30CA-68485] Funding Source: Medline; NIDDK NIH HHS [R01DK47297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; Breyer MD, 2000, CURR OPIN NEPHROL HY, V9, P23, DOI 10.1097/00041552-200001000-00005; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DEVRIES GW, 1995, BRIT J PHARMACOL, V115, P1231; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; JAFFER S, 1995, AM J NEPHROL, V15, P300, DOI 10.1159/000168853; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEPPERT D, 1995, FASEB J, V9, P1473, DOI 10.1096/fasebj.9.14.7589989; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Osada M, 1999, MOL CELL BIOL, V19, P6333; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Reddy BS, 2000, CANCER RES, V60, P293; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; Schmidt C, 1997, INVAS METAST, V17, P53; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	51	549	574	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18075	18081		10.1074/jbc.M009689200	http://dx.doi.org/10.1074/jbc.M009689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278548	hybrid			2022-12-27	WOS:000168866500062
J	Schneider, D; Berry, S; Rich, P; Seidler, A; Rogner, M				Schneider, D; Berry, S; Rich, P; Seidler, A; Rogner, M			A regulatory role of the PetM subunit in a cyanobacterial cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; OPEN READING FRAME; CHLAMYDOMONAS-REINHARDTII; BC(1) COMPLEX; PHOTOSYSTEM-I; B6-F COMPLEX; BF COMPLEX; PCC 6803; GENE; POLYPEPTIDE	To investigate the function of the PetM subunit of the cytochrome b(6)f complex, the petM gene encoding this subunit was inactivated by insertional mutagenesis in the cyanobacterium Synechocystis PCC 6803, Complete segregation of the mutant reveals a nonessential function of PetM for the structure and function of the cytochrome b(6)f complex in this organism. Photosystem I, photosystem II, and the cytochrome b(6)f complex still function normally in the petM(-) mutant as judged by cytochrome f re-reduction and oxygen evolution rates. In contrast to the wild type, however, the content of phycobilisomes and photosystem I as determined from 77 K fluorescence spectra is reduced in the petM(-) strain. Furthermore, whereas under anaerobic conditions the kinetics of cytochrome f re-reduction are identical, under aerobic conditions these kinetics are slower in the petM(-) strain. Fluorescence induction measurements indicate that this is due to an increased plastoquinol oxidase activity in the mutant, causing the plastoquinone pool to be in a more oxidized state under aerobic dark conditions. The finding that the activity of the cytochrome b(6)f complex itself is unchanged, whereas the stoichiometry of other protein complexes has altered, suggests an involvement of the PetM subunit in regulatory processes mediated by the cytochrome b(6)f complex.	Ruhr Univ Bochum, Fak Biol, Lehrstuhl Biochem Pflanzen, D-44780 Bochum, Germany; UCL, Glynn Lab Bioenerget, Dept Biol, London WC1E 6BT, England	Ruhr University Bochum; University of London; University College London	Rogner, M (corresponding author), Ruhr Univ Bochum, Fak Biol, Lehrstuhl Biochem Pflanzen, Univ Str 150, D-44780 Bochum, Germany.	Matthias.Roegner@ruhr-uni-bochum.de						Ajlani G, 1998, PLANT MOL BIOL, V37, P577, DOI 10.1023/A:1005924730298; Bald D, 1996, PHOTOSYNTH RES, V49, P103, DOI 10.1007/BF00117661; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; Cramer WA, 1997, PHYSIOL PLANTARUM, V100, P852, DOI 10.1111/j.1399-3054.1997.tb00011.x; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; Fujita Y., 1994, MOL BIOL CYANOBACTER, P677; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kaneko T, 1996, DNA Res, V3, P109; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; Kugler M, 1998, J PLANT PHYSIOL, V153, P581, DOI 10.1016/S0176-1617(98)80207-1; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; MURAKAMI A, 1993, PLANT CELL PHYSIOL, V34, P1175; NILSSON F, 1990, PLANT MOL BIOL, V14, P1051, DOI 10.1007/BF00019402; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; OSIEWACZ HD, 1992, ARCH MICROBIOL, V157, P336, DOI 10.1007/BF00248678; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pils D, 1997, FEMS MICROBIOL LETT, V152, P83, DOI 10.1111/j.1574-6968.1997.tb10412.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHERER S, 1990, TRENDS BIOCHEM SCI, V15, P458, DOI 10.1016/0968-0004(90)90296-N; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; Schneider D, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1545; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Wollman F. A., 1998, MOL BIOL CHLOROPLAST, P459; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3	42	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16780	16785		10.1074/jbc.M009503200	http://dx.doi.org/10.1074/jbc.M009503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278512	hybrid			2022-12-27	WOS:000168730400026
J	Nicholson, B; Manner, CK; Kleeman, J; MacLeod, CL				Nicholson, B; Manner, CK; Kleeman, J; MacLeod, CL			Sustained nitric oxide production in macrophages requires the arginine transporter CAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; ECOTROPIC RETROVIRUS RECEPTOR; CELL-SURFACE RECEPTOR; MURINE RETROVIRUSES; GENE-EXPRESSION; ANIMAL-CELLS; SYNTHASE; RESPONSES; FAMILY; BRAIN	The aberrant production of nitric oxide (NO) contributes to the pathogenesis of diseases as diverse as cancer and arthritis. Sustained NO production via the inducible enzyme, nitric-oxide synthase 2 (NOS2), requires extracellular arginine uptake. Three closely related cationic amino acid transporter genes (Cat1-3) encode the transporters that mediate most arginine uptake in mammalian cells. Because CAT2 is induced coordinately with NOS2 in numerous cell types, we investigated a possible role for CAT2-mediated arginine transport in regulating NO production. The complexity of arginine transport systems and their biochemically similar transport properties called for a genetic approach to determine the role of CAT2. CAT2-deficient mice were generated and found to be healthy and fertile in contrast to Cat1(-/-) animals. Analysis of cytokine-activated macrophages from Cat2(-/-) mice revealed a 92% reduction in NO production and a 95% reduction in L-Arg uptake. The reduction in NO production was not due to differences in NOS2 protein expression, NOS2 activity, or intracellular L-arginine content. In conclusion, our results show that sustained abundant NO synthesis by macrophages requires arginine transport via the CAT2 transporter.	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	MacLeod, CL (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr,Mail Code 0064, La Jolla, CA 92093 USA.			Manner, Cathyryne/0000-0002-1955-8608	NCI NIH HHS [CA81376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; Closs EI, 2000, MOL PHARMACOL, V57, P68; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; Closs EI, 1996, AMINO ACIDS, V11, P193, DOI 10.1007/BF00813860; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; FORTIER AH, 1994, CURRENT PROTOCOLS IM; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; HIBBS JB, 1987, J IMMUNOL, V138, P550; Ito K, 1997, J BIOL CHEM, V272, P26780, DOI 10.1074/jbc.272.42.26780; Kakuda DK, 1998, BBA-BIOMEMBRANES, V1414, P75, DOI 10.1016/S0005-2736(98)00155-2; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MacLeod CL, 1996, BIOCHEM SOC T, V24, P846, DOI 10.1042/bst0240846; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; Nicholson B, 1998, J BIOL CHEM, V273, P14663, DOI 10.1074/jbc.273.24.14663; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; Stichtenoth DO, 1998, BRIT J RHEUMATOL, V37, P246; Sweet MJ, 1998, J INTERF CYTOK RES, V18, P263, DOI 10.1089/jir.1998.18.263; Thomsen LL, 1998, CANCER METAST REV, V17, P107, DOI 10.1023/A:1005912906436; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG H, 1994, VIROLOGY, V202, P1058, DOI 10.1006/viro.1994.1439; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WHITE MF, 1982, J BIOL CHEM, V257, P4443	35	181	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15881	15885		10.1074/jbc.M010030200	http://dx.doi.org/10.1074/jbc.M010030200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278602	hybrid			2022-12-27	WOS:000168623100043
J	Jacob, RF; Cenedella, RJ; Mason, RP				Jacob, RF; Cenedella, RJ; Mason, RP			Evidence for distinct cholesterol domains in fiber cell membranes from cataractous human lenses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; BOVINE LENSES; LIPID-COMPOSITION; U18666A CATARACT; NATIVE MEMBRANE; OCULAR LENS; RAT LENS; PROTEIN; PHOSPHOLIPIDS; CALCIUM	Previous studies in our laboratory have provided direct evidence for the existence of distinct cholesterol domains within the plasma membranes of human ocular lens fiber cells. The fiber cell plasma membrane is unique in that it contains unusually high concentrations of cholesterol, with cholesterol to phospholipid (C/P) mole ratios ranging from 1 to 4, Since membrane cholesterol content is disturbed in the development of cataracts, it was hypothesized that perturbation of cholesterol domain structure occurs in cataracts. In this study, fiber cell plasma membranes were isolated from both normal (control) and cataractous lenses and assayed for cholesterol and phospholipid, Control and cataractous whole lens membranes had C/P mole ratios of 3.1 and 1,7, respectively. Small angle x-ray diffraction approaches were used to directly examine the structural organization of the cataractous lens plasma membrane versus control. Both normal and cataractous oriented membranes yielded meridional diffraction peaks corresponding to a unit cell periodicity of 34.0 % Angstrom, consistent with the presence of immiscible cholesterol domains. However, comparison of diffraction patterns indicated that cataractous lens membranes contained more pronounced and better defined cholesterol domains than controls, over a broad range of temperature (5-40 degreesC) and relative humidity (52-92%) levels. In addition, diffraction analyses of the sterol-poor regions of cataractous membranes indicated increased membrane rigidity as compared with control membranes. Modification of the membrane lipid environment, such as by oxidative insult, is believed to be one potential mechanism for the formation of highly resolved cholesterol domains despite significantly reduced cholesterol content. The results of this x-ray diffraction study provide evidence for fundamental changes in the lens fiber cell plasma membrane structure in cataracts, including the presence of more prominent and highly ordered, immiscible cholesterol domains.	MCP Hahnemann Univ, Sch Med, Dept Med, Membrane Biophys Lab, Pittsburgh, PA 15212 USA; Kirksville Coll Osteopath Med, Dept Biochem, Kirksville, MO 63501 USA	Drexel University	Jacob, RF (corresponding author), Elucida Res LLC, POB 7100, Beverly, MA 01915 USA.				NEI NIH HHS [EY02568] Funding Source: Medline; NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCALA J, 1985, CURR EYE RES, V4, P1001, DOI 10.3109/02713689509000008; ANDERSON RE, 1969, BIOCHIM BIOPHYS ACTA, V187, P345, DOI 10.1016/0005-2760(69)90008-3; Bach D, 1998, CHEM PHYS LIPIDS, V92, P71, DOI 10.1016/S0009-3084(98)00006-1; BASSNETT S, 1995, INVEST OPHTH VIS SCI, V36, P1793; BENEDETTI EL, 1976, BIOCHIM BIOPHYS ACTA, V457, P353, DOI 10.1016/0304-4157(76)90004-6; BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X; BLOEMENDAL H, 1991, INVEST OPHTH VIS SCI, V32, P445; BORCHMAN D, 1994, INVEST OPHTH VIS SCI, V35, P3938; BORCHMAN D, 1989, CURR EYE RES, V8, P1049, DOI 10.3109/02713688908997397; Borchman D, 1998, INVEST OPHTH VIS SCI, V39, P1053; BROEKHUYSE RM, 1976, EXP EYE RES, V22, P653, DOI 10.1016/0014-4835(76)90010-5; BROEKHUYSE RM, 1969, BIOCHIM BIOPHYS ACTA, V187, P354, DOI 10.1016/0005-2760(69)90009-5; Byrdwell WC, 1997, OPHTHALMIC RES, V29, P191; BYRDWELL WC, 1994, INVEST OPHTH VIS SCI, V35, P4333; CENEDELLA RJ, 1979, EXP EYE RES, V28, P673, DOI 10.1016/0014-4835(79)90068-X; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; CENEDELLA RJ, 1979, EXP EYE RES, V29, P655, DOI 10.1016/0014-4835(79)90021-6; CENEDELLA RJ, 1982, LIPIDS, V17, P443, DOI 10.1007/BF02535224; CENEDELLA RJ, 1985, CURR EYE RES, V4, P113, DOI 10.3109/02713688508999976; Cenedella RJ, 1996, SURV OPHTHALMOL, V40, P320, DOI 10.1016/S0039-6257(96)82007-8; CENEDELLA RJ, 1983, EXP EYE RES, V37, P33, DOI 10.1016/0014-4835(83)90147-1; CHANDRASEKHER G, 1995, EXP EYE RES, V60, P707, DOI 10.1016/S0014-4835(05)80012-0; CHANDRASEKHER G, 1993, EXP EYE RES, V57, P737, DOI 10.1006/exer.1993.1181; COTLIER E, 1978, BIOCHIM BIOPHYS ACTA, V530, P267, DOI 10.1016/0005-2760(78)90012-7; CRAVEN BM, 1976, NATURE, V260, P727, DOI 10.1038/260727a0; DUNCAN G, 1984, CIBA F SYMP, V106, P132; ENGELMAN DM, 1972, J BIOL CHEM, V247, P3694; Feher J, 1996, ACTA OPHTHALMOL SCAN, V74, P573; FLESCHNER CR, 1991, J LIPID RES, V32, P45; GANDOLFI SA, 1985, CURR EYE RES, V4, P753, DOI 10.3109/02713688509020030; GARNER MH, 1981, P NATL ACAD SCI-BIOL, V78, P1892, DOI 10.1073/pnas.78.3.1892; GERSON RJ, 1990, EXP EYE RES, V50, P65, DOI 10.1016/0014-4835(90)90012-J; GOODEN MM, 1983, CURR EYE RES, V2, P367; HARRIS JS, 1995, BIOCHEMISTRY-US, V34, P3851, DOI 10.1021/bi00011a043; Houslay M. D., 1982, DYNAMICS BIOL MEMBRA; Jacob RF, 1999, J BIOL CHEM, V274, P31613, DOI 10.1074/jbc.274.44.31613; KIRBY TJ, 1962, ARCH OPHTHALMOL-CHIC, V68, P486; KIRBY TJ, 1967, T AM OPHTHAL SOC, V65, P493; KUSZAK JR, 1988, INVEST OPHTH VIS SCI, V29, P261; LAUGHLIN RC, 1962, JAMA-J AM MED ASSOC, V182, P129; LEES MB, 1972, ANAL BIOCHEM, V47, P184, DOI 10.1016/0003-2697(72)90291-6; LI LK, 1985, J LIPID RES, V26, P600; LI LK, 1987, BIOCHIM BIOPHYS ACTA, V917, P112, DOI 10.1016/0005-2760(87)90291-8; LI LK, 1987, CURR EYE RES, V6, P599, DOI 10.3109/02713688709025219; LIANG JN, 1989, CURR EYE RES, V8, P293, DOI 10.3109/02713688908997571; MARAINI G, 1973, HUMAN LENS RELATION, V19, P79; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MIZUNO GR, 1981, BIOCHIM BIOPHYS ACTA, V644, P1, DOI 10.1016/0005-2736(81)90052-3; PASINO M, 1982, EXP EYE RES, V34, P887, DOI 10.1016/0014-4835(82)90068-9; Paterson CA, 1997, CURR EYE RES, V16, P333, DOI 10.1076/ceyr.16.4.333.10689; POLLET S, 1978, J LIPID RES, V19, P916; Rafferty N. S., 1985, OCULAR LENS STRUCTUR, P1; RAO RV, 1975, BIOCHIM BIOPHYS ACTA, V409, P329; RICE PA, 1989, P NATL ACAD SCI USA, V86, P6445, DOI 10.1073/pnas.86.17.6445; RINTOUL DA, 1987, CURR EYE RES, V6, P1343, DOI 10.3109/02713688708997560; ROELFZEMA H, 1976, EXP EYE RES, V23, P409, DOI 10.1016/0014-4835(76)90169-X; ROSENFELD L, 1982, EXP EYE RES, V35, P69, DOI 10.1016/S0014-4835(82)80024-9; ROSENFELD L, 1981, EXP EYE RES, V33, P641, DOI 10.1016/S0014-4835(81)80104-2; ROY D, 1982, EXP EYE RES, V35, P113, DOI 10.1016/S0014-4835(82)80060-2; RUOCCO MJ, 1984, BIOPHYS J, V46, P695, DOI 10.1016/S0006-3495(84)84068-0; RUSSELL P, 1981, EXP EYE RES, V32, P511, DOI 10.1016/S0014-4835(81)80030-9; Sato H, 1996, EXP EYE RES, V62, P47, DOI 10.1006/exer.1996.0006; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1237, P127, DOI 10.1016/0005-2736(95)00096-L; Tang DX, 1998, EXP EYE RES, V66, P559, DOI 10.1006/exer.1997.0467; Tulenko TN, 1998, J LIPID RES, V39, P947; ZELENKA PS, 1984, CURR EYE RES, V3, P1337, DOI 10.3109/02713688409007421; ZIGMAN S, 1984, CURR EYE RES, V3, P887, DOI 10.3109/02713688409167206; Zink JM, 1997, OPHTHALMIC RES, V29, P429, DOI 10.1159/000268044	69	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13573	13578		10.1074/jbc.M010077200	http://dx.doi.org/10.1074/jbc.M010077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278611	hybrid			2022-12-27	WOS:000168356600011
J	Plyte, S; Boncristiano, M; Fattori, E; Galvagni, F; Paccani, SR; Majolini, MB; Oliviero, S; Ciliberto, G; Telford, JE; Baldari, CT				Plyte, S; Boncristiano, M; Fattori, E; Galvagni, F; Paccani, SR; Majolini, MB; Oliviero, S; Ciliberto, G; Telford, JE; Baldari, CT			Identification and characterization of a novel nuclear factor of activated T-cells-1 isoform expressed in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFATP; CELL ANTIGEN RECEPTOR; DEPENDENT GENE ACTIVATION; T-CELLS; NF-ATC; CYCLOSPORINE-A; MUSCLE-CELLS; TRANSGENIC MICE; FAMILY MEMBER; CALCINEURIN	The nuclear factor of activated T-cells (NFAT) family transcription factors play a key role in the control of cytokine gene expression in T-cells. Although initially identified in T-cells, recent data have unveiled unanticipated roles for NFATs in the development, proliferation, and differentiation of other tissues. Here we report the identification, cDNA cloning, and functional characterization of a new isoform of NFAT1 highly expressed in mouse brain. This isoform, which we named NPAT1-D, is identical to NFAT1 throughout the N-terminal regulatory domain and the portion of the Rel domain which includes the minimal region required for specific binding to DNA and interaction with AP-1. The homology stops sharply upstream of the 3'-boundary of the Rel homology domain and is followed by a short unique C-terminal region. NFAT1-D was expressed at high levels in all brain districts and was found as a constitutively active transcription complex. Transfection of a NFAT/luciferase reporter in the neuronal cell line PC12, which also expresses NFAT1-D, showed that these cells expressed a constitutive NFAT activity that was enhanced after nerve growth factor-induced differentiation but was resistant to the immunosuppressant cyclosporin A. NFAT1-D was, however, inducibly activated in a cyclosporin A-sensitive manner when expressed in T-cells, suggesting that the activity of NFAT proteins might be controlled by their specific cellular context.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; Univ Siena, Dept Mol Biol, I-53100 Siena, Italy; Chiron Res Ctr, I-53100 Siena, Italy; IRBM, I-00040 Pomezia, RM, Italy	University of Siena; University of Siena; Novartis; Merck & Company	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Fiorentina 1, I-53100 Siena, Italy.		Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019; Ciliberto, Gennaro/J-4131-2017	oliviero, salvatore/0000-0002-3405-765X; Ciliberto, Gennaro/0000-0003-2851-8605; Baldari, Cosima/0000-0002-4414-6744				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; Baldari CT, 1998, BIOLOGICALS, V26, P1, DOI 10.1006/biol.1997.0116; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; BROMBACHER F, 1994, INT IMMUNOL, V6, P189, DOI 10.1093/intimm/6.2.189; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FATTORI E, 1994, BLOOD, V83, P2570; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Galvagni F, 1998, J BIOL CHEM, V273, P33708, DOI 10.1074/jbc.273.50.33708; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HO AM, 1994, J BIOL CHEM, V269, P28181; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Milia E, 1996, ONCOGENE, V13, P767; Naramura M, 1998, IMMUNITY, V9, P209, DOI 10.1016/S1074-7613(00)80603-2; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Park JC, 1996, J BIOL CHEM, V271, P20914, DOI 10.1074/jbc.271.34.20914; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855	43	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14350	14358		10.1074/jbc.M007854200	http://dx.doi.org/10.1074/jbc.M007854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278367	hybrid			2022-12-27	WOS:000168356600111
J	Alderton, F; Darroch, P; Sambi, B; McKie, A; Ahmed, IS; Pyne, N; Pyne, S				Alderton, F; Darroch, P; Sambi, B; McKie, A; Ahmed, IS; Pyne, N; Pyne, S			G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; AIRWAY SMOOTH-MUSCLE; MOLECULAR-CLONING; ACID-PHOSPHATASE; LYSOPHOSPHATIDIC ACID; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; IDENTIFICATION; EDG-1; DOMAINS	Sphingosine l-phosphate, lysophosphatidic acid, and phosphatidic acid bind to G-protein-coupled receptors to stimulate intracellular signaling in mammalian cells. Lipid phosphate phosphatases (1, la, 2, and 3) are a group of enzymes that catalyze de-phosphorylation of these lipid agonists. It has been proposed that the lipid phosphate phosphatases exhibit ecto activity that may function to limit bioavailability of these lipid agonists at their receptors, In this study, we show that the stimulation of the p42/p44 mitogen-activated protein kinase pathway by sphingosine l-phosphate, lysophosphatidic acid, and phosphatidic acid, all of which bind to G(i/o)-coupled receptors, is substantially reduced in human embyronic kidney 293 cells transfected with lipid phosphate phosphatases 1, la, and 2 but not 3. This was correlated with reduced basal intracellular phosphatidic acid and not ecto lipid phosphate phosphatase activity. These findings were supported by results showing that lipid phosphate phosphatases 1, la, and 2 also abrogate the stimulation of p42/p44 mitogen-activated protein kinase by thrombin, a peptide G(i/o)-coupled receptor agonist whose bioavailability at its receptor is not subject to regulation by the phosphatases, Furthermore, the lipid phosphate phosphatases have no effect on the stimulation of p42/p44 mitogen-activated protein kinase by other agents that do not use G-proteins to signal, such as serum factors and phorbol ester, Therefore, these findings show that the lipid phosphate phosphatases 1, la, and 2 may function to perturb G-protein-coupled receptor signaling per se rather than limiting bioavailability of lipid agonists at their respective receptors.	Univ Strathclyde, Dept Physiol & Pharmacol, Inst Biomed Sci, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	Pyne, S (corresponding author), Univ Strathclyde, Dept Physiol & Pharmacol, Inst Biomed Sci, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.		Pyne, Susan/AAF-5001-2019	Pyne, Susan/0000-0002-6608-9584; Darroch, Peter/0000-0002-0852-8569; Pyne, Nigel/0000-0002-5657-4578				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Glickman M, 1999, MOL CELL NEUROSCI, V14, P141, DOI 10.1006/mcne.1999.0776; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Guo C, 1998, EUR J BIOCHEM, V257, P403, DOI 10.1046/j.1432-1327.1998.2570403.x; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hiroyama R, 1999, J BIOL CHEM, V274, P29172, DOI 10.1074/jbc.274.41.29172; HLA T, 1990, J BIOL CHEM, V265, P9308; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ishikawa T, 2000, J BIOCHEM-TOKYO, V127, P645, DOI 10.1093/oxfordjournals.jbchem.a022652; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Leung DW, 1998, DNA CELL BIOL, V17, P377, DOI 10.1089/dna.1998.17.377; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; Stukey J, 1997, PROTEIN SCI, V6, P469; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tate RJ, 1999, CELL SIGNAL, V11, P515, DOI 10.1016/S0898-6568(99)00028-5; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xu J, 2000, J BIOL CHEM, V275, P27520; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181	48	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13452	13460		10.1074/jbc.M006582200	http://dx.doi.org/10.1074/jbc.M006582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278307	hybrid			2022-12-27	WOS:000168198600134
J	Lim, CS; Park, ES; Kim, DJ; Song, YH; Eom, SH; Chun, JS; Kim, JH; Kim, JK; Park, D; Song, WK				Lim, CS; Park, ES; Kim, DJ; Song, YH; Eom, SH; Chun, JS; Kim, JH; Kim, JK; Park, D; Song, WK			SPIN90 (SH3 protein interacting with Nck, 90 kDa), an adaptor protein that is developmentally regulated during cardiac myocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; EXTRACELLULAR-MATRIX; CYTOPLASMIC PROTEIN; IN-VITRO; INTEGRIN; KINASE; BINDING; LOCALIZATION; ADHESION; MODULATION	In the yeast two-hybrid screening, we have isolated a cDNA clone from a human heart library using Nck Src homology 3 (SH3) domains as bait. The full-length cDNA, which encoded 722 amino acids, was identified as a VIP54-related gene containing an SH3 domain, proline-rich motifs, a serine/threonine-rich region, and a long C-terminal hydrophobic region. We refer to this protein as SPIN90 ((S) under bar H3 (P) under bar rotein (I) under bar nteracting with (N) under bar ck, (90) under bar kDa), The amino acid sequence of the SH3 domain has the highest homology with those of Fyn, Yes, and c-Src. SPIN90 was broadly expressed in human tissues; in particular, it was highly expressed in heart, brain, and skeletal muscle, and its expression was developmentally regulated during cardiac myocyte differentiation. SPIN90 is able to bind to the first and third SH3 domains of Nck, in vitro, and is colocalized with Nck at sarcomere Z-discs within cardiac myocytes, Moreover, treatment with antisera raised against SPIN90 disrupted sarcomere structure, suggesting that this protein may play an important role in the maintenance of sarcomere structure and/or in the assembly of myofibrils into sarcomeres.	Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Changwon Natl Univ, Dept Microbiol, Changwon 641773, South Korea	Gwangju Institute of Science & Technology (GIST); Seoul National University (SNU); Changwon National University	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BORG TK, 1984, DEV BIOL, V104, P86, DOI 10.1016/0012-1606(84)90038-1; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; de Bernard M, 2000, EMBO J, V19, P48, DOI 10.1093/emboj/19.1.48; Fassler R, 1996, J CELL SCI, V109, P2989; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kim YY, 1999, CELL ADHES COMMUN, V7, P85, DOI 10.3109/15419069909034393; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIN ZX, 1989, J CELL BIOL, V108, P2355, DOI 10.1083/jcb.108.6.2355; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; PACIFICI R, 1994, J IMMUNOL, V153, P2222; Park D, 1997, MOL CELLS, V7, P231; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIMPSON DG, 1994, J CELL PHYSIOL, V161, P89, DOI 10.1002/jcp.1041610112; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUDOL M, 1994, ONCOGENE, V9, P2145; Yoon SW, 1996, MOL CELLS, V6, P737; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	29	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12871	12878		10.1074/jbc.M009411200	http://dx.doi.org/10.1074/jbc.M009411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278500	hybrid			2022-12-27	WOS:000168198600058
J	Haney, SA; Glasfeld, E; Hale, C; Keeney, D; He, ZZ; de Boer, P				Haney, SA; Glasfeld, E; Hale, C; Keeney, D; He, ZZ; de Boer, P			Genetic analysis of the Escherichia coli FtsZ center dot ZipA interaction in the yeast two-hybrid system - Characterization of FtsZ residues essential for the interactions with ZipA and with FtsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL-DIVISION; PROTEIN-PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; SEPTAL RING; IN-VIVO; SPECIFICITY; DOMAIN; CRYSTALLOGRAPHY; BIOTINYLATION; RECRUITMENT	The recruitment of ZipA to the septum by FtsZ is an early, essential step in cell division in Escherichia coli. We have used polymerase chain reaction-mediated random mutagenesis in the yeast two-hybrid system to analyze this interaction and have identified residues within a highly conserved sequence at the C terminus of FtsZ as the ZipA binding site. A search for suppressors of a mutation that causes a loss of interaction (ftsZ(D373G)) identified eight different changes at two residues within this sequence, In vitro, wild type FtsZ interacted with ZipA with a high affinity in an enzyme-linked immunosorbent assay, whereas FtsZ(D373G) failed to interact. Two mutant proteins examined restored this interaction significantly. In vivo, the alleles tested are significantly more toxic than the wild type ftsZ and cannot complement a deletion. We have shown that a fusion, which encodes the last 70 residues of FtsZ in the two-hybrid system, is sufficient for the interaction with FtsA and ZipA. However, when the wild type sequence is compared with one that encodes FtsZD373G, no interaction was seen with either protein. Mutations surrounding Asp-373 differentially affected the interactions of FtsZ with ZipA and FtsA, indicating that these proteins bind the C terminus of FtsZ differently.	Wyeth Ayerst Res, Dept Infect Dis, Pearl River, NY 10965 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Pfizer; Case Western Reserve University	Haney, SA (corresponding author), Wyeth Ayerst Res, Dept Infect Dis, 401 N Middletown Rd, Pearl River, NY 10965 USA.	haneysa@war.wyeth.com		de Boer, Piet/0000-0002-5375-6317	NIGMS NIH HHS [GM-57059, R01 GM057059] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057059] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; CARSON M, 1991, ACTA CRYSTALLOGR D, V42, P43; Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X; DAI K, 1994, J BACTERIOL, V176, P130, DOI 10.1128/JB.176.1.130-136.1994; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; Din N, 1998, MOL MICROBIOL, V27, P1051, DOI 10.1046/j.1365-2958.1998.00752.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Golemis EA, 1997, YEAST 2 HYBRID SYSTE, P43; Grossel MJ, 1999, NAT BIOTECHNOL, V17, P1232, DOI 10.1038/70792; GUTHERIE C, 1991, METHODS ENZYMOL, V194; HALE C, 1997, CELL, V88, P176; Hale CA, 2000, J BACTERIOL, V182, P5153, DOI 10.1128/JB.182.18.5153-5166.2000; Hale CA, 1999, J BACTERIOL, V181, P167, DOI 10.1128/JB.181.1.167-176.1999; Huang J, 1996, J BACTERIOL, V178, P5080, DOI 10.1128/jb.178.17.5080-5085.1996; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Inouye C, 1997, GENETICS, V147, P479; Liu Z, 1999, MOL MICROBIOL, V31, P1853, DOI 10.1046/j.1365-2958.1999.01322.x; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; MA X, 1997, P NATL ACAD SCI USA, V93, P12998; MA X, 1997, J BACTERIOL, V79, P6788; Ma XL, 1999, J BACTERIOL, V181, P7531, DOI 10.1128/JB.181.24.7531-7544.1999; Margolin W, 1999, ASM NEWS, V65, P137; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; Mosyak L, 2000, EMBO J, V19, P3179, DOI 10.1093/emboj/19.13.3179; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P9146, DOI 10.1021/bi0009690; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Raskin DM, 1997, CELL, V91, P685, DOI 10.1016/S0092-8674(00)80455-9; RayChaudhuri D, 1999, EMBO J, V18, P2372, DOI 10.1093/emboj/18.9.2372; ROCKMILL B, 1991, METHOD ENZYMOL, V194, P146; Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423; SANCHEZ M, 1994, EMBO J, V13, P4919, DOI 10.1002/j.1460-2075.1994.tb06819.x; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; SHERMAN F, 1982, MOL BIOL YEAST SACCH, P463; Smith PA, 1998, NUCLEIC ACIDS RES, V26, P1414, DOI 10.1093/nar/26.6.1414; van den Ent F, 2000, EMBO J, V19, P5300, DOI 10.1093/emboj/19.20.5300; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; Wang XD, 1997, J BACTERIOL, V179, P5551, DOI 10.1128/jb.179.17.5551-5559.1997; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; Yan K, 2000, BIOCHEM BIOPH RES CO, V270, P387, DOI 10.1006/bbrc.2000.2439	50	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11980	11987		10.1074/jbc.M009810200	http://dx.doi.org/10.1074/jbc.M009810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278571	hybrid			2022-12-27	WOS:000168081800073
J	Donovan, M; Carmody, RJ; Cotter, TG				Donovan, M; Carmody, RJ; Cotter, TG			Light-induced photoreceptor apoptosis in vivo requires neuronal nitric-oxide synthase and guanylate cyclase activity and is caspase-3 independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED RETINAL DEGENERATION; CEREBRAL BLOOD-FLOW; CELL-DEATH; PHOTIC INJURY; MITOCHONDRIAL RELEASE; RETINITIS-PIGMENTOSA; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; MUTANT MICE; PROTEASES	Apoptosis is the mode of photoreceptor cell death in inherited and induced retinal degeneration. However, the molecular mechanisms of photoreceptor cell death in human cases and animal models of retinal dystrophies remain undefined. Exposure of Balb/c mice to excessive levels of white Light results in photoreceptor apoptosis, This study delineates the molecular events occurring during and subsequent to the induction of retinal degeneration by exposure to white light in Balb/c mice. We demonstrate an early increase in intracellular calcium levels during photoreceptor apoptosis, an event that is accompanied by significant superoxide generation and mitochondrial membrane depolarization, Furthermore, we show that inhibition of neuronal nitric-oxide synthase (nNOS) by 7-nitroindazole is sufficient to prevent retinal degeneration implicating a key role for neuronal nitric oxide (NO) in this model. We demonstrate that inhibition of guanylate cyclase, a downstream effector of NO, also prevents photoreceptor apoptosis demonstrating that guanylate cyclase too plays an essential role in this model. Finally, our results demonstrate that caspase 3, frequently considered to be one of the key executioners of apoptosis, is not activated during retinal degeneration. In summary, the data presented here demonstrate that light-induced photoreceptor apoptosis in vivo is mediated by the activation of nNOS and guanylate cyclase and is caspase-3-independent.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Tumor Biol Lab, Cork, Ireland	University College Cork	Cotter, TG (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Tumor Biol Lab, Lee Maltings, Cork, Ireland.	t.cotter@ucc.ie	Carmody, Ruaidhri/H-5396-2019	Cotter, Thomas/0000-0003-4626-5613				AGUIRRE G, 1978, SCIENCE, V201, P1133, DOI 10.1126/science.210508; Carmody RJ, 1999, EXP CELL RES, V248, P520, DOI 10.1006/excr.1998.4421; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; Cayouette M, 1998, J NEUROSCI, V18, P9282; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chen J, 1999, INVEST OPHTH VIS SCI, V40, P2978; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; EDWARD DP, 1991, ARCH OPHTHALMOL-CHIC, V109, P554, DOI 10.1001/archopht.1991.01080040122042; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; GOUREAU O, 1992, BIOCHEM BIOPH RES CO, V186, P854, DOI 10.1016/0006-291X(92)90824-5; GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Hamabe W, 2000, MOL BRAIN RES, V78, P186, DOI 10.1016/S0169-328X(00)00074-7; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Katai N, 1999, INVEST OPHTH VIS SCI, V40, P1802; KELLY PAT, 1995, J CEREBR BLOOD F MET, V15, P766, DOI 10.1038/jcbfm.1995.96; Khodarev NN, 1996, J IMMUNOL, V156, P922; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koistinaho J, 1995, PROG RETIN EYE RES, V15, P69, DOI 10.1016/1350-9462(95)00003-8; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM S, 1990, ARCH OPHTHALMOL-CHIC, V108, P1751, DOI 10.1001/archopht.1990.01070140105039; Lambiase A, 1996, GRAEF ARCH CLIN EXP, V234, pS96, DOI 10.1007/BF02343055; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; LaVail MM, 1999, INVEST OPHTH VIS SCI, V40, P1020; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589; Liu CD, 1999, J NEUROSCI, V19, P4778; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MOORE PK, 1991, BRIT J PHARMACOL, V102, P198, DOI 10.1111/j.1476-5381.1991.tb12153.x; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775; Nicholls DG, 1999, BIOCHEM SOC SYMP, V66, P55, DOI 10.1042/bss0660055; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Noell W K, 1966, Invest Ophthalmol, V5, P450; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Reme CE, 1995, DEGENERATIVE DISEASES OF THE RETINA, P19; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; ROSNER M, 1992, ARCH OPHTHALMOL-CHIC, V110, P857, DOI 10.1001/archopht.1992.01080180129040; SANYAL S, 1986, VISION RES, V26, P1177, DOI 10.1016/0042-6989(86)90099-4; Shastry BS, 1997, CELL MOL LIFE SCI, V53, P419, DOI 10.1007/s000180050050; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; Wright AF, 1997, NAT GENET, V17, P132, DOI 10.1038/ng1097-132; YAMAMOTO R, 1993, NEUROSCIENCE, V54, P189, DOI 10.1016/0306-4522(93)90393-T	67	141	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23000	23008		10.1074/jbc.M005359200	http://dx.doi.org/10.1074/jbc.M005359200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11278285	hybrid			2022-12-27	WOS:000169412700136
J	Minagawa, T; Ijuin, T; Mochizuki, Y; Takenawa, T				Minagawa, T; Ijuin, T; Mochizuki, Y; Takenawa, T			Identification and characterization of a Sac domain-containing phosphoinositide 5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; CLONING; ACTIVATION; EXPRESSION; DEFECTS; CDC42	We have characterized a novel Sac domain-containing inositol phosphatase, hSac2. It was ubiquitously expressed but especially abundant in the brain, heart, skeletal muscle, and kidney. Unlike other Sac domain containing proteins, hSac2 protein exhibited B-phosphatase activity specific for phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate. This is the first time that the Sac domain has been reported to possess 5-phosphatase activity. Its B-phosphatase activity for phosphatidylinositol 4,5-bisphosphate (K-m = 14.3 muM) was comparable with those of Type II 5-phosphatases. These results imply that hSac2 functions as an inositol polyphosphate 5-phosphatase.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Shirokanedai, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Ijuin, Takeshi/H-7016-2017	Ijuin, Takeshi/0000-0002-0618-1776				Asano T, 1999, BIOCHEM BIOPH RES CO, V261, P188, DOI 10.1006/bbrc.1999.0998; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Nemoto Y, 2000, J BIOL CHEM, V275, P34293, DOI 10.1074/jbc.M003923200; NOVICK P, 1989, GENETICS, V121, P659; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; WOLSCHOLSKI R, 1997, J BIOL CHEM, V272, P9625; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574	26	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22011	22015		10.1074/jbc.M101579200	http://dx.doi.org/10.1074/jbc.M101579200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11274189	hybrid			2022-12-27	WOS:000169412700005
J	Dutta, M; Delhi, P; Sinha, KM; Banerjee, R; Datta, AK				Dutta, M; Delhi, P; Sinha, KM; Banerjee, R; Datta, AK			Lack of abundance of cytoplasmic cyclosporin A-binding protein renders free-living Leishmania donovani resistant to cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPHILIN-A; ENDOPLASMIC-RETICULUM; PLASMODIUM-FALCIPARUM; CALCINEURIN; GENE; PHOSPHATASE; SEQUENCE; CLONING; COMPLEX; TRANSCRIPTION	The majority of the effects of cyclosporin A (CsA) on cells is caused by the inhibition of phosphatase activity of calcineurin (CN) by the cyclophilin A (CyPA)-CsA complex formed in the cytoplasm, Although CsA inhibits the proliferation of a large number of parasites, not all are susceptible, The presence of structurally altered CyPA with lower affinity for CsA had been suggested to be the cause of resistance. We report here the identification and cloning of a high affinity CsA-binding protein (LdCyP) from Leishmania donovani, a trypanosomatid parasite that is naturally resistant to CsA, The translated LdCyP consists of 187 amino acids with a cleavable al-amino acid hydrophobic NH2-terminal extension. Modeling studies confirmed that all the residues of human CyPs responsible for interaction with CsA are sequentially and conformationally conserved in LdCyP, The purified recombinant protein displayed biochemical parameters comparable to human CyPs. Reverse transcription-polymerase chain reaction analysis confirmed that LdCyP was abundantly expressed. Immunoblot experiments and direct CsA binding studies revealed that LdCyP located in the subcellular organelles constituted the bulk of the CsA binding activity present in L, donovani, whereas the level of binding activity in the cytosol was conspicuously low, CsA selectively facilitated the secretion of LdCyP in the culture medium, Based on these results, it is concluded that the insensitivity of L. donovani to CsA is probably due to the paucity of CsA binding activity in the cytoplasm of the parasite. We suggest that LdCyP, located in the secretory pathway, may function as a chaperone by binding to membrane proteins rather than as the mediator of CN inhibition.	Indian Inst Chem Biol, Leishmania Grp, Kolkata 700032, W Bengal, India; Saha Inst Nucl Phys, Kolkata, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Saha Institute of Nuclear Physics	Datta, AK (corresponding author), Indian Inst Chem Biol, Leishmania Grp, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	alokdatta@iicb.res.in						ALLAIN F, 1995, J IMMUNOL METHODS, V178, P113, DOI 10.1016/0022-1759(94)00249-V; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Banerjee C, 1999, PARASITOLOGY, V118, P567, DOI 10.1017/S0031182099004308; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; Berriman M, 1998, BIOCHEM J, V334, P437, DOI 10.1042/bj3340437; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BHAUMIK D, 1989, J BIOL CHEM, V264, P4556; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; BRIINGER AT, 1987, SCIENCE, V235, P458; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAPPELL LH, 1992, PARASITOLOGY, V105, pS25, DOI 10.1017/S0031182000075338; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DATTA AK, 1987, J BIOL CHEM, V262, P5515; DREYFUSS M, 1976, EUR J APPL MICROBIOL, V3, P125, DOI 10.1007/BF00928431; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FOXWELL BMJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P115, DOI 10.1016/0925-4439(92)90050-W; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FRUMAN DA, 1995, J IMMUNOL, V154, P1846; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HANSON S, 1992, J BIOL CHEM, V267, P2350; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HIGH KP, 1994, J BIOL CHEM, V269, P9105; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; JUNG L, 2000, TRANSPLANTATION, V70, P327; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KE HM, 1994, STRUCTURE, V2, P33, DOI 10.1016/S0969-2126(00)00006-X; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIU J, 1992, BIOCHEMISTRY-US, V31, P8896; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; PAGE AP, 1995, PARASITOL TODAY, V11, P385, DOI 10.1016/0169-4758(95)80007-7; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Rascher C, 1998, BIOCHEM J, V334, P659, DOI 10.1042/bj3340659; REDDY GR, 1995, MOL BIOCHEM PARASIT, V73, P111, DOI 10.1016/0166-6851(95)00103-8; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SUBBARAO N, 1991, PROTEIN ENG, V4, P877, DOI 10.1093/protein/4.8.877; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787	54	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19294	19300		10.1074/jbc.M009379200	http://dx.doi.org/10.1074/jbc.M009379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278494	hybrid			2022-12-27	WOS:000169091000088
J	Krause, D; Lyons, A; Fennelly, C; O'Connors, R				Krause, D; Lyons, A; Fennelly, C; O'Connors, R			Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-INDUCED APOPTOSIS; C-JUN; PROTEIN-KINASE; CELL-SURVIVAL; TRANSCRIPTION FACTOR; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; SIGNALING PATHWAYS; GLIOBLASTOMA CELLS; BREAST-CANCER; JNK PATHWAY	The insulin-like growth factor I receptor (IGF-IR) activated by its ligands insulin-like growth factor (IGF)-I or IGF-II mediates suppression of apoptosis and contributes to tumorigenesis and cell growth. Here we investigated the activation of the stress-activated protein kinases including Jun N-terminal Kinases and p38 MAPK by IGF-I in interleukin-3-dependent FL5.12 lymphocytic cells that overexpress the IGF-IR (FL5.12/WT). We have shown previously that IGF-I protects these cells from apoptosis induced by interleukin-3 withdrawal but does not promote proliferation. IGF-I induced a rapid and transient activation of JNK that peaked at 40 min that was paralleled by a transient and robust phosphorylation of c-Jun. p38 was constitutively phosphorylated in FL5.12/WT cells. Activation of the JNK pathway by IGF-I occurred in the presence of phosphatidylinositol 3-kinase inhibitors and could be enhanced by anisomycin. Analysis of a series of FL5.12 cells expressing mutated IGF-IRs and analysis of 32D/IGF-IR cells showed that neither the C terminus of the receptor nor IRS-1 and IRS-5 were required for JNK activation, although tyrosine 950 was essential for full activation. The JNK inhibitor dicumarol suppressed IGF-I-mediated activation of JNK and phosphorylation of c-Jun but did not affect p38 and I kappaB phosphorylation or activation of AKT. IGF-I-mediated protection from apoptosis in FL5.12/WT cells was completely suppressed by dicumarol and partially suppressed by a p38 inhibitor. In the breast carcinoma cell line MCF-7, treatment with dicumarol also induced apoptosis. These data indicate that transient activation of JNK by IGF-I is mediated by signals that are distinct from those leading to phosphatidylinositol 3-kinase and AKT activation. The data further suggest that the SAPK pathways contribute to suppression of apoptosis by the IGF-IR.	Natl Univ Ireland Univ Coll Cork, Dept Biochem, Cell Biol Lab, Cork, Ireland; Natl Univ Ireland Univ Coll Cork, Biosci Res Inst, Cork, Ireland	University College Cork; University College Cork	O'Connors, R (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Cell Biol Lab, Cork, Ireland.		O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Koval AP, 1998, BIOCHEM J, V330, P923; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Ling P, 1999, MOL CELL BIOL, V19, P1359; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nishina H, 1998, J IMMUNOL, V161, P3416; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Prives C, 1999, J PATHOL, V187, P112; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RESNICOFF M, 1994, CANCER RES, V54, P2218; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Walsh PT, 2000, EUR J IMMUNOL, V30, P1010, DOI 10.1002/(SICI)1521-4141(200004)30:4<1010::AID-IMMU1010>3.0.CO;2-C; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	57	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19244	19252		10.1074/jbc.M008186200	http://dx.doi.org/10.1074/jbc.M008186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278392	hybrid			2022-12-27	WOS:000169091000082
J	El Bawab, S; Birbes, H; Roddy, P; Szulc, ZM; Bielawska, A; Hannun, YA				El Bawab, S; Birbes, H; Roddy, P; Szulc, ZM; Bielawska, A; Hannun, YA			Biochemical characterization of the reverse activity of rat brain ceramidase - A CoA-independent and fumonisin B-1-insensitive ceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE CERAMIDASE; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; DENSITY-LIPOPROTEIN; STRESS; CELLS; SPHINGOMYELINASE; SPHINGOSINE; HYDROLYSIS	We have previously purified a membrane-bound ceramidase from rat brain and recently cloned the human homologue, We also observed that the same enzyme is able to catalyze the reverse reaction of ceramide synthesis. To obtain insight into the biochemistry of this enzyme, we characterized in this study this reverse activity. Using sphingosine and palmitic acid as substrates, the enzyme exhibited Michaelis-Menten kinetics; however, the enzyme did not utilize palmitoyl-CoA as substrate. Also, the activity was not inhibited in vitro and in cells by fumonisin B-1, an inhibitor of the CoA-dependent ceramide synthase, The enzyme showed a narrow pH optimum in the neutral range, and there was very low activity in the alkaline range. Substrate specificity studies were performed, and the enzyme showed the highest activity with D-erythro-sphingosine (K-m of 0.16 mol %, and V-max of 0.3 mu mol/min/mg), but D-erythro-dihydrosphingosine and the three unnatural stereoisomers of sphingosine were poor substrates. The specificity for the fatty acid was also studied, and the highest activity was observed for myristic acid with a K-m of 1.7 mol % and a V-max of 0.63 mu mol/min/mg, Kinetic studies were performed to investigate the mechanism of the reaction, and Lineweaver-Burk plots indicated a sequential mechanism. Two competitive inhibitors of the two substrates were identified, L-erythro-sphingosine and myristaldehyde, and inhibition studies indicated that the reaction followed a random sequential mechanism. The effect of lipids were also tested. Most of these lipids showed moderate inhibition, whereas the effects of phosphatidic acid and cardiolipin were more potent with total inhibition at around 2.5-5 mol %, Paradoxically, cardiolipin stimulated ceramidase activity. These results define the biochemical characteristics of this reverse activity. The results are discussed in view of a possible regulation of this enzyme by the intracellular pH or by an interaction with cardiolipin and/or phosphatidic acid.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bielawska A, 2000, METHOD ENZYMOL, V311, P480; Bielawska A, 2000, METHOD ENZYMOL, V311, P499; Cleland W W, 1979, Methods Enzymol, V63, P103; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Fromm H J, 1979, Methods Enzymol, V63, P467; GATT S, 1963, J BIOL CHEM, V238, P3131; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kita K, 2000, BBA-MOL CELL BIOL L, V1485, P111, DOI 10.1016/S1388-1981(00)00029-9; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Michel C, 1997, FEBS LETT, V416, P153, DOI 10.1016/S0014-5793(97)01187-3; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Wang E, 2000, METHOD ENZYMOL, V311, P15; WANG E, 1991, J BIOL CHEM, V266, P14486; Wiesner DA, 1997, J BIOL CHEM, V272, P9868	34	60	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16758	16766		10.1074/jbc.M009331200	http://dx.doi.org/10.1074/jbc.M009331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278489	hybrid			2022-12-27	WOS:000168730400023
J	Yale, J; Bohnert, HJ				Yale, J; Bohnert, HJ			Transcript expression in Saccharomyces cerevisiae at high salinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RESPONSE ELEMENT STRE; OSMOTIC-STRESS; GENE-EXPRESSION; SALT STRESS; PHOSPHATASE CALCINEURIN; SIGNAL-TRANSDUCTION; BUDDING YEAST; 2 ISOENZYMES; HOG PATHWAY	Transcript expression of Saccharomyces cerevisiae at high salinity was determined by microarray analysis of 6144 open reading frames (ORFs). From cells grown in 1 M NaCl for 10, 30, and 90 min, changes in transcript abundance >2-fold were classified, Salinity-induced ORFs increased over time: 107 (10 min), 243 (30 min), and 354 (90 min). Up-regulated, functionally unknown ORFs increased from 17 to 149 over this period. Expression patterns were similar early, with 67% of up-regulated transcripts after 10 min identical to those at 30 min. The expression profile after 90 min revealed different upregulated transcripts (identities of 13% and 22%, respectively). Nucleotide and amino acid metabolism exemplified the earliest responses to salinity, followed by ORFs related to intracellular transport, protein synthesis, and destination. Transcripts related to energy production were up-regulated throughout the time course with respiration-associated transcripts strongly induced at 30 min. Highly expressed at 90 min were known salinity stress-induced genes, detoxification-related responses, transporters of the major facilitator superfamily, metabolism of energy reserves, nitrogen and sulfur compounds, and lipid, fatty acid/isoprenoid biosynthesis. We chose severe stress conditions to monitor responses in essential biochemical mechanisms. In the mutant, Delta gpd1/gpd2, lacking glycerol biosynthesis, the stress response was magnified with a partially different set of up-regulated ORFs.	Univ Arizona, Dept Biochem, Biosci W, Tucson, AZ 85721 USA	University of Arizona	Bohnert, HJ (corresponding author), Univ Arizona, Dept Biochem, Biosci W, 1041 E Lowell St, Tucson, AZ 85721 USA.	bohnerth@u.arizona.edu	Bohnert, Hans J/A-7104-2009					AKTHAR N, 1997, FEBS LETT, V403, P173; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; [Anonymous], [No title captured]; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Blomberg A, 2000, FEMS MICROBIOL LETT, V182, P1; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Curcio MJ, 1999, TRENDS GENET, V15, P43, DOI 10.1016/S0168-9525(98)01643-6; Cushman JC, 2000, CURR OPIN PLANT BIOL, V3, P117, DOI 10.1016/S1369-5266(99)00052-7; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Hohmann S., 1997, YEAST STRESS RESPONS, P101; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kawasaki S, 2001, PLANT CELL, V13, P889, DOI 10.1105/tpc.13.4.889; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kumar A, 2000, NUCLEIC ACIDS RES, V28, P81, DOI 10.1093/nar/28.1.81; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; Li S, 1998, EMBO J, V17, P6952, DOI 10.1093/emboj/17.23.6952; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mizoguchi T, 2000, RES PRO CEL, V27, P29; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Navarre C, 2000, EMBO J, V19, P2515, DOI 10.1093/emboj/19.11.2515; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nelson DE, 1998, GENET ENG P, V20, P153; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Proft M, 1999, MOL CELL BIOL, V19, P537; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; SHEPHERD NS, 1989, DEV GENET, V10, P507, DOI 10.1002/dvg.1020100610; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5	62	173	179	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15996	16007		10.1074/jbc.M008209200	http://dx.doi.org/10.1074/jbc.M008209200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278394	hybrid			2022-12-27	WOS:000168623100059
J	Luftig, MA; Cahir-McFarland, E; Mosialos, G; Kieff, E				Luftig, MA; Cahir-McFarland, E; Mosialos, G; Kieff, E			Effects of the NIK aly mutation on NF-kappa B activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA; SPLENIC MICROARCHITECTURE; SIGNALING SPECIFICITY; NEGATIVE REGULATION; CYTOPLASMIC DOMAIN; ONCOGENE PRODUCT; KINASE CASCADES; ALPHA; TRANSFORMATION; ALYMPHOPLASIA	Homozygosity for the aly point mutation in NF-kappaB-inducing kinase (NIK) results in alymphoplasia in mice, a phenotype similar to that of homozygosity for deletion of the lymphotoxin beta receptor (LT betaR), We now find that NF-kappaB activation by Epstein-Barr virus latent membrane protein 1 (LMP1) or by an LMP1 transmembrane domain chimera with the LT betaR signaling domain in human embryonic kidney 293 cells is selectively inhibited by a wild type dominant negative NIK comprised of amino acids 624-947 (DN-NIK) and not by aly DN-NIK. In contrast, LMP1/CD40 is inhibited by both wild type (wt) and aly DN-NIK. LMP1, an LMP1 transmembrane domain chimera with the LT betaR signaling domain, and LMP1/CD40 activate NF-kappaB in wt or aly murine embryo fibroblasts, Although wt and aly NIK do not differ in their in vitro binding to tumor necrosis factor receptor-associated factor 1, 2, 3, or 6 or in their in vivo association with tumor necrosis factor receptor-associated factor 2 and differ marginally in their very poor binding to I kappaB kinase beta (IKK beta), only wt NIK is able to bind to IKK alpha. These data are compatible with a model in which activation of NF-kappaB by LMP1 and LT betaR is mediated by an interaction of NIK or a NIK-like kinase with IKK alpha that is abrogated by the aly mutation. On the other hand, CD40 mediates NF-kappaB activation through a kinase that inter acts with a different component of the IKK complex.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Program Virol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kieff, E (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.		Luftig, Micah/AAY-7567-2021	Luftig, Micah/0000-0002-2964-1907	NATIONAL CANCER INSTITUTE [R01CA047006, R35CA047006] Funding Source: NIH RePORTER; NCI NIH HHS [CA47006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Garceau N, 2000, J EXP MED, V191, P381, DOI 10.1084/jem.191.2.381; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Kieff E, 1996, VIROLOGY, P2343; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsumoto M, 1999, J IMMUNOL, V163, P1584; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804	39	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14602	14606		10.1074/jbc.C100103200	http://dx.doi.org/10.1074/jbc.C100103200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278268	hybrid			2022-12-27	WOS:000168528800012
J	Nam, S; Smith, DM; Dou, QP				Nam, S; Smith, DM; Dou, QP			Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; GREEN TEA; KAPPA-B; (-)-EPIGALLOCATECHIN GALLATE; CANCER PREVENTION; CYCLIN D1; DEGRADATION; CELLS; TUMORIGENESIS; LACTACYSTIN	It has been discovered that proteasome inhibitors are able to induce tumor growth arrest or cell death and that tea consumption is correlated with cancer prevention. Here, we show that ester bond-containing tea polyphenols, such as (-)-epigallocatechin-3-gallate (EGCG), potently and specifically inhibit the chymotrypsin-like activity of the proteasome in vitro (IC50 = 86-194 nM) and in vivo (1-10 muM) at the concentrations found in the serum of green tea drinkers. Atomic orbital energy analyses and high performance liquid chromatography suggest that the carbon of the polyphenol ester bond is essential for targeting, thereby inhibiting the proteasome in cancer cells. This inhibition of the proteasome by EGCG in several tumor and transformed cell lines results in the accumulation of two natural proteasome substrates, p27(Kip1) and I kappaB-alpha, an inhibitor of transcription factor NF-kappaB, followed by growth arrest in the G, phase of the cell cycle. Furthermore, compared with their simian virus-transformed counterpart, the parental normal human fibroblasts were much more resistant to EGCG-induced p27(Kip1) protein accumulation and G(1) arrest. Our study suggests that the proteasome is a cancer-related molecular target of tea polyphenols and that inhibition of the proteasome activity by ester bond containing polyphenols may contribute to the cancer-preventative effect of tea.	H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Dou, QP (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, MRC 1259C,12902 Magnolia Dr, Tampa, FL 33612 USA.		Smith, David/AAL-7662-2020	Smith, David/0000-0002-1502-676X; Dou, Qingping/0000-0002-6465-1473				Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Boyer SN, 1996, CANCER RES, V56, P4620; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Dou QP, 1999, DRUG RESIST UPDATE, V2, P215, DOI 10.1054/drup.1999.0095; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fujiki H, 1999, J CANCER RES CLIN, V125, P589, DOI 10.1007/s004320050321; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Jankun J, 1997, NATURE, V387, P561, DOI 10.1038/42381; Kuroda Y, 1999, MUTAT RES-REV MUTAT, V436, P69, DOI 10.1016/S1383-5742(98)00019-2; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Loidl G, 1999, P NATL ACAD SCI USA, V96, P5418, DOI 10.1073/pnas.96.10.5418; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maki CG, 1996, CANCER RES, V56, P2649; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIDA H, 1994, JPN J CANCER RES, V85, P221, DOI 10.1111/j.1349-7006.1994.tb02085.x; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINTER M, 1994, NEUROSCI LETT, V170, P91, DOI 10.1016/0304-3940(94)90246-1; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG ZY, 1995, CARCINOGENESIS, V16, P2143, DOI 10.1093/carcin/16.9.2143; WANG ZY, 1992, CANCER RES, V52, P1162; XU Y, 1992, CANCER RES, V52, P3875; YAMANE T, 1995, CANCER RES, V55, P2081; Yang CS, 1999, CANCER EPIDEM BIOMAR, V8, P83; Yang CS, 1999, NUTRITION, V15, P946	41	434	476	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13322	13330		10.1074/jbc.M004209200	http://dx.doi.org/10.1074/jbc.M004209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278274	hybrid			2022-12-27	WOS:000168198600118
J	Illarionov, B; Kemter, K; Eberhardt, S; Richter, G; Cushman, M; Bacher, A				Illarionov, B; Kemter, K; Eberhardt, S; Richter, G; Cushman, M; Bacher, A			Riboflavin synthase of Escherichia coli - Effect of single amino acid substitutions on reaction rate and ligand binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; LUMAZINE SYNTHASE; BIOSYNTHESIS; NMR; PROTEINS	Conserved amino acid residues of riboflavin synthase from Escherichia coli were modified by site-directed mutagenesis. Replacement or deletion of phenylalanine 2 afforded catalytically inactive proteins. S41A and H102Q mutants had substantially reduced reaction velocities. Replacements of various other conserved polar residues had little impact on catalytic activity. F-19 NMR protein perturbation experiments using a fluorinated intermediate analog suggest that the N-terminal sequence motif MFTG is part of one of the substrate-binding sites of the protein.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Technical University of Munich; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Richter, Gerald/F-3642-2011		NIGMS NIH HHS [GM51469] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051469] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher A, 1997, METHOD ENZYMOL, V280, P389; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BANDRIN SV, 1979, GENETIKA+, V15, P2063; BEACH RL, 1970, J AM CHEM SOC, V92, P2913, DOI 10.1021/ja00712a052; Braun N, 2000, J CRYST GROWTH, V212, P270, DOI 10.1016/S0022-0248(99)00870-2; CUSHMAN M, 1991, J ORG CHEM, V56, P4603, DOI 10.1021/jo00015a009; CUSHMAN M, 1992, J ORG CHEM, V57, P5630, DOI 10.1021/jo00047a015; Eberhardt S, 1996, EUR J BIOCHEM, V242, P712, DOI 10.1111/j.1432-1033.1996.0712r.x; Goetz JM, 1999, J AM CHEM SOC, V121, P7500, DOI 10.1021/ja983792u; HARVEY RA, 1966, J BIOL CHEM, V241, P2120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGVINENKO E M, 1972, Microbiology (New York), V41, P978; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; Meining W, 1998, J STRUCT BIOL, V121, P53, DOI 10.1006/jsbi.1997.3935; NEUBERGER G, 1985, BIOCHEM BIOPH RES CO, V127, P175, DOI 10.1016/S0006-291X(85)80141-8; OLTMANNS O, 1967, Z NATURFORSCH PT B, VB 22, P751, DOI 10.1515/znb-1967-0714; OTTO MK, 1981, EUR J BIOCHEM, V115, P511; PATERSON T, 1972, J CHEM SOC PERK T 1, P1051, DOI 10.1039/p19720001051; PATERSON T, 1969, J CHEM SOC CHEM COMM, P290, DOI 10.1039/c29690000290; Plaut G. W. E., 1976, FLAVINS FLAVOPROTEIN, P737; PLAUT GWE, 1963, J BIOL CHEM, V238, P2225; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; PLAUT GWE, 1971, COMPR BIOCHEM, P11; ROWAN T, 1963, P CHEM SOC LONDON, P21; Scheuring J, 1996, BIOCHEMISTRY-US, V35, P9637, DOI 10.1021/bi9600916; SCHEURING J, 1995, J ORG CHEM, V60, P243, DOI 10.1021/jo00106a040; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; TABOR S, 1991, CURRENT PROTOCOLS MO; WANG A, 1992, I CHUAN HSUEH PAO, V19, P362	30	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11524	11530		10.1074/jbc.M008931200	http://dx.doi.org/10.1074/jbc.M008931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278450	hybrid			2022-12-27	WOS:000168081800016
J	Lee, SA; Dritschilo, A; Jung, M				Lee, SA; Dritschilo, A; Jung, M			Role of ATM in oxidative stress-mediated c-Jun phosphorylation in response to ionizing radiation and CdCl2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; ATAXIA-TELANGIECTASIA FIBROBLASTS; CADMIUM-INDUCED GENOTOXICITY; CHINESE-HAMSTER CELLS; ABL TYROSINE KINASE; RAT L6 MYOBLASTS; METALLOTHIONEIN GENE; CALCIUM CHANNELS; NUCLEAR-PROTEIN; PROTOONCOGENE EXPRESSION	Ionizing radiation-induced phosphorylation of the transcription factor c-Jun is impaired in cells derived from individuals with ataxia telangiectasia (AT), in which the ATM gene is mutated, We demonstrate here that ATM modulates c-Jun phosphorylation following exposure to ionizing radiation as well as treatment with CdCl2m, a potent pro-oxidant. Exposure of AT and control fibroblasts to CdCl2 induced a biphasic increase in c-Jun phosphorylation on serine residues 63 and 73, with the extent of the second phase being markedly greater in AT cells than in control cells, Heme oxygenase-1, a marker of oxidative stress, was also significantly induced in AT fibroblasts. Expression of recombinant ATM in AT fibroblasts, however, reduced the extent of the effects of CdCl2 on both c-Jun phosphorylation and heme oxygenase-1 induction. Our data suggest that ATM contributes to oxidative stress-mediated signaling that leads to c-Jun phosphorylation by acting as a sensor of ionizing radiation-induced oxidative stress and by modulating intracellular redox homeostasis.	Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res, Washington, DC 20007 USA	Georgetown University	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res, Res Bldg,Rm E211A,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA45408, CA63023, CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175, R29CA063023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abshire MK, 1996, J TOXICOL ENV HEALTH, V48, P359, DOI 10.1080/009841096161258; Abshire MK, 1996, CARCINOGENESIS, V17, P1349, DOI 10.1093/carcin/17.6.1349; ACAN NL, 1995, BIOCHEM MOL MED, V54, P33, DOI 10.1006/bmme.1995.1005; APPLEGATE LA, 1991, CANCER RES, V51, P974; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; BEYERSMANN D, 1994, ENVIRON HEALTH PERSP, V102, P177, DOI 10.2307/3431783; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLOCK C, 1992, J BIOL CHEM, V267, P19824; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COOGAN TP, 1992, TOXICOL APPL PHARM, V113, P227, DOI 10.1016/0041-008X(92)90118-C; COOGAN TP, 1994, J TOXICOL ENV HEALTH, V41, P233, DOI 10.1080/15287399409531839; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Evans MD, 1999, BIOCHEM BIOPH RES CO, V259, P374, DOI 10.1006/bbrc.1999.0801; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; HUSSAIN T, 1987, PHARMACOL TOXICOL, V60, P355, DOI 10.1111/j.1600-0773.1987.tb01526.x; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Jung M, 1997, INT J RADIAT ONCOL, V37, P417, DOI 10.1016/S0360-3016(96)00500-7; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOIZUMI T, 1992, J TOXICOL ENV HEALTH, V37, P25, DOI 10.1080/15287399209531654; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; LEE SA, 1992, CANCER RES, V52, P3750; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; LI GC, 1985, J CELL PHYSIOL, V122, P91, DOI 10.1002/jcp.1041220114; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MISRA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P325, DOI 10.1016/0167-4781(89)90155-3; MULLER L, 1986, TOXICOLOGY, V40, P285, DOI 10.1016/0300-483X(86)90061-2; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; NELSON MT, 1986, J GEN PHYSIOL, V87, P201, DOI 10.1085/jgp.87.2.201; OCHI T, 1983, MUTAT RES, V111, P69, DOI 10.1016/0027-5107(83)90009-X; OCHI T, 1983, MUTAT RES, V122, P169, DOI 10.1016/0165-7992(83)90056-8; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shimizu M, 1997, J TOXICOL ENV HEALTH, V51, P609, DOI 10.1080/00984109708984047; SHIRAISHI N, 1995, TOXICOL APPL PHARM, V130, P229, DOI 10.1006/taap.1995.1028; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SMITH JB, 1994, ENVIRON HEALTH PERSP, V102, P181, DOI 10.2307/3431784; Stohs Sidney J., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P201; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SUNDERMAN FW, 1978, FED PROC, V37, P40; SUSZKIW J, 1984, BRAIN RES, V323, P31, DOI 10.1016/0006-8993(84)90262-2; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; TERRACIO L, 1986, ARCH TOXICOL, V58, P141, DOI 10.1007/BF00340973; TERRACIO L, 1988, ARCH TOXICOL, V61, P450, DOI 10.1007/BF00293691; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73; WILLIAMS LR, 1995, CEREBROVAS BRAIN MET, V7, P55; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zheng H, 1996, TOXICOL APPL PHARM, V136, P229, DOI 10.1006/taap.1996.0029	72	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11783	11790		10.1074/jbc.M004517200	http://dx.doi.org/10.1074/jbc.M004517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278277	hybrid			2022-12-27	WOS:000168081800049
J	Sarafanov, AG; Ananyeva, NM; Shima, M; Saenko, EL				Sarafanov, AG; Ananyeva, NM; Shima, M; Saenko, EL			Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; NEXIN 1 COMPLEXES; BINDING-SITE; PLASMINOGEN-ACTIVATOR; VONWILLEBRAND-FACTOR; A1/A3-C1-C2 DIMER; PLASMA-CLEARANCE; LIGHT-CHAIN; C2 DOMAIN; DEGRADATION	We have demonstrated previously that catabolism of a coagulation factor Vm (fVIII) from its complex with von Willebrand factor (vWf) is mediated by low density lipoprotein receptor-related protein (LRP) (Saenko, E. L., Yakhyaev, A. V., Mikhailenko, I., Strickland, D. K., and Sarafanov, A. G. (1999) J. Biol. Chem. 274, 37685-37692). In the present study, we found that this process is facilitated by cell surface heparan sulfate proteoglycans (HSPGs). This was demonstrated by simultaneous blocking of LRP and HSPGs in model cells, which completely prevented fVIII internalization and degradation from its complex with vWf. In contrast, the selective blocking of either receptor had a lesser effect. In vivo studies of clearance of I-125-fVIII-vWf complex in mice also demonstrated that the simultaneous blocking of HSPGs and LRP led to a more significant prolongation of fVIII half-life (5.5-fold) than blocking of LRP alone (3.5-fold). The cell culture and in vivo experiments revealed that HSPGs are also involved in another, LRP-independent pathway of fVIII catabolism, In both pathways, HSPGs act as receptors providing the initial binding of fVIII-vWf complex to cells. We demonstrated that this binding occurs via the A2 domain of fVIII, since A2, but not other portions of fVIII or isolated vWf, strongly inhibited cell surface binding of fVIII-vWf complex, and the affinities of A2 and fVIII-vWf complex for the cells were similar. The A2 site involved in binding to heparin was localized to the region 558-565, based on the ability of the corresponding synthetic peptide to inhibit A2 binding to heparin, used as a model for HSPGs.	Amer Red Cross, Holland Lab, Rockville, MD 20855 USA; George Washington Univ, Washington, DC 20037 USA; Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan	American Red Cross; George Washington University; Nara Medical University	Saenko, EL (corresponding author), Amer Red Cross, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Sarafanov, Andrey/0000-0001-6124-9713				BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW RT, 1994, J BIOL CHEM, V269, P26796; BARROW RT, 1994, J BIOL CHEM, V269, P593; BAYER EA, 1988, ANAL BIOCHEM, V170, P271, DOI 10.1016/0003-2697(88)90631-8; BRINKHOUS KM, 1985, P NATL ACAD SCI USA, V82, P8752, DOI 10.1073/pnas.82.24.8752; BUTZOW R, 1993, J CELL BIOL, V122, P721, DOI 10.1083/jcb.122.3.721; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; Crisp RJ, 2000, J BIOL CHEM, V275, P19628, DOI 10.1074/jbc.M909172199; Fay PJ, 1999, J BIOL CHEM, V274, P29826, DOI 10.1074/jbc.274.42.29826; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fijnvandraat K, 1997, THROMB HAEMOSTASIS, V77, P298; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HARENBERG J, 1993, THROMB HAEMOSTASIS, V70, P942; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; JI ZS, 1994, J BIOL CHEM, V269, P2764; Kamikubo YI, 1996, THROMB RES, V83, P161, DOI 10.1016/0049-3848(96)00117-X; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LETHAGEN S, 1992, ANN HEMATOL, V65, P253, DOI 10.1007/BF01836069; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; Mahley RW, 1999, J LIPID RES, V40, P1; MANN DM, 1994, J BIOL CHEM, V269, P23661; MARUCH D, 1994, THROMB HAEMOSTASIS, V71, P141; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MORFINI M, 1993, THROMB HAEMOSTASIS, V70, P270; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; Narita M, 1998, BLOOD, V91, P555, DOI 10.1182/blood.V91.2.555.555_555_560; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Neels JG, 2000, BLOOD, V96, P3459, DOI 10.1182/blood.V96.10.3459.h8003459_3459_3465; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Oakley CL, 1940, J PATHOL BACTERIOL, V50, P372, DOI 10.1002/path.1700500216; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OVER J, 1978, J CLIN INVEST, V62, P223, DOI 10.1172/JCI109120; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Poletti LF, 1997, ARTERIOSCL THROM VAS, V17, P925, DOI 10.1161/01.ATV.17.5.925; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; Schwarz HP, 2000, BLOOD, V95, P1703, DOI 10.1182/blood.V95.5.1703.005k20_1703_1708; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; Wells MJ, 1998, J BIOL CHEM, V273, P23440, DOI 10.1074/jbc.273.36.23440; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0	61	111	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11970	11979		10.1074/jbc.M008046200	http://dx.doi.org/10.1074/jbc.M008046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278379	hybrid			2022-12-27	WOS:000168081800072
J	Chen, LJ; Haider, K; Ponda, M; Cariappa, A; Rowitch, D; Pillai, S				Chen, LJ; Haider, K; Ponda, M; Cariappa, A; Rowitch, D; Pillai, S			Protein kinase C-associated kinase (PKK), a novel membrane-associated, ankyrin repeat-containing protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; BETA; ACTIVATION; FAMILY; DIFFERENTIATION; PHOSPHORYLATION; SUBSTRATE; ISOTYPES; RESIDUES; CLONING	A novel murine membrane-associated protein kinase, PKK ((p) under bar rotein (k) under bar inase C-associated <(kunder bar>inase), was cloned on the basis of its physical association with protein kinase C beta (PKC beta), The regulated expression of PKK in mouse embryos is consistent with a role for this kinase in early embryogenesis, The human homolog of PKK has over 90% identity to its murine counterpart, has been localized to chromosome 21q22,3, and is identical to the PKC<(<delta>)under bar>-(i) under bar nteracting (k) under bar inase, DIK (Bahr, C., Rohwer, A., Stempka, L., Rincke, G., Marks, F., and Gschwendlt, M. (2000) J. Biol, Chem. 275, 36350-36357). PKK comprises an N-terminal kinase domain and a C-terminal region containing 11 ankyrin repeats. PKK exhibits protein kinase activity in vitro and associates with cellular membranes. PKK exists in three discernible forms at steady state: an underphosphorylated form of 100 kDa; a soluble, cytosolic, phosphorylated form of 110 kDa; and a phosphorylated, detergent-insoluble form of 112 kDa, PKK is initially synthesized as an underphosphorylated soluble 100-kDa protein that is quantitatively converted to a detergent-soluble 110-kDa form. This conversion requires an active catalytic domain. Although PKK physically associates with PKC beta, it does not phosphorylate this PKC isoform, However, PKK itself mag be phosphorylated by PKC beta, PKK represents a developmentally regulated protein kinase that can associate with membranes. The functional significance of its association with PKC beta remains to be ascertained.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute	Pillai, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.			Rowitch, David/0000-0002-0079-0060	NATIONAL CANCER INSTITUTE [R01CA069618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69618] Funding Source: Medline; NIAID NIH HHS [AI 33507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bahr C, 2000, J BIOL CHEM, V275, P36350, DOI 10.1074/jbc.M004771200; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Blobe GC, 1996, CANCER SURV, V27, P213; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Ma QF, 1997, J NEUROSCI, V17, P3644; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Park HY, 1999, J BIOL CHEM, V274, P16470, DOI 10.1074/jbc.274.23.16470; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	27	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21737	21744		10.1074/jbc.M008069200	http://dx.doi.org/10.1074/jbc.M008069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278382	hybrid			2022-12-27	WOS:000169297900124
J	Chen, P; Lee, TD; Fong, HKW				Chen, P; Lee, TD; Fong, HKW			Interaction of 11-cis-retinol dehydrogenase with the chromophore of retinal G protein-coupled receptor opsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; ALL-TRANS-RETINOL; PIGMENT-EPITHELIUM; VISUAL-PIGMENT; IDENTIFICATION; CYCLE; REGENERATION; SPECIFICITY; RHODOPSIN; ACYLTRANSFERASE	Vertebrate opsins in both photoreceptors and the retinal pigment epithelium (RPE) have fundamental roles in the visual process. The visual pigments in photoreceptors are bound to 11-cis-retinal and are responsible for the initiation of visual excitation, Retinochrome-like opsins in the RPE are bound to all-trans-retinal and play an important role in chromophore metabolism. The retinal G protein-coupled receptor (RGR) of the RPE and Muller cells is an abundant opsin that generates 11-cis-retinal by stereospecific photoisomerization of its bound all-trans-retinal chromophore. We have analyzed a 32-kDa protein (p32) that co-purifies with bovine RGR from RPE microsomes. The co-purified p32 was identified by mass spectrometric analysis as 11-cis-retinol dehydrogenase (cRDH), and enzymatic assays have confirmed the isolation of an active cRDH. The co-purified cRDH showed marked substrate preference to 11-cis-retinal and preferred NADH rather than NADPH as the cofactor in reduction reactions. cRDH did not react with endogenous all-trans-retinal bound to RGR but reacted specifically with 11-cis-retinal that was generated by photoisomerization after irradiation of RGR. The reduction of 11-cis-retinal to 11-cis-retinol by cRDH enhanced the net photoisomerization of all-trans-retinal bound to RGR. These results indicate that cRDH is involved in the processing of 11-cis-retinal after irradiation of RGR opsin and suggest that cRDH has a novel role in the visual cycle.	Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Doheny Eye Institute; University of Southern California; University of Southern California; University of Southern California; City of Hope; Beckman Research Institute of City of Hope	Fong, HKW (corresponding author), Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.	hfong@hsc.usc.edu			NCI NIH HHS [CA33752] Funding Source: Medline; NCRR NIH HHS [RR06217] Funding Source: Medline; NEI NIH HHS [EY08364, EY03040] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006217] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY003040, R01EY008364] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; ALPERN M, 1971, VISION RES, V11, P539, DOI 10.1016/0042-6989(71)90075-7; BRIDGES CDB, 1977, EXP EYE RES, V24, P571, DOI 10.1016/0014-4835(77)90114-2; DAVIS MT, 1995, ANAL CHEM, V67, P4549, DOI 10.1021/ac00120a019; Davis MT, 1998, J AM SOC MASS SPECTR, V9, P194, DOI 10.1016/S1044-0305(97)00282-1; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; FUTTERMAN S, 1961, J BIOL CHEM, V236, P1652; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HUBBARD R, 1958, J GEN PHYSIOL, V41, P501, DOI 10.1085/jgp.41.3.501; Jang GF, 2000, J BIOL CHEM, V275, P28128; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; LANDERS GM, 1990, METHOD ENZYMOL, V189, P70; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; OZAKI K, 1986, VISION RES, V26, P691, DOI 10.1016/0042-6989(86)90083-0; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; PERLMAN JI, 1982, J GEN PHYSIOL, V80, P885, DOI 10.1085/jgp.80.6.885; RANDO RR, 1991, J BIOENERG BIOMEMBR, V23, P133; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Stryer L, 1991, Harvey Lect, V87, P129; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; SUZUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P201, DOI 10.1016/0167-4838(93)90182-Q; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Yang M, 2000, MOL VIS, V6, P237; YOSHIKAMI S, 1978, SCIENCE, V200, P1393; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21098	21104		10.1074/jbc.M010441200	http://dx.doi.org/10.1074/jbc.M010441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274198	hybrid			2022-12-27	WOS:000169297900042
J	Swarnakar, S; Beers, J; Strickland, DK; Azhar, S; Williams, DL				Swarnakar, S; Beers, J; Strickland, DK; Azhar, S; Williams, DL			The apolipoprotein E-dependent low density lipoprotein cholesteryl ester selective uptake pathway in murine adrenocortical cells involves chondroitin sulfate proteoglycans and an alpha(2)-macroglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E MESSENGER-RNA; SECRETION-CAPTURE ROLE; I SR-BI; SCAVENGER RECEPTOR; PERIPHERAL-TISSUES; LUTEINIZED OVARY; SURFACE PROTEOGLYCANS; REMNANT LIPOPROTEINS; RICH LIPOPROTEINS; NONHUMAN-PRIMATES	Cells acquire lipoprotein cholesterol by receptor-mediated endocytosis and selective uptake pathways. In the latter case, lipoprotein cholesteryl ester (CE) is transferred to the plasma membrane without endocytosis and degradation of the lipoprotein particle. Previous studies with Y1/E/tet/2/3 murine adrenocortical cells that were engineered to express apolipoprotein (apo) E demonstrated that apoE expression enhances low density lipoprotein (LDL) CE uptake by both selective and: endocytic pathways. The present experiments test the hypothesis that apoE-dependent LDL CE selective up take is mediated by scavenger receptor, class B, type I (SR-BI), Surprisingly, SR-BI expression was not detected in the Y1/E/tet/2/3 clone of Y1 adrenocortical cells, indicating the presence of a distinct apoE-dependent pathway for LDL CE selective uptake. ApoE-dependent LDL CE selective uptake in Y1/E/tet/2/3 cells was inhibited by receptor-associated protein and by activated alpha (2)-macroglobulin (alpha M-2), suggesting the participation of the LDL receptor-related protein/alpha M-2 receptor. Reagents that inhibited proteoglycan synthesis or removed cell surface chondroitin sulfate proteoglycan completely blocked apoE-dependent LDL CE selective uptake. None of these reagents inhibited SR-BI-mediated LDL CE selective uptake in the Y1-BS1 clone of Y1 cells in which LDL CE selective uptake is mediated by GR-BI. We conclude that LDL CE selective uptake in adrenocortical cells occurs via SR-BI-independent and SR-BI-dependent pathways. The SR-BI-independent pathway is an apoE-dependent process that involves both chondroitin sulfate proteoglycans and an alpha M-2 receptor.	SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA; Palo Alto Hlth Care Syst, Vet Affairs, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; American Red Cross; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Williams, DL (corresponding author), SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	dave@pharm.som.sunysb.edu			NHLBI NIH HHS [HL 58012, HL 54710, HL 32868, HL 50784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868, R01HL050784, R01HL058012, P01HL054710] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; Azhar S, 1998, J LIPID RES, V39, P1616; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1988, J LIPID RES, V29, P869; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; Brissette L, 1996, BIOCHEM J, V318, P841, DOI 10.1042/bj3180841; BRISSETTE L, 1996, BIOCHIM BIOPHYS ACTA, V1213, P5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P524, DOI 10.1021/bi9819778; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; DAWSON PA, 1989, J LIPID RES, V30, P403; DeMattos RB, 2001, J LIPID RES, V42, P976; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gliemann J, 1998, BIOL CHEM, V379, P951; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; GREEN SR, 1991, J LIPID RES, V32, P667; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1992, CIRCULATION, V86, P550; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LENICH C, 1988, J LIPID RES, V29, P755; LINLEE YC, 1985, BIOCHEMISTRY-US, V24, P3751, DOI 10.1021/bi00335a050; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1999, J LIPID RES, V40, P1; MORTIMER BC, 1995, J BIOL CHEM, V270, P28767, DOI 10.1074/jbc.270.48.28767; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; NICOSIA M, 1992, MOL ENDOCRINOL, V6, P978, DOI 10.1210/me.6.6.978; OLSEN LM, 1994, BIOL REPROD, V50, P535; Olsson U, 1997, ARTERIOSCL THROM VAS, V17, P149, DOI 10.1161/01.ATV.17.1.149; Reaven E, 1999, BBA-MOL CELL BIOL L, V1436, P565, DOI 10.1016/S0005-2760(98)00169-6; REAVEN E, 1988, ARTERIOSCLEROSIS, V8, P298, DOI 10.1161/01.ATV.8.3.298; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RINNINGER F, 1995, BBA-LIPID LIPID MET, V1255, P141, DOI 10.1016/0005-2760(94)00228-Q; SAMBANDAM T, 1991, ARTERIOSCLER THROMB, V11, P561, DOI 10.1161/01.ATV.11.3.561; Schimmer B P, 1979, Methods Enzymol, V58, P570; SCHLEICHER RL, 1993, BIOL REPROD, V48, P313, DOI 10.1095/biolreprod48.2.313; Seo T, 2000, J BIOL CHEM, V275, P30355, DOI 10.1074/jbc.M910327199; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; Sugiyama T, 2000, BIOCHEMISTRY-US, V39, P15817, DOI 10.1021/bi001583s; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WITTMAACK FM, 1995, ENDOCRINOLOGY, V136, P340, DOI 10.1210/en.136.1.340	64	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21121	21128		10.1074/jbc.M101691200	http://dx.doi.org/10.1074/jbc.M101691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274190	hybrid			2022-12-27	WOS:000169297900045
J	Traverso, EE; Baskerville, C; Liu, Y; Shou, WY; James, P; Deshaies, RJ; Charbonneau, H				Traverso, EE; Baskerville, C; Liu, Y; Shou, WY; James, P; Deshaies, RJ; Charbonneau, H			Characterization of the Net1 cell cycle-dependent regulator of the Cdc14 phosphatase from budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; MITOTIC EXIT; CRYSTAL-STRUCTURE; MITOSIS; PHOSPHORYLATION; NUCLEOLUS; ANAPHASE; MECHANISM; COMPLEX	In the budding yeast Saccharomyces cerevisiae, the multifunctional protein Net1 is implicated in regulating the cell cycle function of the Cdc14 protein phosphatase. Genetic and cell biological data suggest that during interphase and early mitosis Net1 holds Cdc14 within the nucleolus where its activity is suppressed. Upon its transient release from Net1 at late anaphase, active Cdc14 promotes exit from mitosis by dephosphorylating targets in the nucleus and cytoplasm. In this paper we present evidence supporting the proposed role of Net1 in regulating Cdc14 and exit from mitosis, We show that the NH2-terminal fragment Net1(1-600) directly binds Cdc14 in vitro and is a highly specific competitive inhibitor of its activity (K-i = 3 nM) with five different substrates including the physiologic targets Swi5 and Sic1. An analysis of truncation mutants indicates that the Cdc14 binding site is located within a segment of Net1 containing residues 1-341. We propose that Net1 inhibits by occluding the active site of Cdc14 because it acts as a competitive inhibitor, binds to a site located within the catalytic domain (residues 1-374), binds with reduced affinity to a Cdc14 C283S mutant in which an active site Cys is replaced, and is displaced by tungstate, a transition state analog known to bind in the catalytic site of protein-tyrosine phosphatases.	Purdue Univ, Dept Biochem 1153, W Lafayette, IN 47907 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; California Institute of Technology; University of Wisconsin System; University of Wisconsin Madison	Charbonneau, H (corresponding author), Purdue Univ, Dept Biochem 1153, W Lafayette, IN 47907 USA.		Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354; Shou, Wenying/0000-0001-5693-381X	NATIONAL CANCER INSTITUTE [R01CA059935, R29CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031107, R01GM031107] Funding Source: NIH RePORTER; NCI NIH HHS [CA59935] Funding Source: Medline; NIGMS NIH HHS [GM31107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cerutti L, 2000, CURR OPIN GENET DEV, V10, P65, DOI 10.1016/S0959-437X(99)00044-1; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Cockell MM, 1999, CURR BIOL, V9, pR575, DOI 10.1016/S0960-9822(99)80359-5; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; Cuperus G, 2000, EMBO J, V19, P2641, DOI 10.1093/emboj/19.11.2641; de Almeida A, 1999, BIOL CELL, V91, P649, DOI 10.1016/S0248-4900(00)88529-9; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FUTCHER B, 1993, CELL CYCLE PRACTICAL, P80; Garcia SN, 1999, CELL, V97, P825, DOI 10.1016/S0092-8674(00)80794-1; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Gottschling DE, 2000, CURR BIOL, V10, pR708, DOI 10.1016/S0960-9822(00)00714-4; Guarente L, 2000, GENE DEV, V14, P1021; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; James P, 1996, GENETICS, V144, P1425; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Wang YC, 2000, CURR BIOL, V10, P1379, DOI 10.1016/S0960-9822(00)00779-X; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043	49	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21924	21931		10.1074/jbc.M011689200	http://dx.doi.org/10.1074/jbc.M011689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274204	hybrid, Green Accepted			2022-12-27	WOS:000169297900146
J	Balshaw, DM; Xu, L; Yamaguchi, N; Pasek, DA; Meissner, G				Balshaw, DM; Xu, L; Yamaguchi, N; Pasek, DA; Meissner, G			Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CA2+ RELEASE; SKELETAL; INACTIVATION; COMPLEX; PROTEIN; IDENTIFICATION; CALSEQUESTRIN; MODULATION; OXIDATION	Metabolically S-35-Iabeled calmodulin (CaM) was used to determine the CaM binding properties of the cardiac ryanodine receptor (RyR2) and to identify potential channel domains for CaM binding. In addition, regulation of RyR2 by CaM was assessed in [H-3]ryanodine binding and single-channel measurements, Cardiac sarcoplasmic reticulum vesicles bound approximately four CaM molecules per RyR2 tetramer in the absence of Ca2+; in the presence of 100 muM Ca2+, the vesicles bound 7.5 CaM molecules per tetramer, Purified RyR2 bound approximately four [S-35]CaM molecules per RyR tetramer, both in the presence and absence of Ca2+. At least four CaM binding domains were identified in [S-35]CaM overlays of fusion proteins spanning the full-length RyR2. The affinity (but not the stoichiometry) of CaM binding was altered by redox state as controlled by the presence of either GSH or GSSG, inhibition of RyR2 activity by CaM was influenced by Ca2+ concentration, redox state, and other channel modulators. Parallel experiments with the skeletal muscle isoform showed major differences in the CaM binding properties and regulation by CaM of the skeletal and cardiac ryanodine receptors.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	meissner@med.unc.edu			NHLBI NIH HHS [HL27430] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CELIO MR, 1995, GUIDEBOOK CALCIUM BI, P34; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fruen BR, 2000, AM J PHYSIOL-CELL PH, V279, pC724, DOI 10.1152/ajpcell.2000.279.3.C724; GUERRINI R, 1995, BIOCHEMISTRY-US, V34, P5120, DOI 10.1021/bi00015a024; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; LEE HB, 1994, J BIOL CHEM, V269, P13305; Meissner G, 1997, J BIOL CHEM, V272, P1628, DOI 10.1074/jbc.272.3.1628; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; RICHMAN PG, 1979, J BIOL CHEM, V254, P5372; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Suko J, 2000, J MEMBRANE BIOL, V174, P105, DOI 10.1007/s002320001036; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	34	169	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20144	20153		10.1074/jbc.M010771200	http://dx.doi.org/10.1074/jbc.M010771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274202	Green Published, hybrid			2022-12-27	WOS:000169135100064
J	Lin, HS; Ho, AS; Haley-Vicente, D; Zhang, J; Bernal-Fussell, J; Pace, AM; Hansen, D; Schweighofer, K; Mize, NK; Ford, JE				Lin, HS; Ho, AS; Haley-Vicente, D; Zhang, J; Bernal-Fussell, J; Pace, AM; Hansen, D; Schweighofer, K; Mize, NK; Ford, JE			Cloning and characterization of IL-1HY2, a novel interleukin-1 family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONIST GENE; MOLECULAR-CLONING; PROTEIN; IDENTIFICATION; HYBRIDIZATION; ORGANIZATION; IL-1-ALPHA; RESOLUTION; IL-1-BETA; DATABASE	The interleukin-1 (IL-1) family members play an important role in the process of inflammation and host defense. We describe here the identification and characterization of a novel member of the IL-1 family, IL-1HY2, The human IL-1HY2 protein shares significant amino acid sequence similarity (37%) with the IL-1 receptor antagonist and has a predicted three-dimensional structure similar to that of the IL-1 receptor antagonist. The IL-1HY2 gene is located in close proximity to other IL-1 family genes on human chromosome 2, and the genomic organization of the IL-1HY2 gene is highly conserved with other IL-1 family members. IL-1HY2 protein is secreted from mammalian cells, and the purified recombinant IL-1HY2 protein binds soluble IL-1 receptor type I. IL-1HY2 is expressed in human skin, spleen, and tonsil. Immunohistochemical analysis showed that the IL-1HY2 protein is expressed in the basal epithelia of skin and id proliferating B cells of the tonsil. These data suggest that IL-1HY2 is a novel IL-1 family member and that it may participate in a network of IL-1 family members to regulate adapted and innate immune responses.	Hyseq Inc, Funct Genom Dept, Sunnyvale, CA 94086 USA		Ford, JE (corresponding author), Hyseq Inc, Funct Genom Dept, 670 Almanor Ave, Sunnyvale, CA 94086 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; AREND WP, 1994, J IMMUNOL, V153, P4766; Busfield SJ, 2000, GENOMICS, V66, P213, DOI 10.1006/geno.2000.6184; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 1998, J LEUKOCYTE BIOL, V63, P658, DOI 10.1002/jlb.63.6.658; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Drmanac R, 1999, METHOD ENZYMOL, V303, P165; Drmanac S, 1996, GENOMICS, V37, P29, DOI 10.1006/geno.1996.0517; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; Fischer D, 1996, PROTEIN SCI, V5, P947; GEORGE AJT, 1999, CURRENT PROTOCOLS IM; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; Modi WS, 1988, GENOMICS, V2, P310, DOI 10.1016/0888-7543(88)90019-5; Mulero JJ, 2000, IMMUNOGENETICS, V51, P425, DOI 10.1007/s002510050640; Mulero JJ, 1999, BIOCHEM BIOPH RES CO, V263, P702, DOI 10.1006/bbrc.1999.1440; MYERS JA, 1995, J SURG PATHOL, V1, P105; REMICK DG, 1997, CYTOKINES HLTH DIS, P1; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; STEINKASSERER A, 1992, GENOMICS, V13, P654, DOI 10.1016/0888-7543(92)90137-H; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874	31	157	183	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20597	20602		10.1074/jbc.M010095200	http://dx.doi.org/10.1074/jbc.M010095200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278614	hybrid			2022-12-27	WOS:000169135100124
J	Wissenbach, U; Niemeyer, BA; Fixemer, T; Schneidewind, A; Trost, C; Cavalie, A; Reus, K; Meese, E; Bonkhoff, H; Flockerzi, V				Wissenbach, U; Niemeyer, BA; Fixemer, T; Schneidewind, A; Trost, C; Cavalie, A; Reus, K; Meese, E; Bonkhoff, H; Flockerzi, V			Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CA2+ CHANNEL; PANCREATIC ACINAR-CELLS; CAPSAICIN-RECEPTOR; MOLECULAR-CLONING; MESSENGER-RNA; ION-CHANNEL; ENTRY; PROTEIN; MOUSE; TRP	regulation of intracellular Ca2+ plays a key role in the development and growth of cells. Here we report the cloning and functional expression of a highly calcium-selective channel localized on the human chromosome 7. The sequence of the new channel is structurally related to the gene product of the CaT1 protein cloned from rat duodenum and is therefore called CaT-like (CaT-L), CaT-L is expressed in locally advanced prostate cancer, metastatic and androgen-insensitive prostatic lesions but is undetectable in healthy prostate tissue and benign prostatic hyperplasia. Additionally, CaT-L is expressed in normal placenta, exocrine pancreas, and salivary glands. New markers with well defined biological function that correlate with aberrant cell growth are needed for the molecular staging of cancer and to predict the clinical outcome. The human CaT-L channel represents a marker for prostate cancer progression and may serve as a target for therapeutic strategies.	Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany; Univ Saarlandes, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes, Inst Pathol, D-66421 Homburg, Germany	Saarland University; Saarland University; Saarland University	Flockerzi, V (corresponding author), Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany.		Meese, Eckart Ulrich/ABD-1983-2021; Niemeyer, Barbara A./AAL-8972-2021	Niemeyer, Barbara A./0000-0002-6963-0575				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHCROFT FM, 1999, ION CHANNELS DIS, P352; Bonkhoff H, 1999, AM J PATHOL, V155, P641, DOI 10.1016/S0002-9440(10)65160-7; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; CARE AD, 1991, J DEV PHYSIOL, V15, P253; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Colbert HA, 1997, J NEUROSCI, V17, P8259; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; Duncan LM, 1998, CANCER RES, V58, P1515; FISHER GJ, 1987, AM J PHYSIOL, V252, pC38, DOI 10.1152/ajpcell.1987.252.1.C38; GARCIA DE, 1994, J NEUROSCI, V14, P545; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Petersen OH, 1999, EUR J CELL BIOL, V78, P221, DOI 10.1016/S0171-9335(99)80054-5; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 2000, CRC METH SIG TRANS, P321; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Putney JW, 1999, BIOESSAYS, V21, P38; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCARDINO PT, 1992, HUM PATHOL, V23, P211, DOI 10.1016/0046-8177(92)90102-9; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Weinreich F, 2000, CURR OPIN NEUROBIOL, V10, P409, DOI 10.1016/S0959-4388(00)00089-1; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4	48	202	227	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19461	19468		10.1074/jbc.M009895200	http://dx.doi.org/10.1074/jbc.M009895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278579	hybrid			2022-12-27	WOS:000169091000108
J	Wu, L; Davies, SL; Levitt, NC; Hickson, ID				Wu, L; Davies, SL; Levitt, NC; Hickson, ID			Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; ROTHMUND-THOMSON-SYNDROME; DOUBLE-STRAND BREAKS; BLOOMS-SYNDROME; DNA HELICASE; SACCHAROMYCES-CEREVISIAE; SYNDROME PROTEIN; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS	Bloom's syndrome (BS) is an autosomal recessive disorder that predisposes individuals to a wide range of cancers. The gene mutated in BS, BLM, encodes a member of the RecQ family of DNA helicases. The precise role played by these enzymes in the cell remains to be determined. However, genome-wide hyper-recombination is a feature of many RecQ helicase-deficient cells. In eukaryotes, a central step in homologous recombination is catalyzed by the RAD51 protein. In response to agents that induce DNA double-strand breaks, RAD51 accumulates in nuclear foci that are thought to correspond to sites of recombinational repair. Here, we report that purified BLM and human RAD51 interact in vitro and in vivo, and that residues in the N- and C terminal domains of BLM can independently mediate this interaction. Consistent with these observations, BLM localizes to a subset of RAD51 nuclear foci in normal human cells. Moreover, the number of BLM foci and the extent to which ELM and RAD51 foci co-localize increase in response to ionizing radiation. Nevertheless, the formation of RAD51 foci does not require functional BLM. Indeed, in untreated BS cells, an abnormally high proportion of the cells contain RAD51 nuclear foci. Exogenous expression of BLM markedly reduces the fraction of cells containing RAD51 foci, The interaction between BLM and RAD51 appears to have been evolutionarily conserved since the C-terminal domain of Sgs1, the Saccharomyces cerevisiae homologue of BLM, interacts with yeast Rad51, Furthermore, genetic analysis reveals that the SGS1 and RAD51 genes are epistatic indicating that they operate in a common pathway. Potential roles for BLM in the RAD51 recombinational repair pathway are discussed.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Wu, L (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.	wu@icrf.icnet.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1974, CHROMOSOMA, V48, P361, DOI 10.1007/BF00290993; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HIRSCHI M, 1981, CANCER RES, V41, P2003; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; Mullen JR, 2000, GENETICS, V154, P1101; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tashiro S, 1996, ONCOGENE, V12, P2165; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Watt PM, 1996, GENETICS, V144, P935; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; WU L, 2001, IN PRESS COLD SPRING; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	46	237	244	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19375	19381		10.1074/jbc.M009471200	http://dx.doi.org/10.1074/jbc.M009471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278509	hybrid			2022-12-27	WOS:000169091000098
J	Wurthner, JU; Frank, DB; Felici, A; Green, HM; Cao, ZH; Schneider, MD; McNally, JG; Lechleider, RJ; Roberts, AB				Wurthner, JU; Frank, DB; Felici, A; Green, HM; Cao, ZH; Schneider, MD; McNally, JG; Lechleider, RJ; Roberts, AB			Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-DOMAIN PROTEIN; SIGNALING PATHWAYS; I RECEPTOR; PHOSPHORYLATION; INHIBITION; COMPLEX; FKBP12; FORM; IDENTIFICATION; TRANSCRIPTION	Members of the transforming growth factor-beta (TGF-beta) superfamily signal through unique cell membrane receptor serine-threonine kinases to activate downstream targets. TRAP1 is a previously described 96-kDa cytoplasmic protein shown to bind to TGF-beta receptors and suggested to play a role in TGF-beta signaling. We now fully characterize the binding properties of TRAP1, and show that it associates strongly with inactive heteromeric TGF-beta and activin receptor complexes and is released upon activation of signaling. Moreover, we demonstrate that TRAP1 plays a role in the Smad-mediated signal transduction pathway, interacting with the common mediator, Smad4, in a ligand-dependent fashion. While TRAP1 has only a small stimulatory effect on TGF-beta signaling in functional assays, deletion constructs of TRAP1 inhibit TGF-beta signaling and diminish the interaction of Smad4 with Smad2. These are the first data to identify a specific molecular chaperone for Smad4, suggesting a model in which TRAP1 brings Smad4 into the vicinity of the receptor complex and facilitates its transfer to the receptor-activated Smad proteins.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Houston, TX 77030 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; Uniformed Services University of the Health Sciences - USA	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.	Robertsa@dce41.nci.nih.gov		Schneider, Michael/0000-0001-9645-1938				Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, GENE DEV, V14, P627; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nakamura N, 1997, J BIOL CHEM, V272, P11344; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Pastorcic M, 1997, CYTOKINE, V9, P106, DOI 10.1006/cyto.1996.0143; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	40	68	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19495	19502		10.1074/jbc.M006473200	http://dx.doi.org/10.1074/jbc.M006473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278302	hybrid			2022-12-27	WOS:000169091000112
J	Brochier, L; Pontie, Y; Willson, M; Estrada-Mondaca, S; Czaplicki, J; Klaebe, A; Fournier, D				Brochier, L; Pontie, Y; Willson, M; Estrada-Mondaca, S; Czaplicki, J; Klaebe, A; Fournier, D			Involvement of deacylation in activation of substrate hydrolysis by Drosophila acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL SITE LIGANDS; HUMAN BUTYRYLCHOLINESTERASE; TORPEDO-CALIFORNICA; MELANOGASTER ACETYLCHOLINESTERASE; INHIBITION; BINDING; METABOLIZATION; ASPARTATE-70; MODULATION; TRANSITION	Insect acetylcholinesterase (AChE), an enzyme whose catalytic site is located at the bottom of a gorge-like structure, hydrolyzes its substrate over a wide range of concentrations (from 2 muM to 300 mM), AChE is activated at low substrate concentrations and inhibited at high substrate concentrations. Several rival kinetic models have been developed to try to describe and explain this behavior. One of these models assumes that activation at low substrate concentrations partly results from an acceleration of deacetylation of the acetylated enzyme. To test this hypothesis, we used a monomethylcarbamoylated enzyme, which is considered equivalent to the acylated form of the enzyme and a non-hydrolyzable substrate analog, 4-oxo-N,N,N-trimethylpentanaminium iodide, It appears that this substrate analog increases the decarbamoylation rate by a factor of 2.2, suggesting that the substrate molecule bound at the activation site (K-d = 130 +/- 47 muM) accelerates deacetylation, These two kinetic parameters are consistent with our analysis of the hydrolysis of the substrate. The location of the active site was investigated by in vitro mutagenesis, We found that this site is located at the rim of the active site gorge. Thus, substrate positioning at the rim of the gorge slows down the entrance of another substrate molecule into the active site gorge (Marcel, V,, Estrada-Mondaca, S,, Magne, F,, Stojan, J,, Klaebe, A, and Fournier, D, (2000) J, Biol. Chem, 275, 11603-11609) and also increases the deacylation step, This results in an acceleration of enzyme turnover.	Univ Toulouse 3, UMR 5068, Lab Synth & Physicochim Mol Interet Biol, Grp Biochim Prot, F-31062 Toulouse, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Fournier, D (corresponding author), Univ Toulouse 3, UMR 5068, Lab Synth & Physicochim Mol Interet Biol, Grp Biochim Prot, Bat 4R3, F-31062 Toulouse, France.		Czaplicki, Georges/ABC-7047-2020	Czaplicki, Georges/0000-0001-5348-4107				BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; BARAK D, 1994, J BIOL CHEM, V264, P6296; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; CAUET G, 1987, BIOCHEM CELL BIOL, V65, P529, DOI 10.1139/o87-068; CHAABIHI H, 1994, BIOCHEM BIOPH RES CO, V203, P734, DOI 10.1006/bbrc.1994.2243; CHANGEUX J-P, 1968, Febs Letters, V2, P77, DOI 10.1016/0014-5793(68)80105-X; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; CRONE HD, 1973, J NEUROCHEM, V20, P225, DOI 10.1111/j.1471-4159.1973.tb12119.x; DAFFORN A, 1976, BIOCHEM BIOPH RES CO, V73, P323, DOI 10.1016/0006-291X(76)90710-5; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ERIKSSON H, 1979, BIOCHIM BIOPHYS ACTA, V567, P161, DOI 10.1016/0005-2744(79)90183-9; Estrada-Mondaca S, 1998, ARCH INSECT BIOCHEM, V38, P84, DOI 10.1002/(SICI)1520-6327(1998)38:2&lt;84::AID-ARCH4&gt;3.0.CO;2-V; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; HAAS R, 1988, BIOCHEMISTRY-US, V27, P6453, DOI 10.1021/bi00417a038; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; Harel M, 2000, PROTEIN SCI, V9, P1063, DOI 10.1110/ps.9.6.1063; HELLENBRAND K, 1970, BIOCHEMISTRY-US, V9, P4665; KATO G, 1972, MOL PHARMACOL, V8, P582; KITZ RJ, 1970, MOL PHARMACOL, V6, P108; Koellner G, 2000, J MOL BIOL, V296, P713, DOI 10.1006/jmbi.1999.3468; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; Marcel V, 1998, BIOCHEM J, V329, P329, DOI 10.1042/bj3290329; Marcel V, 2000, J BIOL CHEM, V275, P11603, DOI 10.1074/jbc.275.16.11603; Masson P, 1996, EUR J BIOCHEM, V235, P36, DOI 10.1111/j.1432-1033.1996.00036.x; Masson P, 1997, BIOCHEM J, V325, P53, DOI 10.1042/bj3250053; Masson P, 1997, BIOCHEMISTRY-US, V36, P2266, DOI 10.1021/bi962484a; MOOSER G, 1974, BIOCHEMISTRY-US, V13, P2299, DOI 10.1021/bi00708a010; MOOSER G, 1972, BIOCHEMISTRY-US, V15, P1755; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROUFOGALIS BD, 1972, MOL PHARMACOL, V8, P41; ROUFOGALIS BD, 1969, MOL PHARMACOL, V5, P286; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Stojan J, 1999, CHEM-BIOL INTERACT, V119, P137, DOI 10.1016/S0009-2797(99)00022-8; Stojan J, 1998, FEBS LETT, V440, P85, DOI 10.1016/S0014-5793(98)01434-3; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; THANEIWYSS P, 1983, HELV CHIM ACTA, V66, P2198, DOI 10.1002/hlca.19830660731; TOMLINSON G, 1980, MOL PHARMACOL, V18, P33; TORNEL PL, 1991, BIOORG CHEM, V19, P1, DOI 10.1016/0045-2068(91)90038-Q; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; WILSON IB, 1956, J AM CHEM SOC, V78, P202, DOI 10.1021/ja01582a056; WILSON IB, 1950, J BIOL CHEM, V186, P781; ZORKO M, 1986, BIOCHEM PHARMACOL, V35, P2287, DOI 10.1016/0006-2952(86)90453-3	49	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18296	18302		10.1074/jbc.M005555200	http://dx.doi.org/10.1074/jbc.M005555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278288	hybrid			2022-12-27	WOS:000168866500092
J	Simpson, MA; Reiland, J; Burger, SR; Furcht, LT; Spicer, AP; Oegema, TR; McCarthy, JB				Simpson, MA; Reiland, J; Burger, SR; Furcht, LT; Spicer, AP; Oegema, TR; McCarthy, JB			Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; TRANSENDOTHELIAL MIGRATION; HEMATOPOIETIC PROGENITORS; EXTRACELLULAR-MATRIX; PERICELLULAR MATRIX; SERUM HYALURONAN; LEUKEMIC-CELLS; CD34(+) CELLS; EXPRESSION; ACID	Bone marrow is the primary site of metastasis in patients with advanced stage prostate cancer. Prostate carcinoma cells metastasizing to bone must initially adhere to endothelial cells in the bone marrow sinusoids. In this report, we have modeled that interaction in vitro using two bone marrow endothelial cell (BMEC) lines and four prostate adenocarcinoma cell lines to investigate the adhesion mechanism. Highly metastatic PC3 and PC3M-LN4 cells were found to adhere rapidly and specifically (70-90%) to BMEC-1 and trHBMEC bone marrow endothelial cells, but not to human umbilical vein endothelial cells (15-25%). Specific adhesion to BMEC-1 and trHBMEC was dependent upon the presence of a hyaluronan (HA) pericellular matrix assembled on the prostate carcinoma cells. DU145 and LNCaP cells were only weakly adherent and retained no cell surface HA. Maximal BMEC adhesion and HA encapsulation were associated with high levels of HA synthesis by the prostate carcinoma cells. Up-regulation of HA synthase isoforms Has2 and Has3 relative to levels expressed by normal prostate corresponded to elevated HA synthesis and avid BMEC adhesion. These results support a model in which tumor cells with up-regulated HA synthase expression assemble a cell surface hyaluronan matrix that promotes adhesion to bone marrow endothelial cells. This interaction could contribute to preferential bone metastasis by prostate carcinoma cells.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Davis	McCarthy, JB (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Box 609 Mayo,420 Delaware St SE, Minneapolis, MN 55455 USA.	mccar001@tc.umn.edu			NCI NIH HHS [CA29995, 1F32-CA84619-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA084619, R01CA029995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttila MA, 2000, CANCER RES, V60, P150; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BERTRAND P, 1992, INT J CANCER, V52, P1, DOI 10.1002/ijc.2910520102; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DEKLERK DP, 1983, PROSTATE, V4, P73, DOI 10.1002/pros.2990040107; DEKLERK DP, 1984, J UROLOGY, V131, P1008, DOI 10.1016/S0022-5347(17)50750-8; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; DELPECH B, 1990, INT J CANCER, V46, P388, DOI 10.1002/ijc.2910460309; Dumont P., 1993, In Vivo (Attiki), V7, P167; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FAVALORO EJ, 1993, IMMUNOL CELL BIOL, V71, P571, DOI 10.1038/icb.1993.63; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Frenette PS, 1998, P NATL ACAD SCI USA, V95, P14423, DOI 10.1073/pnas.95.24.14423; FUJIMOTO T, 1989, J PEDIATR SURG, V24, P550, DOI 10.1016/S0022-3468(89)80504-4; Gakunga P, 1997, DEVELOPMENT, V124, P3987; GUO YJ, 1994, CANCER RES, V54, P1561; HAQ M, 1992, CANCER RES, V52, P4613; HASSELBALCH H, 1995, AM J HEMATOL, V50, P231, DOI 10.1002/ajh.2830500402; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Jacobsen K, 1996, BLOOD, V87, P73; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Kaback LA, 1999, J CLIN ENDOCR METAB, V84, P4079, DOI 10.1210/jc.84.11.4079; KATAOKA M, 1985, BLOOD, V65, P1163; KIMATA K, 1983, CANCER RES, V43, P1347; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; KOOCHEKPOUR S, 1995, INT J CANCER, V63, P450, DOI 10.1002/ijc.2910630325; Kosaki R, 1999, CANCER RES, V59, P1141; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Laurent Torvard C., 1996, Immunology and Cell Biology, V74, pA1, DOI 10.1038/icb.1996.32; Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; MANLEY G, 1987, J CLIN PATHOL, V40, P626, DOI 10.1136/jcp.40.6.626; Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Mohle R, 1999, ANN NY ACAD SCI, V872, P176, DOI 10.1111/j.1749-6632.1999.tb08463.x; Mohle R, 1997, BLOOD, V89, P72, DOI 10.1182/blood.V89.1.72.72_72_80; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Naiyer AJ, 1999, BLOOD, V94, P4011, DOI 10.1182/blood.V94.12.4011.424k10_4011_4019; Okada T, 1999, CLIN EXP METASTAS, V17, P623, DOI 10.1023/A:1006715504719; Papayannopoulou T, 1997, ACTA HAEMATOL-BASEL, V97, P97; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; POWELL WC, 1993, CANCER RES, V53, P417; REED RK, 1988, ACTA PHYSIOL SCAND, V134, P405, DOI 10.1111/j.1748-1716.1988.tb08508.x; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Ropponen K, 1998, CANCER RES, V58, P342; SCHER HI, 1994, SEMIN ONCOL, V21, P630; Schweitzer KM, 1997, LAB INVEST, V76, P25; Schweitzer KM, 1996, AM J PATHOL, V148, P165; Shah N, 1998, BLOOD, V92, P3817, DOI 10.1182/blood.V92.10.3817.422k12_3817_3828; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Siegelman MH, 2000, J CLIN INVEST, V105, P683, DOI 10.1172/JCI8692; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; TAVASSOLI M, 1990, BLOOD, V76, P1059; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1985, CANCER RES, V45, P5098; Turner ML, 1998, BRIT J HAEMATOL, V100, P112, DOI 10.1046/j.1365-2141.1998.00543.x; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900; WARE JL, 1982, J UROLOGY, V128, P1064, DOI 10.1016/S0022-5347(17)53345-5; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Wilkinson CR, 1996, CLIN CHIM ACTA, V256, P165, DOI 10.1016/S0009-8981(96)06421-2; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yung S, 2000, KIDNEY INT, V58, P1953, DOI 10.1111/j.1523-1755.2000.00367.x; ZHANG LR, 1995, CANCER RES, V55, P428; Zhang W, 2000, BIOCHEM J, V349, P91, DOI 10.1042/0264-6021:3490091; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831	79	90	92	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17949	17957		10.1074/jbc.M010064200	http://dx.doi.org/10.1074/jbc.M010064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278609	Green Published, hybrid			2022-12-27	WOS:000168866500046
J	Kim, DK; Kanai, Y; Chairoungdua, A; Matsuo, H; Cha, SH; Endou, H				Kim, DK; Kanai, Y; Chairoungdua, A; Matsuo, H; Cha, SH; Endou, H			Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; 4F2 HEAVY-CHAIN; FUNCTIONAL-CHARACTERIZATION; TRYPTOPHAN TRANSPORT; PEPTIDE TRANSPORTER; MOLECULAR-BIOLOGY; XPCT GENE; SYSTEM-T; IDENTIFICATION; MCT2	A cDNA was isolated from rat small intestine by expression cloning which encodes a novel Na+-independent transporter for aromatic amino acids. When expressed in Xenopus oocytes, the encoded protein designated as TAT1 (T-type amino acid transporter I) exhibited Na+-independent and low-affinity transport of aromatic amino acids such as tryptophan, tyrosine, and phenylalanine (K-m values: similar to5 mM), consistent with the properties of classical amino acid transport system T, TATI accepted some variations of aromatic side chains because it interacted with amino acid-related compounds such as L-DOPA and 3-O-methyl-DOPA. Because TAT1 accepted N-methyl- and N-acetyl-derivatives of aromatic amino acids but did not accept their methylesters, it is proposed that TAT1 recognizes amino acid substrates as anions, Consistent with this, TAT1 exhibited sequence similarity (similar to 30% identity at the amino acid level) to H+/monocarboxylate transporters. Distinct from H+/monocarboxylate transporters, however, TAT1 was not coupled with the H+ transport but it mediated an electroneutral facilitated diffusion. TATI mRNA was strongly expressed in intestine, placenta, and liver. In rat small intestine TAT1 immunoreactivity was detected in the basolateral membrane of the epithelial cells suggesting its role in the transepithelial transport of aromatic amino acids. The identification of the amino acid transporter with distinct structural and functional characteristics will not only facilitate the expansion of amino acid transporter families but also provide new insights into the mechanisms of substrate recognition of organic solute transporters.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Natl Def Med Coll, Dept Physiol 1, Tokorozawa, Saitama 3598513, Japan; Japan Sci & Technol Corp, PRESTO, Mitaka, Tokyo 1818611, Japan	Kyorin University; National Defense Medical College - Japan; Japan Science & Technology Agency (JST)	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	ykanai@kyorin-u.ac.jp		Matsuo, Hirotaka/0000-0003-4302-8719				Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Debrand E, 1998, GENOMICS, V48, P296, DOI 10.1006/geno.1997.5173; Eladari D, 1999, J BIOL CHEM, V274, P28420, DOI 10.1074/jbc.274.40.28420; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUDO Y, 1990, J PHYSIOL-LONDON, V426, P381, DOI 10.1113/jphysiol.1990.sp018144; LAFRENIERE RG, 1994, HUM MOL GENET, V3, P1133, DOI 10.1093/hmg/3.7.1133; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; LOPEZBURILLO S, 1985, BIOCHIM BIOPHYS ACTA, V820, P85, DOI 10.1016/0005-2736(85)90218-4; Matsuo H, 2000, NEUROREPORT, V11, P3507, DOI 10.1097/00001756-200011090-00021; Ogihara H, 1999, HISTOCHEM J, V31, P169, DOI 10.1023/A:1003515413550; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Ritchie JWA, 1999, J ENDOCRINOL, V163, pR5, DOI 10.1677/joe.0.163R005; Romero MF, 1998, METHOD ENZYMOL, V296, P17; ROSENBERG R, 1980, BIOCHIM BIOPHYS ACTA, V598, P375, DOI 10.1016/0005-2736(80)90015-2; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; TAKANAGA H, 1995, BIOCHEM BIOPH RES CO, V217, P370, DOI 10.1006/bbrc.1995.2786; Tanaka H, 1998, GASTROENTEROLOGY, V114, P714, DOI 10.1016/S0016-5085(98)70585-2; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1990, BIOCHIM BIOPHYS ACTA, V1027, P268, DOI 10.1016/0005-2736(90)90318-I; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	47	185	191	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17221	17228		10.1074/jbc.M009462200	http://dx.doi.org/10.1074/jbc.M009462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278508	hybrid			2022-12-27	WOS:000168730400083
J	Soejima, K; Mizuguchi, J; Yuguchi, M; Nakagaki, T; Higashi, S; Iwanaga, S				Soejima, K; Mizuguchi, J; Yuguchi, M; Nakagaki, T; Higashi, S; Iwanaga, S			Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VII; SOLUBLE TISSUE FACTOR; BOVINE FACTOR-VII; HUMAN FACTOR-IX; BLOOD-COAGULATION; FACTOR XA; PROTEASE DOMAIN; FACTOR-BINDING; COMPLEX; IDENTIFICATION	Factor VIIa (VIIa) is an unusual trypsin-type serine proteinase that appears to exist in an equilibrium between minor active and dominant zymogen-like inactive conformational states. The binding of tissue factor to VIIa is assumed to shift the equilibrium into the active state. The proteinase domain of VIIa contains a unique structure: a loop formed by a disulfide bond between Cys(310) and Cys(329), which is five residues longer than those of other trypsin types. To examine the functional role of the loop region, we prepared two mutants of VIIa, One of the mutants, named VII-11, had five extra corresponding residues 316-320 of VII deleted. The other mutant, VII-31, had all of the residues in its loop replaced! with those of trypsin, Functional analysis of the two mutants showed that VIIa-11 (K-d = 41 nM) and VIIa-31 (K-d = 160 nM) had lower affinities for soluble tissue factor as compared with the wild-type VIIa (K-d = 11 nM). The magnitude of tissue factor-mediated acceleration of amidolytic activities of VIIa-11 (7-fold) and that of VIIa-31 (2-fold) were also smaller than that of wild-type VIIa (30-fold). In the absence of tissue factor, VIIa-31 but not VIIa-11 showed enhanced activity; the catalytic efficiencies of VIIa-31 toward various chromogenic substrates were 2-18-fold greater than those off the wildtype VIIa. Susceptibility of the alpha -amino group of IIe-153 of VIIa-31 to carbamylation was almost the same as that of wild-type VIIa, suggesting that VIIa-31 as well as wildtype VIIa exist predominantly in the zymogen-like state. Therefore, the tested modifications in the loop region had adverse effects on affinity for tissue factor, disturbed the tissue factor-induced conformational transition, and changed the catalytic efficiency of VIIa, but they did not affect the equilibrium between active and zymogen-like conformational states.	Chemosero Therapeut Res Inst, Blood Prod Res Dept, Kumamoto 8691298, Japan; Chemosero Therapeut Res Inst, Res Dept 1, Kumamoto 8691298, Japan; Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Yokohama, Kanagawa 2440813, Japan; Fujita Hlth Univ, Sch Med, Inst Comprehens Med Sci, Nagoya, Aichi 4701192, Japan	Yokohama City University; Fujita Health University	Mizuguchi, J (corresponding author), Chemosero Therapeut Res Inst, Blood Prod Res Dept, Kumamoto 8691298, Japan.							BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bhardwaj D, 1996, J BIOL CHEM, V271, P30685, DOI 10.1074/jbc.271.48.30685; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BROTHERS AB, 1993, THROMB RES, V69, P231, DOI 10.1016/0049-3848(93)90048-S; Cooper DN, 1997, THROMB HAEMOSTASIS, V78, P151; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; Higashi S, 1997, J BIOL CHEM, V272, P25724, DOI 10.1074/jbc.272.41.25724; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Idusogie E, 1996, THROMB HAEMOSTASIS, V75, P481; Kirchhofer D, 1997, TRENDS CARDIOVAS MED, V7, P316, DOI 10.1016/S1050-1738(97)00094-7; Klausen NK, 1998, MOL BIOTECHNOL, V9, P195; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; Kunitada S, 1999, HANDB EXP PHARM, V132, P397; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MARCHETTI G, 1992, HUM GENET, V89, P497; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MURAKAWA M, 1994, EUR J HAEMATOL, V52, P162; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OBRIEN DP, 1991, BLOOD, V78, P132; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; RUF W, 1991, J BIOL CHEM, V266, P2158; Sambrook J., 2002, MOL CLONING LAB MANU; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; WILLIAMS EB, 1993, METHOD ENZYMOL, V222, P503	37	33	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17229	17235		10.1074/jbc.M009206200	http://dx.doi.org/10.1074/jbc.M009206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278475	hybrid			2022-12-27	WOS:000168730400084
J	Wang, WH; Lee, SB; Palmer, R; Ellisen, LW; Haber, DA				Wang, WH; Lee, SB; Palmer, R; Ellisen, LW; Haber, DA			A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; GENE-PRODUCT; BINDING; PROTEIN; KIDNEY; REPRESSION; RECEPTOR; E1A; P53; COACTIVATOR	The Wilms tumor gene WT1 encodes a zinc finger transcription factor that is required for normal kidney development. WT1 was identified as a transcriptional repressor, based on its suppression of promoter reporters, but analysis of native transcripts using high density microarrays has uncovered transcriptional activation, rather than repression, of potential target genes. We report here that WT1 binds to the transcriptional coactivator CBP, leading to synergistic activation of a physiologically relevant promoter. The physical interaction between WT1 and CBP is evident in vitro and in vivo, and the two proteins are co-immunoprecipitated from embryonic rat kidney cells. The WT1-CBP association requires the first two zinc fingers of WT1 and the adenovirus 5 E1A-binding domain of CBP. Overexpression of this domain of CBP is sufficient to inhibit WT1-mediated transcriptional activation of a promoter reporter, as is co-transfection of Elk Retrovirally driven expression of either the CBP fragment or of E1A in human hematopoietic cells suppresses the induction by WT1 of its endogenous target gene, p21(Cip1). These observations support a model of WT1 as a transcriptional activator of genes required for cellular differentiation.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, CNY 7,Bldg 149,13 St, Charlestown, MA 02129 USA.	Haber@helix.mgh.harvard.edu	Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910; Lee, Sean/0000-0001-6211-3498	NATIONAL CANCER INSTITUTE [R01CA058595] Funding Source: NIH RePORTER; NCI NIH HHS [CA58595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAWLEY RG, 1994, GENE THER, V1, P136; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Menke AL, 1996, ONCOGENE, V12, P537; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577	49	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16810	16816		10.1074/jbc.M009687200	http://dx.doi.org/10.1074/jbc.M009687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278547	hybrid			2022-12-27	WOS:000168730400030
J	Kamura, T; Burian, D; Khalili, H; Schmidt, SL; Sato, S; Liu, WJ; Conrad, MN; Conaway, RC; Conaway, JW; Shilatifard, A				Kamura, T; Burian, D; Khalili, H; Schmidt, SL; Sato, S; Liu, WJ; Conrad, MN; Conaway, RC; Conaway, JW; Shilatifard, A			Cloning and characterization of ELL-associated proteins EAP45 and EAP20 - A role for yeast EAP-like proteins in regulation of gene expression by glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEINS; MYELOID-LEUKEMIA; COMPLEX; T(11-19)(Q23-P13.1); IDENTIFICATION; DELETION; TSG101	RNA polymerase II elongation factor ELL was recently purified from rat liver as a component of a multiprotein complex containing ELL and three ELL-associated proteins (EAPs) of similar to 45 (EAP45), similar to 30 (EAP30), and similar to 20 (EAP20) kDa (Shilatifard, A (1998) J, Biol Chem. 273, 11212-11217), Cloning of cDNA encoding the EAP30 protein revealed that it shares significant sequence similarity with the product of the Saccharomyces cerevisiae SNF8 gene (Schmidt, A E,, Miller, T,, Schmidt, S, L,, Shiekhattar, R,, and Shilatifard, A. (1999) J, Biol, Chem, 274, 21981-21985), which is required for efficient derepression of glucose-repressed genes. Here we report the cloning of cDNAs encoding the EAP45 and EAP20 proteins. In addition, we identify the S, cerevisiae VPS36 and YJR102c genes as potential orthologs of EAP45 and EAP20 and show that they are previously uncharacterized SNF genes with properties very similar to SNF8.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Saint Louis University; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA.			Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [R37-GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brachmann CB, 1998, YEAST, V14, P115; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Li Y, 1999, MOL CELL BIOL, V19, P3588; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; Schmidt AE, 1999, J BIOL CHEM, V274, P21981, DOI 10.1074/jbc.274.31.21981; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shilatifard A, 1998, J BIOL CHEM, V273, P11212, DOI 10.1074/jbc.273.18.11212; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; VALLIER LG, 1991, GENETICS, V129, P675; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; YEGHIAYAN P, 1995, YEAST, V11, P219, DOI 10.1002/yea.320110304	19	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16528	16533		10.1074/jbc.M010142200	http://dx.doi.org/10.1074/jbc.M010142200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278625	hybrid			2022-12-27	WOS:000168623100127
J	Hung, CH; Pollard, HB				Hung, CH; Pollard, HB			Activation of annexin 7 by protein kinase C in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; GTP-GAMMA-S; CATECHOLAMINE SECRETION; MEDULLARY CELLS; PHORBOL ESTER; MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; DEPENDENT AGGREGATION; INSULIN-SECRETION	Annexin 7, a Ca2+/GTP-activated membrane fusion protein, is preferentially phosphorylated in intact chromaffin cells, and the levels of annexin 7 phosphorylation increase quantitatively in proportion to the extent of catecholamine secretion, Consistently, various protein kinase C inhibitors proportionately reduce both secretion and phosphorylation of annexin 7 in these cells, In vitro, annexin 7 is quantitatively phosphorylated by protein kinase C to a mole ratio of 2.0, and phosphorylation is extraordinarily sensitive to variables such as pH, calcium, phospholipid, phorbol ester, and annexin 7 concentration. Phosphorylation of annexin 7 by protein kinase C significantly potentiates the ability of the protein to fuse phospholipid vesicles and lowers the half-maximal concentration of calcium needed for this fusion process. Furthermore, other protein kinases, including cAMP-dependent protein kinase, cGMP-dependent protein kinase, and protein-tyrosine kinase pp60(c-src), also label annexin 7 with high efficiency but do not have this effect on membrane fusion. In the case of pp60(c-src), we note that this kinase, if anything, modestly suppresses the membrane fusion activity of annexin 7. These results thus lead us to hypothesize that annexin 7 may be a positive mediator for protein kinase C action in the exocytotic membrane fusion reaction in chromaffin cells.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Pollard, HB (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat & Cell Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	hpollard@helix.nih.gov						BITTNER MA, 1986, J BIOL CHEM, V261, P182; BROCKLEHURST KW, 1985, BIOCHEM J, V228, P35, DOI 10.1042/bj2280035; BROCKLEHURST KW, 1990, PEPTIDE HORMONE SECR, P233; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; BURNS AL, 1990, BIOCHEM SOC T, V18, P1118, DOI 10.1042/bst0181118; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHURCHER Y, 1990, CELL REGUL, V1, P523, DOI 10.1091/mbc.1.7.523; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; COORSSEN JR, 1990, CELL REGUL, V1, P1027, DOI 10.1091/mbc.1.13.1027; CREUTZ CE, 1979, J BIOL CHEM, V254, P553; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1982, J CELL BIOCHEM, V18, P87, DOI 10.1002/jcb.1982.240180108; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; Furge LL, 1999, J BIOL CHEM, V274, P33504, DOI 10.1074/jbc.274.47.33504; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HONG K, 1982, P NATL ACAD SCI-BIOL, V79, P4642, DOI 10.1073/pnas.79.15.4642; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; Hung CH, 1996, P NATL ACAD SCI USA, V93, P10797, DOI 10.1073/pnas.93.20.10797; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISOSAKI M, 1994, JPN J PHARMACOL, V64, P217, DOI 10.1254/jjp.64.217; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; KNIGHT DE, 1982, J MEMBRANE BIOL, V68, P107, DOI 10.1007/BF01872259; KNIGHT DE, 1985, J MEMBRANE BIOL, V83, P147, DOI 10.1007/BF01868746; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MICHENER ML, 1986, J BIOL CHEM, V261, P6548; NIR S, 1987, BIOCHIM BIOPHYS ACTA, V903, P309, DOI 10.1016/0005-2736(87)90221-5; OSULLIVAN AJ, 1990, J NEUROCHEM, V54, P1805, DOI 10.1111/j.1471-4159.1990.tb01238.x; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; POLLARD HB, 1992, PROG BRAIN RES, V92, P247, DOI 10.1016/S0079-6123(08)61180-2; POLLARD HB, UNPUB; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REEVES J, 1968, CELL PHYSL, V78, P49; ROSARIO LM, 1991, NEUROSCIENCE, V41, P269, DOI 10.1016/0306-4522(91)90215-A; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SMOLEN JE, 1989, CELL SIGNAL, V1, P471, DOI 10.1016/0898-6568(89)90032-6; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; SRIVASTAVA M, 2001, IN PRESS P NATL ACAD; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; TACHIKAWA E, 1990, BIOCHEM PHARMACOL, V40, P1505; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TSUTSUI M, 1994, MOL PHARMACOL, V46, P1041; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; WEI W, 1992, BIOCHEMISTRY-US, V31, P9934, DOI 10.1021/bi00156a011; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; YANAGIHARA N, 1979, FEBS LETT, V105, P296, DOI 10.1016/0014-5793(79)80633-X; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	65	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12813	12821		10.1074/jbc.M008482200	http://dx.doi.org/10.1074/jbc.M008482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278415	hybrid			2022-12-27	WOS:000168198600050
J	Werth, N; Schuette, CG; Wilkening, G; Lemm, T; Sandhoff, K				Werth, N; Schuette, CG; Wilkening, G; Lemm, T; Sandhoff, K			Degradation of membrane-bound ganglioside GM2 by beta-hexosaminidase A - Stimulation by GM2 activator protein and lysosomal lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G(M2) ACTIVATOR; ENZYMATIC-HYDROLYSIS; LIVER; GLUCOSYLCERAMIDE; SPECIFICITY; VESICLES; TOPOLOGY; STORAGE; GA2	According to a recent hypothesis, glycosphingolipids originating from the plasma membrane are degraded in the acidic compartments of the cell as components of intraendosomal and intralysosomal vesicles and structures. Since most previous in vitro investigations used micellar ganglioside GM2 as substrate, we studied the degradation of membrane-bound ganglioside GM2 by water-soluble P-hexosaminidase A in the presence of the GM2 activator protein in a detergent-free, liposomal assay system. Our results show that anionic lipids such as the lysosomal components bis(monoacylglycero)phosphate or phosphatidylinositol stimulate the degradation of GM2 by P-hexosaminidase A up to 180-fold in the presence of GM2 activator protein. In contrast, the degradation rate of GM2 incorporated into liposomes composed of neutral lysosomal lipids such as dolichol, cholesterol, or phosphatidylcholine was significantly lower than in negatively charged liposomes, This demonstrates that both, the GM2 activator protein and anionic lysosomal phospholipids, are needed to achieve a significant degradation of membrane-bound GM2 under physiological conditions. The interaction of GM2 activator protein with immobilized membranes was studied with surface plasmon resonance spectroscopy at an acidic pH value as it occurs in the lysosomes, Increasing the concentration of bis(monoacylglycero)phosphate in immobilized liposomes led to a significant drop of the resonance signal in the presence of GM2 activator protein, This suggests that in the presence of bis(monoacylglycero)phosphate, which has been shown to occur in inner membranes of the acidic compartment, GM2 activator protein is able to solubilize lipids from the surface of immobilized membrane structures.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Bonn	Sandhoff, K (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.							BECKER E, 1999, THESIS U BONN; BERTOLI E, 1981, BIOCHIM BIOPHYS ACTA, V647, P196, DOI 10.1016/0005-2736(81)90246-7; BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P595; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; BURG J, 1983, H-S Z PHYSIOL CHEM, V364, P821, DOI 10.1515/bchm2.1983.364.2.821; COJNACKI T, 1988, BIOCHEM J, V251, P1; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GARAVEL RA, 1995, METABOLIC MOL BASES, P2839; GEIGER B, 1977, AM J HUM GENET, V29, P508; Giehl A, 1999, EUR J BIOCHEM, V261, P650, DOI 10.1046/j.1432-1327.1999.00302.x; Glombitza GJ, 1997, J BIOL CHEM, V272, P5199, DOI 10.1074/jbc.272.8.5199; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAHURAN D, 1980, CAN J BIOCHEM CELL B, V58, P287, DOI 10.1139/o80-038; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; NOVAK A, 1979, J LIPID RES, V20, P678; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; SANDHOFF K, 1977, H-S Z PHYSIOL CHEM, V358, P779, DOI 10.1515/bchm2.1977.358.2.779; SANDHOFF K, 1971, J NEUROCHEM, V18, P2469, DOI 10.1111/j.1471-4159.1971.tb00204.x; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Schutte CG, 1998, PROTEIN SCI, V7, P1039; SCHUTTE CG, 1999, THESIS U BONN; STREMMEL W, 1976, H-S Z PHYSIOL CHEM, V357, P803, DOI 10.1515/bchm2.1976.357.1.803; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; Wilkening G, 2000, J BIOL CHEM, V275, P35814, DOI 10.1074/jbc.M006568200; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; WU YY, 1994, J BIOL CHEM, V269, P16276; Wu YY, 1996, J BIOL CHEM, V271, P10611, DOI 10.1074/jbc.271.18.10611	34	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12685	12690		10.1074/jbc.M007970200	http://dx.doi.org/10.1074/jbc.M007970200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278374	hybrid			2022-12-27	WOS:000168198600030
J	Dickson, LM; Lingohr, MK; McCuaig, J; Hugl, SR; Snow, L; Kahn, BB; Myers, MG; Rhodes, CJ				Dickson, LM; Lingohr, MK; McCuaig, J; Hugl, SR; Snow, L; Kahn, BB; Myers, MG; Rhodes, CJ			Differential activation of protein kinase B and p70(S6K) by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; IGF-I; MAMMALIAN TARGET; INSULIN; PHOSPHORYLATION; INHIBITION; AKT	It has been shown that IGF-1-induced pancreatic beta -cell proliferation is glucose-dependent; however, the mechanisms responsible for this glucose dependence are not known. Adenoviral mediated expression of constitutively active phosphatidylinositol 3-kinase (PI3K) in the pancreatic beta -cells, INS-1, suggested that PI3K was not necessary for glucose-induced beta -cell proliferation but was required for IGF-1-induced mitogenesis, Examination of the signaling components downstream of PI3K, 3-phosphoinositide-dependent kinase 1, protein kinase B (PKB), glycogen synthase kinase-3, and p70-kDa-S6-kinase (p70(S6K)), suggested that a major part of glucose-dependent beta -cell proliferation requires activation of mammalian target of rapamycin/p70(S6K), independent of phosphoinositide-dependent kinase 1/PKB activation. Adenoviral expression of the kinase-dead form of PKB in INS-1 cells decreased IGF-1-induced beta -cell proliferation. However, a surprisingly similar decrease was also observed in adenoviral wild type and constitutively active PKB-infected cells. Upon analysis of extracellular signal-regulated protein kinase 1 and 2 (ERK1/ERK2), an increase in ERK1/ERK2 phosphorylation activation by glucose and IGF-1 was observed in kinase-dead PKB-infected cells, but this phosphorylation activation was inhibited in the constitutively active PKB-infected cells. Hence, there is a requirement for the activation of both ERK1/ERK2 and mammalian target of rapamycin/p70(S6K) signal transduction pathways for a full commitment to glucose-induced pancreatic beta -cell mitogenesis. However, for IGF-1-induced activation, these pathways must be carefully balanced, because chronic activation of one (PI3K/PKB) can lead to dampening of the other (ERK1/2), reducing the mitogenic response.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Program Cell & Dev Biol, Boston, MA 02215 USA; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	cjr@pnri.org			NIDDK NIH HHS [R01 DK043051, DK 55267] Funding Source: Medline; PHS HHS [R01 43051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055267] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; Billestrup N, 1998, ENDOCR J, V45, pS41, DOI 10.1507/endocrj.45.Suppl_S41; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cousin SP, 2001, ENDOCRINOLOGY, V142, P229, DOI 10.1210/en.142.1.229; Cousin SP, 1999, BIOCHEM J, V344, P649, DOI 10.1042/0264-6021:3440649; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; KADOWAKI T, 1996, ENDOCR J, V43, P33; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rhodes CJ, 2000, J MOL ENDOCRINOL, V24, P303, DOI 10.1677/jme.0.0240303; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SWENNE I, 1992, DIABETOLOGIA, V35, P939, DOI 10.1007/BF00401422; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; YANO H, 1993, J BIOL CHEM, V268, P25846; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	49	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21110	21120		10.1074/jbc.M101257200	http://dx.doi.org/10.1074/jbc.M101257200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274216	hybrid			2022-12-27	WOS:000169297900044
J	Adams, CS; Mansfield, K; Perlot, RL; Shapiro, IM				Adams, CS; Mansfield, K; Perlot, RL; Shapiro, IM			Matrix regulation of skeletal cell apoptosis - Role of calcium and phosphate ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; PARATHYROID-HORMONE; BONE-FORMATION; OSTEOCLASTS; GROWTH; ENDOCYTOSIS; MACROPHAGES; MECHANISMS; MODULATION; OSTEOCYTES	Previously, we noted that inorganic phosphate (P-i), a major component of bone extracellular matrix, induced osteoblast apoptosis (Meleti, Z., Shapiro, I. M., and Adams, C. S. (2000) Bolts (NY) 27, 359-366). Since Ca2+ along with P-i is released from bone during the resorption process, we advanced the hypothesis that Ca2+ modulates P-i-mediated osteoblast apoptosis. To test this hypothesis, osteoblasts were incubated with both ions, and cell death was determined. We noted that a modest increase in the medium Ca2+ concentrations ([Ca2+](e)) of 0.1-1 mM caused a profound and rapid enhancement in P-i-dependent death of cultured osteoblasts. An elevation in [Ca2+](e) alone had no effect on osteoblast viability, whereas Ca2+ channel blockers failed to inhibit killing of ion pair-treated cells. These results indicated that P-i-mediated cell death is not dependent on a sustained increase in the cytosolic Ca2+ concentration. Terminal dUTP nick-end labeling analysis and measurement of caspase-3 activity of the ion pair-treated cells suggested that death was apoptotic; Apoptosis was confirmed using caspase-3 and endonuclease inhibitors. The mitochondrial membrane potential and cytosolic Ca2+ status of the treated cells were evaluated. After incubation with [Ca2+](e) and P-i, a decrease in mitochondrial fluorescence was noted, suggesting that the ions decreased the mitochondrial transmembrane potential. Subsequent to the fall in mitochondrial membrane potential, there was a transient elevation in the cytosolic Ca2+ concentration. Results of the study suggest that the ion pair conspire at the level of the plasma membrane to induce intracellular changes that result in loss of mitochondrial function. The subsequent increase in the cytosolic Ca2+ concentration may trigger downstream events that transduce osteoblast apoptosis.	Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania	Adams, CS (corresponding author), Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA.		Adams, Christopher/Z-2537-2019	Adams, Christopher/0000-0003-2100-4417	NIDCR NIH HHS [DE-10875, DE-13319, DE-AR05748] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010875, R01DE013319] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andrew DJ, 1999, IMMUNOPHARMACOLOGY, V41, P1, DOI 10.1016/S0162-3109(98)00049-6; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; ATLAS D, 1981, P NATL ACAD SCI-BIOL, V78, P1237, DOI 10.1073/pnas.78.2.1237; BORKOWF A, 1987, CALCIFIED TISSUE INT, V40, P173, DOI 10.1007/BF02555703; Bronckers ALJJ, 1996, J BONE MINER RES, V11, P1281; Cheung HS, 1997, OSTEOARTHR CARTILAGE, V5, P145, DOI 10.1016/S1063-4584(97)80009-X; Cochran W.G., 1967, STAT METHODS; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FROST HM, 1973, NEW ENGL J MED, V289, P864; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Ihbe A, 1998, CALCIFIED TISSUE INT, V63, P208, DOI 10.1007/s002239900516; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kingsmill VJ, 1998, J ANAT, V192, P245, DOI 10.1046/j.1469-7580.1998.19220245.x; Kitajima I, 1996, J BONE MINER RES, V11, P200; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Mansfield K, 1999, J CELL PHYSIOL, V179, P276, DOI 10.1002/(SICI)1097-4652(199906)179:3<276::AID-JCP5>3.0.CO;2-#; Mayer I, 1999, J INORG BIOCHEM, V73, P221, DOI 10.1016/S0162-0134(99)00019-7; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756-3282(00)00346-X; Noble BS, 1997, BONE, V20, P273, DOI 10.1016/S8756-3282(96)00365-1; OWENS JL, 1986, CALCIFIED TISSUE INT, V38, P170, DOI 10.1007/BF02556877; Radding W, 1999, EXP CELL RES, V253, P689, DOI 10.1006/excr.1999.4714; Ryder KD, 2000, CALCIFIED TISSUE INT, V67, P241, DOI 10.1007/s002230001115; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Sun JS, 1997, J BIOMED MATER RES, V37, P324, DOI 10.1002/(SICI)1097-4636(19971205)37:3<324::AID-JBM3>3.0.CO;2-N; Sun JS, 1999, J BIOMED MATER RES, V45, P311; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267	32	151	153	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20316	20322		10.1074/jbc.M006492200	http://dx.doi.org/10.1074/jbc.M006492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278303	hybrid			2022-12-27	WOS:000169135100088
J	Yu, SH; Castle, A; Chen, M; Lee, R; Takeda, K; Weinstein, LS				Yu, SH; Castle, A; Chen, M; Lee, R; Takeda, K; Weinstein, LS			Increased insulin sensitivity in G(s)alpha knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XL-ALPHA-S; TISSUE-SPECIFIC EXPRESSION; GLUCOSE-TRANSPORTER GLUT4; RECEPTOR TYROSINE KINASE; RAT ADIPOSE-CELLS; CYCLIC-AMP; PROTEIN-KINASE; PHOSPHORYLATION STATE; SUBUNIT; ADIPOCYTES	The stimulatory guanine nucleotide-binding protein (G(s)) is required for hormone-stimulated cAMP generation. Gnas, the gene encoding the G(s) alpha -subunit, is imprinted, and targeted disruption of this gene in mice leads to distinct phenotypes in heterozygotes depending on whether the maternal (m-/f+) or paternal (+/p-) allele is mutated. Notably m-/+ mice become obese, whereas +/p- mice are thinner than normal. In this study we show that despite these opposite changes in energy metabolism, both m-/+ and +/p- mice have greater sensitivity to insulin, with low to normal fasting glucose levels, low fasting insulin levels, improved glucose tolerance, and exaggerated hypoglycemic response to administered insulin. The combination of increased insulin sensitivity with obesity in m-/+ mice is unusual, because obesity is typically associated with insulin resistance. In skeletal: muscles isolated hom both m-/+ and +/p- mice, the basal rate of 8-deoxyglucose uptake was normal, whereas the rate of 8-deoxyglucose uptake in response to maximal insulin stimulation was significantly increased. The similar changes in muscle sensitivity to insulin in m-/+ and +/p- mice may reflect the fact that muscle G(s)alpha expression is reduced by similar to 50% in both groups of mice; GLUT4 expression is unaffected in muscles from +/p- mice. Increased responsiveness to insulin is therefore the result of altered insulin signaling and/or GLUT4 translocation, This is the first direct demonstration in a genetically altered in vivo model that G(s)-coupled pathways negatively regulate insulin signaling.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Weinstein, LS (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C101, Bethesda, MD 20892 USA.	leew@amb.niddk.nih.gov	Weinstein, Lee S/I-5575-2015	Weinstein, Lee/0000-0002-1899-5152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043302, ZIADK043302] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 1999, FEBS LETT, V460, P338, DOI 10.1016/S0014-5793(99)01369-1; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Bauer R, 1999, NEUROSCIENCE, V91, P685, DOI 10.1016/S0306-4522(98)00668-X; Bauer R, 1999, NEUROSCI LETT, V263, P13, DOI 10.1016/S0304-3940(99)00091-9; BRICKMAN AS, 1986, J CLIN ENDOCR METAB, V63, P1354, DOI 10.1210/jcem-63-6-1354; CAMPBELL R, 1994, J MED GENET, V31, P607, DOI 10.1136/jmg.31.8.607; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; CIARALDI TP, 1989, BIOCHEM J, V264, P389, DOI 10.1042/bj2640389; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; DAVIES SJ, 1993, J MED GENET, V30, P101, DOI 10.1136/jmg.30.2.101; ERIKSSON JW, 1992, BIOCHEM J, V288, P625, DOI 10.1042/bj2880625; Eriksson JW, 1997, ENDOCRINOLOGY, V138, P607, DOI 10.1210/en.138.2.607; Ferrara CM, 1999, BIOCHEM J, V343, P571, DOI 10.1042/0264-6021:3430571; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; GEJMAN PV, 1991, GENOMICS, V9, P782, DOI 10.1016/0888-7543(91)90377-Q; Green A, 1996, AM J PHYSIOL-ENDOC M, V271, pE271, DOI 10.1152/ajpendo.1996.271.2.E271; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; HARING H, 1986, BIOCHEM J, V234, P59; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Ischia R, 1997, J BIOL CHEM, V272, P11657; ISSAD T, 1995, EUR J BIOCHEM, V234, P108, DOI 10.1111/j.1432-1033.1995.108_c.x; ISSAD T, 1992, FEBS LETT, V296, P41, DOI 10.1016/0014-5793(92)80399-2; JOOST HG, 1987, J BIOL CHEM, V262, P11261; JOOST HG, 1986, BIOCHEM J, V233, P677, DOI 10.1042/bj2330677; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; KEHLENBACH RH, 1994, NATURE, V372, P804; KLEIN HH, 1991, BIOCHEM J, V274, P787, DOI 10.1042/bj2740787; Klemke M, 2000, J BIOL CHEM, V275, P33633, DOI 10.1074/jbc.M006594200; KLIP A, 1988, BIOCHEM J, V255, P1023, DOI 10.1042/bj2551023; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002-9343(83)91008-2; Lovisetti-Scamihorn P, 1999, BRAIN RES, V829, P99, DOI 10.1016/S0006-8993(99)01345-1; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; MONTIEL F, 1989, MOL CELL ENDOCRINOL, V61, P167, DOI 10.1016/0303-7207(89)90127-5; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; OBERMAIER B, 1987, DIABETOLOGIA, V30, P93; Pasolli HA, 2000, J BIOL CHEM, V275, P33622, DOI 10.1074/jbc.M001335200; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; PESSIN JE, 1983, J BIOL CHEM, V258, P7386; Peters J, 1999, P NATL ACAD SCI USA, V96, P3830, DOI 10.1073/pnas.96.7.3830; Ploug T, 1997, AM J PHYSIOL-ENDOC M, V272, pE7, DOI 10.1152/ajpendo.1997.272.1.E7; RASMUSSEN MJK, 1982, BIOCHIM BIOPHYS ACTA, V693, P389, DOI 10.1016/0005-2736(82)90446-1; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; SAAD MJA, 1995, FEBS LETT, V370, P131, DOI 10.1016/0014-5793(95)00809-N; SHANAHAN MF, 1986, BIOCHIM BIOPHYS ACTA, V887, P121, DOI 10.1016/0167-4889(86)90132-1; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; TAYLOR WM, 1976, P NATL ACAD SCI USA, V73, P4359, DOI 10.1073/pnas.73.12.4359; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; Wang HY, 1996, INT J OBESITY, V20, pS26; Weinstein LS, 1998, CONT ENDOCRINOL, V6, P23; YU KT, 1985, BIOCHIMIE, V67, P1081, DOI 10.1016/S0300-9084(85)80105-X; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Zheng XL, 1998, J BIOL CHEM, V273, P23649, DOI 10.1074/jbc.273.37.23649; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	64	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19994	19998		10.1074/jbc.M010313200	http://dx.doi.org/10.1074/jbc.M010313200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274197	hybrid			2022-12-27	WOS:000169135100043
J	Sasaki, A; Masuda, Y; Ohta, Y; Ikeda, K; Watanabe, K				Sasaki, A; Masuda, Y; Ohta, Y; Ikeda, K; Watanabe, K			Filamin associates with Smads and regulates transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; CYTOPLASMIC DOMAIN; SKI ONCOPROTEIN; KINASE; ADHESION; PATHWAY; ABP-280; EXPRESSION; COLLAGEN; DIFFERENTIATION	Members of the Smad proteins transmit signals triggered by the ligands of transforming growth factor (TGF)-beta superfamily, Ligand-activated receptors induce phosphorylation of so-called receptor-regulated Smads, which then accumulate in the nucleus to participate in target gene transcription, in collaboration with Smad-interacting proteins. We performed yeast two-hybrid screening and identified filamin, a cytoskeletal actin-binding protein 280, as a Smad5-interacting protein. Filamin was found to be associated not only with Smad5 but also with other Smad proteins, including TGF-beta/ activin receptor-regulated Smad2. TGF-beta signaling was defective in filamin-deficient human melanoma cells M2 compared with a filamin-transfected subline A7, as determined by TGF-beta -responsive reporter gene activation and Smads nuclear accumulation. M2 cells restored TGF-beta responsiveness following transient transfection of full-length filamin encoding vector. The defective TGF-beta signaling in M2 cells seemed to be due to impaired receptor-induced serine phosphorylation of Smads. These results suggest that filamin plays an important role in Smad-mediated signaling.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Watanabe, K (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo,Morioka Cho, Aichi 4748522, Japan.	kwatanab@nils.go.jp	Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Takeuchi Y, 1996, J BIOL CHEM, V271, P3938; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xie ZW, 1998, BIOCHEM BIOPH RES CO, V251, P914, DOI 10.1006/bbrc.1998.9506; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang WJ, 1998, J NEUROSCI, V18, P914; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	57	139	148	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17871	17877		10.1074/jbc.M008422200	http://dx.doi.org/10.1074/jbc.M008422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278410	hybrid			2022-12-27	WOS:000168866500036
J	Williams, SJ; Wreschner, DH; Tran, M; Eyre, HJ; Sutherland, GR; McGuckin, MA				Williams, SJ; Wreschner, DH; Tran, M; Eyre, HJ; Sutherland, GR; McGuckin, MA			MUC13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; SIALOMUCIN COMPLEX; MOLECULAR-CLONING; PROGENITOR CELLS; BETA-CATENIN; NULL MICE; IDENTIFICATION; GLYCOPROTEIN; CLEAVAGE; TISSUES	Transmembrane mucins are glycoproteins involved in barrier function in epithelial tissues. To identify novel transmembrane mucin genes, we performed a tblastn search of the GenBank(TM) EST data bases with a serine/ threonine-rich search string, and a rodent gene expressed in bone marrow was identified. We determined the cDNA sequence of the human orthologue of this gene, MUC13, which localizes to chromosome band 3q13.3 and generates 3.2-kilobase pair transcripts encoding a 512-amino acid protein comprised of an N-terminal mucin repeat domain, three epidermal growth factor-like sequences, a SEA module, a transmembrane domain, and a cytoplasmic tail (GenBank(TM) accession no. AF286113), MUC13 mRNA is expressed most highly in the large intestine and trachea, and at moderate levels in the kidney, small intestine, appendix, and stomach, In situ hybridization in murine tissues revealed expression in intestinal epithelial and lymphoid cells. Immunohistochemistry demonstrated the human MUC13 protein on the apical membrane of both columnar and goblet cells in the gastrointestinal tract, as well as within goblet cell thecae, indicative of secretion in addition to presence on the cell surface. MUC13 is cleaved, and the beta -subunit containing the cytoplasmic tail undergoes homodimerization, Including MUC13, there are at least five cell surface mucins expressed in the gastrointestinal tract.	Mater Misericordiae Hosp, Mater Med Res Inst, S Brisbane, Qld 4101, Australia; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, N Adelaide, SA 5006, Australia	Mater Research; Tel Aviv University	McGuckin, MA (corresponding author), Mater Misericordiae Hosp, Mater Med Res Inst, Level 3,Aubigny Pl,Raymond Terrace, S Brisbane, Qld 4101, Australia.		Sutherland, Grant Robert/D-2606-2012; McGuckin, Michael/G-2310-2010	McGuckin, Michael/0000-0002-8375-2675; Wreschner, Daniel/0000-0003-2102-2164				Agrawal B, 1998, CANCER RES, V58, P4079; ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Biemer-Huttmann AE, 1999, J HISTOCHEM CYTOCHEM, V47, P1039, DOI 10.1177/002215549904700808; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Brugger W, 1999, J CLIN ONCOL, V17, P1535, DOI 10.1200/JCO.1999.17.5.1535; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; DeSouza MM, 1999, J REPROD IMMUNOL, V45, P127, DOI 10.1016/S0165-0378(99)00046-7; DOUGHERTY GJ, 1989, EXP HEMATOL, V17, P877; DOUGHERTY GJ, 1989, J BIOL CHEM, V264, P6509; Duan Y, 1998, BIOCHEM BIOPH RES CO, V253, P401, DOI 10.1006/bbrc.1998.9700; Gum JR, 1997, J BIOL CHEM, V272, P26678, DOI 10.1074/jbc.272.42.26678; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; HILKENS J, 1988, J BIOL CHEM, V263, P4215; Kardon R, 1999, INVEST OPHTH VIS SCI, V40, P1328; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; MCGUCKIN MA, 2002, LEUKOCYTE TYPING, V7; MCGUCKIN MA, 1998, TUMOR DIAG THER, V16, P1; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PANDEY P, 1995, CANCER RES, V55, P4000; Parmley RR, 1998, J CLIN INVEST, V102, P1798, DOI 10.1172/JCI3820; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; REX M, 1994, BIOCHEMICA, V3, P24; Sambrook J., 2002, MOL CLONING LAB MANU; SHANKAR V, 1994, BIOCHEM J, V300, P295, DOI 10.1042/bj3000295; SHENG Z, 1990, J BIOL CHEM, V265, P8505; Slomiany BL, 1996, GEN PHARMACOL, V27, P761, DOI 10.1016/0306-3623(95)02050-0; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; Weiss AA, 1996, J HISTOCHEM CYTOCHEM, V44, P1161, DOI 10.1177/44.10.8813081; Williams SJ, 1999, BIOCHEM BIOPH RES CO, V261, P83, DOI 10.1006/bbrc.1999.1001; Williams SJ, 1999, CANCER RES, V59, P4083; Winterford CM, 1999, J HISTOCHEM CYTOCHEM, V47, P1063, DOI 10.1177/002215549904700811; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; ZEGERS N, 1990, J IMMUNOL METHODS, V130, P195, DOI 10.1016/0022-1759(90)90048-Z	43	240	262	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18327	18336		10.1074/jbc.M008850200	http://dx.doi.org/10.1074/jbc.M008850200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278439	hybrid			2022-12-27	WOS:000168866500096
J	Verger, A; Buisine, E; Carrere, S; Wintjens, R; Flourens, A; Coll, J; Stehelin, D; Duterque-Coquillaud, M				Verger, A; Buisine, E; Carrere, S; Wintjens, R; Flourens, A; Coll, J; Stehelin, D; Duterque-Coquillaud, M			Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; CRYSTAL-STRUCTURE; NUCLEAR-RECEPTOR; BINDING DOMAINS; GENE-EXPRESSION; FAMILY MEMBER; PROTEIN; PU.1; JUN; RECOGNITION	Jun, Fos, and Ets proteins belong to distinct families of transcription factors that target specific DNA elements often found jointly in gene promoters. Physical and functional interactions between these families play important roles in modulating gene expression. Previous studies have demonstrated a direct interaction between the DNA-binding domains of the two partners. However, the molecular details of the interactions have not been investigated so far. Here we used the known three-dimensional structures of the ETS DNA-binding domain and Jun/Fos heterodimer to model an ETS-Jun/Fos-DNA ternary complex. Docking procedures suggested that certain ETS domain residues in the DNA recognition helix alpha (3) interact with the N-terminal basic domain of Jun. To support the model, different Erg ETS domain mutants were obtained by deletion or by single amino acid substitutions and were tested for their ability to mediate DNA binding, Erg-Jun/Fos complex formation, and transcriptional activation. We identified point mutations that affect both the DNA binding properties of Erg and its physical interaction with Jun (R367K), as well as mutations that essentially prevent transcriptional synergy with the Jun/Fos heterodimer (Y371V), These results provide a framework of the ETS/bZIP interaction linked to the manifestation of functional activity in gene regulation.	Inst Biol Lille, CNRS Unite Mixte Resch 8528, F-59021 Lille, France; Inst Pasteur, Inst Biol Lille, CNRS UMR 8525, F-59021 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Inst Biol Lille, CNRS UMR 8527, F-59021 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS)	Duterque-Coquillaud, M (corresponding author), Inst Biol Lille, CNRS Unite Mixte Resch 8528, BP 447,1 Rue Calmette, F-59021 Lille, France.			Duterque-Coquillaud, Martine/0000-0003-3943-5629; verger, alexis/0000-0002-0299-2344				BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Wolberger C, 1999, ANNU REV BIOPH BIOM, V28, P29, DOI 10.1146/annurev.biophys.28.1.29; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	44	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17181	17189		10.1074/jbc.M010208200	http://dx.doi.org/10.1074/jbc.M010208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278640	hybrid, Green Submitted			2022-12-27	WOS:000168730400078
J	Xiang, Y; Moss, B				Xiang, Y; Moss, B			Determination of the functional epitopes of human interleukin-18-binding protein by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-INDUCING FACTOR; BINDING-PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; IL-18 BINDING; RECEPTOR; POXVIRUS; CLONING; INTERLEUKIN-1-BETA; EXPRESSION; CYTOKINE	The human interleukin (IL)-18-binding protein (hIL-18BP) is a naturally occurring antagonist of IL-18, a proinflammatory cytokine that is related to IL-1 beta and has an important role in defense against microbial invaders. As its name implies, the hIL-18BP binds to IL-18 with high affinity and prevents the interaction of IL-18 with its receptor. We genetically modified the C terminus of hIL-18BP by appending a 15-amino acid biotinylation recognition site and a six-histidine tag and then performed site-directed mutagenesis to determine the functional epitopes that mediate efficient binding to IL-18. The mutated IL-18BPs were secreted from mammalian cells, captured by metal affinity chromatography, biotinylated in situ, eluted, and immobilized on streptavidin-coated chips. Using surface plasmon resonance, we identified seven amino acids of hIL-18BP which, when changed individually to alanine, caused an 8-750-fold decrease in binding affinity, largely because of increased off-rates. These seven amino acids localized to the predicted P-strand c and d of hIL-18BP immunoglobulin-like domain, and most had hydrophobic side chains. Just two amino acids, tyrosine 97 and phenylalanine 104, contributed similar to 50% of the binding free energy. Information obtained from these studies could contribute to the design of molecular antagonists of IL-18 for treatment of inflammatory diseases.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Drt Dr,MSC 0445, Bethesda, MD 20892 USA.			Xiang, Yan/0000-0002-7633-1629; Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000714] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aizawa Y, 1999, FEBS LETT, V445, P338, DOI 10.1016/S0014-5793(99)00148-9; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Born TL, 2000, J IMMUNOL, V164, P3246, DOI 10.4049/jimmunol.164.6.3246; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Calderara S, 2001, VIROLOGY, V279, P22, DOI 10.1006/viro.2000.0689; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Dale M, 1999, GENOMICS, V57, P177, DOI 10.1006/geno.1999.5767; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Ioerger TR, 1999, MOL IMMUNOL, V36, P373, DOI 10.1016/S0161-5890(99)00032-2; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; McInnes IB, 2000, IMMUNOL TODAY, V21, P312, DOI 10.1016/S0167-5699(00)01648-0; NAKAMURA K, 1989, INFECT IMMUN, V57, P590, DOI 10.1128/IAI.57.2.590-595.1989; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Parnet P, 1996, J BIOL CHEM, V271, P3967; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rost B, 1996, METHOD ENZYMOL, V266, P525; Smith VP, 2000, J GEN VIROL, V81, P1223, DOI 10.1099/0022-1317-81-5-1223; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Tsutsui H, 2000, IMMUNOL REV, V174, P192, DOI 10.1034/j.1600-0528.2002.017418.x; Ushio S, 1996, J IMMUNOL, V156, P4274; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Xiang Y, 1999, VIROLOGY, V257, P297, DOI 10.1006/viro.1999.9676; Xiang Y, 1999, P NATL ACAD SCI USA, V96, P11537, DOI 10.1073/pnas.96.20.11537	29	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17380	17386		10.1074/jbc.M009581200	http://dx.doi.org/10.1074/jbc.M009581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278524	hybrid			2022-12-27	WOS:000168730400105
J	Communi, D; Suarez-Huerta, N; Dussossoy, D; Savi, P; Boeynaems, JM				Communi, D; Suarez-Huerta, N; Dussossoy, D; Savi, P; Boeynaems, JM			Cotranscription and intergenic splicing of human P2Y(11) SSF1 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-C; MESSENGER-RNA; P2Y RECEPTORS; UP-REGULATION; CYCLIC-AMP; CELLS; CLONING; PROTEIN; LEUKEMIA	The P2Y(11) receptor is an ATP receptor positively coupled to the cAMP and phosphoinositide pathways. Ssf1 is a Saccharomyces cerevisiae nuclear protein, which plays an important role in mating. The gene encoding the human orthologue of SSF1 is adjacent to the P2Y(11) gene on chromosome 19. During the screening of placenta cDNA libraries, we isolated a chimeric clone resulting from the intergenic splicing between the P2Y(11) and SSF1 genes. The fusion protein was stably expressed in CHO-K1 cells where it generated a cAMP response to ATP qualitatively indistinguishable from that of the P2Y(11) receptor. According to both Western blotting and cAMP response, the expression of the fusion protein in the transfected cells was clearly lower than that of the P2Y(11) receptor. Both P2Y(11) and SSF1 probes detected a 5.6-kb messenger RNA with a similar pattern of intensity in each of 11 human tissues. The ubiquitous presence of chimeric transcripts and their up-regulation during granulocytic differentiation indicate that the transgenic splicing between the P2Y(11) and the SSF1 genes is a common and regulated phenomenon, There are very few examples of intergenic splicing in mammalian cells, and this is the first case involving a G-protein-coupled receptor.	Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Sanofi Synthelabo, F-34084 Montpellier, France; Sanofi Synthelabo, F-31036 Toulouse, France; Free Univ Brussels, Hop Erasme, Dept Med Chem, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Communi, D (corresponding author), Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, Campus Erasme,Bld C,5th Floor,Local C5-145,808 Ro, B-1070 Brussels, Belgium.							ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; Communi D, 2000, FEBS LETT, V475, P39, DOI 10.1016/S0014-5793(00)01618-5; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Conigrave AD, 1998, BRIT J PHARMACOL, V124, P1580, DOI 10.1038/sj.bjp.0701985; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; Kim J, 1998, GENETICS, V149, P795; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; Magrangeas F, 1998, J BIOL CHEM, V273, P16005, DOI 10.1074/jbc.273.26.16005; Migeon JC, 1999, MOL BIOL CELL, V10, P1733, DOI 10.1091/mbc.10.6.1733; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Motte S, 1996, EUR J PHARMACOL, V307, P201, DOI 10.1016/0014-2999(96)00234-8; Schachter JB, 1997, BRIT J PHARMACOL, V121, P338, DOI 10.1038/sj.bjp.0701136; Suarez-Huerta N, 2000, BIOCHEM BIOPH RES CO, V275, P37, DOI 10.1006/bbrc.2000.3259; YU Y, 1995, DNA CELL BIOL, V14, P411, DOI 10.1089/dna.1995.14.411	19	57	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16561	16566		10.1074/jbc.M009609200	http://dx.doi.org/10.1074/jbc.M009609200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278528	hybrid			2022-12-27	WOS:000168623100132
J	Kim, SW; Rhee, HJ; Ko, JS; Kim, YJ; Kim, HG; Yang, JM; Choi, EC; Na, DS				Kim, SW; Rhee, HJ; Ko, JS; Kim, YJ; Kim, HG; Yang, JM; Choi, EC; Na, DS			Inhibition of cytosolic phospholipase A(2) by annexin I - Specific interaction model and mapping of the interaction site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; N-TERMINAL PEPTIDE; PROTEIN-KINASE-C; CRYSTAL-STRUCTURE; P388D(1) MACROPHAGES; LIPOCORTIN 1; CELL-LINE; A(2); BINDING; TRANSLOCATION	Annexins (ANXs) display regulatory functions in diverse cellular processes, including inflammation, immune suppression, and membrane fusion. However, the exact biological functions of ANXs still remain obscure. Inhibition of phospholipase A(2) (PLA(2)) by ANX-I, a 346-amino acid protein, has been observed in studies with various forms of PLA(2). "Substrate depletion" and "specific interaction" have been proposed for the mechanism of PLA(2) inhibition by ANX-I. Previously, we proposed a specific interaction model for inhibition of a 100-kDa porcine spleen cytosolic form of PLA(2) (cPLA(2)) by ANX-I (Kim, K. M., Kim, D. K., Park, Y. M., and Na, D. S. (1994) FEES Lett. 343, 251-255). Herein, we present an analysis of the inhibition mechanism of cPLA(2) by ANX-I in detail using ANX-I and its deletion mutants. Deletion mutants were produced in Escherichia coli, and inhibition of cPLA(2) activity was determined. The deletion mutant ANX-I-(1-274), containing the N terminus to amino acid 274, exhibited no cPLA(2) inhibitory activity, whereas the deletion mutant ANX-I-(275-346), containing amino acid 275 to the C terminus, retained full activity. The protein-protein interaction between cPLA(2) and ANX-I was examined using the deletion mutants by immunoprecipitation and mammalian two-hybrid methods. Full-length ANX-I and ANX-I-(275-346) interacted with the calcium-dependent lipid-binding domain of cPLA(2). ANX-I-(1-274) did not interact with cPLA(2). Immunoprecipitation of A549 cell lysate with anti-ANX-I antibody resulted in coprecipitation of cPLA(2). These results are consistent with the specific interaction mechanism rather than the substrate depletion model. ANX-I may function as a negative regulator of cPLA(2) in cellular signal transduction.	Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea; Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Sogang Univ, Dept Life Sci, Seoul 121742, South Korea	University of Ulsan; Seoul National University (SNU); Sogang University	Choi, EC (corresponding author), Univ Ulsan, Coll Med, Dept Biochem, 388-1 Poongnap Dong, Seoul 138736, South Korea.	ecchoi@snu.ac.kr; dsna@www.amc.seoul.kr						BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckingham JC, 1996, BRIT J PHARMACOL, V118, P1; Buckland AG, 1998, BBA-LIPID LIPID MET, V1391, P367, DOI 10.1016/S0005-2760(98)00026-5; CIRINO G, 1993, BRIT J PHARMACOL, V108, P573, DOI 10.1111/j.1476-5381.1993.tb12843.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; CROXTALL JD, 1993, INT J CANCER, V54, P153, DOI 10.1002/ijc.2910540124; Croxtall JD, 1998, BRIT J PHARMACOL, V123, P975, DOI 10.1038/sj.bjp.0701679; DAVIDSON FF, 1990, J BIOL CHEM, V265, P5602; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DURHAM ACH, 1983, CELL CALCIUM, V4, P33, DOI 10.1016/0143-4160(83)90047-7; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FavierPerron B, 1996, BIOCHEMISTRY-US, V35, P1740, DOI 10.1021/bi952092o; FLOWER RJ, 1990, PROG CLIN BIOL RES, V349, P11; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; HUH K-R, 1990, Korean Biochemical Journal, V23, P459; Kang SA, 1996, BRIT J PHARMACOL, V117, P1780, DOI 10.1111/j.1476-5381.1996.tb15354.x; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; KIM KM, 1994, FEBS LETT, V343, P251, DOI 10.1016/0014-5793(94)80566-0; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Lee KH, 1999, FEBS LETT, V442, P143, DOI 10.1016/S0014-5793(98)01643-3; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Ma ASP, 1996, ARCH DERMATOL RES, V288, P596, DOI 10.1007/s004030050109; Mira JP, 1997, J BIOL CHEM, V272, P10474; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Oh J, 2000, FEBS LETT, V477, P244, DOI 10.1016/S0014-5793(00)01812-3; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RAYNAL P, 1993, BIOCHEM J, V292, P759, DOI 10.1042/bj2920759; Rhee HJ, 1999, J BIOCHEM MOL BIOL, V32, P28; Rhee NJ, 2000, EUR J BIOCHEM, V267, P3220, DOI 10.1046/j.1432-1327.2000.01345.x; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; Seemann J, 1996, MOL BIOL CELL, V7, P1359, DOI 10.1091/mbc.7.9.1359; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; WENG XW, 1993, PROTEIN SCI, V2, P448	46	66	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15712	15719		10.1074/jbc.M009905200	http://dx.doi.org/10.1074/jbc.M009905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278580	hybrid			2022-12-27	WOS:000168623100020
J	Billiard, J; Umayahara, Y; Wiren, K; Centrella, M; McCarthy, TL; Rotwein, P				Billiard, J; Umayahara, Y; Wiren, K; Centrella, M; McCarthy, TL; Rotwein, P			Regulated nuclear-cytoplasmic localization of CCAAT/enhancer-binding protein delta in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; FETAL-RAT BONE; C/EBP-BETA; TRANSCRIPTION FACTORS; PARATHYROID-HORMONE; GENE-TRANSCRIPTION; ENRICHED CULTURES; RESPONSE ELEMENT; DNA-BINDING; KINASE-A	Insulin-like growth factor I (IGF-I) plays a central role in skeletal growth by promoting bone cell replication and differentiation. Prostaglandin E-2 (PGE(2)) and parathyroid hormone enhance cAMP production in cultured rat osteoblasts and stimulate IGF-I expression through a transcriptional mechanism mediated by cAMP dependent protein kinase (PKA), We previously showed that PGE(2) activated the transcription factor CCAAT/enhancer-binding protein delta (C/EBP delta) in osteoblasts and induced its binding to a DNA element within the IGF-I promoter. We report here that a PKA-dependent pathway stimulates nuclear translocation of C/EBP delta. Under basal conditions, C/EBP delta was cytoplasmic but rapidly accumulated in the nucleus after PGE(2) treatment (t(1/2) < 30 min). Nuclear translocation occurred without concurrent protein synthesis and was maintained in the presence of hormone. Nuclear localization required PKA and was blocked by a dominant-interfering regulatory subunit of the enzyme, even though C/EBP<delta> was not a PKA substrate. Upon removal of hormonal stimulus, C/EBP delta quickly exited the nucleus (t(1/2) < 12 min) through a pathway blocked by leptomycin B. Mutagenesis studies indicated that the basic domain of C/EBP<delta> was necessary for nuclear localization and that the leucine zipper region permitted full nuclear accumulation. We thus define a pathway for PKA-mediated activation of C/EBP delta through its regulated nuclear import.	Oregon Hlth Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Yale Univ, Sch Med, Sect Plast Surg, New Haven, CT 06520 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Yale University	Rotwein, P (corresponding author), Oregon Hlth Sci Univ, Div Mol Med, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code NRC3, Portland, OR 97201 USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817; Wiren, Kristine/0000-0002-6159-4450	NIDDK NIH HHS [T32 DK007674, 1-RO1-DK56310, 5F32-DK09802, 5-RO1-DK37449] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009802, R01DK037449, R01DK056310, T32DK007674] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BIRNBAUM RS, 1994, ENDOCRINOLOGY, V135, P223, DOI 10.1210/en.135.1.223; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fornerod M, 1997, CELL, V90, P1051; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HARRIS SA, 1995, J BONE MINER RES, V10, P178; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIKAELIAN I, 1993, J VIROL, V67, P734; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NISHI K, 1994, J BIOL CHEM, V269, P6320; Osada S, 1996, J BIOL CHEM, V271, P3891; PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TRATNER I, 1991, ONCOGENE, V6, P2049; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Williams SC, 1997, GENE EXPRESSION, V6, P371; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	52	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15354	15361		10.1074/jbc.M009973200	http://dx.doi.org/10.1074/jbc.M009973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278589	hybrid			2022-12-27	WOS:000168528800110
J	Korotkov, KV; Kumaraswamy, E; Zhou, Y; Hatfield, DL; Gladyshev, VN				Korotkov, KV; Kumaraswamy, E; Zhou, Y; Hatfield, DL; Gladyshev, VN			Association between the 15-kDa selenoprotein and UDP-glucose : glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE-CONTAINING PROTEINS; GOLGI-APPARATUS; PURIFICATION; EXPRESSION; SEQUENCE; CHAPERONES; INSERTION; ELEMENTS; CERAMIDE; ENZYME	Mammalian selenocysteine-containing proteins characterized with respect to function are involved in redox processes and exhibit distinct expression patterns and cellular locations. A recently identified 15-kDa selenoprotein (Sep15) has no homology to previously characterized proteins, and its function is not known. Here we report the intracellular localization and identification of a binding partner for this selenoprotein which implicate Sep15 in the regulation of protein folding. The native Sep15 isolated from rat prostate and mouse liver occurred in a complex with a 150-kDa protein. The latter protein was identified as UDP-glucose:glycoprotein glucosyltransferase (UGTR), the endoplasmic reticulum (ER)-resident protein, which was previously shown to be involved in the quality control of protein folding. UGTR functions by glucosylating misfolded proteins, retaining them in the ER until they are correctly folded or transferring them to degradation pathways. To determine the intracellular localization of Sep15, we expressed a green fluorescent protein-Sep15 fusion protein in CV-1 cells, and this protein was localized to the ER and possibly other perinuclear compartments. We determined that Sep15 contained the N-terminal signal peptide that was essential for translocation and that it was cleaved in the mature protein. However, C-terminal sequences of Sep15 were not involved in trafficking and retention of Sep15. The data suggest that the association between Sep15 and UGTR is responsible for maintaining the selenoprotein in the ER This report provides the first example of the ER-resident selenoprotein and suggests a possible role of the trace element selenium in the quality control of protein folding.	Univ Nebraska, Dept Biochem, Beadle Ctr N151, Lincoln, NE 68588 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr N151, Lincoln, NE 68588 USA.		Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016; Korotkov, Konstantin/0000-0002-2182-6843				Amouzadeh HR, 1997, CHEM RES TOXICOL, V10, P59, DOI 10.1021/tx9601364; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Ilgoutz SC, 1999, EMBO J, V18, P3643, DOI 10.1093/emboj/18.13.3643; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kumaraswamy E, 2000, J BIOL CHEM, V275, P35540, DOI 10.1074/jbc.M004014200; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Matouschek A, 2000, NAT STRUCT BIOL, V7, P265, DOI 10.1038/74012; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; TROMBETTA S E, 1991, Glycobiology, V1, P155, DOI 10.1093/glycob/1.2.155; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Tujebajeva RM, 2000, J BIOL CHEM, V275, P6288, DOI 10.1074/jbc.275.9.6288	26	117	128	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15330	15336		10.1074/jbc.M009861200	http://dx.doi.org/10.1074/jbc.M009861200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278576	Green Submitted, hybrid			2022-12-27	WOS:000168528800107
J	Listenberger, LL; Ory, DS; Schaffer, JE				Listenberger, LL; Ory, DS; Schaffer, JE			Palmitate-induced apoptosis can occur through a ceramide-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN SPECIES PRODUCTION; ALPHA-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; OXIDATIVE STRESS; SIGNAL-TRANSDUCTION; SERINE PALMITOYLTRANSFERASE; MYOCYTE APOPTOSIS; HYDROGEN-PEROXIDE; REDOX REGULATION; FATTY-ACIDS	Cytotoxic accumulation of long chain fatty acids has been proposed to play an important role in the pathogenesis of diabetes mellitus and heart disease. To explore the mechanism of cellular lipotoxicity, we cultured Chinese hamster ovary cells in the presence of media supplemented with fatty acid. The saturated fatty acid palmitate, but not the monounsaturated fatty acid oleate, induced programmed cell death as determined by annexin V positivity, caspase 3 activity, and DNA laddering. De novo ceramide synthesis increased 2.4-fold with palmitate supplementation; however, this was not required for palmitate-induced apoptosis, Neither biochemical nor genetic inhibition of de novo ceramide synthesis arrested apoptosis in Chinese hamster ovary cells in response to palmitate supplementation. Rather, our data suggest that palmitate-induced apoptosis occurs through the generation of reactive oxygen species. Fluorescence of an oxidant-sensitive probe was increased 3.5-fold with palmitate supplementation indicating that production of reactive intermediates increased. In addition, palmitate-induced apoptosis was blocked by pyrrolidine dithiocarbamate and 4,5-dihydroxy-1,3-benzene-disulfonic acid, two compounds that scavenge reactive intermediates. These studies suggest that generation of reactive oxygen species, independent of ceramide synthesis, is important for the lipotoxic response and may contribute to the pathogenesis of diseases involving intracellular lipid accumulation.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Schaffer, JE (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, 660 S Euclid Ave,Box 8086, St Louis, MO 63110 USA.				NIDDK NIH HHS [DK54268] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054268] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Carlsson C, 1999, ENDOCRINOLOGY, V140, P3422, DOI 10.1210/en.140.8.3422; CHUN-LAN Z, 1992, Thrombosis Research, V65, P65, DOI 10.1016/0049-3848(92)90226-Z; deVries JE, 1997, J LIPID RES, V38, P1384; DOI O, 1978, BIOCHIM BIOPHYS ACTA, V509, P239, DOI 10.1016/0005-2736(78)90044-5; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; GORDON GB, 1977, EXP MOL PATHOL, V27, P262, DOI 10.1016/0014-4800(77)90035-1; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hickson-Bick DLM, 2000, J MOL CELL CARDIOL, V32, P511, DOI 10.1006/jmcc.1999.1098; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Joshi B, 1999, CANCER RES, V59, P4343; KELLY DP, 1994, NEW ENGL J MED, V330, P913; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kleinfeld AM, 1996, AM J CARDIOL, V78, P1350, DOI 10.1016/S0002-9149(96)00651-0; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Moellering D, 1999, FREE RADICAL BIO MED, V26, P1138, DOI 10.1016/S0891-5849(98)00300-1; MORAND O, 1982, BIOCHIM BIOPHYS ACTA, V711, P539, DOI 10.1016/0005-2760(82)90070-4; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; RODRIGUES B, 1995, J MOL CELL CARDIOL, V27, P169, DOI 10.1016/S0022-2828(08)80016-8; ROSELL S, 1981, CLIN PHYSIOL, V1, P3, DOI 10.1111/j.1475-097X.1981.tb00870.x; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; SPECTOR AA, 1986, METHOD ENZYMOL, V128, P320; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; TEPPER A, 1997, J BIOL CHEM, P24308; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	44	461	475	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14890	14895		10.1074/jbc.M010286200	http://dx.doi.org/10.1074/jbc.M010286200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278654	hybrid			2022-12-27	WOS:000168528800050
J	Atabey, N; Gao, Y; Yao, ZJ; Breckenridge, D; Soon, L; Soriano, JV; Burke, TR; Bottaro, DP				Atabey, N; Gao, Y; Yao, ZJ; Breckenridge, D; Soon, L; Soriano, JV; Burke, TR; Bottaro, DP			Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; PHOSPHATE-CONTAINING LIGANDS; PAPILLARY RENAL CARCINOMAS; C-MET RECEPTOR; EPITHELIAL-CELLS; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR ISOFORMS; DOCKING SITE	Hepatocyte growth factor (HGF) stimulates mitogenesis, motogenesis, and morphogenesis in a wide range of cellular targets during development, homeostasis and tissue regeneration. Inappropriate HGF signaling occurs in several human cancers, and the ability of HGF to initiate a program of protease production, cell dissociation, and motility has been shown to promote cellular invasion and is strongly linked to tumor metastasis. Upon HGF binding, several tyrosines within the intracellular domain of its receptor, c-Met, become phosphorylated and mediate the binding of effector proteins, such as Grb2. Grb2 binding through its SH2 domain is thought to link. c-Met with downstream mediators of cell proliferation, shape change, and motility. We analyzed the effects of Grb2 SH2 domain antagonists on HGF signaling and observed potent blockade of cell motility, matrix invasion, and branching morphogenesis, with ED50 values of 30 nM or less, but only modest inhibition of mitogenesis. These compounds are 1000-10,000-fold more potent anti-motility agents than any previously characterized Grb2 SH2 domain antagonists. Our results suggest that SH2 domain-mediated c-Met-Grb2 interaction contributes primarily to the motogenic and morphogenic responses to HGF, and that these compounds may have therapeutic application as anti-metastatic agents for tumors where the HGF signaling pathway is active.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bottaro, DP (corresponding author), EntreMed Inc, 9640 Med Ctr Dr, Rockville, MD 20850 USA.		Burke, Terrence R/N-2601-2014; Bottaro, Donald P/AAF-3853-2020; Atabey, Nese/A-1853-2018; Bottaro, Donald P/F-8550-2010; Yao, Zhu-Jun/E-7635-2015	Bottaro, Donald P/0000-0002-5057-5334; Atabey, Nese/0000-0003-4966-2980; Bottaro, Donald P/0000-0002-5057-5334; Burke, Terrence/0000-0001-9925-8586				Balkovetz DF, 1999, INT REV CYTOL, V186, P225; Bardelli A, 1997, CIBA F SYMP, V212, P133; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier W, 1997, CIBA F SYMP, V212, P230; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Gao Y, 2000, J MED CHEM, V43, P911, DOI 10.1021/jm9904248; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; MARSEIGNE I, 1988, J ORG CHEM, V53, P3621, DOI 10.1021/jo00250a043; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MOTOYAMA T, 1979, Acta Medica et Biologica, V27, P49; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SORIANO JV, 1995, J CELL SCI, V108, P413; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Streit ACE, 1997, CIBA F SYMP, V212, P155; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yao ZJ, 1999, J MED CHEM, V42, P25, DOI 10.1021/jm980388x; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHU H, 1994, J BIOL CHEM, V269, P29943	46	82	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14308	14314		10.1074/jbc.M010202200	http://dx.doi.org/10.1074/jbc.M010202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278639	hybrid			2022-12-27	WOS:000168356600105
J	Buschmann, T; Lin, YH; Aithmitti, N; Fuchs, SY; Lu, H; Resnick-Silverman, L; Manfredi, JJ; Ronai, Z; Wu, XW				Buschmann, T; Lin, YH; Aithmitti, N; Fuchs, SY; Lu, H; Resnick-Silverman, L; Manfredi, JJ; Ronai, Z; Wu, XW			Stabilization and activation of p53 by the coactivator protein TAF(II)31	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RNA-POLYMERASE-II; P53-MEDIATED APOPTOSIS; ONCOPROTEIN MDM2; TRANSCRIPTION; DEGRADATION; COMPLEX; UBIQUITINATION; ASSOCIATION; STABILITY	Regulation of the stability of p53 is key to its tumor-suppressing activities. mdm2 directly binds to the amino-terminal region of p53 and targets it for degradation through the ubiquitin-proteasome pathway. The coactivator protein TAF(II)31 binds to p53 at the amino-terminal region that is also required for interaction with mdma. In this report, we demonstrate that expression of TAF(II)31 inhibits mdm2-mediated ubiquitination of p53 and increases p53 levels. TAF(II)31-mediated p53 stabilization results in activation of p53-mediated transcriptional activity and leads to p53-dependent growth arrest in fibroblasts. UV-induced stabilization of p53 coincides with an increase in p53-associated TAF(II)31 and a corresponding decrease in mdm2-p53 interaction. Non-p53 binding mutant of TAF(II)31 fails to stabilize p53. Our results suggest that direct interaction of TAF(II)31 and p53 not only mediates p53 transcriptional activation but also protects p53 from mdm2-mediated degradation, thereby resulting in activation of p53 functions.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Baylor College of Medicine; Baylor College of Medicine; Oregon Health & Science University; Icahn School of Medicine at Mount Sinai	Wu, XW (corresponding author), Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419, P01CA080058, R29CA069161] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69161, P01 CA80058, CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CORDONCARDO C, 1994, CANCER RES, V54, P794; DEOCALUNA R, 1995, NATURE, V0378; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	37	38	38	142	148	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13852	13857		10.1074/jbc.M007955200	http://dx.doi.org/10.1074/jbc.M007955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278372	hybrid			2022-12-27	WOS:000168356600050
J	Russo, R; Benazzi, L; Perrella, M				Russo, R; Benazzi, L; Perrella, M			The Bohr effect of hemoglobin intermediates and the role of salt bridges in the tertiary/quaternary transitions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVITY; BINDING; HAEMOGLOBIN; RESOLUTION; MECHANISM; CHLORIDE; SITE	Understanding mechanisms in cooperative proteins requires the analysis of the intermediate ligation states. The release of hydrogen ions at the intermediate states of native and chemically modified hemoglobin, known as the Bohr effect, is an indicator of the protein tertiary/ quaternary transitions, useful for testing models of cooperativity, The Bohr effects due to ligation of one subunit of a dimer and two subunits across the dimer interface are not additive. The reductions of the Bohr effect due to the chemical modification of a Bohr group of one and two alpha or beta subunits are additive, The Bohr effects of monoliganded chemically modified hemoglobins indicate the additivity of the effects of ligation and chemical modification with the possible exception of ligation and chemical modification of the ct subunits, These observations suggest that ligation of a subunit brings about a tertiary structure change of hemoglobin in the T quaternary structure, which breaks some salt bridges, releases hydrogen ions, and is signaled across the dimer interface in such a way that ligation of a second subunit in the adjacent dimer promotes the switch from the T to the R quaternary structure. The rupture of the salt bridges per se does not drive the transition.	LITA, CNR, Ist Tecnol Biomed Avanzate, I-20090 Segrate, Italy; Univ Milan, Dipartimento Sci & Tecnol Biomed, I-20090 Segrate, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan	Perrella, M (corresponding author), LITA, CNR, Ist Tecnol Biomed Avanzate, Via Fili Cervi 93, I-20090 Segrate, Italy.	michele.perrella@unimi.it	Russo, Rosaria/AGJ-3883-2022	RUSSO, ROSARIA/0000-0003-0011-5775				ACKERS GK, 1981, J MOL BIOL, V147, P559, DOI 10.1016/0022-2836(81)90400-9; ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ACKERS GK, 2000, PROTEINS STRUCT F S4, V41, P23; Benazzi L, 1998, METHOD ENZYMOL, V295, P208; BENESCH R, 1961, J BIOL CHEM, V236, P405; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; DAUGHERTY MA, 1994, BIOCHEMISTRY-US, V33, P10345, DOI 10.1021/bi00200a015; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; KILMARTIN JV, 1971, BIOCHEM J, V124, P31, DOI 10.1042/bj1240031; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LICATA VJ, 1990, BIOCHEMISTRY-US, V29, P9771, DOI 10.1021/bi00494a003; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NISHIKURA K, 1978, BIOCHEM J, V173, P671; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PEREZ A, 1990, EUR J OBSTET GYN R B, V35, P97, DOI 10.1016/0028-2243(90)90148-T; PERRELLA M, 1990, BIOPHYS CHEM, V37, P211, DOI 10.1016/0301-4622(90)88020-S; PERRELLA M, 1977, FEBS LETT, V78, P287, DOI 10.1016/0014-5793(77)80325-6; Perrella M, 1999, J BIOL CHEM, V274, P2605, DOI 10.1074/jbc.274.5.2605; PERRELLA M, 1994, BIOCHEMISTRY-US, V33, P10358, DOI 10.1021/bi00200a016; PERRELLA M, 1994, METHOD ENZYMOL, V232, P445; Perrella M, 1995, METHOD ENZYMOL, V259, P468; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1969, NATURE, V222, P1240, DOI 10.1038/2221240a0; RUSSO R, 1997, THESIS MILAN U; Shibayama N, 1998, BIOCHEMISTRY-US, V37, P6221, DOI 10.1021/bi980134d; SILVA MM, 1992, J BIOL CHEM, V267, P17248; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; VANBEEK GGM, 1979, EUR J BIOCHEM, V99, P379; WILLIAMS RC, 1975, BIOCHEM BIOPH RES CO, V62, P118, DOI 10.1016/S0006-291X(75)80413-X	33	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13628	13634		10.1074/jbc.M010009200	http://dx.doi.org/10.1074/jbc.M010009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278597	hybrid			2022-12-27	WOS:000168356600019
J	Zhu, CH; Huang, YH; Oberley, LW; Domann, FE				Zhu, CH; Huang, YH; Oberley, LW; Domann, FE			A family of AP-2 proteins down-regulate manganese superoxide dismutase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN-MELANOMA CELLS; GENE-EXPRESSION; MAMMARY-CARCINOMA; MESSENGER-RNA; BREAST-CANCER; TUMOR-GROWTH; PROMOTER; METASTASIS; OVEREXPRESSION	Manganese superoxide dismutase (Mn-SOD) is a primary antioxidant enzyme whose expression is essential for life in oxygen. Mn SOD has tumor suppressor activity in a nide variety of tumors and transformed cell systems. Our initial observations revealed that Mn-SOD expression was inversely correlated with expression of AP-2 transcription factors in normal human fibroblasts and their SV-40 transformed counterparts. Thus we hypothesized that AP-2 may down-regulate Mn-SOD expression. To examine the functional role of AP-2 on Mn-SOD promoter transactivation we cotransfected AP-2-deficient HepG2 cells with a human Mn-SOD promoter-reporter construct and expression vectors encoding each of the three known AP-2 family members. Our results indicated that AP-2 could significantly repress Mn-SOD promoter activity, and that this repression was both Mn-SOD pro meter and AP-2-specific, The three AP-2 proteins appeared to play distinct roles in Mn-SOD gene regulation. Moreover, although all three AP-2 proteins could repress the Mn-SOD promoter, AP-2 alpha and AP-2 gamma were more active in this regard than AP-2 beta. Transcriptional repression by AP-2 was not a general effect in this system, because another AP-2-responsive gene, c-erbB-3, was transactivated by AP-2. Repression of Mn-SOD by AP-2 was dependent on DNA binding, and expression of AP-2B, a dominant negative incapable of DNA binding, relieved the repression on Mn SOD promoter and reactivated Mn SOD expression in the AP-2 abundant SV40-transformed fibroblast cell Line MRC-5VA. These results indicate that AP-2-mediated transcriptional repression contributes to the constitutively low expression of Mn-SOD in SV40-transfromed fibroblasts and suggest a mechanism for Mn-SOD down regulation in cancer.	Univ Iowa, Dept Radiol, Free Rad & Radiat Biol Program, Med Labs B180, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Domann, FE (corresponding author), Univ Iowa, Dept Radiol, Free Rad & Radiat Biol Program, Med Labs B180, Iowa City, IA 52242 USA.			Domann, Frederick/0000-0002-0489-2179	NCI NIH HHS [P01 CA-66081, CA-73612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073612, R01CA073612, P01CA066081, R56CA073612] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang YH, 1999, ARCH BIOCHEM BIOPHYS, V364, P241, DOI 10.1006/abbi.1999.1142; Huang YH, 1999, DNA CELL BIOL, V18, P643, DOI 10.1089/104454999315051; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kuo SY, 1999, J BIOL CHEM, V274, P3345, DOI 10.1074/jbc.274.6.3345; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LI JJ, 1995, ONCOGENE, V10, P1989; MARLHENS F, 1985, BIOCHEM BIOPH RES CO, V129, P300, DOI 10.1016/0006-291X(85)91437-8; MCCORMICK ML, 1991, CARCINOGENESIS, V12, P977, DOI 10.1093/carcin/12.6.977; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; SAFFORD SE, 1994, CANCER RES, V54, P4261; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SKINNER A, 1993, ONCOGENE, V8, P3393; STCLAIR DK, 1991, CANCER RES, V51, P939; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	43	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14407	14413		10.1074/jbc.M009708200	http://dx.doi.org/10.1074/jbc.M009708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278550	hybrid			2022-12-27	WOS:000168356600118
J	Chiu, YL; Coronel, E; Ho, CK; Shuman, S; Rana, TM				Chiu, YL; Coronel, E; Ho, CK; Shuman, S; Rana, TM			HIV-1 Tat protein interacts with mammalian capping enzyme and stimulates capping of TAR RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNA; CARBOXYL-TERMINAL DOMAIN; P-TEFB; SACCHAROMYCES-CEREVISIAE; CAP METHYLTRANSFERASE; MUTATIONAL ANALYSIS; NASCENT RNA; IN-VIVO; POLYMERASE; TRANSCRIPTION	HIV gene expression is subject to a transcriptional checkpoint, whereby negative transcription elongation factors induce an elongation block that is overcome by HIV Tat protein in conjunction with P-TEFb. P-TEFb is a cyclin dependent kinase that catalyzes Tat-dependent phosphorylation of Ser-5 of the Pol II C-terminal domain (CTD). Ser-5 phosphorylation confers on the CTD the ability to recruit the mammalian mRNA capping enzyme (Mcel) and stimulate its guanylyltransferase activity. Here we show that Tat spearheads a second and novel pathway of capping enzyme recruitment and activation via a direct physical interaction between the C-terminal domain of Tat and Mcel. Tat stimulates the guanylyl transferase and triphosphatase activities of Mcel and thereby enhances the otherwise low efficiency of cap formation on a TAR stem-loop RNA. Our findings suggest that multiple mechanisms exist for coupling transcription elongation and mRNA processing.	UMDNJ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center	Rana, TM (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	rana@umdnj.edu	Ho, KIong/GPP-6051-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43198] Funding Source: Medline; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; GUNNERY S, 1995, MOL CELL BIOL, V15, P3597; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Lo HJ, 1998, MOL CELL BIOL, V18, P665, DOI 10.1128/MCB.18.2.665; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MUTHUKRISHNAN S, 1975, NATURE, V255, P33, DOI 10.1038/255033a0; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SHUMAN S, 1982, J BIOL CHEM, V257, P7237; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WU BF, 1998, J MOL BIOL, V277, P179; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	46	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12959	12966		10.1074/jbc.M007901200	http://dx.doi.org/10.1074/jbc.M007901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278368	hybrid			2022-12-27	WOS:000168198600072
J	Kalhan, SC; Mahajan, S; Burkett, E; Reshef, L; Hanson, RW				Kalhan, SC; Mahajan, S; Burkett, E; Reshef, L; Hanson, RW			Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TURNOVER; FATTY-ACIDS; IN-VIVO; GLUCONEOGENESIS; METABOLISM; PREGNANCY; INSULIN; LIVER	Glyceroneogenesis, i.e, the synthesis of the glycerol moiety of triacylglycerol from pyruvate, has been suggested to be quantitatively important in both the liver and adipose tissue during fasting, However, the actual contribution of glyceroneogenesis to triacylglycerol synthesis has not been quantified in vivo in human studies. In the present study we have measured the contribution of glycerol and pyruvate to in vivo synthesis of hepatic triacylglycerol in nonpregnant and pregnant women after an overnight fast. Five nonpregnant women were administered [C-13(3)]glycerol tracer as prime constant rate infusion, and the appearance of tracer in plasma glucose and triacylglycerol was quantified using gas chromatography-mass spectrometry, The contribution of pyruvate to hepatic triacylglycerol was quantified in nonpregnant and pregnant women using the deuterium labeling of body water method, The appearance of [H-2] in hydrogens on C-1 and C-3 of triacylglycerol was measured following periodate oxidation of the glycerol isolated from hydrolyzed triacylglycerol, After a 16-h fast, similar to6.1% of the plasma triacylglycerol pool was derived from plasma glycerol, whereas 10 to 60% was derived from pyruvate in nonpregnant women and pregnant women early in gestation. Our data suggest that glyceroneogenesis from pyruvate is quantitatively a major contributor to plasma triacylglycerol synthesis and may be important for the regulation of very low density lipoprotein triacylglycerol production. Our data also suggest that 3-glycerol phosphate is in rapid equilibrium with the triosephosphate pool, resulting in rapid labeling of the triose pool by the administered tracer glycerol, Because the rate of flux of triosephosphate to glucose during fasting far exceeds that to triacylglycerol, more glycerol ends up in glucose than in triacylglycerol, Alternatively, there may be two distinct pools of 3-glycerol phosphate in the liver, one involved in generating triosephosphate from glycerol and the other involved in glyceride-glycerol synthesis.	Metrohlth Med Ctr, Robert Schwartz MD Ctr Metab & Nutr, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-991120 Jerusalem, Israel	MetroHealth System; Case Western Reserve University; Case Western Reserve University; Hebrew University of Jerusalem	Kalhan, SC (corresponding author), Metrohlth Med Ctr, Robert Schwartz MD Ctr Metab & Nutr, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.	sck@po.cwru.edu	Adiels, Martin/C-9278-2011	Kalhan, Satish/0000-0002-8012-4171	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011089, P01HD011089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00080] Funding Source: Medline; NICHD NIH HHS [HD11089] Funding Source: Medline; NIDDK NIH HHS [DK25541] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; Botion LM, 1998, METABOLISM, V47, P1217, DOI 10.1016/S0026-0495(98)90326-2; Chandramouli V, 1997, AM J PHYSIOL-ENDOC M, V273, pE1209, DOI 10.1152/ajpendo.1997.273.6.E1209; DENNE SC, 1990, BIOL NEONATE, V57, P284, DOI 10.1159/000243203; ELIA M, 1987, METABOLISM, V36, P251, DOI 10.1016/0026-0495(87)90184-3; GORIN E, 1969, EUR J BIOCHEM, V8, P370, DOI 10.1111/j.1432-1033.1969.tb00537.x; Kalhan S, 1997, J CLIN INVEST, V100, P1775, DOI 10.1172/JCI119704; KALHAN SC, 1995, J MASS SPECTROM, V30, P1588, DOI 10.1002/jms.1190301111; KNOPP RH, 1986, BIOL NEONATE, V50, P297, DOI 10.1159/000242614; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; MIYOSHI H, 1988, J CLIN INVEST, V81, P1545, DOI 10.1172/JCI113487; PATEL D, 1992, PEDIATR RES, V31, P52, DOI 10.1203/00006450-199201000-00010; RESHEF L, 1969, J BIOL CHEM, V244, P5577; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; SHRAGO E, 1963, J BIOL CHEM, V238, P3188; Sidossis LS, 1998, AM J PHYSIOL-ENDOC M, V275, pE798, DOI 10.1152/ajpendo.1998.275.5.E798; Siler SQ, 1998, J LIPID RES, V39, P2319; TSERNG KY, 1983, AM J PHYSIOL, V245, pE476, DOI 10.1152/ajpendo.1983.245.5.E476; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354	22	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12928	12931		10.1074/jbc.M006186200	http://dx.doi.org/10.1074/jbc.M006186200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278297	hybrid			2022-12-27	WOS:000168198600067
J	Pollakis, G; Kang, S; Kliphuis, A; Chalaby, MIM; Goudsmit, J; Paxton, WA				Pollakis, G; Kang, S; Kliphuis, A; Chalaby, MIM; Goudsmit, J; Paxton, WA			N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SYNCYTIUM-INDUCING PHENOTYPE; AMINO-ACID SUBSTITUTION; CHEMOKINE RECEPTOR 5; DISEASE PROGRESSION; CELL TROPISM; V1/V2 REGION; V3 DOMAIN; GENOTYPIC CHARACTERISTICS; SOLUBLE CD4	The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage. To substantiate this we generated isogenic HIV-1 molecularly cloned viruses that were composed of the HxB2 envelope backbone containing the V1V2 and V3 regions from viruses isolated from a patient progressing to disease. We show that the V3 amino acid charge per se had little influence on altering the virus coreceptor phenotype. The V1V2 region and its N-linked glycosylation degree were shown to confer CXCR4 usage and provide the virus with rapid replication kinetics. Loss of an N-linked glycosylation site within the V3 region had a major influence on the virus switching from the R5 to X4 phenotype in a V3 charge-dependent manner. The loss of this V3 N-linked glycosylation site was also linked with the broadening of the coreceptor repertoire to incorporate CCR3, By comparing the amino acid sequences of primary HIV-1 isolates, we identified a strong association between high V3 charge and the loss of this V3 N-linked glycosylation site. These results demonstrate that the N-linked glycosylation pattern of the HIV-1 envelope can strongly influence viral coreceptor utilization and the R5 to X4 switch.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Paxton, WA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	w.a.paxton@amc.uva.nl	paxton, william/R-9747-2019; Georgios, Pollakis/Y-2341-2019	Paxton, William/0000-0001-5200-0801; Paxton, William/0000-0002-2654-5186; Pollakis, Georgios/0000-0002-9659-5461				Abebe A, 1999, AIDS, V13, P1305, DOI 10.1097/00002030-199907300-00006; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; BACK NKT, 1994, VIROLOGY, V199, P431, DOI 10.1006/viro.1994.1141; BAHRAOUI E, 1992, AIDS RES HUM RETROV, V5, P565; BENJOUAD A, 1992, J VIROL, V66, P2473, DOI 10.1128/JVI.66.4.2473-2483.1992; BOLMSTEDT A, 1992, J GEN VIROL, V73, P3099, DOI 10.1099/0022-1317-73-12-3099; Bolmstedt A, 1996, J ACQ IMMUN DEF SYND, V12, P213, DOI 10.1097/00042560-199607000-00001; BOYD MT, 1993, J VIROL, V67, P3649, DOI 10.1128/JVI.67.6.3649-3652.1993; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; Carrillo A, 1996, J VIROL, V70, P1310, DOI 10.1128/JVI.70.2.1310-1316.1996; Chabot DJ, 2000, J VIROL, V74, P4404, DOI 10.1128/JVI.74.9.4404-4413.2000; Chan SY, 1999, J VIROL, V73, P2350, DOI 10.1128/JVI.73.3.2350-2358.1999; Cheng-Mayer C, 1999, J VIROL, V73, P5294, DOI 10.1128/JVI.73.7.5294-5300.1999; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; CONNOR RL, 1996, J EXP MED, V185, P621; DEJONG JJ, 1992, J VIROL, V66, P757, DOI 10.1128/JVI.66.2.757-765.1992; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Fouchier RAM, 1995, AIDS RES HUM RETROV, V11, P1473, DOI 10.1089/aid.1995.11.1473; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; HAGGERTY S, 1991, AIDS RES HUM RETROV, V7, P501, DOI 10.1089/aid.1991.7.501; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hoffman TL, 1999, MOL MEMBR BIOL, V16, P57, DOI 10.1080/096876899294760; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Hung CS, 1999, VIROLOGY, V264, P278, DOI 10.1006/viro.1999.0013; Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Kostrikis LG, 1999, J VIROL, V73, P10264, DOI 10.1128/JVI.73.12.10264-10271.1999; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Ly A, 2000, J VIROL, V74, P6769, DOI 10.1128/JVI.74.15.6769-6776.2000; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Mondor I, 1998, VIROLOGY, V248, P394, DOI 10.1006/viro.1998.9282; Morikita T, 1997, AIDS RES HUM RETROV, V13, P1291, DOI 10.1089/aid.1997.13.1291; Nakayama EE, 1998, FEBS LETT, V426, P367, DOI 10.1016/S0014-5793(98)00375-5; Palmer C, 1996, VIROLOGY, V220, P436, DOI 10.1006/viro.1996.0331; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Reed DJ, 1997, J IMMUNOL, V159, P4356; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Schonning K, 1996, VIROLOGY, V218, P134, DOI 10.1006/viro.1996.0173; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Shieh JTC, 2000, J VIROL, V74, P693, DOI 10.1128/JVI.74.2.693-701.2000; SHIODA T, 1992, P NATL ACAD SCI USA, V89, P9434, DOI 10.1073/pnas.89.20.9434; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SULLIVAN N, 1993, J VIROL, V67, P3674, DOI 10.1128/JVI.67.6.3674-3679.1993; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; Weisman Z, 1999, J ACQ IMMUN DEF SYND, V21, P157; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WILLEY RL, 1993, J VIROL, V67, P3639, DOI 10.1128/JVI.67.6.3639-3643.1993; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; WU Z, 1995, J VIROL, V69, P2271, DOI 10.1128/JVI.69.4.2271-2278.1995; YU XF, 1995, J VIROL, V69, P4649, DOI 10.1128/JVI.69.8.4649-4655.1995; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	71	182	190	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13433	13441		10.1074/jbc.M009779200	http://dx.doi.org/10.1074/jbc.M009779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278567	hybrid			2022-12-27	WOS:000168198600132
J	Koul, D; Yao, YX; Abbruzzese, JL; Yung, WKA; Reddy, SAG				Koul, D; Yao, YX; Abbruzzese, JL; Yung, WKA; Reddy, SAG			Tumor suppressor MMAC/PTEN inhibits cytokine-induced NF kappa B activation without interfering with the I kappa B degradation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTIONAL ACTIVITY; IKK-ALPHA; PHOSPHORYLATION; AKT; PROTEIN; COMPLEX; CELLS	The phosphoinositide 3-kinase (PI 3-kinase) pathway has been implicated in the activation of the proinflammatory transcription factor nuclear factor kappaB (NF kappaB). To investigate the role of this pathway in NF kappaB activation, we employed mutated in multiple advanced cancers/phosphatase and tensin homologue (MMAC/PTEN), a natural antagonist of PI 3-kinase activity. Our results show that cytokine-induced DNA binding and transcriptional activities of NF kappaB were both inhibited in a glioma cell line that was stably transfected with MMAC/PTEN. The ability of interleukin-1 (IL-1) to induce inhibitor (I kappaB) degradation or nuclear translocation of NF kappaB was, however, unaffected by MMAC/PTEN expression, suggesting that PI 3-kinase utilizes another equally important mechanism to control NF kappaB activation. It is conceivable that NF kappaB is directly phosphorylated through such a mechanism because treatment with protein phosphatase 2A significantly reduced its DNA binding activity. Moreover, IL-1-induced phosphorylation of p50 NF kappaB was potently inhibited in MMAC/PTEN-expressing cells. Whereas the mediators of NF kappaB phosphorylation remain to be identified, IL-1 was found to induce physical interactions between the PI 3-kinase target Akt kinase and the I kappaB.I kappaB kinase complex. Physical interactions between these proteins were antagonized by MMAC/PTEN consistent with their potential involvement in NF kappaB activation. Taken together, our observations suggest that PI 3-kinase regulates NF kappaB activation through a novel phosphorylation dependent mechanism.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Reddy, SAG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Box 78,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R55CA056041, R01CA056041] Funding Source: NIH RePORTER; NCI NIH HHS [CA56041, CA5526] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Davies MA, 1998, CANCER RES, V58, P5285; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	42	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11402	11408		10.1074/jbc.M007806200	http://dx.doi.org/10.1074/jbc.M007806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278366	hybrid			2022-12-27	WOS:000167980900112
J	Quaglio, E; Chiesa, R; Harris, DA				Quaglio, E; Chiesa, R; Harris, DA			Copper converts the cellular prion protein into a protease-resistant species that is distinct from scrapie isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; REPEAT REGION; PRP 27-30; BINDING; MICE; RECOMBINANT; OCTAPEPTIDE; EXPRESSION; FORM; SUSCEPTIBILITY	Several lines of evidence have suggested that copper ions play a role in the biology of both PrPC and PrPSc, the normal and pathologic forms of the prion protein. To further investigate this intriguing connection, we have analyzed how copper ions affect the biochemical properties of PrPC extracted from the brains of transgenic mice and from transfected cells. We report that the metal rapidly and reversibly induces PrPC to become protease-resistant and detergent-insoluble. Although these two properties are commonly associated with PrPSc, we demonstrate using a conformation-dependent immunoassay that copper-treated PrP is structurally distinct from PrPSc. The effect of copper requires the presence of at least one of the five octapeptide repeats normally present in the N-terminal half of the protein, consistent With the idea that the metal alters the biochemical properties of PrP by directly binding to this region. These results suggest potential roles for copper in prion diseases, as well as in the physiological function of PrPC.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbio.wustl.edu	Chiesa, Roberto/G-1561-2017	Chiesa, Roberto/0000-0002-3842-3733; Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040061] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS40061] Funding Source: Medline; Telethon [139/B] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Harlow ED., 1999, USING ANTIBODIES; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Linder M, 1991, BIOCH COPPER; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Marcotte EM, 1999, BIOCHEMISTRY-US, V38, P667, DOI 10.1021/bi981487f; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1971, NATURE, V230, P115, DOI 10.1038/230115a0; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; PRUSINER SB, 1999, PRION BIOL DIS; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2000, BIOCHEM BIOPH RES CO, V276, P1217, DOI 10.1006/bbrc.2000.3604; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	58	144	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11432	11438		10.1074/jbc.M009666200	http://dx.doi.org/10.1074/jbc.M009666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278539	hybrid			2022-12-27	WOS:000167980900117
J	Singh, Y; Khanna, H; Chopra, AP; Mehra, V				Singh, Y; Khanna, H; Chopra, AP; Mehra, V			A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL FACTOR CLEAVES; SEQUENCE; TRANSLOCATION; MACROPHAGES; MEMBRANE	PA63, a proteolytically activated 63-kDa form of anthrax protective antigen (PA), forms heptameric oligomers and has the ability to bind and translocate the catalytic moieties, lethal factor (LF), and edema factor (EF) into the cytosol of mammalian cells. Acidic pH triggers oligomerization and membrane insertion by PA63, A disordered amphipathic loop in domain II of PA (2 beta2-2 beta3 loop) is involved in membrane insertion by PA63. Because conditions required for membrane insertion coincide with those for oligomerization of PA63 in mammalian cells, residues constituting the 2 beta2-2 beta3 loop were replaced with the residues of the amphipathic membrane inserting loop of its homologue iota-b toxin secreted by Clostridium perfringens. It was hypothesized that such a molecule might assemble into heteroheptameric structures with wild-type PA ultimately leading to the inhibition of cellular intoxication, The mutation blocked the ability of PA to mediate membrane insertion and translocation of Lf into the cytosol but had no effect on proteolytic activation, oligomerization, or binding LF. Moreover, an equimolar mixture of purified mutant PA (PA-I) and wild-type PA showed complete inhibition of toxin activity both in vitro on J774A.1 cells and in vivo in Fischer 344 rats thereby exhibiting a dominant negative effect. In addition, PA-I inhibited the channel-forming ability of wild-type PA on the plasma membrane of CHO-K1 cells thereby indicating protein-protein interactions between the two proteins resulting in the formation of mixed oligomers with defective functional activity. Our findings provide a basis for understanding the mechanism of translocation and exploring the possibility of the use of this PA molecule as a therapeutic agent against anthrax toxin action in vivo.	Ctr Biochem Technol, Delhi 110007, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB)	Singh, Y (corresponding author), Ctr Biochem Technol, Mall Rd, Delhi 110007, India.	ysingh@cbt.res.in						ARORA N, 1992, J BIOL CHEM, V267, P15542; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1999, COMPREHENSIVE SOURCE, P243; Marshall E, 2000, SCIENCE, V289, P382, DOI 10.1126/science.289.5478.382; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; QUINN CP, 1991, J BIOL CHEM, V266, P20124; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SINGH Y, 1994, J BIOL CHEM, V269, P29039; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i	23	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22090	22094		10.1074/jbc.M010222200	http://dx.doi.org/10.1074/jbc.M010222200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11278644	hybrid			2022-12-27	WOS:000169412700016
J	Zhao, J; Morozova, N; Williams, L; Libs, L; Avivi, Y; Grafi, G				Zhao, J; Morozova, N; Williams, L; Libs, L; Avivi, Y; Grafi, G			Two phases of chromatin decondensation during dedifferentiation of plant cells - Distinction between competence for cell fate switch and a commitment for S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO MESOPHYLL PROTOPLASTS; CYCLE; PROTEOLYSIS; NUCLEI; REACTIVATION; REGENERATION; CYTOKININ; DIVISION; PATHWAY; PROTEIN	Cellular dedifferentiation is the major process underlying totipotency, regeneration, and formation of new stem cell lineages in multicellular organisms, In animals it is often associated with carcinogenesis. Here, we used tobacco protoplasts (plant cells devoid of cell wall) to study changes in chromatin structure in the course of dedifferentiation of mesophyll cells. Using flow cytometry and micrococcal nuclease analyses, we identified two phases of chromatin decondensation prior to entry of cells into S phase. The first phase takes place in the course of protoplast isolation, following treatment with cell wall degrading enzymes, whereas the second occurs only after protoplasts are induced with phytohormones to re-enter the;cell cycle. In the absence of hormonal application, protoplasts undergo cycles of chromatin condensation/decondensation and die. The ubiquitin proteolytic system was found indispensable for protoplast progression into S phase, being required for the second but not the first phase of chromatin decondensation, The emerging model suggests that cellular dedifferentiation proceeds by two functionally distinct phases of chromatin decondensation: the first is a transitory phase that confers competence for cell fate switch, which is followed, under appropriate conditions, by a second proteasome dependent phase representing a commitment for the mitotic cycle. These findings might have implications for a wide range of dedifferentiation driven cellular processes in higher eukaryotes.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Grafi, G (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.							BLANK T, 1992, EXP CELL RES, V202, P224, DOI 10.1016/0014-4827(92)90069-K; Carle SA, 1998, J PLANT GROWTH REGUL, V17, P221, DOI 10.1007/PL00007038; CHIABRERA A, 1979, J HISTOCHEM CYTOCHEM, V27, P375, DOI 10.1177/27.1.86566; DURR A, 1993, BIOCHIMIE, V75, P539, DOI 10.1016/0300-9084(93)90059-2; Fransz PF, 2000, CELL, V100, P367, DOI 10.1016/S0092-8674(00)80672-8; GALUN E, 1981, ANNU REV PLANT PHYS, V32, P237, DOI 10.1146/annurev.pp.32.060181.001321; Genschik P, 1998, PLANT CELL, V10, P2063; Gray WM, 2000, TRENDS BIOCHEM SCI, V25, P133, DOI 10.1016/S0968-0004(00)01544-9; HANKS SK, 1980, J CELL BIOL, V87, P285, DOI 10.1083/jcb.87.1.285; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; JAMET E, 1990, CELL DIFFER DEV, V29, P37, DOI 10.1016/0922-3371(90)90022-O; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Meskiene I, 2000, PLANT MOL BIOL, V42, P791, DOI 10.1023/A:1006405929082; NAGATA T, 1970, PLANTA, V92, P301, DOI 10.1007/BF00385097; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; SAXENA PK, 1985, PROTOPLASMA, V128, P184, DOI 10.1007/BF01276340; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; TAKEBE I, 1971, NATURWISSENSCHAFTEN, V58, P318, DOI 10.1007/BF00624737; Trehin C, 1998, PLANTA, V206, P215, DOI 10.1007/s004250050393; van Blokland R, 1997, MOL GEN GENET, V257, P1, DOI 10.1007/s004380050617; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Vissenberg K, 2000, CELL BIOL INT, V24, P343, DOI 10.1006/cbir.1999.0516; Woffenden BJ, 1998, PLANT PHYSIOL, V118, P419, DOI 10.1104/pp.118.2.419; ZELCER A, 1976, PLANT SCI LETT, V7, P331, DOI 10.1016/0304-4211(76)90089-4; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	29	124	133	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22772	22778		10.1074/jbc.M101756200	http://dx.doi.org/10.1074/jbc.M101756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11274191	hybrid			2022-12-27	WOS:000169412700106
J	Sorokin, A; Kozlowski, P; Graves, L; Philip, A				Sorokin, A; Kozlowski, P; Graves, L; Philip, A			Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ANGIOTENSIN-II; COUPLED RECEPTORS; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; SRC; CALCIUM; PHOSPHORYLATION; IDENTIFICATION	Endothelin-1 (ET-1), a member of a family of 21 amino acid peptides possessing vasoconstrictor properties, is known to stimulate mesangial cell proliferation. In this study, ET-1 (100 nM) induced a rapid activation of p21(ras) in human glomerular mesangial cells (HMC). Inhibition of Src family tyrosine kinase activation with [4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine] or chelation of intracellular free calcium with 1,2-bis(2-aminophenoxy) ethanesN,N,N',N' -tetraacetic acid acetoxymethyl ester significantly decreased ET-1dependent p21(ras) activation and suggested the involvement of the cytoplasmic proline-rich tyrosine kinase Pyk2, We have observed that Pyk2 was expressed in HMC and was tyrosine-phosphorylated within 5 min of ET-1 treatment. ET-1-induced activation of Pyk2 was further confirmed using phospho-specific anti-Pyk2 antibodies. Surprisingly, Src kinase activity was required upstream of ET-1-induced autophosphorylation of Pyk2, To determine whether Pyk2 autophosphorylation mediated ET-1-dependent p21(ras) activation, adenovirus-mediated transfer was employed to express a dominant-negative form of Pyk2 (CRNK), CRNK expression inhibited ET-1-induced endogenous Pyk2 autophosphorylation, but did not abolish ET-1-mediated increases in GTP-bound p21(ras) levels. ET-1-induced activation of the p38 MAPK (but not ERK) pathway was inhibited in HMC and in rat glomerular mesangial cells expressing the dominant-negative form of Pyk2, These findings suggest that the engagement of Pyk2 is important for ET-1-mediated p38 MAPK activation and hence the biological effect of this peptide in mesangial cells.	Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Univ N Carolina, Dept Med & Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sorokin, A (corresponding author), Med Coll Wisconsin, Cardiovasc Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	Sorokin@mcw.edu	Graves, Lee/AAG-5470-2021	Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL 22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Chang JHT, 1997, J NEUROSCI, V17, P5881; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Clark GJ, 2000, CANC DRUG DISC DEV, V5, P213; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dunlop ME, 2000, KIDNEY INT, V57, P464, DOI 10.1046/j.1523-1755.2000.t01-1-00866.x; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; EARP HS, 1995, J BIOL CHEM, V270, P28440; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Force T, 1998, CONT BIOMED, P121; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fukuhara S, 2000, CANC DRUG DISC DEV, V5, P83; Guay J, 1997, J CELL SCI, V110, P357; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HILEY CR, 1997, ENDOPTHELINS BIOL ME, P3; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Kelly K, 2000, CANC DRUG DISC DEV, V5, P165; Kohan DE, 1997, AM J KIDNEY DIS, V29, P2, DOI 10.1016/S0272-6386(97)90004-4; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; Muller E, 1999, J CELL PHYSIOL, V181, P462, DOI 10.1002/(SICI)1097-4652(199912)181:3<462::AID-JCP10>3.0.CO;2-T; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pandey P, 1999, J BIOL CHEM, V274, P8618, DOI 10.1074/jbc.274.13.8618; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schieffer B, 1997, AM J PHYSIOL-CELL PH, V272, pC2019, DOI 10.1152/ajpcell.1997.272.6.C2019; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; SCHRAMEK H, 1997, ENDOTHELINS BIOL MED, P81; Schwartzberg PL, 2000, CANC DRUG DISC DEV, V5, P325; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Sraer JD, 1996, KIDNEY INT, V49, P267, DOI 10.1038/ki.1996.38; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; VIHTELIC TS, 1991, GENETICS, V127, P761; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; Xiong WC, 1998, J CELL SCI, V111, P1981	65	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21521	21528		10.1074/jbc.M008869200	http://dx.doi.org/10.1074/jbc.M008869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278444	Green Published, hybrid			2022-12-27	WOS:000169297900097
J	Cline, GW; Vidal-Puig, AJ; Dufour, S; Cadman, KS; Lowell, BB; Shulman, GI				Cline, GW; Vidal-Puig, AJ; Dufour, S; Cadman, KS; Lowell, BB; Shulman, GI			In vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MICE; ENRICHMENT; OBESITY; ACIDS; ASSAY	To clarify the role of uncoupling protein-3 (UCP3) in skeletal muscle, we used NMR and isotopic labeling experiments to evaluate the effect of UCP3 knockout (UCP3KO) in mice on the regulation of energy metabolism in vivo. Whole body energy expenditure was determined from the turnover of doubly labeled body water. Coupling of mitochondrial oxidative phosphorylation in skeletal muscle was evaluated from measurements of rates of ATP synthesis (using P-31 NMR magnetization transfer experiments) and tricarboxylic acid (TCA) cycle flux (calculated from the time course of C-13 enrichment in C-4 and C-2 of glutamate during an infusion of [2-C-13]acetate), At the whole body level, me observed no change in energy expenditure. However, at the cellular level, skeletal muscle UCP3KO increased the rate of ATP synthesis from P-i more than 4-fold under fasting conditions (wild type, 2.2 +/- 0.6 versus knockout, 9.1 +/- 1.4 mu mol/g of muscle/min, p < 0.001) with no change in TGA cycle flux rate (wild type, 0.74 <plus/minus> 0.04 versus knockout, 0.71 +/- 0.03 mu mol/g of muscle/min). The increased efficiency elf ATP production may account for the significant (p < 0.05) increase in the ratio of ATP to ADP in the muscle of UCP3KO mice (5.9 <plus/minus> 0.3) compared with controls (4.5 +/- 0.4). The data presented here provide the first evidence of uncoupling activity by UCP3 in skeletal muscle in vivo.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Yale University; Howard Hughes Medical Institute; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cline, GW (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 9812,295 Congress Ave, New Haven, CT 06510 USA.		Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Vidal-Puig, Antonio/0000-0003-4220-9577	NIDDK NIH HHS [R01 DK040936, R37 DK053477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, R37DK053477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainscow EK, 1999, EUR J BIOCHEM, V266, P737, DOI 10.1046/j.1432-1327.1999.00856.x; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Jucker BM, 2000, J BIOL CHEM, V275, P39279, DOI 10.1074/jbc.M007760200; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; LIN CS, 1980, FEBS LETT, V113, P305; MASON GF, 2000, ISMRM P, V3, P1870; POWERS L, 1995, J MASS SPECTROM, V30, P747, DOI 10.1002/jms.1190300514; Previs SF, 1996, J MASS SPECTROM, V31, P639, DOI 10.1002/(SICI)1096-9888(199606)31:6<639::AID-JMS336>3.0.CO;2-S; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; SABINA RL, 1982, J BIOL CHEM, V257, P178; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wolfe R., 1992, RADIOACTIVE STABLE I, P207	18	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20240	20244		10.1074/jbc.M102540200	http://dx.doi.org/10.1074/jbc.M102540200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274222	hybrid			2022-12-27	WOS:000169135100078
J	Forzani, C; Loulergue, C; Lobreaux, S; Briat, JF; Lebrun, M				Forzani, C; Loulergue, C; Lobreaux, S; Briat, JF; Lebrun, M			Nickel resistance and chromatin condensation in Saccharomyces cerevisiae expressing a maize high mobility group I/Y protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HISTONE H1; MOLECULAR MECHANISMS; ARABIDOPSIS-THALIANA; HO-TRANSCRIPTION; IN-VITRO; HMG-I/Y; YEAST; H4; CARCINOGENESIS	Expression of a maize cDNA encoding a high mobility group (HMG) I/Y protein enables growth of transformed yeast on a medium containing toxic nickel concentrations. No difference in the nickel content was measured between yeast cells expressing either the empty vector or the ZmHMG I/Y2 cDNA, The ZmHMG I/Y2 protein contains four AT hook motifs known to be involved in binding to the minor groove of AT-rich DNA regions. HMG I/Y proteins may act as architectural elements modifying chromatin structure. Indeed, a ZmHMG I/Y2-green fluorescent protein fusion protein was observed in yeast nuclei. Nickel toxicity has been suggested to occur through an epigenetic mechanism related to chromatin condensation and DNA methylation, leading to the silencing of neighboring genes. Therefore, the ZmHMG I/Y2 protein could prevent nickel toxicity by interfering with chromatin structure. Yeast cell growth in the presence of nickel and yeast cells expressing the ZmHMG I/Y2 cDNA increased telomeric URA3 gene silencing. Furthermore, ZmHMG I/Y2 restored a wild-type level of nickel sensitivity to the yeast Delta rpd3 mutant, Therefore, nickel resistance of yeast cells expressing the ZmHMG I/Y2 cDNA is likely achieved by chromatin structure modification, restricting nickel accessibility to DNA.	Univ Montpellier 2, Ecole Natl Super Agron Montpellier, Inst Natl Rech Agron, CNRS UMR 5004, F-34060 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier	Lebrun, M (corresponding author), Univ Montpellier 2, Ecole Natl Super Agron Montpellier, Inst Natl Rech Agron, CNRS UMR 5004, 2 Pl Viala, F-34060 Montpellier 1, France.							Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Bal W, 1999, ARCH BIOCHEM BIOPHYS, V364, P161, DOI 10.1006/abbi.1999.1137; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P239, DOI 10.1081/CLT-100102423; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Briat JF, 1999, CR ACAD SCI III-VIE, V322, P43, DOI 10.1016/S0764-4469(99)80016-X; Broday L, 1999, MUTAT RES-GEN TOX EN, V440, P121, DOI 10.1016/S1383-5718(99)00018-2; Broday L, 2000, CANCER RES, V60, P238; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CAMPBELL I, 1988, YEAST PRACTICAL APPR, P277; COSTA M, 1991, ANNU REV PHARMACOL, V31, P321; COSTA M, 1995, AM J CLIN NUTR, V61, p666S, DOI 10.1093/ajcn/61.3.666S; COSTA M, 1994, SCI TOTAL ENVIRON, V148, P191, DOI 10.1016/0048-9697(94)90396-4; DAILY GC, 1995, SCIENCE, V269, P350, DOI 10.1126/science.269.5222.350; ESKEW DL, 1983, SCIENCE, V222, P621, DOI 10.1126/science.222.4624.621; Freyermuth SK, 2000, PLANT J, V21, P53, DOI 10.1046/j.1365-313x.2000.00655.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; Gupta R, 1997, PLANT MOL BIOL, V34, P529, DOI 10.1023/A:1005828430861; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kramer U, 1996, NATURE, V379, P635, DOI 10.1038/379635a0; Krech AB, 1999, GENE, V230, P1, DOI 10.1016/S0378-1119(99)00067-0; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Lechner T, 2000, BIOCHEMISTRY-US, V39, P1683, DOI 10.1021/bi9918184; LEE YW, 1995, MOL CELL BIOL, V15, P2547; Loulergue C, 1998, GENE, V225, P47, DOI 10.1016/S0378-1119(98)00531-9; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MINET M, 1992, PLANT J, V2, P417; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NIETOSOTELO J, 1994, NUCLEIC ACIDS RES, V22, P1115, DOI 10.1093/nar/22.6.1115; NIETOSOTELO J, 1994, PLANT CELL, V6, P287, DOI 10.1105/tpc.6.2.287; Nishimura K, 1998, J BACTERIOL, V180, P1962, DOI 10.1128/JB.180.7.1962-1964.1998; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; Pearce DA, 1999, J BACTERIOL, V181, P4774, DOI 10.1128/JB.181.16.4774-4779.1999; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sambrook J., 2002, MOL CLONING LAB MANU; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; SUNDERMAN FW, 1984, IARC SCI PUBL, V53, P127; Thoiron S, 1999, PLANT PHYSIOL BIOCH, V37, P759, DOI 10.1016/S0981-9428(00)86689-9; Tripoulas N, 1996, GENETICS, V143, P913; Wechser MA, 1997, EMBO J, V16, P2086, DOI 10.1093/emboj/16.8.2086; Zhao J, 2000, J BIOL CHEM, V275, P27494; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	49	8	9	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16731	16738		10.1074/jbc.M007462200	http://dx.doi.org/10.1074/jbc.M007462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278346	hybrid			2022-12-27	WOS:000168730400020
J	Nagavarapu, U; Danthi, S; Boyd, RT				Nagavarapu, U; Danthi, S; Boyd, RT			Characterization of a rat neuronal nicotinic acetylcholine receptor alpha 7 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; CENTRAL-NERVOUS-SYSTEM; BETA-4 SUBUNIT GENE; PC12 CELLS; BUNGAROTOXIN; EXPRESSION; FAMILY; BRAIN; SP1; ACTIVATION	Neuronal nicotinic acetylcholine receptors (nAChRs) containing the alpha7 subunit are expressed in the central nervous system, autonomic nervous system, retina, adrenal medulla, and PC12 cells, alpha7 nAChRs have been implicated in several important biological, activities apart from synaptic transmission such as mediating neurite growth and presynaptic control of neurotransmitter release. A 178-base pair promoter was sufficient to drive high level expression of the alpha7 gene in PC12 cells. The alpha7 promoter was also cell-specific, expressing in PC12 cells but not in L6 rat muscle cells. Within our minimal rat alpha7 nAChR promoter we identified two sequences important for basal level expression. Mutation of a GC-rich sequence at -172 relative to the translational start site led to an increase in activity of the promoter, indicating the presence of a negative regulatory element. Upstream stimulatory factor-1 acted to regulate alpha7 expression positively by binding to an E-box at -116. A site directly adjacent to the upstream stimulatory factor-1 binding site was shown to bind Egr-1. Spl and Sp3 binding also occurred downstream from or overlapping the Egr-1 binding site in the rat alpha7 promoter. Several transcription factors interact in close proximity to control expression of the rat alpha7 nicotinic receptor gene.	Ohio State Univ, Coll Med & Publ Hlth, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Boyd, RT (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Neurosci, 4068 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.							ANAND R, 1991, J BIOL CHEM, V266, P11192; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Berger F, 1998, J NEUROSCI, V18, P6871; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BINA KG, 1995, J COMP NEUROL, V363, P321, DOI 10.1002/cne.903630212; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; BROIDE RS, 1995, NEUROSCIENCE, V67, P2956; BROIDE RS, 1996, J NEUROSCI, V16, P83; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Carrasco-Serrano C, 1998, J BIOL CHEM, V273, P20021, DOI 10.1074/jbc.273.32.20021; Carrasco-Serrano C, 2000, J NEUROCHEM, V74, P932, DOI 10.1046/j.1471-4159.2000.0740932.x; CHAN J, 1993, NEUROSCIENCE, V56, P441, DOI 10.1016/0306-4522(93)90344-F; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; CORRIVEAU RA, 1995, J NEUROSCI, V15, P1372; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Criado M, 1997, J NEUROSCI, V17, P6554; DeKoninck P, 1995, J NEUROSCI, V15, P7966; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; ELOGOYHEN AB, 1994, CELL, V79, P705; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gault J, 1998, GENOMICS, V52, P173, DOI 10.1006/geno.1998.5363; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; HORYLEE F, 1995, J NEUROSCI, V15, P6453; LAMAR E, 1990, Society for Neuroscience Abstracts, V16, P681; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; LIPTON SA, 1988, SCIENCE, V239, P1293, DOI 10.1126/science.3344435; Matter JM, 1998, J PHYSIOLOGY-PARIS, V92, P245, DOI 10.1016/S0928-4257(98)80027-2; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; PUGH PC, 1994, J NEUROSCI, V14, P889; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUIK M, 1994, BRAIN RES, V655, P161, DOI 10.1016/0006-8993(94)91610-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; SEGUELA P, 1993, J NEUROSCI, V13, P596; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	54	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16749	16757		10.1074/jbc.M009712200	http://dx.doi.org/10.1074/jbc.M009712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278551	hybrid			2022-12-27	WOS:000168730400022
J	Bao, SL; Qyang, YB; Yang, PR; Kim, HW; Du, HY; Bartholomeusz, G; Henkel, J; Pimental, R; Verde, F; Marcus, S				Bao, SL; Qyang, YB; Yang, PR; Kim, HW; Du, HY; Bartholomeusz, G; Henkel, J; Pimental, R; Verde, F; Marcus, S			The highly conserved protein methyltransferase, Skb1, is a mediator of hyperosmotic stress response in the fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; ARGININE METHYLATION; CELL POLARITY; KINASE; ACTIVATION; SHK1; PAK; INTERACTS; CYCLE	The p21-activated kinase, Shk1, is required for cell viability, establishment and maintenance of cell polarity, and proper mating response in the fission yeast, Schizosaccharomyces pombe. Previous genetic studies suggested that a presumptive protein methyltransferase, Skb1, functions as a positive modulator of Shk1. However, unlike Shk1, Skb1 is not required for viability or mating of S. pombe cells and contributes only modestly to the regulation of cell morphology under normal growth conditions. Here we demonstrate that Skb1 plays a more significant role in regulating cell growth and polarity under conditions of hyperosmotic stress. We provide evidence that the inability of skb1 Delta cells to properly maintain cell polarity in hyperosmotic conditions results from inefficient subcellular targeting of F-actin, We show that Skb1 localizes to cell ends, sites of septation, and nuclei of S. pombe cells, Hyperosmotic shock results in substantial delocalization of Skb1 from cell ends and nuclei, as well as stimulation of Skb1 protein methyltransferase activity. Taken together, our results demonstrate a new role for Skb1 as a mediator of hyperosmotic stress response in fission yeast. We show that the protein methyltransferase activity of the human Skb1 homolog, Skb1Hs, is also stimulated by hyperosmotic stress in fission yeast, providing evidence for evolutionary conservation of a role for Skb1-related proteins as mediators of hyperosmotic stress response, as well as mechanisms involved in regulating this novel class of protein methyltransferases.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Genes & Dev, Houston, TX 77030 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Miami	Marcus, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NIGMS NIH HHS [R01GM53239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Alfa C, 1993, EXPT FISSION YEAST L; Bauman P, 1998, BIOCHEM BIOPH RES CO, V244, P468, DOI 10.1006/bbrc.1998.8292; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Clerk A, 1997, FEBS LETT, V403, P23, DOI 10.1016/S0014-5793(97)00020-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; Le Goff X, 1999, CURR GENET, V35, P571, DOI 10.1007/s002940050455; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Ma XJ, 2000, TRENDS BIOCHEM SCI, V25, P11, DOI 10.1016/S0968-0004(99)01509-1; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Mata J, 1998, TRENDS CELL BIOL, V8, P163, DOI 10.1016/S0962-8924(98)01224-0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Rupes I, 1999, MOL BIOL CELL, V10, P1495, DOI 10.1091/mbc.10.5.1495; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; Schwarzler A, 2000, J BIOL CHEM, V275, P9557, DOI 10.1074/jbc.275.13.9557; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Yang PR, 1998, J BIOL CHEM, V273, P18481, DOI 10.1074/jbc.273.29.18481; Yang PR, 1999, J BIOL CHEM, V274, P36052, DOI 10.1074/jbc.274.51.36052	33	34	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14549	14552		10.1074/jbc.C100096200	http://dx.doi.org/10.1074/jbc.C100096200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278267	hybrid			2022-12-27	WOS:000168528800005
J	Srivastava, M; Ahmad, N; Gupta, S; Mukhtar, H				Srivastava, M; Ahmad, N; Gupta, S; Mukhtar, H			Involvement of Bcl-2 and Bax in photodynamic therapy-mediated apoptosis - Antisense Bcl-2 oligonucleotide sensitizes RIF 1 cells to photodynamic therapy apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; HELA-CELLS; ACTIVATION; DEATH; CLEAVAGE; INHIBITION; SURVIVAL; INDUCTION; PATHWAY; CANCER	Photodynamic therapy (PDT), a promising treatment modality, is an oxidative stress that induces apoptosis in many cancer cells in vitro and tumors in vivo. Understanding the mechanism(s) involved in POT-mediated apoptosis may improve its therapeutic efficacy. Although studies suggest the involvement of multiple pathways, the triggering event(s) responsible for PDT-mediated apoptotic response is(are) not clear. To investigate the role of Bcl-2 in POT-mediated apoptosis, we employed Bcl-2-antisense and -overexpression approaches in two cell types differing in their responses toward PDT apoptosis, In the first approach, we treated radiation-induced fibrosarcoma (RIF 1) cells, which are resistant to silicon phthalocyanine (Pc 4)-PDT apoptosis, with Bcl-2-antisense oligonucleotide. This treatment resulted in sensitization of RIF 1 cells to PDT-mediated apoptosis as demonstrated by i) cleavage of poly(ADP-ribose) polymerase, ii) DNA ladder formation, iii) terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) positive cells, and iv) DEVDase activity. This treatment also resulted in oligonucleotide concentration-dependent decrease in cell viability and down-regulation of Bcl-2 protein with a concomitant increase in apoptosis, However, the level of Bax, a pro-apoptotic member of Bcl-2 family, remained unaltered. In the second approach, an overexpression of Bcl-2 in PDT apoptosis-sensitive human epidermoid carcinoma (A431) cells resulted in enhanced apoptosis and up-regulation of Bax following PDT. In both the approaches, the increased Bax/Bcl-2 ratio was associated with an increased apoptotic response of PDT, Our data also demonstrated that PDT results in modulation of other Bcl-2 family members in a way that the overall ratio of pro apoptotic and anti-apoptotic member proteins favors apoptosis.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	hxm4@po.cwru.edu		Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [R01 CA 51802, P30 CA 43703, P01 CA 48735] Funding Source: Medline; NIAMS NIH HHS [P30 AR 39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048735, R01CA051802, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 2000, METHOD ENZYMOL, V319, P342; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Gao G, 2000, J CELL BIOCHEM, V80, P53; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V54, P1093, DOI 10.1111/j.1751-1097.1991.tb02133.x; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gupta S, 1998, CANCER RES, V58, P1785; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kalka K, 2000, J AM ACAD DERMATOL, V42, P389, DOI 10.1016/S0190-9622(00)90209-3; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim HRC, 1999, CANCER RES, V59, P3429; Klotz LO, 1998, CANCER RES, V58, P4297; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; Murphy AN, 1999, ANN NY ACAD SCI, V893, P19, DOI 10.1111/j.1749-6632.1999.tb07815.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Separovic D, 1997, CANCER RES, V57, P1717; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P204, DOI 10.1111/j.1751-1097.1993.tb09550.x; Zhang WG, 1999, PHOTOCHEM PHOTOBIOL, V69, P582, DOI 10.1562/0031-8655(1999)069<0582:ABRVIT>2.3.CO;2	45	85	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15481	15488		10.1074/jbc.M006920200	http://dx.doi.org/10.1074/jbc.M006920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278320	hybrid			2022-12-27	WOS:000168528800126
J	Espanel, X; Sudol, M				Espanel, X; Sudol, M			Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; CELLULAR PROTEINS; SOLID SUPPORTS; BINDS; LIGANDS; PEPTIDE; 53BP2; P53; DYSTROPHIN; HOMOLOG	To understand the role of the Yes-associated protein (YAP), binding partners of its WW1 domain were isolated by a yeast two-hybrid screen. One of the interacting proteins was identified as p53-binding protein-2 (p58BP-2), YAP and p53BP-2 interacted in vitro and in vivo using their WW1 and SH3 domains, respectively. The YAP WW1 domain bound to the YPPPPY motif of p53BP-2, whereas the p53BP-2 SH3 domain interacted with the VPMRLR sequence of YAP, which is different from other known SH3 domain-binding motifs, By mutagenesis, we showed that this unusual SH3 domain interaction was due to the presence of three consecutive tryptophans located within the betaC strand of the SH3 domain. A point mutation within this triplet, W976R, restored the binding selectivity to the general consensus sequence for SH3 domains, the PXXP motif, A constitutively active form of c-Yes was observed to decrease the binding affinity between YAP and p53BP-2 using chloramphenicol acetyItransferase/enzyme-linked immunosorbent assay, whereas the overexpression of c-Yes did not modify this interaction Since overexpression of an activated form of c-Yes resulted in tyrosine phosphorylation of p53BP-2, we propose that the p53BP-2 phosphorylation, possibly in the WW1 domain-binding motif, might negatively regulate the YAP p53BP-2 complex.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Espanel, X (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.				NCI NIH HHS [CA45757] Funding Source: Medline; NIAMS NIH HHS [AR45626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nakaga H, 2000, CANCER RES, V60, P101; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904	33	107	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14514	14523		10.1074/jbc.M008568200	http://dx.doi.org/10.1074/jbc.M008568200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278422	hybrid			2022-12-27	WOS:000168356600132
J	Tagalakis, AD; Graham, IR; Riddell, DR; Dickson, JG; Owen, JS				Tagalakis, AD; Graham, IR; Riddell, DR; Dickson, JG; Owen, JS			Gene correction of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN; TRANSGENIC MICE; E PREVENTS; ATHEROSCLEROSIS; VIVO; CELLS; DNA; HYPERLIPOPROTEINEMIA; OVEREXPRESSION; CHOLESTEROL	Apolipoprotein (apo) E is a polymorphic plasma protein, synthesized mainly by liver. Here, we evaluate whether synthetic DNA-RNA oligonucleotides (chimeraplasts) can convert a dysfunctional isoform, apoE2 (C --> T, R158C), which causes Type III hyperlipidemia and premature atherosclerosis, into apoE3. First, we treated recombinant Chinese hamster ovary cells stably secreting apoE2 with a 68-mer apoE2 to apoE3 chimeraplast. About one-third of apoE2 was converted to apoE3, and the repair was stable through 12 passages. Subcloning treated cells produced both apoE2 and apoE3 clones. Direct sequencing and reverse transcription polymerase chain reaction confirmed the genotype, whereas phenotypic change was verified by isoelectric focusing and immunoblotting of secreted proteins. Second, we established that the APOE2 gene can be targeted both in vivo, using transgenic mice overexpressing human apoE2, and in chromosomal context, using cultured lymphocytes from a patient homozygous for the epsilon2 allele. We conclude that chimeraplasty has the potential to convert the apoE2 mutation in patients with Type III hyperlipidemia to apoE3.	UCL, Dept Med, Royal Free & Univ Coll Med Sch, London NW3 2PF, England; Royal Holloway Univ London, Dept Biochem, Egham TW20 0EX, Surrey, England	University of London; University College London; University of London; Royal Holloway University London	Owen, JS (corresponding author), UCL, Dept Med, Royal Free & Univ Coll Med Sch, Royal Free Campus, London NW3 2PF, England.	j.owen@rfc.ucl.ac.uk	Owen, James/C-5908-2009; Tagalakis, Aristides/E-8883-2011; Owen, James S./AAP-8628-2020					Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322; BANKA CL, 1991, J LIPID RES, V32, P35; Bartlett RJ, 2000, NAT BIOTECHNOL, V18, P615, DOI 10.1038/76448; Boletta A, 1997, HUM GENE THER, V8, P1243, DOI 10.1089/hum.1997.8.10-1243; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Desurmont C, 2000, ARTERIOSCL THROM VAS, V20, P435, DOI 10.1161/01.ATV.20.2.435; FAZIO S, 1992, J BIOL CHEM, V267, P6941; Friedmann T, 1997, SCI AM, V276, P96; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; GENEST JJ, 1991, ATHEROSCLEROSIS, V90, P149, DOI 10.1016/0021-9150(91)90109-G; HIXSON JE, 1990, J LIPID RES, V31, P545; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Kmiec EB, 1999, GENE THER, V6, P1, DOI 10.1038/sj.gt.3300789; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Kren BT, 1999, SEMIN LIVER DIS, V19, P93, DOI 10.1055/s-2007-1007101; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Kren BT, 1999, P NATL ACAD SCI USA, V96, P10349, DOI 10.1073/pnas.96.18.10349; Linton MF, 1999, CURR OPIN LIPIDOL, V10, P97, DOI 10.1097/00041433-199904000-00003; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, J LIPID RES, V40, P1933; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCDOWELL IFW, 1989, CLIN CHEM, V35, P2070; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; NEGRI C, 1991, CYTOTECHNOLOGY, V7, P173, DOI 10.1007/BF00365928; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Rando TA, 2000, P NATL ACAD SCI USA, V97, P5363, DOI 10.1073/pnas.97.10.5363; Riddell DR, 1997, J BIOL CHEM, V272, P89; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; STEVENSON SC, 1995, ARTERIOSCL THROM VAS, V15, P479, DOI 10.1161/01.ATV.15.4.479; Tsukamoto K, 1999, ARTERIOSCL THROM VAS, V19, P2162, DOI 10.1161/01.ATV.19.9.2162; VANDENMAAGDENBERG AMJM, 1993, AM J HUM GENET, V52, P937; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMAMOTO K, 1995, DIABETES, V44, P580, DOI 10.2337/diabetes.44.5.580; Ye SZ, 1998, MOL MED TODAY, V4, P431, DOI 10.1016/S1357-4310(98)01344-6; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071; Zhu T, 1999, P NATL ACAD SCI USA, V96, P8768, DOI 10.1073/pnas.96.15.8768	43	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13226	13230		10.1074/jbc.C000883200	http://dx.doi.org/10.1074/jbc.C000883200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278248	hybrid			2022-12-27	WOS:000168198600105
J	Zhang, YG; Mattjus, P; Schmid, PC; Dong, ZM; Zhong, SP; Ma, WY; Brown, RE; Bode, AM; Schmid, HHO; Dong, ZG				Zhang, YG; Mattjus, P; Schmid, PC; Dong, ZM; Zhong, SP; Ma, WY; Brown, RE; Bode, AM; Schmid, HHO; Dong, ZG			Involvement of the acid sphingomyelinase pathway in UVA-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SIGNALING PATHWAYS; PROGRAMMED CELL-DEATH; N-TERMINAL KINASE; DNA STRAND BREAKS; NEUTRAL SPHINGOMYELINASE; CERAMIDE; ACTIVATION; STRESS; PROTEIN; TRANSDUCTION	The sphingomyelin-ceramide pathway is an evolutionarily conserved ubiquitous signal transduction system that regulates many cell functions including apoptosis. Sphingomyelin (SM) is hydrolyzed to ceramide by different sphingomyelinases. Ceramide serves as a second messenger in mediating cellular effects of cytokines and stress. In this study, we find that acid sphingomyelinase (SMase) activity was induced by UVA in normal JY lymphoblasts but was not detectable in MS1418 lymphoblasts from Niemann-Pick type D patients who have an inherited deficiency of acid SMase. We also provide evidence that WA can induce apoptosis by activating acid SMase in normal JY cells. In contrast, UVA-induced apoptosis was inhibited in MS1418 cells. Exogenous SMase and its product, ceramide (10-40 muM), induced apoptosis in JY and MS1418 cells, but the substrate of SMase, SM (20-80 muM), induced apoptosis only in JY cells. These results suggest that UVA-induced apoptosis by SM is dependent on acid SMase activity. We also provide evidence that induction of apoptosis by WA may occur through activation of JNKs via the acid SMase pathway.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Henan Med Univ, Dept Pathophysiol, Zhengzhou 450052, Peoples R China	University of Minnesota System; Zhengzhou University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.		Mattjus, Peter/ABE-3596-2021; Mattjus, Peter/AAQ-7531-2021	Mattjus, Peter/0000-0001-8991-5933; Brown, Rhoderick/0000-0002-7337-3604; Zhang, Yiguo/0000-0003-3910-2779	NATIONAL CANCER INSTITUTE [R01CA081064, R37CA081064, R01CA077646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928, R01GM045741] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081064, R01 CA077646, CA81064, CA77646, R37 CA081064] Funding Source: Medline; NIGMS NIH HHS [R01 GM045928-08, GM45741, R01 GM045928-09, R01 GM045928-07, R01 GM045928, GM45928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Beissert S, 1996, CRIT REV BIOCHEM MOL, V31, P381, DOI 10.3109/10409239609108723; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DeLaat JMT, 1996, CANCER SURV, V26, P173; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; FOLCH J, 1957, J BIOL CHEM, V226, P497; Godar DE, 1999, J INVEST DERM SYMP P, V4, P17, DOI 10.1038/sj.jidsp.5640175; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li X, 1996, EXP CELL RES, V222, P28, DOI 10.1006/excr.1996.0004; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; Loo DT, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P65; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Slominski A, 1998, CLIN DERMATOL, V16, P503, DOI 10.1016/S0738-081X(98)00023-6; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tada-Oikawa S, 1998, BIOCHEM BIOPH RES CO, V247, P693, DOI 10.1006/bbrc.1998.8869; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; TYRRELL RM, 1996, STRESS INDUCIBLE CEL, P255; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	51	123	130	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11775	11782		10.1074/jbc.M006000200	http://dx.doi.org/10.1074/jbc.M006000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278294	Green Accepted, hybrid			2022-12-27	WOS:000168081800048
J	Dong, F; Gutkind, JS; Larner, AC				Dong, F; Gutkind, JS; Larner, AC			Granulocyte colony-stimulating factor induces Erk5 activation, which is differentially regulated by protein-tyrosine kinases and protein kinase C - Regulation of cell proliferation and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-CSF RECEPTOR; DISTINCT CYTOPLASMIC REGIONS; SIGNALING PATHWAY; PROTEIN-KINASE-1 BMK1; TRANSCRIPTION FACTOR; RAPID ACTIVATION; MYELOID CELLS; JUN PROMOTER; MAP KINASE; INHIBITOR	Granulocyte colony-stimulating factor (G-CSF) plays a major role in the regulation of granulopoiesis. Treatment of cells with G-CSF has been shown to activate multiple signal transduction pathways. We show here that Erk5, a novel member of the MAPK family, and its specific upstream activator MEK5 were activated in response to incubation of cells with G-CSF. Different from other members of the MAPK family including Erk1/2, JNK, and p38, maximal activation of Erk5 by G-CSF required the C-terminal region of the G-CSF receptor. Genistein, a specific inhibitor of protein-tyrosine kinases, blocked G-CSF-induced Erk5 activation. In contrast, inhibition of protein kinase C activity increased G-CSF-mediated activation of Erk5 and MEK5, whereas stimulation of protein kinase C activity inhibited activation of the two kinases by G-CSF, The proliferation of BAF3 cells in response to G-CSF was inhibited by expression of a dominant-negative MEK5 but potentiated by expression of a constitutively active MEK5. Expression of the constitutively active MEK5 also increased the survival of BAF3 cells cultured in the absence of or in low concentrations of G-CSF. Together, these data implicate Erk5 as an important signaling component in the biological actions of G-CSF.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Dong, F (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NCI NIH HHS [CA77741, CA77736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077736, R01CA077741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avalos BR, 1997, EXP HEMATOL, V25, P160; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; Cacace AM, 1996, ONCOGENE, V13, P2517; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; Deshpande RV, 1997, J CELL BIOCHEM, V66, P286, DOI 10.1002/(SICI)1097-4644(19970901)66:3<286::AID-JCB2>3.0.CO;2-L; Dong F, 2000, BLOOD, V95, P1656, DOI 10.1182/blood.V95.5.1656.005k29_1656_1662; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Dong F, 1998, J IMMUNOL, V161, P6503; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hunter MG, 1998, J IMMUNOL, V160, P4979; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	56	45	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10811	10816		10.1074/jbc.M008748200	http://dx.doi.org/10.1074/jbc.M008748200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278431	hybrid			2022-12-27	WOS:000167980900035
J	Gupta, S; Radha, V; Furukawa, Y; Swarup, G				Gupta, S; Radha, V; Furukawa, Y; Swarup, G			Direct transcriptional activation of human caspase-1 by tumor suppressor p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; IL-1-BETA-CONVERTING ENZYME; MICE DEFICIENT; DNA-BINDING; APOPTOSIS; DEATH; GENE; EXPRESSION; RESISTANT; GROWTH	The tumor suppressor protein p53 is a sequence-specific DNA-binding protein, and its biological responses are very often mediated by transcriptional activation of various target genes, Here we show that caspase-1 (interleukin-1 beta converting enzyme), which plays a role in the production of proinflammatory cytokines and in apoptosis, is a transcriptional target of p53, Caspase-1 mRNA levels increased upon overexpression of p53 by transfection in MCF-7 cells. Human caspase-1 promoter showed a sequence homologous to the consensus p53-binding site. This sequence bound to p53 in gel shift assays. A caspase-1 promoter-reporter construct was activated 6-8-fold by cotransfection with normal p53 but not by mutant p53 (His(273)) in HeLa, as well as MCF-7, cells. Mutation of the p53-binding site in caspase-1 promoter abolished transactivation by p53, Treatment of p53-positive MCF-7 cells with the DNA-damaging drug, doxorubicin, which increases p53 levels, enhanced caspase-1 promoter activity 4-5-fold, but similar treatment of MCF-7-mp53 (a clone of MCF-7 cells expressing mutant p53) and p53-negative HeLa cells with doxorubicin did not increase caspase-1 promoter activity. Doxorubicin treatment increased caspase-1 mRNA levels in MCF-7 cells but not in MCF-7-mp53 or HeLa cells. These results show that endogenous p53 can regulate caspase-1 gene expression.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, Minami Kawachi, Tochigi 3290498, Japan	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Jichi Medical University; Jichi Medical University	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.		gupta, sanjeev/B-2824-2008; Gupta, Sanjeev/AAG-9749-2020; Furukawa, Yusuke/Y-1342-2018	gupta, sanjeev/0000-0002-4691-6853; Gupta, Sanjeev/0000-0002-4691-6853; Swarup, Ghanshyam/0000-0002-8098-0509; Furukawa, Yusuke/0000-0002-7249-6418				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Tak PP, 2000, IMMUNOL TODAY, V21, P78, DOI 10.1016/S0167-5699(99)01552-2; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	20	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10585	10588		10.1074/jbc.C100025200	http://dx.doi.org/10.1074/jbc.C100025200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278253	hybrid			2022-12-27	WOS:000167980900003
J	Nash, MS; Saunders, R; Young, KW; Challiss, RAJ; Nahorski, SR				Nash, MS; Saunders, R; Young, KW; Challiss, RAJ; Nahorski, SR			Reassessment of the Ca2+ sensing property of a type I metabotropic glutamate receptor by simultaneous measurement of inositol 1,4,5-trisphosphate and Ca2+ in single cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; SH-SY5Y NEUROBLASTOMA-CELLS; CAPACITATIVE CALCIUM-ENTRY; PROTEIN-KINASE-C; EXTRACELLULAR CA2+; EXPRESSION LEVEL; STRUCTURAL BASIS; STORE DEPLETION; PHOSPHOINOSITIDE; ACTIVATION	Transient transfection of Chinese hamster ovary or baby hamster kidney cells expressing the Group I metabotropic glutamate receptor mGlu1 alpha with green fluorescent protein-tagged pleckstrin homology domain of phospholipase C delta1 allows real-time detection of inositol 1,4,5-trisphosphate. Loading with Fura-2 enables simultaneous measurement of intracellular Ca2+ within the same cell. Using this technique we have studied the extracellular calcium sensing property of the mGlu1 alpha receptor. Quisqualate, in extracellular medium containing 1.3 mM Ca2+, increased inositol 1,4,5-trisphosphate in all cells. This followed a typical peak and plateau pattern and was paralleled by concurrent increases in intracellular Ca2+ concentration. Under nominally Ca2+-free conditions similar initial peaks in inositol 1,1,B-trisphosphate and Ca2+ concentration occurred with little change in either agonist potency or efficacy. However, sustained inositol 1,4,5-trisphosphate production was substantially reduced and the plateau in Ca(2+)concentration absent. Depletion of intracellular Ca2+ stores using thapsigarin abolished quisqualate-induced increases in intracellular Ca(2+)and markedly reduced inositol 1,4,5-trisphosphate production. These data suggest that the mGlu1 alpha receptor is not a calcium-sensing receptor because the initial response to agonist is not sensitive to extracellular Ca2+ concentration. However, prolonged activation of phospholipase C requires extracellular Ca2+, while the initial burst of activity is highly dependent on Ca2+ mobilization from intracellular stores.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Nash, MS (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.		Challiss, R.A. John/A-9412-2008	Saunders, Ruth Mary/0000-0001-8893-6687; Challiss, John/0000-0001-5506-2848				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; BATTY IH, 1997, NEUROCHEMISTRY PRACT; Biber K, 1999, J NEUROCHEM, V72, P1671, DOI 10.1046/j.1471-4159.1999.721671.x; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; Hermans E, 1999, BRIT J PHARMACOL, V126, P873, DOI 10.1038/sj.bjp.0702359; Hermans E, 1998, J NEUROCHEM, V70, P1772; Hiltscher R, 1998, NEUROPHARMACOLOGY, V37, P827, DOI 10.1016/S0028-3908(98)00079-3; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kubokawa K, 1996, FEBS LETT, V392, P71, DOI 10.1016/0014-5793(96)00786-7; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Nakahara K, 1997, J NEUROCHEM, V69, P1467; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Prothero LS, 1998, BRIT J PHARMACOL, V125, P1551, DOI 10.1038/sj.bjp.0702203; Putney JW, 1999, BIOESSAYS, V21, P38; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2; WILLARS GB, 1995, MOL PHARMACOL, V47, P509; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Willars GB, 1996, BIOCHEM J, V316, P905, DOI 10.1042/bj3160905; Wise A, 1999, NEUROPHARMACOLOGY, V38, P1647, DOI 10.1016/S0028-3908(99)00119-7; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; Yamaguchi T, 2000, ADV PHARMACOL, V47, P209; Young KW, 1998, CELL CALCIUM, V24, P59, DOI 10.1016/S0143-4160(98)90089-6	38	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19286	19293		10.1074/jbc.M007600200	http://dx.doi.org/10.1074/jbc.M007600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278354	hybrid			2022-12-27	WOS:000169091000087
J	Kao, SC; Jaiswal, RK; Kolch, W; Landreth, GE				Kao, SC; Jaiswal, RK; Kolch, W; Landreth, GE			Identification of the mechanisms regulating the differential activation of the MAPK cascade by epidermal growth factor and nerve growth factor in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR SIGNALING PATHWAYS; INSULIN-RECEPTOR SUBSTRATE-1; CRK PROTEIN BINDS; B-RAF; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; KINASE ACTIVATION; NEURONAL DIFFERENTIATION; ADAPTER PROTEINS; EGF STIMULATION	In PC12 cells, epidermal growth factor (EGF) transiently stimulates the mitogen-activated protein (MAP) kinases, ERK1 and ERK2, and provokes cellular proliferation. In contrast, nerve growth factor (NGF) stimulation leads to the sustained activation of the MAPKs and subsequently to neuronal differentiation. It has been shown that both the magnitude and longevity of MAPK activation governs the nature of the cellular response. The activations of MAPKs are dependent upon two distinct small G-proteins, Has and Rap1, that link the growth factor receptors to the MAPK cascade by activating c-Raf and B-Raf, respectively. We found that Res was transiently stimulated upon both EGF and NGF treatment of PC12 cells. However, EGF transiently activated Rap1, whereas NGF stimulated prolonged Rap1 activation. The activation of the ERKs was due almost exclusively (>90%) to the action of B-Raf, The transient activation of the MAPKs by EGF was a consequence of the formation of a short lived complex assembling on the EGF receptor itself, composed of Crk, C3G, Rap1, and B-Raf, In contrast, NGF stimulation of the cells resulted in the phosphorylation of FRS2. FRS2 scaffolded the assembly of a stable complex of Crk, C3G, Rap1, and B-Raf resulting in the prolonged activation of the MAPKs. Together, these data provide a signaling link between growth factor receptors and MAPK activation and a mechanistic explanation of the differential MAPK kinetics exhibited by these growth factors.	Case Western Reserve Univ, Sch Med, Alzheimer Res Lab, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; NINDS, NIH, Bethesda, MD 20892 USA; Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Case Western Reserve University; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Beatson Institute	Landreth, GE (corresponding author), Case Western Reserve Univ, Sch Med, Alzheimer Res Lab, E504,10900 Euclid Ave, Cleveland, OH 44106 USA.	gel2@po.cwru.edu	Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016; Kao, Shih-chu/0000-0002-6294-5494				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carthew RW, 2000, CURR BIOL, V10, pR532, DOI 10.1016/S0960-9822(00)00587-X; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; Khwaja A, 1996, ONCOGENE, V12, P2491; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lu LG, 2000, EXP CELL RES, V259, P370, DOI 10.1006/excr.2000.4984; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Okada T, 1999, MOL CELL BIOL, V19, P6057; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Torres M, 1996, ONCOGENE, V12, P77; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	62	312	318	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18169	18177		10.1074/jbc.M008870200	http://dx.doi.org/10.1074/jbc.M008870200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278445	hybrid			2022-12-27	WOS:000168866500075
J	Sindic, A; Aleksandrova, A; Fields, AP; Volinia, S; Banfic, H				Sindic, A; Aleksandrova, A; Fields, AP; Volinia, S; Banfic, H			Presence and activation of nuclear phosphoinositide 3-kinase C2 beta during compensatory liver growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; C2 DOMAIN; PHOSPHOLIPASE-C; MU-CALPAIN; TRANSLOCATION; CELLS; DIACYLGLYCEROL; REGENERATION; PLATELETS; CALCIUM	Highly purified liver nuclei incorporated radiolabeled phosphate into phosphatidylinositol 4-phosphate (PtdIns(4)P), PtdIns(4,5)P(2) and PtdIns(3,4,5)P(3). When nuclei were depleted of their membrane, no radiolabeling of PtdIns(3,4,5)P(3) could be detected showing that within the intranuclear region there are no class I phosphoinositide 3-kinases (PI3K)s. In membrane-depleted nuclei harvested 20 h after partial hepatectomy, the incorporation of radiolabel into PtdIns(3)P was observed together with an increase in immunoprecipitable PI3K-C2 beta activity, which is sensitive to wortmannin (10 nM) and shows strong preference for PtdIns over PtdIns(4)P as a substrate. On Western blots PI3K-C2 beta revealed a single immunoreactive band of 180 kDa, whereas 20 h after partial hepatectomy gel shift of 18 kDa was noticed, suggesting that observed activation of enzyme is achieved by proteolysis. When intact membrane-depleted nuclei were subjected to short term (20 min) exposure to mu -calpain, similar gel shift together with an increase in PI3K-C2 beta activity was observed, when compared with the nuclei harvested 20 h after partial hepatectomy, Moreover, the above-mentioned gel shift and increase in PI3K-C2 beta activity could be prevented by the calpain inhibitor calpeptin. The data presented in this report show that, in the membrane-depleted nuclei during the compensatory liver growth, there is an increase in PtdIns(3)P formation as a result of PI3K-C2 beta activation, which may be a calpain-mediated event.	Univ Zagreb, Sch Med, Dept Physiol, Zagreb 10000, Croatia; Univ Zagreb, Sch Med, Croatian Inst Brain Res, Zagreb 10000, Croatia; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Ferrara, Dipartimento Morfol & Embriol, I-44100 Ferrara, Italy	University of Zagreb; University of Zagreb; University of Texas System; University of Texas Medical Branch Galveston; University of Ferrara	Banfic, H (corresponding author), Univ Zagreb, Sveuciliste Zagrebu, Fak Med, Zavod Fiziol, Salata 3,POB 978, Zagreb 10001, Croatia.	hrvoje.banfic@zg.tel.hr	Volinia, Stefano/A-3029-2010; Dugandzic, Aleksandra/AAL-7581-2020; Volinia, Stefano/AAA-9264-2019	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893				Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Bavelloni A, 1999, J CELL SCI, V112, P631; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; CAPITANI S, 1981, PHYSIOL CHEM PHYS M, V13, P153; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Misawa H, 1998, BIOCHEM BIOPH RES CO, V244, P531, DOI 10.1006/bbrc.1998.8294; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; MURRAY NR, 1997, PROTEIN KINASE C, P97; Neri LM, 1997, CELL SIGNAL, V9, P353, DOI 10.1016/S0898-6568(96)00178-7; Neri LM, 1999, BIOCHEM BIOPH RES CO, V259, P314, DOI 10.1006/bbrc.1999.0786; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Prior I A, 1999, Mol Cell Biol Res Commun, V1, P162, DOI 10.1006/mcbr.1999.0126; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vann LR, 1997, BIOCHEM J, V327, P569; VITALE M, 1991, CELL PROLIFERAT, V24, P331, DOI 10.1111/j.1365-2184.1991.tb01161.x; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Yu HY, 1998, EUR J BIOCHEM, V251, P281, DOI 10.1046/j.1432-1327.1998.2510281.x; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	46	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17754	17761		10.1074/jbc.M006533200	http://dx.doi.org/10.1074/jbc.M006533200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278304	hybrid			2022-12-27	WOS:000168866500020
J	Clement, JQ; Maiti, S; Wilkinson, MF				Clement, JQ; Maiti, S; Wilkinson, MF			Localization and stability of introns spliced from the Pem homeobox gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; LATENCY-ASSOCIATED TRANSCRIPTS; POLYMERASE-II; NUCLEOLAR RNAS; BRANCH POINT; IN-VIVO; EXPRESSION; CELLS; DEGRADATION; SEQUENCE	RNA splicing generates two products in equal molar amounts, mature mRNAs and spliced introns, Although the mechanism of RNA splicing and the fate of the spliced mRNA products have been well studied, very little is known about the fate and stability of most spliced introns, Research in this area has been hindered by the widely held view that most vertebrate introns are too unstable to be detectable. Here, we report that we are able to detect all three spliced introns from the coding region of the Pem homeobox gene. By using a tetracycline (tet)-regulated promoter, we found that the half-lives of these Pem introns ranged from 9 to 29 min, comparable with those of short lived mRNAs such as those encoding c-fos and c-myc, The half-lives of the Pem introns correlated with both their length and 5' to 3' orientation in the Pem gene. Subcellular fractionation analysis revealed that spliced Pem introns and pre-mRNA accumulated in the nuclear matrix, high salt-soluble, and DNase-sensitive fractions within the nucleus. Surprisingly, we found that all three of the spiced Pem introns were also in the cytoplasmic: fraction, whereas Pem pre-mRNAs, U6 small nuclear RNA, and a spliced intron from another gene were virtually excluded from this fraction. This indicates either that spliced Pem introns are uniquely exported to the cytoplasm for degradation or they reside in a unique soluble nuclear fraction. Our study has implications for understanding the regulation of RNA metabolism, as the stability of introns and the location of their degradation may dictate the following: (i) the stability of nearby mRNAs that compete with spliced introns for rate-limiting nucleases, (ii) the rate at which free nucleotides are available for further rounds of transcription, and (iii) the rate at which splicing factors are recycled.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA078023] Funding Source: NIH RePORTER; NCI NIH HHS [CA78023] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASH J, 1993, MOL CELL BIOL, V13, P1565, DOI 10.1128/MCB.13.3.1565; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BEREZNEY R, 1995, NUCL MATRIX STRUCTUR; BERMAN SA, 1990, SCIENCE, V247, P212, DOI 10.1126/science.1688472; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Clement JQ, 1999, RNA, V5, P206, DOI 10.1017/S1355838299981190; COLECLOUGH C, 1984, MOL CELL BIOL, V4, P2017, DOI 10.1128/MCB.4.10.2017; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CURTIS PJ, 1977, COLD SPRING HARB SYM, V42, P971; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; FARRELL MJ, 1991, P NATL ACAD SCI USA, V88, P790, DOI 10.1073/pnas.88.3.790; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HARTMUTH K, 1988, MOL CELL BIOL, V8, P2011, DOI 10.1128/MCB.8.5.2011; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KEOHAVONG P, 1986, NUCLEIC ACIDS RES, V14, P5207, DOI 10.1093/nar/14.13.5207; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; KORB M, 1993, NUCLEIC ACIDS RES, V21, P5901, DOI 10.1093/nar/21.25.5901; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lindsey JS, 1996, DEV BIOL, V179, P471, DOI 10.1006/dbio.1996.0276; Lindsey JS, 1996, BIOL REPROD, V55, P975, DOI 10.1095/biolreprod55.5.975; Maiti S, 1996, GENOMICS, V34, P304, DOI 10.1006/geno.1996.0291; Maiti S, 1996, J BIOL CHEM, V271, P17536, DOI 10.1074/jbc.271.29.17536; Matsuura M, 1997, GENE DEV, V11, P2910, DOI 10.1101/gad.11.21.2910; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Nam K, 1997, MOL CELL BIOL, V17, P809, DOI 10.1128/MCB.17.2.809; NAORA H, 1982, P NATL ACAD SCI-BIOL, V79, P6196, DOI 10.1073/pnas.79.20.6196; NICOSIA M, 1994, VIROLOGY, V204, P717, DOI 10.1006/viro.1994.1587; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Pitman JL, 1998, DEV BIOL, V202, P196, DOI 10.1006/dbio.1998.8978; QIAN L, 1992, NUCLEIC ACIDS RES, V20, P5345, DOI 10.1093/nar/20.20.5345; ROGER AJ, 1993, NATURE, V364, P289, DOI 10.1038/364289a0; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Sambrook J., 2002, MOL CLONING LAB MANU; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARP PA, 1987, COLD SPRING HARB SYM, V52, P277, DOI 10.1101/SQB.1987.052.01.033; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Sutton KA, 1998, J ANDROL, V19, P21; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; Wetterberg I, 1996, RNA, V2, P641; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; WILKINSON MF, 2000, PURIFICATION RNA, P69; Wu TT, 1996, J VIROL, V70, P5962, DOI 10.1128/JVI.70.9.5962-5967.1996; Wu TT, 1998, VIROLOGY, V243, P140, DOI 10.1006/viro.1998.9036; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; ZEITLIN S, 1984, CELL, V39, P589, DOI 10.1016/0092-8674(84)90466-5; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	66	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16919	16930		10.1074/jbc.M005104200	http://dx.doi.org/10.1074/jbc.M005104200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278282	hybrid			2022-12-27	WOS:000168730400043
J	Whiteman, P; Smallridge, RS; Knott, V; Cordle, JJ; Downing, AK; Handford, PA				Whiteman, P; Smallridge, RS; Knott, V; Cordle, JJ; Downing, AK; Handford, PA			A G1127S change in calcium-binding epidermal growth factor-like domain 13 of human fibrillin-1 causes short range conformational effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; MARFAN-SYNDROME; FACTOR-IX; POINT MUTATIONS; HEMOPHILIA-B; DATABASE; GENE; EDITION; SPECTROSCOPY; DEFICIENCY	Human fibrillin-1, an extracellular matrix glycoprotein, has a modular organization that includes 43 calcium-binding epidermal growth factor-like (cbEGF) domains arranged as multiple tandem repeats. A missense mutation that changes a highly conserved glycine to serine (G1127S) has been identified in cbEGF13, which results in a variant of Marfan syndrome, a connective tissue disease. Previous experiments on isolated cbEGF13 and a cbEGF13-14 pair indicated that the G1127S mutation caused defective folding of cbEGF13 but not cbEGF14, We have used limited proteolysis methods and two-dimensional NMR spectroscopy to identify the structural consequences of this mutation in a covalently linked cbEGF12-13 pair and a cbEGF12-14 triple domain construct. Protease digestion studies of the cbEGF12-13 G1127S mutant pair indicated that both cbEGF12 and 13 retained similar calcium binding properties and thus tertiary structure to the normal domain pair, because all identified cleavage sites showed calcium-dependent protection from proteolysis. However, small changes in the conformation of cbEGF13 G1127S, revealed by the presence of a new protease-sensitive site and comparative two-dimensional NOESY data, suggested that the fold of the mutant domain was not identical to the wild-type, but was native-like. Additional cleavage sites identified in cbEGF12-14 G1127S indicated further subtle changes within the mutant domain but not the flanking domains, We have concluded the following in this study. (i) Covalent linkage of cbEGF12 preserves the native-like fold of cbEGF13 G1127S and (ii) conformational effects introduced by G1127S are localized to cbEGF13, This study demonstrates that missense mutations in fibrillin-1 cbEGF domains can cause short range structural effects in addition to long range effects previously observed with a E1073K mutation in cbEGF12.	Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Div Struct Biol, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Handford, PA (corresponding author), Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, S Parks Rd, Oxford OX1 3QU, England.							CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Collod-Beroud G, 1998, NUCLEIC ACIDS RES, V26, P229, DOI 10.1093/nar/26.1.229; DENTON PH, 1988, BLOOD, V72, P1407; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Park ES, 1998, AM J MED GENET, V78, P350, DOI 10.1002/(SICI)1096-8628(19980724)78:4<350::AID-AJMG9>3.3.CO;2-#; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; REITSMA PH, 1995, THROMB HAEMOSTASIS, V73, P876; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sasaki T, 1996, EUR J BIOCHEM, V240, P427, DOI 10.1111/j.1432-1033.1996.0427h.x; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Varret M, 1998, NUCLEIC ACIDS RES, V26, P248, DOI 10.1093/nar/26.1.248; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Whiteman P, 1998, PROTEIN ENG, V11, P957, DOI 10.1093/protein/11.11.957; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807	30	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17156	17162		10.1074/jbc.M006547200	http://dx.doi.org/10.1074/jbc.M006547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278305	hybrid			2022-12-27	WOS:000168730400075
J	Akama, TO; Nakayama, J; Nishida, K; Hiraoka, N; Suzuki, M; McAuliffe, J; Hindsgaul, O; Fukuda, M; Fukuda, MN				Akama, TO; Nakayama, J; Nishida, K; Hiraoka, N; Suzuki, M; McAuliffe, J; Hindsgaul, O; Fukuda, M; Fukuda, MN			Human corneal GlcNAc 6-O-sulfotransferase and mouse intestinal GlcNAc 6-O-sulfotransferase both produce keratan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHONDROITIN 6-SULFOTRANSFERASE; DYSTROPHY TYPE-I; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; N-ACETYLLACTOSAMINE; L-SELECTIN; EXPRESSION; SULFOTRANSFERASE; PROTEOGLYCAN; GENE	Human corneal N-acetylglucosamine 6-O-sulfotransferase (hCGn6ST) has been identified by the positional candidate approach as the gene responsible for macular corneal dystrophy (MCD). Because of its high homology to carbohydrate sulfotransferases and the presence of mutations of this gene in MCD patients who lack sulfated keratan sulfate in the cornea and serum, hCGn6ST protein is thought to be a sulfotransferase that catalyzes sulfation of GlcNAc in keratan sulfate. In this report, we analyzed the enzymatic activity of hCGn6ST by expressing it in cultured cells. A lysate prepared from HeLa cells transfected with an intact form of hCGn6ST cDNA or culture medium from cells transfected with a secreted form of hCGn6ST cDNA showed an activity of transferring sulfate to C-6 of GlcNAc of synthetic oligosaccharide substrates in vitro. When hCGn6ST was expressed together with human keratan sulfate Gal-6-sulfotransferase (hKSG6ST), HeLa cells produced highly sulfated carbohydrate detected by an anti-keratan sulfate antibody 5D4. These results indicate that hCGn6ST transfers sulfate to C-6 of GlcNAc in keratan sulfate. Amino acid substitutions in hCGn6ST identical to changes resulting from missense mutations found in MCD patients abolished enzymatic activity. Moreover, mouse intestinal GlcNAc 6-O-sulfotransferase had the same activity as hCGn6ST. This observation suggests that mouse intestinal GlcNAc 6-O-sulfotransferase is the orthologue of hCGn6ST and functions as a sulfotransferase to produce keratan sulfate in the cornea.	Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Matsumoto, Nagano 3908621, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan	Sanford Burnham Prebys Medical Discovery Institute; Shinshu University; Osaka University	Fukuda, MN (corresponding author), Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA.			Nishida, Kohji/0000-0001-9069-3610	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Degroote S, 1997, J BIOL CHEM, V272, P29493, DOI 10.1074/jbc.272.47.29493; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Hasegawa N, 2000, INVEST OPHTH VIS SCI, V41, P3670; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; HUCKERBY TN, 1995, BBA-GEN SUBJECTS, V1244, P17, DOI 10.1016/0304-4165(94)00180-6; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kawakami M, 1997, CANCER RES, V57, P2321; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P239, DOI 10.1515/bchm2.1983.364.1.239; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P253; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; KLINTWORTH GK, 1986, OPHTHALMIC PAED GEN, V7, P139, DOI 10.3109/13816818609004130; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Liu NP, 1998, AM J HUM GENET, V63, P912, DOI 10.1086/302001; Liu NP, 2000, MOL VIS, V6, P95; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Nakazawa K, 1998, ARCH BIOCHEM BIOPHYS, V359, P269, DOI 10.1006/abbi.1998.0897; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; SHIOZAWA T, 1991, GYNECOL OBSTET INVES, V32, P239, DOI 10.1159/000293040; THONAR EJM, 1986, AM J OPHTHALMOL, V102, P561, DOI 10.1016/0002-9394(86)90525-8; THONAR EJMA, 1985, ARTHRITIS RHEUM, V28, P1367, DOI 10.1002/art.1780281209; Tsutsumi K, 1998, FEBS LETT, V441, P235, DOI 10.1016/S0014-5793(98)01532-4; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Vance JM, 1996, AM J HUM GENET, V58, P757; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	45	72	75	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16271	16278		10.1074/jbc.M009995200	http://dx.doi.org/10.1074/jbc.M009995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278593	hybrid			2022-12-27	WOS:000168623100094
J	Chen, CM; Wang, CT; Ho, CH				Chen, CM; Wang, CT; Ho, CH			A plant gene encoding a Myb-like protein that binds telomeric GGTTTAG repeats in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; FISSION YEAST; DNA; DOMAIN; LENGTH; LOCALIZATION; EXPRESSION; TRF1; TELOBOX	A gene (AtTRP1) encoding a telomeric repeat-binding protein has been isolated from Arabidopsis thaliana. AtTRP1 is a single copy gene located on chromosome 5 of A. thaliana. The protein AtTRP1 encoded by this gene is not only homologous to the Myb DNA-binding motifs of other telomere-binding proteins but also is similar to several initiator-binding proteins in plants. Gel retardation assay revealed that the 115 residues on the C terminus of this protein, including the Myb motif, are sufficient for binding to the double-stranded plant telomeric sequence. The isolated DNA-binding domain of AtTRP1 recognizes each telomeric repeat centered on the sequence GGTTTAG, The almost full-length protein of AtTRP1 does not form any complex at all with the DNA fragments carrying four or fewer GGTTTAG repeats. However, it forms a complex with the sequence (GGTTTAG)(3) more efficiently than with the sequence (GGTTTAG)(5). These data suggest that the minimum length of a telomeric DNA for AtTRP1 binding consists of five GGTTTAG repeats and that the optimal AtTRP1 binding may require eight or more GGTTTAG repeats. it also implies that this protein AtTRP1 may bind in vivo primarily to the ends of plant chromosomes, which consist of long stretches of telomeric repeats.	Acad Sinica, Inst Bot, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biomed Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, CM (corresponding author), Acad Sinica, Inst Bot, Taipei 115, Taiwan.	bocmchen@ccvax.sinica.edu.tw						Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; BURR B, 1992, PLANT CELL, V4, P953, DOI 10.1105/tpc.4.8.953; Chen CM, 1997, CHROMOSOME RES, V5, P561, DOI 10.1023/A:1018449920968; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FAJKUS J, 1995, MOL GEN GENET, V247, P633, DOI 10.1007/BF00290355; FANG G, 1995, TELOMERES, P69; Fitzgerald MS, 1996, P NATL ACAD SCI USA, V93, P14422, DOI 10.1073/pnas.93.25.14422; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; FUCHS J, 1995, PLANT SYST EVOL, V196, P227, DOI 10.1007/BF00982962; GANAL MW, 1991, PLANT CELL, V3, P87, DOI 10.1105/tpc.3.1.87; GREIDER CW, 1995, TELOMERES, P35; HARLEY CB, 1995, TELOMERES, P247; Heller K, 1996, MOL GEN GENET, V252, P342, DOI 10.1007/BF02173780; HENDERSON E, 1995, TELOMERES, P11; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KILIAN A, 1995, P NATL ACAD SCI USA, V92, P9555, DOI 10.1073/pnas.92.21.9555; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; Kim JH, 1998, PLANT MOL BIOL, V36, P661, DOI 10.1023/A:1005994719175; Lee JH, 2000, PLANT MOL BIOL, V42, P547, DOI 10.1023/A:1006373917321; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUGERT T, 1994, PLANT MOL BIOL, V25, P493, DOI 10.1007/BF00043877; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; OSBORNE MA, 1993, ANNU REV BIOCHEM, V62, P219; REGAD F, 1994, J MOL BIOL, V239, P163, DOI 10.1006/jmbi.1994.1360; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Riha K, 1998, PLANT CELL, V10, P1691, DOI 10.1105/tpc.10.10.1691; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SILVA ODE, 1993, PLANT J, V4, P125, DOI 10.1046/j.1365-313X.1993.04010125.x; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VANDERKROL AR, 1991, PLANT CELL, V3, P667, DOI 10.1105/tpc.3.7.667; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	57	53	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16511	16519		10.1074/jbc.M009659200	http://dx.doi.org/10.1074/jbc.M009659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278537	hybrid			2022-12-27	WOS:000168623100125
J	Gangloff, M; Ruff, M; Eiler, S; Duclaud, S; Wurtz, JM; Moras, D				Gangloff, M; Ruff, M; Eiler, S; Duclaud, S; Wurtz, JM; Moras, D			Crystal structure of a mutant hER alpha ligand-binding domain reveals key structural features for the mechanism of partial agonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR BETA; MOLECULAR-BASIS; NUCLEAR; TRANSCRIPTION; ANTAGONISM; MODULATION; RAR	The crystal structure of a triple cysteine to serine mutant ER alpha ligand-binding domain (LBD), complexed with estradiol, shows that despite the presence of a tightly bound agonist ligand, the protein exhibits an antagonist-like conformation, similar to that observed in raloxifen and 4-hydroxytamoxifen-bound structures. This mutated receptor binds estradiol with wild type affinity and displays transcriptional activity upon estradiol stimulation, but with limited potency (about 50%). This partial activity is efficiently repressed in antagonist competition assays. The comparison with available LED structures reveals key features governing the positioning of helix H12 and highlights the importance of cysteine residues in promoting an active conformation. Furthermore the present study reveals a hydrogen bond network connecting ligand binding to protein trans conformation. These observations support a dynamic view of H12 positioning, where the control of the equilibrium between two stable locations determines the partial agonist character of a given ligand.	Inst Genet & Biol Mol & Cellulaire, Lab Biol & Genom Struct, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Inst Genet & Biol Mol & Cellulaire, Lab Biol & Genom Struct, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Wurtz, Jean-Marie/P-4652-2016; ruff, marc/J-3011-2013	Wurtz, Jean-Marie/0000-0003-2963-8617; ruff, marc/0000-0001-5451-6377; Gangloff, Monique/0000-0001-6131-0115				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Bruger AT, 1998, ACTA CRYSTALLOGR D, V54, P905; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CLAIRE M, 1978, FEBS LETT, V88, P295, DOI 10.1016/0014-5793(78)80197-5; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DAUVOIS S, 1993, J CELL SCI, V106, P1377; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; EILER S, 2001, IN PRESS PROTEIN EXP; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; KATZENELLENBOGE.JA, 1998, CHEM BIOL, V3, P529; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Makino Y, 1996, MOL PHARMACOL, V49, P612; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Morel Y, 2000, BIOCHEM J, V348, P235, DOI 10.1042/0264-6021:3480235; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; RAFESTINOBLIN ME, 1989, J BIOL CHEM, V264, P9304; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ruff M, 2000, BREAST CANCER RES, V2, P353, DOI 10.1186/bcr80; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x	39	125	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15059	15065		10.1074/jbc.M009870200	http://dx.doi.org/10.1074/jbc.M009870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278577	hybrid			2022-12-27	WOS:000168528800072
J	Bibbb, JA; Nishi, A; O'Callaghan, JP; Ule, J; Lan, M; Snyder, GL; Horiuchi, A; Saito, T; Hisanaga, S; Czernik, AJ; Nairn, AC; Greengard, P				Bibbb, JA; Nishi, A; O'Callaghan, JP; Ule, J; Lan, M; Snyder, GL; Horiuchi, A; Saito, T; Hisanaga, S; Czernik, AJ; Nairn, AC; Greengard, P			Phosphorylation of protein phosphatase inhibitor-1 by Cdk5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; RABBIT SKELETAL-MUSCLE; REGULATED NEURONAL PHOSPHOPROTEIN; GLYCOGEN-METABOLISM; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; SYNAPSIN-I; DARPP-32; DOPAMINE; PURIFICATION	Protein phosphatase inhibitor-1 is a prototypical mediator of cross-talk between protein kinases and protein phosphatases. Activation of cAMP-dependent protein kinase results in phosphorylation of inhibitor-1 at Thr-35, converting it into a potent inhibitor of protein phosphatase-1. Here we report that inhibitor-1 is phosphorylated in vitro at Ser-67 by the proline-directed kinases, Cdk1, Cdk5, and mitogen-activated protein kinase, By using phosphorylation state-specific antibodies and selective protein kinase inhibitors, Cdk5 was found to be the only kinase that phosphorylates inhibitor-1 at Ser-67 in intact striatal brain tissue. In vitro and in vivo studies indicated that phospho-Ser-67 inhibitor-1 was dephosphorylated by protein phosphatases-2A and -2B, The state of phosphorylation of inhibitor-1 at Ser-67 was dynamically regulated in striatal tissue by glutamate- dependent regulation of N-methyl-D-aspartic acid-type channels. Phosphorylation of Ser-67 did not convert inhibitor-1 into an inhibitor of protein phosphatase-1. However, inhibitor-1 phosphorylated at Ser-67 was a less efficient substrate for cAMP-dependent protein kinase, These results demonstrate regulation of a Cdk5-dependent phosphorylation site in inhibitor-1 and suggest a role for this site in modulating the amplitude of signal transduction events that involve cAMP-dependent protein kinase activation.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Kurume Univ, Sch Med, Dept Physiol, Fukuoka 8300011, Japan; Ctr Dis Control & Prevent, NIOSH, Morgantown, WV 26505 USA; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Tokyo 1920397, Japan	Rockefeller University; Kurume University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Tokyo Metropolitan University	Bibbb, JA (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	bibbj@rockva.x.rockefeller.edu	O'Callaghan, James/O-2958-2013; Ule, Jernej/C-6315-2013	Ule, Jernej/0000-0002-2452-4277; Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Alder R, 1995, NEUROREPORT, V6, P2368, DOI 10.1097/00001756-199511270-00022; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BARBAS H, 1993, J COMP NEUROL, V334, P1, DOI 10.1002/cne.903340102; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1977, FEBS LETT, V76, P182, DOI 10.1016/0014-5793(77)80147-6; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 1998, METH MOL B, V93, P41; Czernik A. J., 1997, REGULATORY PROTEIN M, V30, P219; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; FERNANDEZ J, 1999, J BIOMOL TECH, V10, P120; FOULKES JG, 1979, EUR J BIOCHEM, V97, P251, DOI 10.1111/j.1432-1033.1979.tb13109.x; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HEMMINGS HC, 1984, J NEUROSCI, V4, P99; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KING MM, 1984, J BIOL CHEM, V259, P8080; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Lazaro JB, 1997, J CELL SCI, V110, P1251; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LOWENSTEIN PR, 1995, BRAIN RES, V676, P80, DOI 10.1016/0006-8993(95)00091-4; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; MIKKELSEN JD, 1993, BRAIN RES, V623, P147, DOI 10.1016/0006-8993(93)90022-F; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1988, J NEUROCHEM, V50, P257, DOI 10.1111/j.1471-4159.1988.tb13258.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; NIMMO GA, 1978, EUR J BIOCHEM, V87, P353, DOI 10.1111/j.1432-1033.1978.tb12384.x; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Nishi A, 2000, P NATL ACAD SCI USA, V97, P12840, DOI 10.1073/pnas.220410397; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; Nishi A, 1997, J NEUROSCI, V17, P8147; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Oliver Carey J., 1998, Frontiers in Bioscience, V3, pD961; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413; ZHANG WZ, 1994, PROTEIN SCI, V3, P677	71	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14490	14497		10.1074/jbc.M007197200	http://dx.doi.org/10.1074/jbc.M007197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278334	hybrid			2022-12-27	WOS:000168356600129
J	Gamero, AM; Larner, AC				Gamero, AM; Larner, AC			Vanadate facilitates interferon alpha-mediated apoptosis that is dependent on the Jak/Stat pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL LINES; PROTEIN-TYROSINE KINASE; C-MYC EXPRESSION; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; INDEPENDENT RESPONSES; HYDROGEN-PEROXIDE; PHORBOL ESTERS; MAP KINASE	Type I interferon (IFN) dependent inhibition of cell growth can occur either in the absence or presence of apoptosis. The mechanisms that determine whether or not cells undergo apoptosis after exposure to IFN-alpha are not clear. This study shows that a variety of cell lines that display growth inhibition but not apoptosis in response to IFN-alpha will undergo programmed cell death when low concentrations of the protein-tyrosine phosphatase inhibitor vanadate are added with IFN-alpha. In contrast, the combination of tumor necrosis factor-alpha with vanadate did not trigger apoptosis in these cells. Caspase-3 activity was detected only in cells exposed to IFN-alpha and vanadate but not to IFN-alpha or vanadate alone. The ability of IFN-alpha and vanadate to induce apoptosis did not require expression of p53 and was blocked by N-acetyl-L-cysteine. Activation of the Jak/Stat pathway and expression of IFN-inducible genes was not altered by incubation of cells with IFN-alpha and vanadate compared with IFN-alpha alone. However, mutant cells lacking Stat1, Stat2, Jak1, or Tyk2, or cells expressing kinase inactive Jak1 or Tyk2 did not undergo apoptosis in the presence of IFN-alpha and vanadate, These results suggest that IFN-alpha stimulation of Stat dependent genes is necessary, but not sufficient, for this cytokine to induce apoptosis. Another signaling cascade that involves the activity of a protein-tyrosine phosphatase and/or the generation of reactive oxygen species may play an important role in promoting IFN-alpha -induced apoptosis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Larner, AC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,NB-30, Cleveland, OH 44195 USA.				NCI NIH HHS [CA77741, CA77736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077741, R01CA077736] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; JEWELL AP, 1994, BRIT J HAEMATOL, V88, P268, DOI 10.1111/j.1365-2141.1994.tb05017.x; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lajarin F, 1999, FREE RADICAL BIO MED, V27, P1008, DOI 10.1016/S0891-5849(99)00148-3; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MILNER AE, 1995, INT J CANCER, V61, P348, DOI 10.1002/ijc.2910610313; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Petricoin E, 1996, MOL CELL BIOL, V16, P1419; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; Platanias LC, 1998, J BIOL CHEM, V273, P5577, DOI 10.1074/jbc.273.10.5577; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Rimbach Gerald, 2000, Molecular Cell Biology Research Communications, V3, P238, DOI 10.1006/mcbr.2000.0219; RODRIGUEZVILLANUEVA J, 1995, INT J CANCER, V61, P110, DOI 10.1002/ijc.2910610119; ROOS G, 1984, CANCER RES, V44, P2358; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	46	43	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13547	13553		10.1074/jbc.M007948200	http://dx.doi.org/10.1074/jbc.M007948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278370	hybrid			2022-12-27	WOS:000168356600008
J	Strauss, E; Kinsland, C; Ge, Y; McLafferty, FW; Begley, TP				Strauss, E; Kinsland, C; Ge, Y; McLafferty, FW; Begley, TP			Phosphopantothenoylcysteine synthetase from Escherichia coli - Identification and characterization of the last unidentified coenzyme A biosynthetic enzyme in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND PYRUVATE; DECARBOXYLASE; PURIFICATION	Phosphopantothenoylcysteine synthase catalyzes the formation of (R) 4'-phospho-N-pantothenoylcysteine from 4'-phosphopantothenate and L-cysteine: this enzyme, involved in the biosynthesis of coenzyme A (CoA), has not previously been identified. Recently it was shown that the NH2-terminal domain of the Dfp protein from bacteria catalyzes the next step in CoA biosynthesis, the decarboxylation of (R) 4'-phospho-N-pantothenoylcysteine to form 4'-phosphopantetheine (Kupke, T., Uebele, M,, Schmid, D., Jung, G,, Blaesse, M., and Steinbacher, S. (2000) J. Biol. Chem. 275, 31838-31846), We have partially purified phosphopantothenoylcysteine decarboxylase from Escherichia coli and demonstrated that the protein encoded by the dfp gene, here renamed coaBC, also has phosphopantothenoylcysteine synthetase activity, using CTP rather than ATP as the activating nucleoside 5'-triphosphate, This discovery completes the identification of all the enzymes involved in the biosynthesis of coenzyme A in bacteria.	Cornell Univ, Baker Lab 120, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Begley, TP (corresponding author), Cornell Univ, Baker Lab 120, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.		Strauss, Erick/G-1783-2010; Zhang, Ning/F-1387-2014; Begley, Tadhg/B-5801-2015	Strauss, Erick/0000-0002-9898-8226; 				ABIKO Y, 1970, METHODS ENZYMOL A, V18, P354; Abiko Y., 1970, METHODS ENZYMOLOGY A, V18, P350; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Begley TP, 2001, VITAM HORM, V61, P157; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BROWN GM, 1959, J BIOL CHEM, V234, P370; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Lee C. H., 1982, PYRIDINE NUCLEOTIDE, P189; LITTLE DP, 1994, ANAL CHEM, V66, P2809, DOI 10.1021/ac00090a004; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; MARTIN DP, 1994, J AM CHEM SOC, V116, P4660, DOI 10.1021/ja00090a014; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCANDURRA R, 1974, EUR J BIOCHEM, V49, P1, DOI 10.1111/j.1432-1033.1974.tb03805.x; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YANG HC, 1987, BIOCHEMISTRY-US, V26, P4076, DOI 10.1021/bi00387a050	19	83	84	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13513	13516		10.1074/jbc.C100033200	http://dx.doi.org/10.1074/jbc.C100033200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278255	hybrid			2022-12-27	WOS:000168356600003
J	Vivo, M; Calogero, RA; Sansone, F; Calabro, V; Parisi, T; Borrelli, L; Saviozzi, S; La Mantia, G				Vivo, M; Calogero, RA; Sansone, F; Calabro, V; Parisi, T; Borrelli, L; Saviozzi, S; La Mantia, G			The human tumor suppressor ARF interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; NEURABIN-II/SPINOPHILIN; P53-DEPENDENT APOPTOSIS; NUCLEOLAR LOCALIZATION; CATALYTIC SUBUNIT; ONCOPROTEIN MDM2; STABILIZES P53; OKADAIC ACID; P19(ARF); GENE	The INK4a gene, one of the most often disrupted loci in human cancer, encodes two unrelated proteins, p16(INK4a) and p14(ARF) (ARF) both capable of inducing cell cycle arrest. Although it has been clearly demonstrated that ARF inhibits cell cycle via p53 stabilization, very little is known about the involvement of ARF in other cell cycle regulatory pathways, as well as on the mechanisms responsible for activating ARF following onco-proliferative stimuli. In search of factors that might associate with ARF to control its activity or its specificity, we performed a yeast two-hybrid screen. We report here that the human homologue of spinophilin/neurabin II, a regulatory subunit of protein phosphatase 1 catalytic subunit specifically interacts with ARF, both in yeast and in mammalian cells. We also show that ectopic expression of spinophilin/neurabin II inhibits the formation of G418-resistant colonies when transfected into human and mouse cell lines, regardless of p53 and ARF status. Moreover, spinophilin/ARF coexpression in Saos-2 cells, where ARF ectopic expression is ineffective, somehow results in a synergic effect. These data demonstrate a role for spinophilin in cell growth and suggest that ARF and spinophilin could act in partially overlapping pathways.	Univ Naples Federico II, Dept Genet Gen & Mol Biol, I-80134 Naples, Italy; S Luigi Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet Gen & Mol Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lamantia@unina.it	Calabro, Viola/H-6156-2013; Saviozzi, Silvia/M-4282-2015; Calogero, Raffaele/K-9428-2019; Vivo, Maria/S-3390-2017	Saviozzi, Silvia/0000-0003-3278-9061; Calogero, Raffaele/0000-0002-2848-628X; Vivo, Maria/0000-0003-2458-4226; Calabro, Viola/0000-0002-6508-8889				Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Calabro V, 1999, ONCOGENE, V18, P2157, DOI 10.1038/sj.onc.1202532; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GAVIN AC, 1991, EXP CELL RES, V192, P75, DOI 10.1016/0014-4827(91)90159-R; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ide N, 1998, BIOCHEM BIOPH RES CO, V244, P258, DOI 10.1006/bbrc.1998.8243; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Okamoto A, 1996, Nihon Rinsho, V54, P1037; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Stephens DJ, 1999, J BIOL CHEM, V274, P30080, DOI 10.1074/jbc.274.42.30080; Stephens DJ, 2000, BIOCHEM J, V345, P185, DOI 10.1042/0264-6021:3450185; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14161	14169		10.1074/jbc.M006845200	http://dx.doi.org/10.1074/jbc.M006845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278317	hybrid			2022-12-27	WOS:000168356600088
J	De Petrocellis, L; Bisogno, T; Maccarrone, M; Davis, JB; Finazzi-Agro, A; Di Marzo, V				De Petrocellis, L; Bisogno, T; Maccarrone, M; Davis, JB; Finazzi-Agro, A; Di Marzo, V			The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTORS; CAPSAICIN RECEPTORS; FUNCTIONAL-ROLE; CB1; ANTAGONIST; EXPRESSION; INHIBITORS; LIGANDS; BRAIN; RAT	The endogenous ligand of CB1 cannabinoid receptors, anandamide, is also a full agonist at vanilloid VR1 receptors for capsaicin and resiniferatoxin, thereby causing an increase in cytosolic Ca2+ concentration in human VR1-overexpressing (hVR1-HEK) cells. Two selective inhibitors of anandamide facilitated transport into cells, VDM11 and VDM13, and two inhibitors of anandamide enzymatic hydrolysis, phenylmethylsulfonyl fluoride and methylarachidonoyl fluorophosphonate, inhibited and enhanced, respectively, the VR1-mediated effect of anandamide, but not of resiniferatoxin or capsaicin, The nitric oxide donor, sodium nitroprusside, known to stimulate anandamide transport, enhanced anandamide effect on the cytosolic Ca2+ concentration. Accordingly, hVR1-HEK cells contain an anandamide membrane transporter inhibited by VDM11 and VDM13 and activated by sodium nitroprusside, and an anandamide hydrolase activity sensitive to phenylmethylsulfonyl fluoride and methylarachidonoyl fluorophosphonate, and a fatty acid amide hydrolase transcript. These findings suggest the following. (i) Anandamide activates VR1 receptors by acting at an intracellular site. (ii) Degradation by fatty acid amide hydrolase limits anandamide activity on VR1; and (iii) the anandamide membrane transporter inhibitors can be used to distinguish between CB1 or VR1 receptor-mediated actions of anandamide. By contrast, the CB, receptor antagonist SR141716A inhibited also the VR1-mediated effect of anandamide and capsaicin on cytosolic Ca2+ concentration, although at concentrations higher than those required for CB1 antagonism.	CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Grp, I-80072 Arco Felice Napoli, Italy; CNR, Ist Cibernet, I-80072 Arco Felice Napoli, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; GlaxoSmithKline, Neurol, Harlow CM19 5AW, Essex, England	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); University of Rome Tor Vergata; GlaxoSmithKline	Di Marzo, V (corresponding author), CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Grp, Via Toiano 6, I-80072 Arco Felice Napoli, Italy.	vdimarzo@icmib.na.cnr.it	Di Marzo, Vincenzo/AAD-7742-2019; Bisogno, Tiziana/B-7891-2015	Di Marzo, Vincenzo/0000-0002-1490-3070; 				Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; Breivogel CS, 1998, J BIOL CHEM, V273, P16865, DOI 10.1074/jbc.273.27.16865; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chaytor AT, 1999, J PHYSIOL-LONDON, V520, P539, DOI 10.1111/j.1469-7793.1999.00539.x; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DePetrocellis L, 1997, BIOCHEM BIOPH RES CO, V231, P82, DOI 10.1006/bbrc.1997.6000; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2000, J NEUROCHEM, V75, P2434, DOI 10.1046/j.1471-4159.2000.0752434.x; Di Marzo V, 2000, EUR J PHARMACOL, V406, P363, DOI 10.1016/S0014-2999(00)00687-7; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; Di Marzo V, 1999, CURR MED CHEM, V6, P721; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DIMARZO V, UNPUB; Edgemond WS, 1998, MOL PHARMACOL, V54, P180, DOI 10.1124/mol.54.1.180; FINAZZIAGRO A, 1973, BIOCHIM BIOPHYS ACTA, V326, P462, DOI 10.1016/0005-2760(73)90146-X; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hayes P, 2000, PAIN, V88, P205, DOI 10.1016/S0304-3959(00)00353-5; Hillard CJ, 1997, J LIPID RES, V38, P2383; Hillard CJ, 2000, CHEM PHYS LIPIDS, V108, P123, DOI 10.1016/S0009-3084(00)00191-2; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; JERMAN JC, 1999, BR J PHARM S, V129, P73; Jung J, 1999, J NEUROSCI, V19, P529; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; Maccarrone M, 1998, J BIOL CHEM, V273, P32332, DOI 10.1074/jbc.273.48.32332; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROSS RA, 2000, BRIT J PHARMACOL, V132, P631; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 1999, PHARMACOL REV, V51, P159; Szolcsanyi J, 2000, TRENDS PHARMACOL SCI, V21, P203, DOI 10.1016/S0165-6147(00)01484-X; Tao Q, 1998, J PHARMACOL EXP THER, V285, P651; Tognetto M, 2001, J NEUROSCI, V21, P1104; Ueda N, 2000, CHEM PHYS LIPIDS, V108, P107, DOI 10.1016/S0009-3084(00)00190-0; van Zadelhoff G, 1998, BIOCHEM BIOPH RES CO, V248, P33, DOI 10.1006/bbrc.1998.8910; VANAARLE PGM, 1991, FEBS LETT, V280, P159, DOI 10.1016/0014-5793(91)80227-T; White R, 1998, BRIT J PHARMACOL, V125, P689, DOI 10.1038/sj.bjp.0702127; Zygmunt PM, 2000, EUR J PHARMACOL, V396, P39, DOI 10.1016/S0014-2999(00)00207-7; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; Zygmunt PM, 2000, TRENDS PHARMACOL SCI, V21, P43, DOI 10.1016/S0165-6147(99)01430-3	54	294	299	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12856	12863		10.1074/jbc.M008555200	http://dx.doi.org/10.1074/jbc.M008555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278420	hybrid			2022-12-27	WOS:000168198600056
J	Gilchrist, CA; Holm, CF; Hughes, MA; Schaenman, JM; Mann, BJ; Petri, WA				Gilchrist, CA; Holm, CF; Hughes, MA; Schaenman, JM; Mann, BJ; Petri, WA			Identification and characterization of an Entamoeba histolytica upstream regulatory element 3 sequence-specific DNA-binding protein containing EF-hand motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; HGL5 GENE; KINASE-C; PHOSPHORYLATION; LECTIN; DOMAIN; SITES; PURIFICATION; ADHESION	The hgl5 gene of Entamoeba histolytica is negatively regulated through the upstream regulatory element 3 (URE3) DNA motif TATTCTATT, This motif is also present and significant in the function of the E, histolytica fdx gene promoter. A yeast one-hybrid screen was used to identify an E. hisdolytica cDNA encoding a protein (URE3-BP) that recognized this DNA motif, Analysis of the predicted amino acid sequence demonstrated the presence of two EF-hand motifs but identified no canonical DNA binding motifs, URE3-BP, expressed in bacteria, demonstrated Ca2+-dependent and sequence-specific recognition of the URE3 DNA sequence as assessed by electrophoretic mobility shift assays. Antibodies raised against URE3-BP blacked the formation of the URE3 DNA-protein complex by native nuclear extracts. The URE3-BP protein was present in the E. histolytica nucleus and cytoplasm with an apparent molecular mass of 22.6 kDa. Our results represent the first use of a yeast genetic screen to identify, on the basis of function, a DNA-binding protein of an early branching eukaryote, Since the URE3 DNA can modulate gene expression in both a positive and negative manner, this protein may have more than one mechanism of interaction with transcriptional machinery. Characterization of URE3-BP should provide insight into transcription regulation and virulence control in this parasite.	Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Petri, WA (corresponding author), Univ Virginia, Dept Internal Med, MR4 Bldg,Rm 2115,POB 801340, Charlottesville, VA 22908 USA.		Petri, William/AAL-3642-2020; Petri, William A./D-3639-2019	Petri, William/0000-0002-7268-1218; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046, R01AI037941] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37941, T32 AI007046] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Bakalkin G, 1997, BIOCHEM BIOPH RES CO, V231, P135, DOI 10.1006/bbrc.1997.6062; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown T., 1997, CURRENT PROTOCOLS MO; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; Carbajal ME, 1996, EXP PARASITOL, V82, P11, DOI 10.1006/expr.1996.0002; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Cowley DO, 2000, GENE DEV, V14, P366; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Gilchrist CA, 1998, INFECT IMMUN, V66, P2383, DOI 10.1128/IAI.66.5.2383-2386.1998; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P297; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; Li XR, 1999, J BIOL CHEM, V274, P35203, DOI 10.1074/jbc.274.49.35203; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; MASON GGF, 1994, J BIOL CHEM, V269, P4438; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Petri WA, 2000, PARASITOL TODAY, V16, P320, DOI 10.1016/S0169-4758(00)01730-0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; Seidman CE, 1997, CURRENT PROTOCOLS MO; Sheffield PJ, 1999, ACTA CRYSTALLOGR D, V55, P356, DOI 10.1107/S0907444998009032; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; Singh U, 1998, J BIOL CHEM, V273, P21663, DOI 10.1074/jbc.273.34.21663; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V236, P611, DOI 10.1006/bbrc.1997.7019; Vines RR, 1998, MOL BIOL CELL, V9, P2069, DOI 10.1091/mbc.9.8.2069; Voigt H, 1999, J CELL SCI, V112, P1191; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; [No title captured]	35	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11838	11843		10.1074/jbc.M007375200	http://dx.doi.org/10.1074/jbc.M007375200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278344	hybrid			2022-12-27	WOS:000168081800056
J	Phelan, DR; Price, G; Liu, YF; Dorow, DS				Phelan, DR; Price, G; Liu, YF; Dorow, DS			Activated JNK phosphorylates the C-terminal domain of MLK2 that is required for MLK2-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE-2; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DIFFERENTIAL ACTIVATION; JUN; CASCADE; MEK; SPECIFICITY; BINDING; PATHWAY	MAP kinase signaling pathways are important mediators of cellular responses to a wide variety of stimuli. Signals pass along these pathways via kinase cascades in which three protein kinases are sequentially phosphorylated and activated, initiating a range of cellular programs including cellular proliferation, immune and inflammatory responses, and apoptosis. One such cascade involves the mixed lineage kinase, MLK2, signaling through MAP kinase kinase 4 and/or MAP kinase kinase 7 to the SAPK/JNK, resulting in phosphorylation of transcription factors including the oncogene, c-jun. Recently we showed that MLK2 causes apoptosis in cultured neuronal cells and that this effect is dependent on activation of the JNK pathway (Liu, Y. F., Dorow, D. S., and Marshall, J. (2000) J. Biol. Chem. 275, 19035-19040), Furthermore, dominant-negative MLK2 blocked apoptosis induced by polyglutamine-expanded huntingtin protein, the product of the mutant Huntington's disease gene. Here we show that as well as activating the stress-signaling pathway, MLK2 is a target for phosphorylation by activated JNK, Phosphopeptide mapping of MLK2 proteins revealed that activated JNK2 phosphorylates multiple sites mainly within the noncatalytic C-terminal region of MLK2 including the C-terminal 100 amino acid peptide. In addition, MLK2 is phosphorylated in vivo within several of the same C-terminal peptides phosphorylated by JNK2 in vitro, and this phosphorylation is increased by cotransfection of JNK2 and treatment with the JNK activator, anisomycin. Cotransfection of dominant-negative JNK kinase inhibits phosphorylation of kinase-negative MLK2 by anisomycin-activated JNK, Furthermore, we show that the N-terminal region of MLK2 is sufficient to activate JNK but that removal of the C-terminal domain abrogates the apoptotic response. Taken together, these data indicate that the apoptotic activity of MLK2 is dependent on the C-terminal domain that is the main target for MLK2 phosphorylation by activated JNK.	Peter MacCallum Canc Inst, Trescowthick Res Ctr, Melbourne, Vic 8006, Australia; Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA	Peter Maccallum Cancer Center; Northeastern University	Dorow, DS (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Ctr, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	d.dorow@pmci.unimelb.edu.au						Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerezo A, 1999, CELL DEATH DIFFER, V6, P87, DOI 10.1038/sj.cdd.4400458; CHOI KY, 1994, CELL, V78, P499; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	51	18	19	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10801	10810		10.1074/jbc.M008237200	http://dx.doi.org/10.1074/jbc.M008237200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278395	hybrid			2022-12-27	WOS:000167980900034
J	Tu, YP; Woodson, J; Ross, EM				Tu, YP; Woodson, J; Ross, EM			Binding of regulator of G protein signaling (RGS) proteins to phospholipid bilayers - Contribution of location and/or orientation to GTPase-activating protein activty	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; MEMBRANE ASSOCIATION; DOMAIN; SUBUNITS; RECEPTOR; GAIP; PALMITOYLATION; LOCALIZATION; PURIFICATION; INHIBITION	Regulator of G protein signaling (RGS) proteins must bind membranes in an orientation that permits the protein-protein interactions necessary for regulatory activity. RGS4 binds to phospholipid surfaces in a slow, multistep process that leads to maximal GTPase-activating protein (GAP) activity. When RGS4 is added to phospholipid vesicles that contain m2 or m1 muscarinic receptor and G(i), G(z), or G(q), GAP activity increases similar to3-fold over 4 h at 30 degreesC and more slowly at 20 degreesC, This increase in GAP activity is preceded by several other events that suggest that, after binding, optimal interaction with G protein and receptor requires reorientation of RGS4 on the membrane surface, a conformational change, or both. Binding of RGS4 is initially reversible but becomes irreversible within 5 min. Onset of irreversibility parallels initial quenching of tryptophan fluorescence (t(1/2) similar to 30 s), Further quenching occurs after binding has become irreversible (t(1/2) similar to 6 min) but is complete well before maximal GAP activity is attained. These processes all appear to be energetically driven by the amphipathic N-terminal domain of RGS4 and are accelerated by palmitoylation of cysteine residues in this region. The RGS4 N-terminal domain confers similar membrane binding behavior on the RGS domains of either RGS10 or RGSZ1.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	ross@utsw.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dowal L, 2001, BIOCHEMISTRY-US, V40, P414, DOI 10.1021/bi001923+; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	31	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20160	20166		10.1074/jbc.M101599200	http://dx.doi.org/10.1074/jbc.M101599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274219	hybrid			2022-12-27	WOS:000169135100066
J	Xia, CZ; Bao, ZM; Yue, CP; Sanborn, BM; Liu, MY				Xia, CZ; Bao, ZM; Yue, CP; Sanborn, BM; Liu, MY			Phosphorylation and regulation of G-protein-activated phospholipase C-beta 3 by cGMP-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SMOOTH-MUSCLE CELLS; PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-TRANSDUCTION SYSTEM; PIG CORONARY-ARTERIES; GTP-BINDING PROTEINS; I-DEFICIENT MICE; CYCLIC-GMP; NITRIC-OXIDE; INOSITOL PHOSPHATES	Among the drugs that are known to relax the vascular smooth muscle and regulate other cellular functions, beta -adrenergic agonists and nitric oxide-containing compounds are some of the most effective ones. The mechanisms of these drugs are thought to lower agonist-induced intracellular [Ca2+] by increasing intracellular cAMP and cGMP, activating their respective protein kinases, However, the physiological targets of cyclic nucleotide-dependent protein kinases are not clear, The molecular basis for the regulation of intracellular Ca2+ by signaling pathways coupled to cyclic nucleotides is not well defined. G-protein-activated phospholipase C (PLC-beta) catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphrosphates to generate diacylglycerol and inositol 1,4,5-triphosphate, leading to the activation of protein kinase C and the mobilization of intracellular Ca2+ In this study, we shown that G-protein-activated PLC enzymes are the potential, targets of cGMP-dependent protein kinases (PKG), PKG can directly phosphorylate PLC-beta2 and PLC-beta3 in vitro with purified proteins and in vivo with metabolic labeling. Phosphorylation of PLC-beta leads to the inhibition of G-protein-activated PLC-beta3 activity by 50-70% in COS-7 cell transfection assays. By using phosphopeptide mapping and site-directed mutagenesis, we further identified two key phosphorylation sites for the regulation of PLC-beta3 by PKG (Ser(26) and Ser(1105)). Mutation at these two sites (S26A and S1105A) of PLC-beta3 completely blocked the phosphorylation of PLC-beta3 protein catalyzed by PKG. Furthermore, mutation of these serine residues removed the inhibitory effect of PKG on the activation of the mutant PLC-beta3 proteins by G-protein subunits, Our results suggest a molecular mechanism for the regulation of G-protein-mediated intracellular [Ca2+] by the NO-cGMP-dependent signaling pathway.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr,Dept Med Biochem & Genet, Houston, TX 77030 USA; Ocean Univ Qingdao, Dept Biol, Qingdao 266003, Peoples R China; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Ocean University of China; University of Texas System	Liu, MY (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr,Dept Med Biochem & Genet, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009618, R37HD009618] Funding Source: NIH RePORTER; NICHD NIH HHS [HD09618] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ANWER K, 1990, BIOL REPROD, V43, P851, DOI 10.1095/biolreprod43.5.851; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; EcklyMichel A, 1997, BRIT J PHARMACOL, V122, P158, DOI 10.1038/sj.bjp.0701339; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Guibert C, 1996, AM J PHYSIOL-LUNG C, V270, pL637, DOI 10.1152/ajplung.1996.270.4.L637; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; HIRATA M, 1990, J BIOL CHEM, V265, P1268; Hofmann F, 2000, J CELL SCI, V113, P1671; Hoiting BH, 1996, BRIT J PHARMACOL, V117, P419, DOI 10.1111/j.1476-5381.1996.tb15207.x; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG629, DOI 10.1152/ajpgi.1998.275.4.G629; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG H, 1992, J BIOL CHEM, V267, P1015; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; Kumar R, 1999, J PHARMACOL EXP THER, V291, P967; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lincoln TM, 1998, ACTA PHYSIOL SCAND, V164, P507, DOI 10.1111/j.1365-201X.1998.tb10700.x; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MADISON JM, 1988, J CLIN INVEST, V82, P1462, DOI 10.1172/JCI113752; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MCATEE P, 1990, J BIOL CHEM, V265, P6788; Meij JTA, 1996, BIOCHEM BIOPH RES CO, V225, P705, DOI 10.1006/bbrc.1996.1239; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; MURTHY KS, 1993, AM J PHYSIOL, V264, pG967, DOI 10.1152/ajpgi.1993.264.5.G967; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SARCEVIC B, 1989, J BIOL CHEM, V264, P20648; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Somlyo AP, 1997, NATURE, V389, P908, DOI 10.1038/40002; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALDMANN R, 1989, EUR J PHARMACOL, V159, P317, DOI 10.1016/0014-2999(89)90165-9; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; WATSON SP, 1984, J BIOL CHEM, V259, P3199; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; Word RA, 1998, AM J PHYSIOL-CELL PH, V274, pC748, DOI 10.1152/ajpcell.1998.274.3.C748; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	73	73	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19770	19777		10.1074/jbc.M006266200	http://dx.doi.org/10.1074/jbc.M006266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278298	hybrid			2022-12-27	WOS:000169135100014
J	Iida, J; Pei, D; Kang, T; Simpson, MA; Herlyn, M; Furcht, LT; McCarthy, JB				Iida, J; Pei, D; Kang, T; Simpson, MA; Herlyn, M; Furcht, LT; McCarthy, JB			Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE 1; TISSUE LOCALIZATION; PROGELATINASE-A; CELL-ADHESION; MT-MMPS; EXPRESSION; INTEGRIN; SURFACE; ACTIVATION; MIGRATION	Tumor cell adhesion and proteolysis of the extracellular matrix proteins surrounding the cells are tightly linked processes in tumor invasion. In this study, we sought to identify components of the cell surface of a vertical growth phase melanoma cell line, WM1341D, that mediate invasive cellular behavior. We determined by antisense inhibition that melanoma chondroitin sulfate proteoglycan (MCSP) and membrane-type 3 matrix metalloproteinase (MT3-MMP) expressed on WM1341D are required for invasion of type I collagen and degradation of type I gelatin. MT3-MMP co-immunoprecipitated with MCSP in WM1341D melanoma cells cultured on type I collagen or laminin, The association between MT3-MMP and MCSP was largely disrupted by removing chondroitin sulfate glycosaminoglycan (CS) from the cell surface, suggesting CS could mediate the association between the two cell surface core proteins. Recombinant MT3-MMP and MT3-MMP from whole cell lysates of WM1341D cells were specifically eluted from CS-conjugated affinity columns. The results indicate that MT3-MMP possesses the potential to promote melanoma invasion and proteolysis and that the formation of a complex between MT3-MMP and MCSP may be a crucial step in activating these processes.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; The Wistar Institute; University of Pennsylvania; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Iida, J (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Box 609 Mayo,412 Delaware St SE, Minneapolis, MN 55455 USA.	iidax002@tc.umn.edu			NATIONAL CANCER INSTITUTE [R01CA021463, R01CA082295, R37CA021463] Funding Source: NIH RePORTER; NCI NIH HHS [CA21463, CA82295] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; CHATTOPADHYAY P, 1992, P NATL ACAD SCI USA, V89, P2684, DOI 10.1073/pnas.89.7.2684; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; Deryugina EI, 1998, CANCER RES, V58, P3743; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; ETO K, 2000, J BIOL CHEM, V86, P299; Etoh Takafumi, 1992, Journal of Dermatology (Tokyo), V19, P841; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; Gilles C, 1997, LAB INVEST, V76, P651; Goss KJH, 1998, INT J CANCER, V78, P629; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HERLYN M, 1993, TUMOR PROGR MELANOCY, P21; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hofmann UB, 2000, J PATHOL, V191, P245; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; LU C, 1993, CANCER RES, V53, P2708; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Mueller BM, 1996, CURR TOP MICROBIOL, V213, P65; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nakamura H, 1999, CANCER RES, V59, P467; Nath D, 2000, J CELL SCI, V113, P2319; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; REISFELD RA, 1987, ADV IMMUNOL, V40, P323, DOI 10.1016/S0065-2776(08)60242-4; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Schon M, 1996, J INVEST DERMATOL, V106, P1175, DOI 10.1111/1523-1747.ep12347929; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Skubitz APN, 1996, AM J PATHOL, V148, P1445; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Ueno H, 1997, CANCER RES, V57, P2055; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; YOSHINAGA IG, 1993, MELANOMA RES, V3, P435, DOI 10.1097/00008390-199311000-00006; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	54	77	83	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18786	18794		10.1074/jbc.M010053200	http://dx.doi.org/10.1074/jbc.M010053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278606	hybrid			2022-12-27	WOS:000169091000020
J	Morales-Ruiz, M; Lee, MJ; Zollner, S; Gratton, JP; Scotland, R; Shiojima, I; Walsh, K; Hla, T; Sessa, WC				Morales-Ruiz, M; Lee, MJ; Zollner, S; Gratton, JP; Scotland, R; Shiojima, I; Walsh, K; Hla, T; Sessa, WC			Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a G(i) protein/phosphoinositide 3-kinase pathway in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; KINASE AKT; ENOS ACTIVATION; SYNTHASE; MIGRATION; PHOSPHORYLATION; ANGIOGENESIS; SPHINGOSINE-1-PHOSPHATE	Sphingosine l-phosphate (SPP) binds to members of the endothelial differentiation gene family (EDG) of receptors and leads to diverse signaling events including cell survival, growth, migration and differentiation. However, the mechanisms of how SPP activates these proangiogenic pathways are poorly understood. Here we show that SPP signals through the EDG-1 receptor to the heterotrimeric G protein Gi, leading to activation of the serine/threonine kinase Akt and phosphorylation of the Akt substrate, endothelial nitric-oxide synthase (eNOS). Inhibition of Gi signaling, and phosphoinositide 3-kinase (PI3-kinase) activity resulted in a decrease in SPP-induced endothelial cell chemotaxis. SPP also stimulates eNOS phosphorylation and NO release and these effects are also attenuated by inhibition of Gi signaling, PI 3-kinase, and Akt. However, inhibition of NO production did not influence SPP-induced chemotaxis but effectively blocked the chemotactic actions of vascular endothelial growth factor. Thus, SPP signals through Gi and PI 3-kinase leading to Akt activation and eNOS phosphorylation.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Connecticut, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA	Yale University; St. Elizabeth's Medical Center; University of Connecticut	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Morales-Ruiz, Manuel/L-1031-2014; Hla, Timothy/G-5873-2012; Morales-Ruiz, Manuel/Z-2332-2019; Sessa, William C/B-6844-2011; Morales-Ruiz, Manuel/AAM-1487-2020	Morales-Ruiz, Manuel/0000-0002-9074-2272; Hla, Timothy/0000-0001-8355-4065; Morales-Ruiz, Manuel/0000-0002-9074-2272; Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	NHLBI NIH HHS [HL64793, R01 HL57665, HL61371] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R01HL061371, R01HL064793, R37HL061371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boguslawski G, 2000, BIOCHEM BIOPH RES CO, V272, P603, DOI 10.1006/bbrc.2000.2822; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Graler MH, 1999, CURR TOP MICROBIOL, V246, P131; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HLA T, 1990, J BIOL CHEM, V265, P9308; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Noiri E, 1998, AM J PHYSIOL-CELL PH, V274, pC236, DOI 10.1152/ajpcell.1998.274.1.C236; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, EXP CELL RES, V247, P17, DOI 10.1006/excr.1998.4327; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	46	235	240	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19672	19677		10.1074/jbc.M009993200	http://dx.doi.org/10.1074/jbc.M009993200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278592	hybrid			2022-12-27	WOS:000169091000134
J	Biswas, N; Weller, SK				Biswas, N; Weller, SK			The UL5 and UL52 subunits of the herpes simplex virus type 1 helicase-primase subcomplex exhibit a complex interdependence for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI REP HELICASE; ESCHERICHIA-COLI; INTRACELLULAR-LOCALIZATION; CRYSTAL-STRUCTURES; DEPENDENT ATPASE; GENE-PRODUCTS; PROTEIN; MUTATION; MOTIF	Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex composed of the products of the UL5, UL52, and UL8 genes. The UL5 protein contains seven motifs found in all members of helicase Superfamily 1 (SF1), and the UL52 protein contains several conserved motifs found in primases; however, the contributions of each subunit to the biochemical activities of the subcomplex are not clear. In this work, the DNA binding properties of wild type and mutant subcomplexes were examined using single-stranded, duplex, and forked substrates, A gel mobility shift assay indicated that the UL5-UL52 subcomplex binds more efficiently to the forked substrate than to either single strand or duplex DNA. Although nucleotides are not absolutely required for DNA binding, ADP stimulated the binding of UL5-UL52 to single strand DNA whereas ATP, ADP, and adenosine 5'-O-(thiotriphosphate) stimulated the binding to a forked substrate. We have previously shown that both subunits contact single-stranded DNA in a photocrosslinking assay (Biswas, N., and Weller, S, K. (1999) J, Biol Chem 274, 8068-8076). In this study, photocross-linking assays with forked substrates indicate that the UL5 and UL52 subunits contact the forked substrates at different positions, UL52 at the single-stranded DNA tail and UL5 near the junction between single-stranded and double-stranded DNA. Neither subunit was able to cross-link a forked substrate when B-iododeoxyuridine was located within the duplex portion. Photocross-linking experiments with subcomplexes containing mutant versions of UL5 and wild type UL52 indicated that the integrity of the ATP binding region is important for DNA binding of both subunits, These results support our previous proposal that UL5 and UL52 exhibit a complex interdependence for DNA binding (Biswas, N., and Weller, S. K. (1999) J, BioL Chem 274, 8068-8076) and indicate that the UL52 subunit may play a more active role in helicase activity than had previously been thought.	Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA	University of Connecticut	Weller, SK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA.		Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	NIAID NIH HHS [AI21747] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021747, R37AI021747] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Barrera I, 1998, J VIROL, V72, P1203, DOI 10.1128/JVI.72.2.1203-1209.1998; Biswas N, 1999, J BIOL CHEM, V274, P8068, DOI 10.1074/jbc.274.12.8068; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CARMICHAEL EP, 1989, J VIROL, V63, P591, DOI 10.1128/JVI.63.2.591-599.1989; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DAS RH, 1980, J BIOL CHEM, V255, P8069; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; GAC NTL, 1996, J BIOL CHEM, V271, P21645; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GravesWoodward KL, 1997, J BIOL CHEM, V272, P4623, DOI 10.1074/jbc.272.7.4623; GravesWoodward KL, 1996, J BIOL CHEM, V271, P13629, DOI 10.1074/jbc.271.23.13629; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Hamatake RK, 1997, J GEN VIROL, V78, P857, DOI 10.1099/0022-1317-78-4-857; Healy S, 1997, J BIOL CHEM, V272, P3411, DOI 10.1074/jbc.272.6.3411; Jezewska MJ, 1998, J BIOL CHEM, V273, P9058, DOI 10.1074/jbc.273.15.9058; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; Joo WS, 1998, MOL CELL BIOL, V18, P2677, DOI 10.1128/MCB.18.5.2677; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Malik AK, 1996, VIROLOGY, V224, P380, DOI 10.1006/viro.1996.0545; Marintcheva B, 2001, J BIOL CHEM, V276, P6605, DOI 10.1074/jbc.M007743200; MARINTCHEVA B, 2001, IN PRESS PROG NUCL A; Marsden HS, 1996, J GEN VIROL, V77, P2241, DOI 10.1099/0022-1317-77-9-2241; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; OLIVO PD, 1990, HERPESVIRUS TRANSCRI, P137; PATEL SS, 1993, J BIOL CHEM, V268, P10668; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WELLER SK, 1995, IMPLICATIONS DNA PRO, P189; WELLER SK, 1993, HERPESVIRUS TRANSCRI, P105; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; ZHU L, 1988, VIROLOGY, V166, P366, DOI 10.1016/0042-6822(88)90507-7	48	22	22	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17610	17619		10.1074/jbc.M010107200	http://dx.doi.org/10.1074/jbc.M010107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278618	hybrid			2022-12-27	WOS:000168730400135
J	Lyons, RJ; Deane, R; Lynch, DK; Ye, ZSJ; Sanderson, GM; Eyre, HJ; Sutherland, GR; Daly, RJ				Lyons, RJ; Deane, R; Lynch, DK; Ye, ZSJ; Sanderson, GM; Eyre, HJ; Sutherland, GR; Daly, RJ			Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; GROWTH-FACTOR RECEPTOR; PLECKSTRIN HOMOLOGY; MOLECULAR-CLONING; INSULIN-RECEPTOR; BREAST-CANCER; SH2 DOMAINS; KINASE; FAMILY; CELLS	Tankyrase is an ankyrin repeat-containing poly(ADP-ribose) polymerase originally isolated as a binding partner for the telomeric protein TRF1, but recently identified as a mitogen-activated protein kinase substrate implicated in regulation of Golgi vesicle trafficking. In this study, a novel human tankyrase, designated tankyrase 2, was isolated in a yeast two-hybrid screen as a binding partner for the Src homology 2 domain-containing adaptor protein Grb14. Tankyrase 2 is a 130-kDa protein, which lacks the N-terminal histidine/proline/serine-rich region of tankyrase, but contains a corresponding ankyrin repeat region, sterile alpha motif module, and poly(ADP-ribose) polymerase homology domain. The TANKYRASE 2 gene localizes to chromosome 10q23.2 and is widely expressed, with mRNA transcripts particularly abundant in skeletal muscle and placenta. Upon subcellular fractionation, both Grb14 and tankyrase 2 associate with the low density microsome fraction, and association of these proteins in vivo can be detected by co-immunoprecipitation analysis. Deletion analyses implicate the N-terminal 110 amino acids of Grb14 and ankyrin repeats 10-19 of tankyrase 2 in mediating this interaction, This study supports a role for the tankyrases in cytoplasmic signal transduction pathways and suggests that vesicle trafficking may be involved in the subcellular localization or signaling function of Grb14.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Rockefeller Univ, Dept Cell Biol & Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, Adelaide, SA 5006, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Rockefeller University; Memorial Sloan Kettering Cancer Center; Womens & Childrens Hospital Australia	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Daly, Roger J/C-8179-2009; Sutherland, Grant Robert/D-2606-2012	Daly, Roger/0000-0002-5739-8027				BENNETT V, 1992, J BIOL CHEM, V267, P8703; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; HARLOW E, 1988, ANTIBODIES LABORATOR, P524; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; JANES PW, 1994, ONCOGENE, V9, P3601; KAPFHAMER D, 1995, GENOMICS, V27, P189, DOI 10.1006/geno.1995.1023; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P170; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Sutherland GR, 1985, OXFORD MONOGRAPHS ME, V13; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Wang J, 1999, MOL CELL BIOL, V19, P6217; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Zhu LX, 1999, GENOMICS, V57, P320, DOI 10.1006/geno.1999.5771	47	111	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17172	17180		10.1074/jbc.M009756200	http://dx.doi.org/10.1074/jbc.M009756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278563	hybrid			2022-12-27	WOS:000168730400077
J	See, RH; Calvo, D; Shi, YJ; Kawa, H; Luke, MPS; Yuan, ZM; Shi, Y				See, RH; Calvo, D; Shi, YJ; Kawa, H; Luke, MPS; Yuan, ZM; Shi, Y			Stimulation of p300-mediated transcription by the kinase MEKK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; C-JUN; ADENOVIRUS E1A; HISTONE ACETYLTRANSFERASES; MOLECULAR-CLONING; CELLULAR PROTEINS; DNA-DAMAGE; P300; CBP	p300 and CREB-binding protein (CBP) are related transcriptional coactivators that possess histone acetyltransferase activity. Inactivation of p300/CBP is part of the mechanism by which adenovirus E1A induces oncogenic transformation of cells. Recently, the importance of p300/CBP has been demonstrated directly in several organisms including mouse, Drosophila, and Caenorhabditis elegans where p300/CBP play an indispensable role in differentiation, in patterning, and in cell fate determination and proliferation during development. CBP/p300s are modified by phosphorylation during F9 cell differentiation as well as adenovirus infection, suggesting that phosphorylation may play a role in the regulation of p300/CBP activity. Here we show that the mitogen-activated/extracellular response kinase kinase 1 (MEKK1) enhances p300-mediated transcription. We identify several domains within p300 that can respond to MEKK1-induced transcriptional activation. Interestingly, activation of p300-mediated transcription by MEKK1 does not appear to require the downstream kinase JNK and may involve either a direct phosphorylation of p300 by MEKK1 or by other non-JNK MEKK1-directed downstream kinases, Finally, we present evidence that p300 is important for MEKK1 to induce apoptosis. Taken together, these results identify MEKK1 as a kinase that is likely to be involved in the regulation of the transactivation potential of p300 and support a role of p300 in MEKK1-induced apoptosis.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Radiat Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Warren Alpert Bldg,Rm 120,200 Longwood Ave, Boston, MA 02115 USA.			Kawai, Hidehiko/0000-0003-2213-7166	NIGMS NIH HHS [GM58012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBEAU D, 1994, ONCOGENE, V9, P359; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERIJARD B, 1994, CELL, V76, P1; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EGAN C, 1989, ONCOGENE, V4, P383; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; See RH, 1998, MOL CELL BIOL, V18, P4012, DOI 10.1128/MCB.18.7.4012; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	52	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16310	16317		10.1074/jbc.M008113200	http://dx.doi.org/10.1074/jbc.M008113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278389	hybrid			2022-12-27	WOS:000168623100099
J	Shen, X; Li, JM; Hu, PPC; Waddell, D; Zhang, J; Wang, XF				Shen, X; Li, JM; Hu, PPC; Waddell, D; Zhang, J; Wang, XF			The activity of guanine exchange factor NET1 is essential for transforming growth factor-beta-mediated stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 FIBROBLASTS; TGF-BETA; RHO GTPASES; PROTEIN; EXPRESSION; CELLS; CYTOSKELETON; INVASIVENESS; ACTIVATION; FILOPODIA	To examine signaling pathways underlying transforming growth factor-beta (TGF-beta)-mediated changes in cell morphology, we used a microarray system to identify downstream target genes that may play a role in this process. Through this approach, we found that the NET1 gene was induced upon TGF-beta treatment in several cell types. NET1 is a guanine nucleotide exchange factor for RhoA whose activity has been implicated in stress fiber formation. In the Swiss 3T3 cell line, TGF-beta induces NET1 expression, and this correlated with an increase in stress fiber formation. Overexpression of the wild type NET1 gene increases stress fiber formation, and overexpression of a dominant negative NET1 mutant (L392E) prevented TGF-beta dependent increase in stress fiber formation. Furthermore, treatment of the cells with a RhoA kinase inhibitor Y-27632 blocks TGF-beta -induced stress fiber formation, By using a stable cell line expressing dominant negative Smad3, we found that the Smad signaling pathway is essential for the induction of NET1, which in turn leads to the increase of Rho activity. Taken together, those data suggest that induction of NET1 is important for the increase of Rho activity upon TGF-beta treatment, which may represent the critical trigger for a variety of downstream events in different cells. Our results support the presence of a novel signaling pathway by which TGF-beta may regulate the formation of stress fibers and reorganization of cytoskeletal structures.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.		Waddell, David/J-7435-2015	Waddell, David/0000-0001-6749-4461	NCI NIH HHS [CA75368] Funding Source: Medline; NIDDK NIH HHS [DK45746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Chan AML, 1996, ONCOGENE, V12, P1259; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; GARBI C, 1990, EUR J CELL BIOL, V53, P281; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lee KM, 1999, CELL BIOL INT, V23, P507, DOI 10.1006/cbir.1998.0401; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI L, 1990, J BIOL CHEM, V265, P1556; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Moustakas A, 1999, J CELL SCI, V112, P1169; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; VAN AL, 1997, GENE DEV, V11, P2295; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940	27	87	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15362	15368		10.1074/jbc.M009534200	http://dx.doi.org/10.1074/jbc.M009534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278519	hybrid			2022-12-27	WOS:000168528800111
J	Tanaka, M; Kirito, K; Kashii, Y; Uchida, M; Watanabe, T; Endo, H; Endoh, T; Sawada, K; Ozawa, K; Komatsu, N				Tanaka, M; Kirito, K; Kashii, Y; Uchida, M; Watanabe, T; Endo, H; Endoh, T; Sawada, K; Ozawa, K; Komatsu, N			Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes - Regulation of cell cycling as a downstream molecule of thrombopoietin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; COLONY-STIMULATING FACTOR; NF-KAPPA-B; C-AKT; PHOSPHORYLATION; GENE; ACTIVATION; SURVIVAL; INSULIN; HEAD	FKHRL1, a member of the Forkhead transcription factor family, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt. This molecule is a mammalian homolog of DAF-16, which plays an important role in the longevity of Caenorhabditis elegans. In this study we found that Akt and FKHRL1 proteins were detectable in highly purified normal human megakaryocytes and that these molecules were actually phosphorylated by thrombopoietin (TPO). To clarify the functional role of FKHRL1 in TPO signaling, we established a tetracycline-inducible system in the human TPO-dependent leukemia cell line UT-7/TPO. Induced expression of active FKHRL1 led to cell cycle arrest at G(0)/G(1) phase in this cell line. These results suggest that FKHRL1 plays an important role in the cell cycle of megakaryocytic cells as one of the downstream target molecules of phosphatidylinositol 3-kinase-Akt, presumably mediated through the activation or inactivation of cell cycle-associated gene(s).	Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Pediat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan; Hokkaido Univ, Dept Internal Med 2, Sapporo, Hokkaido, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Hokkaido University	Komatsu, N (corresponding author), Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan.	nkomatsu@ms.jichi.ac.jp	Kirito, Keita/AEO-6802-2022					Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong F, 2000, BLOOD, V95, P1656, DOI 10.1182/blood.V95.5.1656.005k29_1656_1662; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Koizumi K, 1998, EXP HEMATOL, V26, P1140; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; Komatsu N, 1997, BLOOD, V89, P4021, DOI 10.1182/blood.V89.11.4021; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LONGMORE GD, 1993, BLOOD, V82, P2386; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ozes ON, 1999, NATURE, V401, P82; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SATO N, 1994, EXP HEMATOL, V22, P973; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Yamaguchi M, 1997, BONE MARROW TRANSPL, V19, P373, DOI 10.1038/sj.bmt.1700659; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	35	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15082	15089		10.1074/jbc.M007958200	http://dx.doi.org/10.1074/jbc.M007958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278373	hybrid			2022-12-27	WOS:000168528800075
J	Heximer, SP; Lim, H; Bernard, JL; Blumer, KJ				Heximer, SP; Lim, H; Bernard, JL; Blumer, KJ			Mechanisms governing subcellular localization and function of human RGS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; PHOSPHOLIPASE-C-BETA; NUCLEOTIDE EXCHANGE; KINASE ACTIVATION; PLASMA-MEMBRANE; FAMILY; REGULATORS; BINDING; DOMAIN; INHIBITION	RGS proteins negatively regulate heterotrimeric G proteins at the plasma membrane. RGS2-GFP localizes to the nucleus, plasma membrane, and cytoplasm of HEK293 cells. Expression of activated G(q) increased RGS2 association with the plasma membrane and de creased accumulation in the nucleus, suggesting that signal-induced redistribution may regulate RGS2 function. Thus, we identified and characterized a conserved N-terminal domain in RGS2 that is necessary and sufficient for plasma membrane localization. Mutational and biophysical analyses indicated that this domain is an amphipathic Lu-helix that binds vesicles containing acidic phospholipids. However, the plasma membrane targeting function of the amphipathic helical domain did not appear to be essential for RGS2 to attenuate signaling by activated G(q). Nevertheless, truncation mutants indicated that the N terminus is essential, potentially serving as a scaffold that binds receptors, signaling proteins, or nuclear components. Indeed, the RGS2 N terminus directs nuclear accumulation of GFP. Although RGS2 possesses a nuclear targeting motif, it lacks a nuclear import signal and enters the nucleus by passive diffusion. Nuclear accumulation of RGS2 does not limit its ability to attenuate G(q) signaling, because excluding RGS2 from the nucleus was without effect. RGS2 may nonetheless regulate signaling or other processes in the nucleus.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Heximer, SP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	sheximer@cellbio.wustl.edu	Blumer, Kendall J/C-5268-2012					Beadling C, 1999, J IMMUNOL, V162, P2677; Benzing T, 2000, J BIOL CHEM, V275, P28167; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Cocco L, 2000, ADV ENZYME REGUL, V40, P83, DOI 10.1016/S0065-2571(99)00028-X; Dong MQ, 2000, GENE DEV, V14, P2003; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Ingi T, 1998, J NEUROSCI, V18, P7178; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; ROBINSON A, 1987, BIOCHEM J, V246, P249, DOI 10.1042/bj2460249; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	46	105	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14195	14203		10.1074/jbc.M009942200	http://dx.doi.org/10.1074/jbc.M009942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278586	hybrid			2022-12-27	WOS:000168356600092
J	Xu, YX; Liu, L; Lopez-Estrano, C; Michaeli, S				Xu, YX; Liu, L; Lopez-Estrano, C; Michaeli, S			Expression studies on clustered trypanosomatid box C/D small nucleolar RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLATION GUIDE SNORNAS; INTRONIC U14 SNORNA; RIBOSE METHYLATION; LEPTOMONAS-COLLOSOMA; STRUCTURAL ELEMENTS; STABLE TRANSFECTION; PRERIBOSOMAL RNA; SITE; SEQUENCE; PROTEIN	We analyzed three chromosomal loci of the trypanosomatid Leptomonas collosoma encoding box C/D small nucleolar RNAs (snoRNAs). All the snoRNAs that were analyzed here carry two sequences complementary to rRNA target sites and obey the +5 rule for guide methylation. Studies on transgenic parasites carrying the snoRNA-2 gene in the episomal expression vector (pX-neo) indicated that no promoter activity was found immediately adjacent to this gene. Deleting the flanking sequences of snoRNA-2 affected the expression; in the absence of the 3'-flanking (but not 5'-flanking) sequence, the expression was almost completely abolished. The snoRNA genes are transcribed as polycistronic RNA. All snoRNAs can be folded into a common stem-loop structure, which may play a role in processing the polycistronic transcript. snoRNA B2, a member of a snoRNA cluster, was expressed when cloned into the episomal vector, suggesting that each gene within a cluster is individually processed. Studies with permeable cells indicated that snoRNA gene transcription was relatively sensitive to alpha -amanitin, thus supporting transcription by RNA polymerase II. We propose that snoRNA gene expression, similar to protein-coding genes in this family, is regulated at the processing level.	Bar Ilan Univ, Fac Life Sci, IL-59200 Ramat Gan, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Bar Ilan University; Weizmann Institute of Science	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-59200 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Michaeli, Shulamit/AAC-8255-2022; Xu, Yu-Xin/G-4041-2010; Estrano, Carlos E./B-3576-2009	Liu, Li/0000-0002-3733-6961; Xu, Yu-Xin/0000-0002-0200-4633				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; GOLDRING A, 1994, EXP PARASITOL, V80, P333; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; GRAY MW, 1979, CAN J BIOCHEM CELL B, V57, P914, DOI 10.1139/o79-111; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kiss-Laszlo Z, 1998, EMBO J, V17, P797, DOI 10.1093/emboj/17.3.797; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Leader DJ, 1999, PLANT MOL BIOL, V39, P1091, DOI 10.1023/A:1006157022319; LEVERETTE RD, 1992, CELL, V71, P1215, DOI 10.1016/S0092-8674(05)80069-8; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Li L, 2000, J BIOL CHEM, V275, P2259, DOI 10.1074/jbc.275.4.2259; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Ooi SL, 1998, RNA, V4, P1096, DOI 10.1017/S1355838298980785; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; PAYS E, 1996, MOL BIOL PARASITIC P, P88; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; ULLU E, 1997, MOL BIOL PARASITIC P, P115; Villa T, 1998, MOL CELL BIOL, V18, P3376, DOI 10.1128/MCB.18.6.3376; Watkins NJ, 1996, RNA, V2, P118; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Xia L, 1997, RNA, V3, P17; Xu YX, 2000, J BIOL CHEM, V275, P27883; Zuker M, 1994, Methods Mol Biol, V25, P267	55	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14289	14298		10.1074/jbc.M007007200	http://dx.doi.org/10.1074/jbc.M007007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278327	hybrid			2022-12-27	WOS:000168356600103
J	Chennathukuzhi, VM; Kurihara, Y; Bray, JD; Hecht, NB				Chennathukuzhi, VM; Kurihara, Y; Bray, JD; Hecht, NB			Trax (Translin-associated factor X), a primarily cytoplasmic protein, inhibits the binding of TB-RBP (Translin) to RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE GERM-CELLS; DNA-BINDING; MESSENGER-RNAS; NUCLEAR EXPORT; BRAIN; LOCALIZATION; GENE; TRANSLOCATIONS; DIMERIZATION; COMPLEX	Trax (Translin-associated factor X) has been shown to interact with TB-RBP/Translin by its coimmunoprecipitation and in yeast two-hybrid assays. Here we demonstrate that Trax is widely expressed, does not bind to DNA or RNA, but forms heterodimers with TB-RBP under reducing conditions. The heterodimer of TB-RBP and Trax inhibits TB-RBP binding to RNA, but enhances TB-RBP binding to specific single stranded DNA sequences. The in vitro interactions between TB-RBP and Trax are confirmed by similar interactions in the yeast two-hybrid system. Cell fractionation and confocal microscope studies reveal that Trax is predominantly cytoplasmic, In contrast, TB-RBP is present in both the nuclei and cytoplasm of transfected cells and uses a highly conserved nuclear export signal to exit nuclei. In addition to a leucine zipper, two basic domains in TB-RBP are essential for RNA binding, but only one of these domains is needed for DNA binding. Trax restores DNA binding to TB-RBP containing an altered form of this domain, These data suggest that Trax-TB-RBP interactions modulate the DNA- and RNA-binding activity of TB-RBP.	Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Yokohama Natl Univ, Dept Engn, Yokohama, Kanagawa 2408501, Japan	University of Pennsylvania; Pennsylvania Medicine; Yokohama National University	Hecht, NB (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Dept Obstet & Gynecol, 1310 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	nhecht@mail.med.upenn.edu		Kurihara, Yasuyuki/0000-0001-7305-6599	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028832, T32HD007305] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HD07305, HD28832] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki K, 1999, FEBS LETT, V443, P363, DOI 10.1016/S0014-5793(99)00010-1; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Atlas M, 1998, LEUKEMIA, V12, P1895, DOI 10.1038/sj.leu.2401223; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; Devon RS, 2000, MAMM GENOME, V11, P395, DOI 10.1007/s003350010074; Emmons RB, 1999, DEVELOPMENT, V126, P3937; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Finkenstadt PM, 2000, J NEUROCHEM, V75, P1754, DOI 10.1046/j.1471-4159.2000.0751754.x; Gu W, 1998, MOL REPROD DEV, V49, P219, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;219::AID-MRD1&gt;3.0.CO;2-R; HAN JR, 1995, BIOL REPROD, V53, P707, DOI 10.1095/biolreprod53.3.707; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hecht NB, 2000, MOL REPROD DEV, V56, P252; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Johnston SD, 1999, MOL CELL BIOL, V19, P923; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kasai M, 1997, J BIOL CHEM, V272, P11402; Kobayashi S, 1998, BIOCHEM BIOPH RES CO, V253, P448, DOI 10.1006/bbrc.1998.9704; Kruyt FAE, 1997, BLOOD, V90, P3288, DOI 10.1182/blood.V90.9.3288; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Morales CR, 1998, DEV BIOL, V201, P113, DOI 10.1006/dbio.1998.8967; Moroianu J, 1999, J CELL BIOCHEM, P76; Severt WL, 1999, J CELL SCI, V112, P3691; Taira E, 1998, J NEUROCHEM, V71, P471; Wang QT, 1999, DEVELOPMENT, V126, P5097; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Wu XQ, 1999, BIOCHEMISTRY-US, V38, P11261, DOI 10.1021/bi990573s; Wu XQ, 2000, BIOL REPROD, V62, P720, DOI 10.1095/biolreprod62.3.720; Wu XQ, 1998, NUCLEIC ACIDS RES, V26, P1675, DOI 10.1093/nar/26.7.1675; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	34	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13256	13263		10.1074/jbc.M009707200	http://dx.doi.org/10.1074/jbc.M009707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278549	hybrid			2022-12-27	WOS:000168198600109
J	Sribar, J; Copic, A; Paris, A; Sherman, NE; Gubensek, F; Fox, JW; Krizaj, I				Sribar, J; Copic, A; Paris, A; Sherman, NE; Gubensek, F; Fox, JW; Krizaj, I			A high affinity acceptor for phospholipase A(2) with neurotoxic activity is a calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; NEURONAL PENTRAXIN; VACUOLE FUSION; AMMODYTOXIN-C; RECEPTOR; IDENTIFICATION; PURIFICATION; ENDOCYTOSIS; INHIBITION; SEQUENCE	One of the high affinity binding proteins for ammodytoxin C, a snake venom presynaptically neurotoxic phospholipase A(2), has been purified from porcine cerebral cortex and characterized. After extraction from the membranes, the toxin-binding protein was isolated in a homogenous form using wheat germ lectin-Sepharose, Q-Sepharose, and ammodytoxin-CH-Sepharose chromatography, The specific binding of I-125-ammodytoxin C to the isolated acceptor was inhibited to different extents by some neurotoxic phospholipases A(2), ammodytoxins, bee venom phospholipase A(2), agkistrodotoxin, and crotoxin; but not by nontoxic phospholipases A(2), ammodytin I-2, porcine pancreatic phospholipase A(2), and human type IIA phospholipase A(2); suggesting the significance of the acceptor in the mechanism of phospholipase A, neurotoxicity, The isolated acceptor was identified as calmodulin by tandem mass spectrometry. Since calmodulin is generally considered as an intracellular protein, the identity of this acceptor supports the view that secretory phospholipase A(2) neurotoxins have to be internalized to exert their toxic effect. Moreover, since ammodytoxin is known to block synaptic transmission, its interaction with calmodulin as an acceptor may constitute a valuable probe for further investigation of the role of the latter in this Ca2+-regulated process.	Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana, Slovenia; Univ Ljubljana, Dept Chem & Biochem, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; Univ Virginia, Biomed Res Facil, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, WM Keck Biomed Mass Spectrometry Lab, Charlottesville, VA 22908 USA	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana; University of Virginia; University of Virginia	Krizaj, I (corresponding author), Jozef Stefan Inst, Dept Biochem & Mol Biol, Jamova 39, Ljubljana, Slovenia.			Sherman, Nicholas/0000-0003-3206-3113; Copic, Alenka/0000-0003-0166-7731				APODACA G, 1994, J BIOL CHEM, V269, P19005; Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; Copic A, 1999, J BIOL CHEM, V274, P26315, DOI 10.1074/jbc.274.37.26315; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DODDS D, 1995, J NEUROCHEM, V64, P2339; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GUBENSEK F, 1980, PERIOD BIOL, V82, P443; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495; Hseu MJ, 1999, FEBS LETT, V445, P440, DOI 10.1016/S0014-5793(99)00177-5; Krizaj I, 2000, BIOCHIMIE, V82, P807, DOI 10.1016/S0300-9084(00)01172-X; KRIZAJ I, 1989, BIOCHIM BIOPHYS ACTA, V999, P198, DOI 10.1016/0167-4838(89)90218-5; KRIZAJ I, 1994, BIOCHEMISTRY-US, V33, P13938, DOI 10.1021/bi00250a049; KRIZAJ I, 1992, EUR J BIOCHEM, V204, P1057, DOI 10.1111/j.1432-1033.1992.tb16728.x; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Montecucco C, 2000, TRENDS BIOCHEM SCI, V25, P266, DOI 10.1016/S0968-0004(00)01556-5; Mounier CM, 1998, J BIOL CHEM, V273, P23764, DOI 10.1074/jbc.273.37.23764; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; OZAWA M, 1993, J BIOL CHEM, V268, P699; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; Scott D. L., 1997, VENOM PHOSPHOLIPASE, P97; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Valentin E, 2000, BIOCHIMIE, V82, P815, DOI 10.1016/S0300-9084(00)01168-8; Vucemilo N, 1998, BIOCHEM BIOPH RES CO, V251, P209, DOI 10.1006/bbrc.1998.9427; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247	40	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12493	12496		10.1074/jbc.C100048200	http://dx.doi.org/10.1074/jbc.C100048200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278260	hybrid			2022-12-27	WOS:000168198600005
J	Saito, T; Kinoshita, A; Yoshiura, K; Makita, Y; Wakui, K; Honke, K; Niikawa, N; Taniguchi, N				Saito, T; Kinoshita, A; Yoshiura, K; Makita, Y; Wakui, K; Honke, K; Niikawa, N; Taniguchi, N			Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; BONE; OSTEOBLAST; GENE; FACTOR-BETA-1; FIBROBLAST; ACTIVATION; RESPONSES; BINDING; PROTEIN	Transforming growth factor (TGF)-beta1 is secreted as a latent form, which consists of its mature form and a latency-associated peptide (beta1-LAP) in either the presence or the absence of additional latent TGF-beta1-binding protein. We recently reported that three different missense mutations (R218H, R218C, and C225R) of beta1-LAP cause the Camurati-Engelmann disease (CED), an autosomal dominant disorder characterized by hyperosteosis and sclerosis of the diaphysis of the long bones. Pulse-chase experiments using fibroblasts from CED patients and expression experiments of the mutant genes in an insect cell system suggest that these mutations disrupt the association of beta1-LAP and TGF-beta1 and the subsequent release of the mature TGF-beta1. Furthermore, the cell growth of fibroblasts from a CED patient and mutant gene-transfected fibroblasts was suppressed via TGF-beta1. The growth suppression observed was attenuated by neutralizing antibody to TFF-beta1 or by treatment of dexamethasone. On the other hand, the proliferation of human osteoblastic MG-63 cells was accelerated by coculture with CED fibroblasts. These data suggest that the domain-specific mutations of beta1-LAP result in a more facile activation of TGF-beta1, thus causing CED.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 8528102, Japan; Asahikawa Med Coll, Dept Pediat & Publ Hlth, Asahikawa, Hokkaido 0788510, Japan; Shinshu Univ, Sch Med, Div Clin & Mol Genet, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Med Genet, Nagano 3908621, Japan	Osaka University; Nagasaki University; Asahikawa Medical College; Shinshu University; Shinshu University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/I-4182-2014; Saito, Takashi/G-2563-2015; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Saito, Takashi/0000-0002-9659-9251; 				Bas F, 1999, J PAEDIATR CHILD H, V35, P401, DOI 10.1046/j.1440-1754.1999.00381.x; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Cooper MS, 1999, J ENDOCRINOL, V163, P159, DOI 10.1677/joe.0.1630159; CRISP AJ, 1982, ANN RHEUM DIS, V41, P183, DOI 10.1136/ard.41.2.183; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; FAN WM, 1993, J CELL PHYSIOL, V156, P88, DOI 10.1002/jcp.1041560113; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; Ghadami M, 2000, AM J HUM GENET, V66, P143, DOI 10.1086/302728; HOCK JM, 1990, ENDOCRINOLOGY, V126, P421, DOI 10.1210/endo-126-1-421; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563; Janssens K, 2000, J MED GENET, V37, P245, DOI 10.1136/jmg.37.4.245; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Makita Y, 2000, AM J MED GENET, V91, P153, DOI 10.1002/(SICI)1096-8628(20000313)91:2<153::AID-AJMG15>3.0.CO;2-U; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; SUBRAMANIAM M, 1995, J CELL BIOCHEM, V57, P52, DOI 10.1002/jcb.240570107; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vaughn SP, 2000, GENOMICS, V66, P119, DOI 10.1006/geno.2000.6192; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932	25	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11469	11472		10.1074/jbc.C000859200	http://dx.doi.org/10.1074/jbc.C000859200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278244	hybrid			2022-12-27	WOS:000168081800007
J	Even-Ram, SC; Maoz, M; Pokroy, E; Reich, R; Katz, BZ; Gutwein, P; Altevogt, P; Bar-Shavit, R				Even-Ram, SC; Maoz, M; Pokroy, E; Reich, R; Katz, BZ; Gutwein, P; Altevogt, P; Bar-Shavit, R			Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha(v)beta(5) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; VASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; UROKINASE RECEPTOR; TYROSINE PHOSPHORYLATION; THROMBIN RECEPTOR; TISSUE FACTOR; NUCLEAR-ORGANIZATION	The first prototype of the protease activated receptor (PAR) family, the thrombin receptor PAR1, plays a central role both in the malignant invasion process of breast carcinoma metastasis and in the physiological process of placental implantation. The molecular mechanism underlying PAR1 involvement in tumor invasion and metastasis, however, is poorly defined. Here we show that PAR1 increases the invasive properties of tumor cells primarily by increased adhesion to extracellular matrix components. This preferential adhesion is accompanied by the cytoskeletal reorganization of F-actin toward migration-favoring morphology as detected by phalloidin staining. Activation of PAR1 increased the phosphorylation of focal adhesion kinase and paxillin, and the induced formation of focal contact complexes. PAR1 activation affected integrin cell-surface distribution without altering their level of expression. The specific recruitment of alpha (v)beta (5) to focal contact sites, but not of alpha (v)beta (3) or alpha (5)beta (1), was observed by immunofluorescent microscopy. PAR1 overexpressing cells showed selective reciprocal co-precipitation with alpha (v)beta (5) and paxillin but not with alpha (v)beta (3), that remained evenly distributed under these conditions. This co-immunoprecipitation failed to occur in cells containing the truncated form of PAR1 that lacked the entire cytoplasmic portion of the receptor. Thus, the PAR1 cytoplasmic tail is essential for conveying the cross-talk and recruiting the alpha (v)beta (5) integrin. While PAR1 overexpressing cells were invasive in vitro, as reflected by their migration through a Matrigel barrier, invasion was further enhanced by ligand activation of PAR1. Moreover, the application of anti-alpha (v)beta (5) antibodies specifically attenuated this PAR1 induced invasion. We propose that the activation of PAR1 may-lead to a novel cooperation with the alpha (v)beta (5) integrin that supports tumor cell invasion.	Hadassah Univ Hosp, Sharett Inst, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Pharmacol, IL-91120 Jerusalem, Israel; Med Ctr, Dept Hematol, IL-64239 Tel Aviv, Israel; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Helmholtz Association; German Cancer Research Center (DKFZ)	Bar-Shavit, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.			Even-Ram, Sharona/0000-0002-5540-3822				Albini A, 1998, Pathol Oncol Res, V4, P230; ALMONDHIRY H, 1975, THROMB DIATH HAEMOST, V34, P181, DOI 10.1055/s-0038-1651366; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; Bissell MJ, 1999, CANCER RES, V59, p1763S; Bissell MJ, 1999, CANCER RES, V59, p1757S; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Carriero MV, 1999, CANCER RES, V59, P5307; Carroll VA, 1999, SEMIN THROMB HEMOST, V25, P183, DOI 10.1055/s-2007-994920; CAVANAUGH PG, 1988, HAEMOSTASIS, V18, P37; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Crowe DL, 1999, HISTOL HISTOPATHOL, V14, P665, DOI 10.14670/HH-14.665; Cupit LD, 1999, TRENDS CARDIOVAS MED, V9, P42, DOI 10.1016/S1050-1738(99)00005-5; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; Filardo EJ, 1996, J CELL SCI, V109, P1615; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kahn ML, 1998, J BIOL CHEM, V273, P23290, DOI 10.1074/jbc.273.36.23290; KIM JP, 1994, J BIOL CHEM, V269, P26926; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; LIOTTA LA, 1983, LAB INVEST, V49, P636; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RICKLES FR, 1983, CANCER-AM CANCER SOC, V51, P301, DOI 10.1002/1097-0142(19830115)51:2<301::AID-CNCR2820510223>3.0.CO;2-7; Rudiger M, 1998, BIOESSAYS, V20, P733; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; Schaphorst KL, 1997, AM J RESP CELL MOL, V17, P443, DOI 10.1165/ajrcmb.17.4.2502; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Shoji M, 1998, AM J PATHOL, V152, P399; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Tang SQ, 1999, J CELL BIOL, V147, P1073, DOI 10.1083/jcb.147.5.1073; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	67	133	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10952	10962		10.1074/jbc.M007027200	http://dx.doi.org/10.1074/jbc.M007027200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278329	hybrid			2022-12-27	WOS:000167980900053
J	Mathieu, AL; Gonin, S; Leverrier, Y; Blanquier, B; Thomas, J; Dantin, C; Martin, G; Baverel, G; Marvel, J				Mathieu, AL; Gonin, S; Leverrier, Y; Blanquier, B; Thomas, J; Dantin, C; Martin, G; Baverel, G; Marvel, J			Activation of the phosphatidylinositol 3-kinase/Akt pathway protects against interleukin-3 starvation but not DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CELLS; HEMATOPOIETIC-CELLS; GLUT4 TRANSLOCATION; KINASE-B; BCL-X; P53-DEPENDENT APOPTOSIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GROWTH ARREST; BAF-3 CELLS	Baf-3 cells are dependent on interleukin-3 (IL-3) for their survival and proliferation in culture. To identify anti-apoptotic pathways, we performed a retroviral-insertion mutagenesis on Baf-3 cells and selected mutants that have acquired a long term survival capacity. The phenotype of one mutant, which does not overexpress bcl-x and proliferates in the absence of IL-3, is described. We show that, in this mutant, Akt is constitutively activated leading to FKHRL1 phosphorylation and constitutive glycolytic activity. This pathway is necessary for the mutant to survive following IL-3 starvation but is not sufficient or necessary to protect cells from DNA damage-induced cell death. Indeed, inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in Baf-5 cells does not prevent the ability of IL-8 to protect cells against gamma -irradiation-induced DNA damage. This protective effect of IL-3 rather correlates with the expression of the anti-apoptotic Bcl-x protein. Taken together, these data demonstrate that the PI3K Akt pathway is sufficient to protect cells from growth factor starvation-induced apoptosis but is not required for IL-3 inhibition of DNA damage-induced cell death.	INSERM, CERVI, U503, F-39007 Lyon, France; Fac Med Laennec, INSERM, U499, Lab Physiopathol Metab & Renale, F-69372 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Marvel, J (corresponding author), INSERM, CERVI, U503, 21 Ave Tony Garnier, F-39007 Lyon, France.		marvel, jacqueline/H-8638-2014; LEVERRIER, Yann/M-3767-2014	marvel, jacqueline/0000-0001-6241-459X; LEVERRIER, Yann/0000-0002-4227-5446; Thomas, Joelle/0000-0002-0461-6131; Mathieu, Anne-Laure/0000-0002-2893-7001				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Attardi LD, 2000, GENE DEV, V14, P704; BAVEREL G, 1979, BIOCHEM J, V184, P599, DOI 10.1042/bj1840599; BAVEREL G, 1978, KIDNEY INT, V14, P567, DOI 10.1038/ki.1978.165; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frasca D, 1996, INT IMMUNOL, V8, P1651, DOI 10.1093/intimm/8.11.1651; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; GARLAND JM, 1984, LYMPHOKINES, V9, P153; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HASTHORPE S, 1987, J CELL PHYSIOL, V133, P351, DOI 10.1002/jcp.1041330220; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; LAKINND, 1999, ONCOGENE, V18, P7644; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; MARVEL J, 1994, ONCOGENE, V9, P1117; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Miyajima A, 1999, INT J HEMATOL, V69, P137; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mor F, 1996, J IMMUNOL, V156, P515; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	51	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10935	10942		10.1074/jbc.M007147200	http://dx.doi.org/10.1074/jbc.M007147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278333	hybrid			2022-12-27	WOS:000167980900051
J	Gassama-Diagne, A; Hullin-Matsuda, F; Li, RY; Nauze, M; Ragab, A; Pons, V; Delagebeaudeuf, C; Simon, MF; Fauvel, J; Chap, H				Gassama-Diagne, A; Hullin-Matsuda, F; Li, RY; Nauze, M; Ragab, A; Pons, V; Delagebeaudeuf, C; Simon, MF; Fauvel, J; Chap, H			Enterophilins, a new family of leucine zipper proteins bearing a B30.2 domain and associated with enterocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL TYPES; MOUSE SMALL INTESTINE; SUBCELLULAR-LOCALIZATION; TRANSCRIPTION FACTOR; MEDITERRANEAN FEVER; MULTIGENIC FAMILIES; MOLECULAR-CLONING; PHOSPHOLIPASE-B; FINGER PROTEIN; MESSENGER-RNA	Enterocyte terminal differentiation occurs at the crypt-villus junction through the transcriptional activation of cell-specific genes, many of which code for proteins of the brush border membrane such as intestinal alkaline phosphatase, sucrase-isomaltase, or the microvillar structural protein villin, Several studies have shown that this sharp increase in specific mRNA levels is intimately associated with arrest of cell proliferation. We isolated several clones from a guinea pig intestine cDNA library, They encode new proteins characterized by an original structure associating a carboxyl-terminal B30.2/RFP-like domain and a long leucine zipper at the amino terminus. The first member of this novel gene family codes for a 65-kDa protein termed enterophilin-1, which is specifically expressed in enterocytes before their final differentiation. Enterophilin-1 is the most abundant in the small intestine but is still present in significant amounts in colonic enterocytes. In Caco-2 cells, a similar 65-kDa protein was recognized by a specific anti-enterophilin-1 antibody, and its expression was positively correlated with cell differentiation status. In addition, transfection of HT-29 cells with enterophilin-1 full-length cDNA slightly inhibited cell growth and promoted an increase in alkaline phosphatase activity. Taken together, these data identify enterophilins as a new family of proteins associated with enterocyte differentiation.	Hop Purpan, INSERM, U326, Ctr Hosp Univ Toulouse, F-31059 Toulouse, France; Univ Toulouse 3, Inst Federat Rech Claude de Preval, F-31059 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Gassama-Diagne, A (corresponding author), Hop Purpan, INSERM, U326, Ctr Hosp Univ Toulouse, F-31059 Toulouse, France.	Ama.Gassama@purpan.inserm.fr	Hullin-Matsuda, Françoise/N-3880-2017	Hullin-Matsuda, Françoise/0000-0002-6042-2841; PONS, Veronique/0000-0001-5821-8481				Aksentijevich I, 1997, CELL, V90, P797; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Bernot A, 1997, NAT GENET, V17, P25; BIKLE DD, 1993, J BIOL CHEM, V268, P620; Bikle DD, 1996, J BIOL CHEM, V271, P9075, DOI 10.1074/jbc.271.15.9075; BOLL W, 1993, J BIOL CHEM, V268, P12901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchner G, 1999, HUM MOL GENET, V8, P1397, DOI 10.1093/hmg/8.8.1397; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Cao TY, 1997, J CELL SCI, V110, P1563; CHAN EKL, 1995, J EXP MED, V182, P983, DOI 10.1084/jem.182.4.983; Chen XG, 2000, P SOC EXP BIOL MED, V224, P32, DOI 10.1046/j.1525-1373.2000.22362.x; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; Cox TC, 2000, HUM MOL GENET, V9, P2553, DOI 10.1093/hmg/9.17.2553; Delagebeaudeuf C, 1998, J BIOL CHEM, V273, P13407, DOI 10.1074/jbc.273.22.13407; Delagebeaudeuf C, 1996, BBA-LIPID LIPID MET, V1303, P119, DOI 10.1016/0005-2760(96)00090-2; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ElHodiri HM, 1997, J BIOL CHEM, V272, P20463, DOI 10.1074/jbc.272.33.20463; Ghadessy FJ, 1996, J BIOL CHEM, V271, P25575, DOI 10.1074/jbc.271.41.25575; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; Harada H, 1999, MOL CELL BIOL, V19, P3808; Henry J, 1997, IMMUNOGENETICS, V46, P383, DOI 10.1007/s002510050292; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hirst JD, 1996, PROTEIN ENG, V9, P657, DOI 10.1093/protein/9.8.657; Inoue S, 1999, BIOCHEM BIOPH RES CO, V261, P412, DOI 10.1006/bbrc.1999.0874; Ishii T, 1995, BBA-GEN SUBJECTS, V1245, P285, DOI 10.1016/0304-4165(95)00102-6; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; Iwata Y, 1999, BIOCHEM BIOPH RES CO, V261, P381, DOI 10.1006/bbrc.1999.1037; JACK LJW, 1990, J BIOL CHEM, V265, P14481; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Loeffler M, 1997, J THEOR BIOL, V186, P41, DOI 10.1006/jtbi.1996.0340; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; ORIMO A, 1995, J BIOL CHEM, V270, P24406, DOI 10.1074/jbc.270.41.24406; Perry J, 1999, GENOMICS, V62, P385, DOI 10.1006/geno.1999.6043; PINTO M, 1983, BIOL CELL, V47, P323; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; RAYNAL P, 1992, BIOCHEM BIOPH RES CO, V186, P432, DOI 10.1016/S0006-291X(05)80826-5; Rook F, 1998, PLANT MOL BIOL, V37, P171, DOI 10.1023/A:1005964327725; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Ruddy DA, 1997, GENOME RES, V7, P441, DOI 10.1101/gr.7.5.441; SAMBROOK J, 1908, MOL CLONING LAB MANU; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; Seto MH, 1999, PROTEINS, V35, P235, DOI 10.1002/(SICI)1097-0134(19990501)35:2<235::AID-PROT9>3.3.CO;2-O; Stott D, 1991, Methods Mol Biol, V7, P327, DOI 10.1385/0-89603-178-0:327; Suh E, 1996, MOL CELL BIOL, V16, P619; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Takemori H, 1998, J BIOL CHEM, V273, P2222, DOI 10.1074/jbc.273.4.2222; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Taylor MR, 1996, BBA-GENE STRUCT EXPR, V1306, P1, DOI 10.1016/0167-4781(19)60000-X; Tidow N, 2000, BLOOD, V95, P1451, DOI 10.1182/blood.V95.4.1451.004k52_1451_1455; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; VANBEERS EH, 1995, CRIT REV BIOCHEM MOL, V30, P197, DOI 10.3109/10409239509085143; VERNET C, 1993, J MOL EVOL, V37, P600; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Ye TZ, 2000, GENE, V242, P337, DOI 10.1016/S0378-1119(99)00516-8	74	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18352	18360		10.1074/jbc.M009784200	http://dx.doi.org/10.1074/jbc.M009784200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278568	hybrid			2022-12-27	WOS:000168866500099
J	Boilard, E; Surette, ME				Boilard, E; Surette, ME			Anti-CD3 and concanavalin A-induced human T cell proliferation is associated with an increased rate of arachidonate-phospholipid remodeling - Lack of involvement of group IV and group VI phospholipase A(2) in remodeling and increased susceptibility of proliferating T cells to CoA-independent transacylase inhibitor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PLATELET-ACTIVATING-FACTOR; ACID INCORPORATION; HUMAN NEUTROPHILS; LEUKOTRIENE B-4; LYSOPHOSPHOLIPIDS; BIOSYNTHESIS; MECHANISMS; EXPRESSION; GENERATION	In this study arachidonate-phospholipid remodeling was investigated in resting and proliferating human T lymphocytes. Lymphocytes induced to proliferate with either the mitogen concanavalin A or with anti-CD3 (OKT3) in combination with interleukin 2 (OKT3/IL-2) showed a greatly accelerated rate of [H-3]arachidonate-phospholipid remodeling compared with resting lymphocytes or with lymphocytes stimulated with OKT3 or IL-2 alone. The concanavalin A-stimulated cells showed a 2-fold increase in the specific activity of CoA-independent transacylase compared with unstimulated cells, indicating that this enzyme is inducible. Stimulation with OKT3 resulted in greatly increased quantities of the group VI calcium-independent phospholipase A(2) but not of the quantity of group IV cytosolic phospholipase A(2). However, group IV phospholipase A(2) became phosphorylated in OKT3-stimulated cells, as determined by decreased electrophoretic mobility. Incubation of cells with the group VI phospholipase A(2) inhibitor, bromoenol lactone, or the dual group IV/group VI phospholipase A(2) inhibitor, methyl arachidonyl fluorophosphonate, did not block arachidonate-phospholipid remodeling resting or proliferating T cells, suggesting that these phospholipases A(2) were not involved in arachidonate-phospholipid remodeling. The incubation of nonproliferating human lymphocytes with inhibitors of CoA-independent transacylase had little impact on cell survival. In contrast, OKT3/IL-2-stimulated T lymphocytes were very sensitive to apoptosis induced by CoA-independent transacylase inhibitors. Altogether these results indicate that increased arachidonate-phospholipid remodeling is associated with T cell proliferation and that CoA-independent transacylase may be a novel therapeutic target for proliferative disorders.	Pilot Therapeut Inc, Winston Salem, NC 27103 USA; CHU Quebec, Ctr Rech, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Surette, ME (corresponding author), Pilot Therapeut Inc, 101 N Chestnut St, Winston Salem, NC 27103 USA.	marc.surette@crchul.ulaval.ca	Surette, Marc/AAW-1078-2021					ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; BALSINDE J, 1994, EUR J BIOCHEM, V221, P1013, DOI 10.1111/j.1432-1033.1994.tb18818.x; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burke JR, 1997, BBA-MOL CELL RES, V1359, P80, DOI 10.1016/S0167-4889(97)00094-3; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; CHILTON FH, 1990, METHOD ENZYMOL, V187, P157; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CHILTON FH, 1995, BIOCHEMISTRY-US, V34, P5403, DOI 10.1021/bi00016a011; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; DENHOLM EM, 1991, J IMMUNOL METHODS, V144, P247, DOI 10.1016/0022-1759(91)90092-T; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FONTEH AN, 1992, J IMMUNOL, V148, P1784; Ghomashchi F, 1999, BBA-BIOMEMBRANES, V1420, P45, DOI 10.1016/S0005-2736(99)00056-5; HOLLENBACH PW, 1992, J BIOL CHEM, V267, P39; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MACDONALD JIS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P151, DOI 10.1016/0005-2760(89)90263-4; Markwell M A, 1981, Methods Enzymol, V72, P296; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; SUGIURA T, 1984, FEBS LETT, V165, P273, DOI 10.1016/0014-5793(84)80184-2; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; Surette ME, 1998, FASEB J, V12, P1521, DOI 10.1096/fasebj.12.14.1521; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Surette ME, 1998, BIOCHEM J, V330, P915; TOU JS, 1984, LIPIDS, V19, P573, DOI 10.1007/BF02534713; Trimboli AJ, 1999, CANCER RES, V59, P6171; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; WINKLER JD, 1995, J PHARMACOL EXP THER, V274, P1338; Winkler JD, 1998, MOL PHARMACOL, V53, P322, DOI 10.1124/mol.53.2.322; WINKLER JD, 1994, BBA-LIPID LIPID MET, V1215, P133, DOI 10.1016/0005-2760(94)90102-3; Winkler JD, 1997, BBA-LIPID LIPID MET, V1346, P173, DOI 10.1016/S0005-2760(97)00032-5; Winkler JD, 1996, J PHARMACOL EXP THER, V279, P956; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O	47	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17568	17575		10.1074/jbc.M006152200	http://dx.doi.org/10.1074/jbc.M006152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278296	hybrid			2022-12-27	WOS:000168730400129
J	Englund, GD; Bodnar, RJ; Li, ZY; Ruggeri, ZM; Du, XP				Englund, GD; Bodnar, RJ; Li, ZY; Ruggeri, ZM; Du, XP			Regulation of von Willebrand factor finding to the platelet glycoprotein Ib-IX by a membrane skeleton-dependent inside-out signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID SEQUENCE; FACTOR A1 DOMAIN; CYTOPLASMIC DOMAIN; MONOCLONAL-ANTIBODIES; ARTERY SUBENDOTHELIUM; ALPHA-CHAIN; IIB-IIIA; COMPLEX; ADHESION	The platelet receptor for von Willebrand factor (vWF), glycoprotein Ib-M (GPIb-IX), mediates initial platelet adhesion and activation. We show here that the receptor function of GPIb-IX is regulated intracellularly via its link to the filamin-associated membrane skeleton. Deletion of the filamin binding site in GPIb alpha markedly enhances ristocetin- (or botrocetin)-induced vWF binding and allows GPIb-IX-expressing cells to adhere to immobilized vWF under both static and flow conditions. Cytochalasin D (CD) that depolymerizes actin also enhances vWF binding to wild type GPIb-IX, Thus, VWF binding to GPIb-IX is negatively regulated by the filamin-associated membrane skeleton. In contrast to native vWF, binding of the isolated recombinant vWF Al domain to wild type and filamin binding-deficient mutants of GPIb-IX is comparable, suggesting that the membrane skeleton-associated GPIb-IX is in a state that prevents access to the Al domain in macromolecular vWF, In platelets, there is a balance of membrane skeleton-associated and free forms of GPIb-IX. Treatment of platelets with CD increases the free form and enhances vWF binding. CD also reverses the inhibitory effects of prostaglandin El on vWF binding to GPIb-IX. Thus, GPIb-IX-dependent platelet adhesion is doubly controlled by vWF conformation and a membrane skeleton-dependent inside-out signal.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Scripps Research Institute; Scripps Research Institute	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	xdu@uic.edu			NHLBI NIH HHS [HL52547, HL62350, HL42846, R01 HL062350, HL48728, HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R37HL042846, R29HL052547, P01HL031950, R01HL062350, R01HL042846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; Bodnar RJ, 1999, J BIOL CHEM, V274, P33474, DOI 10.1074/jbc.274.47.33474; BOOTH WJ, 1984, BIOCHEM BIOPH RES CO, V118, P495, DOI 10.1016/0006-291X(84)91330-5; Celikel R, 1997, BLOOD CELL MOL DIS, V23, P123, DOI 10.1006/bcmd.1997.0128; COLLER BS, 1981, BLOOD, V57, P846; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, BLOOD, V70, P985; GEORGE JN, 1988, BLOOD, V71, P1253; GRIGGS TR, 1973, P NATL ACAD SCI USA, V70, P2814, DOI 10.1073/pnas.70.10.2814; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HANDA M, 1986, J BIOL CHEM, V261, P2579; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; PUSZKIN EG, 1990, BLOOD, V76, P1572; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; Ruan C.G., 1986, CHUNG HUA NEI KO TSA, V25, P547; RUAN CG, 1987, BLOOD, V69, P570; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SIXMA JJ, 1984, J CLIN INVEST, V74, P736, DOI 10.1172/JCI111489; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1988, J BIOL CHEM, V263, P18473; WARD CM, 2000, ADV VASC BIOL, V6, P41; Ware J, 1998, THROMB HAEMOSTASIS, V79, P466; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	49	64	66	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16952	16959		10.1074/jbc.M008048200	http://dx.doi.org/10.1074/jbc.M008048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278380	hybrid			2022-12-27	WOS:000168730400047
J	Ashida, N; Arai, H; Yamasaki, M; Kita, T				Ashida, N; Arai, H; Yamasaki, M; Kita, T			Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; RHO; CHEMOKINES; RECEPTOR; KINASE; TRANSDUCTION; FIBRONECTIN; SPECIFICITY; MIGRATION; BINDING	Transmigration of monocytes to the subendothelial space is the initial step of atherosclerotic plaque formation and inflammation. Integrin activation and chemotaxis are two important functions involved in monocyte transmigration. To delineate the signaling cascades leading to integrin activation and chemotaxis by monocyte chemoattractant protein-1 (MCP-1), we have investigated the roles of MAPK and Rho GTPases in THP-1 cells, a monocytic cell line. MCP-1 stimulated beta1 integrin-dependent, but not beta2 integrin-dependent cell adhesion in a time-dependent manner. MCP-1-mediated cell adhesion was inhibited by a MEK inhibitor but not by a p38-MAPK inhibitor. In contrast, MCP-1-mediated chemotaxis was inhibited by the p38-MAPK inhibitor but not by the MEK inhibitor. The inhibitor of Rho GTPase, C3 exoenzyme, and a Rho kinase inhibitor abrogated MCP-1-dependent chemotaxis but not integrin-dependent cell adhesion. Further, C3 exoenzyme and the Rho kinase inhibitor blocked MCP-1-dependent p38-MAPK activation. These data indicate that ERK is responsible for integrin activation, that p38-MAPK and Rho are responsible for chemotaxis mediated by MCP-1, and that Rho and the Rho kinase are upstream of p38-MAPK in MCP-1-mediated signaling. This study demonstrates that two distinct MAPKs regulate two dependent signaling cascades leading to integrin activation and chemotaxis induced by MCP-1 in THP-1 cells.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Arai, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	harai@kuhp.kyoto-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Ayala JM, 2000, J LEUKOCYTE BIOL, V67, P869, DOI 10.1002/jlb.67.6.869; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hippenstiel S, 2000, BLOOD, V95, P3044; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; KNALL C, 1997, P NATL ACAD SCI US; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Numaguchi K, 1999, CIRC RES, V85, P5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Weber KSC, 1999, MOL BIOL CELL, V10, P861, DOI 10.1091/mbc.10.4.861; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	32	161	167	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16555	16560		10.1074/jbc.M009068200	http://dx.doi.org/10.1074/jbc.M009068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278464	hybrid, Green Submitted			2022-12-27	WOS:000168623100131
J	Hasler, U; Crambert, G; Horisberger, JD; Geering, K				Hasler, U; Crambert, G; Horisberger, JD; Geering, K			Structural and functional features of the transmembrane domain of the Na,K-ATPase beta subunit revealed by tryptophan scanning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; NA+-K+-ATPASE; ALPHA-SUBUNIT; MEMBRANE-PROTEINS; INTRACELLULAR-TRANSPORT; SARCOPLASMIC-RETICULUM; DIMERIZATION MOTIF; PRIMARY SEQUENCE; XENOPUS-LAEVIS; HELICES	In oligomeric P2-ATPases such as Na,K- and H,K-ATPases, beta subunits play a fundamental role in the structural and functional maturation of the catalytic alpha subunit. In the present study we performed a tryptophan scanning analysis on the transmembrane alpha -helix of the Na,K-ATPase beta1 subunit to investigate its role in the stabilization of the alpha subunit, the endoplasmic reticulum exit of alpha-beta complexes, and the acquisition of functional properties of the Na,K-ATPase. Single or multiple tryptophan substitutions in the beta subunits transmembrane domain had no significant effect on the structural maturation of alpha subunits expressed in Xenopus oocytes nor on the level of expression of functional Na,K pumps at the cell surface. Furthermore, tryptophan substitutions in regions of the transmembrane alpha -helix containing two GXXXG transmembrane helix interaction motifs or a cysteine residue, which can be cross-linked to transmembrane helix M8 of the alpha subunit, had no effect on the apparent K+ affinity of Na,K-ATPase. On the other hand, substitutions by tryptophan, serine, alanine, or cysteine, but not by phenylalanine of two highly conserved tyrosine residues, Tyr(40) and Tyr(44), on another face of the transmembrane helix, perturb the transport kinetics of Na,K pumps in an additive way. These results indicate that at least two faces of the beta subunits transmembrane helix contribute to inter- or intrasubunit interactions and that two tyrosine residues aligned in the beta subunits transmembrane alpha -helix are determinants of intrinsic transport characteristics of Na,K-ATPase.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch	Crambert, Gilles/ABF-2753-2020; Horisberger, Jean-Daniel/A-2538-2009	Crambert, Gilles/0000-0001-7065-9124				Altendorf K, 1998, ACTA PHYSIOL SCAND, V163, P137; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; BEGUINP, 2000, MOL BIOL CELL, V11, P1657; Bowie JU, 2000, NAT STRUCT BIOL, V7, P91, DOI 10.1038/72454; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; Brosig B, 1998, PROTEIN SCI, V7, P1052; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Geering K, 2000, J MEMBRANE BIOL, V174, P181, DOI 10.1007/s002320001042; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; Hasler U, 2000, J BIOL CHEM, V275, P29011, DOI 10.1074/jbc.M002867200; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; HUANG WH, 1979, BIOCHIM BIOPHYS ACTA, V578, P547, DOI 10.1016/0005-2795(79)90186-7; Ivanov A, 2000, BIOCHEMISTRY-US, V39, P9778, DOI 10.1021/bi001004j; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Okamoto CT, 2000, AM J PHYSIOL-CELL PH, V278, pC727, DOI 10.1152/ajpcell.2000.278.4.C727; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; PICK U, 1982, J BIOL CHEM, V257, P6111; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SCHONER W, 1967, EUR J BIOCHEM, V1, P334, DOI 10.1111/j.1432-1033.1967.tb00078.x; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; SHARP LL, 1995, P NATL ACAD SCI USA, V92, P7946, DOI 10.1073/pnas.92.17.7946; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; Wallin E, 1997, PROTEIN SCI, V6, P808; Wang SG, 1997, AM J PHYSIOL-CELL PH, V272, pC923, DOI 10.1152/ajpcell.1997.272.3.C923; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAU WM, 1998, BIOCHEMISTRY-US, V24, P1377; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	57	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16356	16364		10.1074/jbc.M008778200	http://dx.doi.org/10.1074/jbc.M008778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278434	hybrid			2022-12-27	WOS:000168623100105
J	Estrera, VT; Chen, DT; Luo, WP; Hixson, DC; Lin, SH				Estrera, VT; Chen, DT; Luo, WP; Hixson, DC; Lin, SH			Signal transduction by the CEACAM1 tumor suppressor - Phosphorylation of serine 503 is required for growth-inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN CD66A; HUMAN PROSTATE-CANCER; C-CAM; CYTOPLASMIC DOMAIN; ECTO-ATPASE; DIFFERENTIAL EXPRESSION; COLORECTAL CARCINOMAS; EPITHELIAL-CELLS; PROTEIN-KINASES	CEACAM1 is a cell-cell adhesion molecule that mediates hemophilic cell adhesion. In addition, CEACAM1 was also shown to suppress the growth of prostate, breast, and colon tumors. Structural and functional analyses showed that the adhesion activity of CEACAM1 is mediated by its extracellular domain while its cytoplasmic domain is necessary and sufficient for growth-inhibitory activity. The signal pathways leading to CEACAM1-mediated growth suppression are not known. We studied the importance of phosphorylation of serine 503 in this growth-inhibitory signaling pathway. Full-length CEACAM1 was found to be phosphorylated in vivo in both tyrosine and serine residues. Mutation of tyrosine 488 to phenylalanine did not abolish the tumor-suppressive activity of CEACAM1, suggesting that phosphorylation at tyrosine 488 is not critical for CEACAM1's tumor-suppressive activity. Although expression of CEACAM1's cytoplasmic domain inhibited the growth of DU145 prostate cancer cells in vivo, mutation of serine 503 to alanine abolished the growth-inhibitory activity. Tn addition, the change of serine 503 to aspartic acid produced tumor-suppressive activity similar to that of the wild-type CEACAM1, These results suggested that phosphorylation at serine 503 is essential for CEACAM1's growth inhibitory function in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Ctr Acad & Reading Skills, Houston, TX 77030 USA; Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02906 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Lin, SH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [T32 CA67759, CA16672, CA64856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759, R01CA064856, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1998, AM J PATHOL, V152, P1401; Barinaga M, 1999, SCIENCE, V283, P1247, DOI 10.1126/science.283.5406.1247; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BRUMMER J, 1995, ONCOGENE, V11, P1649; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Estrera VT, 1999, BIOCHEM BIOPH RES CO, V263, P797, DOI 10.1006/bbrc.1999.1443; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Hsieh JT, 1999, PROSTATE, V41, P31; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; Lin SH, 1999, ANTICANCER RES, V19, P337; LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pu YS, 1999, J UROLOGY, V162, P892, DOI 10.1097/00005392-199909010-00085; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; ZHANG WW, 1993, BIOTECHNIQUES, V15, P869	46	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15547	15553		10.1074/jbc.M008156200	http://dx.doi.org/10.1074/jbc.M008156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278391	hybrid			2022-12-27	WOS:000168528800134
J	Masuda, Y; Takahashi, M; Tsunekuni, N; Minami, T; Sumii, M; Miyagawa, K; Kamiya, K				Masuda, Y; Takahashi, M; Tsunekuni, N; Minami, T; Sumii, M; Miyagawa, K; Kamiya, K			Deoxycytidyl transferase activity of the human REV1 protein is closely associated with the conserved polymerase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE GENE; APURINIC ENDONUCLEASE APE1; DAMAGE-INDUCED MUTAGENESIS; THYMINE-THYMINE DIMER; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; CATALYTIC SUBUNIT; MOUSE HOMOLOGS; YEAST	The REV1 protein is a member of the growing family of translesion DNA polymerases. A cDNA of the human REV1 gene that we had originally isolated encoded 1250 amino acids residues, which was one amino acid shorter than previously reported ones. The shorter form of REV1 was named REV1S. All individuals examined expressed equivalent amounts of REV1S and REV1 mRNA, suggesting that the REV1S mRNA is a splicing variant. We show that the REV1S protein also possesses deoxycytidyl transferase activity that inserts a dCMP opposite a DNA template apurinic/apyrimidinic site. Deletion and point mutation analysis of the REV1S protein revealed that the domain required for deoxycytidyl transferase and DNA binding activities of the REV1S protein are located in a conserved domain of translesion DNA polymerases. This result indicates that the structure of the catalytic site of the deoxycytidyl transferase closely resembles that of the translesion DNA polymerases. Therefore, the molecular mechanism of the dCMP transfer reaction of the REV1S protein and maybe also the REV1 protein might be the same as that of the dNTP transfer reaction of the translesion DNA polymerases.	Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Kamiya, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	kkamiya@hiroshima-u.ac.jp	Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988				Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE CW, 1979, GENETICS, V92, P397; LAWRENCE CW, 1985, MOL GEN GENET, V200, P80, DOI 10.1007/BF00383316; LAWRENCE CW, 1978, J MOL BIOL, V122, P1, DOI 10.1016/0022-2836(78)90104-3; Lawrence CW, 1996, CANCER SURV, V28, P21; LAWRENCE CW, 1985, MOL GEN GENET, V200, P86, DOI 10.1007/BF00383317; LEMONTT JF, 1971, GENETICS, V68, P21; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; OHMORI H, 1995, MUTAT RES LETT, V347, P1, DOI 10.1016/0165-7992(95)90024-1; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Roush AA, 1998, MOL GEN GENET, V257, P686; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tissier A, 2000, GENE DEV, V14, P1642; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9	41	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15051	15058		10.1074/jbc.M008082200	http://dx.doi.org/10.1074/jbc.M008082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278384	hybrid			2022-12-27	WOS:000168528800071
J	Mazur, DJ; Perrino, FW				Mazur, DJ; Perrino, FW			Structure and expression of the TREX1 and TREX2 3 '-> 5 ' exonuclease genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; ESCHERICHIA-COLI; 3'-5' EXONUCLEASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; SYNDROME PROTEIN; ACTIVE-SITE; RNASE-T; REPAIR; ENDONUCLEASE	The TREX1 and TREX2 genes encode mammalian 3'-->5' exonucleases. Expression of the TREX genes in human cells was investigated using a reverse transcription-polymerase chain reaction strategy. Our results show that TREX1 and TREX2 are expressed in all tissues tested, providing direct evidence for the expression of these genes in human cells. Potential transcription start sites are identified for the TREX genes using rapid amplification of cDNA ends to recover the 5'-flanking regions of the TREX transcripts. The 5'-flanking sequences indicate transcription initiation from consensus putative promoters identified -140 and -650 base pairs upstream of the TREX1 open reading frame (ORF) and -623 and -753 base pairs upstream of the TREX2 ORF. Novel TREX1 and TREX2 cDNAs are identified that contain protein-coding sequences generated from exons positioned in genomic DNA up to 18 kilobases 5' to the TREX1 ORF and up to 25 kilobases 5' to the TREX2 ORF. These novel cDNAs and sequences in the GenBank(TM) data base indicate that transcripts containing the TREX1 and TREX2 ORFs are produced using a variety of mechanisms that include alternate promoter usage, alternative splicing, and varied sites for 3' cleavage and polyadenylation. These initial studies have revealed previously unrecognized complexities in the structure and expression of the TREX1 and TREX2 genes.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Perrino, FW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA75350, CA12197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA075350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIMURA M, 1993, GENETICS, V133, P51; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ito J, 1998, MOL MICROBIOL, V27, P235, DOI 10.1046/j.1365-2958.1998.00673.x; KESTI T, 1993, J BIOL CHEM, V268, P10238; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2521, DOI 10.1093/nar/21.10.2521; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; LIZARDI PM, 1983, METHOD ENZYMOL, V96, P24; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; THELEN MP, 1994, J BIOL CHEM, V269, P747; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Viswanathan M, 1999, J BIOL CHEM, V274, P30094, DOI 10.1074/jbc.274.42.30094; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	47	58	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14718	14727		10.1074/jbc.M010051200	http://dx.doi.org/10.1074/jbc.M010051200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278605	hybrid			2022-12-27	WOS:000168528800027
J	Yasui, H; Katoh, H; Yamaguchi, Y; Aoki, J; Fujita, H; Mori, K; Negishi, M				Yasui, H; Katoh, H; Yamaguchi, Y; Aoki, J; Fujita, H; Mori, K; Negishi, M			Differential responses to nerve growth factor and epidermal growth factor in neurite outgrowth of PC12 cells are determined by Rac1 activation systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; KINASE ACTIVATION; PROTEIN-KINASE; GUANOSINE TRIPHOSPHATASES; PHEOCHROMOCYTOMA CELLS; HUMAN NEUTROPHILS; RAS; BINDING; RHO; GTPASES	Neurite outgrowth of PC12 cells is induced by nerve growth factor (NGF) but not by epidermal growth factor (EGF). This differential response has been explained by the duration of mitogen-activated protein kinase (MAPK) activation; NGF induces sustained MAPK activation but EGF leads short-lived activation. However, precise mechanisms have not yet been understood. Here we demonstrate the difference between NGF and EGF in regulation of Rad, a small GTPase involved in neurite outgrowth, in PC12 cells. NGF phosphoinositide 3-kinase dependently induces transient activation of Rad and accumulation of active Rad at protrusion sites on the cell surface, inducing filamentous actin-rich protrusions and subsequent neurite formation in a Rac1-dependent manner. On the other hand, EGF phosphoinositide 3-kinase independently induces more transient Rad activation but neither accumulates active Rad nor forms Rac1- and filamentous actin-rich protrusions. Difference in the Rad localization between NGF and EGF was also observed with the localization of exogenously expressed green fluorescent protein-tagged Rad. The Rad-mediated protrusion by NGF is independent of MAPK cascade, but the subsequent neurite extension requires the cascade. Thus, the differential activation of Rad and localization of active Rad contribute to the difference in the ability of NGF and EGF to induce neurite outgrowth, and we propose that the MAPK cascade independent prompt activation of Rad and recruitment of active Rad at the protrusion sites trigger the initiation of neurite formation.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.		Yamaguchi, Yoshiaki/K-9418-2013	Yamaguchi, Yoshiaki/0000-0003-4126-542X				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; CONNOLLY JL, 1979, J CELL BIOL, V82, P820, DOI 10.1083/jcb.82.3.820; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hasegawa H, 1999, J BIOL CHEM, V274, P20982, DOI 10.1074/jbc.274.30.20982; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Jackson TR, 1996, J CELL SCI, V109, P289; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Lamoureux P, 1997, J CELL SCI, V110, P635; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERILAINEN J, 1993, J CELL SCI, V105, P647; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAVES H, 1988, FEBS LETT, V235, P141, DOI 10.1016/0014-5793(88)81250-X; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	37	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15298	15305		10.1074/jbc.M008546200	http://dx.doi.org/10.1074/jbc.M008546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278419	hybrid			2022-12-27	WOS:000168528800103
J	Manickan, E; Satoi, JJ; Wang, TC; Liang, TJ				Manickan, E; Satoi, JJ; Wang, TC; Liang, TJ			Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; MAMMALIAN-CELLS; IN-VIVO; HEPATOCARCINOGENESIS; CARCINOGENESIS; DOXYCYCLINE; PROTEINS; SYSTEM	Adaptive epigenetic changes and toxicity often accompany constitutive expression of a transgene or knockout of an endogenous gene in mice. These considerations potentially limit the usefulness of transgenic technology in studying the in vivo functions of a gene. Using conditional gene expression technology, it is possible to override such restrictions to achieve temporal and tissue-specific manipulation of gene expression in vivo. Based on the tetracycline regulatory system, we established a binary transgenic model in which the conditional expression of two transgenes, SV40 T antigen (TAg) and lacZ, can be tightly regulated in the liver by administration of tetracycline. The mouse albumin or mouse major urinary protein promoter was used to achieve liver-specific expression of the tetracycline-responsive transcriptional activator (tTA) in one set of transgenic mice. These mice were crossed with transgenic mice carrying either TAg or lacZ under the control of the tTA-regulated promoter. Analyses of mice transgenic for both tTA and TAg (or lacZ) revealed that the liver-specific expression of the transgenes could be suppressed to undetectable levels and regulated in a reversible fashion by tetracycline administration and withdrawal. Mice with tTA and TAg transgenes developed hepatocellular adenomas and hyperplasia that could be prevented by continuous tetracycline administration. Our report demonstrates the value of this binary transgenic model in studying the physiological functions of any potential genes of interest in a liver-specific manner.	NIDDK, Liver Dis Sect, DDB, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Liang, TJ (corresponding author), NIDDK, Liver Dis Sect, DDB, NIH, Bldg 10,Rm 9B16,10 Ctr Dr MSC 1800, Bethesda, MD 20892 USA.	JakeL@bdg10.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054504, ZIADK054504, Z01DK054502, Z01DK054505, Z01DK054501, ZIADK054505] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agha-Mohammadi S, 2000, J CLIN INVEST, V105, P1177, DOI 10.1172/JCI10027; ARAKI K, 1991, CARCINOGENESIS, V12, P2059, DOI 10.1093/carcin/12.11.2059; BENNOUN M, 1993, AM J PATHOL, V143, P1326; CULLEN JM, 1993, VET PATHOL, V30, P111, DOI 10.1177/030098589303000203; DERMAN E, 1981, P NATL ACAD SCI-BIOL, V78, P5425, DOI 10.1073/pnas.78.9.5425; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HINO O, 1991, JPN J CANCER RES, V82, P1226, DOI 10.1111/j.1349-7006.1991.tb01785.x; Hogan B, 1994, MANIPULATING MOUSE E; Jamieson BD, 1999, AIDS, V13, pS5; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kranias EG, 2000, ANNU REV PHYSIOL, V62, P965, DOI 10.1146/annurev.physiol.62.1.965; Li LP, 1997, HUM GENE THER, V8, P1695, DOI 10.1089/hum.1997.8.14-1695; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SANDGREN EP, 1989, ONCOGENE, V4, P715; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; Serguera C, 1999, HUM GENE THER, V10, P375, DOI 10.1089/10430349950018823; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; Sigmund CD, 2000, ARTERIOSCL THROM VAS, V20, P1425, DOI 10.1161/01.ATV.20.6.1425; Sundstrom L, 1998, APMIS, V106, P37; Sutherland HGE, 2000, MAMM GENOME, V11, P347, DOI 10.1007/s003350010066; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239	33	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13989	13994		10.1074/jbc.M009770200	http://dx.doi.org/10.1074/jbc.M009770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278564	hybrid			2022-12-27	WOS:000168356600067
J	Yakubenko, VP; Solovjov, DA; Zhang, L; Yee, VC; Plow, EF; Ugarova, TP				Yakubenko, VP; Solovjov, DA; Zhang, L; Yee, VC; Plow, EF; Ugarova, TP			Identification of the binding site for fibrinogen recognition peptide gamma 383-395 within the I-alpha(M)-domain of integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; LEUKOCYTE ADHESION DEFICIENCY; I-DOMAIN; A-DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; DIVALENT-CATION; CR3 CD11B/CD18; GAMMA-CHAIN; CONFORMATIONAL-CHANGES	The leukocyte integrin alpha (M)beta (2) (Mac-1, CD11b/CD18) is a cell surface adhesion receptor for fibrinogen. The interaction between fibrinogen and alpha (M)beta (2) mediates a range of adhesive reactions during the immune-inflammatory response. The sequence gamma (383)TMKIIPFNRLTIG(395), P2-C, within the gamma -module of the D-domain of fibrinogen, is a recognition site for alpha (M)beta (2) and alpha (x)beta (2). We have now identified the complementary sequences within the alpha I-M-domain of the receptor responsible for recognition of P2-C, The strategy to localize the binding site for P2-C was based on distinct P2-C binding properties of the three structurally similar I-domains of alpha (M)beta (2), alpha (X)beta (2), and alpha (L)beta (2) i.e. the alpha I-M-. and alpha I-X-domains bind P2-C, and the alpha I-L-domain did not bind this ligand. The Lys(245)-Arg(261) sequence, which forms a loop betaD-alpha5 and an adjacent helix alpha5 in the three-dimensional structure of the alpha I-M-domain, was identified as the binding site for P2-C. This conclusion is supported by the following data: 1) mutant cell lines in which the alpha I-M-domain segments (245)KFG and Glu(253)-Arg(261) were switched to the homologous alpha I-L-domain segments failed to support adhesion to P2-C; 2) synthetic peptides duplicating the Lys(245)-Tyr(252) and Glu(253)-Arg(261) sequences directly bound the D fragment and P2-C derivative, gamma 384-402, and this interaction was blocked efficiently by the P2-C peptide; 3) mutation of three amino acid residues within the Lys245-Arg261 segment, Phe(246), Asp(254), and Pro(257), resulted in the loss of the binding function of the recombinant alpha I-M-domains; and 4) grafting the alpha (M) (Lys(245)-Arg(261)) Segment into the alpha I-L-domain converted it to a P2-C-binding protein. These results demonstrate that the alpha (M)(Lys(245)-Arg(261)) segment, a site of the major sequence and structure difference among alpha I-M-, alpha I-X-, and alpha I-L-domains, is responsible for recognition of a small segment of fibrinogen, gamma Thr(383)-Gly(395), by serving as ligand binding site.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA	Cleveland Clinic Foundation; American Red Cross	Ugarova, TP (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924, R01HL061589, R01HL063199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54924, HL-63199, R01 HL061589] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1985, FED PROC, V44, P2671; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; DeGrado WF, 1999, ANNU REV BIOCHEM, V68, P779, DOI 10.1146/annurev.biochem.68.1.779; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; MATSUEDA GR, 1988, FIBRINOGEN, V3, P133; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Plescia J, 1998, J BIOL CHEM, V273, P20372, DOI 10.1074/jbc.273.32.20372; PROCYK R, 1991, BLOOD, V77, P1469; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Sriramarao P, 1996, BLOOD, V88, P3416, DOI 10.1182/blood.V88.9.3416.bloodjournal8893416; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; UGAROVA TP, 2001, IN PRESS ANN NY ACAD; VALENZUELA R, 1992, AM J PATHOL, V141, P861; WU XB, 1994, J CLIN INVEST, V94, P928, DOI 10.1172/JCI117459; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	46	58	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13995	14003		10.1074/jbc.M010174200	http://dx.doi.org/10.1074/jbc.M010174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278633	hybrid			2022-12-27	WOS:000168356600068
J	Zhao, FY; Li, P; Chen, SRW; Fruen, BR				Zhao, FY; Li, P; Chen, SRW; Fruen, BR			Dantrolene inhibition of ryanodine receptor Ca2+ release channels - Molecular mechanism and isoform selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; FROG SKELETAL-MUSCLE; CENTRAL CORE DISEASE; MALIGNANT HYPERTHERMIA; CALCIUM-RELEASE; CELL-DEATH; CAFFEINE; SODIUM; IDENTIFICATION; PHARMACOLOGY	As an inhibitor of Ca2+ release through ryanodine receptor (RYR) channels, the skeletal muscle relaxant dantrolene has proven to be both a valuable experimental probe of intracellular Ca2+ signaling and a lifesaving treatment for the pharmacogenetic disorder malignant hyperthermia. However, the molecular basis and specificity of the actions of dantrolene on RYR channels have remained in question. Here we utilize [H-3]ryanodine binding to further investigate the actions of dantrolene on the three mammalian RME isoforms. The inhibition of the pig skeletal muscle RYR1 by dantrolene (10 muM) was associated with a 3-foId increase in the K-d of [H-3]ryanodine binding to sarcoplasmic reticulum (SR) vesicles such that dantrolene effectively reversed the 3-fold decrease in the K-d for [H-3]ryanodine binding resulting from the malignant hyperthermia RYR1 Arg(615) --> Cys mutation. Dantrolene inhibition of the RYR1 was dependent on the presence of the adenine nucleotide and calmodulin and reflected a selective decrease in the apparent affinity of RYR1 activation sites for Ca2+ relative to Mg2+. In contrast to the RYR1 isoform, the cardiac RYR2 isoform was unaffected by dantrolene, both in native cardiac SR vesicles and when heterologously expressed in HEK-293 cells. By comparison, the RYR3 isoform expressed in HEK-293 cells was significantly inhibited by dantrolene, and the extent of RYR3 inhibition was similar to that displayed by the RYR1 in native SR vesicles. Our results thus indicate that both the RYR1 and the RYR3, but not the RYR2, may be targets for dantrolene inhibition in vivo.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Calgary; University of Minnesota System; University of Minnesota Twin Cities	Fruen, BR (corresponding author), 6-155 Jackson Hall,321 church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31382] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRITT BA, 1984, CAN ANAESTH SOC J, V31, P130, DOI 10.1007/BF03015252; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; ELLIS KO, 1976, ARCH INT PHARMACOD T, V224, P118; FLEWELLEN EH, 1983, ANESTHESIOLOGY, V59, P275, DOI 10.1097/00000542-198310000-00002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fruen BR, 2000, AM J PHYSIOL-CELL PH, V279, pC724, DOI 10.1152/ajpcell.2000.279.3.C724; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HAINAUT K, 1974, NATURE, V252, P728, DOI 10.1038/252728a0; Herrmann-Frank A, 1999, J MUSCLE RES CELL M, V20, P223, DOI 10.1023/A:1005496708505; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; Lacampagne A, 1998, J GEN PHYSIOL, V111, P207, DOI 10.1085/jgp.111.2.207; LAMB GD, 1992, NEWS PHYSIOL SCI, V7, P270; Laver DR, 1997, J MEMBRANE BIOL, V156, P213, DOI 10.1007/s002329900202; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; Liu W, 1998, AM J PHYSIOL-CELL PH, V274, pC120, DOI 10.1152/ajpcell.1998.274.1.C120; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; Mattson MP, 2000, J NEUROSCI, V20, P1358; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; MORGAN KG, 1977, J PHARMACOL EXP THER, V201, P138; Murayama T, 2000, BIOPHYS J, V78, P1810, DOI 10.1016/S0006-3495(00)76731-2; OHTA T, 1990, EUR J PHARMACOL, V178, P11; Palnitkar SS, 1999, J MED CHEM, V42, P1872, DOI 10.1021/jm9805079; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Pelletier MR, 1999, J NEUROPHYSIOL, V81, P3054, DOI 10.1152/jn.1999.81.6.3054; Pessah IN, 1996, ANESTHESIOLOGY, V84, P1275, DOI 10.1097/00000542-199606000-00001; SHOMER NH, 1994, AM J PHYSIOL-CELL PH, V267, pC1253, DOI 10.1152/ajpcell.1994.267.5.C1253; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tong JF, 1999, BIOCHEM J, V343, P39, DOI 10.1042/0264-6021:3430039; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; WARD A, 1986, DRUGS, V32, P130, DOI 10.2165/00003495-198632020-00003; WEDEL DJ, 1995, MAYO CLIN PROC, V70, P241, DOI 10.4065/70.3.241; Wei HF, 1996, J NEUROCHEM, V67, P2390; Xu L, 1998, ANN NY ACAD SCI, V853, P130; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; Zucchi R, 1997, PHARMACOL REV, V49, P1	42	233	244	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13810	13816		10.1074/jbc.M006104200	http://dx.doi.org/10.1074/jbc.M006104200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278295	hybrid			2022-12-27	WOS:000168356600044
J	Berger, J; Tanen, M; Elbrecht, A; Hermanowski-Vosatka, A; Moller, DE; Wright, SD; Thieringer, R				Berger, J; Tanen, M; Elbrecht, A; Hermanowski-Vosatka, A; Moller, DE; Wright, SD; Thieringer, R			Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11 beta-hydroxysteroid dehydrogenase type 1 expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY-FAT DISTRIBUTION; PPAR-GAMMA; INSULIN-SENSITIVITY; GENE-EXPRESSION; ALPHA; DIFFERENTIATION; ADIPOGENESIS; OBESITY; LEPTIN; THIAZOLIDINEDIONE	Peroxisome proliferator-activated receptor-gamma (PPAR gamma) has been shown to play an important role in the regulation of expression of a subclass of adipocyte genes and to serve as the molecular target of the thiazolidinedione (TZD) and certain non-TZD antidiabetic agents. Hypercorticosteroidism leads to insulin resistance, a variety of metabolic dysfunctions typically seen in diabetes, and hypertrophy of visceral adipose tissue, In adipocytes, the enzyme 11 beta -hydroxysteroid dehydrogenase type 1 (11 beta -HSD-1) converts inactive cortisone into the active glucocorticoid cortisol and thereby plays an important role in regulating the actions of corticosteroids in adipose tissue. Here, we show that both TZD and non-TZD PPAR gamma agonists markedly reduced 11 beta -HSD-1 gene expression in 3T3-L1 adipocytes, This diminution correlated with a significant decrease in the ability of the adipocytes to convert cortisone to cortisol, The half-maximal inhibition of 11 beta -HSD-1 mRNA expression by the TZD, rosiglitazone, occurred at a concentration that was similar to its K, for binding PPAR gamma and EC, for inducing adipocyte differentiation thereby indicating that this action was PPAR gamma -dependent, The time required for the inhibitory action of the TZD was markedly greater for 11 beta -HSD-1 gene expression than for leptin, suggesting that these genes may be down-regulated by different molecular mechanisms. Furthermore, whereas regulation of PPAR gamma -inducible genes such as phosphoenolpyruvate carboxykinase was maintained when cellular protein synthesis was abrogated, PPAR gamma agonist inhibition of 11 beta -HSD-1 and leptin gene expression was ablated, thereby supporting the conclusion that PPAR gamma affects the down-regulation of 11 beta -HSD-1 indirectly. Finally, treatment of diabetic db/db mice with rosiglitazone inhibited expression of 11 beta -HSD-1 in adipose tissue. This decrease in enzyme expression correlated with a significant decline in plasma corticosterone levels. In sum, these data indicate that some of the beneficial effects of PPAR gamma antidiabetic agents may result, at least in part, from the down-regulation of 11 beta -HSD-1 expression in adipose tissue.	Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Berger, J (corresponding author), Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Mol Endocrinol, RY80N-C31,126 E Lincoln Ave, Rahway, NJ 07065 USA.	joel_berger@merck.com						Andrews RC, 1999, CLIN SCI, V96, P513, DOI 10.1042/cs0960513; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; BJORNTORP P, 1991, J INTERN MED, V230, P195; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; CHAPMAN AB, 1985, J CELL BIOL, V101, P1227, DOI 10.1083/jcb.101.4.1227; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Despres JP, 1999, CONT ENDOCRINOL, V12, P51; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Hermanowski-Vosatka A, 2000, BIOCHEM BIOPH RES CO, V279, P330, DOI 10.1006/bbrc.2000.3966; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; JONES PS, 1995, EUR J BIOCHEM, V233, P219, DOI 10.1111/j.1432-1033.1995.219_1.x; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kawai T, 1999, METABOLISM, V48, P1102, DOI 10.1016/S0026-0495(99)90122-1; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; Kissebah AH, 1997, DIABETES REV, V5, P8; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MAYOSMITH W, 1989, RADIOLOGY, V170, P515, DOI 10.1148/radiology.170.2.2911678; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mori Y, 1999, DIABETES CARE, V22, P908, DOI 10.2337/diacare.22.6.908; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; REAVEN GM, 1987, LANCET, V2, P435; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; RINGOLD GM, 1986, ANN NY ACAD SCI, V478, P109, DOI 10.1111/j.1749-6632.1986.tb15525.x; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stewart PM, 1999, VITAM HORM, V57, P249; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155; Wang Q, 1997, BRIT J PHARMACOL, V122, P1405, DOI 10.1038/sj.bjp.0701535; Xing GQ, 1995, BIOCHEM BIOPH RES CO, V217, P1015, DOI 10.1006/bbrc.1995.2871; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	47	175	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12629	12635		10.1074/jbc.M003592200	http://dx.doi.org/10.1074/jbc.M003592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278270	hybrid			2022-12-27	WOS:000168198600023
J	Mohapatra, S; Pledger, WJ				Mohapatra, S; Pledger, WJ			Interdependence of cdk2 activation and Interleukin-2R alpha accumulation in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; IL-2 RECEPTOR; GAMMA-CHAIN; TRANSCRIPTION FACTOR; MESSENGER-RNA; GROWTH-FACTOR; EXPRESSION; LYMPHOCYTES; P27(KIP1); INHIBITOR	We have shown previously that serum promotes T cell proliferation by acting with T cell receptor (TCR) agonists to efficiently down-regulate p27(Kip1) and activate cdk2-containing complexes. In the studies described here, the effect of serum on the expression of the alpha subunit of the interleukin-2 receptor (IL-2R alpha) was examined. We found that serum was required for maximal and sustained IL-2R alpha protein expression and consequent IL-2 signaling in TCR-activated splenocytes. Serum had no effect on IL-2R alpha mRNA levels and thus modulates IL-2R alpha expression post-transcriptionally. Unlike wild-type splenocytes, splenocytes exhibiting serum-independent cdk2 activation due to loss of p27(Kip1) efficiently expressed IL-2R alpha in serum-deficient medium. Conversely, serum did not promote IL-2R alpha accumulation in conditions in which cdk2 activity was blocked. These findings demonstrate that cdk2 activation is necessary and sufficient for IL-2R alpha accumulation in TCR-stimulated splenocytes. On the other hand, IL-2 signaling was required (at least in part) for cdk2 activation in these cells. Thus, cdk2 activation, IL-2R alpha expression, and IL-2 signaling are interdependent events, and we suggest that this feed-forward regulatory loop plays a key role in T cell mitogenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Mohapatra, Subhra/A-1381-2012		NATIONAL CANCER INSTITUTE [R01CA067360, R01CA072694] Funding Source: NIH RePORTER; NCI NIH HHS [CA67360, CA72694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BISMUTH G, 1985, EUR J IMMUNOL, V15, P723, DOI 10.1002/eji.1830150716; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; CANTRELL DA, 1983, J EXP MED, V158, P1895, DOI 10.1084/jem.158.6.1895; CERDAN C, 1992, J IMMUNOL, V149, P2255; Chastagner P, 1996, EUR J IMMUNOL, V26, P201, DOI 10.1002/eji.1830260131; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GILLIS S, 1977, J EXP MED, V146, P468, DOI 10.1084/jem.146.2.468; HERZBERG VL, 1987, J IMMUNOL, V139, P998; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Karnitz LM, 1996, ADV IMMUNOL, V61, P147, DOI 10.1016/S0065-2776(08)60867-6; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; Kwon TK, 1997, J IMMUNOL, V158, P5642; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; MALEK TR, 1985, J EXP MED, V161, P1575, DOI 10.1084/jem.161.6.1575; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEUER SC, 1984, P NATL ACAD SCI-BIOL, V81, P1509, DOI 10.1073/pnas.81.5.1509; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; MODIANO JF, 1994, J BIOL CHEM, V269, P32972; Modiano JF, 1995, ANN NY ACAD SCI, V766, P134, DOI 10.1111/j.1749-6632.1995.tb26657.x; Mohapatra S, 2001, J BIOL CHEM, V276, P21976, DOI 10.1074/jbc.M009788200; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OSAWA H, 1986, J IMMUNOL METHODS, V92, P109, DOI 10.1016/0022-1759(86)90510-7; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; WEINBERG AD, 1990, J IMMUNOL, V144, P4712; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	43	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21984	21989		10.1074/jbc.M100037200	http://dx.doi.org/10.1074/jbc.M100037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274205	hybrid			2022-12-27	WOS:000169297900154
J	Zeibdawi, AR; Pryzdial, ELG				Zeibdawi, AR; Pryzdial, ELG			Mechanism of factor Va inactivation by plasmin - Loss of A2 and A3 domains from a Ca2+-dependent complex of fragments bound to phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; BOVINE FACTOR-V; THROMBIN-CATALYZED ACTIVATION; C-TYPE DOMAIN; BINDING-SITE; FACTOR-XA; FACTOR-VIII; PARTIAL GLYCOSYLATION; PLATELET SURFACE; PROTEIN-C	The coagulation cofactor Va (FVa) is a noncovalent heterodimer consisting of a heavy chain (FVaH) and a light chain (FVaL), Previously, the fibrinolytic effector plasmin (Pn) has been shown to inhibit FVa function. To understand this mechanism, the fragmentation profile of human FVa by Pn and the noncovalent association of the derived fragments were determined in the presence of Ca2+ using anionic phospholipid (aPL)-coated microtiter wells and large (1 mum) aPL micelles as affinity matrices. Following Pn inactivation of aPL-bound FVa, a total of 16 fragments were observed and their NH, termini sequenced. These had apparent molecular weights and starting residues as follows (single letter abbreviation is used): 50(L1766), 48(L1766), 43(Q1828), 46(Q1828), 30(S1546), 12(T1657), and 7(S1546) kDa from FVaL; and 65(A1), 50(A1), 45(A1), 34(S349), 30(L94), 30(M110), and 3 small <5(W457, W457, and K365) kDa from FVaH. Of these, 50(L1766), 48(1766), 43(Q1828), and 40(Q1828) spanning the C1/C2 domains, and 30(L94), but not the similar 30(M110), positioned within the A1 domain remained associated with aPL. These were detected antigenically during Pn- or tissue plasminogen activator-mediated lysis of fibrin clot formed in plasma. Chelation by EDTA dissociated the 30(L94)-kDa fragment, which was observed to associate with intact FVaL upon recalcification, indicating that the Leu-94 to Lys-109 region of the A1 domain plays a critical role in the FVaL and FVaH Ca2+ dependent association. By using domain-specific monoclonal antibodies and an assay for thrombin generation, loss of FVa prothrombinase function was coincident with proteolysis at sites in the A2 and A3 domains resulting in their dissociation. Inactivation of FV or FVa by Pn was independent of the thrombophilic R506Q mutation. These results identify the molecular composition of Pn-cleaved FVa that remains bound to membrane as largely A1-C1/C2 in the presence of Ca2+ and suggest that Pn inhibits FVa by a process involving A2 and A3 domain dissociation.	Canadian Blood Serv, Dept Res & Dev, Ottawa, ON K1G 4J5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1G 4J5, Canada	Canadian Blood Services; University of Ottawa	Pryzdial, ELG (corresponding author), Canadian Blood Serv, Dept Res & Dev, 1800 Alta vista Dr, Ottawa, ON K1G 4J5, Canada.	ed.pryzdial@bloodservices.ca						Bajzar L, 1996, J BIOL CHEM, V271, P22949, DOI 10.1074/jbc.271.38.22949; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BEVERS EM, 1982, EUR J BIOCHEM, V122, P81, DOI 10.1111/j.1432-1033.1982.tb05850.x; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; ESMON CT, 1979, J BIOL CHEM, V254, P964; EWALD GA, 1995, CIRCULATION, V91, P28, DOI 10.1161/01.CIR.91.1.28; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HIBBARD LS, 1980, J BIOL CHEM, V255, P638; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; Hoekema L, 1997, BIOCHEMISTRY-US, V36, P3331, DOI 10.1021/bi9623284; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALAFATIS M, 1997, THROMB HAEMOSTASIS S, V6, P615; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; Koppaka V, 1997, BIOPHYS J, V73, P2638, DOI 10.1016/S0006-3495(97)78293-6; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LAAKE K, 1974, THROMB RES, V5, P759, DOI 10.1016/0049-3848(74)90119-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Mann K.G., 1987, THROMB DIATH HAEMO, P505; MANN KG, 1984, J BIOL CHEM, V259, P2949; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; Nicolaes GAF, 1999, BIOCHEMISTRY-US, V38, P13584, DOI 10.1021/bi991165r; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; OMAR MN, 1987, J BIOL CHEM, V262, P9750; ORTEL TL, 1994, J BIOL CHEM, V269, P15898; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; OSTERUD B, 1975, THROMB DIATH HAEMOST, V33, P553, DOI 10.1055/s-0038-1647849; PACKHAM MA, 1984, BLOOD PLATELET FUNCT, P61; Pellequer JL, 1999, THROMB HAEMOSTASIS, P34; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; Pryzdial ELG, 1999, J BIOL CHEM, V274, P8500, DOI 10.1074/jbc.274.13.8500; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P17871, DOI 10.1074/jbc.270.30.17871; RICK ME, 1986, BLOOD, V67, P1649; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; ROSING J, 1993, J BIOL CHEM, V268, P21130; Samis JA, 2000, BLOOD, V95, P943, DOI 10.1182/blood.V95.3.943.003k34_943_951; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; Tracy RP, 1997, J AM COLL CARDIOL, V30, P716, DOI 10.1016/S0735-1097(97)00230-1; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607; YUEN SW, 1989, BIOTECHNIQUES, V7, P74; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	60	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19929	19936		10.1074/jbc.M004711200	http://dx.doi.org/10.1074/jbc.M004711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278280	hybrid			2022-12-27	WOS:000169135100034
J	Seger, D; Seger, R; Shaltiel, S				Seger, D; Seger, R; Shaltiel, S			The CK2 phosphorylation of vitronectin - Promotion of cell adhesion via the alpha(v)beta(3)-phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ECTOPROTEIN KINASE-ACTIVITY; DEPENDENT PROTEIN-KINASE; HUMAN-MELANOMA CELLS; SIGNAL-TRANSDUCTION; INTEGRIN ALPHA(V)BETA(3); EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; BIOLOGICAL ROLE; FACTOR-VA	Phosphorylation of vitronectin (Vn) by casein kinase II was previously shown to occur at Thr(50) and Thr(57) and to augment a major physiological function of vitronectin-cell adhesion and spreading. Here we show that this phosphorylation increases cell adhesion via the alpha (V)beta (3) (not via the alpha (V)beta (5) integrin), suggesting that alpha (V)beta (3) differs from alpha (V)beta (3) in its biorecognition profile. Although both the phospho (CK2-PVn) and non-phospho (Vn) analogs of vitronectin (simulated by mutants Vn(T50E,T57E), and Vn(T50A,T57A), respectively) trigger the alpha (V)beta (3) as well as the alpha (V)beta (5) integrins, and equally activate the ERK pathway, these two forms are different in their activation of the focal adhesion kinase/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway. Specifically, we show (i) that, upon exposure of cells to Vn/CK2-PVn, their PKB activation depends on the availability of the alpha (V)beta (3) integrin on their surface; (ii) that upon adhesion of the beta (3)-transfected cells onto the CK2-PVn, the extent of PKB activation coincides with the enhanced adhesion of these cells, and (iii) that both the PKB activation and the elevation in the adhesion of these cells is PI3K-dependent, The occurrence of a cell surface receptor that specifically distinguishes between a phosphorylated and a non-phosphorylated analog of Vn, together with the fact that it preferentially activates a distinct intra-cellular signaling pathway, suggest that extra-cellular CK2 phosphorylation may play an important role in the regulation of cell adhesion and migration.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaltiel, S (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	shmuel.shaltiel@weizmann.ac.il						BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN C, 1991, J INVEST DERMATOL, V96, P724, DOI 10.1111/1523-1747.ep12470960; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUSENBERY KE, 1988, BIOCHEM BIOPH RES CO, V153, P7, DOI 10.1016/S0006-291X(88)81182-3; ERIKSSON S, 1993, THROMB RES, V72, P315, DOI 10.1016/0049-3848(93)90140-J; Gechtman Z, 1997, EUR J BIOCHEM, V243, P493, DOI 10.1111/j.1432-1033.1997.0493a.x; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; KALAFATIS M, 1993, BLOOD, V81, P704; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOHRI H, 1991, AM J CLIN PATHOL, V96, P605, DOI 10.1093/ajcp/96.5.605; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; RAND MD, 1994, BLOOD, V83, P2180; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T; SHALTIEL S, 1993, MOL CELL BIOCHEM, V128, P283, DOI 10.1007/BF01076778; SHALTIEL S, 1993, INT CONGR SER, V1042, P311; SIGURDARDOTTIR O, 1990, BIOCHIM BIOPHYS ACTA, V1035, P56, DOI 10.1016/0304-4165(90)90173-T; SKUBITZ KM, 1992, CELL MOL BIOL, V38, P543; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9	61	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16998	17006		10.1074/jbc.M003766200	http://dx.doi.org/10.1074/jbc.M003766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278271	hybrid			2022-12-27	WOS:000168730400053
J	Ching, TT; Hsu, AL; Johnson, AJ; Chen, CS				Ching, TT; Hsu, AL; Johnson, AJ; Chen, CS			Phosphoinositide 3-kinase facilitates antigen-stimulated Ca2+ influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5-trisphosphate-sensitive Ca2+ entry mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; PLECKSTRIN HOMOLOGY DOMAINS; HIGH-AFFINITY RECEPTOR; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; LIPID PRODUCTS; IGE RECEPTOR; PI 3-KINASE; ACTIVATION; PROTEIN; SECRETION	This study presents evidence that phosphoinositide 3-kinase (PI3K) plays a concerted role with phospholipase C gamma in initiating antigen-mediated Ca2+ signaling in mast cells via a phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3)-sensitive Ca2+ entry pathway. Exogenous PI(3,4,5)P-3 at concentrations close to its physiological level induces instantaneous Ca2+ influx into RBL-2H3 cells. This PI(3,4,5)P-3-induced intracellular Ca2+ increase is independent of phospholipase C activity or the depletion of internal stores. Moreover, inhibition of PI3K by LY294002 or by overexpression of the dominant negative inhibitor Delta p85 suppresses the Ca2+ response to the cross-linking of the high affinity receptor for IgE (Fc epsilon RI). Concomitant treatment of RBL-2H3 cells with LY294002 or Delta p85 and 2-aminoethyl diphenylborate, a cell-permeant antagonist of D-myo-inositol 1,4,5-trisphosphate receptors, abrogates antigen-induced Ca2+ signals, whereas either treatment alone gives rise to partial inhibition. Conceivably, PI(3,4,5)P-3-sensitive Ca2+ entry and capacitative Ca2+ entry represent major Ca2+ influx pathways that sustain elevated [Ca2+](i) to achieve optimal physiological responses. This study also refutes the second messenger role of D-myo-inositol 1,3,4,5-tetrakisphosphate in regulating Fc epsilon RI-mediated Ca2+ response. Considering the underlying mechanism, our data suggest that PI(3,4,5)P-3 directly stimulates a Ca2+ transport system in plasma membranes. Together, these data provide a molecular basis to account for the role of PI3K in the regulation of Fc epsilon RI-mediated degranulation in mast cells.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	University of Kentucky	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, 500 W 12th Ave, Columbus, OH 43210 USA.		Hsu, Ao-Lin Allen/AAX-1856-2020; Johnson, Amy/A-5662-2009	Ching, Tsui-Ting/0000-0001-7650-1766; Hsu, Ao-Lin/0000-0002-2864-3134	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1997, BIOCHEM SOC T, V25, P991, DOI 10.1042/bst0250991; DASILVA CP, 1994, J BIOL CHEM, V269, P12521; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1991, BIOCHEM BIOPH RES CO, V179, P641, DOI 10.1016/0006-291X(91)91420-H; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Hirasawa N, 1997, CELL SIGNAL, V9, P305, DOI 10.1016/S0898-6568(96)00189-1; Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kim TD, 1997, J BIOL CHEM, V272, P31225, DOI 10.1074/jbc.272.50.31225; LEE RJ, 1995, MOL BIOL CELL, V6, P825, DOI 10.1091/mbc.6.7.825; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P9776, DOI 10.1021/bi980163o; LU PJ, 1994, BIOCHEMISTRY-US, V33, P11586, DOI 10.1021/bi00204a021; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; ORourke F, 1996, BIOCHEM J, V315, P1027, DOI 10.1042/bj3151027; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Pelletier C, 1998, INFLAMM RES, V47, P493, DOI 10.1007/s000110050364; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Setoguchi R, 1998, IMMUNOL LETT, V64, P109, DOI 10.1016/S0165-2478(98)00086-8; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Vossebeld PJM, 1997, BIOCHEM J, V323, P87, DOI 10.1042/bj3230087; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; Wolfe PC, 1996, J BIOL CHEM, V271, P6658, DOI 10.1074/jbc.271.12.6658; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145; YANO H, 1993, J BIOL CHEM, V268, P25846	51	74	75	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14814	14820		10.1074/jbc.M009851200	http://dx.doi.org/10.1074/jbc.M009851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278575	hybrid			2022-12-27	WOS:000168528800039
J	Sauvant, C; Holzinger, H; Gekle, R				Sauvant, C; Holzinger, H; Gekle, R			Modulation of the basolateral and apical step of transepithelial organic anion secretion in proximal tubular opossum kidney cells - Acute effects of epidermal growth factor and mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; EXPRESSION CLONING; P-AMINOHIPPURATE; RENAL TRANSPORT; PAH; SPECIFICITY; INHIBITION; MEMBRANE; ACID; MRP2	The organic anion transport system in the proximal tubule of the kidney is of major importance for the excretion of a variety of endogenous and potentially toxic exogenous substances. Furthermore, the clearance of model substrates (e.g. para-aminohippurate) of this system is used for the determination of renal blood flow. We investigated regulation of organic anion secretion in a way that allowed us to examine simultaneously regulation of overall transepithelial secretion and to estimate the separate contributions of regulation of the basolateral and apical transport steps to this overall regulation. The data were verified by measurement of initial basolateral. uptake rate and initial apical afflux rate. Opossum kidney cells were used as a suitable model system for proximal tubule cells, and [C-14]para-aminohippurate was utilized as an organic anion. Stimulation of protein kinase C inhibited transepithelial secretion because of inhibition of both apical efflux and basolateral uptake. Inhibition of the mitogen-activated protein kinase (MAPK) kinase MEK reduced transepithelial secretion via inhibition of basolateral uptake and apical efflux. Epidermal growth factor (EGF) enhanced transepithelial secretion via stimulation of basolateral uptake but did not affect apical efflux. EGF induced stimulation of basolateral uptake was abolished by inhibition of MEK. EGF led to phosphorylation of ERK1/2, which was also abolished by inhibition of MEK. Thus, EGF stimulated basolateral uptake of organic anions via MAPKs, Transepithelial organic anion secretion can be regulated at two sites, at least: basolateral uptake and apical efflux. Both steps are under control of protein kinase C and MAPK, The pathophysiologically relevant growth factor EGF enhances transepithelial secretion via stimulation of basolateral uptake, EGF stimulates basolateral uptake via MEK and ERK1/2. Thus, renal organic anion extraction may be modulated, especially under pathophysiological conditions.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany	University of Wurzburg	Sauvant, C (corresponding author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.	christoph.sauvant@mail.uni-wuerzburg.de						Corrigan G, 1999, AM J PHYSIOL-RENAL, V277, pF312, DOI 10.1152/ajprenal.1999.277.2.F312; Dantzler WH, 1996, CELL PHYSIOL BIOCHEM, V6, P28, DOI 10.1159/000154792; Fleck C, 1999, EXP TOXICOL PATHOL, V51, P315, DOI 10.1016/S0940-2993(99)80013-X; FRIIS C, 1991, ACTA VET SCAND, P33; Gabriels G, 1999, J PHARMACOL EXP THER, V290, P710; Gekle M, 1999, AM J PHYSIOL-RENAL, V277, pF251, DOI 10.1152/ajprenal.1999.277.2.F251; Grandaliano G, 2000, KIDNEY INT, V58, P182, DOI 10.1046/j.1523-1755.2000.00153.x; HORI R, 1993, AM J PHYSIOL, V264, pF975, DOI 10.1152/ajprenal.1993.264.6.F975; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Kribben A, 1998, RENAL FAILURE, V20, P229, DOI 10.3109/08860229809045106; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; Masuda S, 1999, MOL PHARMACOL, V55, P743; Masuda S, 1997, FEBS LETT, V407, P127, DOI 10.1016/S0014-5793(97)00314-1; Miller DS, 1998, AM J PHYSIOL-RENAL, V274, pF156, DOI 10.1152/ajprenal.1998.274.1.F156; Nagai J, 1997, AM J PHYSIOL-RENAL, V273, pF674, DOI 10.1152/ajprenal.1997.273.5.F674; NAGAI J, 1995, J PHARMACOL EXP THER, V274, P1161; Nies AT, 1998, HEPATOLOGY, V28, P1332, DOI 10.1002/hep.510280523; Nigam SK, 2000, AM J PHYSIOL-RENAL, V279, pF3, DOI 10.1152/ajprenal.2000.279.1.F3; Pritchard J.B., 1992, KIDNEY PHYSL PATHOPH, P2921; Pritchard JB, 1996, KIDNEY INT, V49, P1649, DOI 10.1038/ki.1996.240; Roch-Ramel F, 1998, CURR OPIN NEPHROL HY, V7, P517, DOI 10.1097/00041552-199809000-00006; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Sauvant C, 1998, J PHARMACOL EXP THER, V287, P13; SAUVANT C, 2000, PFLUGERS ARCH EUR S, V439, pR348; Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Shuprisha A, 2000, AM J PHYSIOL-RENAL, V278, pF104, DOI 10.1152/ajprenal.2000.278.1.F104; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Taira T, 1996, VIRCHOWS ARCH, V427, P583; ULLRICH KJ, 1988, AM J PHYSIOL, V254, pF453, DOI 10.1152/ajprenal.1988.254.4.F453; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; You GF, 2000, J BIOL CHEM, V275, P10278, DOI 10.1074/jbc.275.14.10278	32	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14695	14703		10.1074/jbc.M007046200	http://dx.doi.org/10.1074/jbc.M007046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278330	hybrid			2022-12-27	WOS:000168528800024
J	Wu, JO; Parkhurst, KM; Powell, RM; Parkhurst, LJ				Wu, JO; Parkhurst, KM; Powell, RM; Parkhurst, LJ			DNA sequence-dependent differences in TATA-binding protein-induced DNA bending in solution are highly sensitive to osmolytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OSMOTIC-STRESS; BOX; COMPLEX; YEAST; OLIGONUCLEOTIDE; PROMOTER	The complex formed between the TATA-binding protein (TBP) and the "TATA box" of eukaryotic class II promoters is the foundation for assembly of the complex to which RNA polymerase II is ultimately recruited. TBP binds productively to canonical and diverse variant TATA sequences with > 100-fold differences in transcription efficiency. Go-crystals of canonical sequences and ttl variant sequences bound to various TBP molecules all have similar to 80 degrees bends. In contrast, the bend angles for TBP.TATA complexes in solution, derived from distance distributions, are similar to 80 degrees for a canonical sequence but range from 30 degrees to 62 degrees for five variant sequences (1). We show in this study that the osmolytes used to crystallize TBP.TATA complexes induce profound increases in the DNA bends of two transcriptionally active TBP-bound variant sequences to a common angle of similar to 80 degrees but have little effect on a transcriptionally inactive variant. The effect of osmolyte on the TBP-induced DNA bend of a variant TATA box sequence is also manifest in the kinetics of association, demonstrating a functional consequence of an osmolyte-induced structural change.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Parkhurst, LJ (corresponding author), Univ Nebraska, Dept Chem, 526 Hamilton Hall, Lincoln, NE 68588 USA.				NCI NIH HHS [CA76049] Funding Source: Medline; NIGMS NIH HHS [GM59346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P293, DOI 10.1021/bi00001a036; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200	16	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14623	14627		10.1074/jbc.M004401200	http://dx.doi.org/10.1074/jbc.M004401200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278275	hybrid			2022-12-27	WOS:000168528800015
J	Zabe, M; Dean, WL				Zabe, M; Dean, WL			Plasma membrane Ca2+-ATPase associates with the cytoskeleton in activated platelets through a PDZ-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CALCIUM-PUMP; IIB-IIIA; PROTEIN; INTEGRIN; ATPASE; CELLS; MOBILIZATION; LIGAND	The plasma membrane Ca2+-ATPase (PMCA) plays an essential role in maintaining low cytosolic Ca2+ in resting platelets. During platelet activation PMCA is phosphorylated transiently on tyrosine residues resulting in inhibition of the pump that enhances elevation of Ca2+ Tyrosine phosphorylation of many proteins during platelet activation results in their association with the cytoskeleton. Consequently, in the present study we asked if PMCA interacts with the platelet cytoskeleton, We observed that very little PMCA is associated with the cytoskeleton in resting platelets but that similar to 80% of total PMCA (PMCA1b + PMCA4b) is redistributed to the cytoskeleton upon activation with thrombin, Tyrosine phosphorylation of PMCA during activation was not associated with the redistribution because tyrosine-phosphorylated PMCA was not translocated specifically to the cytoskeleton. Because PMCA b-splice isoforms have C-terminal PSD-95/Dlg/ZO-1 homology domain (PDZ)-binding domains, a C-terminal peptide was used to disrupt potential PDZ domain interactions. Activation of saponin-permeabilized platelets in the presence of the peptide led to a significant decrease of PMCA in the cytoskeleton. PMCA associated with the cytoskeleton retained Ca2+-ATPase activity. These results suggest that during activation active PMCA is recruited to the cytoskeleton by interaction with PDZ domains and that this association provides a microenvironment with a reduced Ca2+ concentration.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA	University of Louisville	Dean, WL (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.	bill.dean@louisville.edu						AUTHI KS, 1988, BIOCHEM J, V255, P885, DOI 10.1042/bj2550885; Bauer K, 2000, BLOOD, V96, P4236; Blankenship KA, 2000, HYPERTENSION, V35, P103, DOI 10.1161/01.HYP.35.1.103; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARONI P, 1981, J BIOL CHEM, V256, P3263; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DEAN WL, 1995, CELL CALCIUM, V17, P65, DOI 10.1016/0143-4160(95)90103-5; DEAN WL, 1988, METHOD ENZYMOL, V157, P351; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1992, METHOD ENZYMOL, V215, P42; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; HAYNES DH, 1993, PLATELETS, V4, P231, DOI 10.3109/09537109309013223; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Paszty K, 1998, CELL CALCIUM, V24, P129, DOI 10.1016/S0143-4160(98)90080-X; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; Rosado JA, 2000, J BIOL CHEM, V275, P19529, DOI 10.1074/jbc.M001319200; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Wu HJ, 1998, J CELL SCI, V111, P2365	27	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14704	14709		10.1074/jbc.M009850200	http://dx.doi.org/10.1074/jbc.M009850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278574	hybrid			2022-12-27	WOS:000168528800025
J	Muller, K; Heller, H; Doerfler, W				Muller, K; Heller, H; Doerfler, W			Foreign DNA integration - Genome-wide perturbations of methylation and transcription in the recipient genomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO METHYLATION; MAMMALIAN GENOME; HAMSTER-CELLS; SEQUENCES; INSERTION; PATTERNS; ADENOVIRUS-TYPE-12; HYBRIDIZATION; FRAGMENTS; PROTOCOL	In hamster cells transgenic for the DNA of adenovirus type 12 (Ad12) or for the DNA of bacteriophage lambda, the patterns of DNA methylation in specific cellular genes or DNA segments remote from the site of transgene insertion were altered. In the present report, a wide scope of cellular DNA segments and genes was analyzed. The technique of methylation-sensitive representational difference analysis (MS-RDA) was based on a subtractive hybridization protocol after selecting against DNA segments that were heavily methylated and hence rarely cleaved by the methylation-sensitive endonuclease HpaII. The MS-RDA protocol led to the isolation of several cellular DNA segments that were indeed more heavily methylated in lambda DNA-transgenic hamster cell lines. By applying the suppressive subtractive hybridization technique to cDNA preparations from nontransgenic and Ad12-transformed or A DNA-transgenic hamster cells, several cellular genes with altered transcription patterns were cloned from Ad12-transformed or lambda DNA-transgenic hamster cells. Many of the DNA segments with altered methylation, which were isolated by a newly developed methylation-sensitive amplicon subtraction protocol, and cDNA fragments derived from genes with altered transcription patterns were identified by their nucleotide sequences. In control experiments, no differences in gene expression or DNA methylation patterns were detectable among individual nontransgenic BHK21 cell clones. In one mouse line transgenic for the DNA of bacteriophage lambda, hypermethylation was observed in the imprinted Igf2r gene in DNA from heart muscle. Two mouse lines transgenic for an adenovirus promoter-indicator gene construct showed hypomethylation in the interleukin 10 and Igf2r loci. We conclude that the insertion of foreign DNA into an established mammalian genome can lead to alterations in cellular DNA methylation and transcription patterns. It is conceivable that the genes and DNA segments affected by these alterations depend on the site(s) of foreign DNA insertion.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany	University of Cologne	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.							Altenschildesche GMZ, 1996, CHROMOSOMA, V104, P341, DOI 10.1007/BF00337222; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CREMER C, 1992, J RADIAT RES, V33, P189, DOI 10.1269/jrr.33.SUPPLEMENT_189; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Doerfler W, 2000, FOREIGN DNA MAMMALIA; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; HUBERT J, 1986, HUM GENET, V74, P1; JAHNER D, 1985, NATURE, V315, P594, DOI 10.1038/315594a0; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LETTMANN C, 1991, NUCLEIC ACIDS RES, V19, P7131, DOI 10.1093/nar/19.25.7131; LICHTENBERG U, 1988, VIRUS RES, V11, P335, DOI 10.1016/0168-1702(88)90006-8; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MULLER K, 2000, GENE FUNCT DIS, V1, P154; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STABEL S, 1980, J VIROL, V36, P22, DOI 10.1128/JVI.36.1.22-40.1980; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUTTER D, 1978, CELL, V14, P569, DOI 10.1016/0092-8674(78)90243-X; TAHIRA T, 1990, NUCLEIC ACIDS RES, V18, P7472, DOI 10.1093/nar/18.24.7472-a; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284	27	91	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14271	14278						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278495				2022-12-27	WOS:000168356600101
J	Phan, J; Steadman, DJ; Koli, S; Ding, WC; Minor, W; Dunlap, RB; Berger, SH; Lebioda, L				Phan, J; Steadman, DJ; Koli, S; Ding, WC; Minor, W; Dunlap, RB; Berger, SH; Lebioda, L			Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN COMPLEX; LIGAND-BINDING; PROTEIN; ENZYME; IDENTIFICATION; AUTOREGULATION; SUBSTITUTION; TRANSLATION	Thymidylate synthase (TS) is a major target in the chemotherapy of colorectal cancer and some other neoplasms, The emergence of resistance to the treatment is often related to the increased levels of TS in cancer cells, which have been linked to the elimination of TS binding to its own mRNA upon drug binding, a feedback regulatory mechanism, and/or to the increased stability to intracellular degradation of TS.drug complexes (versus unliganded TS). The active site loop of human TS (hTS) has a unique conformation resulted from a rotation by 180 degrees relative to its orientation in bacterial TSs, In this conformation, the enzyme must be inactive, because the catalytic cysteine is no longer positioned in the ligand-binding pocket, The ordered solvent structure obtained from high resolution crystallographic data (2.0 Angstrom) suggests that the inactive loop conformation promotes mRNA binding and intracellular degradation of the enzyme. This hypothesis is supported by fluorescence studies, which indicate that in solution both active and inactive forms of hTS are present. The binding of phosphate ion shifts the equilibrium toward the inactive conformation; subsequent dUMP binding reverses the equilibrium toward the active form. Thus, TS inhibition via stabilization of the inactive conformation should lead to less resistance than is observed with presently used drugs, which are analogs of its substrates, dUMP and CH(2)H(4)folate, and bind in the active site, promoting the active conformation. The presence of an extension at the N terminus of native hTS has no significant effect on kinetic properties or crystal structure.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Dept Basic Pharmaceut Sci, Columbia, SC 29208 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22901 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Virginia	Berger, SH (corresponding author), Univ S Carolina, Dept Chem & Biochem, 631 Sumter St, Columbia, SC 29208 USA.	berger@cop.sc.edu; lebioda@mail.chem.sc.edu	Minor, Wladek/F-3096-2014	Minor, Wladek/0000-0001-7075-7090	NCI NIH HHS [CA76560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Chu E, 1996, NUCLEIC ACIDS RES, V24, P3222, DOI 10.1093/nar/24.16.3222; CHU E, 1994, MOL CELL BIOL, V14, P207, DOI 10.1128/MCB.14.1.207; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Chu E, 1999, MOL CELL BIOL, V19, P1582; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DUNLAP RB, 1971, BIOCHEMISTRY-US, V10, P88, DOI 10.1021/bi00777a014; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FAUMAN EB, 1994, BIOCHEMISTRY-US, V33, P1502, DOI 10.1021/bi00172a029; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; KEYOMARSI K, 1993, J BIOL CHEM, V268, P15142; KEYOMARSI K, 1988, J BIOL CHEM, V263, P7708; Kitchens ME, 1999, J BIOL CHEM, V274, P12544, DOI 10.1074/jbc.274.18.12544; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landis DM, 1998, J BIOL CHEM, V273, P25809, DOI 10.1074/jbc.273.40.25809; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PedersenLane J, 1997, PROTEIN EXPRES PURIF, V10, P256, DOI 10.1006/prep.1997.0750; Phan J, 2001, BIOCHEMISTRY-US, V40, P1897, DOI 10.1021/bi002413i; Phan J, 2000, BIOCHEMISTRY-US, V39, P6969, DOI 10.1021/bi000367g; PHAN J, 1997, CURR TOP CRYSTAL GRO, V3, P223; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REILLY RT, 1995, MOL PHARMACOL, V48, P72; Rustum YM, 1997, J CLIN ONCOL, V15, P389, DOI 10.1200/JCO.1997.15.1.389; Sack JS, 1997, METHOD ENZYMOL, V277, P158, DOI 10.1016/S0076-6879(97)77011-3; Sambrook J., 2002, MOL CLONING LAB MANU; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; Sotelo-Mundo RR, 1999, BIOCHEMISTRY-US, V38, P1087, DOI 10.1021/bi981881d; Spencer HT, 1997, BIOCHEMISTRY-US, V36, P4212, DOI 10.1021/bi961794q; Steadman DJ, 1999, BIOCHEMISTRY-US, V38, P5582, DOI 10.1021/bi982910n; Steadman DJ, 1998, BIOCHEMISTRY-US, V37, P7089, DOI 10.1021/bi9725428; Wahba A. J., 1961, J BIOL CHEM, V236, P11; WASHTIEN WL, 1984, MOL PHARMACOL, V25, P11171; ZAPF JW, 1993, BIOCHEMISTRY-US, V32, P9274, DOI 10.1021/bi00087a003	37	67	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14170	14177		10.1074/jbc.M009493200	http://dx.doi.org/10.1074/jbc.M009493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278511	hybrid			2022-12-27	WOS:000168356600089
J	Chen, D; Xu, WD; He, P; Medrano, EE; Whiteheart, SW				Chen, D; Xu, WD; He, P; Medrano, EE; Whiteheart, SW			Gaf-1, a gamma-SNAP-binding protein associated with the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NSF ATTACHMENT PROTEINS; INTRACELLULAR MEMBRANE-FUSION; COENZYME-A THIOLASE; ALPHA-SNAP; EXTRACELLULAR-MATRIX; GOLGI MEMBRANES; MAMMALIAN-CELLS; ATPASE ACTIVITY; IN-VITRO; TUBULIN	The role of alpha/beta -SNAP (Soluble NSF Attachment Protein) in vesicular trafficking is well established; however, the function of the ubiquitously expressed gamma -SNAP remains unclear. To further characterize the cellular role of this enigmatic protein, a two-hybrid screen was used to identify new, gamma -SNAP binding proteins and to uncover potentially novel functions for gamma -SNAP. One such SNAP-binding protein, termed Gaf-1 (gamma -SNAP associate factor-1) specifically binds gamma- but not alpha -SNAP. The full-length Gaf-1 (75 kDa) is ubiquitously expressed and is found stoichiometrically associated with gamma -SNAP in cellular extracts. This binding is distinct from other SNAP interactions since no alpha -SNAP or NSF coprecipitated with Gaf-1. Subcellular fractionation and immunofluorescence analysis show that Gaf-1 is peripherally associated with the outer mitochondrial membrane. Only a fraction of gamma -SNAP was mitochondrial with the balance being either cytosolic or associated with other membrane fractions. GFP-gamma -SNAP and the C-terminal domain of Gaf-1 both show a reticular distribution in HEK-293 cells. This reticular structure colocalizes with Gaf-1 and mitochondria as well as with microtubules but not with other cytoskeletal elements. These data identify a class of gamma -SNAP interactions that is distinct from other members of the SNAP family and point to a potential role for gamma -SNAP in mitochondrial dynamics.	Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA; Baylor Coll Med, Vet Affairs Med Ctr, Roy M & Phyllis Gough Huffington Ctr Aging, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Vet Affairs Med Ctr, Roy M & Phyllis Gough Huffington Ctr Aging, Dept Dermatol, Houston, TX 77030 USA	University of Kentucky; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Whiteheart, SW (corresponding author), Univ Kentucky, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.			Whiteheart, Sidney/0000-0001-5577-0473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056652] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56652] Funding Source: Medline; NIA NIH HHS [AG-3663] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Chen D, 1999, BRAIN RES, V831, P11, DOI 10.1016/S0006-8993(99)01371-2; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Colombo MI, 1998, J BIOL CHEM, V273, P1334, DOI 10.1074/jbc.273.3.1334; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Fukao T, 1996, PEDIATR RES, V39, P1055, DOI 10.1203/00006450-199606000-00020; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAJOIEMAZENC I, 1994, J CELL SCI, V107, P2825; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MOONEY DJ, 1995, J CELL SCI, V108, P2311; MOONEY DJ, 1994, MOL BIOL CELL, V5, P1281, DOI 10.1091/mbc.5.12.1281; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Moudjou M, 1996, J CELL SCI, V109, P875; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Peter F, 1998, J CELL SCI, V111, P2625; ROTHMAN JE, 1994, ADV SEC MESS PHOSPH, V29, P81; Salas PJI, 1999, J CELL BIOL, V146, P645, DOI 10.1083/jcb.146.3.645; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; SHU HB, 1995, J CELL BIOL, V130, P1137, DOI 10.1083/jcb.130.5.1137; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SONG XQ, 1994, BIOCHEM BIOPH RES CO, V201, P478, DOI 10.1006/bbrc.1994.1726; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Sudlow AW, 1996, FEBS LETT, V393, P185, DOI 10.1016/0014-5793(96)00880-0; SUNKEL CE, 1995, EMBO J, V14, P28, DOI 10.1002/j.1460-2075.1995.tb06972.x; Tang DJ, 2000, MOL CELL NEUROSCI, V15, P303, DOI 10.1006/mcne.1999.0820; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Weidenhaupt M, 2000, EUR J BIOCHEM, V267, P2062, DOI 10.1046/j.1432-1327.2000.01212.x; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wigley WC, 1999, J CELL BIOL, V145, P481; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	55	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13127	13135		10.1074/jbc.M009424200	http://dx.doi.org/10.1074/jbc.M009424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278501	hybrid			2022-12-27	WOS:000168198600093
J	Liu, SQ; Jin, HJ; Zacarias, A; Srivastava, S; Bhatnagar, A				Liu, SQ; Jin, HJ; Zacarias, A; Srivastava, S; Bhatnagar, A			Binding of pyridine nucleotide coenzymes to the beta-subunit of the voltage-sensitive K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDO-KETO REDUCTASE; SITE-DIRECTED MUTAGENESIS; 3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE; POTASSIUM CHANNELS; SUPERFAMILY; DETERMINANTS; EXPRESSION; MECHANISM; PROTEINS; CELLS	The beta -subunit of the voltage-sensitive K+ (K-V) channels belongs to the aldo-keto reductase superfamily, and the crystal structure of K(V)beta2 shows NADP bound in its active site. Here we report that K(V)beta2 displays a high affinity for NADPH (K-d = 0.1 muM) and NADP(+) (K-d = 0.3 muM), as determined by fluorometric titrations of the recombinant protein. The K(V)beta2 also bound NAD(H) but with 10-fold lower affinity. The site-directed mutants R264E and N333W did not bind NADPH, whereas, the K-d(NADPH) Of Q214R was 10-fold greater than the wild-type protein. The K-d(NADPH) was unaffected by the R189M, W243Y, W243A, or Y255F mutation, The tetrameric structure of the wild-type protein was retained by the R264E mutant, indicating that NADPH binding is not a prerequisite for multimer formation. A C248S mutation caused a 5-fold decrease in K-d(NADPH), Shifted the pK(a) of K-d(NADPH) from 6.9 to 7.4, and decreased the ionic strength dependence of NADPH binding. These results indicate that Arg-264 and Asn-333 are critical for coenzyme binding, which is regulated in part by Cys-248. The binding of both NADP(H) and NAD(H) to the protein suggests that several types of K(V)beta2-nucleotide complexes may be formed in vivo.	Univ Louisville, Div Cardiol, Louisville, KY 40202 USA; Jewish Hosp, Heart & Lung Inst, Louisville, KY 40202 USA	University of Louisville	Bhatnagar, A (corresponding author), Jewish Cardiovasc Res Ctr, Dept Med, Div Cardiol, 500 S Floyd, Louisville, KY 40202 USA.	aruni@louisville.edu	Srivastava, Sanjay/D-3921-2012		NHLBI NIH HHS [HL55477, HL59378] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055477, R01HL059378] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; Cleland W W, 1979, Methods Enzymol, V63, P103; EHRIG T, 1994, BIOCHEMISTRY-US, V33, P7157, DOI 10.1021/bi00189a019; GRIMSHAW CE, 1992, BIOCHEMISTRY-US, V31, P10139, DOI 10.1021/bi00157a001; Hille B., 1991, IONIC CHANNELS EXCIT; HOEK JB, 1988, BIOCHEM J, V254, P1; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1996, J BIOL CHEM, V271, P30190, DOI 10.1074/jbc.271.47.30190; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Khurana S, 1998, P NATL ACAD SCI USA, V95, P6768, DOI 10.1073/pnas.95.12.6768; KOLB HA, 1990, REV PHYSIOL BIOCH P, V115, P51; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUBISESKI TJ, 1995, J BIOL CHEM, V270, P16911, DOI 10.1074/jbc.270.28.16911; KUBISESKI TJ, 1994, J BIOL CHEM, V269, P2183; LIU SQ, 1993, J BIOL CHEM, V268, P25494; Matsuura K, 1997, BIOCHEM J, V322, P89, DOI 10.1042/bj3220089; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; Penning TM, 1999, J STEROID BIOCHEM, V69, P211, DOI 10.1016/S0960-0760(99)00038-2; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; Ratnam K, 1999, BIOCHEMISTRY-US, V38, P7856, DOI 10.1021/bi982838t; SEGEL IH, 1993, ENZYME KINETICS, P223; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Srivastava S, 1998, BIOCHEMISTRY-US, V37, P12909, DOI 10.1021/bi9804333; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UEDA K, 1987, PYRIDINE NUCLEOTIDES, P549; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Xu J, 1998, TRENDS CARDIOVAS MED, V8, P229, DOI 10.1016/S1050-1738(98)00011-5; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114	36	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11812	11820		10.1074/jbc.M008259200	http://dx.doi.org/10.1074/jbc.M008259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278398	hybrid			2022-12-27	WOS:000168081800053
J	Olson, AL; Trumbly, AR; Gibson, GV				Olson, AL; Trumbly, AR; Gibson, GV			Insulin-mediated GLUT4 translocation is dependent on the microtubule network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; STORAGE-VESICLES; SUBCELLULAR TRAFFICKING; RECEPTOR SUBSTRATE-1; SKELETAL-MUSCLE; SENSITIVE CELLS	The GLUT4 facilitative glucose transporter is recruited to the plasma membrane by insulin. This process depends primarily on the exocytosis of a specialized pool of vesicles containing GLUT4 in their membranes. The mechanism of GLUT4 vesicle exocytosis in response to insulin is not understood, To determine whether GLUT4 exocytosis is dependent on intact microtubule network, we measured insulin-mediated GLUT4 exocytosis in 3T3-L1 adipocytes in which the microtubule network was depolymerized by pretreatment with nocodazole. Insulin-mediated GLUT4 translocation was inhibited by more than 80% in nocodazole-treated cells. Phosphorylation of insulin receptor substrate 1 (IRS-1), activation of IRS-1 associated phosphatidylinositide 3-kinase, and phosphorylation of protein kinase B/Akt-1 were not inhibited by nocodazole treatment indicating that the microtubule network was not required for proximal insulin signaling. An intact microtubule network is specifically required for insulin-mediated GLUT4 translocation since nocodazole treatment did not affect insulin-mediated GLUT1 translocation or adipsin secretion. By using in vitro microtubule binding, we demonstrated that both GLUT4 vesicles and IRS-1 bind specifically to microtubules, implicating microtubules in both insulin signaling and GLUT4 translocation. Vesicle binding to microtubules was not mediated through direct binding of GLUT4 or insulin-responsive aminopeptidase to microtubules, A model microtubule-dependent translocation of GLUT4 is proposed.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, POB 26901,Rm 853-BMSB, Oklahoma City, OK 73190 USA.	ann-olson@ouhsc.edu			ARRA NIH HHS [RA0064] Funding Source: Medline; NIDDK NIH HHS [DK47894] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK047894, R01DK047894] Funding Source: NIH RePORTER	ARRA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; Hamm-Alvarez SF, 1998, PHYSIOL REV, V78, P1109, DOI 10.1152/physrev.1998.78.4.1109; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Khayat ZA, 2000, J CELL SCI, V113, P279; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Macaulay SL, 1997, BIOCHEM J, V324, P217, DOI 10.1042/bj3240217; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOGAWA K, 1978, J BIOCHEM-TOKYO, V83, P1783, DOI 10.1093/oxfordjournals.jbchem.a132094; Soroka CJ, 1999, J BIOL CHEM, V274, P26416, DOI 10.1074/jbc.274.37.26416; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; Yang CZ, 1999, J BIOL CHEM, V274, P25297, DOI 10.1074/jbc.274.36.25297; YANG J, 1993, J BIOL CHEM, V268, P4600	65	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10706	10714		10.1074/jbc.M007610200	http://dx.doi.org/10.1074/jbc.M007610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278355	hybrid			2022-12-27	WOS:000167980900021
J	Gilchrist, A; Vanhauwe, JF; Li, AL; Thomas, TO; Voyno-Yasenetskaya, T; Hamm, HE				Gilchrist, A; Vanhauwe, JF; Li, AL; Thomas, TO; Voyno-Yasenetskaya, T; Hamm, HE			G alpha minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; VON-WILLEBRAND-FACTOR; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; ADENYLYL-CYCLASE; HUMAN PLATELETS; SYNTHETIC PEPTIDES; BARRIER FUNCTION; GENE-EXPRESSION; CELL ACTIVATION	The C termini of G protein a subunits are critical for binding to their cognate receptors, and peptides corresponding to the C terminus can serve as competitive inhibitors of G protein-coupled receptor-G protein interactions. This interface is quite specific as a single amino acid difference annuls the ability of a G alpha (i) peptide to bind the A, adenosine receptor (Gilchrist, A, Mazzoni, M,, Dineen, B., Dice, A, Linden, J., Dunwiddie, T., and Hamm, H, E, (1998) J. Biol. Chem. 273, 14912-14919). Recently, we demonstrated that a plasmid minigene vector encoding the C-terminal sequence of G alpha (i) could specifically inhibit downstream responses to agonist stimulation of the muscarinic M, receptor (Gilchrist, A, Bunemann, M,, Li, A, Hosey, M. M,, and H, E, Hamm (1999) J. Biol. Chem. 274, 6610-6616), To selectively antagonize G protein signal transduction events and determine which G protein underlies a given thrombin-induced response, we generated minigene vectors that encode the C-terminal sequence for each family of G alpha subunits. Minigene vectors expressing G alpha C-terminal peptides (G alpha (i), G alpha (q), G alpha (12), and G alpha (13)) or the control minigene vector, which expresses the Gai peptide in random order (G(iR)), were systematically introduced into a human microvascular endothelial cell line. The C-terminal peptides serve as competitive inhibitors presumably by blocking the site on the G protein-coupled receptor that normally binds the G protein. Our results not only confirm that each G protein can control certain signaling events, they emphasize the specificity of the G protein-coupled receptor-G protein interface. In addition, the C-terminal G alpha minigenes appear to be a powerful tool for dissecting out the G protein that mediates a given physiological function following thrombin activation.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60610 USA	Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 442 Robinson Res Bldg,23rd & Pierce Dr, Nashville, TN 37232 USA.		Hamm, Heidi E/G-2374-2014; voyno-yasenetskaya, tatyana/A-3171-2008; Gilchrist, Annette/I-4465-2014	Gilchrist, Annette/0000-0003-2386-7646	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60678-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aengevaeren WR, 1999, ATHEROSCLEROSIS, V147, pS11, DOI 10.1016/S0021-9150(99)00250-6; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BAYKAL D, 1995, AM J CARDIOL, V75, P82; BENKA ML, 1995, FEBS LETT, V363, P49, DOI 10.1016/0014-5793(95)00278-H; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Blahos J, 2001, J BIOL CHEM, V276, P3262, DOI 10.1074/jbc.M004880200; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; BRASS LF, 1995, THROMB HAEMOSTASIS, V74, P499; Brass LF, 1997, CORONARY ARTERY DIS, V8, P49, DOI 10.1097/00019501-199701000-00008; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Carbajal JM, 2000, AM J PHYSIOL-CELL PH, V279, pC195; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; COUGHLIN SR, 1992, SEMIN THROMB HEMOST, V18, P161, DOI 10.1055/s-2007-1002422; Cupit LD, 1999, TRENDS CARDIOVAS MED, V9, P42, DOI 10.1016/S1050-1738(99)00005-5; DENNINGTON PM, 1994, CLIN EXP PHARMACOL P, V21, P349, DOI 10.1111/j.1440-1681.1994.tb02527.x; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARCIA JGN, 1992, J LAB CLIN MED, V120, P513; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gerdes HH, 1996, FEBS LETT, V389, P44, DOI 10.1016/0014-5793(96)00586-8; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Ho MKC, 2000, MOL PHARMACOL, V58, P993, DOI 10.1124/mol.58.5.993; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Langer F, 1999, BRIT J HAEMATOL, V105, P542; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; Manolopoulos VG, 1997, BBA-MOL CELL RES, V1356, P321, DOI 10.1016/S0167-4889(97)00002-5; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Mizuno O, 2000, EUR J PHARMACOL, V389, P13, DOI 10.1016/S0014-2999(99)00840-7; Molino M, 1997, J BIOL CHEM, V272, P11133; Moore TM, 2000, AM J PHYSIOL-LUNG C, V279, pL691, DOI 10.1152/ajplung.2000.279.4.L691; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nguyen LT, 1997, AM J PHYSIOL-CELL PH, V273, pC1756, DOI 10.1152/ajpcell.1997.273.5.C1756; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PATTERSON CE, 1994, BLOOD COAGUL FIBRIN, V5, P63, DOI 10.1097/00001721-199402000-00010; Ponimaskin E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7; Preissner KT, 2000, J PATHOL, V190, P360; RABIET MJ, 1994, BRIT MED BULL, V50, P936, DOI 10.1093/oxfordjournals.bmb.a072935; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; Senis YA, 1996, BRIT J HAEMATOL, V93, P195, DOI 10.1046/j.1365-2141.1996.4661005.x; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; Vischer UM, 2000, ARTERIOSCL THROM VAS, V20, P883, DOI 10.1161/01.ATV.20.3.883; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; VOYNOYASENETSKAYA TA, 1989, FASEB J, V3, P44, DOI 10.1096/fasebj.3.1.2535990; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang HS, 1997, J SURG RES, V68, P139, DOI 10.1006/jsre.1997.5044; Wu KK, 1996, ANNU REV MED, V47, P315; XU YL, 1994, J INVEST DERMATOL, V102, P833, DOI 10.1111/1523-1747.ep12382086	73	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25672	25679		10.1074/jbc.M100914200	http://dx.doi.org/10.1074/jbc.M100914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11274183	hybrid			2022-12-27	WOS:000169823300007
J	Grant, GA; Hu, ZQ; Xu, XL				Grant, GA; Hu, ZQ; Xu, XL			Amino acid residue mutations uncouple cooperative effects in Escherichia coli D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED ALLOSTERIC REGULATION; PHOSPHOGLYCERATE DEHYDROGENASE; DOMAIN INTERFACE; BINDING; SITE; MECHANISM; ENZYME	D-3-Phosphoglycerate dehydrogenase from Escherichia coli contains two Gly-Gly sequences that occur at junctions between domains. A previous study (Grant, G, A, Xu, X, L,, and Hu, Z, (2000) Biochemistry 39, 7316-7319) determined that the Gly-Gly sequence at the junction between the regulatory and substrate binding domain functions as a hinge between the domains. Mutations in this area significantly decrease the ability of serine to inhibit activity but have little effect on the K-m and k(cat). Conversely, the present study shows that mutations to the Gly-Gly sequence at the junction of the substrate and nucleotide binding domains, which form the active site cleft, have a significant effect on the k(cat) of the enzyme without substantially altering the enzyme's sensitivity to serine, In addition, mutation of Gly-294, but not Gly-295, has a profound effect on the cooperativity of serine inhibition. Interestingly, even though cooperativity of inhibition can be reduced significantly, there is little apparent effect on the cooperativity of serine binding itself. An additional mutant, G336V,G337V, also reduces the cooperativity of inhibition, but in this case serine binding also is reduced to the point at which it cannot be measured by equilibrium dialysis, The double mutant G294V,G336V demonstrates that strain imposed by mutation at one hinge can be relieved partially by mutation at the other hinge, demonstrating linkage between the two hinge regions. These data show that the two cooperative processes, serine binding and catalytic inhibition, can be uncoupled. Consideration of the allowable torsional angles for the side chains introduced by the mutations yields a range of values for these angles that the glycine residues likely occupy in the native enzyme. A comparison of these values with the torsional angles found for the inhibited enzyme from crystal coordinates provides potential beginning and ending orientations for the transition from active to inhibited enzyme, which will allow modeling of the dynamics of domain movement.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.				NIGMS NIH HHS [GM 56676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BELL JE, 1988, PROTEINS ENZYMES, P465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P165; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 1999, J BIOL CHEM, V274, P5357, DOI 10.1074/jbc.274.9.5357; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; HNEDERSON PJF, 1992, ENZYME ASSAYS PRACTI, P284; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Vega MC, 2000, PROTEIN SCI, V9, P2322, DOI 10.1110/ps.9.12.2322; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	23	23	25	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17844	17850		10.1074/jbc.M009957200	http://dx.doi.org/10.1074/jbc.M009957200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278587	hybrid			2022-12-27	WOS:000168866500032
J	Kitagawa, K; Kunugita, N; Kitagawa, M; Kawamoto, T				Kitagawa, K; Kunugita, N; Kitagawa, M; Kawamoto, T			CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER-MICROSOMES; CYP2A6 GENE; COUMARIN 7-HYDROXYLATION; NICOTINE METABOLISM; C-OXIDATION; DELETION; IDENTIFICATION; EXPRESSION; POPULATION; FREQUENCY	By using the polymerase chain reaction technique combined with restriction enzyme fragment length polymorphism (PCR-RFLP), a novel polymorphism of CYP2A6, CYP2A6*6, was detected in 0.4% of the Japanese population. To study the enzymatic properties of the CYP2A6.6 protein with a single amino acid substitution of arginine 128 to glutamine, both this isozyme and the CYP2A6.1 protein (wild-type) were produced in insect cells using a baculovirus system. Coumarin 7-hydroxylation, which reflects CYP2A6 activity, was significantly reduced tone-eighth of normal) in cell lysate from CYP2AG*6-transfected Sf9 cells compared with that lysate from CYP2A6*1-transfected cells. To clarify the mechanism of inactivation of the CYP2A6.6 enzyme, the heme content and reduced CO difference spectrum were examined. Although CYP2A6.6 retained about one-half the heme content of CYP2A6.1, the reduced CO-bound Soret peak was completely lost. These results suggest that the inactivation of CYP2A6.6 is mainly due to disordering of the holoprotein structure rather than a failure of heme incorporation.	Univ Occupat & Environm Hlth, Dept Environm Hlth, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Hamamatsu Univ Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4313192, Japan	University of Occupational & Environmental Health - Japan; Hamamatsu University School of Medicine	Kawamoto, T (corresponding author), Univ Occupat & Environm Hlth, Dept Environm Hlth, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	kawamott@med.uoeh-u.ac.jp		Kunugita, Naoki/0000-0002-6516-8379				ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; Bourian M, 2000, TOXICOLOGY, V144, P129, DOI 10.1016/S0300-483X(99)00199-7; Chen GF, 1999, PHARMACOGENETICS, V9, P327, DOI 10.1097/00008571-199906000-00007; CRESPI CL, 1991, CARCINOGENESIS, V12, P1197, DOI 10.1093/carcin/12.7.1197; GONZALEZ FJ, 1995, METHOD ENZYMOL, V206, P93; GOTOH O, 1992, J BIOL CHEM, V267, P83; GrahamLorence SE, 1996, METHOD ENZYMOL, V272, P315, DOI 10.1016/S0076-6879(96)72037-2; Hsu LC, 1996, J BIOL CHEM, V271, P3306, DOI 10.1074/jbc.271.6.3306; Inoue K, 2000, ARCH TOXICOL, V73, P532, DOI 10.1007/s002040050005; Kitagawa K, 1999, BIOCHEM BIOPH RES CO, V262, P146, DOI 10.1006/bbrc.1999.1182; Koskela S, 1999, BIOCHEM PHARMACOL, V57, P1407, DOI 10.1016/S0006-2952(99)00015-5; LEWIS DFV, 1992, J COMPUT AID MOL DES, V6, P235, DOI 10.1007/BF00123379; LEWIS DFV, 1995, XENOBIOTICA, V25, P585, DOI 10.3109/00498259509061877; LEWIS DFV, 1995, XENOBIOTICA, V25, P333, DOI 10.3109/00498259509061857; Nakajima M, 2000, CLIN PHARMACOL THER, V67, P57, DOI 10.1067/mcp.2000.103957; Nakajima M, 1996, J PHARMACOL EXP THER, V277, P1010; Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212; OMURA T, 1964, J BIOL CHEM, V239, P2370; Oscarson M, 1999, FEBS LETT, V460, P321, DOI 10.1016/S0014-5793(99)01364-2; Oscarson M, 1999, FEBS LETT, V448, P105, DOI 10.1016/S0014-5793(99)00359-2; PORTER TD, 1994, BIOCHEMISTRY-US, V33, P5942, DOI 10.1021/bi00185a035; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SATO H, 1994, CLIN CHEM, V40, P1239; YAMANO S, 1990, BIOCHEMISTRY-US, V29, P1322, DOI 10.1021/bi00457a031; Yamazaki H, 1999, ARCH TOXICOL, V73, P65, DOI 10.1007/s002040050588; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789	30	70	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17830	17835		10.1074/jbc.M009432200	http://dx.doi.org/10.1074/jbc.M009432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278503	hybrid			2022-12-27	WOS:000168866500030
J	Krath, BN; Hove-Jensen, B				Krath, BN; Hove-Jensen, B			Class II recombinant phosphoribosyl diphosphate synthase from spinach - Phosphate independence and diphosphoryl donor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; SYNTHETASE; PURIFICATION; GENE; PRS; NUCLEOTIDE; CLONING; BINDING; PURINE	A recombinant form of spinach (Spinacia oleracea) phosphoribosyl diphosphate (PRPP) synthase isozyme 3 resembling the presumed mature enzyme has been synthesized in an Escherichia coli strain in which the endogenous PRPP synthase gene was deleted, and has been purified to near homogeneity. Contrary to other PRPP syntheses the activity of spinach PRPP synthase isozyme 3 is independent of Pi, and the enzyme is inhibited by ribonucleoside diphosphates in a purely competitive manner, which indicates a lack of allosteric inhibition by these compounds, In addition spinach PRPP synthase isozyme 3 shows an unusual low specificity toward diphosphoryl donors by accepting dATP, GTP, CTP, and UTP in addition to ATP, The kinetic mechanism of the enzyme is an ordered steady state Pi hi mechanism with K-ATP and KRib-5-P values of 170 and 110 muM, respectively, and a V-max value of 13.1 mu mol (min x mg of protein)(-1). The enzyme has an absolute requirement for magnesium ions, and maximal activity is obtained at 40 degreesC at pH 7.6.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen K, Denmark	University of Copenhagen	Hove-Jensen, B (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, 83H Solvgade, DK-1307 Copenhagen K, Denmark.							ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; ASHIHARA H, 1977, Z PFLANZENPHYSIOL, V83, P379, DOI 10.1016/S0044-328X(77)80044-5; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Eriksen TA, 2000, NAT STRUCT BIOL, V7, P303; FOX IH, 1971, J BIOL CHEM, V246, P5739; Gallois R, 1997, PLANT PHYSIOL, V115, P847, DOI 10.1104/pp.115.2.847; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; HOVEJENSEN B, 1992, J BACTERIOL, V174, P6852, DOI 10.1128/JB.174.21.6852-6856.1992; JENSEN KF, 1979, ANAL BIOCHEM, V98, P254, DOI 10.1016/0003-2697(79)90138-6; KHORANA HG, 1958, J BIOL CHEM, V230, P941; Krath BN, 1999, BBA-PROTEIN STRUCT M, V1430, P403, DOI 10.1016/S0167-4838(99)00022-9; Krath BN, 1999, PLANT PHYSIOL, V119, P497, DOI 10.1104/pp.119.2.497; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; NILSSON D, 1989, MOL GEN GENET, V218, P565, DOI 10.1007/BF00332425; Post DA, 1996, MICROBIOL-SGM, V142, P359, DOI 10.1099/13500872-142-2-359; RANDERATH K, 1965, ANAL BIOCHEM, V13, P575, DOI 10.1016/0003-2697(65)90356-8; ROESSLER BJ, 1990, NUCLEIC ACIDS RES, V18, P193, DOI 10.1093/nar/18.1.193; ROTH DG, 1974, J BIOL CHEM, V249, P291; SHERMAN MS, 1996, J BIOL CHEM, V271, P29652; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; White RH, 1996, BIOCHEMISTRY-US, V35, P3447, DOI 10.1021/bi952308m; Willemoes M, 2000, J BIOL CHEM, V275, P35408, DOI 10.1074/jbc.M006346200; Willemoes M, 1997, BIOCHEMISTRY-US, V36, P5078, DOI 10.1021/bi962610a	30	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17851	17856		10.1074/jbc.M010172200	http://dx.doi.org/10.1074/jbc.M010172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278632	hybrid			2022-12-27	WOS:000168866500033
J	Lim, KP; Liu, DX				Lim, KP; Liu, DX			The missing link in coronavirus assembly - Retention of the avian coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and physical interaction between the envelope and membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; STRUCTURAL PROTEINS; INSECT CELLS; ENDOPLASMIC-RETICULUM; 3C-LIKE PROTEINASE; EPITHELIAL-CELLS; SPIKE PROTEIN; STRAIN A59; PARTICLES; RECOMBINANT	One missing link in the coronavirus assembly is the physical interaction between two crucial structural proteins, the membrane (M) and envelope (E) proteins. In this study, we demonstrate that the coronavirus infectious bronchitis virus E can physically interact, via a putative peripheral domain, with M, Deletion of this domain resulted in a drastic reduction in the incorporation of M into virus-like particles. Immunofluorescent staining of cells coexpressing RI and E supports that E interacts with M and relocates M to the same subcellular compartments that E resides in. E was retained in the pre-Golgi membranes, prior to being translocated to the Golgi apparatus and the secretory vesicles; M was observed to exhibit similar localization and translocation profiles as E when coexpressed with E. Deletion studies identified the C-terminal 6-residue RDKLYS as the endoplasmic reticulum retention signal of E, and site-directed mutagenesis of the -4 lysine residue to glutamine resulted in the accumulation of E in the Golgi apparatus. The third domain of E that plays a crucial role in virus budding is a putative transmembrane domain present at the N-terminal region, because deletion of the domain resulted in a free distribution of the mutant protein and in dysfunctional viral assembly.	Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	National University of Singapore	Liu, DX (corresponding author), Natl Univ Singapore, Inst Mol Agrobiol, 1 Res Link, Singapore 117604, Singapore.		Liu, Ding Xiang/A-2226-2011					Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516; ALONSOCAPLEN FV, 1984, VIRUS RES, V2, P153; Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; BRAUTIGAM S, 1993, VIROLOGY, V192, P512, DOI 10.1006/viro.1993.1067; BUDZILOWICZ CJ, 1987, VIROLOGY, V157, P509, DOI 10.1016/0042-6822(87)90293-5; Chen BY, 1996, AVIAN PATHOL, V25, P675, DOI 10.1080/03079459608419174; Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000; de Haan CAM, 2000, J VIROL, V74, P4967, DOI 10.1128/JVI.74.11.4967-4978.2000; de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998; de Haan CAM, 1999, J VIROL, V73, P7441, DOI 10.1128/JVI.73.9.7441-7452.1999; DEA S, 1988, ARCH VIROL, V99, P173, DOI 10.1007/BF01311068; DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990; Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Garbutt M, 1999, VIROLOGY, V261, P340, DOI 10.1006/viro.1999.9857; Haglund K, 2000, VIROLOGY, V268, P112, DOI 10.1006/viro.1999.0120; HOGUE BG, 1986, VIRUS RES, V5, P131, DOI 10.1016/0168-1702(86)90013-4; HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X; Jiang BM, 1998, BIOTECHNOL BIOENG, V60, P369, DOI 10.1002/(SICI)1097-0290(19981105)60:3<369::AID-BIT14>3.0.CO;2-H; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CW, 2000, AVIAN DIS, V44, P650, DOI 10.2307/1593106; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S; Liu DX, 1998, VIROLOGY, V246, P288, DOI 10.1006/viro.1998.9199; LIU DX, 1991, VIROLOGY, V184, P531, DOI 10.1016/0042-6822(91)90423-9; LIU DX, 1994, J VIROL, V68, P5772, DOI 10.1128/JVI.68.9.5772-5780.1994; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; Maeda J, 1999, VIROLOGY, V263, P265, DOI 10.1006/viro.1999.9955; MOUNIR S, 1993, VIROLOGY, V192, P355, DOI 10.1006/viro.1993.1043; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000; Neumann G, 2000, J VIROL, V74, P547, DOI 10.1128/JVI.74.1.547-551.2000; Ng LFP, 2000, VIROLOGY, V272, P27, DOI 10.1006/viro.2000.0330; Nguyen VP, 1997, J VIROL, V71, P9278, DOI 10.1128/JVI.71.12.9278-9284.1997; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000; Risco C, 1998, J VIROL, V72, P4022, DOI 10.1128/JVI.72.5.4022-4031.1998; Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996; Salanueva IJ, 1999, J VIROL, V73, P7952, DOI 10.1128/JVI.73.10.7952-7964.1999; SMITH AR, 1990, J GEN VIROL, V71, P3, DOI 10.1099/0022-1317-71-1-3; SUTOU S, 1988, VIROLOGY, V165, P589, DOI 10.1016/0042-6822(88)90603-4; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOOZE J, 1984, EUR J CELL BIOL, V33, P281; Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x; White LJ, 1997, J VIROL, V71, P8066, DOI 10.1128/JVI.71.10.8066-8072.1997; [No title captured]	49	102	112	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17515	17523		10.1074/jbc.M009731200	http://dx.doi.org/10.1074/jbc.M009731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278557	hybrid, Green Published			2022-12-27	WOS:000168730400123
J	Frejtag, W; Zhang, Y; Dai, RJ; Anderson, MG; Mivechi, NF				Frejtag, W; Zhang, Y; Dai, RJ; Anderson, MG; Mivechi, NF			Heat shock factor-4 (HSF-4a) represses basal transcription through interaction with TFIIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DEPENDENT PROTEIN-KINASE; EVEN-SKIPPED PROTEIN; HISTONE DEACETYLASE; ACTIVE REPRESSION; COMPLEX-FORMATION; INITIATION; GENE; DNA; BINDING	The heat shock transcription factors (HSFs) regulate the expression of heat shock proteins (hsps), which are critical for normal cellular proliferation and differentiation. One of the HSFs, HSF-4, contains two alternative splice variants, one of which possesses transcriptional repressor properties in vivo, This repressor isoform inhibits basal transcription of hsps 27 and 90 in tissue culture cells. The molecular mechanisms of HSF-4a isoform-mediated transcriptional repression is unknown, Here, we present evidence that HSF-4a inhibits basal transcription in vivo when it is artificially targeted to basal promoters via the DNA-binding domain of the yeast transcription factor, GAL4. By using a highly purified, reconstituted in vitro transcription system, we show that HSF-4a represses basal transcription at an early step during preinitiation complex assembly, as pre-assembled preinitiation complexes are refractory to the inhibitory effect on transcription. This repression occurs by the HSF-4a isoform, but not by the HSF-4b isoform, which we show is capable of activating transcription from a heat shock element-driven promoter in vitro, The repression of basal transcription by HSF-4a occurs through interaction with the basal transcription factor TFIIF, TFIIF interacts with a segment of HSF-4a that is required for the trimerization of HSF-4a, and deletion of this segment no longer inhibits basal transcription. These studies suggest that HSF-4a inhibits basal transcription both in vivo and in vitro. Furthermore, this is the first report identifying an interaction between a transcriptional repressor with the basal transcription factor TFIIF.	Med Coll Georgia, Inst Mol Biol & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Mivechi, NF (corresponding author), Med Coll Georgia, Inst Mol Biol & Genet, 1120 15th St,CB2803, Augusta, GA 30912 USA.				NCI NIH HHS [CA62130, CA85947] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062130, R01CA085947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BENIAHMAD A, 1992, EMBO J, V11, P1015; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FLORES O, 1990, J BIOL CHEM, V265, P5629; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Newton EM, 1996, MOL CELL BIOL, V16, P839; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Ren DL, 1999, MOL CELL BIOL, V19, P7377; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; TAN SY, 1994, J BIOL CHEM, V269, P25684; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; UM M, 1995, MOL CELL BIOL, V15, P5007; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zhang Y, 1998, J BIOL CHEM, V273, P32514, DOI 10.1074/jbc.273.49.32514; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	43	28	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14685	14694		10.1074/jbc.M009224200	http://dx.doi.org/10.1074/jbc.M009224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278480	hybrid			2022-12-27	WOS:000168528800023
J	Jaulin-Bastard, F; Saito, H; Le Bivic, A; Ollendorff, V; Marchetto, S; Birnbaum, D; Borg, JP				Jaulin-Bastard, F; Saito, H; Le Bivic, A; Ollendorff, V; Marchetto, S; Birnbaum, D; Borg, JP			The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1PSD-95/DLG/ZO-1 domain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NITRIC-OXIDE SYNTHASE; PDZ-DOMAIN; BASOLATERAL MEMBRANE; CRYSTAL-STRUCTURE; BINDING-PROTEIN; LOCALIZATION; SIALOGLYCOPROTEIN; RECOGNITION; ASSOCIATION	Identification of protein complexes associated with the ERBB2/HER2 receptor may help unravel the mechanisms of its activation and regulation in normal and pathological situations. Interactions between ERBB2/ HERS and Src homology 2 or phosphotyrosine binding domain signaling proteins have been extensively studied. We have identified ERBIN and PICK1 as new binding partners for ERBB2/HER2 that associate with its carboxyl terminal sequence through a PDZ (PSD 95/ DLG/ZO-1) domain. This peptide sequence acts as a dominant retention or targeting basolateral signal for receptors in epithelial cells. ERBIN belongs to the newly described LAP (LRR and PDZ) protein family, whose function is crucial in non vertebrates for epithelial homeostasis. Whereas ERBIN appears to locate ERBB2/ HERS to the basolateral epithelium, PICK1 is thought to be involved in the clustering of receptors. We show here that ERBIN and PICK1 bind to ERBB2/HER2 with different mechanisms, and we propose that these interactions are regulated in cells. Since ERBIN and PICK1 tend to oligomerize, further complexity of protein networks may participate in ERBB2/HER2 functions and specificity.	INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Fac Sci Luminy, Inst Biol & Dev Marseille, F-13288 Marseille 09, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Borg, JP (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.	borg@marseille.inserm.fr	Borg, Jean-Paul/AAX-8096-2020; Jaulin, Fanny/D-7152-2017	Borg, Jean-Paul/0000-0001-8418-3382; Jaulin, Fanny/0000-0002-5110-1800; Ollendorff, Vincent/0000-0001-9751-2202				Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NAT CELL BIOL, V2, pE114, DOI 10.1038/35017119; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Hata Y, 1996, J NEUROSCI, V16, P2488; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klapper LN, 2000, ADV CANCER RES, V77, P25; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3	50	76	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15256	15263		10.1074/jbc.M010032200	http://dx.doi.org/10.1074/jbc.M010032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278603	Green Published, hybrid			2022-12-27	WOS:000168528800097
J	Woolhead, CA; Mant, A; Kim, SJ; Robinson, C; Rodger, A				Woolhead, CA; Mant, A; Kim, SJ; Robinson, C; Rodger, A			Conformation of a purified "spontaneously" inserting thylakoid membrane protein precursor in aqueous solvent and detergent micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; INDEPENDENT INSERTION; HELIX; SEC; INTEGRATION	Subunit W of photosystem II (PsbW) is a single-span thylakoid membrane protein that is synthesized with a cleavable hydrophobic signal peptide and integrated into the thylakoid membrane by an apparently spontaneous mechanism. In this study, we have analyzed the secondary structure of the pre-protein at early stages of the insertion pathway, using purified recombinant pre-PsbW. We show that the protein remains soluble in Tris buffer after removal of detergent. Under these conditions pre-PsbW contains no detectable alpha -helix, whereas substantial alpha -helical. structure is present in SDS micelles, In aqueous buffer, the tryptophan fluorescence emission characteristics are intermediate between those of solvent exposed and hydrophobic environments, suggesting the formation of a partially folded structure. If denaturants are excluded from the purification protocol, pre-PsbW purifies instead as a 180-kDa oligomer with substantial alpha -helical structure. Mature-size PsbW was prepared by removal of the presequence, and we show that this protein also contains alpha -helix in detergent but in lower quantities than the pre-protein. We therefore propose that pre-PsbW contains alpha -helical structure in both the mature protein and the signal peptide in nonpolar environments. We propose that pre-PsbW acquires its alpha -helical structure only during the later, membrane-bound stages of the insertion pathway, after which it forms a "helical hairpin"-type loop intermediate in the thylakoid membrane.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England	University of Warwick; University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk	Rodger, Alison/A-1063-2009	Rodger, Alison/0000-0002-7111-3024; Mant, Alexandra/0000-0001-7169-209X				Bryson EA, 1999, BIOCHEMISTRY-US, V38, P9758, DOI 10.1021/bi990119o; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARRIS ELV, 1995, PROTEIN PURIFICATION; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; Ladokhin AS, 1999, J MOL BIOL, V285, P1363, DOI 10.1006/jmbi.1998.2346; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Rodger A., 2000, SPECTROPHOTOMETRY SP, P99; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	28	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14607	14613		10.1074/jbc.M009600200	http://dx.doi.org/10.1074/jbc.M009600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278526	hybrid			2022-12-27	WOS:000168528800013
J	Lee, JH; Sundaram, S; Shaper, NL; Raju, TS; Stanley, P				Lee, JH; Sundaram, S; Shaper, NL; Raju, TS; Stanley, P			Chinese hamster ovary (CHO) cells may express six beta 4-galactosyltransferases (beta 4GalTs) - Consequences of the loss of functional beta 4GalT-1, beta 4GalT-6, or both in CHO glycosylation mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; POLY-N-ACETYLLACTOSAMINE; UDP-GALACTOSE; COMPLEX OLIGOSACCHARIDES; KNOCKOUT MICE; BETA-1,4-GALACTOSYLTRANSFERASE; CLONING; CDNA; GLYCANS; FAMILY	Six beta4-galactosyltransferase (beta 4GalT) genes have been cloned from mammalian sources. We show that all six genes are expressed in the Gat(-)2 line of Chinese hamster ovary cells (Gat(-)2 CHO). Two independent mutants termed Pro(-)5Lec20 and Gat(-)2Lec20, previously selected for lectin resistance, were found to have a galactosylation defect. Radiolabeled biantennary N-glycans synthesized by Pro-5Lec20 were proportionately less ricin-bound than similar species from parental CHO cells, and Lec20 cell extracts had a markedly reduced ability to transfer Gal to GlcNAc-terminating acceptors. Northern blot analysis revealed a severe reduction in beta 4GalT-1 transcripts in Pro(-)5Lec20 cells. The Gat(-)2Lec20 mutant expressed beta 4GalT-1 transcripts of reduced size due to a 311-base pair deletion in the beta 4GalT-1 gene coding region. Northern analysis with probes from the remaining five beta 4GalT genes revealed that Gat(-)2 CHO and Gat(-)2Lec20 cells express all six beta 4GalT genes. Unexpectedly,the beta 4GalT-6 gene is not expressed in either Pro(-)5 or Pro(-)5Lec20 cells. Thus, in addition to a deficiency in beta 4GalT-1, Pro(-)5Lec20 cells lack beta 4GalT-6. Nevertheless, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry data of N-glycans released from cellular glycoproteins showed that both the beta 4GalT-1(-) (Gat(-)2Lec20) and beta 4GalT-1(-)/beta 4GalT-6(-) (Pro(-)5Lec20) mutants have a similar Gal deficiency, affecting neutral and sialylated bi-, tri-, and tetraantennary N-glycans. By contrast, glycolipid synthesis was normal in both mutants. Therefore, beta 4GalT-1 is a key enzyme in the galactosylation of N-glycans, but is not involved in glycolipid synthesis in CHO cells. beta 4GalT-6 contributes only slightly to the galactosylation of N-glycans and is also not involved in CHO cell glycolipid synthesis. These CHO glycosylation mutants provide insight into the variety of in vivo substrates of different beta 4GalTs. They may be used in glycosylation engineering and in investigating roles for beta 4GalT-1 and beta 4GalT-6 in generating specific glycan ligands.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21287 USA; Genentech Inc, Analyt Chem, San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine; Roche Holding; Genentech	Stanley, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	NCI NIH HHS [R01 CA36434, R01 CA45799] Funding Source: Medline; PHS HHS [P01 13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036434, R01CA045799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; Dell A, 1999, BBA-GEN SUBJECTS, V1473, P196, DOI 10.1016/S0304-4165(99)00179-8; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; Kido M, 1999, FEBS LETT, V464, P75, DOI 10.1016/S0014-5793(99)01681-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; Stanley P, 1996, GLYCOBIOLOGY, V6, P695, DOI 10.1093/glycob/6.7.695; STANLEY P, 1990, SOMAT CELL MOLEC GEN, V16, P211, DOI 10.1007/BF01233357; STANLEY P, 1980, J CELL BIOL, V85, P60, DOI 10.1083/jcb.85.1.60; SUTTON CW, 1994, ANAL BIOCHEM, V218, P34, DOI 10.1006/abio.1994.1138; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; van Die I, 1999, FEBS LETT, V450, P52, DOI 10.1016/S0014-5793(99)00462-7; WIESER RJ, 1992, IN VITRO CELL DEV-AN, V28A, P233, DOI 10.1007/BF02634238	37	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13924	13934		10.1074/jbc.M010046200	http://dx.doi.org/10.1074/jbc.M010046200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278604	hybrid			2022-12-27	WOS:000168356600059
J	Li, SY; Koromilas, AE				Li, SY; Koromilas, AE			Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-RNA-BINDING; TRANSLATIONAL CONTROL; INITIATION FACTOR-2-ALPHA; MALIGNANT-TRANSFORMATION; VACCINIA VIRUS; IN-VIVO; ACTIVATION; DOMAIN; GENE; DAI	The double-stranded RNA (dsRNA)-activated protein kinase PKR (protein kinase dsRNA-dependent) plays an important role in the regulation of protein synthesis by phosphorylating the alpha -subunit of eukaryotic initiation factor 2. Through this activity, PKR is thought to mediate the antiviral and antiproliferative actions of interferon. Here, we show that the human T cell leukemia Jurkat cells express an alternatively spliced form of PKR with a deletion of exon 7 (PKR Delta E7), resulting in a truncated protein that retains the two dsRNA-binding motifs. PKR Delta E7 exhibits a dominant negative function by inhibiting both PKR autophosphorylation and eukaryotic initiation factor 2 alpha -subunit phosphorylation in vitro and in vivo. Reverse transcriptase-polymerase chain reaction assays showed that PKR Delta E7 is expressed in a broad range of human tissues at variable levels. Interestingly, expression of PKR Delta E7 is higher in Jurkat cells than in normal peripheral blood mononuclear cells, raising the possibility of a role in cell proliferation and/or transformation. Thus, expression of alternatively spliced forms of PKR may represent a novel mechanism of PKR autoregulation with important implications in the control of cell proliferation.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Rm 508,3755 Cote St Catherine St, Montreal, PQ H3T 1E2, Canada.	akoromil@ldi.jgh.mcgill.ca						Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; Adams Alison, 1997, P99; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Bass BL, 1997, RNA, V3, P947; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bergeron J, 2000, CANCER RES, V60, P6800; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CLARKE PA, 1994, NUCLEIC ACIDS RES, V22, P4364, DOI 10.1093/nar/22.21.4364; CLARKE PA, 1995, RNA, V1, P7; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hitti E, 1998, NUCLEIC ACIDS RES, V26, P4382, DOI 10.1093/nar/26.19.4382; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Li SY, 2000, EUR J BIOCHEM, V267, P1598, DOI 10.1046/j.1432-1327.2000.01134.x; LOMHOLT B, 1987, ANAL BIOCHEM, V164, P146, DOI 10.1016/0003-2697(87)90378-2; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1992, J BIOL CHEM, V267, P7671; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Xu Z, 1998, J INTERF CYTOK RES, V18, P609, DOI 10.1089/jir.1998.18.609; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	61	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13881	13890		10.1074/jbc.M008140200	http://dx.doi.org/10.1074/jbc.M008140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278390	hybrid			2022-12-27	WOS:000168356600054
J	Touyz, RM; Mercure, C; Reudelhuber, TL				Touyz, RM; Mercure, C; Reudelhuber, TL			Angiotensin II type I receptor modulates intracellular free Mg2+ in renally derived cells via Na+-dependent Ca2+-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; CYTOSOLIC FREE MAGNESIUM; RED-BLOOD-CELLS; FLUORESCENT INDICATOR; ASCITES-CELLS; HEART-CELLS; RAT; CALCIUM; EXCHANGER	Treatment of Madin-Darby canine kidney (MDCK) cells with the peptide hormone angiotensin II (Ang II) results in an increase in the concentrations of cytosolic free calcium ([Ca2+](i)) and sodium ([Na+](i)) with a concomitant decrease in cytosolic free Mg2+ concentration ([Mg2+](i)). In the present study we demonstrate that this hormone induced decrease in [Mg2+](i) is independent of [Ca2+](i) but dependent on extracellular Na+. [Mg2+](i), [Ca2+](i), and [Na+](i) were measured in Ang II-stimulated MDCK cells by fluorescence digital imaging using the selective fluoroprobes mag-fura-2AM, fura-2AM, and sodium-binding benzofuran isophthalate (acetoxy methyl ester), respectively. Ang II decreased [Mg2+](i) and increased [Na+](i) in a dose-dependent manner. These effects were inhibited by irbesartan (selective AT(1) receptor blocker) but not by PD123319 (selective AT(2) receptor blocker). Imipramine and quinidine (putative inhibitors of the Na+/Mg2+ exchanger) and removal of extracellular Na+ abrogated Ang II-mediated [Mg2+](i) effects, In cells pretreated with thapsigargin (reticular Ca2+-ATPase inhibitor), Ang II-stimulated [Ca2+](i) transients were attenuated (p < 0.01), whereas agonist-induced [Mg2+](i) responses were unchanged. Clamping the [Ca2+](i) near 50 nmol/liter with 1,2-bis(2-aminophenoxy)ethane-N,N,N' N'-tetraacetic acid tetrakis(acetoxymethyl ester) inhibited Ang II-induced [Ca2+](i) increases but failed to alter Ang II-induced [Mg2+](i) responses. Benzamil, a selective blocker of the Na+/Ca2+ exchanger, inhibited [Na+](i) but not [Mg2+](i) responses. Our data demonstrate that in MDCK cells, AT(1) receptors modulate [Mg2+](i) via a Na+-dependent Mg2+ transporter that is not directly related to [Ca2+](i). These data support the notion that rapid modulation of [Mg2+](i) is not simply a result of Mg2+ redistribution from intracellular buffering sites by Ca2+ and provide evidence for the existence of a Na+-dependent, hormonally regulated transporter for Mg2+ in renally derived cells.	Univ Montreal, Clin Res Inst Montreal, Multidisciplinary Res Grp Hypertens, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Touyz, RM (corresponding author), Univ Montreal, Clin Res Inst Montreal, Multidisciplinary Res Grp Hypertens, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	touyzr@ircm.qc.ca	Touyz, Rhian/AAM-3564-2020	Touyz, Rhian/0000-0003-0670-0887				Bkaily G, 1998, MOL CELL BIOCHEM, V188, P187, DOI 10.1023/A:1006806925739; BURI A, 1990, EXP PHYSIOL, V75, P751, DOI 10.1113/expphysiol.1990.sp003457; Cefaratti C, 2000, J BIOL CHEM, V275, P3772, DOI 10.1074/jbc.275.6.3772; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Dai LJ, 1998, AM J PHYSIOL-RENAL, V274, pF336, DOI 10.1152/ajprenal.1998.274.2.F336; Delva P, 2000, HYPERTENSION, V35, P113, DOI 10.1161/01.HYP.35.1.113; DEWEER P, 1976, J GEN PHYSIOL, V68, P159, DOI 10.1085/jgp.68.2.159; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FERAY JC, 1986, BIOCHIM BIOPHYS ACTA, V856, P76, DOI 10.1016/0005-2736(86)90012-X; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GILBERT EK, 1992, J CLIN INVEST, V89, P1988; GRUBBS RD, 1984, J BIOL CHEM, V259, P2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1990, BIOCHIM BIOPHYS ACTA, V1023, P455, DOI 10.1016/0005-2736(90)90139-F; GUNTHER T, 1992, FEBS LETT, V297, P132, DOI 10.1016/0014-5793(92)80343-F; GUNTHER T, 1996, MAGNES B, V18, P1; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; Jan CR, 1999, LIFE SCI, V65, P2513, DOI 10.1016/S0024-3205(99)00518-4; KEENAN D, 1995, CIRC RES, V77, P973, DOI 10.1161/01.RES.77.5.973; Mandel G, 1999, NATURE, V398, P29, DOI 10.1038/17933; Morrill GA, 1998, FEBS LETT, V440, P167, DOI 10.1016/S0014-5793(98)01446-X; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; Murphy E, 2000, CIRC RES, V86, P245, DOI 10.1161/01.RES.86.3.245; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Nakajima T, 1997, EUR J PHARMACOL, V320, P81, DOI 10.1016/S0014-2999(96)00873-4; OKADA K, 1992, AM J PHYSIOL, V263, pC873, DOI 10.1152/ajpcell.1992.263.4.C873; OROURKE B, 1992, SCIENCE, V257, P245, DOI 10.1126/science.1321495; PICADO MJ, 1994, HYPERTENSION, V23, P987, DOI 10.1161/01.HYP.23.6.987; QUAMME GA, 1990, AM J PHYSIOL, V259, pC521, DOI 10.1152/ajpcell.1990.259.3.C521; QUAMME GA, 1993, AM J PHYSIOL, V265, pH281, DOI 10.1152/ajpheart.1993.265.1.H281; Quan A, 2000, NEPHRON, V84, P103, DOI 10.1159/000045556; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROMANI A, 1992, FEBS LETT, V296, P135, DOI 10.1016/0014-5793(92)80364-M; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; Romani AMP, 2000, CIRC RES, V86, P326, DOI 10.1161/01.RES.86.3.326; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Touyz RM, 1996, J BIOL CHEM, V271, P24353, DOI 10.1074/jbc.271.40.24353; Touyz RM, 1999, HYPERTENSION, V34, P442, DOI 10.1161/01.HYP.34.3.442; TOUYZ RM, 1994, J HYPERTENS, V12, P663; TOUYZ RM, 1993, J HYPERTENS, V11, P551, DOI 10.1097/00004872-199305000-00011; Wolf FI, 1996, ARCH BIOCHEM BIOPHYS, V331, P194, DOI 10.1006/abbi.1996.0298; WOLF FI, 1994, BIOCHEM BIOPH RES CO, V202, P1209, DOI 10.1006/bbrc.1994.2059; WOLF FI, 1999, FRONT BIOSCI, V4, P1; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6; Zhang GH, 1996, J BIOL CHEM, V271, P29067, DOI 10.1074/jbc.271.46.29067; ZHANG GH, 1995, FEBS LETT, V371, P52, DOI 10.1016/0014-5793(95)00869-B	47	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13657	13663		10.1074/jbc.M008101200	http://dx.doi.org/10.1074/jbc.M008101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278387	hybrid			2022-12-27	WOS:000168356600023
J	Wang, J; Chen, H; Brown, EJ				Wang, J; Chen, H; Brown, EJ			L-plastin peptide activation of alpha(v)beta(3)-mediated adhesion requires integrin conformational change and actin filament disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOPLASMIC TAIL; LIGAND-BINDING; TYROSINE PHOSPHORYLATION; PLATELET CYTOSKELETON; MEDIATED ADHESION; HUMAN NEUTROPHILS; CELL-ADHESION; DOMAIN; ALPHA(5)BETA(1)	L-plastin (LPL) is a leukocyte actin binding protein previously implicated in the activation of the integrin alpha (M)beta (2) on polymorphonuclear neutrophils. To determine the role for LPL in integrin activation, K562 cell adhesion to vitronectin via alpha (v)beta (3) a well-studied model for activable integrins, was examined. Cell permeant versions of peptides based on the N-terminal sequence of LPL and the LPL headpiece domain both activated alpha (v)beta (3)-mediated adhesion. In contrast to adhesion induced by treatment with phorbol 12-myristate 13-acetate (PMA), LPL peptide-activated adhesion was independent of integrin beta (3) cytoplasmic domain tyrosines and was not inhibited by cytochalasin D. Also in contrast to PMA, LPL peptides synergized with RGD ligand or Mn2+ for generation of a conformational change in alpha (v)beta (3) associated with the high affinity state of the integrin, as determined by binding of a ligand-induced binding site antibody. Although LPL and ligand showed synergy for ligand-induced binding site expression when actin depolymerization was inhibited by jasplakinolide, LPL peptide-induced adhesion was inhibited. Thus, both act-in depolymerization and ligand-induced integrin conformational change are required for LPL peptide-induced adhesion. We hypothesize that the critical steps of increased integrin diffusion and affinity enhancement may be linked via modulation of the function of the actin binding protein L-plastin.	Univ Calif San Francisco, Program Host Pathogen Interact, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Div Biol & Biomed Sci, Program Mol Cell Biol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; Washington University (WUSTL)	Brown, EJ (corresponding author), Univ Calif San Francisco, Program Host Pathogen Interact, Campus Box 0654,518 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035811] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35811] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; GINSBERG MH, 1995, BIOCHEM SOC T, V23, P439, DOI 10.1042/bst0230439; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Jones SL, 1998, J BIOL CHEM, V273, P10556, DOI 10.1074/jbc.273.17.10556; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Jones SL, 1996, J BIOL CHEM, V271, P14623, DOI 10.1074/jbc.271.24.14623; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; LIN CS, 1990, MOL CELL BIOL, V10, P1818, DOI 10.1128/MCB.10.4.1818; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PACIFICI R, 1994, J IMMUNOL, V153, P2222; PAINTER RG, 1982, J CELL BIOL, V92, P565, DOI 10.1083/jcb.92.2.565; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; ROSALES C, 1994, P NATL ACAD SCI USA, V91, P3534, DOI 10.1073/pnas.91.9.3534; Sadhu C, 1998, J IMMUNOL, V160, P5622; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang J, 1999, J BIOL CHEM, V274, P24349, DOI 10.1074/jbc.274.34.24349; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	41	35	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14474	14481		10.1074/jbc.M007324200	http://dx.doi.org/10.1074/jbc.M007324200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278342	hybrid			2022-12-27	WOS:000168356600127
J	Arima, N; Kao, CY; Licht, T; Padmanabhan, R; Sasaguri, Y; Padmanabhan, R				Arima, N; Kao, CY; Licht, T; Padmanabhan, R; Sasaguri, Y; Padmanabhan, R			Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TETRACYCLINE-REGULATED SYSTEM; NON-B-HEPATITIS; IN-VITRO; NON-A; HUMAN FIBROBLASTS; EPITHELIAL-CELLS; MOLECULAR CLONE; GENE-EXPRESSION; MAMMALIAN-CELLS	Hepatitis C virus nonstructural protein, NS5A, is a phosphoprotein produced from the processing of the viral polyprotein precursor, NS5A associates with several cellular proteins in mammalian cells, and the biological consequences of this interaction are currently unknown. To this end, five stable NS5A-expressing murine and human cell lines were established, Tetracycline-regulated NIH3T3 cells and rat liver epithelial cells as well as the constitutive, NS5A-expressing, human Chang liver, HeLa, and NIH3T3 cells all exhibited cell growth retardation compared with the control cells. Cell cycle analysis by flow cytometry indicated that the NSSA-expressing human epitheloid tumor cells had a reduced S phase and an increase in the G(2)/M phase, which could be explained by a p53-dependent induction of p21(Waf1/Cip1) protein and mRNA levels. NS5A interacts with Cdk1 in vivo and in vitro, and a significant portion of the p21(Waf1/Cip1) was found to be in a complex with Cdk2 in the NS5A-expressing human hepatic cell line, Cdk1 and cyclin B1 proteins were also reduced in human Chang liver cells consistent with the increase in G(2)/M phase. Our results suggest that the NS5A protein causes growth inhibition and cell cycle perturbations by targeting the Cdk1/2-cyclin complexes.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Kitakyushu, Fukuoka 807, Japan	University of Kansas; University of Kansas Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Occupational & Environmental Health - Japan	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	rpadmana@kumc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI044036] Funding Source: NIH RePORTER; NIAID NIH HHS [R03-AI-44036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; Beard MR, 1999, HEPATOLOGY, V30, P316, DOI 10.1002/hep.510300137; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Chen HF, 1996, J BIOL CHEM, V271, P13959, DOI 10.1074/jbc.271.24.13959; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gallia GL, 1998, ONCOGENE, V16, P1879, DOI 10.1038/sj.onc.1201706; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hirota M, 1999, VIROLOGY, V257, P130, DOI 10.1006/viro.1999.9658; Hong Z, 1999, VIROLOGY, V256, P36, DOI 10.1006/viro.1999.9603; HUGGETT AC, 1991, CANCER RES, V51, P5929; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Kao CY, 1997, IN VITRO CELL DEV-AN, V33, P282; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nishino Y, 1997, BIOCHEM BIOPH RES CO, V232, P550, DOI 10.1006/bbrc.1997.6186; Nishizawa M, 1999, VIROLOGY, V263, P313, DOI 10.1006/viro.1999.9905; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; Reed KE, 1999, J BIOL CHEM, V274, P28011, DOI 10.1074/jbc.274.39.28011; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIH C, 1996, ENCY CANC, V2, P824; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SHUKLA DD, 1995, ARCH VIROL, V140, P1747, DOI 10.1007/BF01384339; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738	65	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12675	12684		10.1074/jbc.M008329200	http://dx.doi.org/10.1074/jbc.M008329200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278402	hybrid			2022-12-27	WOS:000168198600029
J	Guan, E; Wang, JH; Norcross, MA				Guan, E; Wang, JH; Norcross, MA			Identification of human macrophage inflammatory proteins 1 alpha and 1 beta as a native secreted heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; BETA-CHEMOKINES; H-1-NMR SPECTROSCOPY; PLATELET FACTOR-4; CRYSTAL-STRUCTURE; NMR ASSIGNMENTS; CCR5 EXPRESSION; T-CELLS; RESOLUTION; DIMER	Chemokines are secreted proteins that function as chemoattractants for leukocytes. The chemokines macrophage inflammatory protein 1 alpha and 1 beta (MIP-1 alpha and MIP-1 beta) now have been shown to be secreted from activated human monocytes and peripheral blood lymphocytes (PBLs) as a heterodimer. Immunoprecipitation and immunoblot analysis revealed that antibodies to either MIP-1 alpha or MIP-1 beta precipitated a protein complex containing both MIP-1 alpha and MIP-1 beta under normal conditions from culture supernatants and lysates of these cells. Mass spectrometry of the complexes, precipitated from the culture supernatants of monocytes and PBLs, revealed the presence of NH2-terminal truncated MIP-1 alpha (residues 5-70) together with either intact MIP-1 beta or NH2-terminal truncated MIP-1 beta (residues 3-69), respectively. The secreted MIP-1 alpha/beta heterodimers were dissociated into their component monomers under acidic conditions. Exposure of monocytes or PBLs to monensin induced the accumulation of heterodimers composed of NH2-terminal truncated MTP-1 alpha and full-length MIP-1 beta in the Golgi complex. The mixing of recombinant chemokines in vitro demonstrated that heterodimerization of MIP-1 alpha and MIP-1 beta is specific and that it occurs at physiological conditions, pH 7.4, and in the range of nanomolar concentrations. The data presented here provide the first biochemical evidence for the existence of chemokine heterodimers under natural conditions. Formation of heterodimers of MIP-1 alpha/beta may have an impact on intracellular signaling events that contribute to CCR5 and possibly to other chemokine receptor functions.	NIH, Lab Gene Regulat, Div Therapeut Prot, Ctr Biol Evaluat & Res,US FDA,HFM 535, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Guan, E (corresponding author), NIH, Lab Gene Regulat, Div Therapeut Prot, Ctr Biol Evaluat & Res,US FDA,HFM 535, Bldg 29B,Rm 4E12,8800 Rockville Pike, Bethesda, MD 20892 USA.							Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; CHEN MJ, 1991, BIOCHEMISTRY-US, V30, P6402, DOI 10.1021/bi00240a009; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COVELL DG, 1994, PROTEIN SCI, V3, P2064, DOI 10.1002/pro.5560031119; FAIRBROTHER WJ, 1993, FEBS LETT, V330, P302, DOI 10.1016/0014-5793(93)80893-Y; Garzino-Demo A, 1999, P NATL ACAD SCI USA, V96, P11986, DOI 10.1073/pnas.96.21.11986; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Horcher M, 1998, CYTOKINE, V10, P1, DOI 10.1006/cyto.1997.0251; KIM KS, 1994, J BIOL CHEM, V269, P32909; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Korimilli A, 2000, J BIOL CHEM, V275, P8672, DOI 10.1074/jbc.275.12.8672; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Wang JH, 1999, J IMMUNOL, V163, P5763; Wang JH, 1998, J VIROL, V72, P7642, DOI 10.1128/JVI.72.9.7642-7647.1998; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	33	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12404	12409		10.1074/jbc.M006327200	http://dx.doi.org/10.1074/jbc.M006327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278300	hybrid			2022-12-27	WOS:000168081800128
J	Milland, J; Taylor, SG; Dodson, HC; McKenzie, IFC; Sandrin, MS				Milland, J; Taylor, SG; Dodson, HC; McKenzie, IFC; Sandrin, MS			The cytoplasmic tail of alpha 1,2-fucosyltransferase contains a sequence for Golgi localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; MEDIAL-GOLGI; TRANSMEMBRANE DOMAINS; KIN RECOGNITION; PLASMA-MEMBRANE; GLYCOSYLTRANSFERASES; SPECIFY; PROTEIN; ALPHA-2,6-SIALYLTRANSFERASE; ORGANIZATION	The Golgi apparatus has a central role in the glycosylation of proteins and lipids. There is a sequential addition of carbohydrates by glycosyltransferases that are distributed within the Golgi in the order in which the glycosylation occurs. The mechanism of glycosyltransferase retention is considered to involve their transmembrane domains and flanking regions, although we have shown that the cytoplasmic tail of alpha1,2-fucosyltransferase is important for its Golgi localization Here we show that the removal of the alpha1,2-fucosyltransferase cytoplasmic tail altered its function of fucosylation and its localization site. When the tail was removed, the enzyme moved from the Golgis to the trans Golgi network, suggesting that the transmembrane is responsible for retention and that the cytoplasmic tail is responsible for localization. The cytoplasmic tail of alpha1,2-fucosyltransfefase contains 8 amino acids (MWVPSRRH), and mutating these to alanine indicated a role for amino acids 3 to 7 in localization with a particular role of Sers. Mutagenesis of Ser(5) to amino acids containing an hydroxyl (Tyr and Thr) demonstrated that the hydroxyl at position 5 is important. Thus, the cytoplasmic tail, and especially a single amino acid, has a predominant role in the localization and thus the function of alpha1,2-fucosyltransferase.	Austin & Repatriat Med Ctr, Austin Res Inst, John Connell Lab Glycobiol, Heidelberg, Vic 3084, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Sandrin, MS (corresponding author), Austin & Repatriat Med Ctr, Austin Res Inst, John Connell Lab Glycobiol, Studley Rd, Heidelberg, Vic 3084, Australia.	m.sandrin@ari.unimelb.edu.au		Milland, Julie/0000-0003-1368-220X				Andersson AM, 1998, J VIROL, V72, P9585, DOI 10.1128/JVI.72.12.9585-9596.1998; BENDIAK B, 1990, BIOCHEM BIOPH RES CO, V170, P879, DOI 10.1016/0006-291X(90)92173-W; Cohney S, 1996, IMMUNOGENETICS, V44, P76, DOI 10.1007/BF02602660; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Gonatas JO, 1998, J CELL SCI, V111, P249; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Sandrin Mauro S., 1994, Xenotransplantation, V1, P81, DOI 10.1111/j.1399-3089.1994.tb00053.x; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; VAUGHAN HA, 1991, IMMUNOGENETICS, V33, P113	27	37	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12012	12018		10.1074/jbc.M010018200	http://dx.doi.org/10.1074/jbc.M010018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278599	hybrid			2022-12-27	WOS:000168081800077
J	Rogers, MS; Strehler, EE				Rogers, MS; Strehler, EE			The tumor-sensitive calmodulin-like protein is a specific light chain of human unconventional myosin X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED PHOSPHORYLATION; BINDING PROTEINS; EPITHELIAL-CELLS; IDENTIFICATION; GENE; EXPRESSION; TRANSFORMATION; HYBRIDIZATION; ACTIVATION; SEQUENCE	Human calmodulin-like protein (CLP) is an epithelial-specific Ca2+-binding protein whose expression is strongly down-regulated in cancers. Like calmodulin, CLP is thought to regulate cellular processes via Ca2+-dependent interactions with specific target proteins. Using gel overlays, we identified a similar to 210-kDa protein binding specifically and in a Ca2+-dependent manner to CLP, but not to calmodulin. Yeast two-hybrid screening yielded a CLP-interacting clone encoding the three light chain binding IQ motifs of human "unconventional" myosin X. Pull-down experiments showed CLP binding to the IQ domain to be direct and Ca2+-dependent. CLP interacted strongly with IQ motif 3 (K-d similar to0.5 nM) as determined by surface plasmon resonance. Epitope-tagged myosin X was localized preferentially at the cell periphery in MCF-7 cells, and CLP colocalized with myosin X in these cells. Myosin X was able to coprecipitate CLP and, to a lesser extent, calmodulin from transfected COS-1 cells, indicating that CLP is a specific light chain of myosin X in vivo. Because unconventional myosins participate in cellular processes ranging from membrane trafficking to signaling and cell motility, myosin X is an attractive CLP target. Altered myosin X regulation in (tumor) cells lacking CLP may have as yet unknown consequences for cell growth and differentiation.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Biochem & Mol Biol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Strehler, EE (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Biochem & Mol Biol, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.		Rogers, Michael S/A-9814-2009; Rogers, Michael/AAE-2217-2019	Rogers, Michael S/0000-0002-5250-8434; Rogers, Michael/0000-0002-5250-8434	NCI NIH HHS [T32CA75926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BENGURIA A, 1995, EUR J BIOCHEM, V234, P50, DOI 10.1111/j.1432-1033.1995.050_c.x; BERCHTOLD MW, 1993, HUM GENET, V90, P496; Berg JS, 2000, J CELL SCI, V113, P3439; BILLINGSLEY ML, 1990, METHOD ENZYMOL, V184, P451; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Chen LF, 1999, MOL BIOL CELL, V10, p164A; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P6089, DOI 10.1021/bi00074a021; EDMAN CF, 1994, EUR J BIOCHEM, V226, P725, DOI 10.1111/j.1432-1033.1994.tb20101.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Ittmann MM, 1998, ONCOL REP, V5, P1329; JOHNSTON JR, 1994, MOL GENETICS YEAST P, V141; Joyal JL, 1996, BIOCHEMISTRY-US, V35, P6267, DOI 10.1021/bi9600198; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; KOLLER M, 1988, FEBS LETT, V239, P121, DOI 10.1016/0014-5793(88)80558-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; Qian H, 1998, PROTEIN SCI, V7, P2421, DOI 10.1002/pro.5560071120; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; RHYNER JA, 1992, BIOCHEMISTRY-US, V31, P12826, DOI 10.1021/bi00166a017; Robertson GP, 1999, CANCER RES, V59, P3596; Rogers M. S., 1996, GUIDEBOOK CALCIUM BI, P34; Rogers Michael S., 1999, Neoplasia (New York), V1, P220, DOI 10.1038/sj.neo.7900029; Roylance R, 1999, CANCER RES, V59, P1433; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SOLE CK, 1994, AUDIT NEUROSCI, V1, P63; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; YASWEN P, 1992, CELL GROWTH DIFFER, V3, P335; YASWEN P, 1990, P NATL ACAD SCI USA, V87, P7360, DOI 10.1073/pnas.87.19.7360; Yonezawa S, 2000, BIOCHEM BIOPH RES CO, V271, P526, DOI 10.1006/bbrc.2000.2669	45	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12182	12189		10.1074/jbc.M010056200	http://dx.doi.org/10.1074/jbc.M010056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278607	hybrid			2022-12-27	WOS:000168081800101
J	Harrison, JK; Fong, AM; Swain, PAW; Chen, SZ; Yu, YRA; Salafranca, MN; Greenleaf, WB; Imai, T; Patel, DD				Harrison, JK; Fong, AM; Swain, PAW; Chen, SZ; Yu, YRA; Salafranca, MN; Greenleaf, WB; Imai, T; Patel, DD			Mutational analysis of the fractalkine chemokine domain - Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND CHEMOKINE; CRYSTAL-STRUCTURE; DENDRITIC CELLS; RECEPTOR; CX(3)CR1; IDENTIFICATION; INFLAMMATION; ACTIVATION; EXPRESSION; MICROGLIA	Fractalkine (FKN/CX3CL1) is a unique member of the chemokine gene family and contains a chemokine domain (CD), a mucin-like stalk, a single transmembrane region, and a short intracellular C terminus. This structural distinction affords FKN the property of mediating capture and firm adhesion of FKN receptor (CX3CR1)-expressing cells under physiological flow conditions. Shed forms of FKN also exist, and these promote chemotaxis of CX3CR1-expressing leukocytes. The goal of the present study was to identify specific residues within the FKN-CD critical for FKN-CX3CR1 interactions. Two residues were identified in the FKN-CD, namely Lys-7 and Arg-47, that are important determinants in mediating an FKN-CX3CR1 interaction. FKN-K7A and FKN-R47A mutants exhibited 30-60-fold decreases in affinity for CX3CR1 and failed to arrest efficiently CX3CR1-expressing cells under physiological flow conditions. However, these mutants had differential effects on chemotaxis of CX3CR1-expressing cells, The FKN-K7A mutant acted as an equipotent partial agonist, whereas the FKN-R47A mutant had marked decreased potency and efficacy in measures of chemotactic activity. These data identify specific structural features of the FKN-CD that are important in interactions with CX3CR1 including steady state binding, signaling, and firm adhesion of CX3CR1-expressing cells.	Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; KAN Res Inst, Kyoto 6008815, Japan	State University System of Florida; University of Florida; Duke University; Duke University; KAN Research Institute	Harrison, JK (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Box 100267, Gainesville, FL 32610 USA.				NIAMS NIH HHS [AR39162] Funding Source: Medline; NINDS NIH HHS [NS34901] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034901] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hoover DM, 2000, J BIOL CHEM, V275, P23187, DOI 10.1074/jbc.M002584200; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kanazawa N, 1999, EUR J IMMUNOL, V29, P1925, DOI 10.1002/(SICI)1521-4141(199906)29:06<1925::AID-IMMU1925>3.0.CO;2-U; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Papadopoulos EJ, 1999, EUR J IMMUNOL, V29, P2551, DOI 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T; Papadopoulos EJ, 2000, EUR J IMMUNOL, V30, P2355, DOI 10.1002/1521-4141(2000)30:8<2355::AID-IMMU2355>3.0.CO;2-#; Schwaeble WJ, 1998, FEBS LETT, V439, P203, DOI 10.1016/S0014-5793(98)01384-2; SPRINGER TA, 1994, CELL, V76, P310	25	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21632	21641		10.1074/jbc.M010261200	http://dx.doi.org/10.1074/jbc.M010261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11278650	hybrid			2022-12-27	WOS:000169297900111
J	Andreev, J; Galisteo, ML; Kranenburg, O; Logan, SK; Chiu, ES; Okigaki, M; Cary, LA; Moolenaar, WH; Schlessinger, J				Andreev, J; Galisteo, ML; Kranenburg, O; Logan, SK; Chiu, ES; Okigaki, M; Cary, LA; Moolenaar, WH; Schlessinger, J			Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY KINASES; PATHWAYS; TRANSACTIVATION; FIBROBLASTS; CELLS; GAMMA	The epidermal growth factor receptor (EGFR) and the non-receptor protein tyrosine kinases Src and Pyk2 have been implicated in linking a variety of G-protein-coupled receptors (GPCR) to the mitogen-activated protein (MAP) kinase signaling cascade. In this report we apply a genetic strategy using cells isolated from Src-, Pyk2-, or EGFR-deficient mice to explore the roles played by these protein tyrosine kinases in GPCR-induced activation of EGFR, Pyk2, and MAP kinase. We show that Src kinases are critical for activation of Pyk2 in response to GPCR-stimulation and that Pyk2 and Src are essential for GPCR-induced tyrosine phosphorylation of EGFR, By contrast, Pyk2, Src, and EGFR are dispensable for GPCR-induced activation of MAP kinase. Moreover, GPCR-induced MAP kinase activation is normal in fibroblasts deficient in both Src and Pyk2 (Src-/-Pyk2-/- cells) as well as in fibroblasts deficient in all three Src kinases expressed in these cells (Src-/-Yes-/-Fyn-/- cells). Finally, experiments are presented demonstrating that, upon stimulation of GPCR, activated Pyk2 forms a complex with Src, which in turn phosphorylates EGFR directly. These experiments reveal a role for Src kinases in Pyk2 activation and a role for Pyk2 and Src in tyrosine phosphorylation of EGFR following GPCR stimulation, In addition, EGFR, Src family kinases, and Pyk2 are not required for linking GPCRs with the MAP kinase signaling cascade.	NYU, Sch Med, Dept Pharmacol, Skirball Inst Biomol Med, New York, NY 10016 USA; Netherlands Canc Inst, Ctr Biomed Genet, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	New York University; Netherlands Cancer Institute; Fred Hutchinson Cancer Center	Schlessinger, J (corresponding author), NYU, Sch Med, Dept Pharmacol, Skirball Inst Biomol Med, 550 1st Ave, New York, NY 10016 USA.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390; Logan, Susan/0000-0002-7904-5927				BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257	23	175	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20130	20135		10.1074/jbc.M102307200	http://dx.doi.org/10.1074/jbc.M102307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274221	hybrid			2022-12-27	WOS:000169135100062
J	Tu, S; Cerione, RA				Tu, S; Cerione, RA			Cdc42 is a substrate for caspases and influences Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MEDIATED APOPTOSIS; RAS; CELLS; TRANSFORMATION; ACTIVATION; RHO; INHIBITION; PROTEINS; REQUIRES	Fas-mediated apoptosis results in the activation of caspases, which subsequently cleave cellular substrates that are essential for normal cell viability. In the present study, we show that the Ras-related GTP-binding protein Cdc42 is susceptible to caspase-catalyzed proteolysis in a number of cell lines, including NIH3T3 fibroblasts, human breast cancer cells (e.g, T47D), and COS-7 cells. Both caspase-3 and caspase-7 were able to catalyze the cleavage of Cdc42, whereas caspase-6 and caspase-8 were without effect. The susceptibility to the caspase-stimulated degradation is specific; although Rac can also serve as a caspase substrate, neither Rho nor Ras is degraded. Caspase sensitivity is conferred by a consensus sequence (DXXD) that lies immediately upstream of the Rho insert regions (residues 122-134) of Cdc42 and Rac, The removal of a stretch of residues (120-139) that includes the insert region or site-directed mutagenesis of either aspartic acid 118 or 121 within a constitutively active background (i.e. Cdc42(F28L)) as well as a wildtype Cdc42 background yields Cdc42 molecules that provide a marked protection against Fas ligand-induced apoptosis, Overall, these results are consistent with a model in which Cdc42 acts downstream of Fas, perhaps to influence the rate of apoptosis, with the ultimate caspase-mediated degradation of Cdc42 then allowing for a maximal apoptotic response.	Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.			Tu, S. Sean/0000-0003-0391-8186	NIGMS NIH HHS [GM47458, GM61762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061762, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Muscarella DE, 1998, EXP CELL RES, V238, P155, DOI 10.1006/excr.1997.3832; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655	27	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19656	19663		10.1074/jbc.M009838200	http://dx.doi.org/10.1074/jbc.M009838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278572	hybrid			2022-12-27	WOS:000169091000132
J	Husberg, C; Murphy, P; Martin, E; Kolsto, AB				Husberg, C; Murphy, P; Martin, E; Kolsto, AB			Two domains of the human bZIP transcription factor TCF11 are necessary for transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-EXPRESSION; SMALL MAF PROTEINS; FACTOR NF-E2; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; P45 NF-E2; FAMILY; NRF1; TRANSLATION; MICE	TCF11 is a bZIP transcription factor of the CNC subfamily. It has been implicated in the regulation of the antioxidant response and is vital during embryonic development, but its precise biological functions have not yet been fully worked out. Structural characterization of the gene and several of its products indicates that complex regulatory mechanisms are employed. To investigate how altering the structure of the gene products might influence their activity we have mapped functional domains within the protein. We show that two separate domains are required for transactivation by full-length TCF11: an N-terminal acidic domain and a serine-rich stretch adjacent to the CNC-bZIP domains. A naturally occurring shorter isoform (identical to LCRF1) produced by internal initiation of translation is unable to transactivate in our assay. However, the shorter form could interfere with the transactivating ability of the longer form, which indicates a control mechanism for keeping the activity of TCF11 at a desired level. We show that TCF11 and the closely related CNC-bZIP factor p45 NF-E2 show different cell type-specific activation patterns with full-length TCF11 being active in COS-l cells but silent in erythroid cells (K562), whereas p45 NF-ES is active in K562 cells and silent in COS-l cells. Domain swapping experiments show that cell type-specific activity is not fully determined by dimerization/DNA binding domains or transactivation domains alone. The resulting profile of activity is most likely achieved by interaction of the domains and their cell-specific environment.	Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway	University of Oslo	Kolsto, AB (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, 1125 Blindern, N-0316 Oslo, Norway.			Murphy, Paula/0000-0002-8048-6850				Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LUNA L, 1995, GENOMICS, V27, P237, DOI 10.1006/geno.1995.1037; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murphy P, 2000, MECH DEVELOP, V97, P141, DOI 10.1016/S0925-4773(00)00413-5; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; Onodera K, 1999, J BIOL CHEM, V274, P21162, DOI 10.1074/jbc.274.30.21162; Prieschl EE, 1998, NUCLEIC ACIDS RES, V26, P2291, DOI 10.1093/nar/26.10.2291; Sambrook J., 2002, MOL CLONING LAB MANU; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960	35	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17641	17652		10.1074/jbc.M007951200	http://dx.doi.org/10.1074/jbc.M007951200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278371	Green Published, hybrid			2022-12-27	WOS:000168866500005
J	Zarei, MM; Zhu, N; Alioua, A; Eghbali, M; Stefani, E; Toro, L				Zarei, MM; Zhu, N; Alioua, A; Eghbali, M; Stefani, E; Toro, L			A novel MaxiK splice variant exhibits dominant-negative properties for surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; ENDOPLASMIC-RETICULUM; BETA-SUBUNIT; K+ CHANNEL; ALPHA-SUBUNIT; MEMBRANE-PROTEINS; RAT-BRAIN; CALCIUM; SIGNAL; CLONING	We identified a novel MaxiK alpha subunit splice variant (SV1) from rat myometrium that is also present in brain. SV1 has a 33-amino acid insert in the S1 transmembrane domain that does not alter S1 overall hydrophobicity, but makes the S0-S1 linker longer. SV1 was transfected in HEK293T cells and studied using immunocytochemistry and electrophysiology. In non-permeabilized cells, N-terminal c-Myc- or C-terminal green fluorescent protein-tagged SV1 displayed no surface labeling or currents. The lack of SV1 functional expression was due to endoplasmic reticulum (ER) retention as determined by colabeling experiments with a specific ER marker. To explore the functional role of SV1, we coexpressed SV1 with the alpha (human SLO) and beta1 (KCNMB1) subunits of the MaxiK channel. Coexpression of SV1 inhibited surface expression of alpha and beta1 subunits similar to 80% by trapping them in the ER. This inhibition seems to be specific for MaxiK channel subunits since SV1 was unable to prevent surface expression of the Kv4.3 channel or to interact with green fluorescent protein. These results indicate a dominant-negative role of SV1 in MaxiK channel expression. Moreover, they reveal down-regulation by splice variants as a new mechanism that may contribute to the diverse levels of MaxiK channel expression in non-excitable and excitable cells.	Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Toro, L (corresponding author), Univ Calif Los Angeles, Dept Anesthesiol, BH 509A CHS,POB 957115, Los Angeles, CA 90095 USA.	ltoro@ucla.edu			NHLBI NIH HHS [HL47382] Funding Source: Medline; NIGMS NIH HHS [GM52203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047382, R29HL047382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Demolombe S, 1998, J BIOL CHEM, V273, P6837, DOI 10.1074/jbc.273.12.6837; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grunnet M, 1999, AM J PHYSIOL-GASTR L, V277, pG22, DOI 10.1152/ajpgi.1999.277.1.G22; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1995, J BIOL CHEM, V270, P22434, DOI 10.1074/jbc.270.38.22434; Kramer JW, 1998, AM J PHYSIOL-CELL PH, V274, pC1501, DOI 10.1152/ajpcell.1998.274.6.C1501; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LODISH H, 1995, MOL CELL BIOL, P669; LODISH H, 1995, MOL CELL BIOL, P485; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Meera P, 2001, POTASSIUM CHANNELS IN CARDIOVASCULAR BIOLOGY, P49; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Meyer E, 1999, EUR J NEUROSCI, V11, P1105, DOI 10.1046/j.1460-9568.1999.00548.x; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Tsaur ML, 1997, FEBS LETT, V400, P215, DOI 10.1016/S0014-5793(96)01388-9; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Xia XM, 1998, J NEUROSCI, V18, P2360; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	47	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16232	16239		10.1074/jbc.M008852200	http://dx.doi.org/10.1074/jbc.M008852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278440	hybrid			2022-12-27	WOS:000168623100089
J	Oshima, Y; Puri, RK				Oshima, Y; Puri, RK			Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CARCINOMA-CELLS; COLONY-STIMULATING FACTOR; COMMON GAMMA-CHAIN; PSEUDOMONAS EXOTOXIN; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING; IL-13 RECEPTOR; ATOPIC-DERMATITIS; RATIONAL DESIGN; ALPHA-CHAIN	Interleukin-13 (IL-13), a predominantly Th2-derived cytokine, appears to play a central pathological role in asthma, atopic dermatitis, allergic rhinitis, some parasitic infections, and cancer. We hypothesized that an IL-13 antagonist may have profound therapeutic utility in these conditions. We, therefore, mutagenized human IL-13 in which Glu at position 13 was substituted by a Lys residue. This highly purified recombinant IL-13 variant, IL-13E13K, bound with 4-fold higher affinity to the IL-13 receptor than wild-type IL-13 but retained no detectable proliferative activity on the TF-1 hematopoietic cell line. IL-13E13K competitively inhibited IL-13- and IL-4-dependent TF-1 proliferation. It also inhibited IL13-induced STAT-B (signal transduction and activator of transducer-6) activation in immune cells and cancer cells and reversed IL-13-induced inhibition of CD14 expression on human primary monocytes. These results demonstrate that high affinity binding and signal generation can be uncoupled efficiently in a ligand receptor interaction. These results also suggest that IL-13E13K may be a useful antagonist for the treatment of allergic, inflammatory, and parasitic diseases or even malignancies in which IL-13 plays a central role.	US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, 29 Lincoln Dr,NIH Bldg 29B,Rm 2NN10, Bethesda, MD 20892 USA.	puri@cber.fda.gov	Oshima, Yasuo/AGN-3291-2022	Oshima, Yasuo/0000-0002-6236-6986				Akdis M, 1997, J IMMUNOL, V159, P4611; ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; Altmann SW, 1995, GROWTH FACTORS, V12, P251, DOI 10.3109/08977199509028964; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BAMBOROUGH P, 1994, PROTEIN ENG, V7, P1077, DOI 10.1093/protein/7.9.1077; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; COSENTINO G, 1995, J IMMUNOL, V155, P3145; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Fricker J, 1999, MOL MED TODAY, V5, P463, DOI 10.1016/S1357-4310(99)01586-5; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Husain SR, 1997, CLIN CANCER RES, V3, P151; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; Joshi BH, 2000, CANCER RES, V60, P1168; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Kim YS, 1998, J IMMUNOL, V160, P5742; KREITMAN RJ, 1995, CYTOKINE, V7, P311, DOI 10.1006/cyto.1995.0039; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; LELAND P, 1995, ONCOL RES, V7, P227; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; Matthews DJ, 2000, J IMMUNOL, V164, P1458, DOI 10.4049/jimmunol.164.3.1458; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1998, INT J MOL MED, V1, P551; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Murata T, 1998, BLOOD, V91, P3884; Nicola NA, 1999, ADV PROTEIN CHEM, V52, P1; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; PAUL WE, 1991, BLOOD, V77, P1859; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	61	27	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15185	15191		10.1074/jbc.M010159200	http://dx.doi.org/10.1074/jbc.M010159200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278629	hybrid			2022-12-27	WOS:000168528800088
J	Sun, J; Whisstock, JC; Harriott, P; Walker, B; Novak, A; Thompson, PE; Smith, AI; Bird, PI				Sun, J; Whisstock, JC; Harriott, P; Walker, B; Novak, A; Thompson, PE; Smith, AI; Bird, PI			Importance of the P4 ' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RESPONSE MODIFIER; SERPIN-PROTEASE COMPLEXES; TARGET-CELLS; MEDIATED CYTOTOXICITY; DNA FRAGMENTATION; INDUCED APOPTOSIS; PEPTIDE-SYNTHESIS; SERINE PROTEASES; SPECIFICITY; CLEAVAGE	The cytotoxic lymphocyte serine proteinase granzyme B induces apoptosis of abnormal cells by cleaving intracellular proteins at sites similar to those cleaved by caspases, Understanding the substrate specificity of granzyme B will help to identify natural targets and develop better inhibitors or substrates, Here we have used the interaction of human granzyme B with a cognate serpin, proteinase inhibitor 9 (PI-9), to examine its substrate sequence requirements. Cleavage and sequencing experiments demonstrated that Glu(340) is the P1 residue in the PI-9 RCL, consistent with the preference of granzyme B for acidic P1 residues. Ale-scanning mutagenesis demonstrated that the P4-P4' region of the PI-9 RCL is important for interaction with granzyme B, and that the P4' residue (Glu(344)) is required for efficient serpin-proteinase binding. Peptide substrates based on the P4-P4' PI-9 RCL sequence and containing either P1 Glu or P1 Asp were cleaved by granzyme B (k(cat)/K-m 9.5 x 10(3) and 1.2 x 10(5) s(-1) M-1, respectively) but were not recognized by caspases, A substrate containing P1 Asp but lacking P4' Glu was cleaved less efficiently (k(cat)/K-m 5.3 x 10(4) s(-1) M-1). An idealized substrate comprising the previously described optimal P4-P1 sequence (Ile-Glu-Pro-Asp) fused to the PI-9 P1'-P4' sequence was efficiently cleaved by granzyme B (k(cat)/K-m 7.5 x 10(5) s(-1) M-1) and was also recognized by caspases. This contrasts with the literature value for a tetrapeptide comprising the same P4-P1 sequence (k(cat)/K-m 6.7 x 10(4) s(-1) M-1) and confirms that P' residues promote efficient interaction of granzyme B with substrates. Finally, molecular modeling predicted that PI-9 Glu(344) forms a salt bridge with Lys(27) Of granzyme B, and we showed that a K27A mutant of granzyme B binds less efficiently to PI-9 and to substrates containing a P4' Glu. We conclude that granzyme B requires an extended substrate sequence for specific and efficient binding and propose that an acidic P4' substrate residue allows discrimination between early thigh affinity) and late (lower affinity) targets during the induction of apoptosis.	Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; Queens Univ Belfast, Sch Pharm, Biomed Chem Grp, Belfast BT9 7BL, Antrim, North Ireland; Australian Ctr Blood Dis, Melbourne, Vic 3128, Australia; Baker Med Res Inst, Melbourne, Vic 8008, Australia	Monash University; Queens University Belfast; Baker Heart and Diabetes Institute	Bird, PI (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia.		Walker, Brian/C-5263-2008	Bird, Phillip/0000-0002-6695-606X; Smith, Ian/0000-0002-4143-2892; Thompson, Philip/0000-0002-5910-7625; Whisstock, James/0000-0003-4200-5611				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; BODANSZKY M, 1978, INT J PEPT PROT RES, V12, P69; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Chaillan-Huntington CE, 1998, J BIOL CHEM, V273, P4569, DOI 10.1074/jbc.273.8.4569; Darmon AJ, 1998, CRIT REV IMMUNOL, V18, P255, DOI 10.1615/CritRevImmunol.v18.i3.50; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LESK AM, 1986, BIOSEQUENCES PERSPEC, P23; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; Pinkoski MJ, 1998, BLOOD, V92, P1044; POE M, 1991, J BIOL CHEM, V266, P98; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Riewald M, 1996, J BIOL CHEM, V271, P14526, DOI 10.1074/jbc.271.24.14526; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Sun JR, 1997, J BIOL CHEM, V272, P15434, DOI 10.1074/jbc.272.24.15434; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani Joseph A., 2000, P179; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Tucker HM, 1996, EUR J BIOCHEM, V237, P180, DOI 10.1111/j.1432-1033.1996.0180n.x; WALKER B, 1994, PEPTIDE ANTIGENS PRA, P27; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9	48	67	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15177	15184		10.1074/jbc.M006645200	http://dx.doi.org/10.1074/jbc.M006645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278311	hybrid			2022-12-27	WOS:000168528800087
J	Cho, SG; Lee, YH; Park, HS; Ryoo, K; Kang, KW; Park, J; Eom, SJ; Kim, MJ; Chang, TS; Choi, SY; Shim, J; Kim, Y; Dong, MS; Lee, MJ; Kim, SG; Ichijo, H; Choi, EJ				Cho, SG; Lee, YH; Park, HS; Ryoo, K; Kang, KW; Park, J; Eom, SJ; Kim, MJ; Chang, TS; Choi, SY; Shim, J; Kim, Y; Dong, MS; Lee, MJ; Kim, SG; Ichijo, H; Choi, EJ			Glutathione S-transferase Mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASES; CELL-DEATH; PROTEIN; COMPLEX; INHIBITOR; RECEPTOR; ASK1; JNK; TRANSDUCTION; BINDING	Apoptosis signal-regulating kinase 1 (ASK1) is a mitogen-activated protein kinase kinase kinase that can activate the c-Jun N-terminal kinase and the p38 signaling pathways. It plays a critical role in cytokine- and stress-induced apoptosis, To further characterize the mechanism of the regulation of the ASK1 signal, we searched for ASK1-interacting proteins employing the yeast two-hybrid method. The yeast two-hybrid assay indicated that mouse glutathione S-transferase Mu 1-1 (mGSTM1-1), an enzyme involved in the metabolism of drugs and xenobiotics, interacted with ASK1, We subsequently confirmed that mGSTM1-1 physically associated with ASK1 both in vivo and in vitro. The in vitro binding assay indicated that the C-terminal portion of mGSTM1-1 and the N-terminal region of ASK1 were crucial for binding one another. Furthermore, mGSTM1-1 suppressed stress-stimulated ASK1 activity in cultured cells. mGSTM1-1 also blocked ASK1 oligomerization, The ASK1 inhibition by mGSTM1-1 occurred independently of the glutathione-conjugating activity of mGSTM1-1, Moreover, mGSTM1-1 repressed ASK1-dependent apoptotic cell death. Taken together, our findings suggest that mGSTM1-1 functions as an endogenous inhibitor of ASK1. This highlights a novel function for mGSTM1-1 insofar as mGSTM1-1 may modulate stress-mediated signals by repressing ASK1, and this activity occurs independently of its well-known catalytic activity in intracellular glutathione metabolism.	Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Sungbuk Ku, Seoul 136701, South Korea; Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Chongno Ku, Seoul 110799, South Korea; Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan	Korea University; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Tokyo Medical & Dental University (TMDU)	Choi, EJ (corresponding author), Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Sungbuk Ku, Seoul 136701, South Korea.			Cho, Ssang-Goo/0000-0002-0968-7932; Ichijo, Hidenori/0000-0002-5005-6438				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P37, DOI 10.1006/abbi.1997.0335; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIGAKI S, 1989, ARCH BIOCHEM BIOPHYS, V273, P265, DOI 10.1016/0003-9861(89)90483-9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; LEE HC, 1995, J BIOL CHEM, V270, P99, DOI 10.1074/jbc.270.1.99; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEISTER A, 1994, CANCER RES, V54, pS1969; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Plummer J L, 1981, Methods Enzymol, V77, P50; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YOKOMIZO A, 1995, J BIOL CHEM, V270, P19451, DOI 10.1074/jbc.270.33.19451	45	324	343	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12749	12755		10.1074/jbc.M005561200	http://dx.doi.org/10.1074/jbc.M005561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278289	hybrid			2022-12-27	WOS:000168198600040
J	Holscher, C; Bach, UC; Dobberstein, B				Holscher, C; Bach, UC; Dobberstein, B			Prion protein contains a second endoplasmic reticulum targeting signal sequence located at its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPRO-ALPHA-FACTOR; TRANSLOCATION; MEMBRANE; RECOGNITION; TRANSPORT; YEAST; MECHANISMS; TOPOLOGY; COMPLEX; OCCUR	Prion protein (PrP) is synthesized at the membrane of the endoplasmic reticulum (ER) in three different topological forms as follows: a fully translocated one ((PrP)-Pr-sec) and two with opposite orientations in the membrane ((PrP)-Pr-Ntm and (PrP)-Pr-Ctm). We asked whether other signal sequences exist in the PrP, other than the N-terminal signal sequence, that contribute to its topological diversity. In vitro translocation assays showed that PrP lacking its N-terminal signal sequence could still translocate into ER microsomes, although at reduced efficiency. Deletion of each of the two hydrophobic regions in PrP revealed that the C-terminally located hydrophobic region (TM2) can function as second signal sequence in PrP. Translocation mediated by the TM2 alone can occur post-translationally and yields mainly (PrP)-Pr-Ctm, which is implicated in some forms of neurodegeneration in prion diseases. We conclude that, in vitro, PrP can insert into ER membranes co- and post-translationally and can use two different signal sequences. We propose that the unusually complex topology of PrP results from the differential utilization of two signal sequences in PrP.	Heidelberg Univ, Zentrum Mol Biol, D-69052 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Dobberstein, B (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Postfach 106249, D-69052 Heidelberg, Germany.	dobberstein@zmbh.uni-heidelberg.de						Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Gruss OJ, 1999, EUR J BIOCHEM, V260, P785, DOI 10.1046/j.1432-1327.1999.00215.x; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; Holscher C, 1998, J VIROL, V72, P1153; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Martoglio B, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P265; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROTHBLATT JA, 1986, EMBO J, V5, P1031; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	42	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13388	13394		10.1074/jbc.M007331200	http://dx.doi.org/10.1074/jbc.M007331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278343	hybrid			2022-12-27	WOS:000168198600126
J	Fay, PJ; Mastri, M; Koszelak, ME; Wakabayashi, H				Fay, PJ; Mastri, M; Koszelak, ME; Wakabayashi, H			Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; COAGULATION FACTOR-VIII; LENGTH CROSS-LINKING; LIGHT-CHAIN; FACTOR XA; BINDING-SITE; A1 SUBUNIT; THROMBIN; DOMAIN	Factor VIII circulates as a noncovalent heterodimer consisting of a heavy chain (HC, contiguous A1-A2-B domains) and light chain (LC), Cleavage of HC at the A1-A2 and A2-B junctions generates the A1 and A2 subunits of factor VIIIa. Although the isolated A2 subunit stimulates factor IXa-catalyzed generation of factor Xa by similar to 100-fold, the isolated HC, free from the LC, showed no effect in this assay. However, extended reaction of HC with factors Ma and X resulted in an increase in factor Ma activity because of conversion of the I-IC to Al and A2 subunits by factor Xa, HC cleavage by thrombin or factor Xa yielded similar products, although factor Xa cleaved at a rate of similar to1% observed for thrombin, HC showed Little inhibition of the A2 subunit-dependent stimulation of factor Ma activity, suggesting that factor Ma-interactive sites are mashed in the A2 domain of HC, Furthermore, RC showed no effect on the fluorescence anisotropy of fluorescein-Phe-Phe-Arg-factor Ma in the presence of factor X, whereas thrombin-cleaved HC yielded a marked increase in this parameter. These results indicate that HC cleavage by either thrombin or factor Xa is essential to expose the factor Ma-interactive site(s) in the A2 subunit required to modulate protease activity.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38199, HL 36016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; Fay PJ, 1999, J BIOL CHEM, V274, P29826, DOI 10.1074/jbc.274.42.29826; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; KemballCook G, 1997, NUCLEIC ACIDS RES, V25, P128, DOI 10.1093/nar/25.1.128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; REGAN LM, 1994, J BIOL CHEM, V269, P9445; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	37	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12434	12439		10.1074/jbc.M009539200	http://dx.doi.org/10.1074/jbc.M009539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278520	hybrid			2022-12-27	WOS:000168081800132
J	Lin, HJ; Yin, LM; Reid, J; Wilkinson, KD; Wing, SS				Lin, HJ; Yin, LM; Reid, J; Wilkinson, KD; Wing, SS			Divergent N-terminal sequences of a deubiquitinating enzyme modulate substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-UBIQUITINATING ENZYME; PROTEIN-DEGRADATION; SACCHAROMYCES-CEREVISIAE; POLYUBIQUITIN CHAINS; FUNCTIONAL-ANALYSIS; FUSION-PROTEIN; GENE; ISOPEPTIDASE; CONJUGATION; PROTEASOME	Ubiquitin specific processing proteases (UBPs) are characterized by a conserved core domain with surrounding divergent sequences, particularly at the N-terminal end. We previously cloned two isoforms of a testis UBP, UBP-t1 and UBP-t2, which contain identical core regions but distinct N termini that target the two isoforms to different subcellular locations (Lin, H., Keriel, A., Morales, C. R., Bedard, N., Zhao, Q., Hingamp, P., Lefrancois, S., Combaret, L., and Wing, S. S. (2000) Mol. Cell. Biol. 20, 6568-6578). To determine whether the N termini also influence the biochemical functions of the UBP, we expressed UBP-t1, UBP-t2, and the common core domain, UBP core, in Escherichia coli. The three isoforms cleaved branched triubiquitin at >20-fold faster rates than linear diubiquitin, suggesting that UBP-testis functions as an isopeptidase. Both N-terminal extensions inhibited the ability of UBP-core to generate free ubiquitin when linked in a peptide bond with itself, another peptide, or to small adducts. The N-terminal extension of UBP-t2 increased the ability of UBP-core to cleave branched triubiquitin. UBP-core removed ubiquitin from testis ubiquitinated proteins more rapidly than UBP-t2 and UBP-t1. Thus, UBP enzymes appear to contain a catalytic core domain, the activities and specificities of which can be modulated by N-terminal extensions. These divergent N termini can alter localization and confer multiple functions to the various members of the large UBP family.	McGill Univ, Polypeptide Lab, Dept Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 2B2, Canada; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA	McGill University; McGill University; Emory University	Wing, SS (corresponding author), McGill Univ, Polypeptide Lab, Dept Med, Strathcona Anat & Dent Bldg,3640 Univ St,Room W31, Montreal, PQ H3A 2B2, Canada.		Wing, Simon/D-2589-2012	Wing, Simon/0000-0001-8394-7563; Lin, Haijiang/0000-0003-2931-468X	NIGMS NIH HHS [GM30308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BAKER RT, 1992, GENOMICS, V14, P520, DOI 10.1016/S0888-7543(05)80258-7; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARRIO R, 1994, BIOCHEM J, V302, P237, DOI 10.1042/bj3020237; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Haas AL, 1997, FASEB J, V11, P1257; HADARI T, 1992, J BIOL CHEM, V267, P719; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; PICKART CM, 1985, J BIOL CHEM, V260, P7903; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; Redman KL, 1996, BIOCHEM J, V315, P315, DOI 10.1042/bj3150315; REISS Y, 1989, J BIOL CHEM, V264, P10378; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; WILKINSON KD, 1986, BIOCHEMISTRY-US, V25, P6644, DOI 10.1021/bi00369a047; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019	38	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20357	20363		10.1074/jbc.M008761200	http://dx.doi.org/10.1074/jbc.M008761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11278432	hybrid			2022-12-27	WOS:000169135100093
J	Dubois, T; Kerai, P; Zemlickova, E; Howell, S; Jackson, TR; Venkateswarlu, K; Cullen, PJ; Theibert, AB; Larose, L; Roach, PJ; Aitken, A				Dubois, T; Kerai, P; Zemlickova, E; Howell, S; Jackson, TR; Venkateswarlu, K; Cullen, PJ; Theibert, AB; Larose, L; Roach, PJ; Aitken, A			Casein kinase I associates with members of the centaurin-alpha family of phosphatidylinositol 3,4,5-trisphosphate-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; HIGH-AFFINITY; RAT-BRAIN; FUNCTIONAL-CHARACTERIZATION; SCHIZOSACCHAROMYCES-POMBE; DEPENDENT PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; COUPLED RECEPTORS	Mammalian casein kinases I (CKI) belong to a family of serine/threonine protein kinases involved in diverse cellular processes including cell cycle progression, membrane trafficking, circadian rhythms, and Wnt signaling. Here we show that CKI alpha co purifies with centaurin-alpha (1), in brain and that they interact in vitro and form a complex in cells. In addition, we show that the association is direct and occurs through the kinase domain of CKI within a loop comprising residues 217-233. These residues are well conserved in all members of the CKI: family, and we show that centaurin-alpha (1) associates in vitro with all mammalian CKI isoforms. To date, CKI alpha represents the first protein partner identified for centaurin-alpha (1). However, our data suggest that centaurin-alpha (1), is not a substrate for CKI alpha and has no effect on CKI alpha activity. Centaurin-alpha (1), has been identified as a phosphatidylinositol 3,4,5-trisphosphate-binding protein. Centaurin-alpha (1), contains a cysteine-rich domain that is shared by members of a newly identified family of ADP-ribosylation factor guanosine trisphosphatase-activating proteins. These proteins are involved in membrane trafficking and actin cytoskeleton rearrangement, thus supporting a role for CKI alpha in these biological events.	Univ Edinburgh, Div Biomed & Clin Lab Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; McGill Univ, Dept Expt Med, Polypeptide Lab, Montreal, PQ H3A 2B2, Canada; Univ Alabama Birmingham, Neurobiol Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England; UCL Royal Free & Univ Coll, Sch Med, London NW3 2PF, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	University of Edinburgh; Indiana University System; Indiana University-Purdue University Indianapolis; McGill University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Bristol; University of Bristol; University of London; University College London; UCL Medical School; MRC National Institute for Medical Research	Dubois, T (corresponding author), Univ Edinburgh, Div Biomed & Clin Lab Sci, Hugh Robson Bldg,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.	tdubois@srv4.med.ed.ac.uk	Kanamarlapudi, Venkateswarlu/A-9864-2011; Dubois, Thierry/D-2852-2017	Kanamarlapudi, Venkateswarlu/0000-0002-8739-1483; Cullen, Peter/0000-0002-9070-8349; Dubois, Thierry/0000-0003-4739-6164	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggensteiner M, 1998, BBA-PROTEIN STRUCT M, V1387, P117, DOI 10.1016/S0167-4838(98)00113-7; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Faundez VV, 2000, MOL BIOL CELL, V11, P2591, DOI 10.1091/mbc.11.8.2591; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Fu Z, 1999, J NEUROCHEM, V73, P830, DOI 10.1046/j.1471-4159.1999.0730830.x; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1999, J CELL SCI, V112, P2647; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Kao LR, 1996, MOL CELL BIOL, V16, P168; Karino A, 1999, BBA-GEN SUBJECTS, V1472, P603, DOI 10.1016/S0304-4165(99)00187-7; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kreutz MR, 1997, EUR J NEUROSCI, V9, P2110, DOI 10.1111/j.1460-9568.1997.tb01378.x; Kuret J, 1997, J NEUROCHEM, V69, P2506; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Stricker R, 1997, FEBS LETT, V405, P229, DOI 10.1016/S0014-5793(97)00188-9; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; Vancurova I, 1999, J BIOL CHEM, V274, P1147, DOI 10.1074/jbc.274.2.1147; Venkateswarlu K, 1999, BIOCHEM BIOPH RES CO, V262, P237, DOI 10.1006/bbrc.1999.1065; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Voisin L, 1999, BIOCHEM J, V341, P217, DOI 10.1042/0264-6021:3410217; Wang XM, 1996, MOL CELL BIOL, V16, P5375; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9; Zhang CX, 2000, MOL BIOL CELL, V11, P1011, DOI 10.1091/mbc.11.3.1011; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	65	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18757	18764		10.1074/jbc.M010005200	http://dx.doi.org/10.1074/jbc.M010005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278595	hybrid			2022-12-27	WOS:000169091000017
J	Xiong, YM; Zhang, L				Xiong, YM; Zhang, L			Structure-function of the putative I-domain within the integrin beta(2) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; FUNCTION-ASSOCIATED ANTIGEN-1; CELL-SURFACE EXPRESSION; GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING REGION; A-DOMAIN; MOLECULE-1 ICAM-1; CRYSTAL-STRUCTURE; BETA-2 INTEGRINS; MONOCLONAL-ANTIBODIES	The central region (residues 125-385) of the integrin beta (2) subunit is postulated to adopt an I-domain-like fold (the beta I-2-domain) and to play a critical role in ligand binding and heterodimer formation. To understand structure-function relationships of this region of beta (2), a homolog-scanning mutagenesis approach, which entails substitution of nonconserved hydrophilic sequences within the beta I-2-domain with their homologous counterparts of the beta I-1-domain, has been deployed. This approach is based on the premise that beta (1) and beta (2) are highly homologous, yet recognize different ligands. Altogether, 16 segments were switched to cover the predicted outer surface of the beta I-2-domain. When these mutant beta (2) subunits were transfected together with wild-type alpha (M) in human 293 cells, all 16 beta (2) mutants were expressed on the cell surface as heterodimers, suggesting that these 16 sequences within the beta I-2-domain are not critically involved in heterodimer formation between the alpha (M), and beta (2) subunits. Using these mutant alpha (M)beta (2) receptors, we have mapped the epitopes of nine beta I-2-domain specific mAbs, and found that they all recognized at least two noncontiguous segments within this domain. The requisite spatial proximity among these non-linear sequences to form the mAb epitopes supports a model of an I-domain-like fold for this region. In addition, none of the mutations that abolish the epitopes of the nine function-blocking mAbs, including segment Pro(192)-Glu(197), destroyed ligand binding of the alpha (M)beta (2) receptor, suggesting that these function-blocking mAbs inhibit alpha (M)beta (2) function allosterically. Given the recent reports implicating the segment equivalent to Pro(192)-Glu(197) in ligand binding by beta (3) integrins, these data suggest that ligand binding by the beta (2) integrins occurs via a different mechanism than beta (3). Finally, both the conformation of the beta I-2-domain and C3bi binding activity of alpha (M)beta (2) were dependent on a high affinity Ca2+ binding site (K-d = 105 muM), which is most likely located within this region of beta (2).	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	American Red Cross	Zhang, L (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R01 HL061589, HL61589, P01 HL054710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL061589] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; BACK AL, 1992, J BIOL CHEM, V267, P5482; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; CORBI AL, 1992, EUR J IMMUNOL, V22, P1877, DOI 10.1002/eji.1830220730; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Douglass WA, 1998, FEBS LETT, V440, P414, DOI 10.1016/S0014-5793(98)01498-7; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Gotwals PJ, 1999, BIOCHEMISTRY-US, V38, P8280, DOI 10.1021/bi982860m; Griggs DW, 1998, J BIOL CHEM, V273, P22113, DOI 10.1074/jbc.273.34.22113; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KERN A, 1994, J BIOL CHEM, V269, P22811; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Lin ECK, 1997, J BIOL CHEM, V272, P23912, DOI 10.1074/jbc.272.38.23912; LINDBOM L, 1990, CLIN IMMUNOL IMMUNOP, V57, P105, DOI 10.1016/0090-1229(90)90026-M; LORENZ HM, 1993, CELL IMMUNOL, V147, P110, DOI 10.1006/cimm.1993.1052; Lu CF, 1997, J IMMUNOL, V159, P268; Marr KA, 1999, VET IMMUNOL IMMUNOP, V71, P77, DOI 10.1016/S0165-2427(99)00093-8; MATSUURA S, 1992, BIOCHEM BIOPH RES CO, V184, P1460, DOI 10.1016/S0006-291X(05)80047-6; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Moyle M, 1994, J BIOL CHEM, V269, P1008; NELSON C, 1992, J BIOL CHEM, V267, P3351; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; ROSS GD, 1985, J IMMUNOL, V134, P3307; Shih DT, 1997, J CELL SCI, V110, P2619; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	65	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19340	19349		10.1074/jbc.M008903200	http://dx.doi.org/10.1074/jbc.M008903200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278448	hybrid			2022-12-27	WOS:000169091000094
J	Hauck, CR; Hunter, T; Schlaepfer, DD				Hauck, CR; Hunter, T; Schlaepfer, DD			The v-src SH3 domain facilitates a cell adhesion-independent association with focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ROUS-SARCOMA VIRUS; C-SRC; FAMILY KINASES; GROWTH-FACTOR; 3T3 CELLS; PHOSPHATASE-ALPHA; COMPLEX-FORMATION; CANCER CELLS; BINDING-SITE	Integrins facilitate cell attachment to the extracellular matrix, and these interactions generate cell survival, proliferation, and motility signals. Integrin signals are relayed in part by focal adhesion kinase (FAK) activation and the formation of a transient signaling complex initiated by Src homology 2 (SH2)-dependent binding of Src family protein-tyrosine kinases to the FAK Tyr-397 autophosphorylation site. Here we show that in viral Src (v-Src)-transformed NIH3T3 fibroblasts, an adhesion-independent FAK-Src signaling complex occurs. Co-expression studies in human 293T cells showed that v-Src could associate with and phosphorylate a Phe-397 FAK mutant at Tyr-925 promoting Grb2 binding to FAK in suspended cells. In vitro, glutathione S-transferase fusion proteins of the v-Src SH3 but not c-Src SH3 domain bound to FAK in lysates of NIH3T3 fibroblasts, The v-Src SH3-binding sites were mapped to known proline-X-X-proline (PXXP) SH3-binding motifs in the FAK N- (residues 371-377) and C-terminal domains (residues 712-718 and 871-882) by in vitro pull-down assays, and these sites are composed of a PXXPXX Phi (where Phi, is a hydrophobic residue) v-Src SH3 binding consensus. Sequence comparisons show that residues in the RT loop region of the c-Src and v-Src SH3 domains differ. Substitution of c-Src RT loop residues (Arg-97 and Thr-98) for those found in the v-Src SH3 domain (Trp-97 and Ile-98) enhanced the binding of distinct NIH3T3 cellular proteins to a glutathione S-transferase fusion protein of the c-Src (Trp-97 + Ile-98) SH3 domain, FAK was identified as a c-Src (Trp-97 + Ile-98) SH3 domain target in fibroblasts, and co-expression studies in 293T cells showed that full-length c-Src (Trp-97 + Ile-98) could associate in vivo with Phe-397 FAK in an SH2-independent manner. These studies establish a functional role for the v-Src SH3 domain in stabilizing an adhesion-independent signaling complex with FAK.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Scripps Research Institute; Salk Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM26,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu			NATIONAL CANCER INSTITUTE [R35CA039780, R29CA075240] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, R29-CA75240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LERNER TL, 1984, J VIROL, V49, P549, DOI 10.1128/JVI.49.2.549-556.1984; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Potts W M, 1988, Oncogene Res, V3, P343; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	58	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17653	17662		10.1074/jbc.M009329200	http://dx.doi.org/10.1074/jbc.M009329200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278488	hybrid, Green Published			2022-12-27	WOS:000168866500006
J	Pizzinat, N; Takesono, A; Lanier, SM				Pizzinat, N; Takesono, A; Lanier, SM			Identification of a truncated form of the G-protein regulator AGS3 in heart that lacks the tetratricopeptide repeat domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; ACTIVATION; RECEPTOR; AUG; NUCLEOTIDES; TRANSLATION; DIVISIONS; FAMILY; CODON; MOTIF	AGS3, a 650-amino acid protein encoded by an similar to4-kilobase (kb) mRNA enriched in rat brain, is a G alpha (i)/G alpha (t)-binding protein that competes with G beta gamma for interaction with G alpha (GDP) and acts as a guanine nucleotide dissociation inhibitor for heterotrimeric G-proteins, An similar to2-kb AGS3 mRNA (AGS3-SHORT) is enriched in rat and human heart. We characterized the heart-enriched mRNA, identified the encoded protein, and determined its ability to interact with and regulate the guanine nucleotide-binding properties of G-proteins. Screening of a rat heart cDNA library, 5 ' -rapid amplification of cDNA ends, and RNase protection assays identified two populations of cDNAs (1979 and 2134 nucleotides plus the polyadenylation site) that diverged from the larger 4-kb mRNA (AGS3-LONG) in the middle of the protein coding region. Transfection of COS-7 cells with AGS3-SHORT cDNAs resulted in the expression of a major immunoreactive AGS3 polypeptide (M-r similar to 23,000) with a translational start site at Met(495) of AGS3-LONG. Immunoblots indicated the expression of the M-r similar to 23,000 polypeptide in rat heart. Glutathione S-transferase-AGS3-SHORT selectively interacted with the GDP-bound versus guanosine 5 ' -O-(3-thiotriphosphate) (GTP gammaS)-bound conformation of G alpha (i2) and inhibited GTP gammaS binding to G alpha (i2). Protein interaction assays with glutathione S-transferase-AGS3-SHORT and heart ly; sates indicated interaction of AGS3-SHORT with G alpha (i1/2), and G alpha (i3), but not G alpha (s) or G alpha (q). Immunofluorescent imaging and subcellular fractionation following transient expression of AGS3-SHORT and AGS3-LONG in COS-7 and Chinese hamster ovary cells indicated distinct subcellular distributions of the two forms of AGS3, Thus, AGS3 exists as a short and long form, both of which apparently stabilize the GDP-bound conformation of G alpha (i), but which differ in their tissue distribution and trafficking within the cell.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Medical University of South Carolina	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Peridido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu		Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIMH NIH HHS [MH59931] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Fuxe J, 2000, ONCOGENE, V19, P1724, DOI 10.1038/sj.onc.1203496; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LANIER SM, 1991, J BIOL CHEM, V266, P10470; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SaulnierBlache JS, 1996, MOL PHARMACOL, V50, P1432; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	24	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16601	16610		10.1074/jbc.M007573200	http://dx.doi.org/10.1074/jbc.M007573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278352	hybrid			2022-12-27	WOS:000168730400003
J	Frey, S; Pool, M; Seedorf, M				Frey, S; Pool, M; Seedorf, M			Scp160p, an RNA-binding, polysome-associated protein, localizes to the endoplasmic reticulum of Saccharomyces cerevisiae in a microtubule-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KH-DOMAIN PROTEIN; MESSENGER-RNA; 3'-UNTRANSLATED REGION; MAMMALIAN STAUFEN; DROSOPHILA OOCYTE; BUDDING YEAST; VIGILIN; NUCLEAR; TRANSPORT; COMPLEXES	Scp160p is an RNA-binding protein containing 14 tandemly repeated heterogenous nuclear ribonucleoprotein K-homology domains, which are implicated in RNA binding. Scp160p interacts with free and membrane-bound polysomes that are dependent upon the presence of mRNA. Despite its presence on cytosolic polysomes, Scp160p is predominantly localized to the endoplasmic reticulum (ER). Accumulation of Scp160p-ribosome complexes at the ER requires the function of microtubules but is independent of the actin cytoskeleton. We propose that the multi-K-homology-domain protein Scp160p functions as an RNA binding platform, interacting with polysomes that are transported to the ER.	Univ Heidelberg, ZMBH, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Seedorf, M (corresponding author), Univ Heidelberg, ZMBH, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		Pool, Martin R./AAB-9181-2021	Pool, Martin R./0000-0003-3071-1535; Steffen, Frey/0000-0002-5134-9961				Adams A, 1997, METHODS YEAST GENETI; Ayscough KR, 1998, CURR BIOL, V8, P927, DOI 10.1016/S0960-9822(07)00374-0; Baber JL, 1999, J MOL BIOL, V289, P949, DOI 10.1006/jmbi.1999.2818; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Choi SB, 2000, NATURE, V407, P765, DOI 10.1038/35037633; Cortes A, 1999, EMBO J, V18, P3820, DOI 10.1093/emboj/18.13.3820; Cortes A, 2000, MOL CELL BIOL, V20, P3860, DOI 10.1128/MCB.20.11.3860-3869.2000; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Harlow E., 1988, ANTIBODIES LAB MANUA, P55; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; JACKSON CL, 1994, GENETICS, V137, P423; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; Kanamori H, 1998, MOL CELL BIOL, V18, P3991, DOI 10.1128/MCB.18.7.3991; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kruse C, 1998, BIOCHEM J, V329, P615, DOI 10.1042/bj3290615; Kruse C, 2000, BIOCHEM J, V346, P107, DOI 10.1042/0264-6021:3460107; Lang BD, 2000, NUCLEIC ACIDS RES, V28, P1576, DOI 10.1093/nar/28.7.1576; Lipshitz HD, 2000, CURR OPIN GENET DEV, V10, P476, DOI 10.1016/S0959-437X(00)00116-7; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NOLAN RD, 1969, EUR J BIOCHEM, V10, P96; PLENZ G, 1993, CELL TISSUE RES, V273, P381, DOI 10.1007/BF00312841; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SIKORSKI RS, 1989, GENETICS, V122, P19; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STEARNS T, 1990, GENETICS, V124, P251; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Weber V, 1997, EUR J BIOCHEM, V249, P309, DOI 10.1111/j.1432-1033.1997.00309.x; Wickham L, 1999, MOL CELL BIOL, V19, P2220; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WINTERSBERGER U, 1995, YEAST, V11, P929, DOI 10.1002/yea.320111004	52	88	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15905	15912		10.1074/jbc.M009430200	http://dx.doi.org/10.1074/jbc.M009430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278502				2022-12-27	WOS:000168623100047
J	Nakayama, F; Nishihara, S; Iwasaki, H; Kudo, T; Okubo, R; Kaneko, M; Nakamura, M; Karube, M; Sasaki, K; Narimatsu, H				Nakayama, F; Nishihara, S; Iwasaki, H; Kudo, T; Okubo, R; Kaneko, M; Nakamura, M; Karube, M; Sasaki, K; Narimatsu, H			CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX,but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MONOCLONAL-ANTIBODY; DIFFERENTIATION ANTIGEN; MOLECULAR-CLONING; E-SELECTIN; SUBSTRATE SPECIFICITIES; MYELOID CELLS; FUC-TVII; NEUTROPHIL ADHESION	The CD15 carbohydrate epitope is expressed in mature human neutrophils, monocytes, and promyelocytes, We aimed to determine the alpha1,3-fucosyltransferase responsible for the expression of CD15 in each subpopulation of leukocytes. Three alpha1,3-fucosyltransferases, FUT4, FUT7, and FUT9, are expressed in human leukocytes. We demonstrated that FUT9 exhibits 20-fold stronger activity for CD15 synthesis than FUT4, whereas FUT4 exhibits 4.5-fold stronger activity for CDw65 synthesis than FUT9. By competitive reverse transcriptase-polymerase chain reaction, FUT9 was found to be strongly expressed in mature granulocytes and peripheral blood mononuclear cell, but not in monocytes. CD34(+) and CD15(+) cells in cord blood and myeloid cell lines (HL-60 and U937) did not express FUT9 at all. FUT4 transcripts were ubiquitously expressed in all blood cells and all cultured cell lines, with HL-60 and U937 cells in particular expressing a number of FUT4 transcripts. Transfection of the FUT9 gene into Jurkat and U937 cells demonstrated that FUT9 has the potential to express CD15 in myeloid and lymphoid cells. These findings suggest that the expression of CD15 in mature granulocytes is directed by FUT9, whereas it is determined in promyelocytes and monocytes by FUT4. Measurement of CD15 synthesizing activity in cell homogenates of each cell population using the polylactosamine acceptor further supported these conclusions.	Soka Univ, Inst Life Sci, Div Cell Biol, Tokyo 1928577, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Lab Gene Funct Anal, Tsuluba, Ibaraki 3058568, Japan; Yamagata Univ, Sch Med, Dept Forens Med, Yamagata 9909585, Japan; Fussa Hosp, Div Obstet, Tokyo 1970012, Japan; Jichi Med Sch, Inst Hematol, Div Hemopoiesis, Minami Kawachi, Tochigi 3290498, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Lab, Tokyo 1948533, Japan	Soka University; National Institute of Advanced Industrial Science & Technology (AIST); Yamagata University; Jichi Medical University; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), Soka Univ, Inst Life Sci, Div Cell Biol, Tokyo 1928577, Japan.		Narimatsu, Hisashi/M-4757-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603; K. Kaneko, Mika/0000-0002-4158-9208				ALBRECHTSEN M, 1989, BRIT J HAEMATOL, V72, P312, DOI 10.1111/j.1365-2141.1989.tb07710.x; Ashwell KWS, 1997, CELL TISSUE RES, V289, P17, DOI 10.1007/s004410050848; CIVIN CI, 1981, BLOOD, V57, P842; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; FORSYTH KD, 1989, EUR J IMMUNOL, V19, P1331, DOI 10.1002/eji.1830190727; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; HANJAN SNS, 1982, CLIN IMMUNOL IMMUNOP, V23, P172, DOI 10.1016/0090-1229(82)90106-4; Hiraiwa N, 1996, J BIOL CHEM, V271, P31556, DOI 10.1074/jbc.271.49.31556; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kaneko M, 1999, CYTOGENET CELL GENET, V86, P329, DOI 10.1159/000015329; Kimura H, 1997, BIOCHEM BIOPH RES CO, V237, P131, DOI 10.1006/bbrc.1997.7100; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MARER NL, 1997, GLYCOBIOLOGY, V7, P357; MELNICK DA, 1986, BLOOD, V67, P1388; MELNICK DA, 1985, J IMMUNOL, V134, P3346; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; Nishihara S, 1999, FEBS LETT, V462, P289, DOI 10.1016/S0014-5793(99)01549-5; Nishihara S, 1999, GLYCOBIOLOGY, V9, P607, DOI 10.1093/glycob/9.6.607; NOJIRI H, 1984, BLOOD, V64, P534; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHIENLE HW, 1982, J CLIN PATHOL, V35, P959, DOI 10.1136/jcp.35.9.959; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; STOCKS SC, 1990, BIOCHEM J, V268, P275, DOI 10.1042/bj2680275; Streit A, 1996, J NEUROCHEM, V66, P834; TETTEROO PAT, 1984, EUR J IMMUNOL, V14, P1089, DOI 10.1002/eji.1830141205; Warren HS, 1996, J IMMUNOL, V156, P2866; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	44	85	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16100	16106		10.1074/jbc.M007272200	http://dx.doi.org/10.1074/jbc.M007272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278338	hybrid			2022-12-27	WOS:000168623100073
J	Haruta, H; Kato, A; Todokoro, K				Haruta, H; Kato, A; Todokoro, K			Isolation of a novel interleukin-1-inducible nuclear protein bearing ankyrin-repeat motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTOONCOGENE BCL-3 ENCODES; SUBCELLULAR LOCATION; ONCOPROTEIN BCL-3; BETA; PHOSPHORYLATION; BINDING; ASSOCIATION; COACTIVATOR; HOMODIMERS	We isolated a novel gene termed interleukin (IL)-1-inducible nuclear ankyrin-repeat protein (INAP), of which expression was specifically induced by IL-1 in OP9 stromal cells. The INAP has ankyrin-repeat motifs and shares weak amino acid sequence homology with Bcl-3 and other I kappaB family members. The human genomic INAP gene found in the NCBI data base is located at chromosome 3q3.11, Northern blot analyses revealed that INAP was not expressed in any examined tissues without stimulation, but INAP expression was rapidly and transiently induced by IL-1 although not by tumor necrosis factor alpha nor by phorbol 12-myristate 13-acetate in OP9 cells. Immunoblots with anti-INAP-specific antibody demonstrated that INAP was rapidly and specifically produced by IL-1 stimulation and was predominantly localized in the nucleus. Immunofluorescence stainings showed that the INAP newly synthesized by IL-1 stimulation was promptly translocated into the nucleus, and FLAG-tagged INAP forcibly expressed in NIH/3T3 cells was also specifically localized in the nucleus. The possible interaction of INAP with RelA/p65, NF-kappa B1/p50, NF-kappa B2/p52, C/EBP beta, and retinoid X receptor was examined, but we could detect none of these interactions in the nuclear extracts of IL-1-stimulated cells. Unlike Bcl-3 and other I kappaB family members, INAP may play a unique role in IL-1-induced specific gene expression and/or signal transduction in the nucleus.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Todokoro, K (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Koyadai 3-1, Tsukuba, Ibaraki 3050074, Japan.		Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weil R, 1997, J BIOL CHEM, V272, P9942; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	22	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12485	12488		10.1074/jbc.C100075200	http://dx.doi.org/10.1074/jbc.C100075200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278262	hybrid			2022-12-27	WOS:000168198600003
J	Lokeshwar, VB; Rubinowicz, D; Schroeder, GL; Forgacs, E; Minna, JD; Block, NL; Nadji, M; Lokeshwar, BL				Lokeshwar, VB; Rubinowicz, D; Schroeder, GL; Forgacs, E; Minna, JD; Block, NL; Nadji, M; Lokeshwar, BL			Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL PROSTATECTOMY; PATHOLOGICAL FACTORS; BLADDER-CANCER; PROTEIN PH-20; HUMAN SERUM; CELLS; PURIFICATION; ASSOCIATION; CARCINOMA; MEMBRANE	Hyaluronic acid (KA), a glycosaminoglycan, regulates cell adhesion and migration, Hyaluronidase (HAase), an endoglycosidase, degrades HA into small angiogenic fragments. Using an enzyme-linked immunosorbent assay-like assay, we found increased HA levels (3-8-fold) in prostate cancer (CaP) tissues when compared with normal (NAP) and benign (BPH) tissues. The majority (similar to 75-80%) of HA in prostate tissues was found to exist in the free form. Primary CaP fibroblast and epithelial cells secreted 3-8-fold more HA than respective NAP and BPH cultures, Only CaP epithelial cells and established CaP lines secreted HAase and the secretion increased with tumor grade and metastasis. The pH activity profile and optimum (4.2; range 4.0-4.3) of CaP HAase was identical to the HYAL1-type HAase present in human serum and urine. Full-length HYAL1 transcript and splice variants were detected in CaP cells by reverse transcriptase-polymerase chain reaction, cloning, and sequencing. Immunoblotting confirmed secretion of a similar to 60-kDa HYAL1-related protein by CaP cells. Immunohistochemistry showed minimal HA and HYAL1 staining in NAP and BPH tissues. However, a stromal and epithelial pattern of HA and HYAL1 expression was observed in CaP tissues. While high HA. staining was observed in tumor-associated stroma, HYAL1 staining in tumor cells increased with tumor grade and metastasis. The gel-filtration column profiles of HA species in NAP, BPH, and CaP tissues were different. While the higher molecular mass and intermediate size HA was found in all tissues, the HA fragments were found only in CaP tissues. In particular, the high-grade CaP tissues, which showed both elevated RA and HYAL1 levels, contained angiogenic KA fragments. The stromal-epithelial HA. and HYAL1 expression may promote angiogenesis in CaP and may serve as prognostic markers for CaP.	Univ Miami, Sch Med, Dept Urol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	University of Miami; University of Miami; University of Miami; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lokeshwar, VB (corresponding author), Univ Miami, Sch Med, Dept Urol M800, POB 016960, Miami, FL 33101 USA.	vlokeshw@med.miami.edu	Lokeshwar, Bal/O-3196-2019	Lokeshwar, Bal/0000-0002-1763-4718	NATIONAL CANCER INSTITUTE [R01CA061038, R29CA072821, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 71618, R01 CA 61038, R29 CA 72821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; AVUINEN P, 2000, AM J PATHOL, V56, P529; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; Bostwick D G, 1998, Semin Urol Oncol, V16, P118; BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO;2-6; Cote RJ, 1998, J NATL CANCER I, V90, P916, DOI 10.1093/jnci/90.12.916; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; Csoka TB, 1997, INVAS METAST, V17, P297; DAMICO AV, 1995, J UROLOGY, V154, P131, DOI 10.1016/S0022-5347(01)67248-3; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; Epstein J I, 1998, Semin Urol Oncol, V16, P124; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; Godin DA, 2000, ARCH OTOLARYNGOL, V126, P402, DOI 10.1001/archotol.126.3.402; GUTENHONER NW, 1992, MATRIX, V12, P388; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; HOBARTH K, 1992, EUR UROL, V21, P206; Hrkal Z, 1996, FEBS LETT, V383, P72, DOI 10.1016/0014-5793(96)00225-6; Hunnicutt GR, 1996, BIOL REPROD, V54, P1343, DOI 10.1095/biolreprod54.6.1343; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Israeli RS, 1997, UROL CLIN N AM, V24, P439, DOI 10.1016/S0094-0143(05)70391-8; KEMENY DM, 1984, EUR J BIOCHEM, V139, P217, DOI 10.1111/j.1432-1033.1984.tb07997.x; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Knudson W, 1996, AM J PATHOL, V148, P1721; KNUDSON W, 1984, P NATL ACAD SCI-BIOL, V81, P6767, DOI 10.1073/pnas.81.21.6767; Kupelian P, 1996, UROLOGY, V48, P249, DOI 10.1016/S0090-4295(96)00167-7; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Li MW, 1997, MOL REPROD DEV, V48, P356; LIN RY, 1995, J PEDIATR SURG, V30, P304, DOI 10.1016/0022-3468(95)90578-2; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Lokeshwar VB, 1998, CANCER LETT, V131, P21, DOI 10.1016/S0304-3835(98)00197-9; Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0; Lokeshwar VB, 1996, CANCER RES, V56, P651; Lokeshwar VB, 1998, CANCER RES, V58, P3191; Lokeshwar VB, 1999, CANCER RES, V59, P4464; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; Madan AK, 1999, ONCOL REP, V6, P607; Miyake H, 1998, J UROLOGY, V160, P1562, DOI 10.1016/S0022-5347(01)62613-2; MURPHY JP, 1998, CANCER, V15, P2233; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; Pettaway C A, 1998, Tech Urol, V4, P35; Pham HT, 1997, CANCER RES, V57, P778; Podyma KA, 1997, BIOCHEM BIOPH RES CO, V241, P446, DOI 10.1006/bbrc.1997.7829; PUKRITTAYAKAMEE S, 1988, TOXICON, V26, P629, DOI 10.1016/0041-0101(88)90245-0; RODEN L, 1989, CIBA F SYMP, V143, P60; Ropponen K, 1998, CANCER RES, V58, P342; Ruijter ETG, 1998, J UROLOGY, V160, P1368, DOI 10.1016/S0022-5347(01)62537-0; Setala LP, 1999, BRIT J CANCER, V79, P1133, DOI 10.1038/sj.bjc.6690180; Stair-Nawy S, 1999, BIOCHEM BIOPH RES CO, V266, P268, DOI 10.1006/bbrc.1999.1802; STERN M, 1991, JNCI-J NATL CANCER I, V83, P1569, DOI 10.1093/jnci/83.21.1569; STERN M, 1992, MATRIX, V12, P397, DOI 10.1016/S0934-8832(11)80036-3; Tamakoshi K, 1997, BRIT J CANCER, V75, P1807, DOI 10.1038/bjc.1997.308; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; TU AT, 1983, COMP BIOCHEM PHYS B, V76, P377, DOI 10.1016/0305-0491(83)90086-X; Veltri R W, 1998, Semin Urol Oncol, V16, P106; Victor R, 1997, CR ACAD SCI III-VIE, V320, P805, DOI 10.1016/S0764-4469(97)85016-0; Wang C, 1996, AM J PATHOL, V148, P1861; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; ZHU L, 1994, J BIOL CHEM, V269, P32092	70	250	259	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11922	11932		10.1074/jbc.M008432200	http://dx.doi.org/10.1074/jbc.M008432200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278412	hybrid			2022-12-27	WOS:000168081800066
J	Chevillotte, E; Rieusset, J; Rogues, M; Desage, M; Vidal, H				Chevillotte, E; Rieusset, J; Rogues, M; Desage, M; Vidal, H			The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; BROWN ADIPOSE-TISSUE; UP-REGULATION; HUMAN ADIPOCYTES; ARACHIDONIC-ACID; LEAN HUMANS; PPAR-GAMMA; METABOLISM; ALPHA; DELTA	Fatty acids have been postulated to regulate uncoupling protein (UCP) gene expression in skeletal muscle in, vivo, We have identified, at least in part, the mechanism by which polyunsaturated fatty acids increase UCP-2 expression in primary culture of human muscle cells, omega -6 fatty acids and arachidonic acid induced a 3-fold rise in UCP-2 mRNA levels possibly through transcriptional activation. This effect was prevented by indomethacin and mimicked by prostaglandin (PG) E-2 and carbaprostacyclin PGI(2), consistent with a cyclooxygenase-mediated process. Incubation of myotubes for 6 h with 100 muM arachidonic acid resulted in a 150-fold increase in PGE(2) and a 15-fold increase in PGE(2) in the culture medium. Consistent with a role of cAMP and protein kinase A, both prostaglandins induced a marked accumulation of cAMP in human myotubes, and forskolin reproduced the effect of arachidonic acid on UCP-2 mRNA expression. Inhibition of protein kinase A with H-89 suppressed the effect of PGE(2), whereas cPGI(2) and arachidonic acid were still able to increase ucp-2 gene expression, suggesting additional mechanisms. We found, however, that the MAP kinase pathway was not involved, Prostaglandins, particularly PGI(2), are potent activators of the peroxisome proliferator-activated receptors, A specific agonist of peroxisome proliferator-activated receptor (PPAR) beta (L165041) increased UCP-2 mRNA levels in myotubes, whereas activation of PPAR alpha or PPAR gamma was ineffective. These results suggest thus that ucp-2 gene expression is regulated by omega -6 fatty acids in human muscle cells through mechanisms involving at least protein kinase A and the nuclear receptor PPAR beta.	Univ Lyon 1, INSERM, U449, Fac Med Rene Laennec, F-69372 Lyon 08, France; Univ Lyon 1, CRNHL, U449, Fac Med Rene Laennec, F-69372 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Vidal, H (corresponding author), Univ Lyon 1, INSERM, U449, Fac Med Rene Laennec, Rue G Paradin, F-69372 Lyon 08, France.	vidal@laennec.univ-lyon1.fr	Rieusset, Jennifer/F-1595-2018; Vidal, Hubert/M-6674-2017	Rieusset, Jennifer/0000-0002-1587-2253; Vidal, Hubert/0000-0002-9467-0317				Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Boss O, 1998, LANCET, V351, P1933, DOI 10.1016/S0140-6736(05)78617-7; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; Diehl AM, 1999, J BIOENERG BIOMEMBR, V31, P493, DOI 10.1023/A:1005452624640; EZZOUBIR A, 1995, J BIOL CHEM, V270, P2367; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HIMMSHAGEN J, 1985, ANNU REV NUTR, V5, P69, DOI 10.1146/annurev.nu.05.070185.000441; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Jehl-Pietri C, 2000, BIOCHEM J, V350, P93, DOI 10.1042/0264-6021:3500093; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KASAGI K, 1982, J CLIN ENDOCR METAB, V54, P108, DOI 10.1210/jcem-54-1-108; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LANDS WEM, 1979, ANNU REV PHYSIOL, V41, P633, DOI 10.1146/annurev.ph.41.030179.003221; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; MCELLIGOTT MA, 1988, BIOCHEM J, V253, P745, DOI 10.1042/bj2530745; Millet L, 1998, DIABETOLOGIA, V41, P829, DOI 10.1007/s001250050994; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; RICHELSEN B, 1987, BIOCHEM J, V247, P389, DOI 10.1042/bj2470389; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rieusset J, 1999, BIOCHEM BIOPH RES CO, V265, P265, DOI 10.1006/bbrc.1999.1657; Roques M, 1999, J BIOL CHEM, V274, P34005, DOI 10.1074/jbc.274.48.34005; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; Sartippour MR, 2000, ARTERIOSCL THROM VAS, V20, P104, DOI 10.1161/01.ATV.20.1.104; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Tsikas D, 1998, J CHROMATOGR B, V717, P201, DOI 10.1016/S0378-4347(98)00210-2; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; Tu NX, 1999, BIOCHEM BIOPH RES CO, V265, P326, DOI 10.1006/bbrc.1999.1663; Van der Lee KAJM, 2000, FASEB J, V14, P495, DOI 10.1096/fasebj.14.3.495; VANE JR, 1979, ACTA CARDIOL, V23, P21; Vidal H, 1999, AM J PHYSIOL-ENDOC M, V277, pE830, DOI 10.1152/ajpendo.1999.277.5.E830; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Viguerie-Bascands N, 1999, BIOCHEM BIOPH RES CO, V256, P138, DOI 10.1006/bbrc.1999.0303; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298	53	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10853	10860		10.1074/jbc.M008010200	http://dx.doi.org/10.1074/jbc.M008010200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278377	hybrid			2022-12-27	WOS:000167980900041
J	Di Fulvio, M; Lincoln, TM; Lauf, PK; Adragna, NC				Di Fulvio, M; Lincoln, TM; Lauf, PK; Adragna, NC			Protein kinase G regulates potassium chloride cotransporter-3 expression in primary cultures of rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE; CYCLIC-GMP; MOLECULAR-CLONING; MESSENGER-RNA; IDENTIFICATION; ACTIVATION; TRANSCRIPTION; TRANSLATION	K-C1 cotransport (KCC) is activated by nitric oxide donors and appears to be regulated by the cGMP signaling pathway. Expression of KCC mRNAs (KCC1-KCC4) in rat vascular smooth muscle cells (VSMCs) is unknown. We have reported the presence of KCC1 and KCC3 mRNAs in primary cultures of VSMCs by specific reverse transcription-polymerase chain reaction. KCC2 mRNA appeared at extremely low levels. KCC4 mRNA was undetectable. Semiquantitative reverse transcription-polymerase chain reaction revealed a 2:1 KCC1/ KCC3 mRNA ratio in VSMCs. Depletion of protein kinase G (PKG)-1 from VSMCs did not change KCC3 mRNA expression. Analogous results were obtained with PKG-1-catalytic domain- and vector only-transfected VSMCs lacking endogenous PEG, suggesting no involvement of PKG-1 in the maintenance of basal KCC3 mRNA expression. However, 8-bromo-cGMP, a PKG stimulator, acutely increased KCC3 mRNA expression in a concentration- and time-dependent fashion; this effect was blocked by the PKG inhibitor KT5823 but not by actinomycin D, These findings show that VSMCs express mainly two mRNA isoforms, KCC1 and KCC3, and suggest that PEG participates post-transcriptionally in the acute KCC3 mRNA regulation. The role of KCC3 on cell volume and electrolyte homeostasis in response to PKG modulators remains to be determined.	Wright State Univ, Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA; Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA; Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; University of Alabama System; University of Alabama Birmingham	Adragna, NC (corresponding author), Wright State Univ, Sch Med, Dept Pharmacol & Toxicol, 3640 Colonel Glenn Hwy,Biol Sci Bldg,Room 152-6, Dayton, OH 45435 USA.	norma.adragna@wright.edu						Adragna NC, 1998, J MEMBRANE BIOL, V166, P157, DOI 10.1007/s002329900457; Adragna NC, 2000, AM J PHYSIOL-CELL PH, V278, pC381, DOI 10.1152/ajpcell.2000.278.2.C381; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; BOERTH NJ, 1994, FEBS LETT, V342, P255, DOI 10.1016/0014-5793(94)80512-1; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; Di Fulvio M, 2001, FASEB J, V15, pA114; Di Fulvio M, 2000, J ENDOCRINOL, V166, P173, DOI 10.1677/joe.0.1660173; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gudi T, 1996, J BIOL CHEM, V271, P4597; HAMET P, 1995, HYPERTENSION PATHOPH, P565; Hayden MA, 1999, J SURG RES, V82, P222, DOI 10.1006/jsre.1999.5573; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Holtzman EJ, 1998, AM J PHYSIOL-RENAL, V275, pF550, DOI 10.1152/ajprenal.1998.275.4.F550; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Kaldy P, 1999, EMBO J, V18, P6073, DOI 10.1093/emboj/18.21.6073; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Pellegrino CM, 1998, BLOOD CELL MOL DIS, V24, P31, DOI 10.1006/bcmd.1998.0168; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Ruth P, 1997, J BIOL CHEM, V272, P10522; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; Su WF, 1999, AM J PHYSIOL-CELL PH, V277, pC899, DOI 10.1152/ajpcell.1999.277.5.C899; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936	34	43	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21046	21052		10.1074/jbc.M100901200	http://dx.doi.org/10.1074/jbc.M100901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274213	hybrid			2022-12-27	WOS:000169297900035
J	Russo, C; Gao, Y; Mancini, P; Vanni, C; Porotto, M; Falasca, M; Torrisi, MR; Zheng, Y; Eva, A				Russo, C; Gao, Y; Mancini, P; Vanni, C; Porotto, M; Falasca, M; Torrisi, MR; Zheng, Y; Eva, A			Modulation of oncogenic DBL activity by phosphoinositol phosphate binding to pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BRUTONS TYROSINE KINASE; HIGH-AFFINITY BINDING; BETA-GAMMA-SUBUNITS; GUANOSINE TRIPHOSPHATASES; PH DOMAIN; PROTEIN; RAC; TRANSFORMATION; ACTIVATION	The Dbl family guanine nucleotide exchange factors (GEFs) contain a region of sequence similarity consisting of a catalytic Dbl homology (DH) domain in tandem with a pleckstrin homology (PH) domain. PH domains are involved in the regulated targeting of signaling molecules to plasma membranes by protein-protein and/or protein-lipid interactions. Here we show that Dbl PH domain binding to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-triphosphate results in the inhibition of Dbl GEF activity on Rho family GTPase Cdc42. Phosphatidylinositol 4,5-bisphosphate binding to the PH domain significantly inhibits the Cdc42 interactive activity of the DH domain suggesting that the DH domain is subjected to the PH domain modulation under the influence of phosphoinositides (PIPs). We generated Dbl mutants unable to interact with PIPs. These mutants retained GEF activity on Cdc42 in the presence of PIPs and showed a markedly enhanced activating potential for both Cdc42 and RhoA in vivo while displaying decreased cellular transforming activity. Immunofluorescence analysis of NIH3T3 transfectants revealed that whereas the PH domain localizes to actin stress fibers and plasma membrane, the PH mutants are no longer detectable on the plasma membrane. These results suggest that modulation of PIPs in both the GEF catalytic activity and the targeting to plasma membrane determines the outcome of the biologic activity of Dbl.	Ist G Gaslini, Mol Biol Lab, I-16147 Genoa, Italy; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Rome La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; Univ Chieti, Cattedra Oncol Med, Dipartimento Oncol & Neurosci, I-66100 Chieti, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Tennessee System; University of Tennessee Health Science Center; Sapienza University Rome; G d'Annunzio University of Chieti-Pescara	Eva, A (corresponding author), Ist G Gaslini, Mol Biol Lab, Largo G Gaslini 5, I-16147 Genoa, Italy.		Eva, Alessandra/J-8268-2016; Zheng, Yi/J-7235-2015; Falasca, Marco/S-4020-2016	Eva, Alessandra/0000-0003-2949-078X; Zheng, Yi/0000-0001-7089-6074; POROTTO, Matteo/0000-0003-3866-9220; mancini, patrizia/0000-0003-0556-2056; Falasca, Marco/0000-0002-9801-7235	NIGMS NIH HHS [GM53943] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RON D, 1991, NEW BIOL, V3, P372; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	46	56	59	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19524	19531		10.1074/jbc.M009742200	http://dx.doi.org/10.1074/jbc.M009742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11278560	Green Published, hybrid			2022-12-27	WOS:000169091000115
J	Ho, IC; Arm, JP; Bingham, CO; Choi, A; Austen, KF; Glimcher, LH				Ho, IC; Arm, JP; Bingham, CO; Choi, A; Austen, KF; Glimcher, LH			A novel group of phospholipase A(2)s preferentially expressed in type 2 helper T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELLS; PROSTAGLANDIN E-2; PPAR-GAMMA; RECOMBINANT EXPRESSION; P388D(1) MACROPHAGES; MOUSE STRAINS; GROUP IIA; NF-AT; RECEPTOR; GENE	We report a novel phospholipase A(2) (PLA(2)), group XII (GXII) PLA(2), distinct from other cysteine-rich groups with a catalytic histidine motif, by its 20-kDa size and distribution of the 14 cysteine residues within the protein. Alternative spliced forms with distinct subcellular localization, designated GXII-1 and GXII-2, were identified by reverse transcription-polymerase chain reaction. Importantly, GXII PLA(2)s, in particular GXII-2 PLA(2), and group V PLA(2), but not group X PLA(2), were selectively expressed in murine type 2 helper T (Th2) clones and in vitro differentiated mouse CD4 Th2 cells as compared with type 1 helper T clones and cells. Stimulation with anti-CD3 appreciably up-regulated expression of GXII PLA(2)s and group V PLA(2) by steady state analysis of the Th2 cells as compared with type 1 helper T cells. These results suggest that group XII and group V PLA(2)s might participate in helper T cell immune response through release of immediate second signals and generation of downstream eicosanoids.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ho, IC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 651 Huntington Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL36110] Funding Source: Medline; NIA NIH HHS [AG 37833] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHEN J, 1994, J BIOL CHEM, V269, P2365; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Copic A, 1999, J BIOL CHEM, V274, P26315, DOI 10.1074/jbc.274.37.26315; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Demeure CE, 1997, EUR J IMMUNOL, V27, P3526, DOI 10.1002/eji.1830271254; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Hilkens CM, 1996, EUR RESPIR J, V22, P90; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Kalinski P, 1998, J IMMUNOL, V161, P2804; KATAMURA K, 1995, J IMMUNOL, V155, P4604; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kuroda E, 2000, J IMMUNOL, V164, P2386, DOI 10.4049/jimmunol.164.5.2386; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; Paliogianni F, 1996, CELL IMMUNOL, V171, P95, DOI 10.1006/cimm.1996.0178; PALIOGIANNI F, 1993, J EXP MED, V178, P1813, DOI 10.1084/jem.178.5.1813; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Wu CY, 1998, J IMMUNOL, V161, P2723	51	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18321	18326		10.1074/jbc.M008837200	http://dx.doi.org/10.1074/jbc.M008837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278438	hybrid			2022-12-27	WOS:000168866500095
J	Sevilla, L; Zaldumbide, A; Carlotti, F; Dayem, MA; Pognonec, P; Boulukos, KE				Sevilla, L; Zaldumbide, A; Carlotti, F; Dayem, MA; Pognonec, P; Boulukos, KE			Bcl-x(L) expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation by Ets2 and PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; CELL-DEATH; IFN-GAMMA; BCL-X; GENE; RECEPTOR; LIPOPOLYSACCHARIDE; PATHWAY	Depriving primary bone marrow-derived macrophages of colony-stimulating factor-1 (CSF-1) induces programmed cell death by apoptosis, We show that cell death is accompanied by decreases in the expression of anti-apoptotic Bcl-x(L) protein and the Ets2 and PU.1 proteins of the Ets transcription factor family. Macrophages require both priming and triggering signals independent of CSF-1 to kill neoplastic cells or microorganisms, and this activation of macrophage competence is accompanied by increased expression of bcl-x(L), ets2, and PU.1. Furthermore, we show that only Ets2 and PU.1, but not Ets1, function in a synergistic manner to transactivate the bcl-x promoter. The synergy observed between PU.1 and Ets2 is dependent on the transactivation domains of both proteins. Although other transcription factors like Foe, c-Jun, Myc, STAT3, and STAT5a are implicated in the activation of macrophage competence or in CSF-1 signaling, no synergy was observed between Ets2 and these transcription factors on the bcl-x promoter. We demonstrate that the exogenous expression of both Ets2 and PU.1 in macrophages increases the number of viable cells upon CSF-1 depletion and that Ets2 and PU.1 can functionally replace Bcl-x(L) in inhibiting Bar-induced apoptosis, Together, these results demonstrate that PU.1 and Ets2 dramatically increase bcl-x activation, which is necessary for the cytocidal function and survival of macrophages.	Univ Nice, Fac Sci, Ctr Biochim, INSERM,U470,Inst Signalisat Dev Biol & Canc, F-06108 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Boulukos, KE (corresponding author), Univ Nice, Fac Sci, Ctr Biochim, INSERM,U470,Inst Signalisat Dev Biol & Canc, F-06108 Nice, France.		Carlotti, Françoise/AAN-5018-2021; Carlotti, Françoise/H-1060-2014	Carlotti, Françoise/0000-0001-7929-8468; Carlotti, Françoise/0000-0001-7929-8468				Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; Aperlo C, 1998, CELL GROWTH DIFFER, V9, P929; BACCARINI M, 1992, J IMMUNOL, V149, P2656; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; Chang BS, 1999, MOL CELL BIOL, V19, P6673; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; JIN DI, 1995, MOL CELL BIOL, V15, P693; Keller JR, 1996, BLOOD, V88, P863; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Okada S, 1998, J IMMUNOL, V160, P2590; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1987, ARCH INT PHYSL BIOCH, V96, pB51; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHACKELFORD R, 1995, J IMMUNOL, V154, P1374; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	40	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17800	17807		10.1074/jbc.M008270200	http://dx.doi.org/10.1074/jbc.M008270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11278399	hybrid			2022-12-27	WOS:000168866500026
J	Charlwood, J; Dingwall, C; Matico, R; Hussain, I; Johanson, K; Moore, S; Powell, DJ; Skehel, JM; Ratcliffe, S; Clarke, B; Trill, J; Sweitzer, S; Camilleri, P				Charlwood, J; Dingwall, C; Matico, R; Hussain, I; Johanson, K; Moore, S; Powell, DJ; Skehel, JM; Ratcliffe, S; Clarke, B; Trill, J; Sweitzer, S; Camilleri, P			Characterization of the glycosylation profiles of Alzheimer's beta-secretase protein Asp-2 expressed in a variety of cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; N-LINKED OLIGOSACCHARIDES; HUMAN BRAIN; DISEASE; PURIFICATION; CLEAVAGE; BACE	Amyloid 39-42 beta -peptides are the main components of amyloid plaques found in the brain of Alzheimer's disease patients. Amyloid 39-42 beta -peptide is formed from amyloid precursor protein by the sequential action of beta -and gamma -secretases. Asp-2 is a transmembrane aspartic protease expressed in the brain, shown to have beta -secretase activity. Mature Asp-2 has four N-glycosylation sites. In this report we have characterized the carbohydrate structures in this glycoprotein expressed in three different cell lines, namely Chinese hamster ovary, CV-1 origin of SV40, and baculovirus-infected SF9 cells. Biantennary and triantennary oligosaccharides of the "complex" type were released from glycoprotein expressed in the mammalian cells, whereas mannose-rich glycans were identified from glycoprotein synthesized in the baculovirus-infected cells. Site-directed mutagenesis of the asparagine residues at amino acid positions 153, 172, 223, and 354 demonstrate that the protease activity of Asp-2 is dependent on its glycosylation.	SmithKline Beecham Pharmaceut, Dept Analyt Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Computat & Struct Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Sweitzer, S (corresponding author), SmithKline Beecham Pharmaceut, Dept Analyt Sci, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	sharon_m_sweitzer@sbphrd.com; camilleri@sbphrd.com		Matico, Rosalie/0000-0003-2341-3767				AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2000, ANAL CHEM, V72, P1453, DOI 10.1021/ac991268f; CHARLWOOD J, 2001, IN PRESS ANAL BIOCH; Ghosh AK, 2000, J AM CHEM SOC, V122, P3522, DOI 10.1021/ja000300g; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JARVIS DL, 1995, VIROLOGY, V212, P500, DOI 10.1006/viro.1995.1508; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e; SARENEVA T, 1995, BIOCHEM J, V308, P9, DOI 10.1042/bj3080009; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YANG HJ, 1994, BIO-TECHNOL, V12, P193, DOI 10.1038/nbt0294-193	25	78	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16739	16748		10.1074/jbc.M009361200	http://dx.doi.org/10.1074/jbc.M009361200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278492	hybrid			2022-12-27	WOS:000168730400021
J	Fry, DW; Bedford, DC; Harvey, PH; Fritsch, A; Keller, PR; Wu, ZP; Dobrusin, E; Leopold, WR; Fattaey, A; Garrett, MD				Fry, DW; Bedford, DC; Harvey, PH; Fritsch, A; Keller, PR; Wu, ZP; Dobrusin, E; Leopold, WR; Fattaey, A; Garrett, MD			Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITORS; RETINOBLASTOMA-PROTEIN; CANCER-CELLS; DIFFERENTIAL EXPRESSION; GROWTH SUPPRESSION; P16(INK4); PROGRESSION; BINDING; ARREST; P16	Progression through the G(1) phase of the cell cycle requires phosphorylation of the retinoblastoma gene product (pRb) by the cyclin D-dependent kinases CDK4 and CDK6, whose activity can specifically be blocked by the CDK inhibitor p16(INK4A). Misregulation of the pRb/cyclin D/p16(INK4A) pathway is one of the most common events in human cancer and has lead to the suggestion that inhibition of cyclin D-dependent kinase activity may have therapeutic value as an anticancer treatment. Through screening of a chemical library, we initially identified the [2,3-d]pyridopyrimidines as inhibitors of CDK4, Chemical modification resulted in the identification of PD 0183812 as a potent and highly se!lective inhibitor of both CDK4 and CDK6 kinase activity, which is competitive with ATP, Flow cytometry experiments showed that of the cell lines tested, only those expressing pRb demonstrated a G(1) arrest when treated with PD 0183812, This arrest correlated in terms of incubation time and potency with a loss of pRb phosphorylation and a block in proliferation, which was reversible, These results suggest a potential use of this chemical class of compounds as therapeutic agents in the treatment of tumors with functional pRb, possessing cell cycle aberrations in other members of the pRb/cyclin D/p16(INK4A) pathway.	Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; Pfizer Global Res & Dev, Ann Arbor Labs, Dept Chem, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Ann Arbor Labs, Dept Canc Res, Ann Arbor, MI 48105 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of London; Institute of Cancer Research - UK; Pfizer; Pfizer	Garrett, MD (corresponding author), Inst Canc Res, CRC, Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	mgarrett@icr.ac.uk						ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; Barvian M, 2000, J MED CHEM, V43, P4606, DOI 10.1021/jm000271k; Bible KC, 2000, CANCER RES, V60, P2419; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580; Fry D., 2000, CURRENT OPIN ONCOL E, P2; FRY DW, 1994, ANTI-CANCER DRUG DES, V9, P331; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; JIN XM, 1995, CANCER RES, V55, P3250; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; KATO J, 1999, FRONT BIOSCI, V4, P787; Kent LL, 1999, BIOCHEM BIOPH RES CO, V260, P768, DOI 10.1006/bbrc.1999.0891; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kubo A, 1999, CLIN CANCER RES, V5, P4279; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meijer L, 1997, METHOD ENZYMOL, V283, P113; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Rocco JW, 1998, CLIN CANCER RES, V4, P1697; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; Zaharevitz DW, 1999, CANCER RES, V59, P2566	45	111	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16617	16623		10.1074/jbc.M008867200	http://dx.doi.org/10.1074/jbc.M008867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278443	hybrid			2022-12-27	WOS:000168730400005
J	Guzman-Verri, C; Chaves-Olarte, E; Garcia, F; Arvidson, S; Moreno, E				Guzman-Verri, C; Chaves-Olarte, E; Garcia, F; Arvidson, S; Moreno, E			In vivo proteolytic degradation of the Escherichia coli acyltransferase HlyC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL PROTEIN ACYLTRANSFERASE; ACTIVATES HEMOLYSIN TOXIN; SITE-DIRECTED MUTAGENESIS; DEPENDENT FATTY ACYLATION; MEMBRANE-TARGETED TOXIN; IN-VIVO; RTX TOXIN; ENZYMATIC-ACTIVITY; ACTINOBACILLUS-PLEUROPNEUMONIAE; NEISSERIA-MENINGITIDIS	Escherichia coli hemolysin (HlyA) is the prototype toxin of a major family of exoproteins produced by Gram-negative bacteria known as "repeats in toxins." Only fatty acid-acylated HlyA molecules at residues Lys(564) and Lys(690) are able to damage the target cell membrane. Fatty acylation of pro-HlyA is dependent on the co-synthesized acyltransferase HlyC and the acylated form of acyl-carrier protein. By using a collection of hlyA and hlyC mutant strains, the processing of HlyC was investigated. HlyC was not detected by Western blot in an E, coli strain encoding hlyC and hlyA, but it was present in a strain encoding only hlyC, The hlyC mRNA pattern, however, was similar in both strains indicating that the turnover of HlyC does not occur at the transcriptional level. HlyC was detected in Western blots of cell lysates from an E. coli strain encoding HlyC and a HlyA derivative where both acylation sites were substituted. Similar results were obtained when HIS C was expressed in a hlyA mutant strain lacking part of a putative HlyC binding domain, indicating that this particular HlyA region affects HlyC stability. We did not detect HlyC in cell lysates from hlyC mutants with different abilities to acylate pro-HlyA, suggesting that the degradation of HlyC is not related to the HlyA acylation process. The protease systems ClpAP, ClpXP, and FtsH were found to be responsible for the HlyA-dependent processing of HlyC.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Univ Nacl Heredia, Escuela Med Vet, Programa Invest Enfermedades, Heredia 3000, Costa Rica; Univ Costa Rica, Fac Microbiol, Ctr Invest Enfermedades Trop, San Jose, Costa Rica	Karolinska Institutet; Universidad Nacional Costa Rica; Universidad Costa Rica	Guzman-Verri, C (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, Box 280, S-17177 Stockholm, Sweden.		Guzman-Verri, Caterina/AAP-3074-2020	Guzman-Verri, Caterina/0000-0003-1036-920X; Moreno, Edgardo/0000-0001-8771-3959				Bauer ME, 1996, INFECT IMMUN, V64, P167, DOI 10.1128/IAI.64.1.167-175.1996; BUKHARI AI, 1973, NATURE-NEW BIOL, V243, P238, DOI 10.1038/newbio243238a0; CHANG YF, 1993, INFECT IMMUN, V61, P2089, DOI 10.1128/IAI.61.5.2089-2095.1993; CHANG YF, 1989, DNA-J MOLEC CELL BIO, V8, P635, DOI 10.1089/dna.1.1989.8.635; Coligan JE, 1995, CURRENT PROTOCOLS PR; FREY J, 1995, TRENDS MICROBIOL, V3, P257, DOI 10.1016/S0966-842X(00)88939-8; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GOEBEL W, 1982, J BACTERIOL, V151, P1290, DOI 10.1128/JB.151.3.1290-1298.1982; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1999, CURR OPIN MICROBIOL, V2, P142, DOI 10.1016/S1369-5274(99)80025-3; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GuzmanVerri C, 1997, J BACTERIOL, V179, P5959, DOI 10.1128/jb.179.18.5959-5962.1997; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; Harlow E., 1999, USING ANTIBODIES LAB; HARTLEIN M, 1983, J CELL BIOCHEM, V22, P87, DOI 10.1002/jcb.240220203; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HUGHES C, 1992, FEMS MICROBIOL IMMUN, V105, P37, DOI 10.1111/j.1574-6968.1992.tb05884.x; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JANSEN R, 1995, INFECT IMMUN, V63, P27, DOI 10.1128/IAI.63.1.27-37.1995; JANZON L, 1986, FEMS MICROBIOL LETT, V33, P193; Kanemori M, 1999, J BACTERIOL, V181, P3674, DOI 10.1128/JB.181.12.3674-3680.1999; Kanemori M, 1997, J BACTERIOL, V179, P7219, DOI 10.1128/jb.179.23.7219-7225.1997; KORONAKIS V, 1987, J BACTERIOL, V169, P1509, DOI 10.1128/jb.169.4.1509-1515.1987; KORONAKIS V, 1988, MOL GEN GENET, V213, P99, DOI 10.1007/BF00333404; KORONAKIS V, 1989, MOL MICROBIOL, V3, P1397, DOI 10.1111/j.1365-2958.1989.tb00122.x; KORONAKIS V, 1988, NUCLEIC ACIDS RES, V16, P4789, DOI 10.1093/nar/16.11.4789; Kuhnert P, 2000, INFECT IMMUN, V68, P6, DOI 10.1128/IAI.68.1.6-12.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leffers GG, 1998, J BACTERIOL, V180, P1573, DOI 10.1128/JB.180.6.1573-1577.1998; Lin W, 1999, P NATL ACAD SCI USA, V96, P1071, DOI 10.1073/pnas.96.3.1071; Ludwig A, 1996, J BACTERIOL, V178, P5422, DOI 10.1128/jb.178.18.5422-5430.1996; LUDWIG A, 1987, MOL GEN GENET, V206, P238, DOI 10.1007/BF00333579; NICAUD JM, 1985, FEBS LETT, V187, P339, DOI 10.1016/0014-5793(85)81272-2; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Sambrook J., 2002, MOL CLONING LAB MANU; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1996, MOL MICROBIOL, V20, P813, DOI 10.1111/j.1365-2958.1996.tb02519.x; Stanley P, 1999, MOL MICROBIOL, V34, P887, DOI 10.1046/j.1365-2958.1999.01648.x; SUTTON JM, 1994, P NATL ACAD SCI USA, V91, P9990, DOI 10.1073/pnas.91.21.9990; THOMPSON SA, 1993, INFECT IMMUN, V61, P2906, DOI 10.1128/IAI.61.7.2906-2911.1993; THOMPSON SA, 1993, J BACTERIOL, V175, P811, DOI 10.1128/JB.175.3.811-818.1993; Trent MS, 1999, BIOCHEMISTRY-US, V38, P9541, DOI 10.1021/bi9905617; Trent MS, 1999, BIOCHEMISTRY-US, V38, P3433, DOI 10.1021/bi982491u; Trent MS, 1998, BIOCHEMISTRY-US, V37, P4644, DOI 10.1021/bi971588y; Trent MS, 1999, BIOCHEMISTRY-US, V38, P8831, DOI 10.1021/bi990138y; Urech C, 2000, EUR J BIOCHEM, V267, P4831, DOI 10.1046/j.1432-1327.2000.01541.x; VOGEL M, 1988, MOL GEN GENET, V212, P76, DOI 10.1007/BF00322447; WELCH RA, 1988, J BACTERIOL, V170, P1622, DOI 10.1128/jb.170.4.1622-1630.1988; WELCH RA, 1981, NATURE, V294, P665, DOI 10.1038/294665a0; Wu WF, 1999, J BACTERIOL, V181, P3681, DOI 10.1128/JB.181.12.3681-3687.1999; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	56	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16660	16666		10.1074/jbc.M009514200	http://dx.doi.org/10.1074/jbc.M009514200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278516	hybrid			2022-12-27	WOS:000168730400011
J	Jakobi, R; Moertl, E; Koeppel, MA				Jakobi, R; Moertl, E; Koeppel, MA			p21-activated protein kinase gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; RAT-1 FIBROBLASTS; APOPTOTIC CELLS; FAMILY PROTEINS; ACTIVATION; CLEAVAGE; RAS; AUTOPHOSPHORYLATION; PHOSPHORYLATION	In response to stress stimulants, cells activate opposing signaling pathways for cell survival and programmed cell death. p21-activated protein kinase gamma -PAK is involved in both cell survival and cell death pathways. Many stress stimulants activate gamma -PAK as a full-length enzyme and as a proteolytic fragment. Caspase-mediated proteolytic activation parallels cell death and appears to be a pro-apoptotic factor in stress-induced cell death. Here, we show that activation of full-length gamma -PAK promotes cell survival and suppresses stress-induced cell death. Expression of constitutively active gamma -PAK-T402E, which mimics activated full-length gamma -PAK, stimulates cell survival of BALB3T3 fibroblasts in response to tumor necrosis factor alpha, growth factor withdrawal, and WC light. This stimulation of cell survival is mainly due to protection of cells from cell death rather than by stimulation of proliferation. Expression of gamma -PAK-T402E increases phosphorylation of the proapoptotic Bcl-2 family protein Bad and protects from cell death induced by ectopic expression of Bad. In response to tumor necrosis factor alpha, expression of gamma -PAK-T402E increases the early but reduces the late activation of ERK, JNK, and p38, Our results indicate that the ubiquitous gamma -PAK may have a crucial function in cell survival by regulating the pro-apoptotic activity of Bad and the stress-induced activation of ERK, JNK, and p38 pathways.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Jakobi, R (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	rjakobi@mcw.edu						AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AARONSON SA, 1971, J GEN VIROL, V13, P245, DOI 10.1099/0022-1317-13-2-245; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KULKARNI GV, 1994, J CELL SCI, V107, P1169; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Roig J, 2000, J BIOL CHEM, V275, P16933, DOI 10.1074/jbc.M001627200; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang E, 1999, J CELL BIOCHEM, P95; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	47	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16624	16634		10.1074/jbc.M007753200	http://dx.doi.org/10.1074/jbc.M007753200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278362	hybrid			2022-12-27	WOS:000168730400006
J	Rosado, JA; Sage, SO				Rosado, JA; Sage, SO			Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE KINASE; ACTIN CYTOSKELETON; CA2+ ENTRY; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; INHIBITION; THAPSIGARGIN; MECHANISM; GROWTH; INFLUX	Extracellular signal-regulated kinases (ERKs), are common participants in a broad variety of signal transduction pathways. Several studies have demonstrated the presence of ERKs in human platelets and their activation by the physiological agonist thrombin. Here we report the involvement of the ERK cascade in store-mediated Ca2+ entry in human platelets. Treatment of dimethyl-bis-(o-aminophenoxy) -ethane-N,N,N',N'-tetraacetic acid-loaded platelets with thapsigargin to deplete the intracellular Ca2+ stores resulted in a time- and concentration-dependent activation of ERK1 and ERK2. Incubation with either U0126 or PD 184352, specific inhibitors of mitogen-activated protein kinase kinase (MEK), prevented thapsigargin-induced ERK activation. Furthermore, U0126 and PD 184352 reduced Ca2+ entry stimulated by thapsigargin or thrombin, in a concentration-dependent manner. The role of ERK in store-mediated Ca2+ entry was found to be independent of phosphatidylinositol 3- and 4-kinases, the tyrosine kinase pathway, and actin polymerization but sensitive to treatment with inhibitors of Ras, suggesting that the ERK pathway might be a downstream effector of Ras in mediating store-mediated Ca2+ entry in human platelets. In addition, we have found that store depletion stimulated ERK activation does not require PKC activity. This study demonstrates for the first time a novel mechanism for regulation of store-mediated Ca2+ entry in human platelets involving the ERK cascade.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Cambridge	Sage, SO (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.		Rosado, Juan A/H-3488-2015	Rosado, Juan A/0000-0002-9749-2325; Sage, Stewart/0000-0001-8578-3558				BIRD GS, 1993, J BIOL CHEM, V268, P21486; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; LIMOR G, 1997, SCIENCE, V277, P1103; LIMOR G, 1997, DEVELOPMENT, V124, P3535; MAHAUTSMITH MP, 1990, J PHYSIOL-LONDON, V428, P723, DOI 10.1113/jphysiol.1990.sp018237; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SARGEANT P, 1994, CELL CALCIUM, V16, P413, DOI 10.1016/0143-4160(94)90034-5; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; Wang XD, 1999, AM J PHYSIOL-HEART C, V277, pH1498, DOI 10.1152/ajpheart.1999.277.4.H1498; XU X, 1996, MOL PHARMACOL, V50, P1495; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130	39	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15659	15665		10.1074/jbc.M009218200	http://dx.doi.org/10.1074/jbc.M009218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278479	hybrid			2022-12-27	WOS:000168623100014
J	Mittaud, P; Marangi, PA; Erb-Vogtli, S; Fuhrer, C				Mittaud, P; Marangi, PA; Erb-Vogtli, S; Fuhrer, C			Agrin-induced activation of acetylcholine receptor-bound Src family kinases requires rapsyn and correlates with acetylcholine receptor clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; NEUROMUSCULAR-JUNCTION; BETA-SUBUNIT; PHOSPHORYLATION; MUSK; MUSCLE; ASSOCIATION; SIGNALS; FIBROBLASTS; COMPONENTS	During neuromuscular synaptogenesis, neurally re leased agrin induces aggregation and tyrosine phosphorylation of acetylcholine receptors (AChRs) by acting through both the receptor tyrosine kinase MuSK (muscle-specific kinase) and the AChR-associated protein, rapsyn. To elucidate this signaling mechanism, we examined tyrosine phosphorylation of AChR-associated proteins, particularly addressing whether agrin activates Src family kinases bound to the AChR. In C2 myotubes, agrin induced tyrosine phosphorylation of these kinases, of AChR-bound MuSK, and of the AChR beta and delta subunits, as observed in phosphotyrosine immunoblotting experiments. Kinase assays revealed that the activity of AChR-associated Src kinases was increased by agrin, whereas phosphorylation of the total cellular kinase pool was unaffected. In both rapsyn-deficient myotubes and staurosporine treated C2 myotubes, where AChRs are not clustered, agrin activated MuSK but did not cause either Src family or AChR phosphorylation. In S27 mutant myotubes, which fail to aggregate AChRs, no agrin-induced phosphorylation of AChR-bound Src kinases, MuSK, or AChRs was observed. These results demonstrate first that agrin leads to phosphorylation and activation of AChR-associated Src-related kinases, which requires rapsyn, occurs downstream of MuSK, and causes AChR phosphorylation. Second, this activation intimately correlates with AChR clustering, suggesting that these kinases may play a role in agrin-induced AChR aggregation by forming an AChR-bound signaling cascade.	Univ Zurich, Inst Brain Res, CH-8057 Zurich, Switzerland	University of Zurich	Fuhrer, C (corresponding author), Univ Zurich, Inst Brain Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	chfuhrer@hifo.unizh.ch		Fuhrer, Christian/0000-0001-8216-8883				Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Balasubramanian S, 1999, FEBS LETT, V446, P95, DOI 10.1016/S0014-5793(99)00171-4; Bowen DC, 1996, J NEUROCHEM, V66, P2580; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; Camus G, 1999, MOL CELL NEUROSCI, V13, P69, DOI 10.1006/mcne.1998.0728; Colledge M, 1998, CURR OPIN NEUROBIOL, V8, P357, DOI 10.1016/S0959-4388(98)80061-5; Colledge M, 1997, J NEUROSCI, V17, P5038; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Fuhrer C, 1997, EMBO J, V16, P4951, DOI 10.1093/emboj/16.16.4951; Fuhrer C, 1996, J BIOL CHEM, V271, P32474, DOI 10.1074/jbc.271.50.32474; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; GORDON H, 1993, J NEUROSCI, V13, P586; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Herbst R, 2000, EMBO J, V19, P67, DOI 10.1038/sj.emboj.7592228b; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kramarcy NR, 2000, MOL CELL NEUROSCI, V15, P262, DOI 10.1006/mcne.1999.0823; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Martin PT, 1997, DEVELOPMENT, V124, P3909; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Megeath LJ, 1998, J NEUROSCI, V18, P672; Meyer G, 1998, MOL CELL NEUROSCI, V11, P324, DOI 10.1006/mcne.1998.0689; Mohamed AS, 1999, J BIOL CHEM, V274, P20529, DOI 10.1074/jbc.274.29.20529; Nawrotzki R, 1998, J CELL SCI, V111, P2595; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; QU Z, 1994, J NEUROSCI, V14, P6834; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; Watty A, 2000, P NATL ACAD SCI USA, V97, P4585, DOI 10.1073/pnas.080061997; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	56	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14505	14513		10.1074/jbc.M007024200	http://dx.doi.org/10.1074/jbc.M007024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278328	hybrid, Green Published			2022-12-27	WOS:000168356600131
J	Sheng, HM; Shao, JY; DuBois, RN				Sheng, HM; Shao, JY; DuBois, RN			Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTEN TUMOR-SUPPRESSOR; MAP KINASE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; AKT PROTOONCOGENE; EFFECTOR PATHWAYS; CYCLE PROGRESSION; SIGNALING PATHWAY; ONCOGENIC RAS	PhosphatidyIinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt) is thought to serve as an oncogenic signaling pathway which can be activated by Ras, The role of PI3K/Akt in Pas-mediated transformation of intestinal epithelial cells is currently not clear. Here we demonstrate that inducible expression of oncogenic Ha-Ras results in activation of PKB/Akt in rat intestinal epithelial cells (RIE-iHa-Ras), which was blocked by treatment with inhibitors of PI3K activity. The PI3K inhibitor, LY-294002, partially reversed the morphological transformation induced by Ha-Pas and resulted in a modest stimulation of apoptosis. The most pronounced phenotypic alteration following inhibition of PI3K was induction of G(1) phase cell cycle arrest. LY-294002 blocked the Ha-Pas-induced expression of cyclin D1, cyclin-dependent kinase (CDK) 2, and increased the levels of p27(kip2). Both LY-294002 and wortmannin significantly reduced anchorage-independent growth of RIE-iHa-Ras cells. Forced expression of both the constitutively active forms of Raf (Delta Raf-22W or Raf BXB) and Akt (Akt-myr) resulted in transformation of RIE cells that was not achieved by transfection with either the Raf mutant construct or Akt-myr alone. These findings delineate an important role for PI3K/Akt in Pas-mediated transformation of intestinal epithelial cells.	Vanderbilt Univ, Med Ctr, Dept Vet Affairs Med Ctr, Vanderbilt Ingram Canc Ctr,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Vet Affairs Med Ctr, Vanderbilt Ingram Canc Ctr,Dept Cell Biol, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [CA-77839, CA 68485] Funding Source: Medline; NIDDK NIH HHS [DK-47297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BOS JL, 1989, CANCER RES, V49, P4682; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Osada M, 1999, MOL CELL BIOL, V19, P6333; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sizemore N, 1999, GASTROENTEROLOGY, V117, P567, DOI 10.1016/S0016-5085(99)70449-X; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	57	91	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14498	14504		10.1074/jbc.M010093200	http://dx.doi.org/10.1074/jbc.M010093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278613	hybrid			2022-12-27	WOS:000168356600130
J	Huang, XJ; Kadonaga, JT				Huang, XJ; Kadonaga, JT			Biochemical analysis of transcriptional repression by Drosophila histone deacetylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROMYELOCYTIC LEUKEMIA; CHROMATIN TEMPLATES; FUNCTIONAL STEPS; TRICHOSTATIN-A; IN-VITRO; COMPLEX; ACETYLATION; NUCLEOSOME; INITIATION	To study the mechanisms by which deacetylases regulate transcription by RNA polymerase II, we investigated the biochemical properties of purified recombinant Drosophila histone deacetylase 1 (dHDAC1, also known as dRPD3). We found that purified dHDAC1 and Gal4-dHDAC1 polypeptides possess substantial deacetylase activity. Thus, deacetylation by dHDAC1 does not require any additional cofactors, Gal4-dHDAC1, but not dHDAC1, was observed to repress transcription in vitro by about 2-3-fold from chromatin templates, but not from naked DNA templates, in a Ga14 site-dependent manner. This magnitude of repression is similar to that commonly seen by deacetylases in vivo, as assessed by treatment of cells with deacetylase inhibitors. Transcriptional repression by Gal4-dHDAC1 was blocked by the deacetylase inhibitor, FR901228, and thus, deacetylase activity correlates with repression. Single round transcription analyses showed that Gal4-dHDAC1 reduces the absolute number of productive initiation complexes with chromatin templates. Moreover, with chromatin templates that were assembled with completely purified components, Gal4-dHDAC1 was found to deacetylate nucleosomal histones as well. as to repress transcription. These experiments provide biochemical evidence for the requirement of chromatin for transcriptional repression by dHDAC1 and further show that dHDAC1 acts to repress the transcription initiation process.	Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Mol Biol Sect, 0347,Pacific Hall,Rm 2212B,9500 Gilman Dr, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM 46995] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Bulger M., 1994, METH MOL G, V5, P241; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; DeRubertis F, 1996, NATURE, V384, P589; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jiang W, 2000, J BIOL CHEM, V275, P39819, DOI 10.1074/jbc.C000713200; Johnson CA, 1998, GENE, V221, P127, DOI 10.1016/S0378-1119(98)00435-1; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KRAUS WL, 1999, NUCL RECEPTORS PRACT, P167; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pazin MJ, 1998, CHROMATIN PRACTICAL, P173; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Robinson KM, 1998, BBA-REV CANCER, V1378, pM1, DOI 10.1016/S0304-419X(98)00008-0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; UEDA H, 1994, J ANTIBIOT, V47, P301; Wolffe A., 1995, CHROMATIN STRUCTURE; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	45	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12497	12500		10.1074/jbc.C100034200	http://dx.doi.org/10.1074/jbc.C100034200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278256	hybrid			2022-12-27	WOS:000168198600006
J	Kashiwagi, M; Tortorella, M; Nagase, H; Brew, K				Kashiwagi, M; Tortorella, M; Nagase, H; Brew, K			TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEINASES-3 GENE-EXPRESSION; HUMAN TISSUE INHIBITOR; AMINO-TERMINAL DOMAIN; HUMAN SYNOVIAL-FLUID; MATRIX METALLOPROTEINASE; IN-VITRO; ARTICULAR CHONDROCYTES; ESCHERICHIA-COLI; ADAMTS FAMILY; CARTILAGE	The proteoglycan aggrecan is an important major component of cartilage matrix that gives articular cartilage the ability to withstand compression, Increased breakdown of aggrecan is associated with the development of arthritis and is considered to be catalyzed by aggrecanases, members of the ADAM-TS family of metalloproteinases. Four endogenous tissue inhibitors of metalloproteinases (TIMPs) regulate the activities of functional matrix metalloproteinases (MMPs), enzymes that degrade most components of connective tissue, but no endogenous factors responsible for the regulation of aggrecanases have been found. We show here that the N-terminal inhibitory domain of TIMP-3, a member of the TIMP family that has functional properties distinct from other TIMPs, is a strong inhibitor of human aggrecanases 1 and 2, with K-i values in the subnanomolar range. This truncated inhibitor, which lacks the C-terminal domain that is responsible for interactions with molecules other than active metalloproteinases, is produced at high yield by bacterial expression and folding from inclusion bodies. This provides a starting point for developing a biologically available aggrecanase inhibitor suitable for the treatment of arthritis.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England	University of Miami; Imperial College London; University of Oxford	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.		Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032	NIAMS NIH HHS [AR 40994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; Li WQ, 1998, J IMMUNOL, V161, P5000; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Su S, 1999, RHEUMATOL INT, V18, P183, DOI 10.1007/s002960050083; Su SM, 1998, J CELL BIOCHEM, V70, P517, DOI 10.1002/(SICI)1097-4644(19980915)70:4<517::AID-JCB8>3.0.CO;2-M; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; Takizawa M, 2000, ARTHRITIS RHEUM, V43, P812, DOI 10.1002/1529-0131(200004)43:4<812::AID-ANR11>3.0.CO;2-Y; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; WOESSNER FJ, 2000, MATRIX METALLOPROTEN, P130; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	38	390	408	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12501	12504		10.1074/jbc.C000848200	http://dx.doi.org/10.1074/jbc.C000848200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278243	hybrid			2022-12-27	WOS:000168198600007
J	Kim, KW; Kim, SH; Lee, EY; Kim, ND; Kang, HS; Kim, HD; Chung, BS; Kang, CD				Kim, KW; Kim, SH; Lee, EY; Kim, ND; Kang, HS; Kim, HD; Chung, BS; Kang, CD			Extracellular signal-regulated kinase/90-kDa ribosomal S6 kinase/nuclear factor-kappa B pathway mediates phorbol 12-myristate 13-acetate-induced megakaryocytic differentiation of K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PMA-INDUCED DIFFERENTIATION; GLYCOPROTEIN IIB GENE; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; LEUKEMIA-CELLS; GATA; EXPRESSION; ACTIVATION; ALPHA; PHOSPHORYLATION	Two signaling pathways, the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK)-dependent pathway and the nuclear factor-KB (NF-KB)-dependent pathway, have been known to mediate megakaryocytic differentiation of K562 cells induced by phorbol la-myristate 13-acetate (PMA). In this study, we examined whether 90-kDa ribosomal S6 kinase (RSK), known as a substrate of ERK/MAPK and a signal-inducible I kappaB alpha kinase, would link two pathways during the differentiation. RSK1 was activated in a time- and dose-dependent manner during the PMA-induced differentiation. Overexpression of wild-type or dominant inhibitory mutant (D205N) of RSK1 enhanced or suppressed PMA-stimulated NF-KB activation and megakaryocytic differentiation as shown by morphology, nonspecific esterase activity, and expression of the CD41 megakaryocytic marker, respectively. In addition, overexpression of the dominant inhibitory mutant (S32A/S36A) of I kappaB alpha inhibited PMA-stimulated and RSK1-enhanced megakaryocytic differentiation, indicating that NF-KB mediates a signal for megakaryocytic differentiation downstream of RSK1. PMA-stimulated activation of ERK/MAPK, RSK1, and NF-KB and the PMA-induced megakaryocytic differentiation were prevented by pretreatment with PD98059, a specific inhibitor of the mitogen-activated ERK kinase (MEK). Therefore, these results demonstrate that the sequential ERK/RSK1/NF-kappaB pathway mediates PMA-stimulated megakaryocytic differentiation of K562 cells.	Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Res Ctr Mol Med, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Dept Clin Pathol, Pusan 602739, South Korea; Pusan Natl Univ, Coll Pharm, Dept Pharm, Pusan 609735, South Korea; Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea	Pusan National University; Pusan National University; Pusan National University; Pusan National University; Pusan National University	Kang, CD (corresponding author), Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea.							ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Angenstein F, 1998, P NATL ACAD SCI USA, V95, P15078, DOI 10.1073/pnas.95.25.15078; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; COLAMONICI OR, 1985, CYTOMETRY, V6, P591, DOI 10.1002/cyto.990060614; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; FONG AM, 1994, J BIOL CHEM, V269, P18441; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kang CD, 1996, BIOCHEM BIOPH RES CO, V221, P95, DOI 10.1006/bbrc.1996.0551; Kang CD, 1998, CANCER LETT, V132, P99, DOI 10.1016/S0304-3835(98)00165-7; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; ORKIN SH, 1992, BLOOD, V80, P575; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SUTHERLAND JA, 1986, J BIOL RESP MODIF, V5, P250; TABILIO A, 1983, CANCER RES, V43, P4569; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wong EV, 1996, J BIOL CHEM, V271, P18217, DOI 10.1074/jbc.271.30.18217; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	38	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13186	13191		10.1074/jbc.M008092200	http://dx.doi.org/10.1074/jbc.M008092200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278385	hybrid			2022-12-27	WOS:000168198600100
J	Ballif, BA; Shimamura, A; Pae, E; Blenis, J				Ballif, BA; Shimamura, A; Pae, E; Blenis, J			Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent N-alpha-tosyl-1-phenylalanyl chloromethyl ketone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; PHOSPHOINOSITIDE-DEPENDENT KINASE-1; SERINE-PROTEASE INHIBITORS; KAPPA-B ACTIVATION; C-ZETA; MAMMALIAN HOMOLOG; THREONINE KINASE; CELL-SURVIVAL; DUAL ROLE; PHOSPHORYLATION	The anti-tumorigenic and anti-proliferative effects of N-alpha -tosyl-L-phenylalanyl chloromethyl ketone (TPCK) have been known for more than three decades. Yet little is known about the discrete cellular targets of TPCK controlling these effects. Previous work from our laboratory showed TPCK, like the immunosuppressant rapamycin, to be a potent inhibitor of the 70-kilodalton ribosomal S6 kinase 1 (S6K1), which mediates events involved in cell growth and proliferation. We show here that rapamycin and TPCK display distinct inhibitory mechanisms on S6K1 as a rapamycin-resistant form of S6K1 was TPCK-sensitive, Additionally, we show that TPCK inhibited the activation of the related kinase and proto-oncogene Akt. Upstream regulators of S6K1 and Akt include phosphoinositide S-kinase (PI 3-K) and 3-phosphoinositide-dependent kinase 1 (PDK1). Whereas TPCK had no effect on either mitogen-regulated PI 3-K; activity or total cellular PDK1 activity, TPCK prevented phosphorylation of the PDK1 regulatory sites in S6K1 and Akt. Furthermore, whereas both PDK1 and the mitogen-activated protein kinase (MAPK) are required for full activation of the 90-kilodalton ribosomal S6 kinase (RSK), TPCK inhibited RSK activation without inhibiting MAPK activation. Consistent with the capacity of RSK and Abt to mediate a cell survival signal, in part through phosphorylation of the pro-apoptotic protein BAD, TPCK reduced BAD phosphorylation and led to cell death in interleukin-3-dependent 32D cells. Finally, in agreement with results seen in embryonic stem cells lacking PDK1, protein kinase A activation was not inhibited by TPCK showing TPCK specificity for mitogen-regulated PDK1 signaling. TPCK inhibition of PDK1 signaling thus disables central kinase cascades governing diverse cellular processes including proliferation and survival and provides an explanation for its striking biological effects.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Hematol & Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	jblenis@hms.harvard.edu			NCI NIH HHS [CA4569] Funding Source: Medline; NIGMS NIH HHS [GM51405] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; CHOU IN, 1974, P NATL ACAD SCI USA, V71, P1748, DOI 10.1073/pnas.71.5.1748; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Grammer TC, 1996, J BIOL CHEM, V271, P23650, DOI 10.1074/jbc.271.39.23650; GRAMMER TC, 1996, CANC SURV; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Heussler VT, 1999, CELL DEATH DIFFER, V6, P342, DOI 10.1038/sj.cdd.4400501; HIRSCHHORN R, 1971, J CLIN INVEST, V50, P1206, DOI 10.1172/JCI106598; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Kahan BD, 1999, TRANSPLANTATION, V68, P1526, DOI 10.1097/00007890-199911270-00016; Kennedy AR, 1998, PHARMACOL THERAPEUT, V78, P167, DOI 10.1016/S0163-7258(98)00010-2; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KUPFER A, 1979, P NATL ACAD SCI USA, V76, P3073, DOI 10.1073/pnas.76.7.3073; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Ozes ON, 1999, NATURE, V401, P82; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Powers J C, 1977, Methods Enzymol, V46, P197; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; SLAGA TJ, 1980, P NATL ACAD SCI-BIOL, V77, P2251, DOI 10.1073/pnas.77.4.2251; SOLOMON DH, 1985, FEBS LETT, V190, P342, DOI 10.1016/0014-5793(85)81315-6; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Stoppler H, 1996, VIROLOGY, V217, P542, DOI 10.1006/viro.1996.0149; SU LN, 1991, BIOCHEM BIOPH RES CO, V176, P18, DOI 10.1016/0006-291X(91)90883-9; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TROLL W, 1970, SCIENCE, V169, P1211, DOI 10.1126/science.169.3951.1211; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YE RD, 1989, J BIOL CHEM, V264, P5495	73	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12466	12475		10.1074/jbc.M009939200	http://dx.doi.org/10.1074/jbc.M009939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278584	hybrid			2022-12-27	WOS:000168081800137
J	Cao, C; Ren, XP; Kharbanda, S; Koleske, A; Prasad, KVS; Kufe, D				Cao, C; Ren, XP; Kharbanda, S; Koleske, A; Prasad, KVS; Kufe, D			The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL-RELATED GENE; C-ABL; PROTEIN; CELL; ACTIVATION; BINDING; T(1/12)(Q25,P13); CD27; MICE; P73	The Abl family of mammalian nonreceptor tyrosine kinases consists of c-Abl and ARG (Abl-related gene). Certain insights are available regarding the involvement c-Abl in the response of cells to stress. ARG, however, has no known function in cell signaling. The present studies demonstrate that ARG associates with the proapoptotic Siva-1 protein. The functional significance of the ARG-Siva-1 interaction is supported by the finding that ARG is activated by oxidative stress and that this response involves ARG-mediated phosphorylation of Siva-1 on Tyr(48). The proapoptotic effects of Siva-1 are accentuated in cells stably expressing ARG and are inhibited in ARG-deficient cells, Moreover, the proapoptotic effects of Siva-1 are abrogated by mutation of the Tyr(48) site. We also show that the apoptotic response to oxidative stress is attenuated in ARG-deficient cells and that this defect is corrected by reconstituting ARG expression. These findings support a model in which the activation of ARG by oxidative stress induces apoptosis by a Siva-1-dependent mechanism.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Gong JG, 1999, NATURE, V399, P806; Henke A, 2000, J VIROL, V74, P4284, DOI 10.1128/JVI.74.9.4284-4290.2000; Iijima Y, 2000, BLOOD, V95, P2126; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; Yoon Y, 1999, ONCOGENE, V18, P7174, DOI 10.1038/sj.onc.1203144; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	29	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11465	11468		10.1074/jbc.C100050200	http://dx.doi.org/10.1074/jbc.C100050200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278261	Green Published, hybrid			2022-12-27	WOS:000168081800006
J	Doerrler, WT; Reedy, MC; Raetz, CRH				Doerrler, WT; Reedy, MC; Raetz, CRH			An Escherichia coli mutant defective in lipid export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; INNER-MEMBRANE; TANGIER-DISEASE; MSBA GENE; TRANSPORTER; MUTATIONS; PHOSPHOLIPIDS; ACCUMULATION; MOVEMENT; FAMILY	Escherichia coli phospholipids and lipopolysaccharide, made on the inner surface of the inner membrane, are rapidly transported to the outer membrane by mechanisms that are not well characterized. We now report a temperature-sensitive mutant (WD2) with an A270T substitution in a trans-membrane region of the ABC transporter MsbA. As shown by P-32(i) and C-14-acetate labeling, export of all major lipids to the outer membrane is inhibited by similar to 90% in WD2 after 30 min at 44 degreesC, Transport of newly synthesized proteins is not impaired. Electron microscopy shows reduplicated inner membranes in WD2 at 44 degreesC, consistent with a key role for MsbA in lipid trafficking.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIAID NIH HHS [1-F32-AI-10613-01] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Brade H., 1999, ENDOTOXIN HLTH DIS; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Ding JT, 2000, J BIOL CHEM, V275, P23378, DOI 10.1074/jbc.M910319199; DONOHUEROLFE AM, 1980, P NATL ACAD SCI-BIOL, V77, P1867, DOI 10.1073/pnas.77.4.1867; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hrafnsdottir S, 2000, J BACTERIOL, V182, P4198, DOI 10.1128/JB.182.15.4198-4206.2000; Huijbregts RPH, 1998, J BIOL CHEM, V273, P18936, DOI 10.1074/jbc.273.30.18936; JONES NC, 1977, J BIOL CHEM, V252, P7405; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGLEY KE, 1982, J BACTERIOL, V152, P1033; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Osborn M J, 1974, Methods Enzymol, V31, P642; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; ROBERTSON JD, 1982, J ULTRA MOL STRUCT R, V80, P148, DOI 10.1016/S0022-5320(82)90014-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	41	186	189	1	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11461	11464		10.1074/jbc.C100091200	http://dx.doi.org/10.1074/jbc.C100091200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278265	hybrid			2022-12-27	WOS:000168081800005
J	Du, ZY; Tucker, WC; Richter, ML; Gromet-Elhanan, Z				Du, ZY; Tucker, WC; Richter, ML; Gromet-Elhanan, Z			Assembled F-1-(alpha beta) and hybrid F-1-alpha(3)beta(3)gamma-ATPases from Rhodospirillum rubrum alpha, wild type or mutant beta, and chloroplast gamma subunits - Demonstration of Mg2+ versus Ca2+-induced differences in catalytic site structure function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACILLUS PS3; F0F1 ATP SYNTHASE; ESCHERICHIA-COLI; COUPLING FACTOR; ALPHA(3)BETA(3)GAMMA SUBCOMPLEX; MITOCHONDRIAL F1-ATPASE; PROTON TRANSLOCATION; NUCLEOTIDE-BINDING; CORE COMPLEX; H+-ATPASE	Refolding together the expressed alpha and beta subunits of the Rhodospirillum rubrum F-1(RF1)-ATPase led to assembly of only alpha (1)beta (1) dimers, showing a stable low MgATPase activity. When incubated in the presence of AlCl3, NaF and either MgAD(T)P or CaAD(T)P, all dimers associated into closed alpha (3)beta (3) hexamers, which also gained a low CaATPase activity. Both hexamer ATPase activities exhibited identical rates and properties to the open dimer MgATPase, These results indicate that: a) the hexamer, as the dimer, has no catalytic cooperativity; b) aluminium fluoride does not inhibit their MgATPase activity; and c) it does enable the assembly of RrF(1)-alpha (3)beta (3) hexamers by stabilizing their noncatalytic alpha/beta interfaces. Refolding of the RrF(1)-alpha and beta subunits together with the spinach chloroplast F-1 (CF1)-gamma enabled a simple one-step assembly of two different hybrid RrF(1)-alpha (3)beta (3)/CF(1)gamma complexes, containing either wild type RrF(1)-beta or the catalytic site mutant RrF(1)beta -T159S, They exhibited over 100-fold higher CaATPase and MgATPase activities than the stabilized hexamers and showed very different catalytic properties. The hybrid wild type MgATPase activity was, as that of RrF(1) and CF1 and unlike its higher CaATPase activity, regulated by excess free Mg2+ ions, stimulated by sulfite, and inhibited by azide, The hybrid mutant had on the other hand a low CaATPase but an exceptionally high MgATPase activity, which was much less sensitive to the specific MgATPase effecters. All these very different ATPase activities were regulated by thiol modulation of the hybrid unique CF1-gamma disulfide bond. These hybrid complexes can provide information on the as yet unknown factors that couple ATP binding and hydrolysis to both thiol modulation and rotational motion of their CF1-gamma subunit.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	Weizmann Institute of Science; University of Kansas	Gromet-Elhanan, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.				NIGMS NIH HHS [GM08545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDRALOJC PJ, 1992, FEBS LETT, V310, P187, DOI 10.1016/0014-5793(92)81326-H; Bald D, 2000, J BIOL CHEM, V275, P12757, DOI 10.1074/jbc.275.17.12757; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; DU Z, 1995, PHOTOSYNTHESIS LIGHT, V3, P27; Du ZY, 1999, EUR J BIOCHEM, V263, P430, DOI 10.1046/j.1432-1327.1999.00512.x; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GAO F, 1995, J BIOL CHEM, V270, P9763, DOI 10.1074/jbc.270.17.9763; Gromet-Elhanan Z., 1995, ANOXYGENIC PHOTOSYNT, P807; GROMETELHANAN Z, 1989, BIOCHEMISTRY-US, V28, P3645, DOI 10.1021/bi00435a004; GrometElhanan Z, 1995, PHOTOSYNTH RES, V46, P79, DOI 10.1007/BF00020418; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; HOCHMAN Y, 1976, FEBS LETT, V61, P255, DOI 10.1016/0014-5793(76)81051-4; Hu DL, 1998, FEBS LETT, V421, P65, DOI 10.1016/S0014-5793(97)01531-7; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; McCarty RE, 2000, ANNU REV PLANT PHYS, V51, P83, DOI 10.1146/annurev.arplant.51.1.83; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Nathanson L, 2000, J BIOL CHEM, V275, P901, DOI 10.1074/jbc.275.2.901; Nathanson L, 1998, J BIOL CHEM, V273, P10933, DOI 10.1074/jbc.273.18.10933; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1987, J BIOL CHEM, V262, P14978; OMOTE H, 1992, J BIOL CHEM, V267, P20571; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Richter ML, 2000, BBA-BIOENERGETICS, V1458, P326, DOI 10.1016/S0005-2728(00)00084-0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sokolov M, 1996, BIOCHEMISTRY-US, V35, P1242, DOI 10.1021/bi9511189; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WEISS S, 1994, J BIOENERG BIOMEMBR, V26, P573, DOI 10.1007/BF00762742; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	50	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11517	11523		10.1074/jbc.M007568200	http://dx.doi.org/10.1074/jbc.M007568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278351	hybrid			2022-12-27	WOS:000168081800015
J	Larsson, H; Akerud, P; Nordling, K; Raub-Segall, E; Claesson-Welsh, L; Bjork, I				Larsson, H; Akerud, P; Nordling, K; Raub-Segall, E; Claesson-Welsh, L; Bjork, I			A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; ACTIVE-SITE; BETA-SHEET; CONFORMATIONAL-CHANGE; BOVINE ANTITHROMBIN; THROMBIN-III; FACTOR-XA; SERPIN; INHIBITOR; APOPTOSIS	Latent antithrombin, an inactive antithrombin form with low heparin affinity, has previously been shown to efficiently inhibit angiogenesis and tumor growth. We now show that heat treatment similar to that used for preparation of latent antithrombin also transforms antithrombin to another form, which we denote prelatent, with potent anti-angiogenic and anti-tumor activity but with retained proteinase- and heparin-binding properties, The ability of prelatent antithrombin to inhibit angiogenesis is presumably due to a limited conformational change, which may partially resemble that in latent antithrombin. Such a change is evidenced by a different cleavage pattern of prelatent than of native antithrombin by nontarget proteinases. Prelatent antithrombin exerts its anti-angiogenic effect by a similar mechanism as latent antithrombin, i.e. by inhibiting focal adhesion formation and focal adhesion kinase activity, thereby leading to decreased proliferation of endothelial cells. The proteinase inhibitory fractions in commercial antithrombin preparations, which have been heat treated during production, also have antiangiogenic activity, comparable with that of the prelatent antithrombin form.	Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala Biomed Ctr, SE-75123 Uppsala, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, SE-17177 Stockholm, Sweden	Swedish University of Agricultural Sciences; Uppsala University; Karolinska Institutet	Bjork, I (corresponding author), Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala Biomed Ctr, Box 575, SE-75123 Uppsala, Sweden.	Ingemar.Bjork@vmk.slu.se						[Anonymous], 1988, LAB ANIM-UK, V22, P195; Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; BJORK I, 1982, J BIOL CHEM, V257, P9487; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Cary Leslie A., 1999, Frontiers in Bioscience, V4, pD102, DOI 10.2741/Cary; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson H, 2000, CANCER RES, V60, P6723; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; Nordling K, 1996, BIOCHEMISTRY-US, V35, P10436, DOI 10.1021/bi9603579; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	40	48	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11996	12002		10.1074/jbc.M010170200	http://dx.doi.org/10.1074/jbc.M010170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278631	hybrid			2022-12-27	WOS:000168081800075
J	Pinkoski, MJ; Waterhouse, NJ; Heibein, JA; Wolf, BB; Kuwana, T; Goldstein, JC; Newmeyer, DD; Bleackley, RC; Green, DR				Pinkoski, MJ; Waterhouse, NJ; Heibein, JA; Wolf, BB; Kuwana, T; Goldstein, JC; Newmeyer, DD; Bleackley, RC; Green, DR			Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; TARGET-CELLS; CYTOTOXIC LYMPHOCYTES; DNA FRAGMENTATION; NUCLEAR TRANSLOCATION; CYTOLYTIC LEUKOCYTES; CYTOSOLIC DELIVERY; RAPID INDUCTION; PERFORIN; ACTIVATION	Cytotoxic T Lymphocytes kill virus-infected and tumor cell targets through the concerted action of proteins contained in cytolytic granules, primarily granzyme B and perforin, Granzyme B, a serine proteinase with substrate specificity similar to the caspase family of apoptotic cysteine proteinases, is capable of cleaving and activating a number of death proteins in target cells. Despite the ability to engage the death pathway at multiple entry points, the preferred mechanism for rapid induction of apoptosis by granzyme B has yet to be clearly established. Here we use time lapse confocal microscopy to demonstrate that mitochondrial cytochrome c release is the primary mode of granzyme B-induced apoptosis and that Bcl-2 is a potent inhibitor of this pivotal event. Caspase activation is not required for cytochrome c release, an activity that correlates with cleavage and activation of Bid, which we have found to be cleaved more readily by granzyme B than either caspase-3 or caspase-8. Bcl-2 blocks the rapid destruction of targets by granzyme B by blocking mitochondrial involvement in the process.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	La Jolla Institute for Immunology; University of Alberta	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Waterhouse, Nigel/I-9813-2016; Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40646] Funding Source: Medline; NIGMS NIH HHS [GM52735] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Browne KA, 1999, MOL CELL BIOL, V19, P8604; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; CHIU VK, 1995, J IMMUNOL, V154, P2023; Darmon A J, 1999, Results Probl Cell Differ, V23, P103; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; Heibein JA, 1999, J IMMUNOL, V163, P4683; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Jans DA, 1999, J BIOL CHEM, V274, P3953, DOI 10.1074/jbc.274.7.3953; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Mullbacher A, 1999, P NATL ACAD SCI USA, V96, P13950, DOI 10.1073/pnas.96.24.13950; Newmeyer DD, 1998, NEURON, V21, P653, DOI 10.1016/S0896-6273(00)80580-2; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; Pinkoski MJ, 2000, CELL DEATH DIFFER, V7, P17, DOI 10.1038/sj.cdd.4400604; Pinkoski MJ, 1998, BLOOD, V92, P1044; Riera L, 2000, EUR J IMMUNOL, V30, P1350, DOI 10.1002/(SICI)1521-4141(200005)30:5<1350::AID-IMMU1350>3.0.CO;2-J; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schroter M, 1995, EUR J IMMUNOL, V25, P3509, DOI 10.1002/eji.1830251245; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 1997, J IMMUNOL, V158, P5783; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 1999, J CLIN IMMUNOL, V19, P378, DOI 10.1023/A:1020550716138; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	57	144	147	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12060	12067		10.1074/jbc.M009038200	http://dx.doi.org/10.1074/jbc.M009038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278459	hybrid			2022-12-27	WOS:000168081800085
J	Singh, J; Itahana, Y; Parrinello, S; Murata, K; Desprez, PY				Singh, J; Itahana, Y; Parrinello, S; Murata, K; Desprez, PY			Molecular cloning and characterization of a zinc finger protein involved in Id-1-stimulated mammary epithelial cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; LOOP-HELIX PROTEINS; ID PROTEINS; SACCHAROMYCES-CEREVISIAE; STATIONARY-PHASE; DIFFERENTIATION; EXPRESSION; APOPTOSIS; GCS1; TRANSCRIPTION	Id proteins are dominant negative regulators of basic helix-loop-helix transcription factors. Previous work in our laboratory has shown that constitutive expression of Id-1 in SCp2 mouse mammary epithelial cells inhibits their differentiation and induces proliferation, invasion, and migration, Id-1 expression also correlates with the invasive and aggressive potential of human breast cancer cells. However, little is known about Id-1 target genes that are important for regulating normal and transformed breast epithelial cell phenotypes. Now we report the cloning of a novel zinc finger protein, Zfp289, using degenerate primers to specifically amplify cDNAs from Id-1-transfected SCp2 cells. Zfp289 has homology with a yeast zinc finger protein, the GTPase-activating protein Gcs-1, which was initially identified as a gene required for the re-entry of cells into the cell cycle after stationary phase growth. Zfp289 mRNA expression pattern correlates with Id-1 expression in SCp2 mammary epithelial cells under various experimental conditions as well as in the mouse mammary gland at different stages of development. It is predominantly present in the cytoplasm of the cells as evident from green fluorescent protein fusion protein localization. SCp2 mammary epithelial cells with constitutive expression of Zfp289 have a higher S-phase index, compared with control cells, when cultured in a serum-free medium. We conclude that the novel zinc finger protein Zfp289, which may represent the mammalian homologue of Gcs-1, is potentially an important mediator of the Id-1-induced proliferation pathway in mammary epithelial cells.	Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	California Pacific Medical Center	Desprez, PY (corresponding author), Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, Stern Bldg,2330 Clay St, San Francisco, CA 94115 USA.				NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1995, DEVELOPMENT, V121, P2513; Desprez Pierre-Yves, 1993, Molecular and Cellular Differentiation, V1, P99; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hara E, 1996, DEV GENET, V18, P161; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; HRABARENEVEY S, 1989, NUCLEIC ACIDS RES, V17, P2449, DOI 10.1093/nar/17.7.2449; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lin CQ, 2000, CANCER RES, V60, P1332; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maniatis T., 1989, MOL CLONING LAB MANU; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Wang XM, 1996, MOL CELL BIOL, V16, P5375; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185	29	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11852	11858		10.1074/jbc.M006931200	http://dx.doi.org/10.1074/jbc.M006931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11278321	hybrid			2022-12-27	WOS:000168081800058
J	Franco, L; Zocchi, E; Usai, C; Guida, L; Bruzzone, S; Costa, A; De Flora, A				Franco, L; Zocchi, E; Usai, C; Guida, L; Bruzzone, S; Costa, A; De Flora, A			Paracrine roles of NAD(+) and cyclic ADP-ribose in increasing intracellular calcium and enhancing cell proliferation of 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CD38; DOUBLING TIME; CYCLASE; EXPRESSION; RADIOIMMUNOASSAY; CATALYZE; PROTEIN; BINDING	CD38 is a bifunctional ectoenzyme synthesizing from NAD(+) (ADP-ribosyl cyclase) and degrading (hydrolase) cyclic ADP-ribose (cADPR), a powerful universal calcium mobilizer from intracellular stores. Recently, hexameric connexin 43 (Cx43) hemichannels have been shown to release cytosolic NAD(+) from isolated murine fibroblasts (Bruzzone, S., Guide, L., Zocchi, E., France, L. and De Flora, A. (2001) FASEB J. 15, 10-12), making this dinucleotide available to the ectocellular active site of CD38. Here we investigated transwell co-cultures of CD38(+) (transfected) and CD38(-) 3T3 cells in order to establish the role of extracellular NAD(+) and cADPR on [Ca2+](i) levels and on proliferation of the CD38(-) target cells. CD38(+), but not CD38(-), feeder cells induced a [Ca2+](i) increase in the CD38(-) target cells which was comparable to that observed with extracellular cADPR alone and inhibitable by NAD(+)-glycohydrolase or by the cADPR antagonist 8-NH2-cADPR. Addition of recombinant ADP-ribosyl cyclase to the medium of CD38(-) feeders induced sustained [Ca2+](i) increases in CD38(-) target cells. Co-culture on CD38(+) feeders enhanced the proliferation of CD38(-) target cells over control values and significantly shortened the S phase of cell cycle. These results demonstrate a paracrine process based on Cx43-mediated release of NAD(+), its CD38-catalyzed conversion to extracellular cADPR, and influx of this nucleotide into responsive cells to increase [Ca2+](i) and stimulate cell proliferation.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; G Gaslini Inst, I-16147 Genoa, Italy; CNR, Inst Cybernet & Biophys, I-16149 Genoa, Italy; Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy	University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan	De Flora, A (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV 1, I-16132 Genoa, Italy.		Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BEGG AC, 1985, CYTOMETRY, V6, P620, DOI 10.1002/cyto.990060618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2001, FASEB J, V15, P10; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora A, 2000, CHEM IMMUNOL, V75, P79; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Franco L, 1998, FASEB J, V12, P1507; FRYXELL KB, 1995, PROTEIN EXPRES PURIF, V6, P329, DOI 10.1006/prep.1995.1043; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; LEE HC, 1997, PHYSIOL REV, V77, P133; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Munshi C, 1999, J BIOL CHEM, V274, P30770, DOI 10.1074/jbc.274.43.30770; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Ziegler M, 1997, BIOCHEM J, V326, P401, DOI 10.1042/bj3260401; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; ZOCCHI E, 2001, IN PRESS FASEB J	34	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21642	21648		10.1074/jbc.M010536200	http://dx.doi.org/10.1074/jbc.M010536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11274199	hybrid			2022-12-27	WOS:000169297900112
J	Dhiman, A; Rodgers, ME; Schleif, R				Dhiman, A; Rodgers, ME; Schleif, R			Identification of oligomerizing peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The AraC DNA binding domain is inactive in a monomeric form but can activate transcription from the arabinose operon promoters upon its dimerization. We used this property to identify plasmids encoding peptide additions to the AraC DNA binding domain that could dimerize the domain. We generated a high diversity library of plasmids by inserting 90-base oligonucleotides of random sequence ahead of DNA coding for the AraC DNA binding domain in an expression vector, transforming, and selecting colonies containing functional oligomeric peptide-AraC DNA binding domain chimeric proteins by their growth on minimal arabinose medium. Six of seven Ara(+) candidates were partially characterized, and one was purified. Equilibrium analytical centrifugation experiments showed that it dimerizes with a dissociation constant of similar to2 muM.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schleif, R (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	bob@gene.bio.jhu.edu		Schleif, Robert/0000-0002-4430-7085	NIGMS NIH HHS [GM18277] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018277, R37GM018277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; FILES JG, 1974, P NATL ACAD SCI USA, V71, P667, DOI 10.1073/pnas.71.3.667; HAHN S, 1984, J MOL BIOL, V180, P61, DOI 10.1016/0022-2836(84)90430-3; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; Jappelli R, 1999, BIOCHEM BIOPH RES CO, V266, P243, DOI 10.1006/bbrc.1999.1806; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Schleif R, 1999, PROTEINS, V34, P1, DOI 10.1002/(SICI)1097-0134(19990101)34:1<1::AID-PROT1>3.0.CO;2-C; Schleif R. F., 1981, PRACTICAL METHODS MO; Wang BS, 1999, P NATL ACAD SCI USA, V96, P9568, DOI 10.1073/pnas.96.17.9568; Zhang ZW, 1999, CURR BIOL, V9, P417, DOI 10.1016/S0960-9822(99)80188-2	16	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20017	20021		10.1074/jbc.M102220200	http://dx.doi.org/10.1074/jbc.M102220200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11274194	hybrid			2022-12-27	WOS:000169135100047
J	Li, ZG; Joyal, JL; Sacks, DB				Li, ZG; Joyal, JL; Sacks, DB			Calmodulin enhances the stability of the estrogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HEAT-SHOCK PROTEIN; BINDING DOMAIN; DNA-BINDING; CELLS; TAMOXIFEN; GROWTH; ANTIESTROGENS; ANTAGONIST; ACTIVATION	The estrogen receptor mediates breast cell proliferation and is the principal target for chemotherapy of breast carcinoma. Previous studies have demonstrated that the estrogen receptor binds to calmodulin-Sepharose in vitro, However, the association of endogenous calmodulin with endogenous estrogen receptors in intact cells has not been reported, and the function of the interaction is obscure. Here we demonstrate by co-immunoprecipitation from MCF-7 human breast epithelial cells that endogenous estrogen receptors bind to endogenous calmodulin, Estradiol treatment of the cells had no significant effect on the interaction, However, incubation of the cells with tamoxifen enhanced by 5-10-fold the association of calmodulin with the estrogen receptor and increased the total cellular content of estrogen receptors by 1.5-2-fold. In contrast, the structurally distinct calmodulin antagonists trifluoperazine and CGS9343B attenuated the interaction between calmodulin and the estrogen receptor and dramatically reduced the number of estrogen receptors in the cell. Neither of these agents altered the amount of estrogen receptor mRNA, suggesting that calmodulin stabilizes the protein. This hypothesis is supported by the observation that, in the presence of Ca2+, calmodulin protected estrogen receptors from in vitro proteolysis by trypsin. Furthermore, overexpression of wild type calmodulin, but not a mutant calmodulin incapable of binding Ca2+, increased the concentration of estrogen receptors in MCF-7 cells, whereas transient expression of a calmodulin inhibitor peptide reduced the estrogen receptor concentration. These data demonstrate that calmodulin binds to the estrogen receptor in intact cells in a Ca2+-dependent, but estradiol-independent, manner, thereby modulating the stability and the steady state level of estrogen receptors.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Thorn 530, Boston, MA 02115 USA.			Sacks, David/0000-0003-3100-0735				APODACA G, 1994, J BIOL CHEM, V269, P19005; Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; BELLOMO G, 1992, CANCER RES, V52, P1342; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BOUHOUTE A, 1994, BIOCHEM PHARMACOL, V47, P748, DOI 10.1016/0006-2952(94)90140-6; Burrell, 1993, ENZYMES MOL BIOL; Chun KY, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P541; Cohen P, 1988, CALMODULIN; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FRANKFURT OS, 1995, CANCER LETT, V97, P149, DOI 10.1016/0304-3835(95)03970-8; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GRATZER WB, 1988, CALMODULIN, P329; GRIEF F, 1989, EUR J CANCER CLIN ON, V25, P19, DOI 10.1016/0277-5379(89)90046-1; GULINO A, 1986, CANCER RES, V46, P6274; HARDCASTLE IR, 1995, J MED CHEM, V38, P241, DOI 10.1021/jm00002a005; HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1; Jain PT, 1997, ANTICANCER RES, V17, P1167; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KIANG DT, 1989, CANCER RES, V49, P5312; KRISHNARAJU K, 1990, BRIT J CANCER, V63, P346; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; Li ZG, 2000, BIOCHEMISTRY-US, V39, P5089, DOI 10.1021/bi992623z; Liu GX, 1996, BRIT J CANCER, V73, P899, DOI 10.1038/bjc.1996.160; Lykkesfeldt AE, 1996, ACTA ONCOL, V35, P9, DOI 10.3109/02841869609083961; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; McDonnell DP, 2000, J SOC GYNECOL INVEST, V7, pS10, DOI 10.1177/1071557600007001S05; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MOTOHASHI N, 1991, ANTICANCER RES, V11, P1125; NATSUKARI N, 1995, NEUROCHEM INT, V26, P465, DOI 10.1016/0197-0186(94)00156-O; Newton CJ, 2000, J STEROID BIOCHEM, V73, P29, DOI 10.1016/S0960-0760(00)00047-9; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; Pink JJ, 1996, CANCER RES, V56, P2321; RASMUSSEN CD, 1987, EMBO J, V6, P3961, DOI 10.1002/j.1460-2075.1987.tb02738.x; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SINGER AL, 1976, CANCER RES, V36, P60; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; TAYLOR JM, 1992, CANCER RES, V52, P2413; TCHOLAKIAN RK, 1980, CLIN CHEM, V26, P101; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TUCCARI G, 1993, EUR J HISTOCHEM, V37, P57; WALKER RA, 1993, CANCER SURV, V16, P31; Wang JH, 1995, J BIOL CHEM, V270, P30245, DOI 10.1074/jbc.270.51.30245; WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86; WEI JW, 1982, CANCER RES, V42, P2571	54	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17354	17360		10.1074/jbc.M010238200	http://dx.doi.org/10.1074/jbc.M010238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11278648	hybrid			2022-12-27	WOS:000168730400101
J	Jo, SH; Son, MK; Koh, HJ; Lee, SM; Song, IH; Kim, YO; Lee, YS; Jeong, KS; Kim, WB; Park, JW; Song, BJ; Huhe, TL				Jo, SH; Son, MK; Koh, HJ; Lee, SM; Song, IH; Kim, YO; Lee, YS; Jeong, KS; Kim, WB; Park, JW; Song, BJ; Huhe, TL			Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP(+)-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; NUCLEOTIDE-SEQUENCE; REDUCED GLUTATHIONE; IDH2 GENE; HYDROPEROXIDE; EXPRESSION; APOPTOSIS; CLONING; INVOLVEMENT	Mitochondria are the major organelles that produce reactive oxygen species (ROS) and the main target of ROS-induced damage as observed in various pathological states including aging. Production of NADPH required for the regeneration of glutathione in the mitochondria is critical for scavenging mitochondrial ROS through glutathione reductase and peroxidase systems. We investigated the role of mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDPm) in controlling the mitochondrial redox balance and subsequent cellular defense against oxidative damage. We demonstrate in this report that IDPm is induced by ROS and that decreased expression of IDPm markedly elevates the ROS generation, DNA fragmentation, lipid peroxidation, and concurrent mitochondrial damage with a significant reduction in ATP level. Conversely, overproduction of IDPm protein efficiently protected the cells from ROS-induced damage. The protective role of IDPm against oxidative damage may be attributed to increased levels of a reducing equivalent, NADPH, needed for regeneration of glutathione in the mitochondria. Our results strongly indicate that IDPm is a major NADPH producer in the mitochondria and thus plays a key role in cellular defense against oxidative stress-induced damage.	Kyungpook Natl Univ, Coll Nat Sci, Dept Genet Engn, Taegu 702701, South Korea; Kyungpook Natl Univ, Dept Biochem, Taegu 702701, South Korea; Kyungpook Natl Univ, TG Biotech Co Ltd, Taegu 702701, South Korea; Yeungnam Univ, Coll Med, Dept Anat, Taegu 705717, South Korea; NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA; Dong A Pharmacia Co Ltd, Res Lab, Yongin 449900, Kyungi Do, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Yeungnam University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Huhe, TL (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Dept Genet Engn, 1370 Sankyuk Dong, Taegu 702701, South Korea.	tlhuh@knu.ac.kr						AEBI H, 1984, METHOD ENZYMOL, V105, P121; Akerboom T P, 1981, Methods Enzymol, V77, P373; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; BASS DA, 1983, J IMMUNOL, V130, P1910; BERNHART CT, 1989, SCIENCE, V245, P301; Buege J A, 1978, Methods Enzymol, V52, P302; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CUPP JR, 1991, J BIOL CHEM, V266, P22199; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Huh TL, 1996, GENOMICS, V32, P295, DOI 10.1006/geno.1996.0120; HUH TL, 1993, BIOCHEM J, V292, P705, DOI 10.1042/bj2920705; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kehrer J P, 1993, Proc West Pharmacol Soc, V36, P45; Kim YO, 1999, CYTOGENET CELL GENET, V86, P240, DOI 10.1159/000015348; Kim YO, 1999, J BIOL CHEM, V274, P36866, DOI 10.1074/jbc.274.52.36866; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Lee SM, 1999, BIOCHEM BIOPH RES CO, V254, P647, DOI 10.1006/bbrc.1998.0125; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOVERDE AW, 1973, J NEUROCHEM, V20, P441, DOI 10.1111/j.1471-4159.1973.tb12143.x; LUND LG, 1994, TOXICOLOGY, V93, P249, DOI 10.1016/0300-483X(94)90082-5; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MATTEO MA, 1997, APOPTOSIS, V2, P164; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Murakami K, 1998, J NEUROSCI, V18, P205; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Oh IU, 1996, GENOMICS, V38, P104, DOI 10.1006/geno.1996.0602; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; PACKER L, 1989, BIOCHEM BIOPH RES CO, V159, P229, DOI 10.1016/0006-291X(89)92427-3; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINTO RE, 1969, BIOCHEM J, V112, P109, DOI 10.1042/bj1120109; PLAUT GWE, 1983, BIOCH METABOLIC PROC, P285; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; SHULL S, 1991, J BIOL CHEM, V266, P24398; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; STEIN AM, 1967, BIOCHEMISTRY-US, V6, P1370, DOI 10.1021/bi00857a020; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Vogel R, 1999, NEUROSCI LETT, V275, P97, DOI 10.1016/S0304-3940(99)00748-X; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; Yang LP, 1996, J CELL BIOCHEM, V60, P400, DOI 10.1002/(SICI)1097-4644(19960301)60:3<400::AID-JCB11>3.3.CO;2-2; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	69	427	443	2	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16168	16176		10.1074/jbc.M010120200	http://dx.doi.org/10.1074/jbc.M010120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278619	hybrid			2022-12-27	WOS:000168623100081
J	Lethias, C; Elefteriou, F; Parsiegla, G; Exposito, JY; Garrone, R				Lethias, C; Elefteriou, F; Parsiegla, G; Exposito, JY; Garrone, R			Identification and characterization of a conformational heparin-binding site involving two fibronectin type III modules of bovine tenascin-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DOMAIN; DISTINCT; MUSCLE; TISSUE; PROTEOGLYCAN; GLYCOPROTEIN; EXPRESSION; RECEPTORS; NEUROCAN	Tenascin-X is known as a heparin-binding molecule, but the localization of the heparin-binding site has not been investigated until now, We show here that, unlike tenascin-C, the recombinant fibrinogen-like domain of tenascin-X is not involved in heparin binding. On the other hand, the two contiguous fibronectin type III repeats b10 and b11 have a predicted positive charge at physiological pH, hence a set of recombinant proteins comprising these domains was tested for interaction with heparin, Using solid phase assays and affinity chromatography, we found that interaction with heparin was conformational and involved both domains 10 and 11, Construction of a three-dimensional model of domains 10 and 11 led us to predict exposed residues that were then submitted to site-directed mutagenesis, In this way, we identified the basic residues within each domain that are crucial for this interaction, Blocking experiments using antibodies against domain 10 were performed to test the efficiency of this site within intact tenascin-X, Binding was significantly reduced, arguing for the activity of a heparin-binding site involving domains 10 and 11 in the whole molecule. Finally, the biological significance of this site was tested by cell adhesion studies. Heparan sulfate cell surface receptors are able to interact with proteins bearing domains 10 and 11, suggesting that tenascin-X may activate different signals to regulate cell behavior.	Univ Lyon 1, Inst Biol 7 Chim Prot, CNRS, UMR 5086, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Lethias, C (corresponding author), Univ Lyon 1, Inst Biol 7 Chim Prot, CNRS, UMR 5086, 7 Passage Vercors, F-69367 Lyon 07, France.		Elefteriou, Florent/P-2586-2017; Elefteriou, Florent/GMW-8429-2022	Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Florent/0000-0002-2972-5633; Exposito, Jean-Yves/0000-0002-4926-4942				AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Burch GH, 1997, NAT GENET, V17, P104, DOI 10.1038/ng0997-104; BURCH GH, 1995, DEV DYNAM, V203, P491, DOI 10.1002/aja.1002030411; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; Chung CY, 1997, J CELL SCI, V110, P1413; Elefteriou F, 1999, EUR J BIOCHEM, V263, P840, DOI 10.1046/j.1432-1327.1999.00563.x; Elefteriou F, 1997, J BIOL CHEM, V272, P22866, DOI 10.1074/jbc.272.36.22866; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FISCHER D, 1995, J BIOL CHEM, V270, P3378, DOI 10.1074/jbc.270.7.3378; GEFFROTIN C, 1995, EUR J BIOCHEM, V231, P83, DOI 10.1111/j.1432-1033.1995.0083f.x; Hagios C, 1996, J CELL BIOL, V134, P1499, DOI 10.1083/jcb.134.6.1499; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; Ikuta T, 1998, GENE, V217, P1, DOI 10.1016/S0378-1119(98)00355-2; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI P, 1993, J CELL SCI, V106, P389; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Lethias C, 1996, MATRIX BIOL, V15, P11, DOI 10.1016/S0945-053X(96)90122-5; Lethias C, 1997, EUR J BIOCHEM, V245, P434, DOI 10.1111/j.1432-1033.1997.t01-2-00434.x; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Seiffert M, 1998, MATRIX BIOL, V17, P47, DOI 10.1016/S0945-053X(98)90124-X; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VAUGHAN L, 1994, CONTRIB NEPHROL, V107, P80; VAUGHAN L, 1987, EMBO J, V6, P349, DOI 10.1002/j.1460-2075.1987.tb04761.x; WEBER P, 1995, J BIOL CHEM, V270, P4619, DOI 10.1074/jbc.270.9.4619	37	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16432	16438		10.1074/jbc.M010210200	http://dx.doi.org/10.1074/jbc.M010210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278641	hybrid			2022-12-27	WOS:000168623100115
J	Bergeron, A; D'Astous, M; Timm, DE; Tanguay, RM				Bergeron, A; D'Astous, M; Timm, DE; Tanguay, RM			Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; ENZYME; SPLICE; NONSENSE	Hereditary tyrosinemia type 1 (HT1) is an autosomal recessive disease caused by a deficiency of the enzyme involved in the last step of tyrosine degradation, fumarylacetoacetate hydrolase (FAH), Thus far, 34 mutations in the FAH gene have been reported in various HT1 patients. Site-directed mutagenesis of the FAH cDNA was used to investigate the effects of eight missense mutations found in HTI patients on the structure and activity of FAH, Mutated FAH proteins were expressed in Escherichia coli and in mammalian CV 1 cells. Mutations N16I, F62C, A134D, C193R, D233V, and W234G lead to enzymatically inactive FAH proteins. Two mutations (R341W, associated with the pseudo-deficiency phenotype, and Q279R) produced proteins with a level of activity comparable to the wild-type enzyme. The N16I, F62C, C193R, and W234G variants were enriched in an insoluble cellular fraction, suggesting that these amino acid substitutions interfere with the proper folding of the enzyme. Based on the tertiary structure of FAH, on circular dichroism data, and on solubility measurements, we propose that the studied missense mutations cause three types of structural effects on the enzyme: 1) gross structural perturbations, 2) limited conformational changes in the active site, and 3) conformational modifications with no significant effect on enzymatic activity.	Univ Laval, Dept Med, Lab Cell & Dev Genet, St Foy, PQ G1K 7P4, Canada; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Laval University; Indiana University System; Indiana University-Purdue University Indianapolis	Tanguay, RM (corresponding author), Univ Laval, Dept Med, Lab Cell & Dev Genet, Pavillon CE Marchand, St Foy, PQ G1K 7P4, Canada.							AWATA H, 1994, BBA-MOL BASIS DIS, V1226, P168, DOI 10.1016/0925-4439(94)90025-6; BERGER R, 1987, PEDIATR RES, V22, P394, DOI 10.1203/00006450-198710000-00005; Bergman AJIW, 1998, HUM MUTAT, V12, P19, DOI 10.1002/(SICI)1098-1004(1998)12:1<19::AID-HUMU3>3.0.CO;2-3; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; GROMPE M, 1994, NEW ENGL J MED, V331, P353, DOI 10.1056/NEJM199408113310603; HAHN SH, 1995, HUM MUTAT, V6, P66, DOI 10.1002/humu.1380060113; HSIANG HH, 1972, BIOCHEMISTRY-US, V11, P2098, DOI 10.1021/bi00761a016; JOHNSON CW, 1990, PROTEIN-STRUCT FUNCT, V7, P205; Jorquera R, 1999, FASEB J, V13, P2284, DOI 10.1096/fasebj.13.15.2284; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Kim SZ, 2000, J INHERIT METAB DIS, V23, P791, DOI 10.1023/A:1026756501669; KVITTINGEN EA, 1985, CLIN GENET, V27, P550; LABELLE Y, 1993, BIOCHIM BIOPHYS ACTA, V1180, P250, DOI 10.1016/0925-4439(93)90046-4; LABELLE Y, 1993, HUM MOL GENET, V2, P941, DOI 10.1093/hmg/2.7.941; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; MITCHELL GA, 2001, METABOLIC MOL BASES, P1777; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; PHANEUF D, 1991, AM J HUM GENET, V48, P525; Poudrier J, 1996, PRENATAL DIAG, V16, P59, DOI 10.1002/(SICI)1097-0223(199601)16:1<59::AID-PD810>3.3.CO;2-4; ROOTWELT H, 1994, HUM GENET, V93, P615, DOI 10.1007/BF00201558; Rootwelt H, 1996, HUM MUTAT, V7, P239, DOI 10.1002/(SICI)1098-1004(1996)7:3<239::AID-HUMU8>3.3.CO;2-E; ROOTWELT H, 1994, AM J HUM GENET, V55, P653; ROOTWELT H, 1994, AM J HUM GENET, V55, P1122; StLouis M, 1997, HUM MUTAT, V9, P291, DOI 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9; TANGUAY RM, 1990, AM J HUM GENET, V47, P308; Tanguay RM, 1996, ACTA BIOCHIM POL, V43, P209; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanAmstel JKP, 1996, HUM GENET, V97, P51, DOI 10.1007/BF00218833	30	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15225	15231		10.1074/jbc.M009341200	http://dx.doi.org/10.1074/jbc.M009341200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278491	hybrid			2022-12-27	WOS:000168528800093
J	Esparza-Lopez, J; Montiel, JL; Vilchis-Landeros, MM; Okadome, T; Miyazono, K; Lopez-Casillas, F				Esparza-Lopez, J; Montiel, JL; Vilchis-Landeros, MM; Okadome, T; Miyazono, K; Lopez-Casillas, F			Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily - Specialized binding regions for transforming growth factor-beta and inhibin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; III RECEPTOR; PROTEOGLYCAN BETAGLYCAN; MEMBRANE PROTEOGLYCAN; ENDOTHELIAL-CELLS; ATTACHMENT SITES; I RECEPTOR; EXPRESSION; DOMAIN; PHOSPHORYLATION	Betaglycan, also known as the transforming growth factor-beta (TGF-beta) type III receptor, is a membrane-anchored proteoglycan that binds TGF-beta via its core protein. Deletion mutagenesis analysis has revealed two regions of betaglycan ectodomain capable of binding TGF-beta: one at the amino-terminal half, the endoglin-related region (Lopez-Casillas, F., Payne, H., Andres, J. L., and Massague, J. (1994) J. Cell Biol. 124, 557-568), and the other at the carboxyl-terminal half, the uromodulin-related region (Pepin, M.-C., Beauchemin, M., Plamondon, J., and O'Connor-McCourt, M. D. (1994) Proc. Natl. Acad. Sci. U. S. A 91, 6997-7001). In the present work we have functionally characterized these ligand binding regions. Similar to the wild type receptor, both regions bind TGF-beta2 with higher affinity than TGF-beta1, However, only the endoglin-related region increases the TGF-beta2 labeling of the TGF-beta type II receptor, the so-called "TGF-beta -presentation" function of the wild type receptor. Despite this preference, both regions as well as the wild type receptor mediate the TGF-beta2-dependent Smad2 phosphorylation, indicating that they can function indistinguishably as TGF-beta -enhancing coreceptors, On the other hand, we found that the recently described ability of the wild type betaglycan to bind inhibin A is a property of the core protein that resides in the uromodulin-related region, Binding competition experiments indicate that this region binds inhibin and TGF-beta with the following relative affinities: TGF-beta2 > inhibin A > TGF-beta1. All together, the present results suggest that betaglycan ectodomain is endowed with two bona fide independent ligand binding domains that can perform specialized functions as co-receptors of distinct members of the TGF-beta superfamily.	Natl Autonomous Univ Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Inst Canc, Toshima Ku, Tokyo 1708455, Japan	Universidad Nacional Autonoma de Mexico	Lopez-Casillas, F (corresponding author), Natl Autonomous Univ Mexico, Inst Fisiol Celular, Apartado Postal 70-246, Mexico City 04510, DF, Mexico.		ESPARZA-LOPEZ, JOSE/AAQ-7199-2021	ESPARZA-LOPEZ, JOSE/0000-0003-3701-6607; Vazquez-Meza, Hector/0000-0002-8312-3115; Montiel Hernandez, Jose Luis/0000-0002-6258-7092; Vilchis Landeros, Maria Magdalena/0000-0002-7659-7646				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faure S, 2000, DEVELOPMENT, V127, P2917; FUKISHIMA D, 1993, J BIOL CHEM, V268, P22710; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MITCHELL EJ, 1992, J CELL PHYSIOL, V150, P334, DOI 10.1002/jcp.1041500217; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Ponce-Castaneda MV, 1998, BBA-PROTEIN STRUCT M, V1384, P189, DOI 10.1016/S0167-4838(98)00033-8; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts VJ, 1996, ENDOCRINOLOGY, V137, P4201, DOI 10.1210/en.137.10.4201; Sambrook J., 2002, MOL CLONING LAB MANU; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Taniguchi A, 1998, IN VITRO CELL DEV-AN, V34, P232; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	124	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14588	14596		10.1074/jbc.M008866200	http://dx.doi.org/10.1074/jbc.M008866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278442	hybrid			2022-12-27	WOS:000168528800010
J	Maeshima, Y; Manfredi, M; Reimer, C; Holthaus, KA; Hopfer, H; Chandamuri, BR; Kharbanda, S; Kalluri, R				Maeshima, Y; Manfredi, M; Reimer, C; Holthaus, KA; Hopfer, H; Chandamuri, BR; Kharbanda, S; Kalluri, R			Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ANTITUMOR PROPERTIES; IV COLLAGEN; TUMOR-GROWTH; IN-VITRO; INTEGRIN ALPHA(V)BETA(3); GOODPASTURE AUTOANTIGEN; NONCOLLAGENOUS DOMAINS; ALPHA-3(IV) CHAIN; MELANOMA-CELLS; AUTOANTIBODIES	Components of vascular basement membrane are involved in regulating angiogenesis. Recently, tumstatin (the NC1 domain of alpha3 chain of type IV collagen) was identified as possessing anti-angiogenic activity. In the present study, the anti-angiogenic activity of tumstatin was localized to the putative 54-132-amino acid Tum-5 domain, and the activity mediated by alpha (v)beta (3) integrin interaction in an RGD-independent manner. The recombinant Tum-5 produced in Escherichia coli and Pichia Pastoris specifically inhibited proliferation and caused apoptosis of endothelial cells with no significant effect on nonendothelial cells. Tum-5 also inhibited tube formation of endothelial cells on Matrigel and induced G(1) endothelial cell cycle arrest. Moreover, anti-angiogenic effect of Tum-5 was also examined in vivo using both a Matrigel plug assay in C57BL/6 mice and human prostate cancer (PC-3) xenografts in nude mice. The in vivo results demonstrate that Tum-5 at 1 mg/kg significantly inhibited growth of PC-3 tumors in association with a decrease in CD31 positive vasculature. These in vivo studies also show that, at molar equivalents, human Tum-5 is at least 10-fold more active than human endostatin. In addition, these studies for the first time suggest that through the action of endogenous inhibitors, alpha (v)beta (3) integrin may also function as a negative regulator of angiogenesis. Taken together, these findings demonstrate that Tum-5, a domain derived from tumstatin, is an effective inhibitor of tumor-associated angiogenesis and a promising candidate for the treatment of cancer.	Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; ILEX Oncol Inc, Prod Res & Dev Div, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, 330 Brookline Ave, Boston, MA 02215 USA.	rkalluri@caregroup.harvard.edu	Hopfer, Helmut/T-5954-2019; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hopfer, Helmut/0000-0003-1755-2170	NIDDK NIH HHS [DK-55001, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Colorado PC, 2000, CANCER RES, V60, P2520; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; Dhanabal M, 1999, CANCER RES, V59, P189; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HERLYN D, 1990, CANCER RES, V50, P2296; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 2000, CURR OPIN NEPHROL HY, V9, P413, DOI 10.1097/00041552-200007000-00013; Kalluri R, 1999, KIDNEY INT, V55, P1120, DOI 10.1046/j.1523-1755.1999.0550031120.x; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shahan TA, 1999, CANCER RES, V59, P4584; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; WILSON C, 1996, KIDNEY, P1519	42	176	208	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15240	15248		10.1074/jbc.M007764200	http://dx.doi.org/10.1074/jbc.M007764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278365	hybrid			2022-12-27	WOS:000168528800095
J	Noguchi, T; Tsuda, M; Takeda, H; Takada, T; Inagaki, K; Yamao, T; Fukunaga, K; Matozaki, T; Kasuga, M				Noguchi, T; Tsuda, M; Takeda, H; Takada, T; Inagaki, K; Yamao, T; Fukunaga, K; Matozaki, T; Kasuga, M			Inhibition of cell growth and spreading by stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1) through dephosphorylation of p130(cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; FOCAL ADHESION KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; FACTOR ACTIVATION; MAMMALIAN-CELLS; FACTOR RECEPTOR; PTP-PEST; PHOSPHORYLATION	SAP-1 (stomach cancer-associated protein-tyrosine phosphatase-1) is a transmembrane-type protein-tyrosine phosphatase that is abundant in the brain and certain cancer cell lines. With the use of a "substrate-trapping" approach, p130(cas), a major focal adhesion-associated phosphotyrosyl protein, has now been identified as a likely physiological substrate of SAP-1. Expression of recombinant SAP-1 induced the dephosphorylation of p130(cas) as well as that of two other components of the integrin-signaling pathway (focal adhesion kinase and p62(dok)) in intact cells. In contrast, expression of a substrate-trapping mutant of SAP-1 induced the hyperphosphorylation of these proteins, indicating a dominant negative effect of this mutant. Overexpression of SAP-1 induced disruption of the actin-based cytoskeleton as well as inhibited various cellular responses promoted by integrin-mediated cell adhesion, including cell spreading on fibronectin, growth factor-induced activation of extracellular signal-regulated kinase 2, and colony formation. Finally, the enzymatic activity of SAP-1, measured with an immunocomplex phosphatase assay, was substantially increased by cell-cell adhesion. These results suggest that SAP-1, by mediating the dephosphorylation of focal adhesion-associated substrates, negatively regulates integrin-promoted signaling processes and, thus, may contribute to contact inhibition of cell growth and motility.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Adachi M, 1996, CELL, V85, P15; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Keane MM, 1996, CANCER RES, V56, P4236; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lin TH, 1997, J BIOL CHEM, V272, P8849; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SEIMIYA H, 1995, ONCOGENE, V10, P1731; Seimiya H, 1998, J BIOL CHEM, V273, P21187, DOI 10.1074/jbc.273.33.21187; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; Sommer L, 1997, DEV DYNAM, V208, P48, DOI 10.1002/(SICI)1097-0177(199701)208:1<48::AID-AJA5>3.0.CO;2-1; Sorby M, 1996, J BIOL CHEM, V271, P10963; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806	55	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15216	15224		10.1074/jbc.M007208200	http://dx.doi.org/10.1074/jbc.M007208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278335	hybrid			2022-12-27	WOS:000168528800092
J	Zhang, YG; Zhong, SP; Dong, ZM; Chen, NY; Bode, AM; Ma, WY; Dong, ZG				Zhang, YG; Zhong, SP; Dong, ZM; Chen, NY; Bode, AM; Ma, WY; Dong, ZG			UVA induces Ser(381) phosphorylation of p90(RSK)/MAPKAP-K1 via ERK and JNK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; N-TERMINAL KINASE; AP-1 TRANSACTIVATION; CELL-TRANSFORMATION; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; SUN EXPOSURE; DOCKING SITE; P38 KINASE	UVA exposure plays an important role in the etiology of skin cancer. The family of p90-kDa ribosomal S6 kinases (p90(RSK)/MAPKAP-K1) are activated via phosphorylation, In this study, results show that UVA-induced phosphorylation of p90(RSK) at Ser(381) through ERKs and JNKs, but not p38 kinase pathways. We provide evidence that UVA-induced p90(RSK) phosphorylation and kinase activity were time- and dose-dependent. Both PD98059 and a dominant negative mutant of ERK2 blocked ERKs and p90(RSK) Ser(381) phosphorylation, as well as p90(RSK) activity. A dominant negative mutant of p38 kinase blocked UVA-induced phosphorylation of p38 kinase, but had no effect on WA-induced Ser(381) phosphorylation of p90(RSK) or kinase activity. UVA-induced p90(RSK) phosphorylation and kinase activity were markedly attenuated in JnK(1)-/- and JnK(2)-/- cells. A dominant negative mutant of JNK(1) inhibited UVA-induced JNKs and p90(RSK) phosphorylation and kinase activity, but had no effect on ERKs phosphorylation, PD169316, a novel inhibitor of JNKs and p38 kinase, inhibited phosphorylation of p90(RSK), JNKs, and p38 kinase, but not ERKs. However, SB202190, a selective inhibitor of p38 kinase, had no effect on p90(RSK) gp JNKs phosphorylation. Significantly, ERKs and JNKs, but not p38 kinase, immunoprecipitated with p90(RSK) when stimulated by UVA and p90(RSK) was a substrate for ERK2 and JNK2, but not p38 kinase. These data indicate clearly that p90(RSK) Ser381 may be phosphorylated by activation of JNKs or ERKs, but not p38 kinase.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Henan Med Univ, Dept Pathophysiol, Zhengzhou 450052, Peoples R China	University of Minnesota System; Zhengzhou University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@smig.net		Zhang, Yiguo/0000-0003-3910-2779	NCI NIH HHS [CA77646, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081064, R37CA081064, R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Baek SH, 1999, LIFE SCI, V65, P1845, DOI 10.1016/S0024-3205(99)00436-1; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Beissert S, 1996, CRIT REV BIOCHEM MOL, V31, P381, DOI 10.3109/10409239609108723; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Chakravarthy BR, 1999, J NEUROCHEM, V72, P933, DOI 10.1046/j.1471-4159.1999.0720933.x; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dardevet D, 1999, J ENDOCRINOL, V162, P77, DOI 10.1677/joe.0.1620077; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DeLaat JMT, 1996, CANCER SURV, V26, P173; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gasparro FP, 1998, PHOTOCHEM PHOTOBIOL, V68, P243, DOI 10.1111/j.1751-1097.1998.tb09677.x; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; Halliday G M, 1998, Australas J Dermatol, V39, P71, DOI 10.1111/j.1440-0960.1998.tb01251.x; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Katsambas A, 1996, ARCH DERMATOL, V132, P444, DOI 10.1001/archderm.132.4.444; Kawakami Y, 1998, J IMMUNOL, V161, P1795; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lian JP, 1999, J IMMUNOL, V163, P4527; Loo DT, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P65; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; NEL AE, 1994, J IMMUNOL, V152, P4347; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Pathak Madhu A., 1996, Journal of Dermatology (Tokyo), V23, P783; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STEVENBORG HJC, 1990, PHOTOCHEM PHOTOBIOL, V51, P325; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	68	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14572	14580		10.1074/jbc.M004615200	http://dx.doi.org/10.1074/jbc.M004615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278279	hybrid			2022-12-27	WOS:000168528800008
J	Szabo, I; Seraglia, R; Rigoni, F; Traldi, P; Giacometti, GM				Szabo, I; Seraglia, R; Rigoni, F; Traldi, P; Giacometti, GM			Determination of photosystem II subunits by matrix-assisted laser desorption/ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; ULTRAVIOLET-B RADIATION; D2 PROTEIN; D1 PROTEIN; PSBH GENE; DEGRADATION; PHOTOINHIBITION; IDENTIFICATION; MEMBRANE; SITE	Photosystem II of higher plants and cyanobacteria is composed of more than 20 polypeptide subunits. The pronounced hydrophobicity of these proteins hinders their purification and subsequent analysis by mass spectrometry. This paper reports the results obtained by application of matrix-assisted laser desorption/ionization mass spectrometry directly to isolated complexes and thylakoid membranes prepared from cyanobacteria and spinach. Changes in protein contents following physiopathological stimuli are also described. Good correlations between expected and measured molecular masses allowed the identification of the main, as well as most of the minor, low molecular weight components of photosystem II. These results open up new perspectives for clarifying the functional role of the various polypeptide components of photosystems and other supramolecular integral membrane complexes.	Univ Padua, Dept Biol, I-35131 Padua, Italy; CNR, Res Area, I-35100 Padua, Italy; CNR, Ctr Study Stabil & React Coordinat Complexes, I-35131 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	Giacometti, GM (corresponding author), Univ Padua, Dept Biol, Via G Colombo 3, I-35131 Padua, Italy.	gcometti@civ.bio.unipd.it	Seraglia, Roberta/AAS-4869-2021; Szabo, Ildiko/AAW-5972-2021; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; 				ABDELMAWGOOD AL, 1990, PLANT MOL BIOL, V14, P445, DOI 10.1007/BF00028780; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBATO R, 1995, EUR J BIOCHEM, V234, P459, DOI 10.1111/j.1432-1033.1995.459_b.x; BARBATO R, 1992, FEBS LETT, V311, P33, DOI 10.1016/0014-5793(92)81360-X; BARBATO R, 1991, BIOCHEMISTRY-US, V30, P10220, DOI 10.1021/bi00106a021; Barbato R, 2000, J BIOL CHEM, V275, P10976, DOI 10.1074/jbc.275.15.10976; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; Barber J, 1998, BBA-BIOENERGETICS, V1365, P269, DOI 10.1016/S0005-2728(98)00079-6; Barber J, 1997, PHYSIOL PLANTARUM, V100, P817, DOI 10.1034/j.1399-3054.1997.1000408.x; Barnidge DR, 1999, ANAL BIOCHEM, V269, P1, DOI 10.1006/abio.1999.4012; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; CHAPMAN DJ, 1990, METHODS PLANT BIOCH, V5, P171; CHIARAMONTE S, 1999, EUR J BIOCHEM, V260, P1; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; FRISO G, 1994, FEBS LETT, V339, P217, DOI 10.1016/0014-5793(94)80419-2; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; Giacometti GM, 1996, EUR J BIOCHEM, V242, P799, DOI 10.1111/j.1432-1033.1996.0799r.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; Hankamer B, 1999, NAT STRUCT BIOL, V6, P560, DOI 10.1038/9341; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; Kettunen R, 1996, PLANT PHYSIOL, V111, P1183, DOI 10.1104/pp.111.4.1183; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KUHN M, 1988, Z NATURFORSCH C, V43, P413; Mate Z, 1998, J BIOL CHEM, V273, P17439, DOI 10.1074/jbc.273.28.17439; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MAYES SR, 1991, PLANT MOL BIOL, V17, P289, DOI 10.1007/BF00039508; MICHEL HP, 1987, FEBS LETT, V212, P103, DOI 10.1016/0014-5793(87)81565-X; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; RACE HL, 1993, FEBS LETT, V323, P35, DOI 10.1016/0014-5793(93)81443-4; Rajagopal S, 2000, J PHOTOCH PHOTOBIO B, V54, P61, DOI 10.1016/S1011-1344(99)00156-6; Sharma J, 1997, J BIOL CHEM, V272, P33158, DOI 10.1074/jbc.272.52.33158; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; Sharma J, 1997, J BIOL CHEM, V272, P33153, DOI 10.1074/jbc.272.52.33153; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHIMADA H, 1991, NUCLEIC ACIDS RES, V19, P983, DOI 10.1093/nar/19.5.983; Vass I, 2000, EUR J BIOCHEM, V267, P2640, DOI 10.1046/j.1432-1327.2000.01274.x; Worrall TA, 1998, ANAL CHEM, V70, P750, DOI 10.1021/ac970969e; XIANG F, 1993, ORG MASS SPECTROM, V28, P1424, DOI DOI 10.1002/OMS.1210281211; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122	40	13	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13784	13790		10.1074/jbc.M008081200	http://dx.doi.org/10.1074/jbc.M008081200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11278383	hybrid			2022-12-27	WOS:000168356600040
J	Joyce, DE; Gelbert, L; Ciaccia, A; DeHoff, B; Grinnell, BW				Joyce, DE; Gelbert, L; Ciaccia, A; DeHoff, B; Grinnell, BW			Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEPTIC SHOCK; RENAL INJURY; FACTOR-VIII; SEPSIS; ADHESION; PATHOGENESIS; PATHWAY; CLONING; DISEASE; MICE	Human protein C is a natural anticoagulant factor, and a recombinant activated form of the molecule (rhAPC) is completing clinical evaluation for treatment of severe sepsis. Because of the pathophysiologic role of endothelial dysfunction in severe inflammatory disease and sepsis, we explored the possibility that rhAPC might directly modulate endothelial function, independent of its anticoagulant activity. Using broad transcriptional profiling, we show that rhAPC directly modulates patterns of endothelial cell gene expression clustering into anti-inflammatory and cell survival pathways, rhAPC directly suppressed expression of p50 and p52 NF kappaB subunits, resulting in a functional decrease in NF kappaB binding at target sites. Further, rhAPC blocked expression of downstream NF kappaB regulated genes following tumor necrosis factor alpha induction, including dose-dependent suppression of cell adhesion expression and functional binding of intracellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin. Further, rhAPC modulated several genes in the endothelial apoptosis pathway, including the Bcl-2 homologue protein and inhibitor of apoptosis protein. These pathway changes resulted in the ability of rhAPC to inhibit the induction of apoptosis by the potent inducer, staurosporine. This new mechanistic understanding of endothelial regulation and the modulation of tumor necrosis factor-induced endothelial dysfunction creates a novel link between coagulation, inflammation, and cell death and provides insight into the molecular basis for the efficacy of APC in systemic inflammation and sepsis.	Lilly Corp Ctr, Lilly Res Labs, Div Res Technol, Indianapolis, IN 46285 USA	Eli Lilly	Grinnell, BW (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Div Res Technol, Indianapolis, IN 46285 USA.	grinnell@lilly.com		Sontag, Angelina/0000-0003-4012-4537				Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Coughlin SR, 1998, ARTERIOSCL THROM VAS, V18, P514, DOI 10.1161/01.ATV.18.4.514; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Esmon CT, 1997, THROMB HAEMOSTASIS, V78, P70; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; Esmon CT, 2000, BLOOD, V95, P1113, DOI 10.1182/blood.V95.4.1113.004k54_1113_1116; FIJNVANDRAAT K, 1995, THROMB HAEMOSTASIS, V73, P15; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Garber K, 2000, NAT BIOTECHNOL, V18, P917, DOI 10.1038/79371; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Grinnell BW, 1998, CORONARY ARTERY DIS, V9, P89; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee JH, 1998, BONE MARROW TRANSPL, V22, P883, DOI 10.1038/sj.bmt.1701445; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mizutani A, 2000, BLOOD, V95, P3781; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Parent C, 1999, INFECT DIS CLIN N AM, V13, P427, DOI 10.1016/S0891-5520(05)70084-2; Rintala E, 1998, CRIT CARE MED, V26, P965, DOI 10.1097/00003246-199805000-00038; Shin YT, 2000, BLOOD, V95, P3232; Smith KJ, 1999, THROMB HAEMOSTASIS, P738; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TSUCHIDA A, 1990, TRANSPLANT P, V22, P2134; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	42	537	574	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11199	11203		10.1074/jbc.C100017200	http://dx.doi.org/10.1074/jbc.C100017200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278252	hybrid			2022-12-27	WOS:000167980900083
J	Kim, KH; Lee, K; Moon, YS; Sul, HS				Kim, KH; Lee, K; Moon, YS; Sul, HS			A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; OBESE ZUCKER RATS; GENE-EXPRESSION; PREF-1; PREADIPOCYTES; MICE	A 12.5-kDa cysteine-rich adipose tissue-specific secretory factor (ADSF/resistin) is a novel secreted protein rich in serine and cysteine residues with a unique cysteine repeat motif of CX12CX8CXCX3 CX10CXCXCX9CC. A single 0.8-kilobase mRNA coding for this protein was found in various murine white adipose tissues including inguinal and epididymal fats and also in brown adipose tissue but not in any other tissues examined. Two species of mRNAs with sizes of 1.4 and 0.8 kilobases were found in rat adipose tissue. Sequence analysis indicates that this is because of two polyadenylation signals, the proximal one with the sequence AATACA with a single base mismatch from murine AATAAA and the distal consensus sequence AATAAA. The mRNA level was markedly increased during 3T3-L1 and primary preadipocyte differentiation into adipocytes. Its expression in adipose tissue is under tight nutritional and hormonal regulation; the mRNA level was very low during fasting and increased 25-fold when fasted mice were refed a high carbohydrate diet. It was also very low in adipose tissue of streptozotocin-diabetes and increased 23-fold upon insulin administration. Upon treatment with the conditioned medium from COS cells transfected with the expression vector, conversion of 3T3-L1 cells to adipocytes was inhibited by 80%. The regulated expression pattern suggesting this factor as an adipose sensor for the nutritional state of the animals and the inhibitory effect on adipocyte differentiation implicate its function as a feedback regulator of adipogenesis.	Univ Calif Berkeley, Dept Nutr Sci & Technol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Technol, Berkeley, CA 94720 USA.		Han, Zaiqi/AAI-2233-2019; Lee, Kichoon/G-2234-2012		NIDDK NIH HHS [DK50828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GREGOIRE FM, 1995, INT J OBESITY, V19, P664; GULICK T, 1996, CURRENT PROTOCOLS MO, P9201; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HE E, 1996, J BIOL CHEM, V271, P10697; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; JOSEPH D, 1989, J BIOL CHEM, V264, P574; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Moon YS, 2000, J BIOL CHEM, V275, P10121, DOI 10.1074/jbc.275.14.10121; PENICAUD L, 1991, BIOCHEM J, V279, P303, DOI 10.1042/bj2790303; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Smas CM, 1998, J BIOL CHEM, V273, P31751, DOI 10.1074/jbc.273.48.31751; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WIENDERER L, 1987, J LIPID RES, V28, P649; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	199	240	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11252	11256		10.1074/jbc.C100028200	http://dx.doi.org/10.1074/jbc.C100028200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11278254	hybrid			2022-12-27	WOS:000167980900091
